<SEC-DOCUMENT>0001104659-21-148265.txt : 20211210
<SEC-HEADER>0001104659-21-148265.hdr.sgml : 20211210
<ACCEPTANCE-DATETIME>20211209190749
ACCESSION NUMBER:		0001104659-21-148265
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20211210
DATE AS OF CHANGE:		20211209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259624
		FILM NUMBER:		211483213

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>tm2134694-1_424b7.htm
<DESCRIPTION>424B7
<TEXT>
<html>
  <head>
    <title>tm2134694-1_424b7 - none - 40.4377592s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed Pursuant to Rule 424(b)(7) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-259624</font>&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:19pt; text-align:center; width:456pt;">
          <img src="lg_humacyte-4clr.jpg" alt="[MISSING IMAGE: lg_humacyte-4clr.jpg]" height="59" width="288" >
        </div>
        <div style="margin-top:23pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to 90,006,840 Shares of Common Stock</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Up to 5,177,500 Shares of Common Stock Issuable Upon Exercise of Warrants </font>
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the issuance by us of an aggregate of up to 5,177,500 shares of our common stock, $0.0001 par value per share (the &#8220;common stock&#8221;), which consists of (i)&#160;up to 177,500 shares of common stock that are issuable upon the exercise of private placement warrants (the &#8220;Private Placement Warrants&#8221;) originally issued in a private placement to AHAC Sponsor LLC (the &#8220;Sponsor&#8221;), Oppenheimer &amp; Co. Inc. (&#8220;Oppenheimer&#8221;) and Northland Securities, Inc. (&#8220;Northland&#8221;), in connection with the initial public offering of Alpha Healthcare Acquisition Corp. (&#8220;AHAC&#8221;), and (ii)&#160;up to 5,000,000 shares of common stock that are issuable upon the exercise of public warrants (the &#8220;Public Warrants&#8221; and, together with the Private Warrants, the &#8220;Warrants&#8221;). We will receive the proceeds from the exercise of any Warrants for cash. </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus also relates to the offer and sale from time to time by the selling stockholders named in this prospectus or their permitted transferees (the &#8220;selling stockholders&#8221;) of up to 90,006,840 shares of common stock, which consists of (i)&#160;up to 17,500,000 shares of common stock issued on August&#160;26, 2021 in a private placement pursuant to subscription agreements, dated February&#160;17, 2021 (the &#8220;PIPE Shares&#8221;), (ii)&#160;up to 71,696,679 shares of common stock, required to be registered pursuant to that certain Investor Rights and Lock-up Agreement, dated August&#160;26, 2021 (the &#8220;Investor Rights and Lock-up Agreement&#8221;), by and among us and certain of the selling stockholders and (iii)&#160;up to 810,161 shares of common stock purchased by a selling stockholder. We will not receive any proceeds from the sale of shares of common stock by the selling stockholders pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of common stock, but we will receive the proceeds from the exercise of any Warrants for cash. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The selling stockholders will bear all commissions and discounts, if any, attributable to their sale of shares of common stock. See the section titled &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;HUMA.&#8221; On November&#160;18, 2021, the last reported sales price of our common stock was $11.49 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the U.S. federal securities laws. See &#8220;Prospectus Summary&#8201;&#8212;&#8201;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#8221; This prospectus complies with the requirements that apply to an issuer that is an emerging growth company and a smaller reporting company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">4</a> of this prospectus to read about factors you should consider before investing in our common stock.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:36pt; text-align:center; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is December 9, 2021.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:224pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Table of Contents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:367pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAID"><font style="letter-spacing:0.2pt;">MARKET AND INDUSTRY DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAID">ii</a></font> <a href="#tMAID"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTRA"><font style="letter-spacing:0.2pt;">TRADEMARKS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTRA">iii</a></font> <a href="#tTRA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFOST"><font style="letter-spacing:0.2pt;">FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOST">iv</a></font> <a href="#tFOST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">3</a></font> <a href="#tTHOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">4</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">46</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOP"><font style="letter-spacing:0.2pt;">DETERMINATION OF OFFERING PRICE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOP">47</a></font> <a href="#tDOOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIFC"><font style="letter-spacing:0.2pt;">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMIFC">48</a></font> <a href="#tMIFC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:429pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMDAA">49</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:0.2pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBUS">65</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAN">116</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:0.2pt;">EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXCO">124</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBEOW"><font style="letter-spacing:0.2pt;">BENEFICIAL OWNERSHIP </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBEOW">140</a></font> <a href="#tBEOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCRAR">142</a></font> <a href="#tCRAR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOS">147</a></font> <a href="#tDOS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEST"><font style="letter-spacing:0.2pt;">SELLING STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSEST">150</a></font> <a href="#tSEST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">159</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">163</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">165</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">165</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">165</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#ITCFS"><font style="letter-spacing:0.2pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#ITCFS">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a><a name="tMAID">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement on Form S-1 that we filed with the SEC using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling stockholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling stockholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of any Warrants. We will not receive any proceeds from the sale of shares of common stock underlying the Warrants pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the selling stockholders have authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus or in any applicable prospectus supplement or in any related free writing prospectus prepared by or on behalf of us or to which we have referred you. Accordingly, neither we nor any selling stockholder takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. Neither we nor any selling stockholder will make any offers to sell or seek any offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus, any&#160;applicable prospectus supplement, and any related free writing prospectus is accurate only as of the respective dates of such documents, regardless of the time of delivery of the respective documents or any sale of securities offered hereby. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021 (the &#8220;Closing Date&#8221;), Humacyte, Inc. (&#8220;Legacy Humacyte&#8221;) and AHAC consummated the previously announced business combination pursuant to that certain Business Combination Agreement, dated as of February&#160;17, 2021 (the &#8220;Business Combination Agreement&#8221;), by and among Legacy Humacyte, AHAC and Hunter Merger Sub (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Business Combination Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (the &#8220;Business Combination&#8221;). On the Closing Date, AHAC changed its name to Humacyte, Inc. and Legacy Humacyte changed its name to Humacyte Global, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Humacyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Humacyte, Inc. (formerly known as Alpha Healthcare Acquisition Corp.) and its consolidated subsidiaries (including Humacyte Global, Inc.) following the Business Combination. References to &#8220;AHAC&#8221; refer to Alpha Healthcare Acquisition Corp. prior to the Business Combination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Under this method of accounting, AHAC will be treated as the acquired company for financial reporting purposes, whereas Legacy Humacyte will be treated as the accounting acquirer. In accordance with this accounting method, the Business Combination will be treated as the equivalent of Legacy Humacyte issuing stock for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC will be stated at historical cost, with no goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of Humacyte. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET AND INDUSTRY DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Humacyte&#8217;s own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTRA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:524pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TRADEMARKS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that&#160;the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tFOST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this prospectus, words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;strive,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When we discusses our strategies or plans, we are making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, Humacyte&#8217;s management. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Forward-looking statements in this prospectus may include, for example, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our anticipated growth rate and market opportunities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to maintain the listing of our securities on Nasdaq; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential liquidity and trading of our securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to raise financing in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our plans and ability to execute product development, process development, preclinical development efforts successfully and on our anticipated timelines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to use our proprietary scientific technology platform to build a pipeline of additional product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our plans and ability to obtain marketing approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other regulatory authorities, including the European Medicines Agency (&#8220;EMA&#8221;), for our bioengineered human, acellular tissue-based vessels (&#8220;HAVs&#8221;) and other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials, including for our ongoing V005 Phase&#160;II/III clinical trial and V007 Phase&#160;III clinical trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our plans and ability to commercialize our HAVs and other product candidates, if approved by regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the expected size of the target populations for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our assessment of the competitive landscape; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the degree of market acceptance of HAVs, if approved, and the availability of third-party coverage and reimbursement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to manufacture HAVs and other product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding our strategic partnership with Fresenius Medical Care Holdings, Inc. (&#8220;Fresenius Medical Care&#8221;) to sell, market and distribute our 6 millimeter HAV for certain specified indications and in specified markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the performance of other third parties on which we rely, including our third-party manufacturers, our licensors, our suppliers and the organizations conducting our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain intellectual property protection for our product candidates as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to maintain the confidentiality of our trade secrets, particularly with respect to our manufacturing process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iv</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:212pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our compliance with applicable laws and regulatory requirements, including FDA regulations, healthcare laws and regulations, and anti-corruption laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to attract, retain and motivate qualified personnel and to manage our growth effectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future financial performance and capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to implement and maintain effective internal controls; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic on our business, including our manufacturing efforts, and our preclinical and clinical studies and preclinical and clinical trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements are only predictions based on our current expectations and projections about future events and are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Moreover, we operate in a competitive industry, and new risks emerge from time to time. It is not possible for the management of Humacyte to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Humacyte does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in expectations, except as required by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus, the documents that have been filed as exhibits to the registration statement of which this prospectus forms a part, and any accompanying prospectus supplement with the understanding that the actual future results, levels of activity, performance, events and circumstances of Humacyte may be materially different from what is expected.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">v</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained in this prospectus. This summary does not contain all the information that you should consider before investing in our common stock. You should read the entire prospectus carefully, including the &#8220;Risk Factors,&#8221; &#8220;Forward-Looking Statements&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections, and our historical financial statements and the accompanying notes included in this prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte believes its technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Business Combination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On the Closing Date, Legacy Humacyte and AHAC consummated the previously announced Business Combination pursuant to the Business Combination Agreement, by and among Legacy Humacyte, AHAC and Merger Sub. As contemplated by the Business Combination Agreement, Merger Sub merged with&#160;and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC. On the Closing Date, AHAC changed its name to Humacyte, Inc. and&#160;Legacy Humacyte changed its name to Humacyte Global, Inc. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">At the effective time of the Business Combination (the &#8220;Effective Time&#8221;): </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">each outstanding share of common stock of Legacy Humacyte (the &#8220;Legacy Humacyte common stock&#8221;) was cancelled and converted into the right to receive approximately 0.26260 shares of our common stock; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">each outstanding share of preferred stock of Legacy Humacyte (the &#8220;Legacy Humacyte preferred stock&#8221;) was cancelled and converted into the right to receive the aggregate number of shares of our common stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by approximately 0.26260; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of our common stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">in each case, rounded down to the nearest whole share. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Prior holders of shares of Legacy Humacyte common stock and Legacy Humacyte preferred stock also will be eligible to receive up to an aggregate of 15,000,000 shares of our common stock based on the share price performance of our common stock in accordance with the terms of the Business Combination Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Concurrently with the execution of the Business Combination Agreement, AHAC entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (the &#8220;PIPE Investors&#8221;). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of common stock (the &#8220;PIPE Shares&#8221;) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175&#160;million (the &#8220;PIPE Investment&#8221;). The PIPE Investment was consummated in connection with the consummation of the Business Combination. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated in Delaware on July&#160;1, 2020, under the name Alpha Healthcare Acquisition&#160;Corp., in order to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. AHAC completed its initial public offering on September&#160;22, 2020. On August&#160;26, 2021, AHAC and Legacy Humacyte consummated the transactions contemplated by the Business Combination Agreement. In connection with the closing of the Business Combination, we changed our name to Humacyte, Inc. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The mailing address of our principal executive office is 2525 East North Carolina Highway 54,&#160;Durham, North Carolina 27713, and our telephone number is (919) 313-9633. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, and therefore we intend to take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in this prospectus, our periodic reports and our proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1)&#160;December&#160;31, 2025 (the last day of the fiscal year following the fifth anniversary of the consummation of AHAC&#8217;s initial public offering), (2)&#160;the last day of the fiscal year in which we have total annual gross revenues of at least $1.07&#160;billion, (3)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and (4)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt securities during the prior three-year period. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies including, among other things, providing only two&#160;years of audited financial statements. We will remain a smaller reporting company for so long as (1)&#160;the market value of our common stock held by non-affiliates is less than $250&#160;million as of the last business day of the second fiscal quarter, or (2)&#160;our annual revenues in our most recent fiscal year completed before the last business day of our second fiscal quarter are less than $100&#160;million and the market value of our common stock held by non-affiliates is less than $700&#160;million as of the last business day of the second fiscal quarter. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:6pt; width:144pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Issuance of Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Shares of common stock offered by us</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 5,177,500 shares of our common stock, which consists of (i)&#160;up to 177,500 shares of common stock that are issuable upon the exercise of Private Placement Warrants and (ii)&#160;up to 5,000,000&#160;shares of common stock that are issuable upon the exercise of Public Warrants. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Shares of common stock outstanding prior to the exercise of all Warrants</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">103,003,384 shares (as of November 10, 2021) </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Shares of common stock outstanding assuming exercise of all Warrants</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">108,180,884 shares (based on total shares outstanding as of November&#160;10, 2021) </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Exercise price of Warrants</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">$11.50 per share, subject to adjustment as described herein. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of Proceeds</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will receive up to an aggregate of approximately $59.5 million&#160;from the exercise of all of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. See the section titled &#8220;Use of Proceeds.&#8221; </font>
          </div>
          <div style="margin-top:6pt; width:144pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Resale of Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Shares of common stock offered by the selling stockholders</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to (i)&#160;17,500,000 PIPE Shares, (ii)&#160;up to 71,696,679 shares of common stock pursuant to the Investor Rights and Lock-up Agreement and (iii)&#160;up to 810,161 shares of common stock purchased by a selling stockholder. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of Proceeds</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will not receive any of the proceeds from the sale of common stock by the selling stockholders. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Lock-up Restrictions</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Certain of the shares of common stock issued in connection with the Business Combination are subject to restrictions on transfer until the termination of applicable lock-up periods. See &#8220;Certain Relationships and Related Party Transactions&#8201;&#8212;&#8201;Humacyte Related Party Transactions&#8221; for further discussion. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk Factors</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Before investing in our securities, you should carefully read and consider the information set forth in the section titled &#8220;Risk Factors&#8221; beginning on page 4 of this prospectus. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Ticker Symbol</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our common stock is listed on Nasdaq under &#8220;HUMA.&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">An investment in our common stock involves a high degree of risk. Before you make a decision to buy our common stock, in addition to the risks and uncertainties discussed in the section titled &#8220;Forward-Looking Statements,&#8221; you should carefully consider the risks and uncertainties described below, together with all of the other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our common stock. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of principal risk to which our business, operations and financial performance are subject. Each of these risks is more fully described in the individual risk factors immediately following this summary. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We have never generated product revenue and have incurred significant losses to date. We expect to continue to incur losses for the foreseeable future and may never generate product revenue or be profitable. We will need to raise additional capital to finance our operations, which we may not be able to do on acceptable terms or at all. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The terms of our existing indebtedness may limit our ability to incur future debt. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If our clinical trials fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce favorable results, we may incur significant additional costs or experience significant delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We may experience delays or difficulties in the enrollment of patients in our clinical trials, which may delay or prevent additional clinical trials and our receipt of necessary marketing approvals. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Lack of experience by investigators and surgeons with our HAVs can lead to incorrect implantation or follow-up procedures which could harm the results of our clinical trials and market acceptance of our HAVs, if approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our near-term prospects are dependent on the success of our 6 millimeter HAV, and if we are unable to successfully develop and commercialize it, our business, operating results and financial condition will be materially harmed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We may not be successful in our efforts to use our proprietary scientific technology platform to build a pipeline of additional product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Even if our HAVs receive marketing approval in the future for one or more of our product candidates, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The sizes of the market opportunities for our product candidates have not been established with precision and are estimates that management believes to be reasonable. If these market opportunities are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the relevant patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our distribution agreement with Fresenius Medical Care imposes obligations on us that may restrict our ability to operate our business in ways we believe to be in our long-term best interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If we receive approval for a product candidate that is not subject to our distribution agreement with Fresenius Medical Care, and we are unable to establish our own marketing, sales and distribution </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">capabilities or are unable to enter into agreements with third parties do so, we may not be able to generate product revenue and will have to alter our development and commercialization plans. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The outbreak of COVID-19 may continue to adversely impact our business, including our manufacturing efforts, and our preclinical studies and clinical trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The manufacture of our product candidates is complex, we have not manufactured commercial product, and we may encounter difficulties in production. If we or any third-party manufacturer encounter such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We rely on third parties to conduct and support our clinical trials, and those third parties may not perform satisfactorily, including by failing to adhere to regulatory requirements or our stated protocols or to meet deadlines for the completion of such trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We rely on third-party suppliers, including sole source suppliers, to provide certain components for our product candidates. Any failure by a third-party supplier to supply these components for manufacture may delay or impair our ability to complete our clinical trials and to commercialize our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We intend to rely on our strategic, global partnership with Fresenius Medical Care to undertake, or assist with, the marketing, sale and distribution of certain of our product candidates in certain markets if we receive marketing approval from relevant regulatory authorities. Disruption of this arrangement could materially adversely affect our business, prospects, operating results and financial condition. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Our ability to successfully commercialize our products may be impaired if we are unable to obtain and maintain effective intellectual property rights for our proprietary scientific technology platform and product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Development and Commercialization of Our Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our clinical trials fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce favorable results, we may incur significant additional costs or experience significant delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. If we experience significant delays or significant additional costs, our business will be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As with all regulated biologics, before obtaining marketing approval for any of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive and time-consuming, and its outcomes are uncertain. We believe the novelty of our research and development efforts, which are focused on the development of bioengineered human, acellular, tissue-based vessels for use across a wide spectrum of applications in vascular surgery, augments this uncertainty. The scientific discoveries that form the basis for our efforts to develop our product candidates are relatively new, and the scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. At this time, no products based on HAVs have been approved in the United States or in Europe. The clinical trial requirements of the FDA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and&#160;market of the potential product, and we may not succeed in obtaining marketing approval even if we view our clinical trials as successful. Data obtained from preclinical and clinical activities, and manufacturing comparability studies, are also subject to varying interpretations, which may delay, limit or prevent marketing approval. In such circumstances, we could experience significant delays, or be prevented from, developing or commercializing our HAVs, and our business, prospects, operating results and financial condition could be materially harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our V006 trial did not meet its primary endpoint, and if we fail to achieve the primary endpoint of our other ongoing or future clinical trials, or if safety issues arise, or if our comparability demonstration between </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our former and new manufacturing process fails or is not accepted by the FDA, or if the results from our clinical trials are otherwise inadequate to support regulatory approval of our product candidates, we may incur significant additional costs or experience significant delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we receive FDA approval for our HAVs, we may face a number of difficulties if the results of our clinical trials are unfavorable, inconclusive, or only modestly favorable or if there are safety concerns, such as adverse events (&#8220;AEs&#8221;) or serious adverse events (&#8220;SAEs&#8221;), which could include clotting, mechanical failure, immunological rejection, or infection, that could outweigh potential benefits associated with such product candidates. This could result in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining approval for indications or patient populations that are not as broad as intended or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining approval with, or later becoming subject to, labelling that includes significant use or distribution restrictions or significant safety warnings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">being subject to a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) or equivalent requirement from a comparable foreign regulatory agency, to ensure that the benefits of a biological product outweigh its risks or to change the way the product is used; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">being required to perform additional clinical trials to support approval or comparability or being subject to additional post-marketing testing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">having regulatory authorities withdraw their approval of the product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">being sued; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suffering damage to our reputation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could cause us to incur significant additional costs, significant delays and prevent us from achieving or maintaining market acceptance of or commercializing one or more of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we experience failures or delays in our preclinical and clinical programs, we would be prevented from developing and commercializing our product candidates in a timely matter, if at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A number of factors impact the timing of our preclinical and clinical programs and the development and commercialization of our product candidates. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Events that prevent successful or timely completion of the development of our product candidates beyond unfavorable or inconclusive clinical trial results include, among others, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in the testing, validation, manufacturing or delivery of our product candidates to the clinical sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in reaching&#8201;&#8212;&#8201;or inability to reach&#8201;&#8212;&#8201;agreement with the FDA or other regulatory agencies on trial design, including final confirmation from the FDA as to the parameters of our V005 trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in obtaining required Institutional Review Board (&#8220;IRB&#8221;) approval at each clinical trial site; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in recruiting suitable patients in sufficient volume to participate in our clinical trials and in having those patients complete participation in our clinical trials or return for follow-up, including delays related to the ongoing COVID-19 pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the occurrence of SAEs associated with any of our product candidates that are viewed to outweigh their potential benefits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure by CROs, other third parties or us to adhere to clinical trial requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure to perform in accordance with the FDA&#8217;s good clinical practices (&#8220;GCP&#8221;) or current good tissue practices (&#8220;cGTP&#8221;), or applicable regulatory guidelines in other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical trial sites dropping out of, or being removed from, a trial; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols or data. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any inability to successfully complete development of our product candidates would likely result in significant additional costs to us and impair our ability to generate revenue. Clinical trial delays could also allow our competitors to bring products to market before we do, which could materially impair our ability to successfully commercialize our product candidates and may harm our business and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our progress in early stage clinical trials may not be indicative of long-term efficacy in late stage clinical trials, and our progress in trials for one product candidate may not be indicative of progress in trials for another product candidate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The product candidates in our pipeline are at various stages of development. Trial designs and results from previous studies are not necessarily predictive of our future clinical trial designs or results, and initial results of ongoing trials may not be confirmed upon full analysis of the complete trial data. A number of companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in earlier stage clinical trials, and we may experience similar setbacks. Favorable results in clinical trials for one of our product candidates also do not necessarily indicate that we will obtain positive results in clinical trials related to other product candidates. The novelty of our proprietary scientific technology platform adds another layer of risk that early-stage clinical trials may not be indicative of long-term efficacy in our late-stage clinical trials. If we are unable to demonstrate favorable results in future clinical trials for our various product candidates, we expect that our business, prospects, operating results and financial condition will be materially adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate. Some open-label clinical trials test only the investigational product candidate without a comparator. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in an environment with an active control. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, although we may not have received or had the opportunity to fully and carefully evaluate all data at the time such preliminary or topline results are released. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials.&#160;Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">outcomes may materially change as patient enrollment continues and more patient data become available, or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. In addition, the information we choose to publicly disclose regarding a particular clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </font>
        </div>
        <div style="margin-top:10.22pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If SAEs occur at an unacceptable rate or other unacceptable side effects are identified in our HAVs we may need to delay, abandon or limit development and marketing of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our HAVs may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval. The reported SAEs related to the HAV for hemodialysis access, a patient population which typically has a high prevalence of existing medical conditions, are detailed in the table below which summarizes results from our V006 HUMANITY Phase&#160;III study in which subjects were randomized to receive either a HAV or a commercially available expanded polytetrafluoroethylene (&#8220;ePTFE&#8221;) graft. </font>
        </div>
        <div style="margin-top:10.12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SAEs Reported in V006 Phase&#160;III Clinical Study in AV Access</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:136.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:320pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of SAE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of SAEs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(% of total subjects) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:36pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">HAV </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:36pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">ePTFE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:320pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of subjects in V006 study </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">177</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">General disorders and administration conditions: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Implant site extravasation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Infections and infestations </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site infection </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">5(2.8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Injury, poisoning and procedural complications: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Anastomotic stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:226pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:320pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of SAE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of SAEs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(% of total subjects) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:36pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">HAV </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:36pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">ePTFE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site hematomas </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site hemorrhage </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3(1.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site pain </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site pseudoaneurysm </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10(5.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site rupture </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999994pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">41(23.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">28(15.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Skin and subcutaneous tissue disorders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Skin necrosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Vascular disorders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Steal syndrome </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Subclavian vein occlusion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34(19.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27(15.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:320pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Venous stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3(1.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In our V002 and V004 Phase&#160;II clinical studies in peripheral arterial disease (&#8220;PAD&#8221;) in 35 subjects, another patient population which typically has a high prevalence of existing medical conditions, the SAEs reported for the HAV are detailed in the table below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SAEs Reported in V002 and V004 Phase&#160;II Clinical Studies in PAD</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:101.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:357.85pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of SAE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">SAEs (% of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">total subjects) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of subjects in V002 and V004 studies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">N=35</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Arterial bypass thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3(8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Anastomotic stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1(3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Graft thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2(6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vascular graft complication </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1(3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our HAVs are associated with undesirable side effects in clinical trials or have negative characteristics that are unexpected, we may need to perform additional clinical trials, abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Even if one of our product candidates is approved, the FDA and other regulatory authorities may take action to withdraw it from the market if serious safety concerns emerge. Any of these events could cause us to delay, abandon or limit the development and, if approved, marketing of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may experience delays or difficulties in the enrollment of patients in our clinical trials, which may delay or prevent additional clinical trials and our receipt of necessary marketing approvals.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are currently enrolling patients in several clinical trials, including in our V005 trial, which is a Phase&#160;II/III clinical trial of our 6 millimeter HAV in traumatic vascular repair and our V007 trial, which is a Phase&#160;III clinical trial comparing the safety and efficacy of our 6 millimeter HAV to arteriovenous (&#8220;AV&#8221;) fistula for hemodialysis access. Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in such trials. Additionally, the COVID-19 pandemic has had and may continue to have a sustained impact on our ability to recruit and follow up with patients. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA and other regulatory authorities, and as such our product candidates could be delayed or otherwise adversely affected. Patient enrollment and trial completion is affected by many factors including the: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">size of the patient population and process for identifying subjects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">availability of clinical trial research resources at clinical sites in the era of the COVID-19 pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">availability of persons to provide or obtain patient consent for trial participation due to COVID-19 restrictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">design of the trial protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inclusion and exclusion criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">safety profile, to date, of the product candidate under study; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">perceived risks and benefits of the product candidate under study; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">availability of competing therapies and clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">severity of the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">degree of progression of the subject&#8217;s disease at the time of enrollment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">proximity and availability of clinical trial sites for prospective subjects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic or future pandemics or similar events on patients&#8217; willingness and ability to participate in clinical trials or on study site policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ability to obtain and maintain subject consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that enrolled subjects will drop out before completion of the trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient referral practices of physicians; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ability to monitor subjects adequately during and after treatment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lack of experience by investigators and surgeons with our HAVs can lead to incorrect implantation or follow-up procedures which could harm the results of our clinical trials and market acceptance of our HAVs, if approved.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our HAVs are currently in various stages of preclinical and clinical testing and have not been widely used. We do not have the personnel capacity to directly conduct or manage all of the clinical trials that are necessary for the development of our HAVs. Therefore, we rely, and will continue to rely, on third parties to assist us in managing, monitoring and conducting our clinical trials. Some of the investigators in our&#160;clinical trials have not been, and, if our HAVs receive marketing approval, surgeons may not be, previously exposed to the implantation and follow-up procedures related to their use. As a result, our HAVs may be, and have been in the past, incorrectly implanted and follow-up procedures may be performed incorrectly, resulting in violations of our trial protocols, increased interventions or failure of the HAV. Our efforts to educate investigators, surgeons and interventionalists regarding the proper techniques for use of our HAVs both&#160;during clinical trials and following potential commercialization may be costly, prove unsuccessful and could&#160;materially harm our ability to continue the clinical trials or marketing of our HAVs. Regulatory authorities may also seek to impose restrictive labeling or proactive communication obligations on any marketing approval granted for use of our HAVs as a result, which could reduce market acceptance of any of our HAVs that receive marketing approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our near-term prospects are dependent on the success of our 6 millimeter HAV, and if we are unable to successfully develop and commercialize it, our business, operating results and financial condition will be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently have no products approved for sale and, while we are developing a number of product candidates, we have invested and continue to invest a substantial portion of our efforts and financial resources in the development of our 6 millimeter HAV. None of our remaining product geometries and modifications have advanced beyond preclinical development. As a result, in the near term we are dependent on the success of our 6 millimeter HAV, and if we are unable to successfully develop, obtain marketing approval for, and commercialize it, our business, along with our operating results and financial condition, will be materially harmed. Even if we succeed with the development of our 6 millimeter HAV, our ability to generate product revenue and become profitable from our 6 millimeter HAV depends on our assumptions regarding the relevant market opportunity, for which our estimates may prove inaccurate, and market acceptance in any approved indication, which may never occur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be successful in our efforts to use our proprietary scientific technology platform to build a pipeline of additional product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A key element of our strategy is to use our proprietary scientific technology platform to expand our pipeline of HAVs and to progress other product candidates into and through clinical development. We may not be able to identify or develop future product candidates that are safe and effective. Even if we are successful in building our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including if they have harmful side effects or other characteristics that render them unlikely to receive marketing approval or achieve market acceptance. Research programs to identify new product candidates require substantial technical, financial and human resources, and we may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. If we do not successfully develop and commercialize additional product candidates based upon our technology, we may have difficulty generating product revenue in the future, which could result in significant harm to our business, prospects, operating results and financial condition and adversely affect our stock price. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if our HAVs receive marketing approval in the future for one or more of our product candidates, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even with the requisite approvals from the FDA in the United States, the European Commission in the European Union (the &#8220;EU&#8221;) and other regulatory authorities internationally, the commercial success of our HAVs will depend, in part, on the acceptance of physicians, patients and health care payors, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community due to ethical, social, medical and legal concerns. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The degree of market acceptance of any of our product candidates that receives marketing approval will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efficacy and potential advantages of our product candidates compared with alternative products or methods, including convenience and ease of administration; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prices we charge for our products, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of third-party coverage and adequate reimbursement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the willingness of the target patient population to try new products and methods and of physicians to use these products and methods; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the quality of our relationships with patient advocacy groups; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the strength of marketing and distribution support; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of the product and our ability to meet market demand; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence and severity of any side effects; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any restrictions on the use of our products, if approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The sizes of the market opportunities for our product candidates have not been established with precision and are estimates that management believes to be reasonable. If these market opportunities are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the relevant patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our estimates of the market opportunity for certain of our product candidates, as set forth in this prospectus, are based on a number of internal and third-party estimates. While we believe our assumptions and the data underlying these estimates are reasonable, they may be inaccurate or based on imprecise data; in addition, the assumptions and conditions underlying the estimates may change at any time. For example, the number of patients who ultimately use our product candidates, if approved by regulatory authorities, and our total market opportunities for such product candidates, will depend on, among other things, pricing and reimbursement, market acceptance of those product candidates and patient access, and may be lower than we estimate. Additionally, any approval we receive for our product candidates may be based on a narrower definition of the relevant patient population than we have estimated. Either of these circumstances could materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face and will continue to face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do, which may adversely affect our ability to successfully market or commercialize our HAVs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The development and commercialization of new biological products is highly competitive and subject to rapid change and technological advancements. If approved, we expect our HAVs would compete with the use of a patient&#8217;s own blood vessels, as well as a variety of marketed products, such as conventional&#160;synthetic grafts, xenografts, and allografts, as well as developing technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to face competition with respect to any additional product candidates that we may seek to develop or commercialize in the future from a variety of sources, including major pharmaceutical companies, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">specialty pharmaceutical companies and biotechnology companies, hospital product-focused companies, as well as public and private universities and research organizations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of our existing or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than the products that we develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain the same approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to seek marketing approval for our HAVs in the United States as a biologic and in the European Union (the &#8220;EU&#8221;) as a medicinal product. In both the United States and the EU, our competitors may try to market vascular conduits similar to our product candidates as medical devices. Such competitive products could have comparable characteristics and could function similarly in the body (and could even be protein-based like our product candidates). Companies may be able to obtain marketing approval for such products on the basis of less data than the data required for a BLA and marketing similar products as devices could permit our competitors to circumvent regulatory exclusivity for biologics in the United States and medicinal products in the EU. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our distribution agreement with Fresenius Medical Care imposes obligations on us that may restrict our ability to operate our business in ways we believe to be in our long-term best interest.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to rely on our strategic, global relationship with Fresenius Medical Care for the development and commercialization of certain of our product candidates. As discussed in more detail in the section of this prospectus titled &#8220;Business&#8201;&#8212;&#8201;Distribution&#8201;&#8212;&#8201;Distribution Agreement with Fresenius Medical Care,&#8221; Fresenius Medical Care will have the exclusive right to develop outside of the United States and EU and commercialize outside of the United States, among other things, our 6 millimeter x 42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter, or configuration of the foregoing), which we refer to as the distribution product, for use in vascular creation, repair, replacement or construction (including renal replacement therapy for dialysis access, the treatment of vascular trauma, and the treatment of PAD, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients). We refer to these indications wherein Fresenius Medical Care has rights to develop and commercialize Humacyte&#8217;s products as the field. The distribution agreement also imposes a number of restrictions on our business. For instance, outside the United States, the distribution agreement restricts our ability to engage a distributor for the distribution product outside the field or for HAV products other than the distribution product: we have granted Fresenius Medical Care (i)&#160;an exclusive right of first negotiation for exclusive distribution rights outside the United States for the distribution product for use outside the field, and (ii)&#160;an exclusive right of first negotiation for exclusive distribution rights outside the United States for our other HAV products, if any, subject, in each case, to certain conditions. These and other obligations may restrict our ability to operate our business in ways we believe are in our long-term best interest, which could harm our business and our prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we receive approval for a product candidate that is not subject to our distribution agreement with Fresenius Medical Care, and we are unable to establish our own marketing, sales and distribution capabilities or are unable to enter into agreements with third parties do so, we may not be able to generate product revenue and will have to alter our development and commercialization plans.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently have limited internal marketing, sales or distribution capabilities, and our management team has limited experience commercializing products following marketing approval.If one of our product </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">candidates that is not subject to the distribution agreement with Fresenius Medical Care receives marketing approval, we will be required either to develop these capabilities internally or to make arrangements with third parties for the marketing, sales and distribution of the relevant product candidate. The establishment and development of our own marketing, sales and distribution functions will be expensive and time-consuming and may delay any product launch, and we may ultimately be unable to successfully develop the product candidate. In addition, or in the alternative, we could seek one or more partners to handle some or all of the marketing, sales and distribution activities associated with any such product candidate. However, we may face significant competition in seeking appropriate strategic partners, and the negotiation process is time consuming and complex. Therefore, we may not be able to enter into arrangements with third parties to do so on favorable terms or at all. In the event we are unable to develop our own marketing, sales and distribution functions or collaborate with a third-party organization for this purpose, we may not be able to successfully commercialize a product candidate that is not subject to the distribution agreement with Fresenius Medical Care, which would adversely affect our ability to generate revenue. Further, whether we commercialize any such product candidate on our own or rely on a third party to do so, our ability to generate revenue will be dependent on the effectiveness of the organization performing these functions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we receive marketing approval for our HAVs, there is uncertainty with respect to third-party coverage and reimbursement of our HAVs. They may also be subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, any of which could harm our business, prospects, operating results and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">There is uncertainty around third-party coverage and reimbursement of newly approved regenerative medicine type products, even those with the Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from FDA, such as our 6 millimeter HAV for AV access for performing hemodialysis, which received the RMAT designation in 2017. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which medical products and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and government payors develop their coverage and reimbursement policies. Currently, no RMAT tissue engineered product has established coverage and reimbursement by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;). Even if our HAVs receive approval from regulatory authorities, it is difficult to predict what CMS or any comparable foreign regulatory agency will decide with respect to coverage and reimbursement for novel products such as ours, as there is no body of established practices and precedents for these types of products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could also cause us to decrease any&#160;price we might establish for products, which could result in lower than anticipated product revenue. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including our costs related to research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our business, prospects, operating results and financial condition will suffer, perhaps materially. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In some countries, particularly in Europe, the pricing of our product may be subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our&#160;product candidate to other available therapies. If reimbursement of our products, if approved, is unavailable or more limited in scope or amount than we anticipate, or if pricing is set at even lower levels than we anticipate,&#160;our business could be harmed, possibly materially. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Product liability lawsuits against us could cause us to incur substantial liabilities that may not be covered by our limited product liability insurance and may limit development, approval and commercialization of our HAVs and any other product candidates that we develop in the future.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk, if and when we commercially sell our HAVs and any other product candidates that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">decreased demand for any product candidates or products that we develop or sell, leading to loss of revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injury to our reputation and significant negative media attention; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal, or slower enrollment, of clinical trial participants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significant costs to defend the related litigation and reduced resources of our management to pursue our business strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inability to further develop or commercialize our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently hold limited product liability insurance coverage, and it may not be adequate to cover all liabilities that we may incur. We also may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The outbreak of COVID-19 may continue to adversely impact our business, including our manufacturing efforts, and our preclinical studies and clinical trials.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ongoing COVID-19 pandemic has impacted our business and we expect it to continue to do so. In response to the spread of COVID-19, we limited entry into our facilities for non-essential personnel, and instituted daily health checks and weekly COVID-19 screenings for employees who entered the facility. In addition, we have experienced delays in the ongoing enrollment of our clinical trials as a result of COVID-19. If COVID-19 continues to spread in the United States and elsewhere, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">further delays or difficulties in enrolling patients in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in hospital or research institution policies or local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals and clinics serving as our clinical trial sites and hospital and clinic staff supporting the conduct of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, or the closing of clinical trial sites due to the virus, the occurrence of which could affect the integrity of clinical trial data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption in global shipping affecting the transport of clinical trial materials, such as our HAVs and other supplies used in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption in supply of raw materials required to manufacture our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, or will withdraw from the clinical trial due to concerns over COVID-19, which could impact the results of the clinical trial, including by increasing the number of observed adverse events, or reducing the statistical power of the clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruptions or delays in preclinical studies, including delays in obtaining and housing experimental animals and in performing surgical interventions on animals to test our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in receiving feedback or responses from the FDA regarding regulatory submissions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in obtaining meetings with FDA reviewers regarding manufacturing and clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials or the manufacture of our product candidates, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes to the clinical endpoints, statistical analysis plan, or enrollment plans for ongoing clinical trials due to limitations in patients, resources, or sites, including due to COVID-19; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unanticipated deaths of clinical trial patients due to COVID-19 or due to lack of healthcare resources and follow-up as a consequence of COVID-19; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption or delays to our sourced discovery and clinical activities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and more may be authorized in the coming&#160;months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials for the products needed for our clinical trials, which could lead to delays in these trials. In addition, the competition for bioprocessing, quality control, manufacturing and logistics personnel due to ramping up of COVID-19 vaccine production in the North Carolina region may make it difficult to recruit and retain necessary employees. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with&#160;confidence. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Manufacturing Our Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The manufacture of our product candidates is complex, we have not manufactured commercial product, and we may encounter difficulties in production. If we or any third-party manufacturer encounter such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The process of manufacturing our HAVs is complex, highly regulated and subject to multiple risks. The manufacture of biologics such as our HAVs is susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which would harm our business, operating results and financial condition as well as our reputation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently manufacturing the 6 millimeter HAVs for our clinical trials at our manufacturing facility in Durham, North Carolina, where we have created a scalable modular manufacturing process, which we refer to as the LUNA200 system, that we believe will enable us to manufacture our HAVs, if approved, in commercial quantities in compliance with current good manufacturing practices (&#8220;cGMPs&#8221;). Our efforts to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">scale out our manufacturing operations may not succeed. Scaling out a biologic manufacturing process is a difficult task, as there are risks including, among others, cost overruns, process reproducibility, stability issues, lot consistency and timely availability of raw materials. Prior to the establishment of our internal manufacturing facility, we employed a contract manufacturer who produced our HAVs using a smaller-production system known as the AURA system. We have limited experience manufacturing our HAVs in-house with the LUNA200 system, and no experience manufacturing the volume that we anticipate will be required to supply all of our clinical trials or to achieve planned levels of commercial sales following marketing approval, if received. Additionally, our manufacturing process has evolved over time and we may not have the experience, resources, or facility capacity to handle adoption of future changes or expansion of capacity. The forecasts of demand we plan to use to determine order quantities and lead times for components from outside suppliers may be incorrect, and we may be unable to obtain such components when needed and at a reasonable cost. In addition, we may not be able to develop and implement efficient manufacturing capabilities and processes to manufacture our HAVs in sufficient volumes that also satisfy the legal, regulatory, quality, price, durability, engineering, design and production standards required to commercialize our HAVs successfully. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to produce sufficient quantities of our HAVs for our clinical trial needs or commercialization due to production system limitations, we may need to make additional changes to our manufacturing processes and procedures. Such changes to our manufacturing platform could trigger the need to conduct additional bridging studies between our prior clinical supply and that of any new manufacturing processes and procedures. Should we experience delays or be unable to produce sufficient quantities of our HAVs utilizing our current or a modified version of our manufacturing system, we expect that our development and commercialization efforts would be impaired as a result, which would likely materially adversely affect our business, prospects, operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our manufacturing facility is subject to ongoing regulation and periodic inspection by the FDA and other regulatory authorities to ensure compliance with cGMPs. Failure to follow and document adherence to such regulations or other regulatory requirements may (i)&#160;lead to significant delays in the availability of product for our clinical trials, (ii)&#160;result in the termination of or a hold being placed on one or more of our clinical trials, or (iii)&#160;delay or prevent filing or approval of marketing applications for our HAVs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To monitor compliance with applicable regulations, the FDA routinely conducts inspections of facilities and may identify potential deficiencies. For example, the FDA issues what are referred to as &#8220;Form 483s&#8221; that set forth observations and concerns that are identified during its inspections. Failure to satisfactorily address the concerns or potential deficiencies identified in a Form 483 could result in the issuance of a warning letter, which is a notice of the issues that the FDA believes to be significant regulatory violations requiring prompt corrective actions. Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could result in enforcement, remedial or punitive actions by the FDA or other regulatory authorities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Reliance on Third Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third parties to conduct and support our clinical trials, and those third parties may not perform satisfactorily, including by failing to adhere to regulatory requirements or our stated protocols or to meet deadlines for the completion of such trials.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not independently conduct clinical trials for our product candidates and instead rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to perform various functions, including implanting our HAVs and monitoring patients. The FDA and&#160;other regulatory authorities require us and these third parties to comply with GCP and, where applicable, good tissue practices (&#8220;GTP&#8221;) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of patients in clinical trials are protected; ultimately, we remain responsible for ensuring that each of our clinical trials </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is conducted in accordance with the general investigational plan and trial protocol. Failure by us or these third parties to do so could require us to enroll additional trial subjects beyond those we anticipate, could require us to modify our protocol, which may cause us to lose previously established Special Protocol Assessment (&#8220;SPA&#8221;) agreements with the FDA or similar agreements with other regulatory authorities concerning whether the design and size of our clinical trial adequately addresses scientific and regulatory requirements to support marketing approval, or could materially harm our ability to complete our clinical trials, including as a result of the need to remove trial sites and participants from the trial. We have in the past and may in the future need to terminate trial sites due to failure to conduct a trial in accordance with its protocol, applicable regulations, and generally accepted research standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The performance of the sites for our clinical trials may also be adversely affected by various other issues, including familiarity with the properties of our HAVs, intervention rates, insufficient training of personnel, variances in medical infrastructure, lack of familiarity with conducting clinical trials in accordance with international regulatory standards, communication difficulties or changes in local regulations. If these third parties do not successfully conduct our clinical trials in accordance with regulatory requirements or our stated protocols, carry out their contractual duties, or meet expected deadlines, we may not be able to&#160;obtain, or may be delayed in obtaining, marketing approvals for our product candidates and may not be able to, or may be delayed in our efforts to, successfully commercialize our products if approved by regulatory authorities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third-party suppliers, including sole source suppliers, to provide certain components for our product candidates. Any failure by a third-party supplier to supply these components for manufacture may delay or impair our ability to complete our clinical trials and to commercialize our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently rely, and expect to continue to rely, on third parties for the supply of certain components necessary for our product candidates, such as donor tissue, other biologically derived substances, the PGA polymer mesh and the bioreactor bags in which our HAVs are grown. Our suppliers for certain of these materials, including SeraCare Life Sciences, Inc. (&#8220;SeraCare&#8221;) for the supply of human plasma and Confluent Medical Technologies, Inc. (&#8220;Confluent&#8221;) for the supply of polymer mesh, are sole source suppliers. Failure of one or more of our suppliers, including these sole source suppliers, to deliver components necessary for the production of our HAVs in a timely and sufficient manner, whether due to shortages of such materials, difficulties in scaling up supply to satisfy our clinical trial and commercial needs, contamination, recall, the COVID-19 pandemic or otherwise, or to source or manufacture such components in accordance with cGMPs and cGTPs, as applicable, could delay our ability to complete our clinical trials, obtain marketing approval and commercialize our product candidates. Establishing additional or replacement suppliers for these components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. In addition, as part of the FDA&#8217;s approval of our product candidates, the FDA must review and approve the individual components of our production&#160;process, which includes raw materials, the manufacturing processes and facilities of our suppliers. Some of our current suppliers have not undergone this process nor have they had any components included in any product&#160;approved by the FDA. If our suppliers fail to comply with applicable regulations, and if we do not qualify alternate suppliers, the clinical development, marketing approval or commercialization of our product candidates could be delayed, thereby increasing our costs to complete clinical development and to obtain marketing approval and depriving us of potential product revenue. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We intend to rely on our strategic, global relationship with Fresenius Medical Care to undertake, or assist with, the development and commercialization of certain of our product candidates if we receive marketing approval from relevant regulatory authorities. Disruption of this arrangement could materially adversely affect our business, prospects, operating results and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the distribution agreement, Fresenius Medical Care has the exclusive right to sell and distribute the distribution product in the field outside of the United States. In addition, under the terms of the distribution agreement, Fresenius Medical Care will collaborate with Humacyte in its commercialization of the distribution product in the field in the United States, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic&#160;analyses. As a result of our arrangement with Fresenius Medical Care, we expect to be reliant on Fresenius Medical Care to undertake or assist with the development and commercialization, as well as, in some cases, obtaining </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and maintaining regulatory approval, of the distribution product in the field and for Fresenius Medical Care to do so in a manner consistent with applicable law and regulatory requirements outside of the United&#160;States. If Fresenius Medical Care otherwise fails to undertake or assist with the development or commercialization, or obtaining or maintaining regulatory approvals, of the distribution product in accordance with the terms of the distribution agreement, our business, prospects, operating results and financial condition would be adversely affected, perhaps materially. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fresenius Medical Care also maintains certain discretionary termination rights on a country-by-country basis with respect to any country outside of the United States under the distribution agreement, as discussed in more detail in the section of this prospectus titled &#8220;Business&#8201;&#8212;&#8201;Distribution&#8201;&#8212;&#8201;Distribution Agreement with Fresenius Medical Care.&#8221; If the distribution agreement is terminated, we may not be able to secure an alternative distributor in the applicable country on a timely basis or at all, in which case our&#160;ability to generate revenues from the distribution product in such country would be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, if Fresenius Medical Care fails to undertake or assist with the development or commercialization, or obtaining or maintaining regulatory approval, as applicable, of the distribution product in a manner consistent with applicable law and regulatory requirements, patient access to, and demand for, the distribution product could be reduced, our reputation could be damaged, and, under certain circumstances, we could be exposed to potential liability. Furthermore, while Fresenius Medical Care has certain commercialization diligence obligations, Fresenius Medical Care is not restricted from offering its own products and services or the products and services of other companies that compete with the distribution product, and may not undertake or assist with the development or commercialization of the distribution product effectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Position and Need for Additional Funding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have never generated product revenue and have incurred significant losses to date. We expect to continue to incur losses for the foreseeable future and may never generate product revenue or be profitable.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since inception, we have generated no product revenue, and prior to receipt of marketing approval from regulatory authorities, we will be unable to do so. We incurred net losses of $66.5&#160;million and $85.4&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively, and $69.1&#160;million and $50.3&#160;million for the nine&#160;months ended September&#160;30, 2021 and 2020, respectively. As of December&#160;31, 2020 and September 30, 2021, we had an accumulated deficit of $388.1&#160;million and $457.2&#160;million, respectively. Up to the date of the consummation of the Business Combination, we financed our operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through grants from governmental agencies. We have devoted substantially all of our financial resources and efforts to research and development,&#160;including preclinical studies and clinical trials and development of manufacturing technology, and we anticipate&#160;that our expenses will continue to increase over the next several&#160;years as we continue these activities. Our V005 and V007 trials are currently enrolling, and we currently intend to submit a BLA to the FDA relating to&#160;vascular trauma in 2022 and a supplement for AV access for hemodialysis in 2022. We also intend to continue&#160;scaling out our manufacturing facility to satisfy potential demand if the FDA approves our BLA, advancing preclinical and clinical development of additional clinical applications for our HAVs and funding our operations. Accordingly, we expect to continue to incur substantial operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To become and remain profitable, we must succeed in obtaining marketing approval for our HAVs in the United States, in commercializing our HAVs, and in developing and commercializing additional product candidates that generate significant revenue. We may never succeed in these activities and, even if we do, may never generate revenue that is sufficient to achieve profitability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability. Our failure to become and remain profitable would depress the value of our company and could impair our ability to maintain our research and development efforts, expand our business, diversify our product offerings or even continue our operations. A decline in the value of Humacyte could also cause you to lose all or part of your investment in our securities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to use our net operating loss and tax credit carryforwards to offset future taxable income may be subject to certain limitations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we had net operating loss carryforwards for federal and state tax purposes of approximately $232.7&#160;million and $232.6&#160;million, respectively, which begin to expire in 2025. In addition, we had tax credit carryforwards for federal and state tax purposes of approximately $10.7&#160;million and $15.1&#160;million, respectively, as of December&#160;31, 2020, which begin to expire in 2021. The future utilization of net operating loss and tax credit carryforwards may be limited due to changes in ownership. In general, if we experience a greater than 50% aggregate change in ownership of certain significant stockholders or groups over a three-year period (which constitutes an ownership change under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), utilization of our pre-change net operating loss carryforwards is subject to an annual limitation under Section&#160;382 of the Code (and similar state laws). The annual limitation generally is determined by multiplying the value of our stock at the time of such ownership change&#160;(subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the pre-change net operating loss carryforwards before utilization and may be substantial. In&#160;the past we may have experienced, and in the future may experience, ownership changes as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset United States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may need to raise additional funding, which may not be available on acceptable terms, or at all, and any failure to obtain capital when needed may force us to delay, limit or terminate our product development or commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to incur significant expenses in connection with our ongoing activities as we seek to (i)&#160;scale out our manufacturing facility to satisfy potential demand if our HAVs receive marketing approval in the United States, (ii)&#160;continue our preclinical and clinical development efforts, including the ongoing clinical trials, and (iii)&#160;obtain marketing approval for our 6 millimeter HAV, and, if marketing approval is obtained, to commercialize our HAVs for one or more approved indications. We will need additional funding in connection with these activities. Our future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the progress and results of our clinical trials and interpretation of those results by the FDA and other regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost, timing and outcome of regulatory review of our product candidates, particularly for approval of our HAVs in the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our additional product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of our future commercialization activities, including product manufacturing, marketing and distribution for our HAVs if approved by the FDA, and any other product candidate for which we receive marketing approval in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount and timing of revenues, if any, that we receive from commercial sales of any product candidates for which we receive marketing approval; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adequate capital may not be available to us when needed or on acceptable terms. If we are unable to raise capital, we could be forced to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition. As of December&#160;31, 2020 and September&#160;30, 2021, we had $39.9&#160;million and $240.4&#160;million, respectively, in cash and cash equivalents. Based upon our current operating plan,&#160;we believe that our cash and cash equivalents will be sufficient to fund our operations, including clinical trial expenses and capital expenditure requirements, for at least 12&#160;months from the date of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pursuant to the terms of our outstanding indebtedness, we may be limited in its ability to incur future debt.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, Legacy Humacyte entered into a Loan and Security Agreement (the &#8220;Loan&#160;Agreement&#8221;) with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P., which provides a term loan facility of up to $50.0&#160;million with a maturity date of March&#160;1, 2025. We became a co-borrower under the Loan Agreement in connection with the Business Combination. The obligations of Humacyte and Legacy Humacyte (now known as Humacyte Global, Inc.) under the Loan Agreement are secured by substantially all of their assets, except for their intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Loan Agreement, we are limited in our ability to incur additional indebtedness. In addition, a failure to comply with the covenants under the Loan Agreement could result in an event of default and an acceleration of amounts due. If an event of default occurs that is not waived&#160;by the lenders, and the lenders accelerate any amounts due, we may not be able to make accelerated payments, and the lenders could seek to enforce their security interests in the collateral securing such indebtedness,&#160;which could have a material adverse effect on our business and results of operations. Our payment obligations under the Loan Agreement reduce cash available to fund working capital, capital expenditures, research and development and other corporate purposes, and limit our ability to obtain additional financing for working capital, capital expenditures, expansion plans and other investments, which may in turn limit our ability to implement our business strategy, heighten our vulnerability to downturns in our business, the industry, or in the general economy, limit our flexibility in planning for, or reacting to, changes in our business and the industry and prevent us from taking advantage of business opportunities as they arise. If market rates increase, we will have to pay additional interest on this indebtedness, which would further reduce cash available for our other business needs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that our business will generate sufficient cash flow from operations or that future financing will be available to us in amounts sufficient to enable us to make required and timely payments on our indebtedness, or to fund our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">To date, we have not requested or obtained marketing approval for, or commercialized, any of our product candidates, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a development-stage company. Our operations to date, with respect to the development of our product candidates, have been limited to organizing and staffing our company, business planning, raising capital, identifying markets for our product candidates, undertaking preclinical studies and clinical trials of our product candidates for various potential indications and establishing research and development, manufacturing and distributing collaborations. We have not yet demonstrated the ability to obtain marketing approval for a product, to manufacture an approved product at commercial scale or to successfully commercialize an approved product. Consequently, any predictions you make about our financial prospects may not be as accurate as they could be if we had received marketing approval and begun commercializing a product. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not obtain marketing approval from the FDA for any of our product candidates even if we successfully complete our clinical trials, which failure would materially harm our business, prospects, operating results and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to commercialization, biologics, like our HAVs, require the submission of a BLA to, and&#160;approval of the BLA by, the FDA. A BLA must be supported by extensive preclinical and clinical data, as well as extensive information regarding chemistry, manufacturing and controls (&#8220;CMC&#8221;), sufficient to demonstrate the safety, purity, potency and effectiveness of the applicable product candidate to the satisfaction of the FDA. We have never submitted a BLA for approval or otherwise obtained FDA approval for any of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The BLA approval process is expensive and uncertain, it may take several&#160;years to complete, and we may not be successful in obtaining such approval. The FDA has substantial discretion in the approval&#160;process. The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">target and the regulations applicable to any particular product candidate. The FDA could delay, limit or deny approval of our product candidates for many reasons, including because it: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may not deem the product candidate to be adequately safe or effective; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may not find the data from preclinical studies, clinical trials or CMC data sufficient to support approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may not approve the manufacturing processes or facilities associated with the product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may conclude that the long-term integrity of the product candidate for which approval is being sought has not been sufficiently demonstrated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may change approval policies or adopt new regulations; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may not accept a submission due to, among other reasons, the content or formatting of the submission. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In some cases, the FDA may agree to an SPA for a clinical trial, when it determines that the trial is adequately designed to provide necessary data to support a license application. Even in such cases, however, the FDA may subsequently abandon the SPA if a substantial scientific issue essential to determining the safety or effectiveness of the product candidate has been identified after the testing has begun. In addition, if a company alters the protocol for a trial, the SPA may no longer apply. Further, the results of pivotal clinical trials are always subject to thorough FDA review. Even highly significant clinical trial results are no guarantee of approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to submit a BLA to the FDA relating to vascular trauma in 2022 and a supplement for AV access in hemodialysis in 2022 based on the results of our V005 and V007 trials. The FDA may decline to approve our 6 millimeter HAV on the basis of these or other trial results, or for other reasons. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we obtain and maintain approval for our HAVs from the FDA, we may never obtain approval for our HAVs outside of the United States, where the regulatory process is also complex and subject to significant uncertainty. Failure to do so would limit our market opportunities and adversely affect our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if we receive FDA approval to market any biologic in the United States, we must comply with the numerous and varying regulatory and compliance related requirements of other countries, including the submission of extensive preclinical and clinical data, manufacturing and quality information regarding the process and facility, scientific data characterizing the relevant product candidate and other supporting data in order to establish safety and effectiveness. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might&#160;differ from that required to obtain FDA approval. The marketing approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all indications requested and that such approval may be subject to limitations on the indicated uses for which the product candidate may be marketed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may in the future seek orphan drug designation for the use of our HAVs to treat congenital pediatric heart defects. We may be unable to obtain such designation or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or more in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease, as well as the same drug or biologic for a different indication or disease. The FDA can also approve the same drug or biologic for the same indication or disease if the subsequent drug or biologic demonstrates clinical superiority. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we seek &#8220;rolling review&#8221; or priority review, the review time for BLAs for our product candidates may be longer and more expensive than for other products because of the novelty and complexity of our product candidates, which would delay our ability to begin commercialization and earn product revenues.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The marketing approval process for novel product candidates such as ours may take longer to complete and be more expensive than the process for other, better known or extensively studied pharmaceutical or other product candidates. We may be eligible for a &#8220;rolling review&#8221; of a BLA, which means we may submit completed modules of a BLA rather than waiting until every module of the BLA is completed before submitting the full BLA for FDA review. Such &#8220;rolling review&#8221; is common for indications that are part of one of FDA&#8217;s expedited programs, such as our 6 millimeter HAV, which has received Fast Track and RMAT designations for AV access in hemodialysis. The FDA may also designate one or more of our product candidates for priority review after we submit a BLA. Under priority review, the FDA&#8217;s goal is to review an application within six&#160;months of the 60-day filing date, compared to ten&#160;months for a standard review. Even if we are able to utilize a &#8220;rolling review&#8221; and/or the FDA designates one or more of our product candidates for priority review, it may not lead to a shorter review period. The FDA could also decide to consult an advisory committee as part of our BLA review process, which often leads to a longer review time. We are not permitted to commercialize our product candidates in the United States until they have been approved by the FDA, and if we experience a lengthier review period than expected, our ability to generate product revenues would be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Inadequate funding for the FDA and other government agencies, including from government shut downs, global health concerns or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, policy changes, and the risk of slowdowns and shutdowns due to the COVID-19 pandemic. Average review times at the FDA have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years the U.S. government has shut down several times and certain&#160;regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. As of June&#160;23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">line with its user fee performance goals and conducting mission critical domestic inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to maintain this pace and delays or setbacks are possible in the future, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. On March&#160;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials which the FDA continues to&#160;update. As of July&#160;2020, FDA began utilizing a risk-based prioritization system to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#8217; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments. In August&#160;2020, FDA published guidance outlining its approach to facility inspections during the COVID-19 pandemic.&#160;According to the guidance, FDA intends to, on a case-by-case basis, conduct only mission critical inspections, or, where possible to do so safely, resume prioritized domestic inspections, which generally include pre-approval inspections. FDA plans to use similar criteria for both domestic and foreign inspections to determine whether an inspection is mission critical. According to the guidance, should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA intends to defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Additionally, regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we receive marketing approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to significant penalties if we fail to comply with applicable regulatory requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we obtain marketing approval for any of our product candidates, the approved product will be subject to ongoing regulatory requirements from the FDA and, if applicable, non-U.S. regulatory authorities. Any marketing approval that we receive for our product candidates may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up trials to monitor the safety and efficacy of the product. The FDA could also approve our product candidates with a REMS, which could include significant restrictions on distribution and/or use of our products. In addition, if the FDA and non-U.S. regulatory authorities approve any of our product candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to the manufacturing, labelling, packaging, AE reporting, storage, advertising, distribution, promotion and recordkeeping for our products. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and, if relevant, other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issuance of warning letters or untitled letters by regulatory authorities asserting that we are in violation of the law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">imposition of injunctions or significant civil monetary penalties or pursuit by regulatory authorities of civil or criminal prosecutions and fines against us or our responsible officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspension or withdrawal of marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspension of any ongoing clinical trials or refusal by regulatory authorities to approve pending marketing applications or supplements to approved applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seizure of products or refusal to allow us to enter into supply contracts, including government contracts, or to import or export products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voluntary or mandatory product recalls and publicity requirements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on operations, including marketing efforts, or restrictions that mandate costly new manufacturing requirements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could reduce market acceptance of any or our product candidates that had&#160;received marketing approval, substantially reduce our revenue, increase the costs of operating our business, and cause us significant reputational damage, among other consequences. If we ultimately receive approval for any product candidates in jurisdictions outside the U.S., we expect to be subject to similar ongoing regulatory oversight by the relevant foreign regulatory authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our products may be subject to product recalls that could harm our reputation and could materially and adversely affect our business, financial condition, operating results, cash flows and prospects. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, the FDA restricts our ability to promote a product for uses that are not approved by the FDA. The misuse or off-label use of our product may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory authorities if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. We may also face risks in other non-U.S. jurisdictions from product recalls and advertising/promotion rules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We could also face product liability suits or regulatory delays due to defects in our products, which could be expensive and time-consuming and result in substantial damages payable by us and increases in our insurance rates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Designation of our product candidates for expedited programs, such as Fast Track designation, Breakthrough Therapy Designation, or RMAT designation, or accelerated approval by the FDA, or priority designation by the Department of Defense, may not lead to a faster development or regulatory review or approval process, and even if granted, will not increase the likelihood that our product candidates will receive marketing approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2014, the FDA granted Fast Track designation for our 6 millimeter HAV for use in the creation of AV access for hemodialysis, and, in 2017, the FDA granted RMAT designation for our 6 millimeter HAV for the creation of vascular access for performing hemodialysis. We have not received designations pursuant to any of the FDA&#8217;s expedited programs for vascular trauma, peripheral arterial disease or our other indications, although we may in the future seek such designations if such product candidates meet the criteria for that designation. As a result, even if we submit a BLA for vascular repair, reconstruction and replacement, including in AV access in hemodialysis, our Fast Track and RMAT designations, and their attendant benefits, may not apply to this broader requested indication. In addition, even with one or more of these designations, we may not experience a faster development process, or faster review or approval, for our product candidates compared to product candidates that are not part of the expedited programs. Further, the FDA may withdraw a designation if it believes that the designation is no longer supported by data&#160;from our clinical development program. In addition, a product candidate may no longer demonstrate a potential to address unmet medical need if, for example, a new product is approved that addresses the same need, which could lead to loss of a designation. The loss of a designation under an expedited program, including a Fast Track designation, Breakthrough Therapy Designation, or RMAT designation, could significantly increase the costs of development and length of time required before we could seek marketing approval of such a product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may seek accelerated approval for our HAV relating to vascular trauma. A product candidate may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of accelerated approval, the FDA may require that a sponsor of a product receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials post-approval. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and receiving accelerated approval does not provide assurance of ultimate full FDA approval. Accelerated approval may also be withdrawn if, among other things, a confirmatory trial required to verify the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in 2018, our HAV product candidate was assigned a priority designation by the Secretary of Defense under Public Law 115-92. Similar to the designations described above that FDA may grant, a priority designation by the Department of Defense does not change the standards for approval but may expedite the development or approval process. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our industry is highly regulated, and changes in or revisions to laws and regulations that make gaining coverage of and adequate reimbursement for our product candidates more difficult or subject to different criteria and standards may adversely impact our business, prospects, operating results and financial condition. In the United States, there have been and we expect there will continue to be a number of legislative,&#160;regulatory and other changes to the healthcare system to contain or reduce healthcare costs that may adversely affect our ability to set a price we believe is fair for our product candidates, our ability to generate revenues and achieve or maintain profitability, and the availability of capital. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;), enacted in 2010 and amended by the Health Care and Education Reconciliation Act, contains a number of provisions that were intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies for fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional health policy reforms. The Bipartisan Budget Act of 2018, among other things, amended the ACA to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole,&#8221; in part by requiring greater discounts from manufacturers. Various members of Congress have expressed a desire to repeal all or portions of the ACA, and in December&#160;2017, portions of the ACA dealing with the individual mandate insurance requirement were effectively repealed by the Tax Cuts and Jobs Act of 2017. In June&#160;2021 the United States Supreme Court held that the individual plaintiffs and states lacked standing to challenge the constitutionality of the ACA. On February&#160;10, 2021, the Biden administration withdrew the federal government&#8217;s support for overturning the ACA. Further, on January&#160;28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which ran until August&#160;15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.Additionally, in December&#160;2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. In addition, CMS published a final rule that gave states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required&#160;under the ACA for plans sold through such marketplaces. At this time, it remains unclear whether there will be further changes made to the ACA. The ACA, as currently enacted or as amended in the future, may adversely affect our business and operating results, and we do not know how future federal or state legislative or administrative changes relating to healthcare reform will affect our business. Other legislative changes that have been adopted since enactment of the ACA could also affect potential pricing and utilization of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Secretary of Health and Human Services, various members of Congress and CMS have made statements and issued proposals regarding containment of drug prices through various means, including enabling CMS to negotiate U.S. drug pricing to align with foreign drug pricing, pricing transparency measures, reform of drug rebate programs, and conditioning coverage and reimbursement of certain drugs </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">upon the prior failure or inadequacy of less expensive therapies, sometimes referred to as &#8220;step therapy.&#8221; Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies. At the federal level, on March&#160;11, 2021, President Biden signed the American Rescue Plan&#160;Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a&#160;drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. for drugs. In addition, at the state level, individual states have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CMS altered the fiscal year 2019 and 2018 reimbursement formula on specified covered outpatient drugs (&#8220;SCODs&#8221;). A SCOD drug product may also be a covered outpatient drug under the 340B program, which allows 340B-participating hospitals to purchase the drug product at the 340B discounted rate and, when prescribing it to a Medicare patient, be reimbursed at the Medicare rate. Under the prior Medicare reimbursement rate, this created a significant, positive gap for 340B-participating health care facilities. CMS&#8217;s change in the Medicare reimbursement rate for SCODs significantly impacted, or eliminated, the positive gap for 340B-participating health care facilities. On December&#160;27, 2018, the District Court for the District of Columbia invalidated the formula change under Medicare and the court ruled this change was not an &#8220;adjustment&#8221; that was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, on July&#160;31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September&#160;14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, before the full court), but was denied on October&#160;16, 2020. On July&#160;2, 2021, the Supreme Court&#160;agreed to hear the case. It is unlikely the Medicare rate litigation will impact 340B pricing for our approved products in the future, but it possible it could affect covered hospitals who might purchase our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA also released a final rule on September&#160;24, 2020, which went into effect on November&#160;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Additionally, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The 2020 rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to a court order, HHS subsequently delayed the effective date for aspects of the rule, including those relating to pharmacy benefit managers, until 2023. Although a number of these, and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ultimate content, timing, or effect of any healthcare reform legislation or executive order or the impact that the resulting changes may have on us is uncertain, but we expect there will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of health care. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with healthcare regulations, we could face substantial penalties and our business, prospects, operating results and financial condition could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business even though we do not and will not control referrals of healthcare services. We could also be subject to patient privacy regulation by both the U.S. Government and the states in which we conduct our business. Our employees, independent contractors, consultants,&#160;commercial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. The regulations that may affect our ability to operate include, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs, even if the person does not have actual knowledge of the statute or specific intent to violate it; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the U.S. Government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of items or services reimbursable by a federal or state governmental program; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act and its implementing regulations, which require applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the State Children&#8217;s Health Insurance Program to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;HIPAA&#8221;), which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participating in federal health care programs and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment, exclusion, or restructuring of our operations could adversely affect our ability to operate our business, prospects, operating results and financial condition. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy and fraud and abuse laws may prove costly. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business and operations, including our development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or third parties on which we rely, including our CROs or other contractors or consultants.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our internal computer systems (including our LUNA200 manufacturing system) and those of third parties on which we rely, including our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could have a material adverse effect on our business operations, including a material disruption of our development program. Unauthorized disclosure of sensitive or confidential patient or employee data, including&#160;personally identifiable information, whether through breach of computer systems, systems failure, employee&#160;negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have previously been, and expect to remain, the target of cyber-attacks. As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks, such as ransomware attacks, and attempts to gain unauthorized access to computer systems (including our LUNA200 manufacturing system) and networks, may increase in frequency and sophistication. These incidents pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. While the effect of these incidents has not historically been material to our results of operations, financial condition or prospects, cyber threats are persistent and constantly evolving. Such threats have increased in frequency, scope and potential impact in recent&#160;years, which increase the difficulty of detecting and successfully defending against them. As cyber threats continue to evolve, we may be required to incur additional expenses in order to enhance our protective measures or to remediate any information security vulnerability. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other data that is stored on their systems. Any cyber-attack or destruction or loss of data could have a material adverse effect on our business and prospects. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or destruction or loss of data and may incur significant additional expense to implement further data protection measures. It is also possible that unauthorized access to data may be obtained through inadequate use of security controls by our suppliers or other vendors. While we are not currently aware of any impact that the SolarWinds supply chain attack had on our business, this is a recent event, and the scope of the attack is yet unknown. Therefore, there is residual risk that we may experience a security breach arising from the SolarWinds supply chain attack. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although we have general liability insurance coverage, our insurance may not cover all claims, continue to be available on reasonable terms or be sufficient in amount to cover one or more large claims; additionally, the insurer may disclaim coverage as to any claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, prospects, operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines and penalties or incur costs that could harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. In the event of contamination or injury resulting from our use or production of hazardous materials, we could be held liable for any resulting damages even if we contract with a third party for their disposal, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties resulting from contamination or injury from our use or production of hazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use or production of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous materials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may be required to incur substantial costs to comply with future environmental, health and safety laws and regulations. Compliance with such laws and regulations may divert resources away from our research, development and manufacturing efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and adverse publicity and could negatively affect our operating results and business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state privacy and health information privacy laws and federal and state consumer protection laws (</font><font style="font-style:italic;letter-spacing:0.2pt;">e.g.</font><font style="letter-spacing:0.2pt;">, Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to civil or criminal penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">International data protection laws, including Regulation&#160;2016/679, known as the General Data&#160;Protection Regulation (&#8220;GDPR&#8221;), may also apply to health-related and other personal information&#160;obtained outside of the United States. The GDPR will increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU (which also includes the European Economic Area, or &#8220;EEA&#8221;) data protection rules. Further, the&#160;United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created more uncertainty with regard to data protection regulation in the United Kingdom (the &#8220;UK&#8221;). The UK retained the GDPR in UK law, which sits alongside the amended version of the Data Protection Act 2018. The EU adopted an adequacy decision so data can be transferred from the EU to the UK. Additionally, there are no new requirements for transfer from the UK to the EU. However, going forward, the EU and UK&#8217;s data protection rules could diverge and data transfers may not be possible and/or new arrangements may need to be put in place. In particular, it is unclear to what extent the UK regime will begin diverging from the GDPR and how data transfers to and from the UK will be regulated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, California recently enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA became effective on January&#160;1, 2020, but the California Consumer Rights Act (&#8220;CPRA&#8221;) was recently enacted to strengthen elements of the CCPA effective January&#160;1, 2023. In addition, there are a number of other states that have considered similar privacy proposals, with states like Virginia and Colorado enacting their own privacy laws (also scheduled to come into effect in January&#160;1, 2023 and July&#160;1, 2023, respectively). These privacy laws may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We or the third parties upon which we depend may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Natural disasters such as hurricanes could severely disrupt our operations and have a material adverse effect on our business, prospects, operating results and financial condition. In addition, flooding, lightning strikes, meteor strikes, and polar vortices could affect our building operations. If a natural disaster, power outage or other unforeseen event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our in-house manufacturing facility, or that otherwise significantly disrupted our operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently may prove inadequate in the event of a natural disaster or similar event. We may incur substantial expenses as a result of any natural disaster, which could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are subject to anti-corruption and a variety of other laws governing our international operations. If we fail to comply with these laws, we could be subject to, among other things, civil or criminal penalties, other sanctions and remedial measures, and reputational damage, which could adversely affect our business, prospects, operating results and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the U.K. Bribery Act and other anti-corruption laws. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We are conducting certain of our other trials at a number of trial sites around the world. Certain of these jurisdictions pose a risk of potential FCPA violations, and we have relationships with third parties, including government-affiliated hospitals and universities, whose actions could&#160;potentially subject us to liability under the FCPA or local anti-corruption laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. Department of Commerce&#8217;s Bureau of Industry and Security, the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control, and various non-U.S. government entities, including applicable economic sanctions on countries and persons, customs requirements, currency exchange regulations and transfer pricing regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we fail to comply with applicable anti-corruption laws and other legal requirements, we may become subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, including the loss of export or import privileges and debarment, and face substantial legal expenses. Likewise, even an investigation by U.S. or foreign authorities of potential violations of such laws could damage our reputation. In either case, our business, prospects, operating results and financial condition could be adversely affected. Under certain circumstances, we could also be held liable for the activities of our employees, contractors, and partners that violate anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. Even allegations of such violations could potentially damage our reputation and harm our business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to successfully commercialize our products may be impaired if we are unable to obtain and maintain effective intellectual property rights for our proprietary scientific technology platform and product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary scientific technology platform and products. We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates that we and/or our licensors view as important to our business. This process is expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we and/or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents or enforce the patents, covering technology or products that we license from third parties. Our existing patents and any future patents and the existing and any future licenses to third-party patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unresolved. In recent&#160;years, patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Additionally, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or licensed patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. We, or our licensors, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent&#160;position. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of future product candidates, patents protecting such candidates might&#160;expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The patent protection we obtain for our product candidates may not be sufficient enough to provide us with any competitive advantage or our owned or licensed patents may be challenged.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In some instances, agreements through which we license patent rights may not give us control over patent prosecution or maintenance, so that we may not be able to control which claims or arguments are presented, how claims are amended, and may not be able to secure, maintain, or successfully enforce necessary or desirable patent protection from those patent rights. We have not had and do not have primary control over patent prosecution and maintenance for certain of the patents and patent applications we license and therefore cannot guarantee that these patents and applications will be prosecuted or maintained in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents. Moreover, some of our in-licensed patents and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">patent applications are, and our future owned and licensed patents may be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in any future patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is possible that defects of form in the preparation or filing of our owned or licensed patents or&#160;patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments or extensions. If we or our partners, collaborators, licensees, or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees, or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our owned or licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, we cannot be certain that parties from whom we do or may license or purchase&#160;patent rights were the first to make relevant claimed inventions, or were the first to file for patent protection for them. If third parties have filed prior patent applications on inventions claimed in our owned or licensed patents or applications that were filed on or before March&#160;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of such owned or licensed patent applications. If third parties have filed such prior applications after March&#160;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our owned or licensed invention was derived from theirs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our owned and licensed patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all of the potentially relevant prior art relating to our owned or licensed patents and patent applications has been found. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior&#160;art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or to other patent offices around the world. Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation&#160;proceedings, </font><font style="font-style:italic;letter-spacing:0.2pt;">ex parte</font><font style="letter-spacing:0.2pt;"> reexaminations, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, supplemental examinations, or interference proceedings or challenges in district court, in the United States or in various foreign patent offices, including both national and regional, challenging patents or patent applications in which we have rights, including patents on&#160;which we rely to protect our business. An adverse determination in any such challenges may result in loss of the patent or in patent or patent application claims being narrowed, invalidated or held unenforceable, in&#160;whole or in part, or in denial of the patent application or loss or reduction in the scope of one or more claims of the patent or patent application, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our&#160;technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pending and future patent applications may not result in patents being issued that protect our business, in whole or in part, or which effectively prevent others from commercializing competitive products. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Competitors may also be able to design around our owned or licensed patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or licensed patents or narrow the scope of our patent protection. In addition, the laws of&#160;foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the human body more than United States law does. If these developments were to occur, they could have a material adverse effect on our ability to generate revenue. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Issued patents that we have or may obtain or license may not provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our owned or licensed patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our owned or licensed patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Competitors may infringe, misappropriate or violate our owned or licensed patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly and refuse to stop the other&#160;party from using the technology at issue on the grounds that our owned or licensed patents do not cover such technology. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we do not know how much protection, if any, will be given to our owned or licensed patents if we attempt to enforce them and they are challenged in court. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Inequitable conduct is frequently raised as a defense during intellectual property litigation. It is&#160;believed that all parties involved in the prosecution of our patent applications have complied with their duties of disclosure in the course of prosecuting our patent applications; however, it is possible that legal claims to the contrary could be asserted if we were engaged in intellectual property litigation, and the results of any&#160;such legal claims are uncertain due to the inherent uncertainty of litigation. If a court determines that any&#160;party involved in the prosecution of our owned or licensed patents failed to comply with its duty of candor, the subject patent could be held to be unenforceable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Intellectual property litigation or other legal proceedings may cause us to incur significant expenses and may also absorb significant management time. Uncertainties resulting from our participation in patent litigation or other proceedings could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business, prospects, operating results and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Third parties may assert infringement, misappropriation or other claims against us, or other parties we have agreed to indemnify, based on existing third-party patents or patents that may be granted in the future as well as other intellectual property rights. There may be existing third-party patents or patent applications </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">covering aspects of our technology. Furthermore, because patent applications are published sometime after filing, and because applications can take several&#160;years to issue, there may be additional currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of the Combined Company&#8217;s common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted against us regardless of our perception of the merits of the case. If we are found to infringe upon, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and commercializing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the implicated technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, which could be significant, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement, misappropriation or that we otherwise violated intellectual property rights could prevent us from commercializing our product candidates or force us to cease some or all of our business operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a party to intellectual property license agreements with third parties. For example, we have licenses with each of Duke University and Yale University, for patents associated with our proprietary technology, and may enter into additional license agreements in the future. Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment, milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able to develop and market any product or use any platform technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or&#160;elimination of licensed rights under these agreements, we may have to negotiate new or reinstated licenses with less favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. Accordingly, disputes may arise between us and our licensor, our licensor and its licensors, regarding intellectual property subject to a license agreement, including those relating to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope of rights, if any, granted under the license agreement and other interpretation-related issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether our licensor or its licensor had the right to grant the license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our involvement in the prosecution of the licensed patents and our licensors&#8217; overall patent enforcement strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amounts of royalties, milestones or other payments due under the license agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable to successfully develop and commercialize the affected product candidates. If we or any such licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer. Any disputes with our licensors or any termination of the licenses on which we depend could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be successful in obtaining necessary intellectual property rights to product candidates for our development pipeline through acquisitions and in-licenses.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we intend to develop product candidates through our own internal research, we may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates. However, we may be unable to acquire or in-license intellectual property rights relating to, or necessary for, any such product candidates from third parties on commercially reasonable terms or at all. In that event, we may be unable to develop or commercialize such product candidates. We may also be unable to identify additional, future product candidates that we believe are an appropriate strategic fit for our company and intellectual property relating to, or necessary for, such product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The in-licensing and acquisition of third-party intellectual property is a competitive area, and a&#160;number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be unable to protect the confidentiality of our trade secrets, particularly in light of our reliance on third parties, which increases the possibility that such trade secrets will be disclosed or misappropriated, thus harming our business and competitive position.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to our patented technology and products, we rely upon trade secrets, including unpatented know-how, technology and other proprietary information to develop and maintain our competitive position, particularly with respect to our manufacturing process. We seek to protect our trade secrets, in part,&#160;through confidentiality agreements with our employees, collaborators and consultants. We seek to have agreements with our employees and selected consultants that obligate them to assign any inventions created during their tenure with us. However, we may not obtain these agreements in all circumstances and the assignment of intellectual property under such agreements may not be self-executing. If the employees, collaborators or consultants that are parties to these agreements breach or violate their respective terms, we may not have adequate remedies for any such breach or violation. Our trade secrets could also be misappropriated by our competitors. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, time-consuming and potentially distracting, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent such a party from using that technology or information to compete with us. If our trade secrets are disclosed to or misappropriated or independently developed by a third&#160;party, it would harm our ability to protect our rights and could materially harm our business and competitive position. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may employ individuals or engage consultants that previously worked with other organizations, including our competitors or potential competitors. Although we seek to ensure that such persons do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or they, or both, have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third party. Litigation may be necessary to defend against these claims. If we fail in defending any such claims or settling those claims, we may lose valuable intellectual property rights or personnel in addition to paying monetary damages or a settlement. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent terms may be inadequate to protect our competitive position on our HAVs or our other product candidates for an adequate amount of time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our HAVs are obtained, once the patent life has expired, we may face competition, including from other competing technologies. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to protect our intellectual property rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in countries outside the United States, or from selling or importing products made using our inventions in and into or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products, to the extent approved, and our owned or licensed patents or other intellectual property rights may not be effective or sufficient to prevent them from doing so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual&#160;property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our owned or licensed patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our owned or licensed patents at risk of being invalidated or interpreted narrowly and our patent&#160;applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Some of our internal intellectual property and most of our in-licensed intellectual property has been generated under U.S. Government grants and contracts that trigger certain obligations and U.S. Government rights and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some of our internal intellectual property and most of our in-licensed intellectual property has been generated under U.S. Government grants and contracts that trigger certain obligations and U.S. Government rights under federal statutes and regulations, including the Bayh-Dole Act of 1980 and the Federal&#160;Technology Transfer Act of 1986. For example, the U.S. Government has a non-exclusive, non-transferable, irrevocable worldwide license to inventions conceived or first actually reduced to practice in the performance of a U.S. Government agreement. In addition, the U.S. Government has certain &#8220;march-in&#8221; rights to require us to grant exclusive, partially exclusive, or non-exclusive licenses to such inventions for the benefit of a third party if the U.S. Government determines that: (i)&#160;action is necessary to alleviate health or safety needs not reasonably met by us, our assignees, our licensees, or, in some cases, our licensors, (ii)&#160;action is necessary due to noncompliance with a U.S.-based manufacturing requirement applicable to exclusive licenses, (iii)&#160;action is necessary to meet requirements for public use specified by federal regulations and such requirements are not reasonably satisfied by us, our assignees, our licensees, and, in some cases, our licensors, and (iv)&#160;with respect to inventions made under funding agreements, adequate steps have not been taken to achieve practical application of the invention. The U.S. Government also has the right to take title to these inventions if we, or the applicable licensor, fails to disclose, elect title to, file or prosecute a patent application for, or defend or obtain a patent covering such inventions within time limits specified in particular funding agreements. The U.S. Government also has varying rights to use and disclose information, including copyrighted works, generated or delivered under a U.S. Government agreement depending on the terms of the agreement and the nature of the information. Intellectual property generated under a U.S. Government agreement is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, when inventions that are conceived or first actually reduced to practice under a U.S. Government funding agreement are exclusively licensed, products embodying or produced through the use of such inventions must be manufactured substantially in the United States. This U.S.-based manufacturing requirement may limit our ability to contract with non-U.S. companies to produce a covered product, although this requirement can be waived in certain circumstances. To the extent that any of our licensors&#8217; current or future intellectual property is generated in the&#160;performance of U.S. Government grants or contracts, these requirements may apply to such intellectual property. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may&#160;receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition&#160;based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights do not necessarily address all potential threats.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we own or license or may own or license in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, or our current or future licensors might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or license or may own or license in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, or our current or future licensors might not have been the first to file patent applications covering certain of our or their inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is possible that our and our licensors&#8217; pending owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others may harm our business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Should any of these events occur, they could harm our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Employee Matters and Our Ability to Manage Growth</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our future success depends on our ability to retain our key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are highly dependent on the research and development, clinical, regulatory, financial, commercial, and manufacturing expertise of the principal members of our management, scientific and clinical teams. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, losing or replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize our product candidates. Competition to hire from this limited pool is intense. We also experience competition for the hiring of scientific and clinical personnel from public and private universities and research institutions. In addition, we rely on consultants and advisors, including scientific, commercial and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under employment, consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We expect to increase the size of our workforce in the future, and we may encounter difficulties in managing this growth, which could harm our operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November 1, 2021, we had 144 employees. As we move forward in our efforts to commercialize our HAVs, if approved, we expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs, manufacturing and quality and compliance and support functions. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage this growth effectively could delay the execution of our business plans or harm our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Ownership of Our Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The price of our common stock may be volatile.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The price of our common stock may fluctuate due to a variety of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated fluctuations in our quarterly and annual results and those of other public companies in our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">mergers and strategic alliances in the industry in which we operate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">market prices and conditions in the industry in which we operate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in government regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic on our business and operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential or actual military conflicts or acts of terrorism; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements concerning Humacyte or our competitors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the general state of the securities markets. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that securities research analysts will establish and publish their own periodic projections for the business of Humacyte. These projections may vary widely and may not accurately predict the results we actually achieve. Our stock price may decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on Humacyte downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price could decline. If one or more of these analysts ceases coverage of Humacyte or fails to publish reports on Humacyte regularly, our stock price or trading volume could decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2021, we had Warrants outstanding to purchase up to an aggregate of 5,177,500 shares of our common stock and options and warrants outstanding to purchase up to an aggregate of 6,810,894 shares of our common stock. Under the Humacyte, Inc. 2021 Long-Term Incentive Plan (the &#8220;2021 Plan&#8221;) and the Humacyte, Inc. 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), we also have the ability to issue 7,725,253 shares and 1,030,033 shares, respectively. In addition, such aggregate number of shares under the 2021 Plan and the ESPP will automatically increase on January&#160;1 of each&#160;year commencing January&#160;1, 2022, in an amount equal to 5% and 1%, respectively, of the number of shares of our capital stock outstanding on December&#160;31 of the preceding year, unless our board of directors (the&#160;&#8220;Board&#8221;) acts prior to January&#160;1 of a given year to provide that the increase for such year will be a lesser number. We may also issue additional shares of common stock or other equity securities of equal or senior rank in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our issuance of additional shares of common stock or other equity securities of equal or senior rank would have the following effects: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our existing stockholders&#8217; proportionate ownership interest in Humacyte will decrease; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount of cash available per share, including for payment of dividends in the future, may decrease; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the relative voting strength of each previously outstanding share of common stock may be diminished; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market price of shares of our common stock may decline. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion of the Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual&#160;restrictions and other factors that the Board may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our securities unless you sell your securities for a price greater than that which you paid for it. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Public Warrants may not be in the money in the future, and they may expire worthless, and the terms of the Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Warrants were issued in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and AHAC. The warrant agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of at least 50% of the then-outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants approve of such amendment and, solely with respect to any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants, holders of at least 50% of the number of the then outstanding Private Placement Warrants. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then-outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period or decrease the number of shares of common stock purchasable upon exercise of a Warrant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may redeem your unexpired Public Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your Public Warrants worth less than they would be if you held and exercised them at a later time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have the ability to redeem outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per Warrant, provided that the last reported sales price of our common stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the holders thereof. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Public Warrants could force you to: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&#160;exercise your Public Warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (ii)&#160;sell your Public Warrants at the then-current market price when you might otherwise wish to hold your Public Warrants; or (iii)&#160;accept the nominal redemption price which, at the time the outstanding Public Warrants are called for redemption, is likely to be substantially less than the market value of your Public Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The value received upon exercise of the Public Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their Public Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the Public Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Private Placement Warrants are not subject to the same risk of redemption as the Public Warrants as the Private Placement Warrants are not redeemable so long as they are held by the Sponsor, the underwriters of AHAC&#8217;s initial public offering or their permitted transferees. If the Private Placement Warrants are held by holders other than the Sponsor, the underwriters or their permitted transferees, the Private Placement Warrants will be redeemable by us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have derivative securities that are accounted for as liabilities and the changes in value of such derivative securities could have a material effect on our financial results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Included on the Company&#8217;s condensed consolidated balance sheets as of September&#160;30, 2021 are derivative liabilities related to the Contingent Consideration and the Private Placement Warrants. Accounting Standards Codification 815, Derivatives and Hedging (&#8220;ASC 815&#8221;), provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring fair value measurement, our financial statements and results of operations may fluctuate quarterly, based on factors which are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on the Contingent Consideration and the Private Placement Warrants each reporting period and that the amount of such gains or losses could be material. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the Business Combination, on April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; &#8203;(the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the Public Warrants. As a result of the SEC Statement, prior to the Business Combination, AHAC reevaluated the accounting treatment of the Public Warrants and determined to classify the Public Warrants as derivative liabilities measured at fair value, with changes in fair value each period reported in earnings. As a result, included on AHAC&#8217;s balance sheet as of December&#160;31, 2020 are derivative liabilities related to embedded features contained within the Public Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with its Amended Annual Report on Form 10-K/A for the year ended December&#160;31, 2020, AHAC reached a determination to restate certain previously issued financial statements and related disclosures for the periods disclosed in order to correct the accounting treatment for the Warrants following the publication of the SEC Statement. As a result, prior to the Business Combination, AHAC incurred unanticipated costs for accounting and legal fees in connection with or related to the restatement, and we may become subject to additional risks and uncertainties related to the restatement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AHAC restated certain previously issued financial statements and related disclosures for the periods disclosed, and as of September&#160;30, 2021, our management concluded that the conditions causing the material weakness that led to these restatements did not exist. However, in the future, we&#160;may determine that we have additional material weaknesses. Our failure to remediate any material weaknesses&#160;or failure to identify and address any material weaknesses or control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis, which could cause investors to lose confidence in our reported financial information, which may result in volatility in and a decline in the market price of our common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may be forced to write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in losses. Even though these charges may be non-cash items and may not have an immediate impact on our liquidity, the fact that we may report charges of this nature could contribute to negative market perceptions about our securities. In addition, charges of this nature may cause us to be unable to obtain future financing on favorable terms or at all. Accordingly, a stockholder could suffer a reduction in the value of their shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There can be no assurance that we will be able to comply with the continued listing standards of The Nasdaq Stock Market.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock and Public Warrants are currently listed on Nasdaq. If Nasdaq delists our&#160;common stock from trading on its exchange for any reason, we and our stockholders could face significant material adverse consequences including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a limited availability of market quotations for our securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a limited amount of analyst coverage; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a decreased ability to issue additional securities or obtain additional financing in the future. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The obligations associated with being a public company involve significant expenses and will require significant resources and management attention, which may divert from our business operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a public company, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires the filing of annual, quarterly and current reports with respect to a public company&#8217;s business and financial condition. The Sarbanes-Oxley Act requires, among other things, that a public company establish and maintain effective internal control over financial reporting. As a&#160;result, we will incur significant legal, accounting and other expenses that Legacy Humacyte did not incur as a private company. Our entire management team and many of its other employees will need to devote substantial time to compliance, and may not effectively or efficiently manage our transition into a public company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These rules and regulations will result in our incurring substantial legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for Humacyte to obtain director and officer liability&#160;insurance, and it has accepted reduced coverage. As a result, it may be difficult for us to attract and retain qualified people to serve on the Board or committees of the Board or as executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; within the meaning of the rules adopted by the SEC, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies and smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an emerging growth company as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive&#160;compensation in periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five&#160;years from the closing of AHAC&#8217;s initial public offering, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700&#160;million as of any June&#160;30 before that time, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in which case we would no longer be an emerging growth company as of the following December&#160;31. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the&#160;trading prices of our securities may be lower than they otherwise would be, there may be a less active trading&#160;market for our securities and the trading prices of our securities may be more volatile. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined under the Exchange Act. Smaller&#160;reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of audited financial statements. We will remain a smaller reporting company for so long as (1)&#160;the market value of our common stock held by non-affiliates is less than $250&#160;million as of the last business day of the second fiscal quarter, or (2)&#160;our annual revenues in our most recent fiscal year completed before the last business day of our second fiscal quarter are less than $100&#160;million and the market value of our common stock held by non-affiliates is less than $700&#160;million as of the last business day of the second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective internal control over financial reporting is necessary for Humacyte to provide reliable financial reports. Any failure to implement new or improved controls necessary to maintain effective internal control over financial reporting, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, any testing by Humacyte conducted in connection with Section&#160;404 of the Sarbanes-Oxley Act, or our independent registered public accounting firm, may identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ineffective internal control over financial reporting could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. In connection with its Amended Annual Report on Form 10-K/A for the year ended December&#160;31, 2020, AHAC reached a determination to restate certain previously issued financial statements and related disclosures for the periods disclosed in order to correct the accounting treatment for the Warrants following the publication of the SEC Statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our assessment is that, post-Business Combination, we have a sufficiently staffed and technically experienced finance and accounting team to address the financial reporting requirements of a public company. Because the conditions causing the material weakness no longer existed, and are not expected to exist in the foreseeable future, we determined the material weakness did not exist in internal control over financial reporting as of September&#160;30, 2021. Prior to the Business Combination, AHAC&#8217;s management </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">concluded that its disclosure controls and procedures were not effective as of December&#160;31, 2020, and that its internal control over financial reporting was not effective as of December&#160;31, 2020, as a result of a material weakness in controls related to the accounting for the Warrants. As a result, AHAC incurred unanticipated costs for accounting and legal fees in connection with or related to the restatement, and we may become subject to additional risks and uncertainties related to the restatement, such as a negative impact on investor confidence in the accuracy of our financial disclosures, and may face reputational risks for our business. Effective as of the closing of the Business Combination, the management of Legacy Humacyte is responsible for internal control over financial reporting and the former management of AHAC no longer participates in financial reporting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As long as we are an emerging growth company under the JOBS Act or a non-accelerated filer and a &#8220;smaller reporting company&#8221; as defined in Rule&#160;12b-2 of the Exchange Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act. An independent assessment of the effectiveness of our internal control over financial reporting could detect deficiencies that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-takeover provisions in our Second Amended and Restated Certificate of Incorporation and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult, and may prevent attempts by our stockholders to replace or remove our current management.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Second Amended and Restated Certificate of Incorporation (the &#8220;Charter&#8221;) contains provisions that may delay or prevent an acquisition of the company or change in our management. These provisions may make it more difficult for stockholders to replace or remove members of the Board. Because the Board is responsible for appointing the members of the management team, these provisions could in turn frustrate or prevent any attempt by our stockholders to replace or remove our current management. In addition, these provisions could limit the price that investors might be willing to pay in the future for shares of our&#160;common stock. Among other things, these provisions include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the limitation of the liability of, and the indemnification of, our directors and officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provisions that permit only (i)&#160;the chairperson of the Board, (ii)&#160;our chief executive officer or (iii)&#160;a majority of our Board to call special meetings of stockholders and therefore do not permit our stockholders to call stockholder meetings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a prohibition on actions by our stockholders by written consent; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of the Board to issue preferred stock without stockholder approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent a third party from acquiring or merging with us, whether or not it is desired by, or beneficial to, our stockholders. This could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in our stockholders&#8217; best interests. Finally, these provisions establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. These provisions would apply even if the offer may be considered beneficial by some stockholders. For more information, see the section titled &#8220;Description of Securities.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Charter provides that the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:336pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any derivative action or proceeding brought on our behalf; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any action asserting a breach of fiduciary duty; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any action asserting a claim against us arising under the DGCL, our Charter or our amended and restated bylaws (the &#8220;Bylaws&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any action or proceeding asserting a claim as to which the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any action asserting a claim against us that is governed by the internal affairs doctrine or otherwise related to our internal affairs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. We cannot be certain that a court will decide that this provision is either applicable or enforceable, and if a court were to find the choice of forum provision contained in our Charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the rules and regulations promulgated thereunder. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:516pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We will not receive any proceeds from the sale of common stock by the selling stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We will receive up to an aggregate of approximately $59.5&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the warrants for general corporate purposes. We will have broad discretion over the use of proceeds from the exercise of the Warrants. There is no assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. To the extent that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:540pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">DETERMINATION OF OFFERING PRICE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The offering price of the shares of common stock underlying the Warrants offered hereby is determined by reference to the exercise price of the Warrants of $11.50 per share. The Public Warrants are listed on Nasdaq under the symbol &#8220;HUMAW.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We cannot currently determine the price or prices at which shares of common stock may be sold by the selling stockholders under this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMIFC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Market Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is are currently listed on Nasdaq under the symbol &#8220;HUMA.&#8221; Prior to the consummation of the Business Combination, our common stock was listed on Nasdaq under the symbol &#8220;AHAC.&#8221; As of November&#160;10, 2021, there were 121&#160;holders of record of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividend Policy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid any dividends on shares of our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of our Board will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our board of directors may deem relevant.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes set forth elsewhere in the registration statement of which this prospectus forms a part. Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Humacyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Humacyte, Inc. (formerly known as Alpha Healthcare Acquisition Corp.) and its consolidated subsidiaries (including Humacyte Global, Inc.) following the Company&#8217;s business combination with Alpha Healthcare Acquisition Corp (the &#8220;Business Combination&#8221;); references to &#8220;Legacy Humacyte&#8221; refer to Humacyte, Inc. prior to the Business Combination; and references to &#8220;AHAC&#8221; refer to Alpha Healthcare Acquisition Corp. prior to the Business Combination.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues designed to improve the lives of patients and transform the practice of medicine. We believe our technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues. Our goal is to develop and manufacture these tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are initially using our proprietary scientific technology platform to engineer and manufacture HAVs. Our HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. We are developing our &#8220;cabinet&#8221; of HAVs of varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including use in AV access for hemodialysis, trauma, PAD and CABG. In addition, we are developing our HAVs as conduits for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation for the treatment of Type 1 diabetes (our biovascular pancreas). We intend to continue to explore the application of our technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus and other novel cell delivery systems. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe there is substantial clinical demand for safe and effective vascular conduits to replace and repair blood vessels throughout the body. Vascular injuries resulting from trauma are common in civilian and military populations, frequently resulting in the loss of either life or limb. Existing treatment options in the vascular repair, reconstruction and replacement market use autologous vessels and synthetic grafts and suffer from significant limitations. For example, the use of autologous veins to repair traumatic vascular injuries can lead to significant morbidity associated with the surgical wounds created for vein harvest and prolonged times to restore blood flow to injured limbs leading to an increased risk of amputation and infection. Synthetic grafts are often contraindicated in the setting of vascular trauma due to higher infection risk that can lead to prolonged hospitalization and limb loss. Given the competitive advantages HAVs may have over existing vascular substitutes, we believe that HAVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have generated no product revenue and incurred net losses and negative cash flows from operations in each year since our inception in 2004. As of December&#160;31, 2020 and September&#160;30, 2021, we had an accumulated deficit of $388.1&#160;million and $457.2&#160;million, respectively, and working capital of $30.2&#160;million and $222.9&#160;million, respectively. Our net losses were approximately $85.4&#160;million and $66.5&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and $50.3&#160;million and $69.1&#160;million for the nine&#160;months ended September&#160;30, 2020 and 2021, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The report of our independent registered public accounting firm on our financial statements as of and for the year ended December&#160;31, 2020 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern, as at the time of the issuance date of those financial statements there was substantial doubt about our ability to continue as a going concern. As of December&#160;31, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2020 and September&#160;30, 2021, we had cash and cash equivalents of $39.9&#160;million and $240.4&#160;million, respectively. We believe our cash and cash equivalents on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements for at least the next 12&#160;months from the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our need for additional capital will depend in part on the scope and costs of our development and commercial manufacturing activities. To date, we have not generated any revenue from the sale of commercialized products. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Until such time, if ever, we expect to finance our operations through the sale of equity or debt, borrowings under credit facilities, or through potential collaborations, other strategic transactions or government and other grants. Adequate capital may not be available to us when needed or on acceptable terms. If we are unable to raise capital, we could be forced to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition. See the section of this prospectus entitled &#8220;Risk Factors&#8221; for additional information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to incur significant expenses and to increase operating losses for at least the next several&#160;years. We anticipate that our expenses will increase substantially as we seek to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain marketing approval for our 6 millimeter HAV for vascular repair, reconstruction and replacement, including for trauma and AV access for hemodialysis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">commercialize the HAV via U.S. market launches in trauma and dialysis AV access; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">scale out our manufacturing facility to satisfy potential demand following any receipt of marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">continue our preclinical and clinical development efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintain, expand and protect our intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">add operational, financial and management information systems and personnel to support, among other things, our product development and commercialization efforts and operations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">operate as a public company, which includes higher costs associated with hiring additional personnel, director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Closing of Business Combination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On the Closing Date, Legacy Humacyte and AHAC consummated the Business Combination pursuant to the Business Combination Agreement. As contemplated by the Business Combination Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte surviving the Business Combination as a wholly owned subsidiary of AHAC. As a result of the Business Combination, AHAC was renamed Humacyte, Inc. and Legacy Humacyte was renamed Humacyte Global, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Business Combination Agreement, at the Effective Time, (1)&#160;each outstanding share of Legacy Humacyte common stock was cancelled and converted into the right to receive approximately 0.26260 shares of the Company&#8217;s common stock, and (2)&#160;each outstanding share of Legacy Humacyte preferred stock was cancelled and converted into the aggregate number of shares of the Company&#8217;s common stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by approximately 0.26260, resulting in the issuance of a total of 75,656,935 shares of common stock. Prior holders of shares of Legacy Humacyte common stock and Legacy Humacyte preferred stock also received the contingent right to receive certain Earnout Shares (as defined below), for each share owned by each such Legacy Humacyte stockholder that was outstanding immediately prior to the closing of the Business Combination (the &#8220;Closing&#8221;). In addition, the PIPE Investors purchased an aggregate of 17,500,000 shares of common stock </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in the PIPE Investment, which closed concurrently with the Closing, for an aggregate purchase price of $175&#160;million. Additionally, at the Closing, 2,500,000 shares of AHAC&#8217;s Class&#160;B common stock (&#8220;Founder Shares&#8221;) automatically converted into shares of common stock of the Company on a one-for-one basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Business Combination Agreement, at the Effective Time, (1)&#160;warrants to purchase shares of Legacy Humacyte common stock were converted into warrants to purchase an aggregate of 287,704 shares of common stock, and (2)&#160;options to purchase shares of Legacy Humacyte common stock were converted into options to purchase an aggregate of 6,405,138 shares of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the Closing Date, former holders of Legacy Humacyte common stock and Legacy Humacyte preferred stock may receive up to 15,000,000 additional shares of common stock (&#8220;Earnout Shares&#8221;) in the aggregate in two equal tranches if the volume-weighted average closing sale price of our common stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio established in the Business Combination Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Impact of COVID-19</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic, which began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in -place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on our business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on our business and operations are uncertain. The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay our clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on our business and operations. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on our business and operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, the COVID- 19 pandemic has not resulted in material financial impacts or impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related event or circumstance that would require us to revise the estimates reflected in our financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related economic impact of the pandemic. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Components of Results of Operations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, we have not generated revenue from the sale of any products. All of our revenue has been derived from government and other grants. Since inception we have been awarded grants from the California Institute of Regenerative Medicine (&#8220;CIRM&#8221;), the National Institutes of Health (&#8220;NIH&#8221;), and the Department of Defense (&#8220;DoD&#8221;), to support our development, production scaling and clinical trials of our product candidates. We recognized $30.8&#160;million in revenue from inception to September&#160;30, 2021 from these sources, including $11.2&#160;million from CIRM under a program that ended in 2020. We may generate revenue in the future from government and other grants, payments from future license or collaboration agreements and, if any of our product candidates receive marketing approval, from product sales. We expect that any revenue we generate will fluctuate from quarter to quarter. If we fail to complete the development of, or obtain marketing approval for, our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, developing our manufacturing process and activities related to regulatory filings for our product candidates. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">salaries and related overhead expenses for personnel in research and development functions, including stock-based compensation and benefits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fees paid to consultants and CROs, including in connection with our clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work and statistical compilation and analysis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allocation of facility lease and maintenance costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">depreciation of leasehold improvements, laboratory equipment and computers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to purchasing raw materials for and producing our product candidates for clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to compliance with regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to our manufacturing development and expanded-capabilities initiatives; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">license fees related to in-licensed technologies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The majority of our research and development resources are currently focused on our Phase&#160;III clinical trials for our 6 millimeter HAV and other work needed to obtain marketing approval for our 6 millimeter HAV for use for vascular repair, reconstruction and replacement, including trauma and AV access in hemodialysis in the United States and Europe. We have incurred and expect to continue to incur significant expenses in connection with these and our other clinical development efforts, including expenses related to regulatory filings, trial enrollment and conduct, data analysis, patient follow up and study report generation for our Phase&#160;II and Phase&#160;III clinical trials. We do not allocate our costs by each research and development program for which we are developing our cabinet of HAVs, as a significant amount of our development activities broadly support multiple programs that use our technology platform. We plan to further increase our research and development expenses for the foreseeable future as we continue the development of our proprietary scientific technology platform and our novel manufacturing paradigm. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The successful development of our preclinical and clinical product candidates is highly uncertain. At this time, we cannot estimate with any reasonable certainty the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our preclinical or clinical product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our product candidates, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, rate of progress, expense and results of our preclinical development activities, our ongoing clinical trials and any additional clinical trials that we may conduct, and other research and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successful patient enrollment in and the initiation and completion of clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">development of clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that it or its third-party manufacturers are able to successfully manufacture our product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significant and changing government regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the degree of market acceptance of any product candidates that obtain marketing approval; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining a continued acceptable safety profile following approval, if any, of our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A change in the outcome of any of these variables could lead to significant changes in the costs and timing associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate being required to conduct in order to complete the clinical development of any of our product candidates, or if we experience significant delays in the enrollment or the conduct of any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance, human resources, commercialization, and administrative support functions, which also include stock-based compensation expenses and benefits for such employees. Other significant general and administrative expenses include facilities costs, professional fees for accounting and legal services and expenses associated with obtaining and maintaining patents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect our general and administrative expenses will increase for the foreseeable future to support our expanded infrastructure and increased costs of operating as a public company. These increases are expected to include increased employee-related expenses, increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the Exchange Act and rules implemented by the SEC, as well as Nasdaq rules. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expenses), Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Total other income (expenses), net consists of (i)&#160;the change in fair value of the contingent earnout liability that was accounted for as a liability as of the date of the Business Combination, and is remeasured to fair value at each reporting period, resulting in a non-cash gain or loss, (ii)&#160;a gain on Paycheck Protection Program (&#8220;PPP&#8221;) loan forgiveness, (iii)&#160;interest income earned on our cash and cash equivalents, (iv)&#160;interest expense incurred on our term loan agreement with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P. (the &#8220;Loan Agreement&#8221;), finance leases, and our PPP loan during the periods each were outstanding, (v)&#160;a change in fair value of private placement common stock warrant liabilities related to the Private Placement Warrants, which we assumed in connection with the Business Combination, and which are subject to remeasurement to fair value at each balance sheet date resulting in a non-cash gain or loss, and (vi)&#160;legal, accounting, and underwriting fees and other costs directly related to the consummation of the Business Combination that were associated with the aforementioned warrant liabilities. See Note 6 to our audited financial statements contained elsewhere in the registration statement of which this prospectus forms a part for a description of the leases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Results of Operations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Comparison of the Nine Months Ended September&#160;30, 2020 and 2021</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,367</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,086</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(281<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(21<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:253.21pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">40,879</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">45,091</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,212</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">9,416</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,576</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:9.75pt; text-align:right; white-space:nowrap;">65<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">50,295</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">60,667</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,372</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:9.75pt; text-align:right; white-space:nowrap;">21<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:143.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(48,928<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(59,581<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(10,653<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:11.25pt; text-align:right; white-space:nowrap;">(22<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.21pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other expenses, net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gain on PPP loan forgiveness </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,284</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent earnout liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,661<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,291<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(78<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">277</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(322<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">116<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:253.21pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,384<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,481<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,097<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:253.21pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(50,312<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(69,062<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(18,750<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(37<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2020 and 2021, revenue totaled $1.4&#160;million and $1.1&#160;million, respectively, a decrease of $0.3&#160;million, or 21%. The decrease relates to $0.3&#160;million of revenue recognized during the nine&#160;months ended September&#160;30, 2020 related to our grant from NIH before the program ended in 2020. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table discloses the breakdown of research and development expenses: </font>
        </div>
        <table style="width:456pt;height:97.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:266.54pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:266.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">External services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">10,748</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">11,534</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">786</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lab supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,815</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,141</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,326</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">19<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payroll and personnel expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">14,497</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">17,003</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">2,506</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">17<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:266.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,413</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">(406<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:7.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:266.54pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">40,879</div>
            </td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">45,091</div>
            </td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">4,212</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses increased from $40.9&#160;million for the nine&#160;months ended September&#160;30, 2020 to $45.1&#160;million for the nine&#160;months ended September&#160;30, 2021. The increase of $4.2&#160;million, or 10%, was primarily driven by an increase in payroll and personnel expenses, including a $1.4&#160;million increase in salaries and benefits and a $1.1&#160;million increase in non-cash stock compensation expense, and the purchase of lab supplies used in the development of our commercial manufacturing process and in our research and development initiatives, including the preparation of clinical studies. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $9.4&#160;million and $15.6&#160;million for the nine&#160;months ended September&#160;30, 2020 and 2021, respectively. The increase in general and administrative expenses of $6.2&#160;million, or 65%, was driven by increases in non-cash stock compensation expense of $2.8&#160;million, external services and professional fees of $1.7&#160;million, including those related to preparations for commercial launch and corporate initiatives, $0.6&#160;million in salaries and benefits, and $0.4&#160;million in insurance costs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Total Other Expenses, net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Total other expense, net was $1.4&#160;million and $9.5&#160;million for the nine&#160;months ended September&#160;30, 2020 and 2021, respectively. The increase of $8.1&#160;million resulted from a $9.8&#160;million non-cash expense related to the remeasurement of the contingent earnout liability as of September&#160;30, 2021, a $1.3&#160;million increase in interest expense related to our loan facility with Silicon Valley Bank, which commenced in March&#160;2021, and a $0.3&#160;million decrease in interest income earned on our cash equivalents due to lower interest rates and lower average cash balances during the year, partially offset by a $3.3&#160;million gain on PPP loan forgiveness. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Results of Operations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Comparison of the Years Ended December&#160;31, 2019 and 2020</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:144pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:279.61pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,187</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,491</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(76<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:279.61pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">75,603</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">54,078</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(21,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(28<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,275</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">12,013</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(4,262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">91,878</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">66,091</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(25,787<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">(28<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(85,691<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(64,600<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">21,091</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:279.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other income (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">269</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,924<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,193<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">(815<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:279.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(85,422<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(66,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">18,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">22<font style="position:absolute;">%</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:17.59pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the&#160;years ended December&#160;31, 2019 and 2020, we generated $6.2&#160;million and $1.5&#160;million of revenue, respectively, related to the reimbursement of qualifying expenses incurred in connection with our grants from DoD, NIH and CIRM. The decrease in revenue of $4.7&#160;million, or 76%, was primarily driven by the completion of certain DoD awards during the year ended December&#160;31, 2019 and a decrease of $1.7&#160;million in revenue related to our CIRM awards, a program that ended during 2020. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table discloses the breakdown of research and development expenses: </font>
        </div>
        <table style="width:456pt;height:97.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:281.28pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">External services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">25,249</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">14,675</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,574<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(42<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lab supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">21,423</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">9,769</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,654<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(54<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payroll and personnel expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">17,723</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">17,885</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">162</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:281.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">11,208</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">11,749</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:9.75pt; text-align:right; white-space:nowrap;">5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:281.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">75,603</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">54,078</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">(28<font style="position:absolute;">)%</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses decreased from $75.6&#160;million for the year ended December&#160;31, 2019 to $54.1&#160;million for the year ended December&#160;31, 2020. The decrease of $21.5&#160;million, or 28%, was due to the completion of certain programs, combined with initiatives implemented to extend our cash runway, including decreased requirements for lab supplies used to develop our commercial manufacturing process and used in our research and development initiatives, totalling $11.7&#160;million of the decrease. External services decreased by $10.6&#160;million, or 42%, due to our V006 trial completing enrollment and our V007 trial enrollment slowing due to the COVID <font style="white-space:nowrap;">-19</font> pandemic, which comprised $4.5&#160;million of the decrease, the termination of our agreement with our contract manufacturing organization, which comprised $2.9&#160;million of the decrease, and initiatives implemented to extend our cash runway, which comprised $3.2&#160;million of the decrease. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $16.3&#160;million and $12.0&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively. The decrease in general and administrative expenses during this period of $4.3&#160;million, or 26%, was similarly driven by our adoption of a lower operating budget in 2020 to extend our cash runway, and primarily due to the decrease in professional fees of $2.3&#160;million, $1.5&#160;million of which related to offering costs that were charged to expense in 2019. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other income (expense) was $0.3&#160;million and $(1.9) million for the&#160;years ended December&#160;31, 2019 and 2020, respectively. The decrease of $2.2&#160;million resulted from a decrease in interest income earned on our cash equivalents due to lower interest rates and lower average cash balances during the year. Interest expense on our finance lease right of use assets was not impacted by these lower interest rates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidity and Capital Resources</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sources of Liquidity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, we have financed our operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through grants from governmental and other agencies. Since our inception, we have incurred significant operating losses and negative cash flows. As of December&#160;31, 2020 and September&#160;30, 2021, we had an accumulated deficit of $388.1&#160;million and $457.2&#160;million, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and September&#160;30, 2021, we had cash and cash equivalents of $39.9&#160;million and $240.4&#160;million, respectively. We believe our cash and cash equivalents will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements for at least 12&#160;months from the date of this prospectus. See Note 1 to our related interim financial statements contained elsewhere in the registration statement of which this prospectus forms a part for additional information on our assessment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2020, we received loan proceeds in the amount of approximately $3.3&#160;million under the PPP as established under the CARES Act. The loan and accrued interest were forgivable after a 24-week period as long as we used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintained its payroll levels. On May&#160;25, 2021, the Small Business Administration approved the forgiveness of the outstanding amount of the PPP loan and we recognized a gain from loan extinguishment in the amount of $3.3&#160;million during the nine&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, we entered into the Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P., which provides a term loan facility of up to $50.0&#160;million, with a maturity date of March&#160;1, 2025, of which $20.0&#160;million was funded upon the closing of the Loan Agreement, and the additional $30.0&#160;million is accessible in three tranches of $10.0&#160;million each contingent on the achievement of certain business and clinical development milestones. Our obligations under the Loan Agreement are secured by substantially all of our assets, except for our intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. We may use the proceeds of borrowings under the Loan Agreement as working capital and to fund our general business requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Borrowings under the Loan Agreement bear interest at a rate of 7.5% or the sum of the Wall Street Journal Prime Rate plus 4.25%, whichever is greater. In addition, the lenders were granted warrants to purchase common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2021, principal of $20.0&#160;million was outstanding under the Loan Agreement and we were in compliance with all covenants in all material respects. On October&#160;13, 2021, we borrowed an additional $10.0&#160;million under the Loan Agreement, and principal of $30.0&#160;million is outstanding as of the date of this prospectus. As a result of the additional borrowing, the commencement of repayment of principal was deferred to no earlier than July&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Including the additional $10.0&#160;million borrowed, our contractual obligations under the Loan Agreement as of September&#160;30, 2021, include cash payments related to principal of $0.0&#160;million within one year, $21.4&#160;million within one to three&#160;years, and $8.6&#160;million within three to five&#160;years. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Future Funding Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to incur significant expenses in connection with our ongoing activities as we seek to (i)&#160;continue clinical development of our 6 millimeter HAV for use in dialysis AV access and vascular repair and submit biologics license applications for FDA approval, (ii)&#160;if marketing approval is obtained, to launch and commercialize our HAVs for dialysis AV access and vascular repair in the U.S. market, including </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:26.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">subsequent launches in key international markets, (iii)&#160;advance our pipeline in major markets, including PAD Phase&#160;III trials and continue preclinical and clinical development for proof of concept in CABG and biovascular pancreas for diabetes, and (iv)&#160;scale out our manufacturing facility to satisfy potential demand if our HAVs receive marketing approval. We will need additional funding in connection with these activities. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the progress and results of our clinical trials and interpretation of those results by the FDA and other regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost, timing and outcome of regulatory review of our product candidates, particularly for marketing approval of our HAVs in the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our additional product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of our future commercialization activities, including product manufacturing, marketing and distribution for our HAVs if approved by the FDA, and any other product candidate for which we receive marketing approval in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount and timing of revenues, if any, that we receive from commercial sales of any product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs of operating as a public company, including hiring additional personnel as well as increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as we are able to successfully develop and commercialize one or more of our product candidates, we expect to continue financing our operations through the sale of equity, debt, borrowings under credit facilities or through potential collaborations with other companies, other strategic transactions or government or other grants. Adequate capital may not be available to us when needed or on acceptable terms. We do not currently have any committed external source of funds beyond the Loan Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures. Debt financing would also result in fixed payment obligations. If we are unable to raise additional funds through equity or debt financings or other strategic arrangements when needed, we may be required to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte&#8217;s principal use of cash in recent periods has been funding its operations. Humacyte&#8217;s future capital requirements, both short-term and long-term, will depend on many factors, including the progress and results of our clinical trials and preclinical development, timing and extent of spending to support development efforts, cost and timing of future commercialization activities, and the amount and timing of revenues, if any, that we receive from commercial sales. See the section of this prospectus titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flows</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows a summary of our cash flows for each of the periods shown below: </font>
        </div>
        <table style="width:456pt;height:112.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:230.22pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Statement of cash flows data: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total cash (used in)/provided by: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(71,787<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(55,568<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,373<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(59,742<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(268<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(255<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,052</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,379</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">260,437</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:230.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(79,986<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(53,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(38,249<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">200,520</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:17.3pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flow from Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities of $71.8&#160;million during the year ended December&#160;31, 2019 was primarily the result of our net loss of $85.4&#160;million to support our ongoing research and development, regulatory and other clinical trial costs, and related general and administrative costs as well as a decrease in deferred revenue of $0.6&#160;million related to our CIRM awards, partially offset by a $2.4&#160;million increase in accounts payable and by non-cash items of $11.3&#160;million primarily related to $4.7&#160;million of depreciation expense, $4.5&#160;million for stock-based compensation and $2.1&#160;million for amortization of finance lease right-of-use assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities of $55.6&#160;million during the year ended December&#160;31, 2020 was primarily the result of our net loss of $66.5&#160;million to support our research and development, regulatory and other clinical trial costs, and related general and administrative costs as well as a $2.3&#160;million decrease in accounts payable and accrued expenses, partially offset by a $0.5&#160;million decrease in accounts receivable and by non-cash items of $13.4&#160;million primarily related to $6.3&#160;million for depreciation, $4.7&#160;million for stock-based compensation, $2.1&#160;million for amortization of finance lease right-of-use assets, and $0.3&#160;million for deferred payroll taxes related to Section&#160;2302 of the CARES Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities of $40.4&#160;million during the nine&#160;months ended September&#160;30, 2020 was primarily the result of our net loss of $50.3&#160;million to support our research and development, including clinical trial, manufacturing and regulatory costs, and general and administrative costs, with adjustments for non-cash expenses related primarily to $4.7&#160;million of depreciation expense, $3.5&#160;million of stock-based compensation and $1.5&#160;million for amortization of finance lease right-of-use assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities of $59.7&#160;million during the nine&#160;months ended September&#160;30, 2021 was primarily the result of our net loss of $69.1&#160;million to support our research and development, including clinical trial, manufacturing and regulatory costs, and general and administrative costs, $12.4&#160;million related to payments of liabilities acquired in the Business Combination, and adjustments for non-cash expenses related primarily to a $9.8&#160;million loss related to the change in the fair value of our contingent earnout liability, $7.4&#160;million of stock-based compensation, $4.7&#160;million of depreciation expense, $1.5&#160;million for amortization of finance lease right-of-use assets, and $0.6&#160;million amortization of Silicon Valley Bank debt discount, partially offset by a $3.3&#160;million non-cash gain on PPP loan forgiveness. We also experienced a $1.0&#160;million net favorable change in cash related to operating assets and liabilities primarily related to an increase in accrued expenses of $2.4&#160;million, an increase in accounts payable of $0.8&#160;million, partially offset by an increase in prepaid expenses of $2.0&#160;million. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flow from Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities during the year ended December&#160;31, 2019 was $8.1&#160;million, primarily consisting of purchases related to construction in progress of $4.5&#160;million for the build-out of our manufacturing facility and laboratory equipment of $3.6&#160;million to equip our manufacturing facility with scientific equipment and LUNA200 manufacturing systems. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities during the year ended December&#160;31, 2020 was $0.3&#160;million, primarily consisting of purchases of scientific equipment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities during the nine&#160;months ended September&#160;30, 2020 was $0.3&#160;million, primarily consisting of the purchases of laboratory and manufacturing equipment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities during the nine&#160;months ended September&#160;30, 2021 was $0.2&#160;million, primarily consisting of the purchases of laboratory equipment. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flow from Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in financing activities during the year ended December&#160;31, 2019 was $0.1&#160;million, consisting of payments of $1.3&#160;million in connection with a finance lease obligation, partially offset by proceeds of $1.2&#160;million from the exercise of stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the year ended December&#160;31, 2020 was $2.1&#160;million, consisting of $3.3&#160;million of the proceeds from our PPP loan and $0.3&#160;million from the exercise of stock options, partially offset by principal payments of $1.5&#160;million in connection with a finance lease obligation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the nine&#160;months ended September&#160;30, 2020 was $2.4&#160;million, consisting of $3.3&#160;million of the proceeds from our PPP loan and proceeds of $0.2&#160;million from the exercise of stock options, partially offset by principal payments of $1.1&#160;million in connection with a finance lease obligation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the nine&#160;months ended September&#160;30, 2021 was $260.4&#160;million, consisting of $242.4&#160;million of proceeds from the Business Combination and the PIPE Investment, $19.7&#160;million of net proceeds from our loan facility with Silicon Valley Bank and $0.6&#160;million from the exercise of stock options, partially offset by $0.9&#160;million of transaction costs paid and principal payments of $1.3&#160;million in connection with a finance lease obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contractual Obligations and Commitments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our contractual obligations as of December&#160;31, 2020: </font>
        </div>
        <table style="width:456pt;height:108pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:224.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">1 year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1&#8201;&#8211;&#8201;3&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">3&#8201;&#8211;&#8201;5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">More than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:224.06pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Contractual obligations:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.06pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">36,775</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,773</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,833</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,232</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,937</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.06pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,205</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">212</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">678</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.06pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">PPP loan payable</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,451</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">822</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:224.06pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Noncancelable purchase commitments</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,983</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:224.06pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total contractual obligations</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">49,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,865</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,444</td>
            <td style="padding:0pt;padding-left:4.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">17,615</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The PPP loan was forgiven on May&#160;25, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we had non-cancellable purchase commitments of $8.0&#160;million for supplies and services that are primarily for research and development. We have also entered into contracts with CROs primarily for clinical trials. These contracts generally provide for termination upon limited notice, and therefore we believe that our non-cancellable obligations under these agreements are not material. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table above does not include potential milestone payments, license fee payments, royalties and other payments that we may be required to make under our license agreements with Duke University and Yale University and our distribution agreement with Fresenius Medical Care Holdings, Inc. These payments are not included in the preceding table as the amount and timing of such payments are unknown or uncertain at December&#160;31, 2020. For additional information regarding these agreements and the nature of payments that could become due thereunder, see &#8220;Information About Humacyte&#8201;&#8212;&#8201;Business </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Overview&#8201;&#8212;&#8201;Distribution&#8221; and &#8220;Information About Humacyte&#8201;&#8212;&#8201;Business Overview&#8201;&#8212;&#8201;Intellectual Property,&#8221; elsewhere in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our contractual obligations increased materially from December&#160;31, 2020 as a result of entering into the Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P., which provides a term loan facility of up to $50.0&#160;million with a maturity date of March&#160;1, 2025, of which $20.0&#160;million was outstanding as of September&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;13, 2021, we borrowed an additional $10.0&#160;million under the term loan facility. Including the additional $10.0&#160;million borrowed, our contractual obligations under the Loan Agreement as of September&#160;30, 2021 include cash payments related to principal and interest of $2.2&#160;million within one year, $25.0&#160;million within one to three&#160;years, and $10.3&#160;million within three to five&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Off-Balance Sheet Arrangements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in SEC rules and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Critical Accounting Policies and Significant Judgments and Estimates</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our financial statements are prepared in accordance with U.S. GAAP. The preparation of our financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. Our critical accounting policies are summarized below. See Note 2 to our financial statements contained elsewhere in the registration statement of which this prospectus forms a part for a description of our other significant accounting policies. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Revenue Recognition</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our revenues generally consist of grant revenues, including revenues generated under Federal contracts and other awarded grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2014-09, Revenues from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;). This guidance became effective January&#160;1, 2019 for private companies, with early adoption allowed. We adopted ASC 606 on January&#160;1, 2019 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, there was no cumulative effect of applying the standard as of January&#160;1, 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of January&#160;1, 2019, we determined that there was no material impact that the adoption of ASC 606 had on our financial statements. We have determined that our government grants are not within the scope of ASC 606 as they do not meet the definition of a contract with a customer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We generate revenue primarily from government grants that reimburse us for certain allowable costs related to research and development efforts. We have determined that government grants are not within the scope of ASC 606 as they do not meet the definition of a contract with a customer. We have concluded that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the grants meet the definition of a contribution and are nonexchange transactions and have applied the contribution accounting model in Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition by analogy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We recognize funding received from grants as revenue, rather than as a reduction of research and development expenses, because we are the principal in conducting the research and development activities and these grants are central to our ongoing operations. We recognize revenue only after the qualifying expenses related to the grants have been incurred and it is reasonably assured that the expenses will be reimbursed and the revenue will be collectible. The related costs incurred are included in research and development expense in our statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Accrued Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable vendor personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our understanding of the status and timing of services performed relative to the actual status and timing may vary and may result in our reporting changes in estimates in a particular period. Changes in estimates have not resulted in any material changes to our accrued expenses to date. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stock-Based Compensation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We measure and recognize compensation expense for all options based on the estimated fair value of the award on the grant date. We use the Black-Scholes option-pricing model to estimate the fair value of option awards. The fair value is recognized as expense on a straight-line basis over the requisite service period. We account for forfeitures as they occur. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The determination of the grant date fair value of options using an option pricing model is affected principally by our estimated fair value of shares of our common stock and requires management to make a number of other assumptions, including the expected term of the option, the volatility of the underlying shares, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management&#8217;s good faith estimates at the time of measurement. These estimates are complex, involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These assumptions are estimated as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair Value of Common Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As our common stock has not historically been publicly traded, the fair value of the shares of our common stock underlying the options has historically been determined by our board of directors with input from management, after considering independent third-party valuation reports. See &#8220;Fair Value of Common Stock&#8221; and &#8220;Common Stock Valuation Methodology.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Term</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The expected term represents the period that stock options are expected to be outstanding. We calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Volatility</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The expected volatility was based on the historical share volatility of several publicly traded peer companies over a period of time equal to the expected term of the options, as we do not have any trading history to use to determine the volatility of our common stock. For purposes of identifying these peer companies, we considered the industry, stage of development, size and financial leverage of potential comparable companies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-Free Interest Rate</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Dividend Yield</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We have not paid dividends on our common stock nor do we expect to pay dividends in the foreseeable future. Accordingly, we have estimated the dividend yield to be zero. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fair Value of Common Stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Historically, for all periods prior to this transaction, the fair values of the shares of common stock underlying our options were determined on each grant date by our board of directors with input from management. In order to determine the fair value, our board of directors considered, among other things, contemporaneous valuations of our common stock and preferred stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately- Held-Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;) . Given the absence of a public trading market of our capital stock, the assumptions used to determine the estimated fair value of our common stock are based on a number of objective and subjective factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our stage of development and business strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prices, rights, preferences and privileges of our redeemable convertible preferred stock relative to our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our business, financial condition and results of operations, including related industry trends affecting our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the likelihood of achieving a liquidity event, such as an initial public offering or sale of our company, given prevailing market conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the lack of marketability of our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market performance of comparable publicly traded companies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. and global economic and capital market conditions and outlook. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Common Stock Valuation Methodology</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Option Pricing Method.&nbsp;&nbsp;&nbsp;Under the option pricing method (&#8220;OPM&#8221;), shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Probability-Weighted Expected Return Method.&nbsp;&nbsp;&nbsp;The probability-weighted expected return method (&#8220;PWERM&#8221;) is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, assuming various outcomes, as well as the economic and control rights of each share class. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on our early stage of development, we determined that the PWERM method, incorporating the OPM as one of several scenarios, was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock for valuations performed as of November&#160;13, 2020 and October&#160;23, 2019, which resulted in common stock valuations of $10.28 and $8.48 per share, respectively. In January, February, March and June&#160;2021, stock options were granted at fair market value with an exercise price of $10.28, consistent with the fair market value determined two&#160;months earlier in November&#160;2020. The $10.28 exercise price is greater than the public trading price of the AHAC Class&#160;A common stock as of the date of grant and also greater than the share price reflected in the $800&#160;million equity value agreed upon in connection with the Business Combination. We also utilized the PWERM method for our valuation as of June&#160;25, 2018, which resulted in a common stock valuation of $8.48 per share. In determining the estimated fair value of our common stock, our board of directors also considered the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. The estimated fair value of our common stock at each grant date reflected a non-marketability discount partially based on the anticipated likelihood and timing of a future liquidity event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the closing of the Business Combination, the fair value of our common stock will be determined based on the closing price of our common stock on the primary stock exchange on which our common stock is traded on the date stock options or other awards are granted under the 2021 Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Income Taxes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Income taxes are computed using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements. In estimating future tax consequences, we consider all expected future events other than enactment of changes in tax laws or rates. A valuation allowance is recorded to reduce net deferred tax assets to their realizable values if management does not believe it is more likely than not that the net deferred tax assets will be realized. As of December&#160;31, 2019 and 2020, we have recorded a full valuation allowance against our net deferred tax assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit can be recognized. Assessing an uncertain tax position begins with the initial determination of the sustainability of the position and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed. Additionally, we must accrue interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. We have not identified any uncertain tax positions for the&#160;years ended December&#160;31, 2019 and 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have analyzed our filing positions in all significant Federal and state jurisdictions where we are required to file income tax returns, as well as open tax&#160;years in these jurisdictions. As of December&#160;31, 2019 and 2020, we have determined that no uncertain tax positions would have a material impact on our financial statements. We are no longer subject to U.S. Federal, state, and local tax examinations by tax authorities for&#160;years before 2017 although carry-forward attributes that were generated prior to 2017 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and 2020, we had not recorded any amounts for unrecognized tax benefits. Our policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes, if any. As of December&#160;31, 2019 and 2020, we had no accrued interest or penalties related to uncertain tax positions, and no amounts had been recognized in our statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Recent Accounting Pronouncements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See Note 2 to our financial statements contained elsewhere in the registration statement of which this prospectus forms a part for a description of recent accounting pronouncements applicable to our financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Emerging Growth Company and Smaller Reporting Company Status</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte is an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We expect Humacyte to avail itself of the extended transition period and, therefore, while Humacyte is an emerging growth company it will not be subject to new or revised accounting standards at the same time that they </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:328pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">become applicable to other public companies that are not emerging growth companies, unless it chooses to early adopt a new or revised accounting standard. This may make it difficult or impossible to compare Humacyte&#8217;s financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, Humacyte is a &#8220;smaller reporting company&#8221; as defined in Item&#160;10(f)(1) of Regulation&#160;S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of audited financial statements. Humacyte will remain a smaller reporting company if (1)&#160;the market value of Humacyte common stock held by non-affiliates is less than $250&#160;million as of the last business day of the second fiscal quarter, or (2)&#160;Humacyte&#8217;s annual revenues in its most recent fiscal year completed before the last business day of its second fiscal quarter are less than $100&#160;million and the market value of Humacyte common stock held by non-affiliates is less than $700&#160;million as of the last business day of the second fiscal quarter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Quantitative and Qualitative Disclosure about Market Risk</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are exposed to market risk in the ordinary course of business. As of December&#160;31, 2020 and September&#160;30, 2021, we were not subject to any material market, currency, or interest rate risk. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our primary exposure to market risk is associated with changes in interest rates related to the interest income from our cash and cash equivalents of $39.9&#160;million and $240.4&#160;million as of December&#160;31, 2020 and September&#160;30, 2021, respectively, which we invest in money market funds invested only in obligations of the U.S. government and its agencies. Due to the short-term maturities and low risk profile of our cash and cash equivalents, an immediate 10.0% change in interest rates would not have a material effect on our financial position or results of operations.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Business Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Summary</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues with the goal of improving the lives of patients and transforming the practice of medicine. We believe our technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are initially using our proprietary, scientific technology platform to engineer and manufacture human acellular vessels, or HAVs. Our investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. We are developing a portfolio, or &#8220;cabinet&#8221;, of HAVs with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including trauma; AV access for hemodialysis; PAD; and coronary artery bypass grafting (&#8220;CABG&#8221;). In addition, we are developing our HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. We will continue to explore the application of our technology across a broad range of markets and indications including the development of urinary conduit, trachea, esophagus and other novel cell delivery systems. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is substantial clinical demand for safe and effective vascular conduits to replace and repair blood vessels throughout the body. Vascular injuries resulting from trauma are common in civilian and military populations, frequently resulting in the loss of either life or limb. Existing treatment options in the vascular repair, reconstruction and replacement market include the use of autologous vessels and synthetic grafts, which we believe suffer from significant limitations. For example, the use of autologous veins to repair traumatic vascular injuries can lead to significant morbidity associated with the surgical wounds created for vein harvest and prolonged times to restore blood flow to injured limbs, leading to an increased risk of amputation and infection. Synthetic grafts are often contraindicated in the setting of vascular trauma due to higher infection risk that can lead to prolonged hospitalization and limb loss. Given the competitive advantages our HAVs are designed to have over existing vascular substitutes, we believe that HAVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November 1, 2021, our HAVs have been implanted in approximately 465 patients. We are currently conducting Phase&#160;II and Phase&#160;III trials of our 6 millimeter HAV across two therapeutic indications, vascular trauma and AV access for hemodialysis, as well as continuing long-term follow up of patients in our Phase&#160;II PAD studies. We were granted Fast Track designation by the FDA for our 6 millimeter HAV for use in AV access for hemodialysis in 2014. We also received the first RMAT designation from the FDA, for the creation of vascular access for performing hemodialysis, in March&#160;2017. In addition, in 2018 our HAV product candidate was assigned a priority designation by the Secretary of Defense under Public Law 115-92, enacted to expedite the FDA&#8217;s review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel. Upon completion of our Phase&#160;III trials, we intend to submit a BLA to the FDA for indications in vascular trauma in 2022 and AV access for hemodialysis in 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have developed a novel paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. We have an 83,000 square foot bioprocessing facility housing our modular manufacturing process with the ability to manufacture HAVs of different diameters and lengths at commercial scale. As we continue to expand production, we believe we will have the ability to take advantage of economies of scale to reduce costs of production. We believe our established, controlled manufacturing process demonstrates a significant competitive advantage in the regenerative medicine market. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our technology is protected by our patent portfolio. Our patent portfolio, which includes certain patents licensed from parties as well as intellectual property generated internally at Humacyte, is comprised of 15 families of patents, many of which generally relate to the scaffolds used to make our vessels, the composition of our vessels and systems and methods of manufacturing our vessels. For more information, see &#8220;&#8212; Intellectual Property&#8221; below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We intend to continue to shape our commercial and distribution strategy by indication and pursue collaborations with partners in markets where such partners provide strategic opportunities in launching our product candidates and enabling access to specific patient populations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our world-class senior management team and board of directors will be instrumental in helping us achieve our goals. Our President and Chief Executive Officer, Laura Niklason M.D., PhD., who founded Legacy Humacyte, is an internationally respected physician scientist and a world leader in regenerative medicine technologies. Dr.&#160;Niklason is also a member of three national academies&#8201;&#8212;&#8201;Inventors, Medicine and Engineering. Our current Chairman of the Board is Kathleen Sebelius, the former Secretary of the Department of Health and Human Services (HHS), and the former Governor of Kansas. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Approach</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have developed an approach that relies on two key complementary elements to address the significant market opportunity for the global treatment of cardiovascular disease including patients in need of vascular replacement, repair and reconstruction, as well as vascular access for dialysis and future indications: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our proprietary scientific and engineering technology platform allows us to grow human tissues, which are ultimately decellularized and therefore expected to be non-immunogenic and universally implantable; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our novel, scalable manufacturing paradigm is designed to allow us to produce thousands of HAVs per year at the time of commercial launch, with the ability to expand manufacturing to meet expected future global demand. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Using this approach to manufacture, we are pursuing the use of acellular human tissues to address a broad range of disease indications, if approved. We intend to develop a readily available &#8220;cabinet&#8221; of HAVs of varying diameters and lengths to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Illustration of our Proposed HAV &#8220;Cabinet&#8221; for Vascular Repair, Reconstruction, and Replacement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_cabinet4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_cabinet4clr.jpg]" height="307" width="503" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Proprietary Scientific Technology Platform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved. The working cell stock is expanded using traditional cell culture techniques, and the cells are transferred onto a biocompatible, biodegradable polymer mesh within a flexible, single-use bioreactor bag. Over the course of weeks, the cells proliferate and build extracellular matrix while the polymer mesh degrades. The resulting bioengineered vessel is comprised of the aortic vascular cells and their deposited extracellular matrix. After completion of the culture period, we decellularize the bioengineered vessel using a proprietary combination of solutions. The resulting HAV retains the extracellular matrix constituents and, therefore, the biomechanical properties of the bioengineered vessel, but is cleansed of the cells and cellular components that could induce a foreign body response or immune rejection following implantation. Our functionally closed system allows for the HAV to be grown, decellularized and ultimately shipped within the same flexible bioreactor bag. Our HAVs are designed to be shipped to hospitals, trauma centers and outpatient surgical settings, where they can then be stored at refrigerated temperatures for immediate use by removing each HAV from its packaging. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following image summarizes key information about our proprietary scientific technology platform: </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_keyinfo4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_keyinfo4clr.jpg]" height="289" width="587" >
        </div>
        <div style="margin-top:16.7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Novel Manufacturing Paradigm</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have developed a novel paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. Our proprietary manufacturing process was designed with a modular approach allowing us to produce HAVs in smaller batches for clinical trials and scale out to larger batches for commercial manufacturing. The system used in our clinical trials from 2016 to 2021, including our Phase&#160;III trials, utilized a single tray within one growth drawer holding 10 HAVs per batch. In 2021 we commenced supplying our ongoing clinical trials with HAVs produced in our current, commercial-scale LUNA200 system, which consists of 20 growth drawers per production unit for a total of 200 HAVs per batch. Each growth drawer is capable of producing ten 42cm HAVs, each of which is contained within an individual bioreactor bag. Inside a LUNA200, a tubing network connects all HAVs, allowing the entire system to share nutritive media. In this way, a single LUNA200 can produce up to 200 HAVs (42cm in length) per batch while maintaining the critical operating parameters, such as biomechanical pulsing, that affect growth. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A thorough comparability assessment was performed to evaluate HAV batches produced in the single drawer system and used in Phase&#160;III studies versus the 20-drawer LUNA200 system. The study assessed 22 separate comparisons on the identity, strength, quality, purity, and potency of the HAV product. In this study, we observed that HAVs produced in the LUNA200 system were comparable to HAVs used in our Phase&#160;III trials. Additionally, a crossover study, called V011, completed enrollment of 30 subjects to evaluate HAVs that are manufactured on Humacyte&#8217;s commercial LUNA200 platform with the primary goal to evaluate the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">safety, efficacy and immunogenicity of the LUNA200-manufactured HAVs. Thus far in this trial we have observed comparable safety profile between HAV used in previous studies and the HAV manufactured in the LUNA200 commercial system. The results of the comparability assessment and the 30-day results from the V011 crossover study were submitted to the FDA. In 2021 the FDA authorized the use of HAVs produced in the commercial LUNA200 system to supply our ongoing clinical trials. We plan to also use the LUNA200 system for anticipated commercial launches of the HAV if it is approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our current 83,000 square foot manufacturing facility has completed utility connections for 33 LUNA200 systems, with additional space to further expand manufacturing capacity as needed, to over 40 LUNA200 systems. Currently, eight LUNA200 systems are installed and operational. </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_manufa4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_manufa4clr.jpg]" height="288" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that the LUNA200 can produce HAVs in diameter sizes from 3mm to 10mm and lengths from 10cm to 42cm, making the equipment suitable for the varied array of product candidates in our pipeline. We intend to introduce a 13cm-long HAV line extension after commercial launch of the 42cm HAV for surgeries that require shorter segments of HAV in the setting of vascular trauma and repair. Using our existing LUNA200 manufacturing equipment without modification, we believe we have the ability to generate 400 HAVs (13cm in length) or 200 HAVs (42cm in length) per manufactured batch. We have designed our manufacturing system to be functionally closed, to utilize single-use disposable materials with aseptic connections, and to be fully automated, which allows us to control and maximize HAV production. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on observations to date, the HAV has withstood maximal pressures that are comparable to those reported for native arteries. For example, the human aorta is reported to have rupture strengths around 1,400 mmHg, while human cerebral arteries rupture around 1,800 mmHg. We have observed HAVs withstanding maximal pressures of approximately 3,200 mmHg before rupturing, making their mechanical properties on par with native human blood vessels. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Market Opportunity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a biotechnology company with Phase&#160;III clinical trials in two indications and a strong pipeline for additional products and indications. Additionally, we have had significant interest from surgeons to use our HAV in life and limb saving surgeries as demonstrated by their requests to the FDA to use our HAV in multiple expanded access (compassionate use) cases where no alternative was available. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Initial Market Opportunity in Vascular Repair, Reconstruction and Replacement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe there is a significant market opportunity for our technology across a number of important clinical areas within vascular reconstruction and replacement including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and adult cardiac surgery. To treat these diseases and conditions, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">patients often require invasive cardiovascular surgery, which involves the use of alternative vascular synthetic materials or autologous vessels harvested from elsewhere in the body. For more information about our evaluation of market opportunity, see &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to the Development and Commercialization of Our Product Candidates&#8201;&#8212;&#8201;The sizes of the market opportunities for our product candidates have not been established with precision and are estimates that management believes to be reasonable. If these market opportunities are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the relevant patient population, our revenue and ability to achieve profitability might be materially and adversely affected.&#8221; </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-tbl_vascu4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-tbl_vascu4clr.jpg]" height="313" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:13.19pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Vascular Trauma</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We believe our addressable market opportunity in trauma is approximately $3.2&#160;billion worldwide. Arterial injuries resulting from vascular trauma are common in military and civilian populations, frequently resulting in the loss of life or limb. In military populations, as the rate of battlefield fatalities has been declining due to faster evacuations and more robust protection from body armor, the rate of survivable vascular injuries has been increasing. In civilian populations, trauma injuries are primarily caused by motor vehicle accidents, gun violence, mass casualty terrorist attacks, stabbings and blunt trauma. We estimate that central or peripheral vascular injuries in civilian patients account for approximately 150,000 of all injuries reported in global trauma patients. Furthermore, these injuries account for greater than 20% of all trauma-related deaths. Extending management&#8217;s current estimated average global pricing of $21,000 per HAV to the approximately 150,000 total annual global patients suggests a total addressable market opportunity of approximately $3.2&#160;billion. While we believe our assumptions and the data underlying this estimate are reasonable, they may be inaccurate or based on imprecise data; in addition, the assumptions and conditions underlying the estimate may change at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Civilian patients with central or peripheral vascular injuries are estimated to account for approximately 75,000 of all injuries reported in trauma patients in the U.S., inclusive of urgent and iatrogenic vascular trauma injuries. However, these injuries account for greater than 20% of all trauma-related deaths. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our HAVs will be a promising alternative that can address critical gaps in existing treatment options for acute vascular injuries due to trauma. We are developing our HAVs with the goal of providing an effective solution in all time-constrained surgical environments and in resource-limited, infection prone battlefield environments. The ability to create immediately available, non-immunogenic, universally implantable material that is less susceptible to infection represents a clinically significant advantage over existing options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Arteriovenous Access for Hemodialysis</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We believe our addressable market opportunity in patients with end stage renal disease requiring AV access for hemodialysis is approximately $6.5&#160;billion worldwide. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, an estimated $5 to $6&#160;billion per year is spent on hospital admissions in hemodialysis patients with infection and access complications. In 2017, there were nearly 500,000 patients receiving hemodialysis in the United States. Annually, at least 160,000 existing or new dialysis patients require a new AV access in the U.S. and an additional 150,000 patients require a new AV access in Europe and Japan. Extending management&#8217;s currently estimated average global pricing of $21,000 per HAV to the approximately 310,000 total annual global patients suggests a total addressable market opportunity of approximately $6.5&#160;billion. While we believe our assumptions and the data underlying this estimate are reasonable, they may be inaccurate or based on imprecise data; in addition, the assumptions and conditions underlying the estimate may change at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Hemodialysis patients are a chronically ill patient population, suffering an average of 1.8 hospital admissions, three visits to the emergency department, and four days hospitalized for infections each year. The two most common causes of hospital admissions in hemodialysis patients are infection and access complications, resulting in an estimated total spend of $5&#160;billion to $6&#160;billion per year. For hemodialysis patients, an infected access can lead to sepsis, which is life threatening, is the most expensive cause for hospitalization in the United States and carries at least a 10% overall mortality rate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that our HAVs, when used as AV access for hemodialysis, can decrease infections and dialysis access failures, which would improve patient outcomes and lower the burden of dialysis costs on the healthcare system. We expect to file a BLA with the FDA, seeking approval for the use of HAV in AV access for hemodialysis, and to target our commercialization efforts particularly toward those patients who are at high risk of fistula failure or non-maturation, or for those patients at high risk of vascular access infection. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Peripheral Artery Disease (PAD)</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We believe our addressable market opportunity in patients with PAD is approximately $10.5&#160;billion worldwide. PAD is a cardiovascular disease of blood vessels located outside the brain and heart. PAD occurs when plaque builds up in arteries that carry blood to the head, organs, and limbs. PAD usually affects arteries in the legs, but it can also affect arteries that carry blood from heart to head, arms, kidneys, and stomach. We believe our HAVs can be used as a bypass conduit in patients with PAD. Peripheral arterial bypass procedures are common with as many as 160,000 PAD related procedures reported annually in the U.S. and over 550,000 annual PAD procedures estimated globally. Expanding into markets outside the U.S., annual peripheral bypass procedures are nearly 170,000 per year in Europe, and approximately 220,000 per year in Asia. Extending management&#8217;s currently estimated average global pricing of $19,000 per HAV to the approximately 550,000 total annual global patients suggests a total addressable market opportunity of approximately $10.5&#160;billion. While we believe our assumptions and the data underlying this estimate are reasonable, they may be inaccurate or based on imprecise data; in addition, the assumptions and conditions underlying the estimates may change at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While endovascular techniques have become available over the past ten&#160;years to treat an array of vascular occlusions, depending on the nature and length of the blockage these types of treatment options have met with both mixed success and durability compared to conventional surgical bypass. Both angioplasty and stenting procedures provide near term success, however long-term durability has remained a question. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Type I Diabetes</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Type 1 diabetes, caused by auto-immune destruction of insulin-producing cells in the islets of the pancreas, is a devastating disease affecting more than 1.2&#160;million people in the United States, and costing at least $10&#160;billion to $14&#160;billion annually. In Europe, the number of patients suffering with Type 1 diabetes is estimated at approximately 2.2&#160;million. Even with the newer insulin delivery technologies, less than one-third of patients achieve consistent target blood sugar levels. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pancreas transplantation is limited due to the associated morbidity and cost of the whole pancreas organ transplantation procedure. As an alternative to pancreas transplantation, the &#8220;Edmonton Protocol&#8221; has been developed whereby insulin producing cells are transplanted into the portal vein in the liver. However, the majority of the injected cells are lost to inflammation and clotting, and only 16% of Type 1 diabetes patients who receive the Protocol are cured long term. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our HAVs present a means to deliver a therapeutic number of pancreatic islets to patients with Type 1 diabetes. Pancreatic islets are embedded on the outer surface of our HAV and implanted as an AV graft, analogous to the outpatient procedure done for hemodialysis access. After implantation, the islets </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">have the potential to sense blood glucose and then respond by secreting appropriate levels of insulin to maintain glucose levels in the blood. We have termed this new paradigm for pancreatic islet cell delivery the &#8220;Biovascular Pancreas.&#8221; Proof-of-concept studies in rodents and pigs have shown promise that the BVP can reduce glucose levels. Studies in non-human primates are planned. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that a reliable, low-risk, and easily implantable islet cell delivery method that could ensure the survival and functionality of a therapeutic number of islet cells in a human adult would be transformational for the treatment of Type 1 diabetes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Coronary Artery Bypass Graft (CABG)</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We believe our current market for CABG is approximately $69.5&#160;billion worldwide. CABG is a surgery used to treat a blockage or narrowing of one or more of the coronary arteries to restore the blood supply to the heart muscle. We believe our HAVs can replace existing vascular substitutes and improve patient outcomes, particularly in obese patients or those suffering from diabetes, in whom the risks of saphenous vein harvesting are more substantial. CABG procedures are common, with 350,000 CABG procedures reported annually in the U.S. and over 765,000 annual CABG procedures globally. Extending management&#8217;s currently estimated average global cost for a CABG procedure of $91,000 per patient to the approximately 765,000 total annual global procedures suggests a total current addressable market opportunity of approximately $69.5&#160;billion. While we believe our assumptions and the data underlying this estimate are reasonable, they may be inaccurate or based on imprecise data; in addition, the assumptions and conditions underlying the estimates may change at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Typically, a CABG operation involves the use of both the patient&#8217;s own artery and vein. In patients who are obese, have diabetes, or who are very elderly, there are higher risks for vein harvest complications, including failure to heal the vein harvest incision, infection, and prolonged swelling of the operative leg. Furthermore, complications from the vein harvest incision site are more common than complications from the chest incision in CABG patients. It is estimated that approximately 20% of patients requiring bypass surgery have no suitable grafts available, with sources reporting as high as 45% of CABG patients are without suitable autologous vein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Pediatric Heart Surgery</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We are developing a smaller diameter HAV product for use in pediatric heart surgery as a Blalock Taussig (BT) shunt. The BT shunt is a surgical procedure that is used to increase pulmonary blood flow for the treatment of babies born with a complex congenital heart defect called Tetralogy of Fallot, a common type of &#8220;blue baby syndrome&#8221;. In 2018, there were 4&#160;million babies born in the United States and approximately 1,500 to 2,000 of these babies were born with Tetralogy of Fallot. The BT shunt is a life-saving procedure for these babies, and we plan to submit an orphan drug application for use of our HAV as a BT shunt for infants born with cyanotic congenital heart defects. Although 3&#8201;&#8211;&#8201;4mm inner diameter expanded polytetrafluoroethylene (&#8220;ePTFE&#8221;) grafts are currently used as the most common BT shunt, they suffer from limitations that impact morbidity and mortality in these infants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Clinical and Pre-Clinical Stage Product Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table highlights key information about our current product pipeline: </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-bc_pipeline4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-bc_pipeline4clr.jpg]" height="167" width="507" >
        </div>
        <div style="text-indent:20pt; margin-top:13.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We began clinical evaluations of our HAVs in December&#160;2012, with the enrollment of the first Phase&#160;II patient in our V001 hemodialysis access trial in Europe. Since then, we have completed one Phase&#160;II trial in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">the United States, and currently have seven trials either actively enrolling or in long-term follow-up. HAVs have been implanted in approximately 60 clinical centers in six countries around the world, and by more than 100 practicing surgeons. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Overview of Clinical Trials Assessing the Safety and Efficacy of the HAV in Multiple Indications</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;margin-bottom:5.61000000000001pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:80.34pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Clinical Trial</font>
              <br >
              <font style="letter-spacing:-0.16pt;">Number </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:48pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Begin</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Enrollment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:80.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Design/Phase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subjects </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:60pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Outcomes** </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.263pt 0pt 2.097pt 0pt; width:80.34pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Vascular Trauma</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Vascular Trauma </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:80.33pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II/III Single-arm Historical Comparator Unblinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:80.33pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Targeting 75&#177; total</font>
                <br >
                <font style="letter-spacing:0.16pt;">46 total (32 lower extremity) enrolled as of November&#160;&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Enrolling </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Trial is currently enrolling </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:80.34pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Dialysis Access</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V001 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">40 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">10-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 95%</font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 100%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 97%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 0%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0</font>
                <br >
                <font style="letter-spacing:0.16pt;">Five-year SP: 58% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V003 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">20 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Complete 2-year follow-up </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 95%</font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 89%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 81%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 4% (1 event)</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;white-space:nowrap;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V006 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2016 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;III Prospective Randomized Blinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">355 total; 177 received HAV</font>
                <br >
                <font style="letter-spacing:0.16pt;">178 received ePTFE </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">5-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP HAV: 93%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP HAV: 82%</font>
                <br >
                <font style="letter-spacing:0.16pt;">24-month SP HAV: 67%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP ePTFE: 80%</font>
                <br >
                <font style="letter-spacing:0.16pt;">24-month SP ePTFE: 74%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate HAV/yr: 0.93</font>
                <br >
                <font style="letter-spacing:0.16pt;">% Infection Rate ePTFE/yr: 4.5% </font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of HAV Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V007 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;III Prospective Randomized Blinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Target 240 total; 204</font>
                <br >
                <font style="letter-spacing:0.16pt;">enrolled (as of November&#160;&#160;1, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Enrolling </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Trial is currently enrolling </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V011 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II (LUNA200 manufacturing system) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">3-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 97%</font>
                <br >
                <font style="letter-spacing:0.16pt;">30-day SP: 100%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 83%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate HAV/yr: 0%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of HAV Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Peripheral Arterial Disease</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.33pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V002 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Peripheral Arterial Disease </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">20 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:60pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">10-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 100%</font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 84%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 84%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 0%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:80.34pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">V004 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:48pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">Peripheral Arterial Disease </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2016 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:80.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">15 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:60pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">5-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.427pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 100%</font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 86%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 64%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 0%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Amputations: 0</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">PP: Primary Patency, which is the interval of time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis, or the time of measurement of patency, i.e. patent without interventions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:72.43pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">SP: Secondary Patency, which is the interval from the time of access placement until abandonment, i.e. patent with or without interventions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;&#160;1, 2021, approximately 465 patients worldwide have received our HAVs for the treatment of trauma, AV access for hemodialysis, PAD, and in expanded access cases resulting in approximately 915 subject-years of exposure to the HAV. Our cumulative HAV exposure is approximately 760 subject-years in the hemodialysis access population, 110 subject-years in the PAD population, and 45 subject-years in the arterial trauma population. The longest our HAV has been in a patient and used for dialysis is more than eight&#160;years and, there have been more than 105,000 estimated dialysis sessions using our HAVs. Additionally, a total of 15 expanded access/compassionate use cases have been granted by the FDA. Throughout all of these trials, we have observed that our HAVs functioned as intended and provided functional blood flow to affected limbs. We have also observed consistent durability with a strong tolerability profile. Furthermore, we have observed no evidence of clinically relevant immunologic reactions to our HAVs, supporting the potential use of our HAVs as off-the-shelf, universally implantable, bioengineered human tissues. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Overall, the HAV has functioned well and as intended, across eight different clinical trials in three clinical indications. The HAV has been implanted in approximately 465 patients, across approximately 60 clinical sites in six countries, over more than eight&#160;years (as of November&#160;&#160;1, 2021). Rates of primary and secondary patency were similar across trial designs and disease states, with 30-day primary patency ranging from 95%&#8201;&#8211;&#8201;100%. Six-month secondary patency ranges from 84%&#8201;&#8211;&#8201;100%, and 12-month secondary patency ranges from 81%&#8201;&#8211;&#8201;97%, across multiple clinical trials, disease states, and patient age ranges and demographics. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have observed zero instances of clinical rejection of the HAV in any clinical trial over the past eight&#160;years, suggesting that the HAV was not immunologically rejected after implantation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based on clinical trial results to date, we have observed that the HAVs were highly resistant to infection, with an infection rate averaging approximately 1.3% per patient-year in our AV access trials, and low infection rates currently in our trauma and PAD trials. Vascular graft infections are a potentially serious complication and can result in adverse outcomes such as sepsis, hospitalization, long-term antibiotic use, repeat procedures and even death. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">HAVs Remodel with Host Cells After Implantation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, based on clinical samples obtained during our Phase&#160;II AV access trials and published in three peer reviewed journals, </font><font style="font-style:italic;letter-spacing:0.2pt;">The Lancet</font><font style="letter-spacing:0.2pt;"> in 2016, </font><font style="font-style:italic;letter-spacing:0.2pt;">Science Translational Medicine</font><font style="letter-spacing:0.2pt;"> in 2019, and in the </font><font style="font-style:italic;letter-spacing:0.2pt;">Journal of Vascular Surgery</font><font style="letter-spacing:0.2pt;"> in 2020, we observed that the HAV became populated with healthy, vascular cells from the patient. Over time, we&#8217;ve published that the patient&#8217;s cells have been observed to transform the HAV into a multi-layered living tissue similar to native blood vessels. In these trials we have also observed ongoing cellular repair of HAV tissues that had been previously injured during cannulation with dialysis needles, which suggests that the recellularized HAV was capable of self-healing. The image below shows an HAV that had been implanted in a hemodialysis patient for 44 weeks, that had developed alpha-actin positive vascular smooth muscle cells throughout the wall (red staining in the left-hand panel), and had developed a layer of CD31+ endothelial cells on the inner luminal surface of the HAV (line of red endothelial cells indicated in the right-hand panel). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Histological Images of HAV Repopulated with the Patient&#8217;s Own Vascular Cells</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_histolo4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_histolo4clr.jpg]" height="233" width="549" >
        </div>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Existing Options for Surgical Treatment of Vascular Disease Are Not Sufficient</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The table below contains a summary of the efficacy of autologous veins, ePTFE grafts, cryopreserved human cadaveric veins, and preserved bovine veins. For the treatment of vascular trauma, saphenous vein presents challenges in terms of time to procure the vein, and ePTFE grafts carry extremely high infection rates: 24% &#8211; 29% per patient year in the studies below. Similarly, autogenous fistulas and ePTFE grafts for dialysis access have low functional patencies at six and 12&#160;months, and ePTFE is burdened with high rates of annual infection: 3%-17% in the studies below. Both cryopreserved human cadaver vein, and preserved bovine veins, have low patency at 12&#160;months, and also suffer from high rates of aneurysm formation. Lastly, for bypass of PAD, vein has acceptable patency but is not available for all subjects, while ePTFE carries lower patencies and higher infection risk, and bovine vein becomes aneurysmal at unacceptably high rates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Published Studies in Vascular Surgery</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We derived the data in the table below from data contained in certain published papers on vascular trauma, hemodialysis and PAD between 2002 and the present. These data are from different studies and thus are not directly comparable. In addition, many of these papers reported on additional endpoints that are not included in the table below. </font>
        </div>
        <table style="width:456pt;height:226.94pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:91.8pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Clinical </font>
              <br >
              <font style="letter-spacing:-0.16pt;">Indication </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:80.24pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Type of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conduit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:42.85pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patients </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Published </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Secondary </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patency </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Infection </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">patient-year) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Rejection </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:6.2pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">
              <div style="line-height:10.2pt;font-weight:bold;">
                <font style="letter-spacing:-0.17pt;">Vascular Trauma</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.19pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.17pt;">Saphenous Vein</font>
                <br >
                <font style="letter-spacing:0.17pt;">(autologous) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2002&#8201;&#8211;&#8201;2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">24 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="white-space:nowrap; text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: ~78% function </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">4% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:13.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2014 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">152 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">30&#160;days: ~90% function </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:5.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.1900000000001pt; padding-bottom:-1.8947806286936E-14pt;">
                <font style="letter-spacing:0.17pt;">ePTFE</font>
                <br >
                <font style="letter-spacing:0.17pt;">(synthetic graft) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2002&#8201;&#8211;&#8201;2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">25 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="white-space:nowrap; text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: ~50% function </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">24% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.49999999999994pt;height:13.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">14 of 95 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">30&#160;days: ~79% function </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">29% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:5.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">
              <div style="line-height:10.2pt;font-weight:bold;">
                <font style="letter-spacing:-0.17pt;">Hemodialysis Access</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.1900000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.17pt;">Fistula</font>
                <br >
                <font style="letter-spacing:0.17pt;">(autogenous) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">Post-2005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2,800 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 75% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:13.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">14,892 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">6&#160;months: 51% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.24pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">6,439 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">4% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.24pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">602 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">6&#160;months: 61% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.47pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:5.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.2pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.17pt;">ePTFE</font>
                <br >
                <font style="letter-spacing:0.17pt;">(synthetic graft) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">128 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">6&#160;months: ~60% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:13.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">&gt; 400 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">3%&#8201;&#8211;&#8201;17% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.24pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">&gt; 3,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 70% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.46pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">9% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:5.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.45pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.2pt; padding-bottom:0.566666666666666pt;">
                <font style="letter-spacing:0.17pt;">Cryovein </font>
                <br >
                <font style="letter-spacing:0.17pt;">(cryopreserved human </font>
                <br >
                <font style="letter-spacing:0.17pt;">cadaver vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2002 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">45 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 80% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.45pt 0pt 2pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">100% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.2pt;height:28.14pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.317pt 0pt 0.5pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2004 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.317pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.317pt 0pt 0.5pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.19pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: ~65%</font>
                <br >
                <font style="letter-spacing:0.17pt;">Aneurysm rate: 18% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.317pt 0pt 0.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.317pt 0pt 0.5pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">~100% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:173.84pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:91.8pt;text-align:left;">
              <div style="line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Clinical </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:80.24pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Type of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conduit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:42.85pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patients </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Published </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Secondary </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patency </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Infection </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">patient-year) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Rejection </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.2pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:80.24pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">Procol</font>
                <br >
                <font style="letter-spacing:0.17pt;">(bovine vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">186 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 66%</font>
                <br >
                <font style="letter-spacing:0.17pt;">Aneurysm rate: 3.2% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">5.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.107pt 0pt 1.383pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.2pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:91.8pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:0.17pt;">Peripheral Arterial Disease </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:80.24pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">Saphenous Vein</font>
                <br >
                <font style="letter-spacing:0.17pt;">(autologous) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">12&#160;months: ~86% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.357pt 0pt 1.383pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:5.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:3.49pt 0pt 0.5pt 0pt; width:80.24pt;" rowspan="2">
              <div style="text-align:center; line-height:10.19pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.17pt;">ePTFE</font>
                <br >
                <font style="letter-spacing:0.17pt;">(synthetic graft) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:42.85pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:35.58pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">61 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">12&#160;months: ~80% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:42.67pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:30.91pt;">
              <div style="text-align:center; line-height:10.2pt;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;height:13.95pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">101 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.96pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 76%&#8201;&#8211;&#8201;89% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:42.67pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.24pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2011 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">273 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">12&#160;months: 81% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:42.67pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:80.24pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">496 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:95.95pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.48pt 0pt 1.97pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">3.8% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.2pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:91.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:80.24pt;">
              <div style="text-align:center; line-height:10.19pt;">
                <font style="letter-spacing:0.17pt;">Procol</font>
                <br >
                <font style="letter-spacing:0.17pt;">(bovine vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:42.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">7 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:95.95pt;">
              <div style="text-align:center; line-height:10.19pt;">
                <font style="letter-spacing:0.17pt;">6&#160;months: 50%</font>
                <br >
                <font style="letter-spacing:0.17pt;">12&#160;months: 50%</font>
                <br >
                <font style="letter-spacing:0.17pt;">Aneurysm Rate: 29% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.347pt 0pt 1.97pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">N/A</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.21pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Proposed Indication #1:&nbsp;&nbsp;&nbsp;Use of HAV to Repair Vascular Trauma</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Overview of Vascular Trauma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Arterial injuries resulting from vascular trauma are common in military and civilian populations, frequently resulting in the loss of life or limb. In military populations, as the rate of battlefield fatalities has been declining due to faster evacuations and more robust protection from body armor, the rate of survivable vascular injuries has been increasing. In civilian populations, trauma injuries are primarily caused by motor vehicle accidents, gun violence, mass casualty terrorist attacks, stabbings and blunt trauma. Consequently, we believe there is an increasingly urgent unmet need for novel materials that are immediately available for permanent vascular repair for both civilian and military vascular trauma. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Options in Surgical Treatment of Vascular Trauma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.4pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_surgic4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_surgic4clr.jpg]" height="257" width="597" >
        </div>
        <div style="text-indent:20pt; margin-top:12.11pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Autologous vein is the preferred conduit for vascular repair. However, harvesting of autologous vein is not always feasible, due to damage to vein or lower limb, prior vein harvest, inadequate size of the vein or venous disease. Harvesting autologous vein is a serious operation that requires additional time and resources. Delaying the time from injury to operative intervention from less than one hour, to three hours or greater, more than doubles the risk of limb amputation. Limb amputation, in turn, almost triples the length of intensive care unit stay, nearly doubles the length of hospital stay, and is devastating to patient quality of life. Additionally, the morbidity associated with saphenous vein harvest includes surgical site infections, chronic pain, and limb swelling. Synthetic materials have been shown to be inferior to autologous vein in resistance to infection and durability and, therefore, are generally only used for vascular repair when autologous vein is not an option. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Solution for Vascular Trauma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe our HAVs will be a promising alternative that can address critical gaps in existing treatment options for acute vascular injuries due to trauma. We are developing our HAVs with the goal of providing an effective solution in all time-constrained surgical environments and in resource-limited, infection prone battlefield environments. The ability to create immediately available, non-immunogenic, universally implantable material that is less susceptible to infection represents a clinically significant advantage over existing options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte has a strong working relationship with the DoD that has led to a partnership over the last decade to support their unmet need to reconstruct and repair vascular injuries through the development of our HAVs. As a result of this collaboration and partnership with the DoD, we anticipate Humacyte would supply HAVs for use in military hospitals to treat injured soldiers and veterans. The DoD assigned a priority designation to the HAV technology under Public Law 115-92. Under this law, FDA and DoD work together to expedite the development and review of critical technologies and therapies requested by DoD. Additionally, we have received an approximately $7&#160;million grant from the DoD for the continued development of our HAVs for vascular reconstruction and repair. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Current Phase&#160;II/III Trial for Vascular Trauma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Trial Design:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our ongoing V005 trial is a single-arm, multi-center, non-randomized clinical trial to evaluate the efficacy, safety and tolerability of our 6 millimeter HAV in replacement or reconstruction of vascular tissues in patients with life or limb-threatening vascular trauma. Since the V005 trial is a single-arm, non-randomized, open label study, we have the ability to track ongoing efficacy and safety. The current primary efficacy endpoint evaluates primary patency of the HAV at 30&#160;days. Based on the results we have observed to date and discussions with the FDA and DoD, we expect that the final design of the trial will support the submission of a BLA in the second half of 2022 or in 2023. Based on conversations with the FDA, we anticipate that analysis of data from V005 will focus on patients with lower extremity injuries. The final number of subjects to be enrolled and evaluated in the study is dependent on additional guidance from the FDA, but is currently estimated to approximate 75. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Status of Phase&#160;III Trial of HAV in Vascular Trauma (as of November&#160;&#160;1, 2021)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:77.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Clinical</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Trial</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Begin </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Enrollment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Design/Phase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Subjects </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Outcomes** </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:36pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">V005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Vascular Trauma </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:36pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Phase&#160;II/III Single-arm Historical Comparator Unblinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Targeting 75&#177; total</font>
                <br >
                <font style="letter-spacing:0.2pt;">46 total (32 lower extremity) enrolled as of November&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:36pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Enrolling </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Trial is currently enrolling</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">PP: Primary Patency, which is the interval of time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis, or the time of measurement of patency, i.e. patent without interventions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:5.8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SP: Secondary Patency, which is the interval from the time of access placement until abandonment, i.e. patent with or without interventions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Current Trial Status:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;During 2020, we increased the number of trial sites for the V005 trial in the U.S., from seven to 20 sites. We are currently working to expand sites in the U.S., as well as add additional sites in Poland and Israel. We anticipate that we will reach at least 28 activated sites in the V005 trial during 2021. Increasing the number of sites is expected to provide a broader patient cohort for enrollment in the trial, providing more extensive clinical exposure to differing types of vascular traumatic injury. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The range of trauma injuries in V005 has been broad, including penetrating trauma cases, blunt injury cases, and iatrogenic injuries. Mechanisms of injury have included motor vehicle accidents, gunshot wounds, industrial accidents, falls, and iatrogenic injuries from other interventional or surgical procedures. The HAVs have been placed throughout the body, including in the lower limbs, upper limb, and torso. The HAV has been used to repair the axillary artery, femoral artery, popliteal artery and vein, and the brachial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:107pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">artery in the V005 trial. Many of the injuries treated in the V005 trial, including industrial accidents, motor vehicle accidents, and some gunshot wounds, are contaminated injuries that are at elevated risk of graft infection. Nonetheless, as of November&#160;1, 2021, there has been only one report of HAV infection in any V005 subject, despite a number of instances where the HAV has been implanted into contaminated surgical fields of acute vascular wounds. There have been several instances of local wound infections, but importantly only one of these instances has led to infection of the HAV material itself, which we believe represents a significant advantage of the HAV over ePTFE grafts, which have a higher propensity to become infected in contaminated or infected wound beds. There have been no reports of limb amputation that occurred as a result of HAV malfunction or loss of patency. The resistance to infection we have observed in trials to date is particularly important in traumatic injuries which are often caused by infected material (i.e., knife, car accident, blast injury). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the figure below, a photograph is shown of an HAV that was used to repair both an artery and a vein in the knee of a patient who suffered a gunshot wound. This patient was doing well at the 30-day follow-up visit with both repairs remaining patent and functional. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Intra-operative photograph of HAV repair of popliteal artery (left) and vein (right) in V005 subject.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_havrepar4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_havrepar4clr.jpg]" height="197" width="257" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Indication #2:&nbsp;&nbsp;&nbsp;Use of the HAV for Arteriovenous Access for Hemodialysis</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview of Hemodialysis and Existing Methods of Arteriovenous Access for Hemodialysis</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">End-stage renal disease (&#8220;ESRD&#8221;) develops when chronic kidney disease progresses to a point where either dialysis or a kidney transplant is required for the patient to survive. For hemodialysis to be conducted, a point of vascular access to the patient&#8217;s circulatory system must be created, termed vascular access, so that blood can be transported from the body to the dialyzer and then back to the body. The demand for vascular access conduits includes the need for both new hemodialysis patients who have progressed to ESRD requiring an initial access, and existing patients that require the replacement of their existing access. There are currently three traditional methods for obtaining vascular access for hemodialysis: an AV fistula, a synthetic graft, and a catheter. Each of these vascular access methods has substantial limitations, as outlined below: </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Three Traditional Methods for Obtaining Vascular Access for Hemodialysis</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.99pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_methods4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_methods4clr.jpg]" height="289" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:14.2pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fistula</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;An AV fistula is created by surgically connecting a vein to an artery, typically in the patient&#8217;s arm. Fistulae are often considered the preferred means of access for hemodialysis due to lower infection rates of approximately 0.5%&#8201;&#8211;&#8201;1.5% per patient-year as well as long-term durability. However, many patients are not suitable candidates for fistula placement, due to small vessel anatomy, advanced age, obesity or other comorbidities. Approximately 40% of patients who undergo surgery for fistula creation will not gain any benefit from the surgery because the fistula lacks sufficient vein enlargement and increased blood flow, a process called fistula maturation, that is necessary for hemodialysis. Additionally, during the period in which the fistula is maturing, catheters are generally used to provide the patient access for dialysis. There is a high risk of infection and morbidity, and health care cost, associated with prolonged catheter dependence while waiting for the fistula to mature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Catheters</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A catheter, which is tunneled underneath the skin and placed directly into a large vein in the patient, is generally the least desirable access solution. Given the time necessary for fistulae to mature, the vast majority of patients in the United States begin hemodialysis using a catheter while awaiting fistula maturation. Catheters have rates of blood stream infections as high as 200% per patient-year, with high associated morbidity and health care costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Synthetic graft</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A synthetic graft, typically made from ePTFE and sewn between an artery and vein in the patient&#8217;s arm, is generally used in patients who are not candidates for fistulae. The drawbacks of synthetic grafts include higher infection rates, which can be as high as 10%&#8201;&#8211;&#8201;15% per patient-year, and gradual degradation of the non-healing ePTFE graft material caused by persistent needle punctures. A recent systematic meta-analysis measuring the functional patency of ePTFE grafts shows that, on average, only 70% of ePTFE dialysis access grafts remain functional one year after implantation. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Distribution of Hemodialysis Access Modes in Use in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:38.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:306.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Access Type </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fistulae </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Catheters </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Synthetic Grafts </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Incident Patients: At Initiation of Hemodialysis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">16.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">80.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:18.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.54pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prevalent Patients: For Ongoing Hemodialysis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">64.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">18.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">16.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:18.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.99pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Published Data in Hemodialysis Access</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We derived the data in the table below from data contained in certain published papers on hemodialysis between 2002 and the present. These data are from different studies and thus are not directly comparable. In addition, many of these papers reported on additional endpoints that are not included in the table below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:1.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:251.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:104.59pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Clinical </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:67.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Type of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conduit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41.6pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patients </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Published Secondary </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patency Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Infection (per </font>
                <br >
                <font style="letter-spacing:-0.16pt;">patient-year) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Rejection </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:67.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Fistula</font>
                <br >
                <font style="letter-spacing:0.2pt;">(autogenous) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Post-2005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2,800 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 75% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">14,892 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6&#160;months: 51% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:104.59pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Hemodialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6,439 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">602 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6&#160;months: 61% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:67.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">ePTFE</font>
                <br >
                <font style="letter-spacing:0.2pt;">(synthetic graft) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">128 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6&#160;months: ~60% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&gt; 400 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3%&#8201;&#8211;&#8201;17% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">&gt; 3,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 70% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">9% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:67.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Cryovein</font>
                <br >
                <font style="letter-spacing:0.2pt;">(cryopreserved </font>
                <br >
                <font style="letter-spacing:0.2pt;">cadaver vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2002 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">45 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 80% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">100% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.61pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2004 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: ~65% </font>
                <br >
                <font style="letter-spacing:0.2pt;">Aneurysm rate: 18% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">~100% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:104.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:67.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Procol</font>
                <br >
                <font style="letter-spacing:0.2pt;">(bovine </font>
                <br >
                <font style="letter-spacing:0.2pt;">vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:41.6pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2005 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">186 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:88.89pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 66% </font>
                <br >
                <font style="letter-spacing:0.2pt;">Aneurysm rate: 3.2% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:44.82pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Overview of HAV Experience in Hemodialysis Access:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A table listing our clinical trials of the HAV in hemodialysis access is included below. We have implanted the HAV into approximately 370 total patients for hemodialysis access, for a total of more than 760 patient-years of exposure, as of November&#160;1, 2021. Throughout these trials, we have observed consistent and sustained high primary patency rates, ranging from 95%&#8201;&#8211;&#8201;100% at 30&#160;days. Secondary patency of the HAV at 6&#160;months ranges from 84%&#8201;&#8211;&#8201;100%. Consistently, we have observed zero instances of clinical rejection of any HAV in any hemodialysis access trial. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Implantation of HAV for Hemodialysis</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_implant4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_implant4clr.jpg]" height="97" width="304" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have also observed in multiple clinical trials that our HAVs had a low infection susceptibility during use for hemodialysis, with a rate lower than 1% per patient-year across all studies. The low infection susceptibility we observed in our trials of our HAVs may be a result of the HAV&#8217;s potential to become a living tissue as it becomes populated by cells from the patient&#8217;s body. Since living tissues are known to have resisted infection due to interactions with host white blood cells and immunological defense systems, it is possible that the repopulated HAV resists infection for the same reasons that native arteries and veins resist infections, as is observed with autogenous fistulas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have also observed early evidence of potential healing from the cells that repopulate the HAV after needle puncture for hemodialysis. In examining HAV explanted segments we have observed healed needle cannulation tracts with cells expressing smooth muscle markers. This self-healing indicates that the HAV repaired itself while being used as a hemodialysis access, which we believe is a distinct feature not present in synthetic materials, and, to our knowledge, has not been observed before for any other regenerative medicine product. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Our Current Phase&#160;II and Phase&#160;III Trials of the HAV in Hemodialysis Access</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:11.9900000000001pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;margin-bottom:5.61000000000001pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Clinical Trial</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:62.4pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:62.4pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Begin Enrollment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:62.4pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Design/Phase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subjects </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:62.4pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Outcomes** </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">V001 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">40 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">10-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 95% </font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 100% </font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 97% </font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 0% </font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0 </font>
                <br >
                <font style="letter-spacing:0.16pt;">Five-year SP: 58% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">V003 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">20 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Complete 2-year follow-up </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 95%</font>
                <br >
                <font style="letter-spacing:0.16pt;">6-month SP: 89%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 81%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate/yr: 4% (1 event)</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">V006 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2016 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;III Prospective Randomized Blinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">355 total; 177 received HAV 178 received ePTFE </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">5-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP HAV: 93%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP HAV: 82%</font>
                <br >
                <font style="letter-spacing:0.16pt;">24-month SP HAV: 67%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP ePTFE: 80%</font>
                <br >
                <font style="letter-spacing:0.16pt;">24-month SP ePTFE: 74% </font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate HAV/yr: 0.93% </font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate ePTFE/yr: 4.5% Number of HAV Rejections: 0 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">V007 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">Phase&#160;III Prospective Randomized Blinded </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:73pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">Target 240 total; 204 enrolled (as of November&#160;1, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Enrolling </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Trial is currently enrolling </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">V011 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Dialysis Access </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">Phase&#160;II (LUNA200 manufacturing system) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:73pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:62.4pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">3-year follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:108pt;text-align:left;">
              <div style="line-height:9.59pt;">
                <font style="letter-spacing:0.16pt;">30-day PP: 97%</font>
                <br >
                <font style="letter-spacing:0.16pt;">30-day SP: 100%</font>
                <br >
                <font style="letter-spacing:0.16pt;">12-month SP: 83%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Infection Rate HAV/yr: 0%</font>
                <br >
                <font style="letter-spacing:0.16pt;">Number of HAV Rejections: 0</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:11.99pt;margin-bottom:42.17pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">PP: Primary Patency, which is the interval of time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis, or the time of measurement of patency, i.e. patent without interventions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">SP: Secondary Patency, which is the interval from the time of access placement until abandonment, i.e. patent with or without interventions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Long-Term Data from Early Phase&#160;II Trials in Hemodialysis: V001 and V003</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Phase&#160;II Trial Design and Current Outcomes:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have completed or are in long-term follow-up on two open-label Phase&#160;II trials in 60 hemodialysis patients in the United States and Poland from December&#160;2012 through May&#160;2014, which we refer to as our V003 trial and V001 trial, respectively. Both the V001 and V003 studies were designed as single-arm trials to assess the safety and efficacy of the HAV for hemodialysis access, with assessments of patency at 6, 12, 18 and 24&#160;months. In the 60 patients enrolled in these two studies, blood flow through all HAVs was appropriate for hemodialysis, averaging over 1,200 mL/minute. Secondary patency for the two combined trials was 97% at six&#160;months, 89% at 12-months, and 81% at 18-months. These results compare favorably to published reports of secondary patency for fistula of 51%&#8201;&#8211;&#8201;61% at six&#160;months and 75% at 12&#160;months. Long-term results from the V001 trial showing five-year secondary patency of 58% were presented at Charing Cross (CX) International Symposium on April&#160;20, 2021, and patients from the V001 trial are currently in a 10-year follow-up period. </font>
        </div>
      </div>
      <div style="margin-top:2.00999999999999pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:133pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Images and long-term results from Phase&#160;2 V001 trial of HAV in AV Access</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_avacces4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_avacces4clr.jpg]" height="133" width="387" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">HAV Secondary Patency (%)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-bc_patency4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-bc_patency4clr.jpg]" height="215" width="249" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Phase&#160;III V006 AV Access Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Trial Design:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our V006 HUMANITY study is a prospective, multi-center, multinational, open-label, randomized, two-arm, comparative study. Eligible study subjects were randomized to receive either a HAV or a commercially available ePTFE graft and followed to 24&#160;months post-implantation by routine study visits. After 24&#160;months, subjects with a patent conduit are followed to five&#160;years post-implantation using a questionnaire at six-month intervals to ascertain patient and conduit status. The primary endpoint for the V006 HUMANITY trial was a non-inferiority analysis of secondary patency compared to ePTFE, to be assessed when all subjects are at least 18&#160;months post-implantation. There were a total of 37 sites that participated in the study, enrolling a combined total of 355 subjects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">24-Month Results:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The V006 study enrolled 355 subjects who were roughly equally matched in terms of demographics and co-morbidities. HAV subjects trended older (p=0.06) and had more prior strokes (p=0.02) than did ePTFE subjects. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:106pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial subject demographics</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_humanl4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_humanl4clr.jpg]" height="303" width="359" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The secondary patency of the HAV was greater than that of ePTFE at six and 12&#160;months but lower at 18 and 24&#160;months, an outcome that had not been modelled in the V006 trial design. As per the pre-specified Cox Proportional Hazards test, the HAV did not achieve its primary efficacy endpoint regarding secondary patency. In terms of safety, the HAV had a statistically significant lower rate of conduit infections compared to ePTFE. Substantial differences in antibiotic use and need for hospitalization for infection were also noted in the V006 trial, all favoring the HAV. The safety advantage of the HAV over ePTFE may be clinically important as infection and sepsis are the second most common cause of death in dialysis patients. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial secondary patency results</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_fatency4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_fatency4clr.jpg]" height="177" width="461" >
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial rates of infection</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8.31pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-bc_humtrial4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-bc_humtrial4clr.jpg]" height="217" width="495" >
        </div>
        <div style="text-indent:20pt; margin-top:10.81pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The reported SAEs related to the HAV and ePTFE in the V006 trial, in this patient population, which typically has a high prevalence of existing medical conditions, are detailed in the table below. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">SAEs Reported in V006 Phase&#160;III Clinical Study in AV Access</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:331pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:315.93pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of SAE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of SAEs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(% of total subjects) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">HAV </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:8pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:8pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">ePTFE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of subjects in V006 study </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">177</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">General disorders and administration conditions: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Implant site extravasation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Infections and infestations </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site infection </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5&#8199;(2.8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Injury, poisoning and procedural complications: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Anastomotic stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site hematomas </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site hemorrhage </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3&#8199;(1.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site pain </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site pseudoaneurysm </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10&#8199;(5.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site rupture </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2&#8199;(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular access site thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">41&#8199;(23.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">28&#8199;(15.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Skin and subcutaneous tissue disorders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Skin necrosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999994pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Vascular disorders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Steal syndrome </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2&#8199;(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2&#8199;(1.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Subclavian vein occlusion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">0&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1&#8199;(0.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vascular stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">34&#8199;(19.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">27&#8199;(15.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Venous stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3&#8199;(1.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt; width:8pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9&#8199;(0.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:6.21pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Through an Analysis of Panel Reactive Antibodies (PRA) in the V006 trial, we observed that subjects that received the ePTFE grafts were more likely to develop antibodies against human tissues, and to become more difficult to crossmatch for a future kidney transplant, than were patients who received the HAV. While the cause of this improvement in patient responses with the HAV is not clear, this may have been related to the lower number of severe infection events in HAV patients as compared to ePTFE patients in V006. The&#160;percentage of women becoming sensitized (i.e. cPRA values &gt; 20%) was notably higher in the ePTFE group than the HAV group. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial % of patients developing antibodies against human tissues</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">% Patients Becoming Sensitized</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.11pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-bc_sensitiz4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-bc_sensitiz4clr.jpg]" height="201" width="383" >
        </div>
        <div style="text-indent:20pt; margin-top:11.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also observed differences in the remodeling of the HAV and ePTFE implants in the V006 trial. Consistent with earlier observations from Phase&#160;II studies, microscopic examination of samples from HAV and ePTFE subjects suggest that the HAVs may have repopulated with host cells and microvasculature, while ePTFE grafts did not repopulate with cells and, in certain cases, fractured at sites of needle cannulation for hemodialysis (&#8220;G&#8221; is graft; &#8220;D&#8221; is defect&#8217; &#8220;T&#8221; is thrombus (clot); &#8220;L&#8221; is lumen; and &#8220;A&#8221; is adventitia): </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial microscopic examination of samples from ePTFE and HAV subjects</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.1pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_ptfehav4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_ptfehav4clr.jpg]" height="191" width="520" >
        </div>
        <div style="text-indent:20pt; margin-top:11.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Comparison of flow rates within the HAV and ePTFE conduits revealed similarities in blood flow and diameter over the 24-month period of the trial. Bar graphs below display average blood flow rate, maximal blood flow rate, and mid-graft diameters, all of which were measured by periodic ultrasound examinations. Diameters of the HAV remained close to the nominal 6.0 millimeter diameter. Average blood flow rates exceeded 1.0 liters/minute, which is generally considered suitable for efficient hemodialysis. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3 V006 HUMANITY trial blood-flow rates and vessel diameters</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Mean Inner Diameter of Conduit (mm)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-bc_inerdiam4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-bc_inerdiam4clr.jpg]" height="152" width="503" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33.85pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Overall, although the primary efficacy endpoint concerning secondary patency was not met, the HAV performed in the V006 trial as was expected, based upon HAV performance in previous Phase&#160;II trials in hemodialysis and in other clinical applications. This outcome was due at least in part to unexpectedly high patency of the ePTFE grafts, particularly after 12&#160;months. While the cause of this unexpectedly high patency is not clear, it is possible that study-mandated ultrasounds and examinations may have led to more aggressive vigilance with ePTFE grafts to maintain patency. In addition, the age and comorbidities of HAV subjects in V006 was somewhat worse than for ePTFE subjects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the V006 trial, the HAV displayed significantly fewer infections than did the ePTFE grafts. This was associated with fewer instances of immune sensitization in HAV subjects as compared to ePTFE subjects, which could translate to easier kidney transplantation at future times. Similar to prior studies, we observed that the HAV had good durability, blood flow rates and diameters similar to ePTFE grafts, and also host cell remodelling that was superior to that of ePTFE grafts. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Phase&#160;III V007 AV Access Study</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Trial Design:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are currently enrolling a Phase&#160;III trial, called V007, in 240 patients with ESRD. V007 is a Phase&#160;III, prospective, multi-center, open label, randomized, two-arm comparative study conducted in the United States. The V007 trial is designed to assess the useability of the HAV for dialysis at six and 12&#160;months as a comparison to autogenous fistulas, which are known to exhibit a high rate of early maturation failure of approximately 40% at six&#160;months. Patients in the study are randomized to receive either the HAV for vascular access or an autogenous AV fistula. The objective of V007 is to compare the safety and efficacy of our 6 millimeter HAV to autogenous AV fistula for functional hemodialysis access. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Eligible study subjects in V007 are randomized to receive either an HAV or an autogenous fistula and followed to 24&#160;months post-implantation by routine study visits. After 24&#160;months, patients with functional accesses will be followed for up to five&#160;years. Efficacy endpoints include useability for dialysis at six and 12&#160;months, as well as a comparison of secondary patency via a time-to-event analysis of all subjects at 12&#160;months. Additional safety endpoints include the rate of dialysis access-related infections for HAV and fistula subjects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Current Trial Status:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As of November&#160;1, 2021, there were 204 patients enrolled in the V007 trial, out of a target enrollment of 240 total. We currently expect to complete the V007 trial in time to support a BLA filing for the use of HAV in AV access for hemodialysis in 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Indication #3:&nbsp;&nbsp;&nbsp;Peripheral Arterial Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">PAD involves partial or complete occlusion of blood vessels in the peripheral circulation and is a major cause of morbidity and mortality in the developed world. Patients with severe PAD undergo peripheral arterial bypass surgery where a conduit is implanted above and below the area of the arterial obstruction, to provide a &#8220;bypass&#8221; route for blood to flow around the blocked artery. The vast majority of these operations are performed in the lower limb. Other surgical alternatives include minimally invasive approaches such as stenting and angioplasties that are suitable for smaller atherosclerotic lesions and can delay&#8201;&#8212;&#8201;but oftentimes not prevent&#8201;&#8212;&#8201;the ultimate need for surgical revascularization. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Published Data in PAD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We derived the data in the table below from data contained in certain published papers on PAD between 2008 and the present. These data are from different studies and thus are not directly comparable. In addition, many of these papers reported on additional endpoints that are not included in the table below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:164.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:90.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Clinical</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:67.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Type of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Conduit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:20pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patients </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Published Secondary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Patency Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Infection</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">patient-year) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Rejection</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outcome </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:90.67pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Peripheral Arterial Disease </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:67.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Saphenous Vein </font>
                <br >
                <font style="letter-spacing:0.2pt;">(autologous) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: &#8211;86% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:90.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:67.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">ePTFE </font>
                <br >
                <font style="letter-spacing:0.2pt;">(synthetic graft) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">61 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: &#8211;80% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:90.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.62pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">101 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:96.54pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 76%&#8201;&#8211;&#8201;89% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:42.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:90.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.62pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2011 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">273 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12&#160;months: 81% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:42.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:90.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:67.62pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">496 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.8% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.91pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:90.67pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:67.62pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Procol</font>
                <br >
                <font style="letter-spacing:0.2pt;">(bovine vein) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:20pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2008 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">7 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:96.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6&#160;months: 50%</font>
                <br >
                <font style="letter-spacing:0.2pt;">12&#160;months: 50%</font>
                <br >
                <font style="letter-spacing:0.2pt;">Aneurysm Rate: 29% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:42.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:30.91pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have observed excellent patency rates and no reported cases of infection for the HAV in PAD in clinical studies to date. We are developing our 6 millimeter HAV for use as a bypass conduit for patients with PAD. We are conducting two Phase&#160;II trials to evaluate the safety and efficacy of our 6 millimeter HAV for use as a bypass conduit with PAD, which we refer to as our V002 and V004 trials. For both of these Phase&#160;II trials, the HAV is being implanted as a femoral popliteal bypass graft in patients with PAD. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Current Phase&#160;II Trials of the HAV in PAD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;margin-bottom:5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:69.07pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Clinical</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Trial</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:67.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Begin</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Enrollment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:46.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Design/</font>&#8203;<br ><font style="letter-spacing:-0.16pt;">Phase </font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subjects </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:69.07pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Outcomes** </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:69.07pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">V002 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:67.99pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Peripheral </font>
                <br >
                <font style="letter-spacing:0.2pt;">Arterial Disease </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:36.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2013 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:46.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Phase&#160;II</font>
                <br >
                <font style="letter-spacing:0.2pt;">Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">20 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:69.07pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10-year </font>
                <br >
                <font style="letter-spacing:0.2pt;">follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">30-day PP: 100%</font>
              <br >
              <font style="letter-spacing:0.2pt;">6-month SP: 84%</font>
              <br >
              <font style="letter-spacing:0.2pt;">12-month SP: 84%</font>
              <br >
              <font style="letter-spacing:0.2pt;">Infection Rate/yr: 0%</font>
              <br >
              <font style="letter-spacing:0.2pt;">Number of Rejections: 0 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:69.07pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">V004 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:67.99pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Peripheral </font>
                <br >
                <font style="letter-spacing:0.2pt;">Arterial Disease </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:36.85pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2016 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:46.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Phase&#160;II</font>
                <br >
                <font style="letter-spacing:0.2pt;">Single-arm </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:35.58pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">15 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:69.07pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5-year </font>
                <br >
                <font style="letter-spacing:0.2pt;">follow-up ongoing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">30-day PP: 100%</font>
              <br >
              <font style="letter-spacing:0.2pt;">6-month SP: 86%</font>
              <br >
              <font style="letter-spacing:0.2pt;">12-month SP: 64%</font>
              <br >
              <font style="letter-spacing:0.2pt;">Infection Rate/yr: 0%</font>
              <br >
              <font style="letter-spacing:0.2pt;">Number of Rejections: 0</font>
              <br >
              <font style="letter-spacing:0.2pt;">Number of Amputations: 0</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">PP: Primary Patency, which is the interval of time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis, or the time of measurement of patency, i.e. patent without interventions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6.2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SP: Secondary Patency, which is the interval from the time of access placement until abandonment, i.e. patent with or without interventions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Trial Design:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Both our V004 and V002 trials are prospective, open-label, single treatment arm, multi-center studies. We enrolled 20 patients in our V002 trial in Poland, and 15 patients in our V004 trial in the United States. Both trials have the primary objectives of evaluating the safety of the HAV as a femoral-to-popliteal bypass graft, and determining the primary, primary assisted, and secondary patency over 12 and 24&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Current Trial Status and Outcomes:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;V002 enrolled a total of 20 patients between the ages of 54 and 79 at three clinical sites. 24-month results of the V002 trial were published in 2020. After censoring for three deaths (none of which were determined to be related to the HAV or the implant procedure), we observed 24-month primary, primary assisted and secondary patency rates of 58%, 58%, and 74%, respectively. We observed through ultrasound data that the HAVs were mechanically stable during the follow-up period and </font>
        </div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:16pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">did not develop aneurysmal dilatation in any patient. Overall, we also determined through the histological assessment of explanted specimens that there were normal vascular cells within the HAV and there was no infection or signs of immunological reaction to the graft. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There have been no HAV-related infections reported during the V002 trial as of November&#160;1, 2021, and no amputations of the treated extremity. A sub-set of seven V002 subjects consented for long-term follow-up CT angiograms, which were obtained at 48 to 52&#160;months after HAV implantation. In all cases, the HAV maintained normal architecture and function. A representative image is shown below, taken 50&#160;months post-implantation. Proximal and distal anastomoses of HAV with recipient&#8217;s vasculature are noted, as is the scale bar on the right-hand side of each image. The image presents two views of the same subject, and shows uniform HAV diameter along the length of the implant. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">A CT Angiogram from a V002 Subject at 51&#160;months after HAV implantation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_angio4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_angio4clr.jpg]" height="249" width="263" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Patients in the V002 trial are currently in long-term follow-up out to ten&#160;years. For the V002 trial, six&#8209;year long-term follow-up data were compiled in March&#160;2021, which confirmed durability of the HAV in the arterial circulation. For HAV patients in the V002 trial, there were also no reports of conduit infections, and no reports of amputations of the operative limb. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Long-term results from V002 Phase&#160;II study in PAD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_results4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_results4clr.jpg]" height="111" width="419" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The V004 trial enrolled 15 subjects in the United States, with the 12-month follow-up of the last enrolled patient occurring in December&#160;2020. Patients in the V004 trial included Rutherford 4 and 5 subjects, with severe, debilitating limb ischemia. (Rutherford 4 and 5 patients are classified as patients with pain at rest due to limb ischemia (stage 4), and those patients suffering tissue loss in the limb as a result of ischemia (stage 5)). In addition, enrollment in V004 required that no autologous vein be available for bypass. Hence, the subjects enrolled in the V004 trial had severe and debilitating limb ischemia due to PAD and had no autologous vein that was suitable for lesion bypass and revascularization. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">12-month results from V004 Phase&#160;II study in PAD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-fc_second4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-fc_second4clr.jpg]" height="112" width="425" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the V004 trial, HAV secondary patency was 86% at 6&#160;months, and 64% at 12&#160;months. While lower than patency values observed in the V002 trial, patients in the V004 trial had more severe PAD, which is associated with poorer arterial &#8220;run-off&#8221; and higher propensity for conduit occlusion. Assessment of Quality of Life by the validated VascuQol assessment demonstrated an increase in overall quality of life for V004 patients at 6 and 12&#160;months. In addition, ankle-brachial index, a measurement of blood pressure in the operative limb, was increased at 6 and 12&#160;months. There were no infections of the HAV reported in the V004 trial, despite the severity of the PAD and the often-associated tissue infection that can accompany this disease. There were zero reports of clinical HAV rejection. Lastly, there were zero reported amputations of any operative limb in the first 12&#160;months of follow-up. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The SAEs reported for the HAV in our V002 and V004 Phase&#160;II clinical studies in PAD in 35 subjects, a patient population which typically has a high prevalence of existing medical conditions, are summarized in the table below. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">SAEs Reported in V002 and V004 Phase&#160;II Clinical Studies in PAD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:92.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:336.96pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of SAE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of SAEs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(% of total subjects) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of subjects in V002 and V004 studies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">N=35</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Arterial bypass thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3(8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Anastomotic stenosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1(3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Graft Thrombosis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2(6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vascular Graft Complication </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1(3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:16.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Published literature reports of patients with Rutherford stage 4 and 5 PAD and no autologous vein available for revascularization show that outcomes can include amputation. For Rutherford 4,5 patients with no vein and no revascularization procedure, amputation rates at 6&#160;months are reported at 31%. For stage 4,5 patients who do undergo saphenous vein revascularization, the amputation rate at one year is approximately 10%. The lack of amputation for stage 4,5 patients in the V004 trial at one year, none of whom had saphenous vein for revascularization, supports the use of the HAV in severe PAD. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Examples of the Use of Our 6 millimeter HAVs in Expanded Access Cases</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has granted use of the HAV in 15 special expanded access cases. Each of these compassionate use cases was conducted under an individual, investigator-initiated IND with the FDA. Two cases are highlighted below. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">70-year-old with Critical Limb Ischemia</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The patient is a 70-year-old male with critical limb ischemia and no vein available to perform a bypass, as the vein was previously used for a CABG. He underwent a successful bypass with the HAV. Imaging at one year demonstrated a patent graft. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:10.71pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_70year4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_70year4clr.jpg]" height="252" width="555" >
        </div>
        <div style="margin-left:20pt; margin-top:18.69pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">42-year-old with Infected Dacron Graft</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">An HAV was used in a 42-year-old female to replace an 8 mm Dacron iliac artery bypass graft that had become infected. The patient refused harvesting of the femoral vein for reconstruction and requested the HAV. The patient was seen at one, three, six, nine, and 12&#160;months after HAV implantation. At all visits, the HAV appeared normal with unobstructed patency. Flow and velocities were normal. At three&#160;months, the patient was released to full activity. At six and 12&#160;months, the graft was functioning well. At one-year imaging, the HAV was patent and appeared remarkably similar to the patient&#8217;s native blood vessels. The patient had no signs of infection in the HAV and continues to have no limitations or complications during normal activity or exercise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preclinical Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pancreatic Islet Transplantation for Type 1 Diabetes (&#8220;Biovascular Pancreas&#8221;)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Biovascular Pancreas (&#8220;BVP&#8221;) is a modification of Humacyte&#8217;s HAV product, leveraging the HAV to deliver therapeutic cells to within close proximity of the patient&#8217;s bloodstream. We believe that the HAV extracellular matrix material is both highly biocompatible, as evidenced by adaptive cellular repopulation after implantation, and also highly angiogenic, as evidenced by extensive formation of microvessels surrounding the HAV in vivo. These attributes mean that the HAV may serve as a suitable conduit for delivering large numbers of therapeutic cells to a patient. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pancreatic islets, which sense blood glucose and respond by secreting insulin, are destroyed by an auto-immune attack in patients with Type I diabetes. The outer surface of our 42cm HAV has sufficient surface area to accommodate a monolayer of approximately 800,000 human pancreatic islets, which is approximately the number in an entire adult pancreas, and can reverse diabetes and restore glucose control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have performed mathematical modelling studies that predict, we believe, that a 42cm HAV could maintain viability of a therapeutic number of islets after implantation of the HAV into the arterial bloodstream, or after implantation as an AV conduit similar to that used for hemodialysis access. Bioreactor experiments have confirmed these mathematical conclusions. Furthermore, we have implanted rat-sized BVPs into the aortas of diabetic rats, and observed that the BVP could restore normal glucose levels in all treated animals, while control animals (&#8220;No Flow&#8221; in red in figure below) did not restore glucose control. Studies in large animal models are planned as the next step in the development of this product candidate. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_preclini4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_preclini4clr.jpg]" height="152" width="373" >
        </div>
        <div style="margin-top:14.81pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Coronary Artery Bypass Graft (CABG)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Evaluation of 3- and 4mm diameter HAVs for coronary artery bypass is ongoing at Humacyte. Our initial pilot studies have included the use of our engineered vessels for CABG in canines, demonstrating functional patency and adequate blood flow for up to one month. To further evaluate the utility and durability of the HAV in a large animal model, we have initiated a preclinical study at Duke University to evaluate the use of our small diameter HAV for CABG in adult primates (baboons). The goal of this study is to assess patency and function for six to 12&#160;months, as well as host responses and cellular remodeling. We anticipate that this study will provide sufficient in vivo data to support an IND filing for a Phase&#160;I clinical trial in adult CABG. As of November&#160;1, 2021, we have implanted a 3.5mm HAV CABG from the aorta to the left anterior descending (LAD) coronary artery in five baboons. HAVs are followed by ultrasound imaging of the heart, and angiographic imaging of the conduits. These studies are active and ongoing. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Before (left) and after (right) implantation of HAV CABG in baboon</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8.71pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_coron4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_coron4clr.jpg]" height="208" width="384" >
        </div>
        <div style="margin-top:14.81pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Heart Surgery: Modified Blalock-Taussig-Thomas (mBTT) Shunt</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Tetrology of Fallot is a relatively common congenital heart defect, that is often treated using a modified Blalock-Taussig-Thomas (mBTT). To support a potential future IND filing with the FDA, we have evaluated the use of our HAV as an mBTT shunt for up to six&#160;months in juvenile primates at the Research Institute at Nationwide Children&#8217;s Hospital in Columbus, Ohio. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">BT Shunt Implant Schematic</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8.61pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_btshunt4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_btshunt4clr.jpg]" height="152" width="369" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November 2021, the results for this preclinical study were presented at the American Heart Association&#8217;s Scientific Sessions 2021 meeting. In this study, five non-immunosuppressed juvenile primates were surgically implanted with the 3.5mm diameter HAVs as mBTT shunts. The 3.5mm HAVs were implanted into primates as mBTT shunts using standard surgical techniques, and the animals were studied for three to six months. Each of the HAVs remained parent during the study and exhibited repopulation with vascular cells. Two of the primates showed a stronger xenogeneic to the human HAV material. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 3.5mm diameter HAV has smaller product dimensions but is manufactured using a similar process as Humacyte&#39;s 6mm HAV system currently being evaluated in clinical trials in vascular trauma, AV access for hemodialysis, and PAD. We believe that the production of the functional 3.5mm HAV is indicative of the potentially broad application of our proprietary bioengineered tissue platform and manufacturing processes. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Imaging of 3.5mm HAV mBTT shunt in juvenile primate followed for 6&#160;months</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_imaging4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_imaging4clr.jpg]" height="160" width="417" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Engineered Trachea for Treatment of Severe Airway Injuries</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each year in the U.S., approximately 4,000 operations are performed to repair or reconstruct the trachea or mainstem bronchi. But unlike most other connective tissues in the body&#8201;&#8212;&#8201;such as blood vessel, bone, skin and tendon&#8201;&#8212;&#8201;there currently are no replacements for tracheal tissue that are in widespread clinical use. For long tracheal or bronchial defects, some sort of tracheal replacement is often needed, yet none exists currently. The lack of a functional tracheal conduit commits patients to, sometimes, slow suffocation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have modified the HAV production process to enable the embedding of a biocompatible medical-grade stent within the wall of the engineered vessel. Combining a non-degradable stent with the degradable polymer scaffold used for HAV production results in a composite scaffold that can be seeded with smooth muscle cells and grown in culture. After decellularization, the engineered trachea consists of the extracellular matrix contained in the HAV, along with an embedded stent that prevents the collapse of the engineered airway with inspiration or neck movements. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Summary of Process to Generate Engineered Tracheas</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_summ4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_summ4clr.jpg]" height="111" width="565" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In models where engineered tracheas were implanted into rats and non-human primates, we have observed that the implants repopulate with cells from the host, including cuboidal respiratory epithelium that lines the native airway progressively from two to eight weeks after implantation. We have further observed that the engineered tracheas can function out to two&#160;months. Future studies in large animal models are planned. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Photograph (A)&#160;of Implantation of Engineered Trachea into Non-Human Primate Airway; Microscope Imaging of Cells Repopulating the Trachea after 2 and 8 weeks (B, C)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_photogr4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_photogr4clr.jpg]" height="85" width="592" >
        </div>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Engineered Whole Lung Organs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">End-stage lung disease is the fourth leading cause of death in the U.S., and lung transplantation remains severely limited by donor organ shortages. Dr.&#160;Niklason&#8217;s laboratory at Yale University has pioneered the development of using decellularized native lungs, combined with targeted recellularization of the lung scaffolds within biomimetic bioreactors, to produce whole lungs that are capable of exchanging gas. Gas exchange for several hours has been observed in studies in rodents. Efforts to scale-up the technology to human-sized organs are ongoing. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Structure of Lung, Scaffold for Lung Engineering, and Implanted Engineered Lung</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_struct4clr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_struct4clr.jpg]" height="167" width="533" >
        </div>
        <div style="margin-top:16.61pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have developed a novel paradigm for manufacturing human tissues that mimics key aspects of human physiology. Recognizing that commercial scale production capacity of bioengineered tissue has been non-existent, we prioritized the development of a scalable, reproduceable, commercial biomanufacturing process. At our 83,000 square foot manufacturing facility in Durham, North Carolina, we have industrialized this concept and created a scalable modular manufacturing process that enables us to engineer our HAVs in commercial quantities in a system designed for cGMP compliance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary manufacturing process was designed with a modular approach allowing us to produce HAVs in smaller batches for clinical trials and scale out to larger batches for commercial manufacturing. The system used in our clinical trials since 2016, including all Phase&#160;III trials, utilizes a single tray within one growth drawer holding ten HAVs per batch. These batches were manufactured at a contract manufacturer. The current, commercial-scale LUNA200 system utilizes 20 growth drawers holding ten HAVs each for a total of 200 HAVs per batch. This system is planned to be utilized for ongoing Phase&#160;III trials and for subsequent anticipated commercial launches once approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our manufacturing process utilizes our LUNA200 system, consisting of 20 &#8220;growth drawers.&#8221; Each growth drawer is capable of producing ten 42cm HAVs and each HAV remains contained within an individual bioreactor bag. Inside a LUNA200, a closed tubing network connects all 20 growth drawers as well as the ten bioreactor bags in each drawer, allowing the entire system to share cells and nutritive media. In this way, a single LUNA200 can produce up to 200 HAVs per batch while maintaining the critical operating parameters that direct growth, creating a gross capacity of approximately 900 HAVs per system annually. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A thorough comparability assessment was performed to evaluate HAV batches produced in the single drawer system and used in Phase&#160;III studies versus the 20-drawer LUNA system. The study assessed 22 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">separate comparisons on the identity, strength, quality, purity, and potency of the HAV product. In this study we observed that HAVs produced in the LUNA system were comparable to HAVs used in our Phase&#160;III trials. This comparability report is being submitted to the FDA. Additionally, a crossover study, called V011, has completed enrollment of 30 subjects to evaluate HAVs that are manufactured on Humacyte&#8217;s commercial LUNA platform, with the primary goal of evaluating the safety, efficacy and immunogenicity of the LUNA-manufactured HAVs. Thus far in the trial, as of April&#160;10, 2020, we have observed a comparable safety profile between HAVs used in previous studies and the HAVs manufactured in the LUNA commercial system. The LUNA200 system is planned to be utilized for ongoing Phase&#160;III trials and for subsequent anticipated commercial launches after approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have designed the LUNA200 to have the ability to produce HAVs in diameter sizes from 3mm to 10mm and lengths from 10cm to 42cm, making the equipment suitable for the varied array of product candidates in our pipeline. We intend to introduce a 13cm HAV line extension after commercial launch of the 42cm HAV. Using our existing LUNA manufacturing equipment, we can generate 400 13cm HAVs per&#160;batch. Our modular manufacturing platform can be scaled without impacting the operating parameters that support the HAV growth process. We have designed our manufacturing system to be functionally closed, to utilize single-use disposable materials with aseptic connections, and to be fully automated. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Modular Manufacturing Platform Allows for Production of Multiple Product Lengths Using the Same Equipment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_mod13cmbwlr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_mod13cmbwlr.jpg]" height="113" width="228" >
        </div>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently have eight LUNA200 systems installed, commissioned and qualified in our manufacturing facility, creating an annual gross HAV capacity of approximately 7,200 HAVs. Our manufacturing facility contains completed utility connections for the installation of at least 25 additional LUNA200 systems and space to further increase capacity in future&#160;years, up to approximately 40 LUNA200 systems in total. As we continue to expand production, we believe that we will have the ability to take advantage of economies of scale and reduce production costs. The initiation and pace of the expansion of vessel capacity will be determined based on our assessment of market opportunity. </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2127058d1-ph_mod42cmbwlr.jpg" alt="[MISSING IMAGE: tm2127058d1-ph_mod42cmbwlr.jpg]" height="116" width="509" >
        </div>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We initiate HAV production using primary human aortic vascular cells from a working cell stock (&#8220;WCS&#8221;) that is isolated from FDA-compliant donor tissues and cryopreserved. The WCS vials are stored at two separate qualified facilities to mitigate the risk of single site storage. We qualify all new WCSs for use in HAV manufacturing utilizing biochemical and gene expression assays. Each qualified primary isolation can produce approximately 500,000 to one million HAVs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The working cell stock is expanded using traditional cell culture techniques, and the cells are transferred onto a biocompatible, biodegradable polymer mesh within a flexible, single-use bioreactor bag. Cells inoculated onto this tubular mesh are cultured utilizing a proprietary culture medium and subjected to cyclic mechanical stretch for a period of approximately eight weeks. During this period, the cells proliferate and build extracellular matrix while the polymer mesh degrades. The resulting bioengineered vessel is comprised of the aortic vascular cells and their deposited extracellular matrix. After completion of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">culture period, we decellularize the bioengineered vessel using a proprietary combination of salts, enzymes and detergents, followed by numerous washes in excipient grade neutral pH buffered saline. The resulting HAV retains the human extracellular matrix constituents and, therefore, the biomechanical properties of the bioengineered vessel, but cells and cellular components, which could induce a foreign body response or immune rejection following implantation, are removed. After decellularization, our HAVs are packaged for distribution inside the same flexible bioreactor bag in which they were produced, with sterile phosphate buffered saline as the excipient. Once the package is delivered to the operating room, the HAV is removed from the bioreactor bag by the surgical staff. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Suppliers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We source critical components and necessary raw materials from vendors that have been approved and qualified through our vendor management program. SeraCare is the current single source supplier of human plasma used in our manufacturing process and Confluent is the current single source supplier of the polymer mesh we use. We source custom, Humacyte-designed, pre-sterilized (gamma irradiated) assemblies and single-use tubing sets through multiple approved vendors. We source bioprocess solutions, including culture media and decellularization buffers, from a division of Thermo Fisher Scientific, which has a second production site to provide redundant media/buffer production capacity. We are in the process of developing redundant vendors for all critical materials and we manage all vendor changes through a robust change control process. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Supply Agreement with SeraCare</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2014, we entered into a supply agreement with SeraCare for the supply of human plasma, which was amended in October&#160;2018. We refer to the supply agreement, as amended, as the SeraCare Agreement. Under the SeraCare Agreement, we agreed to purchase at least a substantial majority of our human plasma requirements from SeraCare. In the event SeraCare is unable to fulfill our requirements, and subject to certain conditions, we may engage another plasma supplier during the period in which SeraCare is unable to fulfill our requirements. The SeraCare Agreement is subject to annual price modifications in the case of significant changes in SeraCare&#8217;s cost of raw materials, with any modification to be determined at least three&#160;months prior to the end of the relevant year. The initial term of the SeraCare Agreement expires on October&#160;12, 2023, but automatically extends for subsequent one-year periods unless terminated by either party at least 18&#160;months prior to the end of the initial term. Either party may terminate the SeraCare Agreement for uncured material breach or for the insolvency of the other party at any time. In addition, either party may terminate the SeraCare Agreement without cause upon 12&#160;months&#8217; written notice. We may also terminate the agreement in the event of certain supply interruptions. Each party also agreed to indemnify the other against certain third-party claims up to a specified cap. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Supply Agreement with Confluent</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2015, we entered into an agreement for the supply of polymer mesh, which we refer to as the mesh supply agreement, with Biomedical Structures LLC. Biomedical Structures&#8217; rights and obligations under the mesh supply agreement were subsequently assigned to Confluent in connection with Confluent&#8217;s acquisition of Biomedical Structures in 2016. In 2020, the agreement was amended to align with the growth expected with the transition to commercial distribution following FDA approval. Pursuant to the mesh supply agreement, the price of polymer mesh we purchase from Confluent is subject to potential adjustment if Confluent&#8217;s cost of raw materials increases above a specified threshold pursuant to good faith negotiations from both parties, which negotiation Confluent may not request more than once in a 12-month period. The 2020&#160;amendment also provided volume driven discounts. Confluent is obligated to partner with Humacyte in order to establish redundant facilities for the manufacture of the polymer mesh at established contractual volume thresholds. The amended mesh supply agreement has a term of three&#160;years, which can be automatically extended for subsequent one-year periods and will continue to do so unless either party provides notice of non-renewal at least 120&#160;days prior to the end of the then-current term or otherwise terminates in accordance with the agreement. We and Confluent are each also permitted to terminate the mesh supply agreement for convenience, however Confluent must provide us with at least 365&#160;days written notice and we are obligated to provide 180&#160;days&#8217; notice, prior to such a termination. In addition, each party is permitted to terminate the mesh supply agreement for an uncured material breach by the other party </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">following failure to remedy the breach during a sixty-day cure period. Both parties have agreed to indemnify one another for certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distribution</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Commercialization Strategy Within United States and for Earlier-Stage Pipeline Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For our vascular repair and replacement applications of our technology, including renal replacement therapy for dialysis access, the treatment of PAD, and the treatment of vascular trauma, we have retained the right to commercialize our HAV within the United States, and expect to commercialize the HAV through a combination of our own direct sales and marketing team combined with our partnership with Fresenius Medical Care described below. We plan to own end-to-end commercialization while pursuing collaborations with appropriate strategic partners who have established distribution channels for supplying customer care centers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our first expected market launch, in the treatment of vascular trauma, is a highly concentrated market of approximately 190 Level I Trauma Centers that may be reached with a small field sales forces of no more than 20 representatives. Many of the major trauma centers already have familiarity with our HAV product candidate through their participation in our clinical trials. Our sales effort will include dual targeting of surgeons to create pull-through demand and hospital administration (trauma center Value Analysis Committees) to assure adoption and uptake of the HAV in vascular trauma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that the large market potential of earlier-stage applications of our technology platform such as CABG and biovascular pancreas for diabetes will provide additional collaboration opportunities, and we expect explore strategic partnerships for these product candidates as preclinical and clinical results providing additional proof of concept are generated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Distribution Agreement with Fresenius Medical Care</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We entered into a distribution agreement with Fresenius Medical Care in June&#160;2018 which, as amended as of February&#160;16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and EU and commercialize outside of the United States our 6 millimeter x 42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with Humacyte in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, we agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and we agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the distribution agreement, we grant an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by us during the term to commercialize the distribution product in the field outside the United States, subject to our retained rights to carry out our obligations under the distribution agreement. We also grant a non-exclusive, sublicensable license to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fresenius Medical Care under the patents, know-how and regulatory materials controlled by us during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, we grant to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement provides that we will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of us of the distribution product in the United States in the field. Such revenue-share payments will be a&#160;percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that we have paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a&#160;percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay us under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay us initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing our distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay us a fixed&#160;percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement will generally continue on a country-by-country basis until the later of (a)&#160;the tenth anniversary of the launch date of the distribution product in the relevant country or (b)&#160;the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i)&#160;for certain withdrawals of regulatory approval or (ii)&#160;for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Care&#8217;s rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12&#160;months&#8217; written notice to us, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third-Party Reimbursement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We anticipate that coverage and reimbursement by CMS and private payors will be essential for most patients and health care providers to afford our treatments, particularly in the applications of renal replacement therapy for dialysis access and the treatment of PAD. Accordingly, sales of our products will depend substantially, both domestically and abroad, on reimbursement by government authorities, private health coverage insurers and other third-party payors. Our strategy around HAV reimbursement focuses on achieving alignment and agreement from CMS on coding and payment pathways; both are critical to influencing and achieving optimal reimbursement payment from private payor sources. Therefore, Humacyte continues to develop a comprehensive reimbursement strategy including CMS, private payors, and other key stakeholders to ensure a clear and sustainable reimbursement path for all HAV product opportunities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are pursuing a dual regulatory and legislative reimbursement strategy to ensure separate Medicare payment for the HAV at an appropriate price. The regulatory strategy includes (1)&#160;engaging CMS political and career staff directly on coverage, payment, and coding followed by (2)&#160;submission of formal applications in these areas once FDA approval is obtained. Currently, no RMAT tissue engineered product has established coverage and reimbursement by CMS, and it is difficult to predict what CMS will decide with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">respect to coverage and reimbursement for fundamentally novel products. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to the Development and Commercialization of Our Product Candidates&#8201;&#8212;&#8201;Even if we receive marketing approval for our HAVs, there is uncertainty with respect to third-party coverage and reimbursement of our HAVs. They may also be subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, any of which could harm our business, prospects, operating results and financial condition.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position that may be important for the development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable patents and proprietary rights of third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2021, our patent estate is comprised of 15 families of patents. Of these families, nine are solely owned by Humacyte, one is jointly owned by Humacyte and Global Life Sciences Solutions USA LLC, one is jointly owned by Humacyte and Yale University, two are exclusively licensed to Humacyte from Duke University and two are exclusively licensed to Humacyte from Yale University. For more information regarding these license agreements, see &#8220;&#8212; License Agreement with Duke University&#8221; and &#8220;&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">License Agreements with Yale University.&#8221; </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our 15 families of patents are comprised of: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;eight issued U.S. patents, 64 foreign patents in Austria, Belgium, Canada, China, Cyprus, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Liechtenstein, Netherlands, Spain, Sweden, Switzerland, Turkey, and the UK, five pending U.S. non-provisional patent applications, one pending PCT patent application and two pending foreign applications in Europe and Hong Kong, which are solely owned by us, </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;three issued U.S. patents, 18 issued foreign patents in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Liechtenstein, Netherlands, Spain, Sweden, Switzerland, Turkey, and the UK, one pending U.S. non-provisional patent application, and three pending foreign patent applications in Europe and Canada, which we co-own, and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;three issued U.S. patents, 23 issued foreign patents in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Liechtenstein, Netherlands, Spain, Sweden, Switzerland, Turkey, and the UK, one pending U.S. non-provisional patent application, and seven pending foreign patent applications in Australia, Canada, Europe, Japan, China, and Hong Kong, which we exclusively license. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of these patents and patent applications generally relate to the scaffolds used to make our vessels, the composition of our vessels, and systems and methods of manufacturing our vessels. Excluding any patent term adjustment or patent term extension, the U.S. patent relating to the scaffold used to make our vessels expires in 2032, the U.S. patents relating to the composition of our vessels expire in 2032 and the U.S. patents relating to the systems and methods of manufacturing our vessels expires in 2032. The U.S. patent relating to the entangler machinery used to make tubular scaffolds expires in 2035. Included in our patent portfolio are three pending, Humacyte-owned non-provisional applications relating to the manufacturing of engineered tissues at commercial scale. If these three non-provisional applications are allowed, such additional patents issuing therefrom would be expected to expire around 2040. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned and licensed pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents. For more information, see the section entitled &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have also registered trademarks for use in connection with our products. These include registrations for HUMACYL&#8482; in the United States, Europe, Australia, Canada, China, and Israel; HUMAGRAFT&#8482; in Australia, China, Europe, and Israel; HUMAPASS&#8482; in Europe, Australia, and Israel; and HUMACYTE, in the United States, Europe, Australia, Canada, and Israel. We may pursue additional registrations for future products in markets of interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the above, we have established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing process scale-up, cGMP manufacturing, quality control, quality assurance, compliance, regulatory affairs and clinical trial design and execution. We believe that our focus and expertise will help us develop and expand technology-based applications leveraging our proprietary intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, we rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the intellectual property that we have developed internally, we license rights to certain intellectual property that is material to our business prospects. We have summarized our material license agreements below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with Duke University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2006, we entered into a license agreement with Duke University (&#8220;Duke&#8221;), which was subsequently amended in 2011, 2014, 2015, 2018 and 2019. We refer to the license agreement as amended, as the Duke License Agreement. Under the Duke License Agreement, Duke granted us a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, which we refer to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue will expire in 2021. We have agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, which we refer to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. We have also agreed to meet certain benchmarks in our development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the Duke License Agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with our entry into the Duke License Agreement, we granted equity consideration to Duke in the form of 200,666 shares of our common stock. Under the Duke License Agreement, we have also agreed to pay Duke: a low single-digit&#160;percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit&#160;percentage of any sublicensing revenue; an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and an additional amount in license fees, as certain scientific milestones are met. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Duke License Agreement remains effective until the latter of (i)&#160;the last of the patent rights expires or (ii)&#160;four&#160;years after our first commercial sale, unless earlier terminated. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if we become insolvent. Duke may also terminate the license, convert the license into a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">non-exclusive license or seek assignment of any sublicense if we fail to reach diligence milestones within the applicable time period. If we abandon any claim, patent or patent application, our rights under the license with respect to such patent rights will be terminated in the territory in which we abandon such rights. We may terminate the Duke License Agreement unilaterally upon three&#160;months&#8217; prior notice to Duke. We agree to indemnify Duke against certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreements with Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Large Diameter HAV</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, we entered into a license agreement with Yale University (&#8220;Yale&#8221;) that granted us a worldwide license to the patents jointly owned with us related to tubular prostheses which are large diameter versions of our vessels, which may or may not contain a stent. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheae/airways and engineered esophagi, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. We have agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. We are also obligated to provide Yale periodically an updated and revised copy of our plan, which must indicate progress of our development and commercialization. We may also sublicense our rights without Yale&#8217;s prior written consent, but such sublicense is subject to certain conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with our entry into the Yale License Agreement, we paid Yale an upfront cash fee of less than $0.1&#160;million. We have also agreed to pay to Yale: an annual maintenance fee, increasing between the first anniversary of the agreement until the fifth anniversary up to a maximum of less than $0.1&#160;million per year; milestone payments upon achievement of certain regulatory and commercial milestones of $0.2&#160;million and $0.6&#160;million for this license; a low single-digit&#160;percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and a low double-digit&#160;percentage of sublicensing income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we or any of our future sublicensees bring a patent challenge against Yale or assist another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The agreement expires on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Issued patents and additional patents issuing from this licensed portfolio will expire no earlier than 2032, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Issued U.S. patent No. 10,172,707 will expire no earlier than 2035. Issued patents and additional patents issuing from this licensed portfolio will expire no earlier than 2032, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Issued U.S. patent No. 10,172,707 will expire no earlier than 2035. Yale may terminate the agreement if we fail to (i)&#160;provide written diligence reports, (ii)&#160;provide a commercially reasonable diligence plan, (iii)&#160;implement the plan in accordance with the obligations under the agreement, or (iv)&#160;reach certain research and development milestones within the scheduled timeframe set forth in the agreement; however, any such termination right would be limited in scope to the country or countries to which such failure relates. Yale may also terminate for our non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of our product or insolvency. We may terminate the license agreement (i)&#160;on 90&#160;days&#8217; prior written notice to Yale, provided we are not in breach of the license agreement and have made all required payments to Yale thereunder and (ii)&#160;on written notice to Yale following an uncured material breach. Under certain circumstances, Yale may, at its option, convert the exclusive license to a non-exclusive license if we decline to initiate certain infringement or interference proceedings with respect to the licensed patents. We have agreed to indemnify Yale against certain third-party claims. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Small Diameter HAV Coating</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2014, we entered into a license agreement with Yale that granted us a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1-12mm in diameter), except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. We have agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. We are also obligated to provide Yale periodically an updated and revised copy of our plan, which must indicate progress of our development and commercialization. We may also sublicense our rights without Yale&#8217;s prior written consent, but such sublicense is subject to certain conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with our entry into the Yale License Agreement, we paid Yale an upfront cash fee of less than $0.1&#160;million. We have also agreed to pay to Yale: an annual maintenance fee, increasing between the first anniversary of the agreement until the fifth anniversary up to a maximum of less than $0.1&#160;million per year; milestone payments upon achievement of certain regulatory and commercial milestones of $0.2&#160;million and $0.6&#160;million for this license; a low single-digit&#160;percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and a low double-digit&#160;percentage of sublicensing income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we or any of our future sublicensees bring a patent challenge against Yale or assist another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The agreement expires on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Issued patents and additional patents issuing from this licensed portfolio will expire no earlier than 2034, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Issued patents and additional patents issuing from this licensed portfolio will expire no earlier than 2034, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Yale may terminate the agreement if we fail to (i)&#160;provide written diligence reports, (ii)&#160;provide a commercially reasonable diligence plan, (iii)&#160;implement the plan in accordance with the obligations under the agreement, or (iv)&#160;reach certain research and development milestones within the scheduled timeframe set forth in the agreement; however, any such termination right would be limited in scope to the country or countries to which such failure relates. Yale may also terminate for our non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of our product or insolvency. We may terminate the license agreement (i)&#160;on 90&#160;days&#8217; prior written notice to Yale, provided we are not in breach of the license agreement and have made all required payments to Yale thereunder and (ii)&#160;on written notice to Yale following an uncured material breach. Our rights under the license agreement will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, we do not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive license to a non-exclusive license if we decline to initiate certain infringement or interference proceedings with respect to the licensed patents. We have agreed to indemnify Yale against certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biovascular Pancreas</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, we entered into a license agreement with Yale that granted us a worldwide license to its patents related to a biovascular pancreas. The license granted under the agreement is exclusive in the field of acellular vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. We have agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. We are also obligated to provide Yale periodically an updated and revised copy of our plan, which must indicate progress of our development and commercialization. We may also sublicense our rights without Yale&#8217;s prior written consent, but such sublicense is subject to certain conditions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with our entry into the Yale License Agreement, we paid Yale an upfront cash fee of less than $0.1&#160;million. We have also agreed to pay to Yale: an annual maintenance fee, increasing between the first anniversary of the agreement until the fifth anniversary up to a maximum of less than $0.1&#160;million per year; milestone payments upon achievement of certain regulatory and commercial milestones of $0.1&#160;million and $0.2&#160;million for this license; a low single-digit&#160;percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and a low double-digit&#160;percentage of sublicensing income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we or any future sublicensees bring a patent challenge against Yale or assist another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The agreement expires on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Patents issuing from this licensed portfolio will expire no earlier than 2039, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Patents issuing from this licensed portfolio will expire no earlier than 2039, and the term of each patent may be extended by patent term adjustment, patent term extension, or foreign equivalents thereof. Yale may terminate the agreement if we fail to (i)&#160;provide written diligence reports, (ii)&#160;provide a commercially reasonable diligence plan, (iii)&#160;implement the plan in accordance with the obligations under the agreement, or (iv)&#160;reach certain research and development milestones within the scheduled timeframe set forth in the agreement; however, any such termination right would be limited in scope to the country or countries to which such failure relates. Yale may also terminate for our non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of our product or insolvency. We may terminate the license agreement (i)&#160;on 90&#160;days&#8217; prior written notice to Yale, provided we are not in breach of the license agreement and have made all required payments to Yale thereunder and (ii)&#160;on written notice to Yale following an uncured material breach. Our rights under the license agreement will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, we do not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive license to a non-exclusive license if we decline to initiate certain infringement or interference proceedings with respect to the licensed patents. We have agreed to indemnify Yale against certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Despite the magnitude and critical nature of the diseases and conditions we are targeting, no significant advances in the open surgical market have been made in the last 35&#160;years, and current treatment and products used in vascular repair, reconstruction and replacement suffer from various drawbacks. The large majority of vascular repair, reconstruction and replacement procedures rely on either harvesting autologous veins or using synthetic grafts. However, each method presents significant limitations as discussed below: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Autologous Veins</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The harvest of autologous veins is a serious operation that can result in numerous complications, including infection, chronic pain, and limb swelling that severely impact the patient&#8217;s quality of life. In addition, this procedure can often result in long recovery times, increased hospital stays, and increased risk of hospital readmission. In order to obtain an autologous vein, such as a saphenous vein, for use in a surgical procedure, a second operation must be performed on the patient to harvest the vein. The harvesting process must be completed before the bypass procedure occurs and can take significant time to complete, which increases costs related to the additional operative time and staff required to perform the operation. Even if successful, the patient&#8217;s recovery time could increase as the patient must recover from two surgical procedures instead of one, further increasing morbidity and cost. Additionally, a significant&#160;percentage of patients are not suitable for vein harvesting either due to vein or limb damage, limited vein supply from prior harvest, venous disease or the surgeon&#8217;s desire to preserve the vein for future coronary or other bypass procedures. In acute trauma, the time to restore blood flow to injured limbs is delayed when a vein must be harvested from the patient, which puts the limbs at greater risk of reduced function or amputation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For patients suffering from vascular trauma, some types of injury preclude the harvesting of autologous saphenous vein due to concomitant injuries of one or both legs. Furthermore, time is required to prepare the vein harvest site and to remove the vein from the leg, which adds to ischemia time and can increase the risk of tissue and limb loss. Rates of traumatic limb loss are strongly tied to ischemia time, and therefore rapid revascularization using an off-the-shelf HAV conduit may decrease ischemia time and lead to better outcomes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The use of autologous vein for creating an AV fistula for use in hemodialysis is often limited by vein size and location. The vast majority of veins must go through a process of enlargement, known as maturation, prior to use for hemodialysis. For approximately 40% of patients receiving fistulae, the vein does not mature sufficiently to allow for hemodialysis even after six&#160;months. Even in patients having adequate veins for fistula creation, the fistula often becomes large, tortuous and disfiguring and can be at risk for sometimes fatal rupture. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Synthetic Grafts</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Use of synthetic materials, such as ePTFE and Dacron, while widely available, have known complications, such as continuous chronic risk of infection and clotting inside the graft. Risk of infection is significantly increased in acute battlefield and civilian injuries, as well as in contaminated wounds. The body recognizes any synthetic materials as foreign and, therefore, can mount a host foreign body response following implantation. Synthetic materials also have been shown to be inferior to autologous vein in resisting infection, and generally only are used for vascular repair when autologous vein is not an option. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In hemodialysis access, persistent puncture presents an ongoing risk of graft infection. The annual risk of infection of ePTFE grafts in hemodialysis patients can be as high as 10%&#8201;&#8211;&#8201;15% per patient-year. Furthermore, gradual degradation of the non-healing ePTFE graft material caused by persistent needle punctures can eventually lead to graft failure. In traumatic vascular injury, ePTFE grafts are generally contraindicated, due to the high rates of contamination of the wound that can lead to synthetic graft infection and failure. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Two lesser used products, cryopreserved human blood vessels, known as allografts, and animal-derived vessels, known as xenografts, also involve significant limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cryopreserved Blood Vessels</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To eliminate the need for harvesting autologous vein, some surgeons use allogeneic vessels that have been previously harvested from cadavers and cryogenically preserved. These allogeneic vessels are stored at&#160;<font style="white-space:nowrap;">-80</font> degrees Celsius and must be thawed prior to use, which can take up to 60 minutes. The supply of cryopreserved vessels is limited by the number of cadaveric donors available, and the vessels are often non-uniform in size. In addition, because the vessels contain human cells from a donor, they can generate an immune rejection response that can lead to aneurismal degradation or catastrophic failure. Furthermore, development of antibodies to the implanted cryopreserved human vessel frequently has a detrimental impact on the ability of the patient to receive a transplant in the future. Cryopreserved blood vessels are only rarely used in the treatment of vascular trauma, due to the time required for procurement and thawing, and the high rates of rejection response. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Animal-Derived Vessels</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Xenogeneic tissues, including cow, pig or sheep-derived vessels, are used less frequently in vascular surgery, in part due to the risk of thrombosis and structural deterioration over time. The limited clinical data that are available for existing xenografts in vascular reconstruction indicates lower patency rates and higher incidence of complications when compared to autologous vein. Xenografts are all chemically treated in efforts to minimize rejection to animal components, and therefore do not respond like living tissue. Some of these products require rinsing to remove toxic chemicals used for storage. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Solution</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe our HAVs combine the off-the-shelf availability of synthetic grafts with the regenerative capabilities of autologous vessels. We believe these and other attributes have the potential to address unmet </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">clinical needs in a range of disease states, including atherosclerosis, end-stage kidney disease, coronary artery disease, vascular trauma, pediatric congenital heart disease, airway disease, and others. We believe that the HAV&#8217;s multiple key characteristics will drive rapid clinical adoption amongst surgeons and the broader healthcare community: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Off-the-Shelf</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Our &#8220;cabinet&#8221; of HAVs of varying diameters and lengths is designed to be stored on-site at facilities such as hospitals, trauma centers and outpatient surgical centers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Immediately Available</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;When needed, our HAVs are available for immediate use by opening and removing the HAV from its original flexible bioreactor bag. Since our HAV does not need flushing, harvesting or thawing, as is common with other vascular substitute alternatives, we believe hospitals will be able to use our HAVs for vascular surgery more quickly with smaller surgical teams, reduced logistics and decreased overall cost. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Surgical Harvesting</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The use of our HAVs does not subject patients to the serious operation of harvesting an autologous vein, which can result in greater procedure and recovery time, potential scarring and disfigurement, increased costs, and numerous potential health complications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Non-Immunogenic and No Foreign Body Response</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Given their acellular nature, our HAVs have the potential to be universally implantable and durable across patients. Because our HAVs are derived from human tissue (but cleansed of all cells and cellular components), we believe (and have observed in clinical trials to date) that they do not generate the foreign body response associated with the use of synthetic grafts, or the immune response associated with cryopreserved vessels. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Low Infection Susceptibility</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;In clinical trials to date, we have observed reduced rates of infection in our HAVs as compared to synthetic materials. As a result, we believe our HAVs may be used in complicated and potentially contaminated wounds with fewer patient complications following the initial procedure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Uniform and Predictable Size, Structure and Quality</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Harvested veins vary in size, structure and quality by donor. We manufacture our HAVs to precise specifications under controlled quality standards, which will allow surgeons the flexibility to quickly and easily select an HAV in the appropriate size and shape for each indication. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Regenerative Potential</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Our HAVs repopulate with the patient&#8217;s own vascular cells, creating a living vascular tissue with the associated long-term benefits of self-healing and infection resistance. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If approved, we expect our HAVs would compete with the use of a patient&#8217;s own blood vessels, as well as a variety of marketed products, such as conventional synthetic grafts, xenografts, and allografts, as well as developing technologies. We expect the key competitive factors affecting the commercial success of our HAVs to likely be efficacy, safety, convenience, pricing and reimbursement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Commercial Entities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are several conventional synthetic grafts made of ePTFE or Dacron presently on the market from companies such as Bard Peripheral Vascular, Inc., W.L. Gore &amp; Associates, Inc., Terumo Medical Systems, and Atrium (Maquet Getinge Group) that are used for both AV access for hemodialysis and vascular repair. Xenograft and allograft products are also available, but not widely used. Xenografts, such as Artegraft</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and Procol</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, are processed animal-derived vessels, while allografts are processed allogeneic cellular vessels, such as CryoVein</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and AngioGRAFT</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are also a number of companies of which we are aware that have preclinical and early clinical-stage research programs underway to develop products that could potentially compete with our HAVs, including NovaHep AB, Xeltis AG, Hancock Jaffe, and Vascudyne Inc. We may face competition from these and other emerging technologies such as bioabsorbable polymetric implants and electrospun or 3D printed tubular conduits. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, safer, have fewer or less severe side effects, are more convenient or are less expensive than the products that we develop. Our competitors also may obtain FDA </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or other marketing approval for their products more rapidly than we may obtain the same approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Overview</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the research, development, testing, manufacture, quality control, safety, effectiveness, packaging, labeling, storage, record keeping, marketing, advertising and promotion, import/export, and distribution of our vessels. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the FDA regulates pharmaceutical drugs, medical devices and biologic products under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;), FDA implementing regulations, and other laws. Our vessels are subject to regulation by the FDA as biologics. Biologics require the submission of a BLA and approval by the FDA before being marketed in the United States. None of our vessels have been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. If we fail to comply with applicable FDA or other requirements at any time during the product development process, clinical testing, and the approval process or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Marketing Approval&#8201;&#8212;&#8201;Biological Products in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish the safety, purity, and potency of the product candidate for its intended indications, including from the results of preclinical studies and clinical trials. A BLA must also contain extensive information about manufacturing and product quality control testing, and the applicant must pass an FDA preapproval inspection of the manufacturing facility or facilities at which the biologic product is produced and distributed from to assess compliance with current good manufacturing practices, or cGMPs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The steps for obtaining FDA approval of a BLA to market a biologic product in the United States generally include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Completion of extensive preclinical laboratory tests and preclinical animal studies performed in accordance with the FDA&#8217;s current good laboratory practice (&#8220;GLP&#8221;), regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Submission to the FDA of an IND, which must become effective before human clinical trials in the United States may begin; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Approval of the protocol and related documentation by an IRB or ethics committee representing each clinical site before each clinical trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as GCPs and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the product candidate for each proposed indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Submission to the FDA of a BLA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities and distribution site at which the product is produced: to assess compliance with cGMP regulations; to assure that the facilities, production methods, testing and controls are adequate; and, if applicable, to assure compliance with cGTP requirements for human cellular and tissue-derived products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Review of the product candidate by an FDA advisory committee, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">FDA review and approval, or licensure, of the BLA prior to any commercial marketing, sale or shipment of the product. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">U.S. Biological Products Development Process</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our vessels will be granted on a timely basis, if at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Once a product candidate is identified for development, that biologic candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies to evaluate the product&#8217;s potential safety and activity. The results of the preclinical studies, together with manufacturing information, analytical data, and at least one protocol for clinical study, are submitted to the FDA as part of an IND. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. This is known as a &#8220;clinical hold.&#8221; In such a case, the IND sponsor must resolve all of the FDA&#8217;s concerns to the agency&#8217;s satisfaction before the clinical trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin. Even after a clinical trial has begun, the FDA can issue a clinical hold at any time if it concludes that certain conditions exist, such as patients may be exposed to an unreasonable and significant risk of illness or injury. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the use of the product candidate in human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. An independent IRB for each medical center proposing to conduct a clinical trial must also review and approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical trial until it is completed. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Clinical testing also must satisfy extensive GCP requirements, including the requirements for informed consent. Information about clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of BLA submission and approval, clinical trials are typically conducted in three sequential phases, which may overlap or be combined. For Humacyte&#8217;s development of product candidates, Phase&#160;I and Phase&#160;II trials have heretofore been combined into a single trial design. For the V005 trauma trial, we are in discussions with FDA about converting a Phase&#160;II/III study into a Phase&#160;III pivotal study. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;I.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The biological product is initially introduced into human subjects and tested for safety. These initial trials to evaluate the potential toxicity and pharmacological activity of the investigational product (including pharmacokinetics, if applicable), and, if possible, gain early evidence on effectiveness. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;II</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The biological product is evaluated in a limited patient population to identify potential adverse events and safety risks, to evaluate preliminarily the efficacy of the product candidate for specific targeted indications in patients with the disease or condition under trial, and, when applicable, to evaluate dosage tolerance and appropriate dosage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;III.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The biological product is administered to an expanded patient population, often large numbers of patients of several hundred to several thousand and generally at geographically dispersed </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">clinical trial sites. These trials are designed to generate enough data to statistically evaluate clinical effectiveness and safety as well as to establish the overall benefit-risk relationship of the investigational new biological product, and to provide an adequate basis for product approval. FDA typically requires at least two Phase&#160;III trials to support approval, but in some cases may approve an application on the basis of one trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In some cases, the FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Such post-approval clinical trials are typically referred to as Phase&#160;IV clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the progress of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators detailing serious and unexpected adverse events, any findings from other studies that suggest a significant risk to human patients, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other trials on other products. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the characteristics of the biologic and finalize a process for manufacturing the biologic in commercial quantities in accordance with cGMP and, when applicable, GTP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">BLA Review Process</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The results of preclinical studies and of the clinical trials, together with other detailed information, including extensive manufacturing information, information on the composition of the biologic, and proposed labeling, are submitted to the FDA in the form of a BLA requesting approval to market the biologic in the United States for one or more specified indications. The FDA reviews a BLA to determine, among other things, whether a biologic is safe and effective for its intended use. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMPs (and, where applicable, GTPs) to assure and preserve the product&#8217;s identity, safety, strength, quality, potency, and purity, and biological product standards. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before approving an application, the FDA will, among other things, inspect the facility or the facilities at which the biologic product is manufactured and distributed, and will not approve the product unless cGMP compliance is satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance, and may refuse to approve the biologic if compliance with GCP requirements is found to be unsatisfactory. For a human cellular or tissue product the FDA also may refuse to approve the product if the manufacturer is not in compliance with GTP requirements, in addition to cGMPs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA also has authority to require a REMS from manufacturers to ensure that the benefits of a biological product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the BLA submission. The need for a REMS is determined as part of the review of the BLA. Based on statutory standards, elements of a REMS may include &#8220;dear doctor letters,&#8221; a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution and/or use. These elements are negotiated as part of the BLA approval, and in some cases may delay the approval date. Once adopted, REMS are subject to periodic assessment and modification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The testing and approval processes require substantial time, effort and financial resources, and each may take several&#160;years to complete. The FDA may not grant approval on a timely basis, or at all. Even if we believe a clinical trial has demonstrated safety and efficacy of one of our vessels for the treatment of a disease, the results may not be satisfactory to the FDA. Preclinical and clinical data may be interpreted by the FDA in different ways, which could delay, limit or prevent regulatory approval. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our vessels. The FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Biologics may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the biologic, including changes in indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require developing additional data or conducting additional preclinical studies and clinical trials. As with new BLAs, the review process is often significantly extended by FDA requests for additional information or clarification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its product as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from approving biosimilar applications for 12&#160;years after an innovator biological product receives initial marketing approval. This bar does not apply to submission or approval of full BLAs. Because FDA has determined that our HAVs are regulated as biologics and require a BLA for marketing, we believe that our lead product will be entitled to 12&#160;years of exclusivity upon approval. Nevertheless, the BPCIA is complex and is only beginning to be interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning is subject to uncertainty. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Expedited Development and Review Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA offers various programs, including Fast Track designation, Breakthrough Therapy Designation, accelerated approval, priority review and RMAT designation, that are intended to expedite the process for the development and FDA review of biological products that are intended for the treatment of serious or life-threatening diseases or conditions. To be eligible for Fast Track designation, biological product candidates must be intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a biological product candidate may request the FDA to designate the biologic as a Fast Track product at any time during the clinical development of the product. The sponsor of a Fast Track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A Fast Track product </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A biological product candidate may be eligible for Breakthrough Therapy Designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy Designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development program beginning as early as Phase&#160;I, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any marketing application for a biological product submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy Designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. Any product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a biological product candidate designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application within six&#160;months of the 60-day filing date, compared to ten&#160;months for a standard review. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, FDA may grant accelerated approval to a product candidate intended to treat a serious or life-threatening disease or condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2017, the FDA established a new RMAT designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any biological product that meets the following criteria: (i)&#160;the biological product qualifies as an RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii)&#160;the biological product is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii)&#160;preliminary clinical evidence indicates that the biological product has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of Breakthrough Therapy Designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of clinical trial sites, including through expansion of trials to additional sites. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fast Track designation, Breakthrough Therapy Designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, on December&#160;12, 2017, Public Law No. 115-92&#160;amended the FDCA to, among other things, allow the DoD to request, and FDA to provide assistance to expedite development and the FDA&#8217;s review of products to diagnose, prevent, treat or mitigate a specific and life-threatening risk to the U.S. military. Similar to the designations described above that FDA may grant, a priority designation by the DoD does not change the standards for approval but may expedite the development or approval process. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Orphan Drug Designation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biological product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity, or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other U.S. Regulatory Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For biologics that are human cells, tissues, and cellular and tissue-based products (&#8220;HTC/Ps&#8221;), manufacturers must also comply with the FDA&#8217;s HCT/P regulations at 21 C.F.R. Part&#160;1271. These regulations impose a variety of specialized requirements as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">HCT/P registration and listing.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Every establishment that manufactures an HCT/P must register with the FDA and provide a list of every HCT/P that the establishment manufactures. The definition of manufacture is broad and includes any and all steps in the recovery, processing, storage, labeling, packaging or distribution of any human cell or tissue and the screening or testing of the cell or tissue donor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Donor eligibility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;HCT/P manufacturers must maintain procedures for testing, screening and determining the eligibility of donors of cells and tissues used in HCT/Ps. An HCT/P may not be transferred or implanted into an individual until the donor has been determined to be eligible under these procedures. These procedures must involve, among other things, testing donors for certain communicable diseases and the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">use of quarantines for HCT/Ps that have not yet been shown to meet the eligibility requirements. Manufacturers must keep detailed records regarding donor eligibility determinations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Current Good Tissue Practices.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;HCT/Ps must be recovered, processed, stored, labeled, packaged and distributed in a manner that is consistent with the FDA&#8217;s cGTP regulations. Cells and tissues must also be screened and tested according to these regulations. The goal of cGTPs is to prevent the introduction, transmission or spread of communicable diseases. The FDA&#8217;s cGTPs regulations require companies to establish a comprehensive quality program and to comply with rules related to personnel, facilities and equipment used to manufacture HCT/Ps, as well as rules on how these HCT/Ps are processed, labeled and stored. Companies must also keep detailed manufacturing records and product complaint files. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Adverse Reaction Reports.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Manufacturers of nonreproductive HCT/Ps must investigate and report to the FDA certain adverse reactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Inspections.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Establishments that manufacture HCT/Ps must allow the FDA to inspect the establishment and company records. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Post-Approval Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA approvals would be subject to continuing post-approval regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences associated with the product, as well as any post-marketing surveillance requested by the FDA as a condition to BLA approval. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall our product from distribution or withdraw approval of the BLA for that product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA closely regulates the post-approval marketing and promotion of biologics to healthcare professionals, including standards and regulations for direct-to-consumer advertising, false or misleading claims, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available biologics for uses that are not described in the product&#8217;s labelling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">U.S. Healthcare Reform</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to significantly change the healthcare system. For example, the ACA was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. In December&#160;2017, portions of the ACA dealing with the individual mandate insurance requirement were effectively repealed by the Tax Cuts and Jobs Act of 2017. In December&#160;2018, a federal district court judge in Texas found the ACA to be unconstitutional, although the ruling was stayed while the case is appealed. In June&#160;2021, the United States Supreme Court held that the individual plaintiffs and states lacked standing to challenge the constitutionality of the ACA. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">U.S. Third-Party Payor Coverage and Reimbursement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although none of our vessels have been commercialized for any indication, if they are approved for marketing, commercial success of our vessels will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state and private levels. Government payor programs, including Medicare and Medicaid, private health care insurance companies and managed-care plans have attempted to control costs by limiting coverage and the amount of reimbursement for particular procedures or treatments. The U.S. Congress and state legislatures from time to time propose and adopt initiatives aimed at cost-containment. Ongoing federal and state government initiatives directed at lowering the total cost of health care will likely continue to focus on health care reform and on the reform of the Medicare and Medicaid payment systems. Examples of how limits on coverage and reimbursement in the United States may cause reduced payments for products in the future include: changing Medicare reimbursement methodologies; fluctuating decisions on which drugs to include in formularies; allowing the federal government to negotiate drug prices for federal healthcare programs; revising drug rebate calculations under the Medicaid program; and reforming drug importation laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse health care providers who use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our vessels and operate profitably. Significant cost containment pressure and downward pricing pressures exist in the U.S. and around the world, which may negatively affect reimbursement at any time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Healthcare Laws and Regulations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate include but are not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Physician Payments Sunshine Act, which requires drug and device companies to annually report to CMS all payments and transfers of value provided to physicians and teaching hospitals for posting on a public website; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">state law equivalents of many of the above federal laws, including anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and impact our financial results. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">International Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EU Requirements Applicable to Medicinal Products</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the EU, medicinal products are subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and national levels. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Clinical Trials</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU (currently Directive 2001/20/EC applies; however, as of January&#160;31, 2022, Regulation&#160;EU No 536/2014 will apply) and national regulations and the International Conference on Harmonization (&#8220;ICH&#8221;) guidelines on GCP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an independent ethics committee of the relevant EU Member State in which the clinical trial will be carried out. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The sponsor of a clinical trial must register the clinical trial in advance, and certain information related to the clinical trial will be made public as part of the registration. The results of the clinical trial must be submitted to the competent authorities and, with the exception of non-pediatric Phase&#160;I trials, will be made public at the latest within 12&#160;months after the end of the trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the development of a medicinal product, the EMA and national medicines regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). Advice is not legally binding with regard to any future marketing authorization application of the product concerned. To date, we have not initiated any scientific advice procedures with the EMA, but we have obtained confirmation from the EMA that our HAVs would be eligible for the EMA&#8217;s scientific advice procedures. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Marketing Authorizations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After completion of the required clinical testing, we must obtain a marketing authorization before we may place a medicinal product on the market in the EU. There are various application procedures available, depending on the type of product involved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All application procedures require an application in the common technical document format, which includes the submission of detailed information about the manufacturing and quality of the product, and non-clinical and clinical trial information. There is an increasing trend in the EU towards greater transparency and, while the manufacturing or quality information is currently generally protected as confidential information, the EMA and national regulatory authorities are now liable to disclose much of the non-clinical and clinical information in marketing authorization dossiers, including the full clinical study reports, in response to freedom of information requests after the marketing authorization has been granted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The centralized procedure gives rise to marketing authorizations that are valid throughout the EU. Applicants file marketing authorization applications with the EMA, where they are reviewed by a relevant scientific committee, in most cases the CHMP (although other specialist committees may also be involved; for example, the Committee for Advanced Therapies will also be involved in the review of advanced therapy medicinal products (&#8220;ATMP&#8221;), and HAVs could potentially be classified as an ATMP). The EMA forwards </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CHMP opinions to the European Commission, which uses them as the basis for deciding whether to grant a marketing authorization. The centralized procedure is compulsory for medicinal products that (1)&#160;are derived from biotechnology processes, (2)&#160;contain a new active substance (not yet approved on 20&#160;November&#160;2005) indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders, viral diseases or autoimmune diseases and other immune dysfunctions, (3)&#160;are orphan medicinal products or (4)&#160;are advanced therapy medicinal products. For medicines that do not fall within these categories, an applicant may voluntarily submit an application for a centralized marketing authorization to the EMA, as long as the CHMP agrees that (i)&#160;the medicine concerned contains a new active substance (not yet approved on November&#160;20, 2005), (ii)&#160;the medicine is a significant therapeutic, scientific, or technical innovation, or (iii)&#160;if its authorization under the centralized procedure would be in the interest of public health. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications to the national medicines regulators through one of three procedures: (1)&#160;a national procedure, which results in a marketing authorization in a single EU member state; (2)&#160;the decentralized procedure, in which applications are submitted simultaneously in two or more EU member states; and (3)&#160;the mutual recognition procedure, in which the EU member states are required to grant an authorization recognizing an existing authorization in another EU member state, unless they identify a serious risk to public health. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Data Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Marketing authorization applications for generic medicinal products do not need to include the results of preclinical and clinical trials, but instead can refer to the data included in the marketing authorization of a reference product for which regulatory data exclusivity has expired. If a marketing authorization is granted for a medicinal product containing a new active substance or to a different marketing authorization holder that has carried out a complete set of pre-clinical tests and clinical trials, that product benefits from eight&#160;years of data exclusivity, during which generic marketing authorization applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two&#160;years of market exclusivity, during which such generic products may not be placed on the market. The two-year period may be extended to three&#160;years if during the first eight&#160;years a new therapeutic indication with significant clinical benefit over existing therapies is approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, while a full set of pre-clinical tests and trials are not necessary, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Development</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the EU, companies developing a new medicinal product must agree to a Pediatric Investigation Plan (&#8220;PIP&#8221;) with the EMA and must conduct pediatric clinical trials in accordance with that PIP. The marketing authorization application for the product must ordinarily include the results of pediatric clinical trials conducted in accordance with the PIP. It is possible to obtain a deferral, in which case the pediatric clinical trials must be completed at a later date, or a complete waiver from the obligation to conduct pediatric clinical trials (e.g., because the relevant disease or condition occurs only in adults). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Post-Approval Controls</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The holder of a marketing authorization is subject to various post-approval controls, such as obligations to maintain a pharmacovigilance system and report adverse reactions, and requirements relating to promotional activities, including a prohibition on the promotion of prescription medicines to the general public. Manufacturers/importers and distributors of medicinal products must obtain authorizations from the competent national authorities and are subject to periodic inspections for compliance with cGMPs and current good distribution practices (&#8220;cGDPs&#8221;), respectively. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization, such as additional safety monitoring or the conduct of additional clinical trials or post-authorization safety studies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EU Requirements Applicable to Medical Devices</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the previous medical devices directive, Directive 93/42/EEC, our HAVs were not classified as medical devices in the EU because, with limited exceptions, products incorporating or derived from tissues or cells of human origin are expressly excluded from the scope of the EU medical devices rules under Directive&#160;93/42. However, as of May&#160;26, 2021, Regulation (EU) 2017/745 applies, and this will bring us within the scope of the EU medical device rules products containing or derived from tissues or cells of human origin that are non-viable or are rendered non-viable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Medical devices are generally governed by Regulation (EU) 2017/745 on Medical Devices that directly applies in all EU Member States and harmonizes the conditions for placing medical devices on the EU market. This Regulation, however, does not regulate certain important marketing aspects, such as pricing and reimbursement, which remain governed by national law. Additionally, certain areas, such as advertising, may be goverened by additional national requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A medical device may be placed on the market within the EU if it conforms to certain &#8220;general product safety requirements&#8221; or &#8220;GSPRs.&#8221; These are general in nature and broad in scope. A fundamental GSPR, for example, is that a device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users or other persons. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The manufacturer is obliged to demonstrate that the device conforms to the relevant GSPRs through a conformity assessment procedure. Once the appropriate conformity assessment procedure for a medical device has been completed, the manufacturer must draw up a written declaration of conformity and affix the CE mark to the device. The device can then be marketed throughout the EU. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The nature of the conformity assessment depends upon the classification of the device. The classification rules are mainly based on three criteria: the length of time the device is in contact with the body, the degree of invasiveness, and the extent to which the device affects the anatomy. As a general rule, Class&#160;I (low risk) devices are those that do not enter or interact with the body; Class&#160;IIa and IIb (medium risk) devices are invasive or implantable or interact with the body; and Class&#160;III (high risk) devices are those that affect the vital organs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Conformity assessment procedures for all but the lowest risk classification of device involve a notified body, which are non-governmental, private entities licensed to provide independent certification of certain classes of medical device. EU regulatory bodies are not involved in the premarket approval of medical devices, with only very limited exceptions (such as medical devices that incorporate a medicinal product as an ancillary substance, in which case these regulatory bodies review the medicinal product). The onus of ensuring a device is safe enough to be placed on the market is ultimately the responsibility of the manufacturer and the notified body. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As part of the conformity assessment procedure, the manufacture will need to conduct a clinical evaluation of the device. This clinical evaluation may consist of an analysis of the scientific literature relating to similar devices, new clinical investigations of the device, or a combination of the two. For Class&#160;III and implantable devices, the conduct of clinical investigations is mandatory (with limited exceptions). If a manufacturer wishes to conduct a clinical investigation in the EU, the manufacturer must notify the competent national regulatory authorities in advance and obtain ethics committee approval of the study. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">EU Requirements Applicable to Human Cells and Tissues</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EU rules, notably Directive 2004/23/EC and other implementing directives, govern the donation, procurement, testing and storage of human cells and tissues intended for human application, whether or not they are medicinal products. These rules also cover the donation, testing, processing, preservation, storage and distribution of human cell and tissues that are not medicinal products. Establishments that conduct such activities must be licensed and are subject to inspection by regulatory authorities. Such establishments must implement appropriate quality systems and maintain appropriate records to ensure that cells and tissues can be traced from the donor to the recipient and vice versa. There are also requirements to report SAEs and reactions linked to the quality and safety of cells and tissues. More detailed rules may exist at the national level. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:212pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to regulations in Europe and the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of our future products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our corporate headquarters, manufacturing, and research and development facilities are located in Durham, North Carolina where we lease approximately 83,000 square feet of space. This space includes approximately 55,000 square feet for production and distribution operations including manufacturing, bioprocessing, quality control, mechanical space and inventory. The remainder of the facility consists of offices, laboratories, and common spaces. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees and Human Capital Management</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2021, we had 144 employees. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financing Arrangements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, Legacy Humacyte entered into a Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P., which provides a term loan facility of up to $50.0&#160;million with a maturity date of March&#160;1, 2025. We became a co-borrower under the Loan Agreement in connection with the Business Combination. The obligations of Humacyte and Legacy Humacyte under the Loan Agreement are secured by substantially all of their assets, except for their intellectual property. In connection with the Loan Agreement, the lenders were each granted a warrant to purchase Legacy Humacyte common stock, with an exercise price of $2.699 per share, subject to customary adjustments. In connection with the closing of the Business Combination, these warrants were exchanged for warrants to purchase 287,704 shares of our common stock at an exercise price of $10.28 per share. On October 13, 2021, we borrowed an additional $10.0&#160;million under the Loan Agreement, and in connection with that borrowing, issued Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. warrants to purchase an aggregate of 123,302 shares of our common stock at an exercise price of $10.28 per share. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. We may use the proceeds of borrowings under the Loan Agreement as working capital and to fund our general business requirements. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2021, we had incurred $30.0&#160;million of principal under the Loan Agreement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth certain information regarding our executive officers and directors as of the date of this prospectus. </font>
        </div>
        <table style="width:456pt;height:296.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:17pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:271pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position(s) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:271pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Laura E. Niklason </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">58 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">President, Chief Executive Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Dale A. Sander </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">62 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:271pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer, Chief Corporate Development Officer and Treasurer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Heather Prichard </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">44 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Chief Operating Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">William Tente, M.S. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Chief Regulatory Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">58 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Chief Surgical Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Kiernan T. DeAngelis </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Chief Medical Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">William (B.J.) Scheessele </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Chief Commercial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Non-Employee Directors:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:271pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Gordon M. Binder</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">85 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Emery N. Brown</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Michael T. Constantino</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(3)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">59 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Brady W. Dougan </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">63 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Todd M. Pope</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">55 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Kathleen Sebelius</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">73 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director and Chair </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Rajiv Shukla</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">46 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Max Wallace</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)(3)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">69 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Susan Windham-Bannister</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(4)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">70 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of the audit committee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of the nominating and governance committee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of the compensation committee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Member of the commercial committee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Laura E. Niklason</font><font style="letter-spacing:0.2pt;"> is the founder of Legacy Humacyte. Dr.&#160;Niklason has served as our President and Chief Executive Officer and as a member of the Board since the Business Combination, and previously served as President and Chief Executive Officer of Legacy Humacyte since November&#160;2020 and as a member of the Legacy Humacyte board of directors since 2004. Dr.&#160;Niklason has served in a senior scientist capacity from 2005 through 2020. Dr.&#160;Niklason has served as an adjunct professor at Yale University since November&#160;2020 and previously served as the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University from 2006 to November&#160;2020. She was inducted into the National Academy of Inventors in 2014 and was elected to the National Academy of Medicine and the National Academy of Engineering in 2015 and 2020, respectively. Dr.&#160;Niklason is currently on the board of directors of Self Study Inc., a private learning optimization technology company. Dr.&#160;Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan. Dr.&#160;Niklason completed her residency training in anesthesia and intensive care unit medicine at the Massachusetts General Hospital and completed post-doctoral scientific training at the Massachusetts Institute of Technology. Dr.&#160;Niklason is married to Mr.&#160;Dougan, a member of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Dr.&#160;Niklason is qualified to serve as a director based on her significant experience in the biotechnology industry, her extensive training in medicine and science and her role as the founder of Legacy Humacyte. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dale A. Sander</font><font style="letter-spacing:0.2pt;"> has served as our Chief Financial Officer, Chief Corporate Development Officer and Treasurer since the Business Combination. Mr.&#160;Sander previously served as Legacy Humacyte&#8217;s Chief Financial Officer and Treasurer since May&#160;2021, as Legacy Humacyte&#8217;s Chief Corporate Development Officer since November&#160;2020 and as a member of the Legacy Humacyte board of directors since September&#160;2015. He served as the Chief Financial Officer of Bryn Pharma, a privately held life sciences company, from 2019 to 2021. Prior to that, Mr.&#160;Sander served as Chief Financial Officer of AVITA Medical Limited, a publicly traded regenerative medicine company, from 2017 to 2019, and as Senior Vice President, Global Accounting Officer at Sutherland Global Services, Inc. from 2012 to 2017. Mr.&#160;Sander served as a Senior Manager with Ernst &amp; Young and holds a B.S. in Business Administration from San Diego State University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Heather Prichard</font><font style="letter-spacing:0.2pt;"> has served as our Chief Operating Officer since the Business Combination and previously served as Legacy Humacyte&#8217;s Chief Operating Officer since March&#160;2019. Dr.&#160;Prichard previously served as Legacy Humacyte&#8217;s Senior Vice President of Product Development from April&#160;2016 to February&#160;2019 and served in other management roles with Legacy Humacyte since 2012. Dr.&#160;Prichard joined Legacy Humacyte in 2008 and has been instrumental in leading the process and product development teams for the HAV through all phases of clinical development. Prior to joining Legacy Humacyte, Dr.&#160;Prichard held roles at The Procter &amp; Gamble Company in research, development, and engineering from June&#160;1999 to August&#160;2002. Dr.&#160;Prichard holds a Ph.D. in Biomedical Engineering with a focus on investigating the healing response to implantable tissue engineered biomaterials from Duke University and a B.A. in Chemical Engineering from the Georgia Institute of Technology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">William Tente</font><font style="letter-spacing:0.2pt;"> has served as our Chief Regulatory Officer since the Business Combination and previously served as Legacy Humacyte&#8217;s Chief Regulatory Officer since March&#160;2018. Mr.&#160;Tente joined Legacy Humacyte in 2008 and served in a variety of leadership roles, including as Vice President of Manufacturing and Regulatory Affairs, prior to his promotion to Chief Regulatory Officer. Previously, Mr.&#160;Tente served as Vice President of Operations for Neurotech USA, Inc., a biotechnology company, from July&#160;2002 to August&#160;2007, Director of Operations of Chimeric Therapies, Inc., a former clinical-stage biotechnology company, from January&#160;1998 to June&#160;2002, and Director of Clinical Production at CytoTherapeutics, Inc., a former clinical-stage biotechnology company, from 1992 to 1998. Mr.&#160;Tente was elected to the United States Pharmacopeia (USP) Council of Experts in 1998 and served as the Chairman of its Expert Committee on Gene Therapy, Cell Therapy and Tissue Engineering Products from 2005 to 2010. Mr.&#160;Tente holds a B.S. and M.S. in cell biology and microbiology from the University of Rhode Island and studied at the W. Alton Jones Cell Sciences Center. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Jeffrey H. Lawson</font><font style="letter-spacing:0.2pt;"> has served as our Chief Surgical Officer and a member of our Board since the Business Combination. Mr.&#160;Lawson previously served as Legacy Humacyte&#8217;s Chief Surgical Officer since November&#160;2020 and as a member of Legacy Humacyte&#8217;s board of directors since July&#160;2018. Dr.&#160;Lawson also is an Adjunct Professor of Surgery and Pathology at Duke University. Prior to Dr.&#160;Lawson&#8217;s appointment as Legacy Humacyte&#8217;s President and Chief Executive Officer, he served as Legacy Humacyte&#8217;s Chief Medical Officer from October&#160;2015 to January&#160;2019. Prior to joining Legacy Humacyte, Dr.&#160;Lawson held various professorships in surgery and pathology at Duke University Medical Center beginning in 1999. Dr.&#160;Lawson is an active physician-surgeon-scientist and is an internationally recognized leader in the areas of peripheral vascular surgery, hemodialysis access, blood coagulation, and cardiovascular device innovation. Dr.&#160;Lawson has worked closely with Legacy Humacyte since its founding. He has successfully developed a number of molecular, cellular, and tissue engineered technologies through basic science, translational animal research, first-in-man and large-scale human clinical trials. In this regard, Dr.&#160;Lawson has been directly involved with a number of cardiovascular technologies gaining both FDA approval and successful commercial launch in both the vascular biologics and the medical device space. Dr.&#160;Lawson has over 20&#160;years of surgical experience in treating complex vascular surgery and arteriovenous access patients. Dr.&#160;Lawson also currently serves on the Board of Directors for the Kidney Health Initiative (KHI), the American Board of Vascular Surgery (ABVS), the Vascular Access Society for the Americas (VASA), InnAVasc, and the Foundation for Women and Girls with Blood Disorders (FWGBD). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that Dr.&#160;Lawson is qualified to serve as a director based on his significant medical and scientific knowledge and experience. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Kiernan T. DeAngelis</font><font style="letter-spacing:0.2pt;"> has served as our Chief Medical Officer since the Business Combination and previously served as Legacy Humacyte&#8217;s Chief Medical Officer since December&#160;2020. Prior to his appointment as Chief Medical Officer, Mr.&#160;DeAngelis served as Legacy Humacyte&#8217;s Vice President, Clinical from April&#160;2020 to December&#160;2020. Previously, Mr.&#160;DeAngelis served as Senior Medical Director of IQVIA Biotech LLC, a clinical and commercial solutions company, from September&#160;2019 to April&#160;2020, Global Medical Director of AstraZeneca plc from June&#160;2017 to September&#160;2019, and Senior Medical Director of United Therapeutics Corporation, a public biotechnology company, from February&#160;2013 to May&#160;2017. Mr.&#160;DeAngelis holds an M.D. from The Brody School of Medicine at East Carolina University and a B.S. in Biochemistry and B.A. in Chemistry from North Carolina State University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">William (B.J.) Scheessele</font><font style="letter-spacing:0.2pt;"> has served as Humacyte&#8217;s Chief Commercial Officer since August&#160;2021. He served as Executive Vice President of Global Marketing for Quest Medical Imaging Inc. from 2018 to 2021. Previously, Mr.&#160;Scheessele served as Vice President, Marketing at Sientra, Inc., a medical device company, from 2017 to 2018. Prior to that, he served as Vice President of North America Marketing and Canada Country Manager, among other roles in sales and marketing, at LifeCell Corporation, a regenerative medicine company, from 2007 to 2016, and as Vice President, North American Marketing and Reimbursement at Allergan plc, a global biopharmaceutical company, from 2016 to 2017, after its acquisition of LifeCell Corporation. Earlier in his career, Mr.&#160;Scheessele worked in business development and product management with Cordis Corporation, a medical device company and subsidiary of Johnson &amp; Johnson, from 1998 to 2007. Mr.&#160;Scheessele earned a BSE in biomedical engineering and economics and an MBA from Duke University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of our executive officers serves at the discretion of the Board and will hold office until the election or qualification of his or her successor or until his or her earlier death, resignation or removal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Brady W. Dougan</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since the Business Combination. He previously served as the chair of the Legacy Humacyte board of directors from March&#160;2019 to August&#160;2021 and as a member of its board of directors since 2005. Since July&#160;2015, Mr.&#160;Dougan has served as Chairman and Chief Executive Officer of Exos Securities (&#8220;Exos&#8221;). From May&#160;2007 through June&#160;2015, Mr.&#160;Dougan served as Chief Executive Officer and Member of the Executive Board of Credit Suisse Group AG and Credit Suisse AG, steering the bank through the financial crisis of 2008 and various reforms and changes in the banking industry. Prior to that time, Mr.&#160;Dougan served in various leadership positions at Credit Suisse. Mr.&#160;Dougan currently serves on the Board of Trustees for the University of Chicago. Mr.&#160;Dougan holds a B.A. in Economics and an M.B.A. in Finance from the University of Chicago. Mr.&#160;Dougan is married to Laura E. Niklason, Humacyte&#8217;s President and Chief Executive Officer and a member of our Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Dougan is qualified to serve as a director based on his significant executive leadership experience and his extensive experience related to financing for public and private companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Emery N. Brown</font><font style="letter-spacing:0.2pt;"> currently serves as the Warren M. Zapol Professor of Anaesthesia at Harvard Medical School and the Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience at the Massachusetts Institute of Technology. He has been on the faculty at Harvard Medical School and MIT since May&#160;1992 and October&#160;2005, respectively. Dr.&#160;Brown has also served as an anesthesiologist at Massachusetts General Hospital since May&#160;1992. Dr.&#160;Brown currently serves on the Board of Trustees of the Guggenheim Foundation, the Board of Trustees of the Simmons Foundation, the National Academy of Medicine Forum on Neurological Disorders and the board of PASCALL Systems, Inc., an early-stage medical device startup. Dr.&#160;Brown is a member of the National Academy of Inventors, the National Academy of Medicine, the National Academy of Sciences and the National Academy of Engineering. Dr.&#160;Brown holds an M.D. from Harvard Medical School, a Ph.D. and M.A. in statistics from Harvard University and a B.A. in applied mathematics from Harvard College. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that Dr.&#160;Brown is qualified to serve as a director based on his extensive medical and scientific knowledge and experience. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Kathleen Sebelius</font><font style="letter-spacing:0.2pt;"> is the chair of our Board. She has served as a member of our Board since the Business Combination and previously served as a member of the Legacy Humacyte board of directors since </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">September&#160;2015. Ms.&#160;Sebelius is the Chief Executive Officer of Sebelius Resources LLC. From April&#160;2009 to June&#160;2014, Ms.&#160;Sebelius served as Secretary of the Department of Health and Human Services, or HHS. Prior to serving as Secretary of HHS, Ms.&#160;Sebelius was the Governor of Kansas and served two terms as the Kansas insurance commissioner and four terms in the Kansas Legislature. Ms.&#160;Sebelius currently serves on the board of directors of the following public companies: Devoted Health, Inc., Myovant Sciences Ltd., Grand Rounds Inc. and Exact Sciences Corporation. She also serves as a director of the Kaiser Family Foundation. Ms.&#160;Sebelius co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Est&#233;e Lauder Foundation, and the University of Kansas College of Liberal Arts and Sciences. Ms.&#160;Sebelius holds a master of public administration degree from the University of Kansas and a B.A. in Political Science from Trinity Washington University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Ms.&#160;Sebelius is qualified to serve as a director based on her distinguished leadership in the healthcare reimbursement industry, tenure in the public sector and experience with regulatory process and policies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rajiv Shukla</font><font style="letter-spacing:0.2pt;"> served as AHAC&#8217;s Chairman and Chief Executive Officer since inception and has two decades of buyouts, investments and operations experience in the healthcare industry. Mr.&#160;Shukla served as Chairman and Chief Executive Officer of CNAC, a Nasdaq-listed special purpose acquisition company, from June&#160;2017 to August&#160;2019. CNAC raised $144&#160;million in proceeds from a Nasdaq initial public offering and successfully closed its initial business combination with DermTech, Inc., or DermTech, in August&#160;2019. Since August&#160;2019, Mr.&#160;Shukla has served as an independent director on the board of directors of InflammX Therapeutics, formerly known as Ocunexus Therapeutics, a clinical stage biotech company. From June&#160;2013 to May&#160;2015, Mr.&#160;Shukla served as Chief Executive Officer of Pipavav Defence &amp; Offshore Engineering Company (now Reliance Naval and Engineering Ltd.), an Indian listed shipbuilding and defense manufacturing company. Between 2008 and 2013, Mr.&#160;Shukla worked as an investor at ICICI Venture, Morgan Stanley Investment Management and Citi Venture Capital International. From 2001 to 2006, Mr.&#160;Shukla served as Senior Director at Pfizer, Inc. Mr.&#160;Shukla holds a master in healthcare management and policy degree from Harvard University and received a bachelor&#8217;s in pharmaceutics from the Indian Institute of Technology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Shukla is qualified to serve as a director based on the depth of his experience in the healthcare industry and in providing strategic guidance to numerous companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Max Wallace</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since the Business Combination and previously served as a member of the Legacy Humacyte board of directors since June&#160;2005. Mr.&#160;Wallace served as Chief Executive Officer of Accelerate Brain Cancer Cure, or ABC, a not-for-profit corporation seeking to drive research and treatments for brain tumors from August&#160;2008 to December&#160;2019. Prior to joining ABC, Mr.&#160;Wallace served as the Chief Executive Officer of TheraLogics, Inc. an early-stage biopharmaceutical company, and as President of Trimeris, Inc., a formerly public biopharmaceutical company founded by Mr.&#160;Wallace that created and brought to market a new class of drugs for the treatment of HIV, AIDS and other viral diseases and is now a part of Synageva BioPharma Corp. Mr.&#160;Wallace also founded and developed several other biopharmaceutical companies, including Cogent Neuroscience, Sphinx Pharmaceuticals Corporation, now a division of Eli Lilly &amp; Company, and SARCO, Inc., now a part of PPD/</font>&#8203;<font style="letter-spacing:0.2pt;">Pharmaco, and co-founded and served as President of the North Carolina Bioscience Organization, the biotechnology industry&#8217;s trade organization in North Carolina. Mr.&#160;Wallace holds a B.A. in English and Political Science from Duke University and a J.D. from the University of Florida. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Wallace is qualified to serve as a director based on the depth of his experience in the biotechnology industry, including his service in executive roles at multiple emerging biopharmaceutical companies and his oversight of the development and commercialization of innovative technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Susan Windham-Bannister</font><font style="letter-spacing:0.2pt;"> has served as President and Chief Executive Officer of Biomedical Growth Strategies, LLC, a strategic advisory firm serving the life sciences and healthcare industries, since September&#160;2015. From 2008 to 2015, Dr.&#160;Windham-Bannister served as founding President and Chief Executive Officer of the Massachusetts Life Sciences Initiative, a $1&#160;billion life sciences-dedicated investment fund. Dr.&#160;Windham-Bannister currently serves on the board of directors of Aridis Pharmaceuticals, Inc., a public late-stage biopharmaceutical company. She is the Chair of the National Board of Directors of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Association for Women in Science (AWIS), serves on the board of directors of St. Jude&#8217;s Children&#8217;s Research Hospital, and Chairs the board of BioscienceLA, a nonprofit independent innovation catalyst organization. Dr.&#160;Windham-Bannister holds a Ph.D. in Health Policy and Management from the Florence Heller School at Brandeis University. She was a Post-Doctoral Fellow at Harvard University&#8217;s John F. Kennedy School and a Fellow in the Center for Science and Policy (CSAP) at Cambridge University, Cambridge, England. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Dr.&#160;Windham-Bannister is qualified to serve as a director based on her status as an internationally recognized expert in innovation, market access, and market optimization strategies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Gordon M. Binder</font><font style="letter-spacing:0.2pt;"> served as the Chief Executive Officer of Amgen, Inc. from 1998 through 2000. Mr.&#160;Binder joined Amgen in 1982 as Chief Financial Officer, having previously served as the Chief Financial Officer of System Development Corporation, a computer system and software company, and in financial management positions at Litton Industries and Ford Motor Company. After retiring from Amgen, Mr.&#160;Binder founded Coastview Capital LLC, a biotech venture capital firm. Mr.&#160;Binder currently serves as Chairman of the Board of Directors of NEUVOGEN, Inc., a private immunoncology company. Mr.&#160;Binder has also served as the Chairman of BIO, the biotechnology industry trade association, and as Chairman of PHRMA, the pharmaceutical industry trade association. He has served as a member of the board of directors of the Massachusetts Institute of Technology, the California Institute of Technology, the American Enterprise Institute and Pepperdine University. Mr.&#160;Binder is a fellow of the American Academy of Arts and Sciences and is the author of Science Lessons: What the Business of Biotech Taught Me About Management. Mr.&#160;Binder holds a B.S. in electrical engineering from Purdue University and an M.B.A. from Harvard Business School, where he was a Baker Scholar. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Binder is qualified to serve as a director based on the depth of his experience in the life sciences industry, including his service in executive roles at Amgen. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Michael T. Constantino</font><font style="letter-spacing:0.2pt;"> is a retired Ernst &amp; Young LLP assurance partner who served in the Research Triangle Park region of North Carolina for over 30&#160;years. From 2009 to 2012, he served as the Office Managing Partner for the combined Raleigh/Greensboro office of Ernst &amp; Young with over 200 employees. Currently, Mr.&#160;Constantino serves as the member of the Board and the Chairman of the Audit Committee of 9 Meters Biopharma, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company. He is also the Chair of the Board for the NC State Foundation and Chair of the Board of The Green Chair Project, and serves on the Advisory Board for CREO, Inc., an RTP-based consultancy focused on growth management and data transformation services. Mr.&#160;Constantino holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina Certified Public Accountant, or CPA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Constantino is qualified to serve as a director based on his extensive experience as a CPA and with SEC compliance matters and Sarbanes-Oxley internal controls. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Todd M. Pope</font><font style="letter-spacing:0.2pt;"> has served as the President and Chief Executive Officer of WellAir Group Ltd., a leading clean air solutions company, since February&#160;2021. Prior to its acquisition by WellAir, Mr.&#160;Pope served as the Executive Chairman of UV Innovators, LLC, a developer of medical-grade handheld UVC disinfection technology, from February&#160;2017 to February&#160;2021. From 2008 to 2019, Mr.&#160;Pope served as the Chief Executive Officer of TransEnterix, Inc. (now Asensus Surgical, Inc.), a medical device company. He also previously served as worldwide president of Cordis, a multi-billion-dollar division within Johnson &amp; Johnson&#8217;s medical device business. Mr.&#160;Pope currently serves as the Chairman of the Board of Directors of AdvaMed ACCEL and as a member of the Board of Directors of WELL.Co, a private digital health company. Mr.&#160;Pope also serves on the Kenan-Flagler Board of Visitors and the Educational Foundation for the University of North Carolina at Chapel Hill, where he is the immediate past Executive Chairman of the Board. Time Magazine named Mr.&#160;Pope one of the &#8220;50 most influential people in healthcare 2018.&#8221; Mr.&#160;Pope holds a B.A. in Labor and Industrial Relations from the University of North Carolina. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that Mr.&#160;Pope is qualified to serve as a director based on his extensive experience in key leadership positions at public and private companies within the healthcare industry. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Composition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board directs the management of our business and affairs, as provided by Delaware law, and conducts its business through meetings of the Board and its standing committees. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board consists of eleven members. Kathleen Sebelius serves as chair of the Board. The primary responsibilities of the Board are to provide risk oversight and strategic guidance to Humacyte and to counsel and direct our management. The Board meets on a regular basis and will convene additional meetings, as required. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fresenius Medical Care may designate one representative to attend, in a non-voting observer capacity, all meetings of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board is divided into three classes of directors, with the classes to be as nearly equal as possible, and with the directors serving three-year terms. Mr.&#160;Dougan, Dr.&#160;Lawson and Mr.&#160;Wallace are currently Class&#160;I directors; Mr.&#160;Binder, Mr.&#160;Pope, Ms.&#160;Sebelius and Mr.&#160;Shukla are Class&#160;II directors; and Dr.&#160;Brown, Mr.&#160;Constantino, Dr.&#160;Niklason and Dr.&#160;Windham-Bannister are Class&#160;III directors. The term of office of the Class&#160;I directors will expire at the first annual meeting of stockholders following the initial classification of the Board. At the second annual meeting of stockholders following such classification, the term of office of the Class&#160;II directors will expire and Class&#160;II directors will be elected for a full term of three&#160;years. At the third annual meeting of stockholders following such classification, the term of office of the Class&#160;III directors will expire and Class&#160;III directors will be elected for a full term of three&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Niklason, our President and Chief Executive Officer, is married to Mr.&#160;Dougan. Both Dr.&#160;Niklason and Mr.&#160;Dougan serve on the Board. There are no additional family relationships among the directors and executive officers of Humacyte. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Independence of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Nasdaq listing standards generally define an &#8220;independent director&#8221; as a person who is not an executive officer or employee, or who does not have a relationship which, in the opinion of the company&#8217;s board of directors, would interfere with the exercise of independent judgment in carrying out his or her responsibilities as a director. The Board has determined that Gordon M. Binder, Emery N. Brown, Michael T. Constantino, Todd M. Pope, Kathleen Sebelius, Max Wallace and Susan Windham-Bannister are considered independent directors of Humacyte. The independent directors hold regularly scheduled meetings at which only independent directors are present. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Leadership Structure and Role in Risk Oversight</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board recognizes that the leadership structure and combination or separation of the Chief Executive Officer and chairperson roles is driven by the needs of Humacyte at any point in time. As a result, no policy exists requiring combination or separation of leadership roles, and Humacyte&#8217;s governing documents do not mandate a particular structure. This will allow the Board the flexibility to establish the most appropriate structure for Humacyte at any given time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board oversees the risk management activities designed and implemented by Humacyte&#8217;s management. The Board does not have a standing risk management committee, but rather executes its oversight responsibility both directly and through its standing committees. The Board also considers specific risk topics, including risks associated with Humacyte&#8217;s strategic initiatives, business plans and capital structure. Humacyte&#8217;s management, including our executive officers, are primarily responsible for managing the risks associated with operation and business of the company and provide appropriate updates to the Board and the audit committee. The Board has delegated to the audit committee oversight of its risk management process, and the other committees of the Board also consider risks as they perform their respective committee responsibilities. All Board committees report to the Board as appropriate, including, but not limited to, when a matter rises to the level of a material or enterprise risk. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Committees of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board has an audit committee, a nominating and governance committee, a compensation committee, and a commercial committee. In addition, from time to time, special committees may be established under the direction of the Board when necessary to address specific issues. Copies of each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Board committee&#8217;s charter are posted on Humacyte&#8217;s website. Humacyte&#8217;s website and the information contained on, or that can be accessed through, such website are not deemed to be incorporated by reference in, and are not considered part of, this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audit committee consists of Michael T. Constantino, Kathleen Sebelius, and Susan Windham-Bannister. Michael T. Constantino serves as the chairperson of the audit committee. The Board has determined that each of Michael T. Constantino, Kathleen Sebelius, and Susan Windham-Bannister is independent under Nasdaq listing standards and Rule&#160;10A-3 of the Exchange Act. Each member of the audit committee is financially literate. The Board also has determined that Michael T. Constantino is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audit committee has the following responsibilities, among others, as set forth in the audit committee charter: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">selecting a firm to serve as the independent registered public accounting firm to audit Humacyte&#8217;s financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ensuring the independence of the independent registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and that firm, Humacyte&#8217;s interim and year-end operating results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">considering the adequacy of Humacyte&#8217;s internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing material related party transactions or those that require disclosure; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pre-approving audit and non-audit services to be performed by the independent registered public accounting firm. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The nominating and governance committee consists of Gordon M. Binder, Emery N. Brown and Max Wallace. Max Wallace serves as the chairperson of the nominating and governance committee. The Board has determined that each of Gordon M. Binder, Emery N. Brown and Max Wallace is independent under Nasdaq listing standards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The nominating and governance committee has the following responsibilities, among others, as set forth in the nominating and governance committee&#8217;s charter: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying and recommending candidates for membership on the Board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and recommending Humacyte&#8217;s corporate governance guidelines and policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing the process of evaluating the performance of the Board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">assisting the Board on corporate governance matters; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing proposed waivers of the Code of Conduct and Ethics for directors and executive officers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee consists of Michael T. Constantino, Todd M. Pope and Max Wallace. Todd M. Pope serves as the chairperson of the compensation committee. The Board has determined that each of Michael T. Constantino, Todd M. Pope and Max Wallace is independent under applicable SEC rules and Nasdaq listing standards and a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee has the following responsibilities, among others, as set forth in the compensation committee&#8217;s charter: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:172pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or recommending that the Board approve, the compensation of executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and recommending to the Board the compensation of its directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">administering Humacyte&#8217;s stock and equity incentive plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or making recommendations to the Board with respect to, incentive compensation and equity plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing Humacyte&#8217;s overall compensation philosophy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Commercial Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The commercial committee consists of Gordon M. Binder, Jeffrey H. Lawson, Todd M. Pope, Rajiv Shukla and Susan Windham-Bannister. The commercial committee does not have a chairperson. The commercial committee oversees issues related to manufacturing, pricing, market access, and sales. A majority of the members of the commercial committee&#8201;&#8212;&#8201;Gordon M. Binder, Todd M. Pope and Susan Windham-Bannister&#8201;&#8212;&#8201;are independent under applicable SEC rules and Nasdaq listing standards. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Code of Conduct and Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte has adopted a Code of Conduct and Ethics that applies to all officers, directors and employees of Humacyte and its subsidiaries. The Code of Conduct and Ethics codifies the business and ethical principles that govern all aspects of Humacyte&#8217;s business, reflecting Humacyte&#8217;s commitment to this culture of honesty, integrity and accountability. In addition to following the Code of Conduct and Ethics, officers, directors and employees are expected to seek guidance in situations where there is a question regarding compliance issues, whether with the letter or the spirit of Humacyte&#8217;s policies and applicable laws. Humacyte will provide, without charge, upon request, copies of the Code of Conduct and Ethics. The code of business conduct is available on Humacyte&#8217;s website. Humacyte&#8217;s website and the information contained on, or that can be accessed through, such website are not deemed to be incorporated by reference in, and are not considered part of, this prospectus. For copies of the Code of Conduct and Ethics, please see the section entitled &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">None of the members of the compensation committee is currently one of Humacyte&#8217;s officers or employees. None of Humacyte&#8217;s executive officers currently serves, or has served during the last completed fiscal year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving or will serve as a member of Humacyte&#8217;s board of directors or compensation committee.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As used in this section, &#8220;Humacyte&#8221; refers to Legacy Humacyte prior to the closing of the Business Combination and Humacyte, Inc. after the closing of the Business Combination; and the &#8220;Board&#8221; refers to the board of directors of Legacy Humacyte prior to the closing of the Business Combination and to the board of directors of Humacyte, Inc. after the closing of the Business Combination. Upon the closing of the Business Combination, the executive officers of Legacy Humacyte became executive officers of Humacyte, except for Mr.&#160;Blankenship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section provides an overview of Humacyte&#8217;s executive compensation programs as they relate to the executive officers named below (the &#8220;named executive officers&#8221;), including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The Board, upon the recommendation of its compensation committee and with input from Humacyte&#8217;s Chief Executive Officer, has historically determined the compensation for Humacyte&#8217;s named executive officers. For the year ended December&#160;31, 2020, Humacyte&#8217;s named executive officers were: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Laura E. Niklason, President, Chief Executive Officer and a member of the Board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Douglas L. Blankenship, former Chief Financial Officer and Treasurer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson, Chief Surgical Officer and a member of the Board; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Heather Prichard, Chief Operating Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents information regarding the compensation awarded by, earned by or paid to Humacyte&#8217;s named executive officers during the fiscal year ended December&#160;31, 2020. </font>
        </div>
        <table style="width:456pt;height:146.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:173.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Salary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Bonus</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:173.8pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Laura E. Niklason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(3)</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">President and Chief Executive Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">75,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,990<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font> </font></td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">106,277<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font> </font></td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">208,267</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:173.8pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Douglas L. Blankenship</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(6)</font><font style="letter-spacing:0.2pt;"> </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Former Chief Financial Officer and Treasurer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">385,189<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(7)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">30,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,990<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(8)</font> </font></td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,116<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(9)</font> </font></td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">455,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:173.8pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(10)</font><font style="letter-spacing:0.2pt;"> </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Surgical Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">604,816</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">75,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,990<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(11)</font> </font></td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">14,079<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(12)</font> </font></td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">720,885</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:173.8pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Heather Prichard </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Operating Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">371,917</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">80,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,990<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(13)</font> </font></td>
            <td style="padding:0pt;padding-left:11.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,783<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(14)</font> </font></td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">490,690</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The amounts reported here reflect annual cash bonuses for 2020 paid under an employee bonus program. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The amounts reported here do not reflect the actual economic value that may be realized by each named executive officer. In accordance with SEC rules, these amounts represent the grant date fair value of the option awards, calculated in accordance with Accounting Standards Update 2018-07, &#8220;Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718).&#8221; For additional information regarding the assumptions used in calculating the grant date fair value of the stock options reported in this table, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8201;&#8212;&#8201;Critical Accounting Policies and Significant Judgments and Estimates&#8201;&#8212;&#8201;Stock-Based Compensation.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Niklason was appointed as Humacyte&#8217;s President and Chief Executive Officer in November&#160;2020. Accordingly, her salary has been prorated to reflect the portion of 2020 during which she was employed by Humacyte. The $75,000 in salary earned by Dr.&#160;Niklason for her services as Humacyte&#8217;s President and Chief Executive Officer in 2020 was paid in January&#160;2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an incentive stock option (&#8220;ISO&#8221;) to purchase 2,625 shares of Humacyte common stock, which was granted in December&#160;2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of $4,388 in commuting and related travel expenses and $58,954 for lodging expenses paid by Humacyte. The all other compensation column for Dr.&#160;Niklason also includes $42,935 in fees earned or paid in cash for her service as a director from January&#160;1, 2020 to the date of her appointment as President and Chief Executive Officer. For additional information regarding Humacyte&#8217;s non-employee director compensation, see &#8220;&#8212; Non-Employee Director Compensation&#8221; below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Blankenship served as Humacyte&#8217;s Chief Financial Officer from October&#160;2018 through May&#160;2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an increase in Mr.&#160;Blankenship&#8217;s annual base salary that became effective on January&#160;27, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an ISO to purchase 2,625 shares of Humacyte common stock, which was granted in December&#160;2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of $11,400 in matching contributions under Humacyte&#8217;s 401(k) plans and $1,716 in life insurance premiums paid by Humacyte. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Lawson served as Humacyte&#8217;s President and Chief Executive Officer from June&#160;2018 through November&#160;2020 and was appointed as Humacyte&#8217;s Chief Surgical Officer in November&#160;2020 in connection with Dr.&#160;Niklason&#8217;s assumption of the role of President and Chief Executive Officer. Accordingly, his salary reflects (i)&#160;the compensation he earned as President and Chief Executive Officer, which reflects an increase in his annual base salary that became effective on January&#160;27, 2020 and (ii)&#160;the compensation he earned as Chief Surgical Officer from the date of such appointment through December&#160;31, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an ISO to purchase 2,625 shares of Humacyte common stock, which was granted in December&#160;2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of $11,400 in matching contributions under Humacyte&#8217;s 401(k) plans and $2,679 in life insurance premiums paid by the company </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an ISO to purchase 2,625 shares of Humacyte common stock, which was granted in December&#160;2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of $11,400 in matching contributions under Humacyte&#8217;s 401(k) plans and $383 in life insurance premiums paid by the company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative to Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Base Salaries</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with Dr.&#160;Niklason&#8217;s appointment as Humacyte&#8217;s President and Chief Executive Officer, her annual base salary was $500,000 in 2020, which was prorated for the portion of the year in which she served in those positions and paid in January&#160;2021. The all other compensation column in the Summary Compensation Table above also includes $42,935 in fees earned or paid in cash for Dr.&#160;Niklason&#8217;s service as a director from January&#160;1, 2020 to the date of her appointment as President and Chief Executive Officer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Blankenship&#8217;s annual base salary for 2020 was $371,315, which reflects an increase in annual base salary that became effective on January&#160;27, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Lawson&#8217;s annual base salary for 2020 was $583,495, which reflects an increase in annual base salary that became effective on January&#160;27, 2020. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Prichard&#8217;s annual base salary for 2020 was $360,000. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bonuses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2020, Mr.&#160;Blankenship, Dr.&#160;Lawson and Dr.&#160;Prichard earned cash bonuses as part of an employee bonus program. Because Dr.&#160;Niklason did not assume the role of President and Chief Executive Officer until November&#160;2020, she was not awarded a bonus for 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2021, the Company awarded bonuses for individual performance during 2020 that were payable upon the closing of the Business Combination: (i)&#160;Mr.&#160;Jeff Lawson, the Company&#8217;s Chief Surgical Officer, was granted a bonus in the amount of $87,524; and (ii)&#160;Ms.&#160;Heather Prichard, the Company&#8217;s Chief Operating Officer, was granted a bonus in the amount of $54,000. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although Humacyte does not have a formal policy with respect to the grant of equity incentive awards to its executive officers, or any formal equity ownership guidelines applicable to them, Humacyte generally uses stock options to compensate its executive officers in the form of initial grants in connection with the commencement of employment and also at various other times during their employment. Accordingly, the Board, upon the recommendation of its compensation committee, periodically reviews the equity incentive compensation of the executive officers and from time to time has granted equity incentive awards to them in the form of ISOs. The details of equity grants made to Humacyte&#8217;s named executive officers in 2020 are outlined below in &#8220;&#8212; Outstanding Equity Awards as of December&#160;31, 2020.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The option awards granted to Humacyte&#8217;s named executive officers in 2020 vest as follows: (i)&#160;one-fifth on the first anniversary of the vesting commencement date, (ii)&#160;two-fifths in equal installments over a period of 24&#160;months commencing on the first anniversary of the vesting commencement date, (iii)&#160;one-fifth upon the submission of a BLA, and (iv)&#160;one-fifth upon FDA approval of one of Humacyte&#8217;s product candidates. In the event of a corporate transaction, which is defined in Humacyte&#8217;s 2015 Omnibus Incentive Plan, as amended (the &#8220;2015 Plan&#8221;), to include certain change in control transactions, Dr.&#160;Niklason&#8217;s and Dr.&#160;Lawson&#8217;s option grants will vest automatically. With respect to Dr.&#160;Prichard&#8217;s option awards, in the event of a corporate transaction, where the surviving entity assumes or replaces an option award and an involuntary termination (as such term is defined in the 2015 Plan or Humacyte&#8217;s 2005 Stock Option Plan, as amended (the &#8220;2005 Plan&#8221;)), as applicable, each of which is described below) of the executive officer&#8217;s employment occurs within the period commencing 30&#160;days prior to the effective date of the corporate transaction and ending 12&#160;months following the effective date of such corporate transaction, the option award will vest in full on the date of such involuntary termination. Vesting rights otherwise cease upon termination of employment and exercise rights cease shortly after termination of employment, except that exercisability is extended in the case of death or disability. Both vesting and exercise rights cease immediately upon a termination of employment for cause, as defined in the 2015 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Employment Agreements and Other Arrangements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte has entered into employment agreements with each of its named executive officers. These agreements generally set forth the terms and conditions of employment, including base salary, bonus opportunities, initial awards of equity incentive compensation and standard employee benefit plan participation. The agreements also contain provisions that provide for certain payments upon termination of employment without cause or resignation for good reason, as such terms are defined in the relevant employment agreement. In the event that any provision of the employment agreements would cause Humacyte&#8217;s named executive officers to incur additional tax or interest under Section&#160;409A of the Code, Humacyte has agreed, upon the request of the named executive officer, to use reasonable business efforts to reform in good faith the provision to comply with Section&#160;409A. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Laura E. Niklason</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte entered into an employment agreement with Laura E. Niklason, which became effective as of November&#160;9, 2020, which provides for her at-will employment as Humacyte&#8217;s President and Chief Executive Officer. Dr.&#160;Niklason&#8217;s employment agreement provides for an initial annual base salary of $500,000, which will be reviewed by the Board from time to time but may not be reduced except in connection with a uniform reduction of the salaries of all similarly situated executive officers. The amount of any such reduction in Dr.&#160;Niklason&#8217;s salary may not exceed 10% of her then-current base salary. Dr.&#160;Niklason is also eligible to receive an annual incentive bonus of up to 50% of her then-current base salary. The amount of any bonus will be established annually based on objectives determined by Humacyte and Dr.&#160;Niklason, and awarded in the sole discretion of the Board. In general, except in the event that Dr.&#160;Niklason&#8217;s employment is terminated without cause or she resigns for good reason, Dr.&#160;Niklason must remain employed on the date any annual incentive bonus is paid in order to receive such bonus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of her employment agreement, Humacyte awarded Dr.&#160;Niklason an additional stock option award in January&#160;2021 entitling her to purchase 1,312,984 shares of Humacyte&#8217;s common stock, none of which have vested as of the date of this prospectus. This stock option vests in equal annual installments on each of the first three anniversaries of November&#160;9, 2020, subject to acceleration upon a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">corporate transaction (as defined in the 2015 Plan). Humacyte has also agreed to reimburse Dr.&#160;Niklason for the cost of an apartment and living expenses in Durham, North Carolina near the company&#8217;s headquarters in an amount not to exceed $60,000 annually. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that Dr.&#160;Niklason&#8217;s employment is terminated without cause or she resigns for good reason, including Humacyte&#8217;s material breach of Dr.&#160;Niklason&#8217;s employment agreement or an uncured material adverse change in Dr.&#160;Niklason&#8217;s compensation, as each such term is defined in her employment agreement, Humacyte will be obligated to pay her (i)&#160;an amount equal to 12&#160;months of her then-current base salary (payable in substantially equal installments on the same payroll schedule applicable to her immediately prior to the termination of her employment); (ii)&#160;a pro&#160;rata portion, calculated per diem, of her bonus for the then-current fiscal year (as well as any accrued, earned and unpaid bonus from the preceding fiscal year); and (iii)&#160;reimbursement for the cost to Dr.&#160;Niklason to continue her and her family&#8217;s health insurance under the Consolidated Omnibus Budget Reconciliation Act (&#8220;COBRA&#8221;) for a period of 12&#160;months. Each of the severance payments described above is subject to Dr.&#160;Niklason&#8217;s timely execution of a general release of potential claims against Humacyte and her compliance with her non-competition agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;19, 2018, Humacyte entered into an employment agreement with Jeffrey H. Lawson, which provides for his at-will employment. Dr.&#160;Lawson&#8217;s employment agreement was subsequently amended, effective November&#160;9, 2020, to reflect his transition to the role of Chief Surgical Officer. Dr.&#160;Lawson&#8217;s employment agreement provides for an initial annual base salary of $550,000, which will be reviewed by the Board from time to time but may not be reduced except in connection with a uniform reduction of the salaries of all similarly situated executive officers. The amount of any such reduction in Dr.&#160;Lawson&#8217;s salary may not exceed 10% of his then-current base salary. Dr.&#160;Lawson is also eligible to receive an annual incentive bonus of up to 50% of his then-current base salary. The amount of any bonus will be established annually based on objectives determined by Humacyte and Dr.&#160;Lawson, and awarded in the sole discretion of the Board. In general, except in the event that Dr.&#160;Lawson&#8217;s employment is terminated without cause or he resigns for good reason, Dr.&#160;Lawson must remain employed on the date any annual incentive bonus is paid in order to receive such bonus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of his employment agreement, Humacyte awarded Dr.&#160;Lawson an initial stock option award entitling him to purchase 1,194,815 shares of Humacyte&#8217;s common stock, which award has vested in full as of the date of this prospectus. The details of this and other historical equity grants made to Dr.&#160;Lawson are outlined below in &#8220;&#8212; Outstanding Equity Awards as of December&#160;31, 2020.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that Dr.&#160;Lawson&#8217;s employment is terminated without cause or he resigns for good reason, including Humacyte&#8217;s material breach of Dr.&#160;Lawson&#8217;s employment agreement or an uncured material adverse change in Dr.&#160;Lawson&#8217;s compensation, as each such term is defined in his employment agreement, Humacyte will be obligated to pay him (i)&#160;an amount equal to 12&#160;months of his then-current base salary (payable in substantially equal installments on the same payroll schedule applicable to him immediately prior to the termination of his employment); (ii)&#160;a pro&#160;rata portion, calculated per diem, of his bonus for the then-current fiscal year (as well as any accrued, earned and unpaid bonus from the preceding fiscal year); and (iii)&#160;reimbursement for the cost to Dr.&#160;Lawson to continue his and his family&#8217;s health insurance under COBRA, for a period of 12&#160;months. Each of the severance payments described above is subject to Dr.&#160;Lawson&#8217;s timely execution of a general release of potential claims against Humacyte and his compliance with his non-competition agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Douglas L. Blankenship</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;8, 2018, Humacyte entered into an employment agreement with Douglas L. Blankenship, which provided for his at-will employment as Humacyte&#8217;s Chief Financial Officer. The Humacyte Board terminated Mr.&#160;Blankenship&#8217;s employment as of May&#160;14, 2021. Further details regarding the terms and conditions of Mr.&#160;Blankenship&#8217;s separation from Humacyte are outlined below in &#8220;&#8212; Severance and Consulting Agreements with Mr.&#160;Blankenship.&#8221; Mr.&#160;Blankenship&#8217;s employment agreement provided for an initial annual base salary of $350,000, to be reviewed by Humacyte from time to time. Mr.&#160;Blankenship was also eligible for consideration to receive an annual incentive bonus. The amount of any bonus was to be established annually based on objectives determined by Humacyte and Mr.&#160;Blankenship, and awarded in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the sole discretion of the Board. In general, except in the event that Mr.&#160;Blankenship&#8217;s employment was terminated without cause or he resigns for good reason, Mr.&#160;Blankenship must have remained employed on the date any annual incentive bonus is paid in order to receive such bonus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of his employment agreement, Humacyte awarded Mr.&#160;Blankenship an initial stock option award entitling him to purchase one million shares of Humacyte&#8217;s common stock. The details of this equity grant to Mr.&#160;Blankenship are outlined below in &#8220;&#8212; Outstanding Equity Awards as of December&#160;31, 2020.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Blankenship&#8217;s employment agreement provided that in the event that Mr.&#160;Blankenship&#8217;s employment was terminated without cause or he resigned for good reason, including Humacyte&#8217;s material breach of the employment agreement or an uncured material adverse change in Mr.&#160;Blankenship&#8217;s compensation, as each such term is defined in his employment agreement, Humacyte would have been obligated to pay him (i)&#160;an amount equal to six&#160;months of his then-current base salary (payable in substantially equal installments on the same payroll schedule applicable to him immediately prior to the termination of his employment) and (ii)&#160;a pro&#160;rata portion, calculated per diem, of his bonus for the then-current fiscal year (as well as any accrued, earned and unpaid bonus from the preceding fiscal year). Each of the severance payments described above was subject to Mr.&#160;Blankenship&#8217;s timely execution of a general release of potential claims against Humacyte and his compliance with his non-competition agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Heather Prichard</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;13, 2019, Humacyte entered into an employment agreement with Heather Prichard, which provides for her at-will employment as Humacyte&#8217;s Chief Operating Officer. Dr.&#160;Prichard&#8217;s employment agreement provided for an initial annual base salary of $300,000, to be reviewed by Humacyte from time to time. Dr.&#160;Prichard is also eligible for consideration to receive an annual incentive bonus. The amount of any bonus will be established annually based on objectives determined by Humacyte and Dr.&#160;Prichard, and awarded in the sole discretion of the Board. In general, except in the event that Dr.&#160;Prichard&#8217;s employment is terminated without cause or she resigns for good reason, Dr.&#160;Prichard must remain employed on the date any annual incentive bonus is paid in order to receive such bonus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that Dr.&#160;Prichard&#8217;s employment is terminated without cause or she resigns for good reason, including Humacyte&#8217;s material breach of Dr.&#160;Prichard&#8217;s employment agreement or an uncured material adverse change in Dr.&#160;Prichard&#8217;s compensation, as each such term is defined in her employment agreement, Humacyte will be obligated to pay her (i)&#160;an amount equal to six&#160;months of her then-current base salary (payable in substantially equal installments on the same payroll schedule applicable to her immediately prior to the termination of her employment) and (ii)&#160;a pro&#160;rata portion, calculated per diem, of her bonus for the then-current fiscal year (as well as any accrued, earned and unpaid bonus from the preceding fiscal year). Each of the severance payments described above is subject to Dr.&#160;Prichard&#8217;s timely execution of a general release of potential claims against Humacyte and her compliance with her non-competition agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Severance and Consulting Agreements with Mr.&#160;Blankenship</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the termination of Douglas Blankenship&#8217;s employment with Humacyte as of May&#160;14, 2021, Humacyte entered into a severance agreement and release (the &#8220;Severance Agreement&#8221;) with Mr.&#160;Blankenship, effective May&#160;17, 2021, which provides for the terms and conditions of Mr.&#160;Blankenship&#8217;s separation from Humacyte. In connection with his termination of employment, Mr.&#160;Blankenship will receive the following severance payments: (i)&#160;six&#160;months continued base salary payments; (ii)&#160;a performance bonus for 2020; and (iii)&#160;a pro&#160;rata portion of any performance bonus that Humacyte awards for 2021. The Severance Agreement further provides that all unvested stock options granted to Mr.&#160;Blankenship under the stock option agreement dated December&#160;18, 2018 (the &#8220;2018 Stock Option Agreement&#8221;) shall become fully vested and exercisable. Any stock options granted to Mr.&#160;Blankenship under the stock option agreement dated December&#160;14, 2020, or any other stock option agreement other than the 2018 Stock Option Agreement, that did not vest on or before the separation date are forfeited. Additionally, Mr.&#160;Blankenship received an extension of time to exercise vested options until September&#160;1, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As provided by the terms Severance Agreement, Humacyte and Mr.&#160;Blankenship entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;), pursuant to which Mr.&#160;Blankenship will serve as a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">consultant and independent contractor of Humacyte during the period beginning on June&#160;13, 2021, through December&#160;31, 2021, unless terminated by either Mr.&#160;Blankenship or Humacyte pursuant to the terms of the Consulting Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing descriptions of the Severance Agreement and the Consulting Agreement are qualified in their entirety by the terms and conditions of such agreements, copies of which are attached as Exhibit&#160;10.13.1 and Exhibit&#160;10.13.2 to the registration statement of which this prospectus forms a part, and the terms of which are incorporated herein by reference. </font>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes to Named Executive Officer Compensation in Connection with the Business Combination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte has historically granted stock options with exercise prices that are equal to the fair market value of its common stock on the date of grant as determined by the Board. The exercise price of all stock options granted after the closing of the Business Combination will be equal to the fair market value of shares of Humacyte common stock on the date of grant. </font>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appointment of New Chief Financial Officer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;18, 2021, Dale A. Sander replaced Douglas L. Blankenship as Chief Financial Officer and Treasurer of the Company. Mr.&#160;Sander does not appear in the summary compensation table because he was not a named executive officer of the Company prior to May&#160;18, 2021. </font>
        </div>
        <div style="margin-top:11.82pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards as of December&#160;31, 2020</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides information regarding outstanding stock options held by Humacyte&#8217;s named executive officers as of December&#160;31, 2020. All awards in the table below that were granted prior to July&#160;2015 were granted under the 2005 Plan and awards granted subsequent to such date were granted under the 2015 Plan, each as described in more detail under &#8220;&#8212; Equity Incentive and Other Compensation Plans&#8221; below. </font>
        </div>
        <table style="width:456pt;height:338.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:191.4pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Grant date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">options (#)</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercisable</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">options (#)</font>
                <br >
                <font style="letter-spacing:-0.16pt;">unexercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">expiration</font>
                <br >
                <font style="letter-spacing:-0.16pt;">date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:191.4pt;text-align:left;" rowspan="6">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Laura E. Niklason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="6">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/22/2013</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">262,596</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.19</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/22/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">09/01/2015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,129</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.56</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">09/01/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">03/09/2016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">157,558</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.56</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">03/09/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">09/14/2016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">262,596</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.44</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">09/14/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,532</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">43,766</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.54</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.28</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:191.4pt;text-align:left;" rowspan="5">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="5">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/11/2015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">98,474</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.56</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/11/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">65,648</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.44</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,778</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">39,390</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.54</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">06/28/2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">796,543</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">398,272</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.48</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">06/28/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.28</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:191.4pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Douglas L. Blankenship </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/18/2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">262,595</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.48</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">09/01/2022<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.28</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">08/14/2021<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:191.4pt;text-align:left;" rowspan="6">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <font style="letter-spacing:0.2pt;">Heather Prichard </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="6">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">01/21/2011</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.15</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">01/21/2021<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2012</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,564</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.15</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/22/2013</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,779</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.19</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/22/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/11/2015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,779</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.56</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/11/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">105,037</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">52,520</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.54</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">04/12/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:5.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.28</td>
            <td style="padding:0pt;padding-left:1.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">All options granted to Humacyte&#8217;s named executive officers that are reported in this table vest annually in three equal installments commencing on the first anniversary of the applicable vesting commencement date, except for the options granted on December&#160;14, 2020, which vest as follows: (i)&#160;one-fifth on the first anniversary of the vesting commencement date, (ii)&#160;two-fifths in equal installments over a period of 24&#160;months commencing on the first anniversary of the vesting commencement date, (iii)&#160;one-fifth upon the submission of a BLA and (iv)&#160;one-fifth upon FDA approval of one of Humacyte&#8217;s product candidates. The vesting of the options may be accelerated in connection with certain corporate transactions, which generally include certain change in control transactions and are more fully described in the applicable incentive plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Table does not reflect the grant of an option to purchase 1,312,984 shares of Humacyte common stock at a purchase price per share of $10.28, which was made to Dr.&#160;Niklason in January&#160;2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In connection with Mr.&#160;Blankenship&#8217;s severance arrangements, the vesting of any unvested options to purchase shares of Humacyte common stock granted to Mr.&#160;Blankenship on December&#160;18, 2018 was accelerated. Additionally, Mr.&#160;Blankenship received an extension of time to exercise these vested options until September&#160;1, 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Awards that were unvested at the time of Mr.&#160;Blankenship&#8217;s termination were forfeited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Option exercised in January&#160;2021 prior to expiration. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Incentive and Other Compensation Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bonus Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Humacyte, Inc. Annual Bonus Plan (the &#8220;Bonus Plan&#8221;) became effective upon the completion of the Business Combination. The Bonus Plan is administered by the compensation committee and will remain in effect until terminated by the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Bonus Plan allows the compensation committee to grant cash incentive awards to eligible employees, including the named executive officers. Awards may, but need not, be subject to performance goals established by the compensation committee in its sole discretion, and such performance goals may be on the basis of any factors the compensation committee determines relevant, and may be on an individual, divisional, business unit, segment or company-wide basis. The performance goals may differ from participant to participant and from award to award. The compensation committee will have sole discretion to determine the extent to which performance goals have been satisfied and the actual award payout based on such performance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee may, in its sole discretion and at any time, increase, reduce or eliminate a participant&#8217;s actual award payout. The actual award payout may be below, at or above a participant&#8217;s target award, in the compensation committee&#8217;s discretion. The compensation committee may determine the amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and is not required to establish any allocation or weighting with respect to the factors it considers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Actual award payouts will be made in a cash lump sum as soon as practicable after the end of the particular performance period, but in no event later than March&#160;15 of the calendar year immediately following the calendar year in which the applicable performance period ends. Participants will generally be required to remain continuously employed through the payment date in order to receive their actual award payout, unless otherwise determined by the compensation committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board has the authority to amend, suspend or terminate the Bonus Plan at any time and for any reason, provided that such change may not materially and adversely affect a participant&#8217;s rights with respect to any earned bonus that has been paid. The compensation committee and the Board have the authority to amend or terminate any target award granted under the Bonus Plan at any time and for any reason. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2021 Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2021 Plan became effective as of the consummation of the Business Combination. Humacyte is authorized to grant equity and cash incentive awards to eligible service providers under the 2021 Plan. The </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2021 Plan replaced the 2015 Plan on the date the 2021 Plan became effective, except that any awards previously granted under the 2015 Plan remained in effect pursuant to their original terms (other than with respect to the adjustment required under the Business Combination Agreement to reflect the Business Combination). No additional awards may be granted under the 2015 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Authorized Shares</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte initially reserved a pool of shares of common stock for issuance under the 2021 Plan equal to 7,725,253 shares. Such aggregate number of shares will automatically increase on January&#160;1 of each year commencing on January&#160;1, 2022, in an amount equal to 5% of the total number of shares of Humacyte&#8217;s capital stock outstanding on December&#160;31 of the preceding year, unless the Board acts prior to January&#160;1 of a given year to provide that the increase for such year will be a lesser number. Subject to the maximum aggregate number of shares that may be issued pursuant to all awards (the &#8220;Share Reserve&#8221;), the maximum aggregate number of shares which may be issued pursuant to the exercise of ISOs is 700,000,000 shares (the &#8220;ISO Limit&#8221;). The purpose of the ISO Limit is to comply with section 422 of the Code so that the 2021 Plan does not reach the ISO Limit before the Share Reserve by reason of shares being added back to the 2021 Plan as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shares issued under the 2021 Plan will include authorized but unissued or reacquired shares of common stock. Any shares of common stock underlying any awards that are (i)&#160;forfeited, cancelled, or reacquired by Humacyte prior to vesting, (ii)&#160;that expire, (iii)&#160;that are paid out in cash rather than shares, (iv)&#160;are tendered or withheld in payment of an award exercise or purchase price, (v)&#160;are tendered or withheld in satisfaction of tax withholding obligations with respect to an award or (vi)&#160;are not issued upon net settlement of a stock appreciation, will be added back to the shares of common stock available for issuance. The shares underlying any award granted under the 2015 Plan that are forfeited, cancelled or reacquired by Humacyte prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan. Any shares that are added back to the 2021 Plan for any reason may not be issued pursuant to ISOs. Shares underlying any substitute awards that Humacyte grants to employees, directors or consultants of a business that is acquired by Humacyte will not count against the number of shares reserved for issuance under the 2021 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board administers the 2021 Plan and is authorized to delegate any or all of its powers under the 2021 Plan to one or more committees. The Board or the committee administering the 2021 Plan is referred to herein as the &#8220;administrator.&#8221; The Board is permitted to delegate to one or more officers the power to grant awards to its employees and officers, subject to certain limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the 2021 Plan, the administrator has the authority to award nonstatutory stock options and ISOs, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock&#160;units (&#8220;RSUs&#8221;), unrestricted stock, performance awards and other forms of awards. All awards will be granted pursuant to an award agreement. Awards other than ISOs can be granted to employees, directors and consultants, but ISOs can only be granted to employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The administrator has the authority to set the terms of all awards. In particular, the administrator is authorized to determine the service-based or performance-based vesting criteria applicable to awards granted under the 2021 Plan, as set out in the award agreement. The award agreement will also specify any circumstances under which awards may be forfeited. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The value of all awards awarded under the 2021 Plan and all other cash compensation paid by Humacyte to any non-employee director on the Board in any calendar year for service as a non-employee director shall not exceed $750,000, or $1,000,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Options and SARs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;With respect to options and SARs, the administrator will determine the exercise price applicable thereto within the terms and conditions of the plan, provided that the exercise price per </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">share subject to an option or SAR cannot be less than 100% of the fair market value of our common stock on the date of grant (however, an option may be granted with an exercise price lower than 100% of the fair market value on the date of grant of such award if such award is granted as a substitution for an option or SAR in accordance with the provisions and requirements of Section&#160;409A and, if applicable, 424 of the Code). The administrator also has authority to determine the term of stock options and SARs granted under the 2021 Plan, up to a maximum of 10&#160;years. The administrator may, but is not required to, permit a grantee to exercise any part or all of his or her stock options prior to full vesting. Except as otherwise provided in an award agreement, if an optionholder terminates employment or service for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three&#160;months following the cessation of service. If an optionholder&#8217;s employment or service relationship ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12&#160;months. Options generally terminate immediately upon the termination of an optionholder&#8217;s employment or service for cause. In no event may an option be exercised beyond the expiration of its term. Payment for shares issued upon the exercise of a stock option may be made either by certified or bank check, or such other means as the administrator may accept. Subject to the approval of the administrator, options may be exercised pursuant to such cashless exercise procedures as may be approved and implemented by the administrator from time to time, including pursuant to broker-assisted exercise transactions and/or net exercise procedures. The 2021 Plan does not permit the repricing of options or SARs without shareholder approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Tax Limitations on ISOs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all stock plans maintained by Humacyte may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as nonstatutory stock options. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of Humacyte&#8217;s total combined voting power or that of any of Humacyte&#8217;s affiliates unless (1)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&#160;the option is not exercisable after the expiration of five&#160;years from the date of grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise provided in an award agreement, if a grantee of restricted stock terminates employment or service during the applicable restriction period, Humacyte has the right to repurchase all or part of the shares of restricted stock still subject to restriction from the grantee at the issue price or at another stated or formula price (or to require forfeiture if such shares were issued at no cost). Additionally, unless otherwise determined by the administrator, grantees of restricted stock are entitled to receive all dividends and other distributions paid with respect to their shares of restricted stock, subject to such terms and conditions as the administrator may determine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Units.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;An RSU may be settled in any form specified by the administrator in the restricted stock agreement, including but not limited to delivery of stock, cash, or a combination of cash and stock as deemed appropriate by the administrator</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> The administrator may, but need not, provide that grantees of RSUs will be paid or will accrue dividend equivalent payments on each date that dividends are paid with respect to Humacyte common stock prior to the settlement of their RSUs, subject to such terms and conditions as the administrator may determine. The treatment of any dividends or dividend equivalents shall be set forth in the RSU agreement at the time the award is granted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Performance Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2021 Plan permits the grant of performance-based stock and cash awards that may vest or become earned and paid contingent upon the attainment of performance goals during a designated performance period, as determined by the administrator and set forth in the applicable award agreement. Performance goals may be based on a company-wide basis, with respect to one or more business&#160;units, divisions, subsidiaries, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices, and may be based on financial performance, achievement of strategic objectives, or any other organizational goals, all as determined by the administrator. Unless specified otherwise (i)&#160;in the award agreement at the time the award is granted or (ii)&#160;in such other document setting forth the performance goals at the time the goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a designated performance period as follows: (1)&#160;to exclude restructuring and/or other nonrecurring charges; (2)&#160;to exclude exchange rate effects; (3)&#160;to exclude the effects of changes </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to generally accepted accounting principles; (4)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (7)&#160;to assume that any business divested by Humacyte achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&#160;to exclude the effect of any change in the outstanding shares of common stock of Humacyte by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&#160;to exclude the effects of stock based compensation and the award of bonuses under Humacyte&#8217;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expense under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for such performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the award agreement or the written terms of a performance award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may issue other forms of awards, which may, but are not required to be, valued in whole or in part by reference to, or otherwise based on, Humacyte common stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the fair market value at the time of grant) may also be granted. The Board will have sole and complete discretion to determine the persons to whom and the time or times at which such other awards will be granted, the number of shares of Humacyte (or the cash equivalent thereof) to be granted and all other terms and conditions of such other awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the 2021 Plan, awards generally are not transferable other than by will or the laws of descent and distribution, unless otherwise provided by the administrator. A grantee must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before Humacyte will deliver stock certificates (or other consideration payable pursuant to the award) or otherwise recognize ownership of shares under an award. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Corporate Transactions and Recapitalizations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a corporate transaction (as defined in the 2021 Plan), each outstanding award will be treated as the administrator determines. The administrator has the right to (1)&#160;accelerate the vesting of any or all outstanding stock options and SARs, in whole or in part; (2)&#160;make non-forfeitable any or all outstanding restricted stock or RSUs, in whole or in part; or (3)&#160;cancel or redeem awards in exchange for cash or another form of consideration, including substitute awards in respect of the capital stock of a successor corporation, all subject to any limitations imposed by applicable law and provided that, if the fair market value of common stock on the date of the corporate transaction does not exceed the exercise price of any option or SAR, the administrator may cancel that option or SAR without any payment of consideration. The administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event a successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute awards pursuant to a corporate transaction, such awards shall have their vesting accelerate as to all shares subject to such awards (and any applicable right of repurchase fully lapse) immediately prior to the corporate transaction. In addition, in the event a successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute awards pursuant to a corporate transaction, the administrator will notify the grantee that such award will be exercisable for a period of time determined by the committee in its sole discretion, and such award will terminate upon the expiration of such period. Except as otherwise provided in an award agreement, in the event a successor or acquiring corporation (if any) assumes or replaces an option pursuant to a corporate transaction, and there is an involuntary termination (as defined in the award agreement) of the optionholder&#8217;s employment within the 30&#160;days prior to the effective date of the corporate transaction or 12&#160;months following such effective date, such option will vest in full. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Separately, in the event of a stock split or other change in the capital structure of Humacyte without the company&#8217;s receipt of consideration, the 2021 Plan provides for appropriate adjustments, as applicable, to the maximum number and class of shares reserved for issuance under the 2021 Plan, the ISO limit, and the class and number of shares and exercise price or purchase price of outstanding awards under the 2021 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Amendment or Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board has the authority to amend, suspend, or terminate the 2021 Plan, although certain material amendments require the approval of the company&#8217;s stockholders, and amendments that would adversely affect the rights of any participant require the consent of that participant. In no event will any amendment increase the maximum number of shares of common stock with respect to which awards may be granted under the 2021 Plan without stockholder approval. No awards are permitted to be granted after August&#160;24, 2031, and the 2021 Plan does not permit any awards to be granted while it is suspended or after it is terminated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The administrator has the authority to amend, modify or terminate any outstanding award, but the grantee will be required to consent to such action unless the amendment, modification or termination would not materially and adversely affect the grantee&#8217;s rights under the 2021 Plan, the change is permitted in connection with specified corporate transactions or capitalization adjustments, or the change is required or advisable for Humacyte, the 2021 Plan or the award to satisfy applicable law or accounting standards. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ESPP</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ESPP became effective as of the consummation of the Business Combination. Under the ESPP, Humacyte is authorized to offer eligible employees the ability to purchase shares of Humacyte stock at a discount, subject to various limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions of the ESPP, the ESPP administrator will have discretionary authority to administer and interpret the ESPP and to determine the terms and conditions of the offerings of common stock to be made under the ESPP. Subject to applicable laws and regulations, the ESPP administrator is authorized to delegate administrative tasks under the ESPP to an officer of Humacyte or other individual or group. Interpretations and constructions of the ESPP administrator of any provision of the ESPP or of any rights thereunder will be conclusive and binding on all persons. No member of the Board or individual exercising administrative authority with respect to the ESPP will be liable for any action or determination made in good faith with respect to the ESPP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Reserve</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The initial maximum number of shares of Humacyte common stock authorized for sale under the ESPP is equal to 1,030,033 shares. Such aggregate number of shares may, subject to the approval of the Board, increase on January&#160;1 of each year beginning January&#160;1, 2022, but not after the 10 year anniversary of the effective date of the ESPP, in an amount equal to 1% of the total number of shares of Humacyte&#8217;s capital stock outstanding on December&#160;31 of the preceding year, unless the Board acts prior to January&#160;1 of a given year to provide that the increase for such year will be a lesser number. In no event will the maximum aggregate number of shares available for issuance under the ESPP exceed 13,000,000 shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eligibility</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Employees eligible to participate in the ESPP for a given offering generally include employees who are employed by Humacyte or one of its designated subsidiaries on the first day of the offering, subject to any other eligibility requirements that the ESPP administrator may choose to impose (within the limits permitted by the Code). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Participation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Employees will enroll under the ESPP by completing an enrollment form permitting the deduction from their compensation of a whole&#160;percentage of their compensation during an offering, subject to a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">minimum of 1% and a maximum of 15%, or, to the extent permitted by the ESPP administrator for an offering, an employee may authorize a payroll deduction expressed as a flat dollar amount, subject to such terms, conditions and limits as may be established by the ESPP administrator for such offering. Accumulated deductions will be credited to a notional account and applied to the purchase of shares on the exercise date of the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, an employee will not be permitted to participate in an offering if, immediately after the option to purchase stock in the offering were granted, the employee would own (or be deemed to own through attribution) 5% or more of the total combined voting power or value of all classes of stock of Humacyte, or of a subsidiary or parent company of Humacyte. In addition, a participant may not purchase more than 5,000 shares in each offering or any lesser maximum number determined by the ESPP administrator. A participant may not be granted an option that permits the participant&#8217;s rights to purchase shares of Humacyte common stock to accrue at a rate exceeding $25,000 in fair market value of such stock (determined at the time the option is granted) under the ESPP or any other employee stock purchase plan of Humacyte and its parent and subsidiary companies during any calendar year. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Offering</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the ESPP, participants are offered the option to purchase shares of Humacyte common stock at a discount during offerings, the duration and timing of which will be determined by the ESPP administrator. However, in no event may an offering be longer than 27&#160;months in length. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The option price for an offering will generally be the lower of 85% of the closing trading price per share of Humacyte common stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless a participant has withdrawn from participation in the ESPP before the exercise date of the applicable offering, the participant will be deemed to have exercised the participant&#8217;s option in full as of such exercise date. Upon exercise, the participant will purchase the number of whole shares that the participant&#8217;s accumulated payroll deductions will buy at the option price, subject to the participation limitations listed above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may cancel his or her payroll deduction authorization and withdraw from the offering at any time prior to the end of the offering. Upon withdrawal, the participant will receive a refund of the participant&#8217;s notional account balance in cash without interest. If a participant withdraws from an offering, the participant may not later re-enroll in the same offering, but the participant may (if eligible) enroll in any later offering under the ESPP. If a participant wants to increase or decrease the rate of payroll withholding, the participant may do so effective for the next offering by submitting a new enrollment form before the offering for which such change is to be effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant&#8217;s lifetime, options in the ESPP shall be exercisable only by such participant. The ESPP is unfunded, and all funds received by Humacyte under the ESPP may be combined with other corporate funds and used for any corporate purpose, unless otherwise required by applicable law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination or exchange of shares, reclassification of shares, spin-off, or other similar change in capitalization or event, or any dividend or distribution to holders of Humacyte common stock other than an ordinary cash dividend, we will proportionately adjust the number and class of shares approved under the ESPP, the option price for an offering, and the maximum number of shares which a participant may elect to purchase in any single offering. In connection with a reorganization event (as defined in the ESPP), the ESPP administrator may take any of the following actions, or do any combination thereof: (i)&#160;determine that each outstanding option will be assumed or an equivalent option substituted by the acquiring or successor corporation (or an affiliate thereof); (ii)&#160;upon written notice to participants, provide that all outstanding options will become exercisable to the extent of accumulated payroll deductions as of a specified date that is more than 10&#160;days before the effective date of the applicable reorganization event; (iii)&#160;upon written notice to participants, provide </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that all outstanding options will be cancelled and accumulated payroll deductions will be returned to participants; (iv)&#160;if the applicable transaction provides for cash payments to the holders of Humacyte common stock, provide for cash payments to participants in amounts based on the per-share amount of such cash payments to the shareholders; or (v)&#160;if Humacyte is liquidated or dissolved, provide that options to purchase stock under the ESPP will convert into the right to receive the liquidation proceeds (net of the option price). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Amendment and Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ESPP administrator may amend, suspend or terminate the ESPP at any time. However, if the terms of the ESPP are amended to increase the number of shares approved for the ESPP or in a manner that would require stockholder approval under the rules of Nasdaq, other relevant listing authority or to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423(b) of the Code, the ESPP administrator may not amend the ESPP without obtaining shareholder approval within 12&#160;months before or after the date such amendment is adopted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2015 Omnibus Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte&#8217;s 2015 Plan was adopted by the Board and approved by its stockholders on July&#160;10, 2015 and July&#160;29, 2015, and amended on February&#160;23, 2018 and June&#160;6, 2018. The 2015 Plan replaced and terminated the 2005 Plan on the date the 2015 Plan was approved by Humacyte&#8217;s stockholders, except that any awards previously granted under the 2005 Plan remained in effect pursuant to their terms. The 2015 Plan allowed the Humacyte Board to make equity incentive awards to Humacyte&#8217;s employees, directors, and consultants. Humacyte has not granted and will not grant any additional awards under the 2015 Plan, as of the effective date of the 2021 Plan. Any awards previously granted under the 2015 Plan and outstanding as of the effective date of the Business Combination were adjusted to reflect the Business Combination as set forth in the Business Combination Agreement, but otherwise remain in effect pursuant to their original terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Authorized Shares</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The maximum aggregate number of shares of Humacyte common stock that could be issued under the 2015 Plan was 7,090,200 shares, and the maximum aggregate number of shares which could be issued thereunder pursuant to ISOs was 7,090,200 shares, with both share figures adjusted for the Exchange Ratio of approximately 0.26260 as defined in the Business Combination Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shares issued under the 2015 Plan included authorized but unissued or reacquired shares of Humacyte common stock. The shares of common stock underlying any awards that were forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise or purchase price or tax withholding, reacquired by Humacyte prior to vesting, or that expired were added back to the shares of common stock available for issuance under the 2015 Plan. Shares underlying any award issued under the 2005 Plan that remained outstanding after the termination of the 2005 Plan could be returned to the 2015 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain adjustments, the following limits applied to awards granted to any individual in the same fiscal year: (i)&#160;in the case of awards that were settled in shares, the maximum aggregate number of shares with respect to which awards may be granted (other than stock options or SARs) was three million, (ii)&#160;the maximum aggregate number of shares subject to options was five million, (iii)&#160;the maximum aggregate number of shares subject to SARs was three million, (iv)&#160;in the case of awards that were settled in cash based on the fair market value of Humacyte common stock, the maximum aggregate amount of cash that could be paid was equal to the per share fair market value of the relevant vesting, payment or settlement date, multiplied by the number of shares described in the preceding clause, and (v)&#160;in the case of all awards other than those described in (iv), the maximum aggregate amount of cash and other property (valued at its fair market value) other than shares that could be paid or delivered was $5&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board administers the 2015 Plan and may delegate any or all of its powers under the plan to one or more of its committees. The Humacyte Board or committee administering the plan is referred to as the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">administrator. The Humacyte Board could also delegate to one or more of Humacyte&#8217;s officers the power to grant awards to its employees, directors and officers, subject to certain limitations. Subject to the terms of the 2015 Plan, the Humacyte Board had the authority to set the terms of all awards. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The administrator could grant awards under the 2015 Plan of nonstatutory and ISOs, SARs, restricted stock, RSUs, unrestricted stock awards and cash incentive awards. All awards were granted pursuant to an award agreement. Awards other than ISOs could be granted to employees, directors and consultants. ISOs could only be granted to employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The administrator determined the exercise price for a stock option or SAR within the terms and conditions of the 2015 Plan, provided that the exercise price per share subject to an option or SAR could not be less than 100% of the fair market value of Humacyte common stock on the date of grant. Options and SARs granted under the 2015 Plan become exercisable at the rate specified by the administrator in the award agreement. The award agreement specifies circumstances under which awards may be forfeited. The administrator determined the term of stock options and SARs granted under the 2015 Plan, up to a maximum of 10&#160;years. An award agreement could permit a grantee to exercise any part or all of his or her stock options or SARs prior to full vesting. Any unvested shares received pursuant to such an exercise may be subject to a repurchase right in favor of Humacyte or to any other restriction the administrator determines to be appropriate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any shares of Humacyte&#8217;s common stock awarded under any restricted stock award agreement may be subject to forfeiture to Humacyte in accordance with a vesting schedule determined by the administrator and award agreements for restricted stock and RSUs will be subject to restrictions imposed by the administrator, as it deems appropriate. Generally, if a grantee of restricted stock terminates employment or service during the applicable restriction period, Humacyte has the right to repurchase all or part of the shares of restricted stock still subject to restriction from the grantee at the issue price or at another stated or formula price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Corporate Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2015 Plan provided that in the event of specified corporate transactions (which consist of certain change in control transactions), each outstanding award would be treated as the administrator determines. The administrator could (1)&#160;accelerate the vesting of any or all outstanding stock options and SARs, in whole or in part; (2)&#160;make non-forfeitable any or all outstanding restricted stock or RSUs, in whole or in part; or (3)&#160;cancel or redeem awards in exchange for cash or another form of consideration, including substitute awards in respect of the capital stock of a successor corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte&#8217;s stock option agreements generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination (as such term is defined in the relevant stock option agreement) of a grantee&#8217;s employment during the period that commences 30&#160;days prior to the effective date of a corporate transaction and that ends 12&#160;months following the effective date of such transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, the number and class of securities available under the 2015 Plan was, and the exercise price per share of each stock option or SAR and the repurchase price per share for each restricted stock award or RSU award are, subject to adjustment in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination or exchange of shares, reclassification of shares, spin-off or other similar change in capitalization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2005 Stock Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte&#8217;s 2005 Plan was adopted by the Board and approved by its stockholders in June&#160;2005. The 2005 Plan generally allowed the Humacyte Board to make equity-based incentive awards to Humacyte&#8217;s employees, officers, directors, and consultants. The maximum aggregate number of shares of Humacyte common stock that could be issued under the 2005 Plan was 2,198,504 shares, as adjusted for the Exchange Ratio of approximately 0.26260 as defined in the Business Combination Agreement. The 2015 Plan </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">replaced the 2005 Plan on the date the 2015 Plan was approved by Humacyte&#8217;s stockholders, except that any awards previously granted under the 2005 Plan remained in effect pursuant to their terms. </font>
        </div>
        <div style="margin-top:11.62pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2005 Plan is administered by the Board. The Board could also delegate to one or more of Humacyte&#8217;s officers the power to grant awards to other employees and officers. Subject to the terms of the 2005 Plan, the Board had the authority to fix the terms of all awards. </font>
        </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the 2005 Plan, Humacyte could grant awards of nonstatutory and ISOs, performance shares, restricted stock, SARs, dividend equivalent awards, and other stock-based awards to employees, directors, officers and consultants. ISOs could only be granted to employees. All awards were granted pursuant to an award agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board determined the exercise price for a stock option, within the terms and conditions of the 2005 Plan, provided that the exercise price of an ISO could not be less than the fair market value of Humacyte&#8217;s common stock on the date of grant. </font>
        </div>
        <div style="margin-top:11.52pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Corporate Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2005 Plan provided that, subject to certain accounting considerations, in the event of a change in control (as defined in the 2005 Plan), the Board could, in its sole discretion at any time upon the occurrence of a change in control, determine that all or a portion of a participant&#8217;s outstanding options would become fully exercisable, and all or a portion of the restrictions on outstanding awards would lapse. Upon the occurrence of any transaction or event not constituting a change in control but which the Board deemed to be, or to be reasonably likely to lead to, an effective change in control, the Board could, in its sole discretion, declare all outstanding options to be fully exercisable and all restrictions on all outstanding awards to have lapsed as of such date as it might, in its sole discretion, declare, which could have been on or before the consummation of the transaction or event. The Board could also, in its sole discretion at any time, determine that all or a portion of a grantee&#8217;s options would become fully or partially exercisable and that all or a part of the restrictions on all or portion of the outstanding awards would lapse as of the date that the Board might, in its sole discretion, declare. </font>
        </div>
        <div style="margin-top:11.51pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">401(k) Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte maintains two 401(k) retirement savings plans (&#8220;the 401(k) Plans&#8221;), for its employees, including the named executive officers, who satisfy certain eligibility requirements. The 401(k) Plans are intended to qualify as tax-qualified plans under Section&#160;401(k) of the Code. The named executive officers are eligible to participate in the 401(k) Plans on the same basis as Humacyte&#8217;s other employees. The Code allows eligible employees to contribute, on a pre-tax basis, a portion of their salary, within prescribed limits, through contributions to the 401(k) Plans. Contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Humacyte matches employee contributions up to 4% of each employee&#8217;s compensation. </font>
        </div>
        <div style="margin-top:11.41pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding compensation paid to Humacyte&#8217;s non-employee directors during 2020, which included an annual cash retainer for director service. As the chairperson of Humacyte&#8217;s audit committee in 2020, Mr.&#160;Sander received an additional cash retainer of $4,290. Compensation paid to Dr.&#160;Niklason in connection with her service on the Board is outlined above in &#8220;&#8212; Summary Compensation Table.&#8221; </font>
        </div>
        <table style="width:456pt;height:78.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:248.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fees Earned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">or Paid in Cash</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:248.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brady W. Dougan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dale A. Sander </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54,290<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font> </font></td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,990<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">43,333<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font> </font></td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">124,613</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kathleen Sebelius </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Max Wallace </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:11.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:180pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The amount reported here does not reflect the actual economic value that may be realized by the director. In accordance with SEC rules, this amount represents the grant date fair value of the option award, calculated in accordance with Accounting Standards Update 2018-07, &#8220;Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718).&#8221; For additional information regarding the assumptions used in calculating the grant date fair value of the stock options reported in this table, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8201;&#8212;&#8201;Critical Accounting Policies and Significant Judgments and Estimates&#8201;&#8212;&#8201;Stock-Based Compensation.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the following non-qualified stock option awards held by Humacyte&#8217;s directors were outstanding: (i)&#160;options held Mr.&#160;Dougan to acquire 30,197 shares of common stock, (ii)&#160;options held by Mr.&#160;Sander to acquire 59,082 shares of common stock, (iii)&#160;options held by Ms.&#160;Sebelius to acquire 56,457 shares of common stock and (iv)&#160;options held by Mr.&#160;Wallace to acquire 49,890 shares of common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Sander was appointed as Humacyte&#8217;s Chief Corporate and Commercial Development Officer in November&#160;2020. Accordingly, his fees earned or paid in cash for service on the Humacyte Board have been prorated to reflect the portion of 2020 during which he was providing consulting services to Humacyte in that role. For additional information regarding the relationship between Mr.&#160;Sander and Humacyte related to his role as Chief Corporate and Commercial Development Officer, see &#8220;Certain Relationships and Related Party Transactions&#8201;&#8212;&#8201;Humacyte Related Party Transactions&#8201;&#8212;&#8201;Other Transactions&#8201;&#8212;&#8201;Consulting Agreement with Dale Sander.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects an non-qualified stock option to purchase 2,625 shares of Humacyte common stock, which was granted in December&#160;2020 as compensation for consulting services rendered to Humacyte by Mr.&#160;Sander in his role as Humacyte&#8217;s Chief Corporate and Commercial Development Officer during 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects $43,333 granted as compensation for consulting services rendered to Humacyte by Mr.&#160;Sander in his role as Humacyte&#8217;s Chief Corporate and Commercial Development Officer during 2020. The $43,333 in compensation earned by Mr.&#160;Sander for his services as Humacyte&#8217;s Chief Corporate and Commercial Development Officer was paid in January&#160;2021. Additionally, the table does not reflect the grant of an option to purchase 183,817 shares of Humacyte common stock at a purchase price per share of $10.28, which was made to Mr.&#160;Sander in January&#160;2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A director who is also a Humacyte employee receives no additional compensation for his or her service as a director. Dr.&#160;Niklason was appointed President and Chief Executive Officer of Humacyte in November&#160;2020. Following her appointment, Dr.&#160;Niklason no longer received additional compensation for serving as a director in 2020. See &#8220;&#8212; Summary Compensation Table&#8221; for additional information regarding the compensation paid to Dr.&#160;Niklason during 2020.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBEOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BENEFICIAL OWNERSHIP</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding the beneficial ownership of shares of our common stock as of November 10, 2021: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person known by us to be the beneficial owner of more than 5% of our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of our named executive officers and directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all of our executive officers and directors as a group. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. A person is a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of the security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of the security, or has the right to acquire such powers within 60&#160;days. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The beneficial ownership of shares of common stock is calculated based on 103,003,384 shares of Humacyte common stock outstanding as of November 10, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned common stock. </font>
        </div>
        <table style="width:456pt;height:347.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Address of Beneficial Owner</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Executive Officers of Humacyte</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laura E. Niklason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,706,989</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">22.7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dale A. Sander</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">118,779</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Heather Prichard</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">325,354</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jeffrey H. Lawson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,478,153</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brady W. Dougan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,706,989</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">22.7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Emery N. Brown </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kathleen Sebelius</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">56,457</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rajiv Shukla</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,857,500</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Max Wallace</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">86,747</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Susan Windham-Bannister </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gordon M. Binder </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael T. Constantino </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Todd M. Pope </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">William Tente</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">362,116</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kiernan T. DeAngelis</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">33,192</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">William (B.J.) Scheessele </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">All Directors and Executive Officers of Humacyte as a Group (16&#160;Individuals)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">29,025,287</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">27.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Five Percent Holders</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ayabudge LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,452,504</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">19.9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fresenius Medical Care Holdings, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,312,735</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The GYF Trust</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,942,078</td>
            <td style="padding:0pt;padding-left:9.51000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Less than one&#160;percent. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, the business address of each of the following entities and individuals is 2525&#160;East North Carolina Highway 54, Durham, North Carolina 27713. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;1,148,240 shares of common stock held by Dr.&#160;Niklason, (ii)&#160;1,265,887 shares of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:28pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">common stock subject to options exercisable within 60&#160;days of November 10, 2021 held by Dr.&#160;Niklason, (iii)&#160;810,161 shares of common stock held by Mr.&#160;Dougan, (iv)&#160;30,197 shares of common stock subject to options exercisable within 60&#160;days of November 10, 2021 held by Mr.&#160;Dougan, and (v)&#160;20,452,504 shares of common stock held by Ayabudge LLC. Dr.&#160;Niklason is married to Mr.&#160;Dougan and Mr.&#160;Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Dr.&#160;Niklason may be deemed to share beneficial ownership of the securities held of record by Mr.&#160;Dougan and Ayabudge LLC. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 118,779 shares of common stock subject to options exercisable within 60&#160;days of November&#160;10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;2,625 shares of common stock and (ii)&#160;322,729 shares of common stock subject to options exercisable within 60&#160;days of November 10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;7,877 shares of Common Stock and (ii)&#160;1,470,276 shares of common stock subject to options exercisable within 60&#160;days of November 10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;810,161 shares of common stock held by Mr.&#160;Dougan, (ii)&#160;30,197 shares of common stock subject to options exercisable within 60&#160;days of November 10, 2021 held by Mr.&#160;Dougan, (iii)&#160;1,148,240 shares of common stock held by Dr.&#160;Niklason, (iv)&#160;1,265,887 shares of common stock subject to&#160;options exercisable within 60&#160;days of November 10, 2021 held by Dr.&#160;Niklason, and (v)&#160;20,452,504 shares of common stock held by Ayabudge LLC. Mr.&#160;Dougan is married to Dr.&#160;Niklason and Mr.&#160;Dougan has sole voting, and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr.&#160;Dougan may be deemed to share beneficial ownership of the securities held of record by Dr.&#160;Niklason and Ayabudge LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 56,457 shares of common stock subject to options exercisable within 60&#160;days of November&#160;10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;2,705,000 shares of common stock and (ii)&#160;Warrants to purchase 152,500 shares of common stock exercisable within 60&#160;days of November&#160;10, 2021. AHAC Sponsor LLC is the record holder of such shares and Warrants. Mr.&#160;Shukla is the managing member of the Sponsor. By virtue of this relationship, Mr.&#160;Shukla may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Mr.&#160;Shukla disclaims beneficial ownership of the shares held of record by the Sponsor except to the extent of his pecuniary interest therein. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;49,986 shares of common stock and (ii)&#160;36,761 shares of common stock subject to options exercisable within 60&#160;days of November&#160;10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;52,519 shares of common stock and (ii)&#160;209,597 shares of common stock subject to options exercisable within 60&#160;days of November&#160;10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 33,192 shares of common stock subject to options exercisable within 60&#160;days of November&#160;10, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. Ayabudge LLC has pledged 18,930,004 shares to certain lenders in connection with a financing arrangement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Based on a Schedule 13D filed by Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG &amp; Co. KGaA on September 2, 2021. The business address of Fresenius Medical Care Holdings, Inc. is 920 Winter Street, Waltham, Massachusetts 02451. For additional information, see note&#160;24 to the table under the caption &#8220;Selling Stockholders.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Based on a Schedule 13G filed by PTC Trustees GY Limited, as trustee of The GYF Trust, and Gavril Abramovich Yushvaev on September 8, 2021. Gavril Abramovich Yushvaev has sole voting and dispositive power over the shares held by PTC Trustees GY Limited. The address of the business office of PTC Trustees GY Limited as Trustee of The GYF Trust is 37 Metochiou Street, Agios Andreas, 1101 Nicosia, Cyprus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies and Procedures for Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon consummation of the Business Combination, the Board adopted a written Related Person Transactions Policy that sets forth Humacyte&#8217;s policies and procedures regarding the notification, review, approval, ratification and disclosure of &#8220;related person transactions.&#8221; For purposes of Humacyte&#8217;s policy only, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which Humacyte or any of its subsidiaries are participants involving an amount that exceeds $120,000, in which any &#8220;related person&#8221; has or will have a direct or indirect material interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Transactions involving compensation for services provided to Humacyte as an employee or director will not be considered related person transactions under this policy. A &#8220;related person&#8221; is any executive officer, director, nominee to become a director, a holder of more than 5% of any class of Humacyte&#8217;s voting securities, including any of their immediate family members and affiliates, including entities owned or controlled by such persons, and any entity that employs any of the foregoing persons, of which any of the foregoing persons is a general partner, officer or serves in a similar position, or in which any of the foregoing persons has a 10% percent or greater beneficial ownership interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of Humacyte&#8217;s voting securities, any director or employee with knowledge of a proposed transaction, must present information regarding the proposed related person transaction to the audit committee of the Board for review. To identify related person transactions in advance, Humacyte will rely on information supplied by its executive officers, directors and certain significant stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audit committee will approve only those transactions that it determines are in Humacyte&#8217;s best interests. The transactions described below under the subheadings &#8220;Pre-Business Combination AHAC Related Party Transactions&#8221; and &#8220;Legacy Humacyte Related Party Transactions&#8221; were entered into prior to the adoption of the Related Person Transactions Policy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Humacyte Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investor Rights and Lock-up Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the Effective Time, Humacyte and certain of the stockholders of Humacyte and Legacy Humacyte entered into an Investor Rights and Lock-up Agreement, pursuant to which, among other things, such stockholders (i)&#160;agreed not to effect any sale or distribution of any shares held by any of them during the one-year lock-up period described therein, subject to certain exceptions described below, and (ii)&#160;were granted certain registration rights with respect to certain shares of securities held by them. Pursuant to the Investor Rights and Lock-up Agreement, the Sponsor and certain directors of AHAC prior to the Business Combination have, for a period of 10&#160;years, unless such stockholders cease to collectively own at least 5% of our common stock at an earlier date, the right to designate, and the Board will nominate, one individual for election to the Board. In connection with the closing of the Business Combination, these stockholders designated Rajiv Shukla for election to the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the volume weighted average price (&#8220;VWAP&#8221;) of Humacyte common stock on Nasdaq, or any other national securities exchange on which the common stock is then traded, is greater than or equal to $15.00 over any 20 trading days within any 30 trading day period following the closing of the Business Combination, then, commencing at least 180&#160;days after the closing of the Business Combination, the lock-up period shall be deemed to have expired with respect to 50% of the shares of common stock held by each party subject to the Investor Rights and Lock-up Agreement. The lock-up period shall not apply to any shares purchased in the PIPE Investment by parties to the Investor Rights and Lock-up Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the Investor Rights and Lock-up Agreement is subject to and qualified in its entirety by reference to the full text of the form of Investor Rights and Lock-up Agreement, a copy of which is attached as Exhibit&#160;10.2 to the registration statement of which this prospectus forms a part, and the terms of which are incorporated herein by reference. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-up Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the Effective Time, certain stockholders and option holders of Legacy Humacyte who did not enter into the Investor Rights and Lock-up Agreement entered into a lock-up agreement (the &#8220;Lock-up Agreement&#8221;) restricting their ability to transfer their shares of Humacyte common stock. The Lock-up Agreement has substantially the same terms as the lock-up provision contained in the Investor Rights and Lock-up Agreement, described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the Lock-up Agreement is subject to and qualified in its entirety by reference to the full text of the form of Lock-up Agreement, a copy of which is attached as Exhibit&#160;10.1 to the registration statement of which this prospectus forms a part, and the terms of which are incorporated herein by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with consummating the Business Combination, Humacyte entered into customary indemnification agreements with the directors and executive officers of Humacyte following the Business Combination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Business Combination AHAC Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Founder Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;20, 2020, AHAC issued 2,875,000 shares of its Class&#160;B Common Stock to the Sponsor for $25,000, or approximately $0.01 per share (the &#8220;Founder Shares&#8221;). The Founder Shares included an aggregate of up to 375,000 shares that were subject to forfeiture if the over-allotment option granted to the underwriters in connection with AHAC&#8217;s initial public offering was not exercised by the underwriters in full. The over-allotment option was not exercised by the underwriters and therefore, as of December&#160;31, 2020, 2,500,000 Founder Shares were issued and outstanding. Each Founder Share was converted into one share of Humacyte common stock at the closing of the Business Combination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Promissory Note&#8201;&#8212;&#8201;Related Party</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;1, 2020, AHAC issued an unsecured promissory note to the Sponsor, pursuant to which AHAC may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of AHAC&#8217;s initial public offering. This loan was non-interest bearing, unsecured, and due on the earlier of (a)&#160;March&#160;31, 2021 or (b)&#160;the date on which AHAC completed the Initial Public Offering. As of December&#160;31, 2020, AHAC had $95,136 in borrowings outstanding under the promissory note. The note was paid in full in January&#160;2021 out of offering proceeds not held in the Trust Account. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Administrative Service Fee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AHAC agreed to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for general and administrative services including office space, utilities and secretarial and administrative support. This arrangement terminated upon completion of the Business Combination. For the period July&#160;1, 2020 through December&#160;31, 2020, AHAC accrued $34,334 of administrative fees as a due to related party payable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Underwriting Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;22, 2020, the underwriters of AHAC&#8217;s initial public offering were paid an underwriting discount of 2.0% of the gross proceeds of the offering, or $2,000,000. In addition, the underwriters were entitled to a deferred underwriting fee of 3.5% of the gross proceeds of the initial public offering upon the completion of the Business Combination. The underwriters have agreed that up to 1% of the deferred underwriting fee may be re-directed to other member firms of the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) that have provided services in connection with the identification and consummation of a business combination, in the sole discretion of AHAC; provided, that all such payments to other FINRA member firms may only be made if permitted under applicable law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AHAC was permitted to reduce the deferred underwriting fee by up to 50% based on stockholders redeeming their shares for their pro-rata amount of the proceeds in the Trust Account; provided, however, that (a)&#160;the underwriters&#8217; maximum deferred underwriting fee reduction based on stockholder redemptions would be 50% regardless of whether stockholder redemptions exceeded 50%; and (b)&#160;any sums paid to other advisors as discussed above, would be credited against the reduction of and added back to the deferred underwriting fee payable to the underwriters; and (c)&#160;under no circumstance would the deferred underwriting fee be less than 1.75% of the gross proceeds of the initial public offering. AHAC paid to the underwriters aggregate deferred underwriting fees of $2,446,902 upon consummation of the Business Combination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legacy Humacyte Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PIPE Investment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the execution of the Business Combination Agreement, AHAC entered into the Subscription Agreements with the PIPE Investors, pursuant to which the PIPE Investors agreed to purchase, and AHAC agreed to sell to the PIPE Investors, an aggregate of 17,500,000 shares of AHAC&#8217;s Class&#160;A common stock, for a purchase price of $10.00 per share and an aggregate purchase price of $175&#160;million, in the PIPE Investment. Such shares were issued immediately prior to the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table below sets forth the number of shares of AHAC&#8217;s Class&#160;A common stock that were purchased by Legacy Humacyte&#8217;s related parties (which shares were converted into Humacyte common stock on a one-for-one basis at the closing of the Business Combination): </font>
        </div>
        <table style="width:456pt;height:71.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:311.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Related Person </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Class&#160;A</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cash Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ayabudge LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,522,500</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,225,000</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fresenius Medical Care Holdings, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,500,000</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000,000</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">PTC Trustees GY Limited as Trustee of The GYF Trust </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,800,000</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,000,000</td>
            <td style="padding:0pt;padding-left:9.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AHAC is party to an engagement letter with Exos pursuant to which Exos acted as a private placement agent to AHAC in connection with the PIPE Investment. Exos received a $5.5&#160;million fee upon the closing of the PIPE Investment. AHAC also agreed to indemnify Exos as is customary with respect to placement agent arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Brady Dougan, a member of Humacyte&#8217;s Board and the prior chairman of the Legacy Humacyte board of directors, is the founder and chief executive officer of Exos. Laura Niklason, Humacyte&#8217;s chief executive officer and president, is the spouse of Brady Dougan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Support Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the execution of the Business Combination Agreement, certain Legacy Humacyte stockholders, who held 77.1% of Legacy Humacyte&#8217;s outstanding capital stock, entered into a support agreement pursuant to which they agreed to vote in favor of the Business Combination, among other items, at a meeting of Legacy Humacyte stockholders called to approve the Business Combination (or to act by written consent approving the Business Combination). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Financings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;C Preferred Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February and March&#160;2018, Legacy Humacyte issued and sold an aggregate of 42,808,208 shares of its Series&#160;C convertible preferred stock, par value $0.001 per share (the &#8220;Series&#160;C Preferred&#8221;), at a purchase price of $1.752 per share, for an aggregate purchase price of $75&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;D Preferred Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;25, 2018, Legacy Humacyte issued and sold to Fresenius Medical Care 60,216,780 shares of its Series&#160;D convertible preferred stock, par value $0.001 per share (the &#8220;Series&#160;D Preferred&#8221;), at a purchase price of $2.491 per share, for an aggregate purchase price of $150&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the shares of Series&#160;C Preferred and Series&#160;D Preferred acquired by Legacy Humacyte&#8217;s directors, executive officers, or holders of more than 5% of its capital stock, or any member of the immediate family of the foregoing persons, in the financing transactions described above </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">. </font>
        </div>
        <table style="width:456pt;height:47.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:261.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Related Person </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;C</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;D</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cash</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:261.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gavril Abramovich Yushvaev</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,246,619</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:48pt; text-align:right; white-space:nowrap;">36,158,711.03</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fresenius Medical Care Holdings, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">60,216,780</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48pt; text-align:right; white-space:nowrap;">149,999,998.98</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Yushvaev subsequently transferred these shares to PTC Trustees GY Limited as Trustee of The GYF Trust, of which he is the settlor for the benefit of himself and certain of his family members. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the closing of the Business Combination, each outstanding share of Series&#160;C Preferred and Series&#160;D Preferred was cancelled and converted into the right to receive a number of shares of Humacyte common stock equal to (A)&#160;the aggregate number of shares of Humacyte common stock that would be issued upon conversion of the shares of Series&#160;C Preferred or Series&#160;D Preferred, as applicable, based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by (B)&#160;0.26260. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Related Stockholder Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the financing transactions described above, Legacy Humacyte entered into an Amended and Restated Investors&#8217; Rights Agreement, an Amended and Restated Right of First Refusal and Co-Sale Agreement and an Amended and Restated Voting Agreement (collectively, the &#8220;Legacy Humacyte Stockholder Agreements&#8221;) with certain of its stockholders, including the related parties described in the chart above. The Legacy Humacyte Stockholder Agreements terminated upon the closing of the Business Combination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Transactions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Distribution Agreement with Fresenius Medical Care</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2018, Legacy Humacyte entered into a distribution agreement with Fresenius Medical Care, pursuant to which Fresenius Medical Care has the exclusive right to develop outside of the United States and EU and commercialize outside of the United States, among other things, our 6 millimeter x 42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter, or configuration of the foregoing), referred to as the distribution product, for use in in vascular creation, repair and, replacement or construction (including renal replacement therapy for dialysis access, the treatment of vascular trauma, and the treatment of PAD, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients). For additional information regarding the terms of the distribution agreement, see &#8220;Business&#8201;&#8212;&#8201;Distribution.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Arrangements with Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Legacy Humacyte made research gifts to Yale University of $500,000 in 2018, $422,000 in 2019 and $500,000 in 2020, for use toward research efforts in regenerative medicine. Legacy Humacyte also entered into three license agreements with Yale University and has made payments of license fees and other expenses to Yale, as described further in the section titled &#8220;Business&#8201;&#8212;&#8201;Intellectual Property.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Employment Agreement with William Tente</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;13, 2019, Legacy Humacyte entered into an employment agreement with William Tente, which provides for his at-will employment as our Chief Regulatory Officer. Mr.&#160;Tente&#8217;s employment agreement provided for an initial annual base salary of $319,300, to be reviewed by Humacyte from time to time. Mr.&#160;Tente is also eligible for consideration to receive an annual incentive bonus. The amount of any bonus will be established annually based on objectives determined by Humacyte and Mr.&#160;Tente, and awarded in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:372pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">sole discretion of the Humacyte Board. In general, except in the event that Mr.&#160;Tente&#8217;s employment is terminated without cause or he resigns for good reason, Mr.&#160;Tente must remain employed on the date any annual incentive bonus is paid in order to receive such bonus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event that Mr.&#160;Tente&#8217;s employment is terminated without cause or he resigns for good reason, including Humacyte&#8217;s material breach of Mr.&#160;Tente&#8217;s employment agreement or an uncured material adverse change in Mr.&#160;Tente&#8217;s compensation, as each such term is defined in his employment agreement, Humacyte will be obligated to pay him (i)&#160;an amount equal to six&#160;months of his then-current base salary (payable in substantially equal installments on the same payroll schedule applicable to her immediately prior to the termination of his employment) and (ii)&#160;a pro&#160;rata portion, calculated per diem, of his bonus for the then-current fiscal year (as well as any accrued, earned and unpaid bonus from the preceding fiscal year). Each of the severance payments described above is subject to Mr.&#160;Tente&#8217;s timely execution of a general release of potential claims against Humacyte and his compliance with his non-competition agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Consulting Agreement with Dale Sander</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2021, Legacy Humacyte entered into a consulting agreement with Dale Sander. Under the consulting agreement, Legacy Humacyte paid Mr.&#160;Sander a consulting fee of $25,000 per month and reimbursed his reasonable and documented expenses. In connection with the entry into this consulting agreement, the Legacy Humacyte board of directors granted to Mr.&#160;Sander an option to purchase 700,000 shares of Legacy Humacyte common stock at an exercise price per share of $2.699. This consulting agreement was terminated effective as of April&#160;29, 2021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following summary of the material terms of our common stock and preferred stock is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Charter and Bylaws, which are exhibits to the registration statement of which this prospectus forms a part. We urge you to read our Charter and Bylaws in their entirety for a complete description of the rights and preferences of our securities.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized and Outstanding Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Charter authorizes the issuance of 270,000,000 shares, consisting of 250,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.0001 par value. As of November&#160;10, 2021, there were 103,003,384 shares of our common stock and no shares of preferred stock outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Charter provides the following with respect to the rights, powers, preferences and privileges of our common stock. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Power</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of Humacyte common stock possess all voting power for the election of the Board and all other matters requiring stockholder action. Holders of Humacyte common stock are entitled to one vote per share on matters to be voted on by stockholders. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of Humacyte common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Board in its discretion out of funds legally available therefor. AHAC did not historically paid any cash dividends on its common stock and Humacyte does not intend to pay cash dividends in the foreseeable future. Any payment of cash dividends in the future will be dependent upon Humacyte&#8217;s revenues and earnings, if any, capital requirements and general financial conditions. In no event will any stock dividends or stock splits or combinations of stock be declared or made on Humacyte common stock unless the shares of Humacyte common stock at the time outstanding are treated equally and identically. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidation, Dissolution and Winding Up</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of Humacyte&#8217;s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of Humacyte common stock will be entitled to receive an equal amount per share of all of Humacyte&#8217;s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preemptive or Other Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no sinking fund provisions applicable to Humacyte common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Charter provides that shares of preferred stock may be issued from time to time in one or more series. The Board is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Board may, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of Humacyte common stock and could have anti-takeover effects. The ability of the Board to issue preferred </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Humacyte or the removal of existing management. Humacyte has no preferred stock currently outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte and certain of the stockholders of Humacyte and Legacy Humacyte are party to the Investor Rights and Lock-up Agreement, pursuant to which, among other things, such stockholders were granted certain registration rights with respect to certain shares of securities held by them. See &#8220;Certain Relationships and Related Party Transactions &#8212; Humacyte Related Party Transactions &#8212; Investor Rights and Lock-up Agreement&#8221; for more information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Charter and Bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Among other things, the Charter and Bylaws: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">permit the Board to issue up to 20,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that the number of directors of Humacyte may be changed only by resolution of the Board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least 66 </font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of all of Humacyte&#8217;s then-outstanding shares of capital stock entitled to vote generally at an election of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that special meetings of Humacyte&#8217;s stockholders may be called by (i)&#160;the chairperson of the Board, (ii)&#160;our chief executive officer or (iii)&#160;a majority of our Board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that the Board will be divided into three classes of directors, with the classes to be as nearly equal as possible, and with the directors serving three-year terms (see the section titled &#8220;Management&#8221;), therefore making it more difficult for stockholders to change the composition of the Board; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of Humacyte common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The combination of these provisions will make it more difficult for the existing stockholders to replace the Board as well as for another party to obtain control of Humacyte by replacing the Board. Because the Board has the power to retain and discharge its officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for the Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of Humacyte. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of the Board and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce Humacyte&#8217;s vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for Humacyte&#8217;s shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of Humacyte&#8217;s stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:316pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Anti-Takeover Provisions of Delaware Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Humacyte is subject to the provisions of Section&#160;203 of the DGCL. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an affiliate of an interested stockholder; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an associate of an interested stockholder, for three&#160;years following the date that the stockholder became an interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A &#8220;business combination&#8221; includes a merger or sale of more than 10% of a corporation&#8217;s assets. However, the above provisions of Section&#160;203 would not apply if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the relevant board of directors approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of the corporation&#8217;s voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on or subsequent to the date of the transaction, the initial business combination is approved by the board of directors and authorized at a meeting of the corporation&#8217;s stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions may have the effect of delaying, deferring, or preventing changes in control of Humacyte. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:152pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the resale by the selling stockholders from time to time of up to 90,006,840 shares of common stock, which consists of (i)&#160;up to 17,500,000 PIPE Shares issued in the PIPE Investment, (ii)&#160;up to 71,696,679 shares of common stock pursuant to the Investor Rights and Lock-up Agreement and (iii)&#160;up to 810,161 shares of common stock purchased by a selling stockholder. We will not receive any proceeds from the sale of shares of common stock by the selling stockholders pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may from time to time offer and sell any or all of the common stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term &#8220;selling stockholders&#8221; includes the persons listed in the table below, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the selling stockholders&#8217; interests in the common stock, other than through a public sale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Selling stockholders holding 71,696,679 shares of common stock set forth below are subject to the terms of the Investor Rights and Lock-up Agreement, which includes restrictions on transfer until the termination of applicable lock-up periods. Under the Investor Rights and Lock-up Agreement, such selling stockholders (i)&#160;agreed not to effect any sale or distribution of any shares held by any of them during the one-year lock-up period described therein, subject to certain exceptions, and (ii)&#160;were granted certain registration rights with respect to certain shares of common stock held by them. See &#8220;Certain Relationships and Related Party Transactions &#8212; Humacyte Related Party Transactions&#8221; for further discussion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as set forth in the footnotes below, the following table sets forth certain information as of November&#160;1, 2021 regarding the beneficial ownership of our common stock by the selling stockholders and the shares of common stock being offered by the selling stockholders. The applicable&#160;percentage ownership of common stock is based on approximately 103,003,384 shares of common stock outstanding as of October 20, 2021. Information with respect to shares of common stock owned beneficially after the offering assumes the sale of all of the shares of common stock registered hereby. The selling stockholders may offer and sell some, all or none of their shares of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. A person is a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of the security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of the security, or has the right to acquire such powers within 60&#160;days. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please see the section titled &#8220;Plan of Distribution&#8221; in this prospectus for further information regarding the selling stockholders&#8217; method of distributing these shares. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:644.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:249.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">for Sale</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Hereby</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2163 Holdings LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">360 Family Office Fund&#160;LLC</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">62,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">62,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">715 Management</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aaron Fencil </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">27,545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">27,545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adam B. Fencil </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AI Humacyte Holdings LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,377,410</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,377,410</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Alexandria Venture Investments, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">916,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">916,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Allen Heye </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AM Global Investments (Cayman)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,988,795</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,988,795</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aman Oberoi </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ameeta Walia </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Andrew Seighart </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Antonio Farnos </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aric Hart </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ayabudge LLC </font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,452,504</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,452,504</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brady W. Dougan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">810,161</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">810,161</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bangkok Bank Public Company Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,739,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,739,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Behbehani Finance Company</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">442,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">442,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">BEMAP Master Fund&#160;Ltd</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">194,189</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">194,189</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin Kwasnick </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bernard Heng Jin Meng </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">98,012</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">98,012</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bespoke Alpha MAC MIM LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,148</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,148</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brennan C. Todd </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brian Robertson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brian Walsh </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bruce A. Springer</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Busolantix Investment S.A.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">599,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">599,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carolyn Specht </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrie S. Cox </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">756,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">756,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Challenger Universal Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(15)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,194,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,194,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Charles Schwab &amp; Co., Inc FBO Elinor Hamblin TTEE Virginia C Thomas Trust</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(16)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Charles Schwab &amp; Co., Inc FBO Kathleen A Mangan Individual</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(17)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Christopher Metcalfe </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Christopher Metcalfe Charitable Remainder</font>
                <br >
                <font style="letter-spacing:0.2pt;">Unitrust</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">37,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">37,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">CVI Investments, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(18)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">D. Wilson Ervin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">276,821</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">276,821</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dan Friis Alternatives Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(19)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">619,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">619,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Daniel Heflin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">21,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">21,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:649.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:249.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">for Sale</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Hereby</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dataspring Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(20)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">293,913</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">293,913</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">David Rodricks </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dinan Family Foundation</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(21)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">250,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">250,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dinan Family LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(22)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dinan Management, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(23)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">246,033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">246,033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dustin White </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">DS Liquid Div RVA MON LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">234,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">234,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">EQ Capital Pte. Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(24)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">530,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">530,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eric and Shauna Varvel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">321,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">321,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Erich Grasso </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Eric Weinstein </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Essex Bio-Investment Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(25)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">200,809</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">200,809</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">EWM Alternative Investments SPV, LLC-Series 7-Unicorn Tech Fund II </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">96,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">96,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Farah Financial Services Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(26)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">401,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">401,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fresenius Medical Care Holdings, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(27)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,312,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,312,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furkan Baran </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">George Sertl </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,155</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,155</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grazyna Kulczyk </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,283,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,283,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gudrun Zoeller </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Helman Sitohang </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">176,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">176,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Highmark Long/Short Equity 20</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(28)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">387,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">387,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">IC 401k Trust</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(29)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Iram Zia </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jack Laschever </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jacqueline Berg </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John T. Trauth </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John A. Chetalet </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph F. Skowron III </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">67,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">67,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kareem Burke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">62,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">62,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kenneth and Debbie Hunter Scribner </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kevin Keenan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yili Kevin Xie</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(30)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kwek Buck Chye </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kyle Rusconi </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lau Yuen Yee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">82,435</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">82,435</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laura E. Niklason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(31)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,148,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,148,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legion Method</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leo C. Saenger III </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lilly Tam </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loren T. Niklason </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">65,026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">65,026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:647pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:249.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">for Sale</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Hereby</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lubna R. Singh </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marc J. Bishara </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mark Negley </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Malgorzata Dobak </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">41,344</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">41,344</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marloes Capital Pte. Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(32)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">547,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">547,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Maven Investment Partners US Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(33)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI-CM LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(34)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael and Cristina D&#8217;Angelo </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael and Julie Fair </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Millennium Trust FBO Richard Levinson IRA</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(35)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">13,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">13,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Monashee Pure Alpha SPV I LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">115,419</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">115,419</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Monashee Solitario Fund&#160;LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">148,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">148,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Morgan Creek Capital Partners, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(36)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Morgan Creek Private Opportunities, LLC Series&#160;I&#8201;&#8212;&#8201;Humacyte</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(37)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">144,928</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">144,928</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mu Dejun </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">477,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">477,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mulholland Investment Group</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(38)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">37,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">37,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Natalon Company Limited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,768,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,768,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ngiam Mia Je Patrick </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">135,657</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">135,657</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ngiam Mia Kiat Benjamin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">119,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">119,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Nineteen77 Global Multi-Strategy Alpha Master</font>
                <br >
                <font style="letter-spacing:0.2pt;">Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(39)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Northland Securities, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(40)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8,333</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8,333</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Oppenheimer &amp; Co. Inc.</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">41,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">41,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">OrbiMed Genesis Master Fund, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(41)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">OrbiMed Partners Master Fund&#160;Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(42)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pacific Investment Resources Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(43)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,802,492</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,802,492</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pan Class&#160;F Ventures Ltd</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(44)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Patrick Sturgeon</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(45)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">140,211</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">140,211</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Paul D. Ausley </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Perch Bay Group, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(46)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter and Janet Bernthal </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">30,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">30,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pura Vida Master Fund, Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(28)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">662,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">662,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Qubit PE, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(47)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rajiv Shukla</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(48)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,814,789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,814,789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rebecca J. Mason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(49)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">26,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">26,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rebecca J. and Curtis Mason</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(50)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Humphrey </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Larson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard I. Sichel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richburg Enterprises LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(51)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:531.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:249.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registered</font>
                <br >
                <font style="letter-spacing:-0.16pt;">for Sale</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Hereby</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.333pt 0pt 1.917pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert and Nancy Blum </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">124,340</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">124,340</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert Duggan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">125,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">125,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert L. Basso </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">236,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">236,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scanfert Oy</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">599,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">599,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Schwartz Management, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(52)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">80,004</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">80,004</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SFL SPV I LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">32,955</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">32,955</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shakil Riaz </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">19,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shindell 2016 GST Trust - (Ervin Shindell)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(53)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sirocco Holdings, Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(54)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">884,164</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">884,164</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stephen Scott Roth </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">17,391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">StoneX Financial Inc C/F Meline Doodnauth - IRA</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(55)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">StoneX Financial Inc C/F Nalini Durgana - IRA</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(56)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">StoneX Financial Inc C/F Oswald Durgana - IRA</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(57)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Supreme Universal Holdings Limited</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(58)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,194,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,194,604</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Terrance L. Carlson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(59)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Textile Global Sourcing Inc</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(60)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">14,493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">14,493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The GYF Trust</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(61)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">8,942,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">8,942,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.583pt 0pt; width:249.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">The Family Trust Created Under the Joan Fencil Revocable Trust Dated September&#160;16, 1996</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(62)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">76,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">76,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.583pt 0pt; width:249.51pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">The James Fencil Family Trust Dated September&#160;4,</font>
                <br >
                <font style="letter-spacing:0.2pt;">2019</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(63)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">482,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">482,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.583pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tom S. Nichols </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vikas Srivastav </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">28,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Walleye Opportunities Master Fund&#160;Ltd</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(28)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Walleye Manager Opportunities LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(28)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">100,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">William Alan Jolly </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Xiao Tian Feng </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">44,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">44,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">York Capital Management, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(23)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,069,454</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,069,454</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">York Multi Strategy Master Fund, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(23)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,221,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,221,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yue Wang </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">44,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">44,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Zachary Larson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Zhang Liping </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 2.25pt 0pt; width:249.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">90,006,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">90,006,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The amounts set forth in this column are the number of shares of common stock that may be offered by each selling stockholder using this prospectus. These amounts do not represent any other shares of our common stock that the selling stockholder may own beneficially or otherwise. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mark Boyce has full voting and dispositive power over the shares held by 2163 Holdings LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Antonio Tubbs has full voting and dispositive power over shares held by 715 Management. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Each of Access Industries Management, LLC (&#8220;AIM&#8221;), Access Industries Holdings LLC (&#8220;AIH&#8221;) and Len Blavatnik may be deemed to beneficially own, and share investment and voting power over, the shares held directly by AI Humacyte Holdings LLC because (i) AIM is the sole manager of AI Humacyte </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holdings LLC, (ii) AIH controls a majority of the outstanding voting interests in AI Humacyte Holdings LLC and (iii) Mr. Blavatnik controls AIM and a majority of the outstanding voting interests in AIH. Each of AIM, AIH and Mr. Blavatnik and each of their affiliated entities and the officers, partners, members and managers thereof, other than AI Humacyte Holdings LLC, disclaims beneficial ownership of the shares held directly by AI Humacyte Holdings LLC.</font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Humacyte leases its principal executive office from an affiliate of Alexandria Venture Investments, LLC.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">His Excellency Sheikh Abdulrahman bin Mubarak bin Saif Al-Thani has full voting and dispositive power over the shares held by AM Global Investments (Cayman). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Brady Dougan has full voting and dispositive power over the shares held by Ayabudge LLC. Mr.&#160;Dougan serves a director of Humacyte and is married to Laura Niklason, who serves as President and Chief Executive Officer and as a director of Humacyte. By virtue of this relationship, Dr.&#160;Niklason may be deemed to share beneficial ownership of the securities held of record by Ayabudge LLC. Ayabudge LLC has pledged 18,930,004 shares to certain lenders in connection with a financing arrangement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Brady Dougan serves a director of Humacyte and is married to Laura Niklason, who serves as President and Chief Executive Officer and as a director of Humacyte. By virtue of this relationship, Dr.&#160;Niklason may be deemed to share beneficial ownership of the securities held of record by Mr.&#160;Dougan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Yanchai Tantiratapong is the Senior Vice President and Investment Department Manager of Bangkok Bank Public Company Limited and has full voting and dispositive power over the shares held by Bangkok Bank Public Company Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ali Morad Behbehani, President, Hussein Morad Behbehani, Vice President, and Samiha Morad Behbehani, Director, have full voting and dispositive power over the shares held by Behbehani Finance Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Monashee Investment Management, LLC is the investment manager of BEMAP Master Fund&#160;Ltd, Monashee Pure Alpha SPV I LP, Monashee Solitario Fund&#160;LP, Bespoke Alpha MAC MIM LP, SFL SPV I LLC and DS Liquid Div RVA MON LLC and, therefore, has full investment and voting power over the shares held by such funds. Jeff Muller, as Chief Compliance Officer of Monashee Investment Management LLC, has the right to exercise investment and voting power on behalf of the Monashee Funds. Mr.&#160;Muller disclaims any beneficial ownership of the shares held by such funds. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Brian Robertson served as a director of AHAC prior to the Business Combination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Bruce A. Springer served as a director of AHAC prior to the Business Combination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Patrick Fuchs and Alexander Ospelt are directors of Busolantix Investment S.A. and share full voting and dispositive power over the shares held by Busolantix Investment S.A.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(15)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">His Excellency Sheikh Hamad Bin Jassim Bin Jabr Al-Thani and his family have full voting and dispositive power over the shares held by Challenger Universal Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(16)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Elinor Hamblin has full voting and dispositive power over the shares held by Charles Schwab &amp; Co., Inc. FBO Elinor Hamblin TTEE Virginia C Thomas Trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(17)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Kathleen A. Mangin has full voting and dispositive power over the shares held by Charles Schwab &amp; Co., Inc FBO Kathleen A Mangan Individual. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(18)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (&#8220;CVI&#8221;), has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI. Mr.&#160;Kobinger disclaims any such beneficial ownership of the shares. CVI is affiliated with one or more FINRA members, none of whom are currently expected to participate in the sale pursuant to this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(19)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dan Friis is a director of Dan Friis Alternatives Ltd. and has full voting and dispositive power over the shares held by Dan Friis Alternatives Ltd. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(20)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Seow Voon Ping is the ultimate beneficial owner of Dataspring Limited and has full voting and dispositive power over the shares held by Dataspring Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(21)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">James G. Dinan is the President and Treasurer, and a member of the board of directors, of the Dinan Family Foundation. As a result, Mr.&#160;Dinan may be deemed to be the beneficial owner of all shares of common stock directly owned by the Dinan Family Foundation. YGA (defined below) disclaims beneficial ownership of all shares of common stock directly owned by the Dinan Family Foundation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(22)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">James G. Dinan is a general partner of Dinan Family LP. As a result, Mr.&#160;Dinan may be deemed to be the beneficial owner of all shares of common stock directly owned by Dinan Family LP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(23)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">James G. Dinan is the chairman and a senior manager of York Capital Management Global Advisors, LLC (&#8220;YGA&#8221;) and makes voting and investment decisions on behalf of YGA. YGA is the sole senior managing member of Dinan Management, L.L.C., which is the general partner of each of Dinan Management L.P., York Capital Management, L.P. and York Multi Strategy Master Fund, L.P. As a result, YGA may be deemed to be the beneficial owners of the shares held by each of such funds. The directors and executive officers of YGA are James G. Dinan, Chairman and Chief Executive Officer, and John J. Fosina, Chief Financial Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(24)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ron Sim Chye Hock and Teo Sway Heong, each a director of EQ Capital Pte. Ltd., have full voting and dispositive power over the shares held by EQ Capital Pte. Ltd.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(25)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Essex Bio-Investment Limited is a wholly-owned subsidiary of Essex Bio-Technology Limited, a Hong Kong publicly traded company. Ngiam Mia Je Patrick is the Chairman, Executive Director and single largest shareholder of Essex Bio-Technology Limited, and a director of Essex Bio-Investment Limited. Mr. Ngiam has full voting and dispositive power over the shares held by Essex Bio-Investment Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(26)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ali Kolaghassi is the sole director of Farah Financial Services Ltd. and has the authority to make investment decisions on behalf of Farah Financial Services Ltd. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(27)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Based solely upon a review of a Schedule&#160;13D filed by Fresenius Medical Care Holdings, Inc. (&#8220;Fresenius Medical Care&#8221;) on September&#160;2, 2021, Fresenius Medical Care is a wholly-owned subsidiary of Fresenius Medical Care AG &amp; Co. KGaA (&#8220;FMC AG &amp; Co. KGaA&#8221;) and is the holding company for the North American operations of FMC AG &amp; Co. KGaA. The outstanding share capital of FMC AG &amp; Co. KGaA consists of ordinary shares issued only in bearer form and, accordingly, FMC AG &amp; Co. KGaA faces difficulties precisely determining who its shareholders are at any specified time or how many shares any particular shareholder owns. FMC AG &amp; Co. KGaA has been informed that as of June&#160;30, 2021 Fresenius SE &amp; Co. KGaA (&#8220;Fresenius SE&#8221;) owned 32.2% of FMC AG &amp; Co. KGaA&#8217;s ordinary shares. Fresenius SE is also the owner of all of the outstanding share capital of Fresenius Medical Care Management AG (&#8220;Management AG&#8221;), the general partner of FMC AG &amp; Co. KGaA and, accordingly, has the sole power to elect the Supervisory Board of Management AG. The Supervisory Board of Management AG has the sole power to appoint the Management Board of Management AG, which acts for Management AG as general partner in conducting the business of FMC AG &amp; Co. KGaA. Through its ownership of the general partner of FMC AG &amp; Co. KGaA, Fresenius SE has de facto management control of FMC AG &amp; Co. KGaA. Fresenius SE&#8217;s share capital also consists solely of ordinary shares, issued only in bearer form. Fresenius SE has similar difficulties precisely determining who its shareholders are at any specified time or how many shares any particular shareholder owns. However, based on the most recent notification to Fresenius SE pursuant to the notification requirements of the German Securities Trading Act, Fresenius SE has been informed that the Else Kr&#246;ner-Fresenius Stiftung (the &#8220;Foundation&#8221;) owns approximately 26.7% of Fresenius SE&#8217;s ordinary shares. The Foundation is also the sole shareholder of Fresenius Management SE (&#8220;FSE Management&#8221;), the general partner of Fresenius SE, and has sole power to elect the Supervisory Board of FSE Management, which appoints the Management Board of FSE Management. The Management Board of FSE Management acts for FSE Management as general partner in the management of Fresenius SE. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(28)</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Walleye Manager Opportunities LLC and Walleye Opportunities Master Fund&#160;Ltd. are managed accounts of Highmark Limited (the &#8220;Managed Accounts&#8221;) and Highmark Long/Short Equity 20 is a segregated account of Highmark Limited (the &#8220;Segregated Acount&#8221;). Pura Vida Investments, LLC serves as the sub-advisor to the Managed Accounts and investment manager to the Segregated Account and to Pura Vida Master Fund, Ltd. Efrem Kamen serves as the managing member of Pura Vida Investments, LLC. As a result, Pura Vida Investments, LLC and Mr.&#160;Kamen may be deemed to have shared voting and dispositive power with respect to the shares held in the Segregated Account and Managed Accounts, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and by Pura Vida Master Fund, Ltd. Pura Vida Investments, LLC and Mr.&#160;Kamen disclaim beneficial ownership of such shares except to the extent of each of their pecuniary interest therein. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(29)</font>
          <br >
        </div>
        <div style=" margin-top:3.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Aleksandr Simma has full voting and dispositive power over the shares held by IC 401k Trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(30)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Yili Kevin Xie served as a director of AHAC prior to the Business Combination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(31)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Laura&#160;Niklason serves as the President and Chief Executive Officer and as a director of Humacyte. Dr.&#160;Niklason is married to Brady Dougan, who has full voting and dispositive power over the shares held by Ayabudge LLC. By virtue of this relationship, Dr.&#160;Niklason may be deemed to share beneficial ownership of the securities held of record by Ayabudge LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(32)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Seow Voon Ping and Mr. Seow Lun Hoo are directors of Marloes Capital Pte. Limited and share full voting and dispositive power over the shares held by Marloes Capital Pte. Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(33)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Anand Sharma has full voting and dispositive power over the shares held by Maven Investment Partners US Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(34)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Brian Finn, Bettina Finn and Melissa Kramer share voting and dispositive power over the shares held by MI-CM LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(35)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Richard Levinson has full voting and dispositive power over the shares held by Millennium Trust FBO Richard Levinson IRA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(36)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mark W. Yusko is Managing Member of Morgan Creek Capital Partners, LLC and has full voting and dispositive power over the shares held by Morgan Creek Capital Partners, LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(37)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Morgan Creek Capital Management, LLC (&#8220;Morgan Creek Capital Management&#8221;) is the investment manager of Morgan Creek Private Opportunities, LLC Series I &#8212; Humacyte (&#8220;Morgan Creek Private Opportunities&#8221;) and Morgan Creek Capital Partners, LLC is the Managing Member of Morgan Creek Private Opportunities. Mark W. Yusko is the managing member of Morgan Creek Capital Management and Morgan Creek Capital Partners, LLC and holds voting and investment power over the shares held by&#160;Morgan Creek Private Opportunities.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(38)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The voting power of the shares held by Mulholland Investment Group is held equally by MB Insurance Services, Inc., Halftime, Inc. and Daily Operation, Inc., which entities are wholly owned by Marc Bishara, Dustin White and Tomer DeVito. Any two of Messrs. Bishara, White and DeVito together have dispositive power over the shares held by Mulholland Investment Group.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(39)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Kevin Russell, the chief investment officer of UBS O&#8217;Connor LLC, the investment manager, has voting and/or investment control over the shares held by Nineteen77 Global Multi-Strategy Alpha Master Limited. Mr.&#160;Russell disclaims beneficial ownership of the securities reported herein for purposes of Section&#160;16 of the Exchange Act, except as to such extent of such reporting person&#8217;s pecuniary interest in the securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(40)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Randy Nitzsche is the President and Chief Executive Officer of Northland Securities, Inc. and has full voting and dispositive power over the shares held by Northland Securities, Inc. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(41)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC. As a result, OrbiMed Genesis GP LLC and OrbiMed Advisors LLC may be deemed to have shared voting power and investment power over the securities held by OrbiMed Genesis Master Fund, L.P. and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors LLC exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis Master Fund, L.P. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(42)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">OrbiMed Capital LLC is the investment advisor to OrbiMed Partners Master Fund&#160;Limited. OrbiMed Capital LLC is a relying advisor of OrbiMed Advisors LLC. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise voting and investment power through a management committee composed of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OrbiMed Partners Master Fund&#160;Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(43)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Pacific Investment Resources Limited is managed by Pacific Eagle Asset Management Limited. Mr.&#160;Ong Wey Ter Kelvin, a director of Pacific Eagle Asset Management Limited and acting in such capacity is has voting and dispositive power over the shares held by Pacific Investment Resources Limited. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(44)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Nichola Dunkley is a director of Pelican Point (BVI) Ltd., which has full voting and dispositive power over the shares held by Pan Class&#160;F Ventures Ltd. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(45)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Patrick Sturgeon served as Chief Financial Officer and Secretary of AHAC prior to the Business Combination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(46)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Curtis F. Brockelman, Jr. has full voting and dispositive power over the shares held by Perch Bay Group, LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(47)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Neil Ramsey is the Managing Member of Qubit PE, LLC and has full voting and dispositive power over the shares held by Qubit PE, LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(48)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">AHAC Sponsor LLC, AHAC&#8217;s sponsor prior to the Business Combination, is the record holder of the securities reported herein. Rajiv Shukla, who served as Chief Executive Officer of AHAC prior to the Business Combination, is the managing member of the Sponsor. By virtue of this relationship, Mr.&#160;Shukla may be deemed to share beneficial ownership of the securities held of record by our sponsor. Mr.&#160;Shukla disclaims any such beneficial ownership except to the extent of his pecuniary interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(49)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Rebecca J. Mason has full voting and dispositive power over the shares that she holds of record. Curtis Mason is married to Ms.&#160;Mason. By virtue of this relationship, Mr.&#160;Mason may be deemed to share beneficial ownership of the securities held of record by Ms.&#160;Mason. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(50)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Rebecca J.&#160;Mason and Curtis&#160;Mason share voting and dispositive power over the shares that they hold jointly. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(51)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Michelle Richburg has full voting and dispositive power over the shares held by Richburg Enterprises LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(52)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Daniel A. Schwartz is the senior managing member of Schwartz Management LLC. As a result, Mr.&#160;Schwartz may be deemed to be the beneficial owner of all shares of common stock directly owned by Schwartz Management LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(53)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Allan Shindell is Trustee of Shindell 2016 GST Trust &#8212; (Ervin Shindell) and has full voting and dispositive power over the shares held by Shindell 2016 GST Trust &#8212; (Ervin Shindell). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(54)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Khaled Masri is the director of Sirocco Holdings, Ltd. and has full voting and dispositive power over the shares held by Sirocco Holdings, Ltd.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(55)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Meline Doodnauth has full voting and dispositive power over the shares held by StoneX Financial Inc&#160;C/F Meline Doodnauth &#8212; IRA.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(56)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Nalini Durgana has full voting and dispositive power over the shares held by StoneX Financial </font>
          <br >
          <font style="letter-spacing:0.2pt;">Inc C/F Nalini Durgana &#8212; IRA.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(57)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Oswald Durgana has full voting and dispositive power over the shares held by StoneX Financial Inc&#160;C/F Oswald Durgana &#8212; IRA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(58)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">His Highness Sheikh Hamad bin Khalifa bin Hamad Al-Thani is the sole owner of Supreme Universal Holdings Limited.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(59)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Terrance L. Carlson served as a director of AHAC prior to the Business Combination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(60)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ragini Shrivastav is President of Textile Global Sourcing Inc and has full voting and dispositive power over the shares held by Textile Global Sourcing Inc. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(61)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Gavril Abramovich Yushvaev has full voting and dispositive power over the shares held by PTC Trustees GY Limited, as Trustee of The GYF Trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(62)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">James R. Fencil and Rebecca J.&#160;Mason are co-trustees of the Joan Fencil Revocable Trust Dated September&#160;16, 1996 and share voting and dispositive power over the shares held by the trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(63)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">James R.&#160;Fencil and Rebecca J.&#160;Mason are co-trustees of the James Fencil Family Trust Dated September&#160;4, 2019 and share voting and dispositive power over the shares held by the trust.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion describes material United States federal income and estate tax considerations relating to the acquisition, ownership, and disposition of shares by a a non-U.S. holder (as defined below) that acquires our shares in this offering and holds them as a capital asset. This discussion is based on the tax laws of the United States, including the Code, Treasury regulations promulgated or proposed thereunder, and administrative and judicial interpretations thereof, all as in effect on the date hereof. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could affect the tax consequences described herein. This section does not address the treatment of a non-U.S. holder under the laws of any state, local or foreign taxing jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; is a beneficial owner of our shares that, for United States federal income tax purposes, is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a non-resident alien individual; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a foreign corporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate the income of which is not subject to United States federal income taxation regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust that does not have in effect a valid election under the Treasury regulations to be treated as a United States person and either (1)&#160;no court within the United States is able to exercise primary supervision over the trust&#8217;s administration or (2)&#160;no United States person has the authority to control all substantial decisions of that trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion does not address all aspects of United States federal income taxation that may be applicable to holders in light of their particular circumstances or status (including, for example, banks and other financial institutions, insurance companies, brokers and dealers in securities or currencies, traders that have elected to mark securities to market, partnerships or other pass-through entities, corporations that accumulate earnings to avoid United States federal income tax, tax-exempt organizations, pension plans, persons that hold our shares as part of a straddle, hedge or other integrated investment, persons subject to alternative minimum tax, certain United States expatriates, and foreign governments or agencies). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a partnership (including any entity or arrangement treated as a partnership for United States federal income tax purposes) holds our shares, the tax treatment of a person treated as a partner in the partnership for United States federal income tax purposes generally will depend on the status of the partner and the activities of the partnership. Partnerships (and other entities or arrangements so treated for United States federal income tax purposes) and their partners should consult their own tax advisors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This discussion addresses only non-U.S. holders and does not discuss any tax considerations other than United States federal income tax and certain United States federal estate tax considerations. Prospective investors are urged to consult their own tax advisors regarding the United States federal, state, and local, and foreign tax consequences of the purchase, ownership, and disposition of our shares, including the effect of any applicable income or estate tax treaty.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As discussed above, we have not paid and do not currently expect to pay dividends. If we do make a distribution of cash or property with respect to our shares, any such distribution generally will constitute a dividend for United States federal income tax purposes except as described below. Subject to the discussion below under &#8220;&#8212; FATCA Withholding&#8221; and &#8220;&#8212; Information Reporting and Backup Withholding,&#8221; and except as described below, any such dividends paid to a non-U.S. holder generally will be subject to withholding tax at a 30% rate or at a lower rate under an applicable income tax treaty between the United States and the non-U.S. holder&#8217;s country of residence. In order to receive a reduced treaty withholding tax rate, a non-U.S. holder must furnish to us or our paying agent a properly executed Internal Revenue Service </font>
          <br >
          <font style="letter-spacing:0.2pt;">Form&#160;W-8BEN&#160;or Form W-8BEN-E (or other applicable form) prior to payment of the dividend, certifying under penalties of perjury that the non-U.S. holder is entitled to a reduction in withholding under an applicable income tax treaty. A non-U.S. holder that holds our shares through a financial institution or other agent will be required to provide appropriate documentation to the financial institution or other agent, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">which then will be required to provide certification to us or our paying agent either directly or through other intermediaries. A non-U.S. holder that is eligible for a reduced rate of withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing a refund claim with the Internal Revenue Service. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a dividend is &#8220;effectively connected&#8221; with the conduct of a trade or business in the United States of the non-U.S. holder (and, if an applicable income tax treaty so provides, attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States), the non-U.S. holder is exempt from the withholding tax described above provided that the holder has furnished to us or our paying agent an Internal Revenue Service Form W-8ECI (or applicable successor form), certifying under penalties of perjury that the dividend is effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business in the United States (and, if an applicable income tax treaty so provides, attributable to a permanent establishment or fixed base maintained in the United States). &#8220;Effectively connected&#8221; dividends will generally be subject to United States federal income tax at the rates that also apply to U.S. persons. A corporate non-U.S. holder may, under certain circumstances, be subject to an additional branch profits tax at a 30% rate (or at a lower rate under an applicable income tax treaty) with respect to its &#8220;effectively connected&#8221; dividends. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent a distribution with respect to our shares exceeds our current or accumulated earnings and profits, as determined under United States federal income tax principles, the distribution will be treated, first, as a tax-free return of the non-U.S. holder&#8217;s investment, up to the holder&#8217;s adjusted tax basis in its shares, and, thereafter, as capital gain, which is subject to the tax treatment described below in &#8220;&#8212; Gain on Sale, Exchange or Other Taxable Disposition.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gain On Sale, Exchange or Other Taxable Disposition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussion below under &#8220;&#8212; FATCA Withholding&#8221; and &#8220;&#8212; Information Reporting and Backup Withholding,&#8221; a non-U.S. holder generally will not be subject to United States federal income tax or withholding tax on gain realized upon a sale, exchange or other taxable disposition of shares (including a redemption, but only if the redemption would be treated as a sale or exchange rather than a distribution for United States federal income tax purposes) unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the gain is &#8220;effectively connected&#8221; with the conduct of a trade or business of the non-U.S. holder in the United States (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment or fixed base maintained in the United States), in which case the non-U.S. holder generally will be subject to United States federal income tax on a net income basis with respect to such gain in the same manner as if such holder were a resident of the United States and, if the non-U.S. holder is a corporation for United States federal income tax purposes, may, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or at a lower rate under an applicable income tax treaty) on its &#8220;effectively connected&#8221; gains; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the non-U.S. holder is an individual who is present in the United States for 183 or more days in the taxable year of the disposition and meets certain other conditions, in which case the non-U.S. holder generally will be subject to United States federal income tax at a 30% rate (or at a lower rate under an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S.-source capital losses for the year; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we are or have been a &#8220;United States real property holding corporation&#8221; or USRPHC (as described below) at any time within the shorter of the five-year period preceding the disposition and the non-U.S. holder&#8217;s holding period for our shares (the &#8220;relevant period&#8221;) and the non-U.S. holder (i)&#160;disposes of our shares during a calendar year when our shares are no longer regularly traded on an established securities market or (ii)&#160;owned (directly, indirectly, and constructively) more than 5% of our shares at any time during the relevant period, in which case such a non-U.S. holder will be subject to tax on the gain on the disposition of shares generally as if the gain were effectively connected with the conduct of a trade or business in the United States, except that the &#8220;branch profits tax&#8221; will not apply. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe we currently are not, and we do not anticipate becoming, a USRPHC for United States federal income tax purposes. Generally, a corporation is a USRPHC only if the fair market value of its United States </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">real property interests (as defined in the Code) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FATCA Withholding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sections&#160;1471 through 1474 of the Code and the Treasury regulations issued thereunder (commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) impose a 30% withholding tax on dividends paid on our shares to, and (subject to the proposed Treasury Regulations discussed below) the gross proceeds derived from the sale or other disposition of our shares by, a foreign entity if the foreign entity is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;foreign financial institution&#8221; &#8203;(as defined under FATCA) that does not furnish proper documentation, typically on IRS Form W-8BEN-E, evidencing either (i)&#160;an exemption from FATCA withholding or (ii)&#160;its compliance (or deemed compliance) with specified due diligence, reporting, withholding and certification obligations under FATCA or (iii)&#160;residence in a jurisdiction that has entered into an intergovernmental agreement with the United States relating to FATCA and compliance with the diligence and reporting requirements of the intergovernmental agreement and local implementing rules; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;non-financial foreign entity&#8221; &#8203;(as defined under FATCA) that does not provide sufficient documentation, typically on IRS Form W-8BEN-E, evidencing either (i)&#160;an exemption from FATCA or (ii)&#160;adequate information regarding substantial United States beneficial owners of such entity (if any). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Withholding under FATCA generally applies to payments of dividends on our shares and to payments of gross proceeds from a sale or other disposition of our shares. Withholding agents may, however, rely on proposed U.S. Treasury Regulations that would no longer require FATCA withholding on payments of gross proceeds. A withholding agent such as a broker, and not Humacyte, Inc., will determine whether or not to implement gross proceeds FATCA withholding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a dividend payment is subject to withholding both under FATCA and the withholding tax rules discussed above under &#8220;&#8212; Dividends,&#8221; the withholding under FATCA may be credited against, and therefore reduce, such other withholding tax. Holders of shares should consult their own tax advisors regarding these requirements and whether they may be relevant to their ownership and disposition of the shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under certain circumstances, a non-U.S. holder will be eligible for refunds or credits of withholding taxes imposed under FATCA by filing a United States federal income tax return. Prospective investors should consult their tax advisors regarding the effect of FATCA on their ownership and disposition of our shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting and Backup Withholding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as described below, a non-U.S. holder generally will be exempt from backup withholding and information reporting requirements with respect to dividend payments and the payment of the proceeds from the sale of our shares effected at a United States office of a broker, as long as the payor or broker does not have actual knowledge or reason to know that the holder is a United States person and the holder has furnished to the payor or broker: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a valid Internal Revenue Service Form W-8BEN or Form W-8BEN-E on which the non-U.S. holder certifies, under penalties of perjury, that it is a non-United States person; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">other documentation upon which it may rely to treat the payments as made to a non-United States person in accordance with Treasury regulations, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or the non-U.S. holder otherwise establishes an exemption. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">However, we must report annually to the Internal Revenue Service and to non-U.S. holders the amount of dividends paid to them and the tax withheld with respect to such dividends, regardless of whether withholding was required. Copies of the information returns reporting such dividends and withholding may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:34pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">also be made available to the tax authorities in the country in which the respective non-U.S. holder resides under the provisions of an applicable income tax treaty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payment of the proceeds from the sale of our shares effected at a foreign office of a broker generally will not be subject to information reporting or backup withholding. However, a sale of our shares by a non-U.S. holder that is effected at a foreign office of a broker will be subject to information reporting and backup withholding if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the proceeds are transferred to an account maintained by the non-U.S. holder in the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment of proceeds or the confirmation of the sale is mailed to the non-U.S. holder at a United States address; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the sale has some other specified connection with the United States as provided in the Treasury regulations, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">unless the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or the non-U.S. holder otherwise establishes an exemption. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, a sale of shares will be subject to information reporting if it is effected at a foreign office of a broker that is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a United States person; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;controlled foreign corporation&#8221; for United States federal income tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a foreign person 50% or more of whose gross income is effectively connected with the conduct of a United States trade or business for a specified three-year period; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a foreign partnership, if at any time during its tax year (a)&#160;one or more of its partners are &#8220;U.S. persons&#8221;, as defined in U.S. Treasury regulations, who in the aggregate hold more than 50% of the income or capital interest in the partnership, or (b)&#160;such foreign partnership is engaged in the conduct of a trade or business in the United States, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">unless the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or an exemption is otherwise established. Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge that the holder is a United States person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. A non-U.S. holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the non-U.S. holder&#8217;s income tax liability by timely filing a refund claim with the Internal Revenue Service. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Federal Estate Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The estates of nonresident alien decedents generally are subject to United States federal estate tax on property with a United States situs. Because we are a United States corporation, our shares will be United States situs property and therefore will be included in the taxable estate of a nonresident alien decedent at the time of the decedent&#8217;s death, unless an applicable estate tax treaty between the United States and the decedent&#8217;s country of residence provides otherwise. An estate tax credit is available to reduce the net tax liability of a nonresident alien&#8217;s estate, but the estate tax credit for a nonresident alien is generally much smaller than the applicable credit for computing the estate tax of a United States resident. Nonresident aliens should consult their personal tax advisors regarding the United States federal estate tax consequences of owning our shares.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are registering the issuance by us of up to 5,177,500 shares of our common stock, which consists of (i)&#160;up to 177,500 shares of common stock that are issuable upon the exercise of Private Placement Warrants and (ii)&#160;up to 5,000,000 shares of common stock that are issuable upon the exercise of Public Warrants. We are also registering the resale by the selling stockholders of up to 90,006,840 shares of common stock, which consists of (i)&#160;up to 17,500,000 PIPE Shares issued in the PIPE Investment, (ii)&#160;up to 71,696,679 shares of common stock pursuant to the Investor Rights and Lock-up Agreement and (iii)&#160;up to 810,161 shares of common stock purchased by a selling stockholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are required to pay all fees and expenses incident to the registration of the securities to be offered and sold pursuant to this prospectus. The selling stockholders will bear all commissions and discounts, if any, attributable to their sale of shares of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will not receive any of the proceeds from the sale of common stock by the selling stockholders. The aggregate proceeds to the selling stockholders will be the purchase price of the common stock less any discounts and commissions borne by the selling stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The shares of common stock beneficially owned by the selling stockholders covered by this prospectus may be offered and sold from time to time by the selling stockholders. The term &#8220;selling stockholders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer. The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling stockholders may sell their shares of common stock by one or more of, or a combination of, the following methods: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an over-the-counter distribution in accordance with the rules of Nasdaq; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through trading plans entered into by a selling stockholder pursuant to Rule&#160;10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to or through underwriters, agents or broker-dealers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;at the market&#8221; offerings, as defined in Rule&#160;415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">privately negotiated transactions </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">options transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through a combination of any of the above methods of sale; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other method permitted pursuant to applicable law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, any securities that qualify for sale pursuant to Rule&#160;144 may be sold under Rule&#160;144 rather than pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the common stock or otherwise, the selling </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">stockholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of common stock in the course of hedging the positions they assume with selling stockholders. The selling stockholders may also sell shares of common stock short and redeliver the shares to close out such short positions. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling stockholders may also pledge shares of common stock to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A selling stockholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If an applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell shares of common stock covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by any selling stockholder or borrowed from any selling stockholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from any selling stockholder in settlement of those derivatives to close out any related open borrowings of stock. If treated as so under applicable securities laws, the third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any selling stockholder may otherwise loan or pledge shares of common stock to a financial institution or other third party that in turn may sell the shares short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In effecting sales, broker-dealers or agents engaged by the selling stockholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In offering the shares of common stock covered by this prospectus, the selling stockholders and any broker-dealers who execute sales for them may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by selling stockholders who are &#8220;underwriters,&#8221; and the compensation of any broker-dealer who executes sales for them, may be deemed to be underwriting discounts and commissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to comply with the securities laws of certain states, if applicable, the common stock must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the shares of common stock may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have advised the selling stockholders that the anti-manipulation rules of Regulation&#160;M under the Exchange Act may apply to sales of common stock in the market and to the activities of the selling and their affiliates. In addition, we will make copies of this prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the common stock against certain liabilities, including liabilities arising under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the time a particular offer of shares of common stock is made, if required, a prospectus supplement will be distributed that will set forth the number of shares being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the selling stockholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares of common stock offered by this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:260pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the securities offered by this prospectus will be passed upon by Covington &amp; Burling LLP. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements of Humacyte, Inc. as of December&#160;31, 2020 and 2019 and for the&#160;years then ended included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to Humacyte, Inc.&#8217;s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and our securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement, over the internet at the SEC&#8217;s website at www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the information reporting requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at www.humacyte.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Humacyte&#8217;s website and the information contained on, or that can be accessed through, such website are not deemed to be incorporated by reference in, and are not considered part of, this prospectus.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="TOC3">&#8203;</a><a name="ITCFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:243pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">HUMACYTE, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:137.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Audited Financial Statements as of and for the&#160;years ended December&#160;31, 2019 and 2020</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#RIRPA"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#RIRPA">F-2</a></font> <a href="#RIRPA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBESS"><font style="letter-spacing:0.2pt;">Balance Sheet December&#160;31, 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBESS">F-3</a></font> <a href="#tBESS"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tSOOC"><font style="letter-spacing:0.2pt;">Statement of Operations and Comprehensive Loss for the period from January&#160;1, 2020 to December&#160;31, 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOOC">F-4</a></font> <a href="#tSOOC"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tSCRC"><font style="letter-spacing:0.2pt;">Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit for the period from January&#160;1, 2020 to December&#160;31, 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSCRC">F-5</a></font> <a href="#tSCRC"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSOCF"><font style="letter-spacing:0.2pt;">Statement of Cash Flows for the period from January&#160;1, 2020 to December&#160;31, 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOCF">F-6</a></font> <a href="#tSOCF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNSFS"><font style="letter-spacing:0.2pt;">Notes to Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNSFS">F-7</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:179.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:424pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
                <br >
                <font style="letter-spacing:-0.16pt;">No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:424pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Unaudited condensed financial statements as of December&#160;31, 2020 and September&#160;30, 2021 and for the three and nine&#160;months ended September&#160;30, 2020 and 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fCCBS"><font style="letter-spacing:0.2pt;">Condensed Consolidated Balance Sheets as of December&#160;31, 2020 and September&#160;30, 2021 (unaudited) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCCBS">F-33</a></font> <a href="#fCCBS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fCCSO"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine&#160;months ended September&#160;30, 2020 and 2021 (unaudited) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCCSO">F-34</a></font> <a href="#fCCSO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fCCSO1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">Stockholders&#8217; Equity (Deficit) for the three and nine&#160;months ended September&#160;30, 2020 and 2021 </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">(unaudited) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCCSO1">F-35</a></font> <a href="#fCCSO1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#fCCSO2"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Cash Flows for the nine&#160;months ended September&#160;30, 2020 </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">and 2021 (unaudited) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCCSO2">F-36</a></font> <a href="#fCCSO2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fNCCF2"><font style="letter-spacing:0.2pt;">Notes to Condensed Consolidated Financial Statements (unaudited) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fNCCF2">F-37</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="RIRPA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Board of Directors and Stockholders of Humacyte, Inc. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying balance sheets of Humacyte, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, and the related statements of operations and comprehensive loss, of changes in redeemable convertible preferred stock and stockholders&#8217; deficit, and of cash flows for the&#160;years then ended, including the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for the&#160;years then ended in conformity with accounting principles generally accepted in the United States of America. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Accounting Principle</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As discussed in Note 2 to the financial statements, the Company changed the manner in which it accounts for leases in 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has generated no product revenue and has incurred net losses and negative cash flows from operations in each year since inception. This raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits of these financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ PricewaterhouseCoopers LLP</font> <br ><font style="letter-spacing:0.2pt;">Raleigh, North Carolina</font> <br ><font style="letter-spacing:0.2pt;">March&#160;22, 2021, except for the effects of the reverse recapitalization described in Note 2 to the financial statements, as to which the date is November&#160;19, 2021. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2013.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tBESS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Balance Sheets</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share and per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:589.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:8.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">93,713</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,929</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">1,407</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">94,954</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">41,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.75pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">25,552</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">23,492</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">47,288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">40,978</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">168,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">106,688</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:6.917pt 0pt 0.5pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,272</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,274</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">6,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">4,592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">PPP loan payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,451</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred payroll tax, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">10,842</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">11,233</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.75pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">PPP loan payable, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">822</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred payroll tax, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">24,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">23,090</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">36,490</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">36,016</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.75pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Commitments and contingencies (Note 12) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Redeemable convertible preferred stock (Series&#160;A, B, C and D) $0.001 par value, 69,613,565 shares authorized, 69,613,562 shares outstanding as of December&#160;31, 2019 and December&#160;31, 2020; liquidation preference of $435,579 as of December&#160;31, 2019 and December&#160;31, 2020. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; deficit </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, $0.0001 par value; 340,216,780 shares authorized as of December&#160;31, 2019 and December&#160;31, 2020; 5,627,157 and 5,822,396 shares issued and outstanding as of December&#160;31, 2019 and December&#160;31, 2020, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">32,783</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">37,778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(321,572<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(388,096<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(288,788<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(350,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">168,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">106,688</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:19.51pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:312.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Statements of Operations and Comprehensive Loss</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share and per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:246.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:17.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:341.17pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:11.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Grant Revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,187</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,491</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Research and development (includes related party expenses of $571 and $620 </font>
                <br >
                <font style="letter-spacing:0.2pt;">for the&#160;years ended December&#160;31, 2019 and 2020) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">75,603</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">54,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">16,275</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">12,013</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">91,878</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">66,091</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(85,691<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(64,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expenses), net </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,567</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">278</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,298<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,202<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other income (expenses), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">269</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,924<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss and comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(85,422<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(66,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:7.75pt 0pt 2.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:7.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:7.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(16.17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:7.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:7.75pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(11.54<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.583pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,283,628</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,765,688</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSCRC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:303pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:244pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:17.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:133.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Redeemable Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:11.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:133.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:133.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2018</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5,006,326</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">27,108</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(234,289<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(207,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:133.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">620,831</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,218</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,218</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:133.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,457</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,457</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:133.31pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cumulative effective </font>
                <br >
                <font style="letter-spacing:0.2pt;">adjustment from adoption of </font>
                <br >
                <font style="letter-spacing:0.2pt;">ASC 842 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,861<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,861<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:133.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(85,422<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(85,422<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:133.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5,627,157</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">32,783</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(321,572<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(288,788<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:133.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">195,239</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:133.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,694</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,694</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:133.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(66,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(66,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.917pt 0pt 1.583pt 0pt; width:133.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">5,822,396</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">37,778</td>
            <td style="padding:0pt;padding-left:1.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(388,096<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(350,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSOCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:4pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Statements of Cash Flows</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:569pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:358.26pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(85,422<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(66,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,689</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,291</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,694</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss on disposal of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">69</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">177</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-cash operating lease costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued interest on PPP loan obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">488</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(767<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,434</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(889<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">372</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,408<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating lease obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(82<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Deferred payroll taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(589<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(71,787<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(55,568<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Purchase of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(318<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from sale of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(268<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,218</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from PPP loan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Payment of finance lease principal </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by (used in) financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net decrease in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(79,986<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(53,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at the beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">173,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">93,713</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents at the end of the period</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">93,713</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">39,929</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of noncash activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease right-of-use assets obtained in exchange for lease obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tNSFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1. Organization and Description of Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Organization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte, Inc., or the Company, is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues to improve the lives of patients and transform the practice of medicine. The Company is leveraging its technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Going Concern</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since its inception in 2004, the Company has generated no product revenue and has incurred net losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through governmental and other grants. At December&#160;31, 2019 and December&#160;31, 2020, the Company had an accumulated deficit of $321.6&#160;million and $388.1&#160;million, respectively. The Company&#8217;s net losses were $85.4&#160;million and $66.5&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively. Substantially all of the Company&#8217;s net losses resulted from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company does not believe its existing cash and cash equivalents will be sufficient to fund its anticipated operating expenses, including clinical trial expenses, and capital expenditure requirements for at least twelve&#160;months following the date these financial statements were issued. Until such time, if ever, as the Company is able to successfully develop and commercialize one or more of its product candidates, it expects to fund its operations through the sale of equity, debt, borrowing under credit facilities or through potential collaborations with other companies, other strategic transactions or government contracts and grants. The Company&#8217;s future capital requirements will depend on many factors, and adequate capital may not be available to the Company when needed or on acceptable terms. If the Company is unable to raise capital, it could be forced to delay, reduce, suspend or cease its research and development programs or any future commercialization efforts, which would have a negative impact on the Company&#8217;s business, prospects, operating results and financial condition. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these financial statements are issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of COVID-19</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic, which began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on the Company&#8217;s business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company&#8217;s business and operations are uncertain. The COVID-19 pandemic may affect the Company&#8217;s ability to initiate and complete preclinical studies, delay its clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on its business and operations. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact the Company&#8217;s ability to raise additional funds to support its operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1. Organization and Description of Business&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company&#8217;s business and operations.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, the COVID-19 pandemic has not resulted in material financial impacts or impairment losses in the carrying values of the Company&#8217;s assets as a result of the pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise the estimates reflected in these financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related economic impact of the pandemic.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Presentation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has prepared the accompanying financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reverse Recapitalization</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021 (the &#8220;Closing Date&#8221;), Alpha Healthcare Acquisition Corp. (&#8220;AHAC&#8221;) consummated a merger pursuant to which Hunter Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of AHAC, merged with Humacyte, Inc., a Delaware Corporation (&#8220;Legacy Humacyte&#8221;), with Legacy Humacyte surviving the Merger as a wholly-owned subsidiary of AHAC (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Business Combination Agreement dated as of February&#160;17, 2021 by and among Legacy Humacyte, Merger Sub, and AHAC (the &#8220;Merger Agreement&#8221;), the &#8220;Reverse Recapitalization&#8221;). As a result of the Merger, AHAC was renamed Humacyte, Inc. (&#8220;New Humacyte&#8221;) and Legacy Humacyte was renamed Humacyte Global, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio of approximately 0.26260 established in the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Segments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues that can be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comprehensive loss</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; deficit that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for the&#160;years ended December&#160;31, 2019 and 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use, or ROU assets, accruals for research and development activities, fair value of common stock, useful lives of property and equipment, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash and Cash Equivalents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company considers all short-term, highly liquid investments purchased with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. Cash deposits are held with financial institutions with investment-grade ratings in the United States of America, or US. Cash deposits typically exceed federally insured limits. As of December&#160;31, 2019 and 2020, cash and cash equivalents consisted of cash on deposit with banks denominated in US dollars and investments in money market funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redeemable Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company analyzes all issued equity instruments to determine the appropriate accounting and classification. The Company evaluates its equity instruments under Accounting Standards Codification, or ASC 480, </font><font style="font-style:italic;letter-spacing:0.2pt;">Distinguishing liabilities from equity</font><font style="letter-spacing:0.2pt;">, to determine whether the instrument embodies an obligation of the Company and, if not, the appropriate classification within temporary or permanent equity. Equity instruments that are classified as temporary equity will have at least one of the following characteristics: redemption at a fixed or determinable price on a fixed or determinable date or dates, redemption at the option of the holder, or any condition of redemption or liquidation which is not solely within the control of the Company without regard to probability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company records equity instruments that are classified as temporary equity at fair value upon issuance, net of issuance costs. The Company accretes the carrying value of its redeemable convertible preferred stock to the redemption or liquidation amount once the Company has determined that it is probable that it will become redeemable or be liquidated. The accretion will be recorded as charges against additional paid-in capital until the additional paid-in capital balance is reduced to zero. At that time, additional accretion adjustments will be recorded as additions to accumulated deficit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company also analyzes instances where the equity instrument has a conversion feature pursuant to ASC 815, </font><font style="font-style:italic;letter-spacing:0.2pt;">Derivatives and hedging</font><font style="letter-spacing:0.2pt;">, to determine whether the embedded conversion feature should be bifurcated from the equity instrument and accounted for separately. As of December&#160;31, 2019 and 2020, the Company did not have any instruments that have been recognized as derivative liabilities with respect to its outstanding redeemable convertible preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s revenues generally consist of grant revenues, including revenues generated under government and other awarded grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2014, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update No. 2014-09, Revenues from Contracts with Customers (Topic 606), or ASC 606. The new guidance became effective January&#160;1, 2019 for private companies with early adoption allowed. The Company adopted ASC 606 on January&#160;1, 2019 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, there was no cumulative effect of applying the standard as of January&#160;1, 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, ASC 606 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Grant Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We generate revenue primarily from government and other awarded grants that reimburse us for certain allowable costs related to research and development efforts. The Company has determined that the grants are not within the scope of ASC 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are nonexchange transactions and has applied the contribution accounting model in Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition by analogy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes funding received from grants as revenue, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these grants are central to the Company&#8217;s ongoing operations. The Company recognizes revenue only after the qualifying expenses related to the grants have been incurred and it is reasonably assured that the expenses will be reimbursed and the revenue will be collectible. The related costs incurred are included in research and development expense in our statements of operations and comprehensive loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue from grants not within the scope of ASC 606 was $6.2&#160;million and $1.5&#160;million for the&#160;years ending December&#160;31, 2019 and 2020, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of Credit Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash balances exceeded insured balances by the Federal Depository Insurance Corporation as of December&#160;31, 2019 and 2020. Cash equivalents are invested in highly rated money market funds invested only in obligations of the US government and its agencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The majority of the Company&#8217;s revenue has been derived from government grants. The Company&#8217;s grants which represented 10% or more of the Company&#8217;s total revenue during the&#160;years ended December&#160;31, 2019 and 2020 or accounts receivable balance as of December&#160;31, 2019 and 2020 are as follows: </font>
        </div>
        <table style="width:416pt;height:89.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.78pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:243.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:243.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant B </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">67<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:243.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant C </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">34<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">67<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:243.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant D </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">18<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <table style="width:416pt;height:46pt;margin-left:20pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.78pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:243.78pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">95<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of the Company&#8217;s revenues were generated from grants from government and other entities located in the United States, for the&#160;years ended December&#160;31, 2019 and 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Risks and Uncertainties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase&#160;II/III clinical trial and V007 Phase&#160;III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates, the expected size of the target populations for the Company&#8217;s product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Company&#8217;s strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Company&#8217;s implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and commercial success of its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Company&#8217;s strategic partnership with Fresenius Medical Care Holdings, Inc., or Fresenius Medical Care, to sell, market and distribute its 6 mm HAV for certain specified indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company applies the two-class method to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities. The two-class method determines net loss per share for each class of common and redeemable convertible preferred stock according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and redeemable convertible preferred stock based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the redeemable convertible preferred stock does not have a contractual obligation to share in the Company&#8217;s losses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securities that could potentially dilute net loss per share in the future that were not included in the computation of diluted net loss per share are as follows:</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:160pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:341.17pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;A redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;B redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;C redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;D redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,220,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,813,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrant to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value of Financial Instruments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. ASC 820, </font><font style="font-style:italic;letter-spacing:0.2pt;">Fair Value Measurement and Disclosures</font><font style="letter-spacing:0.2pt;">, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1&#8201;&#8212;&#8201;Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2&#8201;&#8212;&#8201;Inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s cash equivalents are classified within Level&#160;1 of the fair value hierarchy because they are valued using quoted market prices. The carrying values of other receivables, accounts payable and accrued expenses as of December&#160;31, 2019 and 2020 approximated their fair values due to the short-term nature of these items. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment, Net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net are recorded at cost less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet accounts and any resulting gain or loss </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is included in the results of operations for the respective period. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives for significant asset categories are as follows:</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:107.5pt;margin-left:20pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:145.26pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimated Useful</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Lives (Years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Scientific equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5&#8201;&#8211;&#8201;7 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5&#8201;&#8211;&#8201;7 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Lesser of useful life or life of lease </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:258.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Construction in progress </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.26pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">N/A</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impairment of Long-Lived Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company reviews the carrying value of property and equipment for indicators of possible impairment whenever events and circumstances indicate that the carrying value of an asset or asset group may not be recoverable from the estimated future net undiscounted cash flows expected to result from its use and eventual disposition. In cases where estimated future net undiscounted cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the asset or asset group. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment, there was no impairment at December&#160;31, 2019 and 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Income taxes are computed using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements. In estimating future tax consequences, the Company considers all expected future events other than enactment of changes in tax laws or rates. A valuation allowance is recorded, if necessary, to reduce net deferred tax assets to their realizable values if management does not believe it is more likely than not that the net deferred tax assets will be realized. As of December&#160;31, 2019 and 2020, the Company has recorded a full valuation allowance against its deferred tax assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit can be recognized. Assessing an uncertain tax position begins with the initial determination of the sustainability of the position and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed. Additionally, the Company must accrue interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has analyzed its filing positions in all significant Federal and state jurisdictions where it is required to file income tax returns, as well as open tax&#160;years in these jurisdictions. As of December&#160;31, 2019 and 2020, the Company has determined that no uncertain tax positions would have a material impact on the financials statements of the Company. The Company is no longer subject to Federal, state, and local tax examinations by tax authorities for&#160;years before 2017 although carry-forward attributes that were generated prior to 2017 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and 2020, the Company had not recorded any amounts for unrecognized tax benefits. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December&#160;31, 2019 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions, and no amounts had been recognized in the Company&#8217;s statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company seeks to protect its intellectual property by filing patent applications in the United States and abroad related to novel technologies and product candidates that it views as important to its business. The patent positions of biotechnology companies generally, including the Company&#8217;s patent positions, is highly uncertain and involves complex legal and factual questions for which legal principles remain unresolved. Patent costs have been expensed as incurred as general and administrative expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company expenses research and development costs as operating expenses as incurred. Research and development expenses consist primarily of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">salaries and related overhead expenses for personnel in research and development functions, including stock-based compensation and benefits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fees paid to consultants and CROs, including in connection with clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work and statistical compilation and analysis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allocation of facility lease and maintenance costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">depreciation of leasehold improvements, laboratory equipment and computers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to purchasing raw materials for and producing product candidates for clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to compliance with regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to the manufacturing scale-out initiative; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">license fees related to in-licensed technologies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accrued Research and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into various agreements with CROs and a CMO, which conduct preclinical studies and clinical trials and contract manufacturing activities. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company terminated its agreement with its CMO on March&#160;6, 2020 but will continue to rely on its CMO to store and ship HAV inventory until such time as its HAV inventory is fully depleted. As of December&#160;31, 2020, the inventory value held at the CMO is immaterial. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for stock-based compensation for employees and non-employees measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">using the Black-Scholes option pricing model and recognizes the expense over the requisite service period using the straight-line method. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying common stock on the date of grant. Forfeitures are accounted for as they occur.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective January&#160;1, 2019, the Company accounts for its leases under ASC 842, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases</font><font style="letter-spacing:0.2pt;">. The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company&#8217;s operating lease assets are included in &#8220;operating lease right-of-use assets, net&#8221;, and the current and non-current portions of the operating lease liabilities are included in &#8220;operating lease obligation, current portion&#8221;, and &#8220;operating lease obligation, net of current portion&#8221;, respectively, on the balance sheets. The Company&#8217;s finance lease assets are included in &#8220;finance lease right-of-use assets, net&#8221;, and the current and non-current portions of the finance lease liabilities are included in &#8220;finance lease obligation, current portion&#8221;, and &#8220;finance lease obligation, net of current portion&#8221;, respectively, on the balance sheets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease right-of-use assets and lease obligations are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Operating lease right-of-use assets are adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. As the implicit rate for the operating leases were not determinable, the Company used an incremental borrowing rate based on the information available at the respective lease commencement dates in determining the present value of future payments. The incremental borrowing rate represents the interest rate the Company would expect to incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably certain the Company will exercise any option to extend the contract. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Lease expenses for minimum lease payments for operating leases are recognized on a straight-line basis over the lease term. Amortization expense of the right-of-use asset for finance leases is recognized on a straight-line basis over the lease term and interest expense for finance leases is recognized based on the incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In calculating the right-of-use assets and lease liabilities, the Company has elected to combine lease and non-lease components for all asset classes. The Company excludes short-term leases, if any, having initial terms of 12&#160;months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the adoption of ASC 842 on January&#160;1, 2019 the Company was deemed to be the accounting owner of leased space during the construction of its headquarters in a build-to-suit arrangement. Upon substantial completion of construction in June&#160;2018, the Company assessed the facility for sale-leaseback criteria qualification. The Company determined that the transaction did not meet the requirements of a sale-leaseback due to the Company&#8217;s continuing involvement in the leased facility. As such, the facility was </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">accounted for as an asset financing, with the building asset and related facility financing obligation remaining on the Company&#8217;s balance sheet. The Company availed itself of the practical expedients provided under the ASU and its subsequent amendments regarding identification of leases, lease classification, indirect costs, and the combination of lease and non-lease components. Upon adoption of ASC 842, the Company removed the building assets and facility financing obligation, under the failed sale leaseback, for its headquarters lease from its financial statements, with a corresponding adjustment (addition) to accumulated deficit of $1.9&#160;million, and recorded a finance lease liability and corresponding right-of-use asset, each for $27.6&#160;million in connection with the headquarters lease. In addition, the adoption of this guidance resulted in the recognition of operating right-of-use assets and operating lease liabilities of $0.9&#160;million as of January&#160;1, 2019, which included the lease of the underlying land associated with its headquarters.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The cumulative effect of initially applying the new lease guidance on January&#160;1, 2019 is as follows: </font>
        </div>
        <table style="width:456pt;height:235pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:299.93pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">January&#160;1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:31.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Beginning</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Balance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cumulative</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Effect</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Beginning</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Balance,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">As Adjusted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Building asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">25,091</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,091<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,612</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">27,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">923</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">923</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities and stockholders&#8217; deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,048</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Facility financing obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">276</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(276<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,292</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Facility financing obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22,955</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(22,955<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">26,319</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">26,319</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">870</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">870</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(234,289<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,861<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.975000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(236,150<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.7pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Adopted Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8201;&#8212;&#8201;Changes to the Disclosure Requirements for Fair Value Measurement, which makes a number of changes to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level&#160;1, Level&#160;2 and Level&#160;3 fair value measurements. This guidance is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2019. Early adoption is permitted upon issuance of the update. The Company adopted ASU 2018-13 as of January&#160;1, 2020. The adoption of this ASU did not have a material impact on its financial statements and related disclosures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, &#8220;Debt-Debt with Conversion and Other Options (Subtopic 470&#8201;&#8211;&#8201;20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815&#8201;&#8211;&#8201;40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">current U.S. GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. This guidance is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2021, with early adoption permitted. The Company plans to adopt the standard effective January&#160;1, 2021 and is currently evaluating the impact of this standard on its financial statements and related disclosures.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3. Property and Equipment, Net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consist of the following: </font>
        </div>
        <table style="width:416pt;height:143pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:323.26pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scientific equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">27,822</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,412</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">218</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">340</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">26,337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">26,355</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">55,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55,239</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(8,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,261<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:323.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">47,288</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,978</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.09pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation expense totaled $4.7&#160;million and $6.3&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively. All long-lived assets are maintained in the United States.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4. Accrued Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses consisted of the following: </font>
        </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:336.59pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued external research, development and manufacturing costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,872</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,615</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued employee compensation and benefits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,009</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued professional fees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">968</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5. Debt</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;30, 2020, the Company received loan proceeds in the amount of approximately $3.3&#160;million under the Paycheck Protection Program (&#8220;PPP&#8221;). The PPP, established as part of the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. All or portion of this loan and any accrued interest may be forgiven after a twenty four week period as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of the loan forgiven will be reduced if the borrower terminates employees or reduces salaries during the twenty four week period. The unforgiven portion of the PPP loan is payable over two&#160;years at an interest rate of 1%, with a deferral of payments for the first ten&#160;months. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5. Debt&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2020, the Company applied for forgiveness of the outstanding amount under its PPP loan. The Company used the proceeds for purposes it believes were consistent with the requirements of the PPP. The Company determined that loan forgiveness would become probable upon approval by the Small Business Administration of the Company&#8217;s forgiveness application. If and when the loan forgiveness becomes probable, the Company will recognize income for debt extinguishment on our statements of operations and comprehensive loss.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6. Leases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s finance lease relates to its headquarters, which was substantially completed in June&#160;2018 and leased through May&#160;2033, and its operating lease relates to the land lease associated with its headquarters. Historically the Company&#8217;s operating leases included a lease for laboratory and office space in Ohio. In March&#160;2020, the Company terminated this lease, effective September&#160;30, 2020, and paid termination fees of less than $0.1&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2019 and 2020, the Company had finance lease liabilities of $26.3&#160;million and $24.8&#160;million, respectively, and right-of-use assets of $25.6&#160;million and $23.5&#160;million, respectively, and operating lease liabilities of $0.9&#160;million and $0.8&#160;million, respectively, and right-of-use assets of $0.9&#160;million and $0.8&#160;million, respectively, all of which were included in the balance sheet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have been included in the calculation of the lease liabilities and right of use assets as the Company is reasonably certain to exercise the options due to the specialized nature of the leased building. Variable expenses generally represent the Company&#8217;s share of the landlord&#8217;s operating expenses. The Company does not act as a lessor in any lease arrangements. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following summarizes quantitative information about the Company&#8217;s leases: </font>
        </div>
        <table style="width:416pt;height:122pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:336.59pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Amortization of right-of-use assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Interest on lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,298</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,180</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total finance lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">137</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,392</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:100pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:278.27pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Finance</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Finance</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:278.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash flows from leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,298<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(137<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(182<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:278.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Financing cash flows from leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:278.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average remaining lease term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.38</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5.52</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.24</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:278.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average discount rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6. Leases&#8201;(continued)</font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the maturities of the Company&#8217;s lease liabilities were as follows: </font>
        </div>
        <table style="width:416pt;height:153.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Finance</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Year Ended December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,773</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Year Ended December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Year Ended December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,965</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Year Ended December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">106</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Year Ended December&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">106</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,937</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">678</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">36,775</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,205</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: present value discount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,956<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:322.14pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">769</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Redeemable Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Redeemable Convertible Preferred Stock and Preferred Stock Terms </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as &#8220;redeemable convertible preferred stock.&#8221; The series A redeemable convertible preferred stock, series B redeemable convertible preferred stock and series C redeemable convertible preferred stock are individually and collectively referred to as &#8220;junior&#8221; series of preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and December&#160;31, 2020, redeemable convertible preferred stock consisted of the following (in thousands, except share amounts): </font>
        </div>
        <table style="width:456pt;height:168pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:181.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Redeemable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Redeemable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issued and</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Liquidation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Issuance</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:181.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;A redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,079</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,079</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4.0212</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:181.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">127,358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">136,500</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5.6550</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:181.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;C redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,286</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,283</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,704</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">75,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6.6717</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:181.45pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;D redeemable convertible preferred </font>
                <br >
                <font style="letter-spacing:0.2pt;">stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">148,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">150,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">9.4859</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:181.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">69,613,565</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:3.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">435,579</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the series D redeemable convertible preferred stock financing, the Company granted Fresenius Medical Care the right to purchase up to an aggregate of $30.0&#160;million of its common stock in a private placement effected concurrently with its initial public offering at a price per share equal to the initial public offering price. See Note 13: Related Party Transactions for further discussion of the Company&#8217;s relationship with Fresenius Medical Care. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Redeemable Convertible Preferred Stock&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Election of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of the series A redeemable convertible preferred stock and the series B redeemable convertible preferred stock may designate one individual and two individuals, respectively, to the Board of Directors. The holders of the series C redeemable convertible preferred stock may designate one individual to the Board of Directors and Fresenius Medical Care may designate one representative to attend, in a non-voting observer capacity, all meetings of the Company&#8217;s Board of Directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion to Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each share of redeemable convertible preferred stock is convertible, at the option of the holder thereof, into that number of the fully paid and nonassessable shares of common stock determined by dividing the original issue price for the relevant shares by the conversion price. Each share of redeemable convertible preferred stock will automatically be converted into that number of fully-paid, nonassessable shares of common stock at the then effective conversion rate for such shares (i)&#160;immediately prior to the closing of a firm commitment underwritten public offering on the New York Stock Exchange or a Nasdaq market pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, if the offering price is not less than $2.7401 per share (as adjusted for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event) and the aggregate gross proceeds to the Company are not less than $100.0&#160;million (before deduction of commissions and expenses), (ii)&#160;with respect to the series C redeemable convertible preferred stock, series B redeemable convertible preferred stock and series A redeemable convertible preferred stock, upon the receipt by the Company of a written request for such conversion from the holders of at least 60% of such series of redeemable convertible preferred stock then outstanding and at least 60% of the then outstanding shares of series C redeemable convertible preferred stock or (iii)&#160;with respect to the series D redeemable convertible preferred stock, upon the receipt by the Company of a written request for such conversion from the holders of a majority of the then outstanding shares of series D redeemable convertible preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following are the conversion prices for each series of the redeemable convertible preferred stock as of December&#160;31, 2020: </font>
        </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:367.26pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Conversion</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:367.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4.0212</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:367.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5.6550</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:367.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6.6717</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:367.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9.4859</td>
            <td style="padding:0pt;padding-left:2.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These conversion prices are subject to adjustment from time to time including for certain share issuances made without consideration or for consideration less than the then applicable conversion price of a series of redeemable convertible preferred stock, dividends, stock splits, and combinations. As of December&#160;31, 2020, each series of redeemable convertible preferred stock is convertible on a one-for-one basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The series A, series B, series C and series D redeemable convertible preferred stock includes an anti-dilution feature that adjusts the conversion price, in certain scenarios, if the Company sells shares at a price below the stated conversion price. The anti-dilution provision is considered a contingent beneficial conversion feature. Due to the inability of the Company to determine the price of the shares sold, the Company is unable to determine the number of shares that the holder would receive if the contingency occurs. Therefore, the beneficial conversion feature is not recognized until the contingent event occurs. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Redeemable Convertible Preferred Stock&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Any dividends on the redeemable convertible preferred stock are not cumulative. The holders of the redeemable convertible preferred stock are entitled to receive dividends pro&#160;rata with the holders of common stock on an as-converted basis, when and if declared and paid by the Board of Directors, out of any assets at the time legally available. Any declared and unpaid dividends on the redeemable convertible preferred stock are payable upon certain voluntary or involuntary acquisition or sale transactions or the liquidation, dissolution or winding up of the Company as described below under &#8220;Liquidation,&#8221; and no dividends may be made with respect to the common stock unless all dividends declared on the redeemable convertible preferred stock have been paid or set aside for payment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of certain voluntary or involuntary acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company, each, a Reorganization, in which the holders of the series D redeemable convertible preferred stock receive less than $9.4859 per share plus any declared but unpaid dividends, referred to as the Series&#160;D Liquidation Preference, or such lesser amount approved in writing by the holders of a majority of the then outstanding series D redeemable convertible preferred stock, the series D stockholders will receive the series D liquidation preference before the holders of the series C, series B, series A redeemable convertible preferred stock or common stockholders would receive any proceeds relating to such Reorganization, and the entire assets of the Company available for distribution would be distributed pro&#160;rata among holders of the series D redeemable convertible preferred stock. In the event that, after the payment to the holders of the series D redeemable convertible preferred stock, the holders of the series C redeemable convertible preferred stock would receive less than $6.6717 per share plus any declared but unpaid dividends or such lesser amount approved by the holders of at least 80% of the then outstanding series C redeemable convertible preferred stock, the entire remaining assets of the Company available for distribution would be distributed pro&#160;rata among holders of the series C redeemable convertible preferred stock. In the event that, after the payment to the holders of the series D redeemable convertible preferred stock and series&#160;C redeemable convertible preferred stock, the holders of the series B redeemable convertible preferred stock would receive less than $5.6550 per share plus any declared but unpaid dividends or such lesser amount approved by the holders of a majority of the then outstanding series B redeemable convertible preferred stock, the entire remaining assets of the Company available for distribution would be distributed pro&#160;rata among holders of the series B redeemable convertible preferred stock. However, in the event of any Reorganization, if the holders of the series D redeemable convertible preferred stock, series C redeemable convertible preferred stock or series B redeemable convertible preferred stock would receive less than 1.25 times their respective liquidation preference per share, the holders of each such series will be entitled to receive, in preference to any distribution of assets to the holders of any junior series, an amount per share equal to 1.25 times such liquidation preference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that, after the payment to the holders of the series D redeemable convertible preferred stock, series C redeemable convertible preferred stock and series B redeemable convertible preferred stock described above, the holders of the series A redeemable convertible preferred stock would receive less than $4.0212 per share plus any declared but unpaid dividends or such lesser amount approved by the holders of a majority of the then outstanding series A redeemable convertible preferred stock, the entire remaining assets of the Company available for distribution would be distributed pro&#160;rata among holders of the series A redeemable convertible preferred stock. After payment to the holders of preferred stock, the remaining assets of the Company available for distribution would be distributed pro&#160;rata among the holders of preferred stock and common stock with the preferred stock being treated as if they had been converted to common stock at the then applicable conversion rate. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Redeemable Convertible Preferred Stock&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Except as provided in the Company&#8217;s certificate of incorporation and as required by law, the holders of the redeemable convertible preferred stock vote with the holders of common stock on an as-converted basis. Preferred stockholders will generally vote together with the holders of common stock as a single class but also have class vote approval rights as provided by law and others as specified in the Company&#8217;s certificate of incorporation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redemption and Balance Sheet Classification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with the Company&#8217;s accounting policy, the series A, series B, series C and series D redeemable convertible preferred stock was classified as temporary equity due to the fact that liquidation is not solely within the control of the Company. As of December&#160;31, 2020, liquidation of the series A, series B, series C and series D redeemable convertible preferred stock was not probable because the change in control events (acquisition, sale or asset transfer) that would lead to liquidation are contingent upon events that have not yet occurred and are not considered probable at this time. The Company has not adjusted the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock is not probable of occurring. Subsequent adjustments of the carrying values to the liquidation preference will be made only when it becomes probable that such a deemed liquidation event will occur.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8. Stockholders&#8217; Deficit</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and 2020, the Company&#8217;s certificate of incorporation, as amended, authorized the Company to issue 340,216,780 shares of common stock, respectively, at a par value of $0.0001 per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority (assuming the conversion of all redeemable convertible preferred stock into shares of the Company&#8217;s common stock) of the capital stock of the Company entitled to vote and without a separate class vote of the common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of common stock are entitled to receive dividends from time to time as may be declared by the Board of Directors. No cash dividend may be declared or paid to common stockholders until paid on each series of outstanding redeemable convertible preferred stock in accordance with its terms. Through December&#160;31, 2020, no dividends have been declared. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of common stock are entitled to one vote for each share held with respect to all matters voted on by the common stockholders of the Company. Preferred stockholders generally vote together with the holders of common stock as a single class but also have class vote approval rights as provided by law and others as specified in the Company&#8217;s certificate of incorporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of a Reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of common stock are entitled, together with holders of redeemable convertible preferred stock, to share ratably in all remaining assets of the Company. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8. Stockholders&#8217; Deficit&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2019 and 2020, the Company had reserved common stock for future issuances as follows: </font>
        </div>
        <table style="width:456pt;height:142.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;A redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;B redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;C redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,286</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,286</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;D redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise of options under stock plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,220,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,813,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Issuance of options under stock plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,736,954</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,948,598</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrant to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">77,603,716</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">77,408,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with a long-term debt agreement entered into on March&#160;15, 2006 and paid in full during 2011, the Company issued a warrant that gave the holder the right to purchase 32,961 shares of the Company&#8217;s common stock at an exercise price of $1.14 per share, which was outstanding as of December&#160;31, 2019 and 2020. The warrant is exercisable and expires on March&#160;15, 2021. There was no activity for the warrant during the&#160;years ended December&#160;31, 2019 and 2020.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has adopted the 2015 Omnibus Incentive Plan, as amended, or the 2015 Plan, which allows for the grant of nonstatutory stock options, or NSOs, and incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock&#160;units and unrestricted stock awards to employees, officers, directors, and consultants in the service of the Company. The Company believes that such awards aid in aligning the interests of these persons with those of its stockholders. The Board of Directors determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Company&#8217;s common stock at the date of grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has granted options that include either a service-based or performance-based vesting condition and a 10-year contractual term. The service-based vesting condition is generally satisfied over 36&#160;months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Option awards under the 2015 Plan generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantee&#8217;s employment during the period that commences 30&#160;days prior to the effective date of a corporate transaction and that ends 12&#160;months following the effective date of such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:1.01999999999998pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Stock-based Compensation&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">transaction. Additionally, the Company&#8217;s board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a corporate transaction.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company used the following assumptions on the date of grant to estimate the fair value of the stock options in the Black-Scholes option-pricing model as follows: </font>
        </div>
        <table style="width:416pt;height:91pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:267.43pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:267.43pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">Estimated dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:267.43pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">Expected share price volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">70.1%&#8201;&#8211;&#8201;87.7%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">89.4%&#8201;&#8211;&#8201;91.6%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:267.43pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">1.76%&#8201;&#8211;&#8201;2.46%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0.34%&#8201;&#8211;&#8201;0.75%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:267.43pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">Expected term of options (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6.00</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6.00</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair Value of Common Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As the Company&#8217;s common stock has not historically been publicly traded, the fair value of the shares of its common stock underlying the options has historically been determined by the Company&#8217;s board of directors with input from management, after considering independent third-party valuation reports. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected volatility was based on the historical share volatility of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company does not have any trading history to use the volatility of its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-Free Interest Rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free interest rate was based on the yields of US Treasury zero-coupon securities with maturities similar in duration to the expected term of the options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Dividend Yield.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company has not paid dividends on its common stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2020, there were 2,948,598 options remaining available for grant under the 2015 Plan. The Company has sufficient authorized and unissued shares to make all issuances currently contemplated under the 2015 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables show a summary of stock-based compensation expense included in the statements of operations and comprehensive loss for the&#160;years ended December&#160;31, 2019 and 2020, and remaining unrecognized cost as of December&#160;31, 2019 and 2020: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Stock-based Compensation&#8201;(continued)</font>
        </div>
        <table style="width:416pt;height:76.5pt;margin-left:20pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:336.59pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,135</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,543</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,694</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:52pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:376.59pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unrecognized share-based compensation cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,919</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected weighted average period compensation costs to be recognized (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A summary of option activity under the 2015 Plan during the&#160;years ended December&#160;31, 2019 and 2020 is presented below: </font>
        </div>
        <table style="width:456pt;height:199.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Term</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options outstanding at December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,638,773</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.69</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">21,354</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">621,031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.49</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(620,831<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.97</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(418,737<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">7.62</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options outstanding at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,220,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.22</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.5</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,044</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">480,856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.79</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(195,239<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.55</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(692,591<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">3.76</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:248.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,813,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">6.04</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">20,422</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and exercisable, December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,392,302</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.99</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.9</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,925</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:248.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest, December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,813,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.04</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,422</td>
            <td style="padding:0pt;padding-left:6.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The total intrinsic value of options exercised during the&#160;years ended December&#160;31, 2019 and 2020 was $4.0&#160;million and $1.4&#160;million, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The weighted-average grant-date fair value per share of options granted during the&#160;years ended December&#160;31, 2019 and 2020 was $5.84 and $7.26, respectively.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not record any income tax expense or benefit during the&#160;years ended December&#160;31, 2019 and 2020. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#8217;s ability to realize these assets. All losses before income taxes arose in the US. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities, including valuation allowances, are as follows: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Income Taxes&#8201;(continued)</font>
        </div>
        <table style="width:416pt;height:264.5pt;margin-left:20pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:314.93pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">50,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">53,515</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Capitalized research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">32,337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,519</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Right of use lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">207</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">177</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">71</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">82,882</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">103,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(82,193<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(101,757<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total net deferred tax asset </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">689</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Basis difference in fixed assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(482<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,728<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Right of use lease assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(207<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(177<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:314.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1,905<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:314.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total net deferred tax asset/(liability) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient future taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes the Company&#8217;s historical operating losses, lack of taxable income and the accumulated deficit, the Company provided a full valuation allowance against the deferred tax assets resulting from the tax loss and credits carried forward as of December&#160;31, 2019 and December&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The reasons for the difference between the actual income tax benefit for the&#160;years ended December&#160;31, 2019 and 2020, and the amount computed by applying the statutory Federal income tax rate to losses before income taxes are as follows: </font>
        </div>
        <table style="width:456pt;height:146pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:8.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:287.85pt;" rowspan="3">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:69.08pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:69.08pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Rate </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Rate </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Income tax benefit at statutory rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,939<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,970<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State income taxes, net of federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">2.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">2.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,821<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">2.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,625<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">3.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other nondeductible expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred rate changes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.5<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,736<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">2.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:287.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">20,980</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(24.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">19,563</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(29.4<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:287.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 the Company had approximately $232.7&#160;million and $232.6&#160;million of Federal and state net operating losses, respectively. Of this amount, $71.5&#160;million of Federal net operating </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Income Taxes&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">losses are carried over indefinitely, while the remaining amount begins to expire in 2025. The Company&#8217;s net operating loss carryforwards are subject to the application of the 80% limitation on taxable income beginning in 2021. Some of these state net operating losses included in these amounts follow the Federal Tax Cuts and Jobs Act and are carried over indefinitely, and others have various expiration dates.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and December&#160;31, 2020 the Company had Federal and state research tax credit carryforwards of $10.7&#160;million and $15.1&#160;million, respectively. These credit carryforwards begin to expire in 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net operating loss carryforwards and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or IRS, and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders or groups over a three-year period in excess of 50% as defined under Sections&#160;382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not determined whether there have been any cumulative ownership changes or the impact on the utilization of the loss carryforwards if such changes have occurred. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company applies the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. Additionally, the guidance also prescribes the treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;27, 2020, the CARES Act was passed by the U.S. Congress and signed into United States law. The CARES Act, among other things, includes certain provisions for individuals and corporations (including a suspension on the application of the 80% limitation described above for taxable&#160;years beginning prior to January&#160;1, 2021); however, these benefits did not materially impact the Company&#8217;s income tax provision in the periods presented.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11. Retirement Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains two defined contribution employee retirement plans, or 401(k) plans, for all employees upon their date of hire. The 401(k) plans are intended to qualify as tax-qualified plans under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended. The plans permit employees to contribute, on a pre-tax basis, a portion of their salary up to the Federally mandated limits. The Company matches an employee&#8217;s contribution up to 4% of the employee&#8217;s compensation. Contributions to the plans by the Company totaled $0.6&#160;million for the year ended December&#160;31, 2019, and $0.6&#160;million for the year ended December&#160;31, 2020.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent License Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Duke University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2006, the Company entered into a license agreement with Duke University, or Duke, which was subsequently amended in 2011, 2014, 2015, 2018 and 2019. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue will expire in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingencies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Company&#8217;s entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Company&#8217;s common stock. Under the license agreement, the Company also agreed to pay Duke: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low single-digit&#160;percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit&#160;percentage of any sublicensing revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an additional amount in license fees, as certain milestones are met. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The license agreement remains effective until the last of the patent rights expires or four&#160;years after our first commercial sale, unless earlier terminated. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three&#160;months&#8217; prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2014, the Company entered into a license agreement with Yale University, or Yale, that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1&#8201;&#8211;&#8201;12mm in diameter), except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (BVP). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingencies&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Company&#8217;s rights without Yale&#8217;s prior written consent, but such sublicense is subject to certain conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">milestone payments upon achievement of certain regulatory and commercial milestones; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low single-digit&#160;percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low double-digit&#160;percentage of sublicensing income. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i)&#160;provide written diligence reports, (ii)&#160;provide commercially reasonable diligence plans, (iii)&#160;implement the plans in accordance with the obligations under the agreements, or (iv)&#160;reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Company&#8217;s non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Company&#8217;s products or insolvency. The Company may terminate the license agreements (i)&#160;on 90&#160;days&#8217; prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii)&#160;on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Company&#8217;s rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company&#8217;s business, financial condition, results of operations, or cash flows. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingencies&#8201;(continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#8217;s or officer&#8217;s service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification arrangements in excess of applicable insurance coverage is immaterial.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fresenius Medical Care distribution agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to Fresenius Medical Care&#8217;s purchase of series D redeemable convertible preferred stock, the Company entered into a distribution agreement with Fresenius Medical Care in June&#160;2018 which, as amended as of February&#160;16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and EU and commercialize outside of the United States the Company&#8217;s 6mm&#160;x&#160;42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Company&#8217;s retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Related Party Transactions&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a&#160;percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a&#160;percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Company&#8217;s distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed&#160;percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement will generally continue on a country-by-country basis until the later of (a)&#160;the tenth anniversary of the launch date of the distribution product in the relevant country or (b)&#160;the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i)&#160;for certain withdrawals of regulatory approval or (ii)&#160;for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Care&#8217;s rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12&#160;months&#8217; written notice to the Company, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Arrangements with Dr.&#160;Niklason and Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, the Company entered into a Memorandum of Understanding Regarding Scientific and Operational Leadership, or MOU, with Dr.&#160;Niklason in connection with her performance of various consulting activities for the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The MOU provided for the Company to make a payment each year through 2023 to the academic institution with which Dr.&#160;Niklason was then affiliated, up to an aggregate amount of $2.5&#160;million for 2018 through 2023, and to pay Dr.&#160;Niklason reasonable consulting fees in consideration of the services she performed for the Company. For the&#160;years ended December&#160;31, 2019 and 2020, the company made payments under the MOU of $0.4&#160;million and $0.5&#160;million, respectively, to, or on behalf of, Yale University, where Dr.&#160;Niklason, currently the Company&#8217;s President, CEO and a member of the Company&#8217;s board of directors, serves as a Professor Adjunct, Division Chief and Vice Chair, Research in Anesthesia. The MOU was terminated effective November&#160;9, 2020. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Financial Statements</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Related Party Transactions&#8201;(continued)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the&#160;years ended December&#160;31, 2019 and 2020: </font>
        </div>
        <table style="width:416pt;height:81.5pt;margin-left:20pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:17.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:352pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:11.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:352pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Expenses under MOU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">422</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:352pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:352pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">39</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:352pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">571</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">620</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2019 and December&#160;31, 2020, the Company was a party to license agreements with Yale University, as described in Note 12&#8201;&#8212;&#8201;Commitments and Contingencies above.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluated the effect subsequent events would have on the financial statements through March&#160;22, 2021, which is the date the financial statements were issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of her employment agreement, the Company awarded Dr.&#160;Niklason an additional stock option award in January&#160;2021 entitling her to purchase 1,312,984 shares of the Company&#8217;s common stock at an exercise price of $10.28 per share, none of which have vested as of the issuance date of these financial statements. This stock option vests in equal annual installments on each of the first three anniversaries of November&#160;9, 2020, subject to acceleration upon a corporate transaction (as defined in the 2015 Plan). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of his consulting agreement, the Company awarded Mr.&#160;Sander an additional stock option award in January&#160;2021 entitling him to purchase 183,817 shares of the Company&#8217;s common stock at an exercise price of $10.28 per share, none of which have vested as of the issuance date of these financial statements. This stock option vests in equal annual installments on each of the first three anniversaries of November&#160;9, 2020, subject to acceleration upon a corporate transaction (as defined in the 2015 Plan). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;17, 2021, the Company entered into a business combination agreement with AHAC and Merger Sub, a wholly owned subsidiary of AHAC, pursuant to which Merger Sub will merge with the Company, with the Company surviving the Merger as a wholly owned subsidiary of AHAC. As a result of the Merger, AHAC will immediately be renamed New Humacyte. Immediately prior to the consummation of the Merger, the Company&#8217;s outstanding preferred stock will automatically convert into shares of the Company&#8217;s common stock at the then-effective conversion ratio. In addition, concurrently with the completion of the Merger, certain investors have agreed to subscribe for and purchase an aggregate of $175&#160;million of common stock of New Humacyte. The boards of directors of both AHAC and the Company have approved the proposed Merger. Completion of the Merger is subject to approval of AHAC&#8217;s shareholders and the satisfaction or waiver of certain other customary closing conditions. The Company expects that the Merger will represent a business combination pursuant to FASB ASC Topic 805, Business Combinations and will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, AHAC will be treated as the acquired company for financial reporting purposes. This determination is primarily based on the fact that subsequent to the Merger, the Company&#8217;s stockholders are expected to have a majority of the voting power of the combined company, the Company will comprise all of the ongoing operations of the Combined Company, the Company will comprise a majority of the governing body of the combined company, and the Company&#8217;s senior management will comprise all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger will be treated as the equivalent of the Company issuing shares for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC will be stated at historical costs. No goodwill or other intangible assets will be recorded. Operations prior to the Merger will be those of the Company.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Condensed Consolidated Balance Sheets</font><font style="letter-spacing:-0.2pt;"> </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share and per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:7.30999999999995pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.28pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.28pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.28pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.28pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,929</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.28pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.28pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">240,449</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.29pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.29pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.29pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.29pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.29pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">240</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.27pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.27pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.27pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,407</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.27pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.27pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">3,490</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.03pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">41,449</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">244,179</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.05pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Finance lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">23,492</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,947</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.31pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Operating lease right-of-use assets, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.31pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.31pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">769</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.31pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.31pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">738</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.29pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.29pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.29pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">40,978</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.29pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.29pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">36,499</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 2.155pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.04pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">106,688</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.04pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">303,363</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:6.37pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt;">
                <font style="letter-spacing:-0.18pt;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.32pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.32pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.32pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.32pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,274</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.32pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.32pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,830</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,592</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,422</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">SVB loan payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,889</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Finance lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,729</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,915</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.34pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Deferred payroll tax, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.34pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Operating lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.34pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.33pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">PPP loan payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.33pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,451</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.33pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.33pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,233</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,245</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.35pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Contingent earnout liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.35pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.35pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.35pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.35pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">169,200</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.36pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Finance lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">23,090</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,627</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.36pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">SVB loan payable, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">14,038</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.37pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Operating lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">727</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">693</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.37pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Common stock warrant liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">555</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.37pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Deferred payroll tax, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.36pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">PPP loan payable, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.36pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">822</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.36pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.36pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.11pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.11pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.11pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">36,016</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.11pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.11pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">227,502</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:8.14pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Commitments and contingencies (Note 11)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0.54pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Redeemable convertible preferred stock (Series&#160;A, B, C and D) $0.001 par value, </font>
                <br >
                <font style="letter-spacing:0.18pt;">69,613,565 and 0 shares authorized as of December&#160;31, 2021 and September&#160;30, 2021, </font>
                <br >
                <font style="letter-spacing:0.18pt;">respectively; 69,613,562 and 0 shares outstanding as of December&#160;31, 2020 and </font>
                <br >
                <font style="letter-spacing:0.18pt;">September&#160;30, 2021, respectively; liquidation preference of $435,579 and $0 as of </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2020 and September&#160;30, 2021, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0.54pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.54pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0.54pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.54pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:8.39pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Stockholders&#8217; equity (deficit)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Preferred stock, $0.0001 par value; 0 and 20,000,000 shares designated as of December&#160;31, 2020 and September&#160;30, 2021; 0 shares issued and outstanding as of December&#160;31, 2020 and September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0.53pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Common stock, $0.0001 par value as of December&#160;31, 2020 and September&#160;30, 2021, </font>
                <br >
                <font style="letter-spacing:0.18pt;">respectively; 340,216,780 and 250,000,000 shares authorized as of December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.18pt;">2020 and September&#160;30, 2021, respectively; 5,822,396 and 103,003,384 shares issued </font>
                <br >
                <font style="letter-spacing:0.18pt;">and outstanding as of December&#160;31, 2020 and September&#160;30, 2021, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0.53pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.53pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0.53pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.53pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.39pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.39pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.39pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">37,778</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.39pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.39pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">533,009</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.37pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.37pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(388,096<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.37pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.37pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(457,158<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.13pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Total stockholders&#8217; equity (deficit) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(350,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">75,861</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.13pt 0pt 2.155pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">106,688</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.13pt 0pt 1.405pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">303,363</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:122.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Condensed Consolidated Statements of Operations and </font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Comprehensive Loss</font><font style="letter-spacing:-0.2pt;"> </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share and per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:7pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216.34pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">For the Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">For the Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Grant revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">241</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,367</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,086</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Operating expenses:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Research and development (includes related </font>
                <br >
                <font style="letter-spacing:0.2pt;">party expenses of $149 and $2 for the </font>
                <br >
                <font style="letter-spacing:0.2pt;">three&#160;months ended September&#160;30, 2020 </font>
                <br >
                <font style="letter-spacing:0.2pt;">and 2021 and $462 and $168 for the </font>
                <br >
                <font style="letter-spacing:0.2pt;">nine&#160;months ended September&#160;30, 2020 and </font>
                <br >
                <font style="letter-spacing:0.2pt;">2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">14,692</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,879</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">45,091</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,435</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,398</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">9,416</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">15,576</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">18,127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">20,784</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">50,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">60,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(20,543<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(48,928<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(59,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other expenses, net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent earnout liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(9,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(9,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(549<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,204<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,661<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Transaction costs expensed </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(49<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(49<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of common stock warrant liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Gain on PPP loan forgiveness </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other expenses, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(547<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(11,020<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,384<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(9,481<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:216.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss and comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(31,563<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(50,312<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(69,062<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(3.07<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.72<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(8.74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(3.69<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,788,130</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">43,950,856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,755,418</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">18,728,471</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font><font style="letter-spacing:-0.2pt;"> </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands except for share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:68.13pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:176.19pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:16.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Redeemable Convertible </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.77pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8199;420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">5,627,157</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">32,783</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(321,572<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.77pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(288,788<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">148,159</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,182</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,182</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.02pt 0pt 1.155pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,674<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,674<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.79pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of March&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">5,775,316</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34,140</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(339,246<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.79pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(305,105<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">11,761</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">48</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">48</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.05pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,114</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,114</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.03pt 0pt 1.155pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(14,878<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(14,878<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.81pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of June&#160;30, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">5,787,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,302</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(354,124<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.81pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(318,821<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.06pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.07pt 0pt 0.5pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.05pt 0pt 1.155pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.8pt 0pt 1.905pt 0pt; width:216.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of September&#160;30, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.97pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">5,788,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">36,484</td>
            <td style="padding:0pt;padding-left:2.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(371,884<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt; width:4.22pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.8pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(335,399<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:542.35pt;height:293.99pt;margin-top:15.31pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:24.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:219pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Redeemable Convertible </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Deficit) </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">5,822,396</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">37,778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(388,096<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(350,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">116,149</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,528</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Issuance of warrants in conjunction with debt </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,360</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.02pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(20,301<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.02pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(20,301<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of March&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">5,938,545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">42,872</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(408,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(365,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.05pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">5,204</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.06pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,930</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,930</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.04pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(17,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of June&#160;30, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">5,943,749</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">45,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(425,595<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(379,762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Conversion of redeemable convertible preferred stock </font>
                <br >
                <font style="letter-spacing:0.18pt;">into common stock in connection with the Merger and </font>
                <br >
                <font style="letter-spacing:0.18pt;">related PIPE financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">(69,613,562<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(420,989<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">69,613,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,982</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">The merger and related PIPE financing, net of transaction costs and acquired liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">27,346,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">209,478</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">209,480</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Public warrants assumed upon the merger, net of transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">13,912</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:219pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Contingent earnout liability recognized upon closing of the reverse recapitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(159,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(159,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.06pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">99,624</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">360</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.07pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,877</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.05pt 0pt 0.5pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(31,563<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(31,563<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:219pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Balance as of September&#160;30, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">103,003,384</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">533,009</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(457,158<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">75,861</td>
            <td style="padding:0pt;padding-left:4.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSO2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Humacyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Condensed Consolidated Statements of Cash Flows</font><font style="letter-spacing:-0.2pt;"> </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:572.62pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:16.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:351.82pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">For the Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.77pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50,312<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(69,062<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Depreciation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,729</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,650</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,466</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,335</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.04pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Change in fair value of contingent earnout liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.04pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,768</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.05pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Change in fair value of common stock warrant liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.05pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Loss on disposal of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">155</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.06pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Amortization expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,545</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,545</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.06pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Non-cash operating lease costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">71</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.06pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.07pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Amortization of SVB debt discount </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">628</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.07pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accrued interest on PPP loan obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.07pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Gain on PPP loan forgiveness </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.07pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(3,284<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.08pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Payment of liabilities assumed in Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.08pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.08pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.08pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.08pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(12,363<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.08pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(127<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(654<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,002<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">539</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">757</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,401</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Operating lease obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(71<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(32<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.09pt 0pt 1.155pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Deferred payroll taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.09pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">133</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.09pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.09pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.86pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:1.86pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.86pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,373<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:1.86pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.86pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(59,742<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.11pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.12pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Purchase of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.12pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.12pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.12pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.12pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.1pt 0pt 1.155pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Proceeds from sale of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.1pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.1pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.1pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.88pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:1.88pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.88pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(255<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:1.88pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.88pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.13pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.13pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Proceeds from Merger and PIPE financing, net of offering costs paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">242,400</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.14pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Payment of transaction costs related to Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(941<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.14pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">596</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.15pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Proceeds from SVB loan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,659</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.15pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Proceeds from PPP loan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,251</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.14pt 0pt 1.155pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Payment of finance lease principal </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.14pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,107<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.14pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1,277<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.91pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:1.91pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.91pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,379</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:1.91pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.91pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">260,437</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.16pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net increase (decrease) in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(38,249<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">200,520</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.15pt 0pt 1.155pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Cash and cash equivalents at the beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">93,713</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.155pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">39,929</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.9pt 0pt 1.905pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Cash and cash equivalents at the end of the period</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">55,464</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.155pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">240,449</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.43pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Supplemental disclosure</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Cash paid for interest on SVB loan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">642</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Supplemental disclosure of noncash activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Operating lease right-of-use assets obtained in exchange for lease obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of warrants in conjunction with debt </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,360</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.2pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Unpaid liabilities assumed in connection with Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,228</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.2pt 0pt 0.5pt 0pt; width:351.82pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Unpaid transaction costs in connection with Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,004</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0.02pt 0pt 0.5pt 0pt; width:351.82pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Conversion of redeemable convertible preferred stock into common stock in connection with the reverse capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0.02pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.02pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0.02pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.02pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">420,989</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:351.82pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Contingent Consideration Liability recognized upon the closing of the reverse recapitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">159,432</td>
            <td style="padding:0pt;padding-left:3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fNCCF2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1. Organization and Description of Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Organization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Humacyte, Inc. and subsidiary, or the Company, is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues designed to improve the lives of patients and transform the practice of medicine. The Company is leveraging its technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021 (the &#8220;Closing Date&#8221;), Alpha Healthcare Acquisition Corp. (&#8220;AHAC&#8221;) consummated a merger pursuant to which Hunter Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of AHAC, merged with Humacyte, Inc., a Delaware Corporation (&#8220;Legacy Humacyte&#8221;), with Legacy Humacyte surviving the Merger as a wholly-owned subsidiary of AHAC (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Merger Agreement (as defined below), the &#8220;Reverse Recapitalization&#8221;). As a result of the Merger, AHAC was renamed Humacyte, Inc. (&#8220;New Humacyte&#8221;) and Legacy Humacyte was renamed Humacyte Global, Inc. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Refer to Note 3&#8201;&#8212;&#8201;Reverse Recapitalization for further details of the Merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Going Concern</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since its inception in 2004, the Company has generated no product revenue and has incurred net losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through governmental and other grants. At December&#160;31, 2020 and September&#160;30, 2021, the Company had an accumulated deficit of $388.1&#160;million and $457.2&#160;million, respectively. The Company&#8217;s net losses were $50.3&#160;million and $69.1&#160;million for the nine&#160;months ended September&#160;30, 2020 and 2021, respectively. Substantially all of the Company&#8217;s net losses resulted from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2021, the Company had cash and cash equivalents of $240.4&#160;million. Based on the cash and cash equivalents on hand, the Company believes its combined cash and cash equivalents will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12&#160;months from the issuance date of these interim financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of COVID-19</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic, which began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on the Company&#8217;s business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company&#8217;s business and operations are uncertain. The COVID-19 pandemic may affect the Company&#8217;s ability to initiate and complete preclinical studies, delay its clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on its business and operations. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact the Company&#8217;s ability to raise additional funds to support its operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company&#8217;s business and operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To date, the COVID-19 pandemic has not resulted in material financial impacts or impairment losses in the carrying values of the Company&#8217;s assets as a result of the pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise the estimates reflected in these financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including current and future clinical trials </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related economic impact of the pandemic. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Presentation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has prepared the accompanying financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The Company&#8217;s condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio established in the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use, or ROU, assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Interim Condensed Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2021 and its results of operations for the three and nine&#160;months ended September&#160;30, 2020 and 2021, and cash flows for the nine&#160;months ended September&#160;30, 2020 and 2021. The results of operations for the three and nine&#160;months ended September&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2021 or any other period. The December&#160;31, 2020 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020 and the related notes included elsewhere in this prospectus, which provides a more complete discussion of the Company&#8217;s accounting policies and certain other information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than the policies noted below, there have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the&#160;years ended December&#160;31, 2019 and 2020 included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company assumed 5,000,000 publicly-traded warrants (&#8220;Public Warrants&#8221;) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the &#8220;Sponsor&#8221;), Oppenheimer &amp; Co. Inc. and Northland Securities, Inc, in connection with AHAC&#8217;s initial public offering (&#8220;Private Placement Warrants&#8221; and, together with the Public Warrants, the &#8220;Common Stock Warrants&#8221;). The Common Stock Warrants entitle </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the holder to purchase one share of the Company&#8217;s Common stock, par value $0.0001 (&#8220;Common Stock&#8221;), at an exercise price of $11.50 per share. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be eligible for a cashless exercise. The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, </font><font style="font-style:italic;letter-spacing:0.2pt;">Distinguishing Liabilities from Equity</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 480&#8221;). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, </font><font style="font-style:italic;letter-spacing:0.2pt;">Derivatives and Hedging</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The agreement governing the Common Stock Warrants includes a provision (&#8220;Replacement of Securities Upon Reorganization&#8221;), the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Company&#8217;s ordinary shares, the Private Placement Warrants are not considered to be &#8220;indexed to the Company&#8217;s own stock&#8221; and therefore are not classified in stockholders&#8217; equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Public Warrants are considered to be &#8220;indexed to the Company&#8217;s own stock&#8221;. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Company&#8217;s common shares, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of common stock, a qualifying cash tender offer of more than 50% of the Company&#8217;s common stock will always result in a change-in-control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders&#8217; equity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Earnout Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Reverse Recapitalization and pursuant to the Business Combination Agreement dated as of February&#160;17, 2021 by and among Legacy Humacyte, Merger Sub, and AHAC (the &#8220;Merger Agreement&#8221;), Legacy Humacyte equity holders are entitled to receive as additional merger consideration of up to 15,000,000 shares of the Company&#8217;s Common Stock (the &#8220;Contingent Earnout Shares&#8221;), comprised of two separate tranches of 7,500,000 shares per tranche, for no consideration upon the occurrence of certain triggering events, including a change of control event that is not solely indexed to the common stock. In accordance with ASC 815-40, as the earnout shares were not indexed to the common stock, they were accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The estimated fair value of the Contingent Earnout Shares was determined using a Monte Carlo simulation using a distribution of potential outcomes on a monthly basis over a ten-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Company common stock price, expected volatility, risk-free rate, expected term and expected dividend yield. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Contingent Earnout Shares are categorized as a Level&#160;3 fair value measurement (see Fair Value Measurements accounting policy described below in Note 4) because the Company estimated projections </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">over a ten-year period utilizing unobservable inputs. Contingent earnout payments involve certain assumptions requiring significant judgment and actual results can differ from assumed and estimated amounts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Segments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s revenues generally consist of grant revenues, including revenues generated under government and other awarded grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, ASC 606 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Grant Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company generates revenue primarily from government and other awarded grants that reimburse the Company for certain allowable costs related to research and development efforts. These grants include the following terms: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Department of Defense grants are for an award of $4.0&#160;million, all of which was recognized as revenue before the program ended, for work on bioengineered blood vessels for vascular trauma, which was awarded to the Company in September&#160;2017 and ended in February&#160;2020, and an award of $7.1&#160;million for work to support human tissue engineered blood vessels for vascular reconstruction in the injured warfighter, which was awarded to the Company in August&#160;2017 and is ongoing. The Company has recognized revenue of $0.6&#160;million and $1.0&#160;million during the three and nine&#160;months ended September&#160;30, 2020, respectively, and $0.2&#160;million and $1.1&#160;million during the three and nine&#160;months ended September&#160;30, 2021, respectively, for reimbursement of certain allowable costs related to these grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The National Institutes of Health grant is for $1.6&#160;million for work to support bioengineered grafts for peripheral vascular disease, which was awarded to the Company in November&#160;2013. The Company recognized $1.6&#160;million for the reimbursement of certain allowable costs related to the grant before this program ended in 2020. The Company recognized $0.3&#160;million during the three and nine&#160;months ended September&#160;30, 2020, and no revenue during the three and nine&#160;months ended September&#160;30, 2021, for reimbursement of certain allowable costs related to these grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has determined that the grants are not within the scope of ASC 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are nonexchange transactions and has applied the contribution accounting model in Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition by analogy. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes funding received from grants as revenue, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these grants are central to the Company&#8217;s ongoing operations. The Company recognizes revenue only after the qualifying expenses related to the grants have been incurred and it is reasonably assured that the expenses will be reimbursed and the revenue will be collectible. The related costs incurred are included in research and development expense in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue from grants not within the scope of ASC 606 was $0.9&#160;million and $1.4&#160;million for the three and nine&#160;months ended September&#160;30, 2020, respectively, and $0.2&#160;million and $1.1&#160;million for the three and nine&#160;months ended September&#160;30, 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of Credit Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation as of December&#160;31, 2020 and September&#160;30, 2021. Cash equivalents are invested in highly rated money market funds invested only in obligations of the U.S. government and its agencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The majority of the Company&#8217;s revenue has been derived from government grants. The Company&#8217;s grants, which represented 10% or more of the Company&#8217;s total revenue during the three and nine&#160;months ended September&#160;30, 2020 and 2021, or accounts receivable balance as of December&#160;31, 2020 and September&#160;30, 2021, are as follows: </font>
        </div>
        <table style="width:416pt;height:129pt;margin-left:20pt;margin-top:10.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180.16pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:31.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:180.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant B </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant C </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">65<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:180.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant D </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:180.16pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">98<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">96<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All of the Company&#8217;s revenues were generated from grants from government and other entities located in the United States, for the three and nine&#160;months ended September&#160;30, 2020 and 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Risks and Uncertainties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase&#160;II/III clinical trial and V007 Phase&#160;III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates, the expected size of the target populations for the Company&#8217;s product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Company&#8217;s strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Company&#8217;s implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and commercial success of its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Company&#8217;s strategic partnership with Fresenius Medical Care Holdings, Inc., or Fresenius Medical Care, to sell, market and distribute its 6 millimeter HAV for certain specified indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company follows the two-class method to compute basic and diluted net loss per share attributable to common stockholders when shares met the definition of participating securities. The two-class method determines net loss per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the redeemable convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. As the Company has only incurred losses, basic and diluted net loss per share is the same. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows: </font>
        </div>
        <table style="width:416pt;height:160pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.17pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:306.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;A redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,421,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;B redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">24,137,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;C redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,241,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Shares issuable upon conversion of Series&#160;D redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,812,735</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise of options under stock plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,516,907</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,399,888</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,465,204</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 15,000,000 Contingent Earnout shares are excluded from the anti-dilutive table for all the periods presented as such shares are contingently issuable until the share price of the Company exceeds specified thresholds that have not yet been achieved, or upon the occurrence of a change in control. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impairment of Long-Lived Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company reviews the carrying value of property and equipment for indicators of possible impairment whenever events and circumstances indicate that the carrying value of an asset or asset group may not be recoverable from the estimated future net undiscounted cash flows expected to result from its use and eventual disposition. In cases where estimated future net undiscounted cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the asset or asset group. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">during the nine&#160;months ended September&#160;30, 2020 and 2021, respectively, the Company concluded there were no such events or changes in circumstances requiring review of the carrying amount of the Company&#8217;s long-lived assets and there was no impairment at December&#160;31, 2020 or September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Adopted Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, &#8220;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; &#8203;(&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. This guidance is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2021, with early adoption permitted. The Company adopted ASU 2020-06 as of January&#160;1, 2021. The adoption of this ASU had no impact on the Company&#8217;s financial statements and related disclosures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2021, the FASB issued ASU No. 2021-04, &#8220;Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#8221; &#8203;(&#8220;ASU 2021-04&#8221;). The FASB issued this update to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal&#160;years beginning after December&#160;15, 2021, including interim periods within those fiscal&#160;years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. The Company is currently evaluating the effect of this update on its financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3. Reverse Recapitalization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021, Merger Sub, a wholly-owned subsidiary of AHAC, merged with Legacy Humacyte, with Legacy Humacyte surviving as a wholly-owned subsidiary of AHAC. At the effective time of the Merger: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each outstanding share of Legacy Humacyte common stock was converted into approximately 0.26260 shares of the Company&#8217;s common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each outstanding share of preferred stock of Legacy Humacyte was cancelled and converted into the aggregate number of shares of New Humacyte&#8217;s common stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.26260; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#8217;s common stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in each case, rounded down to the nearest whole share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, upon the closing of the merger (the &#8220;Closing&#8221;), 2,500,000 Class&#160;B shares of AHAC (Founder Shares) automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Former holders of the Legacy Humacyte common stock and Legacy Humacyte preferred stock are eligible to receive up to an aggregate of 15&#160;million additional shares of the Company&#8217;s common stock (the &#8220;Contingent Earnout Shares&#8221;) in the aggregate in two equal tranches of 7.5&#160;million shares if the volume-weighted average closing sale price of the common stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. At the Closing on </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">August&#160;26, 2021, the Company recorded a liability (&#8220;Contingent Earnout Liability&#8221;) of $159.4&#160;million, based on the estimated fair value of the 15&#160;million Contingent Earnout Shares with a corresponding reduction of additional paid-in capital in the equity section of the Company&#8217;s condensed consolidated balance sheet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Concurrently with the execution of the Business Combination Agreement, AHAC entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (the &#8220;PIPE Investors&#8221;). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of the Company&#8217;s common stock (the &#8220;PIPE Shares&#8221;) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175&#160;million (the &#8220;PIPE Financing&#8221;). The PIPE Financing was consummated in connection with the Closing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of the Company&#8217;s common stock outstanding immediately following the consummation of the Merger was: </font>
        </div>
        <table style="width:416pt;height:130pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:353.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Common stock of AHAC, outstanding prior to Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">10,355,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less redemption of AHAC shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">(3,008,551<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Common stock of AHAC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">7,346,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AHAC Founder Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">2,500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">New Humacyte shares issued to PIPE Investors </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">17,500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon reverse recapitalization and PIPE Financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">27,346,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">New Humacyte shares issued in Merger to Legacy Humacyte stockholders </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">75,656,935<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(1)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:353.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total shares of common stock immediately after Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">103,003,384</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Includes 69,613,562 shares of common stock issued upon conversion of Legacy Humacyte&#8217;s redeemable convertible preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger is accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, AHAC is treated as the acquired company for financial reporting purposes and Legacy Humacyte is treated as the acquiror. This determination is primarily based on the fact that subsequent to the Merger, the Legacy Humacyte stockholders hold a majority of the voting rights of the combined company, Legacy Humacyte comprises all of the ongoing operations of the combined company, Legacy Humacyte comprises a majority of the carryover governing body of the combined company, and Legacy Humacyte&#8217;s senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Humacyte issuing shares for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Humacyte. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Merger, the Company received $242.4&#160;million in proceeds from the Merger and related PIPE Financing. The Company incurred $3.9&#160;million of transaction costs, consisting of banking, legal, and other professional fees, of which $3.9&#160;million was recorded as a reduction of proceeds to additional paid-in capital, and less than $0.1&#160;million related to the Private Placement Warrants, which are classified as liabilities in the condensed consolidated balance sheets, was expensed in the condensed consolidated statements of operations and comprehensive loss. Legacy Humacyte assumed $15.2&#160;million of liabilities, including PIPE Financing fees and legal fees, and $0.1&#160;million of assets from AHAC. Of the $15.2&#160;million of liabilities assumed from AHAC, as of September&#160;30, 2021, $2.2&#160;million was included in accounts payable and accrued expenses. In addition, there were $3.0&#160;million of unpaid transaction costs included in accounts payable and accrued expenses as of September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4. Fair Value Measurements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. ASC 820, </font><font style="font-style:italic;letter-spacing:0.2pt;">Fair Value Measurement and Disclosures</font><font style="letter-spacing:0.2pt;">, establishes a hierarchy whereby inputs </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1&#8201;&#8212;&#8201;Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2&#8201;&#8212;&#8201;Inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis were as follows: </font>
        </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:224pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measured as of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:224pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:224pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,623</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,623</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:224pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total financial assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,623</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,623</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:229.88pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measured as of September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:229.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:229.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">238,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">238,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:229.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total financial assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">238,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">238,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:229.88pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:229.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent earnout liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:229.88pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock warrant liabilities (Private Placement Warrants) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">555</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">555</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:229.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total financial liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">169,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">169,755</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level&#160;3 financial instruments: </font>
        </div>
        <table style="width:416pt;height:117pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Contingent</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Earnout Liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Private Placement</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value as of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:273.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Private placement warrant liability acquired as part of the merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(553<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:273.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Contingent earount liability recognized upon the closing of the reverse recapitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(159,432<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value included in other (expense) income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(9,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value as of September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(169,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(555<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:18.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the Contingent Earnout Liability and Private Placement Warrants liability are based on significant unobservable inputs, which represent Level&#160;3 measurements within the fair value hierarchy. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In determining the fair value of the Contingent Earnout Liability, the Company used the Monte Carlo simulation value model using a distribution of potential outcomes on a monthly basis over a ten-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Company common stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In determining the fair value of the Private Placement Warrants liability, the Company used the Monte Carlo simulation valuation model to estimate the fair value utilizing assumption including the current Company stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note&#160;8). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s cash equivalents are classified within Level&#160;1 of the fair value hierarchy because they are valued using quoted market prices. The carrying values of other receivables, accounts payable and accrued expenses as of December&#160;31, 2020 and September&#160;30, 2021 approximated their fair values due to the short-term nature of these items. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5. Property and Equipment, Net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consist of the following: </font>
        </div>
        <table style="width:416pt;height:138.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scientific equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,412</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,578</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">154</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">335</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">335</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">988</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">988</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">26,355</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">26,355</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55,239</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55,410</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,261<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,911<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,978</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">36,499</td>
            <td style="padding:0pt;padding-left:5.685pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation expense totaled $1.6&#160;million and $4.7&#160;million for the three and nine&#160;months ended September&#160;30, 2020, respectively, and $1.5&#160;million and $4.7&#160;million for the three and nine&#160;months ended September&#160;30, 2021, respectively. All long-lived assets are maintained in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6. Accrued Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses consisted of the following: </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued external research, development and manufacturing costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,615</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,685</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued employee compensation and benefits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,009</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,025</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued professional fees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">968</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,712</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,592</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,422</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Debt</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;30, 2020, the Company received loan proceeds in the amount of approximately $3.3&#160;million under the Paycheck Protection Program (&#8220;PPP&#8221;). All or portion of this loan and any accrued interest was eligible to be forgiven after a twenty-four week period as long as the borrower used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of the loan forgiven was to be reduced if the borrower terminated employees or reduced salaries during the twenty-four week period. The unforgiven portion of the PPP loan was to be payable over two&#160;years at an interest rate of 1%, with a deferral of payments for the first ten&#160;months. On May&#160;25, 2021, the PPP loan was </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">forgiven and the Company recognized a gain from loan extinguishment in the amount of $3,284 during the nine&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, the Company entered into a term loan agreement with Silicon Valley Bank and SVB Innovation Credit Fund&#160;VIII, L.P., which provides a term loan facility of up to $50.0&#160;million with a maturity date of March&#160;1, 2025, or the Loan Agreement. The Company&#8217;s obligations under the Loan Agreement are secured by substantially all of its assets except for its intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. If a minimum liquidity amount is not maintained, 50% of the outstanding principal and interest will become cash collateralized. As of September&#160;30, 2021, the Company was in compliance with all covenants. The Company may use the proceeds of borrowings under the Loan Agreement as working capital and to fund its general business requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Loan Agreement provides that the term loans will be distributed in tranches. The initial term loan tranche of $20.0&#160;million was drawn in March&#160;2021 and is accounted for net of issuance costs which are being accreted to interest expense over the term of the loan using the effective interest method. As of September&#160;30, 2021, three subsequent $10.0&#160;million term loan tranches were eligible to be disbursed at the request of the Company during specified draw periods between now and 2023 if certain business development milestones and other specified requirements are met by the dates specified in the Loan Agreement. Borrowings bear interest at the greater of 7.5% or the Wall Street Journal Prime Rate plus 4.25% (7.5% as of September&#160;30, 2021). Interest only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. Repayment of principal may begin as soon as April&#160;1, 2022 under the level of borrowing outstanding at September&#160;30, 2021, and no later than April&#160;1, 2024. The term loans may only be prepaid in full, and such prepayment requires 30&#160;days&#8217; advance notice and is subject to a prepayment fee of 3.00% (with a step down to 2.00% after March&#160;30, 2022, and a further step down to 1.00% after March&#160;30, 2023). The Company is not obligated to pay a prepayment fee if the Company makes a prepayment after March&#160;30, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;13, 2021, the Company borrowed an additional $10.0&#160;million under the Loan Agreement. As a result of the additional borrowing, the commencement of repayment of principal was deferred to no earlier than July&#160;2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Loan Agreement, the Company granted warrants to the lenders to purchase shares of common stock at an exercise price of $10.28 per share, of which 287,704 warrants were immediately exercisable. The warrants are classified within stockholders&#8217; equity as the settlement of the warrants is indexed to the Company&#8217;s own stock. The Company recognized the fair value of the warrants immediately exercisable within stockholders&#8217; equity using a Black-Scholes valuation model at issuance. As of September&#160;30, 2021, the fair value of warrants ($2.4&#160;million), a 5% final payment fee ($1.0&#160;million) and debt issuance costs ($0.3&#160;million) are being accreted to interest expense over the term of the loan using the effective interest method. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At issuance, the Company initially determined that the funding of an additional tranche was not probable, and therefore no value was ascribed to the remaining 123,302 warrants that were only exercisable upon the funding of the additional tranche. As a result of the Company&#8217;s additional $10.0&#160;million borrowings under the Loan Agreement on October&#160;13, 2021, the warrants to purchase the additional 123,302 shares of the Company&#8217;s common stock became exercisable at an exercise price of $10.28 per share. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB loan payable and net discount or premium balances are as follows: </font>
        </div>
        <table style="width:416pt;height:120.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:356.59pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Principal amount of SVB loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Final payment amount of SVB loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,000</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 0.5pt 0pt; width:356.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net premium associated with accretion of final payment and other debt issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(3,073<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">SVB loan payable, current and noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,927</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less SVB loan payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(3,889<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:356.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">SVB loan payable, noncurrent portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,038</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Future minimum payments of principal on the Company&#8217;s outstanding variable rate borrowings as of September&#160;30, 2021 are as follows: </font>
        </div>
        <table style="width:416pt;height:99pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:351.69pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Year ending December&#160;31: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 (remainder) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,555</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,667</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,667</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,111</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:351.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total future payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:9.8pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8. Stockholders&#8217; Equity (Deficit)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redeemable Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and immediately prior to the Merger, Legacy Humacyte had outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as &#8220;redeemable convertible preferred stock.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of shares of common stock of the Company on a one-to-one basis, then multiplied by the Exchange Ratio pursuant to the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021, the Merger and related PIPE Financing was consummated and the Company issued 27,346,449 shares of common stock for proceeds of $242.4&#160;million. The Company incurred $3.9&#160;million of transaction costs, consisting of banking, legal, and other professional fees. Legacy Humacyte assumed $15.2&#160;million of liabilities, including PIPE Financing fees and legal fees, and $0.1&#160;million of assets from AHAC. Immediately following the Merger, there were 103,003,384 shares of common stock outstanding with a par value of $0.0001. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2021, the Company&#8217;s Second Amended and Restated Certificate of Incorporation authorized the Company to issue 250,000,000 shares of common stock at a par value of $0.0001 per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote and without a separate class vote of the common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of common stock are entitled to receive dividends from time to time as may be declared by the Company&#8217;s board of directors. Through September&#160;30, 2021, no dividends have been declared. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of common stock are entitled to one vote for each share held with respect to all matters voted on by the common stockholders of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of common stock are entitled to share ratably in all remaining assets of the Company. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2021, the Company had reserved common stock for future issuances as follows: </font>
        </div>
        <table style="width:416pt;height:108pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:356.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Common stock reserved for Contingent Consideration Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,000,000</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise of options under stock plans </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,399,888</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Issuance of options under stock plans </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,730,503</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares available for grant under ESPP </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,030,033</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:356.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,465,204</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:356.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">35,625,628</td>
            <td style="padding:0pt;padding-left:1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;26, 2021, upon the Closing, all of the outstanding redeemable convertible preferred stock was converted to Common Stock pursuant to the conversion rate effective immediately prior to the Merger and the Exchange Ratio and the remaining amount was reclassified to additional paid-in capital. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s Second Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue $0.0001 par value preferred stock in one more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were 20,000,000 shares designated as preferred stock and none were outstanding as of September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Activity of warrants for the nine&#160;months ended September&#160;30, 2021 is set forth below: </font>
        </div>
        <table style="width:456pt;height:123pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:188.83pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Legacy</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Humacyte</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Private Placement</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Public Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:188.83pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Outstanding as of December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">32,961</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:188.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Common Stock Warrants issued to SVB </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">287,704</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">287,704</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:188.83pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common Stock Warrants as Part of the Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,500</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,177,500</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:188.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(32,961<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(32,961<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:188.83pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Oustanding as of September&#160;30, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">287,704</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">177,500</td>
            <td style="padding:0pt;padding-left:14.05pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:6.95pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,465,204</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with a long-term debt agreement entered into on March&#160;15, 2006 and paid in full during 2011, the Company issued a warrant that gave the holder the right to purchase 32,961 shares of the Company&#8217;s common stock at an exercise price of $1.14 per share, which was outstanding as of December&#160;31, 2020. The warrant was fully exercised on March&#160;4, 2021. There was no activity for the warrant during the year ended December&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See Note 7&#8201;&#8212;&#8201;Debt for a discussion of warrants issued in conjunction with the Company&#8217;s Loan Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Private Placement Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Private Placement Warrants were initially recognized as a liability on the Closing Date, at a fair value of $0.6&#160;million, and the Private Placement Warrant liability was remeasured to fair value as of September&#160;30, 2021, resulting in a loss of less than $0.1&#160;million for the three and nine&#160;months ended September&#160;30, 2021, classified within change in fair value of common stock warrant liabilities in the condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model: </font>
        </div>
        <table style="width:416pt;height:107.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.16pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">August&#160;26,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Market price of public stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.96</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.61</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.50</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.50</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.00</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.91</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected share price volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">32.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.96<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Public Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Public Warrants may only be exercised for a whole number of shares and will expire five&#160;years after the completion of the Merger. The Public Warrants became exercisable 30&#160;days after the completion of the Merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share. There were no exercises of the Public Warrants during the three&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Earnout Liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the Closing, former holders of Legacy Humacyte common and preferred shares may receive up to 15,000,000 additional shares of the Company&#8217;s common stock in the aggregate, in two equal tranches of 7,500,000 shares of common stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (&#8220;VWAP&#8221;) per share of common stock quoted on the Nasdaq (or the exchange on which the shares of common stock are then listed) is greater or equal to $15.00 and $20.00, respectively, over any twenty trading days within any thirty-day trading period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the common stock of Humacyte. The estimated fair value of the total Contingent Earnout Shares at the Closing on August&#160;26, 2021, was $159.4&#160;million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over a ten-year period using the most reliable information available. The Contingent Earnout Liability was remeasured to fair value as of September&#160;30, 2021, resulting in the recording of a non-cash loss of $9.8&#160;million for the three and nine&#160;months ended September&#160;30, 2021, classified within change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assumptions used in the valuations are described below: </font>
        </div>
        <table style="width:416pt;height:92.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.16pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">August&#160;26,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current stock price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.96</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.61</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected share price volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">79.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">78.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.34<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.55<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.00</td>
            <td style="padding:0pt;padding-left:3.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.00</td>
            <td style="padding:0pt;padding-left:9.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At Closing, the 2021 Long-Term Incentive Plan, or the 2021 Plan, and the 2021 Employee Stock Purchase Plan, or the ESPP, became effective. As of September&#160;30, 2021, 7,730,503 and 1,030,033 shares of common stock were available under the 2021 Plan and ESPP, respectively. On January&#160;1 of each year commencing January&#160;1, 2022, the 2021 Plan and the ESPP reserve will automatically increase in an amount </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">equal to the lesser of (a)&#160;5% and 1%, respectively, of the number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the preceding year and (b)&#160;a number of shares of common stock determined by the Company&#8217;s board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the 2021 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock&#160;units, unrestricted stock, performance awards and other forms of awards. Under the ESPP, eligible employees are permitted to purchase shares of the Company&#8217;s common stock at the lower of 85% of the closing trading price per share of the Company&#8217;s common stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the Closing, Legacy Humacyte had two equity incentive plans, the 2015 Omnibus Incentive Plan, as amended, or the 2015 Plan, and the 2005 Stock Option Plan, or the 2005 Plan. As a result of the Merger, no further awards may be granted under either the 2015 plan or the 2005 Plan. All awards previously granted and outstanding as of the effective date of the Merger, which total 5,886,706 and 518,432 shares of common stock reserved for options issued under the 2015 Plan and 2005 Plan, respectively, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2015 Plan that are forfeited, cancelled or reacquired by the Company prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s stock option plans allow for the grant of awards that the Company believes aid in aligning the interests of these persons with those of its stockholders. The Company&#8217;s board of directors determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Company&#8217;s common stock at the date of grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has granted options that include either a service-based or performance-based vesting conditions, or both, and a 10-year contractual term. The service-based vesting condition for the plans is generally satisfied over 36 to 48&#160;months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying common stock on the date of grant. Forfeitures are accounted for as they occur. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Option awards under the Company&#8217;s option plans generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantee&#8217;s employment during the period that commences 30&#160;days prior to the effective date of a corporate transaction and that ends 12&#160;months following the effective date of such transaction. Additionally, the Company&#8217;s board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a corporate transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of her employment agreement, the Company awarded the Company&#8217;s President and Chief Executive Officer, Laura Niklason M.D., PhD., a stock option award in January&#160;2021 entitling her to purchase 1,312,984 shares of the Company&#8217;s common stock at an exercise price of $10.28 per share, none of which have vested as of September&#160;30, 2021. This stock option vests in equal annual installments on each of the first three anniversaries of November&#160;9, 2020, subject to acceleration upon a corporate transaction (as defined in the 2015 Plan). The vesting of this award did not accelerate upon finalization of the Merger. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model: </font>
        </div>
        <table style="width:456pt;height:127pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:166.63pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:34.52pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:166.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:center;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:34.52pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:100.81pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0%</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:100.81pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:166.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Expected share price volatility (weighted average and range, if applicable) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:center;">91.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:34.52pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">91.4% (89.4% to 91.6%)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">91.4% (91.0% to 92.1%)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:166.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate (weighted average and range, if applicable) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:center;">0.34<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:34.52pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">0.40% (0.34% to 0.75%)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:0.2pt;">0.68% (0.62% to 1.02%)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:166.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term of options (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:13.5pt; white-space:nowrap;text-align:center;">6.0</td>
            <td style="padding:0pt;padding-left:5.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:34.52pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6.0</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:100.81pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6.0</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.91pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The Company did not grant any stock options during the three&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair Value of Common Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As the Company&#8217;s common stock was not publicly traded prior to the Merger, the fair value of the shares of its common stock underlying the options has historically been determined by the Company&#8217;s board of directors with input from management, after considering independent third-party valuation reports. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected volatility was based on the historical share volatility of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company does not have any trading history to use the volatility of its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-Free Interest Rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Dividend Yield.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company has not paid dividends on its common stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At September&#160;30, 2021, there were 7,730,503 options remaining available for grant under the 2021 Plan. The Company has sufficient authorized and unissued shares to make all issuances currently available under the 2021 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine&#160;months ended September&#160;30, 2021, and the three and nine&#160;months ended September&#160;30, 2020, and remaining unrecognized cost as of September&#160;30, 2021 and 2020: </font>
        </div>
        <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:294.84pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">308</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">486</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">781</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,837</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">862</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,391</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,685</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,170</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,877</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:59.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unrecognized share-based compensation cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,789</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,480</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:298.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Expected weighted average period compensation costs to be recognized (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.7</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2.1</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A summary of option activity under the Company&#8217;s stock option plans during the nine&#160;months ended September&#160;30, 2021 is presented below: </font>
        </div>
        <table style="width:456pt;height:164pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:207.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual Term</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,813,262</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.04</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,422</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,838,029</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.28</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(188,006<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.97</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(63,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7.87</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:207.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options outstanding at September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,399,888</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7.33</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">26,705</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and exercisable, September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,092,342</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.74</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.1</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,345</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:207.28pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest, September&#160;30, </font>
                <br >
                <font style="letter-spacing:0.2pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,399,888</td>
            <td style="padding:0pt;padding-left:10.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.33</td>
            <td style="padding:0pt;padding-left:14.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:23.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26,705</td>
            <td style="padding:0pt;padding-left:7.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not grant any stock options during the three&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No adjustment was made as of September&#160;30, 2021. The Company&#8217;s effective federal tax rate for the three and nine&#160;months ended September&#160;30, 2020 and 2021 was 0%, primarily as a result of estimated tax losses for the fiscal year to date offset by the increase in the valuation allowance in the net operating loss carryforwards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not record any income tax expense or benefit during the three and nine&#160;months ended September&#160;30, 2020 and 2021. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#8217;s ability to realize these assets. All losses before income taxes arose in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act was passed by the U.S. Congress and signed into United States law. The CARES Act, among other things, includes certain provisions for individuals and corporations; however, these benefits did not materially impact the Company&#8217;s income tax provision in the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent License Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Duke University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2006, the Company entered into a license agreement with Duke University, or Duke, which was subsequently amended in 2011, 2014, 2015, 2018 and 2019. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue will expire in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Company&#8217;s entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Company&#8217;s common stock. Under the license agreement, the Company also agreed to pay Duke: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low single-digit&#160;percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit&#160;percentage of any sublicensing revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an additional amount in license fees, as certain milestones are met. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The license agreement remains effective until the last of the patent rights expires or four&#160;years after the Company&#8217;s first commercial sale, unless earlier terminated. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three&#160;months&#8217; prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2014, the Company entered into a license agreement with Yale University, or Yale, that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1&#8201;&#8211;&#8201;12mm in diameter), except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1&#160;million per year for this license. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (BVP). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1&#160;million per year for this license. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company entered into a license agreement with Yale that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yale&#8217;s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1&#160;million per year for this license. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Company&#8217;s rights without Yale&#8217;s prior written consent, but such sublicense is subject to certain conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license up to a maximum of less than $0.1&#160;million per year; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">milestone payments upon achievement of certain regulatory and commercial milestones of $0.2&#160;million and $0.6&#160;million; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low single-digit&#160;percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a low double-digit&#160;percentage of sublicensing income. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i)&#160;provide written diligence reports, (ii)&#160;provide commercially reasonable diligence plans, (iii)&#160;implement the plans in accordance with the obligations under the agreements, or (iv)&#160;reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Company&#8217;s non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Company&#8217;s products or insolvency. The Company may terminate the license agreements (i)&#160;on 90&#160;days&#8217; prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii)&#160;on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Company&#8217;s rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company&#8217;s business, financial condition, results of operations, or cash flows. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#8217;s or officer&#8217;s service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any potential future amounts the Company could be required to make. To date, the Company has not incurred any costs as a result of such obligations and has not accrued any liabilities related to such obligations in the condensed consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fresenius Medical Care investments and distribution agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2018, the Company completed a $150&#160;million financing transaction pursuant to which Fresenius Medical Care purchased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Company&#8217;s common stock. In August&#160;2021, Fresenius Medical Care invested $25&#160;million as part of the PIPE Financing and received 2.5&#160;million shares of the Company&#8217;s common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June&#160;2018 which, as amended as of February&#160;16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and EU and commercialize outside of the United States the Company&#8217;s 6 millimeter x 42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Company&#8217;s retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:31.14pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a&#160;percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a&#160;percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Company&#8217;s distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed&#160;percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The distribution agreement will generally continue on a country-by-country basis until the later of (a)&#160;the tenth anniversary of the launch date of the distribution product in the relevant country or (b)&#160;the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i)&#160;for certain withdrawals of regulatory approval or (ii)&#160;for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Care&#8217;s rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12&#160;months&#8217; written notice to the Company, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Arrangements with Dr.&#160;Niklason and Yale University</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, the Company entered into a Memorandum of Understanding Regarding Scientific and Operational Leadership, or MOU, with Dr.&#160;Niklason in connection with her performance of various consulting activities for the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The MOU provided for the Company to make a payment each year through 2023 to the academic institution with which Dr.&#160;Niklason was then affiliated, up to an aggregate amount of $2.5&#160;million for 2018 through 2023, and to pay Dr.&#160;Niklason reasonable consulting fees in consideration of the services she performed for the Company. For the three and nine&#160;months ended September&#160;30, 2020, the company made payments under the MOU of $0.1&#160;million and $0.4&#160;million, respectively, to, or on behalf of, Yale University, where Dr.&#160;Niklason, currently the Company&#8217;s President, CEO and a member of the Company&#8217;s board of directors, serves as a Professor Adjunct, Division Chief and Vice Chair, Research in Anesthesia. The MOU was terminated effective November&#160;9, 2020. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:334.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine&#160;months ended September&#160;30, 2020 and 2021: </font>
        </div>
        <table style="width:416pt;height:100.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:27.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:297.17pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">($ in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expenses under MOU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">375</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">License expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">70</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">85</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">83</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:3.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">462</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">168</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and September&#160;30, 2021, the Company was a party to license agreements with Yale University, as described in Note 11 &#8212; Commitments and Contingencies, above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In preparing the condensed consolidated financial statements as of September&#160;30, 2021 and for the three and nine&#160;months ended September&#160;30, 2021, the Company evaluated the effect subsequent events would have on the financial statements through the date the financial statements were issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;13, 2021, the Company borrowed an additional $10.0&#160;million under the Loan Agreement, and the warrants to purchase an additional 123,302 shares of the Company&#8217;s common stock at an exercise price of $10.28 per share became exercisable. See Note 7&#8201;&#8212;&#8201;Debt and Note 8&#8201;&#8212;&#8201;Stockholders&#8217; Equity (Deficit) for additional information.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:314.5pt; text-align:center; width:456pt;">
          <img src="lg_humacyte-4clr.jpg" alt="[MISSING IMAGE: lg_humacyte-4clr.jpg]" height="59" width="288" >
        </div>
        <div style="margin-top:328.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 328.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_humacyte-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_humacyte-4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 6 &P P$1  (1 0,1 ?_$ .D   $$ @,! 0
M       '" D*!@L! @4$ P$!  (" P$! 0            $" P0%!@<("0H0
M   & 0,# @,#!0D("A,!  $" P0%!@< $0@A$@DQ$T$4"E$B%6%Q,B,6@9&A
MP=47E]<:L4)2,U>'6!GPT8)4M28G1Q@XX6)RDJ+"4W.CTR1%I3:6-W>W*$@1
M  $# @,$!@0%#0P)!0    $  @,1!"$%!C%!$@=187$R$PB!D;$BH4*B%!7!
M4F)RDK+"TB,S<Y,)T8)#4Z/3)#1$E!87\.'B8X-4=-0EL\,U55;_V@ , P$
M A$#$0 _ +_&B(T1&B(T1&B(T1&B(T1&B(T1&B+RY2;AH-J9]-RT;#LB;][N
M4?-8]J7;U[G#M5%$O3[1U1\C(V\4A#6])-!\*V+>TNKN00VL;Y93L:QI<?4
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MYHY\[>V,_4)7#3^2_GA$TNAM\NF(W,NV GLXVL'7B1Z\$I<7YI/&])&33/R
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M6YAJ'*Q(,"V.9L[J_:P^(?@3PZ9]/[S\NJ*#F60PYCA-;8QDKQ?Y$[I$-OO
MJVI=6N)@.7[-]ORZ[;:<MM22M!D\"+#XSS7Y+7+Q;.O.-R?R]YCM3FEZ1O@M
MVAI],\T."<[5OIELN/NT;QRIQS7-P()PJF/+-<]A'<3@7\7G:'W 4?3T[OR:
MYR'E9=N_K%Y&W[5CG>US%Y5F7G9R%KJY7D-W-^EN(X?O(Y_].E.1J7TS.(8]
M1JI=.4.0K,"8#\XE7\?U^HI.A]L2A[7SMAMJS4H''?\ 34'8-M_CKDX>5MDT
M@SW4KQOHUK?JN72[_P ZVI)0X99DEG 3W3)/)*1COHR(.PPV#I3G*W]/%P#A
MP*,V?,]N5V)WA)Y";QK<1*!N[L2@*]%N"@H([CNL80V#;;KORT7+?3L??\=Y
MZWT^] ]JZ7>>;_FY<86IRVV'V%OQ'UR2/&'4!MQW):(/P;^-F$+L.#)&8-N
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M/2;S4V40/47CV."YJV\S_/BU%(]1W9%:^_';O^%\+CZ*T6%R?AD\=TF0Z?\
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MR>X.S\IE^:1M.\U\+*WD#8&T).TO"R6)ROR"9(I_MWQ<DDU]C^^MB[+="O;
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M[8X&"KG.(#0!M))P"Y/)\FS;4&9PY-DEM/=YM<O#(H86.DDD>< UC& N<3T
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M&TOPDQ7;L:S&0V62%[/D)Y=TYAE7'%939(NJU6X((TS-Q-3AUU"'@3*^Z"I
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M_/I?KY%POE(AHB2>)-5[O@C+=5AB*B4/G)5 *W;OE$Q$Q=EC1M4<J%]=P3V
M.O17<LLK:,JMD< @/IHM=<&.4G4W3U^ CZ:(M21Y(+6PR9Y*.8CRKO"/6%JY
M6Y581+IMLY3<"XR#)Q2:C<0%,'!3KE'M[1V-TV'J Z<2VVL]T$]"VRE+CEHB
MG5.)<"(N(NM04<N(D%,1691;5LJ(D$QA(/>D/3<=OMT6HM=_]5'("V\FT"F!
MO7B]BLVP?:-NR>&^WQ'II6BV(F\3:]:N8^&HXK>+3@ZH/45,"U@P[_'N5?:;
M=BPO%'$'I41/U#7AY4Y&4V3YJ\:J]'H9SQM79%_F.EQ;!8K_ #/1H5J5RG-Q
M*+)-1-UD6ELFRO:0R?NR\<((@I[S5JBLJK,<*T*C^^G9\.+C*4A7.?7**JLU
M\;PLDZ7X_8RLK%Q\Q;K1 2*!$<K3L<X*FW&JUZ4:+)1#=<IS/G[<SDQ"MT4#
M.E:JTA /"%>#NH %-MVP '_%F>]  /\ W4[T6'>M4#XF)0RWDTX));B/?R@Q
M"7]^W1P?GTJMIS*-)6VE$0 -Q].G\/YM]%JJEO\ 5A\TVC&*PEP@J,V"D@_>
M_P ]>7V3)P0PM6+-%>'QI!2A"B)R*/7+F0DS(FV^Z@U5VV,4=.*BS1,K4KWO
MIX.3'COX7\.IFP9KY98&H>=LY7R3LELK=AM;1C9ZQ4:NHI6J36Y9$X'4144^
M6>2H$#M#MDR (")0,,U1['%WN@T4TV=_)?XD<_8:RCA.Y<XN.;FK94H5IH<V
M12[M%/;9V:(=19G:9>T@^^Q.X*LF(" E43*(" AOJO$ JACQN*U[O!CEBOXY
M^?\ 1\NLI]C>JGBK(]EHUXDZ+($?P&1<9NW<C4+1(5E][?MRL1+11OQ.+4[-
MEC)MS@ =-IK59G,);A@5MDH2;B;'#Q,_!2#66A)R,8S$/*L52.&,E%R;5)['
MOV:Z8B1=J\:+D43.7H8A@$/71:QP*I2?5I\8)9C,\=>:$"U47A';%[Q]R*HF
MW$21<FV6E[OC=^JJ0#"9*8;.9YLH<_81)1H@4!,9;8%<%EBH3P[TN/TJ_.ZI
MVK#F0>#=VLB3/(U MDKDO$C"2=IIC9\<V=DS&RU^OIJ&$SA[2;/&N'[A/<#&
M;31#)E,5!<Q%:I(PMQ&Q6_@,!@W#TZ_ 0].GQZZ#%82*+G1$D.;<^8;XWX_D
M,J9UR)6L7X]BGL9&OK5:WOR,<E(3+Q)A&,B=I%7#ATZ<*AL1-,YBD*=0P F0
MYBE(!. VI1H"PP-KAHVQ5B9B[# 3+1&0B)R$?M92(E&+@O>@\CI%BJNT>M5B
MCN51,YBC\!T4+V-$6*7FDU;(],ME NT%'66GWBN3-2M=?E4".8V<KM@CUXJ9
MB7Z)P$%6C^/=*)'#U$ING7;1%J%^:N)XOC5RZY*8!@))Q*P.(,TY#H$'(.DO
M;<N8>N660CXLSH/<5W<D8I$*H;N'O. CTWV"*E;;6U *VI7C]XRTCB'P\P+@
MBB%(YC:G0HA[+SAFH,W=KM]F0+9+A;'R'ONS-W$_8Y-PN5$5E0:HF(@0XII%
MU*U2<:IY.BA&B(T14!?JW'PM>:7&T@#L!N+R!Q_I7R('\6HK19XFU:>U60_I
MVE??\2'&541W[W>6QW_-E^[@'\ :E8Y!1Y4V^BHHX?+ZI[7C!YSJ_P#D^.&1
MC?NA$'VT5F"K@.M:W[Q9<.X+R%\R:-Q?LU[F<<Q%NK=^G5[5 13":DF:E.J<
ME8T$$H^0<M6JA'JS $CF$X"4IA$-QT#EL/:&#BHK57]D<PEZ?],S+ ?FQE3_
M .7@U*P^)U+@?I',);=.9N6=_P#\94X/X0GMPTJGB=2M4X4QHTPOAO$V'F$J
MXG&.*,:47&S*;>-TFCN8:4:KQ=8;2CIJ@=1%LYD$(LJJB9#&*0YQ !$ U"QI
M3=$1HB-$1HB-$1HB-$1HB-$1HBT^?DS="7R0^00NP_=YN\K0]?LSO?0] _-J
M%N,'NC'<%N"PZ!]FI6FN=$5<SZI8_M^*B?-U';/.&_3UZNYT-%DB%7J'/Z/)
M7W,P<W]]_NXUPU_#:+U^7\F@5YJT"N_99QK5LRXPR!B:\,0DJ?DFGV&DV1D/
M9WK0]EC',2^% QRG*DZ20="=%38135*4P=0#181@:K5!<A<(<K/#;SJBD5B2
MU0R'B*[?M_@[(R[)(\#D:F1TY(,:_;F*1%EV,C"61@T5:RD>93O2]Q=JL!1W
MWA;0]]NU6J../U=6"9BI1C3E-QVR)1[XRCVZ,U,8>=Q%TI\_))$[7,C$PUD?
M5N;K3=XH7O*S7=R0MP-V_,K;=VE0L1A=N*;5SW^J\_G!QC<L4\)\-6BCS5S@
M7]>/G;)DQ'MIZHLI=JHQD7=,H4"F^;DLY&C@WR4D[EC),5P*H#1<0*)51N4B
M$@XJ,/P&>-+(W.WES4\W7&'G&?'3 %RA<E7J[2K%56-R!>X";9SE?QG%2#Q9
M()21EI- '<NJD#@&C!$Q%O;4=MQ,5GGA'#7%;.8/0-_78-]2M9:W?ZKE<4_)
M_ %#?_JM8G'U^VX92_VM0MF(5:KIOA=-W>*O@J;[< 50?_2/=2L#^\>U2<F3
M(??O*!@$.T0'J A]@AZ?'1571!N@U23;MD4FZ"12D211(5)),A0 "D33( $(
M4H!T  V#1%CMW_\ DRVAOM_Q8G_^"G?\8Z(M2IXC' F\GW HO7[W*;#P=1^
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M:(HH^?/ANX=^2')%.RER-;Y)6M%%I):!!&IET4K+ ( D[+V("NFI&#L'#O\
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5!FH"M@<>X/WN\.W[-0H<]SABO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2127058d1-bc_humtrial4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-bc_humtrial4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2 +F P$1  (1 0,1 ?_$ /P  0 !! ,! 0$
M       ! @<("0,&"@4$"P$! 0 " P$! 0            $" P0%!P8("1
M  4# @($!@@*$@H,"P<% 0(#! 4 !@<1""$2,4$3"5%A<105E8&1(E/35-06
M\*&QP=&45=47&#)"TB-%5I:VUC=7=Y<X6!D*&N'Q4F)UM39V)]=R,T,D)35E
M)D9'MRB"DJ*RPK2%Q6:&9V-S@T1TA$C#-*;&AQ$  @$" P0$!@P,!@,! 0
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M1Y[^]9W>6[NHOFU(O$&W_='C+OG]L&Y.U[(VKX.EK=G+YQW+P3"[$W\[EN<
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M+Q1FJ#EZZ<#V@G,8=8L@TW(LSW5T!;V4MWG=@L,17LM$Y6VO8GOYIF:V\*[
M[EPBA8-L.+*B[<R+C'>)EZ^\I,$+IDKENI%4L&[8Q,PH>>[9T9!L"I0*"5<C
M\6S^YMG.#\0R&S_O MCN4MTW>I)[\+BGLAP%LX=OL^2<J75-Y;>3EL;A;/S*
MG%6FU7QU#VX_)))K&E6#5=B3MCH@B?F!F,$J/,S.NEGM^PKWL/?!V+>>*F%L
M95W%[+FEU[9W*&*I5U\YK@' >=9;-DO;EWQ< YBH>7N05%2R*ZSAFM+.@43T
M46 4ZE,!5)X&'3FR'5J[-OZ.;G#<OBZ^LE;!\$6I<CC<S:L38-PY"A; N^7@
MY)ICV_\ *%@Q,._D5K;B'H@DHLLDLFF=(Z)43*+)I+TE,$8X[R+*_"YMH[]_
M<OLJQ==./.[BS';FQJV<7V^7'UQ8^MS,&X2R=Q>WP+_R9BK&<E%,)5* MYHE
M,-)*039M$EW+D/SHYTE@;L=HZ:9&ZJ:VVXRV^]\MW("."<06_C*">[3-QT5?
M#VR;82@VTB#/&4=Z)3NZ19L2C(2!W$@Y,0[TYG"RBAM#B;C19&6%494_TD:'
ME9G9]M>;Q,9(RKAOWD&S]XNA&LW#Y9)FWG+J\Y=*I-4EE4VR!3!SJ" %+K[H
M0 :B#-?^-=KV,<Q]Y?\ TA&Y<NX6@K_6B\,6(PQZ_O:ST9Q)H>2Q3<:TH-GN
M)1@Z;HR:SV*8]HX9F%4AT4@UT#0:1;3<%W "$TEW/>QEK<:$@TF&6*9-@X9R
MB3AN_9-V>0;S;1S)5LZ CIN1G%I()I)G HII%(4   "HQ&IYP^]/P7N5PKWC
MNX'9%M^BIHF&>_;G,!+W/<S5L]7AL<W+'9(C+>SE-2:D;&F!G'OK4.]7>$,*
M@G;R)E ,(E[,*B-[,ZFS#O/,=0VQ;?YW0V^9S:LXUV9[6K.OO:[D)[8MF3]V
M#A>#F+'E&6.)R5@+1BI.3:VJJDBG'D52;B1(Z $,(**H$5BQ61D\&F:9F^ \
MR/=M4YWGZ6,LF#A&'[]>VM]S6UCV/<OX2I/:U%W([L]]E)KC\(XT^6.3)<!'
MN@H]H#!%9R<"H%[6K4GM5J9'7K@S)O>BJ_TB#=9M=L^\);#^YO%>U.P-M,Y=
M%K7#9CK.5P[;K!@BY)9V7 7)'QT^\3:25F>9-%E&Y".73Q-%/G4!4J<Q&=7T
MGU>Z66QI-[[N[N6[O^S=P]ER%L[7,C1G>O(9)B,JP]NGN)C:<-"6DPR >_#C
M;$MDPF3F" 1X0JAS%8H(@!0205!-A0JSKM/<BG^1Z!#B/TQ$=0\0U#(KH" *
M "(@  (Z:B <1T\(]= 08H&_) 4=---0 =.G7I\0T!2*1!  Y2Z (#^1#0--
M-- TTU#2@H<1&C=,3BFW0(*AA,<2I$*)S#RZF.)2@)C"! X^(*>V"D[)LHH5
M8[=N=8@&*14Z"9E"%. @8I3B',4IM>(==!VDJ-$%BD*J@@J5,Q3D*JD10"&+
MJ!3%Y@'E,4!'00\--I<"L6Z8E IB$$I=!*42@(!H("&@:: (&* AXP :99$P
M\9 M4!6*X%!$5RD,F584R"J5,XE$Z95.7G AQ* F#701 !ZJ8@YA(40$!*&@
M@("&@= @(#XAX#0E !"AIH4H:#KP  XZ@/5IUA2I3@6:H. Y5T45B#IJ55(B
MA1T'4!$I@$NH#T4Q!6F@DF4"D22(4I2D*4A"E*4I-0*4I0#0I2@(Z ' -: J
M[)/41Y"<> ^X+Q#00T'@.ON3"'D&F(H 3( \W(770 U I>&G4 Z:Z4!7H'@"
M@["D4R" @)2CJ&@\ '4-!+H/A#E'3R4)0I*BD4  $TP .&@$*'  Y0#@'44-
M/)0I6)"B.HE*/C$H"/1I]2@(Y"::<I0#R!5JP5   .H 'M!]BH"DQ -T@4>@
M?=!KQ*("7IZ-#!KY: @$B &@$+IJ(Z:!IQUYAZ XB \?#08$\A=- * !U
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M?!T_3 :   !T?1]:@)H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$: /A]L?LT Y0\'30$T H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$";3^V']N@!3 8 $->/A
M 0^KX* F@% * 4 H!0"@*3&Y0UTU -1'Q: (_3TH"J@% * 4 H!0"@% * 4
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MV@MK'<Y<].%-D5_,1MK-;3BI&YG#QW!HQZS](Z;2/*HD?241 @ 4W,;A7TG
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MR<_*45 *4_*',4AA.4#<-0*<Q2"8 'KT#7P4*54 H!0"@% * 4 H!0"@% *
M4!^!523 Y@0:,5$]?<F6?KHF$/&0D:X /;H"CM9?XC&^M77WFH3$=K+_ !&-
M]:NOO-08CM9CXC&^M77WF"@Q':R_Q&.]:.?O/08CM9?XC&^M7/WGH,1VLO\
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MBVHI6\;9@-HMPN+GQQ&1LLW=EE)%\\CY*1"Z7<M'R+I^5])1_;JF0.@;G6.
M:$$"%X]GF[B5NYKW1;VI24W1JOI>CY>LV7>'V)0C%*D4\O#I-@94TBCKV8 .
M@<>01'3CPUXZ5\^]Q9U]DY>1BMG7:G8V><I;?,JW1+7-'SFW*]G%[6:UA%62
M$9)2+E:)<*-9])U'NEUV(*0:/!$Z1_=#[KJKNN&<;O\ #M)J=)8^BU-O<E@\
MLN@XNITL;URW=EC*,JGY-RVT:P]T$YA&>O:7NN)=X*R$SR5:Y+;=1[=!]-,7
M46\2:3/GT9('7CU%8I+F!(43AQT.%;.#\?U/ ])J[&DBG#56MR=:UI6N'C[2
M:K2QU5V#E^(ZKM,HW\<C)13Z,5*)4WS!RR.).4AP3=(*-U!*(@) ,*9^L-/%
MI726K\Z*^EYZ=4NQU2Q[-IRI6H[C@LFJ>Q0U!VQW.E@6.Q<1%B[I-X%CPCB1
M>S!X.T,J,K>ATY"0.0SEPE'QD"V;E64[, ,;E$Y@*4!,( %>A:KUC:O4PM][
MPW12G&B]"-4JUHVWEB\$=*^ P2I"[.*ZF;&\!8;3P+C>,QPC?F1,E$BY"6?%
MNW*-P&N:\'IY9\H_%%],&;MSK(LP7%) !)[A(@%KX[BO%%Q36W-<[=NRY->9
M!;L52*5(KV7UL[/26/LMKN:N5*XO$QZ1V#XO873NYO%"X;W/([QK?5M[(R N
MXH[:#:*Q\U&]M:29(8JS5?L9I37SH[HHF HZ  :#S+_-NL>@T-A).&BG)VZ)
MU\[=KT_ 6PX_W?;??RRE=2J^S>V>,X;MV!8KNW:QC/:5(W)>R%AXNE;4EX2;
M:.H=.Z':]H/I"0C$Y)PI#K1ZJ2BDB8JH)MTS&*' 0'C6>GYQU^GYHU7&H1B]
M5>M-2SIBDGEU(VWM';EI;=O\6+7L%U%=JMD.MU<?NY6E[C^?L;B7\$"4%VS#
MYKG@!EWDT:150&/+)#+ Y>'+J5<$P+^5KBRY@U$N#O@J2^S*]WJS3<DFL/$V
M;(:6"FKDO2I1&(=T]TEA&XI^^_1V3<\V=B[*5[KY O[!%H7VVB<4W#/NWS20
M?J+0X1!GC1D]78(?G2"Y!1!,I4C)D(F0G=VO6'Q:[IK*O:;32U=FTK<)RA'?
MW8Q48U?318MJKVXU9Q5P>Q;O2NJN[*3DU7:ZMX>'47SW$["\4[@9'&MUISM_
MX=R)AY@,#860\/7&%L7?#VTHW5;GMOSQ9J_;N8L4'*I2@8@*$(LJ &Y%%"'Z
MGA?-'%>'V+UFZH2L7[JG.$E&2E+!;S6/0O$ED9:GA]G4W(WXUC<@J88;:ENF
M?==X&:[=,F;>Y*6R+<*.9;G87CD+)LY<J4CDJ;NZ,?H/H2?5E5XX\<56$73#
ML4A;F0-J<RH*'4.8>QGSUQ32<;T_&M/&"=I=VH1CYJC-;M&EC1UJWA1=AA=X
M9;U>E^SWFWYT99_!=?<.TL>[XL,L=M9:7!DC+5X/=IE[/;WL6<NB>CI67GGC
MN19O6D5=#Q2(,=Q#Q*,<@T;)-P;B1LF :\ TT?U=JHW=?W=N$/MD*3232Q4D
M]WMK7/,VW>%V[EZU)MTMY9;*9Y=!T+*/=4X>OJ_[\R!9F2LYX+<Y9YARE;N'
M[V3MRU;X<+*=N]?RT2I'/BE=2!S&%70X)'4,)^S QC<W*T/.?%+5B%K40MW7
M:]!SBI.%%14;KDO'0UKA=F+DK;<5+.FTNO='=Z8.F[!VZ8U@R7!9%H;9;]B\
MA6%&6ZZ9B+V9C78/3A<;B382"TD66?&4<NU2BFLHNJ<W, " %X7]3<0GJ[^K
MU$M_4:BWN2;Z*426S!));*$^Z[*MV[<<(PE4[Q>^T+'F0=R]H[F9][<+BZ+2
MQM<N+4K7[1C\T).VKH:SK&5"3;*1XOUW"S6XUP#E< 3@ <H\:X]KC.IM<+^Z
MH86?M$;U<:[T8R2ZL-YF=[A]NYK5J&W7NG'JQ:,1D>Y]PKZ-;V"ZR[N,=8%9
M7.2Z$-O3O(Z+C%8+$>JR)8Q..&'&8)%^>+''@Z*X'B(J")C&'M(<Z:VQ64+=
MG[4[>YWFY6>[E2NWL?M9Z7P>S.F]*6XG6E<*FU]M$,VD:WC6[,B3!NS38(,@
M+S))-$$0120*103$Y")% H ;ITXC7R#K.^M55[RQ.U6$-U&J5QW/NWA>=>@6
M]LWH8=>WZ7(2NW%G>Z37"YIX'(NQ*2W"1:3M.,\Y'4$@< <J903*<"@%?9V^
M>N*Q[F[I5;MZO3VG;C<C#=FXNM:MYOSGB<&7#H7YMR;W:UI7 OS,]WE@V],T
M7IFG)"$SD>0NO%[G#\3:-V%@U[+Q_8#I'S=2*L2*8Q#)>'<$14<%3=&5.Y2\
M[6$A@$^H<6SS=QG1Z..DTEQP7?N]*2;WI2:2>\_QD]U53JGM,)<,LSG^=Q2R
M6Q=G9TEWMJVVR'VJ8S;XAMB\[WO&U(F9D'UM?/M]'R3^VXE^#<26U%/&$;'Z
M03)PBJHW2.!C(]L8 -RZ%#I^+<2U'&=2M9<487/QJ*F]1UQRQHZ5[,>CEVK2
ML1[N/HF4%<$W"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* M=F_\ :8RW^]C?_P"M*7IM,HY^'2>88-= \.@=?B\-8]/0;\T5 ;PCX?)T
M?EO"%&0I !$>% 1T^4:@)$HAQ$/J4!.G#JU\'#H'CKY: IJ]H)T$?H^M4!F9
ML' 0W*VKK]Q+N_6Z^&LHF$_1-_U4U"@% * 4 H!0"@% * 4 H!0'4[\* V/>
M8_\ PG<0>(?^!WG2'70'EATTZQ#7J 1+T"/@UJ-G(*AX:#S&XAPXC]FI5BB
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M=4F?=TZJP,A0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MIC+?[V-_?K3EZ+K,HYGF&'JUX>Y*.G'H$ $!Z.L.-1^R;B0_V.O'IUTK$$"
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M'[2$ A"D 3"!2@4!.8QS" !IJ8YA$QC<.(B.HT*54 H!0"@% * 4 H!0"@%
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M0T\'I)][7!<.%4TT)]'(^^O_ %E(?*:"G:/1R/OK_P!92'RF@IVCT<C[Z_\
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M7I9X>"9GW:-^VS?=MP=W6C.1L];5R1;*9@YJ/5,JPDXV03[=JZ;*]F41360
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MI5!(%X<?I]&O@$.GV: S*V$_QE;4Z/\ B2[OR.H_]'GW31&,VZ&_ZLC2* 4
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M  Z.CAKU\=>/1U50 $1Z. !Q$>GV?"(T UUX=.HZ:^UU4P!F5L'#3<M:P?\
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MJ'/(>\,_MM?Y%0>=U#GD/B[/[;7^14'G=0YY#XNS^VU_D5,!YW4?J*)A*7G
M .)0$P%$3% V@:@!A*41 !\04*54 H!0"@% * 4 H!0"@% * 4!^,QW_ #&
MB+02:CRB=TL4PAU")2M#  ^R-"$<\CUH,OMM?Y%5=-@Q,?MUQI#\67<-JBS
M!PGD[B#I<P@'S-F>;0/-"@)M.CH\M=MR]3[]TM:T[^W\HX?$*_8[F5=UG\XG
MJ/IT:FT]BOZ'/Z#2?5^XSQ3487Y=OOD5L>9H%0.FP4(*%%""@%"FPCNQC*%W
M3(=F4#".&]PG-S&,31,,)WSSF*8I3#VA=> = ]8A7DGKEI_24J_#7R[9]+RH
MJ<6A<_%CB_(\C9J/5QUX%X].O -/I5^*]+]$Z_"9[+<6[=[W\62P)*!@#AH'
M'KK:S H$=?H]JC5!4:\-/!]77[%0 !TU\8:#X@'KH /3]+V@TJ@DI>;7CI4
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MKF_ZG+XR^7 ^GY67_,D]J7N2-FHAII_L"_\ F%XU^*=-]$_C,]B3<[47/%H
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M=H+97;9N<602-8E(?(K=KYL5^E.)]F\2C%1'G.@)#&$X?D].%6H;KAU&6 =
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MKY 'C[6E-@JR $:5,99/L/21M4  V[8D .CYI-?_ %AS61H,@J 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% 8_[K UVR[AOWD<H?K,F:[;E_\ GNE^OM_*.'Q#
M]RN?%9_-[$- ,'C'[%?T/_V=)]5[C/$]0OS[^,4AT!Y K,T/,F@%""J5*HJ
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M5*R;4Z9TWG3;U8,ZFSIM;>O1[ZN[!4I6J=,L/#VC.&]9O>?E7!&XV&<8%QG
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M84U"'T$Q>8"FY1U*/*(#Q#70:QDKD+CA.+2HJ==:^\91G"?H-,_90R% * 4
MH#1CWCW[?L7^]K;VGKNZ*CS\01@+H Z>,0^F(ZU'F<G8. <PAU::>S4(4ZCI
MIU!U4!(<WCT$=?!J(^/QU00;RB/UA\&O7I0$B  'CX<.OQZAX/!4!35 #IJK
M,DLF>DC:G_%UQ'_FDU_]8<U309!T H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M,A]>8-=>GR=&GDTH"")$3#0A>4- #I$> ='2(T!R4 H!0"@% * 4 H!0"@%
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M2-I(%3.8%" 05"\IAT&E$M@K7%&#FS_>5>FX-QA.2FM\6V1>Y;_;1$U<NW.
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M7\I?-Q7+:BUK(,YY&VS2[Q"WFZQA3CD7BHG[=404"U%%7J/K75W3NS^YGF[
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MYNDFX*7VZRQ9IQ<;F2\X;KVP7 W(<ITG!WRDB)C*IBD(J'7QCW#%#*.PC/\
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MVO'9)PS<"+&)FK9D[DD(A5O/LI6.B'+@S)FHFV/V:KA1U;2[3;Z%0I- * 4
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M+3)#;UF^9,X&*40#34-0#4!T\0Z=8=?CJ&1R4 H!0"@% * 4 H!0"@% * 4
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M]N&XKEM:8AFB[%T^=.%6YVR?(8 * 4!<!3"F*5,QMMP9K!MP<VM,:O<.M\G
MP3"[28MD;H87H]L490-%#VZM=<6WD.P-J!7*?,734VH+I+J4 H!0"@% * 4
MH!0"@% * 4 H!0'YW' FH  B &Z>CH'Q"'#QT5')1>38;:BVLZ'E&VV=Z3O!
MR'OTLC ]T7K:;O'4SG";LJ0C&=HP[1ZY@V<M.MVS-"0266<$<MVT<43J!S&$
M2&$0*!N'O?,O(O*>BY(AQC0SKQ#NE*E99[RV5H?%Z'BG$I\1[AINRYT;PR\A
ML-WC2N;(KO6=CCK 5EXTOJ^AVB;T$U8;*^0[EQG:Y($]];9C2#Y*X;4QSD^3
M4ED7)&Q4FQHXB*B1U#&6(8I /X*J5QR/LY53P+),<S91Q/WKF8LV;Q[4Q%BF
M.Q9W0T[>;H,2Y/NC)T,:Q;<W.KS+R1E9>\\88G<L)M1RP<HE;)M5T3%*F;M@
M,82@P)C5U,*-HF7XG'>=MO>2\OXEW VT;O-AS1A[?%+96VS9NQ[BB6R3FRZI
MC(6SR.:9!O6PX.T[F86Y:#J0QLW$CYXHJTE&RA ! BZI6>!<=FTR.A[JRC&;
M+H_NE278+S<U%[E%-A<Q(.70J33[:B9K^&!+*B#A _;/ -L<E(Y%R[[,"A-N
MA(JBF',0@'I%M"VH6S+8@+1MF.;P]N6O#1ENV_$,R\C.+A(1BA&1,<T3T#LF
MS)@U33(7B!2E  X:493##>]G7(.%&6/%[ DF3)>?=W"C(HN8U&2.N6.)$F;
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/ H!0"@% * 4 H!0"@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2127058d1-bc_inerdiam4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-bc_inerdiam4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y +R P$1  (1 0,1 ?_$ /T  0 ! P4!
M       ! @@) P0&!PH% 0$!  (" P$              0(( P0&!PD%$
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MZ>H_!R?Q@'V"&!:O8.GJ7P<G\8!]@A1"KV#IZC\')_& ?8(8"K'3U'X.3^,
M^P0P%6.GJ7P<G\8![WA1$J]@Z>I?!R?Q@'O>%$*O8.GJ/P<G\8!]@A@6KV#I
MZC\')_& ?8(8$J]@Z>H\E.3\-0#[ ,,!5[!T]2^#D_M\/L$,!5CIZE\')_&
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M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
M( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @
M! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
M ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
M@! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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M4\L(;S)NQ(Z@UY4@']4IY8PJQNK4:Z2*:("5,O" C,0F80G^J,:40RP6@U8
M0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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M $9AM">P8YOD]YJJC+P'%\LRD94G...*Q6@^D5T0Y2G(<BA#[2J)B!TQ+^B
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M=9+3LNO7C7BHM&=L6[5+DK8$7(9-HRHU(7JM2#IU013/U9%L>1A @&$ $0*
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MRD]-6U^*RMU5;Q2MY-\VMMDXN$4FYU;?/6RH(D54,0'"85CS<J0Y4"B8P&Z
M./AE(HC.$867/=;PVB5SB'R;K5;CUNROCIXBIC5+J<4(7E5M]HPK4EQ3HJ-9
M!TD8Q!,#8HU7J")2@XX0$3="/!/<.R>-V-N,J0;I[QR96>:G%7,Q!1>]H3K\
M-%T'EDU6N7[K4;EY:J,4J945KP=J.Z>@^)4R-%A;H31(]30; N ;!F*9!V[M
MD;L=W:C'L-9W76-(X^\?(_OTS$OUB\<MM4D[VC3^^E5>%HMS#UN\! >2?U(A
M( \<X\UT\QZCT:=)2 C/]%W-\^]%:5"*IJ 4!$!GRS$NR>X=G@G&,KSM6I+:
MJ?"5VU/2\$9<NRVJES4^H9/^3MOLJ^*Q;>!R5U7 HH,R$\ZB0W$>FU %N,3"
M,@X9 $:[]]\(SRN5FZ[V_HVF\OL>9G,-Y^U;BG&BQJ\*JJ5*/2]M*&;&X:M>
M#-DW5MNWF-Q.CJ2<-G%;"A$11Z(XBJ1P>G5$%S],!2\'"4!*(F VSA'7R$;3
M\YT-Y<Q+/VHIVH*4M>-/$SI74UJ.5TQX#J.9JS8%=ONLMK@Q=9E)QI9]4H3:
MX+FO7+63+0Q3:UN42KW0\H5!!=Q<U[-/KSI9LCT9#&,8A9B&$XQ4VHO Y[4K
MDK<974E.F*6WX#[N",J9=R;3;@>97TWWKIQ?4I\P;4FC7K?F(K[=7(U=,S+N
MJBQ>8EO6]*>Q08N2="*;Q1NL<3 8I.&8%P5#DQTZBSO41V@^8-.MU42CW)H6
MS)6[;O?-%M8/Q?=U!RYIG5-DVZKPJBC&W#VM93C+2-_&3<4YJYJ;I%Q345J?
M2VKATY*FDV7,G4D*TTF2Y%W4S/#)G9D!B+0JQ'G6 %4KHQP#J)FH)'F0B7KN
ML H)1-,G"$N(5-83K@<385F_7%><-'UGL*?02G==#62W&1VZ5!(2@U U)"E(
M"F+J8\0]8-T<MG'/9V';M;J>]C0_.MYGB,[[A*W%6DW1[U735A1:>?PFHXK-
M\EN%)@TM-@YMXQD2JUXUP W732.F<7"X4<]+44,9!8H%*F"X"<!G,)2&*SE9
MV6[LFIUP6'35&<[W$%F%;C"/54Q=6GX*>,IN&LWO3WC1&A6HPKC)4A3.7:UP
MDI1FYQ6 AB$;'I;PRX%1'CGQ%VA*7+%R^7R?5MJ4E+93QU,,UF>)6;B5NW&4
M?2:^#=9N[CJMWL6C8]NVVPKZYS'ZVBYK@4?JR92S*H01IM1!QQ&V2#AD S[D
M8VX693W6V<M^[Q"W:5RS",GRMKH3%1JMX(4-N]IMN,*A6U"-17HJE=*S;MS*
M"7K8>=34Y<JW5"B/#)$O2R#ZF<%&TW1-Z3*[<S\+>_&$7<IHKXZ>+[A+6KW<
MI;@O7%O,VUQ@FL;S G6 <(=*50X-T_.Y6*:?"NB!3&/T$BF-*0RG%4+76;LF
M]TXU=S\LIUTH15ZK\FM='+3Q%5O5.\7C!RO7[>8T-\F<Y6C)*LEJI7:((E.1
M8[LK!F5J)W BGP"0P@ <4]LHPNQM1G2#\GW>[]TRR\\_<MN5V$5/4JU^&BYL
M4;>W*U>S]9Z2Y+78V^FE+JAT+@3K(NQ,8Q3D,5.F,!; F  (#Z_BG+9')>MV
M(Q3MR;?NY?=L,,M<XA<E)7K<8Q6BC;K\"I\)HTRM7ZM7%FE4M&GTRA$ZR*%7
M1N0'ZRY4P#J\Z6%(;G3,YF(B'3&$DN6(XV4L&2U=XC<O[L[<5;QQWJ_!NK3S
MX&&?M:WE0<7-B-NX9HH-&K6^.H/$WG3FJ!#EL8[PRC<J)>I"U< !"AQ*"J&W
MUNZ-@NXB,5FLS)5JX_E4-)O;,G>62X=9N))*XZ.N+KU;>%%2F%,<:\AB!. @
M8.20 (R&<AENG,>7O1L1&FX_29HSG;'59I2HDW:CKYS2&7T_S(R.L2'T^YR[
M]_+LV09E0N,TI+5!MJ*Q"M2V1']03NUH9HR6<@R3<+BBX J2CKH7 -RGG]7P
M'ES1X7WB6;;['9F5QT6Z\=.T]M=S/TU;[R^ RM6ZY=YJ=*U556-,:.E>8]2=
M JMVNJ14'%:MUE2*P19UU2G-ZT6K(N4R)@9 QGI*<S*@91P<Q1#HC@0H 81&
M<HTHG"UUD4GY-#ZW9>[GWEIW+D(QN*4J)-NNS'=7@U%-L5F]Z@=P%R6PPM]-
M,I!:F:U\M:,[.;C!0@D+2V'5RI<(<)AX@/Q#L"6V7K=J.$!D[N>NU>8A&,5L
M;?2HEDVD/7-DO5TRL*_;>T>99L; &2:36Z[:6<[LR-@ES1:I1:>H]0HM4"Q:
M!D.J9(1;76X8CU(QJ8!.A6(J<Q2" QP8:SOUJJT.Y]2.?,Q85)3WN/=+5\9[
MMT*!7*]=5U6UE'!6-Z+8Z5%X%.CN!;,60['54;N&72N#N6I5TFR*!S*"49 ,
M(;/2AJ?N355I_LW/K/"EXXJ97XZ7=VU:&0ZY:BU:J-F><^K4J^FE0LZH711G
M="N6E?RC3#)K"#UD=)5,PI+IJ#:<IA*;BZ4+B;HK5W4Y-G\F;99W"HL94')7
ME="AE; 0J8HB0PTRH]9!4YA T@+P!MV[HY;-NU*5+\G&%-23Z6NDX,Q>OP@G
MEXJ4ZK2Z="9%;JUW,:.@[I%O,*M5CG;%<TI6M!3DD"J$$7!BU U.<E5ZN8)%
M^M$Z7]+#+V^'2NM2FXJFE*OC\9AF;O$+=E3MVXRG715KX:/7R!.JW>>VAJ(V
MRQ)<0(J');YJ\0&PK%4$A4O/?FX4^%1,./CZO(-TN6)=M\/5])S;AMIXJ^,R
MA=S\\N[FY'K=E?'37S&G0:O>+^EO7%7MYC2*DBJX*RIZ=<+42/4R($.@H=X1
M@U!F"KDQDQ 2'X0+Q[0-PQG=CEXW*6I.5NBHZ4U<[U\ICEYY^Y8=R[",9U:I
M5OX:+H-*V:Q?%05>EN>UZ=;P)%3%EU2X?/H.S&$!5*82TJF@W!( ];]6)Y[B
MR&$X65%.+KC[O=\(R]W/SG)7H1BDJJCK7X%TE%%K5]/*N\;5BU6%'I"0N>J5
M,E?+4%'/1JE!OTC$M,;"V!9$W$,U#B0P"7;OBW;=F,51U]W.86+W$+EYQG;B
MH8T=6^;#=1'GR^?E+U MI, MT50*%P?*(IW )=$4YE1HP4PIIE6$4^'K [ X
MI\@56[+M[U?*H)W^(1S*M=7'JJZ:X\]*>,FM5F_&U4;H46TJ?5:4J1 RU55N
M(M/614.J!%T@IHTIV=0J"(B?CZ4 ,(<,@WQC"-FE6\1F+O$8SW+=N+AABY-?
M!NOI%T5N\Z7YO);EM4^XEW(. =%<UX*(DV,0$Q0#I#TNH"?IN(P"(%]:(!L&
M8RY;-O*3C.5V4HI4I@G7X5XRYJ]Q&SU4;4(RWVZU;5*4IJ>GEH;2_KMN:T;+
MJ5STRVFE<>TNG*U%[23UCS<DF1%N*S@I:EYN>@J"/"(;$0XP">R<3AF1R.?S
ML<FKCCUDU%.B>+>RJI[MAU..\3SW!^%7N)6["O3LVG-PWFJ[JK1-1EC[QB$'
MM;J^43@3!M)42$QI&)D%1,IBB8>#B3/:W2;2\^P8]Y9?N+CF<DLS\J>C[SQU
M--LW[8N8X;FKV6O< G2VZ55U]#M>[24!VM5= 1#YB*1,!&8!D(X2VB @ ?)4
M.6?=D,IQE'N(C**E\I>*3\S]TX+7MG=9!3^@9XK]-_[7[A2':TUXO#+!5+V;
MO]XAI@,Y[?\ NM,P;-PS"+^H>']Z?\3]TY?]YB6'T#/_ -7_ -LJ'M:[BX/K
M6#*2D8)!Q!D$QS2#> @-JB8TP\([HYK'<);G<4?E4J4;\S8F_ON0P?MFQ:2E
MP65J+DEO.[@JM+]&NDR(Z<-0%ZY[L^CWF?'U-H%&J+AZW</"W49ZHV%DJ=N8
M08*4%HJ<PJD'9QA(.48].=I>S>1X#Q">2E<E.4.1+Q^(VH[!]LL_VTX/:XM;
ML0MV;GX3;\&ZND[YK%9OEK66C6E6I3JI15.K@XK)[B*R60,<XE<%+2_-+@ZW
M0$]<'UT./=LC\2U;L.#JVFCS#,WN(VKJA"W%VWKWFO@W7XBV7.C74_0<N6GD
M3#N)\(YILOYO+HLZY;6O6Z#8MR/0;C?U2F/Z+6K:R,%B9!1J=EU1%$[2KT=5
M!F=$Q4GB)G9BBWC@:2?DZ#OQWZ)SPD<'T?8%S1I@P7B73X]HN.[EIBS#49?V
M5+RIMVU="EV+D;*^8:QENWL;8XQ^[L@_RNQ53WF3:O2BNEZC1%J=3*&R*#-<
M7A@:JH)85+,\ =G'>-+SSIVR!?>GO 6#6VG>]KORU6[IP_DS(=YLLLY0K%@Y
M QE1*=C?&5U4QE2L#XN&G9)J-?J3!JY-TM6:LT.KJ)I==+/NEIL]S,W(O:X+
M>HF2IK4[ML=<M/;B_ H/B)D**2AUNK&!H*RHB40$I^$  =LXY8QM5\INAP7)
M9Z%N3C%-ZL:5^ ^;;%5O"H).CW-;;"WETSD*U3;USST#H!*83F.L2G,00Z,P
M<,N$>+?.,[L+$56+;9PY2[Q"Y!J]",7JQ;VZZ(VE KEZNZH_;W!:K"@,T2&,
MS<M[A)5Q=R6$B8&2"F,.@,JB '$!.;A'9MWPE"TK:DF]YDR][B-Z_.U=MQC:
MBJI[S;Z$OA96E6KY-</45K68)V^"BP#7BW"51<R92%,B8*.%+*;ZZH(E&;@
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MGU_T5XS1KVT_J3AWQLNFV88#!,P"/YX"^D/JQLFO-:Y7XC0ZY^=B]MN/C*1
M!V;N28CN$-X#X(IC15(^I -H#,1W=R7+OBZ65K!%S^CS9J<PH/\ YP:^@W<#
M]./"^\)?Z$SW.^AGMKN'=.]'@B_[J[TQ/4C=/^J-W_S'</WN>QI!#S5S'U\7
MF^^^DP7<HC]/F )>G#4<H&>Z6SGY>[RPPTZP2  &Z(W4 >39RAZ<N2*@9<=*
M/XD[=_G"XOOV]@CC+CH 0 @! " $ ( 0!P'*GXM+]_!&O_>QS'?X7]8V/C8]
M)^9QGZJS'Q4N@\=G/WR?L9QOEE?J7+>CXCXCYQ+K<Z]?TA^6;-3ZLP?I_2,<
M/2C]%:*G%G?G=Y:NLETLH$PB,QC*E#@K4U$=IQ'E AQ_6#%6#]VPQ>%N?Q<_
M59Z8NSE_JN6GW*S<?WQ6C2GO,^U]]\BZ#ZT>SI^RGABY'Z[. ZV/QC6M^!#8
M?'7ZV/TX\ >D]YK26<<_? /'+T=L0R !+9Z','I[8, 0V2V^/U85U@N#TN!+
M-5J@'M=6'_LQS%TXD>@R^0.-"!1 " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
M " $ ( 0 @#I'4-^(S,'_M]=D_!07T?M=F/M)E?C8>L>']X'V+XK_@KO]&SR
M(J;S=\?V:D;YY;\Q#T3XO7J;[]*?KS-*0CXP#PC'.<',5;^$ #;+?WHG05:3
M>B.PW?\ I&CCM_GKWH,RS[7R#.4_3QZ9GJ*T!_U2L3?Q&O\ _JFMQH[VY^U.
M;^,\1]B^Y_\ 9OPC_!VO4B=":T?QJ4?\!*1]_+FCQ)GLN'N\"+0"@:8#R?1R
M3BMHS-3Z/HWQB (RVC %T.D(P?/ UV_Z!K/[FE%HS&6@RNP,1 " $ ( 0 @!
M &BX_:3]X/V01P9GYO/T690\]<ZZ3RBZQ _^3V:AV?ZZ/.>?^3M_0C>7L _]
M)<(^+\2/D1W^?M#X[H_/OUY%KYAGZ/TH\UBJ'IO61W^;GV]R*4K+N-Z?.,PC
M##Y3:]/Q,SAKYC,_V1_^<LN?XBUO04K0CZ QKUW\X9FQ7;XC?GV/G_5L]Z)D
M+UF_BE9?AC2/O;6XUS-W48M%-@CR#Q#ZD5&924P &T>6#6()VRV]V>W;R[AY
MXFO &]IPAUMKW'3?O_MQ=_=E!Z#%F>EC_D3/^*M_W(D$8FZ@! " $ ( 0 @!
M &$'M>9>=L'S]P9#[_\ E%B_2CW_ -QOS[,>BOQC1GVTZ?0O#MG6RZ;9AB$9
M",]DPD'H2[T;)17D_P )FA\_/2U]5'QFD.WT_P SNQD8:-( =GC_ #0\,4I=
M!HZV:FL)SY+Q:_N#F/"N\/[#9Y<KZ)'MSN&_:?P1_P#=7?6B>I*Z?]4+P_F*
MX?O>]C1^/FKF1]>UYO\ "9@OY1\<O%+THK.43[_B&(" G,>;9+Z<-0)@#+AI
M1_$G;O\ .%Q??M[%.,N.@! " $ ( 0 @! ' <J?BUOW\$:_]['$=_A?UC9^,
MCTGYG&?JG,?%2Z#QV#O'^^)XN'T-T;Y97ZEROH^(^)&<:=[.U_\ L'^.;-4/
MKI@#G'TQC]&/FG%G/GEWXR724!+EW@,N_/?/O17\!UC53#UV\!D4VX0'8!1B
MQ?E>'H)*+4)^A+U6>F'LY?ZKEI_SS<?WP6C2KO,^U]_F\1]:/9T_91POF?KL
MX#K6_&-:\_\ 8AN'_;]<"/ 'I/><2SD=W/W(AD0$_0W\^_TH @!V[S3V[Y2Y
M>:+JU N$TN2^>NU.7ZU5_O8Y@1Z#+V'TQ],8&!, ( 0 @! " $ ( 0 @! "
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MQ?=*7J0P Z=W[B^Z4O4B$Q-=(ZARS42Z(TY</&!]G/,  (%Q-6 $ ( 0 @!
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M:-X#+?0K@W=RGO1C1^"\E<Q]?(^;_"?28,.?Z.0('*!&0<WT<D 0$A#=Z$-
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M$!,/AY \$.0I(" [ V2Y_P"[!K:"J(#+AI1_$I;O\X7%]_'T$8/27'12" $
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M?*OAWV<'UIH)(Y&M<J103G9#8>4=]>KXRVB/*,> ZL=![T6FI9]R>",3(@
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MC?GV/FGE<[3[SQF0K69^*5E^&-)^]E;C7,W=7C,6H[![TPY.<(/$S-,3!/8
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MW-FV*\05@,^0=O.&R)2@+@]+@?[ZK5E(/K=6^]CD?I0TD>@R^0.-"!1 " $
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M?$(A/BF,^?D\4?HQ^ X<W7Y7<KIZR72:<A'9*0\X[!'FV1=',=>CT&HB ](
M"$N+UNWF'8/H1E%JOO/H9)5ZN?H2]5GIA[.3^JW:D_AFY F.R<JBOZD:4]YG
MVOO4V+H/K1[.G[*>&5V2]=G M:X_[QK8Y_D0A+PUZN2E'@&L]YK2RSF)K,BF
M4_!S@._E$)"&P8M: @)\7++;SRBNE.4%PVEV?SU6K_BZM][',8HCT&7H-WA'
MTQBF!, ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0!M#J/ .8"-4CD ?6F
M%T)1,'.).KFX?&,7 F)3TK[W&C]N#[VA@,1TK_W&C]NC[UA@".E?>XT?MT?>
ML, =;99M:O7QC>];0IB=/;/[CMNM45HN]J"I6A%ZE3W#1$[@4V"Z@)E45 1X
M2F, ;H_1X1G(\/XA:SDE7JY*7@/Q>TO#;W&."YCAN4:ZV]:E#'1Y2:QTU7O&
M#/\ LJL_*C,+GQQZT. 1+6J^8!$HB(& PVK,)@/+N&-C<MWYY"WEH6K]FMR,
M:526*\)H9?\ 9"[59G.W\U?SME*Y=<HJ-4E%TPIN;:OWQ_939_\ ]J,=#_\
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M0;Y;PWRGZ4 .(NP.()CN"8;>]#D!5 " $ ( 0 @! " $ ( 0 @! " $ ( 0
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M\\Y\GIQB<C5"J!! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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M3<II%2*!" !2E "E*  !2@ 2 "@&P  -@!N ( KE $P @! " $ ( 0 @! "
M$ ( 0 @! $0!, ( 0 @");^3O>GS<L  "4 3 " $ ( 0 @! " $ ( B7T>&<
M 3 " (E   E :R8 0 @");?I=V )@! " $ ( 0 @! " $ ( 0 @! " ( )3[
ML !"?T>+Q0 EW?3\'+ $P @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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M ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
M@! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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M6ZEJKR^V.R:$*85F_F>9PD(*D !&#*B_5,9EG*7I;=NR0CLVQ"E< ( 0 @!
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G! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2127058d1-bc_patency4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-bc_patency4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!0@%X P$1  (1 0,1 ?_$ 10  0 !! ,! 0
M       ! @,)"@0&" 4' 0$  00# 0$              0(#" D$!0<*!A
M 0$& @,'"0P1"PX+"0   0( $0,$!08A!S$2"$%187$3% F!D:&QP2(RE%7P
MT7+2)%34%246%SA2LB,S4],T1'65U28V=K97&$)BDJ*SA+1E1B@9X8+"0S5%
MA9:FUB=WEUBC9'2DY+7%5F9'"O%C<X.3I88W9Q$  0(# @<&# T1!P,#!0
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MNJ#62\!TNYZQS#@(9$'>*\LF;0>IR2[,G7_0,F0$07P(B(B(WC%5?IY[+O\
MO"9:?LIKZ>U7D=UF?J:M]H51](C4M_Y%=WP@3]/+9=_WA,M/V<S]/9Y'=9GZ
MFK?:%/I$:EA__17=\($_3SV7?]X3+3]G,_3V>1W69^IJWVA3Z1.I7_R*[OA
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MO"V</O8HV./M9)_P2&VG>\!^5NE8P[IE?13<UEU2NH' %VQN*#%=DC2B,4'
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M>2)]K)![YJ./K5 4[U(7N&C^HVG2]@.^CFQY1C&SU5]%MRYWS5+SH9V8(9,
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M^S2R]8<KYQG\(75WMW:_-Q*,4(Q$8B@Z#Q$]AKDKE= KBU9(E CU[>N"XTX
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MW7CN--/@<<2Y%Z_&Y('*6[O:$^4VU1G24]C3) N3+J4[7E48>$XZKL7-IZO
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M?H];SOB<?TK()G!<"-489Y9'(38)2,3*1@D/>YY*0&X[FVL/X=O"IF$"03;
MAW %I.7P7WS>S\";PNM920X@*N*J /!#](;;SHR -'J$9*67UH7SUZ8B&E=Y
MG+>$_?'&"ZPW=K\RC%*,4%&(CW \1[37)7*Z!7&JC"6.K;UP7$GL99^\1W.-
ME-R7+D7M95R=X+=WL^HPQ;%&'(3A]RY$_4D?0J60[]3I#L7/<VGF\016OFG
M2>%?11<Q!NF4ZV 8. 8EVM-00?K>=W?K2/VM1N&&P]%=H3#T%5S]'K>=\3C^
ME:J"IS@H-0A@$\WG='K2-Z5D"ICOKQ9TA$]#B[&^=\,09I*E6]3@G7EHJ \7
M-1#B5#>;T+50(ZP[J-EE6SIKPG:=\PVDX_9;N%A6IPAP2D:>\&+L#H(X=UMH
ME/V$'=/"5I,O.RK A]QD]QEJOAX_-BUY<# 8A0Q4HQ$8BI'SQ/H5]@/[C5?<
MSOA42_C;>I/ 5Z[V!(G);9N2B]5:W52Z.]0E2U$^\&Z@')2"ISSB=P8MY5KP
M$=4M[#V$CY5(7O6S%!NT-H^8'LM7@\ JUMLPZDC52.;SN#A]1S&X'?(-K"^Q
M><0BMX8L#2<85[VP1ZWG>K)QQH_K&K )$4C:IY^AS^;SOBD?TC3!(VP7&F*E
M#2A),O.#OQ]:1^']8UJ8#%FZ\<!5;+7@95A!Z9:93,TG(_4AQT!-6NQ1,:!$
MA:96F#]6D/;++9/\<7R++*4#_P#,Q:]]O(AUWZ,PCXQFXO\ #35@MWVS@*UE
M(T(CV)$C C$1B*$DE9&^D[G"U4W"S>]111.+I-6#@SQTUFZZ&J81+JSWUH<=
M85,67\Z@Q(SM2'<!+^30<>#=;#O:R8755SFRR54<,I;$_P"GTX-I=(6VVS:3
MTFSEG:1488 '(3IP2/J./\B,?!;#0&)AC"V4NY9RA<J!-)CJ*4PIA&JEY,:!
M%A X@.25I )QT;S3!1%<IH4JQ% *X> TGM-:/9?M3PA5#DNWNFM7_I5S_.SG
M '.^#VS-P:.7KY/;;8ILS>;"7X0_I+3=MK>?0@_J^4L;[>_+%0QBC%$",*G0
M>IVVC"I%A@<BAI4(TA0[DG>5!\&+U7Z/,YKGYRK!MN)D/7+9TZ*,/V2[:('\
MJKY)XO?#&[3VUU;21_F=5C\#3]Q:MQNQ3YCZ'PFJ[L5DT2' C]<6\!&!9;*I
MI1&(N#,N"(YT=Z_JXM8)&>R/WYO"HF=A=O.X%I&WR$B^KW<,??C=8>X?]XJG
M@3NXMMYT9_X]0^"2NM7SVZ9P_P!47EE^<:CK@NL-W:_+E&(C$3<ZS%.*"@Z#
MQ'M-<E<KH%<2K[$.K;UP7$G?J;B<>TRGP.7(O6(K),,,%O#6=C;%&^QDGN ?
M6D/>;3M> /?+F_99W37T5W-XJE=0. +MK<8+LD:44'$'B+$7BCI#A_,TSPP#
MO>]3MP'^4U$W^)O0]5/G$NKPMG37A&T[9J%TG/[+=US%J6P_ 0 [P4'0[2G@
MXFVB4_8!OGA*TEWG'OL=ID]Q8JVO+KT8+5",4J7_ /LQZ[0IBK8^?(W>\5AN
MZ"US[B=]6F?'&]2> KU_T?\ \=#)(?QK<X(X[!NO=;RC7CYI+VZB1\JD+WO9
MAMVA]'R,'.U?\/JUMRPQWB> #Y4MK"Q.Z*WB"$&[RO-6,"(THK,</2/1CM%K
M4S"WJATU4SE!8..F>_N5D:/XWNW^"4SJMEGLG>-[X\%'=F+7SMZ67=HQ#]8S
M?DTU8)2V;^):R2;;$\SO-O,0P1BB$$<Q3 Q@C%")\,^A/4<[SVJF86;RBACS
M-5U?JK.!T,;];/?2X35E=?D;@Q;#O:T(%3<_:JCKI2V*_P!/D?DFD/;:3K9R
MSQPQAHW$_*AL,QE6R@GC%7&E0C$5F)X4/C/<:T>R?:'I*H<D[RU?>E6^-E.'
M_P#GUF_N]>#;%-F;S8R_"'K3;MK>?-QQ_-\K@"QPG2WORQ5.%0Q"C]UB@G&@
MZ[$%J,&%0X<4[RI([V*_>4>MH+7?SE6"!\Q-R16SKT4/Q2K<_&F^ /\ &"+Y
MS:Z-I'SH5G::?N+5N.V*O,?0^$U7=BLF8W>/N!O!%EKB4L1&(N#,!Z(_H?/;
MC.Y3.WMX5$SL+NI<M(Z^?PZOC\<KL_**I^>VWK1G_CE!X)+ZU?/3IB8Z6WH,
MEXS^N"ZNW>+\VC$1B(Q3!0=!XCVFN2N5T"N+5]B'5MZX+C3H]3M%/R7+E7LT
M=^R@/6]-;PMFX6O1.&ER9ZO-(3:>[Q\93.J/7%?1/<WBJ5U#> +M8[K<!F/?
M*[-2U:(Q0<"\4](=\33/#\7J=^4U%;T/53YQ+J\+:O"=I[S"Z3C]ENZYBU+(
M8^9I./@([ _JMM#I^PC?/"5I-O(?E,<?,2>XL537UUJ,1/,YBE&(53ARB-W!
M6#5_<SOJVP1JV]2>FO7^P!\=#),[GMK<_P"0%U'2WE&O#S27MU$CY5(7O6S#
M9M#:/]MJ_P"'U2VY(?@IXD]E#VUA?8NZ*WB#DMWE>:L8$1I168Y<D>B':+6Y
MF%O5#IJIG*"P<=,]_<K(W[+7=_!*:6RRV3K;WOCP4=VEK7OMZF%W:,']H3?D
MTU8)6S@. +64C0B,4X5+\6)$Q4,4(G!2O0*T[A?N;[VJFX9>]ZB4413U9]GZ
MJSA=#$<<^-_G5DOXC#N$=ML.=K7XU<W:JCAE+8K_ $]S^1Z0]MI."<L\,/0#
MOI3\J&PW.!;)CRE<:$7F2Y-K7*.U+@K%LU9%_P#MG0JC-4N?,AEG?53DN=2<
M54**96H2%#CR<Y *TG5B0EJ0H8@N:1:H,18NOQ-M/),EX1F6HN</]$F8F&(>
M7&W@6I>TYN<!@PY55+<TS!+)@X@X<"P0[>D.XL[MH:>OS+FS;[N*V9FS:'2H
M4W,VA<](B0:A(5"L1HD$2E0ID*.E,*7FT#6<[OG#!LS=1^M/0G170X71?%49
M54)I<6@$B!Q#  [+O85K7VG]06LG3K6;_J+1ND9/DNIQ+87OS6@BV+X!T6P!
M PVG +5XS^"#.'=RNO'[35C[GM['Y=-6/Z=,]J/=K'OZ*>OX_P#;KNAVT_BD
M^!_.#\U]X#_ M8^YS/+IJQ_3IGM1[M0=E/7]^KKM^%/XI/@@S@_-=>7VEJY[
M<@SRZ:L?TZ9[4>Z3Z*>O[]77=\*?Q2J^"#-_\UUY?:.KCM2(9Y<]6/Z=,]J/
M=*1LIZ_A_P!NNWX4_BU!R@S@_-?>75HM8 ZIYB6CRZ:L?TV9[4>Z4G94U_$0
M^;KM^%/XI6E9/9PD$?!A=_?;HH]6=V*>6K\NNK.,16S(Y<VWKU:9LGZ_ \29
MEWW<960S.+Z',K.EL!YW6ED7L]T2Q,R*/F%1+HDK@NJ>F*=+9<WI5H2):IU5
M4W)+3-R-$BR\01H"@=4%Z2\%L+M=FD5T:4:;U%\W+,,V@?*DM#CA);+#78S@
M-F%;,-F_0K2+5]JUI-&]*),F3>\N=/<YLHQE@/FN<R!S6X6P)XN%>X/TU<E
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MXRX 0)PP,5G#LFZJ-.-5])>TO3*FIJ>96/IS*$@QCF";GYW$9@+FPPXUE?\
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M[F(N2Q$8B,1&(C$1B(Q$8B,1&(K2XR(:DI4]ZGD.!(P!)Q&AP#$5*9B&I2$
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MB&'#UE.<'D)WU.Q:$M7C'8RVZ<H]MS):XLZ\N:;?-D4VR,P\R,J\Q++S9I5
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M$"%0YF5C[7EEPXTM%2KO5PXR"4ZKCK/T.8IQ6_5:LS/_ *A>1E)3H^,B9:#
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M)$!N+*)_ZB6$JX]@_+2PZ++1IB_LSMMK8XL_+,RB J>E;O7F_2+A349%.$Q
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$C$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2127058d1-bc_pipeline4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-bc_pipeline4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ^@+X P$1  (1 0,1 ?_$ 1@  0$  00# 0$
M       !" (&!PD#!0H$"P$! 0 !!0$!              $% @,$!@<("1
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M6TPRYBB&:'N+YDAF9'V"MV-I%*8?/FH4')H&20UO[COT!*JC=%75$Y=3@);
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MP4N[E57<$XA4LN5$,BQF9MC[8<8,Z*;1+?)+TN25=IR1[7!KI6?**M'EBE.
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MJ?U,GZ0O^M"N:,2Z^_YY]\K756E*(E$2B+\E[;)WENK;*B8$UTU4#\ RB9N
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M9LU37M.+'2+!ZX,M2I8,LEN%X@YQ($,)PKC/(_*=9MCV#8K+F-#%OE98(#M
MY!R5#[.%SR8A(&C ,VO(,J[V1&Y[:[+&T*E-^WKBJY.5[>*VJYBIH6]QP#B&
MQ4;35DF0#^RTIHF6FM:YT>K>UA<P@P:V).!Y)APA<NZMS^SE9>\UL]UXBXYS
MJ5LB;UE/++#5RGS9<MX>P]=- :(B4T M#B8"!'=]BZ6JSW'$"G*MF%@M-(7%
MI6K9)G%5.R4D3'8NREL100+V4EN>[$I3:!J 5W"EGZ31RZF$!,EM=#^T 8=U
M>!;076+EOZMN9KC,%)5SI%J$"[JICF6H9(V8P77=RF@:6>'0UUT6G(:COC^U
M17=&L!M)BD?V^1>G[H/M+R_VP^,KG#E QTV+,PD$1!.XB39:JF#>!)=T:R'$
MP:A[C3?]2N1M*87!4<,HCC"Q>Z9C7[S[N+L;:R(]\$D+Y!09&SF*I 'J#['N
MZ\+$F6X##A@OT=?75C7$-^:KWC;.:JET1'W]71F9U!>%8J+&V=N2'Z;]E31Y
M>=-85?N'R)WC;-!_;4NN_9A0T[,ZFL*O,?=\"H,;9S5D1^FT_7U-'9D*NL:W
M/W%.\C7VQ+KA]]5T9G.4UA6*]XVOMB/7C[X:FCLYRNL*SAXE.\;9VU( YH<(
M=[G?1U='EY\*FL*R.7B3O&U]L2ZX??TT=O.33ZM.\;5I]51YVO"]7G<+6FCL
MSJZPJ_</D4!C;.8JD'1'WU-'9E/=07A5G%\2O>-M'Z\EZPF_9U-&EYTT^LC\
MB QM@?74>NT]@X5='9G33ZQ.\;7O]E2Z _LAIH[,Z:PJQA3O&U\U1(?IM/8$
M::.S.FL*LY^)7O&U]L2Z[]E31F<Y-85ON"=XVOMJ/7_LZ:.S.FL*Q:>\+7VY
M+KQ]H]7J&9T%X5?N"=XFSMJ73$?UU31V9U=/K"J+&U[FBB6Y^B'WVY31F<Y3
M6%8G>)L'ZZET^J:FCRQE[J:?6>X*]XVP/KJ77B/L'IH[,Z:PK,JT]Y&OMJ(#
MK^>ZIJ:,W/@33ZSX/@5[QMFNZJD/TW[*FC2\A4UA6</$G>1JWNR);^]POV5-
M&;G5T^L]P061K#ZXCUX^T:FCL/TDT^LX>)0&-KW/VU'=W=.%\SZ*FCMSII]7
M".%46-L#>51Z\?:/31V92II]84[R-7;40']-^RUIHS<ZNGUON 4[R->Y^W(]
M<(^R:FC-SJZPK.'B5[QM?;4NN'WVY31V9U-85F-7O(V<Q5(/IM?UU-&EY^ZF
ML*PJ=XFP/KR77:_KZ:.S.KK"L3O&UZ?54O5'A>UPJ:.S.IK"KRH+(V#]=2ZX
M1_7TT9F<)I]7DBG>)L[:EUW[*FCLSJZPJ_A4[R-8_7DAT_1?LJ:/+&(II]9E
M5[Q-G;DNN#WU-'9G36%9B"G>-L[:ET_V5!3LSK2;PK,BH,;7VQ/KAY_Z:FCL
MYR:PK.%7O&U]L2ZX1]@]-'9G5UA6* QM?;4NNT_7:TT=F=36%9[@KWC;.:JB
M/TX^_J:.S.KI]9D6D&-K[8EUYO;/6K1V<[XE-85?P^\$[R-8;ZJ77#[1JFC,
M.(K5K"LX5J[QM?,42 ?TP^T8!IH[,I6G3ZPX!\7R*=XVT?KJ77=4]-'EYTT^
MM"=Y&O3ZJF/TP^^IH[,Z:?6##R)WC;.8JD'J<,P>PH%-'EY2KK"L]P" QMH?
M7$>N-[X*:-+YR:?695!8VP1^K)=,??4T:7G[J:PK G>-M[:GZF[^R&FC,SJ:
MPK!CCQ*]Y&S3ZJEUP^T< IHS,ZNGUB=Y&L=Y5(/IM?9-31F9TUA6J]XVS3=5
M2'Z8??U-&9G36%7PQ]W G>-LYBJ8?3"/ZZKHS,I5T^L6GO&V;_9D]_\ /#[1
MJHIF1Q]U0WA60P8UX5V5M*BJ/9D]Q,XA[L1^A((A^;'=K0ZGE]6["M^56U;I
M@M?>'^\%Q=LK8M9)5BH7F_OK-*Y6ELJ1.1902G$J+D*9!'0P;@AO5@'TDN8^
M82<6+C"]5F[0UE$UE)*9^RZMA.#*0V/=7T_\@,LJ.P';MYC&/;,N;\PME@(Z
M< +0']"\T2$ W2#<WBAN;[HPU] ; $]F)(.1\S_$<OR__-.X3-\==40@^934
MCG#AT:6/B 7=E7=%\ZI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%
MB_MF_P FK)W^XF+_ )U,=<&\?\H[WV_&%V+93^?2/?=_=*R=3^ID_2%_UH5S
M1B77W_//OE:ZJTI1$HB41--:(N-'S#>*9-=3J]D./(B]7>3HJE!LB7#DR6-V
MK-8<@@X6R,9DIUDC"[LB-NZW)"VZW"3*5<X 'NAKCOI*:87F8QI+V678,;<.
M \&%9>EO^^*%M,RDJ)DMM'4"?)LP'5S@01,;@^<"T0)CB6TIYLO;.N4;MHOL
MBX4QM-;MAC8PYH6DD4:74UE$^&"I8TF%W;J%,Q)+!V1.U,!D4U/=E*!MVMF?
M=E!4O;,GRFN>QMD1YN8YQP&,%D+JVSVHN.7,DW36SI$N9.ZYUF'VHA^T:2"6
M.,!$L+20 #$ +\,@V2MF*6/:,DDV!,4OS];L\?8$G9VA3'?7I6>)BB,7L>S7
M%H<QDXZ%N0MB(ZGM2% J8E+N5I==5W/?UCY32^P&Q,<+1B!PX89(X1A&5:J3
M;;:N@I=#HZZ?+INN=-#01@>_Y[@81%K 7 $ D D1 (WK;X1Q!:7-K>6N-87;
MW=C.W7)]G<HL#>FO:Y%?$ET7B:H*E0 Z<E<TKI0J]V ]F4 X@8PZUO:%2\QO
MVAF?]\XW>_A7 =M%?CFN:ZIFEKJ1M*<..G9"S*Q?,%D0' M@ONQ]LLR<K6G(
M=G[$SRFRHR6V;$G&%,ETE:VTR<U'N56I4E+0R:EH_/2IKRY2.!DU+LPK"'9!
MX5;$RZ;NFV0^2PV22,?TL<<.&)PX8X<.-9.EV[VNHF/ETM?/8Q_5Q& _9 ME
MEL0;):TEL6P):2TD@D+GEC8F:,LK3'(^VVC,PL+98,K*TMR);6P:VEKM4K%N
M;K*W2X*:%I96:!$DB%  (0H &X%<YDMDN6)3 !+:  ,P&(?!!=9JZJHKJJ;6
MU;S,JYTQSWN.-SWDN<X\)))*ZQ.4TW+3#@<SL\Y^8E%*ZWM+BD'_ ,SD7K^Z
M#Y]Y_P"V'QE<^[?#8NZ[$FT 2W*<ZK;B9ZD6A-1,5&,61)!<J  >Z#@6K<<1
M$-X-VN3M&PON"IAALR'.]^RV,.XL%NOJ-'WH728PZR]9,OQDX,[MI?#^$_ =
MZX#G;BFO.]6OG$UL3:C!N*&8C"?C"_507/$!SA"(P<.$X?T? KQ^_A ]?\^I
MIG"AN@9E./I>W"'TX>U33!G5U.,RO'\/A ]?5TSA[J:H;F5&?AS+C7UCC[8U
M-,AC/=35#3D6GC^'PG3USAU::8,Z:G&97C\ ;]SI]/\ /"FF\/=34[1B"G'X
M!_? CZO#]7UZ:8,Z:G;F5X_@'[X'H*!U::7F*NIQF4X^AV\>?]&&E-,SE:=3
MB.+N*\?@#]\"'TX=4*:;'+W5=3C($X_!\(Z/#W?9IIHS]U-3C'!7CZ'P@>N^
M?05HSJ:G!R)Q]+\)-UP>^IIHS]U:M3C,IQ^+S+D>N_94TT9^ZH;G R)Q^_A
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M8<<?-R5$0KC5D3((&<?&%G=G/YJW]W-_PW+(D@ 4A0 - T#V*Y*P9QGWU1$
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M1:JF!$JHH.@[^G1HB:!S@Z5$30!WP :(F@<X.E1%:(IH&_H%$34 YH=.B)H
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MC@RN[3:63M$G/"D:=9;D%]EEL#HH#;%&EA;TUBWJ1EP4"^MM"AV0>!N,ORC
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MQXU>)0]J+UH=2FC<"NN69W<:<21YJ72*'5"FBC,FN69SQJ<2><D'1*7JC31
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MN8FICS5I\H8#]> .B'4I;FH+FA]%4,AE^$!T_P#4I;FH;F/-0<@@'UXNO/U
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MT8$'5XM;.YN;:P[H&V(!_=AYS3LKV44XS950Q]#*;3,>R-IXMMMN;$$'YHC
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M6ND--H39TJC%)0NE&79>?V9F/FV)D' NM!KHM('$VU-AK:5G>TGRDSU@E9B
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M_FG\F?(?K]YI9^,VFL=V7F\SHSO"3LM^<WTO3>-H?)(&9_R?OS9\A^!I8/\
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M.U7B,7?[ 7K1]C@TT1V.)BFNW9VJ<1RZ:]@ /I!U^8 4T-YQE-=']5!@Y>T
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MMDS9O5L?&S8)A^T+0Z(ED.QFRN$IARHRKWA*</3!C":X4G$NV2I=M)[.#WD
M\2?VG(33&8_:7SPM9-;,Y.AK*XCEPY6ZO<KHG;*7]F<5R)@0!+7!J]I!H,Z9
M+EODU0IIDV1:A^TZMKG$8,Q;A!R80<*[+<>YJ:_:2AI:JJIZVZA>]-25PD.<
M'2!/?*:"7. P.$RR'-C![7"'>E9"S/;]:,9YBQ9AV5XTDZEGD"_QQ%!R8$D@
MEC8EF&0K4.]X-N/[A^)/WR/V]X*:5VY6M@-I;JJ&*(CV/4V0=?;9,Z5(FRW1
MF.8RT( 6GY(1B0,I75J'=C6WQ=E?>MVU,@BBEU,YTHVRX2:8!SB7V; >0<#
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MC7%6^37BUY>O-W=V:3FZ.-HWW=RHJBD4W [$&SU'8=(>Z::-X>.KM=[!X%K
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M-:' !H:YK@ (0.%HQY,"SK]\.T.M95]LIZ-M]L,QTR>6N,R<^;33*68YY+L
M<R:]SFM@TS(.A@@N5,T[ ^,<V/67)*ZS+)T5DN6G#9^>[A]B;G%D;B&O^S6]
M7[[CQXB"3S$GBW+?JWCDJ%\5Q(XH*E H)D1$!$V[4W)3U#YSK3VS)SI3B1#!
MU186@= 16(N+>3?5Q"B;32Z>9)H:>LD-#FGOY=<V<R>UYCFGOLP A@BLYFVW
M5M&^TM%;JYOU+6WM[92]NA1[KNSHID3/=78VZ5O;=T7 EX:@ID(3A"/!* :
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M93>(<J'?AN6/_P @N_I.\%/1M<HUS-E'*P?VOL?C2G8S:+S&;Q#E0;[]R_\
M4%W=)W@+4/)M<HR'^BEE4?\ O"Q^-*=C=H_,9O$.5/7?N7_J&[^D[P5/1L\H
MSO\ ^:CE;^P+'7_TI3L9M'YC-XARIZ[]RW]07?TG>"IZ-OE&O-1RM_8%A\:4
M[&;1^8S>(<JOKPW,?U!=W2=X">C;Y1KS4LK^#K#XTIV,VC\QF\3>57UX[ELN
MT%W])W@*AR;?*->:EE;HM]@']TQIV,VB\QF\0Y5I._#<MDV@N_I.\!/1M<HU
MYJ65O!]C\9U.QFT7F,WB'*@WX;E_Z@N_I.\%!Y-KE&O-2RMT&^Q^-*HV,VB\
MQF\0Y53OPW+_ -07=TG>"IZ-KE&M?Y*.5O!]A[/?6G8W:3S&;Q#E4]=^Y;^H
M+OC_ &G>"@\FURC/FHY7\'V(_P!U*O8W:/S&;Q#E5]=^Y48]H+OZ3O 5]&UR
MC.G\E'*VO^X+'V.^E3L;M'YC-XARJ>O#<MDV@N_I.\!3T;7*-#_HI96\'V'Q
MH%4;&[1C_0S>(<JOKOW+''M!=W2=X"!R;7*->:EE;HM]B']U*'8W:/S&;Q!0
M[[]RV3:"[^D[P%J]&SRC7FI95_L"Q^-*G8W:/S&;Q#E4]>&Y?^H+OZ3O 6GT
M;7*-\W91RL/_ 'A8_&E.QFT7F,WB'*M1WW[EH8-H;OZ3O!5]&URC/FI96Z#?
M8B'_ *3IV-VCR4,WB;RJ>O#<MEV@N^/]IW@*>C:Y1H/]%+*W@^Q^- J]C=HS
MCH9O$.5!OOW+9=H+OZ3O 3T;7*->:EE;P?8?&M3L9M%YC-X@M7KPW+?U!=_2
M=X*>C;Y1KS4LK^#['XTIV-VC\QF\3>53UX;E?Z@N_I.\!/1M<HUYJ65O!]C\
M:4[&[1^8S>(<J>N_<J</:"[^D[P%?1M<HQS-E'*W]@67MN@4[&;1C_13>(<J
M@WW[EC_\@N_I.\%/1L\HUYJ65O6[@L?C2G8W:/S*;Q#E3UX;E\7:"[^D[P4]
M&SRC/FI95_L"Q^-*=C=HQ_H9O$.53UX;EOZ@N_I.\%/1M<HUYJ65O!]A\9T[
M&;1>8S>(<JU#?AN7_J"[^D[P$]&WRC/-V4LK>#K#VG,:G8S:7Z-'. ]X<JCM
M]VY4_P#R"[^D[P5MU?DS>4ILG^V?&395R@C?7* -=R9=N;AM^QK'*FFK<<-R
M(4J:0F PG-N$X(".X%<J1L?M$7"6^DF!IP1($![^$_$DS?MN:E2'6+_H'0;&
M$7$F&& !:!'-AX<B^V7DZME4FQKLDXOPC>*HW4L;+*ZDF1'%%0MP2^R!++H[
MY).Q71;:T[KLVQ>Y+86J@I@8UI:)<(1-J(^];/77J:Z9-WN-J8QIM'):<2XP
MX!& ]Y?EMO9VW=O#V_O#:AL6TLZ8UDIN:5)ELDRSP%[9?6.&1SBLY*S:\Y2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB418][4/\4:W^,3"O\ EF@5<:J^R']MG]X+-W!_,#^XG?X3UD$7
MZ$/6"N2L(<9]]:J(E$2B+28-P1UTW!UUWM/5Y]3+P(OS=T) (AKO;AM#%UUU
MT !X)M0$ TZ=6T,0PE+#H1(@"O*4P&W0X0>ZTU'3W72$=0"I"&'$D8Q&9:%%
M0)H4PE 1'4."8 ]R&@Z[NF]KKSJEH ]\<$4LF& +4*I +PAUT$O.#F:\S7@Z
MUK RC$A,.].-1-4%1'03!P3 &@\$!YNFN@[H&K3 QSA"('&M1#@)A* @;03
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MN: %:8]]#(AQ0&-?++>X9VA,Y[2^VFM@^ Y'O9]%-M-G;(_M!VFT86#P?$#
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M0A(#J/8C:B(B81 H[HCNZB(ZZZU\SZ(7.BZ)/OF$3C7ZYR[XER9;9,L@-:T
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M%TWM;/![G&*(WP\!==\6>R7UL_D.B)0#1.M]\Z]M8.'636-;.=9[QQ8Z39,
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M5TVGH7.<ZRRS%KG !Q:X@N:2 ,(,< @LE"VX%+P0$HF  T$2:AN"(Z  ^ZT
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M$HB41*(E$2B)1$HB41*(E$2B)1$HBQ^VF1TQHU?XY]F__K"XP"N)6",IH_\
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ME$2B)1$HBVK.V*ZE$(F49L+X6N^D45D+%9N91, MUT[M%XWV]\ D 3@-HM<
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M+[%!RBH6S;<NZ5X8LDLKI$]B82 6Z[.D5,3&53 VR+JO1TLSFTT\RA&+A+=
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M?[EFCRH6XJWQ44U5P$PZ%K+R[WND2J&?,=-=6T,HM# ! OMOF--K,"X$B!B
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MH,B4Q;\JP*;P[8^89LZ2O+$^BJL <MFBVL$795DCK"TJ*RMIO5[(M]'T.[[
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M+0>6-+08-+2UYC@>7.#07 @QBM4F^J:8^>*D_LW%I$6DAUD. [T%I!-J())
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M36;UFSD^]BVU73%-0VS'A2\X _1 1RQ\PN*0F#F&%*Z*(AZM?+FT!C?M8?\
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2B)1$HB41*(E$2B)1$HB41?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2127058d1-bc_sensitiz4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-bc_sensitiz4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+@)  P$1  (1 0,1 ?_$ /(  0$  @(# 0$!
M       ! @D$" ,%!P8*"P$! 0$  P$! 0$           $" P<(!@D%!!
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MZVGJ344E2ST81TY,^5GAFZ66B.?@"EMRA
M                                               <"I=6NCF=#5N5
M!2SM$E]%4UE/(F:"HZ*M";,2K1.!P.$,@#.EKZ.N2:Z*JIJN6DS2J92SY50A
M*H$K1-<E:TDJ!D<#RP%I+<)U?VAD\G-V=&UL*KJ95'2'7UU-1E4U<\S*53R3
MJ9DLILY>B>BA)FI4,A&>0*&+I<#2R4,US>7-N:&Z29%/KG2NI:&CI])92T>4
M5-1.ET\K34HB**LYED(*ZBTG/S;2T).M6X-],T*33JEN<^NII5!-16')31S9
M=6N8FG7)JE5"$H5I%IJ41))6DDP+Q;W9?*(J@           D/A\.V H
M
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M-CM/5C?J=/XL-FQ*@V,T=5M^IT_BQ;DJ#8[5U8WZG(^H(M0;&:>K&_4Z>/\
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M^[+"Y'GIZ"CI#4=+24U-IZ.ET$B5)TM']3I=&E.E \I1S .6
M                                                           #
MJ1OEI(\+VHS*/^NC1V\M"ZD>7.G)#,&5CXVK8HYXGE(LQ(RY.&*0PU2Q[.7B
M@B/< HB?9^27R!@I<O&?:@CZH8*3Z7_"^27R"%$3[/;@@^X1BE&?C/\ Y*/G
M20;"G;S<N_*@[% O_P /<<L"CD<V8R(X9"AIGF!F6T,$
M
M      !U)WRSAA:U?CFT1^*A=3/BX!8&K32^BDX9R*':AV,@E6Y BB9*S=CM
M?I!=8&1IR%E@9<(6&8NP1";1"5I'FADS_ A9BA<Y%Q\9PR1+@ 4B@(.W>Y?
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M13ZJ<2H9*B<J="$#^B:BB43#:KF"
M                                       .I6^5^2UJ_'1G^\G47=*P
MU;%F^[\N49EL+E^Z<0  /(1F Q(]+@/)Q'Q_(+,4(?ZGL&9]GA/A%C:"<Q_
MOT3"1V^W+ORGN_XH.7\ILHF]G4VA@R
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MSVL88,\QT#UY\V^KZSN[6#Z/.9.@>O/F[U?6>UC#!GF7H'GSYOU"L]JA@R=
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M&7*II=<@U>5SZ:<60T=!3SY,,N72.;55$<F:$,XJN:(
M                                                      ZD[Y7Y
M+FO\<V?[R=1=R[FK?.,MD0$(R/,%4* Q49</!E+[O8%B]PN0^U]R'!D$$.'#
M#+PPR]PQ8L=O-R[\J+L99OP.<\O^DF. <S.IM$!D
M
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M7*+@RY5+.JYIK\HHU4I%#1TI\F=I9H_V(S)/Q\0E0KF@
M                                                       ZE;Y7
MY+FK\=&C[R=0W+#5K^E]S/V1&T,S+1R9SR\(M#(NR(&<!CHD7'P?<%L9""&1
M'G")H=O-R[\J+O\ B>YE\CFR"LZFT,&0
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M[)E7)=]W5#/.J:I4EKD2J6CE4=-ISUR5SYB9M:SEL&$4
M                   !U*WROR6M7%^&C1'477YP&K3*E/' ,2V:7 >?L9LH
M5OC8H:H0[.;X1((BPTR[/P^,.[(A_2S<''V18QM%T<D.&!<)P$O-C R,LXU$
MVCM_N6_E0=NS9SE'B.#DR< DIJ;1!&0
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M4"4<2+.4<_"?RA,;U51$?#F_0R_$)&!V]W+ORH.WXGN7\I,G="\LZFT,&0
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M61XL"H-FMW5]%JLCQ8%0;-;NKZ+59'BP*@V:W=7T6JR/%@5!LUNZOHM5D>+
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M1R%QF7;^X0SO$49Y(1[.2(L5O';W<NRXGO!\5GN)'P93<F0-[.J6T,&0
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MW5\YCV=/6FA*X5RSXX*(XY<D3A&.0.CO=7SF.33U_,JBIUH.69R%$HH&DS3
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MW!)Q@9"#W=MD1O[%Q;9;/Y0I(_#LBW3,M\1?#X=D&5
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MC(LA?%E$NY&*N"'9X8=V L3 ]];7\/L?'M=L^7:%$(C?$68NT*Q.U0
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M(*@(%\#,NX%0$""H,$""H*@@7P,S[H3$2$""(B-@HH
M#6W[UKWBC/[KC='>-ZY]PL<\8Z!HONR;(5933==+9M9/FWG6U-'+<4O=8Q7%
M)1+;SI])4OR8SF$<"4D6(M)FHMU#7[]K"1'NC6SWJJL'[A-#Q<2</FS=K1>%
M"N_Z[%=6,57A(6'-+<";?.5/>="BF/L";.GV0@YA2(P(U9.]%6[1^[7]YK9'
MO"]R]BWT*RR9.[Y:#M<]]VY7,EZWVT/-,QIL=_6PSW.ONV:UVJVHI'"81+(U
MR):9)J))J49Q)21-N^MO8M8<W=:M5?=J7[9-S6-02ZR=7WE;UU,3W:E#(;J5
M%<XU57<3:X5#13TU!0S$SIZYDU"9,D]-9I2(UT/4ECQ@\I]MRV$XJ89'<5X4
M5,YVFP'?MJ[:NIJK$S#I'*VFM+LNN?:*JZ)1RIM-+F(F)29I,X&'/N+P^L29
MAS4:1I-)QAV#+.1I/AB1@/,
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MU$U4=.945+=33JB8J.6*YRU&,MP_2B*
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MG\/?+J>MHJN7+E25R95',5HS-&;#$1;NU=&[!A#O5^]T]])^<OA_08BKPVW
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M>32TTE$="33T\M,J3*1I&I6C+EH(BB9G A%<H
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MFI\I\FV9-FU\Y1I5*-49JLHG,N^W8,B@1%Q *
M                                  \9S4$K1-4#B19<F4S@4#//$S 9
MQ(SAPD Q-:"C%1%#/V.V G2RXF6FDX1C XP,B(S(X9C@<8<0M#(E),X$91XN
MUGAQYQ"V0   ,26DS@1D9Y,A9X'&!]HX9P E).,#(X9#@<2(XPA'-&( I:4%
M%1P+X?* I*(RCP<@")6E68\O$><*2PUI+(9E&)%\9@K(
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M2U&>D%I5=#M$0C2@
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M7@]U]!LY+FS27U2B?:RBH&R5*GJEG&7+)!&68P^4Z&R41H
M
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M#RE"/T3.$89C(@C9C8LW\+D@
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2127058d1-fc_fatency4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_fatency4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!"@*T P$1  (1 0,1 ?_$ 1<   (!!0$! 0
M       ! @0%!@<( PD* 0$!  (# 0$!             0(#! 4&!P@)$
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M4/LVY^:;L4][V]/_ *@Q7^\3/RE5LN*[B7.\:D/KGJ<<AW"93%&[I42B43
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M7=(SI=0P7C$9;I-TF-+I;J"7@0C10128;5U]\W-8W+)NV&SY%XO\N8&36 N
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MG$7'LW]Q YEG%F*N"W%',3.[;:LNM,00H4ZJZ;9P80!%8^=.(-X&%6"XRYP
M(!H&FH]U5Q"(TA<Y^YO%!)86W^X.O,R5/>UH,V!,DO!:"94:F@F(@8FP70I\
MF'#S=$F_2BF%P6@\DT)B(A;C8-GTP8]ENYXJI8XMQN5H-!B<B;MNH@Y.P6>E
M073W!VE$U&>;JYG2,E.Z.R7-)(YUFN $3&BH@:Z:8:+IN=QF;,Z*\7NYMGA[
M&O#3.-@S.X#B9+122(D$B-%!(5PC=#&I6D\_?:@VPI&-K#F;O@Y:%/.+L91Y
M#3'D-Q$JF>VVDZ1ZN_* &.=L5%4QTQ24,43B77/SG$RY;)!M.G-88D4!Q[KA
MX(4ZP%VV&[I&M?,]+Q"[=$;L^:P@3#$L,"T_FP130:(:B1!9#>W#4]:7_-6O
M8MS0=QQ[&[&]KB'699S)Q!GL3)33$\H!+>9I2(JQ\*[ A(PKX_3H"B)>D$"C
MQ\-SIT]U;>+W*+']',>8=R3+L<T1),>?3&B$($TP['%=T,,8GX9A=[N[[NR=
M*E@DO,T=*)A!="4UAHEFR&N,2"'63 'GF[K94M&84AU)6(FE$V[9P9W#G?\
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MN_&8O;[_ $__ ,K7K]RE_BS%R^/K=S:.SO8]CI*^./JZY2$,JT[M>;&)K6;
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MGL2;+G37WB7Z'*@6O <1,#FVQ V8-):1W=FF(KH6B,AJ'Y(M*Y^*)1 !"@T
M0J-:5 *A0>7'N?S+I3)LMQ<7 Q$(0J7R*?)F7:^3;FX42S '72='6[(3-F 4
MI2O+R5Y,NUC6L#0-/^E0[@4Y=N*I"--*]4_S8O?#O"/JXMXHN;M<-BPND#C$
ML>%\B_373_\ YY4Y/DQ4_P#Y%IC\>1__ )-C_P#FO_BK^K'_ -O,/_\ &O\
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M<I]S+HB<Q[2ZTR)M-LZ(-$! #FPHIIB3Z#']X%XO^8[MC%W8W^ROEN8VQ,L
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M<V@%C&CAI@=-8T+#%MZ>.8OAS[C/DX:?S$EH=T<[GV9KYA$.B(@TD0YM1TN
M(R(.(2Z.GG9!*"M9I,3:,BU6DV87*P.5G)P#2W%F+MHUFBQTX@U9-06;^4$7
M -G9U%24^E[O7NR/*=,NC[7,E2 '"TVAP<3QZJC!>C&^N_LD7FZ3+O=FVYK[
M+Y4N9SF%C6&(+6!P@#"T'0-HB%$= FH8QQ*% \;= 2@7=*/L2@4HF M "F0T
MQ[^9)Z)K)<DAS1"/.&CC*^(WJ]LOE[=>"'!Q/>G3Q!,.R.0;,J[.YC493^#Q
MAM03F  &U1X#MB= $:[<@IMVARX=$^&CQF[5.FEVHFU5WKMB\AKO#7;E4:#3
M8'8YL427PCS?&;M5Z9CC1:\4_*%?;:#]\4"/--18\HY ^0$=H!R!CJ,P?F<"
MOKYD /1)PK!I,MP%1)7J<D3&^U^&"G]?D"HZ9K1J70W&84?E+ZH9#D\@RB \
M_FO"C2FW\ECSN[N?+;E2Z2B>>Z].A0:><S35H7O-_C2=[5Y8 ZVZY2X4&DV9
MG N7QH8 VA01Y-M0+GCW!E/M&%GQAM7QOII0,'6Z^]=V:%&G)G3DR';WL.A?
MX/C#:AO,J$(/A]!U?(@ $ '/;EL'/L;,9MEN:Z)LG^4-JUNG6V%DMSV$B!YK
MZ0=%#5LS3;4AYIL]E7\?;]O33N4B5H<KB=)/D<Q*#LZ77UH)_;MP6^_CGKI)
M!-(ZQ5-\J J$()=\^_YS,.7GXNUMB:6%KH\US*:# &T' @1B(0I 7T#=]GG#
M-W\U\X7#TN=-8&VC+)+8FD@ES"*H&N@F !BJMCK)?,&Y>EM27D+3A7K&5:)6
MO!3MW(6W&'F6ZB#I['LG4\]=)2!5#]*"@K" + !P+6HCIO&1<)?<I43*F7ML
M+1-FT8:"0 (< H782-[N.R<;O8D.GRL)F!XEAIFV!:$(AKG%P)I,33&!T+!V
M%P.F%NSEO((ME&$W)0$HZ!<BG605@ EB,TD5DEB$!$Z4L<J]2AT@ &Z) +XW
M)Q#+LJ^3+O*<X&3+HC:$*A&(KKU#MKR.!YLQ?#)-[$@7-K;Q-](_.2WV^DE.
M=T;(B4YL7  B)(LD1<V"V>VUPN9NM)&4BK7=H3-PW;<,NR<1TD#-^>\HI.!F
M(Y84Y,%TV7DYHDHB"(I+(N WA5KF/!OF0\-,P^CS19Z-C00X?,J-5<33$0.I
M>RN.]G'V2G/OLC#7OGF\37L,N;0Z9+Z+HS^;%#FL;W+HP,"\F!%EN'567GV;
M*&)#6[$P<:2W$(N,C6K\R4>VMEW/R#,B3E^]<OUEWKVYW:SU5PHHHJ<P%3$A
M:@.-RR#A[&N,^:+9:X4N%)(&H0C0(0@. K7B.]S&ITYO073#NA$F[!H;*F66
MF7-<XM%J670:'.<223SN:13&]3FN-Q3[:32=PUK$=RJM\&5?I-9A!5NVU!ER
M3LTP;MBS M 1;253MCJ HHF41 XGH XXTC(=TNUY;.:^TUI'SFTV8B)HC4:1
M5$" %*Y6([X\<Q"5-N[[MAX:YUZ@3+F&B:R4:(RX<YX<!&)K+B:"JV"U]N.!
M?IRS6#MDTJS:P+*-? G<+$Z;>$@4(!%K)>3+@9!,Q2K)HB9=F]!VU65!0P%2
M*84S8WK(-VG7IUY;- #W$D!S=/&#"&@@@C6NRNF^N_72[-NQN\OI9;&M#FRY
ME@66PYH#F!S2 +0>PMH- !6B%#"HJ*GC")BDK4B939%$ %0B10("YB" JB41
M**HFH'*/MY=S%WD-EL<TD5\X<'+&M?'K[B3+[>G7E[7T^"[AHH&BJOLKS*4:
M"/.%,P$.4!Y0[&*93ZN;XS=JXPO$O4[Q7;%,=AAYQR&@Y;.QMPZ)Y/S?&;M5
M](E@'NJ?!=L0B-%BCG3>'D&N=0[V>)>FD71T2VKOAM6N[S!*Q:49@< YPA%K
MM7$OTV?_ (\__MC_ /V+C\=Q'O-C$0]:_P#B+^K=K_\ YWM4_P"6NO\ J^I?
M/G7?@5O^^]9]3[S87[IJP97/>MP3;1E)3+MN_:H/WZRY$'B)6*A$W"93T, &
M$*AMQ]/RWO'PK#< N>'S<.O,R9)N[&%X!(<6M B*:CH7P'/FX/',>SGBF-R,
M5N<J3>K[-FACGM#FA[R0TB%8J*U/^#IU*^^3I1LV!.NQSKS^3\=W[U,&^R[W
MXKMJ\E]VS,/VQ</';L3_  =&I7WR-*/LZ\#U8_#WJX-]EWOQ3M3[MF8/MFX^
M.W\E+\'3J4'\Y.D_V>=_:[#WIX-]EWOQ7;4^[;F'[9N/CMV(_!T:DC_.3I3W
M)YYZ\?A[T\&'^%WOD=M3[MF8-.,W'QV[$OP=.I/WR=*,O]?//M?3%]Z>#?9=
M[\5VU/NV9AT8S</';L0'S=.I6==2M*1[/EUWEV?UOQ/>I@VC"[WR.VI]VS,6
MG&;AYQNQ ?-T:EY?\RM*/LZ[SSV?K?3DQ?>G@OV7>^1VU3[MN88P]<W'QV_D
MJ7X.C4KDU(TH[L\\#D_:^NS$]Z>"Z<+O?BNVK(?#;F$?XS</';L4?P<^I>0_
M&5I3MV>7GG/LKY/&N+[U,%J]57OQ7;5C]VS,48^N;CYQOY*?X.C4K[Y.E/,%
M)UY]K@Y\#O3P7[+O7BNVJ#X:\P:<:N/CMV(_!TZD[/C)TI^SSS[7XGO3P;[+
MO?BNVK/[MF8(?QFX^.W8D/S=.I05#XRM*,\QK//![F4?EBC>G@U?JN]^*[:L
M?NV9A- QJXP_2-V)_@Z=2OODZ4[?]///M=GB>]/!OLN]^*[:J?AMS#]LW&/T
MV[$_P=.I8_SDZ49;?U>><G[G;<\/>G@P_P +O?BNVI]VW,)_QFX^.W8C\'1J
M5R:DZ55_;UW]KL/>G@VG"[UR.VH?AMS#HQFX1^FW8HA\W3J32@ZE:4Y<TZ[Y
MJ?Z.Q?>G@WV7>_%=M4;\-F88?QFX^.W8G^#HU*^^3I2/;GG?K1U<0;U,&^R[
MUXKMJI^&W,$/XS<?';L2_!T:E??(TH^S[W[7XOO4P;[+O?BNVK'[MN8?MFX^
M.-B?X.C4KEU)TI[D\\^UV'O3P;[+O7BNVJCX;,P5'&;C#Z;=B/P=&I(?SDZ4
M_9UY]K\/>I@WV7>O%=M5^[9F#1C-Q\XW8E^#HU*^^5I2'[NO/M?A[U,&^R[W
MR.VI]VS,'VS<?';L2_!T:E??*TIY_P!?7G:_T?A[U,&^R[WR.VK'[MF8H_QF
MXP^FW8@WS=6I)2B8=2=*  GCB(3KTP^+F   1PYB.,I>]K#9$Z7,N^'7EDRV
M!%S3"!-5)K.A1_PU9A=*=_ZS<8AI(Y[35IJ70NKG!A>]Y:9</MK-K\T]9KV)
M:4U"O';^5<I-'QY"7:/NL12@,Z.&R16XE,(T$##W_'X!O&E83C&+W\79Q,\L
M/<]S $"/>T:U]?S[N:Q[,F4\#P@8G=);KNQ[22X0>2X&+8B!T"C_ $\^!\W3
MJ3]\C2G[.O/5\G\F/7>]3!OLN]^*[:OD?W:\P#_&KCX[=B/P=&I7WR-*/L\[
MR[GD[$]ZF#?9=[\5VU!\-N8 :<9N'CMV)#\W1J6'\Y6E ?NZ[K_Z=B^]3!3_
M (7>^1VU/NV9@T8S<(?3;L3#YN?4K[Y.E/=GG?J>3MF(=ZF#?9=Z\5VU0_#9
MF _XU<?';L1^#HU)Y=2=*0$>:=>#ZL=V</>G@WV7>^1VU4?#;F$Q_P#6;AX[
M=B!^;GU+^^3I3MK7R\\S[GD[EP]ZF"_9=[\5VU0_#9F'[9N _EMV(#YN?4KE
MU)TI^SSOUX[#WJ8*?\+O?BNVJCX;<P:<:N)_EMV)?@Z-2QV:E:4U_;UYZ=(_
M%]ZF#:<+O<.)VU5WPV9@A_&;C'Z;=B ^;IU+ *#J3I0(\_EUYW*_J=GA[U,&
MC1A=[\5WY2@^&W,4/XS</';L3#YNG4H1_E)TH']WG@?[/P]Z>#?9=[\5VU/N
MV9@%/KFX^.W8D/S=&I5!'XRM* H-!*$\\$1_\O[. WJ8-]EWOQ7;4=\-N8#*
M(]<W"OOV[%O+AOX'[\TWUHLB]Y*_].'S*"<3"JS.*EW2S]87=NR\<D#=([$I
M#B15X4QJCD4HCCS.<-XN%8IEZ?A\G#KQ*F3#+@YP,!":QQC$PI @.$A?1=UN
MXW'<KYKNF-3L5N<V5)Z6+6N!)MR9C-#?"6I)[YO/41_.SCYOJ/I81%S+/W*2
M:TX[*L":SI0Y"G(5@8"G @A4,Z&KCO+GO:EW2XW:Z>BOYK .XKXEY+,'P[YD
MQ7&+UBEWQBY OF$]VVBJOF\:M/X.G4L0RU(TH =N<Z['F_U=3'*]ZN#DQ?AE
M[)UV75\JZ;[MN8B!'&;C:T\]NQ ?-T:EAMU)TH$?V]=@'I1]<3WJ8+HPN]^*
M[:K]VW,(%.,W'QV[$_P<^I6WXR=*.T$\\]>.P]ZF#?9=[Y';4'PVY@K.,W"'
MTV[%'\'3J4 5^,G2C;3]?GOVOIB^]3!OLN]^*[:I]VS,'VS<?';L1^#HU+$?
MY2M*@[4Z\[WZWAA[U,%A_"[UR.VH/AMS$?\ &;CX[=B!^;HU*K_*3I1MV>7G
MOVOY\!O4P:'\+O?BNVJ'X;,PQ_C-QA]-NQ/\'1J4 ?RDZ4!L&H3SOFIRQV'O
M4P6/\+O?BNVJCX;<PU#&;AX[=B7X.C4K[Y.E%.?RX\KV/V/'#WJ8-]EWOD=M
M5^[9C_VS</';L4OP=&I5/Y2=* _=YV/JQV5<3WIX-]EWOQ7;5?NVYA/^,W#Q
MV[$A^;HU*I_*5I33;^OKO9W(_;A[U,'C_"[WR.VK'[MN8-&,W'QV[$@^;IU)
M#^<K2G[.O.W\ P]Z>#?95[Y';5?NV9B^V;AX[=BD/S=&I0T'XR=*0VU_5UX
M<M=D?V<!O4P:KU7>^1VU/NVYAC$XS<?';L2#YNC4NHA\9.E @&7Z_//5&/Q?
M>I@OV7>^1VU3[MN8?MFXP^FW8F/S=&I7WR-*>Y///M=A[T\&^R[WXKMJ'X;,
MP&K&;AX[=B ^;HU*^^1I2/;GGGVOQ/>I@WV7>_%=M5'PV9@ IQFXQ^FW8O5M
M\W5J.FY;&4U*TJ*0'*&\8LV[.8 Z4OL2 Q)O&[N.'B.]#"YMPGRY.&WF7,,I
M\'.:;(YIKB3HBNTP7X>,=N&,76^/QBXEDN>QQ%MNAPJHK6X^(G@AOS4C6>_+
MXC=0-.&3.8<QZZ3*5F';:01!K!1K(2+H@Q$O2'%J(@&7BB&.IRIO-D85E^XW
M)MVF.;+G1C8B#SXP!U\"];O1W%YCS9F^]X[<L5N<D,D0#7/$6P96>;4M*E^;
MIU+^^3I3RC^OKL,N0/UORQZ-V]3!B23A=[C'O7;5\^'PW9B@"<9N$?IMV(_!
MTZD_?)TH^SSS[74P]Z>#?9=[Y';5/NV9AC_&;CX[=BE^#IU*'9J1I0/[NO/6
MC\3WIX-IPN]^*[:K]VS,(_QFX>.W8E^#HU*Y=2=)Z?MZ\_2&'O3P;[+O?([:
MI]V[,-7KFX^.W8@?FZ-2MGQDZ4<G[.NQV?N?A[U,&TX7>^1VU#\-N8!5C-Q\
M=NQ'X.C4K[Y&D].6D\]K7['Y8OO4P;[+O?BNVI]VS,'VS</';L2_!TZD_?)T
MH^SKT?\ 9^)[T\&^R[WR.VJ_=LS /\8N'G&_DI_@Z-2N34G2BO[?._4\G8OO
M4P;3A=[\5VU8GX;<P_;-QC]-NQ ?-T:EC7_F5I36N?ZO._M>&'O3P7[+O?BN
MVJCX;<P_.QFX^.W8G^#HU*K7XR-*=M?U_>;?L> 8GO4P:KU7>_%=M3[MF8(Q
M]<W#QV[%$?FZ-2P'+4G2?NSKP*]P(_, P]Z>#?9=[Y';4^[;C_VS<?';L1^#
MGU+V_&5I1]G7GZ0Q?>I@OV7>^1VU8_=MS#]LW&/TV_DH_!T:E[?C*TI[7EUX
M'^SZX>]3!?LN]\CMJOW;<P_;-Q\=OY*E^#HU*^^1I0':GWGKQ^)[U,&'^%WO
MQ7;5E]VW,&G&;CX[=B8?-S:CB'C:FZ3D$/HIY[VZY1V+[UL&'^%7L_R7;5IF
M_#!C5Y-J9CER:0( "8W8KA#_ #=VHS*7B79M3M)E"-Y2/6,5*?>JJF*1TD<Q
M2)#&I 8P@&S>QP<5WHX7/PN\RI&&WB7,==Y@M.:8"+'4F)JX=%:[G*_PUXK@
MN8KEB?KRYS.AO4IUGI!3!XH%%:VQQ%<$%\ZC:RWW>T?J#IJQ;2[J/629RTZZ
M:22/5(6.8&(LW)'G 3G.T$P;/%,';QTV4-Y\C"\$N-S%V>YLN>XQL1CSP8 Z
M_P "]5O0W#9BS7G.^9AN>*W22&7=C0TO$6V6NI/-X5I0OS=.I7WR=*!J%<YU
MZ'('^KZ#CT[MZF#%Q)PN]UZG;5X%OPVYAL@G&;B70[]NQ'X.G4JM/C)TGVT_
M7UYZODZF)[U,&^R[WXKMJOW;,PU^N;AX[=B?X.C4KDU)TIS_ ->N_M=A[U,&
M^R[WXKMJOW;,P5>N;CX[=B/P=&I7WR=*<O\ 7SO[78OO4P;[+O7BNVJ?=LS!
M]LW'QV[$?@Z-2OODZ4_9YY]KL3WJ8-]EWKQ7;5/NVX_7ZYN/CMV)C\W1J4(9
MZDZ49U_9YX Y_N?S8>]3!OLN]^*[:J?AMS :\9N,/IMV*/X.C4GEU)TIY?V>
M=\O[G8OO3P;[+O7BNVI]VS'R/XS<?';L3_!T:E;0U)TI[L\[IMKR1X8GO3P;
M3A=[\5VU/NVX_P#;-Q\=NQ'X.?4O[Y&E/V>>#ZL<.+[U,%^R[WXKMJ?=LS!]
MLW'QV[$?@Y]2A#^4G2H:T_9YWR9_Z.RSQ/>I@P_PN]>*[:GW;<?^V;C3X;=B
M!^;HU*Y=2M*0_=UWG_Y>&S ;U,&^R[WR.VI]VW,)/\9N/CMV(_!SZE??)TI^
MSSK[78>]3!OLN]^*[:GW;,?^V;CX[=B/P=.I09?&3I2/;G7@^I'TQ?>G@Q_P
MN]\CMJ?=MS!HQFXG_:-V)?@Z=3 -4-2=*-[*E9QZ( /-0&%:9XU'>E@LV4YC
ML*O<#'YKMJVO^&S,$R\RYWKBXQ;#Y[='67VE^+24^21\4WE.'\K_ !+>9?E?
MK"GD/KGFUY+Z[UKH>DZAO^-O[E=W.F/@7K2[>V?KCH'^B^G=)T7SK-N-B&O0
MOVA[,7OW4>R73R_3/4_H_2Q%BUT5FW&$+,:8PAP+1^H84OFZZUIY=D>0.5P>
ME,]F/;X,3ZJN^KHF]I?-<RN/K^^4G]8?^,5AP4IE7;SALYQRV8[.G6NCMNUE
M(0_I0[-1R[=1H%.7!9-))I)AQJ( .S>* YC0<L@VC7,*!BQ6V#>^[*6\&^)*
MCO%I4HEW1#>*)@ 0&@@82ALVXL4@W0X\J8B(95"OT.Z F[651KX,2(X5;+>^
M[*/95J8M"A4P"(!0,AWAK0=T*@->8<8.!(@(Q6+@+/='E3H%=T:5J 4 :A40
MWMVH"(;V[G3&'1OKB8K7 =\>4IEIV\@&F0#R#R;?9!C7TT[2U++1\\\I0)J5
MRKNUKL].HAL]+&8$R8+1B"MC0(=V>5(1WJ4KL$U0SV#0P!0=H4S#:&!Z66(B
M)/*L7M!'=&O6H@8O/2H5"H#L&G-EF Y5VY\PXG33:B%L9-ELYI=V4Z9;U0 ,
MZB-  *" ;1RSKESXO3S=16-J7WYY2F% #+/N=[EKF&-C7%PB:UJ<\QYI);QH
M]'+X<9*6G:RG3;R"'9-ZXB&)%6T[64Z%H'IY>GM#+")2T_64J9 -1Y@]%>QA
M$U):>=)1GW.?/+T\(I:=&LI5Y\_1ER\^+2I;=K*=0IR<OT7;Y^4<*4MNUE 4
MYQKS!^/B4JASM9Y4#W>T(?BX E+;M9Y4@ !$N09&+3_I!SUQA- <PVJ84TZQ
M41P\*6WQ B:2!65L2\?X*:>U&M(%T&?-UTHCV@''EL(8U^(3VO (<1&.F@5Z
M^NO=YH)9@UT+:"&&$-'.-2UX.7('I\X]G'K8G65X.T[64;H[0$*&RY!$!VCM
M#+&ITQ[3!HB%OE@%L7.(/&E0W.!@Y*TS'DW?HNY7/%9,>X\X0"KBUE+71/&F
M:H#NC01Y@,')2FRE*CD&>W&P5K S3HK3 *[.2O-SY![+EPB5KM/)K/*H#2HA
MD.8YA4U!#= P#NUS*)@J%:YXUEKW&(CRE;!.+1 IA2@U"M!H-0, @.VE*AGB
MM:YM<5BZ:YQH)1RTK0=HU'=H&7/3TL9&)!$5&EQ,(F'&@1SI3, $1H("%"YB
M-0$0"@;<:^C?I)[*W45!W92K6GL<ZYU"FW.M!&E,Q[ 9[,;10*Z5@9L#"-".
M0,A <ASW@V@!LPKM ![F-<QQT5+-KRYM9@L\TS*'GS UY57H<_[&O1Y:XZ;&
MR789-!\'\9J]#E=[ACDAL39)=^(Y8<_^OGV0?7KS(-F;I7D[>.1A\MC[JTO:
M'$"B(%'$NKQ%SV8@]K"0V-0H"INX&60CLY<ME,=H*-<%U9<Z-9K17L!V\_7'
M%B5+3M92J(]_L4SY]F"R:\@QB>5*H^Q"FS/,  .V(B%,.'2L^E/"I 6M*& :
MA7(2\NRF8U$>2E:XU>E.[WJY%L \+LH  KEM !$0#,1 # %:5RS&@]G+&P3"
M]MHT+2\N#J"8<:50#\D&P>4*9#G3.H@'*.P.7&+W.:.:(E67$GG$@<:C40$
MWAV5H( 'BARYT&F,!.FF@M*VD,A$.IXRI9#RU[^WD :\N-UHZ%Q[3M9Y4QJ
M5 :!7^A *CV:!GC29TQI@!$+>T-+8EQCQJ/9J \G;YJ4VABB\/;W3:T+@P<T
MQ'&GRTH(#F.>8" 99"&0UKSXHO+G&S"M8&82*TZAER9<@?BXV1*U6G:REZ ]
M%<(E6V[645]'H'%Y5+;M94RA4Q:"/LR<G]$ Y9\E,<2^TW5X-1:N=AA+L1D
MTCIF5_2"SG5D-V_[G( T O5Q* 9 'U"VK0-@5#FQT.7V-.#NB 0T$B@4'6-1
MXEZ'-+WMS%?6M)#3+@8$]X%@?( =B@X],TFR.)>1M.A64^;9V-GXX8L2EMQT
MF/&F(!RT'FIGZM<(E YVLI" <^5>Q0.W01H'<PB812+HPB4AJ%?'#( $1V
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MM$*#D/Y+(<BCR#L'")5B^J)Y4"( -*YY9B 4\81* 5K3,<(E5KW-I)/92 !
MU,JUH-! :>F-<6,16LC-T1I4N4H"&8TI4#!6NRG*/JXQB=:UQ?K*B%##0!K4
M<AH--M-M  !KSXQ-X<TV0(@+>V%F)=V2BI0"HF  &G9$*T$*@ B)3" [!H.*
MV<9E8A!83#"HT\:D-*5J/8RH.RNP1KC*)6JT[64<@#S]ODY\\2)C!+3M943@
M  (\VZ% KRT#;7LXUSBYM1A1H6]CG6VTE=UT#XG*<GF/_LO'RZ)]I(Z?2OYR
M^^T^QG_(_P Q<D:B?PXNH>>>DO2<GICZ'@W\*N_Z)O:7Q;,W^8+Y^\/_ !BL
M- ?6#N#6N.R*Z)8C?LJ^@[)NV9C5 2D(NW9A^R5,4A@3=-6*RZ*@E4^EG JA
M &ALAI3&Z1*$Z<V48@'8N-?9KY%TF360MM;1'C'$N-K:XD;EE;ET):RT?<]K
MP4O85ZS]^REV6ZTB8NXG,'945,(RD$^ZVJ08]JYZPX4W>B*8JZ7((X[;U3*H
MYSN4;%YP8ZYL!.%F+236!0(F$3P%819?$S?UXV[JDI&W/ O[E1AV>K.G\7&+
MP[QW&6>A<KL9VR)QLU<NCGF6UJL&ZBH#]-*H^-0U" &+-PNZV1T#GF9"F);7
MXHHT+B8=CU[O FNO(8&M+BVR"#9B:XN,3"!,(<2Z:TLU)E]5[]NV9@9!)33&
M#MRVXF-3(BU50>WI)MB7!*N2/D]XZAXR)EF:"A"&W2&,(B%1H'!-RZ)UB\$A
MQ$8#5R'45VEPQ.9B,V8Z[P-U8(1\* .O0"-'(N?X#B7OJ5M_2=DI%78WEYW6
MMC:\Y>:]KLD;+F+=6N6Y&2D3&2Q'2Q3/.J-44ZD1*8!;GS <<N[X==YAH<\F
M&L;%PG8W.Z&T1!_2M;&!@028P,3LHIU+8\%J[>KZTN':44F$EW]]Z@O8&Z#%
M:-P![&IL;K7303(5.C90JD6D(F)0PT': CC*9A[)9@"ZCBV+D,Q0OE,>#%SG
M0[>I<J,^*_6D-+HILM+,EK^?S3"Z?+9(MF():9KP[9V<ZK J8D* S8*L04 @
M5.0  U3 ..WO.#W253++B.$CY %YVZYJO4X 36M#HZG5==QTKH*]^)M] :\0
M%MMKAMQM94/+6K9EZ13YW%-9A:=OAL_.C.-S.'*3@8FUSILRNQ(4H$%R8<P+
MXO7.PZ69/21=;B:!"$.*'RKMO7MY%\Z%H8+O!L28D@GA!%51H6-R7$=J-!RN
MH<),/6;0CC5)6&TOG$V:!D7,5!Z@Q5L7/:KHY@!$\NC&O"N4*EZ0R2JAZB">
M6QF&23*MDDOTB(H["TS<Q7B1/,N:&B7;LM(!IIJ--<*:("M4]RZHZQJVC>EX
M1>H:\6:!UQ<Z;M(I"WH=ZW/$/[A@8QJY.Y63*N9Q'-954" &]O"/C<X<=ERE
MOM1T GDI64_$KX0'R'?UH;"!J)@=(UE;$U N_6W3:X8C3Z.GBWU+:KQ[2(T^
MN:5B(MFG:UVQJIG%SO9]BP4;%-$EM]8)! "E6.)VYBY ;$DW>ZONIFO,)H'!
M#@T<JY=^O5^NUYE2) M-FD $Z*:37JI%'96V]5=5)O22%B@0C$+M>)6C>5PR
M+V4?#&&72L:W@F'?1^3V+A%5[** )"$ J29 J:N5,<"[7=M[G%IB*='%Q%=U
MB%\.&R1#G$-TQU1T06KK3XR+<G9]E'2L,:'B?BU:79+2957#MPVN\\Q!P[VR
M(U@FUZ23>-7%Q-  P"10QE@#HZ (XYD_")DH@LB6\/X%U-SS/=KP^Q,L@PT1
MKU5]6E;?^45IF88@P2,H1O-'=I-'R]OS)&1';%600=Q;EP#2B,LU5BUB*HG
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M&6[I T36FS3$@FFF@\5'&(Q@%OG3*[E;[T^LZ\7"!&[FX;=C91Z@2@)I2#I
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M#.1[A@@WZ5,!"*>&)4"E.'%O=R@YC;GSFF-J-.J$(0X8UKG73%B[I!>(!PA
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MC5LZM2OCC1_3U>6MB;2MYK'2-H-I9A#FBR>36YXV:C$H=^P?H-#(DDV1V")
M(BN!BHF #E'? !PE7F<PVFN;$TUK8_"KA0&L(:**JQ53K$%7:;Z8V?I/;YK7
ML>+&*A32#V4,W,Y<.U!?OQ3%RL*[DRBPU*B0"AL(0I2AD&--[O,Z?/$QY;0T
M"L:"=JVX;A]RPYIDR@X2G1)H,8D0^0*R(:*V$WM^V+:3BW'DJSKM1O>!0/*R
M9E4;B;R4G))NW#H5A.]2ZW)+&%%0!2,"M!"@8V7:\NENBUPCQA:_5=R,HRY@
M=0^(H)TQICQZE9[<X=],K5N1G=,5'32;R*D923A(MS<]P/[6@GTX"Z4N^@[:
M>2:T/%NWB;E0!%- "E*<:  T'&R9>[PXUMY0M5VPBXRYEIP>&QH@"0.MU!6Q
M/A:T:19H,BVVY,5M:+:Q6ZP2TKUU.V6LX-P),C/!<E4,J#]4V\O^:G1HF(;H
M8@Q2\N/.<WEZRT'+^&M$&L- A&!!A:CP4Q)IU4+(UM"=-'%OW3;R]OE7;7B_
MD9.<>KJ*K33A_**I+N724TLLJ^8G37;IF1Z P="!*%QK&(7CI:2WHX:^LMOJ
M>Z,DEC&NB2=%.NLU4CMZU"2T#TSF85.!E81P]CT+Y-J0W%62?F?)7D+P9$95
M-^9<S@@KO5%!43WA3,41"GC#@W$+PV:8%HE6:*1K'X:ED[!</O$IK+PUT1,M
MQ@8Q@:8]>%/;4W.A.G3FWYJV30[KR7/7L74"02"5D"'5N=.18R";Q-V5<'#9
M$KABF?H" *8@3<'(1PDWZ:PFV6TQTK9-PNYAMF0UT+0-6F,>MR==9C<-CP%R
M3MG7')-7"\M8S^4?V^NFX72307E8IS$/!<-TUT4G29V3LY0*H!BE'.E0KCC&
M=, LM+;'&%RKQ=[O.Z-\'=(S@ZNK1!87J5I7\8<E;JKI\U3A6D?=D#<<2X0>
MJ+2]OWA%%B)-I'O6C^,-%R": B9)P8%RIYT3WA P=C=9S9($QI%OC6G$;G*O
MSB"'=&6PJX #_IZZL3;A@T=9]>ZG;:C;RBM+NWADI64WS/9^0MN7D729@=$,
M18C^T(X4*"7H 1$I1W1,4V,[%;[;,2SHX44K@,R[A;8.#7VK430:Z-1&KK:-
M,:H>''3,72+Q5G-NG":3-,QGUQS;@K@[!Q(.VCAR8[DQE'2:\LXYBF(I00H
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MBPA32^PE+O5OPULL!NU5!1N>:JX!P8IVJ;(5@: ;J'7Q: *(N@(#D4:D$XE
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MGCK,N-<[")@ -17?9N;T>8I[W$0FM ;QV84ZE@6V@4'(  <AV@ !ZH8]$TL
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MKQ$J(E%&1:R<))0$E&/DQ .D9NF<CO" #[-(E:E#=&R+Q> V!L1XPLIEUD3
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MO!(#@[00#U?Z334MBP$,PMN&BX*+;E;1T/'-(QBW2(0I$FK%!-N@F4J9$R%
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M0(TR]6G@Q50F)A'T>'$@$0%=M<^;T4P@H2I$J)BT'\D&T.;/E$0Y,5!0JZ5
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M)[UNAPA(7)*6P1I.R[0PF9W#)P+UW;SJZ6!NC2+Y/NH\5Y2;;H 7J[HE,L9
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M;9+'((Q[&*DKU:M&-QS#:-0 K,LM(M&AFYG(E%4K5XY2*8"JF 0%,5"="V2
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M0"D9%$P !DDS &P#$*(!VJAEB1*L H]7;^X(^]$]KA$J0".KM_<$?>B>UP2
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MKK/,T[,/:WK0(8IW69)A1<II/Z3ZJS9\0N]Q[H/QMK6Z^AE[ CY=?%GRZSS
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M"$=7$VD5FX/U A4K:>W&V>BR1>(F KYDSWDBBH00W@J XT8SF9MTPSUA=X/
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M05XF-=1Y1U/N[+M2SBG?Q^E\D?Y0PW]SE?BA?STWP '>CF"/VM>/^\*YYIF
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M4Y>7$2M3(%:=T?QL6, @:'$DZ(*0CLJ.==@T[=1&@8#@6QDQS'ASN35H4:&
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M6R'NO.G$DK9#:<LNYYJ+L64NR:CB*(63#]/*7"U@2Q[DT'!P,9;C1O!+Q/2
MB5)3K*I0.L.8E-YLY)OS2YS' .<&BHFAL?"B8QX".'1[.];Y\!Q&;=NENCWR
MKF7D<YK3%P8!18+0&ED2 2'455'RL[7RPK+DT99E 7O+RA;W>WHXDY=:Q7DY
M<BLHV9(/6TI,NK=6=L$6SELJJ7R>*)G8J@14Y1(00W7G(V(7MC6.<VR)8; -
M( KIA:-8(XH1%!6-QWT8#=+Q-O=WNLSI)EX=-B7,BZT086K% :X$@ &U:@:0
M"L 3U;@GSN2:2T--GMN;TW@M/)3R:^:%F$$8219R"$I' JDZC5"*.8XG2(JE
M#Z6<Q0'Q:F[.5DF\F0!::)C'DB+8BD&@B(UUQ7G)>]^ZWV]3G3I+VW9TMLLV
M7<[FD$/:2"*V]R14:Z(K+T->;0*[FU7]J7#(0+AK!HL;7F5K6FX&22A;+AK1
M9*399F#>#"NT%(@%@?0QFCD04%,1 A"F#A3LDWD%EAS>D:\.C9(I#K5 #J:*
M(&.NNA=B-\F&RF3G39$QTETNP&%[7 @L;+YQ+.;$BU:99<.YH BM4Z;ZGEL%
MN]0Z@H\.^GK3DW $<)(MSQL)Y80E88Y%07,NE*1LL*13E!3= E3@&]COLPY>
MO>.2I%Y!@)$NS5&D5'K&E>(R7O(N>6KY>9;KM$WJ<'T&%%,0:"3:%' -&A9^
M?7:&DDY6$E;=EB6O.&NB&%&,DFJ,I#VC)N+$6M>+A7(HF:B^MUMI^S2,50E%
MT=X!.0QMX>B=DF<836O;;@T]S1:%JT2 1W5J.L$1I7M&[[,/+W29EU?Z.XO!
M@\%P8>CLM;%L"6"4T", X4<U>A-;;1?-4+<E[5N0;.@7]C3-M>2I>.;7!UK3
MV&?P#-.>=+LE(Y=M+H2)U%P:I@#90H F D*4"PY(O  <V8WI#:C%I(YQ!H%H
M50TDQBK*WV84^>;NZZ3/118+(/:'1EAS!:)9#G Q( YL*-*N4OQ#Q\G&/_U(
MN2,FRM;\C8D\>XMQ.,487I)W#(@I+.GT*XG4W<>G<:J2B;-4$79"% W1D,H4
M_'E;NYYF=('-+0 3S230!&%.F&GN3'NES9^_##KU:D"3-E7@!Y#@\!I!+CSC
M8!HM$$-[ML.X$5K9SJFS5U1N?4(\8^(WN%&YFZ<:+E(56Y[E@9"' #*D4%N<
M4UI P"8 $QDTRU'>WAQZV;@KKSEEN'@TL<*8</&OEUVSY);G.9FZP1*<'-LV
MJK0A7IAQ:.-97%:TVU$K%N-"WI\UV2$'9EL3XGD61;<+$6?.6U,*R,,U,W2?
MI2;U.U6Q 144ZL@8RAP YQ(4.BO.2)IO%ASV]':<1S::0:"8F@$UBDCKQ]F=
MZ=PE85-G767,-Y-VN@?SH,LM<PQ:(1M%K8<ZAIJB8 :$<R8+S[N:,DH!5YAU
M)"@8Y3*E36?G=@D94=XJARD, "<3#4U:CCV#,*,C"I>%Q[BGKF)^5?+\2S(Z
M]9OFXO,[I]YF 4TP#R*^MVUONW]=&$)>MXW7Y%>*HW)==JW"DW3>M 78%MR6
M0ECHK&'>(99R43%2$ _(U$HY8\]B64_3+E=[HYW]$^-5?-(C"/8IX#6OH5PW
ME-P3,5\Q#HR1/E-H#X0Y[7PC9->@P$(1+30L+B=2TX]"QDDX]P(6G9=]6N(@
MHV%-PK=<A<[])R!"G I&Z:MR(B=(V:W0@(U$2[NF?DZ5*EN:'#G.:11"$(4=
M>%>B.F%-E[VGS0U]@QE2IK3SHQ+K=,-$+55,;)I$8#*M4-:&5_1#X&S2<:3%
MS24?*7"DZ-;J4&@9B183M(HD7#,)EXBL^/TJ:CM8XH>Q+O&\?&."Y1?AU\%Y
M):6,%!A3KI,?DIK)T)G;>E=\=P>5=Y0>)\U[2X%XL:0( -&DD@Q-D& $(E5B
M6L%I2%CPMD7+ 7/U!K9["W)B0@I.-;N1<05\W/=T'(Q@OT#% BI[O>(.D5Z$
MW"IF*H82;F,,4RG.OF(7K%V.'/F!PC$T=&UI%>L1!XQI)/:X7O<P_#,(N66+
MU(>[HI)8XM+08]*^8TB+=3RUP)%$'1, %B:6IT>YU62OJ0@W9(5)JYAS13-R
M1232A@MA>UT0\H'1!N:1*P7*<ZHE BJP"-,\N]&#SI>567:4[G<Z)AIH-48P
MX(T#25XN;O$N<O.[L7FW0BZ2[-J#A$-@6@1LPC &F B8T#1=F-Z:51L5<%IH
MP>HR]LW6I!2<@N\FK>)<+*8M19^,7U(S*-2BU8]TQE%4ERJ@"I3[BH&%4N?5
M7K+.(3I-WG3'R^D:X@<TAL'!L8BTXFD:^"JD>MD;R<MX--O#KA=9IN=]:VW!
MS+=IA<YM/1M$++H0(HH,21 Y8_UZ@96$NQK*VG)O@E&T\UA860&!F+7C3R$.
MC$0TH9W*0*EQ0\K#E;I*JJQ[AL#Y0/' /%$.I;D6<R>V<'"#81,*3 TZ:01H
M,8<*[)^^_#)ETFR9EU=TCK0 BTL%H0!I82TM,#S86H"I8KJ?JO;U_P!LQC%O
M 32DTUD64BXN:Y%8-Y,,F#**<LS6LA/144PFK@C =+E63<R2RKM($4TP'V5>
MUP3*U\P^\S9UL=$X.@T"#:71#H1,**("%=.B'39OWE89C^&7>4V4YMX98<7N
M<'/ #(&7$!I<(TVG$P@(46BZ\(ZVVVR,]FVUN3A;GNE*Q6ES@O,L/(B;.R9N
MW9Y)2%9H)-WZCF66MM H@Z$Q&B9U-P1 U,<"9DV\WF\N?,>+#2Z'-IY\:Z=$
M=$(\:[.Y;W<-PR2R?*E/])=*9+=%_-YA8>: V,7V162&B-8((U+;5RP4;>3N
M<F(=W*Q#Y67 R+1ZG'3<4,@JX<-)6$DTT5$V<Q&K'(H0VZ9,3[]0 5.D#U5]
MPB<[!GW.2X-F<V%$10]I((U&&@@ZB(0/S?+N:;KA>:'XU>99FR;P7N(!LNI8
MX @D0B#H((U@QB-_)<1<.F5.VE6%]S-O+6TZ@W,W<$G!S=_.#*7#'SK0HJ/X
MIU$/HMB+ R M%@5 R:R@](&]0/&LR'?IS8Q8#&,&@AM1!B(FN-?%113]6D;\
M\*E7OH!=YQDV2VT]S733S@X0-F'-A"$3$1YPC1BTYJ_:MU@=.Z8.ZWA(&9<2
M]H@A-QJ*[HSJ"@(,C2Z7+2+8ID01-;;=0@QK=OT93*$*4H;G1\IN4[_<G!K7
M-BYH#N::8$F+1:H[HUQT4UKBWW>7@]_),]DPALQSF0>*W!H F$LB0 P0+;.D
M0%$+LQUVMV,F5[I0MBX/.6=\QD[L(I)-E(0D?9$U!S9C6ZW3:];%>2=6XW*
M/!$C<AC@7?J%-1R7>&NL37-L0<1!HCS@133HB:H$Z84QU3][-PD#TB[RYGI#
MIET9,B_F09,M<R C:<6@&U%K8T1C1BEMZMPS2P TRGH.7<P,J\O!6<<Q+YHC
M,D\JR%C3,0K$"[1<M3+M7]D%ZR"@47([/F40\;E7S)4^=&9)?SHLH+>]MQB8
MTQM4:H!<3"]Z]T=)=*O<LF2^\7H.+7"U2;LYMF+2! LIT.!-5"S"WM>+-MNX
MY6X4;4FRK^7;4F(-4A+6?R9V-KP,?#A!OY&<A94(M%ZO'E7._BTTGB9AW2F
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M1(0$RDQRKMDJ;(,9A;$%IH;JCK)KT#1X5:Z[&=[UUO+2VY"99+7CG/%!=9@
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MPY1^2D/ 'Q0U_@$S_C3:_P!L\/>IEH?./(H?AMWN$]Q<.7ZJ/D"<4/)8+/\
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M- "@9!F'+7MXIH$34J(FI6N9DB1$/*2ITCKDCHY_(&23,!3&*R;'7,D!C (
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MQ=0[QN2W+?>S.GR-N7A)$>:?N6#@S:21:,C?5"K@Q=TASL7N8IMF C\UVB/
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MK481TPAJ*QEA\Z/PKO9>?<*W7*1^G49I3IYJE%WF]L?5=A/W0&I6IMX:46U
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MXB %3*0!,=0U1 -T@ (B-<@#&$VEH6]LJ=.YHC!12,D<1Z)9)?> #!N*$ P
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MMRV=9;PUKM>+N=U*6/)2EMK0L_?,BP,[M]Q$NG42H5!8QCE*J7,8%*:(-C5
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M6R<L]D5P.NZ4(FDFGB<+EQ#C$D&-? 1#BA$ZXZ5?:2;9+&AH!$*!X0=&LTT
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M=75U17J%0'_I!L$.3D <P[N-4^KK+6!"<%W-_,S_ ,$?[-Q\N_\ D?\ S/\
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M";<+5R+"^(B;5,;/.B(ZR(4"$-:^R <FSL9U >4*&I0P#7;CTK_Z40U+Y_9
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MPKTQ71O ';^LQ;NXPM0KY8:\*/;[@- O,BY>(&P('3R\KDE[8TPN".GNJVY
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M$80.E?9$HUH-*5+6F>60C3//+LX]-.B0(UP7A@8S0=97='\S/_ _^S<?+O\
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M'9Z8<]*[/7Q%KK$5M;1E(JE[MTCAO$4CWP&*.P0$J93%',!H8HCCR^:ICFW
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MD-BV, _P:9A4.558>YF7DQD,P8N?GGE&Q8>R^">2;R':D%CV,&?FRS'/W94
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MAMRKMS]0/2Q=*H$$!O (95V\G?Y-H815K081KM[@;>7*@9URPTJ"JE UI78
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MRQ^D.J.MLC&'7<1\<A9FF[BU+8*W4F$4G9&4S<-_Z@P;5H11$Y3,0D%@*8R
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M@Y=M0]3!2"!'FR[6(J M27WHEIYJ7<\'==ZP2<^Z@+(U.TZ2BGYB+V_*6AK
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MIMV;<$I3W:[0#L4$?7Q$2W,$IZR0%,&P0]'<Q4A%&X(CF/H[V(E"KHX!*]0
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M@D $<F>WDVYAS^E@@CHJ2]EMY.R/>S':."J*#S98*1"KH_Q7J-.97_ J8CJ
MJVFM41A$#&#DJ(=X:8)!1KV ]/PXJ)UKEL#N^I7!.VC9LS[X>OB*5UI5[ >G
MX<%4=SU?#@B>\/HKX:8J02$1',<1$P'/G[%1V]_%0IB80R#+T\^V-<$"?]4
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M,VQ'I&ZR17*;<A3@(%#&) 5B8*TM]--/&B5FMFECVDT;Z<D!/3IJTMN%:M[
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1"(P1&"(P1&"(P1&"(P1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2127058d1-fc_humanl4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_humanl4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!R (< P$1  (1 0,1 ?_$ /P   $#!0$!
M       ! @<#!08("00* 0$! 0$! 0$! 0$          0(#! 4&!P@)$
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MBD,U?%@&]#=G0!_G$Y<Y_P#'::[Z?E0]NKT]/^%#/5Q8#O1W95I_.)R[7_\
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MK#4Z6GP&>KB_44=Z&[*G_2)R[V<KVF_J.M7IZ?!#/5Q8@;T-V0\0W$Y=[O\
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M*+23:.@)N17AD%G$PBPBGSQ2+;ME3(.',B1NB<S)%NZ3.FH*O0)#%Z3% P"
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M%>E9>1)*6#?,-#-;EEK+NV*MY[X0LYZ3MN=80K@%O2;G2E7D<@P,1P0/0$5
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M9DA;_G;N>;LL72^0)R%E8I@Q:V@[C8;'TL2/B'3151>0:*GO4Y!,KTF $"B
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M:NK,[Z\G#K*D%E@MMVW?:T?$K3]N1,S,P0/481?V<1-HNJQ>+M2& @&!N<A
MJ !3,2X2O1,ZRMF990AK2R7N(]VG<>4D(Z2>7YC-&5NYZ_3;D2N*=;6Q'3L%
M[3 ")I+^-<72'28!*<%"DIQ -14ZEJX%55,JTRS%V0]PV3-XN=<+9KA%9+;R
MA!WTQD[;F[8;$L^ MQN;IM>2CI<\>0?W6V3 "JBNL90%#*%*44P,6W4IA56P
M0+8[^\,7^[UD+EVG&E@N^1W!7"QO*X;4CDIF[4[>:2+YA& 8A6SIPDW"'9Q
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M9Z4M^ 3E9.1?J,4G,%;#U55@],2%E*N%3(T(550A1$P4#47U-L-I1-YL^5"
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MI.C4V'J5CWS9H@\<,W:#*0,Y39.UFRR;5[ZHIZN\]6763*BX%NK4BA2]?0-
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M+5AX.=-#JH-5$SM&OJ"R9!0,4H"FJ!1#CQUEW':R21;2M&W,1;<MO\_;%X8
MLV^,KQES7A>EPYE@B73)34:TN!S&Q%LP#*0M>YXYE%Q;(G0]51%NY46,%3!3
M44S)<(Q-0MWL=BEIE*/DL1OK:=0MS63;MPW&QLXDH6VH:^'0OFER1T&$RT9O
M"Q*BC)%RB!2$1*1Q0A0XZ[Z9QU;&N,&NUL_Y1P':'MF+X_\ ?R'DIK>I]#.*
MO/N?_P#9/_D[_P"K=?./<?''O(;+.]W>X%JW+UN'.9+Q00( "83++3[HB10
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M 4B/M5Y:H.3@0I2"HJ8:"(B(D[;3BU'Q-8 ^EP^(.>O2C!O+(_\ \E_W@O\
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M2)9.'9@+Q@S%)VB*+Q^@J!D5#4'A3RZY:%:HG-B=*TVG!HI_FV=Y?9A]X/\
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MC"F Q8R;GH)J^G8XH @@!"L9=19(! H%$   Y:LRB.\V0 M1^#S<>_GS'6)
M[B7S_4[AU42_R&'Y#W<.'EKQ'SCHG++&(P#" 4X:K28'F^24>_XP\PZB0FV
M+Q^Y$WEX#31H2*8G#MY]O'ZNI,"9$Z>%*_HX_7UK,2+9'"/&HTY '=RK]?69
MDJ4#1)7TA&@CR#GRX<ZAJRDAB)42=HC7R]WQ\ZZ*T,7Q?)0:4K7ZFK!($ XB
M-!X^2M '@//GJ1 @2H@;O'ZO?K> @?U4^Q[Q&H]H\^''6<I)'=G5V#R^$/J:
MRU!9FP:/&E> 4[>T>ZM>>M*X-6CN)N% #S#]0::B=LAH<F'2 A6M!*/]6 ZT
MOFL.FGB7J:_?H_Z@E](1^IJ+\#>I<RP&$*\2U'F'&E.(^317'$J=/E^'A3Z>
MLDDA_<#<=S6=@[+]V65$R-PWG;>,+\F;0MZ'9N7LO-72PMQZZM^-C46B+ATH
M]>R:*9$B)D$3F-S 2EUJ/E*CY\]A<=9>W%ULD;;J=J>[+#>6<C6S9EG6MN%R
MKN+N[(-I7ON ?6(5Y-VY>V.(C,%TL[$E;S=)/E8I"<BBH'Z?#.1%PF<I)!TI
MEU$'YBOO$#/"GO)\S9ES7?EI>\PQ)E7<6&!H%ME;(D5D:SW%F,W$EMKM[$N(
MHN;91EQ8JGV8,3OW#>*?0[]!\]4DE3$35.D\SJ['!WZ8Y>RIE+W?,5GO&T*H
M.9,D;0X7+5E09"-@<)9 N[$$;=T-&D153%L+@L^^22!N=,4A,AT&#IXZU@>?
M&5><"+?SQMGP9B+W>V<L!YQO>]]WM\[AMN%A[E(]QE;(U[7I>".7KT@L>Y[B
M,]XWGI=\UM).'F[C51A!DF$;[->MVX1M*@&IA.)<(P/K6 :AR$M.P1KSKV@
M /+RZE1A#ND $1YB'Z.\=!>+S^#F/UQ[=3S%Q4DN%ISG:'X'_LB8#KT;'_&+
MS_ ZK^6R%1K4?J^8/-K]%7$\CB)K"O M>^G']'?KM>#YL=\&39;+_O"+]V^7
M; [@LB8WPWA-C<=LXIP!<<U:,I*7A<T-%3DI?EPR\1,VZ1=M:46Y$6:2[A7K
M>)@DDF)U1(/]E]M;#3[5[/H]RZ%>E1N*]=Z=6=38I^5*;<RA80G-K/Q?==T]
M;?5;>M-T4</AX_43]:V*+ W*;1-LM_2^\_*;O:KB>%R!(Y4"[',M9-^9&]G2
M*[%A!Y#ORW+DA)6,7QLXC%F2214GBCM,"]"IC]!]? U-?N?9/<6YVNEMJ:>X
M:E5.6/FL<N:;/WI3=ULSS]VYTMOK[&FFBJ<BMPOX^F),'NCW]QR^,LYR;&8O
M^8V\N<X3Q=KCW)$A,R=Q&Q>E%L6JJ[9[<JSFX'%NJRR:OJA'1S*ATF$1[1^=
M_4?H:&ZV"T,M7<=2E/=)74MT5.'&*J7V\#U^W5N-/2JHT)R-N/(T4WHY.FLR
M>\*RW@F\;=W!9+QAA7!</,6YBO;[<LO9TBA=S]M'2LODZ=D8N8MT\BG;K*>\
M-NU<+.O%5*F4B1A,/3^U[!V/9=M]@[/O6C5I4;_5W=*J=2F?K67RJRJRQ7NU
MGYS?[[6K[@]HU4VL%]_P^)V:V(W+;-W[5,-S5HY$O#+< >WW;2.OV_4D6EZ/
MACI>6CG<9<[1OU%++6X^9KQIS&$RB@-"B)S4J/\ +?=.CJ:7>]2K5HITZZM1
MO+3;2LUJRV*QIW0H/VO:-VJJ::4Y:IBV^59:;@<AIW?7K3AS'7P73%3\8'MU
M*8K;XL!&FM47_ PB]VYQG(@0X?Q@CP^/7FW?T5>1JGZOB2[+C20<AWB4>[[
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M<2V]"#7R\*?#0*B&B11.!@X<1'LIY_K:L$\Q"=7'B-* (_#JN(#O14  $!J
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MW.8'@=P5K;6);)EOL=P5YV0\R1;.+1*^/<DM8[)X]BU[D(D1JLT;,B2$6Z3
M55TE#BCP3$..GWB&[8L)W\4*@%2B<1H4H]-3&X\ #Y0CZ(\.?#3E!(=UI&^/
MLO8YRB\O]C8-V1MR.\6WU-8SO]!@DZ UL7W;R#)U-6X_.Y0;$.^CD))$ROA
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M[!A+LW)! #IG;.D5"G,54M29&GAX\>.>=B<0IR'RC3Z@4"NBY$GF G-V!3@
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MJ^P0#AS$U:?I>5:^3OT<F+;T- PB-"F"O8%*<O+3NT+(OB=( )Q >KY//O
M#C7B(FH'>.GE:)$!PF< $AB& 0 0$! 0$!$P ("',!$H@'>(#W:*> BKBQ!6
M* 5,*90]'F-/E 8Q>?VQ2"(=X (\M7X$BI7MC@5*)NGJ)6HEIPX& "B)1_3
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MB-E,2\.WF/#R!3Z^JK0V/"@ '=3B/DU'?!<!IC4$!#R_$-*#\.K"84X@(^B
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M/J*XZZEJ99*EX\0X<N(<//QXUUF#SD79EQ!C[/V+KUPSE6#)<^.<APJMO7=
M&?/(X):)751759F>QKAJ^;%440+4R2A#T"@#K4<;Q)RY;^Z-QK;>^';MN-L9
MW/L,:X=Q?D2 EK?G<T9BFKJ7OR7N>PYRQ7T.1]+/H]2T8MC;3U-^R7?)H.>M
M(AVZH% 01;R-JIJZP3<)M'WMY5OO,]LPRVT&<QQF%S+0EM;BL@15RI;I,$XH
MO6)"+O['%H0T'CI:W[H6;(/'Y+=DG%PQIF:+L@O$'"B1A,CT8=7%FV"NV^[7
MS;^:M+P6'Y;W=2NTU/"S^TG[C(:>X"0OSUQK:2T:_DV"K.Q?S1.<2^(DJ* $
MG#3)A$# U^38]#,XXFHMS^Y[Q*7='M3S!89[FB<<X/ALLIW?;LGFS-CJXWC^
M?;6.3':%H>N3DJV:QT6O NQD&PNF*"Z?AD,FJ4I0"0C6>KC)O9N-PK>F=[IP
M793H8,N (*^QR5G&.=O7J4S>;S'BK"YL3V4U8HM56JUMO,F-FTM,%5.4JS>)
M(W$#E<*:>5PEMRS3;'FRC.EL[@[;?RWYLC8DL/>!N!W;1&2VDS.'R]=2>=(*
MZ&:&,):W3VXG&,$[:DKN79O7HRZJ#J'BV())@H8Y2(X$S6'7X*% 4^!2EJ0
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MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
M&@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
M : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#
M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
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MWK+<ZTI7JI7R<]:B3/48OK*]1 5E. C_ &U4.7;3JJ%-21U&+ZRXY HK3O\
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MN#6>92F?F'F^J.M4W$*AB\JB/4/,W<''AP\NB,SC@4A$>7.O(>WC]?52-"E
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M*WG8EV7QN!W,9JLRU;#9W;<J-NP*]8.&=XUQH!8.VHV%M^&A;$876O)R"Z:
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M[FQ/@.?W/3V'+8CK%>0U\*+[G+Q>7A)MLBW6ZN:3C99&PDI9VRCC,V*!GY%
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MA&=LF41\Q?VS27B'2@"/B^R3+7S%'^STD94*,=&CSDR_<!^V:2\"0A/4(O\
ME,/ZG]LU)+E%+'QWV,F%.TH%*-1J40K0PCP$-62-<SW2#-DJOXB[P$5.@A.G
MIXT . CZ?&NHO(KYGA]GQO\ *A?@*'[9I:2*< !A&?RF0?.4#!\0*:3P+E2O
M8[U*- ?\)$^Y* >?BIJRR95\ %G&_P J$_J!_P"V:9F,JXB>IQG(),GQ%_;-
M,S&5<0]2C.8R9/A ./\ 5Z27*EB LXS^4R? !:<@#]D[M)P)E7$!91@U_C,G
M'N OE_NG !KHZN152L&,]GQG\IA\1.7=\OEIF&4<5C&%Y28?"!/OPTS#+.)4
M>1\>M#2+922(FV7 GB.A$H%;B7H$HFHH " TY5[=:HJU%6G2K5<$K"/OFU;0
M\?G@TX\.*(=G#\M#7N6MNTOH98$^;5M_\<&GXD/]G:G5W:_=90^;%L#\J[VH
MAV=**0<?+XCE4!IYM%K[M74,D( M>UJ4^=R'XEMY_M^_5ZV\OR/[0X8OS7M8
M/_:YOV<TD*_06*.IU]Y_!4%YB_-JV.'_  O0X=GAI4IW4]8Y:=;=_P #$"?-
MBU_^-S;\4CP\WX?3K;O^"H1S#YLVO_QN;<?[DC^WZ=;>?PL1S$^;-M!\F\&H
M5YU2)QYAQZ79-.MN_P"%B!?FU;?_ !P:?B0_V=JK6W?\+$(]T7;MO(R3)PA=
M"+IPBY2.1%--,HJT$W2D(^,J>@\>0AKS:VIN6OF32)"DSIZR9+.5%%GY$3FZ
M:E M1#I"@ ;\)SX:\Z;B!"D\?J$9R]J%\] ^EUZ3R&7F'L^,_E4OP=(?UQ])
MY#*+ZA&<O:A?B+]_I/(N7F ,8P/\9D'^F @_V>K/(F7F.]1C0+_A,@!_2E^_
MZ>W27P)E4WB>IQG\ID'S@7]LIQTGD,JX@+&-I_A), I]B0H<_P!7I;? A8#?
M4(S^4P_J?VS3,RY>8OLZ-'_&A?N0^_TMX"SB)[-C?Y4 /U ??Z2^ A<1Q8Z.
MZ@Z9,E0$! .D K3LJ)Z<=$WP)%*,NH'12O#II7R4Y_%K!O C^0,(/G05H'CJ
M ' .76(!]B--;P/)755F:7$PNY[\LNR$XE:\KMMRU$9^=C;7@U[BF(Z&1F+D
MF5A;1%OQBD@X:E?3,FN42-VR74LL8! A1IJRT3-4^)E *D&@E-6HB " @(&$
M"]0@4:B!A HUX:CD37ZEBG[JMVUD&3NY9Z(@&LE+QT!'.)F1:1B#Z;F'B,?$
MP[15VJBFXE)-ZX(DW0((JK*F I2B8::6_ N:KXE]\3C0#5-W5"M/( @-0#O#
M2TF:JZ1"J]8")3=7$P#TF 1_6^NE  /2Z/2 .=..EHFI8AXH]@UJ <!$*@'>
M'H\M7SN+FJXLQN2O>TX>X[:LZ6N.&C;KO)*;7M2W7<BU;S-Q(6V@T=7 M#1Z
MBA7,@E"MWZ!W1DRF!$JQ!-0#!J*9)-5\L6[[UM+'UOR-V7Q=$%9]L1"!G,K<
M-SRT?!PL:@4X)^*]DY-9NS;$%00*'6<*F&@<=5B:S"\69ZPMG&,=S6&\L8^R
ME%L'2C)^^L*[8.ZF[%VF0BAF[P\,\=@V5Z%2B 'Z1$!J'#CK,U8%EF9S5[VE
M;C5L^N"Z("&:/)IA;;1U*RT>Q0<7#**%2C8)!9PX335F'RIP*BV*(K*&&A2B
M.EO%"6KI,EZAZ0-R*(AZ7(O$0 *&'T>(CJRQ-?%R'56M!$U.(B/(*" =G;4P
M>7CJ_,155/$0%:C3J*(>2G&M0#C0. B'?34M$U8-EDN"ZK=M.,--W--QL#$%
M<L&0R$J[19-!>2CU"-CFA5G!R$,Y?/W*:*28")SJ' H (CJJ<3I0V[S#VF;<
M02&1I##[#*%AO,JQ+%.3DL<M;JA5[UCF"J"3M-V\MI-X>7;H&:+D5ZCHA^".
M4_R1 1MAIS$F4Q-Y6Q-S%RVY$7!%2D]9SB,:W9$,7Z#F0MUU-1J,U$MIAJB<
MRK!Q(1#A-RD10"F.@H4X!TF 1S:<754[1]O79;MV,UY"VI^*GV+62D8=RZBG
M;=XBWEHAXO'2D<N=N<_@O8Y\U4262-0R9R"!@ =)>!K-4^)?Q4$ YC3]+VU^
M.NDOXDFKB'BB'V0C\(A](!TM&:KBQP'$W=RJ/:-//2NDM$S5<1/$$H5[QU)D
MK=6#%!41"O'CYOK:76$MOFT.LP^7ST'XJ &D\!-2O8=8]P4[:<_@TGB)JXC?
M$#O#X:ZLU%S5<6+X@#P W'R%^J.DN)$OBP 34XGY@'8 _4TS#-5@V'C"/#Z/
M#L^ 0T4D=5?$/$_3#\ A3Z!0TMX#-5Q%$YNP1+Y>?GX#J)R)J5LBE,)J#U5$
M! 0-T@': <=:.NFVW:7B:$WKM./ZPF/&E*T'L[]11\#5;A%EZA#C41J/ !Y_
M!0 KI+PN..:KC:*)U/MJ"'D*/T*:D\@JJN)BEYWW9^.K=?W9?]V6[9=KQ8)F
MDKCNJ8CH"$8@JH5)+UJ2DU6[-$553E(4#' 3&$ "HC35&:J2O:EZ6I?4%'71
M95S0-VVY+-DWD9/6U+,)J'D&RAC%*NSDHU5PS<I&,F8 $AS!4HAS#2W DU8L
MN,O-Q4!&24U.R;"&AX=BZE):6E72#"-C(UDBHX>/W[YT=)NT9M&Z1CJ**&*0
MA"B(B :?,5-\68'?&;,18TM6+OK(>3K%LBS)M6-1A;JNBZ(:$M^76F&HOHI*
M.EI%VBR>FD&1161!(YO$2 3A4H5TEXB:N9DSR^;0CB6VJ_N>$:EO&291%J'6
MD6H$N24D6BT@Q8PA@4$)-P[8-E%R%1ZNI%,QP]$HB%<DS5F3B<>'&@^0H#Y>
M-?)J3%XS5,.L0YCPIY/HT*'T])?Q+FJXAUF'B4>%0#LYCR^4 Z6XC,UBQ\F
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M+5CVADO'\XVN2R;[MR&NZU)]D1P1I+V_<3!&2BI!$KI%NLF5PU6J9-0A%$S
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M;PPS$Q:70XN<V7MP^6-P;MPZC6\;[%D,J2X2[JVVZ:+]^F[9PHD\,CA3I46
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M%]@- X>*Y^ Q/J$TDD![!:?LKGXR?M>F8L>+ ]@-!_MJ_P :?W@:9B95B*$
MU 0$%EZ@(#S3'E^ITF"PF7SI]'IXTIT]E:<O-K)H=H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
M T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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M=OEF[+XW&WW 7+N"RM['90ZEQV/#*Q[%[B3&=A1TZ2S\*VA.6;$$AEEH4AI
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M6B*CAT[!JW1(*JSAPY!%%),H5,HJJHH4B9"]HB( ';JS4,QYU)I@DX;L5)=
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M)SE^C6E>[1-X0)>( Y/0/PJU1KR4,(#QI0!ZN=>'GX:2_B)8"Y-U=/K!P'F
M>(H81X 8> #00 # /"O 0'M#29O_  $U0(*Z]:^,I0!_93!RXTXF#C3LT&9P
M .SF'I%=01H @4JIA, #PJ8O54*B'QZ6B6K@]:'J$H.5.L  PE%8> "(  F
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M;LBZ!-NLH5FT55]$J1JQWR:I;4P;!;IL.7+N-Q*;#L%=#:U[.R%<-ILLKR*
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MXYRKC7+]H160,4W_ &?DFQ9XAE(:\;$N:)NFVI,"& BI6<S"O';!=5%3T%"
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M]RMGUQY;D!R8QLJZHEJQ5:1$D@<K=\5XH@Y\)7U5.J\Q5]-AV0$:^2@!4>(
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M^(]U KKPLA&@X2(H[\/H6$!$A.D2F'J"ODUTT-3HZW5B4L/A!>G\KIF\P/\
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M3@(<AY4U7Y&,U,WVAXM:?A#A4:!4Y^(^3C0=2$5UKB+XH\NLX"'/TC\*>01
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MB8 $G2<Q@4*:G09(0$P*D/6@"6H"-0#B ZJY7D:8[QP&H@H?Y12<#'_7#"
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M(QP^S#MKVAJ\L!F1(]?0KQ^37R\OIZYG; CR4 !>/*D*8!74$2G*50H])C&
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M8-NK+VXC!EY7!*QJ6$L%(W%D%M90@=VMD#-LLT+ V3+3R*A"-VT-BR$7DGK
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ML)C4'C7C]7M\^I$G BO-[K*K7$&27&#(J!F\Q)V=.CC2+NF2)#VX\O,S%4D
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MJH_PM'[@_P!#TPIJV#IKB'S=6'F\0^X/]_I*5PZ5/$4MOJEJ .D1J)>13!0
M&H\S&&HTX:LXFE0J;CVOXI5VY\4JZ*8>$4E# (C4O;S#AJ)I(M5.:^X\/S<4
M'Y3M$1[^@WWP:28Z5/$3YMJ?E:'W!_VS5S0.G3Q#YN*_E:'W!_VRNI).E2 6
MXH'\*0#]0<?IGT=4EZ5*%^;BG/UM"O.O0?G]WY-,W$=*D0+<4#D[0#CU<"'
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M@GS<4X?NM#[@_P"V:N;B.E3@+\W5?RQ#\6?LY?VS24.FN(@VZK^5H?<'^_\
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M\ODTLPN*FF7::,8K[@(@'@)B  (_7IQU*3532EO LXK"' 3G ?.;6DT<\U.
M@*B;@!SUY\1'Z^I8BNJG%@9<24 3B%1I4QP(4  ICF,8QS  %*!>(UH B "(
M5#5E03-3@)XYNKIJI7S&IPKVB;A4H5X\P$!U"YZ4-.Z%,:'.8OE,(E#LH%1,
M%3#6@ %1$> 5$0#4Q+GI?$!<& .HQE"EX>D(B4I2B%0,L8WHMP&G#Q.CL[1
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M:_)H(<>05[N?#2$F$ #7IKW5J'+S '(-0MR PF[.?&O3Q#ZO'5A!#J\/2Y4
M1[.-*!J6_ "U P!T\:4_HZ-6<R*\0* -> #VC_HZDMV8!I"&$>(@/5P"@AYQ
MKRU8"$*)N8\N51  X_%I9@7D5B#4![JEY4^W* ZJNM-Z=[+Q-_OT?]02^D.B
M_ Z:ES+'TE$*T$>%:@ \?@$=)?$\W(0IC<:]W#@ <:AY [-1Q%A8./7O8\D9
M!AY39CAJR%-TC6(S3GFXCY->[07-R1>938^QKBJZKK5M^ GK>?Q7L0;OO!2(
M8K+.'39(K8RIQ63!,>JX6&D2K[M^\L.3L'F*U,=9&WA3=^V)>4''9?QAO<R#
M>=Y9FQ++/X07-MLE6=USEQ$B;>NZ #VDQ5CWKEE()F!8#@("4"#YFB6[O<LS
MR#OPR_MXORX-X$KC+ .&<63<-@78RCD%AER\[ZR:YO.0N#,=\77C:3MZX"6-
MC:"B8V-8,SRC:.&5DP750=G!/P)>[0K+3S/[NN;(.WW9A.3FXG/&XG:BNUW!
MM;\S1B!ME>Q\YSN0HI/U/;W#Y7:X=1B+Z:3ELIL)6)G1.BB@[NMFT6?)=9RC
MH>A7DVX2SO?%TS^W&W]QN5HO&33:3CRR9/=1*WG=+:U4+ZW,9<LLR&)<83\P
M[<-VLO.VA9[Y2XIYB>IB3$A##^$ 3@5YW'*N_F=L&[E!ZBDY;+)N&[E))=!=
M)0JJ*J*Z9545TE2G.1=)RF('(<IC )1Y]H[.5QZN(></I\M<V[2PH'5K6H]@
M_HJ''29)$7#I+_)*<_O(>?TT_K:].P_QB\_P.J_ELA@>>OT-5YQQ&C6@TY]E
M>5>ROFU%":FZ41M)-NZ#C5[X7(F\2RL"W_(8,5M['F*;9L>'N?(&60G7[;(Z
M\@^O-C (6!8L>R3,G''7+(-';R24,42I)G13$!.;7[7V)M?;NMNJJ>XUUNNJ
MII*GZ5\OU5/X0K<;L5\/W7K:_0T?RCA8\;[B:<TXJS[G;#&VQO:>XJ5P1C!&
MSX>Y]Q5UV[+.(3*5PPZ=IPKQJE:UZ*Q\FUA/!=%67>*.!*50QPZNHE2Z\VTW
MG;.T=VW=6II4ZRZM?255M*M:4VJRYMJV)-:>RWVYV]-==32RIMW3]A&_NJ,C
M9#O)#<];[K*%[YOP%CK+R=J;>LM9'73D[INR!0))A=1%+B23;?.&.BI<B2;=
MT*28'*<: 7Y!?9[TVNRT]+9;K0IHT]WK:=56I33=2_DCX3F2M;L+[?>YJUMQ
M1K-O2H=*I;OMS3]R*'O3=T]]V=CV\,!;=9(6V<Y#%=X92OBX6BJK<<4X/LZ,
ME'T]<Z\DW,9>/G+HD6)8N(*!#*&66.IZ!4NH?7[![-M-WW+2W'<DOR6=4I/]
MZNJRF%C#M^$X'F]T;[5T-O75MW_?4J?@K_5&O0W-EZ\]A?N\KKF)S.%QV/-L
MVTKN"G\92=U.LBRB:MBW:%H+2TA:ZQKL5C%+P(Q*X,@L!Q7(D*INCJ*/IT]/
MMNCW[>[:E4+4536GFA*%4LUKQB3GI?GM7L].X;;E2_3]AGN),JY:O=OM3P[F
MJ_)&S/S#V?&9GW>W%/7$-N2J+M:6?GV\X\NNX%'+8I)&XVXEDYQHH<BKIL@4
MA@'Q#&'Q=QV&ST?S.YVJFFNN-*+<%GJX0FG#XKF-ONZM5Z6GJ_4J5F\\$=M8
MN193$<RE8U\TDX^0;).F<BQ7(Y9/&QR 5!PT71#U95!5(I1**?HTY4U^ U$U
MJU)\;O'XGZMTQIT/_1/<(T_H@ _3TH;S&$B\VX(^W(CE_A!+L\@]@=FO-NXR
M5?V35,9EYHE^8_?SBG*I ^@ 4U\' M?ULM7I#T@:O"ODIW<0U7]IA?8/ . \
MQIQY\^84KK*#*)^O\)\KD;D UY<*4*80^ !\P\M50,#B$E9M_P"_7=1[P*W)
M3<%GC$4)M*NS&V%]N[+"F3;EQPPMN]9?#MJ90NS)MZ,(1=-GDR7<79/-62#*
M;(^B4XQCX16W6X55%B;M-T?=R[C;JW,^[[VS[B\CBW4O:^,,Q<W?;AH@5NTD
M+G@BOX&Y)5NU^0V0F)."6=$2"A2%6H % .D"=DXF:K^1QGN;(^9S>[XNWWQ$
M;GO-">;8/(C[)L'C8N1[D)@ ,'0&=3X]'!#O#)UT[*>0DS9I%CN919JI/C(G
M]8%YX903*+.'VG2[<MA)Q=,[E7<;N@W:Y,P_M6LO%5JKXOL_#>8+ZP4G8DDT
MBY!_>>3,C3MI.8Y]>E^KRDB@TB&BJ[N*08ID2]1,N8QE$-WEG!(G[W<EY9CO
M_9?@N[\]GG'62IF FUG\C=,>C%W1.6PA>5R,\;W+<T<BDW1:W)<N-F\2_?@5
M)&KQPH(IE$1*!6(R[3=HHF'MKP[A^MQT9.0&,;J[>'#X?BT7.\OD54B@"B?"
ME3ITY_;EU+<2J\DO[#]1]363U8$>R9>MV]"HE_#J\2TZ@'K/0Q*@(=11&H5X
M<-;X'DKLK;YFHF"=M;W#6:MV>67%VMI]#<SDFR[]90B,,K'*6BG:F.;9L(\8
MN^-+2!9I1ZI F<E5(FW A5 2Z3"%0JLD-X(]6Y[;FZW$*[=E&EU-;3'!>Y[&
M6X1QX\,O+C<K7'\7=T>M:R H2T2:+=RIKF(8CM07)$/5A#PAZ^$:),&L>>_=
MJV[N+RCO(NZ_;[41M'=GM6PSMS""BH8Z<_CZ9P]>N2+\ALCQT^,NFQD':%QW
MFP<LV@LVY45XH!.H8J@B"\U*2N,=0V);E\LY"V_W+N\W,V%E2U]L4K/W98-M
MX[PV]QL[O_)4A9<O9$'D?*;IY?%SL%'MHMI55^TC(ELQ:*OEA.L;H3*AI#Q(
MH^!M[LFVXN]I.US$6W61NUM?+K&,)*Q*MUM856 ;R_M&Y9N?!5*)6DI99GX1
M)?PQZG!Q,)!'T:]()@CY7$(YPVE[B5MQJ^Y[:=N3A\3W3=%@0&-\J8LRMCV1
MRKB*_P".M1_*/[:NIDR8WK:,U8=[1"<LJV,ZCE12>M>"Y!, "#&<"S9"(/?^
M["OC)F(=_49GK<)$W=GW?[C"W,57ED2S\5)678>-K4L" NV$QS!6ICXEVRK^
M:9P"MX.W+MT_E3OI!180$Z14TPTBR<2YO0G?$>S[*D#N6LK=)F++5EWM?,+M
M#9[8[IA[+QY)VC!3DK'Y1G;\1O6*-)7A/.H9I[(DV[ S X.A.X0,L"Y4S@D4
M1OT-=)OW;^Y)CC;,^UG%&[&T<?;1,W7'?[Z2AE<+KS>;L>61EV5?2.3\96'>
M_P"<!C;(Q$V$[*E8RKV+4D8TDFH!!,9% 0>5PE$GWU[K'#^1LA9"EKI=,G6+
M[QV,8CV4VY9!(,4;FL&/Q+D'(U\0=\VY>WM-5VQD&REX,/54DTR+(NXHJYEC
MB8"$1/H),'3]WMN4MZYL2YDMC<KBNX<_6QA-K@/-,SE? 1KOQ]GNUK1N"3D<
M6W7(PS"^H:X;$ORS&<JOZPXC'JC:677<>,F1,4R$6_8)6)O;M7PG?."L7J6M
MDO*RN9+^FKJNN\;EO%.UH^Q8!%[=4HYDD+=LZRXQX_:VW:%J,3(,(] 7*ZYT
M$/$6.*AAI58K0WPN-;L!P4I@G??NSQD]A7R=H[HD+>W;8[NP$%%85Y=T/!VM
MAK,=AK.134;,YR';VY;LRDDLHF=VTDUSH)G]65,2*WR+\29[TVU3.2]QBF7+
MYNTKJPK4PK<&,\4X_8H*%&VKWR+(//SD98D%E5/"6N9Q;*#"%B@ %B,6J;PY
M3=;X]%[)F1 .V#9_D; =U65?F8,BV',P.WG;P^V_8S3LBV)2(6E+(4N2.NJ7
MO/(KB5D71T9M!G;#!))DS%RV3$KE4IP%;PM(BXLQ87OW;>.I=E9.>=R-TQS^
M)NK>=N+R%GXL7*(.6\A%XV*=ECW!;)Z@YZ%6SI?#-E0KY1$Z2*[=1Z9)8@*D
M-JKC@1\[T=(:B''A\(\ ^OK"L8:D I3AY: /,?-RKJM"1@%Y\>P0Y?%QY<M6
M8$2)2A@#GQ#X=5.R05P&ODKPI\ UH%/)K!&H*8DKQKW<*5$. ?*XA36IA"1H
MAT]M:\^'=\??J7E'4Z@X^CVAY> \N6ES)."'%"E>V@<.'+Z>C<B!HC41*/>(
M 8>-*#V4 .[6A@.*'2'?42AQ 0$*_#K+M "41ZB\ I3GRH/^AI%LB; *4 X5
MKQ'EV4#EH[1+$$>OAR[/BXTIJQ%H7 >F%"B']+_7 .K@=-.]EZF_WZ(?W!/]
M'T=1?@=-2YEDJ(< Y>:GT.S678<(3M$Z:<NGX-!)I!N[8[T(:?Q#E7:.M:60
M&-@/;N:Y8VOWK(VQC^/SC!W9%,HJ E87-LI:5VS6-[GQ=)$5DFZ"*'J4TDJJ
MV<^D" EN!4:P89P]O,Q[-[O=[,AA[%J^ZG=*K@>#@=M09<.K8N/\>81CIFUH
MN.GLR)6A'(7'=SEC=\K)N'2,5X)C> T QTR)F+J VEY>1[LN85W78$W@9'W=
M[4L08]W$M-P>)\<8WR?B>Z,H-<*W-:-V8MD;C=6WD."OZ3M6\8Z<M9Q$7"9J
M_AS-6:WK*"*Z:@D R>IS052)?VB;?\I;/]HEWPCMA!Y&SQ=%X9UW!W!:EIRB
M-OV>^RQFF\KBR2MCZV)JXC%8QEM0LI,(1:+Y4C9%9)L#@42J*JE-4H1,TV2:
MAY"V2YALN"VJWHRQ);.ZNZ;(3W(3^XK&,_=5DVV2^\L;E;<0.OD!*1OY0EGR
M;?',XW&*;>L'.NSMT2'9%.9!-N.8:4FL;+SJ'M&Q7=&$=L>!L17M(-)*[<;8
MKLZS[C>Q[IV]C59:'A&3-VBP=/Z/G3".50%%!5:JATJ=0U =4Q,HV+X %*<>
M_P#H:RRVWR,$P!SY_H\FJDF')6DO\DIO^\?]D)KOL/\ &+S_  .B_ELA<>8Z
M_0UNTXB:P6E34D[I-,O>%82OG<7L^S9AC&K:,=WQ?,)!,(%"7D4HJ.47C[RM
MN<= ZD%B*$;I PBU1 1 :GH6E1U]SV]OJ.V[[3W55M-%4Q\(/E]QV56M-/%&
MEN_S;QO?RWM^P5M]V\LK2"U$;7@V&X DK?1+56N-&VXRW6K&R&<BW0+*%M^1
M<LESNUFJZ)U@(0@_@Q$-?K?;'>_;>S[[N>Y=SH=5=6K4Z5$Y<TMN(OAI<OBS
MYO>-IWO<;#1VVT<:=-,3Z$L[>8;?9C?;GD&R'&!]N>,[PLB'MZ*VZV18MU23
MJRWZ-7YYQ&ZWSAXHNQ\ YT#%6,91PNJHHHH<3&$ ^1WS7['O-\MQV^O6KI;J
M=6>,8B(I25SL5B1[>W[?NFRVRHW:4U)1'*_%\2(]R'NNV^>[<RSF8UX9%MG=
M#E+#1H2:MRULBNH/&DC>2%H@S8VM((@FJ5Y8IKA$2K)KJF242,8QBC7A];L'
MOQ]BU]#1KT]*K8Z5<_,I:5MJ>%4.QJYG@[IV%=RT-3-54JZEAYK[/%QM3L(V
M\7KM"V>6OCB>++7AD:)AY*X9FW%[M1E6;:YE8]J0]HVE./E6K")MM=6*(* "
M*:*+A8YN <!_.^[.]=N]P>XOS<+3HKJ66%Y_,[I=KY-(^CL=H^V;"C;4RVE:
M:=7;LHS8ZP_CC(S^Q(7)^<);<?'[B-QV*I:ZH&+:WXT.O*QD#8J-Q2+Y:U'"
M&,[4%BW8)+B=@Y5:*"F ^.(C][:^X^WO?U;5OIZ"T%IT5)2Z6J8=4<6[7:KE
M+/GO8.OM]=436]1MX3\SL^!OWL(PW?V!-JF,<7Y..V+>D*I>DI*1C.1"796V
MA=E^W/=\7:;*4(LN@_:6M%SJ+ BB(^!1OTH@"14P#\O[CWNSWW=]76V*C;RD
ME\%,V)H^QVO0JV^QHIJ<U-?BS<,>6OC4*WX'O5Y>K<_PY$A_W>B'Q@;Z^O-N
M[:&^1JFUKS)?EP_=SD.X4Q^@ Z^%A)=3ZYYEM[.OF U&G?Y-8Q,<AH&X<NSB
M%?./'AK3A$5H#Q+2H%[:B/ H\ZB/#@745Y8.-M^8;WP[;MQNZW(VT/$V+\W6
MKO8?6-=K]]?^8TL4+[=LJV9C2%Q6O=#R+6LJZ7F2+1F8^'920,63AHZ1=,E$
MJ"19,26WQX\8&I3LP-BMO6!LJ;.,#[,=IV+[5M3*V-+ M,<?9YR//W0I9DQ;
M[)C;JTB:[[.M,C*4)<:]V7L]<%49'<(>IME0,!E #I!@D/.PYWW!L<WF26"[
MD]UZPQ]C1OLVN3);^0-NP'*Y%;RB<$2V5$LJ2.-#8-4M+UY;(_Z]!H2)9WV<
M5!R1T9/K(<HH=S$\"_;O,,>\1R-O19W4SVIXQW,;-,-6U;(8(P_=6Z.(PW;<
MQEA) CF<S)E"V1QW=;V[I.$%P,9"Q,B=:)9%;"\\!1PHF9"M3<).S^#IS*-Q
MXMM6:S1C* PYDQZW?!<N.+8OEODB!ME1O+R"$8@PO1O"VXA-D>0Z3=P8Q6+?
MPCK&2H/0 B\[R7DM?K85Y]G=SXU#G74F;#,2Q ](*UYU[JU[Z\..H:*J11\1
M/A2AB=M:^F7LH'=HH"=I)7V'ZCZFLGKP,><P)UUUE@<@0%5#'Z13KT]0B-*]
M7'GK68Y/2ER4?FV<>;LO'G^! :^?TN.KF7 G1#YN'_*R_B0Y=WRN6IF7 ='F
M'S;/6OK9:]_@A7CY>K5S+@.CS#YMF'F[#\2 ?V6IF7 =+F'S</\ E8?"B'WV
MKF3O0Z/,/FX<?X64/,ES\_I:F9< M'F'S;/00];+0>8>"''^J[M,RF0]&<0^
M;A_RP/Q5>RG:;NU<RX#H@-MG$.+ROG3_ --RU,RX#HX38)\VS_E8<>(_@N8^
M7TN.KF7 =$7YMC^5!7L$4A&G?2IJ<::F8=$/FV?\K+^*I](VKF7 ='F41M4I
ME2K'63.H0:IF.W*<4QH8!$AS"(D&AQ"H4&@B 4 Q@%F]2])\;"J%MF   711
M_O8]U!^R#GJ9D3H\Q#VP"A#$4<%43. E43.E4JA# (&(< , B4Q1H(5XAPY:
MN9)S Z/,:2V3%* %=@ <QJD-3&$  QS#U (G4$*G'[(PB;F(Z9N1>ES*GS;/
M^5E_$!]]J2N Z/,/FV?\K+^)#[[3,N!.CS#YMF#D[#\2'WVDK@7I/B)\VS?E
M9?Q ??:2N Z/,7YMG['8?B@'^RTE<"='BQ?FX;\K#\4(>;@!Z:9EP'1YB#;9
MORHOPHU^F8=,RX#H\P^;A^%79>'+\#Q#S>EPTE<!T>8OS<.'\+#X4J_V6DK@
M.CS&_-LX#4'90'_4>_\ 5:N970.CS%&W%!_A@?BJ?2-J2N Z(GS;/6HNP'O_
M  8_?:9EP'1YBC;A^QV 4_N8_?:9EP'1YB?-L_Y67\0'WVDH='F/+;I@K5T
MU$.28%Y#7L'CRTS)8&J=/*[SVOH@7:OB@OT#X94Z"2H^CVUJ 5'15&JJ<R+>
M-MG'^%A^*_TVDK@<^B^(OS;/^5A^*^KU:33P'2YB#;9A"@N^?:5,2F[N!BF
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MPY\1K0X<1'6:=YIT59J::I=]IVILIRNU+C:)^:Y8?\:(>8&YP :U 0$.JE!
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6#I*)T<4S):#TTX5Z:>3E2NLG?"#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2127058d1-fc_keyinfo4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_keyinfo4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!M -R P$1  (1 0,1 ?_$ 0H  0 !! ,! 0$
M       ! @8'" 0%"0,*"P$! 0 !!0$!              $" P0%!@<("1
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M/#/%G"7$M1K.E U0,82C$$]&+X+ROCSNS[S. !*>J3K5=/)&[7HRE(!]DA*
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MPBLVUH(@^I)@23*;Y8MM#%(4I@T@YX> @ #H/+H/?#".KWPB_)%VGS:]H#>
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M3>"^MX;.S%*J?&9RI*5/C4(;M(6]0\LY3AY(QDK'D^U)VM]ME2.=T>PI:[)
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MRMAS(ZVID[O7(HS(CB0355?SD;744F9TGBI)25<&;,T7!$%#F;D,H4=3'TT
M![V38ZJQ).=IS;:$G6=9*WM\W/N[%8:X,17*N]F'[5>JNHUE/2#ELW-UP1;!
MQ+( )R =0P&$2D$"F$"CKD,NTMM>_OR5 2=323AU..JI&6EU#K-J1-6]B@LN
M\J</9%E"MY"=;^2KIF3(7D%PW61*<54SD"MLVH[K/^1569;?[<I'[LVW^0;!
MA%>>$7Y(>U &O:%W@'34/E_8O%#0!Y1=" \>&@@ ZAKWL^UN[YJG"=K3V]C%
MCX@OR3[]7/>AJ$,Q4N)@\P!!QY,G'*S+WP^CUO\ %6_LTTJ(9.DU)&F%<UF9
M;$'[8U7;.5%6G6!H!M%6"R1@-QUU$>X.?,G>3IE73>*KGM7W9S>)Y1S<J_0/
MN!U^RUONWL:-I[=I#L9C:#!ACTCK7?=M;:VZ;GTC:2,H$$>?DJYVE]B+U--T
MWL<S,RJE4NB$G89@RDD]9$73C6114%),QUSAJ"9#&X9T6,LR3F%[20<^=;C@
MH5)N90XE*5,AC&'730"AJ.HCWM.G !D=T8DJ2D(1,I8 +\I?:^OT9N+VCMS[
M1"+)N8568:Q4:[3^ [3A(F/C%70= B55PW4$NH? Y>[KGV=W<Z?7L>%[*SK>
MV:4JDO\ BE(Q'-GESK\F>_7B&TU[O+U._LR)6]&M&D"&8F-*FY?QD=*UM -/
MJZ>QKPSO>]O@2.;!>/TV,<,B3YU''7VL;%D/:;8R#T#@)(D MFH*(CKKE+;%
MC R+[R@#&YM.YKWL,&=8.3/=.3J3";AI];  5D\?94AT![&1:HR#YJH..18G
M#+E495DP=]JCP^#"F1=0 !KKW<KE01B"XS5619+9+L>?ZS.S?[MX+_C<\][T
MO]HU_P 4_P TKV_^&_\ ZG6?X_RA?J\+T>V/UQSXW7ZJ#)3A5,(F$3"+%>\M
MO"D4.7G14ZLR"8E(;4 \<2&,  (\/U.85);L#+,@+M'!VFPU;B"WLJF,9S ;
MI++P@W][9-M@'"MEK3IR"3,.8Y6ZNH$53/SCJ &XB)AUZ!#.OU=8["NVP')?
M?O#'<!INL</SLY1A]IG$R!)9\,@O4KL#]L.J=L39AO<H5V4MCK$D>GWN+,3J
MEXZRQ[5JLLH*1R@<K210<%61-^J(;P9SEM<PNZ?:0SVKX<[S.!-0[ON)*FD7
M\?4EZU.6PQ<CS@K>G-=>>IA$$0 -1X '$1'H ,(H$Q0Z3 'LB'<R.$7DMVZ/
MIG^Q%V#EI*L;@[B#=]VV0)BGM!MLU-8;2F*ATN89R1(!:Y5P31.*@D?.TES
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M3H(WK68O+0#(L" .ECX%9G[.WTVG9\W+DFE/WGC9;82['4*Q6&QH+OJFK*$
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M* RKNJP#0  .YPRJ*<(F$3")A$PB9#S(J1*!NGZXA[NG3AD=4 @D  '('#@
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MVHH()Z@D/0';*&K]UO&<A2URVGI5_+#M*3]F^S"+Y\IBN'J6O%VB#_)U8W=
M?>SS;QD'RK(O9^^F]V4M<NWHG:,K$]L%>$%5(R2?R;-[*5,DLWYB+)/!:LSS
M5?YU2\NCE 4R&^&H!=1#;\0]R6N6=L=3X9J0U#3&<;LHB;-F7(?H&.6"UM/X
MXLZE<66JQE;WFUP=WDS8CRKUYD-T*\M 1LU6)2-LR%@9E>03J(>H/HYZT6*(
MI2!'K45D#LB\/&*81,/ O'H\HM=(O*MR:5Q"5,0+2$@Q'B*[/>ZI;V]+?IR$
MI$.&+^-8_AH>0NDHZ6DWX'>))]>4YB@9NW'K$PZIJ@"@%1((&[@B8=?&XYSM
MQ<4M*HQC;QP)8_R^ 7"4+:6JU95:DBS./&KS+MDL'1*)](ZZ-1[_ '-51'HX
M>QG&_'=[.&/2N2CH^X"(R#+Z'VU$I0$TJB4 U$QC-].&GA/H :].0:X/F'K4
M.C,/TBP;=+55:>Z\A6EQ>N3$54*5LS4ZLY$3D34'KP R2>IS@!>L$@''7EU
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M CIG1MO]OY]S-5FN69Q.PVVT:6&@W3=6:8N @Y=1B)TEU6P<ARB4>0#  Y7
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MW<B6;B(QA"U7S:W67.5,RJWVP@]5IS@;##)-I7-'M#;IQT ]K]@2AH>_OK[
MTNARQZDS>'MSN6JTQ<'[,M%C]SW:4)+143!KFYI&<9-EFX H01.8$1,^6:;V
M#E=?M%VE]TM\H^!3B3[?[=2$;575FM+ZV1LA,1%G4:7VW4E9I5#LK4P3C637
MY(G6>.3.'WDYWB1"E.7QC&1_$OA [O[WPDCN1&3USHDRO,=ISYGJ5(OJJ]C(
M6@L75"AK4D]DQ0LZBLZQ4*(M6+4QFZCB2<EYW $.1-,RC[-JNR#WFWGL-\;[
M31\AML>;A+O9ZU9[XE S3B"E8ROTZE6\BU?@$[&*C"; EL%D[06>+H(.$3&
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MR8\AVK]TG8 W.LUX[.E$AMP9!@[W'H<-'5*W&8JE61>G8H<D'+I*&30.L$O
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MI0U$0#,1@&1%99@@Z;,5W39!Z]*X,Q:+.$4W+TC-,BSL[1 YP57(U25**@E
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MF,^>.W8FZ?[86%0F@CQT(GH4/ &=_I1,*,89-$+I%0[U8U>5?02 /-WS=WO
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MDDYG$JU<[:NK*/JX14*<=2]SE,(C[0AIF0+!^7!1MXL-F*S)M8\ZZ <,N/\
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M3A&=;\AFH*MCJ)B.J8B-P9UB'V>'AMZU>U:W>[1U@#:@'MBVT8*;IT;>*YJ
MUHLVY+5B[6R4"UBF+0'-T3+,&LS>QIF=*+&1!MU)@1 P&U!SJEU:$AVP]WY:
M&ITA7JO"1:TCV?ZOO$Z3>-ZP>*FIR=<2S9U!#(V_=>AN8>ML5(PI%UVR,BY1
M,[(8PF O5*L-N:;,,EMMLC<=QK_9MVG]F=UZ-K51OKBCP%4C(5P,J@5"I4JQ
MN'\S95)UXTD5TWUB<MRE:M$43)IE-S:ZE 0V!09+7>N[S=HJS63;&-^4FV,1
M'[H[J[Z[?) 6A3CUY5H?:SY9/H*;24/>VR,Q*S32I&0<I+)I-R&<%43#5,2*
M$\ZM1UVM=YI*&@EXN!@&3]OM'&WN3>"PK2<!9IUQ8K;77C)-Q<=VJ(]KE?9#
M6$SJBV"5<(GD"<YR=6F5U,$"ZKM$[X[C.JAVC*-;"UR#B+!L-O1'4Z&A6\;:
MSNIA#8V<L3F*LMDB[TI)5RP,7)7'.FI!^0+-2$%-?G.!AK=2.5MMLO9=Q_EG
M,;>WN4K$RE%[9[<W.-?5^ D:^JR/9#V.-D8%9-Y.SB<FTCUX%,Z#L!15,"A@
M4((Z"$QS5R++:7")A$PBLRW?VY2/W9MO\@V#*BO/(B_)%VGQ_E$;Q=[Y?3X#
MX/[*-GVKW>-^R-F_NS\B_(SOQ<]Z>JME]J'GJ+M=H7<=9Z1N7M$M),8:=M@P
M%AJ+N0=$9,Y2P5ARY%&M+.E3%11/,)/C"ESB5,3IZ"8!$!S2XFIU;#5+37Q"
M52VI/"I$!S&,MV6\W(-QB3\Y;_N]%AKG#.K<%UZD:%]>&$Z,R6C*<-Z.Y(DL
MY[1XC %B_*+;>; [H0,;*S5PKBM+B(5BJY-)6A1*(;2CA Y5$XB#45,H:6D7
MQ>*1$0,4P%$>8- UUX\6Z76J"CIU3M;ZK+U(Q]<!XD/(#V1BS9XKC*7=?Q3I
ME*O>:S1-MIUN!+?JR$1(B0+47 >4HN SAB?%O(=Z)):G6NBUG<.>H$968$R+
MJ(W$@(;:ILBVA44YR+LD0K7A:L2F=%5(]3<GZYP8W 1U#/-)Q$X7%KJ%6E3U
M0UR1$TY]KC/#</:##=_!+!?1HJ4HU+'4=(MKJMHD+6+F%:F+:+40)QJ@TBWK
M B0,@3)8CVU?QRI^S:X:IH1S13>K<%TDP%P57S<U56AU&Z!U#<OVM-'Q2G$
M Q2:\-,YK4J%R(W\(F4P;>B'D,9-" PY2"&\2ZKH>HVDJ.A2B:5*C+5+DB((
M]4&=8A@^ (+]!"TBDR@,E)<O'^S'0Z^ 5CB ^QIGJNG2B+&C$X'LXX>)E\S<
M0 5-<NA B<C6F,-K8D>(9KA#PT]C-]O XA<-&$H#UPSJ $-?8Z<N6:;P+L<4
M[GZ/!A7:F%7"81,(F$'*OEXPZAW,RP"VY,R^;*HH=\/=R$\BSA##U@JM>X A
MKD;E69(/JC-3PPJ%LEV/O]9K9S]W4)[@'*/V<\][TO\ :-?\4^8KW#^' _\
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M>V9MS+]#O91W?3W'H*43*R)'MKIJ#")EW)C:*2T>9%48&P@ F'G\\QJ)3JB
M  .05+W #.>H5(U*8,<^1?)/&&A#1-4E3IDFWJ$D$\NT>)UM7FLNIIA%8^Y=
M)C=QZ#;:)+@7S?:H-[#K*&(106ZCI/E:O$RJ 8H+LG8$63-\(JA $-! !QTJ
M')>;3#="RSL#8M\KJK9(&P;<,*EV;VRT>+*#CX[<61M4*SW<NB+RS1LM&0\$
M]ED&30TBJBL -$# 34YR9>8ISKA+=I'<R)AZ]+2>XJ,E"5^]VB&,PKKZ))=M
MPXN/L$"$.^@U9^G1\7>F1(Z4.V,U9(1KM]JFHW,?X1FWF4?9M5^J;\VP*WN9
M:9;=)_!;J0$UN0U:;&%AHLY8:JU:P.$861/&J13BP.%?D:BC*GD1<"V>>4""
M90)RD+%=K\ZX&X6\K*_;KT25K<FI;:7M[O;7UXQY7&)W@"=;8+<F6F@8+%;]
M1+*>5JD3*)!,F58>K$1$!#*F>2M&$[06Z]E1E8FH[@/5FMDDNSHY832IX*VV
M*FI[C[U1U-M\2Z/'U.#KS*22JKL3'9B#\S!< .HH)>8AZ6*F*W.WLLMGV^J^
MW,:%LDX&MR5G85[</=IXG&*2U7A21+Y9K+N5%6!X5H[L5@;M6!W)VODR NN!
M"B)!+%7P6L%KWRO32V%A:KN[%NX5A6*Z\VTL5AFH6*9;KRTC-S;&05D4&5%D
M#VMNS?MT(P[:',S<!_3P 143/AD=6M&OK+7[1:)R&EHNGS$>';O=M;%/-W80
M<*NZWWVR<(O'*Q&;KR9H=$#G37,BJ0H?;#D.0IBY5B,UL=M_NC,VSLP[CVSR
MR0G9RM1VXD:E(3ZU;M+26=P+%R=%=@_K<9&0EEA%#:%2.#8AU  2JDY@$,GF
M67G6O\MVBMT:S8MR8>,M1+7-$AI!]$)UA.&G:QMY QEQI$--/K#3$X9A<82?
MI]7FWCH 5<O&,JHT4%/0H$)EV\ZA+!UV<[?Y2<ME7AH6[/\ >+;ZK;O[)SK2
M_E)$/7;6P.QLZ\Q5O+X*/CXR5\E8H-W9>1/5N9<$SFX@!<>A58\LN\5[W)H6
MZ+.)W*LJ46]VJ:;G)JQ\U!/[92'<;?8%HO"2QX2F1<;5SJ0DJL+Z,.L]=-A9
M>,J0.<5+MP4V+(,+OINJZO"D1'WZ&7<1MSK=9H%<G)V,:I;G4!Q&1*Z%N/&,
M::YE)^1MZ:[Q5"2CGS:/;*I%343("*W,;E5SR74Q5_>7S>SL7/Y;=-]-W9SN
M]NB\O&U7D$<+3;U\S[-^_L<+8",XU"4@2Q3ERFTUD'"Y7ZAP.37AHP3' +U9
M+\$OL!^CCD556$3"*@X<Q1#40$0TU#I#PAX0P@+%UHEO5LWN+.J2+>O6;>^:
M1FA4.H%>W8@*4WCDU3& K=BDK"J.$P;B< +S 8 #I,.;FC.,/7.Z6Y0Z]!X7
MX@TK3YTZEU2MNU@0?SE*<\L?O:D?&O!+M']G7MPU6Q+K0D5V@W4-%%(C#E8R
MXW!&01T.)5I"<K+R/254$X@!P,V3.(AKKPSN>DZK9UJ/87 H4QRR'R[P7VKP
M=QWW3:I0H:G7J:>-3PC5IR H0+9M&H9G+;O,L;I$[?,71W;.X;';@[AMD4$7
M+>R;B;;FL9:\R1;*J+LP6F(YU(JH)B(\INN,F70!Y<T:%32+>\D*]2H;8DX4
MSCXP'PY%VS5_W*ZQ6I5]!UBQL-0F2*E*%6GN.3@8QVR;;CBL8/.T/NC74*W&
MR58VF<E61(XE(B/V[K\;(M775&*+=Q*%@DE(YR@=/02B8QDQ#03:CFYAIEO<
M1J7T# 6HEZL9R(D?$".7D78;'N]X(O:_82NKVK7G3 %:1C.DSG*.X,'QS;%;
M3]D+Z03M"4ZV>98[:N)M\8NL1,U>&P'AYI1D8RJBQ((]@LR$6NOS@ I]6W,
MEX#FQU*VTN=K&=F9QJYS=MWR!_*O(.\KN*X.C0J5;O5.PN8D;LQ2'9@,<3CA
MLQ)88K]#VT':OH6YODL"_1E=O=PA9E>/]O+JV+&6!HD8X%%5JIRC&RS7Q@$%
MFRZI=!#70>&=9JVTX-+.)&!V%?$VO<'WVB2WJ%2G=Z<2=VM2]:+<[.RV3?66
MO1@@61FHMD8Q 4*1T^;H'%,W0<"J*%'D'N#T#FVC"4O9!*ZY3M;FL2*5.<B"
MQ8'/D7,92T9))=?'R#-ZCW%6CA)PF/L'2,8HZ:Y#$C,+2J4JM&6Y5B8RY"&7
M. Q1TT, Z]&@AQ]COY%BQ&:D! >(=&%%.$3")A%H<C/4Z@=H/?Z0WYD:]"$M
M9J@XVEG[J9D$.]V\BJ9%M;%7:Z\E$E6C-:-MWE:TDS(H0S@7:2PIF 0,&06)
M"QI:=[;.SN:D1MG9*Q1*/'PVWB^RD/(JHU.N7]C9"(>6'&OJTB1G)R/3D5!9
M))1BS([8G*J8H@H4XXO@LB[X9+H8J0M%:L6ZL]"34;2Y=LW[4AV5FL:3GS)%
M'<[\4$2N'#DC-\5H11F902.#HKI(F$JQR&(0P#5CDLZQ%NL.Z79"W-E&EDM[
M2Q,*UNO$MK(C)5N8F7SZM(3B+9>!L->AFD).Q;HS<J2#QLU06.3]8N4QLA60
MSYUAR(W5N$'1;A<5-WKI/TO;C;C95"%&#)3C.).P;@-',-8)6PV.1K[YF=I7
M))9N8R@D3(P3;K*K@L/ *!@H>97/M[N1NYN'\DZHAN0Z0BE=[;W39&ZP1(N<
ME)FE0VU;FWQQF%A<5:&B'+E*S"FW\O2C2I*-R'(7F.)5@9Y)BK:=[W;GI/=H
M6-CW#?%^4TFUH[V(J!ZU%7AZ_?;C3-'2MKZN6.OO4;!&&9((++&BUFZC(2*+
MBD8G*4"F+*RZ_?\ <W;+;K:"I!>G-8KRNT\G;XVWVF7A((9B[%G';5.I.5UJ
M7,MW\=!QY$'1H])-%^]!X;D5/U>@ J?(WH68&=QW[LYK=(N=QG-=>L]V=HML
MV477(%BX@&#"W4#:6PW"=9FFXKSF_5\YVI\1B=<4DVQ U52,<! "G,NA1WFW
MPC]P'T"PLT5)V^#NLM6FVU=JG6"3VRT^(B)!ZQDF\'$4U&;&Q6*(9IRB,B,B
M6.ZU3J3 F0>K!AFJOOM+>SWO>/LY2C[=M[=K3(4K<>9O]%4AV+9KM_97->@$
M7T41)C&M7U9"-EO*F(,Y%9==;J.8IM2*&,S=3!>F ::!RZ:=S3HR+)3A%QWF
MODCKE^%Y.OR^SU1M/JYJ4OTL?QAYUIU7[*39[I\RU)B>7S8PT_\ [)OH(](^
M(3I_FNG7/0)^T2,BND1F)/$^V%V(]'Z.\.8'):E(O/%9$VU$/.<APT'R4@\?
MZHGJ/N#G!Z]^AI])^1<QH_Z:H-K#Y5\-XIY-LT:0_6E(10AY)Z/$>5H@)B)
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M;3EK58FF-VH[.KVLJ;>JN1GH-C'3"RP<A&$7SN4DG+Y-03$.W( G*H!BF+S
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M1^[-M_D&P817GA%^2/M/AKVA]XN'^?L_I^%&S[4[O/\ :5E_=GS17Y'=^/\
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M2N=.J-Z@,:1)(P/L2R+$^KB.1>61^S+V&&\R$-(=LNW,G+PFAWI=M/)R.D5
M!11)^\:/3+"@)?A)G-H4 TY<['4N==JP&L1A 6@.42'\F/D7T_I_>=WKT;6.
MEVF@4JDH!]TUXD?\+T 'Z%E(GT5Y-P(MH3LT[X;2;AUEPHI)^=GSM^PGDU'0
MI"!'$4A*/$61DA3#0Y"D4YAT/IPS3CQ!3)J5M3I2G<2# G%NA=?N?XD;G0;J
M-+B73;[2[^C+&E3GO0F,BY%..>.PJ]:U]#]N/M](+W&_;@[=/TEN9,8IW=['
M4EDE0,FJ51G:A%T*BG6D H%.F8@B4![V;&OQ#6K4_LXE/L^0[!R="XG6OXIN
M%]6!MM"TJO1N*H_.3]6>_+:-S<#29CO.^S8O4#:J_;:]FFO.(W<#M*QFX+5I
M#H*Q5)GI:'LCRH. 3 5V25Z;I&E9-DNX4!-,[X@<@ 4I=<XFG;7%]5W;:!,M
MK8>1?-?$6F<0\<7<M0TG2I6M R8SBP$W.9B-UCYU@?>?M#[%[X-6Z]=[.>TN
M^,L@Z*DNLI<*BI.L&)S&ZT6K)S'M)B3$>KTZM!0>4Q>C73-Q&SO+&L#4G*G4
M#L<B/&N^<*<!<9\.U:-W<ZK?:=;5(^V*4S3'_%VC [,@M/*G?]F'UP7@)_Z+
M^/=1J*@MU'47#BXEBDYB)G=-RO(LJ7VH@:ZBN ZB  .H".<A>6D(0A6IW<JE
M7G&7CWB>M>@7&G<7G2S<T>-*U&=/"D)QD01R;PF<R!F%LC&=E+Z/+>V58QY5
MMSMM)9(Q5PVYFW]RBB0Z@N$S&9M E6[N-3*1PJ.@-W!BAW- S9V^K:K84I0I
M2)I2=]KORKHFJ=Y'?!P_V5>ZJ4;[L6$*XB^]M!+L3XPMK:Q]%'V5JT89&HIV
M^.D'0IKK/U["O-H/]-#%,\B9WSC#O$S@/$JB @/>SC3J-<C<P =\ W6ND:Q_
M$+WAZW"5MJE:,J3Y ;NZ?P6=EL%M[V-*)MI)-IJFS5AJ\HFLHNZ-45&=/@Y8
MRA#)\TQ4(!%G4I!4I#<%#L14 >.N:,K@S]H ^5>?ZSQWJ>N6WV6^A&I$92DT
MI!\V+.MPFR1D$$DCJJ+F3(4AEE0(!U1 -!.<$RD(!C#W@ /!FV72%]\(F$5)
MP$Q3 '2(" ='V0$/J81:%[G[ WVR3.\4?&5FLS!=X)RGRD9NK)RC1O9-LT:W
M'PS)%-G&C%*2#Q>O.8]9Y$^2N$0*NX-U@ICJ8U=1E\V?95=1M;H$3'PU4:/(
MF'WQ97!T1NW!25<[G,I8&1G:B;8JLFB+Y9JJN0PB0@MR\I?$3 &>?*C;1@67
MQ?;-WY4K27^9^C3KJ6V#9[*N:[-6&&22I3]C*3Z\A-M'00SIK(0EM0EFRSU%
MIU3G6/1+XYM!3JF87;[S;?2T?M7V;*"[CH?<R<K>Y>V[1RSM2RK>*M+RL5&S
MN%O+'"B;SJ3*&CQ,@98BR?6 3K ,'-D596TRV)W C-QQWE+MY4GK1S/V*11V
M(+/1B,1 O9ZIUBM&OD=-KQ@5TUT<EA'1'?(U1 6THL!5CJ"<5*[="@!/6K/M
MVR4KMMM59[-9G]<A9&LTLD]MU&Q3A8S&M;H0&X5AW*H5.K2)44%7\<T?NFL:
MW331#KTS'3*D!#<F39@A<+M8SLDR%EI-ML%BJU84W(W4[/.Y4;8G,J0CEQ&[
MO;Q/G-DF6Y%U4U?)XR"=+M&"+A( .FW8)<@  " BJ!L*;@=DF^.[75+#1E8^
M#@J?0MCXUY3X16 C4+G8-MWFYB<FDY+,P$U!)JM&=JCEF+IVT7 5692Z$Y"'
M*?%"'61*!V:W["Z[)6ZR5N,\EH$7V@GSV+FI&#L;J$MFZEDVWDH=_"A%5R @
MVB_D=;D3+"R:HIMU7!N03=8)A.H 0MY<BR3")A% AJ AWPTR'$(M<KO%#%6A
M98B?5,YI,CM(X:&(+U$@).DA*8>8AS)D*KKT#SF[V=OTBY[:T%"1>I3ZV\,/
M$NKZG;F%QV@PA(>'ASJWPT$ XZAQ]C0?TLY,Y+CZ>$ES&TDI&14\=,IS*.V0
M1Y.774HO%DTCF$P?! $N8/9$,XC6HB=*'C^1<KI9_/R'*/2?,M+NV)N$IL]V
M;=Q+S'ODD;@M&_(VCLSJ\O76*P';,&YTTC<Z;IP0%NM*!B& .J'OZYYC7T:G
MK_$E*E=-]FH4G+Y82D5[+W;V-O<\10%[ FPI/5JR <1A3$=X'FSZRM7]LI>V
M-NRS<YHCR*JECLT<ZAXZ\2K!F,?38YA&+1\U<GBRO4HK.&;(YDT4_P"F+N%2
M@74-<X>GINE5]6:I1C.@2TX-A/$8R&T,""^Q<UH=:WU;C.I<[IKQC*,X4FW1
M/=D (#F<N1EUK#W9SV>VJV]K4%)1,L*MEM!FXLW\@X.=U,UV)D$'LI,/&YEC
M.B*R*SE)8P 41\I=% W0.G6N\#AFZX@E]OQ@8DQ(&318;O0,0RW.J7UY4U2Y
MU2L&E&H8B0+QB2X$!+D !;H7L=M:NA+L8DB3;R<9J8,](EU?(86RCL 1YRZ%
M'@T2('$ \4,[1W<Z7\+X:A#(F9YL!Z77E.KU)U;N=.H T2S\O*5M9?P_YO:=
MYVVZ?]RKGI6C/]N')NE<!J@'V.7B\ZP;G<5U-,(L?;IW^#VNV_M]_L3M)G#U
M2OR<V[64-RB)8]JJN"*?3SK+&*!2% !,)Q -!USD=)T^MJ>HT;*B'J5)B('2
M5L=3O*=C8U:]5Q"$#)^1EX(?1U?2)S='[2%Q1W*E5OFNW]ODC,//*UN9M2K-
M-O\ R6&ETC"F((,/(2HLW? "@@FD<W%( SV7O'[L*-WPW1OM,B!JMM1Q CC.
M,6=R^/J@D;<%YEP3Q[.VUKL[NH9:;<U",2^Z3@".1RV6SQ+]:+)R@[;).FRY
M'#9=,BR#A,_6)K)*D*HFHF<!$IB*%, AIPT'/D8QE&9C)Q(%B#L+LR^EHRC.
M G$@P(<'E"Y>55,(J#D Y>4P:A[8#T" Z"40$!T'"+$55I+V ?."BV (]E;+
M!)1AM4%%#QTVV3<&TT6!0A$WYU Y1\8>GHREB #L9N9@RQ9SCD%E8%1* B#=
M8.Z( D0!'7_[T..8[H!<,ZR7((83% PE,41U\4P !@XCT@!C!]7*BJPB81,(
MF$3")A$PB81,(F$3")A$PB8169;?[<I'[LVW^0;!A%>>$7Y(NT^;^4/O%PZ+
M_/!^R1S[4[O!_P#Q*R']F?-%?D=WX?\ 5#5SR7(_G5?2NLVHN-:J#J0=RL[N
M/5I<YF9HR?V\=177II)*',ZCI&,E'4<D[0=ZE,50' &3,0/$,74!WG$6F7FH
MRA"VA:U8F)B8UAB'8O"0$C$^J/O3FN/X&XET7ATU*FHU;^WNI3C*$[247DS@
MPJQG*F",</7V.QV9I/VEX23DMPHM=.\4^IW&P0UFB96E.8YO;HV;B8?Y/K/)
M1HHO'1,LTGV9^N=H)J(F*Z*!B&$-=.K#@"^L^QJBK;U[^E"0[.H9&F829Q$[
MF\""(L-W)\0O2*W?'I-Q<WMK>4[NPTV[J0JPJ6^X*\90$HDU(RE3C,3$B9--
MQ+=(<.UO1W:(;0-[4D8IYN-,5"3J"].G%[!94ANKAJ\,"ZTM#.6IEF,$[:R)
M$ET42F53$J0D.8W,)@WU7@JXO=+-.X%N-5%83@*<?4_%((>6!8E@N,L>]VST
M[B<7>GB_KZ!.T-"H:U0=MB0=^ $S&!$HN(F1#9E=19=Z6C52K.J99-T+#*5R
MS(6?SIN*_:%:=?'G S%DV@HM](-C\ACF*JY,N*AQ-H0J8#H&XTWA&Z$Z_P!O
MH6=*52A*FT0YQ^_WC&#<P8KC=0[SK'M[<Z)6U.ZK6]UVTC7,(4R!E&(C5K8C
M+>.;[%VT)N1L#6[P;<UA5]PW4TLX<O4JJ\<U\*["24BFX*]<M98CHLM*)(++
MG4:H'0;B0="J'4 ..SEHG%USIPT.5>A"VA(/,[V].(+L8[I PP?>.&/1N;7C
M3NOTOB&?&0M;^>IU8G<HF-/<IU"-V4HU-\2D'Q W =F+8VO4=Y(FMO-MUG,5
M).$Z.YW'=/>I% OEQ;FW129I-#'5( &9BG]MYN4!U#EUS=U.$J\[>Z>5,]N:
M$1$2);<P+EN;Q+9V7>EIUE6TZG4I5NSL?MLIE@#(5X&4!$$X,0V.;@JT:KN
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ME= P+E>2';<V<38V5>;8)IIQVY8)@BY4((-8;<JOLP-!''E A44+5&$5;*E
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M+FVSD$4CF$4%0/T8(1UE/(JF$5IW"N)V.).U!0B#U!0KJ/<F#4$':)#\HFT
MQNJ53$R:@<=4S&[NF;NSNY6E85!C'(CF6TO+475$P&$MBUU3,N4ZS9TD=!VU
M4%N[04^&BL4.)1T#00,/$H]!B\0SN^]"I3C4I8P*ZE%Z50QK#=D/*KNJ\8$R
ME.1_ %%HX>HUZ <)KIJH#KQT^W)EXZ>#NYPFN@]C3 Y3BN7T@_G:@^= CK!
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M^^5=M')!*_<F1;!H8"CJ :[FUT\4);U0L0!XR/#-=%M]3M>&K25"XJ=O7,9
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MA&VV^;?5E#8*%KGRCI:U52++3Z6X5DE%H-\%CK]CU,TCW23@HII)\%>)C=
M2,49\%C_ &SC=SMF:O4XN4KNXUG:C'=HM@N>.)&R4JYLTYNZK8:)(3;5BK&Q
MZ#FPP3APHB\!))HW$=%11Y] N76L0,'Y5CB,VDWXF*-,3T[([JM;XE_%49UU
M EX?-Q8- B]MXC?<46;"8+$.E7+1>9+(*KIK'*LD99L8JH%.+%7')7+;:ENS
M#1MNI+*!N[RH&WLLBE-F//E]L\C"4PVV5-=1#=DE7MP*I9)1C)7=Q+)MU9&2
M,V9*IF%31/JA*)4;'F1';;?.QQL[/6=WN.E:H;LE[+A5&;*V/H=HGO\ 1<CN
M\ZMSA2.AIPD7(6%-)."3=$=^4,UDU"$$5/&$+@B]'(L7(QD<+W7RP6#,7?,!
M0-Y2+=/K^8"") 'K===!$.]F*R7/PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3"+X.4".45$%2@=)9,Z2I#?!.DJ04U""'= Q#"&$\R\:E8JS@,DHT"3<O_
M *.SRI>MI&24 9,KRX%?/.4IB:2;A7LUQAXY/3K *>4,.H*<,N04VXK,53W
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MSKML(F$5F6[^W*1^[-K_ )!L&$5YX1?DB[4'^L+O$/\ T_G@_91AS[4[N_\
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M_G'8/5\X?7= &N0]WO% 8]@X)Y_0A[[.[D$ W\ ",\&Z,\U/^TA[+OI)/_D
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MO!U'T*/G&I8]%@9@/?-UW+[8 3!T;4P'-*1'B]*GQ2Q]X.HJH-Q*9W;''?\
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MVSFD+,P]>A_[XVNQ/D6D5&Q,(T5BF!4M$91Y,+"CUJK5DX<$(FFF!57)R\I
M[N;.TUBM,5[JXN81LJ$-[(^OA@(X/(\P7KMAW5[]K.ZO: C;P@^\9R!E-BT
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M"M-/M7[2A=K[395[-0Q=OX&CV![.2E8L[6*D$KT9VG$,H]884#J2:CA!))-
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M$]IC<>"=5B+;[6P^[K9T=S76\C"+(0=ZCC$ RE<;"M*MD(:TMBD.JU ZIDY
M1ZDH%7ZOG0U*I+ A):=2@0^)5E53Z;KM/1=M;LMSJS2TH!NLZC[$TBJP]86*
M'4,B=MY4V;/Y42*NX=T **-5@*5P"0IF,01YRX#4JV_CDZU):?1E%QCS+L]Q
M/I>^VIMZ_9:M]H)NJSC<TA4KE&561\RV2)*;J_*FJAID/)G;70$W+93E6;*@
M)5 #@(Y3U*M$.V"TXZ;2D<BKH5^F![4EOHB5NVVC-MU)VJQ8*;DT9Y7G;V7;
ME;$ BEWK8EE4UI"M.2\HNT *92,/J)Q%(X'S*.H3D-X%0Z?2C@5>O92^FSM<
MYN6UK7:>CJI$TJ?ZEBQM]7CG,9\FI R@]6[FFZSYV5W$+@8 4.7E,W$.;QB\
MVF5OJ1J3W:@Q4K:9NTW@0OT?PTW%S\:QF89^SDXB29H/XZ28.473-ZS=)D6;
MN6RZ"BB:R*R9P$IBB(#G-#U@X7#3CN2W5VH#KQPL$Z- ]KZGZ6$7/B_\+17_
M *:S_NPF:5Q_I9]!\RU:'^HATCSK9S70H#W@#.AG-=V&2\]>U^]?S==L,;%(
MF>K@DL"+='J!%8M>9.9H"F*N44Q2/+MT$S@.I3 /*.NN@\+K$8779V@F*<JC
MASD/5D7^J5W[NWHTCK]*ZJ@S%.> &9.6?C7B-MM+2-%N[RL "YE;!2$6C&4
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MG;GV2.Z0<_#I7R)J$90N33((W<"X8[VW###D7US?+9)A%'M_6]["*<(OFH(
M0>C7I ..HZ"'1H CKWO#W0Z<#>SCFH8B8W3DOSF?2<63ML=IEZ\V5VD[-&[R
M&Q\#+HN7LX>DRJ+[<.9CE 51D"D.!2M*XU<%U;IB!553 "HF .1,.)U&-:O,
M4HQDW*V'6N:LA1HC>>+]/W5YQ;<=@WM3;=1[;=*4[.>YM@O#&3*?;RDA47[Q
M!I+-# JE<;N*0CU,?#O"D.UCC:'?*AJ?1 H]9Q]*PN8.9"3="WDKV!E@1UA6
ME$?1^=M/<[<)W)7W9C=.")/2DM:+C;I:GR2J_*Z64DYMRR8$*D:7FWBAC%:L
MTA*+A8X%$2!J<)]AN)5':3=!]"S-U3,/:#](7<[G=DOME6AG7Z54.RKO+!;9
M4;R].J1#BH/U):1=OA(65M]H<)B*+FSSY6Z77]2!&Z*22:*1>0@<UJVEQ,;I
MC+J/H4IW5...\.L*]&'8I[6NR-.7;4KL^[HV'=S<&OOHJT6&.JSQY![=5":;
MKMGM6@'+8%F\Q:[+&N!)(/"B9&/0.9JES*G453@LZT<-R744G=PE',-TCTJP
M-MOHZ.TPY&6M.XW9]W?0KU73;N&]2C*L["T7J97,8S*"CR'(<(R%%5L/G"0,
M4X-D1T3!110@9IPL:\:F\8RRY#Z%JRN:<BPD.L>E?*[=C/MZ;T7UM*R_9LW#
MAEY((BNP[<]8?0E7J\$R3".A8E-R\,H2/A8=OIS*N%1X:G.83<<R%A<UI,TA
M'H6B+JE0&\91,N1POT[]@3L,UCL8;<+1X/S67<RVILW=_M8D!)FHY32(*4%!
MMQ.=1&&BS!XACB*BZ@F4,)1$$R<]96T+2GN 8MX>+^5</=W(N#O<Z] <W:V*
M@1 .D=/9QGDB<!X\/:'4,<RKE3A1,AR64/:"R%MH']\94?\ S,GN^4)_7S@^
M(/8I=)^1<WHOMU/%YRL#]KJ:4;0S]LERB(-&$>)=.!AE'13+:CKP,5(A>'=U
MSA+)S6!/LMY5[3W1V0O.-Z+^S"))ZPWRLM*W "VJG(4  "H\O>#HT -1_6A]
M0<Y XS7UM2:>K!O:$O#K6E^XACDU6$>)')%! ![I0$X%T_W09R=$/'#D7K__
M /QZD=G9G^:O>_8EX+JC++B(&Z^M5QRGH;4#<\2J!Q#34!$!TUT[^=;BWVF(
M_#^5?EQQ; T=?U&D,HW%1OI%=07X(:_HTZ,[RO+#@<,E\%TRG(<AB 8IR&*<
M#%Y@$I@T, @/#CE!:0D'W@A<P.T+\F7TE'9T;[&]I=_8()J1K4MV".;C&(H(
ME1083)W)_E S33(0$R)F?'!P' !YE^CH$?K#NRXA.L</?9JOK5K8[I<XLV?4
MY?T+YW[P-#.GZM&YBXHUFDP=@07!YL<!TELV6N]).JF9JJFH=)8ABJ)J$,8A
MRF*;4IR& =2F#374..=NU"C1-+LPYMY1<@C>\[X+JE"M*%05HRD+D9-AALQP
M7L5V8>W[O?M FTA)E^;<BGIAR&B;0^>.99DGS&,4L//G56<H<HF'1-4%D0+X
MH '#3Q#B[NLT#6/\Q9@VUV/F1&Z>G8O5.'.\36=($;>Z_P Q;Y$R)+=!'ARK
MWFV0[5FU.^3) M>F B[$9$BSFJSXI,)E#F,<I@;!UAVTHF02Z\[9130!#F @
MCH'SCKG"&LZ!,QO:<Y4-D@"0W2%[QI'$^E:Q3C*WJP%0_>F0=^C-;+@8@ZZ'
M 0Z!#4. B'=[NNF=8B8LPP'.NQ8DK0'MAPHM['2[(B7E"3;O*LNJ733K'B+H
M[/G-P,  \,D.OZG34-,[;P]4!A.'(?0MS83,-0I@E@</*N7V0)Q-M-7RM@3J
M"NS1-@03YA%(WE[07#@4>/*)@<'6Y^Z&G@',.(*8.[,8F)8^-87 A&\JQ<.#
MCBM]0'4._P#I#IG5P7#K14Y43")A$PB81,(F$00U_1WN.$5'5D$-!* APZ0U
MZ.CW-.&$5>$3")A$PB816Y</VI6G]SDW_DQUA!FOGJ/?_P V-?;[^$7X\;0'
M_."9+_\ J<EW-?\ RTP] ^SGWCPX=W1;4<M.G_,*_&7O'DW%U^?_ %$OYRV#
M[-5E0>7RG4*7IU"GH61DER.W$W48N4EU$SI+K\GG-RF=?0BA Y>\7AG7.-=,
MW;:>I4:E6%P!NG=+ AVZ=O*O0>Z7B C5[?ARI:V]:RF\JAG!Y8F+8OB.9=3#
MV&8W"L\PQ:T+; _F.IWM\#5.M(PC7R9M&JK+2)RQATQ<3$8FWYVAC\"'$>^.
M8U+&ST72NUJW5>!E.F'<%\?9P P)8G'()3U+4N*M=KZ=:Z=ITZ%*WN9;ICN@
M0!8RP(]>.!CS[%:\OLI,0%:\^2]FJ+.8""CK-\C5Y<Z=F4@Y0Z(,W:*2J!62
MRJB2Y5.H(L9;JM1Y<Y&EQA;7-V;"UHS, 90-41/9[T22=I(RY<UP-QW57VEZ
M7"^N+JWC=3A"8IFH!6,*F[[+C=(&][.Z9$;<55:-E)>H1#AW+6:GDG6*<*XE
MZ4G*G^4T0A/D;*1ZBS91N1L\,*#Q,ZB;=54Z)3AS &94>+;.ZJ&E1H5R83F)
M51 [IW-[SF/*I?\ ==JFG64.UO;>%Q.5.4: G$56J;H&\"[@";L.L+JC;06P
M+_8MN0\W#.5EM-.WYS+G\C%."CC2;SR=?J^8Y^H(/)J7B;-:/$^EG3!K),IT
MJA$([N0D9]D\@1L/F7"U> M=I\0U^'*HMJFHV].520J9;L:6^=UI9L,R[DY,
MNRKNRTO-0L5,R5HI]--916)4XVU2:S&2L@("9/RIHBBU7(VCEW0&13=.#(H*
M*$, &X<=O=<86E"ZG;4J5:N:;2J&FV[%XQ(<D')<SI?=9J][84[^5Y;V?VB)
M%&%:6[5J2C(@B(+/ _>GE?-EB^5B9& EI&$EVQV4K%/',=(-%!#G0=M3G272
M, <P>(H00U =![@B&=EM+FG=6T;J,]ZG5Q!(QQR'3S^1="U32[[1[Z5C>P[.
MXI>K,$B1)<A\&9SAM7 $-?8[V;A; A\\DTX::^WC:A!,6VJ"ETURDNL80W4T
M'7IX=[&#*M+>=\%5D6283FV*DQ=>[E!983AO%TYM.CCIW<,ZDI,.4*H!Y@UT
MT[F0AL$A)\%O5]'%_K644/\ ]/M?U*U)&^SGDG>__MN9_"CYPOJ#^%0-W@3_
M +G^C47Z9 Z/J^[QSY0"_2DYJ<*)A$PB81,(F$3"+6G<*&$]BOK,[<XM[-1T
M)5)0B6A3O:PY(B)#J:_;%!1D0\73X)=>YFZLY"G<QJD[0%I5H[\0!F%978X6
MY:U;(I0HE<0DX9D(&+H8&RKA^\: (](E C@=.]FKJ$(=MVT/O_D_E2E4E,&,
M\PMR\V"U4PB810(!WM>X/L9"2,0G,O#'Z4SL,N-PUX_?7;:*%6<\X0<1N%$,
M&Q>MDHU=VVC4+*!$D=3N8M Q2+F$1$4"E']0.GN7=5Q\-'%71;XO0J4Y]G(G
MV9;I( =\SDR\?[Q>"_B-2GJ]B"*L*D-\#:-X E@VSE6]NWE9:4RB5&J1Z1$6
ME>KD-$H)ID*F0J4?'MVB8$*4 *0.K1#0.X'#.O:I=2O=0K74B\IU)'K+KF-,
MMQ;6E*A'"( !5[9L5O>A7OM[^V'_ /)./KI9P^M_Z/\ XXKE-'_U1_%66;))
MIP\+(2*H@'D[<QDP']4L<031('1J8ZIP /9SJFZ)'=(<<B[.79AFO!WM_;]L
M]OTZ- #* $O/SYRNT3%,;1J9D\<OW9S"N0NB;9(4QU Q0Z[B ZY\Z=[&G3XQ
MU&5I3JU#IUE!Z@@P]:7WLG!Y#GR+V_NMT"I4TZ^UXPC*A1I@ R&&\^(?+!EC
M/=968D>S$9G!-K0ON/N:9I2J^V%LW<G<5RXB5BLZ6.@)W<>PB6IEUCJ'4 H
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M./&Z%]0'_>J?9'.5M?9_X%[1;1!L)QEEV9\R]P>S&\.XV\KQC'YA<;<Q1C%
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M  #<>C4>''NYE&8E 2IR+2VY..3;@H *N]7$&@[1<L=KG=;!F;,YJH"E =0
M!U#O%#H\(=&9FC&,&JQ B^R7AFM.5.5.+'L]XYN(R)+X'FPP0" '$2$$1'P!
M[&O<TTS$U8,:<3+<8,.82!;G=F6J*<X3[6(CVK,7+@E\#N\P#>55>+J :  A
MWN[PZ->]F )A FG"&_)P^ZY ?D?-LBI3IRA$Q$@*V/K [N$HLS[1T]&Q.8@Z
MZARZ< $ U#AP'7AQ',ZL)5)"J1O2$0&=LD-6%6I&D?4A&(!&;D;7Y3T*D3 G
MJ)0Y=>]W]>[E WL201S[/2L!ZHE.V@>Q?=Q+D$[/NH40-J8#>R7N"80]G[&)
MB<#ZPP.1&.2H ,B8$=D!B><[ -JJ 0'AJ.OL>SW<,6<8Q64)]KZM'&7(?5]*
M:"'3]?("#DL\7(.83*@4Y$(?H4944"(AT!K[> L22,@Z@":#KK^@?;RN^"PC
M%I.<^159%JMMVK>WZ.$0#M5T@-==8ZU#_P#XU*!GD??#ZW#,A\V4?.%].?PJ
M'_\ 09\]+^C4"_3"7X(>P&?* R7Z4*<J)A$'AA%\RJIG$Q2'*82&$A^4=>0X
M::D-I\$P:APZ=!PB^F$3")A%B[>!J=2AS;]$O.Z@B-K"RT(50Y',&Z0DR"0I
MQY#&,+?3B' !$ Z<.R+@;=LDD;5>9)N0"MIQ*M2K8X% H*HO&+EP!P ISAXI
ME1 >.NH#KF[KS$J,.4/\BQB-O,LP9M%DF$3")A%TED9#(U^;8A\)W%/T"<-=
M%%6JI$QTU+KHH(#IKFYLJ@HW=*J<HU(GJ(*VU[2-:SJT1@94Y#KB0M86:@F:
MMSB&@BB34!'B \H<!X=(:<<[Y( R+%P2ZZ7 'LP2&(P;H_E7-S!57K0# 2?.
M<Q@*0L>Y.<PB  4"BD.HB/<T >/<TSB-:_T@_&"Y32/]4>7=6(+Y.JS3Z<?(
M*BD=Z1^UCS\X$ZENS8N!16YM=2$Y4 -J&@Z\>G/'>.+Z7P/[#0!-U6E*  SQ
M(')L&/B7==.HFM=1]4RQR\WE6C>W\;4[C*6V0V[(:.:1X#/1-B2\BE5K#(-Q
M5:2DFH^442)',Y9SSE4$Y0$B8 8H\IM ^;=1[OM3MC6IV1D+B-!XR,"3*1SB
MSX=+GH7JNIW=Q;WMOIEX34N" !3]DPY!M?R+S%'=ZX;Z;^LZS +";:JA(NV$
M4Z6$%D)>4C51=6&9,]7U4605DEE&;)$3F( I*JI@ CQ[!J_"5'A?@FUM]3EN
M:[7I4ZU0D>Q#=>5+VL29;HWL,GW=B[KK%?2N'](M],H1,N(+F0E7D0!N0E&1
M$&]9RQAMBS,R]S-HH%6,;3$JJ016=-8MDD?DZLA&8(^5=25,3'T,*2J9C&'4
M3',/ .@.W=R5M-ZUZQ%*9,8@X,&+'QMR;5XQQ5<QKRIVT'&Y,AR7=I<FSK6[
MLVV\CV\2;:!S(,XP!TZ!$7+41#V=3ZY]&:2_Q.F^;R_FE=!U0?Y&9Y&\ZPWW
M _W0?7+G<*>-/PY5U(G>J/S?(57E45@[AW)M1()&>>-".6YIZL02O6.4VA44
M[+8HV"%XJNJBH0B+(9,51 1#G FFH:\$B ,5J4QO%ES(R3J"[8HPLC7EVLF]
M.T(K$.XWR=[(G(LX50%1HIRKO1314.)!'G'E,(!IJ.0$''#!92B8EXN21CX<
MBL?<;<B-VVJLK--(-.990L._D5$6#Z.:-4#L)"*CW$>)"+F<HKK.9$#&Y6QR
M@8@@?0PE#+.5.,3(_P JQ$9DY%?*][IUBCR-6;I^9I>Q6B]TR@K1[648)S$6
M6U2WD9)-T@H19Z+6/,IU@I\I=1-IJ43:YAVH &9YO#T*SC4E$Q SWL>1R/0N
M\:Q56I<]:;!,3D4V<7NSQT\B296C60-'S"FU>G)MHQ=VH19<RK"KIJ"&O, J
M'+RZ 4<OJACRH92R;$DJ[)":JS9@Z6D)6(18(*'2>'=/&9FR:P%([5;K H<4
M>N,V#G$A^D@:\=,LI ="Q$*COBK>KVY&V]GA8"?AK16W,/9639> <&?LT2NV
MKHJ1B)MT'"B:Q>854P,F*93D,( )=<Q>+,"LWJ/B,@NV)8Z5(1C^1)-UYY$-
MC"$@[\YQKF/;G,! ZMXX\J5:(G @>*!QYNX'$<R<9.%!&0.\Q]*D]GIYDF!P
ML->!*8#R6-$9>,Y98B)Q3ZID4[HI'Q@%00Y0 >(\HAQT%O1&96(C,8XLL10^
M\T1(6]E1E:VW8,G5HW5JIGRCI D>@CM6G!F.\.W,U*D#>5"5+U9!, HE2TU,
M AD)CLS(60A,YJZ]Q]R(K;L]),E&-Y1]==Q*5MZ?R=TU:.8M.W.G[9E+.3%0
M75.W:>3GZLA^0JF@B!RZ:@ENQRRP\/N+&/:B39LKO-8J4^46<J3%8=&@E %T
ML:0C5_-#Q53R<2JJG7.>/5.<H$ 3B43&\7B.N"0<-JR E&3MX?<5RQSUA(M$
MGT8Z:O63H#*HNF:J3ENX 3B!EB.4#G17 Q@Z0$W$!X](!1$Q#%82+EUW<:/]
M\XX/_/6@]_H<IAIIX<TKC_3SZ/D6O;D"M [?NKI-YYH16GUT#@59)DG"QYS
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M]@UT#737NZ='M:Y%5.$3"*A3X!@TU 0T$/ / ?9X8=L5#B&6KDQ'C"3\K$F
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M''-V?G!_(%M..NOAU'7ZOV<[H%\WEG+9+YB(@ CH!AU+\$!X .H!J >'+F0
MH[;P.1BOS@_3!;[-;/N?1]DX-^"[>BM3SUJ204*<B=@E.=!DU< 0Q^5PUCDQ
M4Y1 I@*L C\(,^C.Y[0C2L*^L5HL93 @2V(R+?2Q7B?>7J^]<TK"D7B(C>9\
M#S]2\XZ;\%'P@&G^Z^OTYZK>Q$\.;->:1JBE,#.)"VFJQA R6NFOU@$=1U[V
MN=;N)",,?3LYES%(.T?OEOAL=LIN;NDJV2I]5DG;0VA59ERW6:0;8!$P 9>4
M7(5H'P1T AC''33E'N^<\0<4Z'I49B^J1E, - 'UB>8+O.B<.ZQJL1&UA*-,
MG,C#K7O9V:-H)?9?;X*O./V4A*.I-S+/%8X%O(T57"#-N5LBJN1%5<$B-?AB
MF341'AIGS5Q7KU+B'5/MM&!A2$& .>>:^@>&]'JZ-I_V:O(2JD@DCH6Q&=:7
M8%Y@]KVMR+?<1H\B)%>%7L];<]7)MFB#E9!]!J-I1MU*3E)1NLLH9F<@ <I@
M$%-.&NN=OT2IVMMN#VH\G2/D)6[TTB-UV<BT:A(^J3YPOEV3JSN7,1=PK+'?
MVU1!*U.B4K9K4Z(Z2.@_ [I%4HO(5=1,3MSI" <W+H;AKG':W1G"4:E1S*>T
M\S#Y%MJP$+JK2&!C,X+;\=J=V.=$QNT;<U2$4*8Z?R+VZ+SE 0$Q>8M? 2\P
M:AKW,X%8K6+:CLG;CTZZ5V5EH#9B$1K.[6Y6X2NY51F[2^W-M\)<[==+"VJL
MU$NJ-6X6/;O6]F03D##(/R!Y-HD'$IR7:ZA"[J+[-F[-7KL?%QC':6XNGVS#
M;:J:)<9.R-8^">-+'=)LDY!E;U25<2S%^A;BE=-5?(%C*LT]%=.)6#,F+KI)
M/L<WE&=?(-K*%PK-GKVUD!./[!>K)5YB&+M]"QL#(.&D=!UR9+/$ED8T'K8H
M/XP[=^JKS*"0X&*?!&ZED:O]F-[68"G-U7<"P?UZ[;Z6F=F89-V>66C-TBWL
MS7S2OYI1<NI5F%D:G52.":?.W'D$X@0!<R,M3$MM;-NE&T/9ZK&V>>#6MHMU
M*82VUQM<T)--.8JA:U%R%_0D*RV&G&?R*Z8NHWK9)TJZ$ZB9]$S +R(Q6[MC
M[/3V8?WV69EK3:5MN].UNY#245*Z"0:P]"KNVT.[;+N$V!CI2RBE/=]05(11
M,19/G.43'Y2$+"5*[']^B7B$7/34;YH@XO<V.A+A%72T+V%52_1\I%-Y *DO
M78Z(C7I&DH<[\RDB_(HN4IT2%, &(Z%6Y51&=D.]2%7=PEK)4P<D-L5&-S'N
MUIM$7*PFV.\%;W#L0NXI[389O%%>QU< D8V 'IDUESD5<$3,)A/R*=*NJ8[+
M=S4W=L%F8R3.3IEJW"I-Z6!U=)ZO256+55(<YHR(KL757T=+$;GAR*,.:28I
MD,<Q%BG('C@>M&V;%R8#L^;H,9?9:+>PFSY*[L]N-(6LUX:OK"IN!:XE:,M<
M<W57CSUI%A&VB5-.I.)A0T@Y0=.2G,0Q -R@3%;WY%4PB816Y</VI6G]SDW_
M ),=809KY^U_FQX?<PJOQYV?0+!.E'00&3DA]C^S%#<!#V=/8S[PX=QT2U_N
MX?S5^-7>& >+M3E']9/G*ONN62#C]GMQ:VZ=I!-S=@I+Z,9&06,=VVBCRQGQ
MP5*B= H( N74HF#FUTT$<X_4=/NKKB&WN(4Y?9A1JQ,XEB'E3SYERF@:[IMC
MP-J5C<S$KZI7H3[,B3RC&-8$@CD?8.E9:FEZ#N7:*UNLKNA#U!"*C*>C8JE)
MI2_RMCG%4CH]JHTIB#%@[C91)Z#'5J N6PI+*#UA0 .;.L4:.K:3:5] A8SJ
M5)U:T8U8RB*<Q*<FE(RQ>+ABQ<$KT2YK\-<2:G8\9#5:5O"E0M^VHRC,U8;E
M* ,*6X) [Q@3[8&]@<0ZZ;='=.N7C;Z69QBRC*2EMY[#;@A%B*D73A'<(S:,
MG;Q4A/(^M641/UA=3"!C&[X#G(Z%H5_8:O&O<1E5A;60@9 AQ,[H9R!O,^.3
M +@.-^,M(XBX5JVE R%6IK$ZD:9$@U,.!*0&6V0<%R #FKAB-T*@VWVV9MZM
M@*C7JK3*I%3$D*;P0C'K*N2#9^AU)$065!)PL4IA(7E,)N B'-KM*FA7\^&K
MVQW";^M=RD!NAY 7#@OL&YO'Q+EZ''&B0[P=(U65U&&E6FGTJ<R!,",C9F.Z
M>?M)0P8MAM=8]I-MJ+';7<:M6-^83V.XT.1)'MRJF7D(J-E'IYD[=0B((IN2
M,UN *F*(B.A= Z.1O]-U"=[;7UI3F94:-2+AA$2%,B! PP$\3EB"5U_A[B'0
M_@NK:3K5R#"YU&C4CZLC*<!5@9\I]D$8$LM@9:[[=0-8W>BXFU[9%@+C0Y.(
MV^KM.JSTEH2(I)QCUBUM\X]ADGC22(BWY#IF<KD5<@8XB0"$$W4J>F:U?7MC
M7N;>Y-V+R$JDZDQN-*8!,0)28/B?5B".A>KWG$_"VDZ)J]O;7=B+:ZLC"A"E
M"7;$"(W8U":<3O",@!Z\\7 S=6C$V^BH6_8#<->YP:;"M4B&IE@A1\XFL,._
MAJU-L5WSIBG&':GBG*BB14545S'.8_$@  B&ZKZ?J].UU#1^PG/?JRJ1E @Q
MF&$0P=]F VK@['B#AGXQHG%LKVC&G2M84:E$@]I%MZ1,SN$;<][!PK.<.ZCN
MQ0Z!6UKU7:!,[='L[)XA<"R[6$GHN<F3RS>6AW4+%S"QY)% 1361533YS%)R
MF,&H%Y6-&^T"]N;C[/.ZMZ\*<HSID TS$2!IRWI1;VL<_3U^=[HG'&C6>F1O
MJ.G7NGU:T)1K"0A,5)1E&I'<A-Y18X'=V%SL[VW;KTR1JNYE8AIE=?J=O=K*
M' 23EFLR<W$]2E$CRT@= @J"S;<I3&1(L<%!;I$$0YM0S3L>&M4M;RTNKB$(
M5#5JU9 $3W=_<E$$9!@6VN<5N=>X]X>U#2=5TG3+BJ>RM+:C"HTJ9K;AD#BX
M+ Q'. 0" 0RP]=+1$2VUVSM>9OA<3%7&^!--1*MJQ2EY6)<QI.L53(0Y7"2"
MA@ HCIW=!'CVW3;6M1UO4;F<3&E6G2(+,"0)[Q#,-HR7FO$FL6=WP?HNF1J"
M=Y;1N1,;TI&.\:)B-Z3DX [?.L4Z\"]X=?J</JYS^T\J\_!8Q;#^13A:R80\
MR#PP@+J##W>]]G &Q82]4;W.J-.?CT=S]'NYE[."Q;M/6."WQ^CC_P!:JB_\
MF6?_ $9EL\A[W_\ ;53\>/R+Z<_A3_ZB3_N/Z,U^F$OP0]C/E'8OTM4X1,(H
M'H]L/KAA%85-_P ,;A_NS'_1JN84&1Z5?V%4PB81,(F$3")A$PB81<5XN+9L
MLN"2BXI$$X((@!EEN4->J2*8Q"F54TT* B "(](89R!L)9^3G\2A+ G$L-B_
M.UO9]*Q9*MVP:]MYN%M%8=I=I6"[VLO7=WBG;"XOE9"2,W8W94AEBQR%93.R
M+U9$#N""F917KU-"E)]$\+=U]I><)5=3M;^C<ZG*(F*=.1(  ?=((!WO:&7)
MSKQ+B'CZM:\1QT^I;5*-*. J3! Q)Q)R&7+M#.O6^-D64FQ:R$>Y1>LGS9%V
MT=H*$50<-UR JBJD=,QRF(HF8!*;H$.C//:U.I1K&E5B8RBXZ&7;;>8KTG=W
M+K(M!*1Q-J(*$ R:L:[3.0>.I#=44X#WP,4PAG!ZRXM=X9;X7.:2?\V82#2W
M58UZI**1EX>2CR/H9VH91FJNF5=(YSB)DA$QR\A'38! I3=)0T,7CH.=+O+4
MW5(1I3W*QE,Y<QP\.1=IH7->SJB=&<Z<SAO1)!QZ-G*%Y#;\TN[=IG<J,VCK
MG)7-DMJ+2FU>L5BJ-SW2^L.0A7BBG5*IJP,&E(<I" (=:[ PZ!R:CM--M*FE
MVLA1&]=UJ)!/S<<^9UZ%I/$6F:%I%>A;QF-;NQN"J,-T%R#O/GEU+%%4[+UA
MMG:7=V11BBC1*>2-H]-60<&70=5BJ/$WDV^%0C<C<3S=Q.Z4+H(@9)(O$=-
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M$_,/)W^0- 'AT:\,SIZ1<C&52#+*6O P(@&Y%<=6JZMA=EZU,Q8U%8AW:ZA
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MA#9T;%K!VL>TE4>RWL[:-RK,Z;&>-&*Z%7A1<))O)^RN$5B1,8T*=9$XE5=
M7KCEU%)'F/T!G9>&= N^(]6HV% $4C,;\M@B^/DV+AM=U:UT:PJ7=?\ 2&!$
M0[%]A"_&5+W^Q;IWZS[C6IXH^L%RGG\Y(JF'4"K2"YU4VB//H)&K),Q442:@
M!$B%#01#7/LBSL+71]/AID *=O2B.7' >A?,5S<W&HWT[K>,ZLY8L,0YV D9
M^)AL?/TE[*_8H[0G:#49N*A2GL/5S@512\6QM(0E6ZL.K$PLWRK(ZDLJ'6?
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M.T;M1V9-NI;<O=JS-H"O1G5HHI&!1S)R[]94J#2+B(YN15T_?.U3:%(0HZ%
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MPY7E-=L8^7M;UXA$?(.QL[77&\:4>3JD&LPP1,<5!54422*F8PE#3(KM6RI
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M9TIC:=S8A"/DB'2;;T;U5>:JTA1I)TB()LQJB[67FA1,<3I&LB F(0J:6"R
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MB]QIFER[H3W.1I#E!M#'IC5!)TE#M:1RNI%]_9#SK4 *0.0XX;#:HZWT -
M.\ !D62G")A$PB816W<!#Y)6D.]7)L?:\V.L(J/_ /6,K>=%KVMV(^RXX5.N
MMM+#*+*J'544-(S_ #'.H/,<QO[[::F'O9S]+BGB"C"-.G=5!",6&.P>+F71
M;GNTX&NZIKW&FV\JTBY)!<D\I=?/^([V5_WH(/\ *$_^=LU?VPXD&5W5ZUH?
MNJ[OL_A=MU'TI_$=[*_[T$'^4)_\[9?VQXE_6ZO6G[JN[[_E=MU'TI_$=[*_
M[T,'^4)[\[8_;'B7];J]:?NJ[OO^5VW4?2G\1WLK_O0PGY0G_P [8_;'B7];
MJ]:?NJ[OO^5VW4?2G\1WLK_O00?Y0G_SMD_;#B7];J]:G[JN[[_E=MU'TJ/X
MCO97_>@A/RA/_G;+^V/$OZW5ZU?W5=WW_*[;J/I3^([V5_WH83\H3_YVQ^V/
M$OZW5ZT_=5W??\KMNH^E/XCO97_>AA/RA/\ V)8,?MCQ+^MU>M/W5=WW_*[;
MJ/I4_P 1[LK]'S00?X?/_G;)^V'$OZW5ZT_=7W?_ /*[;J/I4?Q'>RO^]!"?
ME"?_ #ME_;'B7];J]:?NJ[OO^5VW4?2G\1WLK_O0PGY0GOSMKC]L>)?UNKUI
M^ZKN^_Y7;=1]*?Q'>RO^]#"?E"?_ #MC]L>)?UNKUI^ZKN^_Y7;=1]*G^([V
M5_WH(/\ *$_^=LG[8<2_K=7K4_=5W??\KMNH^E/XCO97_>AA/RA/_G;+^V/$
MOZW5ZU?W5=WW_*[;J/I3^([V5_WH8/\ *$_^=LG[8<2_K=7K3]U7=]_RNVZC
MZ5'\1WLK_O0PGY0G_L2V7]L>)?UNKUI^ZKN^_P"5VW4?2KNHW98V$VVLC.W4
MG;N-@+''D=)LY1L]EU%4$WC=1JX("3F07;'*=!8Q?&(/3W\V5_Q!K&IT^ROJ
M\ZE-P6/,N6T;@?A7A^O]ITBRHT*^/K1!?'QK8 I>4--1'IXCIK[>@!T9PS 9
M+MA+EU5A1,(F$5G+4:$5?R$D1:;:.)1P1V^*PGY=BW6<D;HM06\F:O$D2'%!
MN0H\H!KRZCQU$:ZC)\B(O\8V?UJG_C^1%'R'B_QC:/6J>^/Y753Y#Q?XQM'K
M5/?'\B)\AXO\96CUJGOCV5$^0\7^,K1ZU3WQ[#HGR'B_QC:/6J>^/X1/D/%_
MC&T>M4]\?R(I^1$7^,;/ZU3_ ,?RHH^0\7^,;1ZU3WQ[#HGR(B_QC:/6F>^/
M8=$^1$7^,K1ZTSH?^O9$3Y#Q?XQM'K5/?'LKHGR'B_QC:/6J>^/8=$^0\7^,
M;1ZU3WQ_"*?D1%?C"S](#^VJ?[G<_P (= X=1D"D1(!H#^S!X?E58->[TZR'
M'IZ1XX=5E'R'B_QC:/6J>^/X=$^0\7^,K1ZU3WQ[#NB?(>+_ !C:/6J>^/X1
M/D/%_C*T>M4]\>PZ)\AXO\8VCUJGOCV'1/D/%_C*T>M4]\>PZ)\AXO\ &5H]
M:I[X]AT3Y#Q?XQM'K5/?'\B)\AXO\8VCUJGOC^5$^0\7^,;1ZU3WQ[#HGR'B
M_P 8VCUJGOCV'1/D/%_C&T>M4_\ '\B)\AXO\8VCUJGOC^5T3Y#Q?XQM'K5/
M?'L.BGY#Q?XQL_K5/_'\.BCY#Q?XRM'K5/?'L.B?(>+_ !C:/6J>^/8=%/R(
MB_QC9_6J?^/X11\AXO\ &-H]:I[X]AT3Y#Q?XQM'K5/?'L.B?(>+_&-H]:I[
MX]AT3Y#Q?XQM'K5/?'L.B?(>+_&-H]:I[X]AT3Y#Q?XQM'K5/?'L.B?(>+_&
M-H]:I[X]AT3Y#Q?XQM'K5/?'L.BGY$1?XQL_K5/_ !_#]"*/D/%_C&T>M4]\
M>PZ)\AXO\8VCUJGOCV'13\B(O\8V?UJG_C^'1/D/%_C&S^M4_P#'\B*/D/%_
MC&T>M4]\?RNB?(>+_&-H]:I[X_A$^0\7^,K1ZU3WQ[#HGR'B_P 8VCUJGOCV
M'13\B(O\8V?UJGOC^'11\AXO\96CUJGOCV'1/D/%_C&T>M4]\?PB?(>+_&5H
M]:I[X]AT3Y#Q?XRM'K5/?'L.B?(>+_&-H]:I[X]A%/R'B_QC9_6J>^/X=%'R
M'B_QC:/6J>^/X=$^0\7^,;1ZU3WQ_")\AXO\8VCUJGOC^'1/D/%_C*T>M4]\
M>P[HGR'B_P 8VCUJGOCV'1/D/%_C&T>M4]\>PZ)\AXO\8VCUJGOCV'1/D/%_
MC&T>M4]\>PZ)\AXO\8VCUJGOCV'1/D/%_C&T>M4]\>PZ*?D1%A_[QM'K3/#]
M=]AT4?(B+_&-H]:I[[#[#HI^0\7^,;/ZU3_Q_"*/D/%_C&T>M4]\?PB?(>+_
M !C:/6J>^/8=$^0\7^,;1ZU3WQ[#HGR'B_QC:/6J>^/X13\B(O33SC9_6F>U
M]WR_(BCY#Q?XQM'K5/\ Q_*B?(>+_&-H]:I[X_A$^0\7^,K1ZU3WQ["*?D1%
M?C"SCP$.-JG^Z&FO"0#CAU&3Y$16NOE]F]CY4S^G<T_]X=SZNO'7#HRCY#Q?
MXQL_K5/_ !_(JGR'B_QC:/6J>^/Y43Y#Q?XQM'K5/?'L.B?(>+_&-H]:I[X_
MA$^0\7^,K1ZU3WQ[(B^:]!A'+=9JY>61=NX341724M,^)%45B"DJD< D U(H
MF(@(=X<KJ,KK\B;?<Q_M3R+X9_[6^Y_"Z?#T^'(JN7A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB8<(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%XXV#Z5-&N6&<@5]K
M#K*PTK(11W!)4"@N9B[7;BIH?E$ /U6O@UTSUG3^Z#7K^RI7T:M 0JPWAZTV
M;#^SYU\P:W_%#PGHFL7.A5[6Z-]:533FT(,\7=CVHPPPPQVLNH_VM[4/_E2O
MIIKKYW  T_WNH:YOQW*ZX9;O;V^_R//_  UQ/_=MP?N"I*SO13,7?<I-_P#[
M \R&^EP9B!1#:E4.;H$9?0.D-?A=T-<S/<AQ""\JUL(_CR^2F5*?\6_!M4^I
M;W9BWNX?+6;RI_M;VHAH&U*PC_RN/UATUS3EW)<01Q[6@1S2F?\ PU#_ !<<
M'@L++4#T4Z/RW(3_ &M;;]Z@WY5)_19E^Y3B+;5H=<_\-9?]VO!OZI=?0I_X
MRK#Z6AL(:_-2?\K)A]<VN/W)\1>]H=<_\-9#^++A AQ:73?B4_\ &4C]+0U#
MIVI4_*R7]'E_<IQ#[VAUS_PU#_%CPA^IW9_X*?\ BI_M9VNFOS4'_*Z7]'C]
MRG$/O:/TJG^&J/XL.$3B+.[^A2_QD'Z6AH'3M2?VI9(?K&P.Y3B+WM#KJ?X:
M?]V'"6VSN_H4O\9 ^EH:B&H;4J:?\K)_T63]R?$+_I:'7/\ PU1_%APB0_V2
M[^A3_P 9/]K0U_>I/^5DOZ+'[E.(?>T.N?\ AJ_]U_"7ZI=_0I_XR?[6AK^]
M2?\ *Z/]'E_<IQ$WZ6AUS_PU/^[#A%V^QW?T*?\ C*?]K.U_>I./_P 72_H\
M@[E.(1_6T.NI_AI_W7\);;.[^A2_QE'^UH:_O4J?E9+^BQ^Y/B'WM#KG_AI_
MW7\(C_REU]"E_C)_M:&H]&U*@_\ Q9+^BQ^Y/B'WM#KG_AI_W7\)?JEW]"E_
MC)_M:&O[U)_RNE_18_<IQ#[VAUS_ ,-/^Z_A+]3N_H4O\9/]K0U_>I4_*R7]
M%E_<IQ%[VAUS_P -7_NOX2_5+KZ%/_&6:.SW](<&^VZ]:VT2V^\R>?RRIC29
MY'KO)RQL4]DM 3* \W6BTY?;SK?$O=QJG#.G'4+RI2E 2B&B2?:Z8A=Y[O\
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MB>>[AZ$I^LS'XGA@BZN3M\[$>0+R]0.U9/9N!AA<(3;%X9!Q.2S2):JG1ZE
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M>=ELI:G8QDQF/.N'\YU3_4N7QP_7%B)0I?\ OVA3?4S5^#:@_L!ND>E8'5[
M??'J)57SFU3HZ^1_)$CI[HMPS,:+J!RB/I#TK'XQ8_./T3Z%'SFU3[N__)3_
M .P@.4Z'J/S8_2'I3XS8?.E]$^A3\YM4^[R'Y*??UG7)\$U'YL?I#TJ?&;#Y
MTOHR]"?.;5/N[_\ );[[*(8&B:B?O(_2"OQFP^=+Z,O0H^<ZJ?=W_P"2G_\
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M(I2%C]D)Y0Q^852R5S@2)IZ? %,\7+\Y]0X#S!KKT9NO_@B7!N0.B/I6@/B
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M"RQ\2''3C@8X+%Q&)/.I#OX5,@V+A1KKW^'#CA6.WI6\'T=X?RKMN_ZC;/\
M1.6SRGO?_P!JU/[R"^D/X5<>\2(_L9?^(OTW%^"7V ^MGR6OTT&2G"J81,(K
M1HG[4H;^H+_W6XRRS4&2N[(JF$3"*V[A&*3-7GXQ)0Z2SR(?H(*IJ'1437.V
M4!%0BI#%.F8BF@@8!U >.:M"?9UHS.0(4(?/)>'&W4Y<=L-S6-\ZIL]1AK#(
MQDNH984',G"OY 857RY5(PG<F2</T%=!TT,4#\=./HEQ:VU]I5.(85=TL>KT
M+5[*?8RKCV8F(/C?S,O=B'DD9:,CY)OJ*#YH@Z2'Q?@+)$4#H'3AS:>UGG%2
M!IU#3D,066,H[DC' LNSS%8IA$PB81,(F$4?HUS$2<\R*UYVYURN$1&8DT&:
MKG4&;4PB=X\$. ^2M$^=RL!=0YA*40)KQ$ S=4+6O<%J421R[.M;:XNJ%M'>
MK2 6+97<>8DC<D*V\U-!$2^5/"IKOU"#J&J;;G.@UU#B!CB8P?K0SL%MH=*
MWKDN6R&2X*OK,YG=MP=WE5@+HB\5Z]^X<22HFY^MD5E'HD$1\;JBKF.FW#B.
MA2% H:\ SEZ=.WI84HQA^+@N-,ZDO6E.4BWWVU?8FA2B4H<@!TE*!0 ?]Z4"
MAW<U" #F25'J2&]NQ$56 @'24-.^'O8(.>+* B4MV+;_ "-BIX&'AQ -.CZN
MO#CC$.#FL1*!B#&0)+X8X,6Q5>@>Q[ !]D,CE5- _0 >]AT3E#OC[A?>PZ=:
MHY!YM=0TU_6AKIF6]@RKJL T_P"X'V,Q44"&H"&H^X&GUL LF"@I0#IT'V@]
MX,I+H2ZJT#O![@9'*B:!W@]P,.430.\'N8<HFGM>P 8=54%)H.HZ#WO% ,R,
MG&"$KZ9BHH  [P>X&'*J<H?H />PY1-/"/N%][#HFGAX^$ ][#HG'NZ>U^GC
M#8HJ!(/-KJ&FH?J0US+>P99/@JA#O 7VP][,76*G0.Z >YARB<H>Q[ !]D,.
M430.^(^#0-,.JFG>X>P 8=1- _3PJ@Z &HF$.YP HZC[>4(QWA'E"I$W#AIK
MW-1#3Z^ "C#(Y*D2<W$"AX=-!XY7/.L@8C##QKX'01<@8BR"9BF#0Q3E!0AM
M.(!H)M=-?#CU@I+LMF?,"N5'.)6&,!X>3>, *&GDI3@LQ4#@/*=FXZU%,-=0
MYB 53E,.A@'-M6L[6O\ I8@GE"UZ5U7HAJ4V'._F5RM]Y7T"JJ>W09U85-(I
MAFZZ5P^6;@0I>M5?P8E.]*D8>(>3&<&* #J77.(KZ%O4^UMIC>?V2[GH(#=:
MY6EK$:<NRNP8R;F]*R[5+S5;S$(3U1FF4_$.#"1-['J@J0%2@!E$%TAY5VKI
M$# "B*I"*ICP,4!SK]:E6H5#2K1,9AL^0[7R/B7,T:]&XAOT9"4>979FFZU5
M ^QK^CPY'13E1,(F$6F/;+K3I]26U@C5#MWT:J5)1PF(%,*',90I%1Y3"9(H
M"?AIW1[N:D(RD#N>T!@K!A4'2M:MBYF:VBW%9@Z?)KQU[>)1-D3,W0%<'<0@
M5Q"'\H @G.F[82BZI! 0Y>00Z-=-&A/[1$D>U$@'P\2UZL08[T<EZQ%'4I1U
MUU ./?X9DMNIPBI,;D*)M!'3N!T^UKH&$6OW:![579\[+%-6OW:!W3JNU]82
M W5.[$_ KR0,4Q4Q2B(=F5U,3*_.H4.K:H*G#F#4,W]AIE_J=44;&E*I,\@P
M'22P'C6E4K4Z8>97@)?/_J*V&\EW=;-?1K=E+<[M8[D*J=1&3TRT<4ZDIG/U
MRGG-5F"2DZ6-;IM%C"H_-%$,*>G.4/'SNE#@ 6M,W7$5Q"VH@.1O.0^7L[VT
M@9+CIZH9'L[:)D=GAFKJ@>RU].KVR$BN.T[VP*AV(=O98!%YMKV;85@ZW#38
MG X"U5M[!XL_CE!2.)# G8%2CS")R#\$,*VH\$Z9 PTRVE>7$?OZIEN[W0)0
M/(?95%"_KD2G/<CR#^3[JVGVO^@5["56EV5OWEBMRNUMN W/Y2M;NTKN59[\
M#IZ8Y%U7*U=*[CZX[(LY QS).F[DA^L'FYN&<3<\7ZI4C*E:BE;43@U. 'E+
MGQYCE6O3L*$9"<WE,<J]5MMMCMH-G8HL'M1M;MWMK$$3(F6/HM/@*LV$I"D*
M *)PD:P!4?$#43:B/2.==N+R\NC_ )FM4J#\*4CYRMY&G3@/5B LK 'N=P.X
M&G1IPX9MUDF@=X/<R%]BKJ +H.NHZZ:=.H?HX8'*P=158 1,J*-,A#[2BG!#
MHHTR;O2BCE[@  !W= #WL -DS(N@GZK7K2Q5B[) PL_&+Z@M'S48RE&2I1UX
M*M'S=PW4X".FI>&NN;FWNKJUJ"K:U:E.H-L9&)ZP?,M.I1HU?TD(RZ0ZT3W4
M^BW[%VZB_G-;9Z'H%E3.95M:MIW#K;N7;N!Y1(X!O &1A5UDCE*8IE6J@E$H
M:"&HAG;+'O XML8BF;HUZ/S:\8UH] [02..UB%Q%SP]I=PY$)4Y',PE*+]1"
MU;G.PGVY-@S+2?9![:=LM$4T(0S?:SM!*)6N..V3YM&#&>DT91NV,;JRD3.1
MLQ$2ZE.H :B/:K7C'@?69"/%FCTZ=0L#6M=Z!'X1A&<8YY@1.&0V+A:N@Z[8
M@G1KR<H#$4ZA?Q E_*?&L9I?2H]I?LORK.J]O3LL2=?:K&*FAN1M>ND\A) @
MJ F59)DK(2$,N?JT53&*E))*&  ^T@(CKRT^Z_ACB:E]IX"U:G6K,_8528S?
MD#QCS#;TK0CQ1J6G3[+7+:40,ZD6(;:?5)R7IUL3VX^SIVEHTBVS5_86*523
M3._J[U)>#L[$#E,( K$3"39PX O5FU.W!9/Q1\;/.-<X*XCX;JFGK%K.G#YX
M:4/I1)9]CMR+L6FZ_I>K1WK&M&<AF"XEU%O&MD_/LAW(M?AT_;4@X_[WE#.K
MCLY!XN>3 A^M<NYR.97P/:'A '6%="( /0JD(CIW0#EXY&"I)B=V;B?(N -V
M<D$0/#.R\>Z=/HTX#P ,;L>1'*^B=W$XB7S<JF;@']-3'7HX!]KTU'7)N\B;
MRY,?;P>R[:),V41<.6Z[I/G$# *+<Q"'-J0"EXG/H'L9688K U/68*^<P6JL
M>[E?X#B/#?-MP]V]U\/LX4VK(6%5^.K=,==Q[Z AK_SML&H!P'A*.QTXZ::C
MIWL^Y^$P8\.6LAF+>#=&ZP\2_'+O0];C/5*&(JBZPES@S,NG9T..5>UGT:O:
M-A9[;Y#9*<DF,79*B*QJZB\<(ME)N#=.17%-H*PE\I=LG+DQ!3+J?J]#= #I
M\^][7"MQ8:S+6+:!E9UB\C%Y 2Q=SBR^XOX:.\K2M9X9CPA<UJ<-4LH 0C*4
M8RE3+ ;H)!DQYB<<UL/NOV19G<.XW&R57M"[N[4P^Z$(RKNZ5+KAJU/P%HBV
M316,$T(:X0\R]H<D]AW2C=9Q#G:B?GZP2]:/./C<)X$;N(.>/AX^9?51 )WB
M<?#9M68Y.<VN[+&S48Q<OF]<H^WU?8P<&S=NP6>K-HYN1HP8H>4*"YD9!P)
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MWHU)47$B'.W8[8Y.L<YV-=?3")A%&G=U'V.&GUM<(IPB81,(F$5(F*&HB8H
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M+3>)8BROX;<H2Q <;V3].&*]NJS:*];H5C8*Q.Q5BA9)(KEC+0\DUDX]XW.
M&(JW=LEUFRI!(.NI3"&>,U[:XLZIHWE.5*O$L8R#$'G=>HVUU;WM$5[.<:M&
M0PE$@CK"N,! >@0'V![W3FDMPIP^W8B8<')%8VY%>+::58(4Q0,=TP6ZG4NN
MBI"@<@EXAXVH:9JT9F%02'*H>5>4"Y785Q42F*K,0QT),=1T73E*0],@9,I0
MTT![5)(> _#^KFSI&5GJ)I?U=7(['&;'QK=1:=-G&?I7J[MI82VFC5N;*8IA
M=QJ '$I@, G1 4C&UU$?&Y->.;NM PJ&)V+;98#)7WFFBZ*T+.6U:GW+(PD>
M-X:2<-3%*!C%<(M%E43%*8IP,8JA0$ $!U'N9J4HPE5A&IA3,@^S!P^/0H7;
M#-?B6[(?T'/:-^D.W6M7:M^DIO\ N9'T*6MTPXJ=&FG[U#<B_02$Q()- <G=
M)I!MS3A:HI=0FV1(Z<HF 4@2+RJ9ZYJ7&VEZ#9QTWA>E3-4TQO5<) %@[9N<
M\%Q4+*=:I(W!(B_7R]')ATK]B.P?9KV*[,%#BMMMA=L:SMG3XI$I$(ROL.J6
M<'  YG,K(N#N)26?JCQ.NZ655.;B)ASRF^O[O4*G:W=2<Y\^SQ9>1<E2HTZ,
M=R  "SB"9 Z"@'N_H[N;.+[5JKZ9DHF$3")A$PB81,(F$3")A$PB81,(OF=,
MAP$# /$=1T$Q1U[X"40$!TS&7LE%;UEJ%9N$+(5VT0<=8(.4:KLI"*EVJ;]B
M[:N4S)+(+-W *)G3.0PAIIW>''-:VN;BSKQN+2<Z=>!<&),3Y&6G5HTJ\#3K
M1$H$-B OSR]L[Z&9DR6>;O=BM[)4RW1J@2BNV1)9ZDS=NDG **NZ=-.W:C^(
M?D YA(T44.W,)0*EU?P1^@^#.^8SB-&XXA"XL9@1%0Q'JC8)B( (<#%MX'$E
M><Z[P=*+W6B;T:X)+;Q'4YPVK"?8\^F&W,VKM*6R?;29R<A'13U6#7OCZ(\V
MWBHNFQ1;D8V^)2:MCR[=-<@ HY,0'A-1,<50SG^+^YG3M5L3KO DHRC4CO"E
M&6_"0)Q[.3G'-PYQ#9K8:3QE=V=;X=K8,C' DQ,3'IP#]*_3!6K/7;K 1=DJ
MTS&3]=FV23^(F8MX@\CY!FY+SHKM7:!SI+IJ%'0#%'37AT]/S%=4*MK=2L[J
M,J=[2+2@001LQ!QS7I]O6I7-$7-(B=*0PES=.2J<-2F,8!UYAT !Z>&FOL#H
M&:46EB,5JNV"MU5F8BWBCP*8HZ&$1U$!U*/C"/1IA9-M"XD,<P;@0:8Z?X E
M#>+_ .E:ZZ /\T/Z #(68!:1_2N5G;,%N%CW<OA!1(]T+WMR(>R%[KXAA%D+
M"+\=.Z.OSDW[0-?^=]A_RHZ#/NKA7_;UES6E+^:OQT[T"1QWJ38_YNI\BM&-
MDY2"D&DM#R+Z*D62A%F<C'NU6;QJN0>8JC==L9)=,Q3!KP-TYRES;V>H496U
MU3A4B3[)B3Y7;R8+I^F:IJ^DW8N=)JSI5P THD#(@AL'<$<K>=;CUOZ07M0U
MJ))#I7)E,(H !$G<_$(2$H0@$Y/'>B9)14X%Z#' XZ\>.=#N^ZG@RM7^T585
M:<R?9B0(]'L^5>YZ;_$OWJ:79_8:E:A7D!ZIJQ)J \I:8P^5:^;E[T[H;POB
MR&X=RF;&"9SJ-V+AVJG%-#F_5,XQ,2,VI@#AJ4G$ SLVC<,:+P_'L[&C"D^T
M@2G],".?0O-.*.\+C+C28N^(KRM5+G=HQ.[3'.TM_I8$+%I0TX>YIT9V,G#!
M=$$09M+!2)1YM>CH'W, X,M7LW.\,E5TCKT>#V^GV\G,LX@[Q)7S_5^WF7WJ
MTC^E\:^F8K75/-QTTRM@ZPW_ %MU#%UTXX!9)PWE4&N@!X,G.J(B(=0)N7*
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M&K'(A8$&,F*V[S014F*!BB4=! P:" @ @(#T@(#P$!#"*$R%3*!"\"@   <
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M;E+MCS+SC6N/H48FCID1*?SC]Q>)6]^Z6X&Z,PYE[S:9:P+=8(H(NW2OFY@
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M4J1CN@R+D ;%HTK2WMHM0C&,2788+(O*3N@/M< S:;JU7*DR91*(@4FHAPU
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MX816%61JMHKCA1C!,DX)_+V KR)=1;%-!S)-+"_0E7;UB0AFBSAY,-%%SG.
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M.8*X=ND7*LV\=/4CH-R*BB BU: 1(AA'E$=1$=&WX5O86M&%>5"%S"\%8]G
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M_P!J4-_45_[L<999J#)7=D53")A$PB@0UPB\I]_(3S'O78$UDB!&S+2/G#Z
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MNZ9P5CAJ$>D^<K\K>/Z8H:[J$!D*TAY%>.=O7EJG")A% ] _H]G(A?9FM?\
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M>D>_DN:9N;,TAC4CB%G1F83YET79TM"<)NN^AE3:%NL.G,* / J<L*A&4@B
M&-P.9^Q*.GC"!E>/3EMI]M9@G])' I4/K&0R=>B8= >P&%@IPB81,(F$4:!K
MKA%U$[ 0UGB7D%8(QE,PTBEU#^,D6Z;MD\1U W5.&ZI3)J$YR@;00Z0#"C!6
MBP@-O-I(&4<1477:36V:+B9FGQ?(HF.:I-DCG<R4H\642*!46Y!U54,/*0NF
MN@!C%5E@TO:0V9J$O46D==]OH_:VS5Z_3B5G/-I)M!LT59Z^+F/:O3O/)]5!
ML;MPZ2,0RJ?(!_%3 V7%8EAX>',LMRN].WU:"2?VFZ46 KK48 K.8>VUBF"R
MEAB7TTP([3730;MAD8U@HX8]6NN+Q ASE H%XF*K]2ZEWVE=A6$/%3[W=W;Q
MM#SA9,8=^K:X<J4CYD78-IH&@"ZZU88=:4; [ "B+;KR"IR@8,(Z[-AO3LO;
MV-O)';B4&=C*M'%<7(Z%DA7L?#Q#XKI(KF85!R=HC'.0:K$!50W4G,F<FHB4
MP!,0K@<EC:HW[LG[?0*MNI]IVEK$',N#1@S$;+0K%-\YC4A=*19%/*.O479M
MU14*V -2D'4":#J-4<;5=\3VE-F)K<.M;70UY@):U6^HFNM?3C)2/>LI.&%=
MLFW\E71=F57=/47(KHD(0Q3()*&$P"7ER%T#9K/6%4PB81,(F$6)=VWY8^ES
MJXJBCUA&;,% -R"4TA)LV1=!_FA7]O-.ZJ"%N_*5OM(H]I>-\V,C]4K2,DLX
MC^V94*&Z<6=.$(;<6^0/G2OM*Y&.IZ0JK>.GVD?8E7ZLC?(9%D\ 6[9JT:D:
M*$,91PL")2#J4Y;U.#8EELJA>1G]Z2>H$CRM_(O1-,!$HZ"4=1[_ 'N]P >.
M;H2$1BMK+&0Y5.GA -.'$=/L=&#.)15G#4> Z#IIW^GAT=[CF!J.& 55@BH
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M9T=%9O8N22*0$#F*0%RCS&!,.8>''%]6ZM+2M8T)2OKBH:.YO>KO0C-Y N
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MPBM&A_M2AOZBO_=CC++-09*[LBJ81,(F$3"+0;MBUY4)FD6- B@%?G<U9\<
M\4$'Z+DJ)A']<#A<@EU$>(=&=GX>JL*E(G'/RK7M*AH7,:@+8^#KJ.R!9D4;
MI?*N=0R8R3&*M#- P 003DD&X.1Y!/J<WG=-Z', #IRB CPT#/B"D)4XU0!@
M6/AU+*\H_9[J< &<@KT.Y2CH/*'?#@'3W_9SJJVRQ+NILIMYO!%>:KG7V[T2
M!_8LFV K.78B(Z"+212)UQ $.DIN8@\!$HZ<.9TCB'5M#K]KI]248[8DDQ/3
M%V?G7$:GH>F:M3W+NG$R;V@!O#H++PS[4G8"W/VU0DK10T'.X=,0*"Z@,&ZK
MFUQB1?Z89Y%,VB?ER")?&,LW*80#43$* ";/H'@_O-TO4#&VU64K>Z);$^I(
M[&.<7.S)>(<3]WNI:?.=SIX[6SY!C(>099DODO%R^)J(J.$E2'351$R2R2I1
M(HDL0YR'243, &*<AP$-!#4!SWFPKTJXC,EZ9R,-O.X\[KQZ_I5:%0T9"4*P
M+.<GZ-IYV\:]@/HD-\&\W3[?LE,R 'F:C*+6"NH+'3*JM7)0$4W":&J@&4*R
ME4U!$ */*58G'00SQCO=T+[/?PUJW#T*T6)&.+G/TKUGNYU85K.6FU&]66WH
M'A]Q>SA3 '? 1[@ZZCW->CP9XJ ^(R7J9E*6!V8#G"J'H]SZ^$"X,R*_FIJD
MF ]4,BLH*ABB*15@;:$(;@(!J0PCQSKFMXU(\KA=ET+U:L>T_1[X?DS7@=;H
MR<9;J6)K9$'"$RG8I '1'**J0G(9ZHJFLD58I3BU52.4Q# '()>CHSD:!!H[
ML6"_5G@&_L+KAJTKV8A.VA94XB.$I1]6 YV9B&=^9;5;5D_LLHB8"EY3".OP
M0X@&H]P.8 ]O-A7?$!</QE.G&B2TBY"MWM M8]S&N3*DYG10 &0I% 71G9U^
M5)-JG\-554QP#E#74!RVTS&H-[ +;<+7,;>TG.M.-.W%.1,I'"+1)#^1N=>D
M&Q#&3CJ9!LGS19JY:4ADD_;*D.0S17JVP"FJ4P )%-0 ! 0U 0T'HSC[-CJ8
MD/8)\K_RK\]^\2ZL[WB"_NM/.]2E,O\ -PB 3$;,B7Y<5EC.X+RE,(F$5)@$
M2B :@.@] \H^T( .@Y,#GDJ"07&:UVEMD9==SN&P@;TZ@ZAN<[F9:U00P<9)
M/ EYZ!2KTJ>)E70@=BP?LVB"AT3$4.14AA34(!N7,3 <F"W$*P YU9%>[)L#
M6;"UD(M_%GB"SD/:GZ$G4H"6GU+#%,XQJN,?8'S95:.C9-U&$>'(":CA!R)_
M)UD2&*4N/V</O!0W/,,UT)>QRR5"23D[BHZ*\A[C!%?HUN(1L#YM<I>,EG;N
MR3JG7/9U^R&.(BCS'30*D(Z)@;B-[''%#<.';);,-*&@ULU\LQ))VD\OD9 Q
MCKR8Q$5(L(&,>1B#N,<"4# [63>B?F. @0Y2B4.(YEV0 P4%=X\ZU\H79/94
MY0KIY9RR3Q"NUBLBNRK<7$K/VU7L[:RH3$Z\(*SZ;L$DX;%!RX<'\?F'D!/3
MCCV.+Y!45][%E?EFV.)+70=Q:]9W,!=V,]YXAG9X]I*Q;8CBL(5&7BI".4.4
MSN/DX]L!P$IT5B+D 2G "B!AI X>'A]Q9B9A'UABN7#;,'8;:[@T*<M\A//-
MQY>X3<W8EV,<S<)/+F857I&C%F0C1)HP4 2H$-S&!(I><QC:CF<*48CDQ6E*
MM,G!6E:.S%7+%:WMF:NX41L4168BWH6"HP=H,^:U9JW8LEX-63(=*)</(D@(
M+@L1R@H4 ,5,#AS&&E XMM64:YB&/M<ZR*XV>C5W;-V5^Y1!GNFENDFB5%+E
M\M)!KP01FIP /)@1<\X&T WB@7HR=D",&=)5P!B%8/\ %V>0U@M5II%[=UV9
MNZ=B869=W#Q\ND>)GK3,6E 8I!<S<C67A'<\Y*U6,95$Q#_;D3Z!D[#;M4^T
MA\E]&_9:I#5]7$6[V2^1T!MLQH!J<H5L5I(JQ<-*5>,M;UV" NSS[2LSKIF4
MX& HE.0> H)B,['85>W?$!=KM'L%'[5RY'J+N#?-XR!&MP7D--@X:71C3.$%
M15F)EHCY8_?J(M$TC"GU""@%YS$,?0P91I".6:2N#/+#K7 M/9MBK+9=RK*A
M;K1!+;@521@VJ$,LS:DJDW/,64;/VV 5!L+AO+S3&#8)K"8P@!43<H:JFUAI
M8X'-.UPQS5D*=DQN%>M,8:>K97%L>0CA\V3V^@4J\P\S13N*:JPD<@HA),9,
M"N@7*\\M,Y\H+Q.9,13R=@,N58BX?,*]ZWL!*4]JY@:]N'+)5JQ1<$UNR4I%
ML)BP3\K#U2.ICJ:+/.C:L7=@AH5KY< HJ""Z8G2$@G-D[(MADL^U!#[5T@=F
MB2E&Y$+3N._EDV%6J=*AT6L%&1B;2'I]LB;4Q?NC$!5=[.2*D:5!XIS$;BD!
M122((&YAI'(Y(:[9NNC-V0F#Q2?\Y7%9T:7A-R8-O+>88T+0JVW+T%^XLMC4
M*M(3KJ#!--&/(!F[=)L7E,F8^A@D:$8RWRY(\J"Z)D-G7X> 6Z*).4HAH %$
M?%#3E'0. ")0\4HB&G1PS6R6G5,9'>&)7VPM),(J>.O@XY<&63X89KF1^H/X
M_34!%XUZ.'#KDOL:YH7'Z&?0?,M:U_U ?(%=GVB(B9?P4.]9@JO'1[M0TDBF
M!C%2ZXI"H/EP*40ZA#0P',(@4A3<P\ $<Z(VQ=S.6*LS:-$ 0:@30_.8#<!
MX (D* < UZ-=->C*,L5B<^=;;KJHHM%%%%$DDB(&,8ZBA44RD FHF%0QBE(3
M3NZ@&3:LMG,L$[7M$W%WO,_%(\L Y28LD'J1>5K(/D^=5P=D)1Y5T4M-#'[I
MAT#NX*@Y2J+I^V20_P!VC_<Z>=RTO_0Q\-JZKJ?^JD>96MW_ &1^OF^"V=0
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M@6  <C!:%W?7NI2^T:E4K5KN0!WIS,]W$C=!E(E@ "&P&\6Q=<,P#J'+KH
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ML1*68P5BXDRY78!DKNX@["G:*QYA3/*/S DC((OVR:IQ;NB*$,4Q7'5*BY4
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MK^4(LA9$7XZMT/\ ^)%\_=?8O\J.<^Y^$_\ Z"U_]M2_FE?CGWG_ ._]1_\
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M$!#-6G<5Z/Z*<AXRM*5"C/VHQ/B5H.-LJTOKU19%B/ZD6,@LF4.'0**HKI"
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M2^S[ AEQ66_3V.5.I?#[OZ0X8J=I3&;OXE2(%-P ?^^#WL D*2W*F \/(I
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M]BYUC[53VG(*,[/M/9(^W.U-NC5BJ-YB$?+V=IN/>(3;]DLSDB+I,F:T%8+
MU)()K<O5$5 Q3'* CD8HX5X;O7RY5B.V>E(VLRSJ>GMP8N+E:5#2C05G0R%1
MM"R\6\EUO)X\T;'.T"+KK& "B5#F(4QN4HW8FW!6Q8NU0UJE;EY&=I_F>R5J
MYC2[!5YJUP44*#Y2NH6B/=1,LN<R$XVF(IRF+4K=(53'YP.0G(8<,C]2A#M5
MMYZ/:R=!V\L-V;$VJKV[L_Y(_B8M2"KUJ2DG$'&%!^XY92R/&T.Z5*V2$J8I
MIE'K=5" )BG0MDZ;9$+C5*Y;&K9=FVLD)&3C=HZY0<MD)1FB]2;N ()B]>B1
M8"GT'3F <BJN7")A$PHF$3",F$91I^CAA&4X1DPC)A$PB81,*IA%&GZ.&%&4
MX1,(F$9,*IA1,(R81/T=S"*-/#];WL(RG")A&3")A&3"J81,(F$3")A$PB81
M,(F$6N':CG)NN[<P4E7>K-+CNYLJP9H+R1XEJZ4E=U*E'>2/7Q-138N0<\BP
M:&$Z9A*!1$=!;46,;;OQ8:U:Z_1;]!H(6F/N.W<DLYH5AET8%[6[F6[(LC.R
M.&R#ITZ:O:4Z*XCE]4EB"BH!]#:!5,UP9KM7W*K4R#W G:-7EX'<*@WZY;>1
MT/.O5YA!U2MOYG<5"*MJB[--FFC+PT,HF+IKJFU<B5,P&YRCA!R+G3O:5W*A
M)96K_-_%2=I@:;&7ZS,(5K=9QHYBK$XEQ@J_77<5".B%G/)8=0JSAZ*+05S
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M,!.(\<BJLA/8QLQH.T=.BY9%J_VF+3E(^="':F/)NJ=5W%=07=-P.F)"NSK
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M>'=<TSO C6O[6M2I]E/&42!ZT<"Y"_34 ZAGRP"^*_1]3A$PBI,8"AJ("(>
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M'^S\B?\ 9;_T(_Q+C_-?VGUD_P C_9^1/^RW_H1_B7'^:_M/K)_D?[/R*?\
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35^5\G4\O'K-.7C@<R+.>$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2127058d1-fc_manufa4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_manufa4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L .2 P$1  (1 0,1 ?_$ 0   0  !@,! 0
M       !!08'" D"! H#"P$!  $% 0$!              $" P0%!@<("1
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M_(3W=]0=3U _XTH\#>E (0 ["#_[,GXM28+?D/=X53[2O]\\GB;TJ/(E^U(
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M:2:N!<TT P#0">?>NVX)]W_$WO#O+C2^%V12WUO;&=V>0,:&![6X$D5+BX
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M#<1#@/CVU54LB<^1O7&WD V D\_.K9#8W-#_ )Q(H"*9AOQ-*;1BJRNU L5
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M))V9YZ.'>QJT'> =FW8OH1[((I"@E(.TT3*$5%)%RL1+O"<"*BD0Y4Q5* ;
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MX/'I51XE 0'Q:53Q+D!?"/@X[=N_L:&NP(*;U 0'MY1 /:TJ-BFF_<H !O
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M?%HB;#XATJBY<H[=GM<./@WW]CQ:IJ*JHC! */B[?N>SJ:]]4T4-AXE$!\8
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M,4_DMT7[[G_AF_7+G]D'70[,VS7NTV/_  36I_'R^/\ I\?ICYBD?R7:,/\
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ML"+A=@E88.0KTP5-L\<L5!>0\F@@^9&%9J82@H0!$H@(<!#1%7/?)!V#X=N
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MGUYCXZ:>3#FHOI6+50.XFD6QE5DE3.C&.HD"A%.5 OO?LL2U?QGU9-^F;/\
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MK=8/*_3Q9IZXQ.0KO+6N'&T4\*0:/GJO"/CEAZ.*Z,TLDHTB$&;(42D#N0,
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MC=90Z;@3%Y5  ^H$K!M*@Q/W J]]@E.FBU,ZXTML5CRTM*EYLI6"6.K1DZ6
M.U213;JPOI*.=C&*I$0( "CR" % -]@U':,Y4#'<A\2X/LD].,M;(JTR?Q1?
M7*L(N&=?M<G6TUIJ$0>)F2<MH&?=1YG;!)R0YBG(@J4#@80'?<V\]HSE3LG[
M@?$J 3SYT65>_P O/-9/&D+D>5YFT]9XZJL6EH?@J8@';RUB;11)!UWIT@$2
MK+FYC% ? &J'3QM&)4B)Y.Q3X_4)TFP$5%*#8J%&1=5=N7L"5*#;H-:_(NTW
MB3I]#I)QY0C'CI.0<%.HB!#J%74 1$#GW@7,1Q!4F*0#8OA&]7_25#MY9[&9
M(IT<@(N9^9/',Q:F<KF%,'DJ]*V:)&=.ER@4#JF RA]@W$=@VN=HVE:X*D1N
M)H!BJUC.KKIYF&+:2CLD1#ED[1(X;KD(ZY5$5.)#A^8W #!V:I[:/E5782\B
M^3[K Z=8T$!>Y*B$ <+I-DA.F[V,NN;D23_L' 3FX!IVT?*G82\BZKKK-Z:V
M8B#G*,&B)>T#^<!MQ /"CX!'4]JRM*J.RDY"JOQCU(X6S'.2=<QQ>8NSS4.Q
M2DI%BR[WO6S)8X)IKG[PA"B0QQVX".I:]KMBI+2W:KY:K5*:(FB)HB:(FB)H
MBDEE_B[/?X&D_P"XEM%(VJ=Z*%9SIV_D_P"#?%]#V,]OF7"Z* KQZ*4T1-$3
M1$T1-$31% >P?:T1>7GUGK4O_BRM:FP !X.JB8 #\K:!8@ B =O#6ON'$2+H
M;$DVX&%%KX!)+EVV#??R0V]KL\>K%36JS"7?-H!X OH!$OV1";[;#Y(>'LX;
M=H;:D G8H =O7,J*0#N!0]D +MOP\'   =3D=3%5 $&H7($$A'< Y.(F$3<0
M .S<-NT=]4Y>=59G<WB"^8D,42B0_()>(#QWW]S;COJ:%4TY-J^"RZJ1!$3I
M[[^24>W?Q[#X]*D8*#6BZ7-(.>45"?F.;?8H;"/M;AV>SJ:G8-J#-X%,4E13
M*)>Y.3;@(CQ'?W/!J*FM2J:NKM78*JD!RB;EV#CY0<1X<=O#V!IG557<WP+Z
M\Z9C&#R1* !X/)#W/;'3,2AK3%=/S%H8P[(HF$=]QY0'?<1'B(\1XCIF*M.(
MWKLIM>38A"%Y #@4 * ![0=FA-1BJV.ZW5V]Y1.D"?E&#8/$': _TOAU "N'
M-7&E>\%URE4.;9(!W'?;<#  "/:/$1WU.53F/-X@N8Q G'O#&*<1#B4X &V_
M: @8!W#5/,HS'F\07/T44O-RII<=O)*0H%X;^( #4C'8F8GD\040BQ-L $(4
M1V#8 *7;Q<=N'9I0[?E4YZ"IRT\"X*PWE&,*>YM^7;8HF ?& CX-^P-1UB0T
M'$J.U;2O5H!4][E*IFS/8RIP4G8IA7S:,B6AWCQ<=MB(I>2(@4 $3")O  :B
M4]@") 0\8T.!\2Q+V^BLX#<SEO9 [=RQB8]8& Y,0*2Z,T!YMA!R@L0>' 0\
MI$ WWUBMO&$5(*Y]G&>CR'KY&NV4+37X.59+=.>:\1S^:L4HQ5VA7+ASD"G%
M;I H*:JBA[#'=TD0JB1!$YS[ &LF*XC>\ '&JRG:_IEPPLMWQEYW# _"O=<B
M.Z1!WWW+OOP\/M>#6Z&Q8-:XA?31$T1-$31$T1-$31$T1-$31$T1-$31% 0W
M 0\8"'#M]S1%Y%?YPE(M6'4[A$JP%$5,' 81-Y7 +W:>.W$. ]FL^R<&U!%=
MGRJDA:4:[;&:)BB14NW-N !P'<./ >'BUF'K&@H%+ 5D35L@LVY6W?'-VB8-
MS'-X?" ;]N_9K&FA=NHLB.,N-=RR:A\H-GD.9DAW@JKM3I<IC*=V)5"\NP@(
M 7AXNW6L$$K9*NQJLH0MW\BU Y*=C%WFQL%=@,1^J< *'DCS['$2CX0XZUUV
MQV<XT#=O-WUF1.8V/(%2,*U&9B;."1Q,X1[ON$A'@;GW >8=P#;81XZSM)D&
M8YU@SMJ -]5V.D:NRR3^9:2!RMFTI)E!BL8Y.4?SA2*"/EB!>43=H[?<UN(9
M<CG.#B#\"Q3'O&*W88/R;:<+R\178-9K*(V!^F=80(*@MU$>!MC$,80,(J^#
M;?5BXO9)'MSN!RG#9OIT*K(6L-=IHMIU@NCD2$<F44*NNV0<*%*<R8%.NB"I
M^ CY(<QAV\.NAB9(Z-F!)H/%180J'GD5EWV2W2:AB@HX$.;;<%]@'Q_E;[]N
MJI+8N^<"!WE<V[%;V6R%)+G./G;@"[CY K&/L&K+;1P%,*^!7"X#OJEH^[/%
M92/*9PY'>2:AY2AMN45BAOV[!OOJVZU#&ESJ$JDFIYEE5UM5^^375ATM.J_%
MM'-8?4<&=LD9-R1D"C19.*!%I'.%SE2</A#G$"%$PCL @&M=#<B%],I))Y_A
M5#AF;3$55A>K.@9AQI3K'8HF)E)^#*]2CVM.BTU@F'QWJG=I(%7( $*(%[3"
M.P;:W5UQ%;SQQVQM\I8X$T'S@#6A/..=8D-I*POZVT8<V"P::!F27@8HU[QC
ME&NP;9)TD,"[C).2#T>N F6[F1;F4  $!\HH"':.LL<4V]Q(R9]J(;=@REC=
MCMF)IWJX\JH;9SQM=$Z1Q<[8L:(;&W2W7;U$V5_396L*-ILT@B1_%3+U"942
M6 R[1V@[0,5PD4_$0VV 3#JDZUH%S?Q23-$-HPXT))#L>M05.WFWJ&6-Y9VA
M@MWF1Y-3FV#E )V@<U1R+)_)5LZ3[]5I&KPM'K^/W,BD4JT]'M#Q;M4Y2 80
M(F1JFHF01';;?AX=9'KNE:KK$ANKG)9,RY),N+J-&! %=N\A5A\\5JV,,/:@
MT-/'\JP&6PU!I*;Q%Z9Q]6:G,BF[*X3,\<GYA Q.\.</S@>SQUA0:UI3]7KJ
M+A[.B!:'AN+A7#JM%?@65)'==B'0BDAY_D5D[C0LBV=PYKU:DWL)53$\Q+92
MO4G;P!$ *HX $E]P,0_-MMQX:NPZQP_>ZU21QCT;9G#'9N_0-S? HRWT=L9H
M1_UG=RX*G*1@GJ#J)!CJS=7]F[YZ=RJ\GE#H@9(!$1;MQ,N)B%,7L'L#5M][
MHOMQVGZ9-'-:/<6L=*74'(<=FS:<.=0PW8M1/<L(<-P=4[.8E96*XY>K-(F.
MLEA<1$H])W2J8.G:A0<&Y@V!5$YD^0?!N'9JWJ<3['46Z.XPS7;W"G9N!9UJ
M$"NS80#78:JY;O$MJ;FKP36@-0<,-_>7HR_F\U"EZ#']7["0?C(LG=@PXO$N
M#.UG9S-R-,H <3BL(B01[PO#QAQUI]8L+K3YQ#=1,C>17JN:ZHPVAI-*<]*U
MYDCD[1E:DGG7I&UIU6FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBQ%Z\WI8[H
M]ZAGAF[AV#?&5A5%JU0,X7< "!0[M)(OE'.(CN !QX:D"NS:JF?/ 7A&AH]O
M(ID>M(^5BRK;F*VD$G48\(/$#"9L<R:A $2CL/'<!UAW'SN=;FKZ#9\"O!6H
MIP90@ X?I; &VSQP)0'P!Y1C[AMX-]M6 65H[%4U9^GB>97I91DPF*9R2+HI
M#"D'+Y"A/) 0,.PCN(;^+5!--B/8VG5VU5S89E.K%2(B[(JY$X "?F/-WG.'
M*4A"%-SF,/9MVB.@/?5/5IB,56A6=A;J @N5LFY3X*I+MUFXD$/ <AP Y!V]
M@=7FXGK%4AK3@JTB3R:7(9=HV4X%+NW=JD#@(;^2H4@@&VJ7 YC39WUF1MZH
M HK@MY=0 *D2%>J"F("*A'21B#N( &W,8!-I0JNKFJKTG:! (+B&EB<PEY5"
M-P6+Q$.;<R1S>#VM3UABJ7.>1A2JJAJ,28H'.B[0(( &ZZ"P!S;!N EW#CJ@
MO5JDIVT51M%8A4@<DDV3(7\HIBJHG#V1YB!N.J,>4J '?HY:^!3A (8YD]I=
MD&P@(B9R!/;_ "]O!H&G::JTX'-UOG*76IO"NVL8Z,Y9K@RG8M9!8'21A(=-
M0Y"K!N83$$!/L \. ZJK08;U!:-JN_'MDDVIT06(<JRA#!W9P.50H[[#N41W
M#<=@U! W'%1EKWU.Q;)<A2&5'8H;;<P[@ !Q]GAJ*G^LI[-_(WX%+GR8*1ZQ
M2\QNY50$IA$X@;RC!L4/& #J>MLJIQ&!IX@I-$U%ANN\79H**JG,7F731.84
M2\X =3O"F$1'<!#P[ZH=&'BCJE5,.-20#X%3[VG1+\%FS^-CG2(&W!-5LFH0
MVQA\L=RB&^YNW6/V8:ZC*J2YIP(!"MQ=\$UR2J4^TK<)&PTM,QB\;Z0:$!'D
M(Y,4HF-ML0>[Y-]MNWV]98!+:$JAA;FJ0K05O!M]J-:BX6/M4'(H1,<BS4,[
M9/T5W*R! 3,;G(!DRB;EWX<!\&K/8C<3XU?[=U%15NQQD1TG'*%9P+PC22CW
MZQ4)-5!<R;%?OCIIE<%Y#JJ!P#P;ZJ;&VHY.^G;',*4QVJVELB[25)PJI3Y0
MQC<^Q&[MFZ,4!$-B@":A1\HP#JL,H<-BNU.6M%GKZFA9"6S5F*6)'R;%1E5F
M\"L1\W,399E)(*J@HIL)2*[J[ 3??8-9=J30BA6GN\W:8[%Z--9:Q$T1-$31
M$T1-$31%)+-_%R?_ ,"RG]Q+Z(%.]$5G.G7^3]@S_4]C/_,N%T4#8KQZ*4T1
M-$31$T1-$31$T1>7SUH1S$ZL;1R[B P55 =@[/[Q,OPAK N?G^+XET%@*6P\
M*UUBYV$![M0H &P[%$1$?9\6L99YI7G7V!TD8?V7L\Q! /?'2M-A4=[:OH5R
MF4P&[S?81V#M =M^&WBU67U;E4KZ^<$$N_. "&X^ O:(CQ#PAJA#SKHJNRB8
M4D1 RO@$H[@'@X]NB<V]11:FYA4<&YS#QY0_)#AV!HH[ZF.X% "CN ;!L&JF
M@U5;2 #7%<TS%$0YB^U[_#?V=]0=I6/)7$A=P"$-Q$@;]@>3^(-0%8J5P4;D
M,/, <H!MOM[?X=3@K^[P+X&;!N(E.)0V]D=M_%Q[=%*BFW7.<")F.8PAMY("
M(!O[._ -04KE*[Q(=P8/SIC#L;FVWW#W/:U(3/RJ9IM3)   0 \D0#;B/MCX
M1'564)@NR5,YN&QN!=]P* CP]CM'5)P-$[R[": +"0A2'.J8X 5,B8B8QMP
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M(5CTU-E5125+V)=T8QC'$-C '*!@X;ZV&:(G:KPCDI17AKSJ..HCWR9S% 0
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MI>2 *<JT&]2G4'=:/E!S5:;:9J7@P*JFJ>073=( Y_MA+F3*JFH =T! Y1\
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M]C5#RUM*IGHNX6QQ1P$WG29> >3ORCP$/"/9N&H:]KCE&U,V*X$E$WR@E0<
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MS4;%F4G$HO$TYI  =*G AA$@"9,0+^;,9,/*$"AQV]K5ESG!E#6N*J$P=C7
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MNQ3\ ]G6=)#;F$2NC!?W<RQA+*X;Z55N9_J+N]HE&4O8W8RTLQ<L)!A()I.
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MU33 XC;LKWUKXJ/?N4C<=6]$:51-6+GFA[#'6!ZX*\(BJ,BQ1<N2?FP!9@(
MU23*J)2\W,(J<1#EVUSK=7TXX=LRIKX]I&.VGQX;5NQ87C#_ ';BVE<,<*<V
MQ7!F.KR-S#@2VT&>*UL)"OH]S29Q5F8DHE,M#?VZ[*<[8AFC8[50Q1X@4_#B
M/#6V]4O)]/&I10RFR(-'Y'4--NZJUTLL#9Q;/<T3T^;45QV=WP+#N36,_+!L
M4TR ;SEJ7G[1 H*@F8FX\1Y@'AQUA1R/ZH.\#D.!Y>3PJM[-M-@'=W_ O3)Z
MK1BDPZ8;8P #@5EFB0!/G$3&'>,KIAW'L[0W#5JX:[MPRG6 JKD1KWEIN]8Z
MT*KUBYO*"8+ %JB%0(8  J?>U>'$P%VXCN(CP\8ZQ(072$-VC-7P@J[)E;B5
MAO9&2"E-I K-$N51U:B<Y@( !W3]F [#X@$0X^SJY<!WJX%2.94-#2*JAE#L
MD2@F1!,#!L <I/*$W8.X\OAUA%CL222 *X&OQ5*NAH&*@F8BW,0J)>!#AR@F
M(F$1W$VP@40'@(]G;MMJ[%&\N$=3G() -=FU4OR[6KTMXY#O<&4$0#LZ:UF@
M!X1!.&;;![HAJH@U(.Y2WX"O/-(0SIY8K"Y0$1[A1N(%$P&[&:8B''LXAX];
M738GOB<X#JUHL.Y+62"OSJ577J]0DCVB%D#(?F$YF-,H<I2#RCYVGY0E$3#S
M")O%K8RV$CHG"AJ!7P*S'(TN%=IV+W">I.0!O=<U@'[-%L8> !^S:;"(;!L(
M[ZXVY&\?-K3Q$K9OKA7D'Q+T2ZQ%0FB)HB:(FB)HB:(I)9?XN3_^!I3^XE]$
M4[T16<Z=?Y/V#/\ 4]C/_,N%T4#8KQZ*4T1-$31$T1-$31$'L'1%HJZ\XT'F
M>9TXAQ"*@.4=@$-RQ#8./AVVU@R_/6TLY,L="L&EX0.3@!1W#B($V$>P.T=P
MWU;=\Y9M:BHV*1.(78>(<H<?RR\1]T. AJIKLNQ 2%+!A=AW$ V]L-OO:GM'
M<RFJ^1X<#!OR#MV!L( /N>3MIVCN0)O7S&* /*%(>7<=O=XAX/VNK5#N3:4)
M$ <=@2$-Q'VNP-]^'@[=*%-F]?<((O@2X["("(;EX!XN ZFBBI7>0KQCE 0(
M'@XB4/8#<1Y=]5Y^KE-**'DY#WE-4ZP(F IA( <=M@X<-N'MCJ&QM?RK$%2I
MPVK*(; <@#V; *9=Q\0;\HF'5!8!LJE#6NY5_5L33=K=$:0L.+@3B)C*B3E3
M(4 \H1./*&Q"EW'?8  ?8UE06SY69F#"JM/F;&:. )ISK)C'O3Y7.\7*6-4O
MDXQ,07,=%=RE 1AMC&,$M/N>5BV('((F!(%S^2(<!UG>J1C&:@8/C5E\KGC*
MVM:J^8V>CTM^A""Z4L\]W!"H8LQFDLQAVJP% G<SMA3[E]*'1VY51,*28[>+
M5I]Q&3V5L!AW<J@0R.I7>JL<1>0+@U1<9!L[?%-'2,95*BTTP)N5F28<ZS=Y
M(I@5-+=$O,(E%0^ZG$P#N.L*8N8/WCC59+0R-AWY15:_LU>L7Q%A9:<Q[TY4
M0ELN<<LO%S4^J@I&1+600.5,3R<P?FE)I0NQM^4>43\-S .N4U/B6"R>8[4"
M28'$<A\!"\LXL]ZFG\/E]I:!LU\RH<UV :[FQ',M ><>H:YWFU2EDZA,NN'C
M(RY'3"IM':P13)42 *0,H5L<6Y5$RB8"G,!C<=]RCOKFY-1U'57 1N -?F\G
MC7BNJ\2\1<5'J]H8W5HT5#17O5KLY0L!LA=9U7D)@T32*VM)2$5SH-I:?_-@
MEL  15LD(',8=RE$.'@[=76Z?=/<T7KOW8K7PA9MEP==,@;/?N>6Y2: T  &
MS&IKT+$NVWB\W(DI,7IZ64<MI!NE$.2&[M*.BUA5,+5!']BF=<V_'CN77W?_
M "Q-@L^!=2;'B(]1!QY'1P@GOX8+;Q:;8VNHLM[-I[,P9S4UQQ^##H5/5H4)
M$JJW?G2;B4?..1;DY0((@;9,=P.;R=]MN.OJ3AY[+F.2Y!-784!HUN[$<ZLZ
MN#:RMBRMS[L-M:&E>;;X%MXZ&>NW'6((1YC"0[MW8HU01:K+G4%NS9N%-D$G
M12E "&.!BCP$0 >'LZ_/_P![MN_1_>)JDKH.RL9+EQ:0[,"7&KG5/*:FF[8N
M^X5U.2QL,MPPT=^E3 XX>(+?#@C-$[D.^8VDV,T=M%/K172]Q&*B5%5,\RS(
MJDIL/E$$H[;"&N"9(Y[<I=F%:CO+TIDK)6M>QX=5@PY%ZK"\0 ?&&_BU4KJC
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB@.^P[=NP[?T<-$7BX_G+N:)S&_4Y@R
M)BX=!\#W H2 NW+L&[= YL@6]H*9B\ACFV\VYM]^P=8MQ>-MP&E9]FP.S5KA
M3Y5Y?YGK&R S.=)2RU:NE*("4$BH.E2@'8!15(H;P;#PU@&Y=+C'$23O[N59
MK;@-);R&BM-9^LZV.$ETU<G33PPIB(I1)01(8PA^244RH[;:N-@N7]8MR\WR
MK%ENVM-1M6,MDR[/7I=-,[6W6%P94 (9Q(2"G>F,<#;"B@J<NPAP  #L\>KP
MCR?/VJSVTDWS2LG^G7IJSSD1>;2:8[E(..FFC%-H\D$'293NT7Z2Y5#BH4YA
M A -L/#5P2-:,@WI''-(ZCB<JW#89]4/D>Z-!+>W()Q+XS-=T59%PS;%5:[+
M('*XW 2\JA0WV =]1%;2L-1577]C'M+B/!T+;CA[U9_3]B]9LZ<5Z-L4T4R0
MJGCV J+J*$.BJ7GD70G6*)#I;;IAPYM;$0O'6<L;-$^O(MA].P:SA03&MUJ!
MI#$I2%\\.S*XE!(F0P%,9T[(98JA-QVY>4-Q\.LUC 0K=:5H=BN*SH5>;+"H
MJF_M$F F$RZQE3H;G$.8.[((\A!-Q#B <>S50:,V"MDDC%5JE7W*:1?/%&46
M@F &!NGR=\4-NT2%(0O/[NJR<H4 KL-6C<%"IQ,:=ZX#\M^Z#=N40X")N\,9
M(G']J ZM,D!";\5.#L% %,95\+TV_D,F1>1),W['F5 2[[&[.4-M6S(:X4HE
M2JI1[Q5BHFLX"/:\H F@4H@H80VW,903 H/';PZI<\N%#2BCXU3YG3<500CV
M@2#H!'\\=,#D(<=@YMC 8#"F ;\=^&K@)RGNW*1ABNHYKS!V0OQI5)(E*<5@
M9@H8$Q$H\_!$ODB8A@X!L/N:AKP!UE7\X54LD8R4GT2L8M8]>A&ZA3*+)E(W
M.L4@ )#*"!>8$]Q'@ CV=GBJ<W.TEI./.J*4QWJ-CF7#UBHQCU//9!$4BEF%
MR 0C(4P*1(68%VW%/;<> "(]N^K&0E_9DFI5;:4RD855!%Q7#R\]#W"[N'M@
M=P$6+-NI,B@*3HW.HZ#S=D='E-W9U.5,!WV'59><G9O>0T85*K(8'=52=A4<
M=Y <R"]\J+=2);%5'OUFQ$W3U$I12'O3D AN[Y VV$?R>'9PU>=+<BW[&)P<
MQ6V@5)WJPDWC3I4I<Q*.\5XOJ[&W*I.4C239N5&0=*+B)%R+K$YC&4,4X[\=
MM]66MD:WK;%>8QKL.94%,X496C'2-/M:1V3BS2@K^81?>-D&[$>_+YNN1,4U
M5FS@JH=Z #N8!$.S65'#;N9GNHS(T_ J7G*0QF!"VG>K$Q3'XCA<JUR*@&<2
MQ[O'8IR#- K<LNHDC<14_,@(F*FQ!8I2\PB81.(ZULS&,D(B;ECW!)#4"OSA
M_0MI^K2M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(L*O6,G%/H;ZGSAN.V([
M/P+MN(^;%\(B :;56SYP7YLMBK%DR/$I4^N-D#3<TR33CROW*#)H!FSA5RX,
ML[.<$D"@BB;83"4-_'JZ"7N#&;5D.95I<3L"IF#Z!.K%R\@D!H$*S+9U^XK[
MB3R!3HYJ_.")G'."CJ5(5(BB9/)$XEW'8.W?6W-I<10B3:.=:]LC7$\BV6=*
MGJ1.L;J F;%&'+B^CDK3=HL\>6&[)R[643>+*H&3AGE-C["@95HLCLL10R?+
MS%V$V_#(]<AC:WUEM6YMWA5#HL[J[E<GKJ]4AGOI#Z3;++7N5QW,E3BT(M,U
M+E;++RI3R$D" .BLG5:8)JHI"L'.7GYMNS?LUT%OK%M/ISH((@ UU:^&M5AR
MVY[0D5VA:TZ=<XY[79UTWKC4S:DU&-@KB_=2J+-*!$4FL>A)S  @IY@W<KD
M"]YMN80#@/89J=N^WKAG!HH,+]FU??'N(;!U#7VDXUHR-=:R%V2=.8R94F57
M<7Z,;D%1Y+$,R9*+.FC02 0PD -SF  UJKH-R.-,*+)@!/5*RPQ]ZO7-F++'
MD0I_BY/3%:4;NT6;==\D#]%Q#NQ[E'G;"<JRS0ACI[B #V#MJWIUPW&V/SW'
M!5/BJ\.;L"V;=$V.)['/3G)0=A:"P?O[7,32#8>\W29O4VYD>?G22$3;%X\
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M<L]B6)$SQ2!$4T$F8J(/EVCQ8JBI#E#\V(#QW'5K3]3GM;6@^89,:\G,K5_
MSUK*2<P8LB*UZE;$K:6LL/(66P M63R;I)1KRBB9:(;N'R!>^.@0RA-VQ2F'
ME#@/NZ[:XUSL[ /: <[!C3E\*U,$+FS #=7:LA?4QH"TR+FYJ/, )HE3+OX0
M1=-T@$?; NN N7B2-L@&+B2MP75PWKT,:PE2FB)HB:(FB)HB:(I'9OXMS_\
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M3+&X?U=B]AG0)TX=1F&;OC^LY 5;.&$19:RY3;PYRR0BF>89'447<HN#@4A
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MBU<5\+B#ULG(T_.;OJ%>PV/X)HU:2,M8Q>M5T&KA$A2 @F)'!/S9B"<_=D3
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M%\Q>>KJJJN';%ZP%[!9FM<72ZO/X=Q\3T[()QBJS549-J19TR1E';1!R=HW
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M9UA3?.6WL6?NR5ATX9;&W H>$N_$.S?L'5O;MVK.;E%0]2Y5GRAL)0V#?8>
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MUK['=>BD\U/]V<*_>>G_ ,1#YZA])&//EW3_ )RPWZ9J?8>M?8[KT4GFJ/\
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M)A58Z.7;I><>:N5@3>+-@,*8NDV:)@6.U X<O,/#FX;]NM&;*=D?;NCD-J7
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M5"Q;(VZ"4D7C-I76JB92-52L "3<-ED2"J=5F'=)))_L>)AX@'#?7CE[[U)
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MI*B4YS&(( 41Y.S5F\G9 W$YG<@6;%&T- WKSY9!N62,NVQS>;:]5L,[*.E
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MSM?3FSPVZ#*C(&5A<S388FT$734EH))JH=R";!([!<?,W2A!*N(B3R>',(B
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MS8<I@'CV\-?7'!C;'4=#GL#*UEVQ[JU-'.ZH&?O&E =]%YKJ N+>^;<ACG1
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M&2G)(G-6FSY0Y.^%$I 2Y50W-N<-S (; (>'K=5XWDUS4C?:O*9+^2C7.W
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MWJM:KUU5B(1QTUJ<O>(E+'K!TQK[:G4IK&I^DG#E4QQ>)MW!CNF*;H$S%4$
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M$1$1U+B7FKS4CEQV;/$J6,9&"(P&@DDT%,3B3X3M78V#Q!P[/8U"J4=$31%
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MHLT^BBTS_2QDBM2]AI=6R?7W#0A3QUQH+5=Y)-V\KSJK-FTLHFFW.*;8Q""
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MM-$31$T1-$31$T122R_Q=GO\#2?]Q+:(%.]$5G.G;^3_ (,'QX>QG_F7"Z*
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M,Z<?+-V?,91(8YTY[Q+SEL5,##S  &)N <1WURGO$DL[F^BFNQFL62 4YZ'
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M/:)&HSR4LI=XQRJ\DIAA)M!>&AC(-I!Q'IQ\>JL1/F #*#R!V<=6PYF7*T[
M JW !YQ!Q6/$%!5^6D9-E\9/1JC10.\.99'<JQ53)BV)WPD+^: P^3N(@ :L
MGK5:-I5)PP7I(]2[%IP>,L^,V\MZ4(:PQ2@+@1$HE*6$ H <43F*?FWX:RXA
M1I)W(17$+%WUY;,'5BZ<%E>[[IQC^ZH<RO @*IR$.<ACCQX%'L]D=])J5:#M
M=L4# 5W+1?5*3**UMX*TLP3*9RF1J"CX.[00X*#W0"'YL%#]I0V]G5<-JY\5
M7$5!W%67ESG@C8KT60EZL#VJ*R*K-JQBX5C%>CXM^J@G+,T><A@="Q70V*X
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MYB_'VUH#L!/)V$4AU]>_RV0L?HNIO<YK:7$6T@?H.Y5YEQS"^:]AR-<?W9V
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M*1>7?;R0'EW !#CP\>LJ/J@JB,U-"LP/5OL$F]VR"X(F(&7B40$XAV\KA#<
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MY>LZM?"M9T'F$[Z+M6+%^0T X5NC1@\6,J9ZWF(R0<F:"DH)^[*F!3"4  G
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MOF%&D95?A> ZM:+&J4QP[F(U-CW9#.X]4@-S@*J:B)05*!EA4Y>=,$BCN/8
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MG5I4J5R?\V$]9ZZ)'K(M<"B\;F S@#98,!1X%#R3?%?RP#8>W4@ 8C:HS--
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MBD:PU*K!I_-V/60M 4<I-\+)/N^4,DJEE(Y2<@CNF42?%SEY2 ' !#55MV<
MIB33NWJW+)G=LP5N)W^;:^M G)1:25;X($1X)E-E<YC  !VCO5Q#<1'60;AF
MP55L&FY6EG_YKUZTZ:54,+? '*;<"<V6U X )AXA\51#?8=6S*PG:?$JLV&Q
M6J>_S4'UJZJIU$673R.YBB &S J7L  W\FIAVB&^HSQ\I5+3E*F<)_-9O6^U
MYRFYC2=.Z9DQW*0^95SDW]@!IXB&L9[&2;5=9,YNY96T_P!07ZYFLQIV"D=T
MX' Z*B2AR9>%3F*8![ 6J)1_V=8CK0$X.ICR*Z+M[7$TP/.O0=ZAKU>O5KT&
MQ_56'58VQXWD,NSN)9&F_$"UFM*)FU19Y%2G?2:@Q,4#-4JME:]T  <% $P[
MAR\<IC0QN4*S)(9#F*]!VJE;31$T1-$31$T1-$31$T1-$31$T1-$31$T182^
ML=KSJU]#G4[6V4D,.ZF<2V9@C)\QB@S.X;E)WQA*(;%*7??<0#8=5,C;(X-=
M@"I#LO6WK\\2O=,-,C&\>E:[H$JM'H$3[F/[]NB<Z8GYU0;MEB<HJ&-QXB4=
M9D>F6S2TO.8 ]Y98E+F[:*[,+C?#<";=M7SR2VP )UA5YC"!0#<PJ+J*@ B&
MX<HAK*;!;,J !2M5;<_.:@D!5ZF[CF38 @JLPC]R 4H@EWRY.43  <RHBH [
M  [CN/LZNY0<&4JJ3R.<2.\J9=M[;(+B*2;@R1@V B*"10#<  1#D(0^X=OL
MZJ[)^SI4'* :5JOFA0;*Y[TR\:[4%0>)E4S\P< W\DIPV !]C58MWG](*UF=
MO7)OBI\T< [,T6$X&*8 ,V,?D,';R&V,8N^VKC;-N!)%5!)Y55Z-?GD>X.5%
MSNVY.'<+%YTP "[?D> I=7NQ#3U:(*@U65N)GKR-.@50O]IO0 %BB40,BJ)B
M>5L8-_#MH YH_1/A4GK&BSJJ:ZX"WV(*@"3R-]B@)1]D^Q1#5!J?ZOC5QG5\
M"R&A6RRI4Q5(FB7E*(%,JES;^'<.\VW'3K#;E\:B5S7%5:=-JDGY8@H(!P*4
MR8_[K]D/@VU322N!;3OJS7K8; J'E#M.]4$Y! .'*!N <-]Q#V]6Y#(*4IX"
MLR DC %=J"?MR+ 8A>4  P;F,4H#Q[0YC &K)SN/6"NRM>\55<-Y%(XE\M+Q
M@'.GP'V=C#JQ(*'#<L8M>-OP*=(R!#"4!,3?CP Q-AV';;?F$0W]K5&5Q%?E
M5W,TMH:A5 FNGR@83I]@;E$Y>8!X<. CJL @8[5BO #L-BZ;IVV !#OTR%#B
M(=X381X@'[,1$1]O4?.P"K9M.;D4A7D&P$Y>^ >7B4 $! PB(]AM]O#J,E%<
M.6FT^)4\M+-RB;?M$VPB([AVCQX".W9JGJJGJJ2K6! .8A3E   =QW#L[-^/
MLZJ#3M"<XV*EI&>; !A.X1X]G,H #MS!N/A[-]02:Y2KD8&)6P7U<DDF^M5V
M ARGY8D@^2.X;&=(CN&^P]H[:LW)!:.7#XE$P!ZRVYZPECIHB:(FB)HB:(FB
M*26;A7)\?_W+*?W$OH@4[T16<Z=OY/V#/]3V,_\ ,N%T.U0-BO'HI31$T1-$
M31$T1-$4!X@(>,![0W#L\(<-]$6+&4>A_H]S=:WEZS%TQ8-R=<Y!!FV?6B\X
MUJ=FGG:$>@1JQ07E):,<NU4FC9,I$P$VQ2@ !JX+FYC&6-[PWD!P^-*-Y,5;
MHWJP?5S\H\W0[TM<NW'?"=!'@''B 0?'CJ#-,[%SG$\Y4K@'JQO5RAL =$'2
MT(".P;83H8AQ 1_>,0V$ U(FG_1>X#OJ#11-ZL/U<X;&-T/]+6Q=A#?"=#';
MQ"']XQXAOX-2;BYW2/KWSNQ0 4KBJF@O5\]"M9>A(USI&Z>(-^"9$@?16**<
MQ<@FFJ19-/O4(A-3D362*8 WV 0 ?%K)&IZD"7=O-4BAZ[L1R''%6G0PN.+6
MDGF573O1STF6A-1.Q=.F&9U)40[Y.3Q]6GI3F2.82\Y%8\Y3"501[>P?9U?=
MK^N.;V9O+DQ\G:O\Y/5XOZHJI#&]"'13$F45BNE? ; ZP;*&98PJ: G  V\O
MNHHHF H< WU2W6]9 H+NY'_['^<GJ\-?F-\2ESOU>70C(*)'?=(/3J[.@)S(
MF<8EIBPI"<XJ',03PX\AC*&$>':(ZH=J^J/(+KF<D?VW=*&"&E,K:=X*>MNA
MKHT:)@DTZ7\%()  %!-#&E43)RD#8"\I(P V+MXN&KS=?UQ@HV\N1_\ M?TJ
M@VEN=K&D=ZH17H;Z,U0 %NE[!2@> #XSJI_!V[#%Z'7=<=MO+GTC_.3U2U&R
M*/R1T*6_^ 3H? RBH=)O3YSK!RJG+BNH<ZA1#;90P1.Y@Y1\.J/;6L4H;JX(
M_P Q_2JO5X-F1OB7S2Z ^AMLF5!+I+Z>DD@.)R)$Q33RI@??<3% (C;FW'M[
M>.H&LZN-EU< ?YCNE3V,(PRCQ+HO/5U=!;Y/NGO1YTXN4AY]DW&(J4LF(J;&
M4'D/#B',H(!OX1'4'6=6.)NKCTC^E2((OZK?$%,$O5_=#B*2;9'I)Z>TT$0*
M"2)<4T\J:8$  )R$"(Y0Y [-NS4C6M8 IZW<4_S']*=A#_5;X@I:\]7-T#OU
M>_?]'/3>[5X&YW.(:4N?F*   [GB##N !MJ#K.KFG_57'I']*@00T^:WQ!<E
M_5T=!#I-%)ST=]."R:'+W!5L0TA0J?*'*3NN>''EV#@&VJ3JVJN^=<SG_P#8
M_I4]C#MRM\073=^K=]7V[%0SSHQZ:'(K(E05%?#='5%5 H%Y$CB>%,)TR[!L
M4> ;:H?J.H2#+)/,YO.]Q^52(HP:Y1X@I<AZL7U<[,WG#?HAZ6FYRAS=ZEA2
MA$. ;=HF+" ._'5IMW=L^9+(.\XCY5)CB=M:#X NRZ]6?ZO%^B=NZZ*.F)TW
M4$HG26PO15$SF)N)1,0T((&,3?AOV;\-3)>WDC,DDLCF\A<2/A*AL4334-:#
MW@O@?U8_J[5")IGZ(^EY0B(<A"FPM0S$3* < (483E H>+LU3ZU="@[1].^>
ME!'%^B!X@LA*5TZ8&QS7HZJ4+#N-J=6HI,R4;!5JGP4-%,4SG%0Q6K%@S1;H
M@<YA$>4O$1U;,DKOG.)\)564# #!5DCCB@MUDW"%,K**R1BJ)JIP[$JA#D,4
MY#E," "4Q#D 0'P" #J,SCA4T2@5:@&P  !L < #Q ' /N:A2HZ(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FA1<>4 X@4. <    =@[ #L#48[]B';7>NL]>LHU
MDYD)%RW8,&2"CIX\=K)MVK1LB45%G#APJ8J2**) $QCF$"E !$1VTH-N]%8A
M+JBP<_H$9DZ$NWQDIL[/SU9KS^JUZT69]9)FKRLK"S[:NP,)"OK!.I1C^$=
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MZL9PIYP1&%@E)Q)J\42+W;99RW%(XI"<%P05*H!.40-H,5)Y-ZZ]?ZE,2.*
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M/LF4O'\,P@OC++J,_BS(Y2D995PH[<'=NC=V ()%1!(E#M'=W%6_RITOJ56
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M72<B6%.JTQM6S=RR?6O(\3%H0K8ZAS'02*\=E,JNFD(BHKO.U7O4ZC[E(/\
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MHO(F=BY"%E&@*KH"ZC95JJQ?M^_;*HN416:KG+SIG*H7?<I@'8=-FQ"K.2&
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MBI)1)F?F$I-7.\623;DCJQ8Z='(E?V*QR;LS6.K-KD&;9(3"F@FY,*8%/RF
MG>VJD:_TQ(L[9<[8]<0T'(NL<,,+8V>4N-<-I*BXP8&7540])3KF44D;/*G4
M3!5V8A4TBM4@(3<5#*35%D_5Z]&5. AJQ!M08PE>B8Z$B&8"8Q6L=%MDV3)
MIC>4?NFR)0$P^48=Q'B(ZC!%4&B)HB:(FB)HB:(FB)HB:(FB*1V<0"MV#?\
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M^4^2OUF7;X:T1/HLA_E-DK]9=U^&M$3Z+(?Y3Y+_ %F7;X:T1/HLA_E/DO\
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MT#UO40/9A20^>*'P#J3[A]7^UP?M>:@_G.X;<*C2+WRHO/0?6]1(=N%) /\
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M/SH<-4K[(O:?K1>>H!ZWR(^I60^>*'X(#4'W#ZQNNX/VO-0?SH<,G_2;T?\
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M_P#/)O\ >] ZG\!]7^UP?M>:H/\ .=PX/](O?*B\]<?M?(CZE9#YXH? .I_
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MQ'U*R'SQ0^ =2/<-K&^[@_:\U#_.APT/](O?*C\]!];W$AP'"LA\\6_P!I^
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MVIL0!$-*)4IS&\8^^.E E2F^B8\I4>WCMP\/X-N/BTYD\=%  $>P!'V@WTJ
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M& "F4CTCY22F:3%Q#ZCVQA?9AQ7(&U5.THS-8&PM4^]<PTA()M4G$>^3(&X
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MP60]UZ?:4SFNG\Z.('M5N%^O#R"F\3.\@#*5^6ATD0]'2!;_ !T?(-H19^Y
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M'"VYN'7,/:1]DP/+F@-)%,PHYN85!V8J-+]R'&>H-O7W+[&R;I]R()C=2NB
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M/-/O;&YETPW43(H)'MN##6/J9@71@N:7EKFFC3DS4VTQ73Z3[E]=T7B"Q;Q
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MYXS;3A6AKM*KJY]5+&TNXAR6FNFH1G4:[SR8/3**HKMG;E%V-<,(1PB#A$4
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M\"KGFE<,*';5<CQ][P>%[[A2VX*X'LKRPX9COGW<O;/8^6:9]&THQSVB-@&
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M[1,TM< ZAV-K0X8T5\HSJSJ=12Q/ TG&TVRJ>-<J)Y7<HV2Z_&*P3<T2-6B
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M-SB'@T%7O(8>2H(*^;??'JMAJGO-UO5=,_?V$EPQC<A:6N:R)C7EA)!+@YM
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M*^K7/HG^:@P\G^][_P#<:_\ 6ZD7EGOE9Y3>E1[-U+[-<^B?YJAZ'D_WO?\
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M9KGT3^A1]#R@_P#PY_OXQ9K?@ =/7+/Z5GE-Z4]EZD-EM<>B?T)Z&D_WO?\
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MGT3^A<?0TG^]\A^XUOZW4^N67TK/*;TI[-U/[-<^B?YJ>AI/][W_ .XUA_\
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M'25>BTW5HY!=,@N>U:.K^[>.\-BYGBY=4PJ*L9(ZAAW,HHU7,<_@ 3B)=]P
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M[,U/[-<^B?T* PLF'_P]_P#N-;\6@O;(_P"*SRF]*'3-3'_BW/HG]">AI/\
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MGY.P7\$1_P"CZCVA?_3S>6[I3V/I/V6W]&SS5#XK5CY.0/\ !$?^CZGVA?\
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M\MW2J"WAMNV"WK_E,\U=-7UDO06B.RMJC2>+>B.?N;Q8;ZR1HO%#^LU\M/\
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MZ-GFI\5ZS\G8+^"(_P#1]/:%_P#3S>6[I3V/I/V6W]&SS4^*U9^3L%_!$?\
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M!=Q!PV'\L.8"@'L%$-@ ?<U:C$L3B<X(KR8CX?D69ZQGP(%.\I>XJT0<3 #
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M8HB0O[8PF[4=MMQUEBXE&#0?&%KP:[%-F^*('<H)R7,43;;"F0H<.W8#)AS
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MWA=BX8<QZ$_V[<N?D<'5.W$4JK&R^5,4GG%XMW(2U4/NAW#E_'O',>8%DP$
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M? J@CX^2:J]X3R>;<!#G V_'<-P*/B#PZL-N+?-0D>(]"C)<-._QJ?$"0,
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M5VL>6I;FYC@/'CW]BP#8ZPR0]I<N#*FK0RC=_*[ #=XET9NVQ9C11FF.ZO\
MFHIJ8H*D>/2#N( 3F,=02<R>PCL([ZK+HLM# VOZQ\U7(--G?5TEQ*[']$4'
M>W_&I$-AD7!D5VM<JC?G$3 W1KC)R4>4XAL<BI7(\>7]D4=0'9<0L\6%N6]:
M2X<?[3@/@+?E4Z).7Q6-44CFB3 _G*0D(QJK%N9/D35$H *;% 0)RCL ;&#;
MQ:MN>7;*56O-CIT5Z'2&/+3])P+MF_9\2[3F<S89DQ,U7MJ"R9'.XM&+UJ4
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MI?@33,6D=\9?E5,34#C1F0Y$[_+/^=,H'395(S?NQ[D"[CYW*( 0IM]QVXB
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MB=;E[WMS M+S05(QS/Q.'(0L@6MKZRYF.20<YSL:C)TNJU5CYBVJB@X,0A#
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M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%([-_%N?\
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MP;BXD8\Q)5R"WN;*;_IH+=A>*$M :2 -ARTPYMBK%"=A6#9FU;7K(K!NFS:
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M8PBIB"QOBS'E#AK"<QYZ*I]-KU<CILQD#M/[[LXF/:MY$I6B@I "Q3%!(1(
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M,E7 -&SB2B#KN0.J)S ":#@RA@()A#AN/#7GO%NEZ1J#NTN+QD3N2K?E7K/
M/$6O:2TP:?82SQN=6N5Q\5%@EGR3Q+AB;>)TM!'-\=%D;**R#.<<-(F406:%
M6=-P<M6ZJB#IJ8>0>.PF*.VO)3INCPZJV!DK;F#])U0T_ 0O?+;7.)KS1I+I
MS/4YV@D-<WO_ -96LJ.5L8Y1CQ=)](UO*,<N*7?P5WD3I+N5$TQ7 3*I 5,Q
MQ !Y1[ UW,.C:'=MRV5I-)0;G24\%'4\2\WU'C_B?0W WEW$PO)Q+6;  :C#
M':KL$:X^=-'2<5TR9B:2W=)K-3!;&#EJV.!1+S+)"W,LH0W+MX]QU?=PAH\S
M");&?M ,*NE\Y8<7OJUJ"4AVI6I8*4!:P'P8*ZV.U,"0,>LIGV@7B@1[A<7%
M=;%DS)K2\L@02N"G6(D/*DFW/S#OPX[AOK07W#_#FC%LVH6<_JQ;4]:2M2-F
MWE(75:)[R.,.,));;AZ>.6ZA:7.HQA%!O%!L^15<E-]-5@2))5K!&;)V!*(M
MV$M#6Z/.W>)HF%,QDDU&IU0V,7R@'B [!K/L^%^$]4M1=6]A=93A@Z2GP'G6
MHUGWJ\9<.W?J>K7=K#.&@D.:P;:\O>7R,^P41-?S?IQZC2N^X7!KSV%HJ@DL
M)#"BLJ1-H'.F0W$0WX[:ONX*T.E&6=WF[[_E)6!%[]-=:<=0LJ?JQ]"F6/PZ
M=#/VP9C^D'%40X*8603:J:*\TY03*4[9@L<IN7NRGW/R]@;#X=<UJ7#FD:6_
MM;R&XCM'4&+G@\^^GP+K-']YO$O$>=FERVUS?LCS$-:T[#0#!7*E7O16NNB2
M!9]0$U#H'613F:PTC)N-77*J8JR/G(' P*IG#82F .WPZR;3AKA#4;<S6[+Q
MS0:8.)^.JJU7WI<7\.3^J:QZC#+0$![:&A%?ZP4M!ST<<PB>/ZH2AW@)B0M7
MBS"01*&P?V0HCMRZN#@SALFO87U.[E:M;^.VKAN$NFEW>_\ SJI0T/@EU/.4
M8=?+<-5R(H$&Q72&2C48]'E2!TH[[LXM2<ITP NYN(;ZTVL<':;#$Y]JR>@'
MZ=/D:%N]-]\FIZC=LM6>KR3EQ&5F8D]X9BK^%I'0["11%5<RY(LTLX236?LZ
M?$QLVL@!3E57.WC4%CN%&Z8%$><0V ./'6#H6B<+:BQEJ^>Y]IY"7,8&D-RC
M$#JDX+:ZS[Q.-M*:Z]N-/CCL&EO7DS#;O-7 ;2!3E*D3=AT"\FRV6>HA$X<A
M.0^+C&Y3;"7;B8!\H#<-;U_!/"SB.U=?8[*L-:=YK!4+2'WZ:Z\ B'3SAAB=
MGI%V0B>A$Y'KEAECJ$6D 05*S:J8L42246(4.Z24.!1%--4Q0 QN.P#OJ#P7
MPK&0(I+H/Y2QP^!S49[Z]=+:R6]F,?T7U/\ _L*Q_FE\4-)=.*-.7Q!N1DU>
M-RNH%B1PHD\=+[*K(O#HJ)@ I[  !K@>(])M]/G$5NYYJ<*M_H"]2X0XKU?B
M6Q?>Q,BS,?E(S;J./]8\G*NF#;%K@$RH6JX&,91$ (>OQ(%/RB(%(.SGL A=
M<G<6X%'.<<2N^BO-4RAPB94_VAYRO=1(_IA%AYI;G>3W\WYV/F:<+'!^=;G4
M* "=%MYPBENOY/E<>.VVO1^"M&X7U*S>_6NW,S'Y0&NH"* ^/'<O%_>-[Q^+
MN&-2]6MG01P&(.HYH<14D$ X@[*XUVJOG.0^BA"&695S%^0'<N"JC>84FY5V
MP,X.U65((K)$=)II&(L4P>24 X:VU]-[K;")UO#:3OO03F&>3P;"-N*HTMOO
MEU>"&_==00VDS0X4B9L/_+N'QJ4X:^BK).6TX%+&+<:>=A)N!BW,E(NEUACV
M*SI(JLHHX &Q]B<"<P"(AP[0UQ]I'H^LZZVWLHGVUF6GJDG^K7](D^/'E6RX
MTUGB'@W@Z35[F][?46O#2&L9](&5 R[<<=VVE%75URUAW'-R?5.'Z<J*U29M
MVRB:UFE)9T$L<YBIK^;)NU%VO<HG$1(;F #&#8 \&NBNN'H-/':-%1F: ';2
M"0*X=U5X3H7O.XKXENNRGNW01_JM!\1:JRG,Q1,1$P+F HM/K3"21=+F ](;
M 9! C=!5-4AW+=0Q03%<3?MC$ !]@?0X^$M.CL77(&QA-#3DJO/V^\#6[O41
M;^L/IVM"02*BIKL6(V0/6+S-5QAF=U5WJ$G:Z%CUC/F:%BHV!2BE9.QQT20I
MA:,P)WSHBA3@!MS%(&^VJM'T[1#ITDC8 ;H@@UV4*V>M:EK3-7-JZZF=;L><
MH)K3:WX0?&M*=CZZ.HK,N0$%J)('HLY;7D6W>-X20.L1W,(-EFY'Q_.43]PV
M<)'V4*("F4>/#?6LT_18H-2,UMF$SS@!0 84H#MIX5T6M<07=_I<.FW)<8F-
M KR@ X'Q_ LK^B:J]:\5D61DU89\M5D).<:7:6EIIN1I,+2+,22!2(.SK _6
MWV$JR12\I3!L(!PUU]EHFMQ/DU/3I,C& AS7.:1RG G&O>*\MU%VG#+'^D3@
M5?*1Z,.E>IV(F0DJ,:4?TU^%MF(Q2PS#EDN[C2FE$8^3!!^99!JZ5;!Y0&*/
M+Q+KYGL_>?Q@=?A9=AATYTI:1V;=Q%?T=AYUN\C)+"D3R'4YEO3_ )M1DVI9
M-S!UT2U9QQ5L<&[C%:KJ,K2S]R"Y5I3( )*/G4@NNLX6,)#' W#^R"&W#7T9
MPY<27EQ/>/:6MEZP%* !QK1HW 5P'(K6G,<R$M<:D47K@UUJSTT1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T122S<*Y/CXH64'WF2^B!3O1%9SIV_D_P"#?]3V,_\
M,N%T4#:KQZ*4T1-$31$T1-$31$T1-$31$T1?F1>N+N.7:YZRSJ^0@>H/+E.C
M_I4=*QD#%V2WLH6-:GA(?D:1;=@\!BFV.83'Y2%*4#&$=MP,(ZVZ,[9!1QHM
M<Z2 3%CV]9:_F65NKQ:X%@:IU5YB!7T$P?I-1O-U35$J;$7;M83+J^;["1/F
MX'$WW-6GW%S&RK7&OA4RLLAUI&BJF[7JGZSVY %MUF9>,)4Q.4QKQ;^!1*/#
M\XWV#;;5HWEX37,KHMK)S*NC%>97RQSU']:]CR_5ZK)=6N5Y.#=LXQ5PP^/4
M\==0ZK,7!C$*H4A $3<0\H!#5]ES=2%K>T<''Q+'=:V365,8 K\JV59-B>I8
MMEAHQKG?*:;$B;5R[(6\S*)'@*!SBF()*[GX&V[1X:R;N:ZMRP&0FI^!:V:2
MT8'-C8&NH<5*[O1<MN(B.!_E#):9%INO)&=DN$Z<QP.];E.AW2+]%0Q77, "
M.VVP:"5\Q'7)!I5<;%==E<N )=6O@4JR1ABZ2$"R06N.05R'E1[X4K9,E6Y2
MH+%!(W-([E+P >W5JX:*90XYEFZ;<MSD2$UZ42P!)?$U$JDI;G'< W[_ ,ZL
M<B*YP4<MTS%YUG2A=S<P[\=AU>M64CJ7NK185Y?!LY .\JJ4NFMP_9'4-YPJ
M)FB_,C(O".Q'\T7\V)A*.VX#MN''5B0N<<07*&:D"]M.561K'3^E!VF-4;5:
M,8N#>?$(JHU!9(3%9+J['*<!YRG-JB.U+GG*,N&U=2[4&.B:W!IIM"P>SNSA
MZ[G*#0L%/BY)P@Y=F%5@[?Q:/=&4. %\W;J)@!P. CN'#7$\6!T8RC*:C>,=
MB]S]U\+;NT[4O.#J>&JL!.W6R?21')D2JC>HR5M9P*<(_)Z2,S3<)I%75?E5
M,9\O') //N.X[<"]NM;8Z/9/TCUIHI.3OPP"Z?5]?U.UXE&@QOS6SJ C=UJ$
M+==TDX?J<Q"7!N69@Y1K$V55NRF:"V?P4.^!5HW5.4K1\@W='4;C^;$YP#<
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M,7BFTC:(%BXG6$A*PJ+N68MU)6+B6A)"4DHXBJY#/&$<P4*LNLF!DTD1 YA
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M@KL<!Y>(:(2 IP?+.,244,H'O].+C<8\LJ%]&R0X4\8T^W(^^,(O BO-3B(
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M%%>X, &#?L#<-5>IVHV_$C+F^A/7)IW_ .E5CC/!D6?/C26BMRM&_H9=%N9
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M*0%@_MM>=4DD.Y)&+ =/N#-D!#O"DX".^VP:^9_=+^\XNB<ZHZKMN[JE??\
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MK!F.;]T38O8U^?8-9C)-6B)"8>2TQ%SLD=E%P]CDZ](PT X457 B#V(6*<0
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MN'-R$GX%>51UFRE6>OJY"?SIE'L:T=150L*YF)%&IR]Q'F:-DA,@5%,"AR&
MG*  (=@:TFJR"]M^S<TGGYEOM$-OHMPV]=)2=N%!RU5[<QQ6&*%%5S(Z"T79
M,ARC@@6ROQ\Z#ES4Y#S8OF!G:B+%(KEN](F(&*10X%,  ;P:MVC9I=+;80U
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M3L,/A?U6_5.^D31CIM6KGES%62I]=&3[U,$7SR(8U^)C 3,!.8.7G HC^28
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MT5BSCTT6KKBXE D%#EZN))'AWU\"K>*Z#>K.7!LA =(_4+((*@FF#^QXAO\
M$*-S% OY;9:L!N4N^XB'M:U[K/40^L\=PQU=C6./R*J/5+N]#H8S;1PUI5W2
M' !9*XY]4)UGV@J+RT8VO579&,8 *E2;HR?II"<H=TJU<5H1Y4RE'E#?CL Z
MY[5M?FM&GU.PO)7#_P"%Y^)BUTMOIT%77D[I7NVAKA3X*K.J@>I_?5$1>2N/
M<SRTH< ,X=I4>> KU8AB"H9QO!F.9(VX@!0 HCMKS35.,N.;@%EII-Z(]@I:
MSGX0RBH;Q++IX[+2XLC1AF(Q(\*RJIW07-PQ5_1V%\AH'(JH9,5\?SC<YR".
MX%YG$1P,'(''V>&N1NM1]XEX,]Q8Z@#2@I:S>+YBP7ZK>S@ND< 7'&F]7 'I
M*RB87+8<0W%B@X'<@H4:P"8G*83'.JH6,_*4YA#?M'AX@UH!#QN7F0V&I5K]
MEN/-6&V7+L-#6NT[?&I:3I(N#9$S=QAO(C\H+EY0'']D.5-3F'99+^]8&!,H
M;\1$=M6C%QPQSG1V&H@NV_\ 2S_*Q0'XU&WOG?X5,672C<P RCC"M^ _> 0J
MA*)9"J@D4Y@3X!&;; 38>(#MK'['CWK4LM2Q)_\ &N-__(K,A=*,CR<H-1B1
MLV+[&Z3+CRGVPI?79=Q$ <T6;-N<.(<QCQ  4HD+MQ\.VL0VWO"S5%CJ5/\
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#(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2127058d1-fc_results4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_results4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ I@)V P$1  (1 0,1 ?_$ 1(    & P$!
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M\G%_0IEN'7R 8YC,=I_A'A_&C_">>8F(=7^FAN/T[.64[1J)NS0/R_J)@U[
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M/6B =.*N4FVZT*\_%?\ T 6YW3]FKC[^]F/>. :[_P"==-_4:GYJLN@::/\
MM2J.OUE4:'Y_!\&O'?Q[VE^2_G%<XR_O9?+*\P[@]X/=$>7#B,4A$7DKW((<
MK(2&$#" <BZ //T]GNCQ%20I2P5+)=1/JL2C)[K2B$HZZ:<P]8#]#CT%.<F;
MB'OX)XP+T>@B'+NXF9$0#(WW>3J4/%R"BZ1#7B00;E>(%$/;\WN\4F+0AKZ>
M?"MXH,1PL7U,XT'_ .%TW"?Y7X7_ -Z?!_'YHU$__LID/U27_!9E= H#_P"/
MZP_UH_.TU2]YFC8[WS'-Y#1(Q2J.]RN3&R9C?6 HXMKY%/K$=.DG6<.H>X.?
M'8/#W-1ROAQI-6K[V.G4?O M9U@=[KV;IG^GG]\4Z<QY3&=8*;0ILIFK9^RR
M4_1B31N*WNXRL1>0I!]/1[21@8A&#GV,(DA+32#U$J*:ZZ11,L30Q@XU&'C%
MI%3,3_ YKN(2(,Q2)B&)!)PO)K"S W6=/O+;U:P4YP=KG#N6Y7^T0ONVVK*>
M.L=V#)-SB$*^PJN=)[;K9*_)KJ-K5"Y-K-?2L4U'/(D6YD?86C502>.1<Q3+
M%,4 $  P[SI/B'H.K9RGI5%I5ZU,3C(#LF/0>>QV86<5\.8T?,9>C+,S+1B6
M(Z>I,%XN@#J AK]#Y_&X]YE>A8D/?8B!4O<(_0]7P<'>97H0 ><#T+(# ;F'
M8&OO#ISY]W+B282+T_>\O:J?S^XL@'ZFOJTT'3WN(D#(-%*4C$8N*D?M^VO9
M'W%A<Y&J/Z/4*5C9G$/\BY/RC<(NBXZI*-B>K1U;1GK!(BJJ1Y89!JJW9(-F
M[E=PJ ]*8E(<>-/W9O/3MI4H',XI5JCX8QB92EA9V%UCVDD 6.LQDM+^F FQ
MA>2S"^^WW+>'.DS/FV[)NVVRQE=R.V@W36RUQM<*3<J5/QUNH%\J;M9=LWLE
M2MD6J9C+10N6JB1A I%4EB"14A#<N/IVOO+3]U:=/.9(]J%DA(891-[2%X+$
M=!L(L+GYM4TO,Z?F!2D3:[-;YCU^;K4L,4^6'E3,5%)?:CGO9V$<TQS&95M4
M3+9_BF%DQY39%.,%:1R!$IPSL*P:&>R[=F^*NH!&[U4J0G$W&GZGXLZ-H^<E
MIV>T[.U<V*I@)=W)ID.V OV@8@F+"V(=9/);=S.<IN#%L+N96AVO#]+'IX*&
M.<,0O,&W=>B25ZQ=D1XA%L)4;#B&Z-+Y2U22 K #-.RM4&C0TDS!'5PD)2BB
M!B\QUXW30MRY76LB<]ELCF<JT7_"QE$D.S-(^7J6+J9&ME\[+*5"#$"^\>BW
ME>N?R7C]YB^TFJ<A8J7:G 0E8GB2]!LK6V5Y1"TUV-L;=D269I(HFDXA"3*W
M?H@&K9XFJB(B9,1'Z]+UP9^E/,M.$8&I9,89?@Y2B2W,<+Q/&)!55LI*B3$F
MT!_0_+I2_A?"ETSS;9*E4((H\Y$T2_9%=DF'QH]O]SF-:E+72SB@J1LY\=^$
M1#J^ AH45E!  'CQW'N+)Z%3RN<G8,S5IPL'&I,0'I(?F%JG(Y4YV1@+2 3Y
MK3Z/8D/&>/'F4+I%4B,L=-K+Z82D56\Y?;"VJ54;%BXAY+KC(3L@GT-/&08B
MD@7PS"JX.1(.9M>/JUK6HZ=E_I<8SE3[-D(F4CB(%D;S>YY@"3<O89 ]]W$B
M >EFNX\W+G3>"9/0#D."B8B($4Z#$ X 4I@$2C];\4X#VCRXR-"OW]&-0<?X
M%\=>B:,@#T\O2MV,9*2<BQCVYBE6?NV[- 3CTD\9TJ5%(#' !Z2F4. ".@Z=
MN@\*OF*>5HRS%:VE"))Z@C+T)9BM&@+#(LK1;%Y1V?JY:E,=.LP[1ULLBHR9
MLL1)[A:RTR+*3$JS;/(.O,*_.,X7KGIT7B16[=51,#"J30Q]0'CD>7\:=#S%
M*K5[C-FG3=IBB3"(<@$D.0/(MBEM?-_&AB'#$'ZN7F=1KQ)L>W$9FE<ZUVJ5
M-M'6?;K$3K_)%7M<B6O3K>5K@3QY6H0K1=%8LO<6[6KR*WL &(I[.P74UT)H
M.<SWB-HNBY?(YS4!B&HTZ=2%CL*L1,$L[#M $\'6-RNW\QFJE:()'=F0MZ#Y
M+;$G[8=H>1MU[J_HT*Q8VJC'&%30O%TL64[<G1ZU#5I>1)#DD%IE5E((@4)(
M_ACU%(0.WK$HZ\?1NW?FB;<R&7SN?H5:WTH#N\&(V$FRPBU@3S^A7DM"S%?'
M&)[4)-;=<.);G719GV,9APYC]QEA*QX>S%B^,EV4!9;O@/)\!E*'IDY*)N%(
MIA<DXH4)2OIR@-#E;NU6_L"BG2F"_BF*0WCH6_=O:GJ.7TK)Y/-Y7.YB$I1-
M:$X"0A'$2#*1B18W..("O/:)FLI0.8J$2@"!806?JX^OI(8PS.4"B  ;J$2Z
MZ_%U$-1 !$I3' HB  .FHZ:\=#%H?BL%:#T(&YA[P:>^/U.('^\O_1^X5,;:
M-/%\?V*\'SQ_\86R?]H7@?\ W ^XX)X!_B,_^NU?OBM[WA?3_(Q]2K\V%9RI
MVVG=]@_.N0"3:E-QO9'\W/%K<<A*SGLJ];G(E+Y-8N73%!9<7<BF'QED@ -?
MC!QT??FDYK6MGY[3\G$2S$V8$L+_ .%O*M:T3.1R68[^;X1S7WCV)C\B93ON
M0Y&2&SWJ\V2"?3DA+L(JS626FVJ";EXNNT,FQ=23QF"K9!?0OAB.@Z@4VFG'
MU:#MW3<AIVFRKY:G])&7BYPVB7=\N5T9O4=1E6>)(I/S\'MY6>VP:B;\*CBW
M-GEV9DJ];G9]?:7AR+Q]D>ONB-HL9IVO:<IJ6-*J21'LDW631JF0_&:N'!6Q
M?'(*8]'2"G'/LUX?ZKG=*US2SAIC4,V:T"[AAW4P97 6TSQYK7++9,OJ^5C4
MI=WVC"+-<;R2PO>W^!@Z=_<CO^;V3"^0*C$;YMV6Y6:R _KQJG4;YCFNXKJ>
M/8>.F$91\:_N E+BI?Y]!5NFDV3CQ9LRK$!<3Z?82:AMCPVS4-7RL=1TP4LO
M!Q4J4YU)&9=NRW=B( ]\2";&:\KUS^M9?NY1$Y2)9G  ]USS 7JNO<#O+W+[
MI6%8BL]Y1?9"CZ8Z?OJRT=UVFP98E[*I,V\BLFI6*[".'8ND8YN407.J!03#
MI HB81[MHVS= VIG*D]&A.G4KPAC!,R&B3A;'*0^$79EJ6HZD<]$6O@?@QMY
M>=/'Y5G/S&]FX"'(<Z4\1'40_'S>OEQAO%"S9.J_J-;[PKZMKE]4R_Y0>M<9
MYB_^OCO _;$9:_PVF>/?PT_P%D?R-/\ -Q7T;F_M?_U2]:C#CNI_=W>*I3/N
MEJ]-^Z><CX4;9=I3Y&J5=!\N5 TQ8I047 ,8E@4PJ+'\-30A?K#?6CLFJ9VI
MI>G5L]DHRK5H0,C"(Q2<!V XG@!Q6)AEQ7S486!Y 6V#^+D%,C?1MHPWMQ:[
M8SX7R'*98@LM8$+D6:R(]AWE<BK5/)Y+R!3EY.JUN1;(2D+5CM:ND#--V8[E
M=( <'Z!6Z"Z-X<[NUG=U74?KBEW1RN:%.,6 (& %B1>1>3S$,]YRNN9.&1GE
MJ<2XG2))YSB/HY=43&.*KQ)8NG\SL8KVO'=5NM=H%CFF[EJHI#66V0\M-5Y"
M1CO&+(MV4LT@G8(NO"%L=5 Z76"I>@=QK[GTS+:S3T.H0,U.,Y ,;1"+DNS6
M6.'>UV9?)+3I'*',T[@PX7D@>WA;T.XDC1/+TW6Y)*=2L4&#,DAC.C9CD5I?
M)6-8!O XSR,ZDFM4MMG=SUJC$*S&O21:C@POA1.DT$BZA2)'(8=7SGBQM?3<
MU++YN8>-24&$)R[<??1#0M(NL%I<"T+Z\MMW.YF-G$/:PL-QOX^A1+M]7DJ1
M:[-3)L\8I-U*>F*W,'A)B)L40:3A))W%OAC)^">2,),,/:F2@).6JZR"Y0 Y
M#B4P<;MIFI4M;I0SE%S1G$2BX(+$.'! (+7@@$&P@%8;,9<T*AI2X&WR7W>1
M7@^1Q^)^8I^T:R!I_9[7CB/CM+%F="Z,Z?YJW/9H8U_DGU*AOO[O?X[[CE3J
MSE"..31L^Z6D5G,ZC<)A2?P,PVPQ]3R5?=PKFUVV7K2<#&XWP93)A]293(4E
M/+/"2T])Y*-3KC#5. J+5N0ZB1VQG+Q5<I4PZ2J&)SS>><WD90I:12[N@7,J
MDA$B(#,! RB296VW  DVL#G=+EIPB^8#U'##IZ[?;P'1WN\/ >.<4LMN61<5
MELE:J&Y;";/+[+%-ZEVT]=,9&-9)NLG:O+ WC8 UGJ%A-"G?P<LI&L57[;Q=
M&Y.@O7\/AKN/4]<K9S3M2D)SR4C'$.R)-AMPVX6Q,0\KKW+#TU[3Z="M&5,-
MBMMM9GL]%ALM:QK4Q<EM_P JQ@X:*K6%71-P$>QD<3+1KQC)(6HC^PK58&2"
MK)PO[)*,YY 4'+=<$EFVH'4*4O&PY?>.@3J5X9NL(YC+SD*@.+LX;18UKAF(
M'3P98Z&EU\Q.-2/O9"RT-S<_1Z&Z4^BGEY;HV]'N>27M8I,52:)9<F4V>GIG
M,.)(1N-MQ$HW1O%;BB2ES:JV*59J+F!JG&E=FD!05%MXA2=0XNCXG[6^LHY'
M+59U)U! Q I5C9/WI/8[+\<38?A,+_MJ:!F!2Q5&PA[Y"\<UO+KL$)>D2&$I
MNT![C%,'</:0QBF#GV@//CI%24:M&->E8"M;KP%&>$*\R#'_ .'ONP]_X1A/
MX<;U?Z0\<!S_ /Y]RW_3X_G)+H5$_P#:\APQGU*C,A3G,0B8"*AA*5, ,!1Z
MQY$ !$- Y]X\O3RX[[/&*1-+WZYW4 [',ZL<VO8AVN9%C,14IU0<[[BLW95M
MDM&WR'Q))NJ-&[=:B>=0K\!97QY'']H89(<2C-X>97 CR-8,6J'AK.@ZQ.EP
MS>6O;GTF=3/TJD*.1HD"!DTC6,K2 Q& !A$%I2D2[,!BW73=/R^;REH,JD6?
M^2_/SFSH :^\"'F3,9(4[/&0L,U>P,[<VJV6[9C&MVD%FC&.M"<+<7]4A)WV
MH5C,6+*=!LDOXIE!1135ZA'I+KQU#1M7)VK1US-C#4JY<3D#:032QL6' V.M
M=S61_P!L.6IW8B''-SWWM<+UV!MJ6<$LFY3P^O44FMYPI$7*?R<V>SD$QB*Q
M"41L=[/S"M@=2!81]&@U BC59JNL1Z15(S<52*)F-ACO[31MG(ZZ_9S>:%('
MB220Q%X-G$!N++U.A9D2(D[@6]%]KW-S6VKJ<W;(]PVW6F1%ZR[7*K5X:?1J
MKR#9_?,QU)VN6B;K IV*NS\?2(BSO;>O6GC,5$C2'L8-$W:"K<YR+)'('TZ'
MXA:!KNK5=(R9)S-*=2)_!U  :<C$C$8"#N+C+$S%F*JMH6?R67[^N2(6-:+0
M>+._H;I43 #GVB/O<;=FS(Y#-F7Z--ON2L72D)YRDW])'UA7R>=!_B:\I3]H
M!C,/G5JFZ<?GSP,_KFN?]1GZRMZWA^)R@_U(5"_/YOF]/'Z%+NW!:0P/6K3<
M9[%J@XV)[B=S&5IR7B<IP>.Z?DG!F-&AO9%R8_DLL5G'CW)5U14*N/R'<'<R
M\:0+;1!9?Y,=.1,)"I]?"]P>(N:S&\\EI>C'_8)5)1J2#>^P2D(Q'.P!D2UD
M@ Y);<<KHM,:75S3$3$0PZ.D^>[FZE ;%.(;]G2WEH>,($UDN"L#:; Q@47C
M%F[DF5/@'UGEVT:5\Z;%?2A(:-741:IZKN/#$$2J' 2\=:W!N/);>H9?-9J>
M"C6,8F1=GE8 2Q8.UM@#NM2R63S&=!E2#G$6 ;X+N;^7%.+AC:'G[/\ !(V/
M%5(&R1CS(B&*(XYINOQ2\M?W5/GKZC6(=I,2C%U*2AJK67;H2(D. %*340%0
MA38_7/$';V@U:F4S,A'_ &;O#V26&* <L#QE[O.WV970\WG2P!+76\>C^+^'
MB<T8-ON ;4WI>2"U=O9%XEK+*L:M>*5>TXXCAU(LS1TL^I4_.L(R:9N(=T1R
MR74([;*I="J1##RK;^XLANC2>]R1)A&1OC.!>)<L)")(_E!P6L)X>&:TJODJ
MC3-HYB#?SL3T6=/0G.V.?ZYVU;]L#B+_  TAN//?_P#AK5OU#^8LEH-NLP/2
M/4$]WF[Z_A*MX7^5Q_\ WHB.,%X,?X"TS\B?SDT]TG_GV9^4/O(*,>U+#9=P
M^Y/">#5'JL:TREDBK4^0?MPZEVD5)RJ!99PB @8O6C&IJF =!$HE P .F@[!
MOK6,_H6A9G5,C6A2E1I2D01$F6$.!$2!<OU7KY-*H1S6:CES?,@>0J3V\?"=
M6P[7E0@MCFZ?;]&R=Q]AJF7,T9*D9NLW.OM2RVB):>]P'CLT5,SB)6KQ,BLJ
MJHV\$Y.@XE$P\Y\/]T[AUBO5CG-5R=>C2#FE"$(S)YP7=K>:TF_@<QK60AD:
M6.%.0,KB2_N?Q<RA5!XCR!9L8W?+\+"%?T''$Y58"[2J#Y@+JO/+J66+7'+N
M&]H^63Q3MQ$*(G>)-U&Z*YTDU#$,J37J&K[@R.@ZKE=+K'\-F02 Q8@87M8@
M,9"QWXLP*PN4T]Z9SC-$-;U^7H-RD10_+\W3Y,@8.T4^A1+FO3M'C<G$DYB_
MT"L-8;&\Q8K)5HJ]VM6R62++4:L]EZA(%%U(>"":+;QM#)J(BI@-3\4MLZ=G
MJNGF35J-:=(@0J'M0O PP));XHEQ <@A9.CM_-2!S$/>5.T[BZ1+&]O.1Y+U
M$RU5V0J-@G:M*J1BLG7I=_"R"L/,0]@BSO8QTJS=?)\U OI*(E&I7"!BD7;K
M*)* &I#&#0>-PRN?H:CD9YK+?BI9=Q80;6-H+$=1 (N("UZ%"=#4<%0]IC[O
M*Q^'2KL/(D'7,F['7OV/9V^?[*S^IQPWQM_LW;WZ_2_.E;ELC^L9GY$_=5&@
M=H^_]+Z0\=\R5U3]4C]XM0S7OJWY22G5LKVQQ><4<Q9!M-/R1DBJ8=KU;]@Q
M?B7Q$+SE7(M\EQB:=18V72@[,M QQF;20D)!^A'2"[5NP,3P-5""/,_$3?>=
MT&OE].T3,4LIF*SO*J(X8B(),CBC(7X8@.')Z"L[MW2QGZ<JTPYBU@Y^%HY[
M?(QZN=WA8HQMC&?Q^VIM%S/AJWSU3<O<G8)S<PEG%FQA86DJX8Q(1=VD:M3D
M;]7K?"-0?M5D(]$S42F0. F#4,KX>:_K>HTJ]37,UE\[:,%:B8891P@F.&G"
M(C*$C($'M&^YDM7TZ%"J)Q<5  "#PM+6EK[+6\J8J0PGDB,KF'[6O7%5X'/!
M9HF+W;%XQ='L+RMVI>DS<8+9-P+F/E6-@0Z!;.")K'1616(!T%DEC9.ANW2I
MU,QD82!K9:0G4#&R+.]HM!!OBX<$7@MCI:=4J8*\;,<F'NA2)GO+NW45>J7V
M[62HTRO5;&TQD2M6>8G,NXJB60VK%*8*WFH0:[^WH?=+:X= %3DCV)5G;P&R
MWLZ:G0 &PT/%?:^K9BEI^G3)S%24 ,-.H;)E@2T#ACSRDPC\+"ONSNWLUE:'
M?7 7VC@'-Y] MYG4'A^=S'EIR^;7CH,KU@@/.KT,5_\ 0!;GO5O4Q[\,9CW7
MC@&N_P#G;3?U"I^:K+?=-/\ VG5;GE]\51B?N#YN_CO_ ,&E^2_G%<[RUTOE
M^X%AIS'X/GAIPI0,WA$M(N >9['7L3V?)[BFYL;P3C'+]_N]OW .K-&;<<$X
MZG,F9DD:B8C>PK,=4J_3:W!OW"#AHA.6J[2[)JV3.4QW "<A U^,7G?B!O74
M=M:7'):)"-76JIPP<"3F^5A9V@)2\BSVBZ7#-RQU0>[B'+6=7G+ >5>^<-DF
M1Z/N3SU@_',:>YL,4P%ARQ R!I&,8N[1@I"/96J N\&U>.TU[$*])EVK]9%B
M"ZX)E6$2%\(^GQZ1OG)UMEY;7=6J8-0GF8T*@8O&KA[4#A#!I.'8 <Z\LYH=
M6&<J4Z;L)'H<<#YN'K35X_VH9]RO5*)<L<4%[;(;)N5G>%:&G'OH<LM8L@1E
M>:VN69-H91^$BE"PM>>IN7TLHF6*9D,;QG!!3/QL>K;VV[H6IU\AF*L0:5&%
M0NY C)P^)FM/#WQX!>=#;^:JC% $C$S]-]W5;T<>CM,K[%]Q.&\:2N8K9!TV
M3QE"62)IDM<Z-E/&&0X-E<9A24*E5E7=$M]B#Y=8IQ0G=-] 4;D62.8.@Y3F
M^#2O$?0]:U6EI&4E(9FJ)$1-.<"T0Y+3C$M=;Q-G IYC0<SE*,LS,#NXEKP1
MYQZE#P0]?&^D>98G%P8HN)5+ZFL:?_*Y[A/\K\+_ .]/@_C\TZC_ /TGD/U2
M7_!YE= H?X K?E1^=IJFWS'N7F6[N=!_]:/(7,0U  ^[1R'8)@#O]SU#V<=3
MV2#/PPR8A;,:-1;KP+7]1H0&\*DY'LFO(D<+^*L(\P#(6R3'N^BP6S)&+=P%
M[R=46>'IU_&061*=6<83TK$8XI4G#-CE)6W-O919@3:E="5P+@02'PS%U* <
M4V;MO=.O['JY;3XY<96=61,C3)K.*A%DG O)]BV+6LWE,OG@!BQ,#80W#H/+
MBN)/OCRTRV:9=W,UZ#QLTR=F?S++M93N;/0*=DIE2RSV#(&;<-*O#Y"A+#!(
MK&;]+'VI5H=4S4HZ:*',)<[3V#I\MYT-#KBKBR^C4GC&I4IO,1@#BE"49!K_
M 'PML-EA]):J1D99FG&,JQG8X!%K<"&-_(I[;#C_ .XC<)N9W*5%I@3#5/B<
M ;,K=;<HVC$#/*3/%M^W"XZI\HN3#N"BPLQ5Y::R-,Q[]-<SR/7919%S= )*
M*DXPE?6N\TG);4[W-U\P-0SD13,Y4A.%.=>V6:&&9$7B?QI)( M%BFCD<QE2
M=8$*3&,28F(DQ(M:/3;U=#!=3;0QDSRWM"W%3N/[1E!U;]H&X>VW7*]=VL4>
MIS\!)53(5IJE0W%2NV)-LCCR;88UACMC)$7;^%(1J:#Y1(JAM.,%0K9^6C:C
M0@)4Y4\_0C$'-5#9A@](3-7%V[9."9 V M8ONS&7RAG"M*G!Y0<M$!CQ.&ZS
MS>6U>L+B&BYWS_M S)?[+A7/&*YRF;EY2F9&IV#6F';WE;(F$:BZNT!3,HX%
MA6E3JEDDZ;+&:%;MHUN1O,@FHQ<'4ZQ#CZY[@U#1=#U/2<O])HYJK*@]/O36
MC"%3#"4H9B4IR@:@Q"V<<-A !M45]/R4ZU/,' 1@-P <AS: P+6=?%1*W:W;
M&6<-H%SO#YY;,FY#QWEBI1%*RRPVAT?;;7JJQF$WQ+!BZV2&/WL?%V$ZK) J
M[%%PU5>-%6QNI01-SVO9.:UG0M_C2<L9]QF<GWDZ1K3S4 UHE&I/%A(M<8P[
M\5BM:EE?JV0$02)1#B(#7V./1U6*!6T[;[DC<.SR%"-+H?'&WNG)U2Y[A;],
M+O1I=58,E9:,I3R0AF)O:+7<G[V1?MH&-234<NEU52E#PQ6,7I7B-N/:^U\I
M3S.ITAF-1G&6"#.788K[ 'PXB;+!?8%@]"TJ>>JRGWAA2$K6-G%K/5QO6WO/
MS= 9/FL6T#&U2L%0P;M[H2F,<-M[:W7;W&>@C3TA89RYVH5/L99NU6*27=';
MHB*#,@D23T^,''EX7[<CI&3J593C/,5I8Y@%X@L (QZ   YM-_%&X*QJUXBW
M#&P/>>OI+IX/+ST+C;S*NKE__CWR&<@=G4(Y>PN0Q0$-!$=0#73F'Q=0[.,?
MXG#*5=0T7#3:I'5J>(@,X[G,'A?8OMV^2:.9Q3(>B>/3'V)T]NV6I#;_ .6A
MD#*U'JN.7>2W6[6 I$?;+QCJJ7M] UN3Q9+NI=K%-;7%RS H223,4C'.@<R2
M2IU$NA3I.&-W+I66W3OZA1[W,4LAE]-S%7!3J5*8E.F2 XA*+L6+=#&RQ?7D
M\U1T_3?I$HPG5G6PN1B+$'GZE+6YU5G0MT>X[+]>)@S$]-Q5MGV3FF<JW?%
M93<XPE<FX/QFFR>8[PRVB9:J62V7Z5BWJ#IY)QKE-H!3J=95%!'CFLM4JUM
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M:*;!XX321ZE") 8PZ //>]]9W)ZSJVWLAH>:H5ZU/.RE,4<&(1C&0E(X&(B
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M#2-I$ASJ=3R,,MI%69J/.1A8Y/5?T<.CBJ9!^;NX_1Y9:&$.$@EE]36-0_\
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MK2)9L)-C>;AR*46V['=Q9KK1Y]OF[+]CR'5#SD90))*P34U9X]&WJ)A-5N&
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M-ABPERIT"H8'#KV6SPBA4#Q#<H = $TR(@4"&(QM3:NFT,U2RM*@)@TLU(G
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MK8#@6NFK+9:-:2#A,6R3IHNB"A3=91X74.6TWQ>S%?<,L&6J4?P9E9$M*3@
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MTRB_E0#]S=^85^FFW@/^5&='_P 0 X?[R.TA?0K^8*?L^U_XT/2C']S>>84
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MP_WDMI?H]?S#VH^S_<)^%#THC?N;SS"$RB<97;P)2 )S:90G0'I+\8=!&@"
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M!\4P&+J :E'J#J'L*)B=1"CJ(=H\M>&[(M*Q P#U:"!M.T0,40 I1Z>L1 P
M =7I$!]7"?F0!SI)G[!#U:#EK+89%G#P$#&R$Q-S,DNFUCHN)B&JKV4DWSHQ
M_!;LF#)NHJL<PAX92#KIIP6<4,;UY5BSUZ[5N!N%/F8RSU6U0L78ZU88)\VD
MX>?@9N/;2D3+Q+]HJHU>Q\@Q=IJI*D,)%"&U*(AVM^"&+I;*;KZ@*!NH@:CJ
M AH&I>KG]:42=0:@(AIW\^$Z&0$P"'+J,&@&ZB@8P:#V" #H)O>U$!Y#H.H
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M?IYB'#0Z/7EKIW?-W\#*3>BZM?X? J8(=0]GTQX$,@'/J](E-S ?0&O9Z>7
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M9(V2]VNWW#S.J261<BQ]?B[G!'MD-)"REI)@A3$/D<'UZL*\4P>DJ=$BAL+
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M:Z=)@'D  (F P%,!N?,- Y]P=G% O:I(M2RG^A _GT/Y$.%\+R)\/*D8W3S
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MMYDK MD+ =W@8UMD"(J;%&#0J-A+//I=P[7E2#XR!A3:<-)<7FO"U>VA11Z
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MM;"$<"ZA65XBX]\PB+RTB%P [5.5;NB-] *F!2@ <-#AENYBV7;8<^V^&O\
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M4PE)PGH(7I(!0[BC[@!W!SYB!0Y:\/UH*6B#I#&'T/=?=Y%[.)^$G\%(9]3
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M[Y6DD"K_ (G'MY>;#VYZDV313>OA%RN"BX]8 '%!O3RAKJ&HCVAV\-(W)7E
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MI.Q$'R:'\0Y]Y9+Z0<%J.SQ1]4:'XVY_)D^_M_B>#M(+>1*<<=F)U@025U\
M_6)U"CH734W2 !S$>$7]*89)FL9IKX;GF(\O%3Y<QY<@UX=O0DP?BB T8(Z
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M_ 5+H:^L?GCR]0\^7#3M1"(@/?\ /'W^_A)H ;W?>$WU>&@HP'ES'D(]_O\
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M_F@>G^J$O7KQ!]\K^"FXRLRN,C2;_'8\<0;._OZU9&5)>V4T@2NL;6[C'B$
M^FS12:LH$4RE#I*K^SE%;PR#T?&TX8]Z@VR5*LEY'.W=;9@AB&$K5*A=W413
M(FQ0.[I&',TOB>YVOR,?>8C+;Z6*W<R::;G)T<1P_521!Z:,46224(J8HD7!
M#VISLA;!,X9,VP>9GBF?MV,VN3M^T&!(658*64:;4+'(;9,8X<F#2[@\*E+&
MABW&H/7: (M5%1CE$>H@+ 9,  \4BR1\P>6#8[QGS.^[.E6>CU+<LHEM@GMJ
MV4A:3)YVAV' =/M5;N5%R$^9QA)=]AC-C.PGC+!$QCGJ?QS@3F*1PT;"FF*;
MA>6>O+3O>;K-F'(LU]X2TV>T;H<)[E:;CC*M:D<@8:FPH6UV@X O&.LC,'T#
M[8$=8'D/)NHR2:-'BD< ,W*C=90JK8[8@NA^'!=GA?RP<9/:?E^O;F<";1FU
M=RGD"D72+PUMNQ1'8YH-1;XXK<E!5[Y;O4% T7(.4[2X4L<DY,]EBHM8_P!K
M%!H@FF"IUBWR)6=17,.-G6\G &YG).2=ET;LX;X7O>(-O.)(BBYLELT-YFC1
M.!H">K,:A!)4^NS;9W'*1DRFDD*[X[@Q$0ZSE'XX#)V<%N;?/+6R!A&_;6<A
MR>2:E;)?&6;=[^X#,R4?%3M>K+BY;NX4[ *_A.G+KSR=1I%2?K:BU7?%45U7
M<@<SARIP$) W->HZ[HO*=SMN!>;MF4D&U;(3_.%HL5HQ%G?.K+)5^R[A:O/0
MC'E:Q#2X)\SE*UC6!K,G'J(M)F"==39LL*YHQRY,8>$Q19SJ6LIM2WC8]NFY
MUOMDR5ARD4K=U?(7+MMNUP:6Z2RE@W)JF*L8X7N4MC&(0B'=.O\ $O*EB^.>
M0[:7-&@PE16,O[0W$B'#M\B=GE6M-^7_ )0?[6L]X&)>Z@]LN7MY=5W*1EHD
M EP9-JY7=PN&,P.8J=*VBB+%LSV&QHZ1*+9 [8KQ9#14J0:I!!-@0XO*0-P/
ME_9KR(WS I4;G19",R3O+K&XR<Q/:YZ_UF@96QG&88IF-I3$F5I2GLE9L&2U
MAK0RQ&Z",C&+^$D1RDL)C"08E#LFZPUY7N3<:Y'EKNF7;+CRN36ZC;'N':XT
MP/3YVAT^KP^#J+D>EV*GM&/R05.Q3LR%I9*A..?8S2BJ;A1=%I]C*<9#CA>I
M];QMM]MW'$VS%K$S PGWD=W&#-PM@">"0#Y6K6+IM:6F(6(+'LWY1FY$BO2V
M\;PT0/\ BAR]HNTWI7=:86Y[&<CV3;+NWP8SMM0;S^X3=!+YSK<PN>P! PM=
M?Y5QQ>6T-.$0C5G@RK:(I"J!@0141%19(H* 0IA";4 \."93)/E^[LS8JSOM
M6PKD# T5MURWFZ<S9#V"]L;VKE&JM[YE9EF;(&+EH^)9NZI*1#^Z"^".FP63
M<-&#@B2S)94@N1;(=(&6_*NM-@RGN0DJABW8+D*M[G,CRN1GF5MR>WZ,R3FW
M"[ZV5^"@+HRK4?,5.PU3*T6@O"'D:^TG'#%NR>/56[I-XQ*5+@9%B<3,GEZ;
M@<F9M8[G(',]2I67]MQ*I [%JS'LY5+$50IS5@VC<M-\P5R+A6!Y&1SG!/GL
M.]3B42-J_'HLCL/$504,H,?(A^*N):>U"T0]M(V1>>"4SM-HH99J1TH(JNB-
MECM69UDBNC& IS)D,H&AS% QAXKUH/1<O;@21@(>_P!GO>GW>&DWF60"'2?U
ME$.79S*;3A)W)8E_KFWYV2^CPHW)GW$V&2KY7\68\O>3K:[)'5/'5.L]YM,@
MIU]+&N52$?3TT]$""!ORK',%#\A 1 - YCP&Y #7JN_#&]?.CW(&V6#W)8EQ
M[BRL;T:G,67!1:G>)NPW&GV.,IS/)(8LS PF:Y%08W%[1%G"Y7$(HNR3=,'"
M/28A2KG5J=EY3B[M=X4WA;)F/\#XW;8H0R1=*-=LMV&[9ZN;ZBX:Q7BVB2]9
MJJM@N,M&I.9I])W"W6EE&0S%J"?CN#N%552E0%,S=)DJFW?V"C[1E=P^<<6+
MTG(1!F*["XAJ-IA[X.3;Z:RR%5QI"8ELC!4C"QM\UO4V#B!.[]G,BVE""\(W
M\%<2HGSH;G3D[*<_R^Z?:O@_<1/5=M297+E#C;;(4]G)&EVU<>/%G)'$4G+&
M33&1,V,0$SJ@4I3'*(%#0 X8MZTC9<I7,/S:V .SQTQ'_L@X9N1$6N;T3W\V
M.N7],&_D0X00;U$3=[N/?;;J!3Y*NU9M>,EY?S#CO 6':B_E?D.+F<F9.D58
M^&&=ETVTDX85JNQ;%],2BJ#5=R#!DH""9E.7")8)V'EZ%SNV?<'DF\Y#S/@#
M/E7HE2SGA9.BV=Y][6R3=AHMYQODZ+<KU&\UW[I(N(L40W^7X"9B73)VDIX+
MN+5,FNL0Y3 ^*%&+*6_O/,-.;Q;GC'"E!GMO6P^2<169YNV7J;A<F9$>UO&\
M!E?(+;#T%%0,O7FPT^K3Y4P-..6P2;TO0B*) !89M-J; #H7O;-_V8;Q8<TN
M]H^*L=94Q7MKQ5C/*F4+G=[Q-UM_D5/*N,D\VPM"PNU@(6Q,AM,1B)_&2SAS
M,*(LU%IUF@F!=3JIO@DP\BLJQ1D:N9BQ?CG+E17,YJF4:#3LC5E?4IA6K]VK
M[&QPRQA(8Z7V6-D$C?$,8GQP$HB \,'G2N+!.M%?T_\ G0?7\/?PI7IQN*2!
M$- #LY!]/ZO%)<% [<-N8S+7\_T+:UMOQY1+IE:UXNL^;+-/Y3L\W6<>T2@5
MNPQM4B$7ZM7AIZQOK'?K,]69QX)H U0*P757Z@*4BDEW3#)P-N^YZ*S=MM+G
MN9A5:>[K2^3*]E.IIODII2EWK"MJL=%RK76K]!JU^4F\/::D^29K&3(*[<$E
M#$(<Y@!VHLO42<5;\\XR_P#HRY-S/B'&>/=OF\:Y1M*P](PV0)V7R=3WMVK<
M]9,0N\GQ;N!95=T.3TH=!DFA"O3JQDA(MB* H05#$3FY#<5CA;?OF?.%XQW8
M:7C;#4M@G*-PE&-9K;7,:!MSK?#S5[8H2O;F7>.G;-G!.,5W-S"IR;>/3='E
M$(6007%157J0(8N*&>Y6T%UZ0U'4>GGJ.H]@!ST*4! ! >>G;KQ0YTN*6T_T
M('UOOI!POA>1/AY4CF^N'T=@_1X:D.UBQ#MU]7T].&D;F6!U4R]748"F*4#F
M 1 -":";4P#_ !)0#GZN?9PG5='!9::@(ZARY#ZM.!"!>WEI[_#2*&O/4?3P
M(X6)8D_Q./\ SF'^UY<1'BG(V!) ]@^H--/7H'/T\6DUK*NS:)OK?[JMQ.Z+
M$S?#MUQK2,'43;I=*%:LC1KRM6W*\1FV3SW&'MZ%)DRMYFKU YL,D&)+((-9
M%TFNJNJW31.W$TCT*K$X&YC<#E*CY+PS@/ -/IMTS7FI*[6)J?(\Y,0./\>X
MSQJQ8*7+(-G/68J6L,T!['9H*%9,&J9?%>RJ9U5DD2*#PB2+D .FJH^Y_=#F
MG%LK-8GQA@:+RWB#,.4<(;D*CDG*=PC*E5+;C1PT42D*78:W0YN2E*];J_+Q
M\\S"1:L72,5*-A4 3"($.TGV4X&P3<7FG=+B67R]EG'E%H4!)7&P0>*7=!M%
M@L\;D&F5B8>5MQD)$+)6ZW(1T-89B/64BNM #/6!2NNDI%$Q$"7K4\F@?EIM
MW_9R?R7%&Y(>^!X+TDN3YP/\T'YX!]3A1N1*TJ)>[7<$_P!O5!JTC6*XTN.2
M<H9.HN&,4U.3EU("&F<@9!E0817W03B3*25B*[$M$7#U\NDV<+E;MS D05#%
MX"_! MO7+;8]P.4;]D+.N LZTZF5#.& 0QK,3R^-)V6LF/KK0LRQEB?8^NM8
M&RQ<78HI525H=@BGD>]1 4GD2J9,YT5D5!3E4;5'O)>]S/:N1MTT1MZP_CV\
MT39+%QSO-CR^WF;JUOO]G6Q\VRH^Q_AME%5^5AF\FRI$@U-\HSBR+%9^Z32Z
M2$!98HY0P7"9$\S"Y2SADYVYT[%<U5XW8;0O,)G;/G"]2U&:VC$V1RW)Q7:A
MCHM<@IANYMC2/I*RTC(O#!%QQGC-(Z9O'ZP3\4,K2,/Y 0RUB?&64VL4Y@VF
M2<?4R_M860*I\IPS:Y5N,L2$5)F,.GMS!&2*BKTE('60PZ<]"T+0D7"=Z*Y'
M<_G5?Z(<!]U$;O(D80^N_P"J'T=XCZ>7#2XJK?<15\J88WW4;>=3<.9%SW2)
M3:A:MK=OJ.)30+R^5BP_?6B\NTZW!%6B;KC*0K;XC.0C':C9T#AHY6;*BF*1
ME#IR572NSV357+&WG ^!<67C$EB6L>4LE;F<EY&<UZ0KCV!P2MF++F8=R4;%
MW=TO/-'4HHDO=T*X*D4C(D/+&$W21KJJ!:R3@]:J0G/+ZO.:G^/, Q&#-TVV
MF INZ>'S7+J.LU1EQV;X>88JR?(Y(B++MKISF<64>S^595BT.C'.H;V: 3EI
M-(I6HFZEETIV7<4^L)Y>V[;"^[GRVY*KY8A,DXQPY9]U5JS)DQ/"U=KE@5EL
MJU6I?=9/9&DAR&YE;ID3/<JR<(&FTVYC1SPXNCHF3)X7 Q0_4OH- # 'QM/5
MIZ/5ZOF]8VILX)8)^@RWJ=D_D$QX1]\G\'RI'Y  B(@&@"/S@U'X.&A&H41(
M<NFA@ 2](EY]0:AH("'?H(:=_N<!-B0#%4UY7C=R6V7<%O?NV'MN>0MP)-XV
M/\9RV+)FE.ZBE"TG,U"QE*XE7K&4E[%8ZV[KE,>-TH>6))($>$%,K],>A4C8
MBTI\2GEHF"K#B79-3=ASW"JF:HW'FR&!I#^=FY&'C\49'N5=J:5.?8O</'$B
MM:(V1GG[472+T&'@-4E$U?: .0Q2A3 Z5#/9_M/MU@W:8"S78<2[N:%4-L6'
M,E1T)-[OLP-LE7D]_P EQ,)36>(* DWM=A3'$U*JJ4N[<RIRH/9.66CA.X72
M;& J8^5!('4K -@V&;OCV+W*Y0R["2T-ES<5NRS9D^91G'$<^D6..&%C-C[!
M%=:N(]PY00@8C#5+@U4&_7HD\<NE?#2,N9,&QXI6-T*?NH%-H/:;70->8^ON
M'37BDF>Y#L][M]_00#U:\ 2(M70$_0%;E^.!R_\ K"7$_#5? 23)G!-R\4$
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MPY A\AIVMQ?)ZQYYPQ$HTUQ4%HU,8)67,B)$XZ(;'2/6BT\N7*WI7U#$Y%*
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M9_V2'\#@Q),401:_VYI[ZX!](.#$AD?R8O\ ;6?Y.4?I#P8DV0^3%Q[56?\
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M(:Z::B7H#J^#AX@;+4FY<BO'Y$U2! XLSMP2\$R:K@JI3)&2!(Y# H02Z'0
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M!^BPM=6W&9'?X<>VJ$;*PR$FDU8PTHV(@NNV56B?&;HJI$,4$Y96Z8YTE?\
M$.<YYJ]C8[<"_1W:U;,EFCJ2_'#>-+COFS-2*=BS&.&0/9I;(SF)H>",$TT;
M[-*.E7+H]B?0[E! 7:9&W#]25Q5SVVW.#+<-B2O9*;P+VIOG;RR5JTU!\]:2
MKFH7RBV:6I5XJZLS&I(1LZ2#M-?>H)2#5,C1ZB4BJ0%(8 %CF"1O=/OR#T<_
M@^?SX:FU[$-"_4X _%#E+Y/T 6#^:!\_VA+E\_B?AJO@)#G&J#TTBR=)%7:N
MO:FSI W(JS=P!TETA^,4=#I&$.T!Y\/X*9O3*06WK#]:PBKMM@:-$1F$3TF=
MQV./$3/SP"E*LJ$BTGZZ*AW9Y0&DTRE'"*I@5 X$<&Z=! !X3%)PO7'&!<6X
MBDK7+8VJ$=5).\#5@MK]HK(NWDTG2*I'4BHMEE)5Z]%!G7:M%-F;5)(2$3(F
M;XO48QSB'\RXNQ;0]NEH9;@XV:Q/7'[#=8YA7.>V;I:5]ER$ZKU?BJO"OIAJ
MG)"@Q>1U<A&J":S &RPK-451'Q$R+$ "2A['3_5^ A:O!PM:@(UI$5Z BH^#
MAH=BF"#.+AXQFBP8QS-(F@)-V;) J1"AR*4H!Q27&U,I/;6<!VBP9(M<_C.#
MD+!EV<Q!8\BR2RKTJUJG<!R3&:Q!)R1$GI"$7HDO%(K,_!Z0-T:+ H ]()O.
MFX173:K@'(DYE>R77&,!8YS.&,8;#&5I20/(BXO&+JT\GY: I\P5%ZBB,:PD
M+0_,44P35ZG1Q$X@!0!,AUQV;]C6U?<79C6S,F'H&[3JU9:TZ2DE9&RPJEDJ
M#-T\>,:K<4*].0Z%UK;%>37.FPE@=LTC++ 1+I4.54(+)O:ZV,O;(-KV=GM?
MD<HXCKUE>52H*T&"5;OI^MBG15#HKC2'Y*K*02,Y2A6;D.:'?E=Q9C:ZHB!C
M"89)T5SV2;7LB6IY<;;A^N/YM_C6#PX_7;/;!#M'^-*[+$GJS3WD/"2T=$N8
MFLRA?$8>*B==GS*B8I!TX,-K<$/QXK5R?L1VGYGNRM^R5A:K6JSO(^O1LV_=
M.)UDQM<?5@.6ML;O7HF6CZ]?6< 4P@U1FVK]!)/[&4"D$Q3#(X=*=4N ,2?*
M^7)[[AH4LOGRMP-0RZ^)[612[5>JUZ5JE<A95)-RFW0:Q5<GG;1(&Q$C>$N;
MJ-U !N#UH)6Y-82QC/X7D-N<K3(M[A.7QB[PQ)T)4[PD*[Q9(U%>B/*8<R3H
MTF$<M4U#,1,5<%?9S!\<#AJ(UG0AUJY!P'B+*^(G>",BT:&MF*'L)%5]Q2Y(
M7I(X\5 ?)I8%%!VU=(R;%S%##-%&ZZ*R;A!9 IBJZAKPV2LN*8.^^7%LIRA/
MWV?R!M^JEK>Y0,Y<9#9R\C:CUJXR:D PK@6":IR-C0JSFV$@HYLW"7]B+*![
M*FI[0"A2G 8\4WML7:V;9AMKN%JOMQM>)*[8;!E'&K;$61G<H[F7C&^T!BW1
M:1\#<(-66+ SIHULD";5ZZ:+OVQ/Q-9/F C(<):P5M&V\[;']EE\-8VBZA8+
MHC"M;99%)&PVFR3<77/:S5Z$>V:XR\_/G@8 )%P#-H58C9J*R@II@)U#G&0Z
MD?\ 6Z%$== #00T'EH'%76*;3:AU>L?G!P.AD-1].GKY#\_@26(ZZ^O@5<%D
M ::^^'_:B/"0"EJ6^N:_G9(?AX4;DSPZDC#STT]>@\4IZ5@ Z#\P<)-9:Z@.
MF@=1>@VO>3M OK+U#KIV:\^!DD!,(ZZ]O(-=1'L]8CV<":!?1Z>WERT] ^CA
MH*VF _EUJ'=XZ?;V_7!PC<G$6NC>_FQT']<'#_M. 7(/.M$Z8*%,F8"&*H!D
MSE. '(<ARB!BG)H;K3,41 P:<RZ\!Z$E%F5V2[79S-:.X*6Q!7765DK/#WHU
MD]LG4FSB]P48$+#7Q_649-&JR%YB(8A6S>978K22"2:92+@!"Z2R8YT]DCCN
ML3ENJE]FXE-[:J,PL<;4Y3VMX'R*A<?DY&R*M&!7!8I1\]91""'M*B N$D16
M13.1-RY*LVM=#^=-GC?:MA#$%SL5^QU2R0%ELY;&20<_+UEEV4<WMUM?WRTQ
M]5AYR:?1-+B[+;I1>2?-8ENR;N7A_$5(J8B9B2Q=TW4B-1#IZNT T'F \^PW
M,  .W7T /=IQ847I8B>0/A_K3B97JH\4D=G/T@&GSM.**GU+P>-6T@T<L7K=
M!VR>-U6CQHY2(NV=M7*9DEVSA!0!36072.8IRF 2F P@/ W!,%E&+"FRS;#M
MRM,G=<+XD@J/:)6!4J1I-F[G)#Y(J*TPG/J4ZI-)N6DF-)J"DPBFL,5#ILH\
M#-T \'1!(22 UB;NNZL6W?#MP2RZC:Z)#V!OG>$:5S+!)(';P;E78N%7@HZ
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ML^.LB5F&N=%ND)(5RVU.P,22,)8:_*MS-9.*E&2OV-RT>-E!*)1TT$=0$H@
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1HZ>H?C@ =G?PK<72G8R__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2127058d1-fc_second4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_second4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ J@*  P$1  (1 0,1 ?_$ 0,   (!!0$! 0
M       ! @0%!@<("0,* 0$! 0 # 0$!             0(#! 8%!P@0   $
M! ,#!0<*#0H.#@@' 0$" P01!08' "$(,4$246$3% EQ@9&Q5)05\*'!T2(R
MTY=8&>%2TB0T1'2$U-46%QCQ0I*R(S.3LSA(<J)3<X/#9,0E)S=G=[=B@L)#
M8^1%M<5'ARAX"N*CXS65=E>GI+1EA5:V:#D1  $# 00$" H' PP ! 8#  $
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M^,Q'IE+YT#M#P_GH:C_C3J?\/QK].MQ3_"<![&'0G>7/_P 9B?3* [3_ +1
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M'Y=[B&[*<![&'0IWEW@>W&8CTR@.T_[1 ?YZ&H[;#_*E5 _W\&!_+O<4?PG
M>QAT*]Y-X/QF(],I_.?=H@/\]'4;#_2G5'L/@Q/T[W%^4X#V,.A.\N?G_68A
MOZ941[3[M#XP_31U'1_TIU3^,,4?EWN*0XRG -_<PZ%#O)G_ .,Q'IGI7<UF
M^T!UNSG0KK4KN;:JKYS&LZ*J_3.SI&IW=PZA6G5.-*GJZJ&E0MY0_.\%=DE.
M6K5--R!! %2D #1AC\VSO<S=2A^9>1Y91R["1RZO2Q!J4Q2B(3,:4C$R#,6(
M!#W%>JR_.\WJ;O8G$5,36.(C.+2,B2/.-Q7#!.T\[1#A_EHZCH!'_K3JB.T=
M_7^4,?I1_+O<3Y1@/M3_ /)A<)R T:K%Y.&\V\!C;C,3Z94_G/NT0^6CJ-^-
M*J/P[&3^7>XHM^$8#V,.A;[RY^?]9B/3*/G/NT0^6CJ.^-.I]O)]G[</T[W%
M^4X#V,.A.\F?Z<9B?3*7SGW:'C_/1U'!L_ZTZHW]Q^&+^G>XH_A. ]C#H3O+
MGY_UF(],H^<_[1"/#^FAJ.WA'\Z=4;OO[%_3K<5G^$X#V,.A.\F?_C,1Z90/
M:?=H@'\]'4=\:54?A^)^G6XINRC >QAT*=Y-X/QN(],]*E\Y[VB'RT=1WQIU
M/^'XGZ=[B_*<![&'0KWDS_1C,1Z941[3_M$ VZT-1WQI5/\ A^+^G6XINRG
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M:HNY.[/SVY=IK63&GIG5$GFE973J:94Y0",QI1XNP=M2SQC()R]%68.FY@:
M+0.D#,W!LQ].KO-@XY12S>E2Q%:E4,?,IQ!FTM($I1%FFT+HX; 1JXVIA*M0
M0V"0YMM&MM? 6KH/4!H*J+3K1"5:U9J-THU,XF-+TW6U,T10ES:EF]=5E2E4
MS4DME$\I:436W\C8OI>JD5=R955TB0$&BQ@$W#CS>4_F3@,QKXNE/!XZG0PU
MAGV<"!9(D2_K'!\U@!M.;V%J^AB\C]UPW:]J)5F<0 M(T7C^2^UF7(J]%NFU
M"(UTO/Z62ZQ5X4FE1JLW!*OCIFD:<\3JLM.*H)F&C54U.KEF'2]$+J"8 /$
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MO&,BG[R83!DT0Z=ZJ#8&$N0,4SMPAQDXO$;R;ZY;D-2.'A&>(QA!)A ?9B"
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MA!E -3]@O]:M*8\[OO\ ]8S'_85_\*2^MD?_ #.$_P!S2_;BK=K+_E@:KO\
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MB"QS! 58A\["[NC&;GYGFN:PK=X*>,A&V1<#8PY<-/9!)E:PY5PG&PF*<,,
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MHVD6V;2[.$QN40QCU*C5[CYI.D,' (8N[W76LOSN:J6-+2[4C?%K1M1S"J9
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M*L$5'R+7KJ#(S)H],;\I._N]/8U(4I1-/8@=HFG$ 2,HD$RFP+Q:T^:2Q))
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MJXF.+Q.*K9=C)&C&NTVE(DP[8;=0BUH")/G7F!)\T"*^M3I[,(1JQ\\1L<6
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MD(P)EMRIR$08F+/-WT ._P"BULSPM#*,,0-L['&/O2=P+7\OC69(ZO:SJ[3
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MY\BW33\4])_B[#O[O=\U/C]93X1D74',.A1^;A[/SY%NFGXIZ4_%F+W\WO\
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MZ@:EF4TE%.5Q2M0321MFKV=2V2U+(YK,I2S>I)K,7,UES%X=U+FSXA^)%50
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MQI+5&$!$(Y!O^A@CI[ SR'</+X,%F\I<7-W>?]7!5D<7*$>;=X.7$5:Q,!B
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M1(A#((CPQ'A*$ VP#((!@P0$J(HIP*0$RE3(/&0H%#A(<0-$R1/>HF'B&(D
MHB(B(QB.".;D D  ?A#@XQ.8X$B0#&5+!03<,"FXQ$PC$!S,.#(Y2Z @B4PD
M").$"B( 80X.+@,F80XB&(*AA 0$#!Q# 8C'$8%'(N4@3(!^/@ 30 I3< <1
M *!H%*?(X%"(Y , B/*,3*NZQ2H:!H>K9G2TYJNC:7JB<4+.C5'0\UJ20RV?
M3*C:A,T6EYY_2LPFC5T[IZ='E[E1 SIF=%8R*AR"80.8!,$<K+!+Q! 0&$1C
ME#(<A#*&X"]X,51T\QS-Q";Z;B.4PCQ":(F*("(@;QC@P0DJ'1%,/$<H'$1
M1%4.DSX>$1'C >(QHC$31&(QC'$9'*.C#B$XA[H1,('X0 Y3']^8IB@!RF&
M9QV  ;L5E70*139&)'W)21@/O>(@B 1C HB0!$-@B4!W!B$.HY"QBHZ$HJL'
M5-OZLI"F*H?49/$JGH]Y4=/RN>.:4J5%LZ9H5'3*\S:.E9#/V[)XLBF\:"BX
M(DL<A3@4Q@$VM'*RD"@0( !LX"(FB<1$"@0.(X^Z,($( 1&.0!BBQ0VH$H[
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M*^=##N_O&#'6G&/H2Z67^1JP^ZQV_P !BM).?Q)](P\C5#[Z'V6\,&.M'X<
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M\Y#V6P8C'6HX%]R?2,?(U?.B_@^#'6CA7:3F;&75Z% Z1@2$!,98% $.-.(
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M1,($(!HG"!AB!0S,&0\H!BV*/H2Z-,3"?@*)A" F@ # 1 39Q$0XX  _3%
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M;#UA)=)8A3$,2)BF ! ,'\WB4/VGXUX46&HYY3=YNS<EJ^G>B-%4^FE-R*[
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M(];M)U5=OW5'OZ,GCE-J[0ZH\IIY;^2G:E;\*9!EB'N8%$!*/:MV 4"E*4
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MR>1(>8![X!#Q8($ .R(!F,-G<P0H 0Y-@".[VL$M"8A'.&T-T(8(]MJ7$'(
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M:*F:ZH6TM-U'=:LJAI6V=OKA42XM_/:%I&1S.8G:(R-*FU$DVZSD',Q3ZF@
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MR9QR_O8#ZW$(X.C<2.HOO)5_X(/;#!PC% L'HA 6K@8_\$'AVX.%6* 8O@@
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5"(P1&"(P1&"(P1&"(P1&"(P1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2127058d1-fc_surgic4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-fc_surgic4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!A .  P$1  (1 0,1 ?_$ 0    $#!0$! 0
M       &!P@! @0%"0,*"P$!  $% 0$!              $" P0%!@<("1
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MFM"]3@\T=2K_ %"XN]?N?O7=2N_6=R)^?.6G_O#:#_\ B=M!P[H3NSZ)&/\
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M>WW&/YE=_>.5?UF<B?GUEWZ06?\ [WU/LSH'JD/FA/;[C'\RN_O'*GZS>1O
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MCV:T#U.'S1U)^H7&GYC=?>OZT?K-Y%_/K+OTAM#_ )9!.I]F= ]4A\T)[?\
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M>;NP33_%^C@2,<4HF\ S]Z#=VC.%98]6XVX\SD4]O'[/X2B>8"%/-6SQAAN
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M_P#?JT?Y]>,>^?M:+$*D R$? %]7?TGFO$=V[?W=/!VU)O\ :RC_ +!XF/\
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MEWC[D%BLM;J1@^6QZBBD.1;NR?QVV9A4\EGRTNQK22[$0U >;4XGN2[VE)4
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M>?5SW\61\5S$Z,L R!H<VM37-@*[&JYHO$/#NG:(V3TH@S6,D<C'@ND,KVR
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M#DQH.54)! 3_ )_K#YM]O;J#+'D[@2-=(-KLU/%0JMUG-)6,1O#:US%AJ#R
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ME>'?4;;S C_#UA'YB\:_H[._E;3\:UC[>;SC]9/97AWU&V\P*O\ AYP?;?\
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M;'_NY.'_ ,5M1^-:S]O-YQZU/LKP[ZE:^8%</3WA ']!>-OT=F_RH=5#7-8
M_P >;SCUJ/97AWU*V\P(_P /F$?F+QM^CLW^5-3^.:Q]O-YYZT]E>'?4K;S
M@^GO"/S%XV_1V;_*FH.N:P1_CS>>>M/97AWU*V\P*W_#UA'YB\:_H[._E;5/
MXUK'V\WG'ZRGV5X=]1MO,"/\/6$?F+QK^CL[^5M/QK6/MYO./UD]E>'?4;;S
M C_#UA'YB\:_H[._E;3\:UC[>;SC]9/97AWU&V\P('IZP@'^@O&WZ.S?Y5.I
M&MZP#_CS><>M/97AWU*V\P*[_#YA'YB\;?H[-_E357XYK'V\WGGK4>RO#OJ5
MMY@7FKT]81VG;!N-AX[;XY-5[#T(%L-P?;J@:WJU3(VYF#C@<SCCXR1\"#A/
MAV-PRV-ID!!'8QK6OQIU\&;CM8Q71HL.)6QXOQL)F# ;6W#81"GRHH3&;=6X
MXVTKR>X)*CV[[:ULKRZ4R2.':Q=C6IY:TVK?QQ-B:&, #!L  %!R"@&^J9L\
M+8KFLNTR"QI<35+E6UBRX[,Q9$^0L1I+C*5.OKLFO-<4$>)3OK/@U>^@9W=O
M/(QGT10#X*'X5J;OA_0KV;OKJW@>_E<T$^.@7JCTU8001]"X1]?"8_M_^FNK
MIUS5]UQ(!_$[K6/[+<.#R+2UI_ "C_#3@W_J/"?T*9_E?3\:U7UF?SG=:K]F
M-!]3M?NFH_PTX-_ZCPG]"F?Y7T_&M5]9G\YW6GLQH/J=K]TU'^&C!_91X1]?
M"F/#< ^-L?ET&MZL-ES-X7'Y:I[,: =ME:$[OY8P*C9R)E?HPXEOK+%^2.3.
M#L,OZAV(S955Y2U\&5#?GP6+*&T\T[; A<F!);>2-]RA8.J)->U-IQN75_B'
M4NMTGW+W^O6;;[3.'Q-:R!U'L@+FT:XM-' 4.((YB$WD7U!_LZ9JWFXO/_IP
MD+BH\R2AF)4DLIW\7"+DA(V^7;4'B#56,KZ4[SSUK/;_ $^ZY7(WAZ0@\D#C
M\BME>H3]G1";:=F<_P#IRCM/!*F5O0ZM"%)5N4J2?I?8A1!^QK''%%\=MT<W
M\8^6I62[^G/B1@SGAN4,VU]'=U+4.>JO]F.R>U_U,^E]M1)&RTTH.XZ[;&YZ
M>.JQQ'J#L?2G #^V.I8KO<'K(=0\///_ ,@]2L3ZJ?V8JT%Q'J7]+RFQXK2B
MF('R^%QJGVHO6G&[=7^,]:J']/\ K=,WLZ^G^0>I8W^+/]EV"0?5#Z6P1N2%
M*IDGH-]CO<ZO,U_4'=MMS)YW758TGN(U.,U?H#A_\D]2PU^LK]E8R5!SU6^E
M%OL)2>YZCZ$>.Y^F?'4_C^IDXW$GG=5%JKKW1PV9S3:*UCQMK$=NS8118Y]:
M7[*12O\ X[/TF^'3=ZBZ^WP^FM5#6]4'^XD\[KJL < :>W!VFP5_R@$?XT?V
M4A/3U:>DPG8[@.4&_@=__@UXZ@ZWJIP%Q)7^(_\ #X%+N ]-I3\,A\$=?@"]
MV_6-^RM<( ]5/I2<W\ ':,_(1MM=;;==6G:_J+,'7$E?XOF69%[KF7+:P:5$
M6_Y/6%F'U<_LN"A2AZH?2R4)3W*(-,H!(\5$BY\ -5-XGO@*>DR5_B^99!]S
M3\N8:&,O^4[J56/5I^R[D%M,?U0>EI\O+#;(:^A5A2U#=*1M<[;J'A\NAXAO
MSCZ4^O\ $?DI\2L-]ST3WY6:(VO^4[J2NG\]?L[Z>)$L+/GKTY08D]I+\23(
MA53;,AA94$O-K^F"DMJ*#L=]CJ@\2WX_W,GC'4LP^YF4/I%H0S?Y1/QA:E/J
M:_9K.H[V_49Z9UH*NP*#-3V]Q'@2+@@?7U3[3WP_W,GG#J63^B-]DJ=!PY>X
M/4G,Q#+?1;R!CLS*\,Y0X+R7'(%BNHEW%155DV#'LFV2^N&ZXU<$H?# [NWY
M-9$>O:K)Y$\Q_P"8_66@N/=K:Z=(8KC2XHW ?O1-_P#4"$UW^)K]FFBPD5+G
MJ0],J+*-(<AR("VJA,MN2RI2'F5L&X"PMHI(4/'IJ9=<U6+R[B0'^+_B?A\2
M6?NVBU24-L]+AFD/T81NY,K:>+XTIV^9/V?K\5R8QSCZ>%Q6AW.2!7U9:2DJ
M0@;J^F.WJI8\-_'5B/BF]<[)Z5)7^(_+5;V3W&Z@ '2:!(T;:BW<!X26K3S/
M41^SBKBZB=ZAO35%<CM,OO(D,TS*VV9&Y9<4A=R%=K@!V/MVUDMU;691FCN)
M,O\ $>L+1W7NVM+%^6XTJ)CB?WHQAX**V#ZC/V<5H0*[U">FV=N4I_W6-4O@
M%84I"5ENW*4*6E!*0=B?9JY^*:U&RKIYO./6K-I[O;'4)NX@TJ*1_P#9B'+3
M=RK>.\S?L_V7@Q(YM]/3,@CN#+M?6-N]#MN4JMPH="#X;==8@XBO236ZF#AM
M[7S+?N]R=V&G_P"R$-._N?F6\IN0?0[D;KC-'ROP3:.M-I><;BU%>\X&E[]K
MB4(MNY2"0>H&VK1XHNA7->2-Z7#Y0LEGN*U:6,.9P^]S1O$!/Q!9,W,?15 2
MXJ;R;PA$0T5)<4]200&RG;N[@;;W -]NNVI;Q-=2>1>R$\F<?( 4F]PVL6S.
M\DX?D:T[S;NIX<%Y_EQZ) MAL\K<#@RE=L9)J:[9Y?:5!*5"W([BE/0=-]7/
M:2^9CZ3(?^;KJL7]%K^W;WLVA4;R]P>I;Z5.](L&-&G2\]X98AS$>9%?<Q^
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MA/\ _C=HGV_)D*O#;5#K^ 'YSUJD<4Z>?)SGP'Y M<]_S'/[...@N/6/,R$
M['NXW:&V_A_[0ZD:E$>S3X5>;Q%9.'9:?$D_._YF#]F-7H[Y60\P- ;_ /\
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M-OD.L&2\>PY6..7G50M '=JI*7=%0_[[#*D>$A@]VW0[.A8"=ATZZU5]<N?
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M6VT*0F/T/DEM:&D[IZCO)\?'Y?9MJRV04I7%91\I//60T*2E'E;K]Q2TI'R
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MCDJ=R#E>7$W:<#:8$N0DQ_-[4K2"VX004$[D^)UG,TC4K@M<6E8/XG;1NHX
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M\B(3,;@SF@E"'0]$84VWL=Q[IV(!'76]X=U.6QN&EM6MYC3XE@:WI3;V!S@
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M[I(Z%7V=;0R98PT1T;RE;"UX0BTVW+)KED43MM*$D<B\5Y+ZC^8([=8.WB7
MWP&I;%6T!?SX7F>]Y2F%[QW5-*V[AVZQG&)@)!J^AZ%RM]+PYH7>'1XF2:CB
M<SP75(W]JHYPNX_[$?B7%L!]4U=/I,?(FR<#R],[+;IP3LDN'W8D8.J>GO\
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M<"<I&^G)N3B<SKH>$RY?W&15MUC##;,BQEOI?KDOL!ESXZG:K[-@2UVG<CL
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M7:$VG#EKWS&A]W(-AW'X.5:2RT_TF0/<>QSJ2%1@5T@Q&8D1BJJH+3?;*EQ
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M1]SW KWUT5I.]M6DXK#,+"N/?J"]+/EJF7M P?B4I"^QEHI0\2MQ11L@* \
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M:FFX^Q"5!1V^?PU3WK6OR8T6TM+9T]H;G][.1X* _*NE#M6S>8U.'EMN+@R
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M>X!M#R)68Y0QZRIAQRTV5-IZ'MVVZ(\1[3KL:FG8V!8/0E;#0F.LN(V[M^@
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M97N79?Q\+6YL*U(EKX9I%!9B3Q.]6,Q.'\15'D"0A=EG]\7E96\_(W^)@X_
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M?0=CJ%O.&R<RG'QKF&+9YB;.)3F[!4R:AUBTKVHT(6$I$<*?B"!,?D)<7VJ
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M(-LK M[^E7$<F\5\27MA&@6I1)@PHU57U4=Q$9J&CX9#X+>P<[6EE.SJ=^\
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MK )6U[AL3]7Q.W[OLU9H5-0L<R6T@E1 ^3=?=O\ :U6(WNV!4E[6[5KY5BA
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MHA*!U 2K.+WW=R" HJ3KRV\:67+QAY17=V;0^)@IA0) TD"4I*GGF4=%%/\
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M&B))9!_'>&?AF;^)+'1%>?Z7Q?[/R_W_ !]$2JT1&B(T1&B+6V*>X-CV;GV
M^S5Z$'-@K%Q_AKE+^T7XK9S?C"]<^&$MUN-)6AI2.X AMTE 0D]0I&XWULRT
MR,+CC1(06L 7RJ\:\V6_I7YE7=93+=1BU:N-#Q^EBJV#R793C3<1N.I10)*%
MI*GG5@G8>/LUJYX2&'#>L^$4Q*^N/TQ>I*IY1Q.DN'KZ*P;!E+\2!&;:?=!Z
M )2E*"ZZGO&W=VI!/AK D!AP.*NR19^U5=!:FZ:GQMD]P4E*>Y2V5M#=0Z%*
M5]Q3OOJMCFEN(Q6(^@&Q-YRA@]=EM1,AOH0ZJ1'=V/:-^XMD]I!(\2-;VS>2
M*.&!"Q))0UV -%P3]1/"E]QS?RK.NAO.5CLEQ2FT)6H;*6KN44CN!^?6Q-L"
M,RJCN <,0H<W5;B^5QYC,^)&ASI<5R%*>[ A:H^Z=VDNI*5L]_;LK;Q'3VZP
M)]++V9VTP5T3AI(QP335E-R5P_#>F<793.KY'TDU8/17'UR(SL:,GNCU[#3P
MD1VV%.-@J4E 43MK3FW>QU"PEH5QD[9!M4J./_VIO+/&?T) Y3JI]T]#AB8_
M]$^7$;;4MU"8[;B3'^_.HC)]Y(( 4=5"V<_%E6*HEH%-JZ!8I^UOX6N7A"S5
MM5.Z8\8B/;0=^U4IL/=K[R&1[Z$D#[KHKIXZN]W>1BC75 5!;$<31/Q4^MWT
MIY VX)-_2PWE+"6X[=T83ZF]@4J*%R$.!;A!V&QW\-7H;O5(J]V =E:JR^WM
MWTKBML/47Z6IU6)+N45Z'5A3B8GY2H;E.#M);'DJD=Y[N@^;69^.:TQN4L;E
M\"H]$M^1-AR!ZC/2=1-1B9T":ZIULK2O)G'$MM[+4X%AJ2$MI01N=_ '53-:
MU5VXA0+:V;Y07,;G'U_<*5<B>QAT"J?9C0WP7H?=;%N0EU/D%#BQ)W4I)4#M
MOT\=8TMYKDX-31O@5UL5O'CEP7+S-O5[G&7+EO5$>W<B+E;Q0WVPH^RVT!05
MW,I3Y94WLD ?<D_)K6223EV6Y?1Q64TV],&FJ]*WE_EARBK$-OKBK5&W?9B=
MDEX!IQ2T!R8ZAM *"D$';<;:R;5MBX?R\;C=AXU?=+"R(FH!25RKE"9])RK+
M+<U7+/PTF.BDJGG7I#Y?'853++=1CK4-^]*-MC];6\M='NKJ3.QM&[-G[<JT
M%QJ,4;Z C8FC>SVRRHLX]C4 5=4TY[L>#NH.N.]5O3)"TEV6ZKKU4>F^N_TS
MAB%@!D <?"N4U+57,=5KL%,;AG!FZ!MF5*47)KH!<6M W2>Y>X )/;T^3IKT
M/3M-BC% VC5RMQJ4CY:N<**9U;DYKF4H2>B$>ZHKV "0/DZ GIM\_36XCL@"
M2RARBN/(M+=7TL;P*X$TJIX^D+B67R1:'D7,&D,X34NE-0Y*0HM6=U%=0M&[
M;:T=T6,%#N+A\LJ(&Q.^O,./>)H[,BQB-)"-QPV+O^&=)EG N'D%M0=A4NO4
M?S;$P2A=K;54.2]-#L6IEI<994N<\D+BM+: 6@[D=O>DCIMN.FO"8 ^25SSB
M7&M%Z><L+*-P7S'>L;U$7%E/@\>QW8TVXR"1,;MI(6VJ1&I'.Q#D9QI*26%O
M)/E@D@E W&O3.!]&DO+QKIFX5^(KB>)=4]&MS4U)!V)/<36AKI6.1E+4@IGU
MJ0CP'_$,(VW'CLG8:^AG6#8;%T;:80N'_25Y*_4Q/=-%#Y;?[P7WAXN>[&<:
M(\#1U1_]\(YU\=7/_D2?QN^,KWZ#_!;T!*'5E74:(C1$:(C1$:(D?A7]'HGX
M0O/Q[8:(C"?XIE_AR[_?[VB)8:(C1$:(K5^'R^/^0Z(5^6S_ ,QHJ0G]L'ZJ
M"R%)2(?#*>](W![N#..>X> '3;;6!+7OC3;4?(OI'W>^D-X7@=#4!PD^"5X7
M$N*\^A7^\.;()Z]QZ?,0#_I'20$=H[5Z-9297@RXMWUVU2_Q+&LCY"L48[C%
M3-M9JT.RBQ'0 D-QDJ4[*>&Z0$-M)W421TU9>\Y,XQ-%VVF6T&L2!MQ01@4%
M4OG7%XACTO#JJ@D.9A:ON1;JU@2'WVI50\T%"H77):*4N)>7W!U*MR.BD]1M
MA^EQ$]L$$<JW;M'O],A#+!A=&2<0-NRB=[C/D'D7BR.U#MJT5-0EI<J-"DU?
M8Y)<.Z'/+DAM3D1Q49U25]Q4%)Z$; ;5SW37P4;]%=MPQ8:I"YMS>-+6@UQV
MIUJ?E09S<-4M#5PL4?FN2'Q;6%DA,9X)9<4^GL=;9B,/N%M7ED[*45  ;G6F
M!<]U&KO[F6T?;YY>TT U2*S=ZO*S5O2V9=?#4M3LN5&0TZ[8I_ZQ"%]P)2W[
MJ@2#N#T\=]9$$,X<2[R:KS?6-2T^.3)8DEY*;.\O:VRH(U3CU9(K)%>N4JVR
M5B:L?2+*_*^%BMP D-MA@)4.X$%942?#686 MS.QHK$3KV@DDQ80DM4XH_:*
M:0A#GDAU*%]5N.RG5.)V;2X%!96X?GVU4UU=BRYBUS:/&VGPK<Y[B5AC$:'&
ML:V57QIK0<;9D)4E2'&E#=Q1"0-GRKH 2-94#FYB'U.*YKB'2&M@[V*G=$8C
M?O73C]FYEEGC,CZ%G_$PWJV6EUCXD+050)[!=C.I0I.ZVU)5[I\.FNDL129K
MQL"\_MIS/;/M3Y3=Z^GZ)/B7^$SZLRD2)LNH;L*\! 20ZRE2G]NWW5'RT;D'
MY==-(X2-#3L*UUG9&WNV7 H75\"^:W]J'C5O"C-S(+TM#,FY;8E-02\RW(=4
MQ)\A4AEE?^\)2YL /#<Z\_NBU]RYO[P-.E>RRW;[2QCF&UPW;!A5<9:QR[I[
M1$"8U+AV+$@-2VWD*CR4D]I4'4%*5I4E*T_5!ZZT]TPQDK=<&ZE<7=V<SB9,
M<=PI1=&:WT^M9CQ;46SU@NLG27%*80_)4N*4.!"WG([)<\MMU:V$^T$JVZZN
M0PSO#(Q^]BNMU_T)K9)+C&1K/E"A[=IC5#-[A4R,J1;P;N/&K;IJ04Q6XZ'7
M?.4^PM"UN-.M#<*"DE':>G765+;]V:.&*\BU21GEP8-^8)+V\AJILD5(>:6_
M!=;5'L807Y,I7ND+BO\ :'"A/R^TCPU+(!G!:N?O+]S;1S7-QRD>,*0>!\]Q
M,9L59-F$V;?7$NI;@R'%2$.W:FX2PRRP_8+[WVXR6VQVHWV VV UMLG9&&(7
MSQK%U<&5UM7RG%;J]]77).9-/5''57^3,/[@R6G43[68DA)3M(>82B.4;'JD
M;_.=4^E%ARK&TK@Z34W.E)=NV>%,W<56<WUA'GYG/GW[[T=]U4.;825NUBBX
MVRF4Z[YFS2 %)4-AL1T]FKCKASJ#E70>QHBHQXP&\J:WH@P?E7#^9<:F5-!8
MLU#-_'5/N(X08+D .=ZFW)2W%_$I<2"4J ][?6=8]X7U&RJX_B[3+:TMQ"RF
M8 K[A^0<$I_5;Z'+/#_C7FLGQG'6[BL=C,*7+;LJR C?R2A:$K*PR@G;J4@;
MZR9LT=P'[.U5>::+=RZ3J@[LCNIG4=T&J^5OE6?E?(.1#EA=7+F6+>.UU5FB
M&4-)F4UE3J=JG;5QAMIE:6%B(.\I2=E;^/CK0:W:7-[>.GCV91\ 7Z&>[J\L
M;+ANV^S+3O&TDGY4U^/LLV,.3'6RA=K)#H8C%]H"<E1)CO,J3LD*>0M.X*>A
MUS#:QW!AH3( O4;?5H&#&AB=OK@NR?[$NPEQ/5C38K=;-NQ,6S:PH8KZ?]YB
M-?1S,:P0WLE"6V'N]M9V[DJ.WAMK=VC'%XD<*&B^;?ZAY;:;@V>6*F8/9L_S
M&%?84@GP_P"G4;ZV2^# :@'E7IHI1HB-$1HB-$2:RC_@ZW^TF,?CZOT5+MHZ
M5CX%_0O%?P!4_O%C15)6Z(C1%0^!^H?\FB+R7_U2M^GNJ_S]=6SM)&RA4.V>
M$+\ZGU 06_\ $/SO(?<"?*YKY36$DD!Y/Y;WA 6 G[GL/3KKR[4"3=29=SEZ
M3IMNYT##0^2$SF1\A8]AU4[8S9C$8)2I9:4ZC8#;<H;3N-SM]?6&QDKW 4-.
MA;R'3B][<WDUVKGURCZM$3#,C8TXJ '&BI,ICM+[CH04*2ZHKV2@CI[O7;6U
M@@#7 NPZ5U]KH-_* V/",G]MR@Y7L99RYDYJ8<EPNR4N+E27WBQ%9C)/FO//
M.+<[ VTG<[;;J UFR2LC;V:46_-G%:-9"UI==G9OJ>;E3KP,=I\<CN8YCE?%
MFVQ#9M;Y:4RGT%H;NEN1L@,-+W/8$^/MUI)YY-1D]#8#@=OSKJK7T3A6Q.O:
MR0+Q[:1Q?O!Q&!+?*PQKLI5;GC7 D6E[(R3(4.F)6.E4=A2]F"^/<#SH2#W]
MIVV^0D_)K:QM%G"+<>4!B>=>/:SJUSKVIO=.0Z=SB6@; *X*13%LQ83VJZMC
M.6,@^84L]I3'94D@>6ZZ"C<IWWV'0#Q.L22X=7*34+HM.T)TD3)+@C,W=N&&
M_D3CJQ:RI9/TS>63)+2VI/QL20I;=;%1N4Q(VR%B,4=NX'4$CJ?#5B.U<7]X
M:D+M;;4;5L(L+1O8WT&).S!-91<S5$K*;VI:M'YMC?S@W5IN6G$IG6"1\,W/
M;=4 GX:(%A;Q)&P&X^36T@TZLADG(]' V5WK7:W$+:WCC+7MNWAU&T-379AM
MY-V*DBYR!64/T2S)>@VLIQEM-BXD.LMK9#"T*D170IMI*O.:"AW$^[T(!.VM
M-=SQ&8Y&UC;A7<L_3= ;^']]=_XH%33:W^(;J<Z=7'>0\'GR+,+@8\]&D08X
MCKR"4)R:T^8$R5MQ2MSW$]Q4D)"O>(.L=C8PP/<*@[%SES<74#LML[)4C*6X
M@]!QJHWV.#S.9.3(%%Q[%G63TN9'A/W+JWY,.BHT2&V)4IR0A $."VVH=J%)
M  V!UF6=K-=3T:' ="V4O%MOPY8]_J3P)>1V!=XR/@4J+R/+XFQ^IX;C2ZB#
M</,6UODN0..P&+"#QW7.M?%W?<)0"+.4M:418Q(<65=!M[PV=Y(ZU@,0IF&W
MF6BTFUCXUX@=Q$QLK[4QUC8 [(9" 10"M6TS8UI6F*C5SQGD&9CD"EQIN2U5
MRFFG8K3B4F?(BH\AB"[)[7'5&;(6HN*3N4A9.W3KKSF^9--=B-U2]V[]L5]#
M>Z_2FZ;Z5JUVX=["QP&7%K2X8C"HJ 3F!-0>12G]*'I?N;J%%L\ZB? XR\W#
MEPZ'R76)\Y*2M:F9CA:"VJ^4LA1;2KN6#[VWAKI;33FV[&N-*TV+B^.>/+6W
MEDATUX>]Q-7 U%:8XU(VKK%34-7C=>U&J8;$"+#9#3,0-):8A-(&R6$) 2$-
MA7R;[GKXZSWR%XRM! 7SOJ6KR7TIDE),KMI_;F6S5,BMM*?LG$JC=H4M(3NX
MYYBD%"6T#HKHKH2=R-6A&=Y6B<YVY:"SN$2$K\WN8@I/EM-H/<M0^Z0'TI"@
M[W%("4C=(!ZZGNR.2B1MR'.3B5HY"G VX)6R6W A3$(+"GW4IV)>DK"4]WE=
MV^P]U"=@ 3JET1(4NOBUX =C5-;9ONF26%K4VMM:NQ;;1^%;9"@II".NZI*N
MI VZ[?4UB/A%>==-%?M[EI#AXQR+*2$2(KBUDM=B4K;:6#NM94E"7%CM\QP(
M6/!(\5>Z2=6Q"<U2%:DU*F_!*&.VMRO5&[%*2XL)><"T$I!44C<=S@;'>GW=
MRHJ(/16VVKG=BA)VK37%VYDN9IVXX<ZQ6;%=?"4P$NN%A;T8K[N]:TI6H)45
ME7N-)2H=?'YAJY'A6NRJTUZ\3O#B=@6DEV:''.]WM3Y2#NI"O,>"1_J[DJ;&
M_P HVU<!%=JUQ<68,.%5T3_9*2@_ZPH)+:D=V"9EY?G*\R04HA,GPW[&FU#J
M$IW/4'PUTG#S(Q?5%*T6)JA!M:C;5?51KO%SB-$1HB-$1HB-$22R#^.\,_#,
MW\26.B*\_P!+XO\ 9^7^_P"/HB56B(T1&B(T1:^=_P"Z^GM/^35^ @.5F<TC
MHH_\QXXUD%!907F4.MNQGDJ21XI*" !L#X!1\.NMK;/!:0=BHBF%*47Q]^O[
MTOBKRVVD/5#:XDJ8_84LE84T8\LONK;1YP1NAE3H[5';<$ZM3LJ.998?4XJ*
M_I&];6>^E;+[ISE6T5*GVUS%H\<I.Y265LI;8=8=BH2ZRS$J8#6ZEG<J=4#L
M"3TU-S$7]"RF'LXK["/39ZJL5Y,QRCGJR;XZTLX?GLP(;J$N;*<5W(,?O ;;
M0-O>6=S[-P=6.Z,8J[ <ZMO:">S2BFB];E^&W)*U!MQ.ZN]05["K;=*R =C^
MYK<VLK7TI2BULT9.S:F/Y#QZAS"$_!M(K;Z7$E(64I!2?%74I.NDM6B44%"%
MK928#F=ATKB_ZA?2U8TCTV\P_P!YE*]RPDJ&Z04]P*0V"#W+^36TCLGN%&M)
M:>8K&??4&!7-ZTR_)L.FNU]RU,94RI3:X[Z%%OW" 2.XC<';5MVE"M' "O*L
M5VJ9#V3VEJ)7).*7+*F+FMA.GM[07FVU[$>P(<[MOFVU(X<[S80J1K<@\JOB
M26EHXGLY'Q4B%Y+RUH<=4Q(\M#RDJ#@\Q)=5NG=.VP UAW'"UXTGNS4;L1U5
M63'Q!& ,[5Z36>,94GXYM"!(#K;P<0\%*"F^U0!W4 4@=!MX'6GDX9UH$]R#
M3H/4LMG$%B1VC\(2;LV<$^(7/CV'ERE;E#H<2IYGV@A2D$]@.W3Q.L4\-Z^U
MX+PZE>0]2OMU[3=I</"?G333$8S$=GO2,KD242/,+J5I9 0XLIW4$^4X2>T;
M 'Q'CK/BX?U88D.\1ZE:?K^G;G#QCK3;2I^!54>6TF?9V#<K8A;)9C.(V6I1
M:#B$M@(45==9K.&=0D;25SPT\WS*R[7K5S<"T@<Z3,_F&DJ(J(%57QBRV@]J
MK!2Y+_<!W$DMO)&VYZ$D#5ZVX,C<2Z4N)KRK7R\2!ARL*;:XYKR&W)BQ9TEI
MM2.U,.#W-I._@"A"B2-S[5:Z'3N$M/A.<-<7@\A6OFU]TH+'&@(6;BF#93EC
MZ9%@ER##61[KA*770M2%*<! 7LI?CUUVMGI3FLRQM( YOF7*7.MLSD!P/A"F
MWQU@-9C; 2S&272V@J?40I:EDG<%92![?JZ[*PT9K&5+=RYNZUX2G?12,KY[
M41*4I6E*@V-MR$GNWV&V^Q.YUN8K2)K<[J"/E. 6MDO3-F$)J^F%,5.3TI^F
M?,.=[&/E5X%4O%5'<M,9!83!);D6S"0E]R'4(3'*7DJ;4$N.]P2@$[;G7GO&
M'&6GZ=;NLX'M%P2-XQVX;5V/"?#MQJG\V^KD&(K7FZUUJY&Y/P/@+#XN-535
M3#PB+ $2%'A!EER.=@A"E@J0F2AU:AWD^^E74D^.OF_4+B[U>\[]U#2N*]QM
M+5ME;B.'  +YI?6?ZSE!FRL[AV6N%77X;QBJBJ09#Y="NYA1<>'8\QY!65#[
MA"A\VMSH7#T]Q=->:D'=3;CT+5ZKJ(M(R7&@7*/#[FWSK+KCDO)"XY9WTU<H
M]W?_ +NP2$1XZ0Y[R6FF&DI\>NV^OH_A70G6I:ZE*;J<^*\@U_6FWCB :M^9
M2VQ"]7^4&/(0\ GZ8JAMW#?_ (R/U !^4:[Z[M&^B2.IB(W?W2N)AE OFD;.
M\;_>"_0=PXE6*8N5?F[3$>SJ:Z+OX]=?"UW_ .5+_F.^,KZBMC6W83MRA*;6
M.KZ-$1HB-$1HB-$2/PK^CT3\(7GX]L-$1A/\4R_PY=_O][1$L-$1HB-$5J_#
M_I]31,,*[*K\N3_F,WG&_P!KOZI0@$($?AH+4!OU5P?QR1X[^!)UAS$=Z3T?
M$%]/^[R=D7"%LT^527X9I*+ARE*YCFP V 3OW$!.P4DJ5\Z^WPU9?60Y1O77
M0O,YH<:?MN4T>'>+<\K*2'FE37VDR!<U%FX^[7V0JX+-4PORGV9UBY#DLAXK
M'>II7:"A0V/=OM<]&=;V[WN!7KO!ALI70VT@[9  '+CNY4JJ*OG5S4S(6J]Q
M<^6'I"K#S%.K6F*A3*$-37$;AEE)2G='4=HV/R<M=QE[FN'DFOR+W]FFP6MK
MWQR$ 8-J"13;4;1N2YXM9Q2UR&OG\N6KLS%7I<.7*K('Q[\IUA^3Y$Z(%0V9
M3@4B,E9* 05="#OTUN]+L[9S,TYH -ZX;6N*)6O[JW: 1R+)YY@\"L+E+X>-
MG62&;J2([$BR/P:*=3L<PVTQ9M5$MF[%GN=\Q2W5!6R0$@^./<Q!D_\ IZT)
M.Y18ZU.+%]O<-:7O'QJ&M[<Y%=6,RD6DV#K\Q;J)#25N3'1LD,1!VC?[V$ ;
M(0?#;?;KK/CJZ,#*2Z@W+SV]AAMKLR.-#G.W8,>?8I#<0XO7-N65?D]8S(NR
MEJODTRXKDJ.U'ELJ6W+F*C.L/U\AGM&SOF*"-S[B_9C2Q/8QV!VUV+O-,N8K
MVV$(+2!OPP\22TN/(J;.165D5$9IN4M;8:5(45)2LAMQ+[OOJ2E)W![4[ZUS
M)"QW,LZ\T=SFM;%OH01CLQ7AR#;W%Q0I1D%D)J82 W&0\YWF.@,+;0AM6W^E
MY7R[D['V:S('YG5K1:+6(GQ6XA?MHI(^C7D!2>1L78D38+GTA1I@K:8<<3*2
M*IQUN.B8E78V71'(VVZ$:ZBVF#:+Q.WA?%/,T@XUHOK0XAL*R8SA;LJ2EENP
M0[4OK(2AM/QL-33*W5A.R4)==2" 3T\.NMXR=SZ&A(&WFZ5G]S*8J,:<Y I0
M5)-<:#>N4OK5QO\ *C'^3*14B*C(**7;FI>0ZKSFYU>P^J*I@D*W'>D$'H1]
M77G-Q?NBU*0.P:3A5>T2<.SW?#5M.T.(+*DT.&',%\]^$X!FF9\GFBOI$J;D
M$EQ$JSER7'I+_E*1'(>?>4''-RA2 2KH/#67W1NG XXT6+H-I^!QF<^7C3EY
M?D75.TR*BX0QG#+&Y\Z92X_D>/.6M0TVEUVP@,SX[EE":2XME!^*C=R>I&RM
MNHUMG$6D\3:BH&.Q4:G<3ZI#+.ZK6%N_#>%RMY"S!K+>4,BR.B9CP(EK/F2X
M<*6PA+$6O#BT0(SR/.D+[FXG:GHH^'CK'O;CO92XC:1\07&&-Q=W-:Y0/A%5
MKFVK L-BU80VIU9$*SKV$&(V7E% ;=5+)#+/>K;<==R-6FO+' A:Z^MAW3FX
M5*3-MB/FQPY6,63LM!=%J[($9,-3@<5Y;\5YIU9*%(W[BH)0>G;MK8B:K<11
M>4:EPZQ]QWPIF#J[<?$ESQ5 \J3&2]*BM+:<[W6 %NJ>3'4LJ0OM0&PI8]O>
M.GSD:U\N+^SB5L;.9^F0GN2 [P*;E;(PN!7.9#9T])&==:<:A+R%+R'U@)2@
M&*I<A<5<9MS8D]I5MMK)A!+>W6H7(ZEKNJRW=&^17=N3Q8QZQN/N$X[$:F3:
MY_>2&67DI@11#H:QUEKL3%,J>N"[(88<62A32%#;KOMK86MZRW<02,5I=1TO
M4]48Y\;<SJ<AQKR?*OJW_8P>L?%_4YQ)G>/6%?'K<RQ]"G)M5%*"^:2SC-0^
MQI3KSKCC3"M_#IL/'IK(GN?2' @;_E7DG$%A?V,K8Y6AKANV'#X=RYW\^X71
M\'\^<L\?NU\:%+'=>5T4I08]E69/ 9?EL%6[)D,Q+R/(*$E![4.C<[G6XB?:
MQL<Z0MV;S\Z]\]W7$=_JFDPZ='4E@IAN\2XX<SU"\ O*Q-%*?@4F3MO6%#,:
M4HN8GD,1[>3 5WAKLIGW??#:NY24J&QVZZYK4+.WMY&Z@!7,=G)NJ>9>QZ=J
MU])(_3),P[D9J\N_P\B[1?L3LH8S'U=X#-DSHAR"FX]SV'>PW(ZH[QE/UK *
MZ=Q"BB96[P?-=6K?M6\GM(&^JRR+)WL>7'D*\?\ >[JD\_#,T$N;(Z1E*X5&
M<?!@OLE1U'_3PV&K"^5:4PY%?HB-$1HB-$1HB364?\'6_P!I,8_'U?HJ7;1T
MK'P+^A>*_@"I_>+&BJ2MT1&B*AZ@_4U!V8[$7D_T;5_YJOL=IU!H&EHY"IPW
M\H7YA/K;YUJ,+]0WJ&B-RVWK%',W*C89+A4VUV9S?,[N=KB>T;M[>&^O.9[=
MQNI/XE[?I !M(Q$S.XM V+D)R+S=;Y;(4#)?=:7YFP)6&D)*EI"&T>84CQ\2
M"2-94<+(VU<NYTO1W0_ZJ<!P=3LTV)N:/&YM[&^DIDPPZYEQ9+BUA/>0KWNT
M.>X$@C;<==^FL66I/\O$K97.HQVCCE=0[F\B=#%(#;C?DXV?OTL+:?F[]F[0
M)#BBI(!+0'L5T/R:P9(I;[4!:P5 #>US;%TMO/I^B:,_B*_ ?(ZG=M..-#4@
M]--R<J/33?+9QK'V7WY$Q6UI+82M<AP$#S7W'$@=J4))V'AK?6<&G:?"9)'5
MNZ+Q+B36=3XCNW..$!D) QPKL&U.\FI%;31:&$\AEG9E#Y0E1GON(">Y"" $
M^:5CJ2.F^M7<W?>5.7&JV^AZ*;<,N+C_ !J)_P"BQ["8M6@O/QZ6/%B-KD2O
MB&!/?D]I[XWFGHTAHD;G?<[G?6"UV8URK?7-W-;%W=^2:?&E)B]/6YZJ;%8M
M7JG#U-N)G34)"S8*;[$-5]<7.YHNOK7U6=T(2D[GPWS(8G2>6<K5C1WS]+)N
MXQG>1Y/(HSY7QO1P.0XUA/I[%C$L#-G<0K.#7H6NULH*/-?C+88<#8B.M=5N
M$ J[?#KK*,IC:6%U0NU#V:[I\$KI!^),=6E,14UY=VQ).YYD:SO(8=2*YP8B
M5M>7)1 0TM@(0X'&F5A:@00-MCV]WR'6! V!MSWKQV!^[RK>:C8=QH4S&R'\
M2>WH%"" I"2?17C69NP+/CS-,@CUTQ#;KQDH,:5)2\\E#+5?&2RM;:4]J@X%
MJZ)3N-_#7436=B;47#0*NP#:;%\Y1\6ZIITIM;ED9>P''<!OIS[%T4PRE@>D
M[B5YN#%D.VGPWP\V3'81+ES&FF%J"9$AM,9PH*R5[$D*4!TUIYI8](MS-&[-
M.2:#D7/.;=<;:B3(7^BLI7DP-/E7+_**O,>4N0Y3%,S<7TVTDJRJ [,<^*L)
M<R3O$:B&6A +%*RADCR%$@*3K5PNEO"7S>2_PKZ)T74;'1-(ABBI''&&Q$8
MTIY6P8X?"I)>G+BRWR'U MU.6PH$Z3C*#*EUYW>KXKT:&M$.(4+:[2F*X ?
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M%Y^/;#1$83_%,O\ #EW^_P![1$L-$1HB-$5JCLD_7_R;_P";10<<.5?EM_\
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ME1I$&:Z66VB'GFRE+3I[DA7=U\0==+8RA\-=]%X9[S^&6UDN8VTPK6B^C_\
M:Z<08TW=\2<Z3BF J5;0<#N[F,I+3DB'9H<;JYLEQ*$?>V;)#*E+!*4I?).X
M&VLIY$O8VKEO<QQ'<Z-J?=%C',#G;:_1Z5P ]7W'\Z%@EG8SV42[3&;H6!=2
MEQY,JIG-!':VM02'7PV"1OVD[:NWD#SI]9-P7T&=0BN[X7-K3/(:. ^%/%_R
M].1VCG[0VAII*?B:V5Q9R&_#6\CS'J_X>OC.^0RXM?>PTZ3N$I!"@G8D$;ZY
M^TE)'=G8"O+O?) 8]">3Y(?'3HSCY:K[Y -MA\W7ZVWV]9R^63B:J[1$:(C1
M$:(C1$FLH_X.M_M)C'X^K]%2[:.E8^!?T+Q7\ 5/[Q8T525NB(T1&B+'E?\
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M$Y$*J;9>92"J,E"']NY*]AV]P('<GM]OLWUDUY5Y(VQG80"TFF_I3EX/*2B
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M:O\ Y<.%4H2VQSU3;(':D_D&M)'S#:R\1K9P>^6*,5%C\(^LM?-[MKN?9>?
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M&VDFE6\BO6?]4G'5D:QP6OFCZJS7?^6B]#DAYJ1*Y ]0DMQG8-JDY?C+I2@
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MONTD$;44UL4R:'<BWKXD'(XR\9L?H&1)R*GLJL6CT:#%DB?52[%II%] >1(
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M4F<N5?)^?WF%IATV$7F'5N*8C6VRDLO7-O2V4BXD7]N\U)F*D)J$I+'P[26
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M851HY!=0EZ^-T8(?^,[5+;3][[]@-^NVO88?>QZ/P\-'=9O=EA$>;-A38,/
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M-;4VVZ)K$6),EM[I6E"7 H]I5XZD.(V(FXXKX5S')+Z''YCQ#/(]-C/'61X
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MGO*">.ZG(CR(X>2<:L,"LKS*G<7L*B%C>)2,G%-+PBIO9E9/ERY;T**TZ_\
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MIF78-R&)3<V2VI)2]*1)C-N!:@5!3:3ON!J$6LL,"PRUNH>266+T$_(*[RS
MN9=3"?LXA95WLF/-<:4^T6E]4D*':?#;1%MEX_2.QYD1ZJKW8UA*^-GQUQ65
M,S)G>PY\3);*.QY_S(S:N]0*MT ^P:(O>RJ:RX@2JNU@1+&NFLJCRX$YAN3$
MDLK&RFGX[R5M.MGY""-$6BK\#PVKJ6J.MQ:@@4[,UBR;K(E5"8@HL8TA,N//
M3';:2T)C$E <2YMWI6 0=QHB5A0"DHV 21MM[-O:-M-NU%IUX[1+JW*5517*
MJ'25.5JH;"H+BE2!+4I<0H\A2E2DAPDIW[_>\=$63:U%7>ULNGN:^':54YDQ
MYM=/CM2H4I@D$LR(SR5M/-$I&Z5 @Z(DKCO&''6'RW+#%,'Q7&[!YDQGIM)1
M5U9*=CE066''X<=IQ316D'M)(W&I))VHM[98QCUTU.:N*6KM&[.&W76")\*/
M+1,@-.NOM0Y27T+#\9MY]:TH5ND*42!N2=0BOH<;H,8K6JC'J:MI*QDK4W J
MX;$*(A3BNYQ:68Z$([W#U4=MS[=$5T?'Z6))CRXU57L2(J;%,:0U$8;>83;R
MDSK1+3B4!:!83$)=>V(\QP!1W.B*K%#413&^&K(,?X%Z7(@^3&:;,5^>753'
MHY2D%EV47E>8I.Q7W'???1%J(N!X;!R%[*XF+4,?)97F?$WS%5#;MGBZ@-N*
M<L$M"2M3J  HE6Z@.N^IJ0BNBX)AT'()&60L6H(F33$J1+O8]5#:MGPXGM<\
MV<AD2%EQ/11*MU#QWU.9R+"7QEQ\Y43:%>&8PNDL;!=M.JE4D U\JS<6''+!
MZ*6?)7+6L;EPCN)]NHS%%FS<"PNRH8^+SL6H)>.1/+^%I)%3"=JXY9W\HQX2
MFBPRIO<]I2 1OIF**^!@^(5;$2+78S10HT&;&LH4>)50X[46QAQ4P8DZ.AII
M*69<:&D-(<2 I*!L#MH23M1*K4(C1$:(D?A7]'HGX0O/Q[8:(K<+.U1+.^W_
M &Y==>G_ *P=^72H&U033%*GOZGW_ ]1W#Y=O#<>T:I(+14YCT!0 ZM 6_#7
MX%[=_@K_ $=M]_D^K]352J6N<NJAF3\&]9P&99( C.S(Z)!*@"D>2IP.$J!&
MPVT1;$+0KH%)/3?ZW3K_ /A#[.B*O<@'Q /A]@?Y@-$5=Q\H^SHB.X=>HZ=3
MU'3ZOV-$1W)Z]1T\>HZ?5^31$=P^4?9&B(W'RC[/U_\ )HB-QX;C?P\=$1W)
M^4?9&B([D^'<-_JC1$=R?E'V1HB-Q\H^SHB-Q\HT1&X^4?9T16+=;:2I;CB4
M( *BI2@E*0D$DE1V   ).YT152XA8!2I*@=MB#N#OX;'P.^B*[<?+_DT1)O(
M,QQ/%#5)R;)J''EWEDQ34J;RVKZI5M;R0HQZRM1.D1U3[!\))0RUWN* .R=$
M2A4ZVA"G%K2A"$J4M2E)"4I3N5%1WV  '71%BU]E MH<>QK)L2PKYC+<B'.@
MR69<.7'=2%MOQI+"W&7V7$$%*D**2#N#HBS>Y/AW)WZ=-Q[?#[.B([D]>HZ>
M/4=-M$6OA6]79.3F8%C!FNUDM4"R;B2X\EROFI::D&'-0RXM426&'T+\MP)7
MV+2=MB-$6PW'RCVCQ^0['[!T14*T#Q4/L[_Y-$5J'6W1W-K2M.Y *2""4GM4
M!\I"NA^?1%?W#Y1]D:(J*6E(W)^WHBM0\TY]PXA?4C=*@1N"01N#X@C1%Z;@
M^!WT1&B(T1)K*/\ @ZW^TF,?CZOT5+MHZ5CX%_0O%?P!4_O%C15)6Z(O-Q/>
MGMW(W\"#L0?N?$=?]+1%!3%^8,DKX'&.(\7X+6/V').9<\PTKRW,,@E5U YQ
M]E4]<^XFV$ABXMYD2U=6X416ALPXXTV@(92I2")2UOJ(SN]K<,QBJPK'6.8,
MHS#DW$)M597MF,%IU<2VS]=E%U]-1*EZ[G5\IOX=<)H1$OJ5)"7 V$J4*J"F
MU%FV/,O,%3EPQ:WP?!(3>+8%#Y*Y*OFLKNY=?!QM%_D5;81\4AM4,>?;7,ZL
MQY<F*U*3&:0O=MY>P2=*#E1(#B?UFKY$O\)2[4XU^37)49^9CK5%89),R;$X
M;E6[=T[O(2)V/P\=AIEU[8;D+@S)+<:4H("G4??-00!L*++PKU;75_F4W%)&
M/XCE:IF"9WF>,)XMM\FNG)<S!%59>QMRPR'',?I[";=)N&A&?KW760\E:%[#
MM4J$6GKO6DMCC2TS3(&./573N2X?B-)2T-[DX%/D&9I6TU Y"AW.,0<AQYND
MD(49#D>)*+S3:O)0I8"3(:3L19T?U>7SF&9W/:Q:FN<@P>XPF%+OL?.92N-A
M19E,<8=R>7-DX[%RM,/$TPWC9LLP77&B$*"BVX7$5%M!4HI-<6\BO9YQQ"S6
M5*PZ6X\BR\R;B%_)N<4>1727VA)8LY]=7S8K;K3(6XQ(82]%*BA>ZDG5"*+^
M.^L2RFS<WKI]=@EZNDX?S[EC'K#!;7+)U3);P),/XVBLK3),;HF9:ICEBSY,
MNO\ /84$N[A/:V7)&.U$J(7-7J$L+VCQ5GC;C:-<99QU)Y2JI$S,\A-92T-=
M)J8,ZBR LXTJ0]D;DR_AADQ&UQ0DO%2_<1YLT;RHLZF]0/(V?/<:U/'."8\;
M3.>-9O(5I.S#()T"AQ555>1<>G5#IIZZ=9VKDBRD;12VVD+90XMPH(2A8MH*
MHL[ O4?897R%BO&EMBD2ER.0_P K4F8F':N38-1D/&*<,D!-))5$BNV-/?PL
MO;?;<<1'>;3VI6V%=P%*)'7/-',^19MP>C (&#0,=RGD#EO$<D@9#=7#4FP1
M@*,KBH6ER'CEFJ,V6*(2VBA:5KE;-N;-[KU(1>F9>JVTQ/EB%@J(O']Y5V?(
MU)QJQ'I[W*+#**JWR0)CU=ED79C QBJ:8L74IDPTSERVV#WI[E#L,T'*BT6"
M\A\G9%QY-M>9:W&;5,7U&HPV@.(9-DM=)9<K^5GL>B?'J8J,=+U;2%M"66UJ
M<^.:1_O2 5*3I0<J)7/^I/,_R<R7EFNPK'U<(8AEMOC%O+F74]GD69!Q[(58
MK?934TS-:[0&OBVZ'%M1GI:)#\5A2AVK4ELJ#E16WWJ.Y'IW\KR1O <:<XSP
MOE>JXVM)Z\CL1EUHS;W-+2C(*6I35?1:6*R3=H+S4F2EQQ*%]@&R>Z" B?3F
M3D#)<!H*"7B>,P<JR+)<SQO#*RML;-=17)D9(^_%:GSI[<::\S$@+;#CI0TX
MLM=W:E2MAJ$3#9CRMD/&]OGUM(PV':Y]5X?Q+^4TVOO<PM,+KD9%<7M9*M?H
MIJ%,LH.-XP8SK\B1#K_C925CS$$C=%36U1-+E'J.@UF>^G3DFX7C^06>381S
MIBE!7\>74NWH,BRB7EG&%;008EO;PJ=54)2F"9)GH:^"4%I45%([I+*"J+HY
MC;MT[25CV2L5D2^?ALN6L2FER)U5&F*3W.,09<J-#?D,-[A(6IIONV\-4(M]
MHB-$1HB-$1HB-$1HB-$1HB-$1HB-$22R#^.\,_#,W\26.B*\_P!+XO\ 9^7^
M_P"/HB56B(T11N]1_)60<=4>&N4N0XYA43*<UAXQ>9WE=:_<5&(UTJJMIS,P
M5S4ZN9>GV$^ U$86^Y\.A;VZTD; R!4T1;/T[<@W_)7&L7)LB>I["4+[*:B#
MD6/Q)$"DRZHHKV?5UV4UL"5+FOPF;>-&2X4%Q2?-"B@^7VZ$4-$34<K<F\G<
M=\C8Y$1F_'-DSEV88_1XOP^UCD]687&+378<2]OEY$N[;<;M*@JD2>Y$00DQ
M6PA8*SWZA$FY_.'+4FDY&YKJ)^*QN*^+>2;_ !*?@TK'9<J_R7$\*R-C'\TR
MM&4-WC2*ZZ9VEOU\<1S'\N.E+^ZEE;=5!RHD]:^J3.<7Y"N$7YK9--7YGE-'
M+XYA87>-9!5X3 ^+;PK/(^6O6"H-M(S:4(R6V0TEI:9:6VP'6W"9#*["BFGQ
MA)RR7AU/)SF94R\KE)?EW3=$E":FNDRI;S[5/"*2M3J*B*XB,IQ:BXXMHK5]
MUJA$X^B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1
M&B(T1&B(T1&B(T1(_"OZ/1/PA>?CVPT18^)'_L:6-RG>]NO>!ZC_ +0>\-^A
MZZ5(V4.(V]*AQR]JA-,<.;''9@N,UU^T#Y[K^>+'C=B/@HQV)RD_A[2W,=G&
MQ-2C*5TX4N0F[2TJ48@ *PCHOKV^S7T!9^[#09N&VZS(^=DYMQ(0'LH30&@'
M=UWXXKXEF]_W',/O DX:;;Z>;&&\,>;++5S7.('_ '<",OPKN3U#:4DC8IZ]
M.FQ!Z'YMM?/Z^VU![$^(>+N3.7/5(>0\!P_,7F,WP^!&G9%C]79V<"&OC?'7
M_(KK.5&7.K4MR'%/)4RZVM#JBL$'J2)*X1RGD>"X!;8QCN45=M&J.;<BXTXL
MN,VBY?G=MDV,54'Z3<JZN/CSQNLJG8O.+]>EYV2VA$.&HNNK6@!=S(HJO*AY
MIYXY'R+@292.X3BL:[RGF7$<ZHK&HRE#=G8<;6%A4O2V8[\QFPAQ7HM>'X[#
M_P!]C2'%)=*TC49.=*I<2?4=EL3EB@Q]E&)9-@5URM(XH?EX[C>;B?26YB7"
MH[DW,+%<?%)=E"GUGD3(;+.S?<KL>6I!28+:*4Y'J$Y3SKC*!CD[$Z:L<K)\
MNU3DV675#D^34F*PX<#SX3MA58A):N@BPE[M&0GN;8 [E)/@:46NIN>9EGCW
M*=VT<2LV,!XMH>0(-C1S9\NCN7[7%<AO9'E2Y:8DA=.F53!+:_+9=+95W $=
M"+05?,7+W(5HJMXZJ^.JS\G>/\&R[+'LU7D#WTA;YQ1KNX5+CC%),8<@5L>+
M'6EV<^7BE:D@,N;+.@1)[ ^?^7.67\4QS"J;CW'LG7QG7<C9Y+R=>06U$P;O
M(\AQNJHL3:J)U=-F!4O&)3DB8Z4H9;+78TXI92BJ@Y42=9]5W($NEP^M1CN+
M5&=Y)F_,6,V+S5=EV9XK35W$F4V..2I<*NQOR;VYE63D1H-GOC-)#BG%$!*4
M&KNQ2M46??>I'F"!A&,7AP:IQ]3EQF=5F.9WF(\@6^'T_P"3RH:<=GQ<?JD1
M,S@U65IE_P#%2&E-PUL.)*7?=*J"*(ES@V:\M91SBZA.2<<VG%L_BO#\L@Q:
M!B]F.2&[F;;-?2%/:/RTQ9+DE]D;..,H;7&2CW$+[R81*7DCD+EF)R8CCSC6
MMP-0:XLLN19=QFGT_(0F1 OD4T6B9@TLR$ZM-IYFY?4Y]X+144N$A&B)IJ'U
M,\E5>,8%R3R%C6&L89R'@V69; I<37=/Y31/XOBLG+!$L)]E+^C;9FR@0'$)
M\EB.67"@'O&Y%88#M*++X]]27(5M+K7,THL=B8]>X1D67JOJ[&N0:&DP-ZEJ
M6[IB+EM]E#"HEQ6383B@)L-IDAQA6S!2M"DPYN4T&*)*Q_5ER)!K.0W[2EQ*
M[=IN!<KYKPNVJL<SG%J*U.-284,U3OY5O)G6]7,=LVW&YT9$?=(45-I)3O %
M42CRWECD>'59_BO+&+<=7=?:>G3*>5J^MH?RC9AK15ENOM\/R-R?-7(L&G$6
M;&TR*8I4/, ;;*4E567G18=ASIR_65/(TW",:XVAXAPOQOQ[EDB#=+R5VSO(
MESA?Y36&/U#D.:S%JEU<&&MN-)D)D!16V%-D!:C0B72N9>5,VR?D"NXOJ\!@
M4O&-)B\V[<S]=V_99';91B4;-6:^G31S6&:&NA5LYII4R0B07'R>UGL;*E30
M<N*)@*+DWD_DC-O3SS#)K^/8D"U]->><@S,>?C7EB_ G-/XS)MF:N89@BI>)
M\IJ*^&RH-*>"M^Y&TT'*BD^OF.QLZ_A&*JOJT?KGX_R3([7RG7E?1:X.$5=^
MEJL!<'F-*E69;47.X^6$]>[?44'*BP>)<BE8?Z/,,RNO89ES,;X49OHD9\N)
MCOR:G''9K#$CREMN>2\['"5=I2>TG8@]=0$34/\ J2YFC6&'8M/J./*_+,KP
M=/)<IZOQ7DC*ZBCQV:Y%B5%%Y5'+^D;2YDS2\J1*/PD5AM"0AMY2NE64<N*)
M?UO.?)N:+XQQ7%<7H<4SW+\9RO*LF7G\+(4TM)7X;=0\9F+J*B,Y57=L;^UL
M6GX(><BJ17J+KP2YLVJ" -B)K^#.2\UH.5,KP_**O&$VV?\ J+Y%I<ADTLZ?
M)K&%XMQ-AUS#F4292D26V[-384J/*"W&.]222I/>81.A.Y]S6TO(F"893XJC
M+;[EWD#CVGM+]ZQ5CE=0<?TB+ZVNK:+ DL6-A;.,N^4S$9=92MSWE+0E*]YH
M2BT619+ZE('-W >*R[WBR)7Y' Y$?RNMJ(&5.5UPS1?1CZ)#"IDUJ; G(J92
M3';*W4,RU+[U.H"=0BPN/^5<QM4X]QWQ)BN 8K:6EGSKDMK+R%603,=K*G$.
M8+K$G'8-5!L6;.SN<ENI?Q+R1*8CQ0M93[OEM:D ':46RC<^<M7MU@>!X]0\
M?P\SMLOY;P;,[6V5D$[%*N=Q97P9OTOC42')A6DZ#<IE )C/NM.,E8"E_>U%
M4EM!6J)_^&<TR+.<,=GY?"I8&44V3Y?B=ZUCRIGT$[/Q7([*E^.JA8*<G-P[
M"-%;?"'5*6V7"DD[;FE%'+%^3^095YAO'O%.+\<8ZC*(_-N2VDZ^3D4R#4.8
M7R#44GQ+-?736)%E)O9.0EYYM;[*4.*[DK  ;)%)?A/.;?D3 (&17\"#77S-
MOE>-7L:K6^NJ^F<,RN[Q&RDU9EK7+36S9=(MYA+I4XAMP)42H$DB=K1$:(DU
ME'_!UO\ :3&/Q]7Z*EVT=*Q\"_H7BOX J?WBQHJDK=$5J_#IOON/ $[;=? ?
M4T1,WCW"6&XW/Q"RK6K(2L*G\@V=(I^<MQ*)7)D]=ED_Q(+8\]MR2O[R#L&D
M]!OHBU5IZ?<+L(\4Q)&0T=Q79GEF=562TUHJ)>U5WF\M^9DB(DEQAUM599+D
M$.1EH6T4I2"-T@BH$;PB4&-\0X_C\R;9N3+W(;.TQ5G#[:?D]FNW?M*=FTN+
M?MEI=0ELK>E7LD*[4I2&E);"0E(&E1R8(DIBOIUQ+$4PX-=<YD_C%373J>BP
MR=?.N8W25,^.["<KH<9MIN2[$BPGBU%2\XZ([?:E&W:-H)!V(M+BGI7P3$I%
M'(B76>3UXOA^28#BZ9^3/]F/8KE#$%FQ@51C,QO)D(^BV"U)),E)0D]_N[:B
MM,47HUZ6L ?;R!V\L<NR.[OOR;5^5%S<I7D-4O$);\_&7ZB?$A11&F54UY3H
M>4A2W%'9SN'34]X?V"42F8X/A,8_:4WY<<BNSK6UK[E_)5Y(H7;,FK0AF)'B
MA$5-:S6>4G9V+Y'E/DJ+@4KKIF)1;S"^'L3PC";C!*]%A.JLCG9':Y!(LYBG
MY]O:9;(>DY!827FT,);=FO2%J"6TH2V"$I2 -0B;6K]*>!0&W$S;C-[W;C/)
M^(H:+G(3(:K,#RN/7QK"JKV&8K+3<E#%6R$R5)4^2C=2E=-@P1/#'XXH(M_3
MY(TB4+.DPB;Q_"49/<R,>GS*:<^AUDH[7)7Q-#'4'=P0 H ;*)%51R(HWN>G
M>#&Y4PF#CTS-\7H<(X@O:6CRFCMUQY+$RWS:-.F4TR0\T_%FB2RGSO*=:5L&
MDJ&VW6HD%JA+T^EW 8S.,.TUEE]!D.+6F4W43,*R]7^4UA8YNB.C+7[F?)9D
MHLC="(SWA:.U'E(\L("$[6U*S(/IMPJGH,&H*.SRVJ/'F47V68Y<Q[Q<BZ;L
M<I7:?E"S.F3F9'Q\6S:N'T+2X"0E>X((!U((&U%JI'I7P&3D O';/,516N2H
MG+D7&DWZV\<C9Y$F"P^EDQ$QP^XT_*25*9<<6T"LE*02"*JMY$2HKN L2KDW
M41J?DCM1<<@QN2TTDBS#M=59.Q?)R=YZK 8#S,2;=[O.M*6L$DI':-*MY$6D
M?],>!/R[-I$S*8N)W>2JR^[X]CW2F\)M<@>L&K:3*DU1CJ>$:9:-"0_&0ZEA
MYTE2D=2%*MY,42MN.$\.N\?R;&IK%A]%Y;F;&>VR6ISC;QOHUQ6WC/P[B6R6
M(HGU+*BWML4[IWV).J33<B6V38A5Y4*%-LE]:<<R2IRJM\A:FBFUI%/+A%X)
M2KS&0IX]R/!0'4ZA$D<EXAI<BM[^_3;9+0WV00,<@2K;'K=VOD,M8O*L9=8F
M.D,.L>4MRT=\]#B5MO)(2I)]D@D;$2$@>E?BJ-&8CV5=99"I,//8\Y^\FB6N
MV?Y'F4,W)+":VTPPRFP+V-Q/AG&@T8WE[M@'KJ<QI1$]^(8RUB./U..QK*YM
M8U-#:@QY]_-596S[+)6&OC9[B4NS'FV]D^8H=R@D;DG<FE$J=$1HB-$1HB-$
M1HB-$1HB-$1HB-$1HB260?QWAGX9F_B2QT17G^E\7^S\O]_Q]$2JT1&B*/7.
M6 Y;D\K LGPZNQ[)K+ K^;;*PK+I3E?CN2,6=--J%^99-PK--=9UAEAZ*ZN+
M(0"%I(3W!0D;42!P3TV.NXW.1R%:VE1:W.;Y%G*,;XXRN_QW&L35?MU[1QZN
MDU[M<Y:P(_T>'RMQAI"I3[RD-("MS+C4X(L3D7CCFSD6]1C%O5<9?DG%R^IR
M*FY2CJG,9Q1TE3;1;AN@B8RJ"ZD6:G(ZHIG(M&V7&5%PL]2WJE$GK/@;E1B'
MGG#]+^2SO#G*&?7.:W>73;2;&R_':;+;UB^S##8&,-5CT2V<G.,O,Q9ZIS'D
MMS25,J4R.^JK>1$YG-'#62<M2?H-BT;QK&J7$Y;^.SXCRE3).?3$R:^NDVC#
M)CNBLQJ!L\S[Y4X^_P!VR5-))J:X *%7T\<691Q_-S&SO*;'\*@9 C&XM?@&
M)75ED5!6R*")*B3<G3:64.L4++)TOM>>RW&2$)BME:UN*5M;4J46B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T
M1(_"OZ/1/PA>?CVPT1>6'-]]1+!Z@WEV-MSTWGO@^ ^?5+MFTC$;$I7;L3=/
M^FC@V1?.9,]QAB;E^[:KNW+958V9:[5<DS%3R\?>,DRCYA5X]W770-XIUYEL
M+/TF8V^3*!7 #DV+A#[M>"3J;M7.G0&_>_.7TH<U2:[>4GQI\^U0';U.P"?K
M?-]0:T*[M1WR?TO\<99E.1Y;83,Z@S\N>B/9+!H,[R2AI;E<&"S6,+FU59-C
MQW5_ QT-J/0J0D#1$H;O@3CRVH<-QZ'5S,9A\?379V'OXE8R\<L*1^5#EP)_
MP\Z$L.J1:19SB9(7WAXJ*E[JV.JLSN5%K*_TX<;5%)B]!2Q+RECX=D]YE]%,
MK+^T8LV+C)Y<N9D*WK)QUV5*CW+\QPR&W%+#G=U]FHS%%CQO3+QC%R:'D[<;
M(3)K,WF<B5-6[DMN[CU5F,]^2_/NZ^D5(,*.],<FOEQ.Q0?.64A/>=Q).U$N
M>0.+:/D9JM3<SLFK7JLS/A9.,Y'98[)+5@P(TZ)*<KWT(DQWV1]RL* /5/:>
MNH1-G:^E'B"TB-5K=9=5-8,+A\>V-119);U59D&(POBU0ZC((4:0A-HU'%B^
M 5GS"AU:2KM41HB;'E_AN^<N:9G".'?RLK(.#Q<.B7E-S#,XVM4082/AH]'F
M#"8C@R/'$,I2I+B%NR$#O2E!*@3(I7'8B3=QP-E6)89Q%C=!Q>QG<W#<&>QF
M?=8GRI(XJR*H=EN_%R:(3EQGC=X2[)>[0A;OGLJ1YB4$K.]56\B)S^,O2]0U
M'%^*8ME+4BKR*DR3+LV@3</N;&MF8;99S<V=W98_29"TXW/L*ZN8MC 6\\-I
MS;7F+0%*V%)).&Y$X5AZ>,'GT5)0IL,Y@-4";I,>RKLVR*+=3D9$Z'KINWLO
MC''[,3G6TK)=*E(*0&R@:A%O*?A;"<?NL5O,?CV%%(P_%8N%U5=4V4J)3NXU
M7%9KZZSK&UJC6#<!UY2FE+!4@J.QZG1$KW<+I'LH>R]V*X;U[&7<27*#SA0:
M-VP79JBED'L\P3%E7?MW;=![=$2;B\/8+$J<)HT4R7JK *^QJL<ARG7GV8]?
M:TTC'I\>2VZ5)FH>JY2V]E@^._SZ TV(DK2^G'CNDC6=:E&2V]-88U98@S1W
M^4W5Q2U6-V[18L:>GKIDE4>!&>CI2V/%26TI2E0"=M59R$6JK?2SQ;7Q[>.^
MSDUT;O ;#C"7*R#)[>XF)P:R7$<D4$9^6ZLQ8P7!;*.P!22-R3N=07%V")P\
MBXDPO*'93]U6/279."6_&SI3*D-I5B=Z[$>LX0\M1*77E06]G.JTA/0[G;4(
ML<<-8,*K,Z;Z*>^ S_'JG%\H:^+D%4VGIZ%W&X,=*RO=A350\6RI&Q*O>ZG1
M%&;F?AS*;/*K#\DN&HV10+;%JG&V\DI.89O';LJ+ A_ -P.1Z9N#ODE76H=)
MCJ96\\I@*:(3W:J!;3$(GMXFX#QWC[">+,>GH1;W'''&BN-VK)*'&(<JIL6J
MY5VV(/F+1Y$N16M]H45$-IVW))T)&X(O+%?3%Q?AMQ17=5&R*3-Q:IMJ#%T6
M^36]K$QR@NHS<2;25$:4^XS$K2RRD)0$DI"4@*V2!I44V(G)@\<XS7\?M\8Q
M8+J,/9QUS$D5ZI#JG!1.PE0%QOB22\28KA3W D]=_'PI1)C)N#L*RAO&%.B\
MII^(53U'07>-7MA0WD>EDLQ6956]805I=E0I"832E-NA8\Q 6.U1)-9(KL16
M77!&#W=3AU6H9!6/8''=C8O?T^16M?D]='ELH8L&%WK<DSIK-DA"52$OK<2Z
MM*5$%20122#L1)"/Z4.)(=4BLKX&05\EK-97(C.0P\HN&LG9S*?5,4=G<INU
M/*FJD6E6P&Y(4I2'NY7</#8#0U1;-KTQ\61L8C8O"K;> S"RV?G=?<0[ZT:R
M2LRVT0I%G>0K[XI5@U)L$K6'QWJ2\'%!0()U)>4HMA^H'" WA>\C*_C\#MK2
MYHKQ>67#F0+D7;A=NF;&T<?5)FP;4'M>86?+[  G8)&J47G8^G;CF?#IH\:)
M<TDN@M\KN*:[Q^^LJ>_@R<XN9F092PW;1'6WU5UI:3EN+C+[F=PC9.Z$D$6^
MQWA? <4<Q!^FJI#4G"7,FD4LQ^=+ES'9V9I;1DUG:RI#BW;6RMO)"W7G5%96
M2=P3HB6N-8K48I$FP:6.8L:PN;B_E(4M3BE6E]8/65F\"KJE#TV2M03X)WV'
M31$EJ+B?#<:N:N_IZ]UBUIH&65T!XR7W0W$S:\K\CR%LI4L)49=K5L+223V!
M) Z'1$J\1Q*FPNI<IJ&,N) >M\@O7&5N+>)LLGO;'([AX+<4I83(MK5YP)Z!
M(5L   -$2GT1&B)-91_P=;_:3&/Q]7Z*EVT=*QL#(_(K%-^G=C]2?J?[BQHJ
MDK=Q\H^R-$5=$5A<2%=OMWV_<W\/$C8_4T17Z(C1$:(C<#Q.VB*FX^4?9T14
M4L)!)/\ T]F_CMHB$J"QN/9T/U?\^B*[1$:(O,%'>4] 1MTW/7IMO\G3_+HB
M]-$7DV\AS;M((._5)W&Z2 1T^0_N;?+HB]=$1HB-$5JE=HWV!^J=OMZ(K6W4
M.)"DJ20?]4]PZ'M.R@-CL=$7IHB\O-25EL%)4.TD=P[@%;[$I\1U&B+U) \=
M$5 0? [Z(JZ(C1$:(C1$:(C1$:(C1$:(C1$:(DED'\=X9^&9OXDL=$5Y(_*^
M-OTVQ^4/J[SXWV/'1$J>X?*/LC1$;CY1]D:(C=)Z$C[(T14':/#;K\^^B*H
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M*W)F4A6J7-+OT.LJ2XZZX%]"5 ;;Z(L++?5GP5BV$W^>_K H+FCQRRJ*B?\
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MO.Y&PBMEY56HI[&W%K65:B[-@5\IFJ6EDR4)=<0I+G: H:(L&C]0N0.\5/\
M-&7\9.XO@GY U^?5K\++H627%E MX,.PK:]55'JH(A2G8\Q!6I3RD-JZ'IN1
M4UN9%XM^H^>Q,L\1ML$^ Y19ML,K*/"8N5P[6-?HS1F?/B3(N1Q:U"&6ZBCI
MK"=8(7&[F&(2BGS$K;49+:"J*4["RL*/7;?8;DGP)'M^I[-4(O?1$:(C1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%0@*&QT16^6G??[77ZO31%?
MHB-$22R#^.\,_#,W\26.B*Y8WRZ,#UWQZ6-O_P!OCZ;<$Z-J4J6]@=QN3[>F
M_MZ^/SZH+1X.;!017R@#X%;Y2AOV@#Y#TWWWWWWZGJ-5@-:*CRD .>KJ%@&
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M9,S&-*8?;/N-HBIQMLHV]XEU6^VPT1;E&9QHMED;-U)H:>KHETK35C)R6O\
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MH^*@VF39=24ZJR%1_&+<K<7JV&YWFS5-_>U>4X_L5'8U92B3&7>J?+./49Q
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0NW=\5V;=_3?QT4&F%5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2127058d1-ph_70year4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_70year4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!? -  P$1  (1 0,1 ?_$ .$  0  !P$! 0
M       ! P0%!@<( @D* 0$!  ,! 0$! 0           0(#! 4&!PD($
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MFHJ5WJO$M].[NYN6^<+>5BZVDY:5Y>P14@U?S+>NM3(JBFI$V&3DHUL9DY2
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M*4KBG)IT_P U>&Q:JWVR4Z!(BOY^URKXM_B\@JOIB3!RZ<S<?&A"@HZ'RJ(
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M8_K'3@3B:@M.<<?4V?4KD]*.&TF@+0%DDXY\X*3SR1UVPBJBW,CRG33-QYN
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M;ZT*- - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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M1/J(*F*1F9)$S=4J.PI=+\*EL&V^^X#K:HVK5N49P3G+5:;?BI[.1CO-Z?\
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M3!L &CV? .( (MT_L;^.OT2QS>3'S%1T1Z<7&4$X;-(NFMYD- - - - - -
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M:J+*)AQ,   [!5'2H*D,&X#PVYA$>&P<>([^&PAH-#QYE+A[0<1  ]8[CMP
M-Q$-_5PU:,E5P'F4=A'G*!0,)1,81* & -Q*(F -A#4*>@5(.P@(" ^GU?)X
M>/#5H*D.NEOMSEW_ -G?COL \ \1\=0$AU(LF+5P]>ND&C-HW6=.G3E4J*#9
MLW3,LX7754$J:22*)!,8QA "@ B.V@*:(G(F?C&$U"2+&6B)5DWDHN3CG2+U
MA(Q[M)-PU>LGB!CMW35P@J4Y%"&,0Q3 ("("&@X5*_S"6P&Y@$!WXAOML!@*
M/';;@(Z#B>P5(([ (#N7F#;<1VX\=@#PV#2C!*%TD!P)S!N(B4!WX")0$P@
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M#<PCMQ]6V_#4 ZQ-P#<-Q\ WXB'I$/L::C0FZ : : : : : : : : : : :
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M7'[.,R&XSE,73%L[748V?9R$8Z<NRIO7*K2,Z)4BBGVT+OMQ_HV_FV#4*>M
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M@$JA"'*(" @<A3AL(" AL8!#B Z)M.JT:*TI1<):Q>ZX/Q($023 "D33( >
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M>MNDK3#(5RT).8*,<)V.O-6\@U:P,Z19L<LM"MFLLZ23:N 40(DY5(4H%4,
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M56TST9<W=UVK=Q%RO#5!&14>)?-?M4=9%!6D=*?,#2+0M4L@V<BZ*^'RRQ"
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M#B(Q<=X[ Q:AL("'@@3UZ^Y47%)/L.^Q+FL1?&B+GJFT: : : : : : : :
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M]G3_ *]?<682MVXPGK)+4[(2C.VIQV:1<];2C0#0#0#0#0#0#0#0#0&G+/\
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M/):1REB:S9<B9")3:F$6,=%5C+^'W<1(]8 -YE1V\()0Y>AN/,'*>R^T^6=
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MQ;IXFBL4"G,43% 1*E/D3NBPCBBZPF/[_<5*[8K :%(P,YK-O<U]%2QRBL-
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M*_UW-M9-A5Q</Y4^Y47_ +>\MSQXJ)VK,A1%-F)?,G,!5!,F \IC(F#8Q *
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M=O"R5NR(QC;%/2K=_1G"IUN@DB"*R0$(GQ3)&V(K3C^/Q^-CM+0HT T T T
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M_-6F_P"@6']1#B;ZT*0$0 -Q$  /$1\- W35[%&ZDH]CR>=?-&?4WZ8NG**
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M3HT.402,Q"=K<D?HKQBZX/5"?A2$$H" 5]HXG>Q3 8-PWV^4! ?M@/'4!ZT
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MD'*UVS]PD;,8C0JEER#%F:J-KIEUC!N;61I/OF[R001=/2D<)BX."JH_,WI
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MMVG\[,F.5C7,BQC)TE>G7P3Y?_:5C< *CY5V )K*K<A# MOYLC=,4P]H!V3
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MSCK&,5'Z>(;;]I$A0(4I"AL4H 4 #T ' -9&*22HMB)C 4!,80   1$1$ X
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MDS?-&V].2NO+14VVU-*RI8S=O ?)=VD]ZOVU_(GG!-D9P*1UQ Z0"<0V.(*
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MV47:VDTU]6SU\*<3&"L=/N_?YW\RXMM>'@J<:E8UCUD)-%<R@\I52@F3T;B
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M&7_"U\M'VTI*NE>)KS,?-R)PE%4QVU6/=X^/<3?- 8>0J*XE+ML8? !#;;8
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M1PW#0'@&Z8;[%#CQX[^(;[#Z?#?5J#V*28B!N0O,7[T=N(;_ "ZA.![
M/    ^P' -"D= - - - - - - - - - - - - - - - - - - - - - - -
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MH!H!H!H!H!H!H!H!H!H!H!H!H#B#N!,8MO5(H[*V9ECV;AQS)\P'(F5P4R?
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MQC;\GHNZS"SD^VL=YP] RJ]GIM/M437W*L>[,HZ7(<4DWB#50_*6DJ:(@/K
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M#]MSGBYC3Z@O"^^&60:38U$GSD[5LK&0\N@[DB]8J+@P.4FQ#"0@E #GV >
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MUI[%L36>BYZH0RUYB8W/N8*'G&8=QCVNE7I5]QG2<)4FD'H[-[5WL,:O0K?
M$"\-'336:;NW)W2:X*,UB-47Q+0Q]EV!T-4]QDKADO+5ZLU_O/;ED.T668''
M$8Y6G^V&ZPMXQ\C%Q%6QU UZ$B)"0@D$)1%!H"BS;J"@HV<'\QIIOQ"7#@;O
MSWV]Q^=65".>ZVS'=GQC=@O](N-.C:-+2<3/J5BS4A\9>&R)3KQ491J^JMQD
M6XD<1RATCK%51.F<@#I\12JXT,.Q#V=4'#M]ALDQ-LR19[5$5_-U?4>W"5K;
MY*6)GW)% RC=Y.21AZG!_P#:#6QXX8IQP-S-V[9FJNF=)812,B"V,,LG8C4K
M,XNYG.5\N1[2<S*3N H;"--C@J.'LK.$; A/6"DJR&.W[B;CK.E:I%)]%64\
M]%F;NSIHMTMQ,8*&Q:MVQ1->-C"0LF0+_D*S8OR%-Y*BK'.,L=01Y.<G,96_
M%:\;(0E'H55K32OLZY=7:C=!DV9K^<*111PJ7JIJD^(X&B\=88F;OWXY,[G9
M>OW>CTVKXQ@,14VL6YM'L&=]R6UG+"G=<VL(QF\>.4V[.@)Q-?B'RRB3EVT7
M> **:()&5O@3<Z#S9VOT[,-2KM:C)F>Q%)4[)5/RW5+?BZ.IC";A;O25USQ3
M\T;9JG:*C--UFKU=!9%_&NB'35W#8Y"&*;*:JM?8I7[4KD6)^-6:X3&>:SO%
MLY8BBAQ::E95=359BZC<7,DYDL82%NJ Y%@XL"3Z=<DX=!VJNNLW(T675.=4
ME%QW,)^L;PDSL'9!FJDX\HKY:Q3T-CVLQS7'$"L2YC#HY,Q^5TC"NJ\T-/(^
MZX:/%7G1. H)-NIN'3W!5UJ&NS<SJ=[$J7DIE9X_/F4,M]P4?.T*Y8TAF=]<
MT2M)TNH7]2"<6CYNJ8BH6-'/SHD%ZQ'&)+NSN7S(S,@M#-S'<&75%/>)#L9A
MK3BC,6(,CYMS'D.OYBQ_+8TD9&3CL)UB9K=8ET%6[E> #'^':G".[&H0Q3&?
M2S*3$3IALF4@G(>5[!3M9G62NUAM=<AJY:I>6LHX0R-+TZOX[N=BQDWQBZ^?
M5'JTO89RM0UDB\CXVR!%%>UA_;IA2-?LDFCQ 91=)0ZR E2"UXB@Q9V?XKPU
M:X&U4,]I8N:[A8<',XY](,W\<[KRUU>Y"D++++*1A9F1N\S:9%PY>O3NP2<*
M+G,*('-S:5+1&G(#ZN3'E%:U%'%N4\LXV>5[&M$Q+89B(9X?L<CD6HXV&:"G
M+VM/(6)[E%,K/$I3[E()2%:Q+A1 X)J<Y$FY4%> IQJ5>6/J\:!EB9RZ[=Y5
MS'48#/="@:!ENJU0V,%65HCJM6!JE??MIRW8RM5NKCII%@4R[9A((1CU8!,L
MU.*BW4@WT.H,;80K.,;1F&X0;V:=RN:[Q7[[:TI8T:LT82];QA0\3,6D 5G&
ML7C>-4K>/VJZH.5WBHOUW!R*%1.1 EKJ2ASA5.P>F52_U>X$RKER6A*#F:\Y
MUH>/7I<:-*M7;KD=2\+VQ)S(PF-XJ[6N&5<Y!D3-$Y>6>NFP"F'F%.3VI4M"
MZQ_8W4*Q@G!V$,?9+RG1C=NMG&VXKR5'GH,M>HF96C+W7Y$\JUL%$DZ%--)&
ML9(EX\R2D(4B::Y%$^19)-0'=P%./$NQ.S:"CLHS.1:ME+)=3AK3=V>1[CC&
M*CL4.J=8;DV")*_D492=QE+WZM,;2>(*M,,HJ99M7JZJJI2(F67ZKAWC2O<8
M5FW!$?COMR[GJ+CNIY"R;/\ <]9<K3(0S,*V[7@\CYFKQXQK,)NQ2K32NTJJ
MR\<U<"\4%X]CRAU^9<X;:J(]CH?MLP\K@S!>,L5.II[:9NI55@SMURE02/+W
MJ\NR#(WF\S2B::2:LO<;<]>2;E0I2\RSDP[> !&*:').(OJS:)B'%^$<#*9V
M[@LF=ON %Z!*T/$.2I/%KV(5LV+9]A;*%.VFR5?%51NMG;U>VQ366:1KF2&,
M)(-D1,W.@BDW3%HMCE_+W;3(WNK?6O=S+'$.2H6\9B[2\L8>Q!1)IF=[:[%(
MMNWN0J]MM%9H5;?3CMM+91F:[ 1#0$A%_)(P+8X)E%P4#-2;ZHZA[9^SD'&*
M^V":S#E/-^1QQABZ@RM$Q?D@:1#1>++J^PVOCR6D51K&/*=?9RT0M;M,K%H'
ML<A(KLP<JG.!W0]<*31Z&6X\[ *YCAM3F43G3.B[7%E)MN.L/$$<0L%L9U*V
MQ4-"G2C'<9B-HZL\]"M(%N+64GSRKQ4X&,[.Y%5;J3@94UJ5$1V*E@*Y<V,-
MW"Y?C+CDBYL+CD.]M*?VY[7$T94FE&8P<SCYS@YQBQ2*;0<>W5ZR<*G)JOT2
M*J.CI!Y?5KVBAO\ I';ICNA=O47VR1#21=8OB\<N,6@TEET'4F]JSV(=0CXC
MQT@U:M_-NV3L_,*****9C;)I$(4I0G&HX4.?:1]73A&@..U!>!G,E[=HZ5P4
MK"3V;K[E+*D_>6CX\Y<,V@2IH*6ZU!9Y1U8$'+$T21*<<J+B0R8D0*%"WP_U
M=U%B+G!V<,M9E<P5/SO=.XRC4#K8S85ZLY(R(O>'=N56EX[&;6\6F&>.\@R"
MC="8EGZK;\$ +G!,-Q*(VK@_M,C,/9"MN5)C*.1,MY"M]7KU(=V>^1.*X1TA
M5*P_E96+9KHXLQMCQM89A:2F%5W,E*D?/#'V*B9ND*B2C8M*^)UV'  #<1V
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MN'B&_$!W_FT!$  .   !\F@(Z E=%/@(%* @'+OREWY>.P;[;[!OH#T4@%\
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MN]R?JRE[G8P$YA\XF5@%--OY=!,$>FI=61[=QN*U=N2%CRQFG*9K,Y:.<O\
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MYI4E"/*7U!]S['_0'W-"@0 ?$ '[(;Z$H-@_KT*1T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M64<%YC@JR2 8Z!/4R^V=E=GFX_OZ?SE*'(-[R+V]XNQ_A&]VE]47-OL-PHN
M9"!"6B94S\AJ'8RY)%LJI('-'%%\4KA-3D3(H6D^)TI@_$SO'_='W,625Q 1
M@CEISCRW5K*["'IQHYRC$8MI-1N5;E95D_"T-IQW=:ZN\.FHUZ#H@E7ZIQY1
MTJ]QX&C.T3#.8<3=Q<JV98D>QF$G]6RB>5NV5JWB&+RS6+5,9%BK%7*M7<@8
MRLTG+99IMH\_+/E5IIDB[BO*,R&=+*+JE3:;%[^!(M=;B)#NW[OGL[VJ2O<
M6:QI@NJPTZQ<4.90C'B]9N;I]41B<A6* 2IK-_[T;NE)I@0R;LP<KLR0LFQ3
M/@.)A&+.WC*.+(IC%=R';U)=V;N6[:,:XSB)!A*8^N?S-F(!&T(7#&T@.2;/
M"J,D+"M+LE%K(W_X9V5F4'2I3)(@9WH=QK>L]J/<;C>S]M<@&/7^4\F0D3VB
MU#-TWDR$Q+D?%#Z#QT=O"W&UT/(D_;XG+^.[YC.L2\F<ADVKQK8'R":I61S.
ME' JA]QD5$[5LF4K$ULHINW7SS6M]^UZSC><?1;G&<-$]QV$;3D[(UHI,9"R
M9K"RBI<E"+8XJ;5A9T\>BHI&^1*!CJ 00[C3'<UARV!FW$MZ'MU?Q6$\L=[7
M:ZTJG:\^=X\KCZZ6[&/;SWHKY)R<_A8^U&H\(C;8%_66)(Z1>-32A*B'G"$(
MY3YVY#=.9NV/N&R',Y'NF"\<O<%XRF+-VNR$QA:3C<6OWV7%<9W>US&3+2-"
M4MGP^9F<U:3AV@1\J^;)3P0O2<EZ:A#&#4F,.S#(]RB3FM=:MTU4[KWA=LF1
M+1B^T5S$N-J<UI.)&RY;=>6>/*';[!$,&MI:':,9F+<K^8F"0R1C,E".%"JG
M44+EGS!/</<LO"K2\1K0$?3.Y3MHLU D,=4O %8KDGAVAWK&,C;I^S93G9+X
MH)S476(V9:FA(PL651BD5J4KM!8Y#4KH;=A^WFUUNY=UD;7\*(0A\B=Y_;YF
MZL7>&;42*B++C& 1[9$K0V%\SEVTXC(0$QCJQNUV+MND)N8#(]0[E,IYJ-$U
MV$NJ]LN:OC]8*/*0K> [9\2V[)F>NW>R,)V*,1]E7+,3Y"&@)"N-7JD\RC<0
MO[=<WB2;EN1FLI*1IT#',T I"T)3B:P[/>V3.]-NV 391AK1 6/#T-8"7FV1
M= PA PMPEY.M/(:P%F,I5J]3&0\HPF0;$[+/F![')NSO4&[B0!JX1$AA3I?,
MV-;"CW/O\GW' DAW(8PG,%Q^/*O"QY:!/AC^W-K/.RUH%>IY#L$ Q02R!%O6
M"1Y5IU#(EC>BX$J9BB)[!/6C-%Y#P%<3RG>%'6WM0D,\DSQ&U5MV_2[*7Q0W
M;8VJD9A"F4MGB5[,V2X1<MC)/'^2H:8GDI&+36:+GDP7;*J/B@32E2]QKQK@
M_NWQSC7O)Q#(XUL.:+?GB;QG9*QE&$L5)AZQ,$1P]A['>19";<6&T1TO$6!A
M/TB3>HM/)B#TBR724 3&$BJ]I*:=QL&V]G+BQH=_UIM6)K1(VC,W<_C.ZXRL
MM#?XU<7Q_C>CXB[6F\-)1J5VEBUQ>KP63J!,+2E9ES-T[ W9+-UD54W")A.N
MQ/ TN& N\.5A\.3T_CJ"@JS0<@=QR+RI4_#V$WTQ+0UX<5-SCG-%KPQ)Y"2Q
M\UO,JV:34?)M8I^N[:GD 73;E(LL@D6J*TSZ(8F[8TI3LMF^VO+PV5_&Y"KV
M78*R1UC;5.,FH&O9/M5PEFU89,J!*S-6B(ZGQMC3:1+9@\7*R:-D$N?F2-LK
MJ*'S*C.T/O5N+6$ON5ZXK,7[N:EZ_P!NW=C66UXK+.)J7;)5Y&DQI;B4J%@6
M8R<M-PE0L#HJ4:9Q()_/4$SI<R2I2 ZFU,U8#[E\A=P4%8HS#:T*SQ_WM8"O
M5:EZ-7\ 5N!DL!4J<H[.PWFS9.EY9?,5@M1JTG),W4&T)&$]W$\J1%R@0HN)
M0=_'\?CWF[>T'#64<4]P5I)\,I**Q$\K%Z(:UY)IF(XW*4!97^0V]DC:K'Y-
MQS;I69RY4IAO(OG8NI9@5TV411%5VLX463)=O G&IC7>E0^X:8QO]8QC+%F#
M;9DV9[G,/E8X>FX2T4*OUD+(]PLCB^7KMDE+5;H1S5G\<^B ?H+JM_)NDW1"
M J0_,)2*_P RU9I[/KK;:+]978H[&"$IF;*M;AG';7.N)>J&GBV>EX$JL=3W
M-(F'$L4V/I&+RE'*B595=@8[E(JXG,CTSB)3L+AECM$R)*XZ[M[!2:%%(YAR
MMW'8XNJ4JX&H3=CR%A.G)X"&TT=HXGYIO$A V.+HTRT^;TJ\CXR2<B8'94TG
M:BYRXEH:M#LTR=>8&_\ O^KWMQ 7S-W90\FL?RU?Q!B&K2%0POGJMVZ_6QC1
M<;W:=;-G TUHHWE#+G1=33-HFD5 X!OIL-]#.LO=E4XO&=\\KC/#$$UN-_S3
MVU6W!;^)5ID.^2AZ!7< KVE[4';B19(T@K2PU^?6<I :.%\XZQQ*MURG.?:*
MUT/.5L,=Q5\[E8JSI8ND(Z/J7=UA6Y,)ZG5C L'79G"]:5K+>?NEKRK,R"F:
M+#: AD7B#V':)QW*W2!H"+IN ++O =XJ_97E&)[2JKCZD037$.<IGN5R]?K;
M?XX:N]LD&VLN3<\S=6O,I-(2#@\Z1A$7*,.@@BZ.\:-G D;D24()2NY[CPI0
MM%MQ!G*9IF+,8$[8$Z)4:WC?)-1M"]1K^ ,T6:2R0:191Y)6-MN8IB23BL>Y
M4;I+3*TT]CEK Y<' )$K9<#BH%&8[@SM_P MX[ON$KYW"]JUES4K"?5Q]JV#
MK#,*V;%^0IJHYLH4QDYUD>OR-8L5Y\G8WC]M861%+"U%V1(O.3S!D5ESIN\%
M#"]G'=8VQ=8*Q%,35"U2G9OW@XWH:Q[E"ROPSGLL9]D;]A;$!YI&76.X/3<<
M.VD.600!2-:>2V3<<A2:;%U.ENS'!>2JGE\M^MD);J!'0V$28R=5%3&V#L8U
M*5DEYVK3+,CEGBJZVZ0M\S0$X9RWCY94$F'EIAV1(ZAU#%3A#ZL:%&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&IQ!Q%GHCCY[+"4QR
MH*QC'GZ:.X[I^8$.4X\!]K;[6OF.KO\ GZ]B/F.JT66N;:AHIR@L)4R"LZ*=
M0 ,&Q4REYC[B(_)[6^O'_,\_FM%,X1ZR9$>9T51, .*I7)$C;D$!V,.XB)3!
MPV^764XNVJRV,?+E7N*%5JD4P*)D( IE W0.\$P@8V^XF'FV'FVW].VMMB,;
ML.=;5-,XS3HNPMI'38AW+A1-F!12.DN!@,L5-$#IB8X\NX\#  </7K9<4;2Y
MGQ$7*.L]BUJN6(I.D4S-NDNB4$P:L%#*GZ@>ULJ).',&_P!@=%&4X-QILS2X
M.5Q=E4<B=ZD),2O;G:4^DH9.(EH21;%3:%3,BV.\024!PJ(@8X;" ;^ FUZG
M2[<WC_/V?M.BXE'*7)O4T-V,3AVQS013OT/-Q:R*A"J$.H0!\RH4H& =TC**
M\"CMMR[:UWK35UI;?\#T>6<ES.FJ.Z1B?G%2+M!*L2*)2\;9(H/,+)+"[\Y#
M/F12*B4PB7VEQ, B&W,&V^^N'J6)]UT?+LZ<[LM*O:?8>@.KP].^M^D=;O7%
M:LXW5,2[*;=$H0R+<IZOCRIT7%Z''/U7<N*O;9.UUV"9GU%RA;(!V@L E%N9
M3W>_;B4V_LCNX5 NWI'T:^2_3J]95C(Z;<DGD0JW1U5&NT_VU_\ L9Z5:L?K
M%T_JUBY:E8SO3V+D149)R<7._#FY5JJ.V_=4^E)EW?7.5%=@!$A255!(HF*H
MF(;E3,(\4Q#;B(#QU^@?:VJ'\\_.M\*^X.E/,'7)YSIK'%-8ZJ#94.9,@"8$
MTQ$FZO(0-C"'KU5Y\?DA]"V.S&NQA64MF5GE%3!NF9XJ4[8H@0I^BH<";*)E
M3$P@(@)Q#F+PV#6+=QO^92IG:FG*3X-Z%U(5(X)&514(8R'*<5#@&P@ D,F(
M;^R4#AP'6.OL.^S6,U-<"L2*DBF;I @ES+?>&$3B)1*'M%$/1]O3@9WKV2_Z
M1.27 ZY3F,<"A[(%*F/L],.41 -N(B :SY)-&N4;ZCS2IM70"L@Y44334%0H
MI)%5$"F!4! 3 8$Q$ V/\OAK"*ID)/L_>=%IMXDG+?F?P17PW,"J!%&YURIO
M3E* " &('3'B(C]]L'B/IUT1E&.8F]N5F<+D;>,Y3VYD?2J/'=BS'82[M6_
M?$/P1. Z]F.JJ;5LJ;4*O611H"QV2QP]2@YFS6*0:Q%?KT3(3DW+/E2H,HR*
MBFBSZ0?.EC<$V[1HW.H<?04N@/GY#USLV^M9HF NXMLVF\HXTQGD6<N^+0FV
M5FJ]:F+57W"]?";F*=/,XTMGC&;MH9:-6<('0,(%71,("!M78F^Q]&TDBI%
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MOL.X[[B&W#?QV]6X^.VE0>?+)<HEY1VVY>)A'<-@#B(B._AZ?'T\-!0@5LF
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MFQ QS&3Z9TWH%, FY.FFF<!,78!$G#[(<?3H[4;7RPV(6WIJJ%*8I7JYD2I
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M^%8.@G(,47:\BY,X 5FHLSIK*,? [JO^=K+7>UR%RO+-%<<Y'N5=Q\QAZTA
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M]7Y9JMFF$I54N7>5WY8KL$-5ZDK+U^]TK!Y.Y^$J"DN!;HBTF0>4W';$4E3
MJ@C*"653(( 5L%IP%:]OX_'^)]UT1$2AOO\ >%X"("'$-_'TCQ\=0I.T T T
M T T T T T T T T T T T T T T T!Q?G0 )<#K%,8#ILF("0O( F$Y'1-R
M', B7E V^OE^K_UO8?.=32^Y3XT_>:-<'73*D!4M@4V$R0KIAN0P\!X%]@1-
MKQW0X.VI1@F)E"- .EREYN05'AQ !-N<Y#&#Q$@CPU=>#9AR1>I(W.8BA%1;
MJ'2*;VBNE.MS%-MN;<!$2;>''PULA!-59JFE&5%L6TZ93@#L.CSIJ&2XJ+CN
M4"F.!2D 2EV$"CPUL45%U6Y@TI:/8D%*DF7K'3(!7(%4V20/[(F^]'[[F 2Z
MR6KUVJ8^7'VGD$TQ<%;IK)I('4,4Q09F.('$""!]CB(\HG$=_7KMBK4?I3J9
M>7!?\3A/NGB6,/9(M\/,V";<-0%=%@0B:SIH=)%R9R8=C<ZW W'Q$==T?+=E
M5_&ILMQ6R.L\=.??M5BA!=9=1A'MC@;RJ8 D= 2%Y ,('(;\&.X[>T :XJ6^
M8VWHRM<MRUI.OXT9FH"HNHH90CT3-G F!4[5-,@E..Y!34*!1]DP^R80WUFH
MI-&NS>OQN\WR_/H]%M[M"K*!UQ(L0CP2D5.W5,HFGSBH8@ 14?$ X&, &\=6
MIZ4;DH+2GN/>YSI$4.D[*1(ZJ'#E >4I@+XE$OVA#?5*[LVVWQ[B8DAL4KA,
M'!A(N)3D444.*)-B_A=N;VSF]8ZL9-;&RTE<UENBJ$B3@P@HF8IB"42@*Q@.
M8A1V%05>8!$H<H@!?3K-7)19UKY51;%Q.4"&*D!/9Y.9(_,)>H!A#E#?CTS%
M\-_3OK+S[G=[D-RH1 HHF3.CTU><.J"BO3.&QP$!(8=@'?Y=:6ZNK,LJW&L'
MW(J2-P06!8R0&2/L ?A14VW'CS%](?9U.XV7THN--'R_O*R,1!R]*0Q$TBIG
M.)"B;V/O3B'AOL)M91DXR36]3*W.4WR2=8T/H\PX,&0<.#1MP#B'^Y)X>L->
M_'2&G8=RVH:WS7DI+#^*L@914K=GN9:'4IFS?-.E1#J?MEC/%M%'"4/7X9F4
MR\A)OUB DF0NX[FW'AOK/4C:.-OJWI#NXR!BNR9\[O7CFL6S/=F)>Z-@'RBC
M5IV\XZ\BFTK%%<F=MD9->TOF:8/I@RYA CQ42$  #0)Z=Y]'   \ VU"D= -
M - - - - - :<LWZ[\3?X,RW_><<:JV8+1BG]:'<[_FM3?\ 0'$&HMB<3>BR
M)5>4#%(8 '<0/OX;>C@(#]O1N2B^1M2(U71I./&NIZ*0"[ 4 * ;  !P#;[
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M1];Q92(MM%W=KDIFHE!M5'QLB,F3B,:WE[)N2K2<E:V\:\6;IOW"JKDJ"@D
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MIN6E'3\?C_B8#WA=OTEG'MHL.#*6PKC<LI-8?%I%RR9&M<1K5"RYC^X2T4=
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M0D7!-8EA3;M-/9U_-V6L)1I&ON.4F'-HD3.3-A3*OYY8J@&*H8!(-:4.@BD
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MWULK+M-WE-:Z'('>FQ%U3*X_9G6/)%G54"E65(002,1L?JG P@81 X#RB&X
M(!KIC-^6H\"VVU.C-A]MKXR^+DE15>*/T7BJ2B0+B7V031-N57<R>X[B'CK"
M,I6VY2U3.V:YTDS>YB*HI)G6;N0(.RA1,N4W.(\>58#& #<HCP\0UM5Z,GLS
M"-I<RV)IF@-DRIH@X JARF\LFN4^XGV$XB;GY!  ]&_#6SS$^TZ';DNPJ%R
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ML%B3_ES[P+)1X*AU:IM[*EF+%+/+U<D[)B28N5@D+++57)2TL#=DTFV,3%Q
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MID;F4Z8N0 2B4HF'\)RB._X/E]D0X_<UE<;<:]QRR3J.GS(\QA7-Z.("/)L
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M!,8 $.8!XAK8/M^%"X)B5-L!C"AL=,"B<A@Y0VV$#<?: ./\^AT1CRI+L)Q
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M4*=)5)(XH'*?<Q" GL"@AN(D( \"]/?80'??6Z+T'>SPD0$W)#)BD ' Q!3
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M=H"FJB(>V4!'??PVUQ]2P,SI68\++ARW4E77:O\ @=O0NN=/]2=/75.DS5W
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MXES):UA=A"E.,W1.O=V'!_>\1Y=O%BTU.U.?-547(JT]M=]#:I)9J9PFR!=
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MB8"!"G=-$5SE)OQY .H(!Z=M<MR'ES<*UH>E9N>;;5RC54G^1>=8&T: : :
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M[3RLR;60N*I^\R2K]DG9O2&Y6M9[3^W> ,B8G1.QQ31Q63*4"ASD4/$*'*(
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M4-C=PC!3X<NK0P4(A.8[>M;W""H<A$W+F!(JL\BSJ'VZ9;%%KN8\P_??\5N
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MQC2-D54F^+[_  @DDY6(>O6LU9I5&391*KEBWBV*J*0K*)D,@W!NDF0I ,(
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M9]_C?B7U?,S+?W?,XWU5LQ\2T8I_6AW._P":M-_T"P_J+8G$WUH4: : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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MX_Z-5;,G%%HQ3^M#N=_S5IO^@6']1;#B;ZT*- - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MYE@!!L5%3F!51P HD @<PB82G\=@]D..M,]R4U)J::C5HW:F.(J)-4D3J)G
MQ Y0W,783"(#P#[6L2+5D 4$?PI3\RJ($ A%0W2. F-ON)0  $=O3I4$HQ&A
M#&7(W1 RX"94" )?$#>QU#" %+SB ^.V^MUE*JKL55;-:02I%;G)KON4Z+)N
M!40Z^XIKD/T@ "E$0-L!]P'Y-87=+C_' Z8_2O V:580 RO66Y#;B0@D-OL
M<1V .82[?+K#<NAX6;\[0_X9#J>R9,"!R'$RHCT^03![1@,/'CN&HW4E$M5L
M>$=T$2(. <%V-RD.(B8J1#> ** (@.YO 1WU2\=-R<DH0.L7FZR*H@0IQ#V>
MJ7<#E#TB&_JX:? =Q*:F.FDHF!.0 ./+TS[)[#OQ4 =QYOZM/@&B>CTQ QE%
MDU%MP PK%X F8 ,1,H[#N!> : F(<5#E(FJF83$2#<2\JG#G,*.^PFV#AP].
MKJ/ ]G>. 4,10^Z(F $4U$3=3E*(%%(Q>7F'B&XF\-;4].\RV/:@&7.=(42@
MU,B/,=$X 7F*)N9%0H;#P+L)1 -]QXZRJ:;NDM.S]Y>X$"IKM#FYDB H)!(M
M[6Y (/(8> F';6RW]:J:6Y4U9]1F&PL&0AMMY1L(;>&W1)X?)KZ6.D5X'8MD
M5>LBC0#0#0#0#0#0#0#0#0&G;/\ KNQ+_@S+?]YQOJK9@L^*?UH=SO\ FK3?
M] L/ZG G$WUH4: : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : :G$'!O<0*A,@@8I2& L3'GV$3
M<=O.;[B(<O ..O+SOZB\#7/9]IH$KQ(%E52J#NK[/(5<I4P-ON/L"(<0UQ&A
MUW!G J 9)4QTS<X"W75%,04,;Q,GMX\O@'KUAR1[R<-2S3>Q6S9PH=LLHR<H
MN#G,0X_@^IR*F]CAS;["'HURWHM3HMC9"VFJO<JV:R;A8ZR(I"D8H]<O.(^V
M!@'G+N/  3,7[>L8Q=?FV).VHJJ(@;E6%0JA@3-L!D^GSI !!$2&*;8-N8!W
M'QUL\M&LDF53,U<%D$R+MOP@F 2BB4Q"$,<"@(#S& !#?<!#644HHNS-<TCI
M+I32_2;E\T_6 ADR<RY&_F#B %.H*AS[$('$!W#6,DIMR>YT05((S=R^(=LK
MY159-3<Q $"'5/L0@ )2\PFY0,'B(>.M<ER[;LM*:<"M(HNLCN/2()4DA*0A
MP!0IM@VW$=@ _IW#?;?6(V="O,05RI@<% .@ ',!3<_4V#P4V -^74^ +8HX
M()BG;G(0I3B"AE2\J:0 .W$@; ;JB/LZOY#@>5$%.IU$_-%1YR*"F4Q3>8 N
M^X)"7<2\!X;^C2HJ5JYP,!#-#\QC ($2.F&W3 ?:ZG_C%,'CZM$JNAG!)RY7
ML>%'(F22 ";.@YB@Y0W.4"\.J * (" \N_@(;:V<BXF%WY-MR8T<D$G3%82!
MN;E6=@HL8P"'@0ZAQ,41#6:? R6U65[854SB42*= VPBN4=Q$WA[)!#;82AQ
M^32O QE%2?,R],145>M 27(9,5!$163$!*/*;8"#N', ^&X>&MEK^HC'RHM<
M3ZCQW_NYA_ZDU\/_ + FOIE]/L-JV*W60&@&@&@&@&@&@&@&@&@-.6?]=V)O
M\&9;_O..-5;,%HQ3^M#N=_S5IO\ H%A_4X$XF^M"C0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#4X@^?_<B=4F0TN0YC%/&,"J$*(%$.4KPP;".VP:\O._J+P-<]G[#GY543
M"**B:I#";J)'.F5<I=]@V$-^ <-_'7$:'H#NTC_@A2!4S<$2E. !SD$3@8P@
MF3<=MB_)P'6OG7>*Z%@D':0(*@0AC$44(4[<IMTTDQ<B8X"50I!YMQ#?81 1
M\-1RB]]SHM_30KP!NFFH??E!4W*DU/N4Q$1 1Y V$1Y!, <=]1N#6FY)Q<HT
M1+2$%VYF:Z93+ ?G*4RIDQ!'?V#" %X% !VWUC4U^5/N**8</"Q,F3JE$6[1
MP9,RI"G,()(G/RB?F#DZ92B!1VXZRY)4"M2[OS,.I'51AHYT0B;H[@"@HF<V
MPD,J4W.8   W#V_7K5)J+Y7N;E11HS-R*F636?$W;=)%1!#EV,BDWYN50I
M1$1,IZ1W'6N3YEH-2B57*F=(R2Q 62.F)><#DZ0%1$1,;F+LH90/$/1OK#OX
MC4R?K *(G3%7F.4!*  17VA  $I3& =R /$ X>.KWD:*!N8[<BRCMP!^8#G,
MV51 I4-R<XK&4* D$W*;;8 \>&@\=R4BH+3E>=$OEE@*9)5N8XJF!03"!>4Y
MQY0-R^@ U8IOP+3@BO4<*=1$06\L"A!.5JH '(H&P[D4.7<-PWX\0\-9J,DZ
MO8R@U&2D4I#]58IT@4(!3>V5J<"(E_VC%((<-P]&LS&\O,^DKPD17%5N7V1*
M E#K%V 0#<I1YA]D?#Y-.'>$J+O*]N<>5%$Z7.JFF!Q42,(I<O./L 4!'F/O
MQ^QJ.26@T7B7F%.1*30,14VP+%Y@6#<GM%-]XGXD\?3K99DO,20JF?4Z/'=@
MR'@.[-L.X> [HD\/DU].OI]ADMBLUD!H!H!H!H!H!H!H!H!H#3MG_7=B7_!N
M7/[SC?56S)Q+/BG]:'<[_FK3?] L/ZG <3?6A1H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MJ<0?/#N<4 ,A)("8">8CXO93;<2["[ P@&_$ *&O+SJ>8O#]YKG]+\3GE54Q
M$S'443.1KN*Q4U3IF*0!V 3GWZ8''TAZ-<)IH>4WG.4%D55=EQ#=$RJ2W.D8
M.4/84, ;<./IVUSLE"DEB)J( 001;JFY03(9$$3*%*(" " &$HDW'</0.C9O
MM_2135*JH1OR'!9LV(8ZZ*A5C#OMS*B4/[ </L".H9GHSA%)9-910_73'D$Z
MY.CS(\@[ .VVX<-]%N/B665.8S"3,W+UTG#!TF"9 #J 99$Y"GW$1V HFUT%
M6A241RJWKT8;\,!#)E(5,4R@0YP*8JJ(")=Q."7R[B.N.[];]GP,7N9(N=(I
MRMDFH,S'$I4]SG( )'.)AYTA$2\1_GUK)\24Z.14BR#A4AETU"JE.)0$IT@3
MY"#U=@$#E$1#;Y-/$:^TJFJQ52D:+$YA.4W0%-7D-N383;&$0$-PT0):BSAL
M4&JA3G2*78R:J9E$A(!N<0.X#?G4#?CZ-.XO?Q)XK"FV2,T21$BX' 3$4'F*
M ; *94Q$?9#FUM@U34JTX$.=,I"M^L4#EW$$%^!3 <0$2F..P@4-]^'JUE5/
MB-"I;<J+=8!% P$.4X@U$>8IQX!OQ$#&VX_8U:U'P)C519-RX,X!02F 3IJ+
M$#D*3VC%YN&VXE';[.G>.)5D.184UPY%=E Z8],FQ!#TEX>(#\NM4MZD>Y>&
M!R ]35]L3%,81 0#EY@*(\0#PW$=;<=5NJA#ZM18@:,CC!X"P:"&WAQ;ICPU
M]5_#KV&:V*_60&@&@&@&@&@&@&@&@&@-.V?]=V)O7\S<M_WG'&JMF3B:PI>1
MZ%3\M]RS"VW:I5EXZR93'C9G/6&)AG:S4<$8F;^83;R3QLJJCUFYB\Q ,4#%
M$H["&E!Q-N_'/"W[6<;_ $VK?]<D&E!5#XYX6_:UC;Z;5O\ *6E&*HC\<L+?
MM:QM]-JY^4=*"H^.6%OVM8V^FU<_*.E!4A\<\+?M:QO]-JW^4M]*"J(_'+"W
M[6L;?3:M_E+4%1\<L+?M:QM]-JW^4M*,5'QRPM^UK&WTVKGY1U:"H^.6%OVM
M8V^FU<_*.E!4?'+"W[6L;?3:N?E'2@J/CEA;]K6-OIM6_P I:FHJ/CEA;]K6
M-OIM6_REIK^*"H^.6%OVM8V^FU;_ "EIJ*CXY86_:UC;Z;5O\I:"H^.6%OVM
M8V^FU;_*6A:CXY86_:UC;Z;5O\I:49*CXY86_:UC;Z;5S\HZ"H^.>%OVM8V^
MFU<_*.A:D SGA8?_ )M8W^FU;_JDAU:$JB/QRPM^UK&WTVK?Y2U*,5'QRPM^
MUK&WTVKGY1U:"H^.6%OVM8V^FU;_ "EJ:BH^.6%OVM8V^FU;_*6FOXH*D/CG
MA;]K6-_IM6_REOJT8JB/QRPM^UK&WTVKGY1TH*D/CGA;]K6-OIM6_P I:48J
MB/QRPM^UK&WTVK?Y1U*"H^.6%OVM8V^FU;_*6FHJ/CEA;]K6-OIM6_RCI05(
M?'/"_P"UK&_TVK?Y2U:"I'XY86_:UC;Z;5S\HZ4%1\<L+?M:QM]-JW^4=2@J
M/CEA;]K6-OIM7/RCJT%1\<L+_M:QM]-ZW^4M3W"OB/CEA;]K6-OIM6_RCJT%
M2'QSPM^UK&_TWK7Y2THQS(C\<L+?M:QM]-JW^4M*"H^.6%_VM8V^F];_ "EJ
M:BH^.6%OVM8V^FU;_*6FHJ/CEA;]K6-OIM7/RCJT%1\<L+?M:QM]-JY^4=*"
MI <YX6_:UC?Z;5O^N2#2C%41^.>%OVM8V^FU;_*6IJ*CXY86_:UC;Z;5O\I:
M:_B@J0^.>%OVM8V^F]:_*6^K051'XY86_:UC;Z;5O\I:E&*CXY86_:UC;Z;5
MO\I::_B@J/CEA;]K6-OIM6_REIK^*"I#XYX6_:UC?Z;UK\I:M&.9#XYX6_:U
MC;Z;5O\ *6E&3F1'XY86_:UC;Z;5O\I:E&6I#XYX6_:UC?Z;5O\ *6^K1BJ
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M3$X^S:*X(&$P^D#SAP$OV=3^T]Z#I2A.#'V$ 7%8>XS'8FX<"V"KD('+OQY
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M#\R_T7_%.@'YE_HO^*= /S+_ $7_ !3H!^9?Z+_BG0#\R_T7_%.@'YE_HO\
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K'YE_HO\ BG0%='_-SS ^ZO<OFNF;?W?Y'S'1W)S[^6_"=/FY=_1OMH#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2127058d1-ph_angio4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_angio4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!=@&* P$1  (1 0,1 ?_$ -H   $$ P # 0
M       ("0H+ 08' @,%! $  04! 0$!              $" P0%!@<("1
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M3_-+; 37$:2.*8%TJ@1H0C0A&A"-"$:$I"-"1&A"-"$:$)?'M7_O*N!/]+G
M'^\ZN:$]O#TXJ[/U&K*J'?M-)3![VO-4Q@$O>_PF)0'Q$I>.F(R ;Z!*82CM
M][3QDJ\OB3#(]-*HUG0A&A"-"$:$(T(6="5'78?H\?Q:<TTPYJ2-U 1S2_\
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M8,6V\>\D(5M/-TBF3<+R";IR<(QZBZ\QRU=D:'+WF3 A13\P2F[_ (3,%,6
M:O4%@SQP_4?4S5+Z9U/'LK3AR2-LA7ZST62- /&;0'$HS4>*K+J$*E*,C@1
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M,FXG8"/<P<@+!%ZT?-(IX@A$ECR.(A%J1?R';XS,7"YA3)L I%!,%2'*42[
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M1QV[A^C;_)KM*]WM7*N+5XZ:H$:$(T(1H0O8D8Q#=Q1$# )1+L&_4#%,'XA
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MROS0&$>782($CE!*(B?<-.7R_;@G*H_/^JYZ\\_[ITV]$FA(^"YY;[E-PSQ
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MM+VE$2AX:H2SO#L#1:4-HP#O#@DI<I\)P&&;NP;4UQ.OJ38HTLI .[ DW"0
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MXD*5]1N$?!:"H;''RO"[&KB*9-D&DC(O8H9JPN5D2$04D'DPJIZQXN*9^_S
M4+W_ #&VWZ::^6K2K<=FT/'>_!<MO'MC>VYZAE+O>+:<2+%5)?SJ?,R[4J'8
MX3\A=RR4<BW<D$Q0W3V$2E$>@Z@ZI]BM_2LXY^I,>>XKQ9C\!Y56L*%=)9N.
M-]@&Z%J^H:?"-[G3HI-)FO'OXU_"-6#E\QC7WE.2F4$1*=(Z:^Q3"(QQ2%SB
M&X&JAG8P#%M11-+U[C319U\M9(ODECR"QQ#JIOG]EM+*WP$\U(1<%!AHVMK5
MT3SUO(V3$2,F3A43F*(@($ QBWG2.+2QPK4*G#& ]LH[NE_PHG/L)?H0A3(2
M"9V)Y.4$;.D:'L36-!.SOXT[9XW5?R+8RA$6JSYT03D(1$Q4P$!$X[".O/KZ
M=D.X:0T-<<*\E[S9%U_LG7N'$QM864SK48.JNY0]>KXW<*^O-DDG%FG:M#>>
MS*W=IKLV9(D9"/,5J*IG)%4V(H*F*8I#G 0,&V^N7WBTNYKT6\52UW%;.R20
M[9Y7FM&FI<?%E3#E_52+^!D+7+3;LZ3\+8W]>=0N***M39*/>)G?UN?;Q;N'
M=P320!JWCRQZS-1B@NW[3%(D<@'V/MMW6P5AMRUQI@O(-_C8+L:>]CFFA>22
MF/83+*<-GBFVF<:QRKU_<H-FJ55=22DF=U@VBD2F55F1VW82*2"I>PQ.\BG:
M B<.T8YI +HQ.:"VE:K1A+H+5DC36IR4>S*55C*/,9/B4AEI"15G3((++,';
M4T6FV?.!3;R30[9)VR7:L@2#_:.TP"(]VXAN,#G=>=L+0-+36M>']5T]LZ**
MQ-V)2)G"E*?.JUZIN9"XR-?58@@C& TD/K)51<#+$AVA$&;F0D"D,8C0QGRA
MBH$,8#*F+N7II;C;Q;1%[L74K\_@M'9-XN=QN&QL_B:<37,#V)R7C)8\D8WL
MM8)B9%T$X64CFY4$&Y#/I)60=I"$8W5#L!V+] 1V(7N,/0 #?6'9R3R7@Z9+
M6U"V_,8V^2P<V4#605,4J++(:5*91KR0DH4)TC-]-1ZBRWJC'\@AY(%!.LZ%
M*24.=1-3P,4.T@=H] [B)A:*N?5R\*O&,$[F1#N5P7X;1 3[Z!?QKLCR2B))
M+ZL4A7ZRBC19D1L*"QGI52+*.CN$"]NP=IA*)@+MUU9'[@&-*+-="6]M5&=]
MP#V@L36IO8;[A&$=XAN@)^N-%K*(ML5RBA1_.$,NZ 5H1V]'9)$P'%,5?R@
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M5S<#2'5I4IP_,\>./H=FM,BJV?/&X)L43F(1TH914X@H1/8BACG5ZE#8-S&
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M:6V[JC!M"[6<ZDAM*+DL]E:\V1<R\U/R+T1'Y4SNUBHI!L  1% ABH))E H
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M'D1@6C\>,E/JG6'R;>FQ"$ +2*BI [E05_3'?MX@4W+-=LNT:-A, ?FC%[C
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M."-F*:*1$4X]X\42*!A*4W<)A -^G0[%;]6!MS_E4^XD+AO-,S8+I]JWPM
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M<C2%<  .6I%WJTVHD+WRQ5*HHTACK*%#N. K%[C=Y=M9]U:1-MW.P) 5N*0
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M62![#1X-1ZQDN^5W)4/(1#:M9"8?7L2V2$(M^V%1G88,QU!\U-@^(U< Y:'
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M8$@(LKL7<H[%T^^VR6"$RR.J2,*$9J;;MVMKB^$EB")SXJY::\!AC6G$IN;
ME-B+1ERJ5J3;N'T +.7EU7!V:"IURI, 5$/4*+B@T2,X54433.4/G3WZ[=>0
MVZ&1]Y24$-U</7[5T?FO<9F;;^R6DEF/8*8TQS4U;(,2T+0"0<3Z5M7;O36%
M58,RD3!JP61BDXNM B)O,3; U713*!@4-X &PB.O4(HM-D8ZNI0KPYLT(G%P
MYQ<\<#2GP^::,9U^9:WKU,JK7W[ZQV-*7GG;9*251CG31 8E\HT*=$Q&S2/:
M.0,Z(H8YP6%(@[@.X9<4CH7%A_C;[^?I@K\OT=^!(YQ$IS ( PRS!/XKU9FS
M/1JJDO&P\BA.O(-ZUCBBU=I")E@6,ZE3&*8J12&:J-3 !OE 2#V;;COJC<;X
MQTS8!0>K-7["P):_JU$8 I^*:SS-DA?DOD:M5R(7<!5*>@K.3IB+$.HYD#)"
M\%1TJ)E4!D/JXIT^WIV$.(?0(:DD<;H"_4XMICB/R6=(RW9=L8USM9. J/R7
M4O<*RBVC?9ZN:@Q<I!ME7E(PM%-9I(J!W$@Z#SWI6*(K$4.D#..<*E,)=PVW
MZAOK;VEX+-#,0LC>6-#3JK50B1VW'KOU_ /WM;:X]U*FG-9+MXC\!T8DT2 $
MY)R+VM**C;.6E#FGA%O0T9ZWLJRJ1B%5;K)E4%!RF"A#HF,T*D98.\0 /+WV
M';8:.Y2-BMG8C'\PMG:HGOETQUU>GR"F_8DH+C([.0RD_2_,VR%<(IN'*#SZ
MR1CY11YWOFKLC,2.&)5R-W!2F'<AOF[0 P!KA8MO-S<E[VU;5=C<RSQ6M!75
M3BN.PKJQXDRS%R0(OHAVP<##.'S(A@9/VS==*1:J%.NH83.D"(F.43 4O40[
M1W#:&XLY-L>"RI;GC_2BV=LO&7@Z3B""N)<@.<>:*MEZ9A5KM*V6G.HH4H9
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MS!@9#[:K]."\/*T?%-RNDN59K)J0-@G',@9NU=.BJBS>$(=LT>-S)&6,#I)
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M+&^&\2A(Y6D8JH8WC6\-,7^PS#]M'&;01; V78UZ*,X$?K&;L,@V*!VR(&<
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MB1LG>/K9*]2=M7LMTK[QE(1J$+;YZ4+%1$;)'7!-G)/HV'4<&14'N,F5?8!
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M5>21R/4DC-@?O*_'T\69A,45BI.W"IC" EV* CI.*?3NU6S^UA^\KX$_TN,
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M]466:_\ A]E9J<!A%#&Y.2L#*K/X55A(OV3XZ,9/R"31=V!/1I.3>494IP$
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M[[3EY]QC@4/Q<>,6AIXR4$A[U5'_ -*HD:$(T)>Q&A(C0A&E*$:1+1>9-AW
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MG&/;=X[!G/,KEQ(U)O<("EQZ4H\B))FN]AWK]VY(UCD)%NDH@1RB B=04CG
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MDM6VE9DXBJF@/63F3;1-T8D Y_)+&3\4[#U .&"AO)<)BH1R0!%)<@& P!N
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M)VZJTV4&,R+!4H=R<@S;G]0@.X;J(@7?KILK&O%%;M9&1SAQ-&U4T[AYF?\
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MLAU/U%<UN%\9W)H^%NKZ%<M''H(F4*Q.JLT0E60.$TG:IO,*[[TU$%U%T5@
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M\4ZG[]4RE*^Z)GZ$2(BBUH3+'V.VJ"( "34E.H4#$^4F!>WO(DLD.XB'AO\
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MT43B"F^WRZS;5L;CWFAV'%:MS+((^D#@HEOVN*WNF>%<2PADQ0"T6HZ!R%5
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M8.:-1KE[4^O%^X97N"/"#V>X^^XXIUXQ=F#'C.LY#G9YB#^P4J#9IQY%I^M
M<CAN/HR21EGC<R)S.D$?++V'$IM?E')]DMT^ZWW.^XUQY>WV_P!HWNVW!CXV
MVYTA^,P+'D@=UPP&EP(<02*57I5WO8MMO@ZD#-+B*BOY%,]?:1HC/I.3V/YJ
M[6]K=\#V3'32:XYJ0,:UA*]6JN[=*FDJYY#144Y.?:*@F99X<1,[;*('*0A
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M"-8"5?[E#1M:<?>W_E-N/=+V;@=B1A+[*$.DZ)CNQ6_' '2 @F,#MDV@6Y7
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M%MM%;/VIKA)XT0XJ6F*;%6,[=\A:,^?JB</3@TCL;Y!0B$REZ""PK2CT3#]
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MU*)VR8G+W )2B &Z@ ZJW??B+?3,+3M6TQPQ5E>[++0>+G;*2457>IBJZ(L
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M> &'_/$-].B<'QM<,B H+Z-T%U)"_P ;7D&G8N#5MR\93\(]C@,9^SEXUVR
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M2UX?!?,F\0LO+J]EM"!:17+@T95!R(&62;<YN).2<ILQN'A"$<2UE0G3>4
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MY/$H_P#I5&C0A&A"-"$;Z$M3[$:$ T3KGLNV9.O\_,7(**BB2Q0MT@1.(;E
MZM9?/2=W7?M$6.WQZ[:KW7\2NVF,H]2M5<*"@XQ+-P"IP-]81ZJ)2GV+V*@B
MJL!P\?\ -';[@ZQH(XG%_4[/FNA(J&E0 ?>6.TQ[G_.CI2,(X;1^.[DV3<I$
M623C;%?44J?!.TW"0$2%X0Z;[M*;J/EF'Q#8;<$,#9@64U55>[_]9U>7S"BG
M&'<1';;[@>'T]-:RYIV:<1]LKNEN0%SH2@@,=DGC3R>JTDD)0-YB;/!UVM3(
MQ2FW*)T)2MHJ%W =C% ?AI'9*_9'!PX43=PCL/T?\^E]:HDT=@O(ZASCN8PF
M$  -S#N.P> ;^.DH@O)7K'2II-5G?0@E8T)%].*>N(]SZIKOYZ0%,F8NP=@E
M4(;?K\! -M,DA;.W0[PJ[MUQ<V=[%?6A+9X7AX/(CBG<_:9-9N1?N=\35KJ]
M//?HMD.+M;L\J'J&R;"G(K2[=)1,?D\LCIJ00$0$"C]W5:TL;>Q#@P  @^_&
MGQ76^9O-WF+SQN/UV]3N>]C*5)PHUH  ]R15RJG%;!R<Y(WA\]&07D,OY#49
MO!/YHO'SVR2A$'!% WW!F@ '\?\ -+JS%X0%RQJ"3Q7"\;/56&0:?+D,L4T1
M9(J;55;G!-=%"'?)2KE=%0WRIG;MV9C@(]"]NEE\)3(J]6JLD?L^55:RN(J#
M.L?S$;.R]PNL<F4PF79(6V9EIHB!E.A .S(\\G<I0ZD$-Q#8=8LL1E=7DM<T
M#4H[WAK>: XK<C[ \-^:+0)IJ@8Z@&-L=F3RU"B)@V6.H.QMQ#KJ6"73(V/F
M5%,!T7>I54@ZUPL%V:QH34:$(T(1H0G2_9V>BQYP8Z< /:*31^/?X]N[V( H
M@'B/S  #]P=178_;*U+/^7V*U1LIDU<(S+_L:A(+4T%RJ$0!)V42,70*")B#
M^<(J4XE^;P)V[ZRK?YK4GS%.2J3LEU\9#G[?8MR0HD;YWG95V785B"TBIY>=
M=")4^JA#MF@[[? ?$-:[?"%C.'[I2P_;+O4/9,STK'LPDDRC,^*<@>--SDET
MTCQKMMFZI,IG#C=VDX\U,R]<RW&G>-!4*<$S'W_*'?56<8XYJ[ >[AEZ%,[7
M*!F:K;;16+$BLWL%=L4W!3K=P42.&\S$2;J/DT5R&^8JR;UN<#!\!U=6,]:U
MH3$:$+S(<2F*(#L(& 0V^'72')/#J8)^J"<EM7V?.Y,GS,ZXXLYN1;Z"?'4$
M"LE+G#,6#U%$!$VP+IKF[@#M ?NZKT[ZVAC9$]J0Y[CU9;Q>7\37)B@BC'9;
MXI<9<CMQ1,!@5>/\1UN!FSG$  /."=@'(&ZCU#J.^^GPX CM6=<TTL_[4B.&
M/Z=I*K=W:=:)*S1'M$WSOGS9-0HCMTW:D4T^7@K$9[H]2MBO8BHC>@<",#QR
M;4@>94D55# 4"B5<ZT&H)U!#83^<*1MNFW4!UD9R+3?A ?8FS_M=>16L?Q0I
M]126].O/Y$B6JQ _*718.&CMR!0*._8F5#KN'^<&M&+D%2)[JKG*U7I"X6F"
MJD.1)67M$[%5Z)(LH""1Y*9D$(Y@154=R))G=.2 8X]"@.XZL+,=0O-4YIDW
MV@>36'9^@M+Y:,%HT6VYQ@^/=JR_6,L5^Y8ZPWDN<7$B4#F&2KYW3VDN&C))
M9TJ5PWW\E X%W/L44K[D:*)#-0X\Y)R/F:%P;C>-0O%PM=_=8YICB&<%+ VV
M<1DG<<@M#3#P&[12/>BS,JFJ82@"0[FVZ@"\$W0:T&2YA*U&QPKR98R40^;N
M*\^7C9H#-E3)QKUNZ%FHW=JE**:)_4AVE[A#NW 0W =]"305ON<\,V' U[0H
M-H?14A*N*'BG()7$,HX49!$Y=Q?4,K5]L)G**"OK&<#<VR+D.T2 X(<"B8H
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M%71%2&*;_9Q*(B4QBB21M.8Q4-M-)J+:U%%V_P!S^M-XCFEEVTQ[4K>%S*O
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MTX<RJ_;[6_:FUFYG8DJR[Y)L\J^/I9P[0$JZH%4EY*/,GY7DI*%W\E@(  B
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M\W]/:P4NV.%9-O(60!#\J1(V729  $,)!4#=.*F'A6Z^UB(?WEG H0\/^+G
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MVH/K[VG+S^(X%_J\XMT\9*O)XE'_ -*HT:$(_P /X="7!&A"-"1&A"\BB(&
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M!IP2 T6W4U*?>V2N-Z\^.QF4)ADK#/0=BR&*>I."NTY CL#%%H5HJW\T5"B
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MXPF5C]1$=]_#_%]W2A5),35>O2J)&A"-"%T7$D,:PY-H4*4I5!D;9!MQ(80
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MX =P'?IX:5D8::A38 XJL6^T\X,5QAS8C;LT9@A'7>/F3^>DV.@GZQO./'9
M$QC'\PPINA$#= $ \-/')4Y\7)$OO!O%Y3E7@FS/C%/)6KA9PUL<CV'$Z0NW
MV'H)-4$QW#8@@W#8N_R_2.A/([XYIG@X]1^'A_BTH520YKUZ50HT(1H0E/\
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M#<1Z=O7\>EBR*NS9#U)(OO80A[/QHRM DW\EQ2K&T3*'0J"?U)*-Q2+L.^Q
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MYO1?FD'@ODFU>YHBB1X+A07)4Q1XYJI"0JW< =AA+MX"(:4:E$='M7S/U/\
MV*[]JK.O\G>:O]F_1CP2]SL0.'_L5W[56=OP5WFM_9OTO>2=SL1^I_[%;^U5
MG;^3O-;^S?I#JXI.XL?J>^Q7?M5YV_D[S6_LW:!JX)>XC]3WV*[]JO.W\G>:
MO]F[1WD=Q'ZGOL5W[5>=OY.\U?[-VCO([BS^I_[%;^U5G7^3O-;^S?HQ1W$H
MKB'BO[(M'\J..S_CAR4S-.Y_9YGQRYPO"RL#R[1C)7)Z-JC%*2P?JV7 ,-7D
=VKJPE0(<SUVV:@4?SJA";F Q0--<,U/.TU/7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2127058d1-ph_avacces4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_avacces4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ R )& P$1  (1 0,1 ?_$ .D   $$ @,! 0
M      8$!0<(  D! @,*"P$  @,! 0$!              ,! @0%!@<($  !
M P,# P$% P8&"@D,#0T! @,$$04& !('(1,(,4%1(A0)814*<8$R(Q87D:%"
M))0:P5+2,]-4)54F&/"QT6)RU#4VED.TQ)5F=H:V1U=8&32%M=5&QM8W9Y<H
M:#KA@K-TA*1%Q:8G2)BH$0 ! P(#! 8'!@4# P,%   ! !$"(0,Q$@1!41,%
M87$B,A0&\(&1H;'14L'A0B,S%6)RHC0'\346@L(DTD-3DK(E%PC_V@ , P$
M A$#$0 _ /J;Y+YUYCL_(.9VVS9LU#L]OR*[QK=$B0;9+0S&;_FORR79,#O+
M^7555%?HOU-54!/R?S#YDU&EUIT=H$-(AQ+[&^U>TY3R*UJ-,-3*6QVR_:Z
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M.2<HUEN,@.W.FTMM?&JXVLYIK;5ZY:B6C:&9_JJ S;,<:]2L+YB>?/._CO\
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M/R021L7DK\7']28$_P"5L5_-@/'/_P D!J&A]']7W*'DL1^+B^I.?6[XH?\
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M*2Y%35/5::GWBFFV*BJ#@$H=L\*9(:(C-+>CJ*D+2E*DMN$42I*RD%:D^_\
M@U63/4*:IVCV?Y=M*&0J.D CM[/:5%1J4]#51KI-PUHR5.X(28ICNK?R3#[G
M;4M+J2'7DH_6IVUH"D5*DZ(!Y*DKHE%ABF?'G0X^Y)DMN5> '<1TZ)K1!0/A
M 17V^M=.)D!1+!+;43S8CER^63'C4#;B5)<2A)2H +!I3J3UU2P2^U)XUXFL
MI>T_-.5O@E^.XB.B.ZK>M"UK0M*D.H)"@0I(K0^ZM==6T 2'%%4RD=I]J<C9
MGVV ]*+:E-FJDH;V( /2M152AU]VM[1MA[8$2=H022&)<)K=L34A,A="XA*$
M+-$E6Y-=VT&A*"DCJ3[-5':D,U:JK/BF[Y&V-26XJH;\I;C?1+8+X.^@(^!L
M[0/LUNX<,3$>P*,D-P]B,H5D@M-4C-@HW(2IL*0OMF@JE?Q;NAZ=1K)<E*,S
M$$@#<C)#</8N)ME8:3W7(C*D 4&YO=4*/04VFH_-[=4S2.TE6B<CY*/NHF]Z
MW(CMNRNVVA';2VI#;200D"@2@%()I^35+E855A<N"N:7M*$)5HMSC[<@*C-C
M8 6U! 6\^*; *@#<.O3VZRY8C !9+]R9/>/M*9I=K9==D)D-0P0V2TII&U39
M)VU.U5"NAITU'#@?PCV(C<N91VCAO*22K'9Y*68Z&]SG=4HA*2:$-@C]( 5J
M/?JPA&(9@!U)UN[<(/:E[2F!ZPLH<>0S#:[:$MI"WBD..J05A?PKVJZ*I2E:
MZF,(R+2 (5Q.0+@ETF.-Q@X7%QH:'DJ.WNI0VXM0--I!*$[J^ROIK3DAE9@V
MY5(#YMJ&[CA\^6XIYOY:*VP0LT2T^I;1/Q(;:2=U54]E:4U<2D"X)ITI9M6I
M%Y1B3U!,\G$H+Z0A<4+VFI6]'0EJO0UZ[J*!]?=IG'O_ %R?K/S5S&)H0&3*
MKC;&GEON3,?L4T*"4DOVB _4A2DJ(2MG<3N3ZT)TZSJM3";\2;-]1^:5+3::
M7?A ]<1\D$W3AW"D3&0;!;(RUDK9#5O;;94">HVI2E-.M/36^'.-?;[FHO#J
MG+YI9Y?H)XV+)/\ )'Y)KN_">!7!2>_AUK<0A&TJ1&;*>O\ *H@H-:'WZV?\
MGUPIQKK?SR^:5_Q[EQJ;-E_Y(_),#WC1Q7(;"W<7C(44G;L;=9 ^'J%(4M(H
MK[-6CYPYS:&2SGE ;27/M)=9;OEODIG^;&$9[@&'N"&CXO<.-[EC$(3+I #:
MW5.J*% I/Q)+G;ZD]"">FK#SMYAS",1*I;%)/EGE(!.E$3,8TV>Q)?K XS;L
M2_#N>1%BM49J+ B/6)3++ 2AM(=YRL\A= GH=RG"3KZ!RC5\PUMD7]0&)=^H
M8KS>NTL-/.5L,&'V+\M[767'1'9,QRW&FW6L<RG(\?:D+2X^W9+W<[4V\XD;
M4N.H@RF$N+2GH"02!H4N4TW"Y7&[2G9UUGS;E->.YZ9<)3\R4Z2227)$A;CJ
MS4^TG0ARD6A0LT(6:$+-"%FA"E3@VO[Y>+: DG/<6  ]23>8@ _/H*M#O!9%
M2]:.66;M<(LV/ MG(29\R1\E)<#,:%D??D.!"&E*<[;;9Z $FFH3&.=]CK83
MY#<5>,O(?//*/-+WEUA-WP?*,RNN6G&,5PK/G\\N5LFD2466U1+E8H=M9O#Z
MOU <?=2TP?UBJTV& :,K,Y<I_P"5_,ZT<W8!=<DGW*7Q;RKD7F=B?*S%JLUE
MO%Z_8_!L5XFL/']JOS4OY>'#N4N"+&P7V0IMQ]W>H(2@@ ^2FIJVU6&QWR%\
M<;+S?XH\A\A9WP_>,YPGR+Q'*+SR7PAQ-D6#V&Q\."T9&WE#O)MD:L<>1?LQ
MG96NW2$N,)D2&VE2D@?H[H1M6DOE3%H5AS_*K;C>20<^LC5XEN0,KQ^!=H]H
MNS4ETR [%:ND.)-0&R]L5O0#N2:5%#JV*I**MOXU\_VCQ1X@S?,\%M>/YIY
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M(9@;+WRQE=T-I?["MVRM:'6_*X>-0@.SN5WM=TR^[RXMOM]PR*X3I+Z(\6'
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MXVXVH4.NMR;G'+O,'+H<SY7,7-/(8C9T$4((W*;]HVBSEU+OB3XD^3?FC?\
M),=X-;=N+N'6EB\93>+]E]KQ'&;!"F/NQ8'WE?[]<;=;V)%TEM%F,@KWNN_"
M*U&N=YF\W<A\IVK-[F]PQ%XR$8Q!E(Y0"6C$$L :^I4(.QU$?/?&?,GCCR9D
MW$/*1OF.YWATW[NO=L<NWS<=/ZM+L5^!,AR'XDR%*86'&W&W%H4A0(.M_E_G
MO*O,W)['.^3SXFBO1<$AB.@@@$'%P52N)*AD9-DQ&\7N[&@H2)TGTKZ5[E=I
M/LUV,H)4=HX&B[#)LB)2K[]NJ:*J/YY)VH/3XA1SI4CKTZZGA^Q';7)R7(]U
M!?[LOMUV*$Z50;A0[=SM14&AU!B-BFN]>2LER%- +Y=AT!_]G20*4Z4_6>S4
M93MP59&<1BNO[3Y%_GRZ_P!/D_X34,%3B26?M/D7^?+K_3Y/^$T,$<22X_:?
M(O\ /EU_ITG_  FA@C/)<_M/D7^?+K_3Y/\ A-31'$DL_:?(O\^77^G2?\)J
M&".))37P'?;S,S6Z1Y=TN$EAWC_D-+C+TN0XVL#$+JH!25.=0% '4$*\)$FJ
MKN=62CBLT*%FA Q7UB^('_X3?ZLH_P#O+^.?\?D%XM_[FJ[4X?IE??GR1&97
MGF4CL1SOODM1W-I^)3C+2'3Z=2M"B%'VCUU^>_-%ZW<YW<RGN2.;VK[)Y>@?
MVJ/\H^":&F&(C866(SM0UM 0A*6PP/U"OT:E3(_1/\FO37GYZN_*1-ON;.I=
M !@$S2EP)3W97&:4CXD*06D**NZK>K<0DIVK7U-/7VZ5+4:PD%DJ[B&3C;;/
M;G=RQ';^!2W-NU 42M!0H@TZ.*0:$^M-:X:K42CDGM29]UTN8M,-A20&T@_"
MDEIM*/U2 I+;?PI!*6DJ('L%>FISRP2':J?%K2PV5(!.T ("$_%T]/L/IHR2
M.*IGB[+T2H/!FFX+<"5J4KH02:%)'NZ:D6Y(SPWKN8J&%+54;E>E*'<?<0.N
MKQ!!>6"K.0(IBNB8X;558 [U*TH2FA)I[TJ.M$+4Y]W!)?8EZ(9J2&B$*(JN
MM0$UZ^WV:Z7 &Y0,*I4!L"%AU*4I-*&HW"O]FFJY<O995,Q$L<4E?ECN%-4E
M2A[:$ 5J34#H-3&,I4"J;UL8_!<!;;9$A':WH^%5111)Z'V_$=6R2%3@K9A.
M)(P3BQ*,@H#:>VM%2I9)HM!!&T"OIH-^&^G4LM/6DTQ=QD,O)BM&,  &GZ!U
M*2"2L[1T.^M!^35Q.)J%HC.(@'Q3282DJ2]+<+A* %5*A10'Z7;-$C=^75+L
MX@!5N7!-F75U* C8#M2XHT&ZE4]#N4.G3[3I7%@*[$DN:;4/NF.RAT"CR$_$
M?Y0W)J:!1'0C^'62]<C,L,$OARW50>Q.5,>?"HC\1MB2II"G@D%X)6H)6SU)
M*%)%0=9LT0M,828=21W?X91<:+^U"0HB@&\&H*?3V)T"X$V (%4RNO(E"K#C
M[+8W)HX=OL->GK[/?J\+D<RNN("%J2XW(<;!3N2TMY6TK; !)*B0#4G\^M/$
MBH8G#!.<9I;CI1WU40GX&=H[*P?Y6XBO3V=>NG^(M;2J9XOTKSGPXS_;1)#B
ME(62$MK[2#3H00 0:?EU<782J,%+@H"7'8@.K<5M$B9\?RK:MCKFST2DDCX1
MH$XDMM4M5=X5N2^V\7%J0IY.]BH!4T#N^$J H2#J^"E=7[6PAK]-*GDCJM9Z
M*)/Z0)].I&H3L\4@,5X-*4IL$_"DK()2-IZ;SU(34=-"L"X<)L^2<EM2*!M2
MDGXD(2K84D@$CINH*^OIHG^A<'\/VA6A"4[T /J^PJK7UOFPS] #R8:VA&S]
MF4A/4?\ EIL1]O6I'77U;R@W[+;_ )C\2OG?/(F/,[PE0M_VA?E2Z]6O.K-"
M%FA"S0A9H0LT(6:$+-"%*W!=/WS<65]/V^Q7_P!V8=?X1H."O;[R\[*D_OD@
M[$[Z\BM  GHHG)!05 4>I^S2-7EEII@ENR?@FEC)^E7A\F/*?GZP>3/*MG@\
MEY9=\;MV>7>(,0O-RE7;%[E 6ZB,+/.QYQY5OFV]U@]I3*4)4$= 00->>T7*
MM#+0"Z0.(7KMIM?T"MED2XWJ7?(;QAX;P.5?(,2]7_%\*;\J,.PB7'<O:95@
ML^/Y%Q1CF9W=\,*C=I%PB7*ZOM,OK55N,E"% [2H\RUSGF8NSL6HY[HTTY#I
M,9Y15]V*MDEZ>GW*7>".)N-^,/+SQ>O/[D)MJL;W+,>SPKQ:>3+=FF'Y1"=M
MUQ<M,^[W&WJDN6/+'TVWYQF$L(2]'4X=GP$#@<TYSJN8>6+]O3W7YG#)*0,3
M'\<7 =@SEG!;VJ,A#4J2M,W+%QQZ[9[E-PQ7'G,7L3M[N3D2R.7!^[& CYMT
M=K[QE!MZ45J^/JD;0H"IU]1Y9;O#2CC2$IMCZ>Q1$/78%L#\+[^C'O$;RQG_
M +W;_P +N#E'QKCIRS'(=QF7*078/-3ALJD6N3#EIARU-!Q7Q%.]H5]FO(>9
M9:S]VT5O3Z>.HC(R$@9"+!N\Y+4W="K3>U4.>3<JS9+XX8;E%NY<O/D1=8O)
M=ZME^SO);9<HEYX_C.6V,NR8^U*N,B1*E0LO2P[)'=6H(,6B *G73T/'M<^O
M:2Y;C;MC36Y#*0022=HI3!2:+68KJ2?>2?X=>E6<XKC0H6:$+-"%FA"S0A9H
M0LT(7O&H'DU /PKI6M"KMKV#X>OZ9&@YJ-BX^-5>VYD&Q7T.>#V1XABWTO.;
M)/E)CUSO_BM=/).SV[CN;Q@\NW<WV/R*7B=H?1?8ESDG[C:PZ#@K3R76Y#:U
MKD%(;"=RE:^%^<[=_4?Y%TFCY!PSS/PI-SC$1M<*M*U))=Z,'!)"Z-N!$>U6
M#TK5U5[ZOL;D[)/*O'_ON/'NMDG\*\5R.)'(#<U_(97% P:PKQ:9F)DA4A[+
M7;< ;BY539?"NW1( UZ'_$IY9I/+MRUI;HS#4S%V4B(P%QRX@:1R@, VU1JA
M*<P;=8M121P,],QSZ,/E%=\?<D6S))WE;PC:+W,LJU,7B7C[,&^R8]MNRXI3
M+7:(]W0EQ"5D)1( ]NN+SO3:?5_YDY7+5@7.66>7ZC/&7<S7(C(8O24CDF[$
ML "<0X(Q%HOB"%%'U<B)6;^)]XFGO9%?O"SA&[91/=JY<KM>G1D3#L^\R'-L
MA^Z&-&:0I3H4LM(14Z]!_C"QP-%S"U;C"&D',KW"C @Q%MPV!('\NS<J:F(
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MW")3M790)9G,6K[U20S"BJ^?77=8JA@0LU"HLU+*67%?S:&0RYU"A3GX]?\
M/RX_]X'(O_B==]04RUBH,.I2SBLT(6:$+ZQ?$ C^J;?5E'M'DOXYG\Q\@O%N
MG^UJ-J</TROORY%=;8S[*7G>M;U)0$D]$_JF$A5.A^+7YMY__OFJ_F/Q*^U>
M7?\ :8_RCX(7^=+:5)"$N)"!5*ET52H%$I53=3\NN-:_3CU+7U+TB1@M_O%N
MB5%!*0.H*:D*-0>@KUTQ)NBHWHPC168\;<VGJM=%+)!/Z0]*4H!74P[P29CL
M4Z%ZML'N= DH"J**E $&E?:#I[CUI#5*7Q8Y6M:64$J17?W %(]>OZ*4^NM
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M17TK_/[*[7\SD6?PW(3#X5$8R;E6X24+6I(1\Q&;ESY#:#L72M :>W1^VZC
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MT-/.UTR>]F7',;Y4(*_F.58;%%.*2E.U3TYM*_7K0ZT6.47;LC$EFBZB6LM
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M&X9%@/8H8#>GJ\.2K(FV6^;<YE^E3@GO1&9BRH)]:.J2?:""""/=JUN4P3F
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M)>#6T*#;<@4;*U5Z#TU-,&"*XJ%,R9@L76#=K;AEVQNWRWMT:'*94TS%]-R
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M"V=P9DV4]&G3&FZR$*9';2 DMAM2$I3TZGT/NZ:"S,$C48(PF.*9BK7VC1*
M4[-OL0*"A(-:ZT6,0L,:!(;%<F)T!U;2 '5*6EP*2:U%1M_X6[6RZX$/YDS8
M=RUW_7R24_0>\I04[33#S3W5YAQXCT^PZ^D<B_MAZUYS7?J%?D^Z[:Y2S0A9
M[=6_"K# K<#]#*7:H?U">.W;S*,6 <1SYMU8"SO[EA=2&OU=5 N5H#[-=;DG
M]]#K5+_]I/J7W2+Y9P^RX_=K7+XR1>[;<EB'%D7*\.Q"TT[5L2D(6P5K5_*'
M6GLU]!>B\\H#E87B@@72Y6J4S8BZXM]V'WU/-);=V*0TB45 H4BM.@]!K-)\
MQ*A@H:RCBV]RK+ N^)7BTW*W2'7')2'$-S'4[2M#R0X\X@J^)-?=J*IL &2.
MVV=_"K'&7,@6QUU]16J.M:D);_6$]RK2UAMQ5:BG0:C:RFX^53MBL2:Y8S/$
MZSI5/9+C,=] D)A,E(47]QVK<V=?A]>GVZG!)VT7:^7&?9\<=FQ;VS=(\4E+
M]PL3"X(8>33X7&5)*R4FG74= 0D;G)\V\X[ L\U5RFNLK9E-/2FVP7/B V)<
M<11Q"]WLZ]-2I=2B]<K*Q;HH$-BWU8:9ORYLIN4RYW1O4&F5I'7:0*IK0Z,%
M")I''G#%V9QVYV["$3KI'4IU4V%>DPY"^X/B4(SK0*4$FH .BBEMR&LIX[A8
M7$N&08ZJ_B^R'@85F#@N)#+RBE2&SM"%  TK76E"K\+K9+3E_8RV'-M5P0XP
M!\W!E,]H4ZN.!*5-+2HT(IZ5U"BBN8V<2@VN/*MN86Z^)<6W*7;)49Q<<H4
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M@'%.  %=>OLIJ./&Y6(93PSO2>YY_"LS[;A@16[8[(2L2'5;Y+[#AH:$%02
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MK5*.]Q20&6$N5^72X*-"A^+J 2JNHZ2HPP37>KH%PTJ<3L<2*N*4\ @BE4]
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M@[Z_%N%4TVJK7T4:?9J)=Z/\R=:_%U*(?K1.=W\/-Y#NA6X%O%@32E3^^FQ
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M[=;2)R;G%AKQ=*"VAO:R( H/U8H*:BW:MZV%ZTQLAW/J(%.LA(D97_RQB?\
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M'0S&7#9DQ+G;NPJ0%M?--.]Y]"WMU5;=Q-44(%#IB%*5YS]Z,MFV;,>29##
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M>\=R^5\;X5Y3O?&5B$MQ>;V/#+[)PZ)]UJ<;G2EW*+$<CR8D!]A9>>;+C+!
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MK74J4?1;5-GQ;9*MB8S$>*/F!-9""VL-J4"Y(8W!14:5/3J-154N8*/LBO\
MCEKNR4RKTJY7AY8>4U"1\I%96#T:(<0!4H36B2:G0E1[R"&;]:KYD<>2Y9V1
M ;?VW!V6\GN]O:=BVFZ$KJ4'T'3IH3W=-%YRO'6)5R9OL-J3:6U/IM?SCA6
M$E79" NI2"*#TUGD^8J>M0=<)MJN%UB*4['QV&MW?':C,K6AY16.T"MIOIN'
MM!U Q=1U8J?<0LF.3GUMY!:,>G'Y)Q<:5+#;CKR5 =OXUA2DK56IKUKKH".:
MWEWHZT0V/@?#;W+DW6S6%BYO-+2/DI4CLPT.+)JW'0\I"5('J2GII?A]BFBG
MH>-%LGV:,[<L.QRWS66W$LNIE-!,<;#L4'&R30G1X=&RJIKG/$,^"B8MZTP8
M\5F6ZT)T4I>+B6]W6M0XOH*@TUGNV^')NA'4H1<;G6F7"LL:[Q;8IUU"%RYD
M4!LA2DI"@=IW;*Z1/!U"^F;QAALH_#=?4GCIS"#)+GD'P6IR[)84(]O>'-_C
MNE,=QKMBO>6V$@4(JYKGG]4;EI#<(K3!]83GFX8+]6SSNLLF"7[;%\@[[M>8
M<VO-H7:;-NW-J^%P)!%!TIKA:WD]O4]H-F*[.CU7!<2)91KQ5Y0XQ>&8T6)>
M6&9J4E08F+,=XJ26RK<TXE(K7V))&N!?Y'. ($5U;?,;.;8SJZ>,\R0EO,*$
MAO<ZE"ZH)HM1V^FY(KU]/77#U/*;L9 D%F6[Q5NX'BS*\O$W(K+S+:WIH6 I
M*E)<"RHJ624I)0#NVDCU]*:Y\].(C*156C>$BP5U;!>X]RV2)2DMLIV*;>W
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M0$BHZGJ=>ZY+I(<ETOAK!,H,!VMC!J,RXW,M7+F5_C78B,MT7;WI9D.43(K
MMDZ8U:[B4=Y:0X'6VBFBU%:Z@+K7W:V6_P L,*N2?:LD_P R68XL@QWD-Z/
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MUYK6]XK\PW777.7!T(7.A"GCQMR")C/+-ANLP.%EJ/<FJM':XE;T-UM*@KH
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M'<QY5D7+&;9_DD:YY_<6\@DSN/I5Z<$3$;5 R%/S'R80ZMQIMIA;R&VT YY
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M=SNJ5']W4!-5'UZ#(B*'1^P6OJ'L0-2VQ(W_ ,/LPZ04^4]X;2!0I3QM;Q_
MK]I/[&I_8;?U>Y:_W6[N]_W+Q1^'R800$^5%XV"G17&MO)/K7XAE K4Z/V"W
M]7N4?NMW=[_N7A*_#V1WB2UY57AL*%-J>,X/3KZ]<I_L:!R&V)/F'L4CFDR"
M)CV%6 \D/I*9KR1])+/_ *;?'_+5D=R;)Y9EVSDS,[++MEH;6_R<UR \BX6F
MR/7.7M99"HR"A:BI5%*%*C79TVFMZ>&4+F:B1O2=?*.?P5GF?[/+7QP/_M'R
M*/\ ^5:U9EFX72NO]2L\T/\ TM/&_P#[2<B_^].C,CA=*[_U*SS._P#2U\</
M^T?(O_O4=1F1PDOMOX+OS2MLMN6UY;^.:7&PH)*+%R&3122#3=:B >OM!&K1
MF075XPREU)-E_!]>:UJ=4ISRO\=Y;2FU@M*LV?MI6M0IN44V7</S>_3QJ!TI
MB4M?A$?.B,5I9\H?%Y4<N+6EF1C_ "2^K:H]&U..6ZI2$^P4'34^(4%)W?P@
M?F\^\Z\?*7QFC!S;M8B8]R VT-IZJ(<M#WQ$>VOH-'B$/1%@_"#^4YM[;3GD
MKX^.7%0/S$I5DSTM'W!MK[OH@?F_@T>("$XVO\)+Y>0WH3,KR-\<)EMB@J(%
MGY!9E]P"B AY=H?*6OA'0$"M3[='B H*?V?PIGFO D]ZU>3OCS$9#@4F*NV\
MA24_I$[E*5:6E5 IZ&FCCQZ760Z8NI89_"]>5UQMR8V1>3O$:Y#8);-OAYTB
M/N4 "$MOP]S8Z==:;6NC;CE(.*#II8#!-<[\*KY"OQ"RQY!<*)D#JA^1;LZ=
M_6"NU:ML%)!%=7/,('85'ABGC'/PPOEU:X?8N?DMP9.<9D)5#2FS9S\LRRA.
MT!;:H@[BZ?8*^W1^XPZ5/AI;T_Y!^&4\IK@(WW=Y$<&1GMB#)><L69H45@U4
MEM+4(H[1/6G3KJ?W:YN1X:6TINC?AE_+UEN8R_Y">/4I,AL-MN+L.<)4V.J2
MH#[O(W4.H_<LU9/F1X>6]#TC\+3Y.%UJ<QSWP!]YI;4@R!9\YC(%>O4,0*K5
M]IZ:G]QCN*/#'H24?A:O+"4Q*8N?D5P#+;D)=VAZS9V]V5N)VI4VI<'>=M:]
M?31^XQZ5'AI="9;?^%3\LX,J.XOR:X-EQ&#41%VK.VT)ZU2&]D#H!J/W&.XH
M&FD$HN_X5;RIN5\C7IOR,X%2^A*0ZZ]9LY<D!#904,MN&WU+8V^VFLT]5&4S
M*K$J?#'>O0?A7O+-J[2;I&\E.!6#(]6C8,V<"0$[=R2N!T4KV_FU3Q 1X8I/
M<?PKGEK)J[&\B/'EJ?LV_>7W+G(>^*I<!0FT]-RB?17MT>("/#%#"/PI/FO;
MPHV;RKX#C.OJ*I+KMGSU8(7U<2T@VM022>M='B!TH\,=A2N+^%3\UV2XV[Y3
M\"/-."I>7:\]7)#A!*J$6=JJ2H]!NZ#4^("U1BT0-P2%K\)SY@QB%L>5'!:U
M+=6[(:D67.W65*<.Y1:"H-4*J=1X@;DJY:,R#L 3>?PE?E\Y-GR7O*?@M*93
M92R(MGSUEQA=#1>_Y.BE)/4>E#J/$!5MV3"8D4,2/PAWF4ZMH?ZW'!LF.CXG
M$3+1G3CCJB2/C<5:'%4VT]NI&H'2M3AZ!&$?\)CY>041Q;/*7@JW+:;"7ULV
M7.7>^L$$%/>@$M"@ZT/6NCQ 4);-_"@^8CTAN0SY0\! [4A]+]DSY:7EI2!W
M#2""%&GLZ:/$1Z5FN63.3[$MM7X4KR[96%W7R3X >4EY"T.0+3G[#Y0E0.UQ
MQ=O*5#H:^WTT>('2J>&/0O;(?PH7D_>+NW=&_(3Q_#C*-C:W[/GBW%=>G<"8
M-%_;[::/$#I1X:70F2+^$\\OXJ)11Y'^-BG7WTO@.8]R"ME);75">V(2:]/;
M7UT>('2CP\MZ.;1^%>\JX3J9<GR,\?S)+2D.IC6#.D,A:@I(6V%PU+3MJ"--
MCK!$,$>&)JC2Q?A??)F%(#US\C.&):$J)+*+9FO;6D$$ A4#H33V:9#7B)+@
MJ/#%$DG\,MY$RI-'.<^$4VU9'<B)MF9**=H&U2-UN"2KI[3[=,/,8=*D:8KS
M?_#%<]L19(M/.7"\6:Z?U3RK=FH0GI3]8VW#2A0ZG1^XQZ4>&)W!>,;\,9Y%
MMVQ2%\_<+,7I8(<N42V9H@D'J4!*H!.WV>OMT?N,=Q4>&EO3<W^&7\NHD9V+
M \EN%F6Y*5MS"Y;\Y<5)87T+9'W?L0% ]::/W&'2@Z:70A"\?A6O(69"4W$Y
MNX"1,()#TFUYRZWW3ZJHFWI(2HGJ-4N:^$X&(!5X6#&8D5"]W_"$>1DLHDV_
MG;QRB7)SNKE2#:,^[+BW1TVM&TO4"5=?763CQQ6IRHY<_!Y>;ZHCT!'E]X])
M@OJ!^4./<@*:;'2M (" 22/]S1QPI=";WX,CS7=E(?3Y?^/#00"$AO'N0D[?
M=T^0-:Z7*ZYHH+DIU<_!N^;[K1;?\QN WZ(*4*79N0QMZ>@ MQ-/LU0SS!BH
M.Y;=^$_P]GD5QC]&CS)^FK=.=.)[CR9Y)<I\89_C7(L*WY<C$+!"P;DSB+-Y
=T.\Q7XPO+TR9 X[D,M*904AU]O<=NZE74-L7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2127058d1-ph_btshunt4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_btshunt4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y (L P$1  (1 0,1 ?_$ -L   $#!0$!
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M< #AXY &\.>O[5[/]_@WA@X!.)+. 4, !@ , !@ , !@ , !@ , !@ , !@
M, !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@
M, !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@ , !@
M, !@ , !@ , !@ , &N7^$?_ "Y?W9X!*X5'KQU_3#GK^UBS?[C.&, <26,
MH8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #
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M9P &  P &  P &  P &  P &  P &  P &  P &  P &  P &  P &  P &
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MZ&[5MG=4 )6AM:F+NTZ9&A'EU(;=6-?<>P8] Z!NO.M:#F-Y:T/4N9T0%R6
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M*U%.XG[^(FARY&O'^$C_ "Y_W9X04>G'7],.>O[6+-_N,X8P"<26, H8 #
M8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #
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M2+=Y\.VZ^ZKAM6];@XYW,EO7#OVR;BJUE#[*28_SG:M)L]XC+73S&Y;;C:D
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MG_+G_=GA@X>?'7],.>O[6+-_N,X8P"<26< H8 #  8 #  8 #  8 #  8 #
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MUF1(JX3FX=P37;WN:7%5+>F)CS[[-"I\F.T](64-J64H*B0*DDM8O$DD #H
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MB0SB0PXH^]J'0:J4[.M3A^2P#@7&=0*E:J^(_%A<\0[140 2D"GBHKXSD?N
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MU"6&DA#30 R2EI "0.F6/7]M9C:V\+=%X4<+=DKEUW*9L?%BGN-!E)=H:DT
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M+VX9?A<>EU='VG2].T3L0GJHVN9N=N+>$6=9'IX"/>&X\AYE\52=;H<0EVI
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MZSCY.<[RG+Z3%FJ3YZU9 &J1X?C[.S/!;=(*+S2))23;DJT,9HE3H .84#W
M=:D=*'$J:S0VH_+&*RXA&=) KF/Y^>(KGTON'+$E'%(!A;H1^+E:@I2- UA*
MB"4J4E*@,J5*3BQ#%(9DSCWZB_01L_U ;^Y<W/?]WWS;;'+MN].\B6O;Z8[-
M\L6]O39N^Y[GV%N6WW"2Q*8+33MU=\Z.IEP/!2@2G*MBW&J;%K3 USL/V*OI
M8M-UW--@WS?C9W!R)MSDUN/<'MN3G[/>+!NE[>,BUQ+Y\Q,W2?9;YN%:Y;K$
ME2PV7BA!&D4=*%51!5#6Y+^QKV=(;XZA\,\D[EV,]9-T<31-W79]ZUHN;.QN
M.]W[QW:Y-VNIJTF,G>CSNZ7&PI^K!0VUT4A),3M/@#?OJ2M:_L8O3!9KEM^Y
M6K=7, M5J8VU+ONWGK_$7:=^[NVS%N:[/O7<DB3;')S%[$R^27UL,*1'>61J
M 33 K3KB&11=/L;_ $OQKGQ%ONX<E<FV>U^G78DNQ6AIV]69G:\:'#A;KBSM
MQW9N1: NT27XN[9KTE<8T?\ +9\SY!!:XT?: N,_9W\7P>;O0-N^S;KVK#XE
M]*^Q!9N-P\I9WQRION/<W;WM5<Z3;7[;8-P;?V\5+G-:HZ)"Y2W%4*:$IQ [
M31'O.4A14G6G4M:4Z-5=0\10V=+84#TJ2#4$G T#R%1I?RC4@%6!JHC5,A29
M4"E)KEG\.1_TX0;B9(=H0$FH)Z'X\"2&R3=,.)3,4%1G4J&M/DNA8%2-)0=0
MZG(I]F&7:*U)OD_R+^R3\Z'_ .<?S1HOOC:MBOEIO^WKE;TNV6<[)U*+?A5Y
MCJ].ET)*DZ59TI0G'*75YE7'(]LZ;9\W;I/.A\]'KD^S2VKSALBZV"%M*T[9
MY0L3S-UX_P"7-J1&+?>9;<4+4NP;V9;]U-PC/-T0TNA**U*L,\FXM+X4"_TN
MW2N4GW'.WT>\6^HSA6Z[LL'+VQ9VV[0O;;Z8]QEW&)*8?N++D=:5Q6&'5N-,
MO)940DE9IUQ[5_CQ:K[@LZQ_4SE;6RBZY-\.PG?CS<,4<YQ2IPK;>CW&-0GP
M*\Y#3B10T/RFZ8[CU]!VMI+5R_1%O9W+=VY%QK2O'VG7WTJ)9E\W[:0D(0I3
M%U?" 1T:L]P77N31(R&/E/K,U*]<O1^B+=??0U-_9U[?PG:E$Q#;:14%-/DH
M- JH/E]"/9\ &/+NN78[F:G8S36>'><M<V<KBI%*IDOW>*;%*BK "UR&G6_Y
MJ="?$HYY ?!C-W6]?V#V[?C*MCI>X6\C<HJ)<SF[ZL-R.6W;D^<X*1@B0REY
M0(0M;C*PG2:T4:I^'$OI^+]KJ:/4INW:<)\C@'<MP(C;M0^ZH*5*GR*J/_9G
M6O.AZ@],>J=+MRTI'+=)OV_OFL:U.Z/H_M2YEEM]SD1PPP[":DM^9\E: &RG
M2*'J'1C=EM;L5C3WGH,)+=?\?R-VMQ[N@VQI1'D,H2<DU.9H:DT_G4Q'1PP>
M9?M[*Y8L^9=R.+WJ]YI*I$^S1'D./S77(P;;*BHI<3+"LR0$A*5 UPU)O!'#
M=9OUD]/,Y,[JW%;-NMM/3I*&G9C:Y#27WD(4M":*7H0KQ.%237MR/7#E%U/-
MNI2F[OM&="W3&N'EF(=9*' E:2E6LKJ$_P"K)/A0:#O&))7(V\R;8J&XNJW;
M3UOFJ'9W[-O<>ZN(KS<7K\T]]#-[Q8;5P:6?.<MLB-*#D.[AG6"RTH*4DFFH
MT.+VTW$*+,Z3<=%W"L816M+''^!WQ:G1)T1J9#D-R8C[;;S+[1UH<;6V%I(5
ME3(T/<<L;VWNQ<<#CYVKL+\K<TU0Q5!"S7Y)4?"FM3\-.P8E=R,55UH-TNM"
MV5+2MD4*4E8%%=0*U\5/"#[*GIA(7[<\8_D)+P9YFQVQG$KA9?*2VE*LNWS%
M5H>XG%2ZZOVCDT\41?\ X2/\N?\ =GB#@.'IQU_3#GK^UBS?[C.&,*'$R;PL
MIN<T ]'D"A[BBH)^/$T,AN"?88:"$Z5>W/NZGLIWC#A3.9<2I5:=O0_<'W<.
MK[QK+BR"M1'0JZ?\&)%E[!RR,Z,HJ2JO5/R>P'K48;/,1BD.SXOY,,69'+Z2
MHD?#F/X5Z8<1),NL&E?97,Y4K\.&DU:(R&S5::]00,@3V^SL&$>3[A5DC*_"
M<^%(^,G#. Y ?BP@,KKK%%]F=0*4[NTUS.#+($AD<@;2M>]]J7S:UY@L7*WW
M:$N&_$D!986I2=3*E^4M*@/> #D:CX\4M_;MSVTM:S-#I>]ELMY&[%Y'RUR-
MQW:R\B;FV3N>WO6F58+Q<[<[#<92I*%PI+PCI9"DE2F/=/**:]A[\>,]5MVX
M;CP*CU?,^D?3^^>[V2N/C%?H0/S]O!&VGDF,\I#<IDNI20E.I?EMZZBAT@E1
M[J8P^I803Y'H/I_9*_=5>+-'[KRLM[S IPMJKX"E8)RSIGC&\]GINWZ% 9[O
M+,A3Q#4M94G^=IH5)I3.F0)Q/#</2D6WT*U4O-<G766V07\P:"BP*5%,J=N%
M\]D-[HUN"5##>W3<9ATN/N>,Z3^,-?%[,)._6+CS1#_:;:9?C2G7DU+KI45B
M@U @]>^O7%&AF[NPK&,1VP4BB%*S4'@":&IJA6= .E>F+2^E4Y&;/&*;';"2
MD:5"@-0:]F0_BKB6WQ,RYD.R,$U25DU.:=/P??RQ)'ZC(OK6FF*?F)(T@$"E
M#_H^YB:I3\B)D,D(4%UR"305[Q3X^N%*[L*K8YXTN)'AO29"E!M"-:PE)<5I
MH*T;0O7U]F'1M:\>)C]2O/;W%963C7WMK]"ZQ#D75?F22MBWN-2D*A)<2\U<
M(K[32H[SZEMJ=;4$J45(!!!IGA\;:@ZHQW1O4/".PEMOR4!24I+>I).H!*&4
M-("0:_@C/VX?FAJ6)E*32@30%1 )6: #.OQXK$6X6%2^B."D_C$*)/RD"IKE
M0 D]1\&&6_'N/+[C+7AN.?8;'^F?TZ;F]0V]%6F(OYKVI80S*W-?7$J<8\E9
M4ZF#&0A:#)>EM,K0H5!03[,=YT?I,=Q-5X*OQ.0ZSU25B33?']#Z++#M:S[+
MV]9]J[<A1K;8;3$+$*+';\@MA2R\Z\ZDE2RMY]:B=1)J3CU3I>PAMK-%P1YW
MO]P[]S5+,4:%'C!(4GOSR.1KV5 QH?D9]2W)3DE?4D5I[2!7 N0KR,(+#9S(
M%2H ]]$5'WSB6 1'M8'1YL< T/GII4@]6TKJ#3^<<-N?2^X<VZ41+Z?DCX!B
MB*A#NT'SV'<T$K'18]J>O?3$T)84&O!UY&ME]8=A7%:'%MJ02ZH:14 (;21F
M>@JK%RUEVC7D)!=20XFHU*2L"I" I-#4$TK6F)>P3\S3CUF\5\W\P6'AW;W"
MV[;YL=N#S?L2[\GWC;NZ(6VKD>*X$I$C<[+2I7XZ>T?(;4MMLA;@&D*37#)9
MCDZ]YPWY6X?^U8XKEW1S>'(?*.^(7)OJ=VIM7:6WMB\G;=LIW)LRZ[DNR[?+
MB[K:OUPN7'C/T<<CL31)AV]AE]&HCS#JPF.6(N'L)1NOI(^V)N4[95IN6[?G
M&PQ^!>1]A[S7];NTKO"W)<-V;4W='L%HW':[G<HEJGW?;ETF6MDS8\!2I1_&
MN/J*36&YF!L?POZ3/5GM"X<72^9;QO3=6XH_JRX#G[6B,[JM^X=F<:</[(VJ
MPC>MT1&M:W(EO=N-V,N,XE3J];;@("4A*1'1@WAV'T MNCSRE" G44K2%9E!
M6$K6"O604U)(SPN G 76W#Y=<C4]P"?A[.N$%9E(>\(KED:C/I7/LP"4[2I4
MH--N.::)2@K4I1-$(34J43V  8BNRT(M[2PKTVGPH,.?O&UWR%>[=8KBPY+A
MQG4R)3"UNHC+>:4A <TJ20XI9H!WCLQ4O7M5F:7^E_D=+T_IZ5^W7_7'\S6'
M<UY2$N0V7E L40XI>M+14DYJ"7:D^.IZ]N,.FE4/;^C["/D*3R([O6_]MP[:
M8]WM]INKJ!0ONR%PY"* BID14I>( RH,J#$\FO+A5"[KI%R4G.,FH\CDQZM]
M_;13MG=T^%"B6Y-M@RG')'SC)?)85&?-64@ U*DBA4*C'K/H"[Y>[7-M?J8>
M[VD-K:EYN+>1Q,XUW_[_ ,C6NZ0M<E/OSSSCB"I(2P](+*"-531*5C^/'<?Y
M"O.=AKL_0P=AO+3W,;,5BV=R_1]O".GFK8LF2^LMR1<8:5%7B+DBT7!EJO\
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MP'FEH6TMMQ*%I6TY0.I4VL%"M233/$5VQ"]'3<I0FLW[EJ6NU537(^:'U_\
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M117,J2.O:*YX1TIB'=D9R>X4)KT%!_Y:X&0T9Z#USR^+*G9EVX'0%5&.^I(
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M9KW?+\M*-L<3\A70E0U(FV(69L)345+L]U@Y=<M73/#['1;BSS*G_:+?^I?
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MSXD52X+D=\H62#4YD$>SV#LQ;4E3@(RVT@!S36JB-0->O6G;GTPK=%P!+&G
MS$*(\0%:G.E.SX.F6&MK(=7'L,I!)&H]>P_&:=,CA'2N J>!?:4:FM*4P(6H
MJQU$('R2I-2G(5*B"!_'B+<.ENIH]-M0OWXPFU1,Y5?:*\D_0KCN9!:?<3+N
MB%14MME <"7DJ\Q::I4NJ$FN6.2WSC)I*CQX'J;E+;;&$+=:8Y'S$<E;7W--
MO>SXEOARYU]W,MA^S0V1YDR;)F2%-V^/&0M*U!Y2E).0RK4Y#"[7-<ZG.;Y^
M8I2EPBSZ6O09Q!]H)L-7'LCFC?VWCQZQ;VF[AL^X3'[IN&WVERW+:A,%3$;W
M;S6TI14)<!12@.6-^PI*C=3@-RU+<56*.QH>4DE+;M4H::74IT%Q?E@J-'"I
M70"HU=F)YY5&7Y+5%51\TWVZ33RMZ\:2G$@QGN/Y>0 4"I%SN>25#J0,8NY3
MU+ ZCI[7VCRX'#7T[RD,[AD.K!\4RFH@9)\_(:>@(&('%O%)G9=&^CV'>[T[
MJAW%I#)54!#*P"3G^-KV4(RPU-+,[JW."VRC55HN)T;L^T&;]MJ1:GU?[/<V
MO)C.);UN1G?.04+0 I"U54@"A-,\8^[CYSDAERU;<*U53GE>)]TVWN&[;2W"
MCW"_6:0F,XM])2+C'<T^1-8HA +/EK%2D9$9G'-[[8PA;U85,B_!K".)KURU
MM-.Y=[;.=ENI?B664Y?[BMH.%O19H4B:V04D>)"T)(SI7KB'I-(74N!F..N>
MEG/W9&V%;OWU?]P.,HDIW!>KD(^M!>"42I[I,E0%0%,MJJ>XX] ?_P 9)#E8
M3=4CIDWMNR<4<8[9VXTV'9N^KZ]>)+R&U-O/6^UL%FTPT E1#:Y)*\Z J';B
MOO\ =)*C:]YM[&[M]G.MUQKVM&?QGM:<Y?K[NW<T8P3"COVBR,O%*UN%Y*9"
MYM6]+8S32F>>6.=O[E.#543=;W]C<;=.Q**QI@^PU0]=<:% X\MMPE0F9SD?
M=4?RICI2V[!]\@71,EH*J%.L*::2K3GXCETQR^[N*5=327>;/H66[L[R-Z3D
M[;A3XKY'*BV1H5Q\IUQ>MMAY(CQU!Q"5Q7PL*6R4Z6]*T'JKICC]]N90NZ8Y
M-\.\^I]I);C96X-K4TERSH;8<1R9&P;>UMJ_OL/6$JBR;3=1+<DJCL3%+<3'
M9;42ZEMMQ=""<E>S$>XNV^:]Y>CT:_LUJA6XNRK_ "J;HV94B.]$N, &*];U
M,S692%K!2KS542H(_%E;K?C%.PYX;MM_<VUR#M3PKP:YD?5NC6.J])E:OV7Y
MKA*M8M<SO!Z1.2XO(O&R7'+J'+O:/]CNEE?>*G[5(:<2(\A*@4N>YRFD%Q((
MT',]F/H3T7O8[K:2;N1E-*.":;6>:7/M/@__ "?Z.ETG>2OPLS4'JQTM+!5-
MM(#WXU060"5_*SHHJ5\H5%2%=G9CM;CBE2OB?#B>(["Y.]KC1N,:\"2MO54Z
MT:5HI.?8-3J5Y]F9KBM)4S+/$FRT?(6.VB3_  ^[BO//V@B"_P#"1_ES_NSP
MP7@/7CK^F'/7]K%F_P!QG#& .(D;H.F\W(?\9*.S\+2NO_5Q/;&92$A+@4NM
M#357,CMS'WL/$%**X I9(.0R /:K[F#\A4Z&<RZ"ML:.IIG3VYFHP-"UP%'S
M"":&G;T!^+XQAT:T'16!FQU TSI7/V5H:C[N'2^EB-<\C(2*(&5#0GO/RAB(
M:\QH<A;J5L#C_>^^A&>NGT.VGN/=(M41M9?GJL%HFW1$)@M-O/AV48N@%"2J
MJLL#H*?+%PI]L3ZX]^;E])V_=U7+@>Y<8^OKDO>W#&QN(=D;?DR^2?3W/;;N
M,3;&\MU75%U-VO4:VW&(VNZMRXK+;3*DTJ0!A*(4EK_[</CWDE/'GK;YRY!D
M;%WGO+<OJZYRVG<=S0+&];-Y77<=@N&VYMZC2=SR)<U:MHR)SB7(,13-(JE&
MA4!3!V<0S.O$WUB>IK:$V:-^^@#E<6B+)D1V+[Q=R/L7DEV5!9=6B-.19Y,?
M9,YL26-*RT'75)*M-32N$HN> 5P[1IR_M9.&-O24L[XX$]:NP'02'';YZ8-]
M7:"TI/RBJZ;15N6(M(&8TDY5ZTPO8\4%'P)-VK]J#Z*MU-H7)YHMNR7/"Z]&
MY*M-\XUF-^$%*'HF][;8G&G#J\236A%/;B&]<5N&(1MN<JJIGWCU>\0<BJ7&
MX\YGXRO%L4XMFECY VC-F7$N@*  BW=UUL% J!0?=QRV[W=)/E4W^F[&&XN-
M7<E&OQ&G(D6VXMK>C/1Y94-06Q+;?)0H&JRM#JD*J:DFN?MZXP+]MW9U.LL6
M-MMU19HCJ\V>.^R^\_'=5J22V2I1"PDZ0  032G3/+/%3<6#1L7T1'<K%$=4
M0J*$A%%:%))HL#(^*E:COQ45C LK=7HW*1^FHP9NVK8M:Q(A((-13-.JIZD!
M*,B/AQ7W&W6#-*UO-RL%43CL?;JT*"+=#"CF/,;)H<CX22:G[F((6(ZEJRJ2
MK>7VZ2^DJ.S[8TVX6(D="4A;O0A( &H+T-K"G -)-.T8M^58)/N57,8%KV*\
M)CMWW1[M/O+L-,$PXOO+UD;A0I<R9;WVX _$KG@2:%83J 2!4X3S4O"LDQ-2
MEBJ_^(YDPH?O3C+<NWN/-.-E;)>#<S6HI(9<A2E)<0FAR2!3#&O.QX(EMY&=
M=MK,VJ\S0BTQHSKI\Q,@14-.J:=82E:7%A 4ZEI)-$Y],,E8PP)HR<'5FR?$
MG&D>Y[<N%VO3;:8MR=#<9HLJ\ORV=7XS11.C6I?6E*C&;?L4>!D[V_BV^9KS
MR8]MO;F\398#"&(;2A%DN9'_ &A#P11-#\@JS]@Q/9L-T*MF^JX#KM/'KL_;
MUQW"'FHB(S[:66Y2%I;F,I%5+870A3A54 4-*8O:-&%#0^\T\1)W=;HS.W[>
MW<66'3=X#S*+;$6HS2XV^%1I"DA(<:;014*.1KAMS!5%CNO.>A=XWX]O/NS/
MG1A&6VRVG5YSCRPH)\6LA)1J)Q#WCW@9JFFFP%F@T@BBAJR[:=U,*5C,8<96
MC(( -*9=U.P8@G]0/X&1YK -1G\'3^/NPA%<MN:IVEM\M% *#174]._X<)@0
MJQ1U:*X[S8*4>%2CD KL(S.!-K <ZTP"XPVW&"%M-E2P2"#G52>_KVXMV+WD
MNI2N_N3<'P93LWG'=W#%[:E1TO7C:3BT(NNW),ATLHCA"0X] 4 MY$AL$E*4
ME(-<^F-_:>H;FWN)VWX>)E[[HKOP32Q5?C0ZN\4[VVYR);]O;JVK-3<+9+DZ
ME*<T"1"<4TDNQ);8<44.1E I%14TQZALNIV>I;-W*_N4^)Y_OMD[%['-&V(-
M0#W@'+VC$.16/< &*XRT2 H=55&7Q$??P]28G88<IA!4K0@ZC0 )]@S-*YY8
MD@\,<AKQQXB%*9\"DA!)(IF*$9DY@GO.'8"<:C(O%F0^A:@WXZ)[">S/MPJ;
M%P9'+\8QG4@M*"@*!>5 !6@H<SAW>*LZ<"RRI.A[/,'V=E<\':)VF:A: A.8
M^3G]\X19ACQ+:W@E-4FI.7=3H:^W%I+F.JC.BN+7Y9&HE04A   2I=%FA-1F
M$BM<9V_N^7;:Y(N=/DH;I3[?T.&_VK#%PN<W9ME8TMIF++RR05+6TXF*PK2$
MU\6I1^[CA9[FE_O/4-MO/.LQL\&-GTK\!VO=GK%VO=Y=IBOVG@S8]CNLAM:%
M+C&^W.U"!:*H<0I*7DRJNU/10U=F-_I]KS7&YRDG[L3%Z]'[>S-?ZH->]4/H
M 9D/:SYKH4M"?+K6I&GP*S"4T!7JIVT.>.CH>=HRD/E'ET%2EIVAH--5I-?#
MW#NQ#+ZNPJWW2CXU/GZ^W=@^=L[BK<J6 AZ*Q>+*XXD#-MUEV4VW44^0MVM.
MN*.Y7B3[SJ^G+^G]Q\['!0ELSW72APAQ\.)6EM=#62M.JNFAU$5ZXKYGH'1/
M^+V';WTFW1R5N"!!?<6A+JFF"E0I\E1S(ZD&F*&XS-]9'<3;43YM8@Z&0&FD
MIT'3GD\DE=,S2F>**S+MJ'FI0XG-7ULQDVB\-[N@)::N%D5^*=2V#\X07/+7
M(1*4:APLH!TBA.,3K"I"G8;-GHKN[:5VGXH:R[DW!:WN*MW\@L.MZK?QY?UM
MND!"4S9L=^$PI)J$@*6D@=_08S>C0\W<*)RN^VOV\V:2^E"U.7ECWM;1?6ZZ
MW[NE*])2Y+>\= ":^)?WL=UN)_;[=(;MW@;_ '.MO<E37+3$4MT[8M=OLT9:
M5/)");3:GW5,J2E6E8D:JD4!KCD^JWOW##ZY<\FXF\V&S=V-W3:,5N);WH7N
M#J;7<O.)7JN"6%.NNEQ2UZERDI.D&FI73&+N+Z6/8)T[_P#L;<;>>)H5ZM>6
M$-IV_MJ(]!F;;DS'';R\AENZ-,7R!,<8;BW&(M#A2PID.H<"34:QEC!W5ZW)
M>/*OQQ/H3T/TBW!QA>R5O]8FGUNL-CO%YTNMN;8>EQVEQY.WGX[^WI"EOK4&
MD0GD$1* _P"KJ%#MQA7Y[;'F>SQV=RW""L_35$PGC2YM1V52&53V$I;0AYM)
M$A*=8*7FV H!0!ZZ33&)?.WV^]^WVO<B=.(=XQY[Z]I7!QV5<K.Z5H$A#L27
M(8:5H0AK_LUYO@9D]*86S9I!72M;ZE]VG"N>!N=P?RC>^'M^1MUP2N5:S*:M
M^Y[<G6A,^$F2RP4J" I*UPV'#04\6>.O]+^HKG2=VX6W_P CBG[&_F>9^N_1
MEOU!TR]*:KY<)-?^:+^1WTVY>+7N"U6F]VI:9%ON<1J9$D-T*"VZ M0&DJ"0
MRI6DY]E,?3/29VNH;6.YF_W%C[3\Z.L],O>GNJ7=K!-6YMHFW:94$DT)"E-^
MT>$]*TK3PXEW.9FYJO F:T@ *_Y ^+,9>W%.Y]*%5&0;_A(_RY_W9XA%'CQS
M4;SY[&5!RK9#E7J>#^'.OQ 8 Q$G=.=\N &=7F33V  */P#$]M2>7(()2D^X
M1$_*2!I!K3/N!IV$TQ)IEVT'RMQ46Z<#,;=\LG*M:4KW>W/!1E?!YBG$)6L+
M.5:%/<,CW83$<J&>XXAH>)00#4:E*">RO:<Z##H8CUES/42VT$((6"%^4M0&
MHA?C\-,C6I3EW*![1AS6%0;X(6?,J5*!RJ2:Y'2D))50]B017$7<1,3'G(-P
MCJB*>AS8L]#C#D5?EO-R4*_$R& TMF1&F1M"BEY)"DIS"J=,+GF*::<;_9O>
MB/B#E^Z<\<<^G;C7:G*%U=FOG<<3;%O>-GD7M];ESE[9MR6D0=NR[FZVKS'H
M:&5ZE54*$$M;Q'8T-A^#^ .'O3GMS<&TN%=FVS8NW]T[XW)R'?[7:HX98G[R
MW0[&>OE\D@O%2YDWW5H+6$D'2!44P9YYB9*J)S1DD=BJA14FB*D#^<*D=GPT
MP4$KB4/J:="$2$DIR.A_2ZFG4$H-4$9]V$C_ ,=7F.MQDW1U9J?SO:>/-R.J
MVO>MA['W&RH(F7=R];2V]>@I*@L-L*8N5OEM.:20I04DT!S&.:ZQU!0CIMNC
MJ=!L-CYEO6U4T'W;Z'O1KNXN/;@],'!C\M\EQ=QMO%6R+/=4J54U:N5EM-MG
M,.!2JZDN5'9CD)W[UR.J4JX]GR.GVFPTNL8TP[2 [K]G3Z:[:I]S:5UYTXLU
M4\D<6>H;E794:,NH7H:ML&_R;>I""24@,:4DGX<6(;F$+=9/%)EQ[%\F1U>_
M2GO+;K9^KWUQ>KZRN(IY,3>>]-@\GV5I*<@EQ.Z-B2+P\D5_"EE:AU/;BC+J
M=B>#2+-C8W*Y-LCIS9/KUL"7$[?]4'"V^(C:U%D<J<(S8DB6T2H%*[AL+<UN
M>;<TC)0AT"B30Y#$:ZAM?]*^)L6]G*,4Z>+N$J3O3[0ZPI4JY<=^E;D5E@)0
MD[3Y#Y!V=<)21D7$0=S;1EP(SA30A*Y@%<B<07MW9NTT)*C+5NS<CG4M#U0>
MHFP-!6]O1'S'*!06WY'%FY^,-]15$)4/,;C_ $OM5R+:B13\4I7_ !<36XVK
MD7'"K[PG%QBVU6/$;ZOM$^/8/(FP^-=T<+>IC85XWU+E6ZWR-X\-7R U 5'4
MT6G%R4*F1Y<(N/H2Y)CE;*$9J53$%W:*/TO+M*SG!?R_F;_!P.)0M)< 4DK9
M(\#R-8)"D*2/ NAJ0*&O7%&2HZ<C3MVX.W&5,TF-OEO;<_=G%%[O.W[>VK>6
MV'/G!=W@P&VKS*AM);\IQQ]E#DZ8XA:"#7,8M;?!/O)HVXI8(:_$/(-ZY@VK
M:7+HU2[6HN,/./A0<?\ ,#J4A/F*+P4$MG)5,NS%BF-'D*X)JB6+.EMDFQ[/
MLJ%'<HT&X *E-TI4ZC4=$T.,C>2E&?A,3?[>BR.;S_'2.9>;Y#$^]N6_;%FN
M%PN5^9B)6Y,E*:FI,?\ '(2MEJ(O2E-"1E7%KIK=R%9XM%"%EQRP>!,_,W+]
MNV\RQLS:#;#2('XMXM) 2V\TIU"SYR5>45J":I.>H'%JXJRJ5]Y=E:A1_5SH
M:[;/WK*NFXUJO%Q<DK?9,2.\\\GS4A*TK2TVT5*"45-/#3IEB"YE[0V-^4UJ
M55(F%V4I*2&^@2"K2 H=2*J%.I.(6Z8\#=LMR5)".],2%'S%"FDY$IH>A[>T
MXK>?VEKR8<A,=O#2 0BB:"AID?O*PUW(UJ20L6M.7YF(B_,Z@%+4:]4TH?CU
M83S(BO;V_P"6./M^96N]H<11*])"@:J(K3[N%UP>!&]OAEP+;-S47_\ 65!K
M0@]M>\=N'%?[99T'9#DIE,#6HZF\A4J!J#W@BO3 \J,J2L6HS;4?%49&Z(Z9
M:7FE);6GH?,!5I2I!"E((_[3N]F(VW!-P=$/E731#C](7,-YXPYIL.SO,=D[
M2WS?[?:YUN;+BFX5XF2FH<>=$:*PAMI >JX #7NQU7I[J5V,E9C-^)TH<;U;
MID90G?E'!*O$^BYDG2@5J @"M*&J0D&H["34_'CTV#K!-YX'GTE2;2R+^% M
M.I"DC*M"#3^/#HNC$90A)"]1"AUS/2G9\>!Y4$XB5)0HNJ4D53GUSK2O?V4Q
M-'Z1KS$J2PMP%"4H))ZBGW^VN#\@0S[SMQ;S*G4Z0X!D$4/Q&@*JT/=AR8[!
MD3S(+\%U32]8KF4J2H5[1D:8=48\"TA2]*59Z=137LR-#U[L*)C["^?P?;4]
M]?NXGLO4_$.H)>Y+E>+1MR\7/;UH&X+Y;K=)EVRQ>86C=YC2VO)MB'4K0ILO
MI6HZ@I*O" #BGU2PI67*E<":Q=T74DZ59\WDCF+U7^J*_6J]>I/@:#P^+'>[
M9:+,8$*]6]I],JYQ6'X<IB_2I#TQV.VP*+9 2HK5U[/.)J-O<UNJJK@>D;)V
MH;6-V%%<7$[6^D[9\>Q3N9MSL,T^DF]8MK:D%MM+KD#;$14%H/+* _02I>HH
M!TY=,L=ITR[9\I*,4G[?F<YUO?7;[<+LJ^%T-RU$5H2D"A/A21XJZL^TG5C7
MHCE2\R^ L!:2H"@ -0=.661Z8:TGB$81G)*2JCBM]N'9O?/3;MB\(;J+9O'0
MLT)(3)L]R(36AH%*8':.F*&[23C0Z+8JBT+Z3YRN#K:^6(SRVE"K;):U-E+:
MT"2=*M12 HTI7%*;I' ]!Z2E&*2RH=8_3.Z8>];*XE9JY+9!%!\K,Y Y4IBI
M*DFM6*-U/$^@5IK7':;2:!3:4I":)IYE!7*G;UQ0E53PRJ78R=J2<,'@<WO6
M_8'+IL>060?>&0XTXD:OQK:VBVM:E)&L>7D0:C'/]<;C9;6>D]2],VUO-I*U
M-:I.67L7(X37?>.[K%PMS3L&X^>[;3<-I1-M7(*>T/0[V]<'9UN?6HC48\H)
MTT[*XC],*,[BG+&6)Q/K3IWV=YQC'2G3\S:;T-;43'=MZ9:4JCPF1<Y"25*2
M#!8?DENJOP?,0,NW'4=7=+2.2V]N21ME CG>\:Y7,@+7,F2'5Z$A=4AU2DK)
M2%"E%=F/-^H[R;NJLOR,+K5EW56ZJLT8]4NZ.5.%;+;9FR+NNV6"3O.VW3<,
M!$1I7SD(MON:$.+DN(U,16&Q50%1JH:5Q%?4[NW4K?U&KZ%VFW>X_>IIKDWV
MH@[='#VV>2>-OK&XTW:W+EPGINY>5-A;BGMHW/;3<RW*N6X;,S"@IA73:3LN
MB4J*JH<= !%% 8&^N6H;9*:3N:_;DSZBZ#L[3W<%;C2UH]F:XU-=-M[*AR'7
M4Q]P28+8^0PM>@:M1*"V6U+9;"4J&CHHII7'+WMQ9UKP\>T]NAT65[8QGMI*
M-(IO)\/:;*;1WTWMLPK?N&\^_6YM8AL3$)"W8CFDH1[R7S1#1[5 4P^5ZQ+.
M-?>9+VMQK1)X,F2Y<;L7:_6/>MBN:+7-C)1[VVREQ4>YV]QUL.:&VE:DDJ;"
MO,("3V8?*Y^S2WA"F"&6-JK%SP*CJ3RRVPDMKJZE#J7$OAD$1&O-6M&I3:JU
M>\ KVCMQ0MW90OJY%TDG6IL1VDMU![>7T7%1KGV?$Z/>A;EQQ\7'BF^K=;D-
M!V=M:KH4R(H<4N;"94MPDK:91YH0G,=V/H7T)ZBE<5O;W[E=4DN'$^)?\[^@
M8=-W4M_L[.F$:R=*NM,7G4[$;2:=2PT4E)11!2HGY>2JFOL)QZA?FKCU0R/E
MYW;#?EZ:2]I+=JZKZ9H!RZ=1TQ5N5T*N9%2DFB#?\)'^7/\ NSQ" \../Z:<
M^_VK63_<=PY@ 2MQHK?IW94J]M2X*#[E*XM69J#RJ)":@W^,A#2G2M(J2$D5
M/45 Z]*XN.DK;?&A+*ZG&E.!D$4/\,\5:X%?!JO$4(Q<105.E0R)Z =F7082
ME03Y&< I"FUJTK=,B.VA#@_%J"UDJ;)%?$X@$)[C[,L+%I*@[%9YGQ4</[GY
M(Y0^U%]9\?>]X^T4WKMGBWUCSK7M&Y<)<M.6?T[\;;<M;ZK@JW<JV6ZQKDE-
MG#C-7&XY9;;C:.A!&"4ZU0N-#H=QU]MUN7ESU%W#TD7S9G'$[;_*_'O/,;C/
ME;BB_P"ZYD=J^<9[3O,BXPKM>-P0XEKNLDH8 +UL6IIM]I0*J@59FZ,3(Y;^
MB;U&;YV1#^Q5Y+WMR'R%?-N67B'[2'?F_(;^Z+S-?W8QL/=5RNL)N\-2YCB;
ML&6K:&HBW]99;5E08,\!?R.K?%WVU/J/WK=O3\_NOTT;%V=L?UN;=Y(>]).X
M8F\;A<MP+W5M.&7[';.2XGF(C6VW[@3'&HQ34'1K.FHP< -N/L-_5-ZM/5GZ
M8+[R9ZIX.SS*5R5NNT;3W%MJ?*=G7./:5M1I5MGVN1*DHM\2V/>8&2*%0H3U
MP8B/#WG;L&H!H0".T$>S*N# 8^P2[K/:ML23/?TI:AL./J"L@H(;0MM*JUH*
MFF*VXGIL-]AH;*"O2TI8F@UVO3]WN-TNLI+'GRILZ0D(2LFDE:M#0)6? TC(
M"F/+^I;B4KK@F=]TO;*W847CBQOW2]-PVDZ@1X*)UDA)-".F?=BM'<J-O0UB
MN)TNVC%-)KL-?MY;L6VX\M3C8 &HT%!0)%.JJGIC.W&YSY&]M^D?<)7%)+V$
M%W3?S3RO+2\WJ!7J%#2@3WE?:<487;=S UK?27#'AW%N!=URT_*HD)UFA.E(
M(U TZ]#B1Z.6)+<V"MQU-^R@KESPU%5TTYI[:_#6F$=*UB9DHQ;TK!HNB,VZ
M4J<;"CU!4VA>GN^4@]#B9;B4(X+%(;Y46J,J;C(U1W_=FC)8#K;3ZT'S64NU
M\PM/*U%I3FL^%- 1BM<W-Z63&_;6N0N1T%Q3;*6W7E*T-^41I===("4AM(%"
MI2Z4I3$]N6J*KG0:U1Z8K!8#KN_)NU>%;7<;9<YD9S<CD-F;.@/H"AI4-:(;
MRVU-A3[9!"@:XT+,*+&@CEH=.+-47/69:I#LMRT[%0I1D+#'S#81%C!?EEMI
M/G,K#16-1&I5:DGM.)Z4Q)XK2M;]QM?M3EU_??&,><;;=+!+>$B.8=R0EI]M
M4220@!*#5*%AS+K5-,8>_G254JE2_:5_C0U9VAR_<-F[FY L]ML,B?>]T>^R
M3N)*G5FULQWD-""TA!0&V2]18ZGKB;IE[0M+6;*7D7%A2HRY$+<-QOT"/=(E
MS89NSQ>G7=<C1(3YNNCK3[A4@$$]"#B_?FH7$LZJOYCK?2I;Z7E4H^=*C2:A
M77C7D2'#WBW<[_M>4X'=O76UH#DIP2'&EK9F^6A*$E!)&HC.F6(I2A)?50BW
M72WL/VDM4JYTH;AW;W$IM\VT+N/D2%J=D%^.S'#: T%(BU0D**BK,5/3$,]-
M*+,GVVW;56Z#1GS,RK22*G.N5?%0=#GC(\N7,MPAK[!FW.Z%C/2LC+I2G9VX
MCGJAC4F4-+T<1ER]QE#JG,]**G2216H%#D1TQ4ENG'&A9C8:Q;J)JMZ(!)\!
MH1GJ/;V9DX2.\>M8<>99CM'-9I+N'-8MS*D264:20ZHTT$]2.AJ<:-C=J]<T
M*+11W%KR:UQ)IM3ZBTI6E8KXJ$94H.I-<:7EM.E3 W4M$]7,IO#;;C:ET(4$
ME62AXL@*=G0=N&SA^W(=!5BI/)_H1AQ*AIGU$<1:=>H\D;<)!/:+O$R]O7$W
M0+<OO[;KAK*O5]']KO-+Q:#ZCV11/\/YJ.OMQ[3#Z/9^AXG/ZF7N[#E](WB>
MX4#Q1 !J:# !A.I32B55KG3H/XL\L21[1!-=9#83D#7N/4]M>W$B>H8U3 QU
MI"\BDD"F1SI3V]>N%50K[QI7FQ,S%*<#8UZ?E$$]F7W,+6G<*B-I]GD1]20D
ME"5*(.G(CKEGAP4X<Q'6A24HR)IX>E.SOZ8DMS\O%JH.I2/"M"R7"I)#B4I6
MI)0I!\);*5)*5$IJ#7J<37IQW&W\M*C?'VD+A+S5.N%<B!.3.'(O)9@,S)K5
ML9MUY@7M+K33DJ2MVV242VVM"@[&0EQ2<R0,\<M>Z#)W/,UIXY4_B=/:Z[&U
MMU9=MNG&O\"4MD[7MNT+:_:K47ULR;M<+U*<>0WK<F7-X2)*E.)R*0H"@[ /
M9C4VMA;>&AQ??^$8^YW+W-S6E0?2=1R"C[:FOMKTQ:JRM7B7 XI)22HT! KV
M]>SMPN(V5Y6FFU4YB_:[;?;W%Z-=XO%.M5@O%KO:EDFC4:)%N*9"]1!H0EWI
MBCNHMT.HZ;;\U>8G3(^>+B>WV[Z-;02PH)DFWQQ,0=)JZJ2V=!H*FF8%>N,J
MY*C<6>@].6F,>=#H5P=9T)W+9GVAY0;E,T"<]1)6W3+O\S$.;-I4S.]=NDU9
MCMJ;)HRW4Z:$E"5+/7N*J?#B"=FDM5468Z;LEH>*7\#GUZN;@N1LR]HAI6'R
MM$;_ %2G'CYZ"GRV$))4MQ=,A3'-]9MN];IE@>I>C-[#9W4[\:14N?9F<:.=
M[$F)PKM91#Q:OG(6W8SB_+1'43;T73S67TE((TO@*.JM*T&$]/V_MY4K7,J^
MOMSL^H7M5F2BU3#/F;(^F6,S:[-O9YI2U2K5MFX$)1\IMR- 7YB5$  +73O[
M<=%U-.Y9Y'FNWO6M7EFQGH\$7>.PHTE;:'''$+1J?6D("UI2DJ<4?D!I=14]
M^/)^L6)V+ZC6M:F1OW:NV=<VH]YI-ZR=R6G=SFY]H.A+MHLUMN+,M;:4$*<#
M<J.M3:^FI*B=) Z8UME:I8TW&<WT)[BYUA2VUQ>3AX:/GWG/[A^XW':E[VLJ
MSR[S<MN7)V'MB]6U D1[A>K)-N<=B^;=<6E*42@F(TWY* #59%<<?O;5O[V2
MN27EX^^J/MCTW;O?VJ$U%^;&VGW\Q*]4[=CV'NJ??>(V]R7_ (UN,_R;>9]L
MD1IUFGL/J9N-L1(4S'#T2UNI4S6I-$=:XJO8[*[/"XE5\OXF[T_U'U>&K;RM
M22C%IO4Z8+A@:ZQN0+K=&VXBF$MAUM12P\VZ:K":CP*5J*A3%R[T:W:RDG["
M6UZ@N7,/+:_\W\#>_P!-?,%XF(=V[?VTI5!88#$M<=]1AQI#H;+M'U+"(Z"F
MG3Y1KC'W>W5B+2>"X'3])WGWCC#127.O\#?AA+*VXQ/EOF4M4B,^A3)4ZEU(
M6IQ8\-0:9#3C#4E-7&\-"KWYG4-2LW[3MY:L?>B0]DR+MMW==AW-87BBZ6RX
M(D1"^X[Y00EG\<VORRTD)D(JD 9''3>C>I78=0LM)J,;L>.>)YK_ )5Z1M^K
M;.XYR2_;=<*GTI<7WB/NC:MAOS:?*1<(PE/,B@\AZ2 Z\PJA50H=4:#H!08^
MGMANON+7F4]A^;/J_I?V'5G:LKPJN//\?H37;4A.L)^33+(Y#L&>+4Y:DCG6
MM,FI8R('K^Z-7_Z<:U__ $RPP0>?'8/TRYX([>5[.#\7!O"_^DX43B(VZ-:;
M[<M)()": 4ZU30BOPG$UO%C6UQ$!!=U#5JS41G\.5<7E16FN-!'*+R:J9C1*
ME44:BHZ_<-?9BJ",XN'3H0O,+HE*2/DC/++LP5!<S/\ ,7J:T44LOQW"I>8;
M6R5+;4N@H$UR)I6AP@[#@:?\+^B+AG@N^^IW<6SHNX)$SU;;WN>_>58UZN)E
M1I=VNL%=OG-VE3++:K*R8V;::DE2JY]<& 59ISP]]B!Z1N&.2>/N2]NWSFJX
M7'BQ7)R..K%N+?"+IMC95OY7MEUMNZK7:;4JVT]PDMWMU:4+<4K72A\.$P"O
M(D_C7[(/TC<:0_3A M=MW7>(7I@VMS3LKC^V7R^J>M]PV_SO)DO[^B;D2&$K
MGB89;@;*EJT!6D$ 8*<!68?I^^QF]'GITY7VYRKM8\G;J7QZS?(W$FR>0=YW
M#=&Q^((VYRN1>FN/[$[H9MCBVT+:;<*W?*#I'0B@U[Q*LV5]&?H.X?\ 0W"Y
M0L?"M\Y!<VIR=OZ\<@2]G[LW$Y?K%M6ZWMQ#T]C:#+C+"K7;RII"4MI)3I!Z
M$UPF*$P-Y4NE*:$5(]N670"O;A1,"'N:;TFU;%N*PYI>N"V(3:%K"#I4KS'%
M)';X44/L&,CKE^-C:N-4I/@;OIVS*[>2DGD:'/WI+*0@K2'$@UHK(^WMS(QY
M4[DIMRN9U>9ZC:VR@U%+"@Q-Q;A*VAJKD.U0[0>G3OQ!<FDDT:]C;ZFDDZFH
M?+&YG&H<EQAP:U(6A("Z*&A(U5 /1.,3?7W;A)S=,'^1WG1]HVX)Q=&TOB:-
MVKD^7-W$Y:77E!Q,D I4L)3Y9-=0J =)&,';;YRR:9V,^F0MK5-47:;Q[+4[
M(CAU2]562C16H/XI(!.72N.FV\U<M1D_J:./ZGY<;DX6VG%$QV^$ZZR MM":
M:1FD9T&8RZD8LZ94Q3.5E.,)-R:51P"V_BP $Z^H %1V>PGLP2C*CP=1/,M\
MT7OFY:0#I;2HUKX?N'NJ,0^7/DZ!YEO_ %+WB]MGYHL]U7>+]/C,1;1 N%QK
M)4$,*F);U0FEK*LE%TB@[<6;4)TQ36!$I1JWPS-0X&UXW*V_-X;UW6572-%N
MCC<."ZO3!6\ES6IQ;B"A*T>6[D%=F+<YN-$B.2;DG$;V\(&V]M[QA;7M=E8A
M-7.(B2^AIQU#");2T*9#30);4E2DDGX,$?.EDG3N+<(RG#1'&?+CA_ VM:V'
M/M>T&]P0IC+D:,X\NX0 A]- \J(!(:.=4H2":]!3!*Q&7UX$+5'IE]7(A3:E
MOM\J3NF_L,!4LWMVWJ*BZOSX5O2%_BM7A/FN.>*G=BM^W9=8M9D\KFFD9QH,
M;FRW7P6BW72V3W(S#%WT.M!I3J76WF$E+>5"VTTH&I&6*>YWL$JN2U)<SIO3
M45?W:C.%(-YB3M*7,ND:-%NJ];L8!]GSEJ=U-U<"9##A\7EZ\M/X..=N=2NJ
MYICDCO>M>C]O=M+<;;]RYRBJM+&K]E">"5N1T4D//(2A"DA+C@94LH"549-*
MJ3T)[<;.SW$IQ\9Y#U:Q]C<<7X74;TYLI"@HG2,PE72J?ASKGB35%\2C8S(O
MW X5.!(JE 34T.1H,\N_%>]*-'BJEFDG<JDR%[U,<+[C;;B@D$U(4:&B1X:G
MH<9<DYND,6C3LQ3^K(B2[W.3$?UAYU*2=5"LZ:H%.G9B&NF2UX8FQ8L)PK0F
MWAZ;+W Z7%+*TQU+25 $I0K0A2:G("I.-78Q<]PI0Q53&ZC&U"NII(W"MJ2U
M' .9*4@D$TZ"I[<=)*,M3P>9QV]I-^#%%VYJ2$)% 065USZY)IE[<1S34'P'
M6VO*2XHC?BQU)]1/$8H!7DC;Z0?;\[PP/OXEZ'AO;=?]12ZM3^VWN6AGU%M?
M(3\ _P#-3CV2WC;5.7Z'BLZ:RZ,/62&GA(! )S/3VX4"AT$HH 3F,AA8YB,L
M)&BA\JI[#[/@[\.SXX!@L"U(7J;/@%?P:=0?9EAT4]0CR,-+>M !.D]M:9C[
MF)*T$25*HQ'&\E@$$4H.E.G9VG"]HW"HW9T!;B5 I3I56@335F*$TIA!Z&?,
MV^^1J:3E4^$IR H17OKAR?,2BRXC8D6>4TX2KKI(TD'(T/LQ-"24:!D)!CN-
MGQH%0.Q()&H4[145![*86=[0O"JB4/6=0))R2"D#*@H.O=B)[F<O#ISJ*925
MIST+%>T UZGXL,HQICNN.5*0HD]@!';3[V>'+(BOINE%S-7O6-LOZR?3WR/Q
M\$*?G;OVGN6U6V.$Z_.N:]OW4P E(&I3IEA"4 9ZB!GBIN6J>P[3HMJY*U@G
MP/D8V%>G]O3W+!<6ELS]M35V2<P5%(9N-GDJ@SVBDT55J5'6#[<8MQK76IWV
MPLWEI\+.K7I1EJW3OG;%O9 )D2VW"CJ0AEIQ]:BFFK2$-E1/<,,2JZ+(V-$E
MFFCN),NK,-R1$\YG4TTI25EQ":+TC41G7)2Z'X<)?6B-7R)-K"-F?FN2I6I$
M.P]FP]YWZ3OW=D9IVS0Y+D3;UM6%J\QY:5L29TAA=&'VXP-6R03JZ4QRG4K]
ME/3J6JF19W?7+JG%;5^%1HVN#J?-YRG>MX[%]0G-'I>WXU:KW9;-RDOD'C^?
M?%2HK;]BW J1<[7%CN>6RX7&UW4(2E.I!#5*XFZ)*"NK6TE0-%S?P>XG.LJ9
M9DR>GIF3Q]!W#,?@;EO^Y-R3Y]OO$5APFR(B7"2\5W1I3RBL&+'<#:4:14)'
M?CJ-]+;SLTC*+9F[?8R\[-BSQ%RJCTXL;QX[WQ+7:EN+N5SVG,GOKC-7BUO2
M [&9B-OJ"EO15&BB"2>W'F_7MKKOQE%-QQ,C=[/=[^XK-J$M/8F<H-U\^7*^
M7V]6R\0Y<0[AG3E1Y,A;;D?R%271'U/*<;+8*5D@&O7%+>;FW9VRC;DO,Y5Q
M.[]%^AKVVW:O7K=Q1SJXX9HVJXTXMO>Y-F7%-F-]GP#MN_<@V.5"CMH78]W[
M6EQE3(2I847_ "+G:I"'HZ$G)*0:=#CEI;"]ODYW%**SK3X'T=L.JPZ9+[>:
M2M:*5;IR_B:V1M^7J+>)>S]UW:3+39FGFK= O"=4&? GNEU4V"AU=7Y;[A)<
M6 36IKC!W72MS:GKL.4M.."?#$Z/:=0V%R22<*3='CSP9*>W=C\?[MN,24;
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MM[1A!>UFGOJJOJ8<':EH;7Y?G2)TQY-<RVAM"&2:YT)>5U[L<9ZIOT2CQ_\
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M.>= ,CG3#4Y9,4JH.X?<&' >T'2F6  P &  P &  P &  P &  P &  P &
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M%7^9FM_(1_R$_P 0Q*\&T-C]*[BO""A@ , !@ , !@ , !@ , !@ , !@ ,
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MM]%9]:'X_BPE<0P7>9+<NB"E9I4@BF9KJ![.ZF)K/U=HN)E*6E?F*'0N-+[
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MQ1[OT/EZ=-5Q<:O\S-3\D? /XL2O,A61[A!0P &  P &  P &  P &  P &
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M'A314_\ S1VBDZB#\F\0AV>W&ET2,%=C1XU,?U(M>SN)Y:6?9I&J6VZTJ$H
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M%O\ N73DDDY>Y?,65[+WN^4EVR7MU"$E* N.K5E2B2%'S3\8PU['<TI1?'Y
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MTMJI6M-/F)ZBHK4]^/5[<)*TCYT<UYTZ\<O>*6%%#  8 #  8 #  8 #  8
M#  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 #  8 # !X305^Z>
MP#M)[@, &NNE7[)6BGC_ &==.FH^5]6FG37I\K+  ;D_9O\ I=NGZ3?0[Z8>
M_P!O^EWO'F?./SE]';#\V?.OD9^^?1?YNT:O%[KY/X-, (31^RS3P_0K\LP
M>_NM_P!2_P LP >_NN=GT,^+WS #[2G]UJO_ ,%U_P#7/X5PJU!P[#W]UO\
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M3_8"\^N&JIZG]E7/3]!_;3WK"?T?#0*_N>.H\/[*E37Z#^W_ +UUP_\ IO\
M:"^YX:CP?LIYT^@_M_[W@_IO]H+[GAJ*E?LK:?%]"=.73WSKV?)SP+[:N&FH
MW]^N-2@_LI]OT(_+*_>SP?T_^T3][M*S^RK05^A%.S_O7Q>WIAO])7^2HO[_
M /N+9_91KG]!_P LPJ^UX:0_?[2K]U/^I'Y7@?VM,=-!/WNT!^RIV?0CI_\
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M^I?Y7@ /W6_ZE_EF  _=;_J7^68 #]UO^I?Y9@ /W6_ZE_EF  _=;_J7^68
M#]UO^I?Y9@ /W6_ZE_EF  _=;_J7^68 #]UO^I?Y9@ /W6_ZE_EF  _=:[?H
M7^5X *1^RS7+Z%U_]<_\F 7$J_=;_J7^68!#S]UKM^A7Y7@%Q/?W6_ZE_EF
M0\_=:J?Z%U[?^^8 //W6M0I]#-5<J>^??KX:4ZUP 2Y_\M_JI_\ Z#]4/U??
9_A?1?ZM_HY_^Y^8/HQ_S?=O9@_,,/8?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2127058d1-ph_cabinet4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_cabinet4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!S +R P$1  (1 0,1 ?_$ 1P    & P$!
M      ($!08'" $#"0 * 0 " @,! 0$!             0(#! 4&!P@)"A
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MA;&L**\.)S_@YYO[\;NSX5N,&C\BYR[X_MSB?6SXJSNV-GTD?A?HG'E<P?E
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MK\1]<C9Q/RJK];=F25@*J3DH7@?1V8KWW2Y1BX#47!V>LC<;O&KJ2]DU'BR
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M?S3_ )C'N.GQ:XQ]'\-5Z_\ VR^?/9=DCI71#P#S*"3[+D0GN&0&/KH^$HD
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M?I$#/CHO'+!JXJ+:D'ZVD)7Q"3V@E?7B!/F0;0Q0OK.=V9)+>"$@^OAANJS
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M8F'.=J$E45$ .B XN>B-(X)&CW/!SY3@#@2#IPRY5P]3J+ IQTNZ(N0 SL1
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M^!6UWG=DE2]8+I$US$>BEN60R'?C0;_:$C!=IT'K$X7*2 'D4Z[>N<99DYI
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MP$S9?6GA#8W+0B98" ^97DVA$7PP 9^V,U3'G,Y&J]AV<&TA3O9[$^KAC/(
MIXJI'',$98!+U76Q+*1[9L^ .83 "K=2U0I[B2<1$JU46<*1+;M,1\@,;&A$
M1!DGH.6(SF#%E98!%QT_J*TT],$+&$M"^O4+F<:FY:UR=;CO2(LM=5)2PARE
MK7-.C>Q-5RRSQ99L%6#<W/V2;E174S6N(D: A>YSG<IB#5)5<O:QL8V=$=1P
M4+FY.!*A;??46VVB$,@2KJ9F+3TD4@=45 YN0CE1[8&JY>9RHA[,4;G>6K5M
MHGUTA,W HRV]L_<6_P"NCFN37TUO$C6Q4*ES6L8[,S3'D=42N*H79-!08YVY
MN;UZ1UX)8!6HM6T;?M>V4U)34L$4CIX)'%D30]6S,!<XJ5=\N*V4'3[:X1RC
MZ/*'H%[T7(]JX1%"V84H!Y!U\\/WD?4.#;/F>W!;GS")SMO;5F+7. 4NL=&
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M!8W2/#D;-\2$*GM4E["L\T,T7L#D]II"G55R[ACR#K6X%PS<>5>U=$V8MP
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M/U+KB?UB&?2?.H&U5EH?NKJ([E_HK8$"Z[HG!X=MDQ*/4X1K./R_D4)6)'!
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M-E6)/$C@'.#&UWAC3LPDV7)_K'Y6JO;\TE5M?]% LCWT3HGO:![)_0N=,?#
M[$P<BDW!4RN5KN%HJ'4EQI)J2:-Y:IC/*\<3S$@ %/BP_0F_!$2WE+27*"<C
MIH/3IA53='8Y#[!.G$=QUSP^2B35*,$P:1RC(Y?G>E#EG@">(2S!*HR*)G^]
MGKAI(\V0D@AQ0$<3EZLL"2/L>YP3/V54@@Y@\01E@]",W0A4N/*JY'MR]:9
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M[O[.D2'[5=_T+>:]N!(OZY%?(OII\NSEZ#=*Y,N8[5HR3WJ_L/=C\[OB&/\
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MVG_RO+@U<4] 7G>2;810BX;YR7_9*S]W_>[@=&A!_4HV!K[]OE"-!<;/E_\
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M?B00L8B4+V (60NN)"B815TY:1D0&N>TEWYW(7!P[0%0XN(.G5D*GL5<90$
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M^R'5UFY*-9$&65"D2_UO3^-C:#<TVUX(:EK9HZ.ZR6^-D\3EY)?!J'^&YI:
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M?E-:K4:'-&;P&CVY.V1SE).6*C)RCT+9EWKB+#R)K'K3 _%"]@)*%Y>TH._
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M?O!W$[;K?1G"XX>2@]65./+.4I;GD3_+QZ/HX,TS@KNP_0!0Z'$(8E(<5NX
M\3\V)F()= Q=9U09+Q7A\^&6%2AZL@@CL'QX''%(,O=G%2BKZ>[@F#4,'"*.
MF'NP$5MK4I_+J<\?^JHC\V(2F GZ$LU+@)H0#H]I)T"*\YX7M:3S9(4=?.5]
MY/*YGF<O\(+A_,.V3[)R)^I*+T=@Q]Q_=_ EX4N@_FWV^1?&'W@;LQXIM1 #
M=U+TA<[JB29A.:YE%))&O?D<?0=K2:%?-N[A='K028:ZIB)US* >UVE>.,D6
MH26M-^_;R#>7\:,0W6I"%2"%_*/KXXJN;>)'-9EGJ-RVWX?.G/07J5H;S$E"
MB@E<QWG&NN;<9XK>;?>RN2$GI^'-2!;+GXC>4DE.)*:@H-<:F]88X+I[.[ B
M"Y3BBJGE"'J0<QS$?(<8<X:<J+:V;XD*%7O]Y?\ G'_,;Y_I.U_T7[N/+=(_
MQ,O2>]'^'G7SU5#$3-,B54E$'8?3CZGD0OSZC$@!TT:]Q!+0I>I(]I W/0A$
M)]>+(2BU5CW!/ 8HG%%++(/8&G?KD$TPIB.GU<4H:M3%/"W4OAM8YP4DE2./
M<<8S$EUDF@HGU;8$>US4YCWD)JFG%<9,(2QHL.]JD'.2?UL<6\HX\N9X=OQ8
ME*E,UC0B "ZDBQ5I#F1MYM%51J UJ'O)QJ]Y;U!^"Z#IMSNK1A5Y@@=J^KKR
MR2M?Y?\ I*\-*':-O<,^"O!XYZX_,3XG #QSOQ_7'TK]@/A=+5X$Z<3GMX^@
M*7[X>:^;==P--7D HH =3+ICSW2=>I>@,X3^B +1\:Y<,2T@U3&'-;->]/A]
M.),&JA>0=B<<\&D<$857AV=OJ_'@,1P"6-%[@?9SX'Y<\&F*9JHMZE FQ70Z
MCW6< *JI$\J-.S$" )4X(&/)1CY-R?L[U(.@-59 4.:<MQ/=B03DEWJ0#XKR
M#RCDD&9["T+ZS@S1%4BWPH$X("<CCD.PGX\(8<U(I!Z>E(*G+_"AZP6@XB,'
M3%2K.;:*\O8A*?AZ,2R00RE"V@#D>B :IF2NF7JQ&4A$5S4,"I"M1! ('!5
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M41++\*+YU/O(8S+YHMP^SE]0;9<I4H/J:D[ <\?<?P!.GPG>?.^/X*^,OCY
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MW"KIZ66<'Z)9XLS'.:2" @S(]"AE$)!\%#0Z_6O^OBHZ%S;0W/"8=@R[Y=U
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MQ4,C89'N@=)*QL[6L!)+5"##U/1&)=>MM]MMXIC66RMI;A2F0Q"JH9H:J#Q
MA<TRPR.8US 5(<B<< #%/!$JS=%AH:R&WW"\VVBK)^4PTM764U/*\.7E<&2R
MM)#DUPSRQ4:G'!;*G<=GH!)[Y=K;2> V-TOCUM-"8Q.2V(/YYF\IEY26@YN
M48@T^(4L.Q!K+_:*&!E977.W4E+,P/@JZNH@@I90Y0PQSOE#93([)J$J<#3X
MI*!N@_F7V?U^N_5ZR;7M5UH)^CN]X]DWF:Y/I#!<*J6*LE;4VYU'/,XQ.;1D
M@O0%IQ*.K\Y!HJL;F^\PV_:>I?4OIIM7R_=<.I5SZ57)]MW9<-CV6W76AH&
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MJJ3:[<=FMM)%7W"XT=!13IX555U5-!!-S%&B*5\PC>YQT *G ) I,]5ZJO\
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M$' ##<(KBM-=TYV!<ZYMUK]D[7J[BVA^K#45=BH9JCW-K0R.F,]1#(\T\;0
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MG5-^@W/5;5V[/N.F+!27V2S4$ETIV &5H]]DA=4"2*5/TG-S$G)#@<9I/3%
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ME^NGP9#?#GIC_P#5H_.K*UWM7NPEO&FK25T_P8X\].2]1&!4DP_Q3,P<B?\
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M>\+VG+YB,)PBF:QXN2JSTAP7X0,#@=J;+WB#@X>K/Y%P.DP0A* "G*IR)T7
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MQ,KJOEB0!U3."3WC ^:5:A/B%S9,W99C(AI_-520HS&&,4JY)0C<6Z(51.
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MIIJR>>=DDCC!1LK;M75=1&2X(&M< <!9-3XV1"UY$C2Z3E+' %@>W(N8X^T
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M>7H[++]&!IAD(=)M1Y>+W6W6AW!/:K-4WBV0U,%%<I R6L@I:F+EGBC,D!+
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MIB$BG3&\.',PAS'YM0J.4Z(<PAQ.A#LD2P2=<(FNC((.BC,$ J""G+D5'JQ
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MQXKR;-7*5NF31]EG$#2I:22NIKF#X4P.H3?\U3]L8.9N.PD( :2K (U(:^J
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MF6EQ%;(G!<L\RB\<M,AC/VTG56^VP 8L!_D2I3$@J-4U';C<V:Q7$;QK>Z(
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MJ0 _ICGZ\#)A4RZ[2Q6Z^[>IZ>&&)M37[KB=X44<?-';9;*V!I\-K0?"94.
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MXO50J2K(1M#E!#3IJNGP8#Q3='X6  (4Y0$#>Y"F8.1(S& 8@IY<T9&@: @
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MS03V*BYG"5AB,EN:]H1<B1GW+^[BLQ+NZ3$X+ <%4G70$]GQ8E'U<2H]B&H
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M;*WE1I11F#W>O'J%YP'DOFK:QU3 B*IKU;U&93-5^'+&IO@7*QHNUZ5 VGU
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M*S(O11 HYQ0%"J0<OCQ(.[G!% $+F!*)GFB<%X)Z\.B>HC#!9))/, B)K^+
MW))U$/5-I2Q$:F2O3N_10?"N*KF+!61H 3BH^K01?;:[4QTUGR[3SQ?CQ"==
M(_#)-U4OS1/3<6R$&?UGOPE/X4^UA\7+A NXS"G%0ASCO3T=A(.!2*R[VF$*
M@(71?BXY8$ERVWST<Z:CSD[<M VVQMLNG3?<N[JRC-QO/@5>Y(JXO9<YXFW!
M6N$R.Y?99[(RPTB*T4?6CS'=>'](+7ONJZCV2V.W?N^^[-VG8X-GP5M;1?9B
M^76UR.;63U5+1RFIAI6']*^/E_..%@ARR/\ 2OSE]4]RNZ8.W1<+1;J:NO\
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MGBQP4&+!,[J)_D%O4*O]$]P:$_[556%/!.V5Q/HG$6UX.0;XHRXK^_B@J]6
MZ.$C9E1[7TIBB</Y9$=,24#165Z=R'[5;:(_Z@K6E3EJNF''&N"@)"0?FK>2
M4L-?1STM7''+%41.IYF.:' M<" 6J"CPTY=F*[ED7($14@:NJP;MV]4[.N(
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MO#$DS80\,54<F'C@D#6JMK$Y0[)/:5 U,OR3Z^SAA$L*IFJV+B.H'B@.%HI
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M)<R/ @/QXCGS5F2G+R9 OZG]2<@OV?L_?_=DXXE%0EBND[HW<G* S,?E-!:
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MLCRB#V%*#1<=AM[G?61<D&IVK!.8'%4(WB_F_K7R(6[;B(]<\A^$89'K/DF
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M&,Q5.V2""J6WJVR;5W%7V6H<[P!/+-;Y7G)]*Z5P8T?11N60&.'W$CL[^B5
M_I6=$&X*8IRV"]3VFJ@J:< .:\2+S%'#1'(0H0G7'0;'<ZA&M2L:[;,#@RM%
M:;@RZ6^GKF/:X2QJ0#H]N2$A5<3C>0(D%BR%:)2!( T*_$<\6XXI!U$?509V
M ZJZY !!KX4&G?C'N5+*V."8%6%O]I 0)2VE>WE+H=#WDXC<-!Y45>BI]YJ'
M)N+82Z"X]1"5T_OG:RE,'8K!Q5?O%#@]S<V,<8W%2TB0?DC)>;"4Z)Z["V!?
M^H%QJ*2R4E1[M2NC9<K@6AE-2NE>"YD<L[/ ?4MC"\H7# 2)9=%]M=%NE^WK
M+0VYMI%?+%"?>KA<J.&IK:FHD5TDLLDD+6MC#R0UK=&IKB;!5DDXX)>/33I<
M0IL%NY0"'<UJIGID,@]D;4/P8&R2<\T3DZ;]*7<PCV_01.R+0+72^RX#Z2N;
M[7H.!D.M+^FO3$@-;8;>7Y9FU4K0J(KFB,!$'?@;)&K-UB/IETU<3SV"V?1=
MFZUTWTD'T5C[L+2C5VHQ)TYZ74[!)46"U\KB@<ZVT[%<J( 6 *"1@8(JJ]^9
M+;6U=I;4EGLMEM=&Z2.DD;/#21LD6>L@C!!C:W+E=ZEPC2BF'5(;;(';JV$Y
M![6ZK!S>@W2G[,*F:97=2XW*BML+IZV9L-.THY[BTJ7,( :"1[2\2H"8E/V'
M"K>O-1/<^B_2#>=#5Q5FTK!<J&MOM3N&KD;1L8YUYJZ2*@K*X2L<)&S5U)3M
MBDSS#<U&6",20'%4T'?GE]Z0]1[9MFT[LV;:;E0;.>P[=A;"(66IK((Z82TC
MX!&Z.800M9S@<R9*0H*E;)R2U");-)WZM'0SQZFJEZ<;:J:BLMLMLJ9:F@94
M&2&:)D%1*/&7^4U,4;>>5!(\M"G"[H<$C<SQ12W>6'H5:VSNI.FNWFU515V:
MOFKI:5LU?55FWJ]MPM%36U3V/DJ'TE0P.8I5H" C$XVH@X):U+6V=H[>VA;!
M9ML6JGM%L%775WN='&(H!57*LDKZR;D:&M#IJNH>\Y+GGGB1BPHC6"HU?&&[
M\NX"H>5=%S:\IZ,0YYI&;T 2%:D-GW0!E[$P*A1E,WY!AT4BW-<QMS^UO+=@
MXF[*.XBFA^7%:MA0*PWD@:[^M#J:45HV_9R5U(%2YI3X,2#XY*,C%V.*Z:RA
MA]@%O/R@AH)&;M%<W->'8,2YJ%%#>^_+_P!*>I6X[7O'=VUZ2[;CLE'%0VFY
MSR2,J*6DBF,T5/')$6/C:7GF>05<Y5486.*;MV)'E\L/0^2"Y4[>G5BAANU1
M3U-6V"FCB=#+2RRU%(: L#'4#:66=[FB$M5SNPG"[J#H<HW8O+3T1VVR&.T=
M-MLT8B?>)6.BH(BDNX*?W.\/)(\1SJZ D2*4?J<1T1"#+BI@M5FH+):Z"SVF
MFAH;7;*.FM]NHZ9GA0TE'20Q4]-3QL;HR"&( <,343*/%(^^XFC9&\"Y?\E;
M]P"+]5UJZ^C AP_-<)]E*=I6]%_O-Z:A?DT3$<W5X-%;[R^.<W:U5S ^&:FZ
M%P!^DTS1CXW8D_F6/+^<YJ\6S=P5EPDL]CI7FGI?J6.9KP7$^) !S*$  S P
M>E3P4ILH;D,WUX+CP:UX]'$#(8DQ=!E$"JRZDKU!%:HS0GG]I&\Q#>5SB2&Y
MIB1!&:0/ +:*:OC#@;@&\J* IUR:&A5()R].(8IUQ6!35A3FKT+N90A !:"7
M YID!GA=J,4%U+6$D0UY*\'-<2/X63PT,([<%$.H]ZB=*+?U*LYL.X:^<01N
M-133TSG,J*2J>Q(YX<W,</:'.T_2&7'#()Q1J -%R$N]N?:[G=+:Z=E2Z@J:
MJC=4-5HE]W>]@>&%"PEH"@9+IBODKAQ3SZ'!:.Z@G/ZYN8]0I[-B6&*@>7%=
M$^CI:+ON, ZF$'7(>-*F)8.JI.P5CP"4#3]$:*5/?B4&%98)R(/LXKR.X_)\
MPXXL>BJ<+S=%&?+D.U2=5[CA \<$\:I(O-BMVX+?+:[K#%44D[2UWBQ->^(N
M">+$2#RRM.:XQMQM87A49JZW/2JEU7E>J/K]]30WN&.W3. =(80)F1+E["H9
M ..,$=)LXG%6>\'DIZOFVZ':O2C=5FMQ'N]+M'<!D>6!KYYS:ZQSI7D *I.B
M8S+5D68Z J]1E)WJN,%(_EH7JI3G'PGB.P)B1X9*S)6)Z/.Y=FU0*DND3AE_
M+8_QX84).K&].$.[-N.YD2AKT&:<4/I7#54,^U7+H_XK/\PGXSB8+%32@7+P
M!3)>.+'BJC4H()XIV<"@3@IP2#A@I1(%<TS]X;0M6\K7);KC"SQ>4^[W#D:Z
MHIG@GE$;BTN\,\1EC7W]A#<0.IM2R+=\PPQ58+#Y8:NW7Q\M;=Z/ZG]Y;4I#
M%)[R\1O\0QN!!:&R$9]F,6WTJU;+T=1N;C665C:^FBH*"FI*<!L='$RG@C3)
ML;&>&WE* *!GVY8V,8F%O3$*O$+GEO)X#^JS"2C;ON)NNI%1)FAP5P.*GD%%
M_EN<3MN]>T?;N!R4CE*!$SR7$3&)Q3RY*Q9?DG,3J,SH%X=BXE%A@D2B,TX
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MN:2J^6:YLJHVDN!:(RY1DJ*#Q4(AQS^PW$A('+!96ZM >=3-L#=@MM6+=52
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M2:N:+/.9^'U8QKC561"(:F*3)BKB!GV>OCC72()6=8B6<XHC.[E[A^^N*I2
M#%;&S&)'[9)DTA&N:'XOGQCRE2JV%BT2S(F^<@=@#C\F(RF0!PJMH+0:F.DK
M[PO('*7>33RW$JO]6]J.H(7WJKU[,ACXP\>U\6;L_MRNYZ:-.RL_N3\RMK>Y
MA]=;7!<T+%7>D_I*/YL<=19ZDZGG:8FH\!&M(^+3OPW"&X(P)XO[HYSB4 1R
M?,>. '@DQ0O$C+P6*415<NGRG"[451V(%X'*0GM>RO>2JGN.&Z$:9SMR4\Q/
MT?D4A.&!O,A%[T7"SW'F*@T<X]'Z)WXQA(4(]!G 6W=P<WE4TF?>E61GZ\1J
MD>*Z5]'*OW'H7:JCVG--=54[^5I>3'57I],X!H*^TV0@]WHPY'3!RLO:6^\O
MZ,R%'>UV;:M_F:KJ>#9]<S?5;67R"Y[HKJ*]45LDV10V2-UDIK/</>(K%<JH
M7)KFRPN9/51Q$N+@$1PP;-8E\ZR\<%>)$3@$4G\G7-!V'%X$ECD-@O!PS5 #
MIEQ^ XEV(KEBLY<VF7$Z9$=@RTP,X= D5@\J^R5'H_&,0 )+23D0<%"O5]YC
M?MM"<Y+@3G_SN#).S+$)4+#!3C@HSK9OZ36W/,4=I<1Q"NC#<O3A)Y*DGFOG
M=]J-BZ'^<NHX&8_ZHVF3QPCBI1XJ6?(C+S;YZC*0[EVO:21H@-RJ&_&<.)#N
MHW0: XJ]/]:NW:?J)%TRJ'S-W75TDMQI:44U3)3NMC(#,)IJIK#3TY+5Y>8]
MB8#(.@!@!FBG7#:]3O'I3OBQV^LW#1557M^LEI'[8J'TMVDJJ>,OIZ2*802O
M<*E[0U[6@%S2BC SADQ0U7+;J5MGJ/:[1TADV)L'J">KNT]I[*JO>*FTWFJH
M-P.I]JL@-J9?(JID%A^JJICC7P5$;G5<I"<G&B59,'HI!B<4VMS7[S<U=(\[
M)WGYAIA0;)EW/=W7#;$=(8M_1&'WC:%!++:/$K-OMJ7N;&SD#S& DKB2<,1)
M.?F0W,+H7Y59^JYM?4"S]4ZO<UUFL6\86;=N^Z*?PKK56>X;9V_<ZB,3M@IX
M*FFH;K65$,98WV6QH?:!)O$9-R4)2 +*TEPB2W5KF@G^1U&;B%1L#B23VH,!
MH:H HZI6]S?LS6 -/^/ @ U:9"B=N(H3%\UKFLZ?V_-#]76O(Y9"X4P(^' 5
M(8<E1FRS)NK8!#D3=VW06J-/K:C''4<V$/7H,E,@L9?F@576?K+57"\W>GMM
MHK[-;KC9;I;C[S?J&*OMSK=)0?6%QCFH9V>'7/F@:T-B\:F+P".=#D1.N1A'
M$8K)G;[O:V[DO\X"W.I5@MK7"DN>W;)7T,C9*2IME'+ ]E.*.-T;X&N6.C#W
M^[MYM&*0T<<61:KK F"<,DM5$#*F.2"2..HAEC<R2&5JQS1.#N>-P.B_/B,X
M6[T)6[@]60(/8:*43*+2&*J1U"Z?U>S:F>^V!D]18ZB5TU53-+B;=XCRXL8$
M"Q-4)D<<?O>GRV=[59!T+/A?A(?RF*KQ5]0ZBINCJ6&9\;*1W)#+")&N<K0'
M.<GTFL<.[/&#.[N3,:=3%$I[?(U[%??I5<KI<=D6NJNSY7U#FS-BDE"/?!'(
MX-+LR3ECLMD+@LCO,2%AW-+^HH]FE3?E]*:01!3P_2$_(<9N;JLDL'3$IZD_
M9W=1!!_E%5EP3Q&9KZ<14F=<\;J\'=&X7% MPYO[7PHAZ\1]"F,58?R95HHM
M^]6:L%32;6MM0[4@-B+WG3@4SQ&Y2!)5VVAWE^-O,JP^TZJC@ZSP5L%=M*:G
MW/55=(*2IVX*O>$.Y8=N"\7$V_<+8::>T6-EK+&B,^,))?RU]D*U%X>M@4;W
M3&X8P]H*X*.1QY?9 #P4.9R((YE5?BQ='V=)6"T@74']4.G#KE&=P[<A;'>*
M6-\U=2M:&LND88#RM8U"96!AY0JDXY_J/301WMC+L6PL7I$Z9*O]OO9_2PU7
MZ"HB/))%*>1\3T^BYI0AR8TVUW]RU<T2]L+*-N,HN$Y-N]:)+#4RT;9!<Z"-
MXBFBY^1"O*1&Y<BFG;C9CKKW!;.+\"L25D%P,593<]T@N'3O<EQIU$%;LR\S
M\A4HZ2RU;VM![1S8Z2W=[VT)LSA89]IEPGV(][MI6T\13L'QN&?K&$K1@K<=
M I4VO. 5!EN2'1%J&'TH$PQR5!?7570Z5$F_VDA3_,LZ)V<K$PU/$T3SZC=1
MZG9%UL5%1Q6NMJKV^&DI:2Z7.DM40D=5-\><.J9&&JFCB4MC:02F R +'- #
ME@I2KJFFHJ.>KK7M$3&.FD#N21@\,%SW$/:Y3(YJ $*T^C!*0 >5 AF3.M^[
M=J7:H/+#3MDJ%C?)4PQETKUY&QO?X0YF/:%(.(6[MNX6@0Z@1,4;-/&.EMS$
M;%24T,8,3OT4$08U\.<+V@,(,;%]GB#C(TAJ8IA\T;AB9"UK(XVL:U4#&A@<
M54O#6>R.<G/"$3@H%M86_52[Z7)IW!S2=.P# T1BI.,UP&W!.T;BW6AR^N[K
MS=P]XE_%BO-6C!/[R]RI17KG<[V;S<D'_N6R'TX042[.NCW1Y_\ .VY.8$\K
M8B.Y9I0GP8D,:8*J$2;9B/:)HB?7;=,FU-K;VW3%=K=;I]DW3:6X*1]W%UEM
ME5/21.F@M=P98H:NZFGKWN#0((7N+AH>&/;I,GDME<C+W2U)O5D9 ?(C?E0O
M]SW1T4V[N:Z5+JFNOESW57RCEKHXJ<OW3>&NI:-ET<+E'24Y:6M$S6O[6M^B
M,@5"P9N:!65$NF29^E>&HP8)"F*$96KHH"(0[,@>O+  HF))I@LF09J"H"JJ
M+DJ# QXJ8 :HJF1U)E Z=[Y<%RVCN/+_ +3U>9.628/0@ 8!<%*2K::(AS_9
M FU]("=FIQ&N.2LY%6BZ(5+7;'D:' I*]0JY>]L )'?A!(X*T_3N1OVLVVA4
M_5U:!KJF)Q9QP58$@7&*F/J.67*;;NTY*]ULCW30[PC?7QD&2B=;]O2S1UT3
M7'D?)1>/X@!71-#C&N$F\+0]HK>]/$([;=;@.\8AOWQ8*JGE#W"-P]6]\6BG
MWI:]P1]+.G^W=ARTFUCN=MBO-.;Q5-M.Y[\_<D-+2NW/4-L58QXM[70 R3@N
M*1ID0]4 '%:-S*()Q(721C^4.]G-%0.![D4'0?)B<B[,D RTB3(+QR':#IPX
MX1XH?ABM;YO9(/>%)]/PIA<T$.*ID[@D#HWM:'+S$@\,TXX?)#,*<5S5WFX"
MNZKE<S>=PE-=:F4?*<1HY5@% HJZ$-)LMU1R?RYNI'YK?EP@0I'@ITD8YRDE
M6J?7GVG+ [)(B0X$M<NG J?3AT9TD5+VL4EV8R*\!@[<$T7DJ T@,;SM3-RZ
ME>&$$(M)5.<GL!H!&?;\B:8$V\ZCK>4[6U]E/,!_.5-D2NM1%\^'1T51ZXR@
MR@M*YK\.:Y8!4%N"![;KYAOO77>+YNKF=6C9^U2H'_6NFU&F/T!^['3P),\;
M_P R^)_O!2!\8P!_H3Z0J'T*M@8HS3L'X\?2,!JE3!?.G4[L(6J%I,E8:-)R
M]E2>'K[47&RA2*\IWA[W=2?,]N*)RRYD$C+BN*;EQL5N>G],MW "10>=)%14
M,C)<'\ @[RHSX<,8,YF4J8+L]KLK=B(;!-"XW+VN:-ZO1" 5&1UTPQ%94Y 8
M)&\664J]2"%"@J<_3W^G$U%R11=8^5WYKO\ BGD^B[7L]./&O_YFO6/)_NDN
M%#Q\A^#/&7?A4KU+I]Q[$2 ,40<PG@.W(%?W\:\P*Z.,QG1:'1ZD@Y\,5&VY
MJLB-T4 R1&6#7+MS[?B3CC&N;8"JV%JYP2=/&$(*9#Y,8MRS3FMI8J0>*0:E
MI4MRY1Q'#MQKKD6++<V0S<4G29,/]E\.0/SXIN4CRJMG$?P2ON_\@$I'DU\M
MXT3IK:M1Q]XK#CXS\??WJW/[LKL]@1[G:XZ3\RM#N.JY;]M($\OZ&Y%>U):,
M+Z!CCJK-+.I(@JG<C02?H@@]R! F&Z'Y(RRI.I&8TR)[.*X'2<K>VJ>JM:4R
M4\%RU'?AXIB5$K4]2X!2@.2_N86!Y)D.E*.I<<@]>"?N]HPU T1>]RN^IZ_F
M<G+1SY+DOAG4%3A843&*ACH:\_5N["1RA:7,KF0RJT]&$$,X/8NA_3VO?1>6
MV@JHWNC=]:PL#FDAQ#]U11.Y2"$42(<^.%>'\DMGT@:]_ '@?0H_VQ86U/G>
MW->76&KH!:MG$0[FIJ'<#K;>I*MKHI+#75%?6/M$-?2!QF$M' QLK6(YW-D2
MW[2UERWI')= 2% !SR'%> 5#Z<9H (=8QH5LR0 CN&AU^),0QH$D$MR<@4@Y
M>I<^&'@,4P@.'LJ5]8SP*)4$]9)2)-M#,)+<!Z?T<1Q3+%U?'!17<9RW=%"2
M6@>X6CCFH?"GQG$06*>2HAYM;F8]S; Y7)_.748:ZK4;40@]I3"+NG0!3)]W
MW6&HW[U.#RJ;4LP0E!S?6]2@)S^D1@"3ZI@*U%OW30P]>*6EJK=;:FKWA;'^
MXSU-AADN#:2W4$LL<]OO\DC7BD<OA/A:"1(,QQP1]H]JR-Q:%N0;@%:9L@8V
M-I1S2 HR(!SUU] Q9%8YQ497CJ+3VF_3VTT;G,I.1CIGN(FC?-&Q[@PD%W(\
MN*(?EQA#<P%TP.+HJ<$_+;7VVZ4C9Z%\?)(T.D:C2^)SR'F-P"DO!U.IQF0,
M9U"6F24E:JF-C [.0@E7$E25[?BQ+2>*C0LZ*W)1;;@- ZAJ@T!$3P'(/0A^
M'$2&QQ4@:<G5'IBFUY'-*@7H D9YME<NG9B">*CCS7UL;^GE&&N!<VDMS2Y5
M 2Y4IUX'#.'-,'BJ)V2I;]K>GK"X'^F&V^<ZH#=Z0E3ZL$*$J3_R<XG#2/2%
MTJ\S-_;;MA]2[C+0U=<Q^YMN6Z1]OL>WMQ5= 19ZVFAN,%%N2HAHXGTSG92Q
M?RF-59QQBV)'WFYV_,MOOVCLMK$8Z/G)5MNG5/44&QMI4U7%54U3!MRRPU$%
M8Y*N*6*@B8YM2QLM1&V4I[22.SXHF,OTK1@&+\"4^62D @^V"1J=.* ]^$$W
M6NIC@K(98*F".>&5I;)%( ^-X=P<TJ,(PA,^N'"'#*O]3Y>=DSWXWF(U=&US
MA*^AIRP1R/#Q)J6(V-Q&8"8H]SVYEA@GJ<,ISBBAHH(:>GB9!3Q1^'!"T -@
M8,B &Y O5?5C)   B,DG5<JZK:W?E]1PRBC!SR&;NWO&!':HUHJP_4&Z@7@@
M5%6@+N >U4^'"&!4FJJ&W1X.Y;^3QJXQD>)AB*#N3"."F#53IY4JD4>Z>L\J
MM']$K3&2Y$'C3B->&8\3%.X!-LM@LKI__3K7:IF=15?ZXW3NEHJ"SQFDZ</N
MMUJSM3;<-UFL@M=QML5;'NAT,MZJ6LNU5# Z%GA<G-])PTNM'^3 Y*K>5W-S
M]T5T!+^PG,99KQ.2G@,2=8IHO/><B26Z\Q(74$9]J*N$0#ZLL"@%L#55QZM=
M*WW9E9N#;;1%=9(W-N%)$ R*I;R\HGBY0$E1N>N-!O.C]Y<-RS1PLJ&X,8Z2
MJG[#Z7[SNEY@M4MMJX@TALU5/%*R&*,'.1TKARO>"WBN*MOTEB-7M JN=]@X
M5_-R6P6CIEN*VQ'Q6T6S+U 2_4OBLE1'S*$R4''1P@+<!'DJABX7"G8CTVK0
M \:=HRRSYY#\@PL@IJU'0:H(VQ* 0U);F#FBK,N&J3[3J[/2F8G<%E:UQ_Q-
M4:'/(Q-"]F)  ATY8%,3KSNZDM>]-JOJ[G?Z%S-P,H=OT-@NL%N^T-ZCI2Z>
MSW5KIHZBJML43_'Y6!P:X*1QQ3$B4_6I$+:;C;=SL[=X8DJW5XMD=\M=5:*B
M2:&"JC9[4+CS0R-<TAS' %8V_10\,3O6X7(,ZU\6)56+G35^VKK);+I&&.#R
MZEFD>[PJN%N;)&/U#VC+77'.3NQVM\AZ.LN4(RA3%2EM#J&8&QVZXJ^G>\L9
M+(XN?"T\K6-<XE"QJ98WEG=0N1&@Y+$E P-<U-]+515$3)8GL=&4Y7QN4<I"
MID2 3\&,V)<+'E[2--<#S%<VM<"$)S0E-=<1F7+)#!U\].Y*OP]R[LS*&^W<
M>@"IG[N[/$'60,%(?0"L_DEZ (/\]7(ZG-:&SYC/+]S"Q1*L?,NF'1V8&Z[C
M+B/:CI  OYSGG7TG%D:/V*$*2B?VP43>:/<U?8NF?F J[+67VEO-%1;-BLTF
MW*NU4EQ^L*RUAL<)FO'\@%+.I$X>$=&"F>,:!_E"MON(D=,VYS>?\52!Y-;A
M157EXV!54$,].R>"YOK8Y?J1C/K:2[U[KTZG;M]TEN-.^Z&4L*^*A_2*_F.,
M@8+5&I5IG3H 6E3DH71=3IAL<%#&J"*@@@@?&/C":8&9,8XH?O'-K(<SF$R[
M.SLPF.21-4R.IE0T=.=]IF/LAN0D_P#:>L]6!F%5(5*^?%MU8RC>.8<H;,2>
M (=GPTRQ *2LYT&OC9-HSM+E#I<D/#WYHX>G I8A73Z85+9MT;<)"_R&M1-,
MPX^G#&-%'#!2KU!N$5%U(Z/&>8PQ"FZFSN>U[&/:RGVDV25\9E_1M?'&PD%R
M@$*<L85PD=1MC]J?0N@V%K5TC>S&4;?I*JIY(*N@NW57KMN"MH[Y4;KKKQ50
MLW%>?ZO)*JY[,CNE1+M^*YU6TFFZ5E?3/\<QFJ(:*= /;Y@<V-0Y7.BD6Y+I
MEXQ("9 ^TJ  ]F@Q(\DGXK69VE1S!05RU4Y^C!5"TS2JP\IU]'',\,,"M4<D
MQ[_5:QASE!3)$X:\<&*>"YL;OE=]8=5R3_LQN'+O][E].('%6#!15T0G+;+<
M@OM>_CXFM&6"*,113:ZH<55Z $Y.)X'N[<,X(1)]7(&D%P4Y^R>'K4X039)L
ME0\KS%QR_=5>7#:B"P1+WER$<RD:KKV>C!1#NM#JEY;JA#@<R"?P0X3I/YE&
M.\:HNNEE;GG=*)!V_P KB!3T+A)G!.6N>\RM#6M#CRZZZ 'N5#B43CV% Q7S
M-?>E-$WFTNV2IM#:H'I^JZ=0>[+'W_\ =F/^P<O[8>@KXB^\$#]L8\>Z/I"H
MG3Q@-#4R  &/IBQ'U7S7RSUN_*,R"?56^9[0T-71=#^"8RI3:/-<OLMK&]NC
M(^RD.JJ!& A"D\3C N2U'@N\VNRM[>V).[IB7.[2*Z-I *C0@A .&2X(Q99A
MG1@D,5'C=Y<40N7UY)B;-BJ9<<TYK=2MD="7 @ HKE3-%&28@2RM@,#FNNGN
ML'8W_BJ^3^U^#3'C&H_XR7KC\O\ =-<!S&IR_#A\..@GM]>"W.VZK+;ER_G0
M?"_?UQ4-D#Q6UCUN](#2S%8,+=0%"8C+9 5"SK76;P+3;SHK+3-<"@Y?5C"O
M[8@+H-EU8RQQ[4EU%"H.FH_>QKKFVHNEV?4PZ0ZBW9N0)GC N[2JZ+;=1C("
MM$DR43VAZ\"[AW :^G&)/:R$3P_(MU9W$3AP7W->0EYC\GOEV82%_JZM8UT_
M35"<.&/B7Q^&\6[P?MRN_P"GE]E A62WA4)N3:076ENB+V">W9^G'%K,DSAE
M(T,K^1I84R"YY(&@9IGK@31J&H1OM.+23P<Y!Z\!3H<5M%2 2 \GFR)4(H*@
M*<\\"B0CT-20T$O4=@(U3M[L *"&/)'XZI4+BX:Z:_-AN@$9XK7=:DOM=9$U
MY/-33 J<T\-P[^W ^:"RB7I-6.IK1N5N8YIZ,Y$ >RZ8Z9\,+L1$>O'E(%7Y
MVQ5-'E*HZDN;^CO% ]Q>I8&C>=,YTCD:<F,:3H0-3BCJ$H=QWLL!^1;_ ,+6
MS=ZW"S'&>KT'\:C;9&WMNL\^FX+[10O-35[1O=W9=:#;M+1TE0^<T-+]67"_
MP62*HN4HII3,QKJM["@< 3BRW_F@(O'B.Q:+=&=F]<V[1%^4J\7#KIPS)L83
M- 7#@I 55)4KC, 8THL&F-<!Y\U@N11R@ E<A\6 T4P'654 DC,%%.>66(:J
M)Z2:+TDHY<]0 ,BN7#LXX@YQ089*NW6NI+)-LE07":XA,E7PH"F?%#A&@Y*<
M<*J';M7 ;IHFEP4VZSN#26@EO- AS(!5Q ':3A9IAP"5RY\XG5+:TW4';^V[
M=N:WS7_;%SWQ]H[5#5QMJ+2V^';$MJ;6QR\HBFJHK?*6M*$ '"E\Z8-%9+[L
MO<E/>=^=61'4PU!@VC8@\131/Y +I* 7^&XHJIZ<2!:4VX*;"=R(_<J=MB7B
MU5'F%Z>5A@FDJKMTRK*2.>#P"T55/4U$X%P(6:.G]P:&L!*&4J"%3&)LI- K
M9]>VYAU&[^]] 70Z.J]D@A"N8YAED$ XY8RXR,Q5:4A@W:HVZ@;/^T< N5M'
MA7JD1S"S2K8V,!]/+F!S$-]DH47&OWVV>)O6ZS5MLM(.H3V]O&LL=Q*\\%72
MRFGJZ*4Y,:QX;(PL>T*X'B <:S9]1G:N=W>I%9-VT;D'5H=N;OM&XJ<.I)&1
MU0 ;-2OD9X@E:U7<C2&EP [%QO;>YM7RPQ6,83BE^O?&+76<Q:ON=5[1(T="
M]!KW8OTZ:#!0?)4&JJPLL%9".8M^N.8ZYK(7* BG"P":@7S?[AI+7TZH7U59
M!3>/%:XZ>*HFCB=53.KZ6014[7D&:4,87%K5/*%X' 0U4Q\ZH[MC<MNEWCT]
M KJ9\CMV[9:Z-M3"0\/N]#(P@<R$EHR34'OPK?M31.5/(5?KS)7;9%]M'7K;
M.]]F5._;9LO=>SKV^UT]U%N]UK+OM6NNMOKGI648J!2:B(O1^?9EK]J8B_-\
M775]<V<K?1.G[T F,K>HT_8DQ'R@+H!THD]WZ=;'HP8P(=JV->1C8F@.MT(8
MSD$DK 8VQAH <X(/I$JFRC4.,%R<I:SK/\Z?:^;]$!2*VH)#D><BB A->[+$
MGXJ)"$VI(*EZD \1D#KDAUP.$F(H4(U) "N"G0@A?4N$PQ3K@DRLKFMC/*2N
M:YC/5>[+!BF U2JNU=6YV]]Q9Y"&F>OK.I.6%FF111Q#6,;M_=3GEC0R6N>]
MY<UC6-;(U7O>XAK6M3-2$P@G1PJ+F^VBY7R]5U+<Z2KIYJ\@/BJ(GQ\\36PC
MD>Q[F2,/(0K21Z\+%2S4W>6^N8VOZ\UE-(R8T&R[;7/\.1KBV.BG%3,3J&EL
M<9^EEEC%W('<7)']@MMT.-N]U*W9E[4BP[31O+@I/V_=+?<_.7T_NU';74MP
MONQ/K:JNCZ:TU,=VLDFV:YM+'257O(KZ(05M8USW<AYB>7E )(GMC$P@V.@*
MGJUH[3>7=K5XW"#RP/SMS9=,C*0@URS"@HJY+VXRL:K5+69RH^9$P,E1>,Z'
MAF/2.SNP,BF2W0%K@US/#C>4YRT(79C4$<5P%T\V3>W\C=C[SS0#:NX2>P?S
M36DY]@7 F5\_6RKC3':U"34PA(6M5TT>AY\LW$#%8-%8.:GSR[[PLUT@OVWX
MZ^E;=+2:NHGHFU,)EFHY7LEAGBB$@D?'SGE<X AI(!UPPJ3[;+H!TAK!)N&S
M.:0?YCJ<PYI!!,))4<0J<,\ #R!5D@T#+@J^]=[[25%]LM)7/HI*.AZ\5+[I
M;ZFME@K*^FI:>FFHJ.@HXXWLJZB60D@N(,8]IF>F+M7E>N<@5T'5Y1AM=J2*
MRML"NDM)5-,$;@2.9C,GJ'-]D#E(<.;V0 ,U5%QF5R7.\DVMU[>M6Z:"6DK
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MVSK6 !$ (&U'+B,X&8B1.49Q+L/9/;4>A C"$S.WBV8^5.)WWN.Z0%/EFN9
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MHI"'7$KGP8Z!;CJ,9@CG/Z2Q?UY^(KLP+9@W9'Z*EW;GWH_G6NCPV>HV:CG
M#DV;0LU14<P.QS^_^%W1+!TVQ/SR^DNLZ3\4NN[TQE>,'[(_15B+%Y_/-O=&
M,?4S;5YG@?0VM2-.A7\EHS3/')[CP/LMN3$1#.>/XUZ#T_Q;O]V?7EZ/Q*0:
M;SL>:>2)KG2;:3-3]EZ4KGG]$@8TUWPALXRH=/*JZ&'7;NGUB76\^=;S0L]K
MQ-M9:@;9IOW<51\);>1TF9T^5.77;C%B:#\,DD5_GD\TL;21-MH(%"[8IT*$
ME"B<,;&QX*VA_.]*Y7J/C*_M)4)3'NGW@WFMHTY:C:A30-VO3..FB*>W&_V'
MPVZ9N\83;]]])>0^)/CEU;HL=0E!^0@?XJ9\WWDGFWC>8P[:H"Y+M&GTX9@%
M<;VS\).DREJ,)OVR^DO,=Y]ZOK]AQ;[LMQ ?Y(,BDGWD_F]#D\7:2-_[TZ<K
MC*/P@Z,95C/SR^DN;G][7Q89^J+8',./_9E)\WWFGF^8T_I=GM&87[(TR^SI
MD2#BS]3_ $B(I&1\LOI*7_JU\4$@2E:'[T?^[2<_[SSS@1Y>];/''/:-*%XZ
M]N%^I_I@QMR\\OI+8P^]CUV0;O(M^Y'T%I/WH'F_(_OG9IX<QVG3KVIKKGBO
M]4'3/Z*7GG])9<?O4]:$6-Z.K]S'Z*S']Y_YP [^_MG#7V?LA2E/E.)#X0=+
M.-J7GE])1N_>IZX!2[$_O8_1*VM^\\\W\A*5FSE<=?LE2#,_)B0^#_2C3NY
M=LOI+77?O8>((87(_P#)'T$<;]YIYOG.#'5.SG.7CM"E).6N1(Q8/@[TG]C+
MSR^DJH_>S\1@4E'S#Z"/Q_>4^;\GE$NT FJ;1IFCO[,$O@[T@4:7GE])0_\
M5GXI)R/DA]%'F?>1^;LN >=I '(D;3IR,^]5QBS^#_28EFF?++Z2R['WL/$Y
M/\I&WRI'^+!*+?O&O-JG\;M, _\ >K3! G:3EB(^$/1\XS\\OI*^]]Z[Q%B8
MVR,Z?_H1>7[QOS>QJ8Y=HEJ*>;:]*5)'I(&+8_!_HTJ&,_TOI+!O?>U\50'\
MC&V!Y/H%$C]Y%YP6@@?9%Y*?]RE-\&3DTQD1^#O19CV9>>?XU@R^]UXMB:"+
M]@^@M/[2/SA@GV=HAH("':L S7/('/ ?@ST8R]F0\LOI*N?WO/&!%-'EB/H+
M:?O'_-^Y.9FTN[EVI3D? H&)#X,]$&4O/+Z2B/O>>-!0=TW[D?-;1MGWCOF_
M"K#M/,#_ +E*=>XA"<61^#?1.$O/+Z2I/WO/&V+6?^2/_=(K4_>0>;B,<Q&T
MF%H7VMJTX .O:F,B/P6Z)/\ ,D?+/Z2SMO\ >Z\6S A>E:B_"$?H!,"^?>D>
M<JA:\TM5L>,-4#Q=IT3NW\DEN93&3:^"?1L!;\^K\:[GIWWE/$6\ GWEN0(&
M4?-["ARZ??!>=NWSOA-5L!J$^T=FV]Q.O><9UOX$]%N#5H<<M0^<+I;'W@.O
M2&BZ81/%HU_12.[[Y/SM$$-N'3X9A"=F4 3N/M#5,*7P(Z,,(3\\OI+8V_CI
MUFXWK0\T?HK0[[Y;SP (+GT][OZ%6YZ?VI=QQ2?@=T@86Y^>7TEGV/C3UJY/
M3*</-'Z*+N^^8\\;2K;MT]:0-!L6W:_Z+CBN7P4Z1$>P?TOI+;P^+W521$W+
M8[1'Z*TR??->>8GF%VZ?G_P$MWQ^V<8\O@UT?#NY>02_&LN'Q5ZG-_Y2![#$
M?Q44=]\]YZQD+KT^[OZ!6W7T\V,>?P<Z/AW<V_?_ $EN=G\0=_>B92N"(X^K
M^*J+O^^E\]T>?UKT^"#AL*V?,[7&-/X/]&@*PG^E]);*/C;?2I#<0K^Y^BBO
M[:SSUDG^=.GN9*KL*VA""<\BN>*/U2=$RC+SR^DK_M7U%G[Z+X_F_10_VUWG
ML&EXZ?C),MA6\Y>M^6&/A+T08QD_;+Z21\6]4_I1^C]%>_;6>>Q,KMT^/_@'
M;Q_S28?ZI>AG\V7GE])0^U_4W_G@W[WZ*\?OK//B .6[]/3Z=A6TY%?X6(GX
M1]%_-A/SR^DD?&O4H?Y^'Z/T4F5/WV7GXC4BZ]/#V?T!MW;EQT08QKOPJZ9$
MUA/SR^DLVQXLZI-GG#]'\229OON_/HX%LEUZ>.!)#A]@K:$49CZ0*=F,>?PP
MZ/&/\V3,TQEA_P I9DO$75 THS&KR?B51NN_FZZN^:3<NWMT=79[#477;ULK
M;7;S8;+362%M/6U$=1,V:* N;))XD00GACT3P?TG9>&!W.R@T)"N-?.2N9Z_
M.[UB7?[HB<H@L*8GR!='?(7]XY?NB=19^G'5>NKK_P!*ZBKC@HZZ205-PV>V
MIG]N1CO#-556N)\KGO89.9@^CD@Q1X_^&6Q\3[?ZRZ39MCJK5B*/F<V6M\.>
M+]ST*7=]6C([5V X/V+ZF.F75W;.\MO6:_V&_6W<>V+K3,GM5^M=?!44DD$\
M GBBEFA+V^)RN"M/M-T./D?J70NI='W!VN\M2M7 :VY##D#4?*O=MGU+8]1L
MC?;2X#MY81?!\**<(H8ZB(21RLEC< 62QR->QR@.0.;D=<:^+,T00>"RY&M<
MUKDH7YY>T$1 -%^##S8H=$9*24.0-+ES[1GA>E)N"CS>5*XRT1Y.5S*R%^GY
MLT1.##L1BF+=I%F()S#G!0!J#KBJ?L$J5OVR/VI7SJ?>7S-;YGKJ"[7:.U7)
MP)-KAQ^@_P!VG^Y,_P"UCZ"OA+[P!'VSA_\ +CTE<O;[6DO>U5 <YO+ED=3C
MZ5C@O!;AU43. /,JJI5.SNQ >U16&30TI:HHQS<YS!!!XZYI\>)2FU%B$UY)
MW449:P. /*<D ]!SQ49U5L:U."7Z<\N8.FB:9]N*;DN"4CYT?,I:A/K73AIB
MD2*J-J$R\PZZJ^,S\_\ Y*SFU^/'D+GG_?%>M=S;Y?W1;R+Y^RA5._/U8W6X
MB"'6WZ+N)0&@8CL6MHSSQAQ@7;-=0-W(08X>1&&-;QSU[L_AQFP@(AS@L.5_
MOI:<UHGJ6Q1E7(@[NSMQC[C=1C$@%J+I>B])N$B9J^ 3 O=X #P)/9!RT"XX
M_?[XDD/1>J]'Z7HC$B/K9J)+W=2>?E<JNR73B/7CD]YNC(D!=WM-N(-')DQS
M<I3.AD.3 0-0KG>O,C&NUR*VW=1TL OO1^[_ *@R>3+RUO)(<>G%KYCE[7\J
MK1FN6@Q\L>,29>(]S(U.I9FU&BTP70.QQ&6Y4!:PGECE"@Z!8<DTQS/%9*GU
MD'*T* "&@H4/ :ZYH,#C!1=RAED38GODD#&M',7.(8 W4NYCP(PR!!KMP_R>
MK2V;G \48T&*A/J/U5LNWK7<*AMQI+;26ZEJ9+G=ZZIBIZ6CI8HRZ9SII2V)
MC#$'#F)!!TQ=M=GO-]U*/3=E'5>D1I.7&OD5=^_;VD#=W(!L@5JW(?*R^8;S
MT_>AWG>E7>>E_06YSVS:[^>W[BWY&U+CN >#%#4T-F940"2BH8Y!)&^9&OE<
MI8>3E<?J/P'\+;'3C:ZKXB];?2#Q$26'!P"WG7F'B'Q'>O3EM-E(QLDY 'Y2
M"?E7%2HKWSR2/ED=(97.DD<]Q=+),\ESY'O*O+GG4G7'NDMS"W$;:V -K$>R
M./;BO.;NW/>$W2Y)[..83*OLCYXWM"KREJ\4!*#X\<KU2Y*]J=V6YZ=&%LAO
M8[2JO[VMLLA<4.4AYE/<1EV98X7<V3J(&#KTGITA.V(1P90^:&02HN2YZ+WY
M< N-7[M'6[56Z%FX"T2T4[;-02RR1AC0&Z$(/ASX8W.TM&(=9MJ(MQ4B4-K>
M"U&9J >[(>K&?&V3@HSG$5*=E-;GCE!"_AQSQEPL2*P;DQ()T4-"_F:",OA[
M>.-C:V[A:K>7;4;3YIXT-O4M"'&QL[09+D-Y?@!(O@G-3V]S= 41?PXXS[6Q
ME(T"XCJG51")X)3;19!6ZCL)^7&UATVE1DN"WO6"> #E:GT*J@&?=^!Q1<Z=
M2BJVO51<E4>L>Q%S;R.'I13\0.,;ZOGP6WC?UX$>8(;:%R(O9EDH^=<3'3[C
M8J<=V(7-)D ^.",QT/*03FF>O9C,L],+\5HNK;[02\N/*GD2S2T)<6@-4E?P
MUQT6TZ4*.*KR?K74WN2$#7\'3XH+'*8XRUHTRR!S[4(4XVL>GVX9>E<N;UR1
MJ:E.".Q.85<WE4+P'SZ8#LN28N$XE!GHX8T5C7=YS^=%Q=9V1 H"H2FYJ469
M;XW(0Q@R.GKQE=R8Y%5@D++K;DK6C+/+/Y5PN['!.J2ZBAD#2>4C)4/XLQBN
M>VMR%:J0G**2)*$O!*-(T((&66>FARQA7.GVR6C'TJ??3Q=)\UK*^RP'N"G]
MT8QI=+:I%%;'=SC2K<BM;;1*[\@(J]FG=KB'U7#@K??K@K$D>5;VV5[G)X>?
MK7OXXMM],MYQ5<M[N#C(I<I-I/ES+<G-4#-?@7%HZ=8B"\<.U1EN+]PAR4^;
M)L97,\6(N73)#J==-1C#N[>$'%L,KK=P'UKQ5@MF=,36R1B.F(:'-5R?.3EE
MC1[Z486I=X5O=A"5^Y$6AZJNUL#H_!%'$YU.XE6$GEX\C%3/MQYQU>?K/&B]
MH\-[*/= D8 <5:W;_3FGIXP/ <0@*E?9R([4U..!WSSD7K5>K=,MRM $4#)\
MQ[,@8QK1 TIKD"I4\%QIY6(O@MX+IB:8(O4[2@8"E. B\%1,.-K@!YDI[H1!
MXLFA=MK0^&I@S^(YZ^O&[V>VU#!>9>)>H1A$R'MJ"-RV2-CWAS7-S("C0(.[
M'I70=C)B-*^-OB)XFC"6B9:-<E'DMFHP]3$HT((!S[2=<=;:Z5<D7(7SGU#Q
M9M(S+%Y+0ZR43C_$#($#X<B5.N,N71[DLJ+23\8[&(:6*(S;>I'#)A!/=EB$
M^D7HXB@[5.QXGV6X;2D:?:-.\'E&9/%H/RXM&TF/;CZ5L;?4+%T^I,.DN39L
M?,GA,*#7E"DIQ'X98);>(PHLF.X)#O1>CVC&"IB^ #+/M.(^[C%G4N^E(MJ2
ME2[3IFGF,(']D-?@3![H9%A&BJN[JW9#W9,EZ';]%&0D(/>F?>O9A#I5R4O5
M?2M/N/$VUVQJSI3CM%( KH&%-%"?/BT=!NR+U6OGXYVT<-+(RVW4H"^!'EE]
M%4Q(] F6Q41\0K%LG4 3DMPM],G*(6CFS3E.?PGNP3Z#.,7+LH_K)M2.F(B"
MM<EJA>,X&H$U:#EZ\%OH<I-0L5AW_B);!+D4/!%39Z=W^#Q_Z$</5W8SK70)
M1#Q=8Y\?6Y^T8^9!;9Z=I)$$?M9GV1GIG@^H9:O6<E7Q\;[>4'-R,2.2VMM4
M#2HA8">QH3X,TQ>.@!GD/2L6_P"/;,/6$@1Y/F1EML85_1M"?P?G"=N+K?A\
M$.!1:V[X^C(C26/E6FJLL,T4C71-*L(!(&67<>!Q>.A7+<AP"Z[IOB2UO2!*
M3@\E 6]=MQB*I>(0"SF5R:HJ_)C>[?I0B *,5Z5T/J<V,HN!%54W!98YGO>V
M,%X+AV H>*98V$=AW4M)%/,O8NB;X[_9"?YPIY/PS465MMC:'M< ""5"9A,O
M2F6,D[*!BP"VU04W9;<%5A"*F*)=,B0LNQ?G;+Q-5J^KGE  T^H'CIB)Z7$C
M2PTK-^LMW&3@N.P?B6'6J1%,?Q.'R)BF71;<JZ0ZMCUG<Q<2,OP[$6?;9!EX
M?P%1\N,.[T-Z:0L[:^)-U8-)R;G5%I+;P<SXC\OH&-?>\/0.3!=+L/&-T-WI
MKV(D^VC-&_ O:<:J[X=TN(Q]*ZO:>+3=D#(@Q[ B[K>P$>PGK^+/&ON=$TEB
M&706?$EJ9:50RQ[DP9<J_/IV=F*ATF,<0K)=<MR=R\5N91,X-'RXR[72(2R6
M$>L2D7A$,O26]LC?:8#Z@/5Z\.]T'7'!6VO$4[4AK=G3>K;$'J6M =GI^ !Q
MR^]Z!<B3*.++J=AXFMW2 #3!D@?5#H'\Y^DJ_",^[&A/396#5UT4.HPN QCB
M4NT-48_9!.2<P/;Z\\;?8[J5AH@EEK]WMHWX$3 +X?Y5>3RE^<KJ-Y9-S-GL
MM=)=]E5TK&[DV?6O::.I@,@YZB@E+3)1W"($EI8X-=^4"JXP/$O@CHOC;:7;
M=TBUU'22)BA?APKV+"Z3U[K'AO=1B*[=ZQQ'DS'G7U;^5WS;;'ZV[-H=U[+N
MD-915,;8[SMRJJ&Q76P7)H;[Q!50<[9FL9*?8D"Q2-&6/BKQ=X.ZGX,WUS;;
MVW+W43(C<J1($T.8\S+W[P[XIVOB+;PN0TQW!H8\&I\HJK]6VX6^[4;:JBJ8
MJB%[!S/C)YFE,P8RXO"%?@QR?M&F+/1=-)Q/00Q1QM.T,:8GE[25',!S*">T
M*@P^2%'&^J8@Q.0!)!H>(<T_*,(ICDH6NCPVH8'9_I7ZYZ*>Y=,0N![9;%*-
M)%_V)7S=_>AU)C\T%P() .T-K(@1%MT0U] Q^@WW9_6\&7!EWH]!7PE]X4:?
M&=LBG_PX])7,"Y2![BBN1Q)/IU7ACZ3P!7@D3(R["D^($O:F?M:+^/%8<%U*
M3X99)U43 &@E@7ER0+F@/>IQ"Y2JJPQ3CIW\K5X*B*F2#AQQCZB:C!6#!'VU
M CS7V>P@>K/NQ"4F&HX(9!DKFN:1S!.T$8B)<$A0KJI[V/SA_P 5%SZ#3MT_
M<QX^_P#QBO6:?X27!8'X$XKC?:P:+:].V-^T-4A594:^K )0:JW8V]V4M(#K
M5+4,8WVB F6,6_NX1"WO3NBSE,&8_"B9=XN[6-D',,@40]@&28Y?>[X5X+U#
MH_2].GU3@HINUS$A<5.IXD]^6.5W6YUKT'9[;1;$0$P[A,7J\'(E4)X=RC&H
MN2<N5N+41&AQ3;#Q[WVI&S_58K=9C47WJ?=^5;#Y+O+<%((Z;VO09C^5UW?C
MY;\8?WBW/[K\:R;8>V"NE&Q^6IN5,QH+BUJDHGLN(=GW^SCFE:,%/=SK+=::
M)];<:B.DIVCF\60LY"6\QY?:7F+DX:8 \J6P\_PS2J/:I%4KZY^9/:NR]NW>
M_P"XKY0[2V9:F.EK+E5538GU)CYVLAI@K9:FIJ"T<D,8+BN-CTGH?5NN;^WM
M.G69W-R3@ 9 <7Y^5:[J75-ATJT;^ZN1C; Q) KD*\5\K_G;\_V[_,3-6;%V
M8ZKVGTGIJZ5[X8JBI@O&\/#?&8)[[)'/RQ4$<L//'3!6E5<24Q]@^"?AILO#
M=J&^W\1+JDX^MJ'LFO.E&SY+Q_J?B[<]6O3M6#_\$2P(+ZA0T([."YARN=S$
M-/L9!O9ED4XZC'>7+FC^3@3I&%?0M<;MN,03'^40![00:]N*7,J?G+4[O<0B
M2)$?Y>2+U=&9(G>R"?C^'%-_:RE;)(5&QZO8[P6@2W%0EO6U<L$C^4-=SN[\
MT.F.0W^W[NO->K= OPDP$G<*N,[2R9P)XG37,DXYZ5)KM1()V;<F#9 TG/-/
MB[\;/;2]7%6#V5+5O8)6L+1F3\*)PQM=N-5 M;=F02#@G?24)]EQ!/'1/W,;
M>S96KW.Z$(ED[:"@]II+!G^'H7&SL[=V9<SO]Z#;))8)X45"UH!+=/5\''&Z
MVNR!+LN'ZGU"%N!)-"EJ.$- 098W^WV@!%*+RSKG6)QMM$@C@C'AZ*#E\G'&
MT&T #LZ\_P!UU>Y,#4>/S(+HAJ >/Q_%BJYLX-ZH97;#J,S5_6"U>$=?F_=&
M,26SJZZ?:]7G")!K^'E7O"&J9X!M!P4_K(&Z;AK7FM[(^.0[D_!,9^WVH')<
MYUK>Z[<INQX.G+::3Q',)"Y!1W*<;S;[?FO-]S<-RX2I3M5+&R.,O! #=44@
M'AC-[AZ$A4@LC%PEIXXU:0W)45N)0VIQ*9+BJ8-97L<XL#LP>U!V]F,J-N$!
MI.*.[)&:-TLW.6@.7+M[\$ML#4BB@08I=$1:SVL@G#/7MQ4;,>"2(5$0?GS
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MJZ'0V6&-A'Z/F/80T)\6+HV+9/)(!RP"R^UP,#B^-C !D%!)*:! N,B&UB:
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M8T<YX!<UR"9'O&,<7'I(*OF%N?=F GE>7)IKPX9'7 9QPB$@2Z%];B3Z:Z:
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M<**%=R;F%8V1@)<T\RE5RST3(IB=N&FIQ76V]O.<A&W%H?(H/OCA.Q_+F20
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ME)>(^);VY]XE$$N$KN# PC4Z?@,=9=%H6"%RW3)7KN^U')1ONNE$T3FC/4_
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M&!&'%:?9^$(;>^)R&B3\'3/NU2R96H,ESYD)">C'&[_=0O$_C7K_ $;;"Q:
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M+TJ3^10/N3<W-+)%%(\#V@O-F2I7,$Y8P)RD:R9U[_T+H-FT!:L1&L"I:O\
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M^\PY)P-_9H9)^O6F7_XOW=CH]O\ ;G_L7Z2\UZM]CZ]Y[P[Y:/G6YG[-#/\
MSZ/_ , '?KPQLH_;AO\ 47_?+D+_ -B''_3<\-')9/[-!?\ AU?_ -/Z?%GA
MG[=-7W!OWRHC]AWK]8?(@._9FY+^O7ZOU?U^//&)<^W#4]Q_26?MOL7WGJ_6
M/R('_P!+/X?KV>O^H'N^;&(?MO\ ]B_2723^R^GUOK!EYG[,WFS_ %[.;/\
M_%_33/Z6>N,G;_;CO!_T)OWRYOJOV1[LZ_?_ "Z?XR6K?^S74>%^O3Q^E_4
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MF?T>S'-;G[8:B_NOD==OM_L2XT=_E^Q2A_Y'>7+^LOZOZKOBYLL:6_\ :O\
M.[G])=+MOLII]7WC]%:9_P!3[V.;]9I%_P#H6:>K&M/VH>O<?I+81^S;?ZQI
M\BVP_J?9)^LTO%?ZK/4BYXK_ -IZ_P Q\JRH?9W+O_D2W1_JC)^C_64U'T_Z
MKTUXIQPC]IF.ON&\JR8_9]O5[_Y$ZJ+]4_V4_6,^EES_ -6*\-,8%S[0:O\
M,_*MA:^HM-._?R)=9^JLF7ZPNH_\6R:Y?1^;%9^T#>MW#>571^JGIJ;]ZMI_
M577_ (0B?_PY[^S+%1^O?ZA7CZL<-K_116;]5?FS_6)Y>*?U;(G?S<,1'U]^
M;W#^58FY^IV/?=YW>;:4B57ZI:NY_P!8OZ)7D_JR7U+EC>;+[4=X-'<?*O._
M$OV5[@]Y[SY-/SIG5WZG"GQ/UFN;+Z']56J%5\3VTQZ?TK[::!H]R^7YE\<_
M$#]6KR^L?K33I+MIP_?))9^IOS'E_6;7O_JK[.[CCMMK^L#33W#RZE\M]4_]
M/'>_R_V@?]KW"5X?U.^7+]9CE0+S?U4^K7BF,FY^L'4'^KO](M2/_3@W^\WD
M]W67?J<\OM?K+<5_WJ>;7),98_6)I_[O_P!(F/\ TX-ZOVE;_F$1=^INF?ZS
MBYZ?U6*J\>.N*1^L+\[ZN;]^K[7_ *<G&C[1/_S'RLB9_4W4_P"<YK_]"GM[
M\\52^W^?N#?OUMK7Z@&'=_7W^@03^IOP_6=U_P#H4?%B!^W;U]PP_;K+/ZB=
M%/KYO^80F_J;KG^LYW_[U7X:XG#[=OZON#\]:HO?J%[K^6^O='_,HY'^INK>
M7]9Q<O\ Q5^I4QFV_P!867U=^FM+=_\ 3HXU?:%^7<)7B_5 Y<OUE>5 B_U4
M+Z^;VEQ$_K"<_P#V[_2+%/\ Z<'I]IO_ *=D9'ZHBY?K)Z#_ ,5'Q=^(2_6&
MX;ZN_P!(C_\ KEE]IO\ Z9;_ /R2,D_64[D_JI7\$Q=']8C?]VMS[Q1__KE7
M^\__ -,BM1^J*@\;]9CP\M/ZJTU.J=^,BW^L/+ZL?EWBMM?^G35_O*_/W;YD
MCW#]3WE_2?K/(GL^'_50OKYL\9D/UC::?5GE[Q=IT7]1VN/NGUYI?\[N.*C'
M<OZEGA2^\_K8\O*>;W?^J-44Z+[2IBF?ZRM7_=3Y/WB]S\,_JA]V_P#A_KCN
M]7K?S3NPPY*&:[]0WQ7^+^N!S<?]YS7C]++3&+=_68X?ZJ;_ )Q>K]$_5>Q]
MW^MG_;:?\B;51^H$IYOUPM<_#_J7^?%7_B5_^U_Z1=5;_5VX;ZP\NAO(HRW-
M^SZ]VE\;]=;PU=S>Y_U$\VA7^,R1%QD6_P!9+4^JO]*LZ/V#?_O!O^;;\:AV
MH_9KY<_Z]*J>9?Z@EQINI_K#<][[AY.\7<] ^PO=#N^_U.?:T/CYUIC_ &:?
M_GU?VO\ 4#\:<%QJ['V^U#1[D[YZ_F71;O[']V=??LU-.E*]'^S=YAX7Z]'-
MS#7^H)-.*9ICJ=K^L?2-/U;Y>\7CG6?L%[P>\^L-;C#1\Z=,7[.KE')^O"G?
M_4*JK_!SQG?^)7_[9_I%SUS[!OZOUGCGH1S_ .EX\GM?KO>&A_\ $-HA37CA
M?^)3U^K/](E+[!:?6^LW_>)/D_9R)[7Z\*J=/ZA%X:IDF&/UE/\ ]V-_SJ5O
M[ M3ZS?_ )M)%3^S;YSXGZ\?-Q3^H+5."\,1E^LBC_5?^D61:^PC_P#>;OGW
M;),=^S90_P"?+K_] '3/U8JG^L=O^[?TUM=A]B.]I[__ *-%_P#Z6JKE_7HU
M/_B"[3HF28U-W]8FH_\ V[$O[?%=;MOL57_[B[_M</)D@._9I(/\^G0K_O!=
MO?C$N?K ?UO<,,M:VUO[&T_Z8_[;3^#+6/V9_P#Y]']M_4&GK3&%+[>/_J3?
MOEN=O]C6_P!8?GI0#^S/_P#/H7N_J"Y<4G[=/_J/Z2RS]CL^_;]ZM3OV9^?^
M?2G'_>"3]_&//[=/7W/])$?L;EWS_O5H?^S,X_KU(I5/U?U[]<:^[]MVK[E\
MJV=C[,Z?Y/O6_>I/?^S*3_AV\/H?J^JF:]^-5+[:9^X+>6/J#3ZG>NM0_9F?
M^?@O%?U?%3"_VS;_ %!9\?J)J][\B]'^S+4_Y]_<OZOVJ]V"W]M'_P!3_26-
M?^S_ /7?(C@_9G)G^O5_;?J_8S1]L]/^I^5UK3]G=7^=U<F0)/V9">U^O8B?
M^;ZB]RY8JN?;%J^X^5U?;^S>7>^5D7'[,90GZ]OJ_5\1?5\V,7_:[5_J+K)A
M]0Z?4[W37@M[?V97,%_7L3O_ %?M>[CB^W]KWK[D_E6ON_4.HOWK^1&V_LS/
M_/G[E_5_7N7&?;^V=-/N/RK4;W[*_P"=[U\_9Q\JVC]F;E_GTK_ _J ^-,9M
MK[;?F^XOY5H=S]DG+>\MGHT_*WR>5;/_ *6<H3]>Q>_]7_LXXSH?;EO]1_27
M)[O[$ZSK]^?][\Z&W]FCQ_7K3@G]0&G#3%\/MU_V+]):S<?8;33WU\O81B#]
MFGS^Q^O4N?TOU?M%R[],9</MRW^I-^^7,;S[":J_6&IS^Q9+,?[-U!R_KS=_
M^\#\W?BP_;C/W+]-8!^P;?Z^_P"\09/V;Z.7]>GZ)3E_5_YM.[/3"E]MV_U%
MOWZLA]@,_K%_WB2)_P!FKS'Q/U[-!_X@47U\<8]W[;O3W'])9-K]7O>!_K#+
M]@NG?_D.?^=A_P 5Y_\ 0>_WM/\ Y^__ +7X\M_VJ_[)_>3G_.?17K7^R?\
+VS^[G+^:^G\B_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2127058d1-ph_coron4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_coron4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!.@)" P$1  (1 0,1 ?_$ .<   (" @(# 0
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M'M@/O_ZC?]V>L_;S9PAU*ZM*GB/ATBQ[=#W ID@C7H<]MFPIP"?9$@W]^?;
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MV,I7_<D^Z$*9/\Y8J:-W$NIXOB($BB?0#:1%IH-"6&NHU].MHL=C_9]D:_\
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M_C'[P_N#Y)0FO9O.XJP-J*@AP25FAFC8^Y&RQH0S2+W#>FO6/\(:'+U1N?\
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M+]9C 6>,JP,F1>]<BK*?I9B-9#L!"B<-WB70#3XCKYI;S8_+($X)*%)\JDS
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M:K&PZ9$"0G!)FH4/%A/NA=Y"A5VB))YTL;YF>":)$39IW<R+J60?^CI=J:9
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M[HVM%#:]:R92/&.C>MI#OUL57>1'6&JB%5EFCAWF1=X4$!B-#Z]NM+K[+9Q
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MFZA*C*(BD3RYPK,]1DED]J9288U"1B*54+#3M)NC_EF5?X]3$J241\C4VK&
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M$Z3V[4:I''N-78X$H,D8!)VG0^A['I?JVQBDYD079J$$2 /V],+?*0K&WS2
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MH*\V5@S&$3J88F4Y0G,[4B>:*'VV,VZ*:52H(2*4@LP[@NLJGN?ATJ5S&F9
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MA%-5VUETXE4-*T_U3]X^W..JWF? 3QQP<FQLV$D"LCN]B.Y"I<D,$C6$R!-
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M_DH<:/'/+<JT\-3=+0FQ\\]"%]LGNS8Z4K(\A1B6&J[?73MT7_S_ $?)/K,
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MV1C^F)E-2EQP)2?&9R]1CMSY2U2>ODJ.5CN9G*,-YDK>W7I02J%>NKF5EWN
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M*T5M&I2QJ!D!!.H;H+S2?3/) 5(CWQ43S'BW*_$MZ>MDH[61PDCRQ1Y:&!#
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M4<A/#<$-^XP9Y4DFE9G9F.H  [#H);*!VUL@ 3:*UR'^FK\8 [XWZ=ZW-%8
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MP](E*9GNC(X_*O3E#+_/B'<USK[9U'Z@/1#T7IJD82)E NNHE*)4@"4;+O\
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M4E7<%M*+24A:AB00)]_..5;SM=-KN+J$-J0T@D@)20!W 2'LB0',/(5[C_\
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M6=Z[M*'C@G2([-\"2*O\HMWW?AUVSLC?";R/IW=)"PF9U$RPCDW<%@=MU0M
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MTCP^$_-%+.D=,C^E#%K7I)I:;K'9T(V+[LR5'92&!C]I@0Y;4_./[=.M@]D
M*I2!.9Q[!/W?;LAC8"2)K(>.8B>TP@(I12+((V4!X09OY>F^+YG'K^/7H.K*
M!TFN!AI485DDLLCU_II5F2"2:PATE&SZ;2!M):U:O(&+%BK.3Z'J4A*PB9$1
M'@G6=/R@#W#[#VQD\=$4M32"U&5";7KQMNCL2D !@S]@FOYZ:]:'M"FE))X&
M#&W%)3>Z91PDXD^T1';RFTMSR+<KV)H]R+AJVSW =$G]EI(_YIV[M)#J!UR1
MNUM*=T5!. D?[)C^EO\ E<J4N^3=LZAG) $N?YF4.[RK?CPTM#C^#59(?H<=
MCNVG\Z2HC0JH#'1E,K=P>S?PZI^ST(K[T\EHS)41B0.'-4A[8[HN5WIZ;;+,
MVDI3IQRP /?$?:63^LQN2HZ3U+(MSP68I) ![M=RDBLBZJ564'30ZGU]._3V
MTA5FHG&GO \OM!GAV3A'MUS9O-,]T_F2J2.Z0/'#.#7Q5F^0>.>8<6YY@+=>
MOGN)<AQO),--9ABM5TR.'M1VZKSU'61)X&D3;(A&I4GXZ=+K5P>I74N- E6.
M Q^^"*=G-;AM*[/=\*6I2H*DJ4@.U,SQX0U;7G/R)YJ\T<Y\D\LF_P RY_D%
M^M=Y5;I4J^)BG.ZO5J5,?3J0PUH%@A@$<<48=V"!F!]>BM6U<;TTNH0VHD)F
M592G]N$1M@7:Q^7SIL%.]IMU&@!,PM4],P!,@DYXS],2+R5*SR3,+QF;,Y'#
M\%P%*K>YE8Y%5H1V*-[(0.E?#8^@DDEJ3(RQ3@K+,-J*=1W]#=O\I/IZ--YN
M;BF]>(FN>)'),_; ?>/GL@U;EEMK*%7)[!,D8D#&6HG2.XD1(SPQ7J^-Z#<:
M\*X8<&PTKO9O\D2I#DN59R::-?<R%JUD/<2N+6H;L-5/8+IH!(<W4*8&VT:
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M5IZX'RD[.Q_X3T#9I+M:J@K2ZLTL\"2,N[/V0]IL&T+U;4NW5AINH*<0)_\
M1GVQ)O[=?O3\N> N08_!^0)LASCQP]GVIL@QBL9_ 5=5CW/(RI+<J)$H(#CW
M%[]NG"R[I2#TJE4C/D3/V1SCYJ^1]OJ:0U6WD!;FDY+ D<3^N4Q<7RBOX9^[
MKBF/R<-['<AXQD*RV,5F<<&ALU[*AHV]F8;;$<\,FH99%52?7MH>BMQ957._
M4B71"1B9 9GB3*?9',5F.Y-@+4@E:'=<RB8((PD9@D2[B3PE%7?W#?:WS#PH
MO]?H.V=X+%*#6S]<1-+0:9PC5\E7C=O;'N$[74;=/U:=0V[8X6OJ6@%,3E,$
M>Z<XMZS>85OW2ST7="+@D3.$C(9R.1B/. Y'9AL0RZK(]:6O[,HV*S["6<@^
M@(5?CZ]3:1CJ'0@ J':![R((NNI:FMHF1XR,%W*<-P7R)1F&>J5?KU&LEL&2
M.U'99"4E=8G4/O)[D*=>A6XK%0UE.15@)<E]LIP0V[N:Y4-P2W3DJ8GC/EZ8
MAYG>&5;OT@Y#F#8-*V]*.TT(ANPU8@P1!<K(QG@55T#L"Z:_-VT/5 WO;IMK
MRJBB)($I8_?'8>SMSTUTHDVVI0EQ9!U(*9B>?=D0<#'[#XV\L<0I6,]]OO.\
MI9I/#'33#9"Y#8Q5"U.S>[%/5R > UT0$H\2_J.AZPM=WJUK+3NKHIE,F7P)
MA"W[MC:533N&KHVJ2J2%*!2DG5_JA1[9'*))?;/^Y%R'Q9RRQX<\L0S<>N5;
MM*I+D&GKS0YCD%[Z=;"5C41X*GM22Z;9BD8'8=]0&Q5 W<J5:J A=3H,@" 2
MJ6 $Y3F<(Y+W+Y;II :YRG(H73)"LYDX# 34/2!+C%^OA/[IN/>2,4D5?DC*
MWMML2$(;.M=U24:JI"IN(&X J1Z'I2:%;:ZF5Q0XU+FDD>L Q1%\VA3OK4W1
MHU.)SF=/]J42<7R3?S=Z[+QS(BPU*A' V(=XDC-V=6GKS/;D5)T8J---=IZ*
M/W==2[HH%:O9[52A+&V::F0!5)$P3VR]4X0@3D>%YKB?+?G?GMOB-ZA=.-P7
M'^+<@R\N OU;&0C?&17\-CX)'GO.P199I%*@'3737IKHV[A2A+E: "YD I).
M']4F42ZA%K5:'K?:V4O(,M:E @)P($BN4\S@.46E4LW7O\?Q8S-@XVSEI(HB
MU-3(!/,5$2R2>RNCR!_30[3ZZ=/M*M"Z;I/'3KSE,\N^4<X/4CE!<5BA9U-@
MG$E.$IF>)F<N4:W7[RG!<;QOD_!^?5)*#<@PF0%R&I9*-9R6-ADJID9O;&KO
M)5K$N"!\I&IZ4+JQ3VN[MW%@D)0<3(^Z4_9%OV1Q[<^QZJQ/)"W5ID$D@<9Y
MDZ?6837 >:5>7<#QE_$W+;0?0J\0F:-I$0+)*KH8B2(V4;AN]1$1ZG0]6;8K
M4W6VL/4:NI^2B9RQTB?S2[8_(#SAV.[8=^OVQ;?3;+RR4ZDRQ*E9SEZH)K=Q
M,QQZZYE$[&LTD"%0C^Z\>QBVHUU?1G.JZ_CTTI"U SS!E%'LE**YQ$_"VX4\
M^ /QA;X":Q76%')D2MV1F$CI/0E^9(A*A1D7>"S #74=QUEH5++&)SHD^'LF
MY9]_9G[(]\I]?;$THGK1PP*4]HR-OL5Y=29S[:JD>V,E$!T;7N.X.DEHA(DK
M"(KRDJEI.$+7DT&+42RLTEF> :FG&@"B$!D4/*ZC<(1I(Q4G7OZ]^HX0KEA&
MXN.3EQB/'+<37G#&K2$K&I(481R3!J^\R*&;<4229]?P 7\NM120N?"4%Z%8
M+<E_-,_:<"'ABM:;S-XBJ.CQM4\F\1D959/[G(*0!.K!6T7^WKZO6@4N)^V,
M.FUIB]TH5_UWP,?0$[_B?_!_^_\ 'U]>JHP_\:.]O_:Q\[K]Q?CN6\D_NO\
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M7+CSEZ8O/Y+YW^UCR_@O)GBWB7.<YA;/")L)SO@>1Y1D..5.*^YXS6EBTQ/
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M2>1Y"'$5O;Q>4GRF&LQ5XH<3D5@M1P1! 80EV/6U$C1@!=2PU^'2PMYUE$N
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MUG);"U\TRCY^7VKXEN2^>^+U)I4::[R['B**(EV"T)5VLQ/?YW4$_CTNW08
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MD$=QUJ98,IQ1ZM^OODVVI69S(QB<?A26"UQ?%>S8$=JF]N?V@=/?ADE)0O\
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MF'BV$C:GC5BFX[CX(E!CJUZZP2YR:$!0J^W7&G;MN/;OT;:IS]0*A "1H P
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M>75U.#O5(EO4XO\ G$82S1_5U4=IJRA@#,KMHH/J?3JT+C3-U+@<?=2PV5.
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MYNT\XFY?S>7J8[#UL;8E=:5Z6=9H)O8N(DEB$3RK8VR-&V@.H]&4=^HB@$^
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MS_"'GQ#C-N? ^/)X>0'C6*K4N3X*'*+)J('=<I9N)(%*NM>V<H%E[ZD,?QT
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MN!U[:]8O:4JPR@FEE3RP9G3!)]MMYF^X/PD249!Y<X*C*Y,DCHW)* !&USW
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MS'&K6SH;</9RN)]F!)2/3^;5DTU/?<#U9&U+J&VPA1.G"*:\QWJ6S?GG ZB
M9<<)0>>)^8<=Y?5^BKRP2R_3L(W<I[J+M_2S,=?E8]OX]6PQ54U130@6Z_JJ
M1,&<&'],S%.V$;VF@1B4*ZL6C&H4@K\O=>M702<0,(:47.FZ8*OFECWPP^.O
M++.&62 M $TB<#<FIUU'Q/<=3:-&@$#G$"YU#=12J+68PB3G&>0PXJ''M'53
M(W#D:SM'#[<=DU&CDBLK+,Y&^&.-BP4_AT76V7&-)^V,)"6ZX$KF>E]I0X<K
MS^;A5_$Y2K1IWN/9J2/&9%)*<=NLM"VKJWUJZ!0*MD1E64ZHS:CXZ>,*Z$1&
M*&I?J">V,_>R,LGU5G'Y_+8^M>KFI>@COE7A0CO]*\JS*1\X[]P1V!ZFO, I
MG!-F<Y&!JM1?.\EKX>URJ[CH"D%>O#4C@%>W.T25Z\;A$B&Z5069FT&[H(^D
M-KE+A!-+Q9'5&49"2]7X;D+V*;D>0,F,QM_"4Y8,E]1)[UM'BM2J$"P2F:"=
ME#:';VTZ]I_GPXB/%L*N8U#&1GZH\\7X&WD\R(L+@;MZN)5,]IZSVD:1%WI]
M1<EA]I;;!=ZZMIIH=!WZEG$2@)>[C2,TZJ=S]Z$D#O P]L3+\I<AXO2XUP.[
M@<5_2J5S&6ZUI+B;>09;)58XX;>8FFB9X9,;/;U%?N& 'IIT+K"^C_#TQ/*$
M>QOUCJQ]03(]L(W?-5S6%M\:%=N19&O%5G>4A834GC=)S9"E1]6% 6-_501^
M'4FA;>9MKK;_ .]"3/TX^XB&>K?IVG$H5PE]\1IJ0Y^GY?S.'Y.D,S9;)7E:
M] ']R]A5B94]UY"9-]-FV$=P/AUIL'R*[X9+U4-*L3'3S"C[HY?*5#^E\:EQ
MM=#>6DJ[V@4,8H;,1FA2UN9775%['0]."!J;*>8(A.MUU++P2"?F'OBIWSYD
MDCX_DUU9)DWIHY&\#>@ &FO2A=AT)F+&::^IIOJ/7%?OB7E"8+RY6K.XCCRU
M6[6;7LI9$E:,GOW8.=/3I(0K6M:SQ,4OMFZ&B\PW*0'_ )M:_20HG[X<WG;Z
MQ_>K8I7*^YC[$SC<-)2DO?Y/ET^;U(]=.E.Y.LMU #^1G'0F_P"VWFJLCE):
M)S0M&H3X&?XQ'^'6&-89G#R(FA<'<"ZC3X@$ZM\>AJ'V5JDG.*VI;1<[90A3
MV'AY]ASC*8N^RF*4*$D21AKH"%VGL=?50=.B;$HEV"[A5$]3U1GG'MD;*SYF
M.U/\RF.\[L 6( K::IKKW(]/PZ,LXD<HJWS**56APH^71AW:Q%V'[<ERO1\6
M9'/8V.S/=K\KL5JP=MBO%%Q][9FD)*'WH0K$=]-#T)NK87<VSR;3_:5%!T51
M]+3!S&8G%*/%<I!;\J>3,XX*F7D5N523\I)R=EB?[S/H?A\>GNR-:-!A"W34
M?7-.*_HQ:QP:Y:7A%5IH/;=D+L5C6-(PT*LKQNC%@S)ZGJU*<_X8#A'!>[*4
M*O[BCP/QCBRV3$$++[CQ-,8P$$125%T;<\JD[6BD_NZ'7\>I&<!Y"4QQ]$#+
M7T(VG<8MK(DKA9'DD(.T%F/<?Q[]1GSAA!NWTP<;F>9@S^W9P/N'\(^W$I<^
M6N"$;(S$@=>1T=9F<$_*?0#X@]!WB=*B>4.MCI0+I32_ZT>XQ]1O:?\ B_\
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MJ0:RQHVQT*JHV%@SJSKM^ UU[_'HZM94C"*4KK?5TC;C=2D)?))X9'+*(3Y
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M.,>=.1<'XEAH+'$6RWCQ,BMN#&XN9\=3K9"2W))3R&:RM*JTEK*7(=(?I;#
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M'I0KP<;X'RK%9@28_/39K%*N.L#VK9H1U;#F8(X4LAE4#4>G49]0JG$E.4Q
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MSW?"GD8)C(PGM0RBMC6GD0A@7*$Z.P&FXZ=>[->^HJ0>$\('^8(*:33Q $3
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M@[#3JVK95(K,5!*>Z.;-X[<IU._6H2>I/+A MAZ./F K7]*-A](X[2[XP=H
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MT@:N,' K6T"<M(]T!G*XH4I5-L8$I52_<G4F1U^).G;HBV@2XP@;D"0XE:0
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MBG:>ITU(D)Y_HC+JQELUHX]']OYV)['YR-!W]>PUZT.-J23/."25A1 3!JJ
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M0C5M-%/PZRQC1,  \9<?1[(RD%;WF=9H?:F:%)#[D@"%E4 P1@#^9,_JY[Z
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M:^A*V:K4ZT'%B2E)!/?&^X,!EU9X!1BF_F_.>0_<E>K<2P.&7#>&,%F(LO\
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MTU=WNYJ7DI33@RTS$Y<YP\<);K<^HH,YE42I6@BKUJL-C9'72/7:LVD1;YE
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M S[6=XT5=-67Y=%TZ<K52%IN2\$QR_O/>:[S6?3,E)23(R'9 %*K22>X_?\
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M;<06)Y-C]0FOZX^HU2262##)MYDN7BG*P?W@CZLNGYG_ ,!Z?#_;_'I4P_\
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MI2YX52*#RCI/9&ZV54K<ED/HEX2<21RQQGWQ/_P=S>MC<_C[S6(!'[:O,9)
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MQ-:>NF1CAGDB6:Y%(S)DKD)94ELQC0'13^=/5+?6:F)8\X_6058I%"II@1J
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M=_B"5KJ53+:@ 4A>.DJ)(($Y3(!,IR!C-XNI_P U*S&&0))[2N&#(2"P9HF
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M_P"8Y^F-;>QO6O4]M:T+1WGK.;#2/(ON,'$EN)21,Y7Y50>AZ<6@0,8Y^KR
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MJ EA'-NY*^I<NO\ !VU*(0YB9D@@F4YP88FE!/#%"I,0$2D@$_.SZC4_B?\
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MCC QDK4[ZH2K*@01@Q2?-I_VAI^/Q[]:7">$$6PGJ ]G,0S_ +:$L?\ Q'^
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MS7O<M0NQ4I*J&0D92GZ^'I@(H8V"6K%'+.7ET+2#0H(=1J!NT&XD:_V]$5/
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MO?UZ/T/4:3C&VW2=>TN8B%G]H\F"F\VY7%9BM]76MV[-.L@#%?<BM>W"^]2
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M8OTF,_U)+3&)9-Z.@T96TWHJ*._PZ(.K6I.J<5>'%%/3=P*3A.7Z8%VV]YH
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MV7/O+$NIU] --.^J_4W):JGZ<D=,$<>8G\8Z/:VJQ;-N.50;"ZPM$D 9'A+
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M<B$[#ID@A2NFJ<C_ $U1"KR)X0YIQW&M9N\0?%UZJ35K=JK+!_3YFD UL^U
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M96VR-\[G4B-E]$5O23YCZ_ =12(8*1Q'1*9C5R@?R$\<**))G!8[&9PJC4_
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C %?Q_C\.ON$9<8_'_P#P7K_?_P"GKUZG[2CP\(Y>O(^C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2127058d1-ph_havrepar4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_havrepar4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!* &" P$1  (1 0,1 ?_$ .@   $$ P$! 0$
M      <%!@@) P0* @L!  $  @,! 0$! 0          !08#! <" 0@ "1
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M^<Y/)>?2W^\S=O'#?W%K54F>U0J)BI&\22JE2?C^_2O?1-TU';[EM?Z:RR-
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M1EZ CX-T>FX_.FN0U^5#ZDP,GN(<G8>A/K!<XN;J.&RS;-(E28YP]7#5HHE
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M\UJ/I<L-]?KK50QK\-=L-%4EAF=/1V5$BY*R=&$RLK ]P#V %-2UJA.[6)+
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M1U?<SEV-/J4Q$;D-._2HT.FC(J"/(F."2Y(J"?5^"45X)<0WL4"V;+)4+)5
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M;,LL22[5)6O2G7X?"@'?7E XX@%#[NZ$GEK5>DLU:1)G_*1U+"HZCY4/77>
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M:7M5'L S:2IS\>X9Q_D*O;9#+XV-T4A+9%4RQ/LJ#))*K(WU?W2=+\S6BI%
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M4+/*6F:O)'LKV!UDMRSSO'1&7<  .OPT)W&87+]9P7T+^GMS])"82-1)S/@
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M''<\OYWG\?Q[ XJ..5I);F[:9I[AUC29UMK&VC,\KT(CBB=C\-$[>UYPJ<D
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MI\$\G\;D:2XXUF([^\MH9'5KRQ5_]HQ[%9HO31HF:O4!B1J[-Y1WH;N>Q6Q
M>T?F<<L_4K!_>/S#&?S$///%N>^&>.Q\6OK[BB2<IQ&15_TN+,+/%;17<Q@2
M:"#=!"6)&YB6))[#0UT'.))X*QMD+]GCY[B:84KW5\.T* WN7]K/E?VAYW%6
M//[+#WMER2SMLCB;_ S7E[8745WMW&WNF@@BK S$,IZ@COTU$^QJ"*%/.U?J
M).7LMF.QK0?:J'_$[B[0VTL;@QNT,B-]9*UH2@.Z@V?'\=+&XP\A?1O2M[=;
MK:MU$XM:?9PS4M\9;)E>+-<7DLZS0(LT1C ;?M"?22WTA2O6E1^&EV0UE:3G
M5:+-;$6K6NK4,;]P0J3+Q3M%642 2-'-"@8/%0[4+A^Q)[TKH_$?RV^"3;^0
MPRAO:*J0WAWQIG?*&:N,%BKG&X@QVT=XU_F+R.TA2W+JA5#5F>3KTH* :AN3
M^2:=H^]007;FR@X?;TIRYOC$_$KG(8TY*#,Q8V]:VO9+&?>DY2BNT3, &04%
M.FJ++7GBM!1.%A?&F8I7[<4]_'?*VPUW-CK>RAO;2=(Y 00 -X>J,ZL*M&34
M]*ZKNM!#C1:%M-]9WD7Y(Q[E)C[R_P WQB.V]%$BM7>>%H45YD?TVZ.TC+4
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M>FOS/,=(5ZVBU4&DUJO&/Q=WR.81XNU'W'K*K2QD,0Q(V!^IVJ>OPU))$^,
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MC7)X.\O+K 7MD#/>22K;7 4/(B,0M%4]]JDFOX:6%H=I<TM2"1574_Y'M/\
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M>W/)9#%<0MY%R$\M_CK.VGM9C([R!EBA7Z6^776IV3-5NSP6%;L^2:X=(_\
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M1VZ[V=&.RBUZ=1UJ-,T,<!CJ!YO$_%#I'.$C8CE5;!GDN(9HK24LJ@K,5 (
MZ"HJ"1TU!, PT"OR01-#2!B>\H5\FM?KD@ )#!:]6()9UW&I)^%=4Y&->/,J
M-Q'&<Q[3W*K?R+QS'< \Y8WG=_86;X/)/)C,G]VIDCB]18H8[K;60H8GJP-
M:?'52TBC-P[4, _O[53=J= Z*/@%9Y[8^2XN[27&M<P7EONE@M[JTW_;S6\T
MBFW925%&$) I6G2NM'VR1TP#(C1K13@5EN_LN+4N=+\IK3 >[T*Q7&<13/>'
MLS!!*^0NL1>W,]NH =K>,*A$2AB2%4GX=-7+S:WO>)'FK<2DJUWYK)3!4!U>
MY5@^3\1?7:WUA<8U(U,% TBCJ2I#GX4/7M\-)EQ!*+C1CH\$W"Y+;;G'CQ5"
M?NAX6.,<Q>Y2W4072[9#N5E0T'0KN:E?V:BNXFAF79VH>V9UR\<TU%>X?=1!
MK"\DOX<1>8996;&7?6>,E62H[-0JQ8K7Y_U:%,) (':KA%:-[!\5CP+NUO/'
M&3N1B/JZ[4KU[_AVUT]S@,$4MK-KWAL0\U*]OWIYXNTNY;6:2R;[B5)D^EY!
ML&VA(H6VT .HN8_B?8C46UN--7W(D3W,U_B[5GAB@VC;.87#5 #5 "F@:M.F
MN=;E.ZRM79MJ/$_%;6#SF1A L,ED7_3A)2/\K[(>A"G:#2E?GJ>+''BA5_:6
M<32]C:&F.)^*?F4\GPXW"S8O'9:2\F,!CM81"6D5G(%-[*:(/P(T7CC=*W17
M 8I)O-U@MFN)IE@*I+XCRCE?+$M\+/96UB(I':ZO%CA^ZFBZA1NV&3H.HHVI
M194(). *SV\ZADD,C6.PH0,NQ2=XMQ?"XST;:[BMI;MZ>G>W2M--&)0I(#R.
MY 4@FAZ:OM;"WY6T]*5G7\[_ )B5+#COE;V[>,+.&XR^0ES'*K9$,-I:6\KF
M*6/8#&'*>F S U )%-%K3<;2W#1(!4=Z&2VM_.\RQDZ7'!!3RO[]^5Y*48[A
M5C:\0Q'5ON@5EN9>HJL4(@4JYJ2#NZEOPT3FZAB#6BW(&=<NY0G8+^^!:^I
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M2>/\H]0@TJ:]:ZBC?H86$9J>XMZNU!P(3BCN[>#(VS6XA>&$[7A,BIMH!6C
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M;(Z[Z"K2;B%VD=_3%>O[->C! ;K?&N:8^.>: /*\C!/(@D,0WD^GOD",Q ^
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MW@9F,!--B#<?J1* *H<UJ/CJ]%&QA!D IWHO_-!W>O\ !7-?=W'^O_\ V?\
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MZ'FK@MS-6*SI;W#)1E15#+M('0EC4'J6.O,%=>Q[& L%<4W[EVLRDENXB5%
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MY7F+.]+V^+38D;$%E!^I2>U5 Z$?#70:X#'-#R]NDT.-$.?3;UB#$6!-*4!
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M7K6TUO%<PB2W,X<1R;E5B\3'J0-WXZ(7!J$&G-6_[)(6*M5O$C,KEX]M)&%
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M7$L9>6-QZA!5@#MW'X_AJ&XQ;3BO+QSPQI)I2ON1VXKE\]E+Z*R6.>]LE59
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M.8\=<O>:^P]GD9[6!K\LX5K=S$L@9ZD*0*CX#2K="*TF(=D<J)VMH7/M YW
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M51F,9+J25JP/0=:CX:K5U>;@K[;,@4PP38O[>%,E<6SL#;,@VQH&:9GIT C
M[FFJTWSM7Z2WT0.::8I4;CV+Q5MC\C;O/99*6)IP"_IW"%7W1[5!)5QT(!IJ
MY$_EC7V+.MPV/ZF<MH*$XTJM[%9;GF;O567D^6MK3ZC(QNY8YYDH%$;,I (V
M_/KJ?ZP-5JTZ&CF%:U/A^"=EQC;'&6SRP.][?R(3))*?5ED)'9C)(Q-3^.@T
MU[ZEH=I^G\4-'1FIIPK\$N\)XGD;I3>S2RVHF+;8E5@!2GY0%(_KT,EN@YU<
M?8M*Z7Z1EC\P!^8^[N4AK/Q@N&MH[ZY8I!.AD]0L44,WYMQ913MJ/ZEM/WEH
M5Q:_3LT'@$.,YE(<-+=XG!R-<?=N5N7CD61 U.O3<*4)U^^H:1Q0&<5D('&B
M;F)\<WV7N(KZX D)DW-&^[>!3N5% #U^>N:KSZ(UK1%'_=W8PVLB2I&)4B=@
ML@V(IVE@%9B22:@_M.K<)\@[%Q'M;7RN>XBN'W4[$%+VWQG',S#?97'W&0@M
M;E'-E#"98KI(V5_35PRUW!:?OU8C^?!+.[;?'#J+*5-0LD7*[&[\F8/E6%XZ
M.-62SBT>WA1RL>^I]2YDH8U=B>VXFITT[?7!91NMNYMP'&E*J^3P-F8;G$6$
MB7(=D%LZ,"**&0$GO\3IC@S2O?YX*V:Q2WSWB;)8VYF2>2?$W CD< K&RB1F
M8$$GHH^5::O7'.%OY1A1 MAOI(>I0QX(878+![8^*8'S)XYY7PCD5Q]Q#P4S
MRXR&V6-KH1) \6Z(,&:@;ITZ=1I>D$DD3VR9+0NJM^.PW=N^VQYYJ[_8D?%5
MB\A\61S/S&Z2VECAP>=OL:([I6]9H(9&_P 0!2/48$5I\:ZS?<=K)N^8T#/[
M<%N6Q=>V\^Q013FA+&YT_HCO[E5_YQXWDRN<BQ@-K;P()9K:5&VSP[*M'& &
M-3IJL8^1;#4E+?\ ?1/(3;Y'[=JU/9WE3CXN20HBPJC + I(*/0M45 Z=>OQ
MT3MKAHC.:JQ6!NMK$HSK[U('RA=W,G&\KD7E,31P3LHJS$_PV(8&E*$_\F@E
M\_6PG^LF".V<+:,\&Q@>TJH_(Y8VE[R3*W+4N2"L+$BI]1C6E6'>NO;+&*G>
MLYZAE#W&+C51_NIIKB[,K?XCRF1Z_-SU*_AJV?8LW;7ZC#((CXZ.2&+:'"TB
M!J">S$?"@^6J@IDBVWSU?3N]X2V]61 S5)VBI->E /A\AKW@BER\/)([/<D#
M)QR+;R0)1][]DJ32GQZ"FNX3YB>Y+TU X>*:<@:V*R;&7YAA2O4]Z$]-6?W@
MJ.ZFD9/]7W)=M?(M]@+1K.S13ZY+R$'M(12J]>U%&I@"5FU]*'!-NXY;E,P3
M%=91X(Y'K(@?Z1NH"&!["FK#0  EV<8%RT\S9V?VL<EA,;J1/JE*T9J]*$T)
MZ&AU/'\KAX>]5K=A>YU32E$K<=R#7<(@EA5H[=E$AJ1(I ZNE 113WU0N&D5
M">M@MSIX(V8N>.:P6W9(B@ 9+CKZCH%.Y"0"K*W[:]-4J4RS6I64!%L#W(\^
M-8-T-O-%<QFSF#V\F/=]KV\A1@6$=/RL_0&M?PT(EKS'?W1^]'+:W=Y?#W(I
M+PB*:*\O);0&/H+A0FZ3TP2(F52!55/?7#?F"(.<(F:#F4+^4\*Q\=L+FV8P
M%&K $4]34[@5H2 1HY9O#'AQK1+FXV9FA=3)64?RM/<P?"?E?C-A?7J6]G>9
M:**0M,(DW27$(6OJ&,5VH 3H]&SGGC5?-776U'G'Q]Y7?Z]E:<\XFLBR"XQG
M)\7C^08NYA8$)D+18;E$B:NUJM;BM*]->QO-N?ZP*P28:;T \"N37WE7V%\/
M>_&YNW-JW$_+%C'^O&.9$AP_);: 6CVT[5413W4DC, QJ5H2!VU;9,+ENIO:
MOI?H*^%IMC!7&I3:\D</AQ.0L^88*#[@[HA;QA2[R02G='(O?<-C:ZBVZK]5
M, %HQW^.XD,-?-2O#A3XJKKWO\2G2XQW)K6S^VRD4+/<!XBBO#(Q<_4PJQ!/
MP&J^\-Y4![:>Y%-H<;B3O]BK>$(R=G*[Q/) H+4"$B*<-0EJ=!1C7]FD>#,.
M[%>O[)P:<OMZ%T,?I\__ 'IO_EQ?MO[7^)_KNW_A\M&*'_%+$?ISV?ZVZ5QT
M8*^A2HFA>;=$#&$'56-?J-"!0#5:M#WITVZY;$X/Q(HO>6R@C"I&5#,>Q!)
M->FO225:W3=Y"1'7##@BKX<MK^VR+9RVQ]KDI8877T;J-VJ9-M FPI205Z5.
MO,0VO:M Z!VB&;7>S#4\B@SX$*96+7!R8M+GFLN5P$D@%S]CD+!X7O4W-_#L
M9U]16B"[:]0:'7&MU<%M3'ND@$9IRP/!"#D63Q_->=VF%XA8O9660O;#%8ZU
MA1EBC63TXIYW2K,%=B6;^G5-H+KD%_:J%U/(R(QQ&C/7[59-Y*\,7'BCQ[Q"
MUQF4BR-M>XVU^\LHKN:ZA:^GMXY3)]NK*(Y8Y"!^T:,W#PR( < 4,V?F3WAC
MGQC!^V*BSR7+G!6$&-A_]JY6.-;B0_7':6_0NDJ=)$)44I6N@T5RUDVIV(3K
MN,;(+2EO@ZA[T<>'^ZV*SXQ:<4/#L+BL]Q^ V&(Y+8X](\?Z"H*OE8)96N)Y
MI404=: D]AIGBWB(6[FQT$A&'V*QIG2UW<;O]4 "QSB7&IQ!]"ASS'/Y'DF7
MN\I>+9-D&GG,E[9;O1N(Y=S4VR2.5VD=CTTKW&XW4TNDN&GP'P6C6G3,4$&H
M_-XE!IKN]$\D$2,&B>JL!^0$4Z$U 4?\FO8Y9 0'GR^"$7$+FO<V/,$CU%?M
MC-%:7$MRH%WDWH#<,I=(30_3#N!&[KU--?KAXU"F2'FTOK@Z<V>'X+.\%U?R
MAFCEDGD<4DG!=5)/45[J#J-UPYS-!^5$8>F#. "PU/>0GM:\8N<=%!?7L]H\
MDKQPV]I:3F>0M)3:T\2I&R(#\ :@ZAYC1A7BF?;NEY8J "@KAB2B&/&V:LX(
M\KFK,PVUQ1X3)');J%/U#^&?K:H_'0=TCG$AQPJM/VCI5@9S90:^)18X?D>/
M\:L[@YBK?=6Q_31##ZVZ8&E6+L%05&N-.% FBWMFV,7+9VDI!Y'E>9962"U>
MUN[>TO!MMU<[8)$-1OBI^45UPX$9(-N3#-F,2MOB?"K7%M->Y5()I)?J99*M
M*)&ZD+N Z@]M>#4.*$"P8YX<YIK4<2B ./6\LUO-8F6!:AG1F96*4/P!V@;B
M.VN^:_[!%OHX^ 6;/WF)QR06V7G$8EB?[,)%NDF<5J6Z5J)#0?AJ:*>7*N%5
M0N[6&$&9H_,/>> [$&LO<7-YB[BZQ&7@M[O!N\B8V>S0M<1#<U2[I(H)IUKH
MG"23CFD'=:!KR<Z8(>XW/77*,)R/'V.-&/R$-K]\\L\</Z>;BWD28W45Z!3U
MGC&T1 =NVF&VEDCH6G'P60[J_4][C0N&7J4\/:!YB&3P-E83R?[7#,MG.)7I
M('19%;IO%$+(=OQTQV4TA-)#V<*)+O'NKBKDO'5YS6XMII\%R6YEM,I92P9'
M!Y3:^/A@$1C3]*,$8>%GCKN,A)!II_L3:7%LUD@!(;3-*#YYX]PYXP?&[RX#
M(?>GYX?Y_:>"^49&XO;ZZX]^I6=W'ODFC>WO6G9"89;D *8RRCI2O7KH1?V4
M.HB-OE1:XW$;P]G\V.L1Y4HW[J=@2QS;FOCSA?B;DUS?KC,WR7GF8O,];WL$
ML5PN,2?L@?Z/S[:TH>C:3+S;HR\U&(/>B[=QEK'!:.(@9@!AP&"Y^_*/-8<M
MR3D-T"?LH8I%A@HJKOCA"L] ?J#'M\-0EC&LT/'E">.G#->R!EP=0Q3.]L,>
MY^4Y,+_ N;K9$J* P 4@]>QJ="K5[B7-_=J?O6NV\=O;V_TS!2(C+OS11\UY
M=[3A662)KI UI,Q IT)CD7N34=M#;Q[FU8#A6JZE=HMCR\AA]O6J;LQ>W,RR
M&69WWS2*VX_F6II7X=-7['""HS60;_4R.>/GJD&R5Y)RS5(KU[4-*GOJP*E*
M#;5NO5Q1&MF#1J2PZH5/4#\M-O[]<"-H"_,8V"Y#(ZAM/@E*(DP]>ZGZ:]/V
M?MU&X8TX(W*T:M/"B3&AN9&DN'5_MHB5DV4W(U.C?,BHIKJ,4=Z%1FMH=!=3
MS#$8I+R%LL\2-]6RAVLPVM0&@W "AZ:[U.KWI6E<;ASHY<6^K@FW>X2.>!IT
M<%HQ^0&A)IUZ#K2FI>8[M2W?;3;.'Y;37Q*;,&'-P+I=WI2@;HQ2M0>A%2#6
MM-662C2*YH =H<< TZ/$KS&UU8LT1BW-(/3$BG<K4K4$= #UZ=-=\[^@<%%_
M+VV@)+2-7CP_:GYP/TH,S8/-9F\CA<SSV8-8;F%7WO#<%B&I(HH2#743SK/F
MQ",[1=-C\@S*D)!QN^GLLCS#%X9K+$2W<LD./59)+:WCW[O1M069]J[36I/?
M522C<!E1:7METY[ QQ\J<'&;TOD;>[C5XY7EC<Q0U41UZ[?2KL&P&G4:%3L:
M/-Q*=[#EO;YL@%./CMUC\UL^SDI-Z BF]8$;Z*1+](JH&ZNJT9J5X^..0DD9
M8)M<OX<(I$F681#JJH&WI62JJ=K!E'4Z,V]*#5DA\X#0=*C^;V]X!S+&Y6"9
MDCM[RWO;< J23!,K/0M2A8@TT=M;@Q#R4S6.]:[4V;S-;YJ^\KOB_E;>\2+W
M >VS"SP-)>9GQS]C!F8;IHRT6.FEFLKV2,*Y+K%;(S@]*4&K+HV2#S9E?(N]
MV<EK<E[<"'<4+_YEWL-XCYGL^3<RX-C!B_(64QT/+^-Y:(N+?*Y'&6D-U/9L
MJB1H;NXCB4JM "2>VNK-HB=I'R Y=_%.72O4%Q&QL$\@TU.%!EPX*I?B7+I>
M8^,<3:WK&#D''[7_ "OFT<[7MLS@D-K>P J=V]+B(]2 >FG"-UNV$N I)3[<
M5J5I--+,);8@%V!R.!([:\56=[L^7SY[&V^$NKAQ?XBZEB22Y4DRV^YE,>Y*
MLZ@GL=(V_76HEI/VHMWZ9VAP@9+0ZS0G-1*PEUC.&\,FO,GBXKZWR?KPV[(B
M!HY9B4$C^H U-X/Q/<:26O<S!J8MTM2P&@HKROOK7_4Q?_+P?<_F3_ _N=OR
M?CVT4YTG;_R>OI7S[RW?]\Z+BFQTVR5E@81L(P 7VT)4T(%32K5Z:E,94UM=
M,YG+;FGM:<=&5MGN)>DP9$1J #<:4J5)7J=>:#3O3E#M4-U9"5X=]22>RE$?
ML3B,MP_C*/'BH/U"&X@O9E:Y'JO&JHZEH8][>DY/0=?V:YE(:T4JM8Z5C;;6
MPCR ;3L[$<,%Y'Q?,;"&;R#D8;C)X>RG.'Q)M]M@HHGTR2(GTD46FXFOX=M5
MB^F0*>HW-Y) (KI* 7%N0WL7-8\QC)K?'9 Y)TMVA"-!'"7,8*JX4[@E"#TI
MJN'ALG,X(:"7.T$8J469YK%8XN%TY3DLCGK.2-Y+6XNYIK3?*%:1XTDED0;:
M]!0"G34US=MD!#0:4[E?VVW<R[<2.(07Y!GKO*WC7$TSI<2$3R3(3]3=_P G
MP!!T*A>Q[G![3PHB]Y,P1ECR:A(UEF);:">9Y][FH,/5F=#4?E )U;Y3M.H9
M($R_+(7L9373!,J[Y)>W$[)%(+>WC<M<.0RDK7HJ+2K-0'MJ*%A9+K?B*JC<
M;O?NBY;&N)[4Y8^07F4QD.,LL9;P6"2+OR>T??7;% 2'-*JA/?J>NK5Q+'I)
M&:FVZ*6Y+6EIYA J>%>/M3HQ'&TD59)E^W6,;F9]E6'<GH:DZ$2REQ\N2T':
M]E;&TF05)*<L5I'+6+'VQDEC.TR,A"L :;A05)H.FJ^IQ. )3;;[:US-$31S
M/M52%Q?CK@T>%Q%[+?W8Y'>VZS5EC/VUE=E2RU0_G(=?Z]>@$NJ0*CO1:"T;
M;8R-#G#&H6ORJTY;=X^";,Y9[Z."L2VR(%6+T_IC/IK(R_DU7P+L$R1^6,-#
MAZ$@6G';7*V=C#8FXOKR/>;R%^B6REJK0 GZ=3,;4=RJR,TBCS5%*/C=[,UC
M;7-Y/<1VJ[8&:-5*ONZ!B&8CH3KES/+5![@@4)Q3_L^&8ZY2MT[AHTW2,U*?
M2.I#5%2*:@((7,;0XU 2)D>1<>PEG?6D2K=S1+LAN.PCHP&QV_-NH/E37(:X
MXE$BVC.8?E"!^3SF0RMW:9/&6T=Y/BI&E]*1%EB92 *?6-O0J=6(G $!*^ZW
M<.@GN]R#7-N8-D,];^E:"T>;9%G#:ND5NELSJES)Z05 QCB8F@[Z+P]@SJLH
MWW<H6L+6UJ:I8\D8[C?#L9QZTXQY)QG)^/9::&5K;'VT=KE,+-/"SS?>A;F6
M2:*)5H5(0?'\=,MC%D]Q&!JL;O[UG.<P@U<4.+?FB>-/(^(DXIR.3,X:Z-A/
M?7"1-;I',4H\)C1W7<C,:GXZ)RW ;_#!0.X<"0#@35=(7M6\K0Y.?C45[=(]
MADHH$NGW [$F VDUZ] W73#L]Q(VA<?*4MWT#F!TM0:XJR'EGBO@_*5NK/-6
ML=WAKZW$T$R,JO&:/M,4@&Y7Z_ C3.)(M/YA%79)0N;N5C]+ ^M>"H$_F4<>
MY'X$SV&Q/CK-Y=L#=PI<-BKN:65=\DK"D3RREA'L   !%!I9W*XMH'$4)-3D
MGCIB"64-EF(]^2CS<>*^;<F\</Y!RKQ8@2XJ(K =BF0GZ'+#UHNOU?'K325/
M?-GEY<8(\?P6W=-6#K>D[J%A1E]O'C"ZP7#%>_CDLKJ]EDN(WF 47$6]Z-&"
M22&.OT=G):@OD(-<<*\?%.HFU' X)G>YFWEQ_$<C'*P0-;S@DT#%0K+]('3K
MN^.@M[BZJL.)%J6XFI/W!4XYRUV6UM,KEMSL6'R%>G[]7[+^!3C59MO%LZKI
M"1IJ%KV:BBB(_40.]3W'X5^6K=,*H 8A2N"5+:XDAE^VD-"K!B>M 00/E7XZ
M\ XE4#;/,HEJ*)VQ2*0H+K4 &O8=OA^.H'X.5X^8U"WRI5!%&Q,<K;G Z[NA
MH#K]'\Q44K:Q.[:)#Y&);:W0H@16Z]*T %*_ =]= T..:3)FNAD<7"H_!,['
MO<W-]%&E6$C!6ZT!!/2OX=-=!P4,(YQ(<T@ )T7>+@C]12%MYH11F!H"#7IT
M%>AU[5$&P0L8-6*;TMG&+*X1POK*0]NZU-6!:I8TK2FNFR!HQ5"_MH9XPQC2
M3CV=R<7CZ7&6N1ADR22(&:CN"2I5FK2O:GSU(V34[3B@\6RS1,,H;B,:(]\G
M\A7V+BM[7!W47Z7187MTC+Q2Q-&=X]*E$DHO?4,XH2>Y,^W6\T$0EEH&IO<(
MY#9W6860?P2;@LT;5 6I8D-TITKT_'0J9VH::%.NU744C2T.%5+_ (QRB#'7
M=OZ31$7T[0H!**CJ>C ?B=111.SR"(1NH'!V=49,P'R5O"$02U ]4'J!0?N-
M 1J^QY#:#-0RQZA4$44??)_&&O<6;J&W#36-7#QJ?I"[F*GN2?K_ &:OPEQ"
M5M^V\30XTK3XJX;^01[BHN)^Y*7Q;RC.18[BGD/!W6!6WN)C'!)D_L,N(XMA
M^CU6D9*'^]31UAU#RYA?(G5^TR'4]K2,UV+8#"YSD7!>2<2RC12\FX;E;V##
MWDC+)<21E9KFR67?2D4\+K'6M*"FIAY"#P(64"\DM+D -((IZ:KCG]WV+YO[
M6_<MS[ 3V5[9<%\G92YY;QZY^W:&W%]=7ES^KI:-'ZJ!FN@U1T^&I9+UT;#J
M!."^E/TZN8KL,Y@J[1_9*KH]PF5@R63Q<Q,\ES=H969"[!JJ:O4JH!)[UIU[
MZ1=UN'2/)Q"^V.G=K:-O8X 8M&2!&8YGFK[B$?";FVLY\):EI;1&AC6]MV=R
M[%[M4$LA+N2 >@[?#5&$<XZ6X*#?+-L+BQV:O(_3Y_F/_ES/MO\ R_E_X]%N
M4[M'\"GV[E\T\@=G^O>E<6R*;>4&<%58TW;3])J*L.P.W5@XA+;+;^7S![ZE
MO:CAP_*8/'7EA;7.2AO;.\4/-&$VO!*#1-OU=26';4=", M$V+>;8QMA+FZ?
M$?>B;ROD-EGDBQ^!OY(<Q<4AF:)7GDNA6D<4=7HA  'T@:_ -=@:43Y9[S"V
M3E-<V@' A?Q\:\VP<UCA<YB[Z$Y:W,PR,0]:+[0;&GN)!&259-X!6OPU^,<9
M'>F*'=X](+G"GB%[/A_DEE?_ /J7,X+*1>DUV+I\A%CUACC6KIN+N3<Q 'Z?
MB=0\EM%U%O;.=6N%>Y-&VR<5A?J<J\LJQW#QW#I.[!V@D(H)-BJ=S+T[5T/D
M:.>6$X)GMMXB!,E02>\)>/(_NI)Y\+:_=E87!:4@K @ !:0 ,O13TU*+:)I!
MJTD]_P"*#[EO'-+LP.'>EG"\?Y!C<(/)K64=UQ6UG^UFFG*O%=Y$D VL,:-4
M4=QW%?F-7^5&8])P%$$L;V9]P&O8\M+NP_!,3E'*$Y7DH<G'@;/CK2(%DM;+
M?Z!"D .P<*H9QWH!H%=R-AJ&G%.EIHDH'BGBGUQ8O>+96=K 9KN1UAMHH3N,
MSD"B!%Z,SG\"=!6W4LKM)#AC3$?@G?:X+<!O+:"[+#%'>WXMD\-D+2/F-A?8
ME-\,TEG=6SP2O :4*5*U5A^S5AK'$ZD_6%F9&&28:0#@#A[5(Z+$8C*_P>/8
MC&PVUKB8;Q9;4M=WLVR(OONS'TMV9DH5'[]=8M%75'L5X'DGRY IN8_"VUX(
MLI>Y^WMWMIC)^GO.B!/2(HJJS ]&)%->%[<JA3,<Q^#J5\4^\/NYE/D+6V,%
MA8;@)KRY&Z-ST!:%I:+5AVVD:@(TX\5TYDC1\Q3<Q\O&N$<ES%F;V-[9-D;2
MJ=XD!16(#[WZ5/P-=2LJ6KL->8JYK^A\AXJXN9H,6DSEP2"0'W**5525<K4D
M=1U&OSO,V@SJJ+F&0X5IX)B<F\E7DC2V#7+6,*$+Z$3L)6VCK5P1(=Y'S^.H
M'.8P>; J4<J(4=0%#R#)B:62>:6>6"23<T)=JNI:M#4[B17]NN 0148J4D&U
MKP2=D>2W..:ZN,=!);XX+MF444O1B"%W(6_H.I(@20:&E5FV]-+W.(-!3+T(
M!7UVW),M,))6Q]F6,C3A0SN0?\-C]#'>/@=&[?2"=6:R^ZV^:=SFNU'UI,;B
M,UMZCQ[)8FF]5796+$%:=VW,J[?A6FK[;PL.GM0&ZZ7)!D+7$@=A^]-^ZQB-
M?0QW$RXZ"69(S.JN^QP0-RBH7NW[M&[)S)14D4%,Z)$W;:)H!Y0[CP*FWXB]
MPF?\/YC'X3D1NWM4$)Q.1B8-:W<&Q'K&ZH5K$".E20>AT4;<-AP8:CNQ2[+!
M*Z(,>#4#L5U7@'^8#Q',W%CQKR)=38F++N(^+WTSEHI)479%!/\ 3"$>5C6A
M)Z'\!HA:33WCP 3I;W(%<V\,#2Z2E2>VF2&/\P#E]WY,Y=P26XPF*,-E';JC
M2N+>?)6=E(VVYAZ>DT=Q''44'QIK]N=@0=;\^Q$NGMP>^X9;Q-<074P%1]R:
M'DSR)B?)G#.%<5XMQVUXU:74<<%[=G(Q16RK8E6N1<QLM(Y',/04'2E-*38F
M,N*OP'?@OJ3;=O='LD<P8[66UR*&O*O<)Q:XSN%XKCW^WM.,1Q8RYFA 2.5F
M96&R154R*&-"U3TT0NW,='1I!P'%7-MVMTCP9#0GM-%&CW)\O7-XB:&"Y:XM
MY(:1HI5B4D"D@;1N-37X]-*UVTUQSJF:ZVEEO:X4)I7.O"G;W*NGDV*,$$,<
M8=8RI=XV5MHIU&UWJQ_IU?LPX0XX&JQOJ(OC8X $4<$T<!+&;X1R*  VU2QH
M"%Z]*T!I35@5-0DIMPY]6@FH[D^>1V=LD,-W;[2S_P"(4_ZKG<:$@ ;?PU^!
MX*8.X)+QS*]-X+=3_:(KUZ4H1\-1OS4[02VH3Y%MZ-HMP(92JJ"@W _54=JU
MKT&O(P2['L5:<N#: 5->Q;L?&LORVU:7$V*WS6J;Y[2.=&NEC6J-*UN-CJE8
MSUZ@ZD\52=9"8@.S3+PF!E?+3B96LY;.5]T0C);="U&4,KE20>G;7XT 7,^W
MMA& ^]*^7M\=?17FQ)[2=U]*,W3[5]9"=SE:J^UM<X\<D"N'N8X@<%XXMAFQ
MLX@R<ECD+6_MR\*HR2L@^I64N1N1JL*=:G7[$"I7FUN>^ZT2@D$CAXK^_0X[
M#*36PM+I(MRS+&(I6(4T)".P8TZ_/7O.:W$.&H=Z=YH(XY& ,K&:5SIZ4IY3
MA^<OE&6Q01;6!5E-K),@D94%'*Q-5F.T'X:FB+9<UQN-B);0Z!04[UZQ%CB6
MBEO<0+Y^0V<HDR>,E8)$\!4^I<6SG\QBE/:G8:_?2QEQ +:U*0X;J;:;G2\G
M3J/O2WB<_.F7PMS#<S_PK[U:.:C<QJP=7!0%2:=J:@FA$9HVA%%H-MN3;B%K
MB6@TXD*3UEYFB-_]K<1O''%2.:1>S,!7< JCHQ%.GSU6 QP7LTK]%68XC)2'
MP*83D\5G:0W*2G-Q4"/T5-X"A2=X.^H^8T0AH*@J&Z9S(1K"C-CLCRGV^>:H
M,KAYY\7D\#F3DL7>0R"%X2(0T91G#UHQ%2:U'?XZ.0$57S]U9;P<IPTA=YWM
M/]RM_P U\0^%?=+?Y"3,8'E^'BXAY/MO71?TSD,-TV-M<A<(B!6:4O&Q;:@^
MGY,:SR'S:1A@%\X]0V;&S\YC<<.U!3^;5[=7\E^&.39/&V4&5S.+N'\@^-\I
M##_&3'")<AEL"L\9W^D+4;T_-1G-!J:UC;.YS7\&GV43ET9O_P#+7,H0#\N8
M'?[ERN7^=Q')>/V&2R&)!FQ]I)99&H5[B*X@10\>Q I#!ZD] PTA;\S1.0S'
MPQ7](/T\WJ'<-IBJ6EVEN1'<HIYZ"Q>]NKA+A!:='^SBC*7JQ!EWE$)W,0H^
M(U3L7#6 ::DR=164;IB11P[CW>*Z+?3\8_\ >\Q_P!-OP_\ A7_6_G_[=_5H
M[C_BE\K?3M[/_,.GH7(?98?A?&+7#77->)X?E]M<02/-9K^H8Z:RE(('K3QS
M0&2I:NT-UIVT3@^GG.%%%ONP7):1IJ:]B%7DC%<=EN_U/A'#LC@<5=1Q-$ ;
MF:&VE1B2MO/-+))Z9IW+'7MS;L::-Q;1)MO97%JXQZ3JK5-OBV)Y"+U;^R@N
MWO+,K.DD0E<E@5H4H":FM -!S$6NJ4Y[):W#KEKGB@&*-J>1;["9:UR9S>1F
MR<$0$]ED7R%Q;A9$VS0>A(_IK&ZA21VK6NNG4:#5:C_\.CC;'.0'NR]:US?7
MW*()+C'V,2QPM/.#9>M"0\A+2/(OJT)#]OA357ZIH*LML6O_ (%%JW%C=OA9
M;3*70EC9C)]N(8Q,QH33< 6W &G?KH=,X/E+AD42MMLN0T-<,T<O;SX4AYT^
M02;/X[CD5VYL([:ZN8K<3!PPCE=KE'"J?[5.NO&T%3Q")C8Y;ES0YN 7YSWQ
M2OCW*2\8_P S0R8RUN9&DQF-S$UYBKBXC))N#:AOM_4>G<+KN:^T0.:[.B9]
MNZ;:U['2"C12J9TO&<%F'2-;:W@])-JR1TC:21R "Q(VT%*Z"N=]3\N:;H=A
MM#@*(I7/BRPX7@L#GH.28RXO,FOKQ6EE<AKRR*K4F5%"R0L&6E:]]>%A;Y23
MJ".6NVV5H 8G?FC/+/C[5DN,[E+FS:XRAO\ (E$"+?7=Q<WIBC4T&UYY'])1
M\!6FNA/R6^8'T)A9=$0G6*@<4X<5Y0FXIA7M..7CQ7N54QY"Y$*QRB'J!#ZB
M@-Z;!S6AZZCFO(C%4U(5?ZV,$4Q^W%-R?+\>?'2S2QO/F9IU8%9Y4B1&^J61
ME#$-(SD_A359UQ:4J*$^*G?/:::YO[,EN2^1\KD<?9X'%K'B[&VZ/]L\B27#
M  ;I9#)5CTZ:K0WW/?H8/6O&7SYGAL> 2'=WT=LCB^N9&ED&]GW[RQ/0?422
M>VKKI!&-)/F*ENKD6T)8YU7GO2)C<O?1OZF/N7BG%=CHY+#^@T%=#1/*9"V(
MXT0^&ZE<PB(X^*1KVZR-SD-]W(\D[R L[[B6)(J6->O?\-49WW)DH^M51D?<
M.G ?755/RW]2&&+:"S;16B%NI[DCX=-%;9Q :T]B:^66VP;G4)F9^2]N+K[:
M.=_3<=8!4JS  +]/:CTK^_5P3Z/+1(=_9F2Y<!Q/N"4L)PFV;9-=A0& =U4
M4;H?B.^IX[C')?K/IYLA<YXP JMW*65F@]"Q4NY8*P8= .W04&I/JA7BN;C:
MX&UAPH</6F]=<1%\UM#>0+':2S S$ 51*'<^ZG0]?AHU83C,<:+/M^Z>@H:
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M[!EV6WV_8VL/[K?PP4>>/7]K-G4BO;V14]52=C5DFE#4!E9JFB_C\M6F_*/
M)$:ZV^H:#3 HUY_%V'(+>RAM:!(]J3S%NBJ"U78M5>S:J75.:*=GQ3'>OM39
M5%,&H(>8DX>;2WQ^)R"BZQMF/NY(Q&-T@%-M5%6J1JW%4-6$=6S0M@>YGS:A
M]ZB?B[.65I;FK%48A&ZGK\C3]NI&G%95:7/YSB<CDG;>1W(QC+N+%(R&[]"/
MAUU[AFI?JFDTJ*>A8^/Q&0CU'&T!>I^!)']0U^X8(M9SM?&&\:HTXVS2\M%C
M:6$HE %WU-0#U% 1V&O&C%$9+;R!V.)6XV)NK.QNI\3//82[=D\]C,UM-)$Q
M9622:(HTD84GZ3KL]ZC;#1X->/8FKC(K;%1WN4EWB[0N8)'9WW2!E</()';<
M2RDGYZC=4J"_J13A5:V(XOSKRA;\GY9:FSN8,)#6_P!Y2UE*0;C$(;4+M=8P
MX)8=]=\$L2VA?(7 '$H?8@95;]#%<A'9=\B(P9(W4CZ$ KM _P"77+Q2@/&J
MMV5H89-;ADI)8[R%?8*7'O?6&.N;5+9[6_FGLON955OH26JJ68J.O;51UB9/
M,SYE+>[XRWE$3CY24VK?FMY/=9IK"TQ.8QUE#<7+%(Y[>5U,Q9(SZ@C5HQO_
M "J*].^N1%<088@JW!OUK=M$ =CDFEE'S4WVG-\3;BU*,MO?VMO"1'4KLV^F
ME?4C96Z_CUU<L 2]VKYM10W>]M@N&!\.) 'K2#'>RM<Q22?P7GN#):*:(/7F
M?<5(%*1JQU([,U0>W,D+@V7-OW(CQ8^Z1!>WERD=YT*1%_X,E.IJ1\@*_MU2
M8[\X 98IE9<Z8P1E4(^>*N29"QCM;P7L!N+2<31Q/(25$>WH@J**?A^.KAPQ
M1M[>= "W-%SW(G#^0N/8[FN%A,68P]JJY;^#]O),[Q6\4I[%I]M"U:]M789E
MD'5>PET9-#2BN3_D2>[[#9#'\O\ 9OY;N;>3AW.[>\N>*S9)OKL\^?OVM%LY
MIIVCMG$OIL*1BA4&NB0.L!PS"^;NI]HFA)T#R4735XJY';>0/#O*_'')K"SS
M'.?$N1RF'3#7B?<WF3X]CHVAMI2LCE[I+[&JR2$':XZ4[:FB>62BF3L"D.SD
MDM7.DD& :<?4N.W^9+X'7VN^>GR' 8I8.">4HIN58FTG1FQF.S&2N[EK_")&
M%1+=[$(0(SU"TU0WK:2QG, ^8+Z[_0[]0XYF?2%U2W#U*I;DV7NX[^XN)&1+
MR64;BHHK"4>F4'P6,AM9X^&YM[@88 A?4-SU"VY% 5T(^G/_ *FW_P#EUZ?G
M_P#.?W/S?X7XZ/<Z7O\ ]&KZ5\Y_7CM_\P-:YBGM8Y;0?J=CL$I!%Q(AK])-
M60.*$ D=M1V4[HS4DKZINNF;":$F6-KDA\@O#EGL<=E,O-/CK"(16R00B$I'
MU_AM&BJ&I7N0=&_K72.JTX +*-ZZ<L[>9SH8V@X8@(A\;\CX[B-K'!@,1:OG
MXPD>)N9[:!X[=A'M^YN%E4K.R '\/PUQ=D&$%N!KCZEY8;.0RK6^8BE:(;Y/
MQU?<XS$_(LO<36]S>5N+QPD<<#2E0M+>*"/Z%(0=#I?EDDK0$T3'8=".OIF3
M78+@#@#XIT8KQK:X5HO2N;R0;*$1NZJP)/YU4 $:K4E6E[=TG!;&FD )P3\9
ML[9(92BO(S"/TYJ=2QH*,1\OC\-1E[P:'-,3-HA8\#2VJ>GZ1/@XK0O"+1+R
MVBNH_MG%&AD"E/J45'8$'XZ_<US?F.:+1;"V8C2  />MF/$6^5D+26Z3.Z@[
MWC#R.=M =S!B30:@D=$\'4 2F2VV&!K*&FHCU+'><=L+6+;+ +=I 3$[*J*=
MO3H=J]:G4;0UH\HHN)]NAA;\P"'F5X_):B>^7(>L;8O*T)D+>FH?_#I7Z0NZ
ME-5WQRN-17-+,T+()'2!X-'$YI7POE'T>,9GB\F)L;JVRAM$EO9(2;JU6&7?
M6UE+ (7(H>AKJ2( M(G&/>I8-ZC<SE.;5-B[R4'V(CM+0H3U=W +]37;4"M!
MVU#=1P/@,; VJYDNF\NK&GQ6G86L]RJD  =1U'S J"3\P=+<T#FD:1P4]I!)
M<MJ,$[+'%>FC3*BL4(JU/I'[3\*TU+80ECPYV'BCUK9!L9< -02%R"1+G9&J
M;)%IU3OT_#12=\<CP&TK1 ]SU2>2IUI\^/N%WN>AG^SLI7>V@DFFG521&BT.
MYV"T I_5KFUM7AYF%:4(1_8;!DD!U-I)VK+=86M\S%/4^U<(Y"UZQT0DT!_N
MZDEC<Z0'A5$)-N89A)3*B>N+>P@MLC*5A01VAC1IXPQ]1E'T#MM?=JZ(V,Q
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M/;1I';O+,T,!520H1V95[TZ==4MT9)([SDDK?>FG6=GS!$&@,RID,:(-Y#F
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MR0LGIQ>"O)SOV &U5XJ2/S?+52UL[EQ\S'M']R4L=2_JCT;) >3NNUOPR%Y
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MO<6?A'R8MS9L0S&+(6K<9:6)EI4M^4U UYRW=A]2KOZDV:0U%Y:C_P#.C/\
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MBMN6XOAO".1<@:TR4%+0W0LL5CKJ7;/%;*U0 O6M>N@.\;:RZF^J;**ZAY0
M?;J]RVW]).L;?:[J.VOG-$8)JY[PP8X?O#O[4>/]R7F__P#PSY8_X#7^[[_\
M.>6?_B'_ /</_P!F?_&G_P#:?^V_]#0SE.[#_"[/8M'_ .LNR_[O;_\ ;;G_
.. ,5G\+^EG\G]?Y5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm2127058d1-ph_histolo4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_histolo4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!8 ,X P$1  (1 0,1 ?_$ .8    & P$! 0
M       $!08'" $" PH)"P$  04! 0$!              $" P0%!@<("1
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M70&K)J2NBD[*9*T@)!]"#I"$H#EKZ >5/YCX?O\ P_#KMHI:SY$G\?\  _\
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M0(CV'(NO_$^ZO\BH;J3FT*L0!(5 1V-(99*5IV)V3K?6A3TI9N^5N=N9[_\
MIG<^]QV6XQR'RA/]PO/5?8<BXA;Q[^ES^GIJZFK,>RG]8AQH<2PL)]/'9$EY
MIIMIV0A:TI"5=52@DK4<\2+]R2^"/O20/:WS7BW"G)-E]V*3#D3L@Y&K.*+3
M.L67!NE7G'F%9M; L5.79,T$HB%.SI*24$$;Z3I\J+]*^M/V//<?#L.?.>_:
MUG.9^].EYPQ?C[%>0<CX%]T>>X;S/A^+U[DR+5R<PXIY9I([626%=?2IS15&
ML>U(;<26T_+U2G ]*D#W\S)>9??/^T?QED_D5@&/8]S_ ,G4L%]24UUCGU?@
MMM!B2%I>!9D2ZN(>YOM'<COWTM(;FOA5:UOW.J?WQ??-Y;^WQ6>W7+:CB_F[
M%KKD_ ^5^/G,[Y%R;P\>JE0D<7Q50'8*W(U5&E+>CN/M*?6E 0"?51YK3;W1
M$_X48POFB^]F_P!A?'.6O99SC;9)R1[M/>%41/<-FU/&JN/+;BG(,XR*749?
MA-3%\4Z!QC(9;AMQ&YLM#J6@[YT@)4E(3I1U\JLEPE[I_?\ ^USC[[G5=09Q
M,S*HXA]I;7+/'V$9K[BZ;W8<K<2\H3&E14W[N1X_1TSB,;O*EXSF8+X=4T]&
M4L$(5MHM3NM5[R+#($7)_P"GZYEG>\SESW%\B>X/FKCGE/D_$>2.4JC/:>LS
M'(\(5:WF08C01X+%EA4&MLICE;]('3';3LDI\@WT45]J?9U96.#_ -1!]S_C
MC$FG$X%R'PC[;>4<U89)5 B\@QL0_3&)Q2VKPQIMC!)2O<!;@0"=^F@Z4#6O
M29I*6AHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:
M**&BBAHHH:**&BBAHHH:**&BBO*'_5-2LHA8E]N"3A.28!B&8,>\RK=QO)^5
M5-)XVH+=% LPK7-R\VZT,:B/[*EE25#Q ]-*-*:X'I4L?;MY(]W#G)')47W+
M>\;[5W,=;(X:S9S \7]F=A2L\M,9=#AF6;7_ $=F++<I8=2P\7@UW*2L(5Z)
M.E6@#QKX(\:<L>Z_#OM%>U[[DH]Z_NINN9(WOK1Q6YBUUR8[9\;S>/K+FN]Q
M&TI++&Y4%3]T_+C5P6'I<IWQ!9;;"$  )0#:OI]RQR1R/[N_N"_<7XYYW]WW
M+OMBP#VH>U>%D_!/'G'_ "%5\8T>0OW6/OR;+D/)X-U#G1\\K9ZYJXZV7!].
MI#J  DIV(E*OC5 ?9QSERWCGVQOLY^V/&^8\I]O/"ONH]TG-N&\W<]89;1L7
MRB+15N;9G.@8=39Q*2]6XK,RF4GO,A3?D7V (VV5NIU\J:*M%&SWERH]VOW*
MOMCXU[I></<5[1JWV5YER=!SJWY(_O9R9PUFF/8T]DL6DC\NT4-I:(F26"%0
MY,:0E;K[/\L%.R]TIU?,6ZXIJJ_[&OVL9&,<G\@_WEY7]\V$2K>9,S%&2*XU
MNO[P6=-%7@E5.C/1<3:;:[9ABK0ZAR3_ #% [D$\:2OL3:\\>YG[?ONC^[?P
MGQASMS;SM1\0_;MO/<YQ'"YSR57)5QBW*=>W 8>N8TE,& M5;%1.=E?1LM)9
MV1Z=J>HE(O6H)^UAS_[ZI/N=]@^97?,M[DF.>['#[J_YKQCE;W98QRZ>4*J;
M&9L[#.>-N(J?':Z9Q;*PRR6I"H0D*;9:/@<"E[;+YTM5)A<O<I<-?;4YQR'B
M?D++N.KRT^^IR%CME;X==S:*?/H+3E*>U954J3 =:<?@34='&B>Q8Z$:0ZT@
MJQ/W?_=7SEFG-_W#\L]MO/7.W'Y]C]?@5;:SLC]R%9Q#QYB.3R*>IGIJ.).(
M<7H7;[D^QOGW2I;MU,\+DE:TH'84 G5:4JB5<?C/D/*>7/O)_9]Y.SFQ3;9C
MGOVRK;*\GM$LMQ_U&\NZV'.L)OA:);:5(D/*40GY=STZ:/*E%64_J+DXY5S?
MML9=S;#5.]I&*^]C#[#W#B?%=F8G"JE45TU06.9-I3](BBC3U*[UR2ED$]=_
M0@H-6MF<\?9@ROW9>VF'ALWVU\D^ZQRBM$^WRRXJ10Y-;8]#9B+>1"=L,+D/
M1Z0/I"DQTRT;IW7V]NYT)>D6O+U_OD?<6Y3R?G/W5UW-&2X3R#QU[TW>+,8&
M4^ZK&< X8Q2BJ\Z9QFLXBM/;%+QN7<9 O*Z)E3*)3DM,AZ2]YFU >A:A2GA5
MX_<-.M+3[@WWX["]CLP[F=]I+A^7;1(Z^^/&LI'',9Z:PPK<E334A:@@D[E/
MKH/3QH\?E_&H1E_[VTGV,_:#;X<Y'R^]X3J?:,+7E'VU\#>XNFX&]QF460G3
M40<[QE,YA^7D]52P4K;$< ,*D=J5^H(*!7I9^RI[D\%]RWLMJ[O".4^?N5_[
MA9UEG'.1VWN:C8JGE^AR&@E-*EXID-IAC35!D3-&W)0U'G-E3KS?_>'N&DI1
M5$/MLNR,X^YK]]'D;+4..YKC^?U/$U(J4H>:'QSC%);?H$6(TL^1J$^&TO#M
MV0M2N[XZ6@&O*)P*[]S'C#[/-QRCQ_\ [O%A[!<LY>Y7X^Y.GM\1?^('N#XW
MI;S/I-)E^;3US(D6*_CT:SD_R%LR7'([:T[A ZA::/&OKU[D,WY!]ON#_:'^
MWM[)>8<XS+VJ\A<'9AF/_B!@W-%#P-D?,UU7V4BS8JF^8I=9:U6-Q($RQ?<5
M6QVR^H@-%6Z-M)2BM+SWQ>_KCS[/O(_ZQSZ9-JW]PC'?;)6>X;%.1ZSE+-.+
M. [Z951KVDRGE"JK(%1)S/"Y)5!=ME1RE29 425=0:T7ZU/OMWXDP[B7^H@X
M8X]Q3W&\B^Y7'D_;OG3UWW*?(M5RCD^/NW-]D"I5 K*:^'$4NKF(2F<S'D>1
MYGZE6RBVI "H10;E35__ .GQO+J+2_<1XE;2\.-N(/?7RG4\8!96N-&K<EL[
M._OZ^ \26?IHUTZI78WL$*>/Q.D.E*-:]%6DI:&BBAHHH:**&BBAHHH:**&B
MBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:**&BBL$[ G\!OH
MHK 4#_A_@-%%8"TE7:/7_#]^BBH/]P?MJX)]U/'\WBWW"<6X=RU@5@MMY_',
MRJ&+.&W(:<0XW*AN+"94"6A38V=86VOIZ[=-%(0M0+[>?MG>Q;VI4F:8_P"W
MSVT\:<8P.0ZF50YF[0UCYMK^DG-*9EU$R^FR95U^FOH4=V4/I1OUVWVV5:$
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M+I(6&PHG9.BD042YB^UA]OSW \H9)S3S)[5^*<^Y,S&C./Y5E=S3/.3,AKA
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M[BN;>P'V_P"1^V0YG>YIC^-VN85KV:,YGD,"&P_0T=?-L%2;2&SV^8[-H2P
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MM^W;GC@RAQ_,KW ^5&<?D2+7"<H5&32Y%6V6+V=O5A,CZQKOCK>+K?> KJ%
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MNL,71Q9R?BTK$N,LBRQ2HDNMP!ZRPN8EFGB0(W<PYVJD-+F2-E[+':QYVN(
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M;<XU>U4,O.>-CZJPK9,1CS.;**&_,\.X['IOZZ1K@0MT^%+KH:\BOL2]J_\
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MN!D"2#U1,<H#M"/-?C4&9%C0Y,T6.\R0;T:\V+AXI:G5'^Y#[U+]%D\OW?\
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M5R2LD+FL/I:4HM64\F5X_P"7+CQWF5^1\'M0^#L4]B2!WM!1&_J-087$\AF
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M6YUZ1S_;N3QN=#R6/!'/"Z(#;&;;DO(&@N]1^%;/ ]I\SW'@3\A@MW1P@JB
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MB0:$U(.#WL-5?#Q.!QCC>57,=B3;?JK3\MVU??\ IW7F$+4R^M+C,- W^G2
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M#1H/0+>I&6*+2#W*"NX'JD]"/R/J/[-440ITJ,D[K_C2S!EK><>87";L),Y
M9:\G=Y$.E0[%H[2!N-7,:4J^(QMD?*-H)50;7"=?QJ1KU-^M%GU20XAA_O#D
M9?9VN%2NTI4.G:?@G;^P:JO]QCMCSZF6OY'2GGU$#J*4Y\Z38N)2XPPR4LM1
MPVPR605)Z)4$=P!<<*NI/KJ?*S)<R1NYC6N#0 &A/(>-S4NU ITKO6S44\J,
M9U>9;#2U?40Y*@EIU)WW"-D@H44*]=SJ3"R8L++:_(B]QK3ZFNT/E3"UWTM5
M*Y%%<'YTAUJ0S%=07J]B.0M*5A93XWRH=4)[>NW7?37.PWS/E>"QI!+&CQ6P
M*]*:A856U)+S+[:_"6G$*W! 6G8[G8CKL/AJD]KXB2^R=*0DD+3PII<JGA/2
MDM4<Q-G&DPUIM0)#T9:0VKRL)"T*8D)"P$J(/QVUN\=D38$#\EHQ)&RM+4D4
MN'F '!#YTKVO>P-70K3=F2(\EN.(T-,=;;83(\2U*2^YON'@E7<0H>FP.VL2
M:2!VWVVACP+^!_;XT]>O6CD6.RX\A*I<=D(CI>\JPOQ*<2D._3E1._E5V]NX
MZ?EJ7&AB]\%T@#DWW^FU]O\ "I=1M!I>LLD7:2(DEN,FN6R4%2(02U&\S0"?
M*RWVCQA7:"K8]5'6ISW.GEQ"#&R+V8T.U4)%@0%M;SJ;#)Q)!."]IW*"#U&E
M7WXF]\TZLQ![C3FG$4<J<=R*]<!U$F;(;MX*/,CPO1IKSCB Y'"0&U$!0.VQ
MVW&CMK.BPF9./R)R9<"<AQ(</21LVV+396M;KH:^JN'_ /9KF9. @[3[MQ,;
MD.*CC,7N2;C*(BHVD[]IVAQ+?2MAJE6"XEJ^+^0Z#),(X?L,]RK",L9?M[CB
M=Y,.PRBHFPI*OIY,9UE,6-)CK22I3O524@=VYWU[MV0WMJ+@<K.RB)\23<'1
MN>%:Y$ TW70$WZUP_=6='SN*SM?]*9)7\9.LDT$K'%S'?4XL<PL :2%0M<4Z
MTPN9>*^,.!>.L7Y$X]R7-<3Y1@<@/P;3&'+*H*JFI:B.27W&W8C,>19.P+1"
M(ZU=RV$'N05*(Z<G(<&+_NI,=N+CXDWN-:Q?6TD(YRDK_I7F>)E\[VGR3L[
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MCGT/VU<><:3I>!6JK!'+T:P1B>0HL4R\@QB/"3&5(HLKA[-H=B,!Q34=0'<
M2"2=CJIVT<67CIYLTM9'R+$8\@D[;D#4=#^R5ZK^KL'Z;]K\?CO_ $]G.67
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MU_VS\SE?3QHI/N&S)LLQ&_&RD,TF/-)4$[D]Z^W=?XJ.^FYN6_+D!<R-C6M
M :$"?B:F &HKU760WKYVW0_22=CMOL?"OX:I@>H&E\J_$0^X8EM?OD]U(C-J
M"E\[<C(4V5^5:GADLX*5L$)[?(H[A/75MY8YZL&T>&M,.MOJJFJ@I"E)(*5
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M]-'/=Z9O,\7#POM11X..@:0/6=O5Q\S=/E=*L9\^#/D>[B1&+T .]2J0T!=
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MDJ?"N:?.[+]J=DA&,PD[3U/E>R)<(>E,VLS3(L3EHA0G(S+\)R7&\LNOBV
ME(^G>0MF8TXVYV $MJVW2H[@@@:XW&[FY[M\?X:)S6^VYP(<%(/77]UJT63
MN.1=SN@)4?A1*RQ6R^FA7-E66 :GO)4X_(2MAN;]67%LR(C?:GM2KL/0=PW&
MH\OM_.9B0<MD03;9G>HFP=NNTML44?&JHDCD<61D$@?)?"FME-1 JIS4:&J4
MV"A)?9F-!+T9Q002E>Q (/<2"=O3T&L[G./Q>.R6PX[G>Z6 O:X(8W(%:O\
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M;6HS$Y36A&VEICF%NM8T4RAHHH:**]:7].&"KV@?>O &Y/LXM  .I)_0,QZ
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M.]R.M:HTR>?GV7-/\F75@F9'^K_3D.-NLM)K$]BBS6PJU!0B%7L-J[6TH2$
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MK&U3A;PWY#;D)T0_IEI'AFJ[4LNN]_0LHZ[@?-^&KG'3X$0D?GL?(WVR&AI
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M"E2+$V%EO46UX>=Q]*6%$7+*P4W8(><90BR4P\^UX4;N!H=B"TH)):2TD;;
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M8BIB.N2F(C+RUML/K W<9:*TH0I6PW(ZZB;R&8<9N#)--]DPES6!QV@^(:J
MV%Z8&L!5P"IX5+])F%CQ_"K*^YI\6R2!:]UE63+J(;15<ETAF0[VM.MK+A[1
MNAWO_@! UZ!Q7<.7VMCP87(8^'E8\CO<8Z0"38'(':@^2BJSH8YRXM<X.T\*
MC2Q2NZMIHIV8C26/-++L3R16WVV3W*D(0YVJ05#J$]/P&N,S1_DN3E?@,8T-
M5WH]+4!^H I_.K$;2U@822X"Y-R?XFN"+EJ;'1$OG),IB)#<%?X TAUN4HE2
M%275 .OM[J.^ZCU_MT-Y%N7"(.9=)(R-CO:+4W![B""YQ0EMCU*=*7;MN$4D
M?MI3UJ:NA7A+E]46"%Y.P\*VUH)T=,F1,C24+5]?4I;;=<#;"D +4=E)4H$;
M]=N@PN,XZ;MI_)<=*UW-M)9)"YH>2PGZXQM=<>FX0W-1NEE$P8@V'KT%CK38
M?JIK=?6K;O&0)GE:=AKF2&%L]SB4EIY"D) VWWV.^Z1K DP)XL2)XR&$2.VF
M/<YKFE?Z@0 GS-2.V$AS@I'4"GY%P)B_K:J4B]H*A <EU4I^;+6RS$>CL)?9
M1(>\*EE-@04M%*3NH[';78Q]IP\QQ^-E09.) ]H>R0%Q!W-+MJ^GU;[77KY5
M6=EN8X@->;!!U0E/V^5,.*W;X_;(K&FS^K,RFW804%*4U*W"6^UI?\L]X(VW
M02=QKCX8N2XCDVX45N09,-@:5&\HA'2X2K1#'1JX6-/BOJ,U;?R;()T2(Z[C
MZ2JV@73_ (W&A+4M'BC5CY07I'F42$(2-CUVUU6'B=U";*YS):Q\F,PB43.7
MTN!*-:5!! TT6U0ODB+FPM/J<1T_;^=%\OX_A8MAU#D[EO36$K*B9<>MCJ>3
M8U;8"5*3+CJ::8" H]NPW!U#S_:N/PG 8W+2SPR968=S6-)W1C4@M0 ?G46-
MF>]DRX^QS1'U(L3Y7TK?"L6:SNPHJ6SAP<>J["Q=[,@CQ2V\\VTV/J([*U=K
M#R&QN=E;$*(W.VI.V.!_\LR(,#(CBQ<1TA)G:U"1Z06Z%4U"VI<B<8K'EA]Q
MX2WXIX?A7.<C':A;JJBI;E+?9E5%>52&G)4IWZA;(GR:]2G$LJ>: V2#Z]0=
M,Y&+A.-EDCP\82%P=%$2[<XN:=I>6$H%Z?NJU%)* 'Z*VXIKY%/R&QKHT.QI
MXT$XRVQ6O28U>U D^,!26&9ZF@CSJ&Q(*AW;CKZ:YSE,K/RX(\7*@CC=B 1E
MS6-8XH$ >0FXC;J?&D9%Z3(PDL)O?K<_PI(@09JZ][((LMI4FMDL>5M2S]2P
MCIX7T%0)4CN ![3T'KJMC84[\%_+8\C-\,@5JH\#HX*+A4&ORI[9',(>WZ@?
MW5;3$O<7RG;87?8MF&3SLSQO,84FJFTDKZ1^PC&LC[5C\"9,94J)X2VD#971
MM.VWIMZEVIS>3D<;..47,&4V2-L0VF1IVN1WK<T  @&Q)\*Z'EN^.Z.2XYG#
MYF=D/P0B->2YK0- %)0?!$L-*@QK!\JQ"YQ6;-EU-4<B5(EP8]I-2M+<12W&
M$FXB=BPRB6@_*%I^=/4=.HY9O;O-]O\ *8>0]\$#\EQ+ ]Z@ DA)0 ;'3J*Y
M/WXLAKP"26V4=?\ XG]NHHUR7@=M6W5.Y.O,+4]?^%"&J&P91$JD]W\-DAIE
MM,'Q]#OL1\=]2]W]M<AB\K$[,R, R9) _LN1C+?U@,&T? &DQ9V2-+0'^GJ[
MK\*CP4=M7HL9[C#<J/%;6T+!J22SWJ66DR8;R=B[VJ3\JNG78C7*.XK/Q8),
MTM#L:,EN\/L3XMN"?*U66R-=<']]<JBLNK 25U\Q>[#2YTM+DEZ.GL:427'%
MN=K;RCMZ;DZ;Q^)R.8)#B/38W>Y7[0@\RBGPHD+0FY"5KA(LT6MDTJ4RS"@K
M6E#L>/WB*A7;LMY*EJ6I+CI&ZE [[D_#44^8S/S!+(QD6.XA6M"-'B0/&E!.
MU!<>=&ZQKZ?(6J^59/5%>912J2L.J+45SJ'$M;=2IO8IW WZ:L<>P1<LS'FG
M?C8Y<A?Z@C?&U[TA0L0 $^&M+S&93*ZXER7'K&>N+ ?J*&>AU<5]F&A8:85_
M+"?(AR.-BD[C96VMF#N7)P.4EG>Z3(<R-\4#R2T[=P1QT)5HZK<BF.B#FAA
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M$K'%V<J&EI]3,5F0M*GY260@MQF7T[$K[4IVV.K#\O(F=LG>]\ >7[5.V^I
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M;>7D27I*X2IC-<TQ*<"'RZ4+CNJ*0VTX4([N[^$CUUBR86(W!$ARVNE+-XC
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ML^.2.+DH<9KVH&!KG %0Z1NO3\:A#@^1@QF22OD>&-: %)/S _;6HDY+]O\
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MLI)0/B-]9#"PES7@O(^DC_3RII:XO &M&'F:U-7%2'I"+82G$RX[S?;'1'V
M8<0YT()*OF!]#J5[./=@M(=(.2]PAP-F[;HEM=.M-=[S)?:>U&(H/G2:MHAX
MMH4AXH7\KC1)#F^W1!WW4!M^W?5)/;=L:-SEIR(?&E:(BM00F<9(>*GVEA);
M:2RXM!3&<45?,$)=/S?'\=7(6X@:!.'B9Q<-;"P0D_'6DVN#O*C\*N@N(DL2
MI;SC[3P$)B E,AN2XM("RE:2H-]B$_$:8,5WO#$!]SUVV>I5^"U>@AQ)8)'3
MNVS-^@>-)U="3*6\VJ<Q7^%#BMYBRRIY:>XAI/0$N$IV&_3<Z=BX_O/>QTK(
M@U?J*+Y?&JHD<&!I"/O_  I4J+/Z4OQ9X8>9EMJC)=>;;D*C-K7LX\WN"L+0
M/0C5WC.19C;\?(:QT$PV;G!2Q3]3?E221%X]P'UBMLAIJRFE']&MU6D-PM&,
M\J.N/]2SXDJ+S;)^;L;=)3NKI_:-3<WQV#QCQ_CLD31.NU.O\-:BQR\$EPO2
MI'IX\*"+BXM893954I$.+&<1-EM24I;,9B7%#@7$;/:0%G< #IJ]%QL&-B#D
M>4R(]LT!#&@[BJ! 0-$1+HAM2&5SW^VP=:;M"Q72ID>'92Y,:.Z^E+ZV6FUE
M+8.ZU=KI"5.!&^PW&YUB\3!@Y>:S'SY#%B.-W!- "0;Z7 %3O,@CV,'J%/9+
M^!S;V% \-K78RRAB/-7&>2N;.DH6XE5D([RPTEU:E[I1U':#L==1)D]IY'),
MP81/%PK6;7$.^N1"!(A\2G2JK(\@L+T615"_&FZY'726D63#[Y;$28U,C./(
M!:<#3J7&T/=A\7D^0=R?C\=<SR_&OP)W1XSG.Q1=CTL5N+D(M:O&YGLRQ9FU
MADAD!3Q(*@?NJQG)O+4'GYJ@:EX]18SE./0WO/.$ENMCW+266/%&;;#;:$O%
M:%]J>[J%;#U&CMC@!R1R)<[+:WEU+A[A;&'M#?2UN@W%"+=3YU[9^L'ZR<;^
MI7%<5C,XC'X_/XZ#VWNA:1[MUW.N;^-5O<4S 5(C2HC_ .H=ZX?Z?*96KZ=!
M)!>;4KYN_<D >N^I08^/+XYHW.SG*PL>"C?^=NE[VU\:\(+S,CFIM3I^^B-=
M6M3+!$);P::==0T92OY++'D4D)7)6H$-MI!/<=NFJ>'B196:S&D?L@+DW'0+
MU<>B4YP=%&7-"D4X[_&JJJ<?CU-Y&R20E#"DR:<^6&QY-PXA:E-H)<2?E&P(
MW!UT',\!QG&,,''Y3<W)**8T<P#S(ZDFUZ@CR)9U;,W8T==*28M3D#;*G()>
M =+B)<=AQ(D-ML=H4Y+C'^8TT5.#8J !_'65C<7S :6XC7"0DAT:^H):[=0+
M]14CG,)V[MS=:F7 \*Y7O)<ENJDJ@.8LS$CNW,ZX9K&<<19K6ZU%=?==:0U]
M2$K5XQ\P2#TUU6/A=T 2X<CXQ/C0(KY&M]MKD.UI+@%+1IJ@M71]L\+R'*YC
M<OB"&"-X_NN?M#'!>I( T(_XU,O%Z/[Y7]Q;7$W.,TRW':Z3'GO4,./8LPJJ
M,DQ'GGK!T/M_2ML#Y3VCJ-@=]-[>S&<9F19?%.R9YFQ.$[0SW-I>=ME:1M!(
M*BO8.W>/X;OC-SV]^S9.3R&, UCX4<TM80%5H(Z6*WUN:.9FSC7&F*G(.*.<
M;9ZQR.0VW_=^%)1 G0C)*V[;]::CN)4P&MR$+"?G&_X:.0?E<5G/?Q^<DV60
MJ;0T[TW;B @VM539-M:/=7"]B]N]CCDNU>=FER??].('#?&[<6DN: '"P)7S
M ZTRZ+EZ#5\0Y-Q7*P/%+F[FV_ZM%Y'>E%%M'D!PAIZ/+/;YC%6O=)W] =QM
MJSQO<N5Q&++PA9#*YQ.V4D%F]UP\O7;Z21U2UZ\M'+\-E]I3\;E8;7<QOWMG
M+T< ';BK5O91II4*LUF;(@SLG%//<H*Z6F+,LDQ'W*9YUY2U>%Z>A'@=\ZCZ
M%>RAT^.L/'Y/FC-D9>,YCH8/^J&[2';E46501^5<TWM_EAQ)Y9^)E'B'NV>]
M[;O:!"6+]J6W Z]15IJC._9U_P"%']W[+!LD3G4^IC,3<D:07GZ^[1'2)4J&
MI3A0J&[(^9*.T;)Z:U(^XNUH,9V+'@@QS1H]Y^IKRMQ<::_.O7HI/TASNSX,
M;.DR<7N(.&XL87*$&I((0E:2N/\ W#VN0?W7X=O:'&^3,"JY"HF-5F5,QJB=
M'CEQ3OT[%NTIAR&[(4OM'<L@G9)U:XKG9.7S(N"+(\C$8C6.F".VV5MD7IYV
MK&[>[]Q()&\+R6)#F\*I8UKAL< Y 'JU!N :4W?.FYRSQGC=W=P\CXRH+:DI
M+2PEL3:" Z_:MT9AA$>:([QW*TIFA:0.J?COMK;[W[6XO$Q,/GX7^QPL[RUX
MWA&E @8'$ZE;(>E<EE\7#S/.Y'&]GXT[L^-WT;'/075P+1H*A7(N(>1ZY;,K
M(<3R:NK_  $09]A42F1):65.1EETLA+@=;0H[[]-OPUYQ/P^5_D(\!S)&^ZU
MWL^F[FM(0E!?455SNT^YH,.3ELS$R!A1';)*YK@UI*H"2B:'7PKU&?T\V 93
M2>S#[RN0S:Y+=/D?M"O:ZJF-/M.(E36,=RIY^,$MK4I#B$R$]% =3T]-5'\+
MG0&%DD>Z69^QK6E7*AN0%1$NOC6'R?"YW'<='R4X;]A*&[7 @[K:J"=.M>=;
MA;CKV[6F,YO,Y=MLJI<HIXR5T+41@+I;.Q=E!I$:1*2V3'+3BD^0*(!3N0=^
MFO2NW.W.WWXS1RL4S)XW$2O>K81= -Q0 J@UU*5J=L8G:65@Y>3SN9[.1%&L
M<8(W/)( 0(22I4@= 3I58LGA,?WCL:^$W!KJEB<(4B5 =5/@)2WU1(1(3Y%*
M843T4#L=<=SN+B#GY<+%]J' ;(&;VG>P!!<N4_.]M*XZ-SG1VW$D$W"$A2G0
M=$2I!Q7#8])=*IKO,Z#'6+*"T\;-Q]N3'D5\EQ"D);6R'5L.N-=2E7:4GH==
M9P?;\7$\@[!Y#E,?%QLB-I,@+7!\9=< W0D+YU1GS'&(28T;I)&.T"J"/,:)
M5]O]Z_CC#>-Z&@HJYS*#A:DU#/DFA"7GHZ$%VQC=W<\['F.)*MP-NO[]>^XO
MZE]C]H\&]W LCF= X,):C72. ;Z_%P<3JB:^"5S_ "^+W9W48X^=S'G C01Q
M[CM8Q5#0TWW JM_"U4.Y-Y6F\Q3DQZK#XN/OORWEO,TX>*9C+[RGF_KTI2?(
MXSN?YA&Y!UX7WCWYE?J'(S X[!$&0Z0[@Q?6I";A?KJ3I6SQG&NXF$QOD<^/
MINZ63\+62F<MFPX]MF:#*:L382GXK\A""K=^,%)<<:@2T@]%H)25(W._37/2
MMY+L_)_P?/0^YB/<UQ 72]V."7\?E5TB/*:'QDB0'7]OR\Z:%M)IYN2RC3F5
M3T;DU:X+;ZU/.P65*)0@@%)4M'0;]#KF<^;"R.4<[CM\''F0EC7%2P?*IHO=
M]H"8@R]4\:1[%$Y,IU]]<IP^79,MYMU"G#U*5=S@!"E)Z['KJADB<2F24O+E
M/J<#?P-Z<$%P$ HQ$M[F+6V,&,_)16V:FA8I2C=I]3*N]OR.%)^=)4=NH]=2
M1967%C/@C)^WD^I!KUU2G#?M\0:-U<V'&;GP45T>Q<LXJ68\B9W-.074J2XI
MU@H4E)5LDCJ"#OJ3$R8((Y87P-E=(T!KBJM*J2$(_.DV@N1JT;Q3$9N63I%;
M$?0U(0T^N.@I<6F5(CMJ<4P@H2H)4IM!V)^4;==AK2[>[=R>XLI^)B.:)FL)
M /\ 4@5!3)9&Q!7_ $JE.>L3)Q.OO$5MF^[;R&#$DQH*I* Q&(/U#CJX[B-_
M$4D;*!2=];N)[G;N#F0X,YEY.2,L>V,N(8P#U.):>EU6P2H_3,\&0(QILO7]
MOQHH_=2L7KFUT>4R'++(*YUF_BHB;M,QGU=HA_4/H<*R4H^;;;8^AUER<A)Q
M&*V7C,XOS,J)9F[00+N &YS2I150V6G%ON2%T@&QOTGQ\:4QD-O48!3UGZ<@
MTLVW5:NSG8BD*?D(0EI;+$P$>1L))[DI]#ZZT#RF?Q_:T&([&7CY9S)O<TC<
MX)Z0=$J-K6/G<2;@ )_I1N?DE=<UKDZVJX4OZF1%AP643G$3J6OA;F1'AQUK
M(\4A*]@5]Q&W3UU-F<YA\EA29G(0QR3N<(XV[_7"QH4H%5"2$)4**>R-S7HT
MG;3BKJ3%VT3KJHO9=70V4AZNA4;=DU^NQRMH*CR[%(;;[Z]+NX<4G^S6UQW#
M\%L?R&!GR0X$WH$37ALH=T+QJ6BZV2]-EF.[VW1J6W"BWQ!\:0G\.RJFI'XM
M=;3I*79:[$U<!J0_'D5B$+:;OR\VV8ZXBU*[0XH@C]^J65VEW+QG%OCPI9)8
MI)5,<8+@YM_[AVK;2_G3(\B%[@]S0U_B[7X)\Z7:"CY$P=+CC:H*HJJ!5LM+
MDJ$\N'7W/B07$-N.J^GFR 0-NWR!)]!K4XKA^]>UV_VF028SL<2EA>QR-> =
M%4.OI3)9<3*(:XN(7HMT_A>G#1W&9M8Q]328Q'J:J',5'NLB<CJ1^I0[:4F.
MB!9R7E&/(@%\)2 $@)!ZGKK3Q,SN;,X,Q\?QXQ,+W2)IB" YKW( [=;:I%Q5
MS%S(.-S8\AQ;(]A5C'#<I'1.OF*^@&.YKA=WQ5(BYSPAQ;,LXT"6UBTW%X[?
M9:V4-L)DV4AVLFJ>CL)3V*6=@@J!^&^O3.,[;Q\CMIT$IC&0(7>V(]KAN(*D
M$*1<^HKXBO0O_P!Y_%/RL?)Y3A<-['.:)$+FJ&V ^L7.T @7UII\J8KB&<<*
M\:2<;P:NKLDP^3)J\MQB+-8:$K]=9>=@3HS;3KDNQ[I 02I)4&CT5MOKDW]K
M\EC<-BX.?B.Y!^YP#&'TASMVUI+;$J04)6]=UWKG_IWWSV\WF.U(,?B,[ ;_
M -Q"7G<]J+N8'N)(NEO.D;C/D*+P1AAX7YHXW@Y#AF6.N9)+Q)QLIRBF1)8[
M&L@@RUE+*2AI"W&DA6YWVWZ'6A%@8G;O'0<=R4(BG?ND..#O*+ZE"DZ- 0%?
MG7G7:_?!X?$EX7EH&S\#(O\ U&H0YX3?$;%W310H%//(\A]A_+U?!:HX%OAV
M:185;CU U$K$Q9J9C#/:Q9V46.78RVF5A/D<.ZR 20=9/$R=G=R\KM;%"S+)
M/M@':]I&B-5;>+@:[KO7/_27D^TL/_"NFQ^X8U9*-CF@@HA)+4/70U73.?;)
M:VE?;O7=_.E\CUEDA<R7(;+N,S:*44IJYM19H^1UF5N-_E2E/I\=;')_I%G<
M[Q\F5FSO/<#"#ND_Z9C*HUO2Q%Z\#EGQ,#=' YLL4?U;+G\C^^NMIQA0Q>*\
MKRG,:*PRR[J'8&.IRMLS(#$*Z?8\$>G:;\/@FKK5,A)6GY2/VZJ97;W;[."R
M_P#.AN;SV*P1AS/2[<Y=HVM10$06O6SF=O<UC\)!SN)#(SAY''^Z0=OB0#I:
MJ?,8ZJ)!MQE[<VLM)<!A&--6<"4E4Q9ELA)86LM=C?@2H]^R@=MOCKQ*'B3B
MXLS>=CE@RY8PW'$C'A2'-N 0+;5"Z7\Q5,RF5P,;FN8E[V.B"G1C/&.)6U=<
M/9#F\+'+BEEQV&J.2A:9.0B00A**1QY(9+S2Q\P<*0$]=_AJ0=O<9CP2#E,D
MPY\4NPL0*[5"Q0I'G<?OKI. X7'YJ?V9IXL=Y%MQ W.L  IZDI6<LX4YCXO<
MFSI&,WE?"1!8?DV,)HR4(K+=H*B+E2(7F;99G1GAMN0E6Y WUDC YOC,V2+"
M9.UXCU8"5C<T&Z V+77K3[D_3SN+MS%;G\KB$8%DD7<U387!(5:(<,P6JS+(
M>;7M=+E4F+2A/DL&F=MH\Z4R%*%;+82@I9$A)([U;!)&NE[!XM@Y3_.\E'-_
MCL,ESTC+U(!"$ &X)!TMK7"OE<R6/VX_<>7 EH\!?IY"OI!QS1>T;G2CY/N;
MME6,W,[(8N724RH+L"+C>.-MF+.KJ>?'7XEO*DN)[6W.T*61L-AKUW'X[LWO
M6'*CXJ(>U(-[Y' M,;]&FZ !0/QKT?MS)[,9A39G<+?^[,OHB"_2&A$ O]2_
M.OF-D^&P<;Y!NZ"0ZXJBJI\EYE3C[;,M^E\REQW4%0[#)>BE*@D#U/QUX5RG
M;PX/N"3B.0=_9A(<XJ 7,-_2MB4L/$BN!R'PRN?+C B,N=L'[OEHM.+(,1J3
M$CN8_E<V7@:&6Y7U,Z,B.F-<+CH=FU[2$)67'6$GM2XKM2YV_#72\EV_AG$;
M+QN:]W:K?5O< K9#]30C051*H-G>1L<U)::;C>.1GLCKJ:^MI]08<9<!I<-;
M+]G(^3R*D,QR^AOZ92R4]2"!\-]<\1Q$7W>%A9.3)B/C;[;0T_W'A?K1NC?@
M%7RJ="K=P"=?+Y^=+F V^<8_4IRJF7$8J\<L-VIDUB.^S&L)+;G;VLN=Q<>*
M4;H)20"-7>W,ON+CN./+X7M#CL9Z*\-)W'P!"N_-*;(ULH]IQ(!\-;5IR'"K
M9R(>9M9-(MKB^"I>019,!Z!(CV$E*I4E25!*&)$=YYP@*24[G?Y1TTG=>%@3
M01\]C9;I<W)(,K"W86N>"XD!!Z%4#XBHH99GR.AE:D;!8KKTOX&G1@=MDM)Q
M'G#S5&JQQ>W?;KG9T<]KM;8M*;?;<?6AM3R8Y0YT'<E))Z[^FND[7Y#FN*[#
MY"9N-[O#3G;OZL=92HNE09/LR9\36N28!47I\*C7$Z?&<B^FH7YLFLR"VM84
M2'82G&VZ6*PZMP/N3W"GN0D$)ZD[ ;D_CK@N(Q.*Y(-P9'R1<E*\-:\EHB"W
M]2HGAKK5Y[D:7#3K2%?1IT*U=QV9)8FKJ);M>V[$<:=8=*%^,%E]'R.MG8=J
MOB-4N69EX^0>+GD;)]LXL;M(+?J)L1K<KKY4K TA?&__ !KO"L9<=R#!M9,R
M-60W'$I4RVE2T#<.J:1_"EX*6!N"3N-.Q\N>,LCRGO;#&NTC4'4#S"HH\*4@
M@%0*Q<Y(JT<,AF,W#DNLN1ISD5"&F94?9*&P6!NEM90"5*]22>NIN5YC_(R-
MR&QMBR-NV0LL'CH2W0%+%*:T%HLI:M<)J*9%3'*65(M' E1+3P<;[0=CY$]2
MA:@/0ZJ2' &&-H=]\OBK4^&JTXV.@^%(DF0N2XE:T-M=J$-@--A"2$#M[MD]
M"H@=3J@][G$%+III02=4Z:4Y'<?BL4U5:OVM>CZM]:'X:'%KL6FR1XWW(^W_
M '6VXW!]=;;^)ACXR#D7Y,"RN0QAP,C1_N+024^76@%I(&B"D1LI?D_3O6#B
M8*7>TNK+BP6$N!(<#()^;L(/;MK+#C)((9)7>P' *5*-7H/A=!0$4_LM/O$<
M_N.-,@DR,9L6K"M<+L.7#EQ@[7W5<X2E;$V$^"DA3?["DCII2^/"SW3X;FR;
M"0UY8BMTT<+*/$5U/;7=G*=M9/NXK@[$<?[D+E+)6]6N;_$(?.GWRO.X>RW'
M:O,L$C.XAE;CK4#*,'7YI$!3Z6P/UVFF. =L:24'R,'_ +HJ&Q(]%F.-.PY$
M?]N5I'H-R_==S@E@ 2;>"5UG?>=V#S?'8_.]M,=A<X\[<C$O[0-QOB)4[4 )
M!)N3HEZ^MOO,$*9=6VYVJ25MJ*24D=I&XVW2H:J->]CBYAVVKRHKXHX?NI?J
MW;7'C#R%EEHMR!+C1W'4-/)*U-+:=4&EE12XV%[I5MT/IK2Q7Y?&F/DXT#22
M&FQO_I3F%[2'K4Q8/D?$=I02J_/H>1UV;L6,>7C67T*6YZ%R%OM]K5S6OK27
MFHZOG2IH]Y(VV.^NIXOENWLK#;C<Q$^/EFR[FY+%<3IM#FE50CPTJUC'%'O2
MY1D=(X#8 B IJ?FE'>0^4W^3<\IV^6+:RM:?%H+M#"NZVJCP+N17M]OT;\F,
MM" XX/&G<+Z@=-2<GRV%RO/,@[G>\84#7,]R-FR1RHCBU+?A4O.<IR/)M:[W
M ^2)NV-S@ -JZ62OTNOZ4G&<,QC[=.0QL$R(Y-0S^;,FM$3G?"F2S*ETM(9,
M*2RRI09>C+3LI)Z@ZS.]<#M[C\V"+MO(.3@G'!+BGUDE=!8HBCI6;"S/8U<V
M,,+M$T/B0>O2O339?^8S=_01)!V__@N>NN*NO3;4XK\7KWD\1<A\F>]'W3LX
MVF+-AO>X#E)J##<M*Z,\[)C9%->7'C1I4F.\Z_XU#M2!\WH-]='C\+R^;#$<
M9I?C.>&BX1I<0%\@%KJ^V>U.7[JCDAXQ\6V)KW;'/:TNV-W% YP)*:(M_&JA
M\SXGB>+V^.X]B\]$^PB4%>QE#ID)<2SD)"OU&+OL A,-XEL^H!3MOT.KG=7"
M0\'R8P,>1DR1,W%K@4<=04)"Z57YT<%]OBLX9D@RXX"W(W+_ -4/=<*T6V[=
M%^-.#$+.TQCC-W(;C#\6R;&_U*54TSU@W#380KAUM#CSRPVI,V>RAC;9*TEI
M!Z^NJ_V>=#PC.4'L.Q!*0&E"Y;+UW)70=M=QLX?A9X^0XS'S,![2V.1X]4;R
MJD$7/SJ$JG)%5LV?-=J:NP7-9?:2U-B^6/%5(5OYF&@H!#C?^9UZ:RX,L0S/
MF,4;W/Z.!0=; $5PF-EF*1Q<UKE\0J?MTHHY8RGW6)?@884PX51S%:\/SA86
M%$=Q[@"G5;)F&0/4&-'4-":TV.:2"89$=I6O!;Y$7%2GGO-/(G*C&,UF46:9
M;6-4[&-U:(\=$<FLCDK:C/J:ZR5=W4%1.P_(:(<G+]@8,+S["(&CKX*FIMUK
MO.]/U$[C[];ACGG1..#"(F;&-:4#0U21J4%S_,U&+T4^0A _F-D)<2I0W\B%
M]J@G?8="/AJN\.B=LD)WBW_Q^-<-[#2H823YI_*NB(:Y+S*%CPGN<+KKA6YV
MI2AQS^8!U[0@#3XXWSRF-SB7$*?( :^--,+HG+*\)X>'S'C2>6CNI*5(()41
M\/X%J2%)4M0!2KMZ>O\ ;IA5OI():-#X]*79NNU-OA2H_4HC1H$P>?R2?('.
MYA7C#C9)"67$D=Q4 .OYZT9L,18L4JO&]I-VD#KH3K\JBVHZGBW(<L*^KJZB
MAGQG84%;UHY$$B0B=+;D/N(FRHI0XE!9CJ2CH-MA\#KH!D2YV!!Q_&8DK3CL
M<^4L#G;RI.YP0BP"*?W4T1/C<XS._MOZ*+>5(<C)L@;BO58M;!N&]WH=BID/
M,LN)6H=X$5"D-A+B@"24C?;UZ:RY>XN9]E^$^>48SUW-T">"(E7)-WMMC+G$
M-T!.G\*(L5,N4W#?DEPPW&]O,E3:RVRR-UJ#?<HH;2"-BH#UU4AP,J9D>1,'
M#'*HX7V@>('2_6HU:6@.U.A_;Y5R712U?6.-([8\)LO+=<!82IL'M0$H5MW*
M=WZ>O72-XO)D,KF-<8HF[BYP11XA4U^=1O+&N:QVI-J)_5+^F;B+884-POS^
M/:0D=H3XPY\4;]=B-9MW$GJ*NC(+H_90?%+U;KA7W(\S854P,8Q>_<:QO&GG
M+5%2I3<=R6@!KZV''D.@N%3T=KJE'7;J!ZZU^$[?R>8RQF-#Y&XG]P-)0)_4
M&^9:24_*O>/T_P#_ &8_4;],.,@X/MW*CBXJ%Z[3$TEWBTO3<A)\:6_<QS_C
MG.<RGOJ49126M=&4S,:R*[_4XC@\;78BO4DH4V6G&U)VV&^XZ;C6USN!VCF%
M^1Q$DS,@L!<)3N#B@5K06A"#:UD%5/U4_7#N3]49(>1YAWMY<3R 6%S6([4E
MNX@.5+^=1OA//W)6'XCDV#F:NXQ6]KW&)5%>-O383)=*^V=7QY2G6XDME3A(
M=; /Y^FN*EXO(>UT*RQ-&UQ9I8$.5"+#J;:5%VK^NO>G;/;V9VU*Z//X;-B?
M&6S@R;-X/J823L(4&UK"U1O6SK!V-/LOUI%8Q7I2]$@N/24?625+2%,16^XI
M*@@]Q.R0-O7H-;_&\7BY4<_)RRQ0N@:#&'I_<<U"&MN"2O@M>6_^4<[C 8V-
MDSPX;2;->\-!*E0%0:]*S,SZ_MHZXEC;V$F.I?TJXSKCLAF/!=4AUQ,9N4IY
M$<]W7Y D]>GJ=7AW%E9,1AF> Q[D<@!_MZ':JIUTJOG\UR_(L,>3D338ME!<
MY-W3JFE*4>?C^-Y0S^CRU66-6,&&W8BP;#SC")3:FIK;C37:VIV*I14V>NRD
MI._36A)RG']L<HG 2B?CYX6[M]T7<"+;;A>HZU1XF+&R<R+_ #8='BME <&J
MI8HO=35F<7C8O2\D.3_;_P ?3>;,?KDLN2H=SCDZ>$-R(99>CS&(OF;0'GUN
M **0=T @DZOR<W@]O!LG;4;,F60HX.:Z0!1H /%#_&O;.-[8XSF^Z9!V#Q&3
MS7#XP5R"5R*2!N+&MU ZI4G6EEBUFWD<_-O9%;U:1#4TG^ZS67T\*NGA*O'+
M6E=?)C,LCL/<-@#_ &ZYF$YN3G965F84CL,M'H8QP]MPU*E3U*ZUZIRF7VX[
MA?M.:[&GQN2:XI-$R5ON(#Z3N:;=26E;5\\[N(IV1.F16HS%=7/AV/42Y*3)
M@,/3!XZQQ"U,R7'64[(7\I.P)(&B;%RSC-R72Q286.&.#2]I< [2,A57HX)T
MKY#Y(X[N0E;AP.A@?*\M8Y28VJ2&DD J!:XIQ8[9?W?M6.0H!QF(F#:,^+'I
ML=BY:3Y&EK2\Y72PXT_%^7J%D[$[;'UUNX#HL1__ ),TXC&%Z&!0X .;JFY?
M-!H?#2LJ.=S<AL W!S#N!35-;HA7P6FADE^BV=D2IE/!9E64LV'U4%"8[?@+
MSA7'9B, 1X[3KFQVV! 3MK!Y/DX<QJ?:PQ2NDW;F;E+5)1"XCYZU:GD=DY)R
M'DJ\7M91:UO*BUG)I_H8D=FF3!E(<4XY(:GK=,A#B.YK??N2T4D[[>HTO(9G
M&R8T4&/C"'*;=S@XNW BVJH:JM8CR"YQ\D_TI&:KYC\23.2RZXPPZ@//=P/:
MXX$]I4L[GN43N-8[<7)G@?FQ,)Q8R YWAY5+N2PJ5,=SS"*G&[JAG8#%GV$M
M1>JLK%C-B6U2Z4(;26VDGZ24SW()V4G?YCL1J^[+XULS'01/9M'U-<=Q/B;$
M+\ *[C@^Y.!PNWLKA>0XV'(SYG$QY!+FOB]("!" ;WNNM1BRTT^W,=6S)>+;
M"W$J:/<E+BNXA;Q*"0E)VZ[CKOOO\*.-%'-[KGLD>YH)&WIYOL;?AUO7$O\
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MIF2T7')4A5FR4)C(0EIN,([84K^8[LD^9*T[I]=]]4&.BEQC*Z1S>1:1M:
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M#C[;+2$J#245\IW^9'0'"G=""GYMNGQMX.3S$<@Y_&>7'$.UI<=VQNJ%I/5
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MD2(]/(%= %6AAVL:3&DQ0V6D?7-M%L2W&P0H+7N0H _#6;_Y;R3IX996PO\
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M[ZJ[4H3MLKX'X:W.(SLCAL2/DV2Q?;MD#70JCY/%=4MU2FB9\4X=#:9NCO\
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M?WU_E.) [FAFE=' Z*%S+1E54$D7*D+X:U*<1T4I&.&;20;FX*W(M>WPK/\
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M^9B6R=T!*A\O4ZZ-W;D';/&-Q<V-[N>SPYC(VOVEC220YP1RM0 FW6HA,9Y
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MF.K<5#@* *V4M0G C^8"%*ZG3LKN*/ALO#Y?B8"W%#',D *,>J%&]?3>];?
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M-.TNX8,F/N'GH>,Y*!Y;"Q\9<'E&F[A(U 3;0T];CV:7DB#)O./,[P;D"G0
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M3:IY'T\6/7I0%-Q&>]:7DI8^J?4OL[UA?3;J>FES^>YOFL2'$CPBW,BDW,
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M0F+L&I*EH*5%0Z*&Y]=:',8V04RLTQ01RXX,>RXD VA"B7'51J*JQHUNP$D
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M3,[(<")GA6AE@'+KT2GM:B7";EMX^?X5S>5+?<2V^IQQ;A*/YBR"%#M#8*W
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M8_:$T,K9&R-<0UNX-)(8>@!"#1?G6)^J7*_J9VG(>W.[.1R!D8S6%O\ ==(
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MP$I:C16&ZIHJ??+@:<=2\O8*4'%#R*3_ .M'0:HLQY\K')B8-D(5Q)2Q_?\
M*G7(VC6IEQS$[G#:6OY!NZC$LKQ"MLFFG8"KF*^\N:\VZXB+*@QWVIX24,J)
MW "=@">NVO0N,X3+[=P8NX^0APL_A0Y2P/5P*C4%H\/&H2#D1EL+G->FNE2Q
MR]S/19CB^$4.%6BL1Q5DR)=GB=3#4RJFN''D"3*0\%*5);D[J4U_-44IZ$#7
M8=[]^\-S.'Q\/;\[\'$(/O,8Q'QV;X$ C6P-9N!CYN.UT7(.]YS%VGH0?CH;
M7J/,!R*;!RD8]A611Y46R4^'95_#VBR4^+YUSV7FWU-!04H$@[ ;'?6#VGS&
M7!SXX7@<QLN)+N<73-(!**21<J:ER(631B7(C(D6P:;V_*G#>\J9O:8>,(@O
MT==48\N5.G-06VH*II5* <[W''GA/+!< :2VD$()Z$ ZUN9[Y[BR>-EX7 ?#
M&S$&Z7:4!+3M.Q==5&EEJ80P%S'/B(4H'?U*A1?SI$XRR7(JB+E]W1-Y"J4Q
M7LOO3JB8W$B0 9 ;1(M&U(VDMDN%+:1L>\[ZR>Q>?YG#@Y'D<%L[\PMW.<QS
M6M"H"7*X$Z] ?E4/)8\,KHF3!CF%QLX*?XTP&Y+EM>%[)+*QA_7MNRE2'X[K
M\QQ7C=6VI"/(E*D.O( *@K8;G\-<:99N4Y<3]Q9$T3I 7;G-)<B$A+Z'35*N
MN]$#8<<* @_"A28VN^F38:[VLI6DP)LE,NY?,>.I$5#KGT[2D(?4N5(*>UM&
MWS*/PU%Q/!?Y;*FB&1%#"R)[PZ11O#=Q :@/J*>5S3IYS$ HW=$'2B4B4ZY%
MC0W&PJ5%8=8;G+W2EYM9+8\JU.* 2A W2.T;#UU#GYTN1BQ8<K=TL <P2="T
ME /@-1\:>V,[M_\ 21IX478?R.JB.JKWY+<&R C2'$J6B+)V/>I@]J]EI]"0
M=]OPU'C3<UQV$Z7#=(S"G]!(/I<1TU\Z';'. %R*X5DQY^<SVMF0X%@H8>8"
MEJ=[T%/\)4%-J[0" =R3Z:J8$DDF='[;/<DW!&N"J5_=2R-8YG@T?M^%.#+X
MEE43F;J6*1$AYPN?04[S$B,VKY 6)#32UJCA)1MV*V/KKI^Y>-Y/A\QG+9OV
MHF<^S(K@(EG#:/V6H\=XV;+H/&F]8VLRX=BRG*VOK1&8;:4(+79]1N5K$AP
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M+DW.B)02.:'-+=N@*.0%:?GM8H^5.2\I;XCRN72RZ>HC?J[.&<@H?8=G1/\
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MU(K6EM32O&M:62UW;GKUVVUIMCPF_<F#+D$<;4C:5!D4@$6L!\ZB%RMB?/\
MUH_ HJR?;)KK5$R!92:UM5/&I4-3/KYKK"51FW5%YLM>3KW[;D;?$]-7,/C,
M++SCAY@DARWP-,38T<'N+%"DNLNI\+Z4DCG1#=U_"B\?%[F<+2.AIUZ;3L/N
MST*=/^A18Q2IU3A=5ON.X;@?CJ@SA.2F,T+6$SXP/N*X>D"^I-[>"TONL"7N
M:E'A7$L6NLDB7N<^(X?BC]=97U:RZVA_*%*LV8]/B,#;;>7DTT^)Q7HS%2ZY
MO\H!S7M:R,%P]2I;IX?B:E#]OI0(14C^\>+4C/;;+N/8<?'L-DY'=8J]A\"0
MXJ)A.2T+Q;L*BJ9<<7(BTDMM0?B K5\JE)WZ:FR>7Y/):R#)GE>(0C07$[1X
M-O86T"5$UC8QZ!KK53\8MIU%;PK>(1'FP'D2FW7F$/,D,J#B4J8>"FW=RCJ"
M-C\=-XW+GX[+9FP$"2-VX$@$6\BH-2A=1;\J=.3V;D6_;MZC(8C\F>&+-4VF
M0Y"$28\E+ZF$-!MCPKCN.%)[$]NXZ$ZW^;RSB\L.4XS+#IY@)"Z)6;'&Y:B-
M1/ 57A]3"R0%"4*W7\:5L%HLIY-SIY/UKUA<(:F7,N7+=2MQ:(+:I$B4HNJ3
MYGPA)) /<=:':N!S'>/=0<9M^8T.E<Y[E/I(T4$:G2HYW08F/M0"-40: ^-+
M7)F195DMQ4W&1UB$OP:IMYJ:(C5<]-JVG'8[#K3A4GZQ!*B$DGKV[;G;6YWQ
MR?,\IRD>9/![9Q8T#QL87-:=J@@@D=?$KI4.!#%!&YK5V.)*$DH3KKI\!85"
M]G>7&0NPXLJ7)F-Q"N-51G%;IC-.O*6EEI'\*4E2]_PW/[=>=9W*<ES,K&94
MLDI;Z6 E44Z#XU;#6M7:$;Y4HRL&RJ"_#C3*:3'F36UN,1'6_%*[&NY16II8
M0I(*4D@]0H#3\CM[F<9\<$T!;+,S<P% 2T7)\K!;]*4.9L+R1L'^E2=QORA.
MP+%<MI7<9C9'&OG$Q2U:Q%R:VOGI9D,,2PA*V@J8R7BIO<E/KN#KH>U^[>7[
M9@R,:/';/QLJM<U[ YON;4%R#H4ZBK;F<=+A.,K7'D%&QP<0 %5RA4*CQ!2C
MU1F]E8Y"HY#68_72JC%)<*!"D4!F15I;0X^TI->V5,M3'>X[.[! Z$@[:W\+
MNW*S.;,_.Q8K'08;FL:Z$/8#=S?2A2YN1=.M4GXAR"6P;A9;'4 7U77Y_*D/
M'7*._@65SF+5A,K,=4XN)2T[<2*'537%=_?,?!+#9= /;V+V'1.PUG\4[!YK
M#R,_GO<DP\($LCC#0/5X*YI2U@M,<[V7LC:T:WK? 8/&\B1:Q\L=NZ!]J+-G
M0)4>Q::\S?@5]#6I2(DLAYQSJI1(!'X'8ZC[1Q^T<@9$/-.EQLAC=\;]Q&X:
M;/2=>M.G=,)1[ 'MDW""W[?MYQO98W-APHER51C&LY#R(,<RD/3%H0LI2MR.
M@K<2E1Z J/S:Y/*X;+Q\://<&^Q.XA@W N/AZ02?QJ4ENXITUJU>%RN2N$,8
MJ)"K_(<'J<H9_7UQK6.R]CF0N1V6ULPV(C2WW'_,R\E*E+#6R21ON!KVC@</
M,['XN+-R<J7"?*T.=NVEI4 ^T "2IUZ:5"<W(*P-!,2V\/GY?(C3RIF<A<LX
M;D45]RJXQQJ%<7,),>6Y$@V;4.&IMP.FUK$.6CY:FS%K47%%)3Z; :P>YN].
M!Y3']O XZ.3-D:5>^,! ?ZFHI5;J@^- 9)[N\_VVZH#K\?\ 2F!Q_P M76"5
M>3T4$(:CY!$#29$:%#781)3/>IGQ/RF''$QG"X4O(ZE:>GYZY;M7O7-[9Q,O
M!@'HR&6+6MW->""""4(%KBF96*S*>R1Q(+"MB0OQ1%ZZU(^$\@9S_=;)9_Z1
MD<LSH3M':9FJ5-?KZZ)*3XXL24PHNQFMOF;;!1T[MAMMOKNNV^]>>EX7,.;!
M/,)8W1G*W$B)1;T*EM%0D U!D8X?.R9A1@16^)_A;P3\Z@=O%S.J9]HBTBFP
MB628RZHI=$M;"TJ49R>UDM>,%.Q&_<21TUY5%PSLGCIL^.9CLB*5#&5WD$CU
M"VBGQZ&KI<&N#7>&OG2<RU^F/3)$*W8;D0TA+8 ?;7)0\@I?2CN9(!2"1UVW
MU1C8<9[Y8)VME8B(7 N77:4Z=5(\JDL#:IFXNBXM=5F6T][%8B6R**598U-9
M?>C.NSRC=R-(F(2\EY*V4JV0X -S_%UUZ-V%!PG,8F;Q?)1QMS?MWOADNTER
M'TN>+I\5UJEFNFCVOB-EN-1^W[&FVO([K%(ES@5).A6>,9(U5S;>NCOMS67E
MQ>V6E(E.M-KCR&G"0OMV4""D[^IY_*S<O@F3=OX<D4W%Y(:^1K3N%EMO(!!%
M]/*K$)$H;( A1#_PJ*;-R([-?<KXQB1%J"F8Y672RE0W[/(25*"2?B=]<?D/
MADF<_':60G1I*IY+UI[]?3I3MKE7%57U>3+BPY#+<G]/IG5N,EQB7%\3^[D0
M AYOL< _F@@[D? ZU\3[[ @CYEK6%@=LC<2%#M?IZA%UM2':]6O"@A4UL?C2
MEEM=4PJ>NGR95@C,[F2_86M0F&S&JHL*1L]%6@A:0M;Y<*@ GM"0/CJ_SF)@
M0X,69)*]W/Y+C)+&&M$;6N)((3J3TZ5%$]YD<S:D30@\:-4TK%?[OQZ^PQRR
M7;6CB6(5S!EI64+3)/U(^@)#BR6M@E*2C<C?XZM<9+V[_BX\3D,29V;,2ULK
M'!Q7<0NW>$2P 3U5)_?#E:1[?@E_'^?Y4CV.)O,N,QHL2SBQGK23$%I<-JA0
M7@QL4)< #B6'V$*V6#Z'^W6;D\%(V010QS1PF8L$DS2QGB ;%#XT"1I.VRA#
M2#<5?Z3+CI9,E!5VK0^H!+1=2XI)=A.MDK6TE:?E5L#TUFY^#)QN0UHWA]B'
M="5U:0;A18Z^5*"UUVWO3YR9CCRM%,Q7R;+(Y3]:B7;V25.M%5J^GN^A[)':
MOLB+V0X025]=MO773<RWM'#C@BPW39608]TLH)!WDGT(Y-$"D>--:Z9R[P&
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MXC5>!^6R1)!MQ]@=NW D>1"EQ*>5;N3^G/'_ *G8LG*=N\QB9_<L<)+HGL,
M<Q+!KW-C87 IU76D/#,0PF++8PO.ILK <YI9!<J;-]M4ZNFRGMTEF<F.WVQD
M)*D[+*U(/J0-5>0R<@P2<IQ,SI\:4@/C&YI:.NU0++X5D=E=I=EP9D'9/?#S
MP_>F&]SX9R!)#*\KZ7NCW@!"$W:$)3?S[$9]!DQA6\NOGV2YC#\=^KDM/UEL
MB2"Y#D*<24MQ?(""H$#\-AKIN/R\5K8I9,62#!CQFAR'^X26"Y)-U-];5Q_Z
MA]H9W"\Y]KF96/D\B_+!A=&0896DDL)3Z"FJ@7IRY*C-<!A8[D5YC.+M8Y:1
M9!2W'#-M53GBT5%M^,'93L22XEM(!24]>O3KHP>X,;N;"=VQ+DR0XD#GR-#V
MN"N"EMP";D@>%:O=W%]T_IO+Q_>'-<7QD^#E0M:0Q\<K';@YJ.:I+#Z2Y0.B
M*II!P3DG$ZC)9-F<%JLBC+C*911%A34)#\A.WE8<3'<\C_<L!L*(&XZZU>V>
M. >CY/<Y/U>RR5R1EVEVW9?S%97"?J5VKA\SD9QX)F3QTD;0^&.)OI) !+7(
M"%Z7"(:2;O\ N_$>FVLVDD8^S-/G16U5DVZ__.<6XVMU2TK+"D!)2I  [2G;
MX[:P^:XWG\+E?M\ID;92=QNTM"]!M)"6M;Y56S,CLEV++SDF++A02O=MC@EW
M/(.FX/<"PBX*6\%J,3!H)L.[E2I2H0["_3*?\TR0XVD'QM/K:0$M]QWW40-M
MO36AD\SGR0PXLC _):4+AZ06VL--+UY3B\7VWD8V?FRSF$[0['#PZ1SOJLX@
M$!42Y\]*WQ;CS);QE=O$9IE16H<F>8TVQB,(>CQFU%PEA3S:EK2D;I!'<3J7
M$[HBXB=&B2:&-PWL():2[07L0$I_ _I3W'W+B'EL488@+7/!=/$TEK1= 7JT
M^"HO2F]7PJ.9$L'4N6L23$\"PW&2'F'"IQ:7"KQN)<;  W20E7_3J<YI;B2-
MEE+9)7@AH4-.NOP6WQKG<#C.)F;(0,D3Q=6^K0_'</+IYUTBUCD^!:VAIIMC
M65+@,JP#W:^REWN""^EY862/P .E?!DLXULSMC8S)M#^I*$H@NEO"I,?&;E-
MGRG02SX^,%<[> YH.CG!QO\ (&B>.M";9/LEM\5CC2VUN>)"C%;<*4-/.A*=
MSOV]=MSU_;I?\E)@XSF(TN+40@'YC=H:K\%Q\7*\FC][<(JK@WZ1_22@4@_#
MXU(UKQ5DC+-19L"M1&MD.KCK1:P6&)#4-))2K9](0]LC<I7L>[IZZJ0196V/
M(D8=DHWQ@D%4-[ E //I7HW(_IGSL4465BNQW1/%TGC:K=JCTEP<J(?4 :;M
M/D]K)[\+@U#-LW92BS%KW@1)38+!9;,5Y 0/(M1 3\%$CXZ@Y+&^\S?\I+MB
MR UK26@(19J(/Y=*YGBN],WCN-R.TGP,GXISG.#7J'-?KN:\7 !'C>XZU>;W
M9^T/DSV>8WQ!%EY%C.1M<J8:FWR-FM;B.MX7FD!Q<FVP.SF2GI!DVM;!D,.>
M9DI:=+A2GJ@ZV>W<>=O(,R,3VSEXX<^Z (%-U1;51/>/(R<&_MS! CQLA0]N
MT.5'%3O>+:6O\JH+29I)H[5N[17-S;NNDM.1W9_BEP4!I2VU,NQ'FG$/,;$$
M#<!.W3?TUU>1SW&Y;Y,OE(I,C/,;F@$^@*'?225 !*IHNE<SQ'(\EP.='G<<
MR,9,3VO]0:X*TC5I!:5V^=%\BOYV0Y*FYMZBOK)LM#8>^AC)B05J#BEB08[0
M2RAP]W7;91'Y;:X6)S(8=T2NC!.H4_\ Q\T\?.MWG^;S.?[B_P IR./%!E2Q
MM4QAK&.()]6UJ $KX=*=^<0,GO*ZID&SB7,40F6TQ(CZG37M1]F&0ZAU8+15
MW'8 [';T_#0P.6R>2XZ7%Q8/9Q,<-$B;0'.]6THJ^*VK?[U[>Y[D,?!Y#(RH
M\]SX2&-:XDPM!:$1R:J-%T\J:=G29+6P?I539;#$B+":EPW7]TR0CY6_1:D%
M#87T!.XUN9'<.7)(WB,+*F<US&M>QSB6D_,[=M<#G]E<E@0?=9K P6LH))/@
MAIEE"Z*6ZU(;\VQ4A25$. N!)2A:%I<V!2DG;YMM]0QSY/"9TF-E!KGMU"AP
M!"A5"CQT-<Y+AL:@N#T!4+_#\2*3FXO:\B2P$/GR!?B=ZH*E)_@(Z[D*/7X'
M\=9^'DN^]:]K ]Y=H18K\:=+B1^V'1D615'7J/D=:4("8,2S9E6L9Y<!+^SL
M2')##G<XA>Y0I;2T)[5'XI4#^6MO EPH.0^XY5CVP,D(,;0%%C?P(^=4)X9G
M-VPD!W2C0GXW7Y1,G,0+";4K:=3&BR98BRF%NQ2A#ADM,*0?&\=^B?G].F^K
M\?*<%C<_)DX\<LG%O8X,4EKFN<Q%0)HX_A59^-D-B+2?^X2Y/TIU3KI^=%A#
MM8O= ?B,Q3)#%FS(>\3KS2 DNQ"AU)6H!_8?]/II6X'*P;L%[8HFR),'N+7.
M %V^MNXC<@"+J;U(7EQ!>!]* ="?$U8;!?<E9XOA$O#LKH*'D#&K6T5,E1+N
M /KX,QIA,8*B700F6WY(X Z$C?IK/[ESN6YGA8X,G)<^+WKZJ"S9UL"H TKW
M+]+?U=PNQ<*;AN9XC"Y/C<EWJ;*T;FJ$5KT+AXA$OUI@\CW7&\RP@9'QA6VV
M*(,?ZJ;3V\N/9ML6!7W.(K)*&&EKC=I^1+B>X >NKF5A<(SBXN0XZ4LS6#U1
MO4J0FAO^]+5P'=/-</D<Z<[MK'^TP7*0QWJVN4J!=UD0"F;?2,E<KX&0WM@U
M,?EOLQX@<D!^TCM1&D+9 ;!+K3"FUI2V0-NGX:TN>_\ (CQN/R_)S,,TC@(T
M+3(UK0H-K@7"?"N+AGB$KFM",#MQU13J0GPJ:)/+7)UK P6XRS)S23*2M4K#
M<H9@;W$^-%6F(J).L(9$E4>)X.U'D!V^.X.MWE9,SG^VH(>[)(L>%-V/*UFZ
M1Y2^XQM):@VZD:_&NBX'OCG^#[A9S_!YD\7,X[0 ]AV:);4 _/\ .K*X1[Y>
M3ZG%FE9[CN-\E8FS;L@N6/C8M!+2TX66)+K/^D^!U 41W-E)/QW.N;9!W-A=
MO,Y"/*D=P[)EW,E(>'$.(:Y"'EI )1$M?I7U+P/_ +<<H_+='WQQ^-R\KV;2
M^6-I**+@.:6EWBY0;ZUZ./LS<YX+S#[0/NZ7=5Q9783:U/M+R+^\C55+(@Y
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M,\FS2\XMEF.X&5H8<BO)4AY*FU$*^4]5#;T.NIXC(PL7*AR,:.:>=L;C("4
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M 0G@32O9\)2LEK$TD+"J>QR:&TXJKO\ %\H"VGXQ![%RV)+[SB%,@IV3\NP
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M6,9"2TJ)=^SZ@"0K=OEK7O/'<#^@/>O%,XG'XO+Q.<D<%=M<R5ITLQPN"BJ
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M/$L,H%52)^MAR)A9A">XB,ZM"EE"$.J#H:0L$C?YB/S(ZZE;AP9'+'#XT^Y
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M<\DN#"X3.#V-VL0;"0VY=<TY*&9B\']2H[G$D9Y#C(-NC*,&0$753)>6E*I
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MX"ZVZ4ENYO9VST"8QFS-5=(JYL:??3*<(K+";5I<575BW3'<9D6;J4!*'?\
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M\;3B0XYN$-J.WIJ>/C,3$8?9C C<AU6_4^58/+?J#S'<TK!S&=+/F1ES8PB
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M];&'Q.4XF24B5K6^H-;Z2T:+K?5:\UY/N7C,O',/$X\^-F^Z)/<=(7/:H *
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MTT\,#=N[<_JG0'Q-1%S@/2IOTI#6VXB21$4IP,E1;6V>YQ*$$I))2!L3MO\
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M#,5LZ=,*RN9L2%=M1HI666OJY4.*B4SVMDD@E+FPWUR@PL6!TV5F%\W(-?\
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M\=-RT;HH\+'LXN=ZCI](2^HJ3W&AX:;.IF.#Z:=XTJ1,#$A)24@A#_:K<@
MJV7Z?EKG2W9*C3O =TZT]"'*+WISV]S32)\1VL@2ZV.W%C(F(=<3)<5*0V$R
M7D'L8"6U.@J2G8[#IOK6Y/*XZ;)C=@1.AC$;0\&ZO4J>FH2G!P!4ZUHS<L1I
M"FH4J8VT\"WW-]S:G$N]'$+V<[@E6^QU69EG'>X8DCPQUCT4>!O2AS2X#SJ3
MJG#L<RFQJ,:K)TV&R\RW-R&;91XL>/5.I[D+=94)0\D9+>VW<I*E'?7=<5VO
MP?/\E!QF%-+"/;+YWO8 &7 ">N]B3J-*KRY,D>,6@ WZ?A:U1_!D'"["<^W%
MJ+UI]Q^#'$A27O&EEQ21(\ 2L)+@V*3N1MKFL?(;VYG2^RW'RXRXL!< ;-/U
M)ZD7XGXT_:Z1@=H3T_;]])&23'[2_=E64-BJ7)2T5QH;3;4=I*@"E;3;80A*
M5 [[ :S^4R_\CR1GFB9#N0$-%AYZ"E]LQA'WIRYUQTUB34*= R.HR&MFPX+R
M95>ZD*:F2HK<E^O<8*U.AV'WE"E'9*E#IK7[C[6;P>/%F8V7%E8<S6D.;8@N
M"[2W<[1+E?E3!ZV$D(AJ+]<=45/[CB]Q[&<HKKG):&/DM7%4YY::4\XPQ(<7
M'?:9+[K6[R66G7$K(3U5V]OQUT?:^?QG&\Q%F<O ,C$83Z2B7! )!!5"53RJ
M<*@*W_:U(V163$K(+.=%8@B+(D.NLQXS:D1$(<W*4-MD]P"-]AOUV&J?,9$&
M1RD\V*U@QGO.T-"  ^5+N=N\JGGVMSY</F/BQE+T$1I?(>+OR&5--JG(:B6;
M+A<9<4DN)/:@]$^H U8PN3R.-X^:.%T09)J$_N6:="EA?QIX&X*=:A_-)M!-
MM&_[LUUC%4PAQ=FN9-^L,BR\JS+E,(2PU].PM8[@D]Q2#U.J_(R8,SV'C&O;
M&& NW%3NZGX4^0LV@QZBB\.RE4M6H.U=;+B7KK+S;C[3;K[2:]_N=;:7\SC*
M7E$!0Z;I!U+C9DF!BDOABDAR' C<T.(V*"!X+NICA_4MB:[9>VBVO9\VIKH_
MT9:;FJ14Q'H\..A]"7"E+;I6XAIE1*=R>OKOL=3\YLS>1DR>/C8,1 Y(V[6@
M$> Z^)ZFF[2@ZTT8;P9?![PRAQ*FBHH#H2%D DH((5L-834!4Z&E:C;_ -)I
MW4<G#A!>K;6-.;GNS>Y.0,+2M#%>AM?\AJM5V%3KKO:>_P PV'3;6]QDG;QQ
M7XO)LE;DN*B9I7:/]OMV%_'=;PI"0TVUIFREM^9YN.M:XP=46U.=%J1W;!1&
MYV) U@R^V)',B),0)VKX=*8XB[1I6\"!)LI BQ4A3JT.+ 4I*$A+2%.+45$_
MYJ$DZ=CX\F5,(8@LE]2F@7^%( ":=JL+DKI[*PCR8BW*)I,BW"YC"6_&^I*6
M$01W=\MX]VZ@E/RZUV\)))Q\V9"YI=CD>X%&AL-OB5UIQ:A32FJB6VW7OP3&
M94MY]MX2RIP/-I2DI+*4@]BD%1WZ_AK);,!"Z/:"I!4ZA*7=Z2 B?MY5SBI$
MIV/$>E(C,%Y(+KB5+0R'5)2XZ4I'<H)3U('78:;$QKW!CG;03KX>=#;LN:75
M*LJF_6JGM')<B&M;<6TC^5H/-(1_&UY25I0$CT.M"0Y''\B?L9B]["C9&J 1
MY>5Z4M<XH+CSIOH>2J6'YB5R IXN2$]Y0MW<E2_Y@W*5$_'5 /6823JX%RFZ
M$^-Z;H5.E!QYL2U/1V_&V'5+:;6KS=B>XE"5*6/G[1MOOZZ;*6.>YT;2UA)0
M*MO!;+0';7;@+K7-YQ4AU3A">]Q144MI"4[J.Y"4I "1^6H@TBFO+I'*E<O3
M25%71#:E@* /85I05D?(E2_X>Y7H-]/:W=:GM9NHQ/A*@2"PMYAY00A??'<#
MK9"QN %#IN/CI\T1A=L)!^%*]I995%$]0U'0_/\ #2C6E#2=*-M-2W4(;:0\
MIMU9[$I2LI<<2 #V@?*5)[OW;ZF;%,] UKG;C9!J1_QJ7HCJ6HBY$R.S0LL!
M<A4GO0ESM9V5U[F@L[$=_P =SJH]I;(9'%/'XUKXSY,N,<;C@>\YUCI_]/SI
M?,*N^BE1;E355.AQGG(R>UR1]<\V0RW$:6TX>SN422I70;:1V0^P:W>%^"?E
M6F./P_9FASW-Q\F%NYH3=O=IM4(G4]=*93KDIF(U%<0&VEDR6SV]JUI<V'S*
M]5H)3TWU=+G"(1N"--QXUS#@0U#H:($;;="/B/S'Y?EJ&XJ$[FE:'I_A_@="
MKK2*3<T\\/RM_$I$FQA/6,6T+:40Y<&7X E*B ^T^WV*#S;S8*2#TZ^AUO\
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MDG(RSF<$$.W$V\"=4\O&NE_7O]>>#RV9?#=H8?",XUBLEC.+'[KG.)&]CFL
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M<:6TZE"N]).QV':>GH-]C\="V44A#0]/5^%'89D^5$>,'D.+=#8+&_G<*_\
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M6RUY%)Q,^+DS81R6)!,8B-Y(4%'$ A"+E*2Y0CMK$>"A3RE/J;#ZB%)>Z *
MV2G8%?H?PU-$U\A0_P#"LS),$3@S'"D$J55?EH/E1-*FT!:'@MA]G?8( ("@
M0-OQ&WXZD>UX.QUVBJT3XPU'$B0>'Y7UKJ)\B40U(D+5'2LJ&Y*UH0#L>SN_
MB/7X].FDCCA80' AI*%*GFS,J<[)9%C)"+T\E0G\:W>2RE;H;#GAW/8ISJH
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MDJ2$J:824-@)&P)2-@2?7IOUUMYF0W+F,Q8UG@!85R)>77!0>5J3=TIV )6
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ME15$:4HEM.W:/(4HV!)_#3 R4(IJW-G<3NF&/BN)<]Q8I<C02H\.E%(GZ:N
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M+<=1<4J[KDVMNK9>7Y_18*ZTO'Z;(8+K"*]F+#$=D'QN'N\*>GKJL8V.BVN
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MK;X;:YGDH>:P<KWL282L"?VW $@>?7SKVSLWG?TN[FX,<=W!Q<O%\M*]Q&9
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M;_. ^;;X@'X;Z7=2[RGG6GY=>O\ A_ET!330KC6?3H=]QTZ[]#\=]!!'PI7
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M\70^3_?=S+Q%@?,%#PUB]CS[R3 L,PMJ'%:G-)C4]F#6X]B[WS+:4^\E+#2
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MUM3J+)+ZDRVG.TI0APH6H;MK!(&WIZZ8TY3)#/ ]S9&N^E/Q(ZWJR).)..W
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M*L_,'72P$?P^,@[ZERLSMWD.)DY/,QG-D<K8]I0AZ=5!M>K&">/CQI8\DO\
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MWG0/E0MXD(2>AZJVZ:F9CROA=.T'VFD GP6FM9N"T)K<5IQ A.N/(+"%.*<
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M;=1586HO,>$F2_)2TTPE]U3H9824--=YW*&TDDA"2=AUU!,_W9G2(&AQ)0!
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MKD1E&L.B6_F:7<AO6S2X[1LPXL9$1IQ^5.CHW==?D/N.)2^M0!\J&MD@;[;
M:R,:.7W)97N)C_TKJ^>Y>)_$X/"LAAA;$7/=(WZW%QT)3HE@J42I:C(132\E
MITLL1*Y03*DF4RF20ZLI;7].X.]SJ?4#II)IL=TGVLI<Z1UP$M5'B>+Y\<7+
MW#Q/HQX7W<7@$#IZ=3UI.KF_U64T[)9;4U'2^[)EREE#3SBT+=!6I9[4N$H(
M 'KOK:B@;F[<:-T<,@!)<2BZ)TK"9*X3G+RFNGA%R3XN\%^%Z0GH^\1<CO8
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M321-;_54;Y7/<BDBM$N!+:M@"22"5#<[?#]GKI#9Z#2E#TM6H5N/\0.Y_/\
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MOF+UD.@?#O@E!5CRU#J$L0?@?W4S9<IV;)>E/$%QYQ3BR$A(*E'<[ ;#;?\
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MRGITE^7)67'Y+KCSJSM\SCBBI1Z= -SZ:9--)-*^:4K*]Q)/F22:1SC<]:X
M$^@) ^8G;T&^V^_P&Y]=1AIUI&-.M/>@J8]M&,>L@S[3)@^A;,-AGR,*CH)6
MZZ5(5W)\: -SMM\=6GR\7!QDDF0Y[<T$;?\ :BWK5XWCN1Y#,9C\?&97M5Q#
M;FUU/DES4D8U(P6@8DY-G$DWN200]&K,*994VRS+0'&69%C+&P\+*E!80GYE
M=O7ITUR6<>2S96P8'IQ7H7RG4A-!^ %>K]LR]D=OXTW/=U/^[[@BW-AP0ST!
M_P!+7R/5/2H< &E=H!\H8O;J5?V4NRF%*7I3I<\;:4MM-I)^5MMM"4H0A ]-
MAK<@A$$;6 J -:\HY?E,GELZ3.R2-SW* -&CH!Y"LUD^)$B6<:15QI[TZ+]/
M%EO./)=K5E;:S(80VI*%N]J=OGW3LH]-]7X)XH8I(Y(FO>YI )_I/B/VZ50C
M=M86)ZBJ45C3%0ELR8I6S-COI>;?0LCM[-BCM V(4E8WWWU1+1(-KKM-30Y3
ML5[<B!6Y37!P(\O]:>D>C?R"KEY8[:1ES$V):G1&W4JMG%/-^1N;'@I 4XPA
M22%K!^4D:T&\9*SBSG8SXW;'[?;7UC_F1-*T-TW+3R9DY+LAWJ<0+DGK3 =6
MMQ14XI2E*4HE2R5*))ZE1))))U4<27*Z[CK6)+<J=:Y:;458_?Z?]&GGZ:D/
MTU=7V/XAE[G+F,<HU-6S:X1A.7XWB_)GCFQ52ZO%N4S881*LIM0'?U)['PQ8
MNMRI3;:F8Q4CR*1WI)C/G2L!%Z8/N#]O,[@9G%%W%XS(M,NN.2FF<<,9QF?3
MT>$YI,Q*JMIJUK*7&<H5">?C=J0"TC?<[Z55HD\:K2/7_$.F_713&A32W"H+
M:PB2;")#<?B0MC(>1MLT#MU.Y_/4S())(73,']MNO[ZN18>1.-T +A2RVJGA
MR&YCKJD24]K7TJ$;H;3X0/,5]#W]YUH0G%B+<B1Q$@-FCI;5?C43O1I9WY5C
M(C332Y81;>1+G/)86ZW(:V*WUC9]*"#L&V_\TG;?\!JSRC>+D;]SCSR29!0N
M#FI<ZW72FN>7$^Y=W2F9K"OTZU&>A'6E*LAQ9CKJ)4]N"$,./-..I4I#KK:2
MI$?=&Y2ITC8'T!]=M6\2&":4MGD$0VD@D*I&@^=/:+JJ&MZUJ*]816)TU5?#
M=>2B5+:0ITLL$_,XEL$%SM_ :CQHX)<AL<[_ &X7/1SD7:/%*E8@<A<0":S>
M1ZZ%;3(U78?JU<TZ!%L%,KC*E-E"5%:F5_.TH*)!!^(T_,@QX<E\6,_W(&N1
MKM%'BE-E:WW#?<*3HZ$O/M-J<2RAQUM"G5=4MI6L)+B_4]J =SJNUK2X-)L3
M3&M:7 =":,6,5J'.D1693,QMETH;E1]_"^!Z.-]P2KM5\-P-.>P,D+&E6KK3
MGL >6CZ4I>C5ZJJ113);$"Y9M@%-UZ9?<2%O_3^*5XE)=BO%0Z [*V(/IK3@
M@^TGQ\F5C)XY3]&[6Z(;6I2 '!;TA6;#D>PF,N1TQ%M/K0J,E86EC96WC"Q_
M&$_CK/RV.CR'QN9L(<?2JIY?*HI A\J_3R_H[?\ YV)F/_RQ>=#_ /M5 ?\
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M7O0^ZDH*>P>GRDG?J!K+RGQOG=)BLVM+O0'(4;YGQKK,<=KOX:6.;)RH^1"
M,:/1)XDD."?@:93E@J5'2PZXIOP[A*4JV:*4]O8E24]I4Z3OU._33]D4;; ^
M[XURLN;/.UK9"!"P)M!_!?'K?XT3<ARFFQ+>3LP^E:67"D;+[#NK;?K\ITT.
M" #4&HGX\T3?>D ,3]%O^^BS"SW+[G7$CMW2"H]IWZ%.V_H ?32D#P"U7C"$
MIH2I'1;W3YUI].KN"1LH+6/WCH-S^!TMNM*&DDUU6]].HM1R4N$[>4#<[CU
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M/7KMI"3_ %4\.-86YW;$$D>@ WWW&V^^D1/C2AWC6$D_#H-STW_MWT4NX]*
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MAF:U&+L..MF2MVQD*(0U$90TTYVNK)Z;]H/XZ=&S%,4LV3.R%D;5&X$[CX!
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M*Y5M8*I69T6G583%5$>UD,2;-BM,ATP&;&5%CPXLF<U%[4NN-M--K<!*4)!
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M),ESO:CD*[&V#4" #PK;X/NW$X:-[#@X^07%1[K=VTH@13TU^--6RSR_LV_
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MR/9C=B%RL&GQIJN/I"R -_CN3OM^>WPU"T'K607$.*%/.BS+;C[K3"5%"W7
MV@'T/>H)'KL/XCH<0QI<0J4D;/>>W':3[CG@#S)07IY2\7D42G'+AM(+J0(R
M$+2KO60D; H4H;#R#52#+9EN BKJ<[M^?A6&3EVA2/2 B?)":47&$LUSC6^P
M2QUVZ_,.W<_VZ[^;%A@XE?ZR :Y8!KB7-)*I\J8#KA:2$J':YZI^/3;U/X=-
M<99;4KD:$.IHGW K!_#?]AW!VWT5&X^H5>/VG5]]84?)KN,N,-7GZ=4U[+@:
M;=L$1)TQIJ5]&F0H#L2R#W*&W3XZXSN5W%,Y##9SA<.'<\^X0I0H2"C5*J/"
MOL__ -6>.YO,X;N;([2=$.XQAQLC5-Z&6,.V[R ++>GG(Q!S%N%<SR?(LHK*
M?-(.1-1X5:VM+EY/C/NO,R(LI49YQ/T;S.Q2E0(^7?I\:<'(P#N2"+AVODXX
M$A'!S6N8A()4-UZ_S-==R?9^5VW^BW,]Q=U\C!C=[1Y8V1!S7SR++L]MQ:Y]
MG,.\7  'X54@<U9I2QK&!26":J-8@F2U$;:3'>2ZR6G4.-N(67/+ON=_\[KK
MV7/[MY?.XO\ PL)CQN&!!,4; A(*KN0NUO\ 57Q1Q?<G(\/R$G)X9#>0D:X%
M[O4$>PM+=A5MU*':H-P5O43O7,UYUX.ON-?4J)E-();:>3OO\R&MDG<#KKEO
M9C".0.=T\:QI>4S"7J]PDD/]QJ[6.!\0$%Z(2)CKB]U*V4$A'<@!.R$CI_"1
MZ@_M.E#>M4),@RW%C7T,/'N=<A?;ZXFB8+B609=)KO<'R8_8L8_62K5Z$R]C
MV-H9=DMQ6W%,MNK00DD==C^&I6FH$=MN5-+E)P#EN5>V#@FHH>+Y5AR!CON9
MSVHY'CHH&&L@IJJ378)*IHF8.OM-RX52\S]0MCZLI8V[^WJ2-'6C^D5:GE2[
MIN&9.12\(P'BI$[(_N"W''<V5;\>8=D?TV#+QVA7+QVK9MZN=#@ULMR0K<LH
M0I&W\LIW))_*HG.<+>)HTY'XNY/Y!]T7$W(6"\68UQ/PW[C.#JW$7Z'#J#&)
MV*XU><N*QC+(SN254:%=V%?;4SS@D)E2'4I*NY/;VIV+@*-:9J4\*?W,G'O%
M4RFSN+D=,FQAXKRSQU$X@$;VY4'%%-B##V>P*M="C-8=FT]R9076-J+2ENIF
M%?:F0K;<JT4[\ZK![D+^ISO /?\ 8[.P7C*F@<$<K\<L\4N8E@>+8Q98U$O.
M19..W,9%Q2UL*UMHUC6(V<1+=?"5=4[=-*FAIIN#7QQ&E-J5M9T(:50*U&_^
M'0:4Z4BE:V^&D3IUIRVH=-(/"@IJ*QT/^'^73M+TFM8^/I_ATT=*7K6">O\
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MOL"YX]D$K&6.8QB$IC*;/*J*'/PS)(V1PHN1X1/:K\FQ^>ZRVT6+*L=DM*(
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M*4/JDE7UG\SQJ24&)L=TI]2%=QZ?B-08QPO:'O;O<+PJ:;4O\Z21KF2D1D[
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M.?&5S!D9]B.:5.2T4"551;YVNR#'946UC6-O23XLBOFQA8]A;2I+C;BDD*
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'?X'117__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm2127058d1-ph_imaging4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_imaging4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ \@)T P$1  (1 0,1 ?_$ /@   $#! ,!
M       '" D%!@H+ 0($ P$  @(# 0$!              $" P0%!@<("1
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MJ=;9!24%9/NKVU@4M/50Y%C:6UK+CU]96U\1HGI<Z?/E.-1(<2*R*FXXX8@
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MUCC[*.,KCR S;C.>[E<J)CS=];YJV="2-RV)42.Q#]D!9(VG'#2,1BGW>(7
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MT1P5^W]K\/KZ^FR[_BT(7;N3\/["+_K:$9+JCHJO:F_X]NG]FVA"^FA"^9.
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M_C[,_P!RT4"-;N:/^^E^JW_[^WD?_P ?9?\ N6B@1K?S1_WTGU6__?V\C_\
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M45G#QQXFK>Q@YC;#&83Y=9/>B2H4>07MMB7>(@I @J2_=V5<EN\;?)$)&2,
M< 14\UH;CTHZY@O)K3^W7CS;RRLD+8W$ Q!Q-#IRH*]V.%4\CZ=OU$OJLY5Y
MZ^%N/<J^6OD9D7%V<^1'$%#D%-DF8RY%'DF/Y+?5RO5E@Q[6ST&TBFH*AHB$
M*JFKHMRLWG1K!D[%JMY]/NK]BVR/==SLKB"TDAA>#(TBHEC;(".RA6U6_>^G
MP_L7UUF<*KC^-%J+/UG[^O,\X/\ HT_]D#@#5@\*Q9/&5 <FFHC-;'7Z;ULT
M7TR/%F&2=WL<6TZE][?[A!-#[PFBHFW7TU K*&(HO/R9&@N;O."/<VTI#\5[
MU0Q'\.WW](9I$"E4B5760[&8BNK(;CQFO=9]EWVT<-Q43O45Z_E+Z?9IDT41
M0X*^&J;[CS:ON-QW&U)$+U<<5%'J2;KMMJ.I3#:=R;O+QJYX\Y#<R2JDD-1<
MOBW;L-N. #O<2)&E$*[H1LBFR_@T\PEB.]./89L9S#3K#^_NL-.(7S(AVB2*
M7>&ZBI)][23Q5(OY]Q7L,1XDQTI+I>RJ@^![IV[DJ=XIT[$74FM)!/!.-KKD
MZ;8&2F9;C3G7++(\E8=95W'\)*V3.7YB%'=?>=1Q$4"<]L"#<P(B79?7;9-M
M0$C75:<#VJ;X2P_:YLE,]!KI/(UICQ[E?-[RK4UDAZNG>^Q\E']QH!8+VC]S
M\THBZ@DO1"7;?;IJXPTC\PN;0=O\%5J=_HN5+QZZ6Z9D6B._(Q6GS;89]Y#<
ME,""(ADB;(VFSB=-]]TU62W*H4_+DI6A5,2=3-9:2/%':<D; XX#K;BMHXTX
M@"XG<3H]Z].FZ=?AJS1A@YJIJ2[PN]O>E!LXK*V54,=Y"^6@DZK*JBB'NMB@
M[)^2I_=WZ+K&FD$- :G4>'\:+)MX77,OE"C'@5^[##YI(#2?-O.2G34'>RUK
M*MAQ=EW;8JP)!7X[B9=?75A(:X,=Q%>SVQ2CA=/"^:(@B-U".)SQ',8?1)ES
MTBMQ,8HNT5=N9D45:0T$D[OS(=P+Z=RK^WJ0<TY$*LL>R'SRTZ/FKARU:O$,
M;C2#E.1Y-5%BI\NA#VOA[4=MUE&UVW<!M"4>NZ$B:LT#FU-T;A6I%6V[9C_L
MN#2!_M?<*COY+QX%C,6[R=JQH3(WIF/Q9WON*H.&Q(=V,7"1%5#8V437[.NH
M$M;Q"@ YS6N:#I<UK@>QP!'UQ[4NK6/,0)YNS0D*+<9V.T;LHWGIA*B*IMMH
MO8C(>B=WKMJ!<*8$*PQ/;CI)7L)&HDA@@A$+9D! )N@BGNJ=.T51.Y5_8T5'
M%P4'59FTK[MW\&6^8.J4.;'<0$8D)VJ:B;:-DVO>0J*JOKNGIH%.8HK!&2SS
M."OZEL1C6$=052?(B[6A54(C7[R+NNPB*>N^^D.?!1J"*A8X?ZQL\](YN\7W
MI#ONO'P)9H:]XD*=G(>0HB B+N (B[(B^FVK&JJ7(+',U)4+9%_J5'^9+Y<_
MTIX'_)+AFHE9+/"LSS45-)GS5_B<Y9_FSSS^*MKH26B,F?[[E?\ "7_[J6K%
MBG,KSZ$EW;_VP/\ TD_MZ%)OB5YT@JKJCMNIC]U/P[[:162,RGD<+R9LN&-4
MPV3C<5]]TA%-U%3V5=__ ++4"@U3N\5Q22^A2"-&CV10;(5[^B>NZ[;>GVZ0
M!0KW:<GLDD!\D-I>O<J_?3][[:)]FR::78JFE.I"3A*G88JB"H(O8B"J;].N
MZJBKJP1.+-?!"M1J@@1'G7SE*2.DYM'(5V(BW%$W05^*_'5+VQU DKFI![F
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MY*S/&LIB3(^)54&+&E8F%PQ%!R@KL6CT<B5;PK9YN9+..4AX7!15%&075O\
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MZ>FMGDN)-:XKA%V_L312J2/COIUX*6HTHC16F2 XA&DHYKC3!HF#3)"?;O\
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M[D7C>1'S6ZQJJG\@.R+:IR7('IT&!7Y5+L;>&-Q86OR!5U352YT5YDP-U?9
MQ-!1L-Q8R0<#4J$[@^'G?A]SU,I\SKGJ.:S&,+F)#?%V0S46E991'+*.0#(8
M?%ZNEH\P\R1,R =;)LR0Q755U'YMN;:+"%PQ!_@MQLFYLV7=(KR-I=:PN#FM
M(!(<,>-1RXJ96?PA@5?QY!R[&H\JR?RIC')..9!*MIQND&06#:=P,"Z$7O\
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MQ>/ +$,6?[(T"MW:C/FP*>V@N*0A*;W%514(E^W6]?;$-8[4,"%HVRZ ^,'
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MJS2,RX\S&BOW*.QEV<!^)'>!L1-!5$,E]4553M1>G77MOI#8VV^P7FTWL6J
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M0A&A"-"%(M](G^M \"?Z5'#G\<:W2.2LC\2W6.H+(6HJ_6?OZ\OS@_Z-/_9
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M299KW&7GD3N- 15TZFE5$,:<DSKZP_T3^</I6\J//N+-Y'\8LONGH_%/,+(
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MJPL *.Q&5#<E(8,J/1-W25'&EW7;O %W3?9-0<[4XNYE,YIV6&8A5PJIMQL
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M<_CC6Z1R5D?B6ZQU!9"U%/ZS]_7E^<'_ $:?L_\ = X ^W5C<EC2>,J Y/\
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MC7UQ^W7;6[1Z3;5ML8I'$UP[OO<NGZ2W7^][4V_>ZH<3CW8*(MG;YB.B+O\
MG&4W_#[@_;\=>WNKJ*WQ\=>W\E-ABM$_76T@G3V]^+%+834A%?983L0=_CJH
M DJXD#-2'^*7$3EM>.9YD$9Q::D>0Z]F4TOMSY*)W" "YOW@@KOT3?5S(I"0
M0"5'4.!4RM ](.I>R"QAMU5%%CNM&9$@"VR("1#U[!0FP5-D1.FMJX:<UJY0
M73ZAE51'^47.^1<LYC&PJ@LG5QJBE)64<8!54G.F;7<ZI?=V03%2]%WVU49"
M#@KGQ![M7.GT5C<MY+.P+C6#@-4\]^EK*#'D9-(!TV_;)TP<5I.PEV)6C5-M
M]]433O:U#(1JJ<E<_C/].KE;R<XVXYY*Q&-)M*#,O( ^!;EN!B]W>R,&;:IL
M6NW^1\FEU8/M-8LRSE*-N-J /(4<U0]E1$QZ,>=5?NJMC&(VMI7%7[1^!Y%P
MN[RY99MCF(54#FP>+Y$"1&DNW#&$LY+5X1><SN,1WR%S"J#,;:/7/@.\A7"(
MMNA:"]@=IJ-2.Y(/S!X<YEQ!C7(N3<BY'7T;N&<W/<)8K12H<PY_),ROJI%[
M?9-CDM'4BQ:''Z>5727CE(Z4A+5AMLA,-8[GMUEM<:J?EOIJI]I347Z%LI(J
MR^XL-@#&1[8]I@[[/</4=O0E3X=%TG,>\?8*CBJL72M9SK^"D#\#.$9&4Y@6
M0.0;!^!'-5A3D:==8^:;07O:5TD5M70%.Y0W[O3IMKM]CMF&T<XD T7*=327
M-K<-CC:27')2E%#ET^;S("N/%&&C)K9T5;4SCRF1!1;7?80'??[=>/\ KYT]
M;WO05EN.H&ZMKY@<*8M<0\ 'MP7QMZ[74MMZAQS6[:V=U;/HX9.HR,GYYILW
M#U*Y6WG+%G;2),:/99%9?+MC#<>CO,K*EF)* JO;VAM][[4U]?>CQD9T/M-O
M<L(G.TVN!S-;=AJO@GU@WVRW;J';K:V&F:#RV'2*DNC#6$$_RU(//*B3OGGF
MY,VM4X\D2'V/T/5,Q\?DMMJ1)-<1I#1\1V5D55U5W5?5=>?]9O8S>WL9@1F.
M1K^2_8/T9NC=^GVV>:PQF.V:W&F-./SHGQ1.0L7XHXSP3C#(7D:<R?%YJ$XO
M>SW3Q@HZIKV"O<X2O>N_HO77&W,M(7.?@U>FM@:^]8[_ +O'&F&2CF\.,S/
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MF!BJVFF"4OR.,W.=^52,B,BS>],C(E(B(I1$1$1*I$9$NZJJ]575TV95C?"
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MDMD#I\"W]-%*8) U5K9K6'74]S D-I\P[!D,U+J."1_,N=RLIU5/=< D3<=
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M,>![\WL3O<:["NR[]5]4U$G'!,!)+?8)B[#BQJ:,%:3DM]%F1/>!66!(^UD
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M]HDFL_H2VJ))2&D%41"<(-E7<5UF#-832 KZ\DC$^>.5S 4;$\XOC%L45 ;
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MN>I7BE81PG\B4N%/-_P#L&EQL*')O<D9%;5V12^V+90I>T2W:MVH$0''E40
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MADW%)@!5>X43KZZWD49='4YC+V[5B6#]%O\ J?Y@ZA[Q1)J[Q90S[F=&QNZ
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M@"ZO:3V4"\1WR^&Y7CF0/<(R?Y2> K\R$[>5R98OUS=300*RBK0!6A<]I$-
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MQY^Y3,C@H<S3#G0E=39[-NTK]<; <> /UJHBO)WZ@]MEM>_@/&D=NGQ]AI^
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M7V/^UO:9MF]&-JVN[<'WD.O6X8@G5P.'"G!1SMJBOLKUV[VU7[?RTW_M:\=
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MLV#0?$3PY4Y\4L+OFH]C-;CV,<6T-9A-5"D!)NYT!MIVSN_8(28;=DN1B..
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MX,MQ4:?<,G40^[??<_@B^FEFI=JO3&$C5+D>PLGQ9:C.(;B;&).DGWP#M_\
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MH,U/[W=]H_8>0E;%'VV@[D3JGJO395UVMEN#9A0<*?/_  7C,O3XVK=1*/\
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MEO\ ,U,,FH*JI?G9C[K'M,H'MJIG][;9%]5^S7U1Z#=.>1:3;_.,'?:WZU^
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M(GA=1>J].[30GJ9Y63I9F[$)EL'5V;FJ"MO*V[T1Q53N[U0EVWU%/-6OCT(
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M)U6V]:Y,$B4;IC(!UQQLF'F7 05!DD4E%14D]1304 <%])<]^S@2V(,5N"S
M'WA074$G%'JH_,* "7?MMMNNA&->U6/Q_B63N39ZSJY1QVQFO>W(64T[(E.R
M2[76&H/<1MQT55W=-$4UZ[==],\$@DPYLX9GQK!F:,!V-'@JXK<3961DLN.@
MXP;A.)LZOM@JHOHGIH'(I'#'@K9XLPA*\)[T8_80F%<+N9$P%-WA,'![A5>]
M7-T-4WW]-,D#)&:1_F8?D/D_<BL&XVX^Z44B%3=$T$6R0U >J*G<FZKH* D9
MC8]-MU==-L@BFR)HSVJJB^2H*@I>XG>J_A]-'<FKMQW$;663;2,FJMD$<P)
M .T%W3JX?5=B_%H02O6SA3N-6]HY*>?]NS<%E%4@9:8#?M3VC12 E3W.NRZ:
M%66X#46 ] 46%]Q'!1[VR<5P4+JIN]W8II]F^Z]-M%,$JXX)M<O"+BVOK"1W
M*, 93[#0 W[8NL"[WH*$2JHJ2)ZIUTDZ<TX3!\5N8C$AJLBMO2F&3V<,D(11
ML"01-%3\ZA=$7?X:>6:6"C6YJQ+*KN9D+UC#;:@LLVCTDFB$CF.H\\HQO;7[
MK(B\B"*H2]-1(JFI@?"FB]_@_%I[<1(34IIL6Q!XE S@M$SW$)DVB@3@[;+L
MNX)\.ND4Z)UT2RR[(6+3'_T<TPX#1_HRRD2!;!Q6%[D)L#[2;("Z=BKL6W[.
MBB%93M+R@Q8MG)"$E='<!5<;E-H^\*.?G"%M5! $B1>FZZ>"6-4HK>%!>ND_
M:TSS2HVBI(17FXS@FJD+JN('LD7=NOJND,,DR KCQ;B63!L&K6 )V45'%+V4
M$G$8(![%,5Z&9AMZ=$5$TS4I 46-]^LD,&SSKXPJ1.)[G!-L7LGWH+)?R@WO
M<C8'U; E7\E$1$VU)O8H2Y+&[U)4+9%_J5'^9+Y<_P!*>!_R389J+EDQ^'WK
M,\U%329\U?XG.6?YL\\_BK:Z$EHC9G^^Y7_"7_[J>K%BNS7FT)(T(2GX\V1,
M5[H>IG'%-_1%1]!3?[>J?NZ164,@I=)E"3JU3CZD@@Q'[D%4[41&AW+=23KM
MJ":52IAP6*E2;+=M2]W9=D)7!0=E_!LFG041GDJ_6<B7\$#C5,@8JBBM@JKU
M/T3N5%Z$O3[="7%=J5V^.>[.GB4J3)?3[RJA JDF_<G7I]W;38'O=I *'$ 5
M.27VMIY+E:+MC%]LC'O U!"3;9>WUZ]-93K*Z #FTQ6.Z[A:::JE5/#+RUQ+
M)JZ[A(I'62V930)]T7$9-"(/P(7:FL^WM[H$%]- ./=\%B231NQJE'RVQFYS
M;2\KR9N1+;D ;,:$W([04R^^T(JB"J*F_P =9(LGR2ZXR />L9U["P?>:IR/
MBEP3C]Y9SN3,OBJN+XQ]TP=1OV ?)MP&FD1QSW'#5Q$3N0%3?5-_!*YP -2%
ML+>:R; 9<1J%4G^0<FYA?\H971\;2Y5;16I''/Y9Q8ON1& (6!:=W:4&P]M.
MGQZ_L]992WC+<&-C@&TKE^?85POD[ _>&NNIHP\AVD&M3B*\.Y*;A%DN/8Y=
MXSERRI5E>F;$>=)<*0T2N-[*S[A(XJ]5^U-=AMQGNK1\N36MJ0<_<O+>K[W:
M]AZHA@;4W$\E&:<J]M:<$C7*>0R[RPBTK-8+43'18@1Y+;PQQ<- :C*I=4[V
MQ1%7\E=]:,BVDN]-S@RJWV_S;QT_T;+NFW0R3;B]H+"PMPK4XZG!)AD1LXS$
ML8C[ &]);<")(,&G%%LU[D< P05'<?3\>N?W8V<4CQ;')Q^JGZ8;GOV^;/&.
MI(W_ *I\;79C D T..?--:=0ED$2HT^X9*KCA"BEW;JFY]RKZ"O3\&N(N9WO
M?]YJ5[='(YL;;9V3&T'=_BI4?!K"X.;P6(T:-$DN4M@<UYUL&QD 1$\!(2]%
M[4WV^/1-=-LK'.BJ,\5J]U>R*(Z\149>Y7GY4R:G"1=64#B"EK'!Q&N[N,$<
M>14;%!V-4[?MWUOC>"WPDK7L6@@M6[A)ICHTUX_P4=O)U-09"-C:/5[A4E[7
M&W4/N.JA5]NB*>[0+]X#V^W;?[=:C?(#(SS8VF@"V?3%P!.ZPF/];GP_-1XY
MQC&3P6B"X]Q&X1[QWI"]SCL8B0052$]NY1%-<3YGF5)!%#1=0T:2YM0?N30O
M(U>_C>.^BHNUU%1/5?7ILN_3T'\.ILI7%3#S'B.Y,.^:<V_+)-D3\7ILGQ1-
M6ZW\%6Z;5P"\Y$1DI%U)?55555?PJOVJFGJKFJM0I1;3O]4)_JAH?])GFO\
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M'W*3@<)T8$I$JJ:KV\JBG55T5"5#S78?U1S(0,3'ZKW/"$/HO\BU*NWPZ?\
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M:-G[HIGO:FZ)\-80N'*_],.>*2B;^JH\>3#L07S0SD84\R-()\.4CK44B_\
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M+=C?==CDXT:EBFB@:]Q\1HHPL,UPZ*N ;4?+VR3Z.4/K >2^$9KRWR!A/$7
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M(L:@NK?%BFIC5O<TS$%D8\J1%<?:]L=BW3?4(6F%^NN*)29(3%A0C\5:UO\
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3?]3\.A-<Z$(T(1H0C0A&A"__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm2127058d1-ph_implant4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_implant4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ D@'* P$1  (1 0,1 ?_$ -0   $#!0$! 0
M      8$!0<" P@)"@$ "P$  00# 0$             ! (#!08  0<("1
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M[?[[UP^U['R(\JI;:*>&//7'^Z?R*C8VS-&]R]N?]3#TRI%4*1_%^S5;VO\
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M%2>X'>,.\9\C_*M2HX'_ '6^1Q#$\^![H$'6?G<]/F=YTP=AM:_PV>8)))W
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M]=%IE-"1DI8W+OG<.9Q>,PN4S6,Q=GCX)Y(X+8W"7DLDA$TLF0>29_F>1CU
M T!:O/1^X[]>7VW_ $8PQ]%52]MY3L;;=OK6#6!2IIQ IQZ%%MOCL3=+<9.>
M=\F8>IR9&Z8)9!Q!D!0S.H/%N-"-!MC,=D'1N+A3XL\^CS4/E5I?<ECG1,C
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MWNQ)/0*DX>52YA=J93+7T5O';.HD,1(6.C11U1.KIX@=*_NX:@KG>XHX] (
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M$O5: ,HY@$])X#D-,)COIN@I)/CUD$;QQD$NS,I8 MU'J_XJ&NFS*VJ($LP
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M=M-\@+@$P-2@'V 4XG4>)>Q.X*"MT[=SV&GBMY[>4&1#)$WQ2!"%;BM.H5(
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M%2;@[#>$]L;N*U>6&,LLUQ)-%#$I%6^_*5'4%] 3RU"RW&W.>6 ?&KU:7-]
M Q[OW@&*,]N3W^1<I(:M')\<BJZOTD=0-'7@:TU7MZAC$37,%!\7L5SV6YN;
MES@XY4]-5/&&[>[>OH<7+NS+7> Q=W>!K_(P017EW#BE$?SRV./6;\S=RQ ,
MWW0#R''5.L;X0W(!Q;7%.[^+F.U>8_GT^U!^7PFR\;O/.6.QMR76\MFV.1E3
M"9W(8:YP%]DK))&,9N<5=LTMM)1:-_7ZZL=]-]5 .[P*WRM')/0SFIHNH7]$
M9S?>/$,XMX;96_5.;X[>!>B&)(_T_LPL8X'WD)0$FI8\=7';97-Y;#3B0QH]
M"^<7]1S0/'&XID&$?\C5U'V]H""_2"62M.'$TI_\FHP3GNV#J]JXZ#2%E.EW
M^(IIN\?)/<@@#I7B1P%.'#^[6V3G519JIBEXMG^'X@%"]/20 *CAR!XGZ<=/
M=]Q6:L:JV,<Q:,47VD#VM^_E0:, P0Y<$V93'(EY;^_H;J+ <RYY4#>E*:;/
M\3S+ 4Q75DT3OP'0%-/0GEQJ/IHUM=(*PC!!][81NZ/$:59BRN*\C5N/VZ57
M!)TXBB:3@FR"W2!00P84K3VU]?W:'K3/)$EI)KUJ(M\6XL["2TM)$M;J0,8V
MD4M$O1+&)NL CJ7XBQ_;H&ZNS&3&,@I_:-O;/24_,:^C!>=L;9;B7XC=K<&2
MIA]U4*M4=/2:%> -#74>R^=4I.\V;;8-<.)4Y6^ I!<JO1&%#H01T@,5/W#S
M85TXZ_-#7H4&S-.5G@DCMTB^)0%%>L'BQK7@/I70_P!>43BEBXN*:WH8U,H>
MG,@%?W?Q4TZ':QJXD)!F(.D<$A.+CM$'X0I*2I93QZQ6@!Y\1K1C?(X:#2B6
MQW>-)Z%K"\\_U,>V_AK/A>TFT,1D>]_F!W#6TM>TGCOL^.6ZS.9OLD]S#C\I
MN._MDN+3;V%AEA0LT[1RR5(5.D%]3>WVLC91*_\ A-./F^V6*K]_>R:70-^8
M_<L"=F?HO;Y\XKV;R,_5NWQE-S]W\Q=X2[V+V<[?9F.TV'V(V;:;FPV?NMI0
M265N]MGLGN##V!L;]B7"Q,])&E",LM+NL=L*1@T^WV]ZBX[*6Y/QE='>/P6/
MPUA8XK$6MO866-M8,?9V%LO3!:X^TAAM;.V@'2H6*WMX%1. H!RXZK]S=%[B
MX<23[5,BVHT-/S4"?+:.(?+#%\M)8622,CY$8EJUX]-#0?U:BI'E[=1Z4[''
MH.E#5_@1\$CM#\:>YP27;VJ:L"JU(X'GZ:BI)1&2XJ5:0& C.H6A7]67]6_$
M_IGR["PVV>V^WN[&[^Y$.=G3;TV^1AKS;"X=;(6^6S&*M,9D,A-B\D]PZQ3(
M4Z7A*]+UX2^R<O2;H\R!VD8<$'NNYNMXP!]L%LF\*]T=V.]/C/VJ[M^0FR<#
MV_[F[ZP$NZLELS;UQ+?VFV\7ELE?R[7LGN[F4W,V0;;@M9+L,@"7+N@X+75;
MW4,9<Z8SJ:''&E*]>9IY_<C+6X+C4C'H^U%*&[]HVUQ%.;)Q&7:KHZ^K-5B*
M\16N@GFLPKT!3D<U&>51U+M%86_)S0(\<T09I&;@D9/37A]NI.UR\B;G,L@
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M?3&X_$ Z2>'/0&TV;8KCZ>? .)]_L5%W+=;;;0XW/\'B/MUJ.]R1[V[49>+
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ML%4$L&% O$@FO4*?4FG/2[>+\P:YK>@HRXO6P1@'/! ^[^W6.S6.$V!,-_\
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M\9_"Y=MX',=W_(G"9NXE[I]PH,K+<-E>WNQ+6V@A.%N+86A@N:R1_A7 E,C
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M&_\ <O;CM)N.>QQ+M'VUVAN/;+9&'=MQE+ET1'<\+E8Q'TQ_)._1=CMK/EN
M3[X0Z1]: 5KCD2,/3FJ]?W=S?/I;&D=>-/73%;XOTS_$W='B3X>]INTO<?=F
M3WUW5CL;G=?=/=F<SN0SU[E=[[HR%SF;VT.2RLTU_/9X"WN8L?;AR#'!:JI%
M>.@=UW.*^F_V-&QGJ'0G;,S04#B5F3O'MY9YRTNG,-N\]U#+'5DZV#/&RJ5X
MFA!Y4U7KFP81WE*RG,U4[:[C,'AA=^["P'[@=ARM]>?^7CH-7AE,,JJ4!] L
M3A/I3AJ&%O+&_4<.A66&_B(HXU/:L,.X&QYMMEI(<=+*.H)_X96JO62 6!"'
MAK<\@<W]YBY2;"U[:QY\%"DJQ6MW#;W,K13S/TQ02L\3]3<:*&:I;[!H+4RJ
M2YCW_,B:#;+7$:RK.5GCE$A;J8CHK4!03QY:A[B1S7.+<JGUH69M!0I_2RNH
M'4PCY%_CHI]?KPY_MTBTNYB>[)&DGH"BI*:E3=7$$RRPSL0B _-0CA0 JH]
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M!N3)5S_9PTQ<RB2/37BEL!K2B?(_DA0LT;.LB^_W*0 P'MH> H?30&>/%.5
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M /U%>.O.=O?@P1&N0/K*J;MN+;1I''5_B*G3:6YUNH%BE*JWR)T!I O42Q)
M)('$#_HUU+EK?&BW$-<U5KZPS<. 4'8?S[[-YCS#S'A3M[#;_P!T=S=M;5L]
MU[XW#@]N?G^W6Q8,ICKW)8G&;HW*MY3&Y?)1V8CBA:*K22HE:UUU.W@+K=MS
MP(7/;IW>SF'"H*RX&Z<+>6=S-8YC%WF.@D:)KZTO[&[M;>5'4K'-<P7$D,+,
MK@T<K]X <3349NC[CNR #12%O';U%<#3%1UD,W8Y%)A99*PO%@N7BN7M[J*<
MVTXD5NB=8I2L%S&DP)5J.!_"=<SW.=_>=T[^)3^Q6W;8[5HUX9K&C>_EAV@[
M6]UNT':+<&0R&1WEWJR.[<;LFTV_:0YR),EM#!'<&;L\E+:W9?'WOY 5ACD4
M22M04!(T1!LVZW%IWK&DQ-(/VZ<T'N-W:OE[JHU>Y2YV;\@]C=X>V.![IXZ#
M/[+V[N*2[M[*S[EXL[$ST<]C=26D@O<5GI[6:U$S(S)Q+-&58"AJ'-&XU[D@
M_#[%']Y;UI44/M5%_P"47:?#^1NU?%G*7U]#W-W=VVS'=7!NMM"-M2[5PF5A
MQ5S/<Y7\PA-[^<EC,2+$XDZU;KH:ZF8=NO);8W(!TCVH&:>VBG[BHKT(SV=V
M4[/]O.XO<WNOM;;>"P/<+O -OWO<S<=O<B#*[KBVGCSB\#=Y7KNY(HX\19E8
MED5$0 D$DC37>[M<0BR8'?3M)IYZ^LE+D9!4C#@ON[W?OM]V=[9[D[NY&//;
MXV[MLV"7./[8XI=];ED-[D;7&QQX_#8>>6XN@LMXDDJ@CIBJQY4TAEI*PZ),
M'\*X>M,DL9\N:EFRW=MF=L39KF,=:Y/+V5ED;?#7EY:6>8$&0MX[V-),3<7$
M=\MRL$REXUC)4U'IIF3ZQGR ]SQH.''T)M\A>QS>D414TRNE"&]K>\?ALWM
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M]TL1>?S+MUM?<4F7W/<[FQ^Q;=(\O?XV3XW=FJ"!J9-QML;&B_=$XEXQ);0
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MC818?C.=>E6>R=UC;.SCS=W=? F-PV0G-Q"!,Z75S$+2W< <%*RS#CZ:XUS
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MC!Z@P)GJ#_Q$-&].'#GZ:$C<]DG>$UZD5'L5LSB#Y/O2.\_4:[L0PM*N.V]
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MA;J2A%'X:/9:RV&TLN;5Y?<,KJ%.%>(Z.!\B-8^2.0G06L.2%=P[&P.(R]O
MF1F$88P9"\NO?%#(+R:.-[54"L;>.#H]K<2=.VN[W-S:N&BD@%:*,GO+J29S
M/B IGCTJ?;G$9+ [:R4NW-M7.X+';R1-N#.6MKU165C<NS6>0D*RM-!;2HX
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M4*.*U''[H'[=&2V]6Z1FFXG-UEQRK[4*36?2K_@D]1)/4@(K]E>--0US;.U
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M5Q*9.\B/P 8^?[TFS_;?-;:/^;=BW)O8+=XYLG@U8_G(/C8LSQP+'TS6@4@
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M7'CQUVT<?P]!)X-U(>(]U>?I33@;;S'NV?,?8M W,7QR'X F#,8.UE8J)8Y
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MTG^4]]XVUQ3]A_N23S!M@-.^B_&WWJ*C8W%B6Z<!NR0 M5O\J[ED,A-:U/\
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MTWWI9-9Y(K2/;>["6]I)VEN4T6O(?^5 C@=,S<K[P\ "WGP/ZCO<M?S!MO\
MK15_:;[U<&,R(CC5-O[I5J5>NT]R5YG@O_E7#GI3.4]UT'5;2Y?J.]R7_,5@
M!A/'^,>]7(\=E58UP&ZNGIJ*[6W'0?L_\KKIO^5-V_\ MYOP.]R(AYBVXBCI
MXJ];V^],MY'GS>0P1;<W=T=50Z;2W,J<?_O&_E2@\-8_E/>-%?IIJ]3'>Y/G
MF':ZT[^'\;?>E-U'N#J$*;=W6R( .H;0W.17F17^4TJ-"LY4WH5+K:X/_ [W
M+1YBVO\ UX:_MM]Z;+W#YFY@=#MW=G4"K=0VEN8%A3BO_P"%5(!UN3E3>RPA
MMM<5_8?[DIG,>U:JF>&G[;?>K%OA<TD31OMO=Q]K* =I;E(]/_RD\QI,/*>^
M?IV]Q^!WN2)N8MLI\,\/D>WWI#-BLP4]^U-X$H>DJNS]S=1]!0C$\J:(_E/?
M#@+>X_"[W)C^8MM_UXOQM]Z:[C$Y]U(CVMO'J"T7_P!S]T CB?7^4^M=:/*&
M^$XVUQ3]EWN3C.8]LIC/#6OZ[?>D@P6>=!+)M;>(GI0J-G;H  _=B.)TY%RC
MO+'U-M/2GZCO<E_S'M=:=_#^)OO7W^7\Y)& -K[Q%/7_ "?ND']Y_E IHK^5
MMWXVTWX'>Y9_,>UY]_#^-OO3;<;8SK%UCVEO0FM1_P"Y^YVX#[/Y0>5=$?RS
MN^9MYOP.]RS^8MK_ ->'\3?>FR3:6YQ&739V]WYH>G96ZC]0/NX?3K>6]T H
M8)J_L.]RU_,.V?Z\/XF^],EQM/=\:K\>R-^,2>D@;(W80%X\>.&KK3^6MU.5
MO,3^P[W+3^8MM PGBK^VWWI$=G;P;W/L;?['@>.R=U<:<0!_Y1Z:2.6]W'_8
MGI^R[W)D\P[><YXOQM]ZL7&R=V%#38F_BU X(V3NNM>16O\ *":<-/#ES=A\
ML$WX7>Y(&^[4,I8:?M-]Z2?Y.WD2H_R!OSI4&@.Q=V$]8'M-3AB*@Z:?RWO)
M<3W$_P"%_N6_Y@VVE._BI^TWWI.=H[ZBD7XMA;\57)0G_(V[.'*G$8;C72?Y
M:W@YV\_X'>Y-2;_M=/XT/XF^]??Y8W_;'K&Q>X!!%#T;"W8Q/,4X8:M!IV+E
MW>VO!$-P,?U7^Y,.WK:7#29(/.WWISQ9[LX9UN,1MGNMBKE&'QRV6S=[VS*:
MU'N@Q4; ]7'AJ1&S;ZW)ESYGH<[ELYS?;GRL4];,\I_-38ZQ6N!S_?-(8>$<
M-YM'>&2M49& 2B93#9 ?$%IP !IP^S1+MIWO0!W=Q6@K@];>_9"W4)+8$XYL
MXK)+"?J6>=>&^%;O&;FS4:(?D&1[09PF1U44ZC9;>LIF61A][Y$;[-,,L>8H
M32.WF>#^LUQIYPHV0;%(:R3Q-(Z'-]A4Z[:_5W\EK41IN;Q[OLHR/5I\?L?N
M/B)70J>L*?REY"K,.55(U(,@Y@#:FUD:>EK""/,*IB2'EPQD/G81^T.GM4X8
M+]8S<52NY?&;NPBCIZGP^!W'<_AKTDA([[;*-\J@GDU&X Z)9:;L_P#BP3GM
M:X^M,"#EH#X9XQ_Q#WJ4K']6[MCDZ)D^SWD3B)7'6:]IL[<QBO-#-;&O ?1.
M)^FH"^Y:W:<$"&6G[+O<F>[VT'X9HA_QCWIZ?]3SL=<H]T=N]Z,2X6ICNNRW
M<!B&7VG\.TQ%XI%.7']VJQ-R'S+-)6"WD+>L.S\R%FO;&V=W?>QD4SU ^U+[
M'S^[,[D/_AY]\1,  SY/MAW'Q3!F-$'3>;4A6I]*,=+AY!YB:_\ W5O((Z'@
M[/S)K\ULJ8/9YPC&U\GNV]VJ3VV1R+J2"PGV[N:%P30DE)L1&Q%-%#DK<6Y1
MRBG4[W)7YG:?KL\X]Z,K/R9[9$H&RMS!*Q $LF S,:>AZ5)L#0_U:/@Y<W!N
M4$@'[#O<@YKZV/Z;/.$GWSW9V=W!3M5MO;&2N,WG9_)KP]R4./L\7EWN#987
MRO[*YW+WD@:R6.&TQF'Q=Q<SR.52.&%F) &K[R1M5Y:[]%-+$]K034EI'Z)X
MT5<WF6!]BXL<W41P(KFMX51]?2O[OKKOJHJ3Q>GW>0_[7(_>UHY+9R50Y_P^
MG/G_ !<_L_QUM8<@O1_W?X>?]/Z]:6EY_P 7W>:\OV'6)7 *Z.?[ARY?Q?V:
MT%I?>O\ #_CS/+[=;Z5G!>-Z?]H:T.*TO/\ YO,_^L.>LX^1;7J\SSY>O].>
MMA85]]/W?MYCG_3GK1S6+W_[7\/^.ME:5$GW6Y?=7GR^]Z?];Z:Q;"\_X?N?
MT^OVZSBL7OH.7(<^?[M8<EC<U0>?\/K]W_M)R_I]=;6*D<S]SDG[?O>O_5^G
MV5UG!:*J/-/N\_\ I_M_PUI;5+>OW/O?X#G]GTUGO2?>KB_='W>8^[RY_P /
MV_76THYJ[ZC^GUY:Q:XJEON^O,_X_P!FL6*GT].9Y_M'/[-8L7H].?IR_:>?
MV:2<ULKT?>_A_B_;STI85Y_P\N?IR_?]NM#-8JOXOX?\=;"T5XW)>7,?LY'^
MS6ADM\55_P!/I^[GK%B\'\/+[O[_ -VMK2]]/3EZ?X?9K%BI]!^Q>?+]^M<5
M@S7R\CRYG]FMA8>"\;D__=_PUBQ>CU_H.0Y_;]=:"45Z>1^]_0GE_3EK:2O!
M_P!'/_M'^W6+!DO?0?\ UOZ<](XK87HY#]@TI:7G_%^W^+EK:V52/O>OWC_V
M?7^W6+2]/I]WD/O<]:6U[_#_ -W_  UG%:7OI^[T_P -8L*^_A]>7[^7]^MK
M%0?O^G]!K1R6U7].?+_HY_;K%B^'^.LXK%:7D/Z+_#_9K96!??T^S[OK]O\
MCK%BJ?\ I7_#_'6E@5!]?V_N_=K%G2J_1?N_OY<AS^W6+:\',?O_ &\O[M;"
MTY?>IY<_W\SR^W6EI5#E_#S'+]OKK%G!4-]X_M_=R_OUL+?%4>O\/_>_?_\
11^NL6N*O?U_<_I^_6EI?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm2127058d1-ph_methods4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_methods4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L@.0 P$1  (1 0,1 ?_$ 00  0 !! ,! 0$
M       % 08'" ($"0,*"P$! 0 !!0$!              $& @,$!0<("1
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MKY'_ )G=[=Y]V'9(-WJ^JHN_=/$SN9CF8PT2\.+"1&!)ASE>6/Z5OJ52H_\
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MYD\ALNAHBXW?HVCS+;9QAXM&C=G+\YS84DJ;W3F^L33%T ;HV^D/'!4'JO\
M4O\ ()YTY-[74J4C?+[;8A!4%*)^*': 4$$G8 C;QUM-W/W(JFNG2<NH@V3Z
M7Z)MOBY=*Y#^+7%JD>V1/SK-B^?Z'^8F&'AQ?@C"VT1^JO51ZGF]N[FWE-'4
M#964W0VWZ?*[G]D ^.YV&N!*W=X;SII;ZG27_1-AX%R7\1..E,SO79OF;F:(
MU$R,-9BOG^E9ZF=]U<Y<H))V&R\NMD_9)44_),H=%)3N".AVWWUVC]RMQ'2,
M=-049$;S*9'\2X3N,?%&3_J>=YM*G..%K143(<]A%NCP(?5=ZEP03SGR=\OY
M+?;E]KLLD;_)[)1W&QWW\#XCH03&;C;F3) +<OHL6(1_1-V[%L.XK<5LNJ/5
MYV\&<OFS&%S0:B8;!",.UHC#\$"OM']4?JADM2'V.:N5GHT-"%SGV\INUM0F
MW'6H[;TQ:9!3$:<D/H0E3G:E2U@ DG;6JLW-W&D,:TY?1"839^B8(G5=>N5(
MXI<7:UCY]-GF;]W*:7.A4338-?:L!-G.5\E^JSU,)ZGG+D\#I_\ EA<;_P#B
M_$]VI3[F;F$P.6T1/^$SJ7&D\8^*DVU^>9LUO_D3/G+B/5=ZE1U_XY\G[;>'
MYWW'MW_^^=M29N3N?B.'+:("/T3.I69Q>XH,F$#/\UPC_P#LS?G+D/5?ZEC_
M -^?)_\ O?;_ -(UM_8G='W;1_5-ZE!Q>XI&T9_FO\3-^<J_I7^I;_GGR=_O
M=;_TC3[$[H^[:/ZIO4J.+O%$?[_FO\3-^<GZ5WJ5_P">?)W^]UO_ $C3[$[H
M^[:/ZIO4AXN\4??^:_Q$WYR?I7>I7_GGR?\ [W6_](T^Q.Z/NVC^J;U)][O%
M+3G^:_Q$WYRI^E=ZE?\ GGR?_OA<?M?$[:?8K='W;1_5,ZE/O<XH^_\ -?XF
M;\Y5_2N]2O\ SSY._P![K?\ I&GV)W1]VT?U3>I4<7>*&G/\U_B)OSD_2O\
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MJ3[W>*/O_-?XF;\Y4_2N]2WMYSY//_Z7W _:DZ?8K='W;1_5,ZE#Q=XH^_\
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M1V(?5;ZF =CSKR:>F^XS"W(V/AU3((UM_8G<\?[;1_5-6O[VN+%WVAS4D?\
M]B9UKD?5=ZE0-E<Y\G_4R^X!_G(UI^Q.Z)M&6T?U3.I;GWO<4FMPNS_-2[_R
M9OSD'JO]2OLYSY/^KE]P3_.M3[$[HZ<MH_JF=2U-XO\ %$C_ %_-?XF;\Y!Z
MK_4J#TYRY.^KE]P?_2=/L3NC[MH_JF=2@XN\4 ?]?S7^)F_.0^K#U*^'_'+D
M[ZF7V_\ 2=4;D;H^[:/ZIG4J>,'% 6'/\V_B9OSE0>J[U*GPYSY/^KE]N?\
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MNRXWQ2_LQ)F09#4DV<1U2'BB+!C]UD'$%,F3W!+JNT!(VUG'#RHKZLU'KSR
M)SQ"VRVT7FSHN7E/&G*<DR^10S<H;VIE'*>Z!%I<V^P-MVVQC<%KUX@;]3OM
M]3;<'Q.VLY8(1 UKQ":($"^(0#;6M:  +E0C;J/'56DB%HO5/'Q!TYE+_2!B
MBNHT"K[18J GPU=JT D=E<]@=:5ND WJ@^AX:*"RP7*NBU+T<_5=?_K+R_\
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MRR1:Q,)Y%5-1C\3$W :QA;;^-4R66:VCDQI##L*1#KV&&TH#C2P%-=VVY&M
MWLX79DXT[ZVCD3!,FGLO:>VPG&Z\WDD@B^)T)(W+_F%H9W>T\FOF_P#Q5-3]
MN1\.5W6(>B! -80"8@P%@,%:MEZ=O51;W[^56?&?(#^1R9K=D[;IKRS-^-96
MA3$AIY@H++K 91V% 3VE(VVV&N?*W^X<,HF9>,TIYE,UEA+VQ(=%UT=&*'@7
M3UG#?C0^IJ\Z;E%6[>&=-E.:[NGAL&,EM.BST2+[2(Z;+ZNL$];M]46%)9X=
MR/)@7,5,*\2FCK(LBW@H24B/938L=J?8([MB4N. *[1\KQUT\G>3A9ZR)@KZ
M8!I_+;9S6P&I97G>5\?*BAFY=1936.DSY4L/+I;@20YV*)@"ZS#>;2"H!GA_
MUC1LDFY<S@/()R"Q@HJ9]@_4M.+GU28T>*F!-9=;>B28R&8S:0E3>P#:3]D-
M]=K/WLX5OD"EEYA3=Q&[$SGLMUKHOL?QRI]X)^<TF55KGS:8,#G,F1B"V^+3
M8 (:?!>/G;\.>LB]^=7+?!N1I:[NF@8]:A<%);FTE=9L6\&O6A+#2$1(%E#9
M=9;0$=H0$D[ :VLOWMX944]LQM=1G XEIQML)!;$6Z6DCPK54[H<<,Q=F'KV
M5UY%5EU/);"6_P!*6^2]X=98 YCB#$@]$(RYX ]5]_4T-);\8Y]85N-1#!I6
M)-8RMR'#[64-QS(;:9>=;:2Q\D*6H)[U;;:YN7;_ '#O+ILR;)S&D:Z8XDP>
MVTV[=JZVNX<<8LXHY-'F>55[Y<AH:P=V\P #=.'9=HT*W!Z4O4:!M_P?S7V;
M[U2MSM[>BR.NN;]YVXD;<RI?EMZUT#N"W%(FS)JT@6?JW=2K^BGZC-MO^#V:
M^_\ JM?VVK]YVXA_W*E^6WK4^Y7BC&/L:M^K=U)^BEZC/^3V:_V6O[;3[S=Q
M!_N5+\MO6K]RW%'W+6_5NZD_12]1G_)_-?[*7]MJ?>=N)[RI?EMZU1P5XH>Y
MJWZMW4N(]*/J,'_<_FI_^5:A^VO6K[SMQ3?F5+\MO6M X)\4&F/L:M^K=U)^
MBCZC-]_^#V;?V6?NNGWG;B7>TJ;Y;>M3[E.*)='V-6_5OZER_12]1G_)_-?[
M+5]OJ?>;N+[RI?EMZUK^Y;BC[FK?JW=2I^BEZC=__8_FNWY*5]MJ_>;N)[RI
M8_VV]:T_<KQ2C_HU;#_#=U*OZ*7J,_Y/YJ/_ )5+^VUI^\[<4?[E2_+;UK6.
M"O%#W-6_5NZEOA^KLX.Y=X[]0$F^S?C_ "/&:5?'^1P465K#^'BJF/V%"IIA
M*^]1[UI85MN!X:\XXE;Y[LY_D)HLHJY4^I$UAPM<"8 VFPFY?0_\N7#G?3=3
M?4YCO!03Z:C=2S1B>UP )P@ Q O7K?FW.7&G'>;<>\>9?DS%/EO*=C,JL&JW
MF)*U7<Z"EA4AEMYIIQA@I,IM(\U: I2P =R!KP&"^Z;E3E'G/C/AMK$W>1,G
MC8]^?&2P<0Q9EQB3*EW-_8*0B-!BQ8C3SV_<L!:R.Q'<.Y0T@8PTI&"RX'$[
M;E21];W^SQWT16WF&6U.%8KDF87+RFZ?%:&WR.U<:3YKJ*VE@/V,Q3+0(+KH
MC1U%*>G<>FJBKB&3P<OQ?'<L@?$-5V44=1D%<U-9^%F-P;FOC6$1$N,5K+$D
M,R4]Z"HE*CL3J)MT05Q^:WU^6GIX]?=X_3V]NB+YQI<68RB1$DL2H[H[FGX[
MK;S+B=R.YMUM2D+3N/$$Z)!:T<I>KKA3B/(Y>*93?7LJ[JH<2SR"-B>%97FC
M>*ULXN"++RR7C%79Q,<9D);*T&6MI1;'<$E/72XVI&Q9(Q/EW%<SS;+L(HWI
M\BRPN@P+(KB2[ <CUQ@\C0;>QQY$20LI6]*,*F6X^VI*5,AQ&_V6VBA-BRIY
MB#M\H=1N-%1:GF(\>X?^'1$\Q'^</;[?<-SHBHZI(:6HGY(0HG;J>T D[;=3
MTU"[",6@6J&$(&Z"\SO7W-GQ9O&9A/O,EQG)^[RGG&DK2'J3M*PE0!*1OM[M
M]?!?\YV9565LRL4M;.I>_$P' 3; LML.U=3G$V<U\@4[&OO-NNQ>>/SS< D?
M.]SN">B)LCL'AOV_OWV._AT\-?#'VGW@D_HFYK-+6V ESHF%@CVKX+J)M74E
M[N\=-8^)B ! '2!L!NV*OSS<_C>Z_#I'W;4^UF\/O29\IWSEM^M3OI)W0.M4
M^>;G\;W7X;(^[:OVLWB]Z3/E.^<GK4WZ2?T#K3YYN?QO=?ALC[MJ?:O>'WI,
M^4[YR>M3?I)_0.M/GFY/_:]U^&R!_P">U?M9O#[TF?*=UIZU-^DG] 3YYN?Q
MO=#_ ./9'W8:GVKWA]Z3/E.^<GK4[Z2=T#K3YYN-_P"M[LGW_&R/NQU?M9O%
M"'M29\IWSD]:G?23N@=:?/%S^.+K\.D?=M/M7O#[TF?*=UIZU-^DG] 3YXNO
MQQ=?ATC[MI]K-X?>DSY3NM/6IOTD_H"?/-S^-[G\-D?=M3[5[P^])GRG=:>M
M3?I)_0.M<A<6^W]<70._MG2/NIUI^UF\0/\ JDV'.[YRWF54[#9,G]#>M45<
MVX_[8N?PZ0?V=W!K4-[-XKO:DV'.[YRCZN? ?I)_0WK7'YYN>A^=[KV=?C9(
M\.OCYVK]K=X&]IV:3(#XSOG+0*J<3 3)T>8=:MS+>0FL'QC(<RRK+Y]%C>+T
M]C>W=I,LGFX\&MK(CTR9(<W=*E>6PPHA('<L]$_*(W['=ROWQWRSAF39=F,Y
MTZ8X!K07DDDP%@=I) C%;QFU0;''./@'6M;,B]6^347"V&\N(P'/)MIR+E='
MB^#<;2<MI:;(KI636,IJCGRK*RE)IJ=4FFA.3WHTA0>BLI*5D+!UZYD6X>;9
MCOI-W4?GTTLII#IDZ8ULTM;@ #X-Q1=!YP1 @3 BR"GKD^(:7U )LN&A0^2>
MK[DG$L<Q]_(N(\OI<^R*/F=]$X\G\J80RAC!L @T<K(\PDYJFQ7C:6@N^9:C
MP4K7*==6">UL+<3VLCAWF=5FM329;O',=ELA[&&;W4Z(FS(ELON\6*X$EUC0
M-)-A>N3P8%U1T!9IXWY\'*<]7YI.9<_0QL6QR^MKRQFJ@"IM\IKXUU68>Y +
MKK[]_%H)3<N>.Y+<-+["-W5.DM^?;Y97O9NA)$ZJSE_>NGNEM8"\Q:PEKID<
M7HEX+6:70<; +:*R<3#'4<Y#>M9G%Q;A/2XNO#Q^/D^/TO,&O//M9O&?]TFG
MPN^<AJJBW])/Z&]:X_/%Q^-[KI_]^R/9T]CVM?VLWBN]J3/E.^<N/ZU.TS)_
M0WK5?GBY_&]U^'2/NVM/VLWA]Z3/E.ZT]:F_23^@*OSS=?C>Y_#9'W?5^UF\
M/O29\IWSD]:F_23N@=:?/-S^-[G\-D?=]3[6;P^])GRG=:>M3?RY_0.M4^>;
MK\<77X;(^[:OVLWA]Z3/E.ZT]:G?23^@=:&YN3_VO=?ALC[L-/M9O$/]TF?*
M=\Y/6IOTD[H'6GSS<[;?.]U^'/\ W;4^UF\/O29\IWSD];G?23^@*GSQ<_CB
M[_#I/W;5^UF\7O29\IW6KZU-^DG] 5?GFY_&]U^&R/N^GVLWB]Z3/E.ZU/6I
MOY<_H'6GSS=?C>Z_#9'W;3[5[P^])GRG=:>M3?I)_0.M/GFY_&]U^&R!_P"?
MU/M7O#[TF?*=UJ^M3?I)_0.M/GFY_&]U[_OV1]VU?M7O#[TF?*=UJ>M3?I)_
M0.M;->D6SLY/-=*T_8V4AM57<_O<F0ZZUN(NX5V..*05)]G3<>SKKZ+_ )8=
MXL\JN)9D3ZU\^6:"9V27'_UJ>VTGF\*[+*YKYU7A>Z8X!I/: @O:=(':GZ '
M[6OU.&@GTH+(%RUK10=[N*BV4D;%,&6H$'8C:.[\H>W??;73YNZ&7U1>2U@I
MW6B\6+4<3!^C$7E?G<?N+I,B0%6MJE(><"/)FR3NDJ4?EJ+NY/RNGNU^)>;[
MU9\W.*N7*S2>)3:F: '.= =LV-@;EB4^=72WQJ Z4Y]O8 @=<=J^?SU<_C>[
M_#9'W777_:O>'WI,^4[YRV/6IWTD[H'6GSS=?C>Z_#9'W;3[6;PW>U)GRG=:
M>M3?I)_0.M5^>;G\;W7X<_\ =M3[6;P^])GRG?.3UJ;])/Z!UJGSU<_C>Z_#
M9'W;5^UF\7O29\IWSD]:F_23^@=:?/-S^-[O\-D_=AI]K-XO>DSY3OG*^M3O
MI)W0.M/GFZ_&]U^&O_=M3[6;P^])GRG=:GK4WZ2?T#K3YYN?QO=[_P"VO[?Q
MNK]K-X?>DSY3OG)ZU.^DG]#>M/GFZ_&]U^&O_=M3[6;P^])GRG?.3UJ;])/Z
M GSS<_C>Z_#7_NVGVKWA]Z3/E.^<GK4[Z2?T#K3YXNOQQ=?ATC[OJ_:S>'WI
M,^4[K3UJ;])/Z!UI\\7/XWNOPZ1]VT^UF\/O29\IW6GK4WZ2?T!4^>+G\;W7
MX=(^[Z?:S>&[VI,^4[YR>MS?I)_0$-S;C8_.]R1O_+I Z'W_ +ZH[ G?PTF;
MW;Q%S)3,SFXC#X3NM<EM7.P^G/Z M='/5-">]0-=Z>Z^/R')NY..9?D%EF+\
M>75X;6+Q")B,J=31;"P=2N]L?(S6N<=5%"H\?S@@K4YW >G_ &1WUF[A'?<Y
MR1+[]DMLL/)>X/+AB,'DM@6NL< 3>!"U05LYP)#Y]AA<-5X$5@ZY_6&5^*QZ
MK.\OP[DZB]/^36%U48=S:N[IY<')YM177EFS(8PR'.<RN#17\2C=%;-D-H3)
M46U.)9;="T>@47"'>VJDLHV9\79[@#GTX$P%L2T0QEV N:7C&T'LVVF!"GK5
M2\=E]1$VZ%>N(>L>]OW+6AN\-R_'N0&;K":C'L+C9W0Y,YD0SVKG7E3,-Q1O
MNP:I%/354F7<-.AU=?&94X"[W,H<Z;/.'F\^2L%1+SV9,HA)FS'S"V8S!W1@
M1A+HG$2UDN![3G0L@8:#/K&VN=41\'+;:MPFKN[/V5O=;[ _?\A02>W=2$GO
M3W!!.V_37A3MZMX\4#FDV.K$[K"TFJG1].=T!?7YXN3_ -KW7X;('_GM3[5[
MPBSVI,^4_K4];G?23^@*OSQ<_C>Z_#I'W;3[6;P^])GRG=:GK4WZ2?T#K075
MS^-[K\-?^[:'>S>'WI,^4[K3UJ=])/Z!UI\\W/XWNOPU_P"[:GVKWA]Z3/E.
M^<GK4WZ2?T#K3YYNOQQ=?AD@_P#GM7[5[P^])GRG=:>M3?I)_0.M/GBY_'%U
M^&R/VO/T^UN\0_W29TNZT]:F_23^@=:I\\W/XWNOPV0?_/'5^UN\7O29\IW6
MIZS-/_J3N@=:K\\W/MM[K\.D#_SVM/VLWB]Z3/E.^<KZU-^DG] ZT^>;G\;W
M7U9T@_\ GM7[5[PZ<TF?*?\ .3UN;])/Z J_/%S^.+K\-?\ N^GVKWA]Z3/E
M/ZU/6INE\_H"I\\7/XWNOPZ1]WT^UF\/O29TNZU?6YOY<_H'6J_/-S[;BZ^I
M,D'_ ,_I]J]X=.:3/E.ZT]:G:)D_H'6J&YMST-M=$'Q_UV0-Q]']]\-:3O7O
M$ 2W-)D?[3OG(:F:X87/G$'1 =:]O?2\LN\&X ^MUQ]UVMDK>6\HK<4Z;2<C
M=:SNI70#J=]?KEP(GS7\*,IKITU\^JGR8N<XQ,3,<(:5EE!W8HV,EB#0U;"I
M\!]+7M8B;[UO0A8OFX=C[^GA]#<=?V=;4^8Z6S$VZ(CS7+4QL3%>6OKTER(6
M6X((<V9%6Y1VBG?A7G6>Y2945*"?+6GN(:]_@-?GS_./F>8Y/GN6G+JR9(;.
ME$N:"0+(PC Z8 Z%T>=.E][+F-#A-:# MOML/E@M"_GFY_&]S^&R/N^OB_[6
M;Q>])GRG=:Z?UJ;^7/Z!UI\\W7XXNOPV1]WT^UF\/O29\IW6GK4WZ2?T#K3Y
MYN?QO=?ALC]OSM3[5[P^])GRG=:>M3?I)_0.M/GBY_'%U^&R#_Y_3[5[P^])
MGRG=:>MS?I)_0.M5-S<_CBZ_#'Q_Y_5^UF\/O29\IW6GK4X_^I.Z!UJGSS<_
MC>Z_#9'W;3[6;PZ,TF?*=UH*J;])/Z!UI\\7/XWNOPZ1]WU/M9O#[TF?*=UJ
M^MS?RYW0.M/GFY_&]U^&2/V_/U?M7O#[TF?*=UJ>M3?I)_0.M!<W&_6WNOPZ
M0/\ SVH=Z]XM&:3/E.^<M;*J<#9,G]#>M<A<V_XWN?P^3]TU/M9O%[TF]+OG
M+<];G_23^AO6GSQ;_C>Y_M"1]TZ:'>S>/WI-Z7?.5]:G_23^AO6N/SS<[[?.
M]U^&R/V_.U?M9O#"/M29\IW6MEU7.B8S)_0.M!<W _[7N_PZ1[MO_MWNU?M9
MO#[TF?*=\Y:?6IWTD[H'6K0SSDQ/'N*6^7Y!;Y8JLIV6W'(],S:75M-D29#,
M.!75M77EZ5-GV,^0TPTA*=N]P%12D$CO=V\PWSWDSF3D^5YJX5DYT 7/+6@
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MR"B9;F9%Z7O3%5\S8PD.(#L?+JWFC'.1BRV%J2I/SIC?%KD-P((4ZS(6W_E
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M8&/C7]&']2XM#OZMSTX.M_8N4EXO<J<65$Y):]2IQ:EJ) \2==16-:V=!MT
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M5Z36H_?J;Z%L/[NL1_CUQ@LJ*F!J*IHBZ\S[TE?[._\ Q2M%#<J0OO2-_P!
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MB:(ODMU*$(60=E[;?0W3W=?J#5(A&.CS* Q (TKPL];G(B>4><ABD%UQ>/\
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MH70<3*YE));AB8]F V:>:U:I\C9BB[M<KOFEDMVUU9B(K<*2*^$^N#$2D[)
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M.6Q8CB51#91*^R@,Y/':(+$ZAM'#\*^" ^P@)'RD:RG=F>UDR9EDU[7RY[1
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MKF9='VC(A?WK5_,IXZ?5$GUK[(;*TD*05J'E@N)[?E*)[1TW U\?3:MTA\T
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M%=YJ@MSF?@,6%YA#3:O3MWI9?04YF @A@CHA8MB#*62"0KJ"4_*^GM]36/\
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M$T1-$31$T1-$31$T1-$31%')_K9[\G1OYS*U="FE2.HJA\-:7^B45MY -T-
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MWND..MH2IM"R[U2$H/BG]C761+YL3K6^_P!)6G:8<X6)"9+*&T!X>8E?:24
M+[4@D]"=]=K+FX61UKBS!![>=:&\P5(B6$Q@!2D,H\L]-POS 5 %6_\ D#H-
M9UNQ4=H#:%TV<-Q2RW6%Y-\AH37\B4DIO][V5)CK';OL4*6H[GNWV^5L=?4&
MZT__ "33S+XSWUIPZ95-^,[Q.7J[P$ZT^M)*>\R1"=*5=4$.D.=$?)\#X]=9
M_1F+''85\>[TV2X#Z6'_ !+^DG^J2Z^@+@'KO_U+<;*">T'_ *^L?!(*@ -]
MO$^&NFJ/UJ^C=R8_9R1X5Z%VO^FIOHVP_NZQ.MD+*U,:BJ:(NM,^])7^SO\
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MCSEKA,RX8CI5/PNTK<I8D*.RFH4-\QK]M [=U=^.S91Z?Y03[M]<?>:BEU]
M6X&NP@FT W!9'N?4FCGG$2,5G2O/G#4*KN6+R6V2$36$N%25;(6E4"N0""@]
MIV^ /M\![MM>0MF89 IG'LZ!H"],G@0-T5<GJM4Y9XGQO5M2'(RI6=./I<;5
MN\Q)AXQ<A,ILK2X@.(<?21T(WZ$;$ZTR<32&DFQ=UNHQC15S" 3BL,!'T0K
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M"M(#:B.Q9V4I.WAKX2S!SS/F@'_U3_>7VCEDN66RR6@_HQHV+8[":>UQR:B
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MAUREO?OSK-1L0M1[4EU*-S\K?P/7;7ILHX6P%@@OC/>^G[!@('OC_?7]+O\
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M:P;>7B70T3C(I?2@+0!XH%>A4O"3,6S)4B;*:UYF$D71&B/9N6T>%\/\6Y=
M9G2N0.0;5B9M\(B)8U%#YI<<*.]$:/3.2&V)*ANVCS2H).^_77FT_B/FL\1I
M73C:8]HPATKT"IX8T='-#)U-3^@+Y;;[S\%90;])_$+B4+6_R'V@[][F=W25
MJW_SDLA+*5_2 &N&W?O/FO$SMQ!OC=XUUK]QJ)KH-E2 -C6C_E78;])O#Z@0
M)G([2M_LVL]M%N;>SM#K:VS]77(=Q#W@=>9A_.)\I6@[CT5_=28_V1U**F>E
M.A0V\,8Y S>K=[7#'&0R*R^C(6.J Z@5D>:IOV$H?2L>.YVV/,H.)$^FG=[6
M.F/@;G'$!L@3<-"XM9N+(9*_R[);2?R0 >D +!%]@W)_&*C99! :GUC3W8C*
M\07-\F,VC]\$RRA22Y.KVNA*U!3J !KTC*.(F1YU+/KQPM#L.$@0-@MA$C3X
ME@F9;LUV7O\ \M$3(8L3201X1 Z%Z%>E>[O;S"YDJWG.V32YY-?-<*5!Z/Y0
MW\MU"4)?:2H=%;;D^/AK']X3E<RJ;-RLCN2+0+!T+N<I-4*?!5E[INMQ),.<
MVK:76/KM5&U/WHY^4+?^]INB*2T1-$4:W_6\S\G5O\YM-70M/PE):BU)HB:(
MFB)HB:(FB)HB:(O-GU=^COD;U9<G4[-GR7)X\X@PWB[-JW'F\5B8_9Y1:\G9
MZ(]7(N;*/E>.7]=!AXUC\ I@RHH:F-ORU]J@.NK9!-JTCR+]61S7EW%E58Y7
M#XPMO4LKU'8WR/:<HKN)K]M#QBNX:D\:R+:IOI-&Y*K+2#D<ANV:@QV4Q_,9
M4XG9Y>HI"-NE5]-'ZM;DG$LB@VWJ I,7E\=T\F%*NL+>S*OR>EL+*CXSR+')
M6=P\?QOC?!:1FPGW5NAYMZ2F78N-,I=?<\].YHV(;N7+D5M1Z >/^<K?B#(K
M[,^0+:B7^>TG .)\@10M2;ZZ].7&#"<<XJL[J'F4.48649*T95A8O>2"X^\"
MD;;:;5+3S\OQK<I_T\"X?#^8<O\ .&3H*P5UR,^_-6G<Z^"J_!*G$R&TCV%Q
M9^B=4'FN2%U]X47DO"G!?'V-WN5VN!4-NU15<N>Y+S%Z9ESG<TC=H*>REZW/
MFOO%*0=BK=70[ZZ[,ZYF6Y6^HF&&$7Z8\YM7.RVA?F.:2Z:7>]T-G1==LBO%
M-F2Q>Y%?9.[!JZP6EK,L3$J:V+70HK+JUJC1&8T5M#26H<4(:2=AX#7R-GM?
M4YUFS9KRZ8<1/:,?+%?5N3Y1)W?RPRVX0<(&VP>!3##+U_E%52M!*:^"[$R/
M)'E!12IQ#J%U=22H%(:0&0' =MAOK+9AI*3+6S7N<RI+;0.@7;(+%Y4L5M<^
M;.<3+)LB3 0 \&B*SY:9)7X]#93/E(CAPA++*/,7)E+7L$)8C]5+4LI)W"=M
M8O095F.>5I;E\MSKHDC7&%MJY\VJRG*&&9.FP$+ #JZ%A?-.96JAI#KZA6QW
MUF.RW*8?FW<N2M![&8-/$=9V>6/E)#BP2GJ1U&O;LDX0M9+;59Z]DFC%KG8H
M$#1<-)(',L,K^(<J8QU/E#73:L^B(1!MMTZHZ%YQ\J<XV7(UGD4;'./\BS@\
M;V,E5O\ G$U(KZ.AMH\21NJ1 IRV4RFPV4@%QQ22K97B=>NY7E_##<VF%3,9
M(GO ])TMKR?"X16.TLO?7>;/9,BGJ:FB#C:)<Y\H7:0PA8/X"Y2SGE3CODK*
MLH@TW'D''\IML9I*_CMEJL>FLT]9&D6,NTG2(DF;,EHFRFFT K*2G<D;C6&Y
MAQUS"OS25N]D].)4HOL+&-:,.* ]$ZEF^_W 6BW4ROU[-*Q]353&=Y%\U\PQ
M<(FU]MY5D\DX7=4>98K&KLQ8G/+XMK;2?(<B?/,EFSNG/-E19$I,IB.F4F.\
MR5I2D#8C??7H7'C.C4[ATTF.&9VH@&\V6V:3MM7CG"')9<K>R;,:XNEAC8$Q
MB+3=$6>!83ML(OY4IQR7E=@H+4I2@U6TK?;X]$!^#-"-OJG7P*^KE26@3&M<
M=HBOJX9;43)IGXW&)A'$=:QIDF#J9C.>?EF7*0 K=MF7614=H2>X#X*EAK (
M]R@?HZVSF%._L]VP$V>B%V4G+9H&-[B0+;R8K]K'H8].&)7WI"]-]K>Y?S!8
M.R^)<*E*B+Y@SZ)6L^?0PE>1%K:N[@0H\=*0 $!&R1T&OL7=-S/LY3   88K
MY#WI<6[Q5);8 ^"W!F>G+CAG&<TH:JNL8R\WQBVQ:UL+#(;_ "&285K#=C]X
M.0V5FWYC#JDN)5V[A:=]9%&-ZQO:O$[.>"O7-;8@WRADL#/:G*6,AJ>$KR@X
ML>DSN0Y/"?$6.Y#!PK*L=^:,SP&:W)Y$Y,LC<VB6[:,DQ!$#B%(9+6BBNBX]
M/'K5S:-R%^<62^H2OF5/"[5[@4W'N0$8-.ON8JSB?B2-1_G(SBUJ[$LK%K*:
MRW9D,.//Q'74N%:G ON()M-_X.7*Q>]&&JMUXEC"L@#@O%4%.JX#H0EWYT-=
M',_S4M_(2Y\7W]P'0'PU.9:HJY-$49/^^J7\IN_W-;:(I/1$T1-$31$T1-$3
M1$T1-$31$T1-$31%')_K=[\G1OYS*T4TJ1T07(?#6E_HE56_=#=#:3[4$^'N
M(_=URJ9V&U:)C!,BTW+ .=U<:TB6<"6@.PK*!*@RVE[[.1Y4=]F0@@?*/<T\
M1[P1KL)+142WRG7.:1TB"Y5)-=*GL+=#AY5Y(UU?.J,CFTUF%,6^(S7L?L4*
MZ+<C,;OTLT$_Z1J?13(R@K;[(*]FO#,VI'T&>3*>WU1GHN-YLTZ+]2]GI72J
MZF[]Q[<-%UBC^>[0JI>,93KJ2F)G-@RL$[_)?QV<ZVH]QV)\R$L?1UQ)<YTQ
M^)P Y=2[K=\8)<YH^&3'H 67O60XN5Q+B^1P$I>F5.84]I72&DMN2(S\NKL$
MQ%0G "XU\3-6T@ '9Q6PVUE^[LXR*A\X %W=EO@=Y[%A\RFGU%<^7*>&LEN$
M8F_%'R07CYR-S3G_ "';RN1<AY5ET]VB];QBEK*ZO"'X\B"J1<U%)%JH325B
M.]85*4 %*@'E)*MSOKJ:"2:DS<L$R9W39CW 66VDVV;;%GCZ2FR>3(FS&%P=
MA))N'A$--BQCD%/R7B.65F-SL.Q?*[7*346\%S+X$G%X\ZGL5V$TS(4USX)M
M#JE,+8;)6 7"D#ITUT%3*F>M&1:UH.B]9R*VEJ*>74T\YTN8T"QI$/#$$KT7
M]/\ 9YMA=!'>P;AJAFV/=+@3;VNJ[=V>[,A39#4J(_,CO2@\F,IWROD%L.MH
M!.XUZ3D-;GE%EOK-)2R9CB0+0X^0A>;[U9?NQ53AWM=42HWM:Z6 ==[25M:B
M+ZB>4X,.CE08F)U3[C*IZ9C3%3 A-)4Z X_#BSYN07ZHZEDIC/F-%5W?OO=L
ME.NRK9>]&;N#9\L2J=T#V0[4-9*Q<3]Q,B+'4\Q\VNE'% X2#&VV !MLBLJX
M]QK3^GKE#@+(,?E2I=?EUEEO%_(>13O(,ZYO,Z@U-YA<BQ6D^0RPQ<TZHT5M
M(0U'3)[$@=QW[:CRIN6R&AV(S=L(^(;%@>\6\CMX,R=4AH;)  #1$-$!"-MI
M)7IU7J [=UJ! !4E1!(/:"I*C[2#OOMTZ'7)<=-EBQB<W'%T2-BN^(L%)W(Z
M]I\?'?H-O?KCS;3%238(+N[@^&ME;Z:(L'>II/=Z<^>!UZ\/<E>'_P"9MSMK
MJ\ZLRFH_PG+L,J)&92"/I&^5?SI</A.R8<9++8<6A<12BM*5!;3:4+2TGN!
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MB3M[.G77"S*7WV7SY>N4Y<FCGBGK)4YWHMF!?SAL/29- VXTKN*8D2QBG<J
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M?0U'?23A>Z_3Y?-!>:EY!Y;MHV0<72L/Q?$;2E17PS8Y[<R[^P:KY+")>+Y
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MZ9+G-+.[<1'7 K'<9ORUH4">[S K?P[5)6% GKUZC]G7:K8=APZPOZ__ /\
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M_=8HYPCQ>O&LCR.-E]]1*PG'S66^40GB_#OK"+\!Y<FTBNJ);=5NI&Y V"E
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M5E+9<_&ZQL>5RSGRSB^(8^]@V28S3T-,,<O3'>BT%="J$BMFM(4H&+618Z5
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M6_5D3(\CT?XI!:)6YCG(7,^..*W\/FGE7*8Y0K?;[ N( V]^O/LQEO;/+G"
M67943#9!;\)]OTSKJBN[**&X('^'707J+BE02"#U^E_[NVMYA&E1?5;G<$A"
M@KP3LH IW/3KN1L-:W.:X85MS3W;"XW!::\D9A7\A\Z*X.FRXT;#N.Z2HSOD
M>LEGR'L\5+296*X_ C.$"QIZZW2S+G=OF)4ECM4.@UWF726D "%VM=--FO=:
MV,2L)/<0<>>J/U U^12L,JI.*\733,S&[$5MNHRVZC,N1*+"O@U(^$N$4I=6
M^[(V6EC=#/=NGM'/S.M8R7V76@0TKB4E/-F/M%YY&]>A^+8GC.%0#4XEC]+C
M52TX_,<AT5<TS&7(4HNK6ZEE*5*4X/\ *63L!X =-8PRI?.BYYL\*[:JHV2Y
M++(/)AMT+\\?K/Y%YIS'F=CU!<998Y'@<,7&48)QGBLLLLQ78I:F5.4Y1';G
M%N,[*LTNKC(<<4DE#/[V?9K$*K>!DC,13-? XK@#?T?@7O6[G"89MNJ[-1*!
MPR@\DEHLLUD$ZH")7HA^KPX.S>OXOX^YFYMR*9<9]=P,ER.KHYL.'#K\>L\Q
M<29%J7XGFFSF2*B&AMGO40VEP@$>!SV76=[2ASCV2%X/7Y:RES&;22AZ+H$>
M)>EZ%+4$]-D#?L0-MTI'0!6P]FW3?V;:Z6WOL?P5R\)ER,$OTUQ5]#_ [G]O
M6MQB\D716XS$& .]*"KN GK[=]O;U^A[M:;8K4N(&^_T-6*BY ;;*/A]?KJ$
MQL57,.=NZQOLG[( [%23T4GI[QH!!%C;.>3)6'2$L1,$S/*)!99=CKIHT&/5
M/-*45-,/V-K)C0VW$+\3N=O';7+'<N:W$;1X?,MV3EDS,1W=* Z;I$0('PD!
M:2-Y3E'(_J#NOSWX[9Q&NK\$JY,"!\^Q[Y;@5,>:A-V,B"E<=F;(<:)#07]C
MU'362LWIF9;28*1Y[TW"W1XM*XTK<DNJPVLEC ?2M:?(2L8>KGTO93S]B4VC
MP+,*G#YLV)7L.1+.$])K)%E3V[-U1W3"HY#T&9!FM $C<J0@:TTV^=7627R,
MT<0'-(MB[19='2LFD[CT&35DG-Z%H'<N!,/C=G_F6*JJSO\ $GZG ^7*Y6,9
ML(3,*)8+?:DT&8R8K+;+EA1VK2E1UNR$H\SX1Q29/<2-M^FL,FU50UDT2FQQ
M$PM%L>6FY?3F[N]5-,I9$@/BUK0#$$0AS@>*,=JG,RXJMN6J['L9C1DKKGLN
MQBVOW7V'"R*JELH]JYVNE(;0ITQ-D@]>IVUQI+)@.)PAT+A[YUDBLRL2);@9
MD;K5Z*10VF,TAE 2RTA+338/@VT@(0G<>T!.V^K,AC7D;VAI#6W +#G.,NYK
ML7H$XU6-7>4N9MBK])1NR&XC-R_!M&K&1#5+=V9C_P"J1E)[G2E'<=]]:I?I
M;%MESFCLB,>;1SKN8;R909BMW%[IQNKRV172[&ZP>[;0V_3Q_.$=^KF+D@1+
M&+'4I02\VI2'4[K!*3OKL&S)88<7D6V[N\$9H$(6\@L?7&4VW TVT=C8K8Y/
MQ,MNOEP6\>GQYM]B]A:OAI<----=8?<QB9,4IX.I'EQ$JV/:@;ZTCMCLVK:J
M*FFETPP[-!ZEO-QWDE]DM&S)N\)N\,7V1G(T6ZF4DE<AHL+_ 'YCYFG3@.Y#
MB5$+5N H;>.M;I3P+1XUYY-JJ>94OP&W&=!U\RR*E)V3X_9D]?;T_P#=UMD]
MCP]2VG]J9$:EE_"_ZL5_TJOVR/\ %K,LG_90L.S;]H5Y>SZFLA;<%U&E1M1]
MZ.?E&X_O>=JHI/1$T11K?];S/R=6_P YM-70M/PE):BU)HB:(FB)HB:(FB)H
MB:(FB)HB:(L6\S9&K%>,>0+]M[R7:C#KZ<RX-PH/HKY"8_:M/RDK,@I"2/ D
M:ZS.Y@DY/4376 2W>1=MD-.:O.J:F8,3W36V; 8GP0"_-I317)-A45H4ZZY9
MWM#5OE2BX7849SXZQ5]DK;S/)^7OXG7S5E1!IJRK.A]_.0OI;,,$RHIZ6G,2
MQAQ"Z%AUP!\"VRS8KCXK'IF9!BJR&?#@RG4E3);I(:';6Y>':4D($"O+:_H.
M;>W6/T6"IKW&\@\KUE&[,GUEYE.$2(*#],[ MSR/S+;Q&F6+RV70XXIQ" (V
M$8JRE$%J$M0"H\67*><'EIV!6@';H-=E0][4YDV5)&)I/B\*U[ZU@I:>9E].
M3WTMIB+1:+#:;#;M7/UC90F)3<4<75SICS45<C,LOAH46U2KRX5&?0W/[3L\
M^W*>4WUW(2V![->VU!9E>2,DN.&<&&(U1)(M$1<0;U\P9>7YCF[YC@7,QPCS
M6'Q@A9#QBL1AW&-77A 0^NJ?F2" =U+D1W7%K4I*2%* ZGVZ\?KWSJNJ9)E=
MJ<^:S"(PC [8#I7LN7OE4K6L-D9;]!.@:@O+/E#.\TMI_(W'>$Q%-P:,'*<U
MR%YLBLK*V+B598,19A*DK>4ZVRI:6 DJ=<2"H=G4YMQ<;+EY]+D3K)TNG;B%
M\+6B\6&_1%9%P(HLLILA=75#AZV:L=VW"3$DF-P('9B;87*'_5A8;^>?J)Y;
MY2R52Y%!@&!X#<7UK+[50@Z:BWR]^"V5?)2)5@W% ;)Z@@;;#75[KY&ZIS"1
M7X :0")=%NK43'H"]._FDWAE2-W\ORNB?#O9<J+1$?!!-BUJ]2&9Y-S_ ,[9
M5G=H94S&<9S/%,?BKD*+L8Y#<MV=XN,WWGRPY7TK3&VW5.Y]^OI'(<$G=6KW
MA-DII>S%I[(U>EXE\+5],_VY2Y3*$:XACL-EQTXO1\$8K'/*-VA+3O4I_>W"
M=]U*  V3T&Y/1.^OS[S29BS";4.]!\PD'7<OLFBEX*>53L]-LL1&HQ/@6T7Z
MF?T[/<X>L"%R;:TS-IA'"#$G)ISLQEM^$K+YD>7'QB*A+X4TJ9 DJ$L#M*FB
MP%#;Y)UZSPMR"HKLX9739<:.6S$'$MOB +(QTZEYAQ2W@D462NH)4R%;,?A+
M0#=")MA#QK]K2!LA  VV"0![DCH/V!KZA@T7707S!%Q$3?%?315-$31$T1-$
M31%&3_OJE_*;O]S6VB*3T1-$31$T1-$31$T1-$31$T1-$31$T11R?ZV>_)T?
M^<RM70II4CJ(+DT55".X;:(HURGK7@\'X49X2'4/OI<8;4E]]KM\IYY)3VO.
MM=B>U2@5#M&QZ#:Q4@NNYCE$ZX7W:FN<?4L.*?5"C%U3B8ZXB5J<+94I:8BR
MT"3N&SV^'34TQ5O5MP,#Q?'[K([^EHX4"YRY^NDY)91VB)5LY4PA758E.J+A
M\J!! ;:0GM0@;D#<DGD,(("V76$ZUVYD;< A )&_M5L/;\D;D _2UR9;F-/:
MTK8>U[A!FCD%Y0^KZ-#RGU"X-B59(*+&'Q[<.97$:W")\"\M8K6/1I;B#W>7
M'<KI#@!('8L^TZ\PWUF2C4AK?3L\OX%ZWN;W\C+G3G>B(>,CK41AN#OX#B3R
MY ;5-C$J9?V7^]H#;381L=AO\@DGWD]=8^/U YED<V;W]JA,6G(S.S$6W=6I
MJ2M*4%9 3WQR.PCQ^4I30^IKC4\SOB0M-1+[@+(.=\*0\NQIRNI;6=C5M&FP
M[2IN*9XMR:RQ@.F1#E,>8E;3A9D)"@E22#UW\3KL)9]4GXUTXJ/6)[J;8MDN
M%.>WYT^LXTY8,.@Y&4R&*ZY9:<A8YFCS82T#"<EA!@7+H0E3D-9V<428ZG!N
M!F^4Y^:E[9+KQ#J6';P;LSF-=52 2+28<KN5JW1AH43VGV?L#<>._P#F^XZR
MR<6EH(TK"Y#78B'QB%/(3VI ]VN&5S6B @N6BJ:(M?\ U7;?HQ>H;?V<(<JG
M;Z6"WOUQK<E,QS U<+,?V*;_ &#Y%_*PQ_Y @;H6[VAD[#Q24H2L*^@=^NM_
M.*<5N63I!N[EX_X2OG?*<P-)O7*<(]FJ8>B8"O6[AF:^&:8)1Y[#S2$DA6RE
MH"05(<)Z#=73NWV'MU^9'$*E&7Y]42VV$$6;"T+];N'M<<RW>D3S;:?[Q7H9
MC!BSEUT=!C1F0MAQ1?5\LJ2WVEH=G<K= !V/^5[-><T-;):X,=Z07I=1*QC'
MK6^/%2TMY+<1HI[&7L9C-LOMMK?.RI#?<I+3R@M1(3XI^Q&O1\DGR)U--9 7
MM\A70U,),QIYUEBPPRKF%U*2J67'BM_S"VEMY*#LJ/VH)^0L#8CQUP:W(Z2:
M\SW +M*?-2UF"-BLJSXWKWK"*\68S<>*P^\N,A*VDM)40VWV(V)<=: Z?2UC
M=7NR9QC($ NVD9L87JT;'"T[SW&X_F,NQ75*:<W2L0PV&U =PV\R2OH$^(.N
MLEY/44YB(Q7;R\PD5%EB^5$K(X[C"7FEN5:)T")WJ7WK7"BL+4V$(VV4D24H
M!V'0:R*C%1)E Q-D?*N'7"BF,(@.\6>JJZ$-U<AQ#TEMN6ZI+3BEN-^>Y& [
MNW=22ZA*0$=WR1OUVUEN0YTZFK&NGGL@C\*P3,,C%;+>S&666:%A3U,759R!
M4+JV\4BP6KF.[$=MRW7*DQFQ7PVW')!:+V^WS8L[I5XZS+>K/<NS*C$ID/6<
M/9Y[%P,@W=JLIG>L=ZXR 8D1O"\;N=/3*FRJ7A&L&[AEJ#6CSBTM:6VXDALK
MAQT!'<JP;CM(4X!U 5UUY33;R3\FJX/)PB.F&CR17JDJ5EM52 SPTF 7AGZJ
M>!#0Y7&M8U6:^*9[##JT-K#0[76W5K[DI[ @E&Q'0[]#KZVX)[Y3,S IGOQ$
MV+XF_F=W/9+R8[R9.W"QCCBA\4P/D7]%/]1C&,3]5SZ58ZDE"F\6NDJ004[=
MN3W03T.QV( (U](N;@=SVKY^R-P?E<IXTMB>?2O5>V_TU-^5A_=MCJ!=HIC4
M"J:(NM,^])7^SO\ \4O10I"^](W^SL_Q:=4H%RDI"VBA75*_DJ&V^Z3X@CW%
M.^M#KD-J\4_U:J_S<Q/U0\1S5E-GQ5ZM^68#K!W!1"RZU&8UZD!1&S:V9G38
M ;[ZPG-_2.N/+R++,JN!%Q'D_&O2,=QW 5]@KM5TZ[CQ!]QZZZ&Q=Y&-Z)*B
M=CX;GPZ>&^W4:$ !$6.N^WL_=_Q:--B*@.Y&Y'0@]0=NA]NWLT+2X86^D5'0
M+8.]%:Y\^>F+!>?9%3;6DVXQ#-:1I<6ISG#)J(-VS6N(+<JKEN%;34F'(844
MA#A.Q)((UOR9E1(LB0ML"0T6 $:OQ++7'V"T/'6&4&$T+>U?C\!N"'7-E29D
MIL S+2>\"2]86;Q\Q]6Y!7X;@#7)FS#/$'+7+I>Z.,:;>E3EVW<+QR^30-,+
MO7*6X;HS*)1'-NY!6BO^(< )1&^)*4K5UV'T=<9C""Z0WTH*3W#OY;YGZH."
M_-G7PLPYEY;X^]/60<7<I8-=2K&/2Y?*M\/L$8]!8@AZSR"U1>A"*]RLM/@G
M?AWN\+5\2@J2->8/R:I;O&9L[]4281Y_QKZUH.(^395P[%%)PB>YH:8?V?P+
M]+=?5L4U970(S++46'&CQ8B6U-A 8C-I2AAI+82@(;2P G;PWVUZM,;W=,UH
MN@ODJ9/%=F,ZJ9"!))AM7V[5'<]^V_50W/B!L23O]#7!BMRP+DH=!L=]NAV.
M_A[_ &Z!2U-MTI/NW]GT2"?V-(VIL5".T=%=#O[O\>_OTO15[AV@D]-@-O;N
M#X_5TA:B H)'B$[[+^B#]/VC012&M86YHS3%\)I46>0V(B,.MEN/'C1Y5A83
MA&=6IY,>!"9<?=>#1/1*3L=OE#5A:NUR>H]5GN='TBM6N [%[,:O*>6Y$>;%
M'(]R7:2'8LN,286,8\%4U0VIMW]];<>=C//$*Z[+'OULU N//YEG-.SOHS3L
M6=U-_P"42=QLK<)!/<G8A0V'L(Z^S;6PR]=FUS2.ZF>@?,K,Y!JL+L<4NW^0
M8L&1BE973;6T,Q"'4P6H:1)^-:2-I#,IHIV:4U\H+(Z:Y$>A0U+J8_Y<P4'P
MP5S./:66ZS(9BOAY_'Q+*3.5C3KH_-\S5I2@EU=8=]E;J[?'?4)(*VA45;A^
MG)*RUVH&X0-D';;;8=.ONZ#QUQYEKO ME[L1B%\G(T9TM*4WW*:/<VIS910H
MI4C=!4%%*BE9&XV.K+TJ-VW+&/)W$V-<FUD:/:1(Z+6L?>?I;=;"_-KPX%=\
M5]37:J5">2=E-DJZ$[;$[ZWB;%M3VXI3AK"TWG6G)>)VF:X]"IX5O1.8R(4N
MMN[&Q;%(S5N)19(KE1HTMUZ$TV[YR ON0&702H $ZY5.5UM3(!I]JWE]'',+
M'(6$3\4?DS1/PE4%NEC7Z40[]W$)K3BZGS8OFO.26Z]#0CF2DE#W:""1L=<Z
M;:S1&Q81/I!*FF:!823TK<,+'<A(&X"SU'3Y0V\/8?#77_ /.?,N.""[F"RY
MAF_S8H;[_OJCT^B=]9CD_P"RCG6(YM^TE7GK(F^B.9=0HRI^]'/RC<?7MIQU
M4"D]$31%'-_UO,_)U;_.;7132I'15-$31$T1-$31$T1-$31$T1-$31%IEZ[L
MH_-ST_9-":ZR\ME4N+1@#LH_.-M%<?[>O=T8C*!VW^23K!^(>8&@W9FN'PW-
M;TN"S7<&F[[>.5/^C#C_ ,)'G7C+QK!;EY?4. %3-553;4J )3Y]E)2RPE).
MX);9W(/CMKQ&LEC+LH8 (=^ 3TQ\R]OE.QYH7:1$=(AYU>G,DR7.>51UWGJE
MKB0L0@EHJ*EV^93(292D)0@E*(5- >4L^(2Y[M8]1-[AYFB\KTO()'JC'5 T
M-)6ZF#<?P*ROP+CJ$E**YE=+42T);)28<&/YUPZKO )+RXBE*.WV2]_=K+-T
M*43ZUL_4(^1>.;^9V]M ,RCVYSH?*B5H#RQ:KY*]4ULXPL*CR<Z%9#W/>VW4
M4E@6>[H#\A2DJW]FZ=>@;U3L,@@781Y L)W3H@Z<U]Y<8]-OG65O4;GTBEI)
M.)8XV).47E?)CU<9MYII-=7L17Y%G92WU+ 9B0(,)QQ>P)\$CJH:\NRUQF9O
M3'5.'E"]RRS+9#Y%0^<!V9)AX8_@6EF22XD7A+EBY;CH1-RB3E,!4@-$R92W
MF/S3KTN)2D+><;2ZE+22#N>@Z'68<6IOK'$04AN?3P\;3YETG!"J$BDE551^
MR2JIY/@ES(>."S=85M!Z1O2RQQQ5*[>0.=6H>;Y8\TCLDUV/-0JUJJKY31['
M4I<C#M0C;Y 0=]=^TG),@;.%D&#S+#]]=XJG?KB%W)).7TTUS0-$&Q'B@O-7
M(HZ,8XKXYK)'E&XY)Y,Y(YNM%%8[VH#<.IP_'8SA5LKN88B.]I&Z=E]->F;T
MU9R#A/A:8=^W'\IH*\]W; SCBCK$HAH_-<0M)>3L@$IUUI*U)"VE?)W))!2-
M]MM]QOOTVWU\,3F"HF2QH)CTKZQ[SU=\Q^D"'E7[$OU.OIY1P9Z.</L[:O<@
MYCS"^[RED D,J9EM0KYF,SB\!WO2AT(BXU#B*"5 ;+<4?;KZ[X>Y2W+\BE3H
M0>]@Z(+Y+W^S9^8Y[,E1BR6XCPQMZEZO:SU8.FB)HB:(FB)HB:(HR?\ ?5+^
M4W?[FMM$4GHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBCD_UL]^3HW\YE:NA32I'
M4531$T1-$31%\G&@O?<GKK6UY:MM\L.43+C]K:SMN01L?I^W?ZFN1+<'.LU+
MC36%DL[2%Y"YZAU[UO<F29C8\N%B.$5M8"H?(C)JYTMQ0\-@J3(7OM[=>5[R
MF&>,)UG^Z5[1D8'V?E 7%O2KMY&N&XM/)C)0@*=00![.U*=U$>W?;PUTTZ<-
M"WZ(GO\ 85K1B3S]>I2T+#<A.TB-L?E=CCJEA20=AN$D;]==5(/:T@$KM:@V
M"*V8PW.')+B(\IS_ %E20 -D@+*#T/<.W;?Z>NVE3 VPKJ9LK$<0O79Y/Q:H
MS#'5.N-+CV<5/?!G15+C2X$R/W.1941T*0$/1G@'$E)^R2/8=<UTV(:]M@88
MV+11$-F/IYGH31A.Q;1>EWG!/)F.'&[[:+R#A!CU61PGWDE^V@,I$>LRZ-W(
M0'(MVT@K<*20W(2I!Z[ YODF9LK))EFQS5@>\F3>R*H&G.*1,MYK3$:>=;=C
MPUWJQU5T1-$6OWJP_P#U8/4/_P#R1Y3^O@]XG_'K4WT@5P\Q_P!/G?X97\KJ
M@:#J6$#9M22@%?O'ECIU]VNT:TS)+I?Y32.D07RRY_<S'3]+9T8\SHKTUX,M
M'138JH%3H"4)=*0.Y#B'UI4"H=?=O[]?G'QHRXT^\U3&PP']T+]8N"^8MS#A
M]0EFDGG],KT3PY1=M8A<4A/8CXU2TI*O+1VB.D%/A_Y0;?1U\U5;I\@-<WT8
MWKWUS<+B#H7H-P%'L+W,WDQTJ=KJRBGH=:)\B4^C=@)?#I'<A+CKFP3XD;^[
M7I_#V<^NK2'W-:L=SQXEAFV/F6R[GQ2)90N.F(0HJWW2Z#\O926VT**_,('B
M=MSUUF=5((K)HT$KB4<YOJQ-BGUT\67&:<;62 ZAUYWS=UI"@D+92CH[UV^4
MD;@:V.Y("XTBH_3D:(J-MXT)4A:VF@Y'3YI6E;(;0XVPE2O+7VE*MB1T'3<]
M=;9I*?00MV1F,X:%8606M30-0THAI?1(<4HM J+D=SO;<;0@#_2%22H>(UJ%
M)(.D+MY9=4,[TQB?,OG47E1;(>;K7TH+BI"2D;MOB0DI:<>05K4E'8VO8%1'
MMZ:W)<B1+=;!;<YDUKFX-9BM6.7BE*#(CVLEY57&4\:Y+3!\E/>MLI2M#H6M
M1#>Y40HG?P\=^HSKNFD.:>VLDRVI+H2)H@QUA6J4?))%A8N0IL9]4.VCN)9L
MEK\P]SB5/N=D<_)96P4$K41U2 -M835TSJ@DZ5RZJH]6LD6A>9/JUQZINX55
M)KY8=C"Z0EQ;S9"WTLOI#TA:$DEI+NQZ:]__ )?*&MG[QL:X$2P1T#\"^:?Y
MALYI:#<&=+FD8YF(D;23'RK]L?ZG)IAC]73Z=&8R.QENBN&T)*"@@)R.U'@2
M2 1UU]WS!A=AU+X[W<<U^4RWL,6F)\:]);7_ $U/^5A_=UCK2%W9T*7U%4T1
M=:9]Z2?]G?\ XI>BA2%]Z1O^@:_BTZI07+ZN[=O7['<!1]P/3V=?'4A&Q5>
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M5=$6 /5:GN],7J''L_X)<I;]=O\ \B;KW:UL@7 %<',S#+IW^&?(OY7M6@!
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MNEB7:Y)9NK\#LE2HT1._AT/NUXAO]-]=WFIZ4VRY3'"&W%%>W</Y!I=W*BL
MA-?,$--F&'E6ON/2V:O#<@/F?O\ <Y%(80.T;(B);:F2WE#VI1'C*3])6WMU
M@6\0<ZJEM?Z#18O3-T9,A^)\T$XHDVPN'XEM5P/BCM5BTW()[246.32DSU$A
M1<$)ON15L[J [6PPL]!T&P]VNODL:!#2N+O/6=Z\291&$%9-LO->I.1XL=/=
M)E\=62&@.A/DS2'%#WG=0_9UZEN(UC9TYKO2+3#I7DO$'%"1@_5XQYU^?OB*
M\<Y/]1+7#M<ZF34<<0JO-N4>XDQTNQY+CN/4,IH@I?=FO1UK4A7R4I\>NXUT
M&^!D2I;AA/K$3&^&SQ07LW#>=2TN4&H9+)J&RSVHZHZ"8+TCS?$,EY/BR,&P
MQ@N7F1,2(3,AU2A'KXJF%MR)CY0!Y3<1I14GQ 6 ?9KD<, Z1F4S,"V%1* P
MDBSM1Q6$P,8"_P "PSB#FLN=2-+P0Z87 VWAH$(#1>>=:D_K0O4CB_I>]-__
M  )XPR-%KDS\1$&UEUJU1GLGS>T:<JZ"K0VVH$P:]<E!4%DCRT)&VYVUZ;F!
MH*++IE-+!;*<2\VF.*VXWZ;K!H6";LY=.SROIG3VXFR7DLU#LEMHTV'3'05I
M%Q!164/$.,:F^DN2K>-5XHF]F/*4XY(?@P$6^1S75*.ZEO2HSA._T#[->3[F
M_P"<WFFUD^ULM[L!NL$81UKU?>I\NAW==ES/A  @<MBU8Y<S9[*\AR>_<6XM
M5W?V-ENLJ42PYVB.GHKN*O+:V2-^F^NFXL9[)K,SE91+B[$!=K)(7*X?44N3
M0OS*6,#&B!CL UK]6WZF'TG7G GI\L,]SFL-9G/-%NWD"X4N*EJUI\1JTR86
M,U\M[M2OOG)4]-4V"4I^(2#U&O7.'6[T_)*#OYX'K<W3\0>B('3$NB>9>+<1
M\]I\XS04U$3ZC* ,/^H?3,=(@&P&BW65[/A(!W_P]_[>O2Q8(#6O.86Q7+15
M-$31$T1-$31$T11L[[ZI?RD[_<]KHHI+15-$31$T1-$31$T1-$31$T1-$31$
MT11R?ZV>_)T?^<RM70II4CJ*IHB:(FB)HB:(J'V_2.I\,(;BO-SUXXH\_)X@
MRV Y%CSH^07>,RY,GS AR'8TDBSCQPL*V03/IT;;@]5?1UA>^,H.D!P$"86^
M$>6Y9ON;4%LUTD]H0C#I_&M8IE%DK+$>9/H!-CMQPXE^#(\Q#O3N4ZG=*6UJ
M2V-Q\L*WU@TAEEG:6;5#K;1A6/Y4EF0]LO&;QL!>XW8?0A6PWW42I6R3MKCD
MOC#"5RI<MCX#& 5V&(%Y:LJ9HJ5-2E7V<^22^ME.W;LAHI"03OONHZ6N; V%
M2<!(=$$.YEA_*^,\2DY%QKBV8//9 SDG+O&<.Y:DK6ZVW$F9;7,NI)86E<78
M.;I6%I4VH C?PUN4%%)GUK)4\CM. &PK=GU,R30OJ0T@-:8CP+;W,^!+/@[.
M*25E4]&3<93YLF!BEC(=DH?J)4ALIATM^T04*>1!=2RS)2Z$RW $AL.$:RW.
M<FG9?+:93@6&(C ]G:5T&1YY0YDR8TMPU0;$",8F&CJ@L[^E;DB-@6<VW 5J
M\XU7W;<W.>/)3C?EPEMS9C1OL::ENAME^Q=L93D]II *@RMS8 (&_;[O9C++
M/57N&+0L>WHRJ<U@KBPDZ;-&L\W6O2-)W2D^&Z00/H;#VZR[FN6!BZVQ<M%5
M@#U7';TQ^H4__P"$N4O_ .RKK;Z^M<OTASKK\U,,MGG_ *;O(OY:5(VHLME*
M&]^[?OZ?))0""?;T.N_G.PT^*^#8^)?+D1-8]@L+IA'-%T%M'Z?+)UC+T0FN
M\.RF%AGIOV.,)2EE!![@HD+)^D#KYS_F,REE1NQ+KP(DMNTCGZ%]/?RN9^^D
MWGF90XD0=",1 Q@;O"O7GBUQYU\($5M'DMM*;*U%HOKV/>E)5T*DG?ZFOS5S
M<"54X8Q(/4OTYH7=\S"+(!;Z\+31!M;*$\T/-DB-*;[U(6%1DK/<GH #LLCJ
M/9K+MWZAO=%HOL\ZUS9.*-HLY>9;>0Y#ZFWVBTVT=T>6[T)V7MLEK8?))WV!
M\-9A)J"'B6X&T+HI\IKW8+%-P9DUA"T++2E-,O[+?2IUQLNM*2CN2A.SIW/0
M[[;^S7.[Q@M70SF%\PRV7ZU8^3=DJ6S,[4/*^0Z\  6FEH0I/80 ?+4"? ]=
M<85K19A/2LFR^4)#<)M)5LOSG"Q,<[EJ4Q&2MQ *B"EQ0\S=H'<H;Z]?#<:W
M)%4>\+VF#=2YKY3FMQ_!)7G_ ,LY>BPE+@^0]Y++SD)*XC(96\I3H\Q:7'2I
MJ02M0.VZ=@/;[.AS:O=-FP(-G+S+>E4Q(#BX=I>8GJ#GICLV"J^U[Y#$7X61
M'=06QN\I0$A:_L.]O8@[=.T;:RG=)K9[VL(A$CSKKLTG&EDN;>2+UX=^H#ER
MU;J+2C>FDOR7TUD8-O!*F$-K3YSC:M^YQ/PZ 0/ ;Z^IN'F[LAL\3YS0Z5#4
MOE'B9O#/I*.=227'O'.OCMBNYP47V:.LIT+*'[.'Y\A2DGN"W)8W2-@3W*0>
MFW37T33/-.WNV?JM V+X0WD+6O-=,#G32\QUQC GI7].#]3U!17?J[_3K#;[
M VSCMAVI;!"1W74]1&QZ]%*W.MB? O!&D><KV'<U[YF0RWS/2+G=$5Z/6O\
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MQNN!0N$M\X0P68B2+^;2OW!0&!'CMLH"4-M@(0VA"6T-I2 E"$-H"4(2A(
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M'7FW$[+1F.Y]9+F@QE27X1K[)-GA7HG!S.SEN_M$93A&;/9BMN!<!;X%[/\
M%B&;"#)>*W"E*065MJ(.SC*RGY0'3N.OR2WCIZB7.+7M<'ASHV:5^RV5S)>
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MP2#U2W*@;A)\%G?QUJMPPVK"]]&.(8X Z/*O5O" E-8X&]@A+[B4CW */:/
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M?GJ!:9#)1N\S$-;C2E!1*?@5-R'YK8V(\Q^6A* >FX!ULT$V::J:P@X";#;
MK;WFKQ,D2J.6WX-I&@BVWH6VT:V194468\E+;K;(;FI4#LW(0D)="Q[.H)UW
M+I;VV$$16(9>Q[GN!!B?/8M1>1,3;YIRRMH9SZG^/L3?9M,A9![F+ZW;6X8%
M.M*PI2X;:5=[NX(">F^YUM3Y1D?I6N[07JF5U$G=C=X2);!.K)@#7:2! 1C"
MZVU:M^I/B#'KB'DUG16$G%KIVOLD(=K6FC&1)^&<0B4U#;;;276DD% 20%+"
M0GKKN-ULQK*G-<;\1II!!<;8-$,1CJL,5@>\%/13:&89;1W\P7"^) \:\QZ+
MTH3N+N/<CLL@RF5;<A\A/-,V%Q+?=^(IZ.4RB.F*W-E2%.M1Z"E+\I:02DO%
M:B-;6]F\OM#-,-(0^1+;Z33$1.B/@64\,=U@V6V9.EN QVQ%UM]RQ)QS44>-
M0<JR?'J2)04]T]$IL4KV64M.Q<2H&514%1 [_/N[$+E.>Q:W"K;7GM75U%?6
M2Y#6ES'.MA;RM7I^^U934+&TL@M.+:.=0G)ME86[^,8#4M/2K!]V-(F18XW>
MF91?N16XL7M3U+L9)+2!L2A;G7Q&L_K"*')V4LLCU]S1AE_"-F@7FQ>.T<J5
M4U3ZR:0*5A.)_P $<YN"_8O^KK](L#TE<!T^,SH3;O(&5B/E7(=KV-!QZ]F1
MFVT4S2D_OHKJ-AH(:221W+6=]R=>S[EY&S(<K#(?IYH#R86C$ 8>#;:O!]]\
M^=O!G3L+O\C)[+8&PP)M\/DA!>@3?@?DE/RCX^WPZCZ!.LM#<,3&,3%8=B+C
M;HL7TUJ1-$31$T1-$31$T1-$49/^^J7\IN_W-;:(I/1$T1-$31$T1-$31$T1
M-$31$T1-$31%')_K9[\G1_YS*U="FE2.H@N315-$31$T1-$31%TY[#,F'(C2
M$)<CR&EL/-K 4AQMU)0I"TG[)*@K8CVZT3)?>L,LW$%:Y<PRIC9C;'-(/C7Y
MTLUX_P T?Q3EWC2YLXPK\,EY)$B5K<9M]Q3<22^FN4Z7F@Z/^J'FBG977H?'
M7B^9213YDX&\.7O>4UO=OIZD&PAI5I91F<7)_2M=8@F+:3+IG'V'H3C%=(>\
MF?3J27"M;31\E*'XVZ5=02-CXZXM]NA=@UAE9XZ5#TA'QKZ9+E\C-?29,\RF
MOG9C]53W:WOF^1Y$67&82Y.CN.!! <8DEQ/7;HG<^.I/_4!)-)W>9S!X>E3;
M4O);[AC%\T3;5CF#T=IBF1JK8B4.3K-IE^LL)"'I/;V,L'X8I5VK4H>.VN50
MD=](_M^==?F$HL]9_P /S+]'-:\W(@0GFMO*?B1WFB#N"VXTE2"/H%)!U[3+
M_5MAJ7@L[]:X&^)7>UK6VFB)HBP#ZK0#Z8O4,"=O_G*<H?5_]2[KI]76N7Z8
M77YM_ID__"=Y%_+DHG'&FFRVRG=3:02?E;CM \"-M]M9'<UG.%\C57H3"?I#
MY5EFG!4MI:4K#S;?> A(3T24GN)W'AMKJLWH!FN5U5+H,MPMYBNVW<J?8N>T
MF9Z6S&GH(7JGP9?RA1T\X+#\<AB.XSONEM;2$)[W#U/:%:_*/BWDWL;.JFG%
MA;.=Y OV3X89Y]H-UZ*L_+IVGRCS+??$*".[-8F/2%1HMH^'8;[*U)6S//:5
M^2/ LK;W /7KKR_*V=MLS2;EZ.YDI[BV;"+;%N=0+E-LPXCLA3\>*A 2ZXI2
M_*01L4E\H[W76U_9 C;IK+35U@F-8\GN%MS9,@RB&>ERBLP.N;TY0%H=2VE$
MATMH"5.@?(V6 E.X+8UD'K'^7 "Q?U?_ #!BL<QVC;/+28X0YW.+4M*'&T".
MD!,7N4G9&Y!V(]FMFA94XEDPF>KTY(LL63L3^(CSXS,I#;;+2FGB%OK;CH<[
M)'F&7U\Q*'6F0$J'T_'7H>0-?B&..,6K <YF3I[#,;Z+C#HL6H/K@YU#^"5]
M>U-KHS]4'$1XZYR'"Y$LU.H^&E;)DR%1PXGO;<3]CN0=:=Z\Q.8LETD3^A)\
M<.I=AN5DTRCFS:Q\/TN'I$;5^6/U#VR$V-O,5\-\2M,A:DQ7?.1O*0KRBT\I
MIM;R$*)5U\#K)=PY.%H(N!"Z[B%G'=2'TWY3"%X)<\3T-\@Q/-4K=FO#:RX"
MD>=)?DO.*5U.Q >!^B=?96[(CE+>8>1?%V\_Z:L<1?%;1<&2&W*6L\Y2UK0W
MVLI4/DJ:$D$+.WM]VLDR^YW.5X=O4,-,1_U#Y5_42_4J/_$?JU?34[MV_P#J
M_=I 'ALG);5(^L-4KT#=C_1I7,5Z=VO^FIORL/[NL= N_.CG4QJ*IHBZTS[T
MD_[._P#Q2]%"J1/O./[_ (=KZ'_DD^WV:I07+QBY7JU\O?K:^.B5*FXYZ6/3
MK;9%*8[^UB#G7*EU*JZY:R.BY2*6M4H)._R%>&L0SX]NS4/*NYRWT#X?(O1A
M94H=JB5?*"C[N[L\M) ^@D[?2UC,8\RRBG@&QTP7 IV3OMU'AO[NG^+4C:M]
M53]D/J_M:&Y%]" ?'6B)"+YI.Q^MK61$(N2NH6@=#V[D_N?L:@3:N# *EH3Y
M@9_?$_+.^P"3U\-^NQUV%.N#5+3GTEMLQ,O]84%+*O,;]3V1RW%@G?\ ZQI:
MR4QNE)V"5H)UR9Y@"N ST@=,%N<75@;)*1OYA5\A'8I3H/>>W;;K[/=KJ'$A
MT%V\D""XA2/D]K83LG;M!Z$[=3MO[3UZZTK>@=*IW@^([=CM[2/V=1$4=A[-
M!:BXA(4-S[=]]"2#!$4GW;;^X^W0$HJ;JVV(V'U?V]+!:+U1>N('11(\#T^E
MJQN0B"^S10"H%7V?R5>Q7;MN>T_Y)/AO]'6X'=T6O6AEKG07C%^LPQ_)I7-O
M$61X;8N5V28CA,O(J.:EL+0Q,KLFB3&8\Q!!\^N>6T&WP>[='38Z]>W/H96\
M-/.IW@$L#(1^-CZEC%9F,W+ZMDV78V)C#9#K60>(>;^._4WCCV"9@E&,\HP(
M"H^28;=O(A6C,Z,UWO9+BP:>2;.@=\SO;D1P4I"5(6D=A.L,WQW8J,EJ3(DB
M#''1SQ\R]3R/>2DKJ4"H_)"N7'JBZB+7B]UR'E>+YS5]S52J5\&Y46K+3_=6
M/5[+C*V;)EZ&I(<;&[GV0ZG6%RW,IK*B]9)*$BJMI^7,LF0LASS&EN(SFL;N
M:LI[8V08G%DS'U/)/RE6=2YV/QF2WU"V M /0[;C3:+CRO7-[G1J61ZNRCVT
M)$Z&HK8<W[ IM]ET'?[%QJ0TRMM03["-<>9Z2VIC,+H;%)'V?X;]=;+UMK@K
MP/C]0D'Q]XUMFY4+6?U/,.&)QW,=[E5T'/ZB3/6$=Z8S;1+GQ;X2.\MM-I5O
M[#MKE4ZXE08+)]S@T>US:MRY28,R$*A4>7'?2I$N/(@.M2JNPK'VNWL<=>D+
M\W90!3T.^N<+0MV1>"K*R9@S_4]Z5($=!(9M^2[>0%$[M,0Z6C8=DG<G9H.R
MT '?J3K6?0V16-;X_JF<M)7K/A*?+K7$;[_ZROK^SU'T]9AD_P"R[8KRW/#&
M<S^QYU?&L@;Z(71*-JOO1S\H6_\ >TW5"@4EJJIHBC6_ZWF?DZM_G-KI&Q32
MI+15-$31$T1-$31$T1-$31$T1-$7G5^L)S$1N/<;P5A:1)RK*/BGV0=E&MQQ
ME$B2M1'4;RIC.WO(UYEQ0S(4>[[I>EQ7I?#++C5YE-S#X-. /"?Q+S1CU,BS
MBQ:& TMV?9S8T-IM( \MMELN3%GJ-O):=*NX]#MKQ'++<F;,_*$5[!4U&/,6
M3_I 2O2?CVE8I::KJV3W,UT5$9I739U;+;G:M?MW6M6_T];E"?TH"Q[>";->
M_#*]/E%8VS"5-.0W>)T+S)7<.1YTAY"ODU[*$[3%$ 'M4IL_) \5C;VZRBI_
M4-.PJ;ON8USA.].'6NA9JI\(H$PV2VS&CL^8OO.[TJ2H=SK[JE$J6](>W)!.
MR?I:QX2*FHL7=2Z]S/VFY:77TU61V"[1\NLT\.0N1'#G:@SI##BUM=PW^3#A
M+^7UZ*4KP(UN9CF'LG+V9;2?ZC/!#X;20/\ A@K3Y>[-:T3F0]6)$/! 'QQ6
MA/J$O$9=*.,M376&;".A$H@;N(Q],A3]M-6MO_0N7DAGX5C<A18W\-]8B'OH
ML5)._:#:>8W>1>UY6)65T7Z/TK8K6[)+JOK ;:26A442 U KCVH5*M_A/,K8
M"6T[!41AI/FR#ONED>\ZR[=RAE->*Z?#NV D]!AXX+RK>S,YN956"3^LQ6<N
M9;X_JBO25<\Z\Z/^IG.ZY!X^XYN9LVD$Q*@,EY#D1Y;3;;3!:V<AXTT_YSR@
MH-B4ED DI.LRW.R.;GN\#L\J+:"0XPCX0%@N_6?2LBR$9%369C4-!)&BXNZO
MQ+];"$A(&WN&O>1"%ER^?[=-ZYZJ)HB:(FB)HB:(FB)HB:(HV=]]4WY2=_N>
MUT44EHJFB)HB:(FB)HB:(FB)HB:(FB)HB:(HY/\ 6[WY.C?SF5HII4CH@N31
M5-$31$T1-$31%P<!4G8;'J/'J.AZ?7U185#<O*;U.8O88]S+:)JZ^M^&Y.Q)
M4QQR5*>B1U65>6J:P4\F/&D+45)7#5OTWW._3?7FN\E(952:AP$#;H7J6ZE4
M)].VG)BYM@CHU+3G (T.)1<B84IYB&S8XS+^%"UH2P)H#T6Q;CE[RW"@75/,
M&Y"0.[?VZQZ<UH:" LPG8YM:)S"0X"$8G9X5;_#%K62."\TP>3.C%-2^6D-.
MO)"W6)!1NG]\("N];CH&Q/<4DCIUUL/ -,(ZRN?-FX,P9.CV781SP "Q;P_=
M6)])>7X4*"TLE8[^<%09,=;28T>)2O37H<Y^2HI66E1Y V /RTIZ>&M^G$'2
M2+'8UMYPT','$?JGRQ9HNU7+]+/&TE4[ \(EE?>9.'8U)4K??<O5,5P]?:23
MKV*DMI6$WP'D"^?<P[.8SFBQN-WE*OO7(7%31$T18#]50_\ ]9/4+TWVX4Y0
M.WOVPJZUJ9Z877YK_IL__"=Y%_+OHT.^6P4@=J4-O'IT^5VI*0?;T.LD,0QL
M-B^2)Y$'QN[W_F65(##GE><RL%L)6I0W 4KIL6_>!K:GDM!#8B(MAI6U*GAU
M4T$Q:+O%<O0CTERG+*+,J&W XF(EMX,OJ[0D. E?4[E6Q3K\]OYIL@92YA*K
MPT,;.<YU@ CZ.J]?I_\ RI;P"OW7GT#GETR0UC1$DX?2NC=X(+TPJYTI%;CR
M HI$9X#]X 44=CGLZCP21KY%:'2:B4&..$G6OK*0W_+,<ZUYC;IT+<W$G?BF
M8[;[Q<<4>YL.*2$O*<'R4K4.B3UZ@@G68Q):(D]*WH --UQ656V)**^:XE24
MH* E0#OF)!2>TM(.P.Z3^P-<^2Z+8$V+'\,*DG0HS$V695YVR"F1">\V,$-O
M(:)=:2%.I.X)V'9O[NFNQRB:9SQ GD5R<[Q,E=FQ5Y;LZZNKU-0I/DJJH[JI
M/PBBM:0^A/D,R5DMATL-H+@Z$]2/;K):S,7Y;)P"(="\;=JZ3)*4U$\.FC%*
MB;#:+-A7@MZB.3/(L+-YJ<U,E)AR*9#*_(7#$EM2'"]&1)2.S>,K;Y(3VK)U
MTF7=_F%69KRXM)&DK+Z^:RCE , : #8+%XU<M7+3\R1-E*<<0M"6Q&4"?+?<
M3^]GN'>"D;CIOKZ W9E2Y5+  !T!<(+P[>MPKJC'>T1VKQ@]2!\^^-@\VE+P
MEN15!*0GO,<H!((ZD*'AKZ9W.<XT+03$80OE_>246YF\"[$5L#Z<[ZNLXC,+
MS2'8S;#7:!NKN4^A24H0=E!( ZGP&LLE1:\@6=KSKPO?>F?*E8C$-,R/C7]3
M3]2=VC]6AZ9D@@]N.WB20 -E#*+@$*VZ=W36]-ABL7H&[7^C28:EZ@6O^FIO
MRL/[NL=: N\*F-15-$76F?>DG_9W_P"*7HH52)UA1QT^]FAUZC_1)\1N.FJ4
M%R\=?2,9>;^HSU_<Q2&R6+'U PN*:20\#YBZ3B_%8<!26E#8>2+64YN1_EJ/
MT]8=GWI$\RRG)FM[L @1M/B7H(%;;=/I_3]NVL9@N_L%P52I)'@?K: $(N">
MA'T/W-4BQ%51W/0'P^A^[H!!%3;PV(.YVZ>_2*07)0/EN 'Y24[[_0]V@MM3
M0OC%"_.8"NH6\V-C[>Y:0?K;Z["F7 J(K03T1Y"[<\K>O0-K\R+ ]4K=>A?<
M2D%G$JAI[;?_ #'6%CIN K?6_/N7!EC](!L7H!_EGW=J>A]F^WUQKJ7^DN_
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MD-2Q1S?63+/C;(U0%@2JZ,BT3W(#G[Q"<0N9\E7CO%*AN.O7W:YM.!JT+;J
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MZTS[TE?[,_\ Q2]!>BC94]JKQ^18OK#;4"I=F.J4KMV;CQ"ZI7=[-@GQT>8
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M<5I(L4#88[ M;R)D+[3)E5T*1!0 DE:4R"E3I5T)"%* 5MT&^NQ=F$XL# &
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M=BRXLN.H+B3H$UA3;\*;%<^4AQ!!3U'4$@[-5+IZN7W<P&"Y67U-9E\WO94
MX;5K-D?HGQ5G&:RKXNFJX\R*KGV4PY7+^)RZ?=(NXT2/<Q,@183H:[!,E-?&
M*' X@MJCI[4A*E#6/U^0T\ZC$BFL>'1B;%E-'O97MJ2^L[4DM @-8TV^'25F
MS@SA&-P=@,/"*N?)OWDS9US<Y!9*:9G7E_:/^?8V3L9C=B*AU:4I;;22&T(
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M)2N#\#:QRTF8[*YGI<GSBQ;8+D*KQ[$H-E<,JFE3B$-L65NJ,VE*DN*[DD;
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M4"/H'74394R1,=)FV36&!&HB]9935$FKIV5-.0Z1,:'-(T@W'PK /JAYJO\
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M+?2HABOK($ (;:$*)&B]C*4I: CLH:[6TI 2E "=@ !J$*Q7RM?]-3_E9/\
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M"5#C25*0PZY7US$NP4'BA78$M*)V) (!VNB*A-L%<;+P>0' 1LH!2?\ ).Q
M(W23N#L?;J(OKLGQZ#Q]OL]OU- JJ[#V;>)\/I]?KZ(JZ(FB*(M/]-3_ )53
M_=]AJA0J7&HJFB+KS/O25_L[_P#%+T4*P1SGP-C7J&X]:P3*+.WJ*Y4FJLQ-
MI##3.0] _?4)2J=$F,%"RKY0*#TUWF0Y]4[O9@W,*9H=,;<"2+80%HU+$=]=
MS,LWZR";D.:%S::;") !-A!L!LM@K>]-7I:P[TR5F1U6)7F07C.23H=A+=R
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MHN<>RG+(.=7_ !!Q[?8' _..[DFS7!.8(R"5C>..OOUEF,?=4QWI;86F")
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M4J2I*@01T(U%5]M$31$T1-$31%&U/WHY^4+?^]INB*2T1-$4:W_6\S\G5O\
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MC-=<+4-BJTA4D&+8*/R4[;RVEZBJO;1$T1-$31$T11E1]Z.?E&X_O>=M];1
MI/1$T11K?];S/R=6_P YM-70M/PE):BU)HBBK2BI;MD1KJIK;B,EQ+R8]I!B
MV$=#R/L'DLRVGFTNH]BMMQ[#JQ4@NM,Q?';&1"EV%)53I58M*ZV3+@1)#]<M
M*>U+D!YUE3D-Q*>@4V4JVZ;[:BNS0L<8IQ-3U&29[D%O%J+R7E'("\WJGY%3
M%7,QY2\/Q'&#$BRWTO/M2-\9\XNM%LD.@;;C5CI4V+)"L9Q]=HF\535INDM)
M81;_  ,;YS3'2"$QTSBT908 4?D=W;]#2*07RF8KCLQ<%V515,IZLV^;'7ZR
M"^[6E*@M)@+<CJ5#*%@$>7V_*ZZE]RJ^.,XG28G%L(E)#,-BVR"_R>P!=>><
MDW63VLFZN)CCCSCCG=(L):U!.X0VC9" $)2 NYE;-"EC45ODL1TP8B&8KRY,
M1M$9D-Q92_,!DQVPCL9?/G+^6D!7RU=>IT6E="-BV/PI<JQAU%=&LYR/*FV3
M$"*U8S&N\++<J<AE,N2C< [+6KJ ?$#5L*76+&^:<04M]7T5=21:W'FZ[D+#
MLZL$PJJ(TU;KQF\CVLB)+1'3'0Z]9-,J;6\YWK(("NX;; BR378QC]3&,.KI
M:RLAK>^)7"KX$:)",KS4O?$B(RTEA+X>0%]X'?W '?<#2*0TI,Q7&[!V7(GT
M53-D3X:*Z;(EUT.2_+KT+#J(,EU]A:Y$-+H[@VLJ0%==M]2]6Y=B%0U-<AAJ
M'7PHS44I7&:8AQ&&H[B63'2Y';88;0PM,=:D I V2HCP)T31!=";A6(V19-A
MC5#-,=)1'^*J*Y\L(*EK+;"G(RE,ME;JR4I(![U;[]QW14@NPQBN-Q9;MA%H
M:B-/?4RM^='K8;,UY<=M34=;LIME+[BV6EE"25$I2=ATZ:*JK&,8]&F29\:F
MK8\Z;)3-FS&(4=F5,EH:6PB5+D-MI=E24,N+0%N%2@A:D[]JB#5/(N3>-8^U
M8OV[%/6Q[:4D(EVD>%&8L9;8(*6Y4UII$B2VE20H)6I0"@".H!T!@K!?*QQJ
MFL*I=.] :$)4"76-HC($1<.).AO0)*:]Z.&G:Y2XCRFPIA2%)2=@0!J:()M*
M4&,T^,4%+C-'#374>/55?25%>R-V8575Q6H4"&UWA:_*CQ6$(3N=]DCKOH$*
MI!Q/&ZV2[,KZ6LA2GWE29#\2!$BN2):T*:7+?4PRV7I2VW%)\Q6Z^U:AOLI0
M-41G%<=CO6,B/253#UMN+5YBNALNV@4E2%&R<;82N?W)5VGS2O=(V\"01-JL
M N$?#\7B0I%;$Q^HC5TIA<23 CUL%F$_%<+A<BO16V$L.QG"\LJ;4DI5WG<=
M=$7>8H::+$<@Q:NOBPW6VF78L>'&:CN-,-(88;<80T&EMLLMI2D$;)2D = -
M(J7J3;;2VGM3O[-]_:0-B?ID]3]$ZBJ^FB)HB:(FB)HBC9_WU2_E)W^Y[;1%
M):(FB)HB:(FB)HB:(FB)HB:(FB)HB:(HY/\ 6[WY.C?SF5IH4TKZN/\ 9]D4
M?9G;N4E/3KL1N>NM+'":2&M/9*HP,MFN C<NPV2KN)((W';M[BD$CZ/71KP^
M( ((,% (:8@KZ:U*KBH]J2KW#?V^'M\ 23MHBL21R=@,2@M\KE9CC$?&:"7,
M@7E^]?5B*BGG0)9@S8=G8F3\)"EQ)FS2VW%I<2Y\DIWZ:03:NDKF'C%&+1<X
M5GN'?F9.?^%@Y4G):9>/3I9=>9^#A7")IKY<Q+D9Q*FFW%+26U C=)V:(H;[
M%<$;-,9F2Z:#$N:Z5+R*NE7%"U%F,2DW%3"$'XBSKGHZW6)E>CYSC_OS:E(_
M?4]=SMJP4!B%=6HJK&S3D;$N/DTRLJL78*LBO(F-T,>-76=O.MKJ8S)DMP8-
M?30["<ZIN)#>?=7Y8:88:6XZI"$E6B+CF/)&*8&U2N9--DQ',AN&:&FB1*NU
MN+"?:/-.2/)9KZ:#83O)8B,K?>>4V&6&$EQU2$@G12*NFMMH%Q AVE7,B65;
M81F9D&? E,S(4R)(0'&),25'6XQ)CO-D*2M"E)4"-CHJNZVZ'>[8$=JBGKMU
M]Q!!((4.H^GUZ[Z(H"XRRCH)E#7VTU$29D]O\P4+*T.J-C;BMFW!A-%"%)0M
M-96OO$K*4]C1Z[[#5AJ3G5Q)5W#?Z)'M]A^B!J(BU=@W()Z[=/J_N:(K!QOD
MW$,OO<JQW'9\BSL,*L149*XS5VK=976R5NMR*M-V_!9I9]E 6R4R6(TAYV*K
M9+H02!HBELHS;%\,@S;');J!4QJ^DN<DE&4^D/IHL=88DWMHU#1WS942I8DM
M*?4TVYY?FHW&ZT@D\BN5AY$AEI]O?L>;0ZC<;'M6D*3N/8=CHB^NB)HB:(FB
M)HB:(FB)HB:(FB)HB:(H>U_TU-^51_=UAJA0Z.?K4QJ*IHBZTS[TD_[._P#Q
M2]%"D/[TC?[.S_%I.J4%R[.HJJ*'<"-]M_;HBBJ^DJZIVS?KX,2&]<V)M[9V
M-';8<L;,PX5<9\U;8"Y,LP*Z.R7%DJ\ME"=]D@:>5! *T)O&M+/Y,Q_E%Z1-
M^?,=Q'(L-A1D.!,!=;DEI16LUU]H#N<E-/X\P&U;_)25>_1+8[%D,)V&W3KX
M]/'1%Q\L>.YWVV'TNO\ AOXZ(N02 .WV=?9[_']O1-NE<?+'L.V_CT'7KN?J
MD]?IZ(GECV;=.@Z> /B-O#8^W0V\RL>E5"-M^OC]/Z8]OL.BBH6_<=NN_AU\
M=]%5:&6X379B,9%B_)9&+Y939A!^&\M/F6-)\3\*R_WH43&6):^X)[5;[$'H
M=RFE7?V= -_#Z'3I]#W?6T5CJ50@ [_6^C],[G4@HK,S?!:K/&<:8MG9+2<6
MS/&\XK_AE('F6V+S?CJ]N0'$+"XJGOLTC8GV$:J*\O+Z;;^[?IU.WAN?'IL-
MOI:&U!8GEC;;?;Z(Z?X>.BL54(V]OL_P_8WT43L&^XZ= /?X#9/7Z&B*A;!Z
MGJ1OL=A[>G[731%8>=<:XWR*W3Q<H-M)K::X@WC=3"O+BIK+&;6.IE5Z+V'5
M3H35W"ASFVY"(\D.,^<TDJ2H @E#:5?26NT;=V_0#J/<"-SUZGKISJ@D+F4
M_4\/H'K^SX^W16*B[6CJKMF/'MX,.R8B3H-G'9FQF9+3-C62FIU;-;0\E242
MH,UE#K2Q\I"T@CKHHI5([4A/NZ?X>.B+EHB:(FB)HB:(HVJ^]5_E"W_O6;J!
M0*2U54T11"BD6<XJ&X^;:SIMON?BK78 >\ZT/<);"XW!2 )@;EV%/MK3\EY"
M%)]OR 1X#8I4H;'6N4<0Q-:2TK0Y[3V0\-7;0ZE8W!]A/LZ['8^!/MT6L$&Y
M8\SWEC!.,EXJC-[V/1#-<I@89CCDE#RF9V16;<AV! 6^TVMF'\0F,O9QY3;8
MVZJ&EL(Z%388:5,.YQCS.7UV".30,JM<:N,O@U0:=+C^/T%G1TUK8)>"#'"(
MMED<-LI*@LEX$ @*(L$5S.R6F&U.K4A"$@K6I2TI0A(W[EK63VI2.W8D^&D%
M 8I%E,3(S,N,ZT_'D-(>8?8=0\R\RZD+;=:>;4IMUIQ!!2I)*5 [CIHD5;M_
MF%5CMEBM5.$E4K+[Y_'JLL-!QEN?'HKG(G#-<*T_#LFOHGNU6RB7"D;;$J2@
M="1&E7,EU*OI[;G;J/LNWIMU(!T@D5R[T_X;#V;^W455IU^:U-EF62X-';F"
MYQ6DQ;(+)Q; 1 5 R^5D\.J$63YA\^0AW$I7G)[1Y8*.I[NA"0+%]EY=5IRY
M.$@2#=*QM>4C]Z ABJ19MU))D%0WD&6X/D 'Y/4D=-T"D;5<JG D;D=/$^ V
M'O(\=NFB""Y@[C?_  W!V(^H=$5L9IF%%@&+7F9Y-)=AX_CE?(M+>4Q"FV+[
M$*,GN=<:@5L>783'.H"6V6G'%$[ $Z(L<P/4#Q[.Q3)<UD?G9CN.XFU%=MY>
M9X'FN%R")RPS!165V44-58W+TR2M#+2(C3RUO.MMI!6XA)0.E(A0D/U0\5S*
M*9<I>RV+,@7M7C$G#K' ,WKN1?GZ\A.65+7L<>3:!C,)2K:NC/R([C4-;+K$
M=Y87LRYVWR)$*_<<Y<P?+'\1C4-HY8/9M36]]2-M09R74UE$]'B6SULR]';>
MHW8-C)$1QJ8EEU,Q*V"GS$+2F*14AGF?0<#B5#C]1>9':9#;M46/XYC4>%(N
M[JS7#FV;S$)-I85-6VB%45DJ6^Y(E,-MQXZU%6_:E1579/LXU;72K267&X<*
M*]-E+2R\^XU&C-+??6(["'7W5MM-D]B$J6K;9()Z:;$5H8]R3C>47DFAIG)C
MTJ-B6)9MYK\*1#:>H<U>NF:1U#4M+,YB2OYA>4XR\RTXV%(W&_<$DZ5/5.45
M%W*O(=>Z^Y(QRT32V[;D*;'$:Q5 @68:;=DL--3&O@K-E7FL*<:"E%/=WI4E
M)+%.J<V;4L#?M!/:3MX>S?1%@J@]2'%F39DUA%1:VSME,M+RCIK63BV40,0R
M6[QA,@Y'2XMFLVG8Q7)+6D5!D)D,0I;SB%1W0 2TX$H*1'@6=4N)4E"O#OVZ
M'H02GNV(/@0!HD54K W_ />[;_5^EUU8)%5[T^P_XQ^R-QI I'2N(<2?81TW
MZCIX;^.D"K%<P=_\.FHI%5T531%&3_OJE_*;O]SVVB*3T1-$31$T1-$31$T1
M-$31$T1-$31$T11J3M;/?0K8Y_\ DF5HB\5_U@.;^H6BYO@0N,;7D^#C1PNF
M><8Q)-ZJI79N6V0MR'2JO8<C_&+BL,;C?OV"?8=>Y\.J3=.?E,UV>=T:D-=A
MQ7@Q$//8OC7^83-^*%%O#22MR'U+*,S&=X&7%O;Q7\PNTKU5]/4R^L.$^,9V
M4KLG<CE890OW;MQYXLW;-R"TN6Y-3) D(DJ>)*PL!05XC?7D&="2W-9XIRTR
M.\.&  $-%R^I-SIE9-W8H9F88O7C3,,S%?CAVHQVJ]\U>S1BF)P*OH;&_<EQ
M6D-Y+9SJJICPUO)^.F//5M?939#T>,%>4RA"?,=*0I:$[G75K)3LO6!\JRWU
M!*X]R,N\:L5&3RY5!CM:,&RN/F-E$BVLGX7+<SK&K6NPY@MX]6O^?6,/.-R)
M$IO9]++?C0 "J;0M,L'<KZR[P*@<PW)<)XTQGUHW3.1(RR/2PZ]Z3.X$RJ)A
MR+05]K8LOS4<C)K'WEO)"!/?8<*E.*&Q2.M9@AXHQ=97ZA\NQ_-:K!<>X]YJ
MB9?1Y*K'8.38O#O(/">,4W)BI5*J7!$[:19+^(<9<9=:L$N%*UN*>0("A$%9
MW"&:V'&^1)8L\4D6"9-[Q;QG-G7]\Q69CAE-R%Y,WCZGH\#8I769E?(&1(L[
MY;,J (<Z1)C,L.MUH*;'X2EHLY<NKP+:CDC)LQG<GXAQG49V>,*^WQ;(,H>R
M1BJIK.UR*936-9 1CE'^<K$ZH@.1&9RILHJ8D/N,I[4)0D*6'C2/@6LAO.0N
M5,^]'N3R\[57M0.:>9L?$VBH:?YCY @X;@G)46/F4*/:P9TFO9RZBK'H_EH>
M4W'9DN/,+\Q+2P$=*O,L^<XTN33.8> ;"KSB;CT"/-Y!<D4C5%C=K$L3!PBS
MF2O.DVD"5.9^/A(,=P-J 2VLK3VN)!T%R7E83M>9.3:/"N'<Y<R(4^ IXEP#
M(\V1A-1QS.L:^UM9++-A9WV'WMA46PPJ9"6AB$FB#4IB67$^4YLA 76)HCH7
MRX<RKDC"$A5[RU:Y=$R7UH\A\9V$+(ZO'&/FZI%WR>_&1&D0J]F3 &0S8E<6
M&>\,QT);:C)2'2%$-E]ZNBNY'G<DYKC$F5:0+J)AOK5S[!:1^(Q&2U$I,;X4
MRQ],-:V&V_BY,*9,D=SRB5]W0JV3MIHAL0@FTZU:V.\^<JVN0UTJDS!4[&^2
M^/N8+W 7>0H/'6-U$>?A\(2<<R-B)CMG+RNFQ>%,"F9R;DE]31[E(9<24)!0
MWK/7I^SW,LF1FV)9M>9)*S7%C03+5K(:S D/4T+*:F=(JI-7;<>3K#&<@K)\
MJL?<CA:6)K+:0'VB%(6I9>M5MRU0XCO\SPG <XI8W)&77&5<@>L/U XGC[=/
MB_&L:W=FX]R)R7,R1Y%AD;=/C5:U;QZQ,MQ<M<A<;RTQXC)[_DP1OT(;+%W+
MGEW+.0/3ZJ5DTZIM)=YPSZVZF_L!"H79,M[BO*1A=-):F59E0H:Y=6REV8F"
MXF'*=(6!V!H)O4HO4BL[?FVO[>WM^"B]O;MV[>0WMV[=-M15=[1$T1-$31$T
M1-$31$T1-$31$T1-$4/:[>=3?E4;?V=8ZH0J8&HB:(NM,^])7^S/_P 4O0(D
M+[TB_P"SL_Q2=4WJ!=G4531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T11M3]Z.?E"W^M;3= H%):*IHBB% JM)@
M"BC:NK#W [?8S+)6W_TP&WU=#Z,8P4C;9>O#OUJXUZIY_J"R=_C!CEYW#G*[
M'4P%8E:Y!&I2ZFFB?&_#L5\I$;S?B2KS-@DE?C[]>_\ #ZJW-E;O&=F[I'M$
M.,,4(PT6:5\4\=,OXKSM]Y W/95NR-TMO>=V2+8ZP019J*]GN-D6J<$Q!%U\
M4+5&,4+=B)A49B9J:J*B8F4M:EK5(^(02LD[]V^_7?7@5?!D_#3_ *N)VV+[
M+RWO/56&?^MPB.RP+"_J#Q.DS?*^ \3R*L1<8W=Y]GE9D$!Y*U1W*^PX&Y8@
MJ3(6G;R"N1+;0TX"%)>6CL/?VZ@L$5RW$N-JU=J[/F#'.?;K!9]?<7^?\8>D
M?FEGC[-K%E$B%R4Q89IQC+X\L9LI*C%1E"I]"_%LXBU(7YL<R-U-/H4%RGDY
M<@NU57\?-I.,XGQCRCR1G:[["<Z'.L*TRC*WYV*QVL)LW*V>ARP,=>"9>OD>
M/&@-5\$L=]?+D?O2F64.(>56'0LT< 3)U=Z-\7/%%E-S3,J7B"MBUT"]O9ER
MN)R)5X/7-O8F])N)+JZYJHO&TQO@R4LQ-O+ 2!MI&U+(+ E9E6'9/G_I_;P+
MEWDS/LN3:Y),S&DR&5D-BBJNE\49O%1*R&HM&U5_&>0-W(>:9KXYCI[BZCRW
M$-)4E%- 4(_ZCK_(N/.$J?%\ZR>3R# ],O+-ARBQ#;NV;6#R1C_"T-Z.UE!<
MCM)CY= S2'+<;86M;R'TJ<3W)V600W:E<?->67. T6)82UFG(;%[;<7WF=Q,
M\RGE/.*M%QF#C,.)&Q_'8&,4UW)R;+X]BEF3'J%&'7,1WBI#3O<I"9L5N7S&
M88L>2_G_ )CY*S7CIG(_3CP19FSI+.^Q.!>92D\@RK)FSO:&.U)5=UCLY2HE
M:M:/B#)=/D*<;2 4Y[EQR/*N;(^&,9?7Q[1_/?\ @2I"KI]J3!R'\RO^,D5E
MG*)+$2GLK.+DS_'"DV3[+<%<AN0MSLC><V&3;%+1:5=O%.9.VE!RW.O^6G!Q
M3$J<)9CW>#\@\I\C7.-9'+L+DV;M=FV2\?TUB^FSANP&WJ^+\?\ "N(5W^27
M2DDY[UOADD/*K''9<;#KVOQZ\D_#B%=6=2YD$. VJ6RN9(-6)M89KYA>8&DJ
M=0@.E)4"G=.HM16!>1*O)4\2<C0^?\OKWL'>Q]%=8V_&N*WT'(FJUZ6ANQR%
M^)\5E"H#C33J"IIAN4S%;0IY:U(!2 VW);&Q:TN95(N<6Y!G466Y1S3PKQ_G
MOI]RZ'D-I6FVG.QJG-$7/(]-7V46O@.9K6X9 @5UMW"*I;&[C2%O.MA(NQ:;
M/!RY?C5QR4<<<S\F\H<TP\AM87&6#\;\61:WEC$9;]1)C9[A%ES)=7<V@FK@
MR38F@PWD-J.^5L28SILW(P#BVW )85;BK5XWR&ZX5S)BKDPZ:FRC/9>!.TV#
M9#77]EG%]BN8Y9:K>HZ?(FYST-%OA\FWF7&1271)$R\L9C[PCQ_AUNT;%"=:
MV=Y[Q%G*,\].#TJWR^K;B<IW:5G&LFN\>1VJXGY'D,N354\EA#@7/C-,;N=%
M-O+9!"7E R]6[ERUK3C#N;<KR/D2IL,?R')*R)D5?S7 R3"+?.<TS/(,=>H<
M/R>WQT9726&/5.)\>WL:ZHP(<> N0I47Y/>Z%=YOD4C%;;<#R+.?G3UO>F7(
MM++TU>G.3/FSFUI?E7#C_)<BW6^M2!_KAD2@MX?9!2QOXC2*L+N965FUGFES
MES>-,9AEU-56'JUI\1EKHK*572Q@;GI^E9',I(<UGM<AU,S)X_>IQHI4F05=
MJ@L[BH;["LL\ SKN)%YGQJ]M[ZXJN/N7[S&,;LLFL)]Q;*Q56%8/E;3,FWL%
M/SK9F%89-+9:>6IQ0:;2WN?+UIYU=*U^X]YZXJYYYKH5LYQ4TE=@639-&XNX
MZ89E1LAS+)C1VM'<YUD#(B-,UU6U!G6#577N?ZRLDS'R@K983=D;5-/+EX5D
M/U(9IGG&%[C=[CUG=NQ.4:6SX,Q^HB)7-KJ#F/*7/BN,,TDQ.X)9A!V/-B37
M4?+[5,%1 21JF]1:TY[E?,N(Y??8)8\EM4V64%=@E3Q5;91R3R;"DY8T*2HB
MNY6O!\-XRRZMY#FWN7*E(MXSSSTB$T#W!AD(><FFQ7ERY=*O'.>6\@3SY&K*
MO(+_ !^?C?,/&&)7&.3,YS23*O\ &;N10-7UW7\8UM$O$FL#E0KEQ";29,6]
M\:RL?O12VA3R(5%VDW+*WA\<@7O-.2TMK=\W<E5MA&S3.<\Q?&Y>,8OR'R34
MX]A47)\6K[A7'##E3$AR6K#X5?Q@;;97WH+85(G2D!H6]G F4.YGQ+@N2KAW
M\$6>/Q5B/DUJ]>W"@RMZ,F6]>2HL"7=1IZ&!(CS7H\9^7%=;=<88<4IE"R"J
MS'HB:(HV=]]4WY2=_N>VT126B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*$D2XT.
MT4N2^RPEV RA!><2WW%N2\5!._B1YHU86*1M@O@_-HWB%+F5RB#N2XMI1)\/
MLN\=?I[ZU,<^78PD [5H=+D3/UK07>#J7:;N*=M(0B?"2D>"0^T /_JMM:<)
MOMB5K$(0$(+E\^5/XPB?A#7VVD"D5P5<TYW_ .L8@W]OQ#73W?Y7OTPE,7,K
M>GUF#6L"QJ;.-C\^KN''GK>NEQ:Z1#M'GDH0Z[/C/-N,REJ2TGY2TE1[!N>F
MK Z I$:PN$>FX^B8^G%(=?CD3&4,?"HQ^-%KV:=,?O#GDBN;;3&#9<'=L$_9
M==(%!9I"X2:/ )U["R>;"QV9D58RJ/7WLB)7.VD)A7<%,QIRVC)9;V61LE0Z
M$ZA%J)D5+@.6PFZ[*8>-9#!;<2\W$N(=?8L)<2-D.H;EI=0VYM_E) /U-(*Q
M&Q=Q,?$6U51:%&D4)6JD0&H834ER(] <56A*4_!ER%(6P0WV#RG%)Z@[:L-
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M1$K6XXCVZ_,M6 RVRAL,V:@/B$[=KVP[P=+2G0KF3=5"$A(L(>R0 /\ 6&O
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M&^VT@4BW8GQ55_*:_P#AHWVVEJ=G8J?%5/\ *:[^&C?;:6[4L5?BZG^4U_\
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M+D^8J3\3U?X!%^Y:(J_,=+X?-%7^ 1/N6BD J?,5)^)ZO\ B_<M%4^8J0?\
M8]7^ 1?N6B6)\QTA_P"QZO\  (OW+1+$^8J3\3U?X!%^Y:(GS%2?B>J_L^)]
MQT1/F*D_$]7]2OB#]IK1$^8J3\3U?X!%^Y:(JFCI3XU%7^ 1?N6B+I.U=;#L
M*=^) A1753GF5.1HK#"RV:JS64%33:5%)6@';Z&B:5<.B)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB*.3_6SWY.C_ ,YE:NA32NP'>PK\P!.[A[1OU*>H"CN=O9J
M%QLC!4&R#R!"Y?5!4>XD#;<=I'7<;>/CJ>50$Z;M"ZD^TKZM,9=C-B0DS)<:
MOB&7(9CB3/FNH8APH_G+1YTN4\L);;3NM:CL 3JJK@;>M$Y-89L46*X;E@B
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M1K5P8MR%@N;DIP_,,8R@IK8-RH8_>U=PH5%G)L(=;:%-?*D$5UA+J933#_\
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MJ%:0=M^OM'7ZGLVZZB+EW#;?_P!W]K12.C2@4"=@=R.NBJC9_P!]4OY3=/\
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M%4,+G272ZP)[3:4/.H#:2F*VFY9VX'S;FJUR_(\=Y*J+N/4-8K2Y'46>4/\
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M>YL!W'1.A3D6OC0(L:%!9:C1(;#46+':0EIJ-&8;0TRRPVVD(;;:0VD) &P
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M>ELXS18Q(HA@C\;X$8W(C8Y&>0CS_C67F]Q)4%.^86F&I9BX=XUA\1X!18#
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M_9T14[T_YP_P]OTM$VJNX/\ A[]$5=$31$T1-$31$T1-$31%&U/WHY^4+?\
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M9=7-3>4]/3TPK+A/SJ]E5Q>S&GY^:VF53)[CU?+>GY#*<>C&*VWV-*"5CY(
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MM VV2D;;#H .@Z#P\=M]%(*A::.^[:3OMOT'7M.Z=_?L?#155\M'7Y"1OXD
M GV?M:*07S3&83]BT@?8^S_,/<C_ ,0^'NT55C9?Q?@6>2*V7EN*5-W-IV9\
M:KL)32D6,"';)91:P8UA'<8FM0+-$9L26 OR7_+1WI5VIVH<X7) :5=='1T^
M-T];04-7 I:6GA,5U74UD5B%7U\&,@-1XD.)'0AAAAIM( 2D #4-MI120;0"
M2$)!)W)V&Y/AO]/8:(J>4V"2$)W)W)\.NVV_T#L-6.A15#:!T"0!N3L.@W)W
M)^J>I^CJ*H6VR-BA/AMX;$#<'8$=0-P/V-$@N'D-#P0!UWZ?X>&Y_9.K%2$+
MER\M'CV[G;;V^'0=.O3PU%0J>2UN3V)W.^_3QW.Y_9(W.K$HJ>0UU_>TG<=I
M[AW'8J*MBI6Y(W/U-2)2$5R\IOQ[!OL1O[=CX[GQ.^W7Z6K%2"X_#L]?WM [
MB"=AMN1OU.VV_CI$I!<O*;'@A(\? ;;;[[[;>&^^HKS*GDL[@^4C=(V!*02.
MN_0D;^.K%2 -IO7,(0#N$)!/M[1O^SMJ*KEHBA[7_34WY6']W6.J%"I@> U%
M4T1=:9]Z2?\ 9W_XI>BA45(IJN\J37W%?&LJ^;7_  DN%,;#\65&?8#;S#\=
MS=IUMQ"B"% [ZW639DEXF2G%LP6@B];<V3)J9#J>H8R9(>(.:YH((-X,0;%;
M6+\3<9X38KML1P/%,;LW&'(R["FHZ^OF*C.K:6['^(CLH=\AQ3"24]VQ(\-<
MJIS3,*QG=U4Y[V:B;%U&6;L[O9+,,[*:*FIYSC:Z7+:UQC?:!&W2L@J'<DI(
MW!!!'OWZ?7UP%WBL!7&&"'"W^.ABU7^9,EN4T_CO8Y\WN(F6+UM*2I/FAWM?
MLGUO$!?1:C[.FK$QCI12^/XA08JW9-8_41*M%S>6N2VOPX5W3[Z[E*FVMI*<
M6M;CLF9).Y.^R4@)2 E*0&(F^Y(!6P_PWQI)AX_6R,(H)$#%<O<S_&HK\4.L
M4&9+G3K/Y_J4.+6($U,ZR?<3Y7:A!<(2D   22+4L5V5F*453?9!DL"L9BW6
M4?-QO;!"W5/61J8ZHE:'DK=6TCX.*LH3V)3N#\K<ZB+MS*"IFVU9>R*]AZWI
MHMI"JYRTGSH46Y^ 59LLGN"0W.55Q^_<'?RD^'7=:J(*T[3BK [LY.;7&XDU
M>9?-"LC>>DS_ (B8<?5YE&(TE$M$BK%1)*I,?X14?RI;BY"=GW%N**0'C7?I
ML'HL1Q65C&)5R:V$MNU?0TJ7,FOR+*U5(DS)LZRLY,RPL)LR8^5N/2'7'%D]
M5; #16R*P?P/Z;\.XYP3B-%IB,"/G&%8-BL&:&K.RL:.GR^+BT6GR*VQ^GD3
MG<>K[&9)+Z5S(D5IUY*U$J/>K>DE:0%DB#P5Q;7V<FUC8?#0_(%QV1ESK:13
MP7,@8EQKN144$FP=HZ.7:QI[[<AZ%'CNNMON)4HAQ84+G$0)5@(J]SCD*LP\
MXKC\)BO@0<=-!30&ODQX<.+6?-M;#;4LK*68T=M#:=R=DIU H5@7@KTX8=QU
M@7$\>UQ2"SFN'83BL6Q#=K:V-+ S*+C$.JR.[J*9^P<QN):SI9D^9/CQ&I#P
MD.DJV=7W(F$%=.U9#QC@KBW#;>NO<<Q") M:6)95]%+7/N)XQZLMTLIL*G'6
M+*QEQ\?J)*([:3%A(8CA+2 &P$( BMD%W*;AGC>BB-P*_%(?S>R;T1:^=+LK
M:N@1\EAQJZ[KJZOMITZ'6T\V!#;9^"CH;AM-@AMI 4K>J6+HU/!'%E'!N*VO
MQ",J%?8Y,P^Q:L+.[N%'%)[*X\O&83UQ9SWJN@D-.$*B15,,;A*NWN2DB"*0
M'A5RWG'&&Y,W:-7V.U]DW=8V<0LT24N'XO&O.=DBI64/([&!*>+H4G9Q+@"@
MH$)(J6:5'7E'>XW@;N/\90*R9:0HAA44/,K>ZG5B4O.CS?G:VE&XN9K3#3KB
MPEQ:E.;!ON2G8BHK X[].&!X;PK@O"]A51;VCPB/%DPWD)D4SK.1B;+N)M_3
MN5,F)*HIKUS8R'FEQ7&5LI>+:5!/342Y74[P1Q<[3U5+^:J&8U)9S[NLEP[F
M^@WT6WMFG6+:R&3P;6-DCLZW9?6B8ZY+4J4VHI=*T]-(Q2 4[A_%7'^!FM.'
MXE3XY\T0LBKJY-6RIA$.#E>1_G;D49A'>I+;5QD?^NO #J]U\.FEJ0"R+HB:
M(FB)HB:(FB)HB:(FB*-J?O1S\H6_][3=% I+15-$4:W_ %O,_)U;_.;7132I
M+15-$7$I2?%(/TP-$5.Q W^2.OCTWTB4@"J>4W_F)\=_ >.W;O\ 3[>GTM$5
MN0L,Q*LO;K**[&J.#DN1HAM7^01*R)'N;IFO:2S!9L[)II,R<S$:2$MH<6I*
M/8-6+M:*Y.Q'^:/9X@'[$[I_8/AJ)M5/*;_S1^UI%%R[$^U(/T^OM!]N_M&B
M*A;02#V)W!W'3V[;;^[?;IHBJE"$DE*4@G;<@ $[> ^D-]$7+1%P[$C<A(W/
M7<]>H.X/7?VZ116Q/PG$K7(*C*[/&J.PR:@CSHM%D$VKA2;FECV;?DV#%79.
MM*EP&YK/R'0TM'>DD'H3HA5RAEL#8H!\"=^NY&VQ._B1MHBYE"5  I! .XW'
M@??]/KIMTILT*@;;&VR$CM  V2!L!ML!MX#H-(J07( #P 'TM%571$T1-$31
M$T1-$31$T1-$31$T1-$4;.^^J;\I._W/;:(I+1$T1-$31$T1-$31$T1-$31$
MT1-$31%%N+#-DMU86$N0FFTJ#3CB2IM]Y2@2VE7:=G!X^.KH4N*[/QL?WN?@
M[_W/2"@/.GQL?WN_@\C[EJ*QYT^-C^]W\'D?<M6"F+G3XV/[W?P>1]RT@K'G
M3XV/[W?P>1]RT@IBYT^-C^]W\'D?<M()BYT^-C^]W\'D?<M(*QYT^-C^]W\'
MD?<M()'G3XV/[W?P>1]RU()'G3XV/[W?P>1]RU8*8N=/C8_O=_!Y'W+2',F+
MG3XV/[W?P>1]RT@K'G5?C8_O<_!W_N>D$CSI\;'][GX._P#<]()'G5/C8_O=
M_!Y'W+2"1YT^-C^]W\'D?<M()BYT^-C^]W\'D?<M1(\Z?&Q_>[^#R/N6K!(\
MZ?&Q_>[^#R/N6D$CSI\;'][OX/(^Y:02/.GQL?WN_@\C[EI!,7.J_&Q_>Y^#
MO_<]()'G5/C8_O=_!W_N6D$CSJOQL?WN?@[_ -ST@D>=4^-C^]W\'?\ N6HD
M>=/C8_O=_!Y'W+5@D>=/C8_O=_!Y'W+2"1YT^-C^]W\'D?<M1(\ZK\;'][GX
M._\ <]6"1YU3XV/[W?P=_P"Y:B1YU'S7$RI%6ED.*+5@'EDLO)2E AS&NXJ4
MV$@=SH'C[=4)>IL> U%4T1=:;O\ "2=@2?AWM@D=RE'RE_)2!U).B+JQ)C"8
MS"5%X%#3:5 QI(V4E "AU9'M&JM,>==CXV/[W?P>1]RT@F+G3XV/[W?P>1]R
MT@K'G3XV/[W?P>1]RT@D>=/C8_O=_!Y'W+42/.GQL?WN_@\C[EHD>=/C8_O=
M_!Y'W+5@IBYT^-C^]W\'D?<M(*QYU7XV/[W/P=_[GI!(\ZI\;'][OX/(^Y:0
M3%SI\;'][OX/(^Y:04Q<Z?&Q_>[^#R/N6I!6/.GQL?WN_@\C[EJP2/.GQL?W
MN_@\C[EI!(\Z?&Q_>[^#R/N6D$CSI\;'][OX/(^Y:02/.GQL?WN_@\C[EI#F
M4Q<Z?&Q_>[^#R/N6D$Q<Z?&Q_>[^#R/N6D$Q;"GQL?WN_@\C[EI!6/.GQL?W
MN_@\C[EI!(\Z?&Q_>[^#R/N6D$CSI\;'][OX/(^Y:B1YT^-C^]W\'?\ N6K!
M(\Z?&Q_>[^#O_<M()'G3XV/[W?P>1]RU$CSI\;'][OX/(^Y:L%,7.J_&Q_>Y
M^#O_ '/2"L>=4^-C^]W\'?\ N6D$CSI\;'][OX._]RT@D>=4,Z.!ONY^#R#^
MTT3J)'G7QJ@1$5N%#NFV3@"T*;5VO6,IY!*5A*ANAP:(+E):*IHBB/-2S:27
M' YV.082$J0R\M)4U(L%*'<A"AN \.FK!2-J[GQL?WN_@\C[EI!(\ZK\;'][
MGX._]ST@D>=/C8_O<_!W_N>D$CSJGQL?WN_@\C[EI!(\Z?&Q_>[^#R/N6D$C
MSI\;'][OX/(^Y:02/.GQL?WN_@\C[EI!(\Z?&Q_>[^#R/N6D.93%SI\;'][O
MX/(^Y:05CSI\;'][OX._]RT@D>=/C8_O=_!Y'W+2"F+G3XV/[W?P>1]RT@F+
MG3XV/[W?P>1]RT@K'G3XV/[W?P=_[EI!(\Z?&Q_>[^#O_<M1(\ZK\;'][GX.
M_P#<]6"1YU3XV/[W?P>1]RT@D>=#.CCVN_4C23^TUJ*I\;'][OX/(^Y:L%(\
MZ?&Q_>[^#R/N6D$CSI\;'][OX/(^Y:0YE,7.GQL?WN_@\C[EJ05CSI\;'][O
MX/(^Y:L%,7.GQL?WN_@\C[EJ*QYT^-C^]W\'D?<M$CSI\;'][OX/(^Y:)'G3
MXV/[W?P>1]RT2/.GQL?WN_@[_P!RU8)'G3XV/[W?P=_[EJ)'G3XV/[W?P>1]
MRU8)'G70?D)DS*I+27CY4]UU:E1Y#:4M_-5BV%%;C24CY;J1X]2=()&*FM15
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
431$T1-$31$T1-$31$T1-$31%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm2127058d1-ph_mod13cmbwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_mod13cmbwlr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K %6 P$1  (1 0,1 ?_$ +4    %!0$
M      (#! 4)  $&!P@* 0$! 0$                  0(#$  " 0($! ,$
M!0<&"@8%#0 ! @,1!"$2!08 ,0<(02(346$4"7&!,A<*D:$C%188*$)2IB=G
M&K'!8C-#)"8W1QG1<C1FACB"DB4V6/#A\6-S5E>GUX@I.2H1 0$  00" @$#
M P4!       !$2$Q A)!46%Q,H&1(K%" _"AT1,SX?_:  P# 0 "$0,1 #\
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MX=90 ?B&_G"M*:=WY* 8TZ ]KV6M/YPZ*UK7AUF X?WA?YP(A:3][@L?#+T
M[8O\714_X^)B"O[PU\WX2Q1_O;-1TJ:] .V+#E2H'1; X\.L"\_B$_F\%0/W
MNLK<S7H'VQBH^ANB^ XN)CY!K_B#?F]K'&1W<XD#_@)VQ>SV?<MPO&8!7]X/
M^;Y_\7/_ .0?;#_^BW$Q%*H/Q!7S>&%#W<J23@/N%[8E(KRP'1;GQJ<>*!2?
MB#/F\(P7][0G,A-/N%[9#YJT ;^IC 5X7CQG@'?W@CYNY7,O=MAC4?<+VR#E
M3E_4N:\^+TX@^'\0+\W1JE^[6HH3AT'[9< /:1T84UKAQ+PXA1_> _FX95*=
MVA;](@8#H1VSDA34$D'HP:"HX=9Y"NW^?[\W!P<_=BV#Y17H/VS@4K2N'1FO
MYN$X\0Z6_P _;YLS&3U.Z]F ^SEZ%]M*FE/$_<S[N+T@4GY^'S9P0O[UE217
M#H;VUT&/B?N9PX=.(=O^?+\U[*M>ZQLV49OZC>VZF;QY='EP^KC..(/3Y\OS
M7"M3W5#"@_W&]N%2?=_5#PZ\0H3Y\'S6B3F[JA@ 0?N.[<!C1O;TB QS <7K
MQ 3\^#YK56/[U#A00N8]$.VW(37^21TA!\?&O%Z\0M3YZ?S7J5/=8#F%0#T.
M[<3E!'A3I#0D<.G$&/\ /8^:R(_)W1EG]_1#MP ^FGW0\J<.G$)!\][YKW(]
MT:5\3]R7;B![_P#@_7ATXBT_SWOFO#T\G=,B5'F/W(]N#+44-"3TA\O/EX\2
M\>(J7Y[OS71"S+W3AV"G*\?1+MNREN5/]T66I/%Z\0AC^?-\V!:I-W3><#,2
MO0[MP9,O+[0Z/FI!KQ.O$&GY\OS6<V'=6M*' ]#^V[' 8'^J/ <.O$'0_/?^
M;"X>O='&Q&*@=$>W'##E4=(@".'6>@+_ )[_ ,UL-YNZA4. (^X_MP(!(KS^
MZ $F@]G%Z\17_/C^:L.?=0"02/\ <?VX F@K0#[H>9'+AUXBZ_/C^:JU*=U"
MJ*T\W1'MO%2?"IZ0\QPZ\0*7Y[_S6%"Y>ZA:D5\O1'MP>OLK_5!A7AUXBW_/
ME^:HHJW=(6]I^Y#MQ 7ZQTBX=>("?GQ_-7?%.Z?(H\?N/[<6'+-2IZ0GP/#K
MQ%-\]WYKPCS+W22GQJO0_MNYUY%?N@)&'#KQ]":?H[\RCO7W3\D?NQ[O=>ZS
M2WW<3TUZS[.VELCJ">G/22V?1M U7J#T%T*_T\;2L]A6VQM1$VF;SU.'UKO3
M+B=1<EU</'$T>;QF9!YK_P 12LG_ #CN\!E"_9Z 4J>8_=;Z'UP]M5XDV$+$
M8#1HP)$F&8TYU!PI0BA]O&I\;@]+=@ Y!!Y@Y:@"GOXLG[@_T_T8;/4DDL *
M$"I7PY"GT<7X!$0!]4<P&(]M <,3[^)-P>@6H7!5)Q(%:4K^;C6VP%E;/C&:
M<\O(4P',FIK7B9"V*)D5AF )-13S #ZP":\9M #;!B29"37$T'/\O%[ Y4,<
M:TH34X5RYCC4GGX<3.:'2W\\11AEJ:*PKRHO,5\:\^(%P5&%0N8X>:IJ% .%
M#[:\ 2Z,,KD*""U%..%1@*BIY8\ >K%EQ-0:%:C%13[/CP%^ .M_\ZI]F(^G
MBS<.<:ABQ85H0037QK]1&'&Q7)C7!5;RA0*UY<N67V\ OM8?42I=11BI KD(
MK4@D>;'_  CB6AQ:VB"FC!&9:8"@(-*X?5Q,A6%")AX968U)P!!)Q]O%V"^V
M*@%F%0V &(\.?UUXH7H6=XV_G*PRC&HJ:$>/AP#C:7"HS&5F/D0BHKB6H:$\
M_*>7$L"Z!UE&9#F52&I@*GECFIX'C.HO-*I1URN3B5.<"@(J:+3[0)('#2@"
M1KDA0R,09A13(N;RFN-9'9@1_DCBC)XY88D4,Y7-]D.^? 'F6K@#^2G&A=KJ
MU7%IHA7G4@\N5:<N? --Q=6L;E1+'*<:E:D9@14DJ:U)KP">62U>/%P@)#DD
MO'E8<L68KX\30(3$AS@3>K!E4K25CE;,#S6B<AQ*#8E2,Y_,S?9"F0E2/M4*
MM4"IX9%IA,2&5'R'REE>$E0:$FF4C"G &I<.@HDMS@ &*NM33&OE@8"OT\64
M'AF8>HV9,Q!)=@SY:4 <&-:-6G(\0%M)"K#S&M1BJ@U&8-[,.?#0%1G-(,24
M)+8X585I@<1]'$ ;LHLB&DBT4U:$XG_K G#B^0GAG*"2$LBJ%S?I)2\AK7[(
M&&%,>+X"Z"=4C*!BX?S%D9<#3V$ CERXF< &?S49I62N(9S5O'&A%2*<3.N1
MZ1>WP1G\-EWV+3R#N.Z?89F__%OM<;G]H&IY<2W6")_\1(C'YQO>"Z@G+^[^
MM*<\W:UT0J?80!PX["$TU4>4E34#"@H*\L2,. >8IP(Z%F:J%:84!/OK7#C>
M!931*"F8NM014D#E08UQX !4^K*$C94=@:A2%:GB0: 8GB0'I"Q.92*!J$$@
MFE/-BM1X\7/L'0XR2*^,40H%PKBZJN-/?Q+["I0N 4$D 8-3+2E.9:O&0H$<
M88BBA@350P()ISP)X!.ZT<@*6*C, M"V(QH,, .*%4!I$P*E7+# ^ HI(^GB
M!R5DP&=>7M!Y#V< )@C4JP8#'E]G\_CP 05 H" ![QP!OIM133!JTH030<S0
M5H![^+B@R)2DB,PRKFI4^%1[JFG"2AT5U50"1AX@J1]-,V;\W&P,T?"H(&)Q
M\<"IK0\ MLAYLK/492S4."L6">84JJU:@)H">)0[J\8=O4**:-A(P4\L *G$
MGPX0"89JD*Q0I3 *>9P-0:"AY#GQ*'.S"E<K8T7VT*\OM>_C06+&RT97"T+9
M%)\P]N'\W@%"&C*33!E)I[!2O *!*J-(D+USG+S"HM>7@QYCB?8,51(3ZEPB
MY!RS'$@8U%%J"PH/=Q I5HTRH'CQ'E( 0DTK]JA9:"M/?P^PIB=Y$S,"ZT 6
MLP-$P )\G &'U/+ZBPA",*-F8T]IRKRKX\4))U+21A8UP%< M.1%33''GQ!>
M2&/(*2AFYLGEP;P#>5CPTP"HSFSJ@"XA67( *@^)-!YAPU"HO#'B56N850D@
M9@ #[AR\.&@*EPJZHV0"IH"0#@/+@,P/MPXF^P*@)0RL49D8U.'E(\,K#,2:
M<4*D85!4!0,4+.2,W(56I%:>'" ,TEP^552%32M#3STQ-?!:TX?8(CD#2J&*
MAZ@D#[.!Y TH>)YSX"TRDU"4:E<!EK0>(JAK^4\7/H)BF>Z1XU5F*LOF4%0<
MI%""%;'ZZ4X3X!P4%JR*@8 -1,4&/,F@Q]WLX:>0V3SHLTGF9SE4)Z)!C4@X
MY_+@:<,#TE=O>8?AK>^YO40L>X_IZ^<5H%^]KM:\I\M<V0>SF>)9_*014_B)
MI_3^<3W@J0PQ[?\ *0!B3VM=$*^&-*\3C?XB$TO 44!I X/F CJ/_68U)K^3
MBA1"\8&$A-?:H -/&H)Q]W%F J20,5R,H9%;',*\R>1\<<.+H#!<1 99"QPR
MG*[,3B<"M:<3ZW%,!*PRYU"KRQ5LOL!)(.!\:<7[!T2F$N_J@H5Q6@!!%&5#
M7&N%>)=04["20$D %4#8D \JCG[3^;BXQ Y-4K]HJQ-0<J\O;4C'EQ@%QVBN
MZS2N[,I'/RJ<*5-?+0<7/@.=5%*LI!P&1E=J^ R@UY\^( _HVQ5JL20: #'^
M:I'/@#HU,3"N9BXP)K53RH!0#Z> 4>B77*]033$  +7"M0!3@+I$4J%=S3[1
M!!%!]1H#P"I7&4!OY(ICXAN0H,3AQ9?84199.0 H/$@G!2<237PY^'&MP]Z9
MIT^JZII^D07%G;3W]Q%:Q7.HWMIING1R3.L:->:A>2PV=G;H6J\CNJHN)/ 3
M%;[^4CN+I7\N/5._/</7'86[[34=6VU:;(VGTQO;'=F@WPU;<3Z#?2ZQO!5>
MV6\TYH)[=H;-90EQ$RYZU(GG%W3.?IR=V@]M'33K5KEUKG<%W";2[:.C.D:C
MIND7V]MQ1R:KK>MZS?0R7!T39.@PR+/K%W86\(DO+AS\+:)*@=LSH#<:9AG7
M#M[YG7RI-/[&-E=)>N?2?K-9]=^@?6:^CTC;FZQ8Z=INIQ:Q<Z'?[ATQ4CTN
MZO-.UG2=3TW3I&BN(I!()%=62H'$E\"&WRYCY7QQ"H#B2:&A%6R@GV\:4>K1
M^I'$&*N?-Z&4LQB4KGFP9BJ+6C?:(/L'$"MYE%,K!LM2_*@%3S//#+SP]_%%
MHI[>1G2*3/-&ZF>,92(\Y4!G=&9E4YZ'RX$C 5KQ OCFM9$I%*TF3,L@$?FA
MEQ_1DAI%;/$0V!\>)_4)I(HS,BN6%: LI."&M2$\6 .(P_P<:"^UB]%,J22E
M0U/.F4LO(?:!-"/?QFT*"J+YCZM6#$TS!*C[/F) QXD%E2,T+))C1B#(3B,?
MLEB.?#(,)CQ]-P[8U6O*F KB:8^SA@()C'Z@)4YQE,E'=0" *40,$)%/90\6
M?[ NXG1D1@TRE7KC'S%%]I%*@\63 ,@G,X,9>XK)0(ZCRKASI@2"#P_H+M+%
M9IZ0N)6DID\D8('/F"20?IQX;Z@B-#(T3,TH#.QYE,V.#> )_/PH5R0!J!97
M1LU,07JN45 K2BXXFO/#B2Z HO 94R22!HU]/*5"HX_E'.6(6A\<,.&H-BD:
M6JAO3R@4*XGZ\U>7"R34%.@@*SM))+E:E Q_E^4D$$8@GA+X"0R*9G]-YU%3
MB'H2*%C4,:5H/IXHJ$QY3)7,?-0&A',BK-S4TQY<^+J/2;V\N/[M+WY-EH!W
M)=/!XT(^]SM7\P_R*>/LXS?RB(P/Q$+H/G#]WZM0$MT!Q_E?^5KHA3Q (KQ.
M.,*A.548F@4D'G@*GVY13QXLDR!QHDA;(@)4TY*!AXC'V\70*<GVV3+]DYA0
M5 "#S<VQ/TG@!1E$!=$0R*H9B_FJ*8@"@Y<,"S3N:UC0U_-4?R6 ]_LXF K1
M*5ST(:A*X$ T YD8XCV<2T'+ K ,,BU; @#-4&IQIA4 \,A52'_(P]].(!+]
MCR#-EK^0''\W 7C2$.'*E&*@',P"K1JU4 8$TX!RCMU*U1$KF8T"KARQ\*<7
MP*C@9"01F%>8-:FF() 'CSX8!DD<U%RA?* "*BARYC4>SGPLHOZ;B-6"_:!+
M4:IRDX5%/:.&-,A3&JL$)4' "E 2:4 Q(]W&IBZA<D2J<R@I7^3A05YC #BB
M_IAF7,H<DY34+3S$"E&!P(P..(PXE'KPW>L*?A:NG;JL85^H)E<C)E=I.O>\
M9G9V(\S2,Q))Q)YX\9_O_1/^7ELZ<6_3*3>V@0]8-5WGI73AK^(;HO>GMAIF
MH[JM+!CY[O1;#6[ZQTV]OXVRN!)*,WIJ%J54'6GE;GP]2WSC.D73CJ'\M+L^
M[A>U#K)N#</:YT<7;_3O;'335KFR2PG.X;;4]+MMVW[65I#J@W[8W=F-/N89
M9?2C2Y_1+2I?,SF^TFCS;=KG16;N+[A^C/0VVU3]3'JGO[;VSY-28D26%GJ%
MY$+R\1BLOZ>WL5D8%E<9\M585'&OLOP]%?7'=78/V/=[_5[LJZ^]L&R[[LUT
M7H;M6PT"]T?I5MG7NMLG4G6-#VYNI.H%UU3NKK2]^MJ-_<7MY8UBU 6]LB0I
M&D<8>'B:V?*8-'RH^AG;!U4^7_WX]3>J_;MTVZHW?1%^H.H[ UG=&VM+M-]V
M>BP=/)=QZ;97&Z=+MXK^&:VN:,LH+S0.H](H,@6W>3QDL;)L]H]M_6?Y+*=Y
M.].TCM^T;J;T7W/JMCMK3NGNS1LC1]633=;TO1;/3-]WFC7UON'>6GO%>(]Y
M'>7WJ7D\?J-*C22DL_RQ=L#5/S5^B?1O=WRQ.QOO6VCT:Z6=(.J6^M)VKIV^
M)>D.S]*Z>Z!N"TW!H+SHMQH.B1PVUPMIJ^F^M;O.99[>&XD02/44DWL5YH8W
M:X?RB//E\S#*:L":F,E@U,1CAQ5'Y+BM"2JUH5)\P'TXFOU\2V V9W6$U<@B
ME.9J.5"6)X36_ ;C<%@1ZE1XBH]M/ #D?'C6 KN&:. -'3,,M2&H:85.6F(-
M/;QF:T%6KH6:22BD\@X\"#7"O,_FXM"QUC5 9!7U&JN%03@!YJ^4T'$U%1G'
M+'!@V&=0/<06^BAQX:A)=F)6"LB9R2'8@,P &%/(0*GW\(%-K:Y4]0L&SBJY
MG&8&H-*8C+^3BW4#;RT9J(#6C-E.7D*#*6KF(]W/C. 'TC)2OHD5H!E*N1X9
M34@DD\7/[@PQE6*A K4J1@&*CFQH/S<2A M<Z&3&,NQ48T->1R\P"QXU];BK
MN"69PR*E*^<(R*<21R+ _9/"; NSC07$BN,H],TJR%0??B3C7A1Z3^WJ%1^&
ML[\$HN0]R?3T@46F7[W.U@TYT\.,V_R@BH_$5J3\XKN^HV+-V_D>.6G:WT1!
MP'T<9FPA/*TR^9P#057SDBM#RPKQ0H6..$DK*[+XAXRK&E/*:FE17ZN+--0;
M!+"I.0.X(*E0<?> 16F./#06BDA>;*'=02?)E+X^PMRY#BR^@N'IJ:/GY4-,
MM*<P1C[^+] :0F1BYE:A^R/'&O,X"OYN);@#9DBK'ZC1D>;,:,"&/++]'#?4
M7>Y7R*CJSX' >6F-:BI(XD#A;_I(PQ\IJ00AH"*4H:<+N+QV]7J'D',@9585
M!)Q+DD"GLX@<4]14 SE"IKZE?M"AJ#[:\^ #'<2N#2I&8C$UJ,<<" <!P"H9
MBH+5!/O/C4?5RY< )(S(?\XX"\DHN7'QK7,>6/%FH<( %9%)K3V^^M/;X\:F
MF@4@L?$^6M?:<U:#VC+Q0LLXH)[BVBO+AK.W>6%9[L0R3_#1%U]:=HXV!98$
M!D(Q)"T'.O$OH>AC7?F*]E^I?*#V[\MBSUKK2.H&@26VN2]09.F&WEVE)N,[
MUU#>]YI\VG0=3;K6[33;:ZUHV0G"2S.8Q((F#$"?W9^$U<1=NE[\KO<_:_NC
MI]W*R]:>E?<A'N:XU3:'7'9.BW&^MKW^V99KR*RTRXV4-S;?L5A MS'<U$$O
MJMZ\$XR^9^QJ2=:.[W0(>T'8O8AT+UK>>X^C>V>HU_U5WMU WGH=IM'7.H^\
MKR"ZT[3[;2]F:?KNY8]G;2T2ROYYXHFU662>\R2,@(6ETR8N]<=]&>K&Z.AW
M5CIYUAV?+!!NKIMN[0MX:$9\IA.I:9J$,Z6TD3JXFCOESPE2KU#DA2<."I\/
MF =]/RN>_JSZ?=PF^]F=Q6S>XW;FV(="U_IGMJUT.UT'?L6GB=[/1-9W_/J5
MTMII6E&ZGD35+:R.HQVS"/T S"DXZ:79-6O_ )?7S%>U[MC[,>\#M\ZCV75*
MPW'W-7&^+;2SLC9NFZYM#I_I^N;#EVWID,^I:SO?2-1U$63"2=T2V5V@"^GZ
MK2J!;O+X3%+-C?,+[6]I_*4WK\O^^U'JI/U/W-J&L[DCW;%L'18=FV.I76X-
M.U6/2[A&WX=>>Q":4$:ZCMG*F4$(^6K+-?T,?U-?>!\QOMFZQ?+'[<NR;8<O
M50]1^A5AL&.7<^Y=B;>TK9VZ+S;^GR6.JK93VG4#6-0TVWNQ=RR6IDA=V"(D
MBQR,P628M7T@LAN(XU(5T+KR;T<C X#*0:!:*H/(X^)XJC/BVJ"91CC0@8CQ
MJ* X\,06:X]8JK,*8URCPPYBN)X8QL"63(Q",61R26IBHHI IC4AN*"_60AE
M+F@5@2U,* DDX^ \. .A8J!&%#1**%\"6 !^R236@!I3B RX;-!5F=%'D  4
MKB/+2I!% .?T\ &.X$411)3Y0#0*,<V.-6'(FG# (=BX&+,P8'&@8@$FN!Y5
MXH7+//E0ID "T,96K @@5. K4GB8@2RW$DI])BJ93F81IERT&52P'M*U^GBA
M>DRDH'9E6F4L.:L.3>P@\N,X%I+H1.7S"3.I"L1D$>7&I'O Y<) WB62I:&C
M!!4L2,,Q/($C#'C0HLM&,N$A-<"^.))KS&/ 4IE0YED@.;'+Z2FHI6F<U/EX
M#TG]O4C'\-)WX/G7,.Y'IZQ.44J>KW:R0*4I[N7&+^4$6GXB@RO\XKN^16 5
M#V_T7'.2>UOHD>9B-!5O;Q..PA59)2.<@:@K^E5L M01RI[.+BX D61S1VD(
M7+G8T+8FM:'#F.+J%^2.,N//(Q!Q95YL*@@H5Y$^P\)D!9E!JBY<10TYTS M
MCXFOYN*!!T%&]/S"E"2:$@4.%*8< X^%/_E3C +],%LS'-0"@*J0&I0GE7BY
M LJUKE4$>(4#_ .(!*<M"2?*:X8#QI45I2G *;>Z65F4<EQH<#R]I%: \6S
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MR:7J#T0:??5:E0UI, *AO_JS3ZQCQ-PMBTG5/3,<EA>T7[ -O+E4^>K(&CH
M5D8 $$#,<,3P_H%\=E>QR0R?!78.+-(MG,6:10%4NX3,2J J/=P^PJ.GZA(
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M#,@;$$!ER^\5QQX"C4!LU#E (%>6'@U!3@#4? /]GQK7ECSKAP!45#.2?Y9
M#$?:HV(QYTX!9+7.5))4'"@H*>) &&'$"5XU=E)QRU^@@^T<461"C8 9"<0,
M* #D.?,G@#)8%<"7[.&3 YB2H- 1A2M.)\!%*/*E593XY4;&AP!(\33BCTG]
MO$KG\,]WYGTW#+W)=/%RE34J>KO:N*@<R,IXQ?R@B_\ Q$J__P QG=^1FKF[
M?ZXJ%I^ZWT0\<#7#B<<X$+N'N]G@</9]''0 KZ08K0EC6C+F& ."C"@IQFZ
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M+!B:4%!A0UX 2T8E"5#<O#(:^\@GQQX 4JF)LIH00/,N4@$^/+#@ NLD2AF
M9:5SC+RI6C88-3@$WQ1GC,:HD:UJ)*-7RAB?LICAQ 9&A :DJL%J<V5U8FN
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M4MEYTIX<0$W+Y,OIHLS/4,%#*5/N+Y5)'T\4)BT@)S    L#4NH.'/D>7 &
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MA5N25(8'*>8IQ<Q-VLI>Q'K#JU]/=_=%K5O<O(SL[6<,!:1VSN50W:6L=33
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M7[?F!Y>!XF3"OW:^JRQY&ZJZA":_82VW*?IHPE0 'ADP12]LW5MUD?[U=85
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MT)P&-*8@D5XN4PWIHOS-M=V?$8[3I;H>Z+Q(<LE]NK<VOWY]=5RB46EI\):
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MSIZ<8J.&:8C&KOKOUP=E27JAOE^5"-P:BM1]-5'U8<,T%R=9.L-RM9.H^]\
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M*UYRBWD.O7C.]#/#H4$4%<,T:B[U%' IXLH'#/'"?R;&TGY7H5RUUMG7KB,
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MWB5X%EDFC9(DRLQAA5V(^R55/)6H/B3P,#_UQ8M,D*PZN4P"@6Z(U30@T8R
M@< &[.G1D&6TU"21R"L<[)#@:G_10CRU/O/ -T&O6EM))%'MVUG(E:,M+<ZC
M(!@,O^;GB 8_1PRLC.= W/8Q7<(OMJ:6R>0E!>:NK$&0*:CXW^:>++A'76C[
MVZ2Z5M687W2#2M5U&Y@D$>H7.YMTP- T@"B1+>VU2&!LAQHP(XTSBN6=]]0=
M.::"VT/;6BZ1Z:B-YX3>W3S#* *R7-Y.#[#0"O&;=6I&O+3>%ZJRM-!8-1O*
M_P % 'B-?MK1&)QY5XDJV84N^MSLKI'J;+&*Y0;:U *U/E%+<&A]A'#-7$\@
M6>\=R()&N+Z&5"PHL]CI[!B2PHS-:\J>VO%S4L9_MS=U[>'TI++1+CT@K-GT
MBR+8B@H88XP?\/#*,_3<&*^KI>@Y:>7T=-C0@T_E97!K])XTAKU'5XRCF#1M
M$#L#BUK(&9CS/EG 4DFO+QXET^QKVXU6Y20(=)TAI%?D8)F(\W\DM,"%KQ,J
M##JUN)Y8;JTL<CQO(TEM [&(JX*@@RYC]K@$=QN00R9+6RLI8:4621+M'>E>
M8%RRCGAP!$>Y4G#^MIVG@(1CZEX*T(% 3<&G/PX#,=(NM.?(UQ8)Z<B^>*UF
MN1)4MY75I;C*6"G#@-C;LZ[;"Z8;>TN+4]+UO4[C5[L&RMX'LHB$LHS'-=O*
M]ZI$-?IXUVD3%K5LG?\ ;(TETCL])WG!F7,8M/U"S:H\:JVLVP*D^.4^'$[R
M+UHJ;YCNUYI(9EV_O_-;T8^KJ%G^CE 89L-7;(M"?''Z.'>'1Q/W*=;MM=<-
M6TW5-,TG6=,O[/US-)J4EM(+KU8S1L]K.[OD*"F8U!XQRY9V:DPY?2S2(4%<
M<2"%-0?YIH,I]E.,Y:7<1(ZY@"&%&9S7*!6A!-3X'AK07)!;SL6];Z,I7\G+
MD*<-0W2PHM068J#4%6P;#V8?]'&AZ:.W/+_=@>_T #_S,].@1AS^^'M/P/AR
MXYW>$WJ-G\18:?.3[P#RH.W['_\ :WT0XDV5"B[!U !S5;-2AJ*5&!K0CBH+
MK*"" 0BC!CR%<,!]/ '*[M2M2>2M4"E3[ ,17@##ZY(.=10 8$UP]]. &LDR
MUK(#7^=X84]V'CQ<T&)/*I^U4D&C+4!:@@UQYFN'#(6IJ%Q'F :M2:YB6\?
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MM&# >/%P _#@@ET2B_Y5.?TG'B /HP4S>I&G(Y6=@?9AY3[.7 'I;A6!$UN
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LFM0^#_8/]COB8OUK\-^H/V9^,]:T]'X_T_\ V5\3\1Z&7U/-GR4QR\0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm2127058d1-ph_mod42cmbwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_mod42cmbwlr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K@+\ P$1  (1 0,1 ?_$ ,D   (" @,! 0
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MV#0O1D+XC^C#&!8Q?F!O=R:,S-ZNHE,&D212^G_TV'S7XD:H>D(H,_V:'#&
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MI!^S5<P:85 3%JA5"]U+5J@ 6VK2 O$E9T)! H!AR"0VL"N4^;E:JU(:)H0
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MCCEB!A:9D-F/LE2*:OB21BC(2IU$^)PP!XDTRSXY'"@*XU!E*, QHM:!R!0
M@H33,KQ-*8>0L1<M526*UI5K:,<&RI24ACEQ. @5DC)U=U*&"-!7_;!F[^[$
M "#YFH)F134" >T'X4(RX<, ?0X ,;,I/B.EM)S- "<]5:<, &=9%C85#Y5#
M^9)J)[:@D4S/PP $,IMSKTA](T4:0N:,&T_:XT'?BZ6(U!0@R5!J JEJZAD:
MT*D 5^C$ (F8I)YCY5(CJ%+* >^BT_7EBR"J@8*RA?$:!@?V2*FH'9X?IPU\
M@4B@BJ#[RHJ]!E1AD#]K-</X'!53^VU>\@@'OJ6R'PP]1,UH<B#W'+]8X8@&
MRN5(%!7(DLSY? , ,70",9C4!-*:J!UD8FN8H*_2>S%L(3QS:)5CCBIJ0L27
M"D*VKBS=G93 <%55 Q%2H^O+LKQRQ8$70!2RH"Q;,G410\1]JG;B3 #Y;!E;
M1'X34\<QPI4G+CW84./JUAE)-<AVT8=@IEG3$GU$E\Q6JP8KGD#JX_"O9BQ=
MC$K%A10"II7*I!SJ*<1E\,)U] -4CC4^ :@?B >S/A6F)5>HB1'J0@5/:33A
M_B/?A-> Z%2M0%!7Q"E >[O'?C5 @D8C)V(-:T8T/?VX: 9$:@DQH0!7A_L%
M<\)J!Q9$<4550+7(5!S/:*D?HP@9(!X@'Z17% IZ+"0JJ&+99"@\)H1GQ/;E
MC,B:JNA*J/L@Y@'B 33,G.N+ 9MXHG##0*JX-:@?#+/CB3IZ!DA(@=+%:D \
M#F>!\?8/AAK(D?L5\4@8D @)4&E>WLS'8<3R..[&L="4!U&I4A11#7+0=5>&
M=,7^1)F" *<LM)K3P9&FJA--0&7'$CU$%D1(U!8'2 #ISS^'"N+,3,@T8C>+
M4#0$4"UH?C6E<\3R "/3*5H3'IK0DLI8]M&RKBSZ7Y%HB1@:31AQ;,5(''CC
M(C2%W8* 1Q&DY4RRR:E<\ 50S,549**&G&M%(H.% #@)JK"1 : 5%=50>P@#
MLSP#*U4$Z2=3L0!2H![ZD 8"2HKNVI*URXGB5H,@>S &C1V#*@) &D_%<N%<
M74#,8H06*T%-/ZM('V?KXX \=N242N9S-3F1\"*_XL(C<,&%5 K&<_\ '\2<
M:J R$B8@K5:Y'(<0.)^K%&"B$$9]XR/%<P.[,C]. <ME5P/,8  D4-0Q[NR@
MQ)X&9U5)'"AE% =1H!3MI75E]6$>@6#@J0I!)#%: Y@ 9BI-1GQQ18+;JPB?
M3F8VJ23340*?1QQFP HP)%":$@Y&E1_V,:L-VI #YY\0!6N0-*Y95.,]A-5\
MPJP*$G26R>M>VE7&1[,.!-H29O+TBFA=()8:75@=0*'+(X?R -MZ@N&U$#[&
MEGI2G:&K_AQ;H9AM"CAHQKD_8!+:?CJJ6K^C$NQ;V\!E#_,:EF#"@09 9<.(
M[<*B00V2YAE+!3]AJJ6^DJ5H5^&+5#*01P>)1)#7[+*2230\2X<9_2,41C2X
M$C,(XB#DU202IS!8D<33L&)J)- I\3QQK*Q(+(-7;JH"["@/T984%&HO#0!G
MDTC5/QH&&,S 4DA222-@QT_M&KD#C0?;) Q8D%-F 30$U8 4+<"*$GQ9 8NH
MR(I(D"KJ"@KP(-0&!/#O&)K8_?'4_P"K'U\5?Y.?]U_RL_PXY_Z^ZOS8^_R&
M/NV>K$B<Q@-T*!3Y2.8$?RS]&?\ ?#*IX_#&^O\ 5'R"2:)5\M@91Q&F%( M
M>)U+JS.-:"#Z ]!%0']D2>8?AXEH#BAWY>T=%<*%D\.L!*U'%=1[237NP VA
MLDU.Z0B@.HN' %13Q4D/?\,2H"*KMZLPMY8G)\3"&-]-?@[FI.>5,JX!R2UM
MO(,@\193IJI.1H*ZJ>$@_1@%U6V@B= RR,JZF)B-4%*\ :5K\,\- YL7*FY\
MZ[Y9\N<I;3)OG,VXR10V&S[>@EO-PDDM)[MD433)Y.B" MQS /"F;B!VK_*M
MU\$1\_I!SI]UYL=R;/;H+E8Y8LRM;>^\PM3C1 !BUV3*&OWOI_ZW6@BEN.E'
M/;0%4CU)L-_X+BA\N)IH0ZTTIF>PG"IV+AI.]<@=0=JMXQN_('-]A'*Y5UDV
M._!H%3P^8D;$L&-*G2<2N%N'7]_>/LLLB[IM.[V<*45A=;=<6P@4&@)>1:$:
M^ J*XET*.;G/E]F&F]C&I@KJZK&%I09RRPZJ_#*A/'"PS^]7+JD".[@;3]H0
ML)FC/"CF-ZZ"3F64@'MSIA?N,P;SM%R96DW:T4:E)CK;%US&9":)%&>9TX6+
M6*;9GE0&^LKB-E(#?.1P:'I4&1974M]66+,B]"[8(0\<]I.WV5C%W;+7XZEF
MD=0#W*>[ (&RMF<A);15)RT2+(Q)/ AY5KI.52.SAV8@')85C/E2A1J(-%AH
MP H6J)PK \*4P"B[?4U:9G51PC6$&C"H) G%0:X: #;-5BZM,5="A4I;A=-2
M0U#=EO#3N.%0,-MSJ$"02@,*H:#QCM9373ISK7"8@!;;IRNLD4 R"R*GZ1VG
M+"@'Y&3*F1SH6G4#MJ23A04:QEED=-6C3I\2RER*Y D!AI#4Q*D9^2>,JC2L
M216M3GGP !(8CX=V% !M-4I=7:0J!0G5^M1EQ[\!,VQR&H D5S'P)RS&7Z,0
M)$L)=);P@'AD.)S!J<\!B6V,RT)<5(.L5:O=3.AK_@Q?34*)93HV4\R*#4T@
MC/'(4:4NI/PIA,V"+9SA120,2SDLRH';/*L::54GX9# %%FQ+ZV9:*?+!BC?
M4^65&9@/KP"C0O"S#SW5EJY7Y<G30Z2<LN/=EB_8"1;IR0EVR* ?#\HE&J#F
M/,R(![L3T&/+F (>XE+ ',P01QGL^T%U?HP$H@5&EY&SR5A&7S;@0PK4?3BS
MJ,^/64\P-4&E-(=0!]K32I)KW4&)H 2PNNG[4U5[0:J>([>';BQ(A/'*UNJA
M(Z.%5%=@*$5#',@U.66$^H!\E=H 5,84H"236AH>TOD1]&) Q+'?+$2(D"BC
MY$,6H..;9 CNRQ;"\8D>A>9T[='RL;I]%6E);ZA^C$N9#36]UI^[:,Y4>D#:
MA6N=&8A1EV4Q0 VUUE4T)*U^]4?:('#5VUX8@:%LZUU2J2,ZLA!I]-<UJ..+
M &\ T$^8K+P&FI^&5:C+%]0O';2NQ5(PY'>:5 KG]J@KC-;C#1WRL/[-$%0^
M(DDEOC0$9#X8>P8\RX&D&-5J*@+"#JXUXDD4^O#4 :VF8EV++7Q:0GA ->)I
MEGA5_4<6.13E":K2I#'AWTK3,8H+5N.AJ<*^'_[[%N=AAH7G6BANW*@(K3M.
M8%*_1A.L!LVS+&M*:M*\:#42J@#X4([<2)$@ES$JKHR*^8-,<<HJ34C6<U()
MPT!8_F)*I)"TF=1'H122./B%*4PFO A-#<)+&KV5RE6) 25--0:9G3444 <<
M-?46.V;=?;M?VMC9V#7EU>ZHHH%G7Q/0$D,&2FF.,DU.'T ?D[FWEGM[B PW
M,+O'(DA97+1RNC*R.SE"@ [^SAB:A4^<6\H6OGY5H)%!)KIR(0 9_7AR+"VM
M[IQI-J\2K4A*HQJ/B:G]> (;2Z\0%K,VG*@$2-7C2CS5/'NPJ0%E8,RF!T*G
MB6#5XC@I;(T[\0'1"BZQ"PJ#]FE./TUS. E&TJMD*F2I) !TTIEV@B@& =2.
M5Y(P8O,.=09%0#M4@4P@'-O>5<I:L2",B]%IF!60U11W&F>+0)&LE=)C*2$C
M4 RN(Z,.W*I)PKP'8@T0TA26 [B#WGP_[.-1%""1Y,[PG[6>HU%"17N(&?PP
MH/>2BT=6'AH3P&5#EG^RH''%!#"K $FHI5:$U)[@H-?A6F)8P(]0TKP H14
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M"D;4IA1:M'H/N?,EM[7KERHLH!)D>6Y,97,@#P(":'"BT4] >\S<.N_)VKB
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M9R& 7&Z;7 &83QFI(!\9T4%?#]\M*X!"XWO:C&U+U8RS:B\<DH8#MR9GI]6
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MQUKX0S'7EWK4#3]6 8^4MFX&$Z30:@2:#+,D@8+H(+6U45+6Z]PH&/U4;A7
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M$3Y$+Q9#XX7IZ$0M!T_V4@%.>.66%>R6\!^!JT1(POA9@0]-+&8IY?/'*>;
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M7+MLSCUW>EN5/6QZU-CY*N^7N;O29>[Q%&C7%E>$V^P?AD-RWEK)Y5PS+<+
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M=ET 4(2S>8=V34I3/OPR,";>Y;U?:.0 [(I-2"^VL ,N(/8<,TP5Q]R7K0)
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M[IIHNNV<T'T!LL,I*@^GKZZ[A-?S^W94>ORS5-<JT+U&1PR,1/Y^.NQ )N[
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M@5K5>VN%27'W)OZ=^;AF;.[ /'5#E](\MEJM!W88R9;.3>G;F\ %;&[7A53
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M\]7GIRGU&RZ&1(*CQ#<2AJQ&BE=L[,/N4Y'ZF>C=Z EIT5TS$C28KYYV()X
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M57/X>$(*TIV8 :W]L&RAF44-5TEBOZ1D<^[!# O;:11J22A_8>$2#34@ AE
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M'E;IY>LWVI(N5-IL& H14FTLHNVOQPSDPAR'U[<[F,/<]/.G,_ 5FLI%).5
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M^4;J64@2/:<V;5,!JSH"1.U7K6AIC50G,E-T]0\NY*L!Y8MXXI&J7LN8=LO
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M J*"@&)8L]*K1!-;R1ZE U2ZI&KQ.GMIA8PQ@\SRA< QHP\(R^UP&8J.'ZL
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M7,B2364)/WM).#*B.Q4YBC9,,P<L/7UD,M*CQR2+)X&36I((-5%,ZH*9C"M
MNI\P$H^HZ#D@-*T&9\)S'PPK81:55 JML54Y P-K5Z$$DECGGQQ0U;RZ%.I0
M"[#3H4J"-.DDBN9H< \&5@J!S5OV2"!7Z.W%$]"QY2.JY44 D'NI0@XD#C)$
M0PU5--->\G/,T( &&D@<$,4*$R1VDQ!)42R*M-1 _P"]\17Z\ =HXM*@PQ L
M3GYEO4?063[.'T&5M+0$46<^(+6ML^HGL0I$ /K. <-M;JXC".'"D%7T:Z*V
MDYU I]&&D":6ULV82< '@?((KPXLI:AKVX@D]I;BKZ2,P0LDMNBDC_)TA#]-
M:XL#*PV7]8]M&A7Q@I)$(P1PH2&SPO4'5[>4E@=5*"C7-N0>&1K%6A^G%!TM
M;60>8(H(VD<BJRQ^'2#4C1H45/=C.H#-9*X4JQ/]8"/.0U"T/^5VU[:Y8HE;
MVEMJ0R01EP*$F5:5RI4"@IG@&S#;IXXX;?2:U =6)'< 01G\3A]P@T43/XK0
M>4?M .>_(U4 BN'@36VL$!46RQR#/5+<TRIV!B33+"M- -+.S+_>:6!XJ+NJ
MGO&D%#E^C$FPT;"SHWDPL0,]*R1BA%.V20F@P_@"2RVY6\=MY0H"TAG&;MP'
MAJI)[\4$?;;,Q:8XXV .I9&F9C4M4C[)'PX?[.( /:ZUT1Q1,0-#(DZ!JYGS
M-+9 9]W#&@*VV]XZE[56+5/@FH2,C^R$3_#7$#9MX1XI+>5#P#&3S*TIX2I8
MT'PPU 1ML<[>;]K6,P9:"J]JJ$-!]-</4,?AL02- #$=?B*N"I#<31AD?HH,
M-8"\^TPQF0I+(54%EJ%KP0@54$<2< FMHQ<^29?#DQDNO*!/92E&9<- W%:3
MK'I$]RK*VO2)0Z'/[(8D,<^V@PH<:UF<G[QT)!\+."68DYTTMX?K)Q1G\/E>
MVH;V\0APWE1SJ(F-1Q!<$?3@#:98]5);G^KTFMS$:D >(%JL#08@EY4CT22>
M\2H% SK(?"/U5H*]^ %\I,K%HI&1LZ.OV_\ ;$L/MGX8HG NY12L\MW,8B<L
MH*#(#M)8UIW8@M42\D0O\W<*JYA%^6J=7<"*5S[>S#4"*72 LEY,",OLP-VB
MH^T^>?8,!)#NA#.+J;ROLB5Q  'I6@7+/.N*!ZMW(H-S8-G3^HSX4:BQEB?A
MPQ!9K+N#01J=QF5JT8J8-5<J4^[/'Z< "1=Q5&'S$LA+BDC+$9!WZPI(*4'#
M#4'CEW!0OF7SIEX5^2M]#-F%_8+@9=_UXH:";GE_:,^W^SQ :A2O:#3$$BNZ
M"FFY!SS#01@4X\133GVX:B!;= 2RO$3Q^RM":4[22,\-03SMT$0>01@#,@!&
M^.0=J5%<+D3CNKUBI!*LI#$&&W97SK0Z7'$'Z<4=I]&ND75WU"]1;+I5T;Y4
M?G#GO>MOWV_V?EJV%E!?;HG+>R7_ #%NZ6'S5S;Q3S0;5M<SK'J#2-I506(!
MB-(YXY4ZD]-^9[[D[GKE?<>3.:-EN)K/>>7.9MEO-IWO;[R"1!+;7%C>012I
M(E<_Z.?#,E51GW$U#+!I) #+ .ZI(+2$'5\0*4Q0PGS8J"8EIXEK%H4U[@DC
M=H[3@+!&FK4-%ED: #LI7,$8##O+XM7E5/#PFF79PI3Z\ MKF) "1AB?$2@H
M/@.!P$"+@M]F+0.)5#K+5&7=2A_3@/W,5;_5O:T.K^4?[-,_^5'"G?CE_O[K
MX?GU]\J2-/=(]4%6H?\ ,J3E4_\ H[](SPI7MQOI_5F8U?)9;JW:H\S@*^):
M?JH#C11<R6WFJ69A7O2@.>0S6N!JEY\! *R@>(@DIEV@=E108#&N"O\ 6?$G
M1D2>)U4X8&JHW239I+2>.[N;?R65DF,C*&6HS*T((8#A3 =23\@V4[EMOYDM
MVMI9(IK1)8(Y)X8PHR$@-61EH17/$I6^0[##';V\,^XVEQY.DJ1:0H?+ \:%
M@U3J?.IK3%$FV[:T;7\UMM7,@^\>*E &II#*P!  K3 *_*;/',C7%SM:G-E1
M6@4L*',$(I()[L308N+/8YF*1[EMT$M&?2L,3-44J:N12E1BBRY8M>5;?>]H
M/-M[<WG+!W3;FWV#E]=NL=ZGV9;I1NB[3<;C%)8#<FM"?EPZ-'YH\; -43^!
M^\GVBMY]H:UV&PVCTA-RQMO6&]L[2+?[7JVML.OE]N"QW,\QBO-[M88;^! T
MK,.77DLHUHI"A5KCM';[)'+K?W9^8_9^V7U+\M;?ZZ^3>HW,'6.XZ6<N_@M[
MRF_.7X4O)$V]\W0[5 YV#=+.P6[7</GV8LNH@J"?$M77*O%'T?,3]]_RU:4U
M],^M.EUJH,O40>&M%T_^<_V0!EV8U\N!B/G[\M.I98^FW6GM#*MSU$SKD13]
MZ3A\MX/=+]]ORTTGBDZ8=;:+4@B;J(,Z4()_>=J4&'RX/<LW/'Y:)'J.F76Y
M0I!J)>I&0J"2"O,I7CA\^ 0\[_EIG6IZ7];I%/ FYZBC/LTG]XL\L3Y<!<\[
M?EFLO,Z7=:M2FOBN>HS&O?3]Y<7Y<%?5(\Z_EFW4#^%W6ME.8I<=12/"5X#]
MXFI3+$^7 6;GC\L^7(_A=UPTEB31>INFN0%9EY@([>["NW P>?/RSB'S#TQZ
MX+3*L8ZG3"H_VN^@  =N+\N!$\__ )95C1NEW6R5@%!42=32X[M4:[Z64'LK
MQP^7 RO/GY9.E1TKZZ*<Z%5ZGZ1_NOQX 8E=N%9_?O\ +,$T/2WK?2E0"_4\
M=U2?_.#+%^7" 'GS\LB 2W2KK>:L0/'U/!K6IH#OI.&O"I'G7\LE(NK^%'6X
MEJ9E^IE<C4<=^!R(Q/EP)MSS^69DJS]+.N;&M26DZGDDT /'?Z&BB@RP^7"
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ML:5[#S&FG#Y<(5/.7Y:@RR-_"WKD&U%G?YWJ22#7[1 Y@-,/EP)#G?\ +4@
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M_;]2F7AVL.8E6M?HKA\^!@=0?RWH)T=-NNI/]'^(XKV\3S&03A\N!$]0/RX
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MV4FFMY%*BC2R^<J'C6H,I X?5@,_A^WE:>8NM@0TBL)%"*: &2/P5HQK7ZL
M*:#:8"J?-1I6H'WWBSS) +490,36/H!O#8-'X9HW![-85FIF#J742!W=N+8
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MK4J96)XYU(B'B'PQ00V17[3Q1J: EE\RI.7%M)'B/<<2@46+KDY@DC .@K"
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MTT0 !1V+D,L%3=)2:,B-PSD34P%12FD$8#)\T+41 5-*KEF*=G&F A24M0*
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M1PJ((&(X"AHS,:T[\L! 0[GYOF-=+.NBACDCB12>)( 4T('>< Q6^((B> $
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M(!D.JAS)K7ZA@4FUS?D&EO$""*EM0 '^*M<L"D_,O"%;R+<TR)JX '<!JS.
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MBE'!6HK6H!)\)-.S (OL=E)35:P-2F<@&JF7:*5&7UX!>38MM(*FRMZ=O@0
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M:.W*1=)RXD 5IB3]Q&*PMI':,@U:H\+5-5([#6OV>[%D.+9VD \IE9B06HU
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M3$@$-FV67Z1@I:6U5E1/,D+&E7!-17Z$& %<;7K55,T]*!2 [J6 K4Y9TH<
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MJEX&!:?^^J?HRT#_  XJ?1%6DX"W% :5\T#+Z*8BN2MD*VNJAR!G3]%-#<<
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MN=8[-3FI.1--1!'T\,  V%]_W^Y[JU;Z*5J1@%S8W(K]]< @U!!8&OQU%A3
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M<,+[; #>DCVBR#_UMG-HR\)7T4=;*@?_ !2037NIA?;8!;TC>T:=.GW<>;U
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LLW\ ?PK^8G^&7-/XC^Y_XYYO[U_PO^6_>SS?F_NODO*\^GBI3'/7+EI__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm2127058d1-ph_photogr4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_photogr4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ @ -X P$1  (1 0,1 ?_$ -T   $$ @,! 0
M      @%!@<)! H  @,!"P$   <! 0$               $#! 4&!P(("1
M  8" 0,"!0$' 04$! L) 0(#! 4&$0<2 "$(,1-!(A05"5%A<8$R(Q870I&A
ML20*\,$S&-%28B?A<J*R0U,E-;75)H*2-#9VAI8WEQ$  0,"! ,$"0$& @4(
M!P8' 1$" P $(3$2!4%1!F%Q(A/P@9&AL<$R% ?1X?%"4B,58C-RLB06"(*2
MPD-3TS07HM+B8W,E-8.CP^-49'1$A,0V"1G_V@ , P$  A$#$0 _ -_CH4*Y
MT*%<Z%"N="A7.A0KG0H5SH4*YT*%=#C@,_IC_B'\.B-"M?3R^\[?(74?D+?Z
M!4=K?98*+G8IE#PHTNAR*C9!Y&1"ZH%?R54D'ZA07=&'^JH<PY[#C'7EOKC\
M@=<;9OL]IM-]Y5I&4 \FW<GK?$XGVUZ&Z+Z&Z7W;:8+K<+7S)GM5Q\V5JXG^
M60#W"I0HOE;Y%OD&+NS[/=+-W1'!@.C3=?@"J9!4 1%-K4VQTBDX]Q,)0[=4
M"#\N?DF2_BL3NB.GE9$W_9[7!\C@QI_R.#G \N=6^_\ QIT+;0N>+'2C#_UU
MQFF'_6U43XF_EV\XKKYM1,AMW<X2_B'Y-;?\G?'KQXJ+76.I*\VU]>]$2M7<
MT6=>75M2272YAM>$8S#<&CQPB@V=F 2J8*0"[UU!U-OUETM(;/<-/4.VV[+B
MZ=Y4)\R-P+R"TQ%C4 T^ -)"G-*Q:QZ>VE^^NAN(EV[S"T#6\8!?XM6HJAQX
M<ZNYDMZ>4,99WZRM]!"HNY0B4%[M>UPLL9L+5)441%O!'=@<3\A$YLA^G7G*
MX_-/Y+:\&/<_ ?\ ]O:_]Q6NVWX[Z'D9XK+Q(O\ G7'_ 'M2_$;NV^8BZS^W
MF4 B2?!,(.K '-0/E.)4H8%1'M^[IS_YT?D<,!.Y8_\ \/:_]Q4=<?C_ */;
M(0RT\/\ \6?_ +RG&3<NS47+$KJQKE3<J+F',+7?_#XE%)+!(GD !G/Z],I?
MS7^3B$CW1#__  ]I\X*2;T%TB25LUP_[6;_O*R7^\[M'-7Z[NT%;D:& Q5CQ
M<$ '(0HG. $^TC@!],^O34_G3\E1+YNYK_\ T]K\H*7L_P ;=-7<H:RR):3_
M -I-_P!Y0J;%\QMS0[PZ==MXF3%4AFY$Z_3U@5 R)A,F95Y J 1-$>)N0^HB
M(9[=1<GY[_*DEQY=ON>"_P#Z:T/_ /;FM<Z?_!?05RP"_P!L+WI_V]TW%?\
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M X 7D/J&>_5$D_)7Y1%RUEM>F6 @8BWML"IP_P GDE7AVP]*/LW3.C;!*TD
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M7E-K@S,;F:S$]D>3I@$?[VTR(>H?^Y^X%]?W[J*'_'H_)9QKAUU$UI<2,*]
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M[6UI5+K*:PEJ_=;%*P3LE>H=FKTJA]%3;+947+=\]V'9VN"JP' Q#-OF _\
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M,'_WE)8#X_VQ9Q_V 2'-VZ,WMN"FJC\QG$BNX;>H1O24DA__ +7M0?\ &%Z
MOK<X T1>S^85S_+M$#L,G)B/_P#2MK'_ (0F.C%Y">/I[*/6SF*^?Y>H61#[
MK(Y <"']JVP1_7T^RYQUWYS>?NH];.=?1VY10]9.2P XS_:MK /_ ,&Z/S6G
MC0\QG.OG^7Z%WS*R& ' _P#Z6M?QS\0A1^/7+KB-GU'"AK9SKG^7Z#G'W22_
M_P 6M?\ ^2=<_>0<_C1>8S^85]_R_0NX_=)+ ?'^UK7C_?"=#[R#G0UL_F%8
MA]V:Z37*V-+R?O'[%(%4MQA,.,X 2P7#./V]#[R#G0\QG BLT-N44< $A*9,
M F /[7M61* XSC[+G&>C^[@YT/,;S%=1VY11' 2,G_&K6K #^G_W,'?HVW43
MW!K3C1&1G$A*Z_Y=H@=S2<B7X_\ \K6L>P?NAAQTOK;S]/92?G19K[J[#M^@
M  ",O( !AXES5K8&3#\ S"=QZ+6VE?,;FHK!D=WZUBFXNY"=>M6P'33%96KV
MS@!U#@0A>T$/<3#CKETT;2A.-#6SF*S"[=HIR$4+*R D4 !(<M6M1BG*( )1
M*/V8<@(#G^/7'W$/.AYC.==@V[1!$ ^Y261_2KVKU_C"]NA]Q%SHM;.8K[_E
MJC!ZR4ICL&?[7M(CD1P& "$'KC[R#GZ>RAK;SK'_ ,S:^%8S8DR_.X(0%#(A
M5K6*A29P(F#[-@,#Z]*,F9(-3,E2C+VCB*]PV[0Q#(2L@/ZXJUL$/_P7X==:
MN9H>8SG7 V[0Q]):1']U4MO_ .2=#6*/S&<Q2C%;)I\R_0C(^3=*O77+V$G$
M'/1Y%! ,\07D8QJW PX[ )P$1].E4KD2L>? 0:?0=%78K[T*.N="A7.A0KG0
MH5SH4*YT*%<Z%"N="A7FI_(;OC]O[QQ_W]$F)'91+@M::OY$7K1?SKVVD^='
M;)(;!I4>)$>7NK'4AZL),G$0 J)C'P/'OGMUXX_)5I=LW>[N(1J:'XISPKUC
M^.'+L%L[^$-^9J0OR*;.M/C[X3;8N5,0D#W2VQ'^*-9MH=%9>6&_[.=-J+4B
MQ:#+@Y5ERRTR9=N1(1,<6_("CG'6?_C?97;OUS:/W0:+&!YG=JR6 &4*>&+!
MCD!C4QUUN7VVQRFV)-P7,: $7%P&'=57GD/X3?DZUKX"Z*?OJ?X=0M%_'D?7
M?E5!MM4RNZ WZYD-4PCN9NH2*<[5D:H_LKUM(R,S8R%7;I*O&AU"*&.D1+K>
M=LW_ **WCJ+=-K#9_N=T9Y$I<8_+TEKH_"AU(G-$X95A]]8[G;6POAI  ! "
MZAWKABJ<5)!XUM 4>ZU??VE]);@J;PRU.V54ZAL2OG%N=!9:%MM>1FXU!TD8
M.39TFR?$*JD)A.DH E-W#/7EGJ+;)]IWE^V3#QQR.:>0+7$)ZD[:VK9+UMU;
M>8U0K <>[W>F=3TPAVXMW0![9%54$SM4C#Q,B1,H_P#C"(Y*4V.W47)($(!Q
M 2D'7!<2Y,-1!I*G)1&/:-GIO9.1D!U5#'5P93@EQX-P$?G$Q\8ZB;AQTZFN
M 0U,;;8NN9VLQ\9 RR7C0&;(WBHLA-I/T7;:(,X<D5<_((HM4@^9-% RA#*+
M*G^4#9XYZ8P2_<O,;FD]OZ5Z&Z7Z"#-'EN9-.6KI:#GVX569O/R]@*]&';TY
M9)Q)E253>?4N$EBQA2I&455=@DX5X+IE4*( /R@8<#U=^G>DYIKILA&':#[:
M]'](?CJ74+O=@V& !2'#'NJH.\[@E[6^>2II@JSUZ]>(+O5E^+I50"@X3<(F
M(J8J340/Q* @ #C'6W[;TU%!$U=*CL*UL!NH[:U;M6T-:;-F (&9/U)ZUJ*$
M&,I?;DR:*J-B2,NX;LOZ?_*,C)@F5,B@I 80$3\0$0[F$V< /5E9#';L1%[J
M5MH'1D2SAP><U.">GSKC.&,TE2-7"9$E$7WTZR2F<"HW6]M4I@ 1'B8Y1^.<
M#W /3I%\@0D?2A]U7K;]OB?:.FU-:-+O<O+VY]Z94;U/U_\ >5&YWJ$(V]I)
M(/IF;A=4GTA8T4D72I@1]U+VC.0%5,,E,4, .>J7?WCHY2^,ZF<A6:[SO M[
M@VT;R]O9^E$%"Z2:.HAK95KI'DC4WXI(JM6;A%!&59'2>LHITY<I$(FJ*A/>
M(0,]@[=L]5^XW$S$ZX9/*5%X=RU1;_>G7-V_;7PN< ,!@I:<R!FBE%YUBV3:
M-XI8NF\/=$8] 7S^5$H.$"H%E1;C[;X4SGP;WW"8")0+@<X#IO:[3M^Y3A6D
M$'AVTRM.A]HW*8NW"V);PX(OJJ%]5^?^TJO)-XF07:VQNC(**.6<HDU3=N4S
M)NR>\U<";W$W+/WNPAD@I!P,&!ZLU]T9 Z$NML)$P)Q //#TSIKO?X1Z)W6,
MV\+61W3@@7-3C@!GA5F>H/*;3VYTXL)1$:1>?KXVOQC/WB.HZ9?2CD' O"*I
M+BLT%&27S[9@P">0+Z8Z@VLO]B"*7$<A^M>//RO_ ,-5]LQ=>6T!?:XE6AWN
MP1$Q511&V^A33Q5Q!O(Y>13;**QZCH0;G17+'RBA$Y%@53(K,2(.1(!QSDX<
M1 ..1G;'?WNA)G(+B,E"A>![?G7C7<ND[J*\,+('QACRU2,"A(HCZ=7T*_66
M3$Z:!TE&IDQ=%1'!A,FE]2NJ(@0#G2<E$V"_* &ZJ[6&^W(S.^AIR7NJQW%O
M/M^T^4WZBT*GKIES5;7L\@X6<OTBIHMY!%@M'NG#83@\2!N^*"[<$C =FN5-
M3Y!R 9QUI^W[=;N8QY9I8,2?G6-7][N,+WR-=X@?B4IH/86_P3=!C*O8N?:L
MV7LG/)-W+Y\W=-S>VX%A)E(V?.%'+8J8_P!<QNQ#"7.!ZD+BRCN6>59'5(F0
MS]/3LIE'NE_:_P!>8M(Y(GQ]/C557D?^87Q7\=MKTS3%@D)C:UC?W&#BKV;4
M\Q#3D31(EVL,3(.'TG]8I]?/M$7/N&C$T3"8"8.<AL *UC^+;N^MW7MT3$U@
M)1P.*8H%PQ]E2]MU-+&=#&8N/9QJWUIJ*D7RMQUMJDXJLP>1K-_!FL+C[7(N
MHY)5&:C$D%ES*PZYEH];@&5$C>R !Q >HF&[V[;6OLK=@#FOQ)(*E!CS3(4A
MND&Y;A*V1[CH+ /"J9D^VE H?V4JW2/6WJG(JZ17[EF5=HW;BL$DW43DT"BV
M,J(@)>)%#!P],YZC-ROK^2$^3(P,48 &GNW[9;L 9*Q[I#Z95ULGVJSH*"R]
MA$TFJNDW;I@HX4*M*)(KMW)R)*G,D@FY1$#<@P!C=P[])[5N#I#HN2-7,UWN
M&WBV:'1C/E4 KU)N^E'JR4FHFZ779KR1RBFD[05<&,R<)-D_843%-4Z8 8!X
MY >IR\O[>*$L;&XD]HJ'LK?<99@\NP7D:46*4E47J!&3E625(S8\F[DY *@J
MG)+)"<YP$2@8R90*(8ZI-UM[MR'F,.E3Q[.ZK_MVX-L"&SXO3N^-932_W)[+
MP#%.&1.Y0F8M0XE^H,FDDTMS))8@G+V.=ND?D4,8QUUM>TNV_=+21SPY;AHP
M!Y./R2IFXWN"ZMW@1N^A<QV5>IYK")O$/:)C9,)H&LB.>W<UIKG;_:/7N7;C
MA&1_(/\ 5K&"W7.X!!]7SJJ3S7=N/_)%Y/)%(D #XZ[5Y\N7$4S4:73X\2E-
M[GS" X_;GU .I"6828)Z?LIL,'9UJK_^8/6FW/Q&>-_B8CX_;+H%XD*EJ6NL
MO++<&IBZQ\;J)-0UMC)=>\?^89VHNFDW538BFR6;H&.^?'(ECYS'!#S'!NG2
M2G'T]/A1")KO$44^GIZ&MSS5ZHMM?4F/^\(6 C"FU5FG86KP7S:>,A",4#3*
M#L  'J$@0B:Q%2@)3%4 !$#9#I>.0NP<"T=OI^ZDIF"$ M13RIT&?G(=82I*
M"4%3!R#T$,X$<Y]/EZ5]=$UKG8K2HU?"LD0P )1,)@-\?Y0#'Z]&H117#]3!
MG3GC%@#B _,)L?\ #O\ OZ9ND:'D=M,7S.U>NG +E,3@D!0 /_K P&,]_P#=
MCKIKM793.>1SDTE,*SD5"G#!1SCMD# .>WQ_V==HVD0YP<-95M<!8 $0 HX
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M33$%GYS)BN<A!.7)Q ,IWC\>;G%*ZXL;H.;(\G2""6AQ)TD#+3EPRKS)UI^
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M[Y#C&S*"8.:[,1CA!5%O&OHM)U-+I*!];&E/-Q:D-)LW!A2,B!5ECE X@(9
M!#J=/3H,0E72[V54Y[I\TB.8?+YH4]M-FW[34<))R4'%SE8!ZF@85VMC)+L/
M9<J%?HO%R2,<V6:$*H!_E^I5.!AX]_@36"Z^CQ#LQ^%-WODL_P#,C<P_X@1\
M:7*Q<(\K.1E)R]3+5ZH54K!$(==TS7(L@61;.'3B.?2*C= 3IG.')F(XSWQV
MZYFL9[:W\T1O\KGI*>U$I"&:*_O-/F-$R#PJ%3FBKCW46&I8QW9[36).36C7
MU==."G4E8!XHJ[77=24:= 7[+Z)BLW1]T1SDI<_M^%>M9KB;=K1D;7. N0<
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MG B];'(1,X* =, P/IRSCMV'TZ&*H,Z)<,00!7NH[[*!@Q1*4# =, $I0'T
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M]U)RO:0<:, AL 41 H]_F[8R'?\ ?CIU]V?Y#[*:ZAS%=EV[=9$$E$_Z9AY
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M(7BDU _SIF2 >Y@ /V]3-I-M[GATJ 8)B,ZMU[/92/C^UC+'!5*>Q:%]G7;
M6V+B^HJUC4?0]@B"-7)@434*$<HHHZ*3)B@O%HME%TS\BX$H?$0ZT;;+EH"Q
M'PBL%ZZLX[_<V37('D-<2>[TPJ&%6A()\T6:")4W7!%TW^<"_3*<!$JI5  1
M.?F!\C_-G(8#JT0M^XQ%5FP?_:+GSC_X 'U)\*;]!\@Z>XVA-T:LC]=.Q"SI
MM+,Y)HBZ@)4L4Z3^Y1IDS'!0"@J(@)R\3EXB)#<@#KO<^G;NUMVWH']*1"#_
M *04>JJ?LOYNZ#ZXZXN^@]@\P;O:33,E+O\ ++X9#')IP 34J8Y4K;>\BZYI
M.!;N)>1CI:4/,H3<;3V7TJSQD"17@LVJ8OA<G8P:9E<>V8.)P(4PD$>_3G9.
MFIKY1(/"78FJS^=?REL'XUVF6&>Y@DWN(@1P1D:G#Q*7-50A "D)ZZJTGK-M
M/R2F2O;3(OXJG.)!R\(01<&C4S.7!CJK^V4R:;URJ<G$RQN7KC( ..M*MMMV
MS8K<NMVM-V $YG'VX KZL:^=E_>==?FW=&7NY:K?8=2EN(8@P;@4U%0#CEP3
MC?=^+CR TCX<.I6-E:?'R]4F3-'DC9P-&EEF<DFRE&97$Y+$:!)N(U5PH'M%
M,8?I1P! 'D;&+_D?IKJ?JUI9M]R800@'+$98A*V*W_%'1VV;$W3,P7^E3B%4
MGWUL*:+_ ".^*'D=9[+!5J>2I1X1W$H)QUH?-HZ2L:[XWV]ZT@,KB21(:151
M(D0GSJ*& >(  ]8!U'TAUEL6VM?=,?.&YX$JG'C41MNR[3$US($)!(KVW%Y.
MZ:I+JRQ4/<6%KO=;7!D\A(LIG*;:9CWJK8\9*NP.=N!Q;F^?Y^Q4S9#I>PBW
M3<+:&22W,#&L#2U"%0DEWO3U&N-PVV".)P_BQ2JPK_Y!7N_6)I[\@RA8D%%&
MS5.+D%5CM6+55=9A[Y#\$6YC%7%,>&<@'?L/6O;7M5G%MFL?^(!%91?[8^XN
MM$@_HJOKIZQ$]6F31$[R9AGATFXHBH+I(7:#INH211>JJG !34#WE$2"7 A^
MN QTPO);V<^5 J"FM_M=O;Q 88+4V,[7J^9%NC)7.$+&L"-S(L74J@DBH B5
MVFW/S  %%$Q13XCD39P&,]-]HM+F"(G&J/OS+F>0 \%HG-/-= [(N#%"1V!3
MH!LQ>(KBH>PQS0KQ)@Z3>,T&**@I X 6ZIVYPXB'' =P#J/WV7>GQ^7"OVJ^
M_C2NQ11;>3=2PZYTS3N-7-U.FU260@V] 1C5*TR59@@]BU6#\JZH+(*HK/'+
M,HAQ.8O$O(X8$!$0QU*=(VUO!>6T]W]3I /65/RJ%ZGW2\W-YB@C+4<J]B)\
MZ)/S73%3Q1VHF?'((FO!C/P"UUT!#M\.O7UL]K7L,>6GXC]M5BU>8WK)GC\#
M5>;91^FL D<N$PRI@"+*%SC@7B&#!V]L1#]PXZ?\<:[JLSRUB;]4MOZ??:5\
MC-Z#Y)[5W#1?[1T>;8SQ33R6E:[(L6FWY24U(V;HP!ZU"51DNLK*N@.Y3DW2
M8)J\A G7,GT@TVFP4%*L \B-_O= JZ.>OZV[G*OM;?\ 1='66;;2@1R- _R4
MG-,:A:W('34(\9NKHE'Q:A3"EQ%^0W+L)18EFL^OT_2F#&"1Y'90I4/\DRMN
MB[*:-TS((V9+S2C?&&E1,G/ARNNOIV"GKM$^0S5V:*.\+4Y.DU"4D"I 0Y!%
MIQ]P1/R O*3Q5VZW&D]U,GQ]_,KK/?\ NG5.N:[6*F2L[GV3;-:55TPVQ&S>
MTJP]K+2QKL[/L;5S6!0/"5>X*UX46AFSYTJC]0D9<"E-GH!0:;&US6ESQ]_,
MCK/>F\M1:RCZQ24X/=U_N.OZ6M7]LQ-OV1 /*DVG7D=8]B:[:5Q)* K%T1@1
M!FJ@_=':G<)E7*!AZ39_F'G1&V&9I'\$O-^3?>-IH#7&O+!OA#QFT]L.V;WL
M#.P++6I/824Y>[)1],U.(D&3R1MEVLL&P*I[QE/HVJ:J92F4./MAW<1^8&CD
M*3EML0>-6->&/DM*>4&NY#83Z$UQ$,B2C1C'%UIM)MLYLD9:-0?R$1:5"U^N
M2%7M5><N 9O&#A 3$7#)3"7IJ^$-87\:0?!H"\J,U(Y.6# 'S?*&<#CX>O;(
M]-<>&=(*,ZRBI_,'IZCWQ^W'Z=(',TU.9*UF)I8R/( [_L#MGHJ+A74R!BFX
ME'D0P\C?K\/CZ@'^[H+0(K,0)\V![AV# A^@YS_'OT,Z,=E97$#%$ #'P$1#
MT_=GT]/X='Y_!<:0095PO(A>)1R&  !P 8P.>_Z]#7JQ-=)77N&,]@$1R/Z9
M]1']O0"4,Z\U$^0\BCG(#C =Q^'KZXQT5%C71(ALCS,8/AQ#(?\ PXZ-:(!*
M['[?RF,(!W$!$>WJ';/[!_V=%QHUXBO$0+RY%'& #L'H "./W?'HSG1LQ7F*
M\#K F4<AG("/[NP]<E,Z46HZM*S@J@$2$P!\IOE$0SS-@/3'ITZMLZ<VW-:C
M]Y<(>NI*K62;CH9N(_*M*/6[1-0<X$J9USE XEXY$.I0VTU[&(X82XCBE3EE
MM=[N+BVV@+N13/MR]5>E!N%/G=X:,)"6&%F51N%G=)I,7C=X<4T]7WI$5R D
M<^ *+DI1'X";'2MK97EO#*+R,QM&G3@B_4OLPIW!LN]6KWNN8G,C:GS7X>^K
M(-@\O[-F?;$0.*2!P$@@!B 1R@?)>X (\2=NFSG-#':SX4*T5PWS(7 YI6N!
M^3CRAV3HJX^.,4IMK:.I]1[&E[_#7V=TE"0UKV^I88JOLINJ!%Q<G&3LJA5&
MI6CTTBYCF2RB2Y6Y%#%3.81=6-O;3H12%O;@!:P?''S2VY)>&%)V]?K2OLFS
M#1;7=4G\<]CF4U:X:.=3TC5HJ52BEEH)E?Y&ND;)R2;<?8"544+@!# 2AVH\
M!AP[J<FQ!)*5DZO_ "]Z@N&QM(:[5?2"3C=&EG6ZF\\O(-CQM89M(M:9/4YX
MX_,6=&/C)%0!R4HECU1QCN#2XVXL PS%&=O\.13W5E7/\XFN:+$4,ZF@KY,S
M]@T77O(F_5ISLK5U,DM9:XMKZ>3K"9R7&:ACWJXS<# 'E4(B+(=86RR(&."A
MP)U$/L1JRPJ*GL-"D8T]?(;\U7C_ *6LE2K^O*-.[Z3F]25?=MIL%=V+K6D,
MZ;0KM'J3-7,#"^S43)6FPRM?14?ECV)#+%;@7D(&.4!Y-@VE(+7#NJ/#?D";
M5G\@NS(""D;EN)KN;Q4\1;#XP: @)Q)F[ML[LJ=V9.SUDAFLHJ,)58Z.I[5"
M0L4FJ ),F;0YCB(@!1=" -"(N'RKDVRKWGX^GJHQM+^<9MN^5VWO'6LZ2N?V
MG2MHE*7L#;DG=Z,QCH^Z,JO V)"+8ZW<R!+\_KTFC8&[=G-E;%8N'(F(7T$0
M,MT8<*0DBT%.*58"=<P%4.01$Y\<1Y<@SV]/WYZ8-/\ 6]M(2_Y=*D>BLY*B
MDN<3"J8#*\%!( %)D  PB/KTX[.%(#$XTHN1;E.8$3F I3=LCR$Q0],CCX=#
M A:![*3EGJ:10/P*(9^!0# ?$>P?IT7=1Y9TY&$H@JFB4F<B!0 >_<?^X._7
M$@P]==!V-. %.),  &-Z^H!V'N'^P!Z2&8Y4JJ!.-8@.D5.:9% 4.0 $Y"FY
MB4?F^7 XP(CVZ=<<*3!%)K^211! QUOI@*3WG*QSI^TV(7N8JYL\4Q#'^H0[
M=-&VUY-<DD'R%P[N-.[>VFO98[>R:3<.(!3ACQK7?\]_(FP;EN#N(KA7!*;2
M)68C(LC-?YWYV[E:(<V11@FH9"19F4(<#$$P") ]![=;)TUM++>W#G_YCP/5
MV5[6_$O1\&P[:;Z_"7$K6_\ HJ?G5?TW7$UH!Q]Y0ETVZ#%X]^KBE52MGJ8C
M[JPH)M!6]I^WQD,% _\ I'(=7NQ)BG:(R-2@(>![>RM$WJ\CNAY,2:42L"GQ
MM9CJ=5W:5DL"<?6PD (]E5)%J[65>O5?I(B7=JI 8J/%R1LBWRJBN ?,(&*7
MIU<>89W1EK5<1@$3O'/F50C# U6%,!QIG05JC0E)>N3+J*D14;*QL@DNU%TD
MNFU/(*Q[1LNNBWD8Z.,H)@3*KE#/\O?)A>W-HXPLN& A<?;F3P)]]*1QE[]?
M/YTA.F+><9RJ4"SGX>L.&;NO3"$-%,V[9BREV2:#=XWEY::5@'(J.U455D'!
M0<*-T3D$@%X&#H:HP-9:9FXM)*D]B :@@7$*%KB^C4-M"BO"C'-/WGV]]+E4
MH]Z1F9Z9\6:F%F=S$2,>A8+4,#)FJRU';QCL),!5,I%2#BY(-?:;H(D*FFH8
M4@Y"4.F][?17%LR+=90Q#_"H#M2@!,T:N)/^D4J F@@VLB"]*1N<%1>//NP-
M6$4@)[?VO);4NWX1"GVN?A04VE!O&C*%6@(Z*<M7U2=/6<*0A&C1^LV]HYE%
M/=634+[A<%$1HD\3-NN?O+$ZX ?"025)4.0G/TYU&;[)MUI=17%J06<"J^_X
M4D:UK]A^]M-WO74>K7*W+V>&K4'/"Y;LT]7R;..JB=M?$5<.HIM*B5-RH00(
M;BR5(FF)A.IR6O0V5S8&KK>QKE;_ #E)-(R7'YJE<27,%_.D?U:>',!:V'/Q
M^S57L/BAJR8ID\6RU=\:YJ0LHE HUE([ FP+4@BU;P;<I$F+2/*G["/;*B29
M3CW,/63;RV9FY2BX_P T$+Q_A'&O/G4_F'>9A*"'*/\ 5%/C:1TW%Y7;YPHC
M5:\L7MW RTI;@1.4V/E,FJUSG].WZ=0DWZ54KEX:=0JIE_\ AX_&](6Z;O$A
MXO4R5L5EL,Y:Y\TM*65Y&S=BL<@\DYI_(P:LS]G<'D'KU14Y3(B43CG'3?4X
MX4V^X*=E'AK+4^L=,U*)H.I=>TO6M)@VQF\15*)6X>J0$>!EUW)A;1D(S9-"
MG55<G.<_$%3*B)C'$3G$Q<%--=1)4U(J1A @AR#B'RE* 8    P&  "AT#AA
M2T?TKQ6N%#_5VP/ZY_?\.@M**:ZG*81Y% 1 2GR(&[8QD0'XB!O0?V= 9]BU
MPY,3Q2O$R)CG04 < 40,8,9[X[X'UZ=G'OIH,17N<I5@ P?* &#L 8'Y0XB'
MIG!@R _L[>G0Q&!H$\J\PX?*( )1,!P+C/P'&,_ .W^SH98>V@F'97J"ARE
MG?MZ  CV^/;'IC ?[ _3KIN!"<ZY)P(]/3]G*O-4!'B EX@ !C_O^'3E32"5
M\ !#X?J/</B(8_ATW(&HKG2PR KQ6,*?M?/[?\H9$3<Q$N>(E']0#X]=1IC7
M8)]/3XU].<G,0+G B(9Y"(#G].EJ)_TGNKH83% O 2D3 ?F*(B&1$.XACX@
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MLJKQZ%QM6NH5G*K'90SQ8Q"+ W,NHX4; 8I%3B32<D[)_$ @RS7]G&CX(N9
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M2/<KKN$G#22<.2C[R_\ (=5,>0AC&![!)B&)\;)8I 2U.U2.Q/=58D+9/ZD
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M#6,<G=7;;.^EQCB<:\%;!#,$2N'LS$MF_M@H9PZDV:#<I,\1,90RH@ =^XY
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MW)6Q2$+),79"2"01Y>;4ZRB)3E$P@?VC%Y"4<X!S=_;.FCDAE=)%<8@!J9A
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MD$Q)]M53^>7F*RHT5,Z=H\@R<VB0*5E=)1NZ65>UQN_;"Z9Q47'MTO;E7K]
MAO?$CDAFRO%#B90Y &Y=/;,V69LS@ T'),_W?MKT'^)/QY>W5PS>;^+_ &5K
ME(+<$"C/MPX850NBXEW\S(-)=W)KB^(Z4CU&,@\0<A%BB9P2R$@W3-3(LEP,
M9=HN K9 Y#8  $=6@LO+C$K !&$S^&?'G7L 7NVLMFV=D&QM8$0>@Y]M.">8
MSK5=A8*]<"UR2@6)'T<LL#9M(A'NUE!0<.LIG:.DT"LQ35;F#)#G# @&>I2W
MDA+'6\L>L/P/($?JJKV56KJYCF>8Y8]2<5S7U4JVXCVTKQ,S+R!+$N]CHQ0)
MN%.T1*9,K18S@J"3-/FHZ2>GX+"J14.7H(=@Z.T(MF/CB!: 3X2O/#/F,1C3
M%&Z2&#2W'"FU8GM?I48\DRM)B/M+:%1(^;?2.IU*6@YAVVAI)-X1B\:-X9T1
M-VBHFLLBMS*40(!#8'HX#/=SMB<&F$G#%$(QPPQY<$[:;%53,+QIN3$\WF*Z
M:PQVP[1"52 ;O9>7LR2D<XC7QVJ#2+"L1YD$Z\[8.QDDQ21$ZJJ<@(&3,/RB
M8[RWA,-PYDT;'R.<@:5!&)*G-0F>"CMKFZO8H8VL?&TDIQ0]^1IPZ<DI/9M@
M0F)*]R=>KTK#R$16J19Y-Y&KR59;L!.\DS-IB4*V=S<^Z37#^DU!-%$%.*P%
M$I%&^Z-98Q*RW;)-J!,C?X2N2!N0P.)7+ XI'2/LP6RN<-:'!!V>X58II/7&
MT[7,VBVPOD%3Z/JF<J[>#H-,81\:G;$[N];LFI;;]Y>%2>3!VZD?E+V52@4B
M12E(7AS-1]WN[:WB%M/ ^:[<5U9- "NT_P 7#'*LWZBNGS7PCC@5NK->&/\
MA]/A6'9UZ!0]E.="VBE:^OU[V#=X^585^EU.&K)G4PH1ZS"[6VP1["075GIQ
M05EE&V"E(=3W!'D.>KM;,G?9,W"W>^WC8S^)Q>.!1H\( '-.S*I^VBL+2Q$S
M8 RZ(^K5\D]]6)7/7M6V;$R>A%S$J>AJ%'PC>89P;]>OQD<RB#L G(XLZ+UP
MNI7VGMN3KJ</?D'"YP')2E/U4H;JXLYC?OB\RYE#B'.S<7*AT@!#EQ\('?5>
MNP6+#(/\T:M7^EXLN[M_2MD3PYLB5L\<M6S;*GK4**=0*R,%5EDP1&+KL?)O
MXVO\40.K[#=Y#,T'"29C&.1)4H&$1SUC6YLGCW.?SY/,>YZY(A0+W^)3PY)6
M)[W&V+<'L:[4,."<!PQKQV@F4^RWO(>P4NI"(?\ QIN^B!?7U_I#U#S,)D$B
MY"JU=-<'@_PD4S *;F)BF A<XP)0-VSZ@(B''I,>ZD0&9ZD-> A@YR&-G'\I
MOU,;OW[CC(]#M%=R"-@Q>OJKNF502B _TR?-CXY$0QG/PR/1KQXTR>[45;]-
M>J;=$""7D)S!D#EY>G[?41Z"XIPKE%SSKU23]@J@E*(ER4>PY-@1[]L_$!Z+
M#+A1XC&N[I\UBHYU+.0,#5 GNJ\0$3D('QX  F-T,.-*>97HR<MY=DV?LC\V
MCQ+W43F["(Y$O#AD<" AT$4X9UT6ZL:^"3AD#=A 1 ?@'8?C^O1'LKES0 I.
M%=P4 "  E 0QW^;&0_V#\>NF_5VUR= "KPY5D) 3'+CC(  Y'( 'KZ" =.@B
M+7$>A_%!23-V&)@ ;FDW)FY72H(IF!$QR@.>QC"4V #O\1#II(^,.1?$M.V%
MA.@E .*4M)K-G"*;EHNFY16$ +[1@,.! !Y"4##C 9]<==0R1XZSIY<5I=L+
M'2M9J\)7%.2=O;6!(.V4?Q4>N"(I*J$;$.IDI16./%,HF#Y0 X]BX$1$>G+)
M(M0&K!>7[:;PL-TZ5D2_TQ[:['014(0R9P.4V1 0'L; ]^/;/J ]./,A..K#
MNI-\$D8Q!U=U-V?LL)6&2KZ8DVL>1 I3E!8P>X8N3%S[)1%40Y%'YN(E[#G'
MP2B9).YWEM):"4[<:D+'8MQOB/*8?%B,"</=3#<[HI0@X3^Y-%DO977%TJN1
MN@4C,V5  %1RH8WK\H&Z[;:W)):6%>'HGISJV6O0>]'#04/'3^WYTUY3R-I4
M<P5DDWS-6)8';&]Y%4JIWA%P*4R+9%+^H)BF'OW 0#OT\@VVZ<X:VZ1W+3C_
M '#WF2Y9:!BEY3(_KRJ':[Y5&NDY:VM5JLI8O[;;+*E,FNPC&CQ)9P";4/<>
MK>\V%=,V0,8A@ "CGJ3@V4N<!-)H'/2O_2%2_4'XLO.GH&37#U#P#]")_P"F
M:85[\GIYM;ZDR=U@D&C+*/(-95.;&210?O!%#Z1U[,6DBHF@NH54HE.&/Y0'
MX]3!V "3RQ*HT@KHX(O\W95PZ4Z(L9>FY-Z,@,L>K^EHSTC^;5Q7^4U@[@8;
M/J^M%+4:=6CO[<(I*HA&(-2&%A[9"F17<J NJ=-)!83 !P$PCV^ =-]GM8;B
M_%H_![I"T%.28IWGG1;(=IW"=VUOB:RY^H%0<\$1!RH=O)7>^H'&G7"K]>3>
M6MQ6DK5#E5>RJJ4@Z@A153:"FG_R9UGJQ@3( DS@V0 >X=6'9-HGN=YEB>P-
MCAD$9/-KU\289%N6/?5BZ>V;<-GW4[H86BR#2U054E"B)@J9T*WAOM)YMVUU
M'^XHXM6A;HYL,!,5)^^ 5'1FL>5,BJ"8),U<" B(X3 Q3#C(^O5BZCV)FSSO
M@A(F#6:M0"(HP4*[ESRK2?R ^P=TG'O5HT0S!S5:BJN*:O#R/#C4P>#FXI?6
M_P"0.4\0-E0"M<CJK>WBFO+(]>%=J6AW]5$N8E(J96A"HI342L)T,+&*' 0$
M!'IMN.VQW700ZBC<WSY!I,8_A&EQ)U+BF.&D'MK"NMMTDWV$W-I ([=JDD.U
M#(_X16V<E_+_ # ;)C#D/VB(X_AUB<;7-".^HDGVE:QJNQA "B(_H/\ P$1_
MW==T*U<+QH>[;R_//YMQ%5\BMS^.4;#?CZT7+R4]H:3KE=NL[+DLS\E:2<66
MQ5RTI,8&+>)JN'+--N0S\X)%.J5(IR*=5S3%\?O-[RKNVJ?P42MHW;:I&:W)
MYE>06CMWRJ*C-DXW)2=3);<K-9+?$VZ:3:8DG*=,9NW:R((>^]*=7VPY<!)*
M -.WS'\O/)>C>1OYXZO3MTW>#K?CI^.S1&T='1,;+)$8:TV'8JO:74Y::OR2
M5,QF)%['I^\80-R.GG "&>@@(HU14J+921\WZ@]_#?-17Y$?)![9OR0H):[W
MLE8BT:;H=7BE=',MEJ6?4=.7J34U.V$5A"F:H2+IS*D^J<K/%$55#\>A@E$I
M7,4E*^8WDOXW>0WY5?$>>\\Y2%U)XNW_ ,%5J%NWR78'VCY ,:UY"ZZ=W':.
MOM8*T^HE0O&U)URS*UJ3-Q!.D41,914A_F, 09T2DJ/3T].-3CX9>7&T6_Y3
M-.^-U$V;Y]7GQQW1XV;=O\X'Y":*2J6-[L+6TQ!!'26FOO5-UUL",BFS27%"
M53>Q0L%#&*+;W3%4,F$%= XH:$>T[B\UW7X_OR9^>X^=?DE"7GP_\[?*&K:*
MUW7YNN,]:GHNL]W5N)B:7L^!DJQ*R-SADVLB=JDD1XT!M'$]@ $YSJ"$HE[:
MW -23\E;M5ZVMDN=$\K:*!2[%*&;IBD@:2FJ]&R;XR*61]I$73@W O\ I+VR
M/7(42CD :-P5OKK1A_+NDD'G=Y(G*4QU%+?!@?L'MD*6F5<O[#<\%[8^'6*]
M0O+=[FT_S?(5Z'Z0/_R"WY!GS-57I&]M^R6R0I$E4U2G4_TE(;YA,.!'N. #
MIDZ4B%7X-_;5PUL=$Y@(U%IP]5,K71VT3Y0S[<Y@S)2#9T4Y1+@/N0-5,D'/
M;D;(?PZM=Y_6Z0>(\?"[X"LAB_H=2&.;PO<\(*W-=[LV5_\ Q)1J*YU3C46,
M8T,Z4$N&RL<R23*N/+D"J1C&* ?M[]8%:SR?VBV<Q==IN38SP1C@PGX\*E+B
MWNH^HKJ-C#JN;?7&%'B:"BC' 8'-,JTQ]API)9LE,((>X>NO\%<D,":G_/'3
M(D/,N0(FJ9/@/<,@/6PO#C>RVP_RP]6]K2T?-:]0?C3J 6EC:R,<LC&@'/!"
M<Z>.N4E9N79/8^-8JK(N%B+1+HAG3=-9.- 3D<HIJI&417,<W'!P$%,".0[=
M4_J!XVP&2X\$*Y]I7ECPKZ,]#;K%U%M37,>NES23EP//A4RUJCR,'9(IH[C#
MKJJ_1R3)@NF98KI('!>13(H@;ZEJLH E[".?Y?7JK&]CGC%S$[5#S0^K X^Z
MO06WW<$>UR6[)&IY;FEW\JM(4KDBJ>RI_P!X6E*^W1C($I]5IB9D&,6K7J?"
M&B(EF^9('/,J(,U'\BHV._>+&45$YP%0_'^FF("'3)VY2. E:UNE ,, /;SX
M^ZJ;^-^D;GHCIPP7>X/OV.;];R23J)( ): 0T>%O)H&)SH+-WPZ=/</C.1;)
M2<LDT.R*W$17;LTS^X!%#@/$JX!C(!U8^GYQ=%NO)3\:JO7(LHK=]VQP;,_!
M..''NXC'U4(\4FYFK7$K/5E72\C*-7"SUXJJNNJ)SJ"915945%E#&$H9,(B(
MXZOEQ(V"S>QQ1I9AVXU@=E;2W6[1EC%5^!PQSJS.D@=)J<1;IIBR*F(++F$$
MCB!Q+R1#N)E4^W(.V ZQ2[>TSR(>!^%;9<QS>1':-']4#$>F%$M1#Q=M?1->
MC%_9L+4BI$$7BI&3>>44.+E5NP>K"1)E,"M@&Y%!XJE 0 >752O[6<Q&<#^D
MBJHX>^H>^=/M#/N;YI99C-WU =X:IP&)Y"C+C7"E!U9/H6^3/K6/FF[Z59)K
MO'$=<7<NU9+)(-TZXH"LL^8^Z453%42(FJ8N0-Q[]5AGFW1\NS1R.&I"C@>X
MD*..7LK-;Z2RZKZD@DV"%]Z^)-1#48/$"<7Z1J0)F2G"JX;>%L7,I./9M.>:
M21RKIR[1R1PW.LMZE<-0XK,UE ( \3I@'PSGJ]6,5N]C62'_ &D8N&.'?A7H
MRSW+;[.VALHFB&X:$<U.7:%!X\:4-9E;N5#'?>^C]6X$CL@K%;\FS0H>_P 5
M"B<$CJ (@ B'8V,ATSW=IBE'+]/3"I#='O.U2S-=I.A0[%!ECDOLIT;2TY2[
MAK'=LA!&)'3M*>LK57XV7;1HR[ROJBF#ILF_(X3=NGKA%01(@1 $3% 3B<I@
MP:U]*74LDIC+BR,'!45#\>&0K#>IMVW^VO[*+<+<2P2-+3*W%NH!2@Q08$*X
M@Y  \*UX"+._209M&@N7;P6ZR*#<IE5S+@"@F(5(A#F HD >PAV .K[=3B(Z
M2Y0OIZZU/8-N=+ 'M?&-8#@,DXH<,/3NJ1RUL+7!-(.OHG_O&+CY-X>NM*A9
MI&P2Z#9=MQ<)+Q"4@19%!)9<XB=-(I02'(9QEM!,!*"]V'#]U9[UQOPVEXM=
MT<W[,J-?!I5 $^K''$ CMH2K,F\1!^BL8J"@O2IO&:Y56JR3I,%$C@+!4I#(
MJ%,4Q3<BE,!O4 'K0]FN(]; T@NQR7D:P;K%]I:6!+$=:W !:[@0H=Q"\.7"
MA8M];5DO>79'.M[#\6PLTC"9QP,5-07 D_D,D// AG.0'MU?K*[C;F:\5]:[
M3;[MN3VP(7+PP^*5(]/+.0$:^A6B35JA,LCLGBSQN"J1D" 59)($R&*8AU5"
M<<X'L/49=D23OE#E\)3V5=-@EVZPV@6LK0)P $[DXHE7J>'FS_"[6NIH*"V1
M;(U"T+PZ'WT%(J9>BW> V*4S5,K6,%(0*L8PF$!X]>8.NNFNMMRWAYL+:1]H
MY@"A[!Q<N;P<DJ7ONLAM\;+:R<&C0I"',DCX 4_-N>1?CI8X U1UK8$E6"I3
MH\DXR0C$4T%2_P!0016:)B*P 4!]>^>H/9.@>L=NF^];'Y=PA'C<TA" N1=C
MZJ;6?5T<IUWDX/\ A1WZ)3'UQY':>H13M'KN=E4T@2#DQBA4*!4PP=,IU7#;
M)C_#T#I/J+\;]9;R XR6Q=CS_P#5J.WOKG;&LTLD"]Q_2AE\@-QFW1LJ0L,0
MW<Q];0;,XROQKXH$<E9-T4R*N#I)N'21'+UP!EC@4^"B(%#L =;!^..D1T7L
M7V%NW5N1 #A@H 7CEQYUAO5^X_W2X 7PJ?EZ95=-^$'5:H7K<V]7+4H1NNM8
MR5?A';OLF6PR!V,F_7(44PYB@P(F0P@<HA[@!\>JS^0)"V4;=;NU. #W#D7
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MN-<)Q7D?G7HWIWJNZN8A'?QEI/,@_ FH\2.SE\.8R[P:J."^T[@[!&G(50H
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M<  Y[=+2*3CEO;D(UX'NIINVDA+,V< YFGC(D5(I/X2O0D]RLLG(,B%,Y%=
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MFXG+[@$S@ S@?W_#J2MT:X+VT4;2'!1A3.6:J*N .V3*!E  5E#&-@@$#OQ
M,X$?UZD-;5SI< 9<*RHM%H3W 36!4YEN"O PGP83_']H#TQE+7+I*FNYG M
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MMH<[!I*#M/JIPW9KQTY@$3C, 21A@ @7/M%9,5=JN_!%5K.1ZZ+D5")#]4F
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M$W[_ .'3RW9<]M8IN$NU6-T9[@!2>583Y]'LA[.T5G:H<3&(L4Y0Y]B@  ;
MG^&<=NE_M;@XK5,O=SV&1?(F0J>RE*->,N "0A .  83&+D51P/(38# CR$0
M]>_3::-\3],GU)4&;RU).E^L<\ZDB(=(D224Y)B.0-V,!Q$<9_E$YO3/Z=(/
M9J:G"D7W46G^FBTYRR+<B8$,W(XY%[$2'VU#9R(=L!DX#Z_LZ1^WJO7D?GN4
MYTL5U1)U(![P&*1$QC$ HYXE( B8O;(F P (?OZ E\A\UQR;^M5:=YGF X+6
MWOX4U13QP_%Q;;K* 9&>VG_<-@+[H FJ5&=BT6\>D!%0043)]!'%,(@(XY9#
MK K^Z.Z[D^Z.(,FCMP.//#A2ELTNWEMJ?ICC#_60GS6M31GYGWCQ2\D8?8.M
MC1$A-[#W/!T1X$LG]R*\I9)Z(-84P.FNV5147E)-,05(8P![8ACTZWG9NBK;
MJ#:+2*Y:HAF9*!_B#7L'#D\U3>I;\VNX20C(@CWBOT0//\ZSGP/W8X2.1!RY
MH$(N50[,[])!5S-UY0HJ,B95<))**!D@" B >O6S;&RV@W"*V=A"S ]P::J^
MTN$=_'(\X:OU^5:V:U!VT_E*HSVKJS7DDPCTBFL-G;0#.?@IU%1T[3291[=V
M5*2@G+AJ=(0.J90A3D/D,!GK:V2[6VU)L)T*8(2/A6QLW*T?A;8&L38RD5#-
MY*#U9KB!8EB&0JO(]QKR/S)J.6Q_8=1TRT8D*9-N<,F$HYY>O3G9I8G.7<9W
M&$G#Q'X5-;4(I9C)+,6O/!3A0SA19#:VF5YZ UC1+'NBJ24F@K 6=B,$H\CT
MG1_?7BVZC-$RSXL<H(AA8$U#&#)R^O0GD9M^X><QY=9R$!N)3F4%3LE[;[;)
MJ\TOUX9KV\::<5%[FCVJAX&@U>G-H)N+ZQ5&PM+33I%NX;-"R$RVB%9!Q*M)
MUG'D1,0JK8WSB4<!\1F9+W;)($*NG(\*@9\,0!3]FY6\T1/\2=GZT_H;8>K;
M_<J)4HN,LXRUYC#JBV8QS%\SKZPN546P3D>9PUN#"/DSH*F1=IIG;^YV.9,H
MEY-9HY(+<SE$%-#NWD8+4C1>LK/..)F);P+UV,4]42"+=/313YL+<I_=<MB/
M(]-=8JB2>!$YU,B =^HH[I V-CG?4X+3V/=;=[ ]V;@#EZZ:^M=?W.]7ZY1L
MNV?U-A3XUX]KY7%KB95*87CD_=)&2,'&&0D?JG@AQ$P 8F.X].]QN;>WL6O
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MRC8J,U'B!G9%!,"CK.3F')NM+M;,1!C !I'%<.Q1C@<JW:=]AM]M':[> &!
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MKC#6VVM]YUI:MUJX-6P&K.K]5NALT=82.2BM8).]UN1<M7K1TV#VCD<HD #
M!Q.'4>^;;Y6!NS2.ECX:B4/J=A5?OCMR:=ED?<1< ]2/_3J8MSTVBLM'S<31
M&UV9/I<BCU&_M*&C<'=4<QZZ)PC9JNE?A-/(U\T<_.H@7YDC<P-D $&VUS74
M.\ADCG:%Q:7$-&&7+NPICT_N$\._-9*H8,V_PC#ED$X4.GAKK3QRV'(R9'L$
MX8[%65<LWSPREAJ\%92I"[603BHJSB9R5X1 ACG3(*A$3#C/H/4IU+/N+&.;
M9%&%PQ"-(.&"A#E5HZJW_<+,"YL6_P!-I ("#B/UI"EO)MCIG;FR=-Q.NF84
M&&L;1*R3\?,BRL\80@E(W?/$7:!E)5FNW5 Q/IS@FKPP41, AT\CV&>?;([V
M[D4F,D*2>'Q]]38Z?N.H=B;OEU)Y8#<6AR+Z@>9XUX;BV]M=KLBG; &%;N$=
M5JR:^MD3I$>OI*.M;-G]8NZ7;B@#Y9\S*F0@*$%1$R>/7HMHVRTN+&1KR'2$
MG$XY#]M(V'2.VW.T2:G,=*"<3B<N>=633OG.-2US&6"3B2!/+56MR4?#O9-J
MA*+V"9%%/[,V;G1%0QT14XF%3Y2E$>_;J@,Z.EW.;S(VZ6J<L!AGEZ&LD9^/
M)]UE,C"D0)R*#EV5 FU=G;AWK1HV6F82XU1:*.PLEUJ</+J14S'UQ99_'-VT
M7(1K9[$.)%=RF4>)S(>VB(J',(@)1M&Q;=8;3=N8XQN<]H#5&IH=CBGLRJPV
M'3MML1^W8X YE/GZ>^@;G;HIK5Y(7^Z+(#<BU1W<Z)KBJ$*_=R[:MD]R,E-@
M7R!))"L5RA'@)Q<*&4.5/B8I"8'JRRQ6DUH^SN__  FI7O*^%H&(:.)Q&7J7
M&KDZ1]Q9&TM@#I.H@Y889'#C4B7.U4^*I&OO*394Y(SGDS-Z7B=FUO6-)CIM
M>MR$'998C&)D(Q!03(@XBF\F7ZLIN!# ED,&''41MTP#7V&R@.Z5!0R%-:@>
M'/QXY>NH2PNKQLYC:UH3,8</UQHP-5^-%:EJ4_=7&D'J>TMTZ[20L5TJ$(RA
MK+7#K"5R6-F$TIAXX4=N'*?N@5,H%$A0 .P8ZJFY[U)8WXM8071:DU#]?GSJ
ML[AN<UEO\FX N;9O)1H*-"G!&C >RF?J"T[7UQLA[7-L6+7=;I$.5:L4#7E5
MCS+3TC()(8-:K-*L&R*;:8EBLRNG"((B4C@QB\Q* &Z6W:T@O;5ER]Q+U53B
M?4>RE-WM6;E8Q[G([^JYQQ.: D#'/+MRH2MOZ0W#4MEKP>F]=R=1UQ<[:\V#
M:=CQ4PB\EY:PSRI'<J"C!PH0Z*_)(I. _P! R8YR(@'5EVG=;"VVPQW+C))Y
M>D!RN QY%:T7IVZVI^TQVTY8^< _4 2?6?=5GM:BWB.IJ]66=F<EDZ_),G;B
M4<<A5(D"Q7*J:O8B9C^P8Y!R/$ -D>X!U1S-;NOP]C&:C($P&:X5F4T]M!U'
M)"C?*<41, N'*@LJ=WTG5'VR+$>O6[:ZFR-N.-.;";UR(FDUXP)XGV]JA*LB
M^V*L:5NH)C2*(G1+[G+D&.IRX&Y "=C&N(Q&6"5)]31Q-A@=;@!V!4  JO9Z
M=]$!.L_&_34'JGQL=0AV,#L&:FX&A4R53>V8JCI(@R;Q1\^7^I4;%,B4HG45
M.7@8P!WP(=08=ODEV;EP\1*JH4>_"H" ;S'>FYA&;E50I[UK[X'5K6/_ )NM
M27S7EB86UD\M>TZ(L\CF[I$D'*56F6II(5I)NJ=!LS3CS)$2-[2&#B4P\A]>
ME-X??3V)?=YM1"JJI_95CZEWF\W/8O)NFAKH5Y8ZABJ9IIXUL<;-."5 GU3!
M@I&C;.>W;ZUKZXSC =4N$A2N.!^%8_)_E)PH$PEDW"*Q42D3*!S$2$IA./O!
MG^<>(<B_O#H(,D%-0QH"(/93K@WKD[9%!=4IE"'+S3(0"ER ]_A^G2) U8<Z
MC9,'GDII371355$AN1BB81#UQ@?7/KWQUW',6%%-<@8<J2E634B[1N=5)$%E
MA(F0W(QSB41$  0#B7/'XB =2#IM4) Q.'Q%=]U+ ,$P1.4RG QN>,#\0,)>
MPAD!Z:JZN0N58#M=RP32]G^N)3$2. #@P)#C)QS@!Q\?CT,J&=9B:A5 YE,(
M^Z7), (9#'ZCW#]W02B+0:4125*BGQ6X"8!$ X\C=@R/S>A<8^/1H#@3A1"(
M2>$#'/V5\'@8AD\F64 G(2B.!-CCV(&1Y#D?0,C^S'?IC:W4S9B&LU#M"_&A
M#;W%R_RX&:B.Z@R\D_-'5GCHP<-W3]I<[X@NW,36]=?$4FEV1E2E67D)),CA
MA HIFR BN/O&$.*:9S#@)VRV6XO+D-1 :U+I+\6;MU9>MEF88H%Q1 /=5+'D
M%Y8;B\A5D F'2L)1&SLTFPJD"06L9'(&("2?WM5-T=6Q+M!P"CAT":139.5(
MIAZTO;^DV6SP3IU$#EGGA7K?I/\ %^T=(O!?'"^?2%<6M)]J$T.L=&,FHJI6
M-L#4SQ%HZCQ6;E<I/V)U'('7;.Q R7-JH0%!34X''('*(@("-UAC^UC @*YM
M.*(1P2K7NE]%(?):GEM. 3 8)EZ^%)-Q]QO%PLO!VAFQ/&I/EO<?F<QP%,MQ
M27%,WM.P>+-7+@RQB*@(*%4$I![]I>Q!5\<L:AZ#GW'LR3U55[F=J$)CP].R
MH7LMWE5&]=(QA(0S2TU])DD#0R\DS?3STBJ2TTP3=I ,>SD$"-U3-^W/W.Z@
MF(8"3-I9Q@N<7E6.5<D&:$C-,0ONQQ;P%YQ>20O/AZ?NH?I0'4&5>^(,)@%8
MA[%5MW"QCL?L:S.;2>LW1'R9CHN&!5FIEV2K8<F%1=,Y#X*8HR$H9,_[<!ID
M10[#42,?7F"#^^NI(_MW_=N<=).7Z#T[:<\+*-4H"2'1\[*6RT?1UY*4@IUN
MW<M(V 67!H/TLBO'(-)*,=_6E:G,?V5(Q5R!3"?N?J%>@N?+O$\II4$\>*)P
M.':J$X94E<[I%N%J^)0Q\04)@2H.&'<BY8\*/3Q]\/;K.(RFQMX2]>LT<#B/
M;L8M1FU9K0%9 5'[J7EU7'V=RY018%X'8$]TY"$]Q53 @08?>^H0PBTV\%H)
M/TX*>2C+U^I:SB+J:3;[HPR*\.<@)QS-%3"/-:?X:DI6TPL!):.L:@S!7%W@
M[&_G[TZCWJH0LI1:8NR8+/HID=H?Z!;VV23=N4>(B"G%2FW8=-<:8GO%QDH<
MFG(E7 KBHR4G/@M5_==RAW&YQ 'JH@=1732/D[-6FL2-(B(.90J*<+(U>U0D
M<38KZDSC,@.H)Q%,A;R]0B'G-)))5V5L8$SD.F0A<#TQW2/>=CABNK9QD:YV
MK4'',9%2<2,2<3C@<:A[^2:VC;'"7"$\B4/:4P./.J]]D>$^L*-<I>PTAM)T
M)*(/-U1 7EH0G:S 1;AP<QG3-ZC(RKR7M$@"YTRE!RX4;()"(%%80 MOMNHK
M^>TC9<A7.8I"(YQYN& [B<.ZM"Z3OI7/CU*6-:B<!SPX94Y8Z0#0M11@=>+Q
M#F\W*+="1Y8I--"7G)3W?JT#JN95XR;1,/$E+S$H&3(9,@ 0X& QQ9Q6)OYG
MS2@B%CCD,!@G#,D_NJ\=00LO?ZN;6IAF/9ZZ9U=\YG%.>A%(ZOEIJ?@J_+*7
M>XGDFS1-O'QB+B0DU8RJ,&"ZI&3I$G(%572)3D4Y"("/S2O^YHF:OGLCMW."
M-&"DY*515Y-JL2;/;6K/NG2AQP\!QS[#A77>7FQHN<U!4=N[#CCRVTFMFA10
MTXK87,>_KD,E/23%K.6!2 %=O9J\=5A]0K[()F76<)I#QXF-TPM>G[O;MP?9
MM>66^D_U 57N:3X<\%!P%0CKIXNG-B'E,THK<,^P)^ZMM#\=FRFNV_#G2.PV
M-<_M-K8Z]*+MH$A$B),D&EJGHU &P(MF9#LW"#(JJ)_;*91)0IC9,)A'#^I8
M?(WRX@)+@'#Q<U:#[<:P7J)CV;O-K<7$H5)4Y"A7\]M8:FV9N&(<;"B6]@E:
MEKZERE8CSE=+G9O#W+88@]409IJC]*H=E[9SJ% I>( (@(E W.W;Y?;1%);V
MOF>1*QX):3F6:1D<\L1E5FZ1EN(MJN#;XR:P$.6("YU5=O#7*NZO,[053C*>
MRF=>P%2F[1:5V$X@@C'3B"BC=[&JE2.5PLJJX% Z6.X%$! <8'K1]AW(;!^/
MKNXE=*_<)78%VHN  &1*G''C5NVR_P!XLW:G1M\L\,$]8IN><\+:7;L'6HTH
M:='4\4>4OVJ6:S&/FY!XHV!]"JNK"Y316>MP9)B\6*V,LL7@8!*&>D>BFVM[
M!Y>Y&0/>0&N<KD)[U X)PX5?^CNJ-YZ68YSCI<XJ"#WH/?7O^.S;"^X86_U"
MSZOG:;)5)Q1I<B%K%20:.(Z7K4V51W6B/V*;J/8*R[(W<!4'B(<L<B]+=7["
M[:(XY+&9Q8YSOI)"HF!0\,JJ_7/6MYON[?<%B.\H-4=A=^J43'F'I:"\C?'%
MUK"MNF<%MF7DD&5/:NBJ#&2]JB&[P(IF],B &(S?%5$IW)C$1#(Y' "(1G3&
M\7.Q[XV^O0[[%T#F.S.+BTY#BC3GP6J19W][:77W+R]T9"(22,2#DJ<*I4N$
MGNC7AC^,6UZ;)5!D[:-:+!3B]B8"DA*4.,:MPD&HL@4 K*V-#F<M1%4I4BB4
M2F.H!B%U]EAL&X,9NUC,)),7EH:02''+O;W8X@HM;CL75<4EJ&1^!_EE4"?#
M%?TI[:[GH#<M.I&J$5F3RS5*$0YH31W*3VT,$W?TB#-Z\4*B",E]K(4IU#*G
M!P(YP!@$!K>];*^QW)^X0O>R)SU.@HG:=)4A?96@[3O4%IM;H[UYD4?Q*Y/:
MIJ5:'<-MO)[;>NKI5325MI51>3-"0!(8T",VC9\A'Q@/$U$Q<IJL1:BD8I_=
M5,0P  X-B-WK8=NF@MKZ"0-CFD23$^+%%=S&&*X(E-K/>=NEB= P@1E<$PQ)
M/=F34;T2IRGF3?->U*Z+.X_<-%B'T<TEBKN&C%_2"KG>(L?E/[8ECTW*F#'4
M$PD4$ #(B'5IUVW1^U.^V#/LY&CPAN3^) [2F(XJ:S?>?)V;<I+V$ "7 IA@
M,<2,QV&C[UMX$1S1]M"C?:E)>O25JKDM#6F4?$5%H[:1[5$T2Z_K%?/$!,5T
M!5.(F$3&SGB7-*W7K*62W@G<XA[06H.UV8Y$%*J<_5HCN62P$M#' N 4 @%2
M#S4#M6@VM=2A-1>2#K6UKN3K7UD8+PS%W:'[8X0;F'G56,+ J-G,:C(+*SL.
M@X1=IF,4Z;CV3@8P#GJ??KZ@V5MY;1"6*)20F((!<?J3 GAP)K1;#J<6.WG=
MH_$ "=/<%.&2'+*AX9$F]<U;?&E;T_1@;K0-M/XJ\1ZJ974?88.>9"Y@9A-4
M@'*XC; BF440 /E$Y>Y1 .GEI"+N^LMSMUT"$(&E$(=DG# _&K'T]UMM7Y,B
MDVY@\N^8"'- TC4.' >AJTSPG\K=/OO&MU=[Z[KFKW>MHAC1;@UE7CM6O_VL
M[45CZC-BZ4:B+CZ^#2X+I%%0PNR"8 P?(U/JWIW>(^J63VH=-!<:G*H4$.#L
M,<,2<2G <*PGJG:+S:+]\%UI;$WZ$(Q7ZLO^3[>-5W5WRII/BO![35U9K]_9
MJC(;!-,:IL2MBA'<3-*W6,3>MFQHZ,:/9JOQS)F*G_++-/J3$2#D!1.4!T)W
M2D>\B$;O<MABT_U<\ ,R,0,\,TXA:K<&Y.LK65\ 1Z'$8$^L8T0/AX^\FO("
M7O:&[J);'-:O!23D-<4:=%4VBQ#E-HJWC$6<?+?1V"Q-GB"J7O(F8 "Z3?!C
M%$V>J;US<](=*SV[-KN#YH.*%[CVA1[B"<<<JM^S]1.DM0;K%R#-3ZL<5SQ3
MU<*E?3_XF):=FWUA\H+M5KNR*Q<L8FL4VBPM(9QR1'A56[U&6@WK-^@==J<Z
M(D!,JA4SXSVQU'7GY?>^S%MLMI*R2- 9'/,FL@(7:"YQ&HXH0$R2H2]NXGSO
M6]=,Q[B1%I<P,!)(:'%K1X0=*@D$9&CCI?XZ?#BDHLV49HVIJ-H:10G6*\V@
MO+JQ[\A (=8IYI9TLN"I2E ^0 B@%#(" =9K>_DOJV]D,EQ-*C< 6 Q:0>'A
M#5[\>2TQG-O:1>6^V:QL@7Q/$NK@OU/T]V%%7&U?75)25<0-1@&1T"G;*JP<
M(Q9*&33+R.<I8V-("12F5Y"!?7N'44Z7=^H!KN+B=S#_  ND<0JX%'$A00".
M2+F*KQ##-_LD4;7E<F@<.[E4C(2T:#4JS.-1!(.2@*K'.4I?F$0' %,H E/C
M(<.60ZBCM]['?-L[]?,<?!(JN;RTO50>2$)2@FOIP;1S6EF2%$/J.%($Q/*-
MWD5%1\I6XF>G0(:(C'Z$F[2!-8QTQ>?T(]N5=ZK@P%0.J3E@0ZEMOVCRW.DF
M.N0$^(E3AVG&G,UQ&(_++T: B8H/5E49;=T>SW=31K>\ZU&W-HWER.8N/AI!
M2KHN'Y4/;14;O%WR3I@*K?ES(?W,<1[X''4S8;KN&P71N-A =N1'B;P#,4<A
M1JKJ&:X#@E-X[L$JYQ<T88\O0U75O3PHUG.VJEQ>Q;CKW0Q:<J8U?AFCJ(1E
MI.F)H,"(QSIT[?Q"SU-HZ+[?U+<#B J\%"Y,7.I;-UIN\=K(_:HY+ECXR'B1
MI+1)P(!4#!3RY&DKRXV\Q!S"QLQ<,1@43$+FB\.RC-K/BQ08;R-F/)AC80D[
M!8H2&C4V+E=2408)-X-G#OWS8_ON5WB4DRCD2D0,!4T>9C%$<CU1;[K&XDZ<
M.Q[E$V*0.)0 *JJ H';CC2-S:VD\(\0+5'[_ $^52-I3P]I=3\N9;R4:S%JD
M[?>943.(Y06L?6HA@]+#% C=JW:IJ.C M"D. J" EY&[ (YZCK_KF]EV!G2;
M+>/1&<]+5&!"ZD7C37<90&_YSGKS)^9JZ G8@!_V]>JH%3'.JL:^F !*("&0
M$! 0$,@.0QC'QZ.A6K!?:EXB7#_J!?,",\NFNJ9FL)?CTT^O7J]NIZQ3H*WM
M3CLUFDUF=B'^TU):+@A/[2S@IG;1NNX5:B4WN#UT<,:Y"KC5=U0U?7MSUS\3
M&K[PBVV#XJ2WYF_,F.\8(]6><RL7*>*533O"^J8DSU5<\O-U125@GZ)&LJLX
M,[B<('!1FJ5,PHQF*G7\E-"I&N_+'\KE'U]4JQ1:=7_P$E1@ZM3X*+KU>BFR
MNZ[&<[>/AHALUC62(K.#GX))D+R,(XST2^^B(S7E7A=O##QC;-/^FXAVFHJL
MR)O&=;0>XY.,2=QEFVO7 \;VVRG-6V3:F+IM8[[6)"X0K59>.EG3MFJ@@5L<
M@MA,D89T"F%#GOV5T1XU^?'YIM:2E$N['0L;NS\3+>D>/FD+C5])ZCF-BWO4
M;V51BMJ.95 M*JFE;C9T4S6]=-H!W*7M<P.( 43Y4,2:,/QO(U7_ #H:%HXZ
M?\*=/U:Z>#&_VEZU#X9VE38%,L<-]S@$V/\ FV?94#6] N3]T+M;[>R2B55&
M;100<J&263$Q<,*''U>V@9M"L]JK\5OF2CX_-J_2(]U^>7<])\A?[<BY6%B&
M?BNUV;,LIB#V:75P1=^9:<9L46C=^WC%D72,.*Y&W F<&B]]#'A5A'B1K>VT
M[\K_ (@O8G9'XY*4_<Z8W:ML?3WX[JCN9HTV?J9/7YTJ3-;J,\1D=:U]:GWM
MVR<PCN248R;LZCINFHN!@*4!#+XOY:+'R</YOG587Y;#J#^1#RC P?TRW""^
M<QB"D0QZ'5%# 4@@!P-D>V Q_'K*]]A9_=)B"?J^0K>.CWD;'"!B"/F:KG40
M%5 @%<9 IB"!A3$2B!A*(E,&>JW([RE>.1JZ00B9[02<U]F-,?>T 5*JT&;(
M4N$)9VDJ<I3<AX+M3C@ #.,.,]2_2=ZYMXN!\8YU2^OH W3=?QL9ZL_;6R3_
M -/'?S*W':VN%U<H6.II. (93'(Z#9-L813-DWZ@ @'IZ]NJ_N\ .XS.>H%U
M<.A<G !K2".WQG/D*@99C/TY @"VSP0>?TDK^RJ*O)>OQ]0\D=[UR53<BU3M
M=I;IG2 !4:.@1,LP6 5! I (JB4#"!1R41],!TILTL]QL$0#&D-5JX\#6Q_B
MW>O[7U V[TL\Z1S225RQ1$/?0VUJP,6L@5F1\05DW2(E$2F JG!4 /Q.81]4
MLCWQGO\ KUW<V+F[>7N;B2/A7T>Z9ZPVZY8RS<YOW#B"N*@=@7MHGUIU"2B9
M)F=;D=!, (7 AV.'(AL&[E <AUFG]O++IS@M>D>C;XMG^W0>20,3GPIQ:\LJ
MC)RQ,H)3D59+)#[AAXX;K$R @(XXB"6/XCU7]RLG2SXJ/%PJW[W&R7;G2-)R
M7Y5%GE5,>Y.2[=4J1E',9&_1B3& 3;(BF!<?NR'\.M Z1LS';M&* GXUY[ZI
MO&1[88'?4'.][C0LZ9F!CGTTN=--3WV2;,H*E$QTS*+%4,8@YXE$I2#^_JU[
MS"V6)@(^EZ^XU3^@9!_<Y'("'1IW>(8T2]*L2]9D)!THZ; 63@92NMTY!L5Z
MW:)SI2D7=^RBD)TS#Q 2F*4YR"&0 ?3JKW41<0BM:",JU;=-F6,/8]Q). P[
M/1**31R%B?OU63]^\E:FQC7#M>6<7-U7]=M&X*^ZJZLKULY:'!9(4O>(W5;N
M)%4"%!)(XE*4*5OC#<2&.+2YI0%<.?%,NP>RJ'O<<=E&7WL#YG $@:223V!I
M'=C@%4D"C27V''V:@0NO(2SRMMM51L<Y(O;'.H?3%GR/DC W@J])SS!K<'+^
MOLR<2K/TFRSP#&!/!2@8:!=[7+!.96,;J+M1X A!D,#P) ]@&5-.E.G;V'<)
M^I[FV$&R3AHB8U3ITJ'.=XG8$X*,6IB2$0:+))M72C@'8+G5124(<IP$P'<B
M4V!.8P IS3./<#=RCV[]3%HX/@Q #@.'[:U:"SL[D,=:O/WDQ.AN"'3B>"\:
M)#34V\T\\IN\W]*<V.O:PASOWJ(F:HQTA.RZ$@%;C) 7BQ7#IHX?*#]01D11
M8B8X^4N1ZG]H+'31W#FD^5GDA)5.\+BF:>VLY_),]OUQ;N_'FWWKX;^Z=HF?
M&/'#&- D<S! [P$-)4 D''*JZ;K9Q<2KFT.H6&&0D)6<=J-2,A2:)JSKAPX^
MG3]LR*JA&!5_;0Y8]M-,H8'J?MDN+A7@ '@,JV#I^T=MMM#;7DTDP@A$0+T+
MB  ,2 %=AB4Q*FALEI=\\04BEG!SQB+Q9PDS.HJ9LF[.3V%71$>6 661*4IS
M=Q,!0R/8.K1#:01'4U2\C/M_?4/N@BGF(>QKHHSI8JX 8#MP%1\Y36C4%ED0
M+_6YCS 0Y8,;(E#.!+V[=^K!81/>07$X)6-]1.BLQ*)#XGE0.6"(/VT.MWCW
MLJF\28-%5UUE^0 D0IBB  7YE!["<_(,9_3J_P"V30VKV2S%&-7X$#Y5XQ_)
M4)W"*=D30Z0N"#_E-/P6HTK5&EF:KA23:/$#*%]M102E$$.60]P2G5R8HYP
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M2:1E0(#DRQ"-  O(IAZN%M)?6-EHOG?U ,RBHF*(/3*M%DM[:&Q:ZZ>XRQC
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M'.?B7^L7)DPO6R=*N8-<S-3NWTX5ZDZ._ ]IMMO]WN+W^>0%!+$&"\OGBF5
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M<7Y_(/G_ #E7JR[I4&2KA<$4VLO(8*1$G(J93".0Z:;W86<NUMN)GN&Y@8
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M>(F@ZM0:NG-Q&"G#F5PJ)W66;;H77" Z6D@*"I 4#NX%:RM1/MGL_)60\?\
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M?:QAAG*]:VM3E)%$O]<8:3C"N6J)C>V53VRODA$!$QB% PACOUY4W#<)[?\
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M%2*7MGOWZKNY74TI?,WZC6W6FP0VEK#:AOB:P'W>B40SUI7IATR9LVK8ZY"
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MUO\ M\@*CC9K"-2CV#'ZPH2*CINBE#_3+Y48&266</\ ZY,!;HE:J( C[9@
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MMJUNR6MYB80N$B<T2W.*$H_8Q[,Q_P"HV44Y*'ZBMSO9GM,-N]K8I?#@5*G
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MZBF&*T.%F@E&,ZB].AQ!R0H#S3_F.0XB(_'^8H /5AAG:[P@YBKG'LX-]Y@
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M6YO;C2M.:FHRESKUXDTFE^MCRO0\Y4(&#103.FWFF3I8Z+AH^()15,1#Y%3
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M*K95N=;*SAQDQS<0(!L=6.QZ[O=MV$;+.GF1D@E2N9[4[JC+EC&W!O AA><
M@HGW^LJ'KBMRU@@-470M>J\1)3QZCK:$AX?W0C4W+Y5&*B8W[<*\FLH<YDB%
M$XJ*F .^0 *6)9MYO-#W)/*X,:YQ4-+B@*DX $KF*DH=ZCMH'%@'F!I(':GJ
M^=5::A_+;)7K?,+H33GAY<W=5E)5@M(3NQ8MY$V6LP[V5^EG+'8_:!9HC'L(
MH3+H%6 JH"($'D(9ZTVY_%=KM^P?W'=;IIF . +4*!0.^JX_>I+^Y\8([L/0
M<:N&L]8G9Q2-6+&TM>GORKJ3C%U5$["X4;JI?\JHT25,@BF=OG( =-0H\>Y1
M].LRMIHX 8[=Q\IN *XU8+>[@M1FKO;7M0:=J"AP,36J?%,UH^!.\:PL9%PK
M<@0*:_-5X@TC8N.C6K$A2O!$2_3!DQO4>^86>9TLY+G$HF9)S7M[*:W5Y,2'
M-;X2ON3]:=VP6,U>*'(UW6]JE=:R<BU%!A=$*BQ>RD X;*%,F+>%G(EQ$.B+
ME3-@YR"8"'Y%#EU*;;+#!<QSRM!C:Y2#E4:YBO\ ,+B'#MJ.J)0UJ+1PJ3I[
M6=BV!U(#-WJ8<ZW0KRUV?NY'F:PR;*'DFD.C)G6.0ZZ@>VFHKR.5(@&$.EM\
MOVW3A($T-R"DH. ].53E@YZ8$H1SJ'-Z(^72MUHCKQRO^K==Z[8DB(W9%5ME
M,=I6-RW1E4T7KRDV=%9S%-!;P  FDF[]W@YR(9# =.]BW'HR/;Y+??A)]Z\G
M00X("<0"""?9V4SW5T]S( ,4/;PP7OH8O)>S5'R7M)-(UG='D_6/[=FF[6UW
M[34S3C1T5)-G(DCAL.7T+(1YVYFIC) W:FY_.;OU?^E]KW#INV=N\EO87$$G
MBB$X*Z$0AJ%"TKCC2DLD\UNVV"Y</WU 3>"W-XN*WG6&C=L[Z\J=_P!FJ]45
MC8;R>;3MIT0M0&%F<KJOJ$Z2281+"Y(LE44W:+ITL),B B<W'C,R2;?U5*)M
M[M[&QVAI)=]N=#]0:=*A7#%X:< J8FF#8);%AF<]SYAP)48E/@?0U:)JW4M,
MMU,A;MM[56OM<[:G&;*6V0UI\<]C&HVU)5%7WTYZ!-&J2*R?LER*RQNP<1$Q
M0 .L[O=ZGM;UVV[$==F'("Y#AR7"DGV[K\*\D>GNJ0-K7[6E+K[:1FV4A<48
MM^DTAF]<HTS:[<T?< ,(02:*4DU^J[@(',B4!]3B(Y$8[:K"_P!SE=_;BUC2
MXZR3@'$XG,(E/;UC=J8UL?B<6CY5!%9VSI+R>K,RRLNH+?.H0<PDNG7=TZ(K
M\>XCY5BFNR3M;)"W5YW&2;Y1,I2^]_54#@(&P % );<]HWOIW0V*=DMT]'*U
MY=X3AI*'@BIVUUM\,.]C[2[\$1*XX?'#W4D27DPUOT?;Z276T[79JG-TE*1&
M; 1HDF%S>1I1.R85&I(.4A^Z$^C3%J <2$(9,0$  P=2+^G&E\&\;G_4:YVD
MAA(35B7EV. T\3CR/!]]MM]E=':U!A#"Y<,Q@ /;\J[U/;/E=L[65P?6BIV+
MQ7F&,(R85BQVJ1KUDF'CANKQD'8TR/=1\;'JD10$GU"KL"\C!Q*;'7=UM'3E
MAO#9;.X.YOS="W^#$<0"2>!P]E1,4D=W.8+E&0C(X4*6E?)/?6I/*;QRT3$;
M)JF\Z;MVZL)O;.Q]A6& 1N]?=S4N6(&ITZO0\G$IQJ1F$65Z0IDY XB<V#]L
M=6;J/IRPW?9I]VELI(I((W:&M*,&EJAQ"8H<.&"X+C2-Q<G:I!8VH$D+RA<>
M'<1A6T0AV3( @(#@?^/?_;UAD!5OTE@!.'KS]>=<.1<*]^EJYKG0H5SH4*YT
M*%<Z%"N="A7.A0KG0H5XG#B0QOC\W_RAQC_9T$51Z95R3I;V?MJL_P C%D99
M/;T4H=,R7LO8U4 .FB">8-B(%/A5 ZASBX*(#W],9[=>&_R<=/5<KVY^:/C6
MQ]*-$=G;O;]1'S-:(TDZD(6S244N<PJM9-= R78PD*BKQ$0.4?FY&,'<1'K1
M]O DVJ"=V+PGQY5LFV!KRQ[\P:,;1#M1>H[%8O6YU%Y.H6!)%)0P^PFFM%/@
M!7V_E(83"?'S>H!U1]]'E]01/;GX?B:F^H&>=MX;PTFJ>=7N$D]EUMZNH;DT
MNI!%3/SB)9%(_M_+Z")@[=>D-U@;)TX85(;H7#F@KS/8DQ[^6C$=O>:V+_S_
M 'TSJJ>%<F=H05YO6\B4[E50PJI),&];,"( &/<]T%^_;MD.LGZ @#^H;J=Y
M<=,36Y\O,1>92KA:W+(7^0X!!<./M##5GOB;#H*>-6AU'1D&HFTU272I3'%5
MKR2@V@'=+*Y$$@61 ?E[DQG =>:>IL>I[E[   7?ZQKT''?O,,,<)(<$.'8!
MAW?&J[O/OP1H^YV$U?:JB@]N8M'$DNT8-18GF&B"8Y!NK]4W:.UDP3( 8*8P
M_IU8^B^MKG:YO)N'L,> 1R\QV^ZMIZ4W1U]"+7<20Q  6E#Z\_;AWU6!JBT4
M9AJ.S>/&U5U'NS:K/(SVO),R/L'EX&39BTG8LTFU!%VO(U(S(ID4'C@R2Y,)
MMP V2AJ>^Q2;@?[AM6G[8.U9+@G-1^E:9T%=[YL_5YMICJV< M!<JX' KJTJ
M5*G3R&(R9=LJK%:NH/HV12D0.^<J-&ZB2Z4DV;I'*1N+P5"&9E5?)F$Q2D6.
M <1P(]--MW"1Y1Q"C#+B,"N->Q]@ZCLI97NO&G[5K6Z7 \0 O#%#W4P:_6WJ
MSM04E5F#I PE<)B >Z7)>0"<I<>V/PP(?'/3RYO6AWB32:M<6Y6 A%_YC'6[
MW:0 BKB<2O9RJ2(QM<H-Z#IB\761.!C+@GQ(83@(85$>>04  [#^SJ+D^SG=
MXN/;^RN;J[Z?OHG>< YQ:0 2$RP&67.LBR["M0@"TF_=RSLIP21:.SD.H0IS
MG56XJD*8RIU3#\QE"B<1#^;TZ=06%N3Q7U?I33:[#;K2T=]A%'$7@XM"$8)@
M>%,J4E'E@;@)HYPB94/:%(YC 4AU![%]P2%P0,>N/B/PZ<^1:PO!!=K';^SC
M37R8[./67.?(UI +BJYG%$[J&IFBJ6P3<LU.HR= "K%!0IP%-,@^X13D(D$I
M@$HX'MGOD,=72VN&S6H@<? <"IX>ZL?N]HCW#<KF]>")5 "'#!:2V<4ZD%W(
M%,9')03*JD0R[DRO<3&;%(83"8X!V$0QTWW2^MX+<)@QF2GN%,#;/A@DGF.B
M!C<2,TR49\^5&MN$[[QHH<8E8C^YL]H$6C",8Z.11@*Q7YAL=VU>J/>#MM+2
M4TY.H!3'$YVZ@*9[% .JUL-@[>MSUH[REX&LHZOZ]D=$=OLY&F/UKR[/0U7,
M]=HVF'LLG,382+\IQ>@DZY$3-S05>.3$544;$<N$@YIF,;D)C&Y>N.MB@C=:
MR"V8T:6#3CGX</E6/7T=A<VC[BY<\3'$HX9G/@>-09 3*";ELK+22"0&:%.U
M]YTFW(4AL^TV1$IN9CI@(=P-D1 ,CU99HPV)@\O4'!3V>ZL.CWJR?<W$!F9&
MULA 4X]ZX5Z/E$%WP*LS$51[F/P$5C]PR&"\3"/$P^N!ZXBTIY,;"UQY]F/+
MLJG;\XJZ:&<2L489G,98_*O8KI^ I@1FZ HCW/[#@ $  ._RM\9'/P^'7<MW
M;0-T76D@57KN/=+NV @U##@#6.JV7774.**I@( EQ]*H0 #_ -43%2*(@/;L
M(CWZ6=-#* [[9I"!/ZH'=_U9JL7=ON.L"0OPI9C_ *UJ8JB28E*8BA#E,3B!
MBG+Q.02B4HB7CTA<R6\B&8LA:!](<'$XYZD;W(G#.A([<K8!L!>5;QI\093>
MXF!R @(8.4F<I#C/^K/!/.,9  Z3;-;2,^V8'Z"<UX^SYU!7+[M[R^X<[6 >
MZM@;\&NK'-Q\C M)VO!G!':-"* FFHFJHL<7SE--3FF<<IL@R.,=^L _+5S/
M(6;% &E5S"NQPY]O*IZTO9H-G?=N02(4]E63_P#4'7AW:IKQ^\;X(QE'4C+9
M>M4! [@7$X[@$FQ3$$H"/%L!1[" X']O5OO6VUE,Z)ZBUM(CY>/%.//(<JK7
M2T4@VJ9[BGW)&KGAJ1/::N TU0XC6.I=?T)DU^F:U:K0\,1(G(O%TW9(^Z<<
M\C%$RO+.1'N/7A+>KA^Y]075S/\ 69G98!%PY\ZT!OFLT11$&%L;0%Q* )G^
MRI68M&ZLDR.HD!A([;"40$P8-]0E@1'.#=OX=*=.0EG55B2/"+D$=Z%/B:2W
M%[F[?(AQ+?E2=^3HI5/ /R3*I$!8"#K]N!H4ST(LDF'WV!$&8OA.3Z;WL?S"
M..W?MU]<>FGN$EG(U-9#/>$K!MF:'[PQAR,E4(:!-+62MP+21U?7-34J3K+A
MW.UY5^T>3<5;220HH1BK&%1^WK1[IDS(N+HZQUA,<H"7 B/6F=00".[\YQ)<
MH[JO74,?V5P7,<7(1GC1);"OD3KV%8S!H%N9:3=E91\4DBU,W5% #)_7'>*)
M*@Q!) G$!*4#*B(!G]:Y//*^02,>YK%'TGD@J.VVTONHI#%$2P,_E"'GSQH3
M+JG2-+;*?>4MC5MJ6K+178B*3CX^*2FJS2K F0CES=4XY,B\FS,LB*J"WL(@
M5,0/R,(&P%TCOV[GM[+)A61F)/%#@/GPJ:^]GA)V4$>9&/$3]17!/V_NK.E;
MU(OG[:UH1"%DID^R1?T>5:N&CF"L$1,-Q7B/K ^J:K(F3:B4_M'*54.X#@>F
M5MMMI;2:9"\.<4S_ &5)6.W^4#J74ZF3X\["FW*EV@[Q/U.2GJ-)N7LW$LHZ
M2B(RHLY%G(R$%'(*'04([0=,4B"X,"K@4P 1[<<&/=+5T\!MXWR!B<#C\*>W
MM@\6_@).'&B=UI?;98'UFL-VUK"141&HL%Z!?*:Y?V5]88D2N4'[55J:"2=1
MJ46<Y2Y.?BN4PBF01 >H"\L;.SLHHX7/=,& '45Q&? 53-R=*V!D$0\8:CN^
MG!??,6J:B<Q\%<6>PJS#3>3M+6%'DY>M.B."IBLHXDHQF^6C"F!3!O?31. #
MG 8STA'T[)?P>9 OA*G#V<J;P]*/N)8MRB+Q+$"N.&*</50?4";UCJWR$OMT
M7O&IH76M]UQ,VVA2AYV;?[#<JFF36/8SV11FS.&K*M_6-'*A$C%(H40*DB3B
M7B-L$5W<V4=O?,:8X$32$. 0*5*^RINYBW'<9&0R%J-(X<O7Z+415CR'V3'V
M:[/UM9[&_L?R,N$U"Z^N=!MS._Q45$0[1RR"\Q4=&-$DHE(S%@50K8RR:@J*
M8'B8N!?P[+#N#@_S61R1C $@#+!<??[JL5UL]L;..6=[?.8!D@&7>:G;7'D5
MX[3;/5USD:W(3FQ99,])E;K,U%9C:D)1)9:-%G+/FAO<*X8M%0Y J<XE*H7(
MF[=-+O9-R@>7"<.C#B@.+4X8*$[E/-:AI;"_:?.9*U,QAD/^=4DD\<M0Q6S&
M#^(>V*+<'LI-B2\8VDY9")D9"IIO'4 ZD7:S]9ZW:(_<EEB-FW!)43@"W(@
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MGMJW;)!;6[%<OEAI(4\5[N^D+8;W<5PU%3))'3L=>VCDZ*3BS,:N_2LK:(4
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MXE)W(6.ZR+-HQ85=H[4E5F:;IJ:1.V]HQP$_(*G;;W+=W$D,4($8Q<2,UY9
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M&!ZJ550W_".1K81_*@X.W\#-_KE3*H=.&K9RHF>+L06,6\540;D<M5D54U7
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MJOQ[V;<=G;#(@_LTS2J)LF[MIK[B7Z],'.S;R]"@L$%EE1$4TI0C=(P]B%$
M#J(GN+B^MQYDD1MVXCP@'W'XXTTM]LW&Z9YP)\SUI\?UJ=X%+6+I.#DK;3Z3
M5K2BV0DV\*N-8G7\(8QW"F/NC,JPOG34H@*AB#P(<3 7. ,,,_J.:PU1MNI!
M:O&G0''2$P*#M*GCBM"?;[G23/;QF?B_3XCR4J<AAZA4J)W2HD^G,:3!J5<W
M%,4XN5(*IN  0"-T8LAA$Q# *8E^02CG/35EOYL9OX908G%3J0_,? U&':=W
ME?I8UPC' A:7D+'5':2J+:;:N?H@2,J=,3*'0$Q@*<S@I0$R1T>12J!C)3"
M>H=(LOFW ++=K_. *.:< >!RX''.D;O9]R@(='F$)4<O7201.@0SR7EF;"/C
M'KYL=_,S#*OND#/RI@FGS>R9XM-%=+!@'VU%2IC\ QU(Q[K/+$+6[GN)'#
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M5QR!00*FH8 ( <L!U48;ICKH6L4,C&E5>I0$-)'#(G#/C3QT%I=W&MY=J0H
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M$C9+,%CA7J%NM=;D(U?@ -F[!M%TI5&362%,1*N*8K"(_LZJT6Y[[; -L8'
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M+_%5VF42Y M4#UJH3THUGJS9:NQ47E'J=T813!O,52;:./;13.W2.*X!Q$Q
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MN\%U]X6QL<7$.P.D'Z0@'=CZ^='M]QNUG<M,8&G5S/.F9HC3L+XP3;WR/O\
MY+S,UJ:^SC.P6*L1"J$0QW 9.,DX-[ +-K$\6FWS$I)===PF+,IT5EB'()0
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MYPSTXAW2[MG^;$FNEX-SN;602P_6/G0B37X;_&F:\D*QY0*S^T&FP*? ,Z]
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5WX@^X_ZT>\42+5@ 9QW# ].:.O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm2127058d1-ph_preclini4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_preclini4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y@(R P$1  (1 0,1 ?_$ -T  0  !@,!
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M'R%C2Y+H46VU7!#=0E*E&JG A*=D[5(J=6JPG1G"G5!C4J?*#@9,"2W;@"?
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M8%AUHQ=5]FQ3"=O(L\01$W*4RN9/<COOH;2HI+SI!'[B3KZY:4HVMN+<!](
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MR[=#S#Z"\H2I4P Q(CB-0Z@E7M[6,L 5-IN(M2''KO,#T)U80S&6@4;%"5-
M;]Q(5Z^FO5O;X<1MH?FE3S[&J6$B\P3^A4SB&_@XE328EM^F<N49L,PD,&4I
MF,E+6RC\KH0D)JJAW(WUZ=>K86.SRO;*V$:DXB0 C%VEB^!ZK3D)";3#3;+[
ME#MR;#D-NE,%QQ45#Q <<74)4?F[BM0/: : ';KKD-JY/QG>[$;9R&E!O,+"
M<,-6/CBSK)"$H!YA@5$MUN5:Y<=,1Y,:+'JCZ<*!2^%J[DO.+!!54*J/PUO>
M7LEE<"QVFK3HV[@@!P.T9#M29CH..#=ZN#,I^00!:?Z?%"V)3-'G14A#R5IJ
M5J4I.Q2=M:/.H\HI&TJ;.:E2TU1\PQE@ ^)()!.'8%JT:= G"7WJ2M=PLTJ7
M'BO/EV>\M;2T)HIMMQ([U?*02#[M=Z:V[/U!L:>^4^,TZ1-S$PC.?ED.9 $N
M2 [.RV_CRIAX!<95&R'&9,9^.>VWS?:0)2U%+3"UJ)!>%07*IH/77.>INX\B
MVNYHW%G.?Y:Y,M)PCCU&>7BL<*D*LS GXQT\?L46[9! ..-71FDA34U$>00V
M 6>WY7'4)-1M0D;^NHW?F5]_A:%S;U)3GH+D"3N!VLLGT]8U81F"*,I!SW>]
M6_!%MR]U+\MF,TU$7VPGGE!OW$#JA1KVN!)3OU&^M?BV^[?NFFMRZB)5 !HU
MQ$G/M?N6Y4'D'^[_ !?IWJ>RC'Y;-VC>W.#441(S<II@*"7 @5:+!2KM*$T'
M^[7O[YPBTY1O]IN=O 1LZ5-PS!@0&##]6"K:58U)2,BU1RX[#U'8J7D4.ZR+
MM%EPWBS%5'CQW4+6II:>W=*T]J2"IWXUKK7Y+PK=]TY#;7=G<2H6%K3T,)$"
M>((+1!?LQ6>V\JI.8<:@<'_1EESQKPHK.D1+G-;5&M+:@5NN;KD+;)!:;+C:
MNX*[-S2E-?2K>J+2UC:R/F5!$#5X>.*^8<QYK^45I;?";53@ ,>_,8+-"W83
M L<5$"UPF(L5*$CM:;;"G"/]3B@E/N$_$ZUZM4RQ<DKX+O.XW.^5SY\S&GXG
M^53[EE<]N@;)(( [=S0?@-8N]>;ITC2"[*27;'D$)4D@D5_:KU_CJ&'12Y5.
M7!=&Q2K\-MB/XZEE+LH2XO;4J[AM\!MMIT;J@R5$FN-0VG''W%)*0KM3W$"H
M'7;\M0R+QN^<BM1G7&8KU5I)2*.*20=P=NX=-5,A$Z5('4KRJ_93)EJ"_J''
MBOJW55!M0GM[MSM3UU@JR)'P9NKL#FJ:)-SD,DIBNE/:14@I">X;4[B.E=87
MJ=ZAA[%276;BE%5LO=*[J[MQZ_N.H>H^2M@1CFJ.Z[,9)7VO(5N1NO<_EM6N
MJFI4&"!E/VR_2HW_ #5K'<H&A4H$4J?C^.KPJD9H(F6(7LF,98ZREI],EU!0
M4J0XT\M#C:DG925A85W#TUFC5>6E082&86:_&')K&0L-6FZNH3<D);1%?))^
ML:"0E/NJ4I7_ )FH_P#:ZZSJHPP7MVH5DT1-$31$T1-$31$T1-$6!WW&5YZ?
M%?/(?'G!F!^0]WNMQQ>U7;CCD;BV1SEC,C%)=^MZ<BOLGAF!E6$7;D^5CD&L
MIFS0KM!ER'&PIIPK0$*GHJG%8*>&GA;RK:CP3Y4WBT83BO*:9<JS99Q?SYQ7
M)RN=QIQ.K,9<!QOQHR[,\@S+R$\8'K[A%OB3(^%3LNR3'X#JFX3K#/MEQJ?#
M) RWG1G4RF&U)4E7<@*[TDK;40 #VJ50K34]?AJJMT5)?Q#&)4-JWR<>L,B"
MS,5<&H3UFM[L1N>MU<A<UN,N.IAN6Y(<4M3B4A94HFM371%'7CMF7<V;VJTV
MI5ZC1U1(UW5;HO\ 4X\1S_F1F;A[7UC,=>]4)6$[]-2BP^Y0A<B->6GBN_/O
M.&.\>JR'E5%HM$7&[W'S./=!PSD_OO7#)G<KD6.= 40OL::M##B:I'N;5,$J
M&99NCIH@R7.BE-$31$T1-$31$T1-$7!Z:B3@$C-,UJ!^\&!<>(_&W$5I*D9C
MYK>.]FDMC?W8*KU='9C9%3L$I2KH=P/AKOO2VC+\XKWT\/I["[E+NU4*HCEV
MF<1[>QUX?(JDX4Z%.$=0-6/LQ6W9E-6D$@#Y0>T)30?EU^&OGS1)><'D^;!>
MX-3!BRB]JO0@#_U4_P#=III?ZO[ H^/M752%$$;'\.U(_P!^H,*<@PCI/;A@
M@,AB2ZY0CM]"#MUIZ; "A]!K&*'E'5$F15M6KHRBZV(DD.<"H34HFB)HBANB
MH'7KZ?CJ-1C(,,U!QB5HZ\T6IZ^?\J,*6&%FUV%LU:[U(9-IMY7VFG4]:C??
M7)\AXO:[K W%S>&B-/RZI!Q[.U?I+TW;_#]-OWS]ZQ799O+0;BQ)=6U?-(2M
M*G7G2G?N2ZH@#N[CL3MKRY<+H;-.WW&M?$6 Q^:3,&7T8X8J(DRUS \NX"*Q
M'H3%?6$>ZM.Q%*UW/H/CKS^5'8]KW^VW6UO?,IW$C,1>1P.DY>U#@J^QD[3#
M3CKR5*903WI0DJ 0 0"-JTK^>OH/)>17E'8(7^ST/.J#2\6B=6&>.&'ZUCJ$
M%E-HFHNT.J5NQ4O$*9=2?;4TI?SI74@*4/@DBG\-8;&-3FVP4_S*/T6ZD1TT
M_E=L3A' X.66"H?AP'<JY!=:A14QW9:%+6VION+E5*<5_P"]*% DJKN*"FO9
M$MAH68V85A]=$,?F=_%80>BH*9$ZV3W?KKNPY';;[V@*)<=[@5 +] M)5_$:
M^,PN+CA')Y4-VN9>5<3,H8O\,R3'+N(6S"'FX#%1(LNY*N*IJKB78*6UN(8"
M5)(4XDI151^4T/IKNK#;H'>OS W!\NO!LSD7_%91:T*&,P'S72.U'MLF1>G%
M2E)402D_S$Q^ZM5(2$@FI'KMK#?<=M>#59[[9$3NI2=@Y+',XX*GFT*Q^GAG
MG[E6I<^3<H+#MH$?^HU6IQ<IMN.[)C*H $N*3W=S8_6FM;>!NW*]NCO>QT?[
MW!P2&!=G^\*DI^2W<I]VXPQ:%6]YN))O"H['M-OA ]R2$)[T)2H$)60F@-/7
MKJ_(;O;K3:8\5-3ZC>8GX07)<8=?8JT,DQNYO)#CEZ93&0ISV?I%=M66!V@H
M4E/R*"2/UUZG"OS?;]HJ3YA'1/$1$F+0!&CY>[^57KTWF9]P"GK[B8N+29N/
MW-F+$2C_ ,PTQ\R7!W!:B>PA%0*4'37A[EQ/:>0QI[A:U!1M*=R9DXAPT@W;
MU5*-:F9&,S\+*WWK3<E3&G8]P BMACW$+4IQ\>TV@?*E)(HYV5WZ Z\6CQ7;
M=_Y!"&UWK_33C*0U2R@Q(^Q9*D[>4)1BSF)^Y7Y<\T;B6N-"N-O?>^K=<;B/
M*24T4%I1_+[$J2K<CK\-=[R#DESLDZ-E84_/+CH"^/>O.HT0",,U:C4RS1,@
M;:CVUQJY.I;2J1\U/YS=7'#N4I(IZ=*:XP\AO9<RB;BP%*<IP>6F/9'%UNPC
MH)"R&R-B'-XI?N%S@*N282$_^7;=(>;4?:25=R5)7W, UIZ@[Z[;G5.'Y'<U
M81$YSIA@>AQR?+->!"H87Q[&_7@O',9:M]SLSJ$M1[9;A[J4M3 '#)4D* 4$
MK[E+4HU_'X:YWB.[;?MO%XPW^A$P).<0<&Q705;@Z ^ 76?AS[T>+,?;<MUM
MCOJ:9>;!C,.ATU##;7:@**U,]4U_'TUZ/)]DXM6A0W>M5C;V!Q_:&##L6OYP
MPQ62.'\?VW)K-"GW-EAU04Z65-OK<[HZ4@(2Y1=04)(&NLV6YMOI8';IZ[(P
M'ER_>IL-)QQQBQQQ7-[AN?T%24@_Q2/VNO9[%P;9,IN$%V1$"+=:_8]Q2O=2
M'&V:>VRWNDK*O4D]-;56XDY!S=<=OG,*EE:FC0D1=50\6S[%EW;[%!M<./"@
M168D2(CVV664_P M*?6G^LU]2=]]><*SU1'JOC-U<W=[.5QN!,K@EP3G^C.I
MI<;<4 Z?K_'UUG![5H$'JH78!^?3\J:E&Z*&M"2:D$_'8&G^[3O4=RE5Q8ZR
M#V#^"?\ =H0I#JVK^_;[;'<<<]ON#17VDFE "4F@WW'^.JY*</:L*N1<]>=D
M2(\-Q26R2D'N[30^X*4V!V_752?<K@+QF#;[E>W?=1W-LA57'W$GXU.RAW*J
M/AK!,_$K.%Z!"MD"&4!37ON)3NXI()(KUH:]I]=M5Q]JH758+R"CVQWA(-:D
M 4_#IN- @!S*AT9<^4J2?T[:?J.NVGW*5(2X$9X *0A5-DDK4#MK!+"14*T+
MA9(W>"A*FP0X5%*O<W 1V]2  =5/:LU+$EU(PI;T)2(R0M24N!*J(232O_?J
M\3ID)*\FTE>K6;))-ND0G(SI9D1W6I#;J5(2M"TT*00/E(J/7;645RM9;#N-
M<W8S7'V994D7",E+$]H*23[J$@*>2D4(;<.XJ-; .J(EVA2"O1=2I31$T1-$
M31$T1-$31%XSSAP5QCY"<?WCC;EVPRLCP^[2+=/=BP,ERC#;I;Y]I=3)M]TL
MN685><=RK'KI!D(*VY4&;'?14@*H2#./10SYY+6Y;?MU^.]XO]HQW(O-#S$Y
M/Q"=*OD6W<,9'YI90_C%V&'R.V]V9U[#KCC?)F0Q<7D+0BX1G[S(".WLGE:%
M+;6<>U&=;9,.Q7'<&Q3&<+Q*U1K'BV(8_9L7QJS1/=^EM./V"W1K59;9&]]Q
MYXL0;=%;;1WK6JB?F)-3J$R\5<NBE<'I2M*[>G^W1%@SRGC&;1_,3Q:R:9R1
M+N&%2[]RK$MG')Q:P1HUFN".%\G]^ZIR=E/]=G*D=BOY+I]M/>:=!H2Y19SZ
M(FB)HB:(FB)HB:(FB)HBX/\ N_SU!R0+3=]UN8I_-/M\8SV=[%\\R\'FO*[B
M$H_H*#*:40-Z]TD@4WJ=?4_2Z$?IM^K2SCMT@/;'^1>!R _';T\GJ#]2W'HW
M0@CU2/\ +7RWK[5[PR#]B[Z*4T1-$31$T1-$31%T6: #XG_(C4?$X;)"'!6C
M'S6<=;Y]RGV[RU 6J!CR .U*Y#39LL+O5[8/S-J'QZ'7QSU"W^PHR-O(UO/$
M&&DS ?IA'!?IKTUB#QF)8?/)8H*>D/0Q]+<*!M1;1*JE+CVX]QSV:A0"J==;
MM.^V/D>RV^V756XA5(;YY@XMWKO3V!1'H$1Z+%9E2_J'PE:UEIZCI4*5[DH(
M"45_&NO3VW;^([K?0XW"&J[L(^4)3!))A\+O(8DMFZ*(TF0I?TK<6.S%91W_
M %ZGA[BP" &RE2@2H_GOK'2I;YL7(JEO<RE^4Y1$B\1V,#@%7 EE']Z\N.IC
M$-&$E:G$+!0%J)J DGKZ]>FO0M.+;W0Y11WV%Q4GMIE*6G63$"49,P=AFV"D
M1B<PJRIL>TB4II*Y<85:<6HD5%#VFA[34@:Z;E6VPNN.5J]K 0O6_M(@1GG^
M\&E]JTH#^.1T5.D!FY.-NW!3#SX4'>R.I:1'*OW-+*"$.;[^NOD'II.AS&XK
M4-TB:U[:U)TXRKC6?X<C$,9N0,,&P7K1A$'X0 IE;]Z#K42&AK^G+6A;CON-
M5;#9)*"VMM;BO<2 !O2NO8WOB.^VO+:.^W%>K3V^A1A 4X3E&D1&<YN81(@3
M\3$L[ #(**DXMHD 9=_9DKLM<A,DNPY2$I;_ &*[NWMH1\2*&E:_#7V6VE8<
M@L#3N1&5+RR'Z@MVYKSZM(P_BQP/=WJG.1I]JD*?5-,M3:RAI7R(+0/_ "VD
M(224I"3Z#?7)<5K;-LE>MLTZ]4&4G UR^YUDI",OGQ/?C]ZK+T:W2O9N3P#<
M_M5[+RE))6:;#O44DG8>FO7D=BW"_K_3TZ$MVI1)?3$S?Q;5T[5@C2D,02"J
M=:;Q"GSG8RX96F,RX)SCRA[;A*Z+4*TW->OKKYML7J3&YWVMM.]TY&J92A$3
M!,?ADP8$,KQ$AA/$J;=R"3;Y:K+ AEBVOOJ]N0A-(Z8I 0.SN21[@ _XM7W"
MTY)0Y&=MTF.SU03 1#!SE@,,B5>E1IU)$8 %2-@NT&USW8ZW9,Z5(D-L)0I2
MD^VVE07W)2DDJ32E?PURVS5=PX7SBK1%.52C</&6!+"<0'[F=_8LL[.D8$89
M'\5[8_EN'7*TIMSC2!+@,..^\@[L.))633M_#??7UBIR;::XG T0:]'$G2"0
MV.;/]J\2G0J_4,)2;Q*\TDR(TF/*DV-")MUCK96$J4D*7'<0XI80XK8T0KIK
MF+SD5CR>WG';*9&Y1<:@"[CO]R]O2+=Y3Q)[5[#@^>-0,>N-LRAT);DH=: 9
M0'#[SJ@4-J*/D*PD=>NU-=#3W*XV3C7U7)(B8'RZ@YDP#N"[^U<Y>6WF7,*L
M Q)Z?IWJSY6,-9;&?7:7Y3S<&0\IMJ$$AYU+@*G6UH"NSY4C;J:]-:=2UV3U
M'VB-6V)H&B[1@3"))&#QBP.78O3D12$)3Q8]<5Z#F&*Y/=N.K264FW?TB2AQ
ML-I]SZAD-^P2ZVV6UI51)-2#0D^NM_D_#H[WM-'8!4D( ,2"0<AU7E6^X4I;
MAI+:7R_D7JGCD]-DK9QA$=UXH0E9=*5!HJ=5222XJI2$$5HI7X:]C8.,CC.V
MT[#S93A0HPIAY$X0B(C,]@"Y_FWTMI2E<:L9S,F?)W+!;+;;:X=J@QXC#3:0
MVV@+6E [GG0D=SBRH5*B?COK8,I&<G[5^>+NYJ7%8SE(GL<Y#L"F#V T"0$U
M._H1UZ?CTU#=>JUB3+YL2I=W<@]:;;;>M:_AJSEU4@]%*/I!'RI_6OY:/+M5
M2&.&2E:$==9H9*JI-TGL6R*Y)?*1V@J0E2J54D&FHJ%HH%A_GV=NW*2\TPI:
M4)-"4K4H'Y:%(":$ZUW/:588KQA=H3<WVI<T*+2""AGL)*Z'8E0%*@'\]0Y6
MTP5<1'2T AI*D-@42-P!^8V&H/:5AF/B78-NUJ'$U]: ?#IU^&F&2@LA$@ _
M,E0^.P_,==1@H8.XS4!PG8%L'<]%? 5VW'74CO4E4Z4\ ASO:4@)!WJ5=U.A
M%*]NA;JJYG!69,EH6%!I;B"/W5417_Z1'2FL<P %GIJCKE+"B??.Q]:'^)ZG
M^.O,J5#&3N663/P50@7/V7%.J6EPU2.XBI'44ZZVK>M YII!637!V=KL&4V_
MWWBW;KRXF%*2I20D*<*0R[2GRA*J#TUZL2\>YEK3#2=;& :@'X_#H1Z']=$7
M.B)HB:(FB)HB:(FB+S7DSE7 .*;;8KAR#D<7&H649AC. 6%^4U,=3<LOS*:N
MV8U8V?HX\A2)-UFCVT*6$M).ZU)&^I90Z^1'P;S;C_(O)SPY\<AYA^%>6<:^
M+G-&59EP;G/%V"\TVKRO\@<CS:V9NF\XUR3/R>&<1L"LD=R(/9/*9EO"^R(B
M5K2DZ'OS4 A\5]F3':&TI10) V"0*#<@IV W210Z%2%&U"E0W2 VHDT%#OOM
M^.V^V@S4')8/<J8G>&/+GQ7RIWD',Y=KGY!RO!8P"5_:*</M;K7#.3>Y=+9]
M'BT;*EW!XIJOZBZ/M)[U%* *4E.F*SD3T'KL/\OCZZA2N=$31$T1-$31$T1-
M$31%P30$Z%FQR1::ON6%$SR;^V%9E!*T3/)V[7-*%T4E8M6-6TU -4E27I25
M4IMN?2H^H>GE7Z/B?++XC_@:(B>S5.,<.QV.2YC?I2-]90'^L+_8MR$<]S+9
MIVU2#3X5]-?+HG5$2[0ZZB6>&2C:E0FB)HB:(FB)HB:(H;E.W<TW 'YUU!;4
M 2SJ#DM'GF7:8\WR"RN3[:%.IM5@!6>RH1_2(*>VA)-*'X5USF[;SP_9ZT*6
M^V]"=U5($3)WQP P("_3OII_]+Q'\^7WK%'^E,!?O(;[?;!0V0OY4"GS)[4I
M[:=WQ&O;I;-QO<*$-YH4H0A#$"):/;B"Y^U=XTLV4H(+29*W4)'N+ +BT*"E
M(/0A8+@2CN/78:U;._XJ;VOOL*(IFC,^9*&#R<N<7Z@K"93!(88*+(4N(D.I
MB(GEL^Y],M7N]Q ( 2&UI2H[UH2* :\;G1N>;;)YG'-0,I QD!\1;[_<LU,P
MD_G8=C?RNHS-Z 0EZ=!G-)_>Z([;9;:+@JVVA'<M?RU ._37SW9=^]2>+;%*
MSW*E;R-+2(FI"HY&J,?B(JQ_9).#8^Y9O[N[0)U>(95+^JP_;"7G?8#NR&G4
M46X"0!4)6H!5#KL[SU#HT!;[0:8J"X \TQC(F)(<Z&) Q_>$E@C;4A4\T$OU
MR;[E*-Q;4ROWH+B%RY:5*=9/N%#2DFH[@2"%*KOO2O37C;/R+8KR]J;3L5(6
M_(_-DT0"!(:BTI XF1&,B" 2[ 9+*95 6 57@L*>CR&GZ)24E3A9<]I2:=O:
MI!4'""#T_'7>[G?6%.S''^2W.F_J#63"41("7P@#4)-\I.(.:U:HF:FLYM^L
MJI6RVM1T,H3(=4DJ'>'UA;BNE"5A" O] ->ILD=EVBQ\JTN/,H&0)-242??$
M1#>Q15J5)TO+8,_Z=5-RK&S*N"9K<]\.I-%1UNH##BD@!#G8EL++K8&WS4VU
MY=7ANQW^^#?:=Q4$6#@3AHS?K G[5@C.K -$#[5;;K2H<QYN1=O<+8:1'AAM
MQ+C)>:0Z4HK5*DA0H=?*-MN+#B7JS6E6N*U:A5!#F494ACVB([?WNBWOB=V#
M*=FPX;C,=U^4[$>0ZVIRM4LO!0Z.I[>]7\>NNRYP.%V%I#D%\8&8N)&)MC'4
M22<).*F [@,5@G3N)S^ #R_T]BF8%Q8<?]EYUF1%2KV@^EMQ2@K_ (0OY0$@
M"O0ZZ+BO+*'(HQWB[-"GMT:0C0U/&9G@VK5+'X0781Q[,E:O2J4J6N/S*^U6
M*Q.!J>S[#4T,J2V^V$)7V#99*NPJ4K:F]0.FO5W2IQW9J\>1[Q*G]35D!$$Q
MT/)HA@<>S]K]2\^A7N9S(DV&/7[<5%A8SC\D*<M\AM"WZLSJN?,XTJH>J0/E
M44_EOJ\MOV:E;SWBV%(VUR/C,BX ^4Z6(8X=7685JT:GF",=7@?Q79C&K5CA
ME3(<LJ@1"Y,<2%I<?*HS*UH;'<#\O:G8T KUUYFU[=LO']GO-TV>-*J1&<H&
M7QN=(..G3^TXP8LWBEW<W-6 UQB/ ']9*A(N&.Y78KM%:0J"\S)2ZS*04MJ7
M(;0E?NU6'!V+*Z=.NN%L.3[1S>S.V;S/RJL9D&((@P(#:->K%P7^;!EG\N)I
M0/[6/W!1,>O,KCMZU1>UYZ/=7D2/J_YJE.K]U#2VE+9"4#N2Y7<4U6O*7%+V
MVVC8*<IV->J(RG(&1 )8D2AIB,SF"L%S2C6@8R+3;!O]"S2Q_)[1ED%Z,CL6
M&T O,A*1VI6I:%)4DI[?F]OTU]9I2JW%&-2K\,QUC_*ZX>ZL:UC6^H@^?7+[
M&63W$6'VO&K8[/BP68ST]2BWV) [6#12E*H 2IT[C6&I6J3D=1?$KY+S?>KF
M\J>0XTQD7;MQ':O:O=4H  DTIN3U^44/YG6$E\UP^'EQ/72BGP$T/4?F:ZJH
MUX*#]2/A7_M^>I":U+KD @CY14_!7^RFBHXSZJ4>D-I2IQ:TH2V*J*OVA/\
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MV>/:D]P -3O2M!UTY)ZE7O%=PA:UZ,ZI#1P.!P'<>U14H_4ENA4V_D*)Z"Q
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MU%T1<*K0]M*^E>F@0Y+!'E(\N_\ SG>+O]29X[3Q#_5^4TV)Z%.R=SD5=_\
M^C.2&4BZP7X#6,,V<$.>VIF0M\_+W)ZT8(S+.U5 D[5 ]-8JTS3IF<0Y'12
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M/D5_B,,+0I:BM7<@*"NVA36M#\:Z'#P5P ,EY"IUJ0HK#CBUU-$N;I!/38U
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MFIS6-FS"E?:E-+[4^XI'6M-J?P%!I@HZJ?\ 9+I 425#YA4="FA^(WVUGB%
M)R61-M*Y-IM[J5;F(T% ;D%(":&GY:V:;F.':J%@5,/-_*2I&]1U!^'_ ':5
M =.6* J6 [11(I7<[CTWVH:ZQZ2K%<HKW)J=B=_R_'\*C4:9=B@JN0TH+@(2
M%.#]P7W'8$4"=Z5IZ:G2>S!&Z*^HR5/%/L@(H.U:14 )_$5I6F@C(]%&'57S
M;A(1'#=4GM4B@&]$GO*J5J: D::9=1@K# N5-..A()6I22!Z4&^W7;\--)R
M*SO'M5*D/$MI*7">M":=WK3T/PU)C)\!@L,B-1+JCNT*3[@[MC0D>I_AZZ&$
ME3,=ZHTAEI230J&V] *"OZ;:J01B1@I#KPWE2YFV0?IXJ^YPEU3GS?-0(K^.
MR4U)_#52I"]4\1++#>QN]9EWAZ?<[B[;"2WVEAF#V@H0JNZ5J/\ AJ].)#D]
M5;JLP]9%*:(FB)HB:(FB)HB:(H,@T:4>X)/H30)K0T[B=@-$S7RS^'W*G..1
M>27BPA?"W*=A\N)W+/+S7W!LIO/A%C/&'$=RXLN47*IL%5K\HX/'UNM696S
MY=HM$?$7;5=9,S(HTE1G%MPE)DNRJ&7U.(((%.E*"G04-* #_AIJ#FK#)=M$
M7570@>OP-#^FQWU(4'%8*\I\>QX'F/XN\BC+>0Y4BZWKE.TJQ&;F5VE<>P$Q
MN%\F)N%IPQU8M$"ZO!JKDEL%Q?<JHW.H4XDLLVW+G"05-JD,I<33N0MQ*3L4
MU J=SO3\]6T3$=9!T=O3N6,UZ,9Z)3B)]CK4 VEC*?O47!PAMT<<^%$*7'>)
M0M34S*,^DP)2&E=6UHC.I! J2E>XH0==[5)MO22M;SPJU=WA.(/6(!>7>!VK
MP#4IUN30\N0.BD78Y%BMQR*%*:=*#_(?[-?/XD2 ,<05TDLSXKMJ5":(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+HM(4*
M'UZ5K3_L=,.JEY#&.:QSYB\8.(.;H3K&9XI%3<PE?TF0VVL&[PG5=R@\EZ,I
MD2**4=G0L;ZL8CIB5[FU\HWG:9@T:DO)'0D_8M0W.'VU.1\&^MOO&%Q1G5A:
M2Z\+6XRF!?HC"%+4EIM"GY"+A1L)W24*)/[=7H"F*@\SV>*^Q\<]1=NO)^7N
MLC3EIP)/5QUP[U@<Y$BXY"N=CRBP3;9D;+CK3C=RCR(<N.ZE-6PEAWM!"*#T
M(4% ]-?%.04.9SYG2.VF?T/GPU8EM#QU?8Z^J6-3:=QI>=;U@6!([\^]5BS1
MX\_$EIAVIKZUM+KIN3J^T40I9(V^5)[=@ -SKB-YYIOFV>HL-JN3+Z SB^.&
M(#X+VJ8_NW>K?BSIABKEKBRC&96&'I(0?92Y0#M4NA 4?]NOT=+<]EK7M*%O
M6$:THQP["WBM *[;9E,IB N&T4>R\/FHI!7VFE H=A)I^>OFO)?3_<-VY'2O
MJ%YY<*1?KBY_I#)EEIU/+<=JCL7-I2AW 450*%.T]33YJ[;Z^LV4KFQM(654
MFK@VK]?536M#<T)Q/6)^U>N\998+#D+0>41 N:1%E]JDE(4HGV7">WY2E2J'
MI6NHK9E?,N:;3_B#;3(X_3_@WZEF0E=>UP$$J^8*3NDUW!2=Q0UVUH2S*_.<
MXZ)& Z%E--2GFR=R1^?^'KJO@JL^>:J;=S"BD+% =B2KI^E!J5CF/A*J+;S;
MG;3M(/4@]/X:EP5KLRFNY"3W C;;\:'6P&90X&6:]@P:6)5M=C%7<Y%=JFM"
M2RI#02/Q'?7XZSTS\/M4$=5>=-OG;V'J*CI^N^LN>"J5 <0T304'0#X[_D=&
M[44LIDIH00:>AVV]0-R:TU#*074]%5VJ#A!%37?;IL?\=2F2O6TN +0LJ[J*
M"BFO8-Z#K0]-0W56[@O0H,C8=Z@H^I!H!4U _0:E <,5.O)9>VKV_AUIZ]30
M:A^O1 #DJ3(BD =AJ@=-MSU_CJ<RH(+*CR6E%)%.AIZ_KTU)=5R5M7*:S;83
M\I]26TM(6H=R@"5C<4K6IUCF2Q[%;HL=+!CUWYDS9VTQETM,9Y#UVEKK1JW"
M11:4 %!6IPI[0D$$UUKLY5A]JV0V&Q6S&[9%M%GAL08,1EMMIB.TEM-4H"5.
M*INMUPIJI1))/KK.#@K*L:(FB)HB:(FB)HB:(FB*"^:-J-%&@.R02K]IIV@$
M$G\NN@S3HOC]^V;R9RUB?,G#7$V)_=.YSR;Q=Q3FJ'Q=A/$F6?;N\?./.+>4
MK?D.-Y[R)BF/X=S!'R'(N3\6X^R^VXQ<%8Y<"IE4I,0-1D"/V@250,3B<%]@
M3));34U-/F- *J!(40!L 5 _&GQ.A5ADHVH4KJJE-^GYD?XC?1,U@/RKQCQ_
M;/,KQ@Y-AQK@,[O=XY5M%UEKRS*Y5M7;8O"^3B.VWA[U]<Q."]_)3_/9@-O*
M_P",UU$Q3C UJA8Q('B[_@HCA)QFQ6L+C_PF\;O-3[B7W')WD%@DG.H_'V6\
M,VG&$L9=FF+IMSUTP!PW?W%XAD-A5-,ANV,)*9'O)0E-$]H)K]9W'D.X\6XK
MM VRG&G5KQF\S"$];%Q\\9,!CB.Y<MM]O1O=WNJM4 B)[3X+:OXT_;W\3_$'
M*;_F7C]QD]@V0919&<<OD]S-\^R?ZVS,SF;BW#3#RO)KS!ATFQT+*F&VU*I0
MFA.N%W[FW*>26T+3=:L#:TY:HAH!BQ&481Z$]5[]KM=G:UC6HQ:9&>/XE9OI
MZ#\A_EKGX?*'+EEN'-<ZLH31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1<4&VPVZ:("V2=HW-!4BAVZCX:(<0QR71:4?*2
MA*J*%/E!*3ON/@::EM1?J%4L!EU7AW*WCMQ#S'#<:SC#[1/EA"_:N[,-B+>(
MZE-]H6W<6FQ)JD(30$D?*-M6C4G1EYP+2'7N_!>UMV_[CMD@;6K4C$$%A*0&
M;]"%J>YH^W/R#A,.9<>%;ZK+;"KWW58Y< B->XZ5'O[(LE(3'E]O<:=R4JI2
MFOGN[>GFU<@W^.^5ZD8SP+$.,,,V[NJ^U\8]5*.CZ?<8G7_..H>\E:QKY'R[
M%%SL5R*WW2Q26Y*E3;3<8\R&[]0T>U:BU(*?<![/W"M:[;:]B[XG9V%?\THP
MIR 8Q>(?X0W9W+Z=;[A#<J0NK72*=3$#[.G>% =A.P9D"-&N$60].;CK2IAT
MJ9:+YV;>%:!:*;UWU7_$EF;*YN;RD(RM8 Q.D/)]7W:?M6Y&C7CC6 8G!L?%
M>IHQ);:4H_K,:1-[0I;0241BF@) <2HGO!--P=]?(K/_ -0NU2NJEG<T:E.V
M@6,@!@.IP*].F9:,%2EOK@R3'6Z&931 4VE84V2=T$#NW([:]*Z^V;+NNU[]
MM_YC9UIFD0#\3]<NI7C1I4_-E2,(^5/.+!CXC(^U9=\2<C-WBVBQW5WNNMO0
MA#+CA*3*BH: [N]PDJ<;".E:_ :V*HI7<1]+-I1&+%G[<E\']0N)G8JT[ZUI
MP-&O4E(1C$ 1$B9  ,P !8 +W5IUAX)]M8[B 1W$=NYZGT]-8H5HMHE\T<"O
MELH&,8R/S$.RF%QW FI[5#T"4[DU]#\-9!4B3@J,",5U0\ZTDT[@ 3ZD4].E
M=64:8G)E/LS5NK2VJ@JDT.]:A.QK7U.IQ[2M;!UZ9@UQ-ON+2G%4:D%+#HJ?
M4 ]R@-B$D[:V[=]./:JE>\*2WV50L."O;7J?PK^FL_>JYAE)/)2#T%2!Z4(H
M"#N-6&(Q56#X*44V:;*)H:TT92H[2_F;#OR@=U0:GUV%-$97+"<;Z!P HW"1
M7<5V!IZ&NH;%U+CN5R1YRVR>T5[3\?A_A0ZE\&*CJZJ9NJE(2" @@D[5!Z4W
M/KH"%.*BIN)6$CO-1L 5'^'Y:89IJ*Z.2FD J>Z=JC6HZ =:_ 5U)R4.^)6,
MG+.2KN#D>R6ISN=?=1%0&R:+D/%*6T]R2 :J4-4.*O$=JS X<XWB<>8LPQ7W
M[Q=$,3[Q+4E(<,EQE)^D0H?,(\52E "NY))U5@.Q2O7=%*:(FB)HB:(FB)HB
M:(FB+#3SK\LO_DVX'E<K6WC7(.:,WO.;\>\6\7\0XO<[?9KSR)R3R;E5OQ;&
M,?:O=U"[98H@<FN2Y4Q]);8BQ7%4)H-2H);M6E3[3/@_XK9SRYR3Y)M8MY7<
M-\X>//.M_P".\_\ ";E/R/C<M^._CUR[C&/..8K<N,+%9[+;K1=+;:N/^0"K
M%Y:I$ABT0KJ\S#:::([CLJ@.5].#(^1&R1\@V2*"E!3:JJ&GXG\]%<.HVH1<
M*( )/0"I_+1%@ARQ;N)$^8?BY<[= X[1RK(O7*C5\GPHN,IY">LB>%\G^D:N
MLEE R1RU?*@H2\2S0)H.FL->(G QF' B^/:\<?'$X^*M #/JRQG^VL&KUY0?
M=.SAIT/B?Y9)P;N2L.H2>-[3/M#B4G=:"VN;[:AW$)+0   U]:]00:?'>/6Q
M)(&WB;/@/,C3E@.CDE^U<YL[&^NY1# U/N++<,I*5"BDA0^"@"/X'7RB=.G5
MCIJ1$H]A (^U=""1D5R      -@!L /P&K1B(@1B (@8!%SJ431$T1-$31$T
M1-$31$T1-$31$T1-$31$T16Q<LOQRT3%P;E>[3 EMI0M4>7<(D=_L<3W-J+3
MKR5I2OT)&^H,H1(!(';W+?M=JW6]IFM:6U>K2'6,"1[P%3SR'AH&^4X\A5#5
M*[M#-/04*'%"E=/BU$AC3; CJ5LQX[O\Z8F+.X ?K3E^"Y'(6'%!*<GL2J=5
M_P!2BEI)I6BE!RHVUJU;RA3^ U:4:O9*0'ZW5O\ #N]];:L_9I/X+K_U#P\&
MBLHQX';K=(U-_4?/T_/66%3S8@TC"7:Q<?8G^'=].5K6;^A+\%PGD/$"K_\
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M*VW'\"/]IU!4GN!7/=^!_BG_ .MHH#E<=X^!_BG_ .MJ'3'L*Y[OP/\ %/\
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M#,3);>Y'E1Y/NN)<8*FU=KJ'6T%#K>@DU /0TW%:T/J/T.H5EPI'<1TH*UJ
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M!U@3B')DXP=\NY>I*5G*TG1JAS/)XG\%Z'B7-^3X][<>X.B\V\ ?R7U!+[8
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MCKF"TJL,Y$"0K*>,;^UD>.MRUN,2$2+8NX,@/LE(#B"14&AUN.N2;W+7H_\
M9(\2[OR9DW+F77;E/-,US#FW"^<LDF7S(;'$@7B\X#C&>8CCF-S+3CN.V2W.
MX\W8N1;@S)4ILW";1I3\EQ38)ARI8*VL+^P_X=8%P[EO!=AO'*[6!WN3QY-Q
M5/\ 6,1C9-QM<>+<R;SO";CC69VW#(&67R1:,ACLN=N03+RTZAI*'$*%:L49
M9@<:> 7&W'GE3D?F+,S;DK/>9,BXG5PTJ?E]QQE%KMN(R9>,72ZAB'C.,X\[
M/G76[XG'DER<Y*$9;KR8P9;<+8.C+&Q[[*7B:_BN;X>NY\I_TG/O$^[^'-[
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M\L7F1G<B9)RUZ0[[_P!0VJ]2+@ZMSVUMA)6>SMVI7X&TAF6754U:M<G54ON
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MEK"0J0<$([%*S.!?/K%?*/Q0Q]S$>>K=QKPI%\9.(^4^7\7Y6N,OAK,^#HG
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CBG!>I([>T=M"-]_QK\U?Q[NOXZ(%WT1-$31$T1-$31%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm2127058d1-ph_ptfehav4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_ptfehav4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!'@,. P$1  (1 0,1 ?_$ -,    & P$! 0
M       $!08'" ,)"@(!"P$  04! 0$!              $" P0%!@<("1
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MK$?I_3W(A0>*<J>G&-C37WN[^$4/K8;'K#+J?\,/.SLO+AIH\IT''5XLL8N
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MW)O2S/.!L5G75I#JGYEG5GQ'/PFHF6MQ>2H4.N_>KIXR%D2C-&-'JXBZ(NJ
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MJBN[)JB_7]-?X:]/&(6D7A67HI:'110Z**'110Z**QD*P2(KW:;ET3LO=>E
M6D+@T*<J#RL8S>Y?M_1=%77_ %="4HQRK&.4$J[6*[754[M<B:I]4U5-.A#2
M$@%*,=)2T.BBAT44.BBAT44.BBAT44.BBAT44.BBAT44.BBAT44.BBAT44.B
MBAT44.BBAT44.BBAT44.BBL1B((;R+HB,:YRJO9$T15[_P"KI"4"T56B[]E,
M>H[VPQ\P"'GUTET<PX\6631>^Q45&;7(Y$_1>K4-N9@H*4U2 J4Q[;W5X_HW
MG;9BFQTC>/RO2OF$:UY7M&P:^-CG>5Y'(B-1%55ZG9MTS\O=2P-FGR816)?=
MOCUD4DJ2.36H-A7**YB3*J0JCW*K6@DA1[W*UNJ(FJJBIVU73JRW99R%4>HU
M?&WW)R:HZJ:4;\AO$\BV#1H*S_=9'C6-&2KL-)+3#<03P%4'C(Q[6_QU37OT
MCMGF''V4O]NN1]03LIEG_*7Z^0LJOL(L+236952R! 94V=5;PBV#GM>KA5KB
MP]+$HT"1SD#Y-&M[:KVZ:-IF5%%0_9W&H-:%<3@*=4W\C'$40,25XK58LL "
MM.M1:JT1#M8] 'VQ%0,AC7*CF.^YKV[?U1>I#LL_ A.JM./RYNLD?B",IZ=-
M)T7\EG"$Q\N*A[ ,N*=D5XC5%L/=**U=D5CUAN8LA7)IL_FU_3I@VB<N0'C5
MN#RCN]P%:U.S\:.1?R*\6/FS($F#=PI,)8B';(HK@34<?>TRL(^"-I1Q2-1K
MU373<B_JG4CMDG:!B,>@TQ_E3>(Y1&Z,X\?0TZ!>^/&9YLNL "R/80Q&.6*&
MLL"E6/'7864Q@P.<Z*Q_97_3]?ITT;+<$H2*AN?+FXVQ[[>[S3+VTS[S\C?&
ME'FG&V'OQS-9_P#S/*R-39#6X;D$[':^44[0"%?7$6&6OI-RNU19!&*O\.HX
MMJFFC?(, SVUE-L[ETWA:3AQ],:?1/>+CN/:P,?D,E!R&TGWE?74QH4MMA.+
MCR5G[H2-$&(D@T:-^[!W&:U1(KD^[OTQFV3/RJP[;+AF?NHKCGOAQGE6=1..
MZ<=C)R.7+R& P;:FQ2(*=BTFLC7<*3,()@(\R(MQ'7QO5%=OT_3JR[8[IL!N
M AC;G[*K&UD#M)SIY77MOB5$*%)F0+5\6P,T$60"FM'B*\FJ,7>H$:T;U3LY
M51%1%7].JD&WR3CNE#TU/'M\LA0$>VDRJ]S<%N#F#%C3=(\Z/7F*Z',V#DGW
MZM[ 5%\*(U7:+_MIU9.RW R(-76;#<OR<T=AHE:>[G'E-'@2IP+-H9LZ36H]
M:>V:QDN,P#E3?\9=PGJ=$:_1$<J=NF_V>XQQ%%ML-U< D. 3HKZSW2Q!]C*K
MW55H)8LE(I)!*>Z^+YEC@DH)IVP='D49VJB(G?IW]FN.!"U-_P!-W:IJ'J->
M8OO'Q7,5S13W"(V3)BL;*@64=)1(8F'EDB/+&8PP(PWHKWZIIK].D;LMRXIA
M4,VPW4+=3G#/D:;N9^^N#8E)Q6N'16]]<YC8 KZ2JJH,\DJ0]YF-D$T9"D?T
MXL8C2O7_ &6*BZIKU([8[AH+G$(!5-^V7+6]SO.Y 4<MO>_ :8L>)/JK6).D
M#8Y0%KK'0#U;N*PQ%C-8UL=-=SET;VZ=:[!=7;=;2 WMJ[-Y;W6WVZ/<'QG]
M0#NH%"\\4IQT/N7AF01IAH4*<]U?+2!,\<"P,,<AT84MJL>&,1"A4!FNW)VT
MZ)=@N82CG-J%NR7I(:X(4'#F%I1@>WF$V,M\&.AVR1A\Y 2*^RCF$-2D$UQA
MDCHK&D>/[5[HJ*G59NT7+B1Q%3O\OW4;0YSACT&C;_:&N8:2K*.=*B#A^8!H
M4.;*>\S7N:\90C"I!:;?U_3O]%Z:[:YFE#F:SW[=<,<F?90=[68X$\IDJGO(
MXH6-OR8YV4EK+:Z$)Y&&&)@(ZO?)"T3G.8B*YK4[Z=*[:IAQ%']ON.7LJ-<$
M_(#Q;R;DF8XKAD/)I]AAL<)9<J=B>0T]1;ED4\:Y9'QFVGPFP\A+'CRVLD)$
M4W@,P@W(KAN1'G:)@T.):AJR-FN7,#P1B.1ILS/R#Q*NS;63N%>6'.G;?VF1
M78/E%I!.[XKBD=,FQ*5PH"-.BIH335$7^'41VYX_-4#]MF8>\0.RK.U?.H+"
MFJ[0]9^VELP!>R'.^0"2$SQH1X31R 8<3A)KNWM:K=%U3JNZTF!P:2*;]A*,
MW#U&D/*?9*NQ&!6SK:L>,=C;Q*IJ(TSD#\JOE6"2R.1.T1C(R-\G\JN>G3H+
M*:X?H:$-2Q[7(_\ .WU&OD/V@Q6QFR($*/)D&AK!;)\,609K76$1\R*X:B8]
MQ1%$/^9J*B*J:Z=3OVN9A1QI7[-N#<0PN;P(X^VHBRK\@7&F'9&#%[N!>1;:
M<XB5P5H+MPY30E8$KT,D/QHP;G+J[Z(C>GP;/=W+],+21SH@V>\E.EPTNZ?P
MI4QSWTXIR>TD4M:2R_<8RJUXSTMH(,AXR#"=D"0X*"FDCE)M>C5U;U9E\N[C
M"-4C#I%/DV6[C?I/+-#2EC/O)Q%F=KGU-CUR(EAQ;:U='GX;&),K&X_:VSI+
M(P3%F- PH5)$(U2MU$BHGW=].J+]NDC'?(%5!8S%^C"I2J/83%KMXV5MC5SW
MD"ID%"D?),C=H]CG,"\NUCW$1$<O;IHL)"W4"$JJ6$+T5FHN<8>37.2U=1'%
M(#C<V+62K +E.%+%ZR4EQ7-9N^Z*H$1>^OW=9Y.E^A#4;]32B4ZKSD2535DF
MR6O9(8-I5"U-X$+X1O(3[R.5$5-FB(O=WZ?3J=L1=3X6.E=I&&"U&,_V7KJ;
M%Y62W5.>&P0G/APMI7RK,R#\K(<(;6.<66<7W-&B*Y4[Z:=66V+W9&K/VDB9
MBFQ ]O*R?QM-Y&'B5T"/$;(<RC/%E)<'43Q#'''&=&&_Y9'%1/$B;D3OT[^W
M2JG&E^RGSX49Q3W$X^RZTL,>@&E"R6GK@6=U2R*N>"32AD.*T8+1I1-6).10
MOW =_4:C>Z=^HY+-T;02<Z9+:RQ1B1WJI^2/87%85_C6,3YP(=[ET2?/H:\\
M<S#RX=4L9+,JM>5NCX2RV>1C=SQJNCD:J*G3'6SFLUKA4/AOT!_ T=C\VU4Y
MDN76S*RRA5TIT"Q?!:>4L2Q8NCH)B!<\;)"(J+M_FT7LB]$%L9P=)0BAD3WO
M#4Q)%,;DKVWP'B#&_P"[^1"GQ_'?EB@K8%@3BHV2;_=M5C1(YHW:I]RZ)WZL
MVVU7%V_PX4+_ $ZZO_VV?/AU4?P_VDPSD!IR8A(;: B&>"3*&(WQFN:$1FN&
M5Z,0K7M)^GTTZ+O:KFR<63#OCA2?VV<Y$)U4Z:KG"JOAND43H]K$:U^DR$CI
M,-[Q$*$@FR0E>)3M,%[?'KOU;V3JN;5S0"[!:8ZPE;F12E;<KK1QGR[*"K!C
M%',H@19A9#F29/Q1*@MC515)]47[D_5$Z1EL7D-:<33/LW_XA2',YYKX8U*6
M$\2,AMGF&4!VG#%?NT(\3MCNR-[HFJ]3C;GG\PH^T?S'J-,FE]ON.;^UPRIJ
M[3YQ,[L;RII)<2HLCUK+''8'[A9Q+.P&K@UI4']@4*B><WV-[]0OM2S,BD?:
MO8%+AZJLF"[FEIYL]8XTDQG#V@1'=VO9'*J.;O5WD\9E[=EU[:=5].*57TE4
M6F+R.O\ ZG7_ /\ J%__ #C>I8,"O"GP?S.RH[V/5=45$3^"Z?\ ?WZL=U%J
MX0:S?37M]4[+^OU3M^O;IAFY4V%QE*/K*Q-41-$U771%T1VFJZN_R_RZB=(7
M.Z:?*Z.%^@N '71IS'C5HU8]B+]=6K]--6ZZIKW_ $7I?&$(U/P'336S%LC$
M!<USDPQKY%0B.?J1K$1-R;G-1S4;]7(U517:+_GT,NFRM)C&I!PQ]U6MTE@+
M1:P:3._NH"I&K#+/C6<C=_=2-5.R(Y7-3558TG?].['(Y/\ !=>AGZA5^'74
M]I&^PM#XX(3GZ=!]1I7K4VZL545VY?U71SFJJ+WU_P!E6*B_XHO0_2PHH3K%
M9+YI)I#)#&YS"<"&DCV"E3RM5[4\Z-15?N1SF(W1-O\ *NO?15_T=->$ H;%
M=3/TB&0-X]QW'+AUT9WM:HWIH[5=5T5%1_Z*K5U[HG\4Z:&/=D">RH+PLM7"
M)S@"<U*>^E!KM=%5=&HFJ]]-$7315_@B]*A&>!JJ2$U8:>?"LF]PVZI^CEU5
M?IMU_55^B(GZ]1%[UP%."$+PK*4@U:JJO=0D<B*OU5-FU6+KW3NO31&Z;O9)
M4T8)P3NU'UCRGA%)G..<;6=H!,NR>OL[6FJ%,-I#0:QD4LTJ#<9A7(-LYFBM
M:J*B=UZD%G<-89VM>6#H*<JED^W8W4Q[/&_P@A?4JHF=21&>A&L:B:?:U573
M]51%7=_#7MU$9'##C3G1Z6>(SZC0),BJ5XVD:CQKM75435>W;NO\W^'4GOIH
ML)WMU-!+?71X!6-[:KJ5$3LFO=%75?\ /MTAA,G>%1-:^VFT2*&H,3@*-M*W
M5BD[:LU7_+ZZZ?5$T3Z_3IK8M!7C4L[6G]1F+>8Q'KI3&8#6N7R,8W1%U>K&
M+IWU7OIV[?7ISG-!0D57*ANHX-YUZW,1==4<QZ:HYOW;?IV54U[:]+GUBE"'
M*LK&,1J(FCD155%71?UU_P"SI.JE1,#67I**'110Z**'110U3_7T*!16$OC5
M%WJW[45R:JG94377Z_ITFIH*$A::X%">%8%4!&M12(JHY'(C'(JZZN1NK47Z
M:I_V=.#@<&H:(RAQK+HUW=R[%8B:Z*B+K_%=>W?H4#B*5XQ/*L@W;D[.:_1=
M-6JB_P"O3MKT8'*D!6O::_KTE*%XU]Z*6AT44.BBAT44.BBAT44.BBAT44.B
MBAT44.BBAT44.BBAT44.BBAT44.BBAT44.BBAT447EJB1CZIJGB(FFB+K]JZ
M:ZZIIT *4I#E6F?F/+R1N3\NJJBMLG3(\J(5QID4D6.,Q!C:Z15&>S2V!N?H
MY['*QCE1%ZZ2QA.G4 2 *>QCR0@*=1JN^6WTK!R1!3:*=DBSHTC(;&/&K994
MKI=B#YD$4JP<CHKG1?,UKFJB*T@_\%ZVX9&C#2?5716,]GJ <YB]8J L3Q&5
M-I<DSW-175#'FN4M9!,.2()91Y(XQ5ERK%J"B,*+>5SU<C/&Y53]%29TX:XJ
MTIU5T']QMHOT@&DC^/QI+Q[.N'<+OL?=E(<DGV=8^?,K$PRAG9-3QHDJ2(,J
M5-OH!"PW+$=*8J.WN8QJKKIIU"^[:4#6JX="U4O-RM_#"HW'CA[ZFSFO%_7O
MD*#6&L)=7?TUL&'$GB@> .<3ID2!+=5SZ58[U>H0@8I#D\1&:*NJJO3!<',L
M.?(UCF]_4#X!B""$QQ%5CP-M:6O@\7W/(-,_'X,RTA5ALER*A!F5;0QK'P4)
M+QSECB^-&JW-:A5 JC7:I'*O?J;[QN285U-KO.X&! 1J[*;O(@N+N++K)Y/&
M'*D3E@%775RW],2WH;C)0RA C1@IC#ZMD85C%BJ0K#JT9'KMW*Y?KU/!,"CG
M-K4V;>=T9<%MP"R(D(7! >HE%IZ8Y;$R+'*JWE0GA6(^A=7NG,*.QG!RR,>3
M)AD Y&OLID%([$:-NYR?<KM=$TNOF8Y-(6NXOFW<MK]RTMTMXX<?X4[*VNXN
MDY'D.'%G3YP9:Y6&S6OD/**2"DF5068_)./=*#&>67O>B&:N@UU7MTT2-#L&
M^L5P7W%[<3)(YKH@<40^ZK&V.:V+<=Q1N.)*G6=;,/8!VPF_%*R9*$9%JA(P
MI938C7HK%9H-NNB)IU1M4;'.7-P=D$*G'\:TG65HV(2 -\3E^%+.7<>PK2K'
MF68#LZ.+23GW&-9$=&UP'!N1B?<VT:1("YTF6,=9'0FQ7BTV;D[IU#;31N<C
M6C4!CS'7^-<M<SP@D8*"GMJ'(]>7E?G_ (.Y0X[/';C59%R"?=Y"Z4.5#IKV
MS+3E/06S*UL>*6);%A[I)W_U"+&8Y'=G=;8NV,V>6W+5>78(,?R]=8LS6S3!
MS1@E6^/CMS=YYG%/5Y;&OZ<>:7$F%6/R:CF@I[036-6ED5L%C;"(&$H_]R]_
ME$CG:IJJ:\I9O;%^J_ \NNK<(9"0_##A4)6\R'BEU$I)E1:P\B8ES92:*X&2
M#*FD;\8:2J,2M"[)(T-XT>KXS5&-I$WN77K2%XUP[HPZ*UX+Q@"IC3A?'!)M
MJF*1)XHUK'9:S7N&(0IPK)0@CE)*.-\>+#$Z&NFW:K-W=>Z=6C,PM+@BC+BG
MXUJ;3(W2=3"%Z*:V6W[*B- 1LD=9'FW$*C%(KB-E1HE\=C1"LI3R*YQ@1@&8
M]SM5_D7]$Z<'Q@*<3Z85JQOA<"2 ,:-XZ.#DQ9\=V-OM*^NL:\))"1",H!CL
M9+8LZ>"W:J!9\AB.4@T<GV-[]ND=*T$!H[Q7K]!57<9+<6I)TYCXU)TP.-$!
M< BP8B3*BT2KBLNSCC$G,LJRJ$:;1^/QR&16M,T+2HY4*L9S&JKF.3JJZY+W
MAIPZACVKSJAL0AFF_6 #1B"[ >VJQ<E<DX708+EO(LZ76YG08J,:2Z'%G-MY
M=;\)2B9+DNB%*Y@8T@"JKW)H]6KNU[]0[EO$.QV?CC  *OSX?*O1?).T7/GK
MS.[R]&]A8PD  @Y<D)IU<59X?+,6P/D&J#:RL.Y>6PDT+-!3!0)=,LF ZRF3
MX0& @"L)-8Z*()-SBE;M;]R]5=CWJ'?MNCW&$#0_4%&(1KG-./\ N^NL_P#<
M?:#Y'\X7?ENX8?'M_"S"$^)#'*$'4^FMPGR/RARID7-TB:D_!L0KI[Z7C1V6
MX[,J3MF1*:+%L -B2VQ)EM3+>--(:X+ON(56H[5$:FZ61L <UJNX_.O.;C<W
M2N\$QN:X8HAX]E6HX5Q#++/C2.'F7*4R+,:XSQ7$VBJ["AKTCPK>39TAZFGF
MF/:M;^W2(PU(YY&F,BIW14:F7<S.C>/#9@23D<3Z<*=&87M+I AI)R' <8SW
MCK(N/)4F^A8I6KD,1]M)G+29+.+D#Y3I#H*SF#^8V..8J#>Q'-\C=OU[=-:^
M4.U%C]3D_*4PY4W7;\-*"H.JJ;*_7G&>*.,."^+YW)E;BN0B!D]WD=I'HGT^
M+VL^9>6UA(MY#(T:=<B??*X0VIJ]4\6FKD3J8M;)&27AKB,E"@Y99CJJSXL7
MA-1N"=E2S&]T_746=3^-_P#G)$N>18!I3)F"4%E6WMN*V8TEE:5-=6UQWSID
MRF<PB30HQQ0B$3?IM72HZW.;0"T>[I[*Q[M\3BW4=.>:#ESJ1^5^4+/C_C6[
MY%P'CF[YIR<46GE!XNQ:4^+E%E5V]A50;!L6H6/86 '0(%B^81WB_P!R-VBH
MC'*C997B-"UWACB047KRJJ]C2PZ I3A3EBWA\SXNILCR6BD<:S,@QEDJSQVR
M.K[.F8L0T*'76RS& $(\0+T8J(QCU*@T[J_O'8W$3)M3T&/'#E3(N[]6&'&J
M9\?<\<DX=G.3X;D& WQ,%XW2F)=W+<:MCS;VBR%H(.&.QV?%\@9EF>TL8+B!
M5#.8!Q4V-5NK=>_-H]OB1(9".!7/H%:$EQ?A@:QPTIAEEPIV,]D!\V8UF^90
M.)\VX_%Q9D]MB5A%Y6Q"QQS(K6L!:V<(UI45-G65TZ15R/VQ%20%4&[RL[_<
MFM7:Q.7Z7 QL<<"5:"@S!*<\.H\JT]G=<!_]<,=6!(0(GSJ,,7P#CW-\DPW)
M*L[:6=2RW9M45BED5$.T))L LE-NVRSD*)!2K%CD8QS4<YJ:ZZ==!<WD\+#X
MSPZ-""5!X8$)G\ZZ/<18MMS("S4@XBMAV9Y37\,\?\F7TCB[,LYN,:QNIO+.
MOPC +"\N<] \]6Q85,M17RER2U@/E#4[&B(4"#*YVBL=UP3KEEY=^&SNL7!<
MN/SKS&\O'17)TL*=1J'?6CEG,N8+2WSWE;UVL_62#4U]7(PDF79)7OL,^QJV
M!+*TMG1K6UDW%;&H& ##1CHA1E*K7:*G5\1ED1 Q)*=54Q"TG4<*NU5WT"I;
M)+11Z@5(6/\ O)YE9,#,F6$F>QQ&($8B:232M5<KW*[1OT[=9(LSK4@J3R2I
M&6;9!J1:8&,79+S-,BRB'9>&*<</%B@+9 E4;K&I9(CR(C*@>LF#90G=GE>1
M&D=_L)KU:?;QL: W%W14L-HUCB40)5?LCYJXVQ*GS6PR;)X/(]OC>9Y!C-=3
M5.44&57L:<.;*&RB/"H5WU2,.':X!@><&W:]5<U5ZNP1.(&D$8*</3&K B8J
MG):6L:G9+EV+8MGE_C*8C90RC?\ LK+J')K:ZJLV"::=,(P#4E&&';O"B(1-
M$:[NNBV@X Z$)U<\^RK8E8<6MRZ*?F)TT2SBA=B$X5)%G6D>WR7+*(L-LJ[(
M,1FBAV!I0YC["OL45R;@JUS5$B(J:NUI7L0<_O*IR'4E5KZ(20@@(OSI7PVX
MPR^R3+<@QAM7-NJB;88E8V44XKOR,HT>%(;V12F?7J[NBC%XW:_S)V3J*:$"
MW&H8&JD%GJCQ:<.@TTN;,DN@8O9VU7-O\#9AE9#R0EG3 C1Z/()<<TQ\[&,A
M584E4COCQ!J;4@)#AGV>1JJU43;H6/D\,(=3DS"]'MJ86[(G"3(MQ]6/PJGU
MW4<_<J8S7X;*R#!+&]ENOJR;-O:PM-975.D2L5MKB-#>V?GGJ/R%0,QH3":;
MNYJM[)T5DYFW3"21I\,.Q*8 CF<NNK'W0/Y2J5-WK)P=D/KWAT_C.SS6ZMLJ
MNR_W(-9/QO%C\64Q\-D<,Y80Q.BI\3R*XBJK6/3NG6;O6XQ7]R^Y@;J:YQR"
M\N5(;UC<$%3K"S.GQ)8^.WN08M)N;,IF1"1WI%0(;)/!1)<0@R42,^YLAF&
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M1!]A&2WPTTG->28<E/156=,5SX5#GKQ['\T<B^T_)=?FSZS#N/[[AO$<CP[
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M>[;.TP?&\*I+*\N@08$-A 8UC=<QMQ>SO(5[W# %"'<5ZM<]6[&C+C=/O?T
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M8M?-B3*677CC3(B8G +-6!-(03B%'' "-J5/Z:*BJL]S,)86AI5K%%-DTE
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M;I+:74ADEC,;G%01F>C$#VUXOY\V9L.XBYC"^,\EH#4S"HA0J,BH%;F^3/\
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M,@,L;05+,(&:-#!1\"Y6!+$9S?HQS$=KVTU^G/R;7>0GO-=AT+\:\[E\I[_
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MALB#FP)3VK\.>"UKH4^K,2N=O<@U(OB\FKVZNW-KS-=$4:I"^KUFHGI&,2I
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M))\<K#JK=-$7JS#!->/+Y&:(T4%?8?6>&"4_!.FDOA[-N<<GS#.QY_B>+TE
MRGL[+%%JL:OHMP23$LF0$A6]B>UFTY=SY#3#5HASBA8JL(K7:],O8HXM#6'V
MKUGX<NBM6V P7E4WT%-+?#HYN2RBW645LN;8P%D!C08 9YYTD+9<(#XT6S29
M6UQB#W^16JQ?N1RZZU7 98:$3GZ</0U/<0ZWMDXAOQI'SZ%Q+>Y'C]K;9%(N
M;5N1Q:>AB5RW\8 <P#76";6#J61:Y_Q C)Y5DH2.,R,0C5W:=,A,WTZ-*<5&
M7K-3MN?#;IXTKX$6@I9111SPKBQ/8SF1IED6.&TF!)-/(8.>"(E97EE 5K-R
MQP!5SVHY=5U59[UER(0':D [,N&"^LT\,%P%&=./*FUR%G9'8TU/$,R$D,62
M3Y-+'-)CO>UTV)(EF..$V,$[&KML?([<G]-S?IU1MX&L[W$9A/P7U5S3=DVG
M;KG7"UH<JX"H8S7E'%<8@TI80[O+&6LU'?N&#X[/S"I00AJTW[CD%5 OJ6E)
M'>J?88H2;5U8NFG6C;Q?<R>$>//T"UNWFXVZB,_X14:9%["8AQO;9!D\;#[2
MUQNSKZZ=R!-QO#K+(7Q'M4RR8I(&#5RW,B\@2C[#,E$>_1=4:WOK??M<D<.E
MW=>'%"$Q1<<0<#U5EQRVK)=83$?*IHI\I;F5,PT$$"!*K9)9A(%1<NCRX87N
MVU);>!\MTZ&ZRBM>_P $YC'C5NBMU[)G26X;)WB7=8_!/57465U;%@;@AHJ.
MTF-KK$*17ULPV_\ <$MFQY<$\5S]K3^'1%<4+4U%JNP:KW3OVE,>IP)Q:,DS
MJUX=J> HV. "%/B39TFB6?-L22BRL3B0OE;)0=49?RHKY7D,PL=5<\BIIN37
MI&$ECA&':1AWEX'A4$CK9CBWC4DUP*X\:(&,(D6+"*TUA"3X)@RHH'/(^,%@
MVN>QHQKM8Q%15W+WZI2/?&XER*<!G52Y="8_T\\:COE;+F8K3XW(QW);'A6O
M;>#N[_)!T85Q^13-)%8#&[Y;VNGU$Z'?DBG9(BQ7@LBL5J (PB,<B1P>,_O'
M40AQY@]F>%<!NH+B[3]1!2HYN?EY1.Q?GN:7"<JN^&(+JC(<4Q>,2[K,GO<<
M\-]'O,0!%EV,ZGN9;+54VSR&*CQ,U&J(UK99H$<6'45QQX+PJ*WM;G[;TY5<
M3)(>4<@5N7<F8QDJSL+R3 X\6'QA>5E?ABXE?1$NF6F5EL9<"GLQR',47F8:
M6_8R.GB&-'=N?:XVTIC*JN>:T@#FA"BC.OO"_'^4X[QE!E\G7V-!SALI;&;/
MPH%)CN.9!9 .I($%DVQ"]QX<43!M8PQWE64\SW*]'-VRSR!TC0%RQ&)]F?72
M@+5:.>\>XQRRZQ;*<SL<XXOR@]0'%X[L=L Y+:D2#:V,X,&KBQ*FZL#6LL]H
M5^^(Y&:$8UNCOKJ00O,#F.0@]"'T]M,D*M*4V>9?9'&07G&4#"\;S/D4%#FN
M/X'D>)WN%VUQ"T9\21*S3(H;,?AWPQA@68O#*<4,+Y8=?'N1R+8M]N=H(D<A
M=Q"8>M:EA(P08 593B_ 38MGN87669A9983*KJHR+#P#9&I*H>*UM=#G!K<N
MR*) IP,?2703GB"^4-SW#8-Z/U43^=W()$0B(2/4:SMP3O<ZV_Q3QUPFSE*2
M.D5L8,]#H]&A74$6<IGRG.6.0?E75"-T8C4_P5>N2 &H\EKFOS]M<47_ %1G
M$2<G>VGK?(E5EC8U43A:=!1\.,\S2SSYA<N" \K:HP#80C'/5[FHUJKW^O7L
M_P"U]C9[E9W$=XUA:'-34 >!YUZ)Y.V*'<+4S3 .1X&(7/5S%<]$_CKBOCU,
M=K(N(0L=R44;98S8EA"OP3)36G5JN9%DV<N*YZJQ=-&HG;Z=>JV6T[-M,NL0
MP@GDQOJ."U[A8;#M-G"QOAQL>X9@-]10+[*CN5D5C7ECCA8T21%ERI!!(*MF
M(/: J@D&,\(VB'&>1%:CU7:UW\VFB]6)O,$36]V%F)_PCY5''!?6MT/MX_T-
M2H 0#CD0,$/#VU8B@XSR?*^/,DY0EUCL)Q#";&HJ[2Z. ,J*:POD"*NBP35O
MRG*5/D(XA"?\,G\N[?VZQKG>([N0,70Y% Z,E%=[9WS'3-;X++>5/J#6@Y(J
MC&OEGZBY'R%  ^#R%06,G)*YK(;I<^UCT,!-XROG#AHH#*04<;_(YHW)N3;U
M@;QKDM4\=VLJG><@ZL<*W]V\B-W;:'[D;YYG#24\1Z*J<ZQ87Z)TN%OLV9#[
M(8/<V%(Z/<Q<+Q]]^^+.O8T(C(,N0)L18H)?P3%$CB*PK?*J:IJO7#VEC=1O
M=++/(_CB]R8#I-<-Y(\M$WSG2O!NHG*PG_&W%I"XY@<:F2?/YF#B\''$ML&Q
MO#[+%*7*Z;%V\>8W89(.510Z1YI<R_/C<G)/+D$*5)(96RT:TKE5WW[>K-OO
MD]A<XO>4_P Q3U*E=/O5I.;A-SO9HA_EE<!_I<*:5/R9R?/Y(J;05A8XQ$SF
M/*EX/!+6!# 2-(<Z<:%$J0!0"1:A[FQQM\7F0>G9-.NG;YEA>TNE:WO#B,?7
M70>7=P;M;01?336C1W0^1[L/]XFIP#5<[\EXO/LK*#,@9=49S^P0(&0I541L
MF'";9CGGHY,I(=D8T4\=B>0)=4:]4151W5:#>(XYU:T:#D$"85<W3S]<WL\6
MWP32,B=JR>X! @&1JZ6%>C%WE]]E<.>6TH\.QBBLJZSP6)9RQBDC<2-X1++B
MF;+LYLAK%<]2E)IM5->G;EOS70-;$JN" C#MJ.?=6;)#HE<9XY&H0XZP5YZE
M7MKWQWZL8IAW)@L2CY-BM:V\;EQJK$7*YEF,<2P@NQF?5_N(R--9U,2:@Y#B
MJ[1QM6+HY=5=O?AV09I'B #'B3Q4YU;F\U[?#MFF".*$$!=+6M7KT@40PSA\
M^;9)G-9C^;8HWG/%%N#I?V;*F>_%Y$5RA'6_(J0E!+BU2N=H-4>H]RH[35%Z
MJ7.X!T#2IU$#+IK.NI]MW#;F2,;'K>QI72%4@%51:A3@'A2VMN68G# A8]DU
M*&ZJ8W.O(N(SL@AY/+V/>CKZZ3,#BK'2*1DB4X#H+4<-"N75J]UYZX\4J[43
MUDUYTZS,%O-</[SVO*:L4"9!<AT#II_>P^<V5MR3"X+XW$3+^/<9IZB5<7N,
M,H\EQR4013J:3>3[5DMYXKU(]SWC7S![ZJU536!MT8G(UQ:[H*&N<;YU?9DP
M(56KC\=\2<T<P>O4ROBY'CLLU)EH!-O<LCXM;U4['J^ 'SPJ@,8!6E@,&1_Q
MWKJ5BM)N[KW8^_>3WFZR>>*U>FW*WW.'7*QNHCB :=N0\:XQP=BIYG%]/EW,
M$Z7%G7_+.4IEM%-J*4(P,C,<*K2U2WKH4E\,R1Z^.%A!N:]5$B/17(S<]SG_
M $_!8!_L@5Q-EO,D\AB0M:J88"JY^O\ <86^VJ.&:'DD=7*Q$^7VV42)E."/
MALW,;4%994N*V$4E:A+*6\*;6IXWQR>16OW.1VB%EPQRO&DKD,!UX>WH%:%W
M-X8#FDC#A5R\X]5+/G;&X$WG3&8;4HZ>+"2AQ2;/K,??8Q"'.VRK'09(9 Z\
ML9T9YAIN1^CFHBIHG6A!>NMW*#WCT\ZO;?>"ZB,2G4F?&HFRP6"9]8S.,>-L
M7G/!B5":(=L.@?B4K';.DJ"3AW4ET^#66%U4V3B,BHV-Y=Y6O<FKW+UT.W[E
M*QNLN1Q/3D2@%:=F&V#S(YQQZ:K?Q-[&X?QQ[V<45U?9743#(?(6"Q^2;#(L
MD)/Q2@*&QB"BF2-/GR(\+XIF$(<SF(HWD5VJ+WZZW<_+KKCR?/>R:?NC$XA
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M[6**=3[93ZAQKB$>19EA-FM<AI32B5C]&JJHO6C(;I\K',*1:AQ-=:^]EO\
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MOKWY(6V9C8QH>F8 !]:41_Y3<,860LS%<$KL)N+" XS,MBUL.;=T<UT5S6+
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M36W[VVUQC$[(*R-81H3H<>XLHHRHYBL>$>BHK-4Z] L[G[RY?;/=WR5;EBW
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M+NETV64-@1?QJ.>:,:X\]=$@<:4OL/S)29ME>9UUAE]#:Y5<9E>7N/1JRV-
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MD8';*[+,OM\OXQ_Y?\78S-E1:7)["TMGY7F4NRKFU(RMH:N7/K(5R>UD+M(
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M>)*_,'9CF#Z['L I6&^?208L?&:7'\?NVMDX]BI!4DN ^- L(<)RGD!1)9B
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M)(1<1N8KY&N RXM3G7#7QO&[]=7;6@S2L<.A"U, 2/?V5L?_ !]T65^L6/\
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M]%#(D*Y"OW(]R*[8UW6Q:/AB_FY]%94VTR[?=B4Z?!SP.-(?&.#4&05 .09
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MPI)2^_8[!O"H\2/A666&9R:;,\-QN3<_N!(D*-9QL8RB=D_QH0?[>-6HB?$
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M)&A8E$N(88\^/"H:9X? 5 #8]RJKTU[=?:[C+%)$BZ":ZK<-DCMK(;E,BLQ
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M2+PIC2!R)MC)(Z9.DLKHB#.&.-JPF->]K7JKYCXB*K')]1ZNT3Z:]606M 0
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MIQ(-KT5R#N01/<WQ'HORK,GEN%+2NG4:L753<_KXF5U^67> \"<VYKC4F^!
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MMOG$K:B*L:\D)-7X4J8-GE\R.5ZJQ.LVZ4OVB)@THYX!541<>!X+4&V[;)8
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M#V5U+]V!.>^0>>-=!D3D"TSS@43QOLJK-S?OL>:ZZ&H%,N/Y/.I9!([(I9S
MUEK&@H<+FMT<TK5T:JJUJRVKH;EKI /!499XA?77H7D6"*3=G.F&J)>]TA:U
M)^QF793BP:Z'"!D%O,MSR?D#K8D%U=7Q5CD4S)LU\N)-&)SD14)L54TU71=$
M7N=BA@>4?I# B%<5ZLJ^FMGLK(_R(<$Y5I3Y5Q^\R<]\.UCU+W1+.9:)+ID9
M*O0",^2>.T\J9'BNE#:A&N,;RO>14<]=7+HOJ^W16DD(C<XJ0 %R7HY'EERK
MU/>8)[O9[:UMH71/;!& Y$"AK<1TX55['*6-39;"R,WR;B3","25TI[C(=H7
M"<C-Y'JX(T1J]FZ(O4CMIMBY[@I=Q.=<OL_EG<6[S'<7TAE:&XDDG#MRZA5F
M>6O9BTSZXJZBLR>\Q&',/45K@/N+*%$@-1\>.:6C(!Y?QXS0.>]S6H]'*B=E
M5=.N6_LMO;]PD.?J4E$.:HOSKTK=/.>P^7MI.T[:PL\PN*"32&E''$%PYM)&
M6. IDWU-90,D-_S'R4\S!;2XM*VDRZGGSYE5D$#&I'[:R0!D\<65\YZ.;H!X
MAJBD=M31%7J^R"*:(M 21K0=*HA/!R+CS11UUR>P^>3+))M/FJY\."4J&N>=
M*'GT\P >VL.28KD<0#+?CB[L28Y5^>6TSGQH9X\9!N\S;"MD*,)31B/VM<B/
M=HB*U55.J8VX!@:"CCPQ^7OKH?-D?F&XV)ES=N9;VK50QG$LX% !\#2GQOSK
M=9%A<JLMKBZO+O#*V^=7VEQ/DV/]WP[BS@'/C.00K*2L*PC5^QOPR.&KV""Y
M&[-SD7)AV=A>9'A2/=61^W>ZR75^;BP@_N[V -+)P"B%4 ?@A5*V+>M'-MIF
M/[=B(<0;Q74831S\GR:VGGIH6%7E7-+&'7T]%#+9R4BZ)'*I%C0A.;JQ'*B*
MW=R^YV#(Y2PN<22$PZ^(Q/23EVU3\XS[GM^_OO39ML;A[3&(HPW2CB"?H7)!
MGSJ8<;YFMLSP_E'+.3*ZLQ+$,;S?(<*P.V6,@)UK%QNT-&=.0-&"7:05L(K&
MK&?"9XG;E1NC&JY,DV>AVE@)=F1BJ'!<2G7C56Q7S)9.V&8+<M&M.D!%]=2A
MB&>XYR=ZW8GB>4<2XIQ185'*=;G,*?C]?7&ROE3C+%H1X^-W63S)1!6&19Q8
M NB&.6W*FQ[G;3?>Y.LN\VY'N>TDK@>*'CU=('77@EO^T_F:_P!WEO;YW<"D
MJX_*G=Z]WV88GREF6+U)+%G$F75"R,)FVT;%ZRS)=5$D08L>9 @3C&$*6RT>
MIBD^Y%$W9N1R]4(;'0-:8#/JQZ*Z;9MA;L$;7REI?J()4I]1Z,?954?8OC3E
M^BR/B#)Z;DNXEYJ[F.TDY5R*ZGQ(-M@&(5<B(1Q,<K";8<>>]9>DB.!$4[VB
M1R/0>O6Y$[]-T:#3I':#G5W>-N9?0>/$AU'X=7IT5)>,\IY1S=.QDW+G+F:&
MPVVP/)JV?BH:RI-D]GB.+M8ZILLIB#>UM+G=D:WEC*($A1K':)/*C?M2D+(F
M&5[ /I<>C*N#MK:_VJ1[+=I&HE.LX=E:]^*,>Y+Q202DYMNHF<>K_/=^[%L(
M9)NC93-PR\QQ!&HLF!AV3NBXW&N6+D+GE:\R[T")',5JHJ-L879!%'IRP[*<
MS[N>Y_7&/I[:MIDEG6X9[&X%B/,-I2>P=-CM5B=K4YO=2;.3R)5UT:RLWE@+
M&!71L-*[' QA&J1S)Z+%D%>X:"14<LS1H<\,:&XY98]E&X^/8,<]@2-V(KI3
MQ^4+)<2BY-BMA6P:292538V-4(L>;'AS8YY+IE\2QJU_="29H7C&\1G>+:!%
M15U<B<^59,YJZBO'W<J\^M9A)N']2XEQ<N/3PQX(GOXU4WD^HXSS>VFT&23L
M7M,D!)5C226UM=8P#ACK(#'>;QQYEO6/*9ORHVAQ2!/<US%1-.K#'RH&HX,K
MU:&QBFLUB(:],#DE5>_'OC''?&?L7C.)<QVI\^]A'95#OJO): Q 5>/<>7=M
M"I\%J[H13X[$LDD9!4S4&UL.;X$9HUR[6HD^]0.-@OY$'K],J\R_<3:KH;83
MXH*=/0>BNM 7^['_ /(SZ_\ RIUQ[0C0.BOFPA"E>^EI*'110Z**'110Z***
M3V[HATU5$\1=51=%1/$]%T[+_'_1THS'72MSKEA]J>.LW]J_8#DO ^6L,QC'
MN*.)\\QG)\%D09#;"_S652P8<RKO+FNG1OBURLL!M ]["(JHJ+]573O+-I^U
M:%X>_P#C6M;N0@\</95O>,*:BQF8>HOY#ZZSMZ5Y6'G1QVD"MD38:2@LE *R
M5$B0F,:JMV(3=IW[=8=];I<=M7[EXN 4J&K-TN1DIE'.^9C=7 .^=)-%BQJ:
MQ(P;*E[8M/'8RM=\DYM8Y7B&9J*CDT^O71V]G$[;F%^9!_\ $:VM@9X<>GDO
MO-9.0<\PK",-QC(+&H1V0%A&A8%$H(M6"XBUU5'97W=A=6BRJR^AU0)2QQF+
M%4YS/>FT;VZJE".TB;*[PTP%9]\_1?ZCT5&W[WFV7'1O'5-1BESL<QFSLF6P
MY&[+;Z2V$^SF4]I;0W&)71G%(]CI)(YF-:UJ,^Y42WXWA,+#R-:?C#5'_M-]
M]6/Q^XQZ-6@I)56"NY?K\@=%#, ,/[;-DP@3H]_=R7L?\,L +WN"0,QB"(8C
M%5BMU>E)\1G*X:4SZ:GN)P,LZA'VEY>F\-<2"ML&@EY!@7>0P</O;#C$6-IE
MU)<W+YIAK:,=;8_'J,7;\=S9#XLDAVO\+11R#5[F2VD)M9ERQ6LF;O=[G2!Z
MX^IUM:U\_EKFK][M)$1RS\,P#)\DFV0M1E<VNM"H:=,!55-O$*.1/:%[GG78
MK1%:U5;K;QYB?':MBA<5*KV)Z\>%8MS(]C?TQ@:V:8-2)"P^BN<\CXL:Y93/
MD1;*!#9*PFFDF:*2VNPJ'<U<*2&I@OCN5I30(A6HK41.ZZ<;!/-=2:BJ+Z>B
MUH;3:W4\9*9U7WD'D?%S63+8D=^67$0L&UBV,]PF"A%$%Y(UC76893[>D1K5
MT1(8F-^NFO710VQ+=(0!/3#*O0]M\FWTT(N=.">G"HHG<O9A<M? JLG@8;2R
MXIG.C8V>;4&F1&[%E?(GK'KV1R0O(U6$4VXJ$=N7LO5O[1B#6-1!P7%.KEV5
MV%CY:V6S22>("5 N''C[:0;1P8D@+U@5)$M2P56^F*Z3:D(JE^3(M)SF2E:Z
M6[N)[7O1[6KY-BJFY[6.:TZE4<!\,O;746+=LBN&26C0V-N?#'&OARBJX@SV
M01E:C1F<.6$)"0)@FO1J*$:E:%PE5%W#W]E33I\:N.EJCXBM>[$-V\21YBBT
M>XCNQXD^:4]8,)#"#*D0(H)+#._\PZ'&C+(;Y7?4(W;=5[=3Z4=E[3V?C7-W
MK_MRG*G?08V2T.Z(BW3QC0HC+-())!GR B4S8@Y,A8_F!XVJ1CM$:UZ*G=4Z
M8][6#5W0?9VH%K%N=Z;,-()].VI4CMK,<-'2#"AY#8R7I&FG,./90L?$..#^
ME.=-5"&>K51=[FD=J[3^5K>J4C'3XOU!O#@3TX9=E8$EQ(^5&C].O%M*/?R3
M!ND==!:)5%'G,9(@M(9'#_I1R(K1O1NBM:B*FO\ ETK(6Q#N@ 4R:WBDC5B>
M(M*;ZR/$#%-$&[X8&$$UA$:K"2!11J$+4:FCW(_5$31.R=&HY%-50%YBC,;2
MCB"%Y'G1NA5DT<E7%-/, #T+ ^-$*XLM=VXAF2B#$)[6(B#1';DV]T3MK7N?
M%DA+6M11Z)4#[9MI%!<[F\3 $9=[WI6N;E"V]_\ B+F3-\MQVLQ/E_A>Q<&R
MK./*><U+#&*^/10HLA)LB945$X"_( 4NR-*,CE=_'MUXYYD;YUVN9U_M9<[;
MPX=P$X9!V")B5.?&OL/R%M'[!>>/+=O8>:K\[+O#F.'C %CBX/=H[S"3BU&X
M\APIW\,_D-X5Y!D1:W+S6?$&:0I+8\G'\WJ7UWS)BR?C(RFDQY=N\@&NT5'R
MUC(J=_IUJ;+^X^SSP-M]YB='N#1BK&D$]I]J5R/G3_MQ\V6D,FX>2IW^8/*3
M03K9,721M Q>6OT'-1@36PU,FE9%7"G1TC&J;';\655R(\JO.,#GE\I)$8Q4
M^5+8Q4T9N[K^G7H5K>V-Y"RYM95'!$!ZB.7PKYH%DZPGEM].E\1/B,N8SK '
MU",N:X*BZ2'#%,10=$?!DAE/DN@.GF:74K-Y&+XFO09&C&<* \;D<U=V_=_,
MB=7#JF:F9 IGW.VG_@E/]D?.C,VVMKV5%J7-=)C/>)]44A?$B:/:)[T(+<B-
M)(T<3MKM^B?ITYL;((R[\P'>J-UM;3GQ&A&NQ Y5+%=(4208]K;F;"@/CK<G
M24H3),81K@,<P3VA0(B*C6JJ[B#T1435=,MS \F4@8*G4?3L-8N[R?V]C'PG
M JJ=")[Z:,/A;':AM/E-584F9X\#-,GRR7.S"KB75[%M;.%=P _VU.NH4HE7
M*@EL!":^.>.GQVJQ%5/M=&=RN9GL@:ND!.P8\,\N(KF!]QN\3PP$K4P1<OD8
M[CL"[6HG3UNI<&*($%8T^8B%C2W,M9BS)T6/%@D%'356/5[5(Q-G==L<EHRX
MD+)<PJT]K+F*/P"#RKS M9;IHJJPKKBU'D$FS\5A3.AC!1A,R0)S)DV38UT^
M.=P"*,;P,+M*J*CD^O3;D-9I:W)H ]5/; X !RK7A)C,.#;1)L^QOJ#RP U$
M4+1RIE8L, 0&'+M)A@6ULI)+4>]Y5*YJ,T:JM73J9K'/:US<'@<>5/:WPBA^
MDTF.#D4RP=-ETU &IG16K5W$8I(^06#G_>9D^$0#(8HYB,1[-"N<J-75$Z Y
MC20UQ('#-*U(@2T&F/D4N4&1!AL<[RB123JL47XL@L<0V*\XY\)CG(X8WNT7
M>G=4_P >KT#6D$\#D57'J-:4). XTR338Y[]9L<4QU4B16LA2),EYC$8Q4.U
MSI2N8@U)W1&E5'?KIU-#$YL!:2-9X\O3JK8'.G?82(<N?!+LF06@8XR3-Q89
MX(!_54+$>81>ZZ)J[J&%KFL<"A7AFOKJE>_2.5),QKK>8.'%+62A@>V1\XJ.
M=,<1HB-&O_$ ;N4K'N5=J+].IU#.^Y1T<*9;J8<.=$FQ_AE$*2\HQE(V28C3
M25&[QMV+&"(#?$UOZ_=MUZ=JU D9^F-2X"E8D@P8[YII SL>-61EC/<=T8>Y
MK1-E!EJ%K45O9VW=_IZC0$Z0""N/!>I*!AC60DB1)%K+!(U=N>*3&4;(P43:
MNUFI6H5'(Y.R_1=4_3H #7=PCJXTIZ5ILA@ )(C(>9&K5?91C/24W?'L( GN
M^2)J@%*1AS(J-1%VHOZJG3WN>!W03AZC2 "G$8(S))A.\#6B6.0(Q(QP?BE<
M@F,81&[5<KM>VG9%[]-:[2CN:^L48DH*9!6Q'EL?L Z<ADCD($:1V26155XP
MCF#8TZ:J9=6JU&HOT7NO5L*@..E./QI>NLJ$> !PS4:%8_C9)^S28BD[@UC:
M+$*W1>ZN>BJGZ=,/><"W%?5\ZLMP;V5B%:,BE>5T:%/%_1\0E9XFQD1WWE02
M"8W>]%375=-433]>E+"0@)!I71^)CQ%&7RX<N4 7@^(!Q)#6,-(=I*=X6>9_
MC$4J_P!,9-4:-%VII]$Z:KFM()5W533;4:+>- $L(;&SJZQ^^4LR*.S$.2C?
M'(^&*Q;_ $G$"QK571CD1-47J$QAQ#B2'#D4PZ4I!;FFX+$35%U0V4<,G]ED
MVE;(\T8BD*,BS0KH-[_&WQC<FYZ%<Q=J*UN[]5-P/!>TGO"J^[7@9;Z>0 ]2
M5M=BQ7_\OK,&@]RQH[M7.5 ;42,;S,>B*1?L^Y45J??V^G?KC"X?= ]->;ON
M@[<FR_X5'O\ G7/I^=/ ZZPN,$RV71Y*VRL,9J\'H,FH,I=CD&1<3\TAH'&K
MB/&D#EW4:0^R;X@/&X+#&1[U:B*O6OL=T8&O0C4177^3I&QPN+LM)%:[[GTX
M;QSBV0Y1<65Q3YC'XJH\AQ>\EY"2JI*++JRUH9+\'F8[#/*DV"RHL0LAY0C,
M)2$W+W7ICX)9IS+*NG/E[JU@;22<JTJO36MW+\LRW(N1KOVGY+NI>4UC;+'J
MW(TJ2.FXVR%58_ I)5$ =R^N+!9CN1P13"!#&41ID9NB:KN2Z9&.*&MFWN+6
M.3Q' ZNVMSOKQR/Q]&XW([D'F"OL4Y(C LL$M(D.^GW:8Y(D#?MLG"K3PJ]8
M]J4#&QUF-\:Z)]$ZMVC0[N@*WK3\:U1N#Y'F2(HQ.7X5)_%_#W%/!V+YICS)
M4O-HF>S[?)\@JLH0]M#LYEY;&R4TF/''^ZQH0WVZI_4^KE?I^G4DC&-G0Y-Q
MJM>ZG,\0?6<ZI%Z?UF#YY(]F+_-VU-?R7!L\_+BF#1GVV/T%-55I;(5:<9(-
M4<4B34PQC 1C!.,]2*JM5R(G1=RRRZ60GN*%P&2XU:VAD[VEC#^HX$#H)""J
M=>O68R<:QS&GX#:7$GE%LBVLAFRECV8K&@Y%>PI=A=8_%M'!E,IZV=81A>27
M'B29"2VD1BJFO5^* M@U-(U)5UK+J";3<N!9V?"K^P\)X @R7T'-%Q.)R[R?
MDL"OOC6E_-/3S[J-!GV]Q^UPW"/#;5@EU+R1=B[48U-$5J=ZS(WW8,5T08QD
MF!]82H-]:SP&^#@HYU,^6< \8Q,B69A-]A.=8O*QZG-D>86U_)@W&,"K1@'8
M?%(^#*6<V?(*BJ(I0D$HG(B.W*B<^S;9FS.U*&*$!ZSRSX5@.LIPR.2/(JOL
M3XTW>>\X]9O8CD?'>#8&37N-XB*!4Y-%X[QS&4'CF>PPB\=2Z'E )4:8R/!9
M,5KHBQOCKO;J]51O6W"L,>F1P+4K;LK>32)<V-SJH/L7QF3&\;PV\PSBSCVE
M!0<X67&W]ATN60[:XRF)4V-[ B9E>THX0(@;*K#2E<4IWN>)TIS7$17_ '17
M44#XR6J7$=(K3O#;SV^AK5DJ8?2KEF1QISODU7S'!SW-+LN;9IQWQ0 T^%&A
MAIL?EPXE+AM!BEA<,A&L)4>2K6G(H?&@TV(Y-5Z)H##;,=$4!8"?4*Y&2!'%
ML0_4!3MI@<LF@>LF$>P>>0Y8L2J,I]C:^O)8TU^&BY/R?![RORR;7<38-?U$
MF59X=/&M9)=^Z-('XI5#V5R)MBFDGO9F>"?T&L1V'YOAF*ECFOK>S? [!SG*
M,!E@.53\;D6QY1X)S*CB<3Y#DM96VF.8Y55_(><I;V=!10OW)M=?9+/JUOIC
MCTXR*\Y1C.\C7M1.R+H]UJ^-VJ/M[1C6YLMNZ: F4'Q2OLZJUM<2\415Y)X/
MNXTW%(V8>O6?WDK.7V?QK6.F.M-CLQ,O_MJ]'7QK<41E85I?,YKG)IN1B*YO
M5ZSM(! Z%[26N50I'MX5J,VZ"Z>8KH$LRS(]U6XK.:28/><E^RN:!SQF+^P&
M9#%QMB.7H"4.))BJ^3,L[(\>XL6U6(GCW\;:P37.BH%RC$KM=)V20M@#6@*T
M)ZJMVKH;%ACMVZ6\>/OIJ>J7.]%Q5CPL@D8=DESFDR7-L:3.AXQCM/\ N502
MXG%;5I,M+R'+/!KI;G-<9Z-\K6HJ(B)HE8W#)+8N/^(CL05(Z:WD&F9N.=.S
MF+#L^]K_ &%_YD\=XG?7V-VV(TM-@EA-,F,0;8LJ39!RZ;86,;Y%DE'%B.C^
M!A(W_#N0KA:ZKUG:@V(/9@Y0.RJLYMO \.!IU=9JCW-_K!8<&\OU-)R'3TF0
M?_@IDEW4&?D9^3[+ *BYJ;>FK9=_BF11(-?#HH^25\Y\$S9"RGD<NHF(HW=9
M>X1QN9K"KUFN;T7)F_6#O#]7NJQW"'JU[D\8T'#&:7%.VWE8I.RKX]!-NDKW
MUL&S)$FT\N#"B.G1(U3/BO\ Z\17M:%@U>W<I7KU<V2UMVLU/*/3BXUZMY6M
MK-D0,K7 )S/SJGQ.7.1.8?9 ?($ZK/Q??8[,S*3?7;YE;D==B\.#22J\HJJ%
M9S*H%FDT4=VL=SQ,AJJ$&I"+MZW-PM'_ &K7PG]3Y'E6OO!NXGMFVJ)Q;&02
M<2,>LU9W_P"VKELG*)=3F>75D[&X3I51;@O<(J,<0PTJ1&H+/'EI9%NEM(/9
MSQ-(KT8P;A+J_<U41^WV;IK<1SE>>-=9Y2;-O7CWMS&GA1 DG!2"B4HYCS/=
M9A675K@.*X0?%8>*W$?([*^@R*ZS2SB5<B0$BP6TA1W*1&)'*-KBJQ^B-1R*
MG;L]N@BAB;&]Q,>H8*<.JH[W:X=YE<V)I:UBEV)& S3LI@_BKYFA\;<BWN#Y
M;E<P&#9++BV<VJD"2 *DS&QO1R!P*]6R"GG5<NO>&5XF,0+&E<U$[:)I[Y8F
M[V_Q+?O2,!3'T]#7A'FCR_):[AKME#!S*IQXU='\HWKISG[%\J\%89ZV\/\
M%]GA>>.@CYMSDU#C4K)\=Q/%;-^67$BNR:<$-K61KFIJDBD?%<XQ5(L9Z>)S
MW)Y/<VTCH ZXQ<'(2<.0]:X5Y5O-KN3KMP@(T:L5 Y=-.C\=?K/R;PE[@9UP
MW)XQXS9ZE8WBN2Y;ZZ<D2\=Q^RY 9_>K;X&31(N;C#(R6R_9,@N[".D<[@#C
M-!XQIH-$7.;JC<3_ ($3GF/D*I,VJ<)-(@>T8=N:^KLRK;_F=-CN,PV4S[*;
M'/!@!=;6)YL@C8];6A#(.::'16Q8;O&DEZM<JD5RIHJNZT)KJYNAB05.& &)
MP]?"O5O(EDR$^.&%UP2.TKZJT)>UW.UA>9-D5%QC5ERR<^;:-KY<*:*EHF8_
M!B''8(Z2 SC6IY#U9L&HD<Q5VK]VJ==SLE@Z.V;+*<0T%#SP3'A7UUY<@NK0
MP/-N/#<T$@@9X<3E6NG*<@S0..Q+L^ -IGV$!(0&#DNL+23'JI8$,1L<T<3"
M*0850BO>C?$KE[KHB]OM%P&RZ'.+M+BH7)01^(KV/>)-_P!S\K2SP;<PLM4:
MPAS&DM:=+3@X$DC''&J5VV0Y)43PNLJ P8%DIK")(&WQ(2*\RC)O )KO T1D
MVZ:;5733LJ==XR,S-#(F%RXYD=AY5\B?_M'>_+V\.CW6U++5KRJ'5ATD*B9)
M\::N6VC,F_;14@Y#9P3^1I88'>=8Y1N:1).OB<88B:=E7NGZ=8M[M5]+=MCB
M8YK2N/0G&G>:_/VQ>:(F7NUE+QKV'2 A0$*2H& ]U6=Q2#-Y.P+ L,YOYRX\
MX,X$P3+\?S"IR.^HI4B_RK-Z2!/B&HX):2!83B NJ^=.,9IE:%QAC>[5VQ4S
MKVQN-L EMP7W!0%",^9U$#AUXX5X)^X-S?[CNL%V^1_VC&-!+26X@XX@CI/5
M39Y%R&#69]G3ZFUD7N!Y/FMO>85:U3G"0N$V4^4:GKR5+O$'S?$\;7*]R$'I
MHK==>M*"/<F0!]R-1(X 888C\:]X\G><[ZPVEEMN=T^:W<1@\F3!!AWUX4D7
MF68+&QQKY6,Q<:8,_P#P%_!LYE>2,UR.;(B3:^+#3]T4YF)M*YZO#HNUKT<J
M)R][=.BN4/<BTY98U[3++M=K9LW_ &^9MM9D:4B<8B7MQ)[B'B.)J)8.3S<Q
MN(PZ3+;DY:6M^%%IG6<RZKIPY+0)/F"9*((<").+7!T"QI&Z*WNB(FO(W1!N
M=;22\J.)SXU7V-EQYNO?Z29T\S&%W?<7DIF5?BG::LWCG.N98:6#=Y7>6(+>
M1$) I<02.V54N_95$ DF5,0JI7RV>;1KO"]40KO_ !KU.P,:W5=-11E5G93;
M[#YJ>^^@)O#&\:0XHJY8%,_XUN$]/&WN7X4;+N8*F',SVXIVRH6/1[2/$B2L
M5&*.K" ._8UI7*712;&.31$7^'6%N(UH($#53MX55W?=_,4#'0[K:';M>#B$
MDSX8%WH*E#DJ(WBO(\0Y$Q'C]F79%?99$J:EMMFS*;$L.:\6\"YO:-22R4(0
MV/<JN;\=6 T5==NF.7O8WP9"6D*N&)'1ZZX*X@LQMHC<Z2> %Q$B%I<2XN.&
M"(26A1PJJ.+P,WS+V%D9=["9W$06+<Q6M5C \.H*^XP>+8P+E[<GM+^ V7"B
M@BH5(BAGL&]S6JY1,<F[1'75NR)(P0@YFN'FWZ:"5UM; BW9DH7WXU=SGWCS
MAKA#*H/,N&_W9EDN?F461G61X?+I)]%6PIC1+8U]_32[F$R*V:(;$<?:YK&K
MHJ:HK4KVFX2O:^% &N:6IGB<,_0UI;9OMA=MT7K0+@Y'D[@< GKJ-^;^)*_G
M;%.(1\%X)@5CQC^]/O\ )<DKM&6]#DX7PDLQBQ7X*1F2GP& 1QTDJ=&M&B-<
MG=+5DXPO<V7 @X=5776U@]QEFD: .REWCOA+C?EWBSDNOP@&05W*%C6V^#&F
M954FJF?W06N+"AV[JICCQ(YVOEA\<I"*X2"WJJ+N1(K\SPO\9J:'X\ZR]YCL
MY=LD>X@Q-!T%>'Q[:C7B[F//?6#V]HN-^4+:!3U]/C-C16N'\:&NI] VS^+(
MBT5CE$^QJ:%?EEDD<\D:.*4)KFN17KN1>JD0@G@>]@[_ '5X\\O;7E$.W0W+
MXKAWY">)&:<NJK+>RG P<]Y#A<KX_*N:?E&!7QR5X[N9*'CI*]?+)EI)JFO)
M#@SK*%(<+Y3$(^()S3-U>UK46U?J/>0M%>M;;9V=Q8%A<C=*$ZCATTQ_Q'8L
M6]]CZ//,XL29/;6DEX8H,DM%?D=#+QF])-HXT8LXKI$ZJ!+,I8X6[7HDC>HV
M;].K6^W-H[;A&T?J8<^5>6_N=LL4&V%[9SH!_P 1Y5V:#_W;/_D;_P#NIUP'
M5E7RX0F Q%>^BBAT44.BBAT44.BBBLW1(QE5=J(,BN_RV.U3Z+KVZ1'$C3FH
MI6YX5QR^X"9YR#[3\P\?RLER7@W%HG(&.SIV>4\U)$O-Z&/41)\.&R?&L(=Q
MCT4-T".4PQB>,@AN:]48K^O4+.S#[*-T9Q0+ZL:U800*GOUWK.5;TO,-;<9O
M.RK$N/*ZN?7VL@066N8OBUD9X0AG!GSW)&.C-H6L,1I&$U<C$[=9]]% +C+!
M:E@<YTV@Y41R.%R%RE;X.M3D$SBO"L9LZV_R2HFQ8)96:+*QL]2#'R.?. HV
M5UG/8_>[R(UT9$1%ZMS1)9-,!3 ^^NO@:+:+5%@2.NITR'%N&JVSK.3,T/'R
M[*,)IUJ8*A1\REQ<$D8SD#84(AR&V4MSH#'L1K'>9&N<JZ(J]8HNA"#IPE(Q
M^"<*R;N.-[S,\=_GE3HE9789C1X=>S,=?5XWD5*L>/:UN/Q*^)$HZ>I+-%D2
M0I)*^56'M#18Z.B@$I1D.B]VLZ@MI]3],ZD$\>DU6@N6O.J3$-Q]6-:C><?9
M;G;-N0<"P7TVX8L^5>,I()PL_P"0H%BZKNF3QR 1\K'9#R"+4FMA!R Z(Y!D
M,QC&J@W.:FO6Y;/M(SWL^VIIIG3?RBGMK9!Z=^DH,2JLO-89]_?6;91DU;GV
M2XE.QTD3%L8(8%PX6.*ABR*RZ;&CVS4\S$U$\.U41>W5:]OH=3FQC 53=/)_
M)&,@P-7>Y(Y"XBX!J8MERGD=)$2&T0J^EC3)LV;:RQ(J!BR(<*#*\[*]"-#$
M#HJ1V%5J;45>LBVV^\W9[@A\-G' )J]6:>RKFW[=<74A;(.Z$Z*@&RYCLL\@
M,DG1U5BTQ)<B-7RYSCREC&<P[16'E"(L""]HVZQ_O8SNB)W7K:;81V,+@!^K
MTU[1Y?\ +^WPVXEGC.D#'O'TSIC"QEWQIDROJ!+-/'%'$%%&%7!9HP @D>%B
MAC@&WZO1-6_X]6AI#&N<>"UV=KO(A_I+< 0#!$!]N=-?(J=+V VG*2KGCE$6
M#8P8_P#5A0HA&LWA(1Z*LDB*W5?LU:J=EZFB?H!*'MXU-+'+,KI-.D] H]6P
M[9DFFCREK15@Z^RAQ:YD1IA6+!$@O$^20BCD17P6A1/'XUWH5555V]G%X<2I
M.KYUES6@:=<9[B8]=+,18-\(U/7#*!6(,,27+"\Q9/D8](Q%>=C#@%(7=]S_
M **W55TZC.IO?<5 X<J9#N=M ?"C42\R5I:;5PJ"L!$,P=E.9O:HE59HJ^3%
M^Y3'*]KFR9C'NW-<JKL14[]/:]SRN(;[_P *Q-RNI)G9K34QC&)O]_Y#D;\C
MRZW;.KJQT>186[Q8W$522OD0L?H@39$*)+V(QLH[4:IF,8BZ[43J1Q#6J&@$
M]N5<Z+:(%0J]9J;Z^%#"^<4,447YTA),R,$2 620@PQWG,C&M8[>V.Q._P"J
M?X]0@EP4YTCW&+N,^C.E]C8]>!)DAS7SVM9+2(Q%<@DBOU:4KVZCVM8U%<U?
M]743W%_<'\OGUU"U6NU\:4JUQY4V%*BC',CO"^0L=[V,CA&S^N8ZL(NQLOQO
M[:IN1/IVZ848,2053Y5#/&R9I#E*@\4K&6=!B$CR0US@MM3S"I&4SFGFR!B1
MKR*43'J-PRZKN=IJB:=*YSW @.1P'++^-5K"UC9$V"748VY:B3[\:+12OK58
M6'%"^:^:T\@ZO3Y11$&P38[Y"L8IQMT14<NJ:]NAW>C+7'N$(B89U=EMK>XO
M2Z1H(9I+1P" 9#+\:AWFGUBX3]@*^>'/<+IC2I0&129+4C#3Y,TKE1!%_=8T
M;Y1?"]J)MWM1=/KUPV\^1]BW,^(8@R]<>ZX$@*G(%#ZJ]+\L_NUYO\H7##;;
MC/'M,!!= UQ#9!_@+1@X'D5%49F>JGMOZVDK+7U7Y:D9EB='+<].,\\D,='^
M"Q^J0J:)-F2(132W;Q^5Z,5'.W*J)WZX.Y\E^:?+VN[M+LR^$#(R-H'><T$M
M9R*E!B<52OHEO[S?M+^\%G'MOFG;+7:;EP\*2Z$(:X H#*K6!Q<T*X !Q*<5
MI/S'\HF:<=1YM-S#Z^7>&\DUT0;(=0DQRX_>RD.X<E[;0<1T,$@C6$<@Q(1$
M&U.Z(G3I/W W79(XCOD+X=2*K1VY5-L'_;9Y2\\2R,\@;I'N :J M=&5S'U-
M;AUUL]]4^6L3]@<2I>0L7LXBOM:T3+6@:K"R,2L%:04B'*$BH-CFSXA'"?JB
M$$K5U7<G7HFS>:+'S);AUB[N@8D\?77RS^\G[<>8?VHW2;;=Q@<ZY;(0$(((
M0'!"1Q]AJU-5C$> :5.N[.MLX5G8QPL;!8&0&0$$5@&_.:A=T.8.0/147_:U
M^G?K4FD>0Z*$=YHQ_#HKP^ZNIY]O:R]MY&W+E3,=> [*JW[I)F^48A#XXXP%
M<L$>7'FSHF%6JUUPV,U)(P$4< @%%&;/:+R$W]W.3]=.M#8/MK=QNMP:K0.2
M9\DQ]5='Y0@VZVM7?W!A9,1@23@>KY\ZE;@CB7-...#\&I,LL+6RO(<*7^[N
MNK.1>RFNF2C3F17OFF>I/C^(/Z_:B;4_FT6K?7L5W>R-M6I$H3^/;56_?M@N
MR8I6@KUT_5DO5IWP0RW6X8*18MHHFC@ZE,PJ%#%EO$-I!%3Q[=R+HOZMUZB=
M#J(UYBLQT6IQ<W$<^=?6'/$ -LN'/G6.P2DFR7 B_'1X$?-(/XY)._34BM1O
MT5=$^G3PQY'=(TU$\V\) G:2],,3\*56U<R<2ONH)9\B+$A^6OWN^1&-XG:>
M,HI3AE<9J+HJJU5[Z?KTU #H<0.?;QJ>*YM-2ECM/;3&GY)8Q9\&1(:Y@U>1
MK7R8*QVN*K&.43?&USCC56N;XG*U%_U=6Q#'H+>?(^F/36S;!L^,0(HL?&K2
MY>6ZEECACV+V/BQ5(Z.R,$?VJK0CW(-3.5.VB*G2LNH8VB-BJ..:TL5X6G]3
M*BB2KBJ\R.$>%"&U8Z@F$?,'/:U5W. CQHH&.5?U3OIT^-L4H7-ZYY$4Z25D
M[NZ$B^-$"V8B1!M8H(D\)D=$C-$(YF^,10I_QFW:]%4NNUW9.I!&0_%2Q,3D
M/55ED4;8P ,*;LNSM1#<P3T\[='*%7*UDN2B:*)'?[MJN1>^WMKU*&,.-/\
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MP&NL[ M5&8DV-D=9522%/7!=$!$+#..%&&C&N^1KHJJ[Z=6X-VM3(VUG!':
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M55 Y%1JN5&]^HQJ#M+DT_*MF\N9' B(H.'512S.]'R7NR(,FR,^U@19=8'?
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MROS\%T^R@4)ZM#%.%D1R/1FOT^M=[&2!21E6>^S^Y:71G('*I?CX#R;_ ,E
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MQ"OA*P97C(YRB<1$<KDV[2VDDG=(QC@U7%<0..!]?KI?-EQ?2^5G6C87DM:
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MJ+-<=?"#6#G#*04U846RN8XY\ <;:PB$51^9>^BZ]9TFV6#YT;)&J\ZV1/\
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M;]BN8SQM:O?1VJ^:C[C[MMC'"]'O#<&.(&HIFG37HX_=C;/-?F'^WV<<4<.
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M 5S1V>-P,TNI%7$GV+[JC^?B&1Y):2[K$S!K+V$YM<<4"?-AS:X G-<R2,@
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M5^JD9]SOJJKU("5#7_7T954?#'"TB+(X]M+09,DA#^<+(+58!KFRWECQB/\
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M16!< *8@I2&8(;6.E.WN;L^]4&YJ:JB+KW_3I)&D#NHM1R0**4'VH"$6.U&
M8S^N0QG[&(C%5T57GT^Y-6H16HB=U7OITQ'$*/JJ$P%#ISX?"CT&11*0R6LN
M,1'J**0$P8SPY,,JL?X3C<QR26/WN31RHBZIU"Z*=%:,*B(NIQ]OQJKU^1W,
MO/L&L("HC\?<50GY#$#,$6-&=?1?""KBQ?"&4)P?F%&CD:]KD9K]O;J\-5G:
M8 F>8!JC-#GRR'MKL-EF=LNSSL>H>[#EP*^JKZ5]\<D5\FOIBP9=G#BQY=H,
MY!L;'>T(25M>QI$?\$XT^W<QB/ZYY]N&R%2H'XXGIKS2]M+:[TW$^!<2F/4O
MPH6,S]M5[Y%1:0V1PQ8L0>Y:Q4CD(A"/B&BG?H3=JKW-^JKHJZ*O3H8P]P#2
M%JH[;FAA\,'1A1ZVSV'=.K8( O"*M/&(Y9=/7VIY3119(D!)DRI.H%(XZ+YF
MJKNW^/4HLGL5Q.)Z2!GP"58@LM284CW$_':R*R;YWQ;'R'D2:R/'CF8YM@78
MHBN>5$\#F'5-6N5VGZ:]21^(XEIQC"8KR_&I9H9FR-#5SY4QI$ISUBV((4J8
M)3(Y@X[658V:+IIYHI?DR1B;I]KV]]/]/5AB=YFH ^OWX5K?;R.C89!BE'16
M4HA7EK0Q!2#R'(<;Y1U:6*U-'B8QS')'(TBIH]B(NO06C2CR2T#V^G"E$)9W
MJ\SJR'6B%(D>&18V:LW,>J2C%:\)#&63(>P9&AC-9LUT[JGZ=$;R\Z0$8.SU
M==(:9PY0K&6D"3:?MHWL<..U(48L=NQ=6*(DA5*J$1/]'4C]36ZFA35VW@QQ
MSK K CEI_P >0<H2/>]Q!H".JI]K%CL"TC7.)IW54T3MTJDA2,#5F1NAR=%'
M"^-C+!2BC"-L(NL0Y'L(U',\3G/<P1%>QNJ.9_*FO^70U<#BG34,K-;4XK1(
MEG'2,W2,XCVQT:1K1HK#DV:#WJ1R;-$_5JZ]/"KC4 MP,:3F&F2 ACG1BJ=K
MD A%4K8CD^CFN<GVZ?1%5%U3J5 ':A_&K"^JCUI'>A$49FB&!6(U[G^-'M5K
ME0H^RZL1S>ZI^O2,*MZ:A>.\:QQ#^ <C>QA'O*B,E.1'$>UWVM(-SM$>B_Q5
M=.E+5(I!6="(I%4,KP27(@D%(06I%155R[-7,TT7LJ?ITCLL1A11^L))O;0C
M_BP4<Q$%(?JY&[!IHTB,T<Q%U1=VB?33JNY(V<4H5:-7\NKK)8SG/&5D@BQ_
M^ >A$EFDHT;4$FQK=$7LJZIITZ+6Z-,5Z>%"TUCHK$D1 %,PPR-?&<Q6.:35
MR/\ "I$<Y'*S3OV[:]2.. )RJ2/BE+D664"0B3R#89H1HXKG-1J(>2YA%D-:
MKG-BM1FC':?[S5/\>H2%5,OPJ1_T8YUE+,='.5?,Y#M8H8QQ27*(+C*[Q;=G
M9R.3]')II^G2H' <N.%5\J6:.&&\R/&9MR&NGRZN="2"0PA$01GR&-?)&)41
MC9"#T:U4[:)WUZCG 9 YK50@GV55E_Y60\4/OK:G&3_]7]B-&IY$"%CD5C5&
MC_-&1'L%IM377<J?3=WZX1?ZM>%>4I_ZPG_F5SL_FR]CN2."^8< J\.XO=D=
M)?\ %PBW?*,NR?'J..W1<OE%#86%?^WR1VL9A8:;@^<:%1VQSFM<KV]?Y2M[
M::V?%<(2"$]1'Q6O4/VRVNXO+241/<&IPYXI7/IQ_P"P=+AM/--BUZW)+63D
M5UEM]CE1G9<>Q/*+*>T\LT;&JH-/.\$6:,GGD,1KMDQ2(JJOW+9N?)UQ?3ZF
MJ82< GXUZWLW[=7EW*Z2>1Q"8 C\:>?&GN!E?,,'-\!R/AW"L;L%J V/%^7/
M*%SO[GL\@I(SH%[&+40DGUE91V,P_E=)8II 6(B)KVTKCR5N%E=:HG/\ <$_
M&M:P_;W>[>42R,/@C$J.&?.CI>6<4]&ZC*KPV>6G*')&7@' 7'!SUB8?(L;2
M^@OERPU8UM1 DQG/(HI"-\H1,\+4=N14UW;*]D8N/!(=AWD*GT[:Z:7ROL>W
M#^[;N6@N 'AG()@N:XYY52ODCW1J;?/ZJXBU$""RD!/I<FX\HJT<*YN;01D;
M)WY2 3Y&0A!9P7/"JPVJT*]E[]%QML<L".A!EX*JKT5DLV[RZ;K[W;Y&#5^4
M<$Y8_"H=R_%2\BBLKV-BEAB>2YQ%%8Q9I+XV01)[GB>YN)!BDK:L<6R.%Y#M
M-N5X61G,1BJ[5-38/+-[.HDU",]'.K>\;C;P6A:TM>\,) YD#+MIBQ^*>3*:
M%&?9TD^NA':V'&GW\TH(,*3 (".Z7(F/&]B ;XW-81=K7L?JBKKUZSL^S,LX
M"QSFN(&1X)Q],Z\DW+=]WN'+:1: !S(0CCET9\168V,SO 5G]P"!/JYKX+-$
M^1!FBB(X<F3$DJ43O&PC-K/M^]KMR=DZZ5NVZH6R0(&^_P!M-CO-WNHXV3W4
MC9(PB%"!U>G33HC8SD]M7%@,LXMTEH>LDN\;$))JPQA2EB^0CS.?!#)&5ZO'
M_M>-O\.HW2LM 3=7 B5$X+SSY8>NK<VS6U\D^XW(<]N6I!@<^/0*G7BGT^YZ
MY7#)7BSAW-N1(M8ULADK%J(U@681[FJU1#>^/HJ-551>Z)UAW7FWR[: MN+M
MH:.)(&-:,&Z>3MH9H(A?(P*%3$_"MDW"_P"%OW?S.5#GS^*IU% L8XO.[DRS
M+BUGC443&-$V-7E@V'S3-:B(QF\:M1O;77MQNY_N;Y:L&E\4HFQX%?<*PA^Z
MD-A=D6K],"G '#J&%6UQW_I]/::_>V5DN;X-@,V/)0C)-%&#DDFQ$QS?Z<J4
MZQIE!YTUW)M<B:(G7-G]WMJ)+FQ M)P..7#ARK"O?WHW)TT@@;^F7N0KF%*?
MEJ1[#_IV^8S'EF=S[639,I7M(6?B@5A?&?XU442 3*E;&:[QHU6JY>R?X]#?
MWEL(F:6VK7*5*N((X)])K C_ '5W(7(>8^Z>D_\ NU'N:_\ 3R^QLUM=)@9[
M@UX>ME$5KS5T:BD6$4Z,5P"F';6:C<!1HP;M%T;]$ZKO_>7;4)EMQ&"G>U$I
MU*T9Y&MJR_=R2WW!D\ELUZ X$GD0OT\,ZU]<L?AR_(APW9D+!X=N<_K7)*4,
MOB^Q-;OA#8[6(:7XXR;U"Q5WHY45VOZ==5LW[E>7[Q@=+.V-2B.*>\8UW,'[
MG;9N[0+R1D((32'?$BM=^8PLIXMS(^/\A4UEA.<3#R4/$M89JD[#"5!*>&![
M40;PE!HY45=5;UV47F/9S%KMIFSR=)'PKT7R]+Y9WZ[9M$MRQKI"!J48+@N=
M/+%;D BK'R6\OFTDZ/'?-E4<YT6VD2X;SN@2 2FJ1S&,4KD*FQ=41O?JI+NS
M]RM_' :R8.TM ."88\,\5KV:_P#V'M=KLVVFW7/C0S-$HD "J_ CZ^&D9\ZF
M+'9]_D&-W&9MQ&U+C]+9,I[;**]4LCM4C_\ A/FQ-L5Y'+L<HMQ$_J*[3557
MJS#NT32+5Y'BD'2TX$IFG\*\'WO]M?[->?TU[))>ZCW"!](S.9RPHH'%,*LS
M0XD3)+2#(LSLMI<EDLKZU*Z898T\:H]X 5]^YL%S%!N<HMS7>3141;0NKIQ<
MYC>Z @YKT<QT^RJ]Q(^VB;;W7?<.=31C_!7'UO69%.FY&+';*AA$DOC'M7-%
M.:\7F@NA#<,::"*]ZD1-4TTUZS[G=KJW>S0KV./++FN/JJA;;W<1[LV(VK?#
M7I^55IRJGDQUKJ$56/(9+SN">Q;(5X9L'5/D,!$\#VF7X2IN.K_L7LG=.KYW
M"'P/%>B+D?RE<_PKVG8_)?FGS?N)=L@DAVN5K1*Q@5KF@(0Y>!.=-;'>,8UU
ME?[?7,/ 8L>4L:OK&I:29;D%)$00AH^&QJ/41!N7=JS15T73JZ=T9]N)#IUA
M 2J!,NFH/./[<R>1W%[@&0 8L 0%R*2<3B5J;L$QR?0W$8MK"AW6.UA+2KR[
M%YD5EU(I&SZF0%A7O/X%&<L8[/$/:W88B*B_JM>ZN&RLTQNTS.32X%%(((_'
MHKPR]N8]XF<;0:/"Q<!Q#<2#UBI'XC]28_.-J.TJK"0Z&RXLY,*T-!'CM=0T
ME;"UG5DUI)<MIX;3 .PS51K?ZCET73MA[YO3+.#^I[T@ 1"KB3@!@!4%KN,6
MSN\2-B.5<%'9VULU]=\*P[CS RS<5G1J>WCY5:75GEC*$=&:X;CD*36&-%KA
MSI;EK 18S@^5I49*14>FB+IUY1O%U+=S%SE,;FHG $GCTUIQO&ZV=Q>2-5KL
M0.6%;AL%SFCD6?'V*X_;09+LCQ[&;F.U , ,=]E-+#Y#M)TQZ%-X8]G%MRJU
MJM[$*B?7MUY^^![HC/,"C2X=@);\!7DCX_"ADE:WOZL^I:E'D2:K\#R&XCQ@
MU]O0198)5;CQOWGX$3]X9.F3C(P=>ADC#591GI]HFZM=].J\<99.QKET/=QX
MX(/E5#:[VY+S(\DN:?56NKVL]:Z_E'CJMR7$<XR"O-D?[!.M[BK$IQM?.PN7
M'@QI$YLX J:FL9$YDIWVR&FD,"JZ*B*O0[5?20W)ADP:"4"Y@'@*]&\N^;)[
M2<-<\HG/\*TJ\I<0<O\ #,R#CF/%M+'.WX>RD65:2'U\"/!:@8\*SKX.VS!=
MVEU#$ULHBD KF22.5^O76PW;;UKF$AS0<.P\NCX5]#>7?.D<UH(3( K!F>*=
M7.HMX^X/Y>XGH<FR#EJF7%\4/0 R*?9UI5.L.\-DE)4 G3;Y&QS322+&P:\5
M6X36!BIXO,[8J]1LW1T1,+GJTFJFXNAO"]UPYLA=Z>GOJ038U[.YD#$,=RJY
MS]\#/,CLVLN4K3X]CS(%)8E95R)%$.RG1H%08L4)@F\[FG"O;:CNUNVNK$O+
MW-:7@%>>5<RR**QE\6!&@ Y<TJ1\%X0YBA<A91*YES<-]CTYQH]!$PC'64\<
M#(TMLYV0RYP[>2C 5HHJ@.QPTT(=FJHJ(G4LER'1_H #H(QJS8^>MQLYC#<S
M.?; X-.2<LJNC4XQ&BM<$$J?*E6M:.6.PC-61&GAL!ODLL7RA&5AS2=JO&J*
MFK._6%,QSB $\,>SH%=#'YQBN-N#F(':D5>KHK#>X\#('4D.QRNVIZ.FE /9
MS*O?#),\(CB9$)*9(54<P[]KG+KXU<FOUZAAATL<X-&LG!:;N?F!EI$UD":B
MU>TUARC'FS;5)C"K!I(IK:L?6'DNFR)10R(#:Z0.0X8%&^0BD5&Z+HB+U)&U
MS!B.]S1,ZO;9YP$MI]O([]3-?7T4D@LV5=U.IH@FNIR2WLM9<@GQUI2M%*W&
MB'\)U>5^UB.[)W7Z]:$;'.8'_P#$ X<>NN4WF[M[MQU $T]6"Q<T2@>]\"4Z
M3'">@KMK$G."UND2U)*5=^_<JJ1=J:]NZ=.(<YY)!5N;N'2 /=7$BPB!P 2H
MUL8EE6QATL2=*C"O+.0&#*DU?]R_*AQ2"?. Z"237CHH /(B,E(0SG*_L-$9
MKU8!U'#$A%X(JIU]7"IS;11Q:N%/G/%CR*ZHGXHZBDQI(Q6&0S)H6J-\ J#2
M1:SXZ:_'0)0N\1%>[:FJ?KU': N<X3$CD/<!UUEOO8&G0&BFHE1%J;-:I]>;
M)<KM::,(-F!Y/C3:3S$<272F<)[ZL\ESU8I6[E1C?HNG5DPLEB)<[3"A!:>:
M(AQ]E-9>1.'A  -?@>W#XU/M;86F1-;"RNOKLHXU/AZP),'(X@\CJ7O5IA.6
M?CTAHQF2(Q5WN<Y'$;HFB:IUB^ VWF2V)CF#ORG23T XHM9NY[/:NA,D;6B3
MG6FGE7U*]?,VR?(:5F$Q\.DQ<EB2S7_'C8K(UF5"C*E#%A1Q1 PGL^+W&TAE
M;\C7]4Z]2L[E\=HR1W>):%![IPXKBOJ%<.[RRUTWW$BZE4)A[B*JYR3Z89=#
M958[QUGYL@KEM+,%Q2VKDHID(-.P4HIJBS^;.8<I8I$0RM8S;L_77M4WEK-V
MVJ:.V;X<K0$(4YKQPQ7UUZ#L_G#?=I LKBZE=M>G&-QP5N1!S4*:U$X>_+K/
MD_)DN<AE66*8I/G0TE%D%_;&.&J">QA#;-5$@W(KUT7]=$ZY/R/LU[M_BW6Y
METC68J[E6!8>9_,WFCS$ZWW.^G?L\<GZ;''N1CHR3#"MUGXHLIL8WY-/6*/6
M7TV;B4W)$JQ1(\DCJY9;)^-E,Z2]JN&K1QRKK'7NB.1WZIU2\Z3W6X[7.YSG
M&W:ND< .BMO]Y-SE986^W[/<.99%!(QIP<-(5>LX^NOTOA=Q#7_^&S]-/]E/
MT_3KP8! !7RJX(XCIK)TM-H=%%#HHH=%%#HHHK-W)%.K?YD&]4U35%T:J[5_
MP=].E;G3FIJ"Y5S7^X5!C&=\W7\*_.6SFXYD%<2JHSY8:#7_ #)30-;+?5LK
MCCWA#HUI/)WT1O;KI++  #D/<*Z>S:TL(Z*5\ X=RY;X]E(L8LGCT^/_ +7'
MQ5@VBET^3"L8SY]S&LWR'(>$.'\ACVH%-FY$5WTUT7S-)\.7%U49)Y[>41AQ
M#.56]YASBUXHXE9A_#S8\7/957\+$9<Q$_:AE*U\JRN+D3D8U%8*21T9?O1R
M^/OJNG5&WLPZ\=)( 8ERX8)Z&M_:=I-_<MF;B'='9[Q6M_#I68LK#V?(&0"R
M'(["(0]O.ATB04#=031ASGQXR6$Q\@<N6]S6-W#VC:BZ=^MJ6*/NN &D%:]9
MMW6NSVP$[&N>0C5X'-16!+W*+;)IH,!J'8S0P"5EADF?38[X4_*Y4F*23;X_
M1R6LW59*:TD#"]!OD?+&)[E:UJKMMM)=&CLO3T[4K+;!N>]7+7-D>+?4,."+
MC[*D&IBQ2OTDC($#_P!QR,/R3K:"KHEE*;*<%R%;';XP/F-9&%W5P]-$[=-X
M)78VT-OMK/I#I>=,>3'AW^4RL,AU\*YQZJ2-8SXTK6(ZODR([WM.V$HGHXTI
M7+KHY5;_ !ZM"7PX@<G5N06<,\3;N=H(>%QJ7\0X^RV[;5DQ*ACBJB&9$4LI
M?BAAU3&$')E1'Z-23\-%:FWLJ^1/KUERR1DD/(U#T%4M]\TP[#:#^VHU[@5T
MG-$3@>9J8<LS"GXYGT&,<9XG!R";+CRG99G+/L96HQH@+'@(L4S"RCD>I6JA
M&>-&JGZ=5VQN>\NG/Z:X#Y^Y*XC:F;QYRN/O)9)!"PJ1P([4IK)(C$ V7+82
MRNKDQ0*,]@YRJUVB/,YOA+H0FB:]_P!.K("O1J-8!RKK?[:-MP=B:03RHU0V
M:EF8,42/1&HW4H8XR+J]2E31KWL3Z,[*J)IVZMA2 6_*DE,.GZ0IIQ@<:2CK
M",QCJZN6, \Z4=JC5"M<U@&PW":V01JM[*A$5R_I^O2$Z3H=]9Y>]:R)=&I&
MHE&GRH$QA%0\R0)[XSBRO@^#0[T<C1, IG*,8UT3=HNFO2MUA 4'0OX54E8U
MK"YHQI1%"CA>*+":Q\ANC9QG(JJK':/1&/=IO5&O371537I5*:G?3PJKK=SH
M'B#9)%\-5C1H\?[(I%0SCS#?:XLA$T0(PHBKW1$[]*TX8XFJ1\525-)((<Q\
MZ3\]T M86&$8 LCL>1"?(>XTH9%?KN^B)HGT3J96>'D=:_"D:9P[ZSIHZ&-M
M$C'[A,\ANRZ/>P#6M5B*/5BJ,JZ_7Z]^H3(-1 SJP3XS1'K0JM85E+'.C2%9
MOT,J#6(C6(C@,5C6ZGU1/&J?ITK>\.BI;F)L$8(Q-*( G&K9:^-K9(E4*&%J
M8K&_S*QCU342?Q1/ITA+2=/&JW#HK,()9KWC5I94D0VL8,;7-:)%=JK =U14
MVNUT3ICCH5,!2>*ATK6.1$'5C<8BE\LD+D<,R*U2*U[FJQ45-55JM5/]'2M.
MLXX@4]KP\TTRVQ4&GF$]IVJ8:#(F@2@*SQ#<NJ:.<->R+_%.G$-9WCD,?5C6
MC%"Q[<!W^'0:2ELR0F2X\N3'\I ;@H9RJB3WHK0#7_900M$<BJNB*G5EKFW"
M%C< <4Y<:!:.A=KU=[G3.]:+FU;12[>^ &U=/RR^)4.?';&7;7VMK >U6/WN
M&+Y4![VN75';^WZ=,W=F#6Q'O!J%/3E5&8W4[I(WN)B)RJV1+"]M9RQ4:^MG
M-(R6K :LELCC&A4>CF#%HP:#3:B=E9IUGZ(&PAX0@X'K_C7.?;AT[8IPK&DZ
M0>"HJ>H4X9MA=6$)K\AMI(8C _):11;B# -SHOG(Y7;MCGL75O\ %>J\;(6$
MF!HU^A]U:#V1LE9&T 1DXCLIAP[2P8J-,Q@8<ASW1'O7:V0!')\:9N541_F:
MBKXT[]67#5_M#T2K+1 WZ6@4F?W(E=>./*''F.:K2QFV ]@))=58KXX%7:_P
M;MRM5=4VZ_IU.;5LD* D+FG#KIKN\[4<^%'["\:X@9ZG!(EMD.\S5KD<R,.1
MHY%C1%,Q#-8A/X_7J!L'AM+$/KJ*660N +B4%+,>3N(OF\#@;6K$F)1#K9#]
MQ&/+N"V1(T;N;]5<FJ_ZNFM:@7%>(5:@>Y[@@-*5_7$F!69!DU\B(P)D3XTA
MKI(&O.UQ@M!M=H=&;M$UUT8O;Z])'(&G2X.#ND>VHBV7F:8,>%N20/[I0WN0
M,9QYGFF@1G\I7!<)CD'M[?5.I=0!]M:;89P%:\K7MLF/!FB4\E(T:1LCFDNA
MI)*P+=WF0 R&'IJNG^/3].IG= +AP5*=X4SG*YY.%):S4G2I"!M&':8;I**^
M T>\;G,1=J.D_P 53IP:@"M3M_"K9@+&ZB5KTV0^;'+#E"1T2(]A%>,21I#E
MTT:HW,<1Q$VKV9^OUZ"QH*CZCV^G732,*]0[N/CZ2)9JTQHRZL9(E?[T2N3Q
MA<T"MU<C7*G;^'371NDPU54TR<S60$IUF*481H;XKG!0:D(U&;40FC1*YBHU
MBO\ \?UZ=@Q 56I&Q$A2<:2#C?&<V"=I'L;&EC\S'JQBO5^H0B1=4*K4=VTZ
ME:X''JH,8;F,*,(Q)20#M&PA8K'CCN8Y/*B(BM558G=>Z:+JGZ='="]-)I:F
M5*9W. &(P)"0G'!(22X:JQ[Y#$8IAHY-%U1CFZ?YKU" "NK'EU4:6I2*^:Q\
M6M!_3\P7F:+Y _&@U<[5J-EK]ABN7Z,[.UZ> CBF6'HE2AC" 4%>9A1(0']8
MK$(\SFN4NKXAT8WN;Z?):9?JJ:::)T]K2<P"1Z=E.#&#*O#&2%*9&:L?XF^1
M#:OT9J[=L>O8@%_1$_VU5>@M8B\:<QC7. (PI6B2$$$<A6M8-\H82&T\S5,P
M:.8SQIJK7(UR*B_IU&6A=/%*CE8UN02G)BLD?]TTK=%:U+B"F]45K'.4[%V_
MHFJ_PZAN!^@__9-4[AC!9O*<*VTQC$_L&Q*C%WI$ 16;?N1%)'=JJ::Z>+1W
M^77GZ?UNFO'O_P"WZ/$KC/\ ^I;LLF@^V?KT''J2KR*5%X8N3RJ_+ZR+9X?
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MW9L5J)_(OUZ;%"86!K$(YY4Q[2XK28DN=# 5D:HG1'N*KX<L5L1R%&CDU62
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MD1$I'1GP]M,25'DQ<C%(@UE+6/EQHE:,\6*G[K'KS.(TD:OLVM:ZUL'#8BC
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M.E/JASHP#D4Z$\(I/GA& K4<'[4)IHNFNO2/!<" H!&?*G(YP48X4^(U+&N
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M^+2/W2^RE5&9U7C\H:K$6<VQ>(ORT:\31/8/1-==S9GN33"GW#FX+DU#B>/
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M<-H]RIY/)J-RL1R]OKVZEQ1>-78?I2LM;>DA6;8O_"QWA5Z#D#FHP3WD1O\
M]-P4=_*B]MW2EH<W'*JT\'&I3'D#)(F1IX8:/?\ TVE##\P5<O?=)8DEKU8Y
MJ_SIKU3,6EW=)3KK+<"UVFDJ8'?*"*,=!A$A"2TC/=X"D([='>!WW.8-$_F9
MKWZECXDTTJM%)H2/,-SF.<,+?(,RL3>JM;J\KG.T8HTT_5?M1.G8:3TU?@;J
M"'C7J@RIM?(FUD,%G'LHP73&E5J!C30JC]Z12*]XC:^/Z(W]>H7P!R%R::CG
M@]5?;1?WF6*<,#T?&')2"B-53Q2R&>*;Y-JL$ORM/U9K_!>E:T,&*+3HP&L
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MTJ5#0?74F4M03&X<TN1Y!595C-1 K[G&J9E,2RO:Z_++6%Y62DGJLKREAC&
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MF'"11HU_W&1N\AT5'*%XR:Z/5BHOD5R]*N*)5EK'Q@1EQ+AQ6D4LQ(YHI%=
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M%*I:-+:<D"*DB*-3B5DQS%C1@.57O"CWN^Q%:UB(HFIV^J)TW+'\M5[FX>>
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MWRR\<J7!QO&HO$U&,5G=BK^O\4U7MW7IDK72L"8D50TAKRF I0$US6_=]?\
M/7]5ZD:"  <TJ4D%$K+TM-H=%%#HHH=%%#HHH=%%#HHH=%%8)*(L<^J(J>(B
MZ*FOT8O2C.A%PKE_]JX[)OLGGPYL-AVK;PF"'J\B.8M?'<!'AT[-1_=$1?K_
M  Z[+:4,>/*OK_\ ;S;;:3RD9')J$8.?$-J+*JCF%D3"3&7$9?E+\>L!">&4
M^($BA>5K7*]T.(I>R.^Y")W1>MC*KVTQ7UV\*U+;CD*?%RL+]O*,1S+)KI,5
MIY->K7RAO(QAHXE'J]I6L YK':(BKIW[](PN.)P%=7=06D5N(+<J6_'$^TFL
MTX-E-? ;3QQSIB,(C1^5D51'EJTKA+JCO)JC-RZ_14^O2DHI-9,]PV)K&N^K
M44HW(8ROG2*V+7!GV<>" LN7_4FCBN;(!^X"26-S!@8R4W:BZ*BN7LO3/J&K
M$ Y#W5LQ21OMUFSTX4X(L2Z':R?CC,&/:1 6#9ISHD9D:<@9;)^]S49";\(G
MWZ]D([;V[)U"0 %//V\JXJPEN674_A_RJ.G2O+)+'A1X\MA?Z=0K2>)([PN1
MDFS>[:KO.8O\JZJW9_CU, 0!BE7H'ZH6GH^-.(WQF.HX3R,,69^X$LSQR-*_
M4 PN4#4U[JKGZ$5$W=TZ82\ZG 88)5Z$1.#M>>">GJI'APBF4UA(@C%%4"#&
M0*//\62)=XH<@B.T0GB:J:+JY=>I% *+WO3&JSWM:_#*G!-219_M1&/&%1M:
M6M2&K1#BN1="(46KV_7OIJJZ]-:&M7->*U5G5^+:1R'<LN=\F2<Z0P%D3K1X
MG,#%>+:E-&?(1S0C+)=Y][43[D8FB=ETF! 1H QR'O\ A49B<T*<J+5]S"C^
M(]E#G)"F!KRU,:L$5Z,'8"DD>R61J[@B<T&N]?II]>_3G![@C"%7%:B5,3E3
MJ=\LE.Z9-A!K:G8KA299486R+]R!JZL+O"Z2\SNSTUW(JZ*O42M$ND$E_(<.
MDU"Z>-=)./4:P"M)$B8!EA&:,DM0TU"$C%BB$\[G/&K(;MZC"8941#:JUSD=
MI].\@:UC20<!B3^/95"4%Y[M&32)09J5%7+F6Q$>V'=W0-S8)GQ]7&C04:Y[
M/$1%T,5'JBHGZ=,;WQXCP !B!QZS\J8SP_#+3GVBCXODJ9(%2UHS*90U3:QF
M_P 3%0:F(T^JZG:YWWJJ.5$T_3J8%@:LGT\5K.9&R)^EV:KAC1=(DAKR2OGM
M4PR:27K(9X9#QZJU1&:B;R.<G=J=E7I=2HT#N^ZKDO@&'O'C2Y76#K&<"%-
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MA,,3]1R&_>]@?&[5':Q$&XI':=F=W=NI2X?57&NDF>XJ!I/2*5:@QH3FO''
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MRB;M8U$UUUZTQ%,YO>0%./9U5!(P,<@&%.*'G?+.;4<6!.PE_&D,OF'+%=&
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M$XTTS.?^URK-UDV")9LKS6,>0)(J1V0FO(,3?"YSB!T4C=5^Y5TUZ>3CI14
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MG K7WHI:'110Z**'112."J!'GR;!A2J62,0',56^-J!>]RJ-J-16JY2=^_\
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M1G[A NJG!V[_ )0Y>C^->2,XF\.A38V@O&_N5(FY0JKMVGD%N\*/_A]OD_\
MCZ:?&XZO;3V.WK5W0]?3IHG 9PNE9>)!+BJUBDB_ORL2-X4+L D+YNHT3?KX
MU'KWWZ:=^W3?U?\ -3+D[N7CQP\'TZ?04UYHO7%UG*^3)PEEHGB^9XVP_.Y?
M%_3\FP#_ +_%KKMT=MUU[:]6!]WI":M/"KEB_P PAG](UY:GHF(H;/6[63J;
M!E3>'YVJ1=GE\;/ L[^F@O(H]NSR]]--/TZ7^LX:J>]WFC5WFSKV_.BIF>L7
M?RFP+3<_<FD7;OU3=Y-HM-^[33=WU^G?J0?W!,-2=E,U>95RF7M^=$9HO599
MX?D2./&VN@U%XVP?W%7*)WA3^D%TOY21]^G_ -;Q[_\ 9W='_J"8Z]*\:GB?
MYI _3;*6^G32K,'ZV_(ITG'PKYFS_P!"4S8_RM.__P"C=0^7?IK_ +O[M.HF
M_=H=&I.*5'&[S,IT-D52OHM8H(O6A,IQ]8<C!79>LM?[;;MA_OJ3-S=WP-0-
MG[_IKWTTTZ27[PM/B:PWC3+MWF(PD739!$F*\NG&K%M06U-KE5/U71>_;]?M
M1->J(T)T5SSM:=ZDVR96.C%2:9!A75'O5&JC?M757HHGM5NWZ[D5NGUZ=$@_
MEXU):F</6 *Y/3B*KLP7JLC9OAD\=N9YM9_Q&U^SRZOW)(^&!$W_ ,V[7OIN
MU[:]:0_N&":JU)7;P6]YK@U/3C52&L_$!^X2-2^J'[@CG?,4Z8SW)N;Y/E)(
M'X/)N_GW?=KKKWUZL,_O*=WQ--4G_P!PPU:_;5E,?%Z5K0C7$9/#R8UX/L;B
M[:#]I0&K-$)^TQU%KV[;UW:*[3]>HA_=-93Q-:X^GI[JT[=^^","!A+$[?>M
M(MD+T36&)+25P^V)_<"*UTUM5L_N3:#1#_(CJS]U5J,T\B>7OVZL#^^(4\33
MIQY)4Q=YFTE6RZ$*YHF.>.7LJXU2VJ2/'_;"(Z-L7P;4<C%8O=JLW,;_ $T;
MILT^W;IIVZPY/J[^=<Y,9#(LN#TI8;MVIM^FO^/\?_?T[&HC7KI**'110Z**
M'110Z**'110Z**'110Z**Q'\?B)YNP]C]Z]_Y-CMWT[_ ,NOT[]%!RIHN3#M
M!(]P/Y6^)2_*^G^RK?(FFO4@\1,,JO1??Z/T=>A."Y)1C3&/M^YOZ[=OR]/H
MNO\ (GUTZ3]3A5#O\?$_U4-,7W.[LW?TMV_YFG^SX]=Z::KVZ3O]M*/$X>+_
M *Z]D_MC5GD46OD3;_YG_>:+_-HG\/KKVZ4>+P6C]3_S?]=853$]B?=&TU=H
MK?-KKM[_ $;KV3Z=+^M_FH/BI_Q?]=9-N-;>SQZ:)IM0WT_3Z,Z7]7IJ,AW$
MS?ZZ#4QC5='!UV_<KO+HK=.^_<W;II]=>G#QDP5*D E3 RI_O5XTQ/8+18R,
MW.\:M\^F[5-^FB:?7Z]'ZZ\:7]7AXO\ JKS_ /@IY/TW[U^G[CX]W?7Z?TM/
M^SH/C]- \7AXJ_[]9B)C&S^HX*#WIV7SZ;_]GZHJ_P#=U'^KTT[]?_SO]=%"
MIB/_ -5VO?M_^D=/JG\FQ--/\NHR'+^9>V@>/P\7_77K3%-$U<NW:[3<EAI_
ML:JF]->W;3IPU)QIA\3CXO\ KKR],2T3<ID3<[;M_=]-=R;MNU%3Z_PZ>WQ%
MP6F/73WO$T_[]91IBZ-7:XJIK_M_N>J=D^F]J+I_W]/_ %JB1G.3_77Q$Q3>
MFBOW;':;?W+9M_77MX]?^WIW]1Q6C]/_ ,S_ %UE1,8W!^YNOW>'=\O^'W:;
MF_P_CTGZ]",YR?ZZQN3%M':N54T9KL2?V3_9T\;=>FN\5,52D2-<Y/\ 71=$
MQ#4OW%_VM^]+;8B;$W;=[=G\OUTZ:/$X+2_IK_Q/]=>T_M#R.V[]^GW;/W;;
M]$_\/]/733IWZW34W7K_ -59M,87NCRHG;1-+'_#3^9JNT7H_67BM0R"+\Y?
M_JK&]F*JR-J78FA/!N24K]NJ^1">5CG_ %UT\G^CIC_%_-JJ)+0HF![5^?KK
M$YN&Z_>\>Y&IKY$F[U9N=ILWMW>/=]-OV]#?$3!:U(?N/"/@Z_"3'/D?@M9?
M'BV]7-.B=B?8QI]G\O\ 5TT$KM-O\VB_3J AOBJ2==42&>(I+M?;\J](W%-I
M-'L3^F'?VE;O'N3P[-6J_3^&WOI_AU/)XA;BH;T5* =6;M7;7AS<3U(KB)IX
MA[FHDWQ[-B[%'HQ4\NS7^5=_UZK0!H+O"+B<%7MRP%3?J_YO;69&XMN;H\&N
MQZ(BH;338[<YVYNF[Q:_S?IU8[_32GQL5U>VL(TQ+5J#>W;M^Q42;X-O^ULU
M;\;_ .;3_3TD^OPR)=6GVTT^)QU)7I6XD@TW/ H?)]J:2-F_;HNS8U/\UTZC
MB0 >'B$IA7BM!Z8>J)N6,C>W_P#<[=-?]KMIW7Z:_P"UIIWZL#Q4XI4C?$3N
MJE8&)A?E!L<+R[G>)5^=MW:/U\N]/'N^NGD[Z_3I?U4Z*'>(F*I1L:8GVV+&
MTU;IKY]-VB::[DV_P^OZ]-_4IIU<:\*F(ZF3='1^Q?([^O\ R[DW;-6J/Z_7
M:FO3>]4>%!S<4U8I"#5J[?"UZ2/&W16Z^/[$^UWV[NZIITK?$U=U52IH_%3]
M/5I7@J>RO:IBJC[."UFQ/Y?DZ[-?M^J*_3=].HY?J_67\:CN-6C^HU:5XKG1
M<B8CY/ZSG*3?V4O[G_O-4_DW)MU_CIVZ@'@ZAI74O34#?#3#5_JHVQ,8V/V*
MW9VW*SYGUU[:;4^NOTT[]:!^X7%5H'A<-7^JB;FXDK [7E:U53XZL2T7:NB:
M::-775/INU[::=M.C^H_S4X:$PU)VT88F+J4NQ[4(A$4VY)FBKJFJ+Y6J/37
MZZ= ^X3!::[0O>U?ZJR%3&=S_(OW*Y/Y/G:([1-OC\:;.W;3;TC_ !]!UKH0
MKU)C30(5S=_JK C<5\@]'_U=I?#JDW<C-&^3Q[F_R_3K,2UY^^E/A<=2_P"]
M654QCQN^Y/%HW?I\S9^NFNUOU7J[&N@>']"84OZ:?F3_ 'J\G3&-K/*XFW1=
MFS]RTT[;O]TW_7KTR73AXG2GH*/T^.K_ %4&)B^POB<]&[/ZNS]PW;=O_P J
MOUT_AWU_QZKN%NA4GVT?I)^9/]ZBK&XEX7;'R?%_4^J7&]/M3R;=[/+]/X=1
M):\W?ZOE2?H_YO\ 57D+<-1S_"\BK]N_1+3:B[>V_P"Q&[E3^/?7_'JZ [0,
M7Z$PSR]57A]SI'\S0F"JB=O"E\?['^W'\?Q_V_<WY&W=MW[A[/)_]3R;MNGZ
,ZZ=*AYE:C[R]-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tm2127058d1-ph_struct4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_struct4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ _ ,@ P$1  (1 0,1 ?_$ .(   (" @(# 0
M       (!PD&"@0% 0(#"P$! 0 !!0$!              $"! 4&!P@#"1
M  8! P,"! (' P<%"@@/ 0(#! 4&!P 1""$2$S$)05$B%&$5<8&1,B,6"J%"
M%['!T5(S)!CP8B4H>.&"DK(T)B>GMQGQ0Z.VESA8.7*B4W.#TS55AI8W1U=W
M:!$  @$"! 0#!04& P8"" <   $1 @,A,00%05$2!F%Q!X&1L2(3H<$R% CP
MT>%"(Q528C/Q<H*2TA8D-**RPD-38R47XG.#L\-T-?_:  P# 0 "$0,1 #\
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MPCII](V:/H#!G)6]^5Q'1KN.B6,*SD$3'6?+-DU#* 1,3GW*%@23-J%#0!H
MT : - &@#0!H T : - &@#0!H T NO*GE-A_AG@V\\BL[S$E 8OQXV9.K)*1
M4.]GY!(LC(-(MBFTB8XJKUXLY?O4TRE(7?<=QV#KJP24)[Q4]X[@[R^R;#X6
MQQ;<AU++=HKJMPI>/<Q8DO\ BFP7JHHL_P Q4LU._FR$9QL_#_8@*P*(N!,9
M,IC 42@(Z)2)7M+/_P P;=_8!A,;?;IV]-@W^K<P=G7IUVW'2"R1;CO/V&,N
M3N0*SC')-3O<]BJ<3K&1XNL2[:5=4NQ*D<J%@Y\C8YP8R@$9J"9$P]Y.P>X
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MW0,Y7\U/;3*M@0.V03$RA#-O(4OU"4"B!M6"#%:A0T : - &@#0!H T : -
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M69LWJ:K?RF!0R9^P"ZG@S-Y&MCBKB=RNC(+WLV3+"G* ]3S_ ,%:I*8W97_
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M  ]=B\A5LF4J9:W.+,;Y%6:,8O.M=O=6;J5NV,BN5#L/LXU8SQNX<$4-L
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MVKEQ?QR]N&*X[9(E%K/5IIU"9<CZ]8V!F$7#%=.7DFV2<R28$?MRBCL8?J$
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MX(3G';!-,Y$DXY<EQR_DG%E\O-1H]=N%091D('\MOWUP\D<Z8V%9@JU7)X'
M@D81,F("&H&I%0Y?\&>9_+_VZ;7QUI'MIX#X0WAIREP%E&%QEBS-.)9VKW6N
MUM]+N;W;Y66K4#28.-EXE C=%%NLFJY=)J;$, $$-7Q*2+RE]KK/.;?<*Y'9
MKD2Q./N.>2O:0LG$P,H(6N&:OJSDQ<THZ.G(UYJY+,FJ\:T. O%P)X%6GD2
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MA911ZK($3!)N4QU#*JE<D!(I$RB._4!$-NF^N2:#06=5;FI_/R3^XW'6;/\
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M?"E\2 /H'7KZ>GKH \2?7Z0Z["/KUVWVW^>V^@//C)L =H;!U#U]?GZ^N@@
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M1''W85RA5R,K,.+K[=)I]R=C%-VR"C@6R!"=Y@$W:4 WTD02OH4- &@#0!H
MT : - &@/&X!ZB'[?U?Y= &X?,-!)YW#0!H)#0'CIH#SH#QL'[1_;MH V* ^
M@;^O^;0!T /P#0'G0'KVE#X!_I'IU'YF_'UT =I?78/AU_1Z?Y= =2-?@A?_
M )J,/&?F?:)/S'[)O]\!!/Y!(#OQ^<""I]0@!MM^NA,#MB@4H;%V#X[;_MT*
M>=@WWV#?_3M_ET ;!MML&V@/':7?TZC^K?\ [NP: .TH;= ]>G[=^@_IT!PI
M"*C)9$C:4CV4DW3537(@^;(NT2+I;^)8J:Y%"%53WZ& -PT!S0(4H 4 V*
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M6:4@WBKI?ZI59)PQ65711>-V$[+,'3AJHJV4*"A"B7N((;]!V$DQ,.6G%@1
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M : - &@#0!H T : - &@#0!H T!^9/\ UE3A=+W+,/%2653+_P )E,'9-0Y
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M^G>-]A=/R)%53R/,HD,DD"(J$+&1(]Z@ 4.\PFW^KXAHU!DFVI9:GJ%#0!H
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MZSR)GB1<QE;<A8F*SPTBJ!5 (HF05@2,0>@]R@ )0#?3CB,(P'9C<A-HJ!!
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MXMU.E<DVCXT-U?<+Y@>8WR#WMYAD[3+Y2+>5I(-%$3*MG[,X"('1<I'W^91
M2FV, @&BW"Q9OVG>M44JF."1J]/JGJ%T-MT\I'$Y!8G_ ,=\//8Z#?(1-_@%
MFMUQ3:UD ,-3R77"*N:M-@.X*F9><YVKQ(HE^X9.%TQ$ ,&_#_PWTJ</F-+=
MHILZFK!*E/PY&K#[B=R)G67X[.6\6O7)DMRLB-[J4F*8R%3NE$5<P-JK[\Q
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MK^4Z PRW86-]CI8(B:IL]*F!OCZNGG6J94+#3*HX64BZV[ ZQDUG1RB] X*
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M\37&-2\M,V+XNB6T/#Y%H4(G<%(5FSC*X_L5:5<JLW;-N@D@0[U1JNL1<Y
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MO7\Z<<1LM<CCV5:M7&F/IMU,)Q[QR@NXCI>!7=@1R$<8C1=)9(W><IB@8#"
M]4IDQ1L!^Q:,B;B#-&E962F'9LFS8G=RCD7*^PQ<1VI$$1$$T2%'8I0';1E1
M=+J%#0!H T : - :=O\ 67@ \)N+0".P#R9=_P#LSM0AJK,'YTC(QDU_M%1$
MY%@[@ X]Q3)@ "H02F$0$1#?X:H.KD6IF;H";;$./>F8H  =AA'8-@]! ?GH
M8Y$F8@K*]IO<!&% 3(F?$<.2F'Z1;MA*=3<1';M'Y?'1Y>!2XZP2I*=BV8>%
M,=)6861CVA #?<I$#I"*(E 1)VB7J/0.@:G"""KXQA5Y>>2 Q$S(,NU9<% (
M8HJ>,IP3$.HCU'X;AOK%#@/_ %9NFB1$Q"E3 RA"$3 !^74P].T/PUF3B,7"
M-P*T[@*'?T$1V#N'H7?KZZC,D,9B>-45=.'H)]ZR*96Z ?28>Y01 _:(C].P
M!Z]-#%L]K6N1I+2A)1V":9T3H@110J:8'(*9B% 1'M$=OEJR$8)$66@-Y;R@
M+=\Z;@!0;IL!-WCL '[EEB&2$2FW_#Y:@Q&JKE[ICR.+YVGA,<  2I)I !N@
M;=Q"%^KKJ-.9*H6:,@F6\2X-%R<>D0!("J:Z:@]H'0$I! W:8"E,)0/TVW'5
M4\2.(PR,_)]LO1$68()-05%XN0Q>SNV'N3*83%WZB4-MO78 UCQ,HGR%*L:-
M)JT''2[QJ9ZL@Y4*04=A/]X954?&!#%[3;^O7TUD8YY$02N93&6%&,BV\>F7
MZ2$=@4SDY=A^OL+L(#OMU]=67PR$+B=5$Y9L2QRBBQ35.H<P;D;J$[B=PAN!
MQV+^[^O4+& QV-[^M*/RMI5@9N*VQ!*HAYD%0[1+N(% VP@(^HZ/(F3\#GY%
MQ^FC(DDH@@)G61.LX:=Q4B&4#<>Y(PF*0![2^@COHG.8<)QP%OMS7RL7::@"
M!TS; 40Z@=,![MO4 [?G^S594*M:(XNYSID*/<)O)W%*.YM@]-_C^.A&0+-(
M"@X5*!>TIRB8H!L ;!ZCL'0/7494Y0O^0E1(V<G3$PGV$P%(.VZ1"F-]("&P
M'V+^D?AUUB\RYEW_ )3<!OZ?:Q6OO4@\R>YQE5:IME"*&+(_X&5EE-H^/<"F
M.FQD&#%R=<FX HE,% Q>IPU>!#4M4?NXMXH]8+F;.""(@JF/9W@.X"0^XE$Q
M5"F$-A^?SU<S/@3]@'+UTB[,FRB'2B,6':XGF:H]\2HR.<".17:+[)G$>\!
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MO[391XW<2\%\5J<E2\,4J/J\< %._>%(5W,2[P0(*K^6DG(KN';Q8R8&,(F
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M\/Q&HS'X[LF2<X/;),-7[EC)VA_89)=RH)W*Z*[E4Q 6%0YB&[DR)I&'H $
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M\63AZEY..A#_ .C*UAHLR?O/SL6J(R2)BH;?F;$@.TB#T%RW('<J!!#8/(0
M$ #X[:R!]G27YBBD5/<70% 2E/Z;AT,GTV^L3%Z:%XC,\58!XA;EWKIHJ#IS
MXXN**(" K.W!NI$=Q[=^P>N_349!\^3JAH$L%6GBA&:=;ATW$FEW;D&3<F.<
M4-PWW5*0Y>[](:CG(A'V#TQ_+7#T2"19\]\A^[;N* AV@3\ V#1!CFU\Q3.6
MK8@_Q0,F8Y?@4.H (;?/62(,[ MSN1:M44P,HJ)4R@ ["(B00$1$1VZ!UUCQ
M@RX#8TD[*C5J3?O5"G=H@FJ;?;<AE#G A$@$/J$!V$=5IY&*?+,K?RGD"9D+
MN[2?/?\ =_OECII"/8FFFJ"1D1W IA$3%W]?[-"^05T)I65^Y:,U#IJ$ "*;
M)@0XB/=N4QS%#M$!#08CBXUJMA463<2Z:221DQ.5,%4S&^H"["':(E  _P V
MA&QB6<:L++_I+R**MU"E:B0P 4=S#]"G9])0 NW4?75)&!)4+1Y:78&3<RYF
MC-1!0J+0ABB8Y>_OV!0I!V$1Z;A\]8SQ+',7JVT^(EXTY>]VQ90TFX2[7+@A
M2++MP./W1C"03 4!$0W'UU1D*7D6XX\I29G0':R*[)+<ZR3=9RH538XA]9RE
M((?3^]U#]NC*L<Q0B<NS#(]L<Q,+=$XD 5#(  IE'8-NTA0 # 'ZM28 U>)^
M2C"6DXU)PP50667;D[D3)*"8#G+W?2!1$ ('753!9B>>K]K9M$DW21G8JG^V
M. B7<0() !4#@/0JG0?T:D-!M/#B+KE>N_DV[M5( ;/D52D7)]:9UR"L&WT_
MN@(%#X==690B,&)M/QZ:Q3?2)0-N;TWZB ?V;Z)A\A?KC"["84^X1*00WV H
M@ "4?B&W7?5:&6' ANHXIG\Y9LQ;A&L-EEK%D^_5.BQQ$RD'M7LDJUC#.!\H
ME3!-JB[%4QA'M ";>NL(QPS+@6$?U&>5X)IR"PMPAQX[3/C#@KA"CXI8I-A,
M1LK='<#$.K&Z<% "F,Y2BV,>V6$3G$52J /J.]^!&:]];Q!*6L"2:_<C$.#G
M+NFJ3S'$HFZ ;8W: CMON&_XZ3!9P)*?P,!CJ"?Q\:R%FHZ%(B[H1.NX5 H!
MW$,<1$QB'$.NIF\084VSGD"J4Z9J;&41:P$TW<-@*JW*+@S1P04E00%0150'
MM$?PU5X#,5=T_,L94&YM@.8P]P@ F,)C")C;B'7<PB.LBYGJV,*0BD(%$QA#
M<P!OOW_2(B/SV-H#]*W^C\,)_;FR\(]/^M7</3\<?X\/_E-J/(%__/AU]MQ6
MR6&X +D*NT#<=MQ7M\" %#YB;M]/EK4:-?UEX(U6D7]3V"T\)6 H0;!3LV$4
MT-MPVZ""?7\-]M:K7_ZGL1J-4F[N&4(G#E>Z,G4%4R]=T2?IV*5P41$ ]-;=
M8_\ ,J,SY:>W74WAP_<8?[;H;8OOX[;&'(SSX=?_ "%KL _AZZW#><[?^ZOB
MC3WDU<^8;CD!CMOE3$%XI*R13K2D*NI'B( )DI1@)7T>H01]!!TW*&_R'6CT
M]SZ=VFI_AX^1;%=-N\JZLDRES!-U<H0;Z&D@!H^BQ68ODW!O$=NNW,=NJ"I5
M!*)>Q4@@.^P;AIN]NFZ_KZ?&FEJ>&4<SF%NS;UVFZK>,T_MF:_\ R9@8W,^=
MIRR2[=1PPRG4,B/X994%"NTZQ!*LXRH2+,.GA.=JP2ED!*( *CH#%V 2Z]+>
MAMJSK=-JG1C\M"?");7$\M^L55_;=?M]ZY-.GI_,3&,S11":7!D]^W7@FK9=
MQK 35IC^_).'+',(OV;EJ5-PL63CC,(6T%;J?QEHNP1JOF04 !(9V4Q '<A@
M#K[>>Y]S[?[FW':+57_A[U#IJQX8_'X'<G:=O:-_V#:-3N.EHG3VVJ*XETW'
M'2TL?>7)<?LZ6+B?:',-,-G\CB:?>^6:CDDCK/:Z\*@J'YM#MNXH'[U1)YTO
M0Z?4.I>O#=59HW3YTU]7@;]N&WW=/7UVZ?Z+XEY=-O%5R!7F%GJ,Y'ST)(I%
M5;/XYP1=$PF+U14[#&%%P03;&3-L<H^H:XU?M5Z:IT74U4C::7U/#*2J[E+F
M^7QGRE8UZ1%RTBK'3X?\E=F[B-U#N5WT>N<BI_X6[9Z)?( =0$ W^&MNUM-7
M33<_D2.SNT-MT>XV?ZK771<IP?CU?N-'M[A^\0W(_-,I:W2[MXIE&].)-ZZ%
M0VSD9^347.H=4/K%RLKW[[]>[\=:"BY3=7RSA[#V_P!LZ!:78=-])4_0IMTR
MTURPP3G.#)#4&2E[E RS-A..7BD.1-HU19N!9/U'CMVF#Q=T9,2@BBW#J8>@
M=OKJ55TT**CE5BWIZE\^?D3ZVXLYRR)D.&=5*RUMFP;*-D%8DLF8[E\#8B!.
MT0.V @',<IM@[O7;7Q<>\RU=G5Z>T[G2E1'-9%G.2K#7N.^":K6LGU6$M%F?
M&055A9\BOV3-&+("3B=.5(R"A7(F[BIG+])P)ZB&H\SC5O5:G4UW+MNXZ;"H
MZ7'/YG\&B4^.4RXSS@/+]8Q-%-*?9IBR*2<)(L$W:K9PR<PD"Y_*B'6,)BI"
MGT 0'?X#JJ<EF=9:'67=#N5W6ZNOJT%+:^9J)>"S(QRI>\AXU;0.'F=CD&SR
M@0C1*PN$5@!RZG7J2,DN<YMS 0C5LZ*D&_IZ_'4GF=C[+1M6LLO7W*;?T.<K
MSRF2$,@6^=R'Q:R0E<I-5X>"M\22!?2788Q7#AA(*R;=!0X@)D5$B(^0@=-P
M 1Z[:W;;M0[&Y5-?Z=61T'ZF:+2:56K^FLTU6U5.&/V(C/V^O<PS[Q_R-#XA
M:1DOFO&,J1ZSE,3/%QDGT<QBN]U+3%-*N0"-3Q,0Q45,V54^W5(&Q@#<##M6
M[7-=M6YW-6Z:*M-52II=5*P>,Q,XF[6>V>T^]>V=,ZNK;NY'7%.I3:K?2DJ:
M:J,U2O\ $TDXP9:YFR\^W7RH@#7C&< SQCGQI"I6=>P3;$,;DK;85O*[>7!P
MX4:QT@S05!4O8D545Q*(%$?77 ^XMR[4W:V[5%FBG<F\7$1SQR>,?$YUV+M'
MKQZ7[E8OZS57=U[0NOZ="MU+4.(ZJ:JJ:$ZK2Z:6FZXI3?3,M%9N+;/F-M=[
MW8L.$RCFVMT]Q]Y%9&Q93+0"R+<@%\[U"1C4R(IMD%P5*5 IE.\I-]@V$ ZM
ML;!W)MNMKUO;_P!:Y;GJ72G#X\LL\#VGW/W3Z.;QVEI[/?\ J-LTFOJM17:J
MN6ZZTVFNETTU.KJB/*2VWA=[J>2+ [2K-YKUARU7HQR5E*6*&@G:>1ZNH=8Y
M!2LU?0*@W>)LSB(**%!-<A2;B4PCKM+M#N?N/4:RG1;II]2KM7_RJWY2^ET_
M:>)?7;].OIQL^AJ[C[7WK16M17IZ;U&F5ZVZ:K;4RHJFAO'!XSP+A+CS%Q?4
MXHCIBK)V!\HT*N#%FT%($S*IG.1%RHY,GX5 . %4* &.01V$-^FO0VV=I;GK
MFKEVAT6JL9JA?%H_.?=>X-#H+EVW3715=LN*J::E5DI_EF94>\KJR;S1Y+98
M=&J^(*](00K*'13/48YS,S9B"H9,/(^.D=)J8 #ZNTI=OGKG.G[8[;V=*]N%
M=-RI_P#%$>%)P>]W+O.\4?3VM54TRU,=,_\ ,1A3_;'SWG*>"TYYN3^LLWQ@
M6<'?.QG+8[*H;<R9DW(E3CP!,-MQ$1+N'0=M?;7]_;5MVGJT>T6Z6ZJ6DU2\
M'[3X:7L/<-??IU6[W'FG'4G/A@6W8!X38"XZ-$34BE1[BP]@%=VV802?3KLV
M_<8P.%>XK<!.'0" &P=-=;[EW%NNY_+=O5*WR3.?[;VYM6V_-:M4N[S8VY2%
M*4   #H'0 #]G3IKCE5I5.:FVS?TXR4'TU]4H4 - &@#0!H T!I1?U&&0G5+
MYJ8[2BE4S2B^ *VY(T.<" JDVNUQ55-OXS]"H$.(^@;=/CJHC*N,8\Z.0&'\
M>2]2I<PQK49<9)Q+K.X-%O'SWD<I$37;I/5#*.6[<Z8_4!"E'R!W;]-#'X&2
MUKF#.92DD83,2TK(L8YJL"-D0D):0$' J@B95ZDX64273(GT,=,3#W!MVZ!\
MC-;I&13J/CI>%>??0<FJ4Z,VP*JI&.P2'M4177V[45DOW3 (@(&Z#UT^(7V'
M31391$\=&E4*FJNH=)N]7-L1% I3*"=4=P(+9J01ZB/:/;JAF498I[_*F+3X
M^1B&TI%Q;E:00,_,9P[6D4RF*DY3.*/D;E7*.X$3$!$ #4A%3]Y+/%).S87J
M#N'N@(3S&<0;,1J*JF[-G'H&<!W@#=(5D70)J%!,X]2B  (]W3098CXJ8CKE
M]H,)?($DL6HG;G4;%^Q3\+!8KKM73=N#")E$T'!NPJ@#L(:>18DB=Y/1N.E%
MG31N1![M]K'K *9E0351%)<R9NHD$##N7MWV^.L<6\ X1 %AL5BFJT>(B%TA
M5"6?/EWKUQW*N6YD3 =LH1,A@,W4.?81'8-_TZR@QX> U...-N=.4%?JKZ-L
M3''6+XJO0, XM]@24CV*;N$:HLI4(>/3!%Q..#+)G,7L'Q_3L<0ZZ1[RI299
MDKVF\-*4EXS0Y!9!LTS-'5C'3]*&@&44008D*^=(-G*KM==!=8! A3&(!?0?
MGH5)E=9O:*LE,>*%J6:ZLX<KH.0,SL-=>L?."QA40;=R3A^V^V.!-CF[>@[[
M '34\20U@8N;@MS H$,BYB:3C:SK,G2KQ*'HMI:*OUDRG46,H=M)(L3.%#''
M<@ ;?<=OAJE@1/-O"'FARCCIFJFXF3T5;$WS8T1D&Y1["KM8OL?)*N <65TJ
M1%TQ%$IRCL*P !N@==0)0>F,?Z>'/*CF!LF5>1M#P_(P?C%9.DJ/+G.M6^P*
M"HF^16CXL5TU%#)"7J00 !VV'5GW!J?,V >*O&C _ ^BVM/'$M*7F_7<A4KC
ME"VE8*6F50:'%PA&1Z;)+QPL&U\NP-T3& X@ F$1U,L1P(@N^9T81=Y+SL[$
MQ+1)\H[27E)-M&IBQ4+VOP1,]70+N5( [@U$B.K@5793]QWCIA[*;JR5S(,%
M?ON8N3JTO6*N]3F7!V$OY1?)%D6AS1[-1)TBF8#^01+VATV'?5"(WQ?[IF/<
MC7U-C(9=?8I1CV8HQ;:XR[21A9I)XFJ1>(E)T4OMD"LC*%%(JR@E[BB/?Z!J
MQS1.I<'B0?R<]R:YUO.F.8[ -EK^6I]5S&L7R\,[!_&N3N%D6L54&#N)%=%9
M%^#Q3R]ACF W7IOI'N"8X,_&\RLX1=9=9!Q37(Z)C#?>)5BG23U:50EES,4Y
M"62-)-DP<G:H);B0QB@42B)=]3P+);8W=254?1$N^%Y(*1K!L5R\?(%7^_02
M;B54/"4JA#/!;(_67;;NWZ=1U.)<BNZ]>W3Q^Y.+6DTM3#41U.VY]88Z>K";
M=I/Q3 RJAC1'WP 8JS9=J8/+W%, &'H/IK*8)$O'(9[BMA"N\,,>63$&+7,Q
M^7.)]:RN9F3>%7FYI!9JR:D06>E(@'_1:B2@$3#M*":OTA^]J3R*A>N<\!RZ
MG9N'OV'L>35VAF=+0)/2U>6CW,W)RB$D9%DU<PP"I).G$4T, D!$@J&2#<=P
MTEI$P9BS?!'.1E06MI6FJ0K9SU]22<X^^]=)6QN06AUC-TP5:)(NK <A0!-N
M)R@*G:'X:3/F(XE9\36,C6AR:6J='MMBF_MU)"0) P$C._F<:HY#[\')6C8Z
MIC'[C'!4 [@, !O\-!Q&KPSRB>P+0U2?P@N'T,N9L6/GCNHV28&0%4BS!T =
MBQU$.G80Y0,'3?53)!=SQZYEI#9*U(04ZJ!8@Z<@E5WA%44U!3 5?RUV!SB@
M#955,2B(B/<7U -]3%&>9='['L(>!XSY+9JQY8QPIG:XNG+5-($42KN642J?
M[=, *!6^Q@[.FPEZATTXD61=%H4- &@#0!H T!IV_P!9BEY.$?%T/ER9=#\/
M_P#&=J^>JLQP/SE6;M:,?MG27^T;*)K$ 1Z' .P1*;KU*(!Z?$-6#',;?%KK
M'$LF$;(U9)_;YIV#&&.951)JW=NTR@60<"3?9)LH(F[?4=M8N2XEI/$?"%,0
MM<=)R5A<VI>KJNGB$46,^Q9H2OVYCG4,L8Q2J,VBA=B&'X!UT24^)&X*[N4.
M0E;7F";@FDG^9,VUC.Y>.P4[RN55%$MF^X")#)MO$)0^ Z>)4,5BT"HQR&W1
M,BP".WKL(_3OUWU%GX#$;>FF$\PD8^PG%0H=P!N E]2A\M9D'9QS&^=XZ?F
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M0H?,]!Z>?-#XT^A7O'F4V5C;9<:146@Y(H1A+2R;9N9 J@*J@JV.<7!@ @"
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M<LC8.[/U(>LW;>W+M71[;;V]W?G^K=M5NJJS53@J'74DG+3G%PBY*JXZ;4:
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M)D1';_:'#8ZQ]S'$1'4D>0OQ,[V5.7;M3.3N8Y$%TS(*'**2(KCOY"@<=Q(
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M &E;UUQ7=.OZB68R[7VI^6N4V+VPX^)CB*AE7K9,LBYAP@5F;8Q.QRW8G8-
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M7A%Q0EGCZ+4Y$)DLR,M97C-=&Y8_5M,*J<)09<B/W(NG*,A$2EK$YEA2(H@
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MZ3PR$U4@E").,J8_5= 4KUG8H6[+7%RQ;SK(J+J,,]9,';!397Q' =E"B41
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M56<%G"3$6LI!M2"Y(%8E6+MLHX%=8A=SI+#](_(>IE\S<']KK'F#,=\=WC3
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M":*8CZ].IA#;KMMJ(?$7R^UH9W,4Y)N2">+CW0'5[P$P.5!.H8J0B8!#M*H
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M(_#X'+^W5XE:@_2F_H]0V]N/+X?_ /5MN_\ 9YCC4>1C&/[>)MFZA0T : -
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M)&VUA'+N28Z&BH^I0KV'0G8>F2,H9ZYDYCQ[+Q<E+LF3?[) 7"*Q2"IW@(&
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MP!A_-[O,V.QR7.9V1/)3<XTL-P;OJ,E:%8Y/[EN1D_9I@B:%$I4TS'<J-SG
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M]NX0.B<@>G4-.)/ U<K+%Y-P'6\AO.*V>;<M49&W+L:;1$JTWLCQ:%DILS.
M81 RC6<?1LLFU>@4@I%357(3O'8W4,ECF2'& [G ;@[CGE#B"3R%S+LV4W]H
M>6UY5X:KP\F%*D*'(Q*J**TA,LUF1W,I+/1>^0J#EN0J11$2"(CN&.615/',
M;?+/L88YL\49;&W)G(>(%FA18Q4'=4I.[UJ4<ME3$:2*3QQ.1\@V2< 3O53
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M_P#O'&H;#\P <8CM^O0L'3S> IB9BI&)=\@,[JMI-@\CG)?S+&VPMWS=1JN
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M5ZM-O99C;&\G7W$KD"8@Z\D*9(R'D9]1!P!R&2!,IZ_:H17PK)E[P(HEN(=
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M$M"=9O\ )9&CDH&,DY4M<K2Z-'*SA'<M 24:V4& L<Y(1 NSKHF[%3*G,(E
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MFT=%,+14"F. @!1]!-T';8-]O3X]-9%\22:4QDH)RG-S2ZD/&)"*@>0P@$D
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M084MMP6W>W?G7D'+<C*9ANT4P)-I&U]\BD_!F[@'L6Q21;>"RODWBI$7+0A
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M)<Q:Y/8NL= K%:+EW(BL*JZJ;U!-M(&KTTW,=_ V%6S+]RT>\C)8B:H)H*"
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M1>*"BLH4Y3IM3$$R9]AW+W[#Z;EZZO@0RF0NSJPB7\V.!P*0$T4"?0DU*
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M>W]E#'D-:<Q^WH>+EI%BDM:7-:@8HC=@NH@8KIS'NX>9B'*R _O@4J:0E'H
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MF4W[1*8!W[3;Z8P091G?(]-@JC"Q]3A';!<I&3I5FBL5R@!T@%(4U$2]RIR
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MR7O9:Q@LV@*ID>[M2M[&X<SN2;).31S/K'9$TSFCZ@1T^?F5= &[[S  B($
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MR%B5G<LDY$>76X_DSUMY @8.P6N7DHHCHA^XB;DL&Y0474,)?#N!1W'TCQ+
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M6#!(F.E.UVCN']Q4?7T$Q]_E\-]1X%+7./<[]G]HB=,!%V1!N4!Z]3;;;F$
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M:6<&_=MU6EN2MWJNE7/E3\6_ U0>9&=ZYGJO1E%Q;'/;1:7R_>W)"IE5<M!
M$W/F<+)&$&I 3)ON?MZ"&WJ&L]/15.*.W[6EHT=OZJJFWS*V;>RS_C'\C6R;
M"39(1%XS,=58570I($$#;+=AMRD!,H[[AK[.A2YSDW:UJGJ+*5C%07S8.]Q&
MK4W"\9!$>E!X6#2;- )W?O"T A2&_P!Y* [;@  '4-?*M*F$C;;G;]K57OK5
MU?.OO@145T.5O(6.:3IBEBGLN=\Z[S&1(HB9<YBE[C"?8IMO3Y:P^+-QN+^W
MZ.I6L:TE'O1=?ECBY@&IX+>-(V'CTY-%@=,BQ_M1,([@)3F,5(#"(CZ" CMJ
MM'#-)O6X7=Q=I45=,\UR\S6CRNN_Q&LZD8%^8K(W>=9L*@J(@4AQ3*< *8H%
M O=OK&EIX([&73:2=5,5M+WGOQP2<3]@_P 49E^TD%D$W#>,9=X"!%%Q[%7*
MR2P]  #;@;??<-2OKI<)8,^_T:;Z^O<PC#V9_>23R*D%4&#&XLGGY-/P#I&2
M8R3-0K9P@Z9+%=MUBKD,"I!372 VX"&OIIJW3<FO"F#;MWTEG4:"JUTJ,Y\C
M>JXL7F>R;QVPQ?K4W4;V*V8ZK4W-)K(G05_,'D8@+E51)3=0IG!]U.N^_?\
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MYZGS=#E^Q9<R:KZ'C(^8;1#B0:/FT+&3<RDN9TL7^"DS.H.Q2;Z%^!I1HT;
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M#0!H T!IV?UF&W_!+Q<_[3+O]O\ AI:O\^A#\Y[N #% 1^GZ-_7T$H;^FL\
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M%Q#%M&QS) O:BT8LT2(-6Z0#O]"**92_JT^!TW=N57KCN5_B9V^H8!H#CN1
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ME4$@@0J9"[* (?O@ ?HU$7#VG85S&JED5;Q<:DL=$A05DW!.X"E3Z]B?>)1
M3F,&W3X:2PFQMZ!QZ(KV'3B5P:I)E3 W:815. E[C',)![BB ATTQ9!OZK@!
MG!M2R\BQ#S%*!8MJH(BH!RE 044)V=OC+OTZZ0BXG">8E<KO#O7C<YE%E!.4
M" )MA]  "]NP !0#5@C.W88H,FMV@W7ZG+_# .TXB(]-OITA 82JT!O468OW
M$>=:17)_N2)C"<4BCM_&4)VAOV[=/AH#"[%0?S=ZXD7[+=PY*!CB &*43AT
M  2].@Z8 C65PNR>B!31QSF/MVE*.P" [;AMV^NVD(8Y'1/.,, 5+[U9D4SX
MX!]LTW,;ZS_NBL'CV  'UU,/:,1?+1QJL:DBH9Q'+%;D,84$T2"#=,I=MA*
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M1^F_H#Z:;+^G[M'5>J_JFM/1O][3?4TEFZE75;=N;B5%.*HN5OI4_BI\'$[
M'%7C]7^-6$*+B"#21<?RU$I_GLSX"(K6.SO3JO[%8'1.]8?N)29=+K"7O,!
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MJ&8\65F1QABBSRN5&,W%(N8^'R-0J^DG7XY#N%)RH[N3./7(DX(F9/N$QS"
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M703.!U2<''IJ'5.B0YCAW !R[[=?0!V'8/[-,"RP=PK1XW.FHU;F3, @4"E
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M-<N0<OC^8B1FD2B4" (@ @([=1U0E T.H4- &@#0!H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
M T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
): - &@#0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tm2127058d1-ph_summ4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-ph_summ4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ J -2 P$1  (1 0,1 ?_$ .(    ' 0$! 0$
M      ,$!08'" D* @$ "P$   <! 0$              0(#! 4&!P ("1
M @$# P(% 04& P0$" ,9 0(#$00%(1(&  <Q02(3"%%A<3(4"8&10B,5%J&Q
M4L$S) K18A<8\.%R@J*R)2;Q0U,T1(0G&9)CDU1DE#6%E;4VPN*STW2D1:4:
M$0 ! P($ @8'! 8'!@<  P$!  (#$00A,1(%009187$B$P>!D:'!T3(4\+'A
M4D)R(S,5%O%BDK(D- B"TE,E-1>BPD-C<],)DZ/45?_:  P# 0 "$0,1 #\
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M%Q^JI\[(E('>V7W*58_VCP<@CRVD\8%3^SH7\W\S 5#C7];\$'\M;',?#B:
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M_&7N^8?%$?\ *:*WSSO*@>.:6+:6!J $*5IZVUZ5J4AD:(QC)M@)BFJ15U8
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MK'GYG?%K(8K,9COUV7LB.1+;G^^N&V\#-:<SX_\ \2;Y_P M#'(!D;:,;D)
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MN==Q>)<DR67XAD;?D/'>!8J\S61L[[%X;.765XUR3)8>W_,V6/NXA/<(T2@
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M<V/,;K(2<KPO++7+6O*<AAL^UA;R2O/:"X(FW+Z0BBW77-FW^%]?926SH)6
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MM!&'B2"8O<:C$'(#LZ_6C6O+%G&Z0R '4T 4]^7L4$<#_30X1PBSRG$\SRS
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M21KM:4JTK,Q8$A&'\19A7>:@:'P\*CI&3 A*,P!KTI1M+5IA5SZ&/X5--"?
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M?Y9!70T!'4_96OB'4X?+CET8K ^=-T=91';(759CD:JX^-R+S0M[@ 8(66I
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M6N[R25Y'VN]8W#(U""JIHC$>D^'7"/1GQ0Y]J-BZR, 8PQW3NC*KV\SQ*0A
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M(_==Y;2.*A82>FI=]S5G^^[W<2_\MM*ESR00!ZO>G)\,_B]9=H\:,]GH5O\
MF^<A2;,9*=TF,3SQP2R6=L]6/LK*#5@ 7.OWH<T;^Z_D^F@/^&!I0#(#)/.6
MMF?8#Q9A1[OO6J>+MD]F,R$J!%1=OX0!2@UZS^?$JY]J6;:[AAHE"U6V*17R
M/B:T!KU%F2Y#B ,%V"(WEPS3M0Z*P(I]*>'1VND<*R?,E6##TH.1F8;]A]*E
MJ,-#I6@I]>E&4U()/E](6\GZ%LON<O[^$ILIQKB8H*4/_'Y-J_OT_9UK_EP/
MVCNU9USR*Q1]OQ72!3_U*=:]7[UG%5SB_)2UC;O]WA&RW??S;)M)ONG0M01-
M&OM [ $(U\/MZD+>62FD'NT"0E: *C-5[%G&ZM%+:T*;I8GMW;:L()J/054A
MB?$@].  W!N2182X5/2O< L[=C&F_88Y0L22-<1BX",5#@SH00PI4   ]"N>
M2!5O2B$RY:&0K!87*6LNWV[M2XB67<KLK&4344GTJ=VOB.A%*I(O<1FOEM)?
M6]\TS8Y(F93'(@NC-+("-6V,^_=ITXSQ14HSW1C6*[_+7(="2:[42%5JJ,8J
MA*BFA;Q/GT&J4&C3W>S\$DYS@2 E(9"RNXU=EMIYXU]:.RM,0YJ3HKD,K> !
M\>@#I#\YJBZS1%O;=4=O;M88GD)8"XE$A4T&U@63<Q7R)T/1EVLG Y(W#%/-
M[I2^DA1X@D,;T10P%=U/;+%0"/,U!Z[[T ]B&MFELY(U_-Q70=5_%,4B1_$Q
M@R51F\M:'I5K&D \4D7.J4KV=^7DGW>[&7?:E?8,04 C^7-&HD5C73U:]%>
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M"-"X))T%&!J*@DT^\=&%U)T%!1 V_<B-Y#$MS VUC&V]2#&U:$%"V[H_U0.
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M.0*0_83 D$5::4Z_L4ESY.PF<LID9Z'U.X84T\J>?4@+5S6]XT"9R111]YY
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M5JLNZ,E@K$$BE%J-.E66NAP?6M$S,);('@&@/0G=<]X[>)0JWBI04]!9/ Z
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ML[^:!"%FMTC6[*TT55 52U?%C4_9TYAL,>M-C.G/PKN#@YKS$X]7ENH);_\
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M !/<-9(]#Y,=/L'218P D 5HMNY4W 2VC!*[4\M&>)K@E+^XII;.'%6C%E4
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MP!E#A%I%KI*N\D];1R?O&M\C9JN'<S/ZRJN\6QE8W1W:5]WP4 W7,LT-X'(
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M:CIHFT\Q;*6M-1A]R4>07&+R\#*)\E$ZDM GOG;[9%'C4T'X?Q*-=>EGQP@
M< BM>^; 9A"X;!8:>"W_ #F1OFR26WY,7B11&>2TFCT]Z1 /^(A*>G=7RKX=
M"QT8&D#-"Z*8M(Z05Y/';K#7,GM<HG%:>_:S2A))?<8*)@J1?@*D5'U!UZ7>
MX21Z"/2FT<4[#2I*=$4%Q;06JY/*6=OC+B=HKB: E9&-0$9R^\"JFM-.D8;5
MK.]4^K\4>21SFZ'&A">/),+B<KVNR6'Q\W]S\>NL?>6LHLKJ.2[D1IF'M54@
MQS!V;ZG3J7ACMK@Z+C(9>G-1$S987!T3M5:U]%*+,#.=C>S-E<B&[[:\LN'$
M\9E$V1L4_EC<#0?F3*M3X52OV=3\'*FPW4>MQ[Y'0/BC-WJ[C'A%E6',U/P5
MC>R/">*X+'20<;XWD>.89+F>:&RR%V)92U4+L&A;:-WT\>HR\Y?VVQ)\%M:=
M2,;KQL\,>E3G+9V,PDB(MC[H*F$S.DJ1E@XW;W#L2P'J4&AUZBC;LRI0*2;(
MT-&.- F9D</8V-M()([:YOT>2XBV2.2LLOI>555G=SM%/LZ;S6C"\.X4Z$JU
MS78ZDW(<!ELA;RQK/>XMY(R=Z2,\4C4)C)0KN2II4Z]*,A;IT!M2A<&D4#N*
M2K+MIG<-(US#>39%<E6ZRMP=\DAO0?:B2-75ECB2-E.WP)^_0WTQ_(B>$W@\
M_;TJ2N+<.NY+V$W<D9D@WT]J)2YF<[U81J^T$G2E/V]%A!A-1BD?I(:?-CV*
M:>-\<Q"V>1GO6]^YAMY9+EF>@1XC(P!CF601R,H )6NG3YMQ/(^HPCIDDWV\
M3>ZTX]*I+F[C.7&5R"6EMPVQI<SL99>+V1E1/S3R1-'(S>J=E)#.1ZO&@ZDB
MZW=%0V[2[IK^"0^DD)J)G4IT?BNJ;_EU8\@>W/R)N+V[Q]P9>>X%E%AC[>P1
M O';12&%N![I-/$T\>J-S!&R)[=(H"59M@@=&'$O+N[]N*4?U><P;#Y%]MSO
MVE.UN+G*AOQQKR[E19?J*D4ZPKG?_J#!U#WKU3Y4P^+R[.^OZ1/_ (6K,_CG
M=_E%ARW/O@!;>VL*.QNT#Q1*%5-G^\1BQ/W5'1-JBU3A]<:>Y-]]W*]LMN+(
M7'2'NP_VBG]9?(7EAO\ '39+"<7RB6#RSB 6+I*Y"N#29;RL==WCM;[NK.X5
MD:S@2J)8\Q7H<3,-0(/&G7T%1)W8[S9>YP_+NXF2E_HW'N$\8RF5:P@G=DN,
MFML?Z?#(P;VV62Z(]!_AKTVWRX_AUA(V/O/=$X Y4)::+2/+&*3F_FVTM)F^
M';MO(=5.]J;XC:C&E*BH7/K:][N[;W$]_)W Y,PR%[=72UOG*QK<7,C1((35
M%6)6"CRH .L@N-SO*T#CZU]#K;D[8+:U^G%NTGI^P5I_CWWWYOQ?FN!Y#R_D
MN;RUCCLBMS>R2@3P1XM(7268(BJWNL)B-/IU3=[OYY<-6HGA7BH_?.1-OFV5
MUO;0LJ]IQXCV+2IOU$.QXG=9^6SVM9"%$UI,@522:_C( KU3Y-BOII&S1Q.X
MUH">CJ7GYGE-N5O*]\ &AIZ#C7T<*>U5<^7_ ,U.&Y_A5C>]KN4V>:Y+<Q?T
MR&*("1\>L<PFDO9X2^]31M*^/CU9-LV*=UU'/*2QK#4X4^]:AR)RO>;-!.^X
M8TM>T YX8GJQ]BH9V9^4'/L7W X[=\LY1"V"DR$:9B2]C2-4BNFCB>4W (]L
MQ@5%? =7^.62%GAM)HI_F/E.*^L?$AP<>%.H]:TSG^3O$9E=8^X>%DC-&1XL
M[%.J1LM'CAC:XVB.5CN)VU)U/3]FY-8P-=F  L@B\OM\GF+61#PZFAQRKA^C
MT(G8_)*SB26VQO<B&TM2O^[M^0B&%R34^Y"DR1$D:4 &GGTA-N[&D4'M4PWR
MKWYH!\,.)ZG?[J"?Y 65X'1.8VR?R)(6+9J)5D61E:4U$Y:DBH01Y@^/3=V]
MQ1MU25#4L?+CF&-N-N T<1J_W0OW_;-;3R>[%RFW"S1QQ_\ XU6,@Q,-L8]M
MU+1[5% 377QZ2_F6QZ7>SXI2/RXWM_\ Z9'H/P4/=U.]YQE[82V!Q6<G:"<S
M1RW'YI[1]YE$A8,9-STH-=/'JO[I>OW)U(NX*4KGQ]"USRSY!O[9DQW.8PRU
M-&Z*U&G#$D*[O97O;CD[7\;9;ZTL7N8#</:/?PHT,DH0NNUI0RT>M 1X=4&^
M;<>-ID&MP&?I/:L"YYY&WJ7F"1T,.N.F!H1^D[J*EB#O99VUO?WDN3MQ':V-
MW-(OYN*LBI;R51294]3DT'25LV7Q10:>M56W\O=WDNX1<V]8_%:<CG7]58\Y
M+Y'<:O[Z\N9.*9!'GN[B9W6\0U]R5FJP+K0Z]:3!-.R ,/$+V?!R?/:6D0BN
M',/A_+HKP_6'W*>N,\[P$V%L38Y&UM?ST:W!@:\M@R_F-1&Y$CKO79J/'I2T
MOS:LT$ZAUX?%>>N;^6-^9=CPFEV/0?@EM>80+(T<.5=9EC>@$B['+T0(A5@*
M%!6OGT_CWBT#?VA+7] H??[E7QREO,@#IHM3Z9X_!*EOS>[5RD=_(EM*\4#0
M-(=P((W.K$T.^GEX="_=K=^$+B7=>&'K25QRM?V[ ]\994TJ 3]]$!><P=[A
ME&2N8@LS0(RR)(4VFBDZJ3&$&K>-?+IW%N;M!H[&BBW[1>@Z"UQ!Z6JO_>+O
MUP7'9.'C&9Y1E+67'R0WX_)1/<1"5HXREO<,DJA"I2OTH>EV7$KH_$Q)5LV7
ME(.C\5[-)[%=OLAS""_7C'),??2W%G!C[2]MIWE8JX%LK+*=6HS+KH:#PZS;
MF2X^KOM9;I?&1UUR/4FO.%H+/:W63*N!:12F55;BT[RY62X5%NV8%P PE.@J
M?$;J$=0;9O&>^1[M- />L<99216HAA%"2:X9Y*NOR ^2G:2+EF)XYSGNIF.)
MY_ XTNMIAKHVYF7)+#.K7+F:A=%510#0&OV=;5R%N%K%:/;)WL,U+[5R9<7L
M;I#;:SVD5_\ "4-V-^6&!EY5C</Q3Y&#,KDO^'AP65SEO+?27>XD1V_NE02P
M)T/TZT&VW.QEE\,'3U_8IY?\@WIV>:7P&QEHPQ)Z>EH6H.*[F\_N1'^3YC_4
M+FVMV8V4RQO"L)TF;<DCJ\BUTJ!KU.U!'=-6<#TK#X+."#7;RN N68.PXC \
M5:OX><EYS;]\>-8Z*7W^,9."ZGOP8"1^=E>*2:4N&98I''VZ@=.[3]^%6]W:
M&6<T<F))P/K6Y]= ?J1_B1_T]3JS19(?J.P"7F7;4FOIXWR!=//_ -HX<_[>
ML)\T_P#/Q]C?>K=R^_2VG65G((HU.L:FGTJ"?VU/65.D(5A+L5]>98T+-6J^
M  \O^FO1"[5B,$(Z4G/?R@A@PH#HH8T)'AX4\.BM<6FJ%Q%.M$+FXAR#@WMK
M!> 4VO.&,P^WWT,<F[[?"GET?Q*\$77B@KK\Q;*DN.R0$?I+V>99$!"@U]F^
MC#$L2=-R*-?'H(VAYSHD?ISTE,W+9Z6-P+U+G&AS_+:[95M78:D1WH)M64GP
MHU>ES;#.OL1)6G2(N@UK[E7?F7.[*+FAPK2!)4L%NK:0-&T=PS(2T".LK'<I
M8BGC4=(RP!D9<#BM.Y3#AX<;C0#&OJ2AP7D'YF07$)K(CNP9@&:([W])0Z$U
M'GTAM\Q;)IHMX=0VL8 J,%6/O%D>6<XY]DYLA+>W%GB[I+*QAF:;VC!&@+2"
M-8Q& ['R&E.I.ZD?3N9JX[9#9Q1"32 >A2YV1PF3QSWSO'*MJ(XMR.SB#<H%
M"L96@?3QKT%G-+@URB=]G@HZ2$4E.84EY^YD3-XX1M2/=.98QX,/9-*G[->I
M#<6"2)AKB*^Y97S-'KVJ6YN#WF-<0.G!)5Q>>!!\::5^H%!]G4"]H;W2<.E8
MG8TTF;\QR36N[AG!8CZ^?TIIK]:]$,4?!Q]7XJ0J.*;-W-4A-WKD-%34L['0
M+&B@LS-Y:='$ I@2G?BAD8(QP2'F,'+"$?)S18M&];0W3J<@X.JK#CT+3[I%
MJ07V+0:GHS80TYIN)73YC2&^VJ8F5Y#;6""'$XV$R6]1_5;N/W;J6C;%>*(2
M"& E#X>NE?'SZ.(VD9XI1D57BI*8%W?O?R^[/<222DU/NLQ7Q\*5( !^P=+1
M]Q._IP>*V?\ T-Q3Y,=QCH?_ *5DOAX>O.V,FGV#W*?LZTSRT/\ S<CI#O[K
ME1^>(PV!M#T+JF!W%AX;6'^!_P#%UNI&)/\ 6]P67@XT69OS:RMO8\VXS%+%
MO)P,SU^E;M@-#]HZQCS*=_S.%IR\+WE:9R0-=J\_E?\ > J6V?)H1(?^&2E=
M 1K337QZS&.82R:,J*^5/H1C*9\SD%(8@$%=3N!T^FT:].7M\,5S*,"P8Z<4
MTY<[)(Y(A4>5-M-1]E>F;IY [NY(-49_1"3,KDKV?&WD8]F"22VG6%G\1*\,
MBIINKJ33J-W265UD]HXIW8F#ZIOB=UOVP52XLM?VV4LH[M"UTUQ+:3 ,1[9
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M84(^FUNCMAM1W2QKO0BRV>V^'5D3#Z!\%[AY1G@5_P#;64V*:J$O+A0K#4$
MRTK^SH)+: CN1!I^W0H&:SLGG3+ US.QN:2,KS'D\8=H,_FX9!6DPR5R&U);
M^&;<0'-2//I6&WC!IAV8J'N]MVIS'!MJP$@XZ6X8**+N26^N)KG(W=Q<W,NX
MRW+%I9I#2@]4CDBM?KX=2;>['H:H)]K;00%D8&JG *?> _(KNIP7"6N!X_RF
M2'%6BA(+>YQ]E=-' M6$"RSVTLOM5)&W=0#0:=05UL]O<O,CQ1[LU!3<IV6[
M-\6Z+07<"*TX>Y6-[:_*_N3D<ZN/RF7MI5FA4Q2G'V"E)BU#(L1B1'*?Z2"#
M7JK[ML;;>#Q(<R?Z%"W'E[M4,L>CPR*G]$]2@'Y 9.VY'>8SE&8GO<IF7N,C
M99BYN2K2W,D3I^58R'\.R%: :!5T'4GRNV6)K[>M-5",<JYJ8=91[7;F&"-M
M"*:@ *=?2H)X;RJZP?,N*9G$Q_D3B.08VZ5800[PI=Q>X![=/X1J?*NO5SLH
M R?O/-3VJ#NK0W6US6IE E<,!CUKK?XYRD36.*Y%C9)XWRN*L;ZS:WE]M?:N
MXED="J$!T*UJ*$$CK6=ODC=:QL8ZI#17[%?.[G:WO-DYBNXG ZFW+P?[2O5\
M),]R'(_)7@'YG*7(M))YT:REN93'(@CC "P!A%05\QX]2UFX&<4.2I^YW5S=
MVH?I.@-Q*Z1__%U/<54."R._4CN3!R_MFB_B;CW(6TT)_P#:6''B/V=83YI_
M]0B']5OO5KV#Y>NI6;#7#5)\=? _?]NG63ECZY8*P%V*#>=I%*,2@84!#?YT
MI7H-#T=CA3&E4E3M%&0"?2=0X%#4>1(U^_KA&XG (7$4PS10SK7TRH@^@C'[
MR=M:]&\*3H^Y))/D]F>1A,9Y$W AC15\"-(U;:#KX]*0QO:>\*)S5%9A"BF%
M27A-=T$R"2$@^%8VJA_=T\H2<$(CUD=JRU[GY:*TY[D;ZULOZ<]CE'BB-L\G
MM'V9PSD1$?R$FVT(!H33[^DYXI##EGV+0MH!MHHI#@-0J5+/"N9V^'O+>6YF
MB:RRZ?F8IBZ!%DD4R-#N!V[XW:A'EU&6MM-&\N<V@]"WK:I(;^T;X)#G- )Z
MJ9YJ<8K[B&6)O+J"*1I-?=BFB5]^A+;&959F \:]3$)C?\Q%%T]Q>"6EN'&+
MMI]Z.Q\JP-BLUK:R6^,M%C>6:22>%FE]E2]2[.#6@T4:$Z=//IZ'5$*M38!T
M\YC=4W!_1QZ.G+VJ/\=R2UY1D<A?V%P;BUL))+6 $;GDE&X22JP=]RD:?9TA
M<:V "6H&-%DGF'NDUM$=NEJV4AP Z:]F"$FEFE?VK:*>XN-OIM[5))I_V1P!
MG !\] .HHM#Y #\I.*RV%SVVT=*U#JGJ"]+AIHQ[F:N5L5)W"R@7\UD9D&KI
M(@:.''R/5:$EZBM*$&JKH;1OS/ ]?P3ILQ=D:HGDLE=V5LXP=I:X:(QL))HY
M7N\I.M-6DO;I"T=?':E$%=!T75&,&FK>"=PO>XZ3DH2R,\EP\\\\KS32$[Y)
M&W.X))H3X4J/*@Z1G<21HQ4DV.@JW,IB9*2IVU4&I]34 !'B:D^)^O18R_6*
MY)1@+7@NX)KW$HBJ%969_P 0WK(M*T) 5F"M^X]/>I/6C5\JVN_0RJ?DOW"H
M[D#M14JP.E<]$-6/B:(!^P=:5Y:8[N>P_P!TJA\]@BW%1^7W+JN4$,_VMUN_
M3V^X+*0,5EO\ZL=+>\\XILEB1/[>E!$C[:D7A/C]G6(>:!T;E$[_ -H_>5I_
M(S'"SE)&!?AZ %2RRP7MM_,NK==?X95(^GB3]G610.D;,7.P:KWH<E2^PP2,
M>W<6:D@Z^[I3[A6AZG)9HG#NE<&.Z$W9,,65&?*V49J0426C:::^%:]1[L37
M@N <$0GX[;.*3Y>*A-:A2[5UI7\/GKX^/170^,TLSP1)&.-*8$&OL*K;SSB=
MQ8<N%]8LMY;S6D0CE5&1#('8R[S_ +L2M3Q)J>L(Y^V-XD<^%E23\5J/+6ZM
M, A>ZM!10MS:\R9MU@BBN(4FD:*Z/MR":'8?2 Q *[R/$:=9WMY-M'X5QW9.
M@JY6S8WNPQ4?6O)7P:PP+'-,1*0[Q1;B"Y_%,4)/XFUKJ>G>MI=0%.)[8FM!
M4I8XKR9K0,T(2.]>=I3^8E6.)G,A(KO8 O3P)\.F>X,C=%^T-!PP/N3-EG*'
M$Z?N4U<2Y%;7/(+;.W5Q&BC9;W4;&)ULFA;6:)@2-LAJ33Q!^G4;M=Q!;W;-
M;Z-\0<'=(ZDSO+"=T+P&YL/$=':K@\6Y/QG)+#;V\F*N&NC;N+Z6]B9%B3;^
M9!AD?V@[:Z'6O6Q;/-L]XX-?(W5UAWP5(N;*ZAX'UH#NMW(P&+QD.(Q($=GC
M;ZYEL[E_95IXKN&DBKL:K?S/IX]3-_<Q%XL;(:RS# 4^^B"P@$(=/=&@=E7[
M%4%YKS"QR4\9ND.0,8<Q!XU A$H3>$8-N;>$%:_3JX[-8.M;=SW"DCM/LK\5
M7=QO1<3:?T&UIZ?Z%']OS3!8YY W&;:[)8C<\DB$:G4@;J^'TZLD#9#"XRBC
MZ8>Q1KB'"@S1>[[GXQ)%6#CV-MT)'X;B56KKX^@&O2='))Q#<T<O>ZME;XX>
MWQ[%SEE4-[UE%<ZDJ!ZI?Q!2:@_M\>DC##B2ZA]*=-#B 0,PHWDYRUS(UW+A
M\*%#4"'%V_I'C2E:5UZ,P,!T,()*3E8ZHP0L7.R:"+%XA!739B[1:?=H*:]'
M<0PZ78%$ =A@MN_T:LW-EN5=ZTEBMHQ'@.,.WL01PMZKW(A ?;K6A/6P^6#F
M^(X=-?N"H//AI"RN=?<5OQ4?^C7]G6SXK,?@N;_Y,I*/D!W9EM9JLG,,F)8F
M3T;XHHRBLK,-RM0UZL=@28CV*-<,56#(R>Z]Q))'#&ZTW+$\:IN*U.F]=HJ?
MIUW%%46\AOPEK0SI'*9ML<8<ZMZE"!Q516OF>DWOT-JEX/G/9[PHQSULF1B0
MOOA:*@<E6HT@(#%BIK0-Y_3J*DGJ^ARJGE,*IIPX<_FT,]PDD5"J*(QN=J:*
M/X=OVGIUXML@Q2K%;/9/$+*[BC19":R1>I9']+0,K4#1ER?$^=>C>.QN#/E2
M+H=3M11VXI>;'DG"NI*/M156HI1EV.Q4$_OZ,+A!].%XO+**2VCM8W]TE'4R
M!4B]QB=Q4R;"REO &M>@-PTCO9(/ ('=^;@D-;*/%P!;FU1E+Q*ACD4IJ S,
MR21C4&0:^?11);<4F8KG@E3)PL+6![.%#5I%#4C=UU !4TJ0/KTI5I%6_+P3
MI@(;1V=$) ^4CLT::2-CNDC0O"LC*&7::C4 4;H4VN*:@$Y\7CHGVR3"WWRA
M (EF$,5#0BGDK >?B>C-:QY#'?*4B'.80]OS#)*[<4LYKJ9Y((O;:/TRQDUK
M3P)(VR??TK]);4I050_5W724\L%QV&"T%K&D#$#<M/9\)!H#J3N-?IX]!X=L
M,*!+?4.ICF5./"+C)8Q?R'Y6U3;2..-DMUK&YJZL^PJ3M-0>EHA&T'P\JIC=
MOUO!ZO>I32P6Y]$]I;B*4&%A2)ZMXM(NX$4\*'Z]+Y)NQVDZN*;V6XA<VMQ%
M<Q6UI*BU4.IBCN'U/MT"E$)'[^NHE/'XE&8+.YW1.]@T;HDA!>2,U(B<'<%8
M^G[>FE,4Z^HZ5M)\% R]CE5XQ$PY3R*JJ00?^,7U"GD>H>\'[<]@]Z>VK];-
M76N8;]8JT@E^=W<6:1%:G%> @DG;^'$7(!TUU!ZVSR^;KV C_P!P?^99WS+_
M -1/8LJ&P]C=3.H0.-"%/J0'3PJ/W]7?P!15VGJ0$?&[8OM2".N^C&@V_<"!
MKT/@#@NPXI3DXQ;11*?975]FU0 !5=U01K6IZ69#W5W=*,2<;LAY;3&H],FJ
MFHK70:$'HW@XH,"O=KQFTV;SLDH^YB0 NA)H0!J /W]=X-!7H0X)5@Q:0G:D
M@<$B@5110/  'PZ*NJE:+$I),K/*05HWMK1:CZ'2K=+M-&A=5>IL9 [;B&0D
MD @U_#IX$:5Z*]FNE%U"OS8]%"MZ**!0A5+!? !J^8KT0Q:<4+/G"!7'VZ2,
MQ+$?ZM!O70L-O@/V=%""<H<XR)FJL9C2FX&JZUU45\16M.A\'B@&('8C:P1Q
MQH75=P(!4'</LU.HZ2D@Q2\9H/2OD4$33,XA12U2Q;;K0$B@'W=)^ CZRS'B
MO<L4)6KC45 VZ#;Y:#P-3UW@#)=]03B@8[>( N%%?($?4T_>.D#;A.M2+7,"
MZD&A8 : #PKI0=(/@Q0U"2_RZL*,HH!74T&@^HJ>DW0_>B/I1=*OZ!4$<7!^
M_P#[:A=_,\ 6"ZBO]#MQNUU\NLH\P8M+H^LJW\L?I?J^]0]^MC;D_(OM[,I-
M8^S%F5  _$G-N3L-?NZ\U\\_YEO8/>O:WD-#X^TW;?U_N8J&W5K;7_&.-WI:
M4$)#$1%IZO:"FM?^MU6MFE+;S3PI[E%\SP^!%)&!E([VN1[CO'I(LDN0$;%+
M>QO?=K3;N_+2;*D:ZTKU?I)"_0.OW%9!,-0<W[9K,;]3;*NLW8CBR.ZHW'+G
M-W, J%E>2\>DK'PJ"O\ CU3.:L"#U+W1_I@V[_"/GID*^H+."QLO>N<="J^N
M>ZM857QK[C@FI\_P#K.IB0'=B];SH?DLQCG6S)(,<MS<LH-!N#&W04\"%*]=
M:0U;J'$)&,=[J3#R)WI"*$EPS>G76J^?4HQF@)S,*,";=QO1P:4H3_F?']_2
M@RHH>7YT* D@17'F*4 KUV62)2IQ3^Q*E(85 &P4 ^T  !B!I7II-Q5LVS ,
MI^4?<EM@F[736@_=_LZ9U."L,M*M[$-;.8YE5?,DU/D I/A^SHSL68J0MNCM
M3KL'M;AV64A"5TUUWZ^%1ITS<'#L4G$,<4VKPQ1S7"QN6U(+'2OJ--/LZ=BM
M HBZH*]J;<BN&:36@'^WS/2M1DJY-(62TZO>4;@E B!K6NOU \=/ ]":Y)R;
MLQQ:NM!3W0#HA (.M=01_@.N%4B=Q*"DGB8*ZBE6"U%?H=/VTZZG!-C.."$G
M*^T*FH/C]@^@^SKF'O);Q_V5$D>XJ2T##4Z Z ?3]M.GC_D"9^)J=U).RJ#\
M+5-:4*BHJPKK7RUZ".NH)C,*]T\4T;JV&UV6N@^@U\?]O3X.4+<VZ%LO3$%(
M%1XGZU)_RZ0>>\DHQI8 G/QR^DL,[C;B+4_F$4I6@8'2A)UIKTRO(/'MW-/
M)O= %[.T^Y2CW"B.0XQGKM88$%A?6MX4\0!= P,:G4#>.H/;#X5XQN.(IZL4
MRW(5CHJ[2M<#'CV6BC-2Q]L$2ML( $91&>NI/B/#JT0OI=5Q5>;;DX\%TX?&
M[-SY'L#V=RDK--(G&[''R2,&W$VT5VE26]9:E!K].M3V4@PM/]5>&?-G:P_F
M:]>>-W)_>*TV^"U\+CY/=L_=,L3?F[M(_<W?S23"12F@'EU8=O\ \R>U9'NU
MK])8:1Q8NH2N@/W?XD=6'BL^*Q__ %+&*\T[8$ &G'.0_P#Z3P__ $=85YJ?
M]0B_5;[U:M@^7TE9K/,0&-/W>/C]O6755A+:&J)_F:JSD%=CE:'Z #72GC7K
MD5)#7)G(])4*#3=XGPUIY=&9\R%?.ED"",B 5KYL/W:?LZ%.*(A).I8UTJ/\
M.F[IM,NE.&@MC#^M9]?(+BAL<O>Y".(F&[NUF#J JAWJY!*_B!%:U^G3PR:X
MP%;MMNO&A$1_1%55:3*74&/3&32S-8+.+B%86(EAE)J1&X.X+N\1X'HF6)R6
MA<M\PBQ=H>>Z,^SBGM@>7P6T:0W]WEI !4)!.$D"'R(D4A2/MZ>6\MM7)6V\
MYOVZ0?X?[C\$O766DS-K=I@;/(WT,25N1>SS1[10M1IH_:MXT4ZDN=M/'3I9
M]P ZC?E47'SVRUNXHF1!SZTK3.I4L]ELQQ'%V4F,S5W.]]>2FYM,3 9+%&(9
MP4FR=XL"O1_*/<K#P)Z:SN\>@/!9AY@7\V\;FV>5FAH%1UUS4YWW-;I()+>P
M@M\79QAD]NQMT2210*!Y;K;[TK;?$UH>FXMQZ5GKI='<Z4SSRB,N$FC(?P#D
M,S%?+W&:K&E=/OZ;7%NG,!KB$FY/(QS12'< &1R"K#Z'R\1TT TB@X*4ASZU
M"N1G8%D#48BO^)IKUW:I=F29M_-(#Y!O.ITKI7Q^_H[/F 1J5!/%-V5E+;]I
M74 G_4Q\/(:=.>-4[MRMMOT+I3_WF.XHVL".U+@U8$>C/Q> !\]W6F>6=/XN
M>P_W2J/S[C;CM;[EU<5_%_Y0'[PO6ZYD_K!9,LJOG8S?W]Q4!B!_;\^@/_WX
M>L-\U33<8O\ XA]Y6K\EX6'^V?<J/1LX;5CM^IU/W=9*,2KN,4H2SUBVUK3^
M+6M/\.GO:@ZDV+M5+,49@!0T!T)IT4H<D6%P[>EZ&O[QIKTDZ5S*$=-$!(H=
M70FAR3/V&(M_=N]DH9MD,)4%I7/\"K0@Z#Q\NH'?7V+HB;BFJGN*?;1%>F75
M$>[^(5?N79,7]U--%C+8M<Q1L(PCHD4<14 R2;U0MJ 0/KUAF\-LY)OV "TV
MRDN0<RH-S61M)+QQ+B,9;!(V27VVGWR%HA^("786*G0^736&&)E!)\RER^YK
MF:II-D,';VMT3B+AZ(2ACNI8_6*[6!4U)'TZD? LY6TD&"[7= <4?PF:F9&C
MM+.<+)%OE4SLS$[/22Q-:A1TP?8[<) X-&!'!%>ZX+2#E1/?C^7O'B$26-](
M4E*VZ6UPT9#D^JH6A(! J>E+>D5R/I\%'ODMV?O\0GID;?DYC9[H2/[T8I!+
M+/($HOA1VVJ?NTZT;9[FTB<'3T,O'M57W!CIY'>!^Y)P[%$&5BN;0D7X5&4D
M +XT\]W["*=:9#?6UXQHM_T<_3E]Q5,O+22U<#)^E7V?TJ,N099H&5;.(DD%
M3*VE"-P+4'UIU+1%M*O^5-6?."HWFENII@\CM3>&)KX:^ ^SI8OMJX!$N,U)
MUM:?F,/;;G4M0-J?$4! /W=04A'B.IE4_>I)F,;>B@35RTJ6J%%=-?%:G\7A
M6OUITXLX_$EJ4G+\V"2K.^0L*O34:_M_RKTK?0Z7!R(W T6^/Z)$GO<K[[&M
M:<?XI0_4?G\@>M6\K_WSOMT+.O,"GA, Z?<5T.?_ ,KK;OBLQ^"YL?E/%:0_
M(+NY<F!F$_,,FTDJ23F8.JQ!C&H/MJ-:'Z]6&PPBZJ*.=\Q/%5=R,EO,A:-)
MD!%/ U<"H!9CXLWT\NDI#WJ([:::GI44\A9TC,2VW\D:LK)(U**3NH0034=,
MKD.='1I.?N*<Q4U\,E$-UD[N6XD:-6"K53&4VE@!0EE  IIY]0DK'@UJ<.M2
M4(:X9!)L=Q-<C<LKRG>H_+I1BBJ=Q92E9-*?=T7ZIWY?8EOHX^GVH_/*$$DL
MUQ)+L'NNX4^R410P1E8;BRTU-/LZ=1R.>T.R3=\;6/+!D$4M\L\@66"\MU@W
M[7W1,RL-**2(R=/L\.C5/6BMB$O$"GH3B>\6YBCCK"A!6CJ/Y4H77:JL-U1]
MHJ.@$A9WL2 CFU8T:JXCK19M]S!21D]U95#-5?3&*A35O0XH-!4]#]:!^B/4
M$0 +RDTL3*"6,:$Q^YMCV5%17:FH%?LITHVX)%:T74&=,$X[7*VLZ3)%-%-)
M$-_LK&0[$HBD>I!6K ]*,O'1]=?2DWQ!]* 8);L9[<I#'<;%D5] (I=Z!!7U
M4-"U%UZ%U\YXTC"O4BF  5("=EI?BZ]T6S+(JA0R/&R! "-0)=/ >73F![CQ
MJDBQO$"J?N%M('N-TSJBF-)3[#[91H$1?:H=&)!U%.GX Z H]WS'M4SX.VMH
MI$#,T\9<.8IG'I)51_+DB"T-/+PKTY@<QK2"!FFDXJX4Z%(+):0*/2[)3<$5
M]5+:>V"#4*HU^G2SGM<*!),^;%$T;'7[-!+%<LP-$K._I(_TU:E1]G28IZ$M
MI;7((2XMDM"2'D55CE_F2%WT,;505J?5^[3KM(X)K"XDXGBMC?@YZ^Q\)44_
M]Y^0"E1Y70UK]OC]G5>W<?M &X8!6*SIX'74KG0_5F[?9'/?-'GV0A16MVXQ
MP@@T\?9Q4ZN"Q.NTM3[:];7R'?V]OLK8Y" :^\JA;]:/?>N?1909'C,V)E,;
M6[>Y3TNB[5^I# $$Z_7J^,N;:7%K@H,V4E,L$DK$Z$_RR/XJ4'C4"M /'7IT
M)K:OS IO]',>!7LO<.CGVR=M33:/&FE*FE2.A\>VR!",+9[10YHZH+Q(S1LL
MCE4UHQ).@%17_'HKIH'9.1O /$(TEFRR(%7<'(W*K*NQZ[:'4;OV5Z(7Q4KJ
MP[4!A<!6F*-OB[J<JL,+UKJ4(%!IYU /27C6_P"8)+1/^7V)4@P%Z/;DAAF>
M01O&P/B-T@*FI-&.WZ5Z*;VW:::@E6QRT!+<>Q+MIPG*WBF+\O-_+V[6*@%T
M;<=Q)8&NGGT5VXVS/TABEXK5\E=0RI[UZN>!Y:V#[XCMU*Z@,0/#<-U"=.DW
M;G:N!;J"/+9N9&7M&(34DQUR))()8&VJ"AHE"!H=P'C6OTZ6AO+7BX*/+)G9
MM1=;=C_\5)O0!5\0H'X?4#0$_P"WI?\ PSC7Q,#CFE@R:@HSV!'6L9F0'VC7
M\7@"2/KXU/3>66",T#Z^E'$<O!N*(+:W!9G$-"#M&T%G_P!)HC:>'[NB-NK=
MKJEPHBR-FTT#4:@Q&1)W"U>3>U*R@*%72GH! _PKTWFO[8'!P2 9+Q;CV)RV
MG"<S?5-O;[5(TJ*BNGAZJ=%EOK8"NH54J+22F*78NT7)[B(N;9OP@#04T/C^
M+[>HB3<8!+37PZ4NRS>1DD'.]NLMCT]2+0#U;4%? ^.M!7ITR]MW"FH57/LG
M$4 Q70G^@O:M9\,[_6\B%6',\+XCS&"LO,"AI7K+O,$MD?'I-<3]RL_+L?AA
MP.=%&WZU6+=^\O;W)JGH';&WM6DJOX6Y3R5PI!(8C<.O,W/===>-![U[,_T\
MW31+-;$X.#L.!P8LWN&9..XX3B[>2,32I<"W(T+(X8J#4Z&GV'JI;(20'?I5
M./IZ5/\ F+9,BW&=C6M#>Z: 88@')6:X!P>>\6_M+B8/!-;7#12-$X,=;*1J
ML=NYPA\NM#AQB;7-><+R-[+MU/EJL+?U-K&<=U.TFA:WL> RV!VN#&\]OD+@
M2,K;OP.E* ?7JF\RDUZ5] /]-(C=M$T43@+ET;@W'](M('MHF#\-_B!W-^5G
M-+FR[?)C([#A+6.8SN1S%TMO8PPR/+'! ) '>6YF>NP#32ITZRK>=R^E8X4[
MQ;ZEM_.W.VW<HVT4>\R,8^E20 2<:9M5P>3?HE?*V^R5W=V.3X#-!+^8]BN;
M*N4>ZDEC4[[<T.PBOE7J,L>96NC#-/>;2N)Z.Q9Q<>?G*T9:V&1NC@=!Q].:
MS[^3WPJ[P_$^;%)W);CTZ9&Y>TC.!R\>2-G.+<7*I<J(@5+IJ*Z&A^G5@VSF
M&WW&1]NS"2,#TUK\%I?*W.FW<VQ.DM2"(]-<"/GK3//Y2JX\*[6\L[L<D7C7
M!,?;9/,RV,V0_+S7D%HAM[=5,[B:ZE2)60MJ#6I\ >K*&$4'Z3LE*[[N&W[9
M$7W3PV*F)Z/4I$R/Q*[_ .'*QWG;7*SE9#66QELKJ+:OB?<@F%5/UIT?P)_R
MFG8JW;\W\ID8W&/:Y?H^R/=^QVBZ[=\G@CC.TL^-8KM0$54@DN--/KTP?!/K
M/=.95PV[F[8 &EDS"S2*8\*(*?M;W)4N/[*Y"66A-,;-45%17T_3]W2+X):_
M*:44S><V[(]@+9F@TZ5\R';?GN#Q?]=R_%,SCL5 \44U_>6CQ6\;W%(HU=_%
M=[N #3Q(Z2,<D;=3FFGXI_L_,>W7;FV]K*U]TZM!6M<,?4*E6%[%?$#O;\AL
M)D<]VHX9;Y^SPM['8Y"[GS]CC-EU*B.B0I=SJ9-H<$D#;U$W%X(W%CJZ>H?T
M)OS1YE<F<G 67,5R(KB3+%]<>C2G#W%_3X^4?;M+3(<K[?0V5K?RO!#/;YS%
MWB22Q(9664P7#)&0NM=H!^O3FUO6W5&1@DUIDJTWS6Y(W9P^FN@689%P4*S_
M !<[V-4)Q!B#Y?U+' ,/J 9Q4'Z]3(LYZ8M*>7'._)]!6=M:=+O@G!C_ (:?
M(*[B'M\)AC+@F..?.XF)V /BJF6)B?LK^SHPLY@:EI]2B)?,7E"TK)XX<*4H
M:D>JB;&:^'?R*Q=P)KGMUD;J"OMC^FWMG?,M=68QQW)8;:_M\NC_ $\U,&X]
MBBK?G_E2]FI]0!Z7!>\#\._DKR^2ZM^-=HN79*3',GYQ;:TA00[AZ0WN3E23
MO'A7J.GW*.P=HG #NL53J[YTY1LA5]T*?K.4?]R^T'<GLMF++C?=3B&6XAF;
M^P7*66-R\<<=Q<V#RO MU%[3N&0SQLM/&HZ*R[9=]^.@'4**7V#>MIYAC\;;
M9M<!K2A)R-#GUIHXCMWS;E$+Y+CW%\MF+"&Z:W,MA;>^B3#:C))M8, HD'B*
M5^[J1@AEE&E@)P2E]NVV;=<&+<I/#9P-2,>C#JJE/*=I^X5E*(9^%\C1]I4
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M'$N+1B4I'<;G$XN9-(!7 84'LR1>9^V\9G]O%W*[AZ29"JD?Z:@ D _;7H?
MMWC40*A.9=TWDLIXKJ* .^W&^V',^W[\>R27N&QMQE;.:6ZQ*R2WDSQRAU0;
MF.U1)&"=-0#Y=1=]# ^W?'0 &F/805>>0MYW>PWFWO#(YQ8YQH<C5CACZU=S
M],O']N^T/:KE=CQ9KO)V^4Y9)<R7>=1X[E7%M;5AC505]E$ ((IJ3UG&[>';
MDD4)ZU3?/G>IN9M^@N)V-#V4[K2X X\<:^U3)\P^XO&\AQCB-M<6=H_N9[(D
MPJ_HDW8MA1BKK39MW?6HZ<<N36HF!S[P6=\EQ7,;R"]Y[YXY=2S_ +;/\."A
M'PUJK(P1&1BW\LG2I9V%:UZU7ZR$@:&-(IU_%:9<NNM0[QII^*67[B\>LI$@
MCMK(F0N(*$22Q!*:%B"Q!)UKIUPGCD[I8T>OXJ-DBF.))->M'3W)P1L&BDL;
M!VF)>4J66@4G<P]:T8=-Y;B-AH&M]OQ0VUG(QWB-<\>E6*^+W<'BL'-L];>T
MJP77&TFD5)O0UQ#D;1$DU8UD9)""?IUE_-\EI)<>(#3L4'S<RY9M[;AKWZW'
M*N&155?U1^TO;?N_G>V?/,CR;^U;O%8JYX@62&.[2[MH[V^S<?N(TB$2(]T2
M"?+]G3/E\F[!+#2-HPIQ6G^0&_7ME<&P<=4;&O<-6=7%I]ZIC\?.WO;S@/*L
M5;Q=POZIB+R(VMWBUM?9%S/<B4)>-20MN63;KX:#K4]A9%# ;F<9]W[>I77S
M+W>YW(.EH&.C?7NUQX8UKTJ^]Q8<'QU%M9A+-$$7W4:&1G$:+4U*L#^&G5@;
M=V-1@U8<[<=P-KXM2'$T[*FE44ECX)=W=K<7-]+#*LD98;1Z4#>L@*0OAY].
M/J['H";17NZ193//J^"&O+7MU[4_M9*65][E+=XE=Y%-2&4M4E"3K].FUQ=6
M+F::-R4A'NV[.T@R.P59>=]D^U?*>Y/$.YJ08?&YGC]K>17$F8M]UIEKN.CX
M^2YC=_RGN6;RN02NNX5K3K-^;[4W.WGZ-SFZ:ZJ4Q%,*X%:#RUS!?2N-G=.H
MUP !X\:]7L6EOQ&[EXS,V&;XMS*/CF4?%+#+;9!,;CKB)X6FD4IN]D"5=M-N
M[\)\*=8=M-P8'2-E<2X>M5#S L-PL[EDEC<S5=4XZ?\ =3H^8/QT[.?)[L;S
M+MS:8SBF)Y/<V/YWC&?@Q>/Q-SC<W:,)+:9[ZU6.86\I&V4>I2OB-.K;M&Z"
M/=8K<.JQYQ/%57EKF#?-GO?'NIWN _,!3V *NWQ>[!/VD[+=N^ \RS'%,Q>X
MFWN8\B_'\O'=6T<RK((VMW3V?<.^1MW@OA4=>HMMB9#:L=&206#-5OG#<OX_
MO$M](1K\5QPXU/I6GOPU[4X:+O3Q?DV/Y/B+J?#7E_#<8E+J.6_MV1()%#QJ
M:K5&'4U8,!N-5<5E?,;C' YH%0\$K=\C6OW?X$'JQG'!9KDL<_U-+HP\R[8
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MXU4PK\5<^7KE@JPAN(*@^ZOKEZ1R/<T4E&1:I(M& <@TUHO6<22OCX*W06[
M4R,KC,K/,)<?=2E5<^DD,SQUTJ0*E]HZ%DY+ 34%*21T>0T"B2+K#9F68W"7
M%TLML!2+U^LTJ:@:D]*B1KVEIK0A)EC?_4 ",ELM+C0TDEU%=6\NZW#AQ29#
M6,>JM0S >/4>V&-DFEI))-/6DY&P^&ZG0?N4BY&/D/\ ;.%BOW=KBZL3.40,
MKNRDJ4HM*ED((KY]/G2311^&TX)C#$QV8%$PL=?Y*VN(I(9G@6)MJT!!1JCQ
M!K0@CII%N#[)X<QU9#G7@C26Y?4-:-*?N7Y'><LBE?(/.VRU$0D<E$F6)"&(
M*TJWI'5BM)YKR:.7BWWT^"0%L8(W'2#JIGU5^*IQR,R?U&Z%LS101R.JQN)&
M#/O>I%3J:=;)M;JVH>_Y@ J9N+'"6I:* ]:85S:7]P_HBGD.[;_NFVFOTT!Z
MD/&XZ6^WXJ-UC\H05IC<NDKK*3;Q FN]R#0UIZ?+RZ=/A@E#7.&-!DEAB@YX
M,7#<!KR=IBFNU=?KH2*#QZ5[K &L:"$C)\WH2SC>26UN/9L;4FI.Y6!\CH:@
MUK7I.4L+.^-+>D>Q(OI2I6[7Z+MW<7G*N]DDZM&HP'%@ 5"J ]]D=:4\1]3U
MJ7EH'"5Q;BS'/L6>\YO$D;1U_%= _P"WR^S]_6R+/:+GB^2L-N>^W=1XYYVE
MDY=>^AF4Q!@HK5?$I7QIU;MN8XP>@?<HJ1P:XU5<;FUN6/MR21AG)  1E!'A
M1=:?[>BO@D)+@,.U)B:,\4@7./MV+I,;J=XP 8MNQBC*1O=BI]"[O ^=.D=.
MDT?DEF$9\$TEQ4<3%%"2AW<-*$$?MQ[BT:[?!G7PK^WH28Z89)0O:@&QJH?:
MWEX2=WM[5!I4 @M4G;]G2.EA2>IZ\_TJR WO[3(6J/0?0H;U>1U'7:&I9EQ&
MUH:X][L1:3# W/\ "8]H:-74"BL2*CPJ".BOB::40F5C_E)JAQQT)&[6_M!Q
MK0H*N=": T+ ])B$ UH@\0 528+6[V2"ZMAJP53+$OJ6I\&4E62M.EBUB+]2
M.E*-OAW=?=]N(*'(95:H=*FGI/H0*!34TZ(;<DDTP*#ZH'BOMSA+28%Q;.I#
M*3M=0BN:U+&+>7333RZ*;<#,('3%_P IR1VPQZ0Q[8T@:2<LI049)'A8*K':
M R4I36A/7"( ]:#6X4)^5+Z6+K''-_3KX7N^@6,!;<@>EMRR +(M/MZ[0Y")
MH^)3NQUK[%O'/-"KF.6=G6%)(Y C4"K*@+K(HUI0Z=.!&ZE>I,G/;J..%4^;
M40/&RM;KL9%DC3WA_+)44W* WCXTZ7C8ZB2<03@C M,=_,VB>VE=#N1;DK74
M*?X*+N8TZ.6D(F:&N;>UB2LD-S&&C5Y)1(TL4)%%74"KNVE=M12G0?<N.:%6
M]MX640B8M1BQ#/ &81LH.YT IKX==E@AXK9KX13>_P!DH)?6=W)^0@[VW$$7
MH%*T%0-O4#N?[_T*8L1^PKPJ54CY:K(O>_..*T;#8.A!!T6U.ZO^GI>U#70
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M!N#P3TINW-S2N^K:'S\/K]_27ANX*7MWM3?N)ZABM -2=1H#Y>.IZ(<Z%/\
M23CP3>FN"&J#0+J &(H?J /.O0H-+AP3?R-Q!<[OSUO%>*"0KN";F-:T]%RP
M#IM4Z 5IT+=.K')"&N) &:+VEA(+:9,)?I*I'_S%F16X(.I6RR$="&%=?=4+
M3I.5C7_*@=XC<Z+9K]!JVN;;Y6]SA=VDUK,.TDBNI*R0[O[AATCEC9HVT^A/
M5V\KXGC=W2_^F"X?^%P^]4_GB0OMFCJ;[EUM@'<Q/@:4ZW_+TGX++<:K,+YP
M^W_?G%MYT_MZ2H_^C&_Z>L2\RF,?NL+7_+X?O*TSDAP9:2ZOTGX>@!4J]RW6
M@0T!\J$Z_L'6<FVM.)*O7BM249GWU6@KI_MIY=(5J4>F&*].S;?][J=:4.G0
MHOH2=<H]*ZTW#S^P_;TD^E!7I2C*$GL25-$LC[9@60%24%!4>=*Z&O47N5C'
M>,TM%4YL9I;9^K(+W<</X=DXXYX&DL+]:[_S$49AFKX@^VE1I45/GKU4[CE:
M/+2!Z0K!#O\ *WYC]Z3,3VDPHN)8KC(6XC8S7$,IN;?<KN58( #6D6WTU^G4
M3)RL026M[O:$X/,!)K7V%'<IVC@2Z@>QO\3-,QCWH9K<1RQEO_C U6$AZ3;R
M\&UJT^L+OXZQ_P YP["B.3[/7=O!.R8^"[LKF,S>[ ('FLKF,-5H]L5?:++7
M[!Y]-I^7S&#+I-&C5ZL4+=X@<X-U'$TR*A/*8O*6UY#BK]Y8C9I7&W<E55[9
MV+,KK4GTG0=0LUNYV%#ZE,6LT4GRN"+9#B<;/%+[?LF:BM)&H]CU!?YE0#M
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M)Y)+9I% :$":BU-22%\17[^E_P#T_24Q9\R)W5BDT<C>W0"+;*(I-A!T4$$
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M_P!/3\W<?*CM1<37:R+^9G?VAZ=NY82T8^H3PZD;)FAV/$JI;T*6G:U=7K>
M_P#*3_UAU-<%12L0/U6X()NX':1KJ^N(;9.)\FWV5JBQS7;'*8L+2]#"2V1?
M.@->L4\S/\]&>IOO5JY?&'I*RB2Z@M=T6+M(;%"*221*/S,BD4)>\?W;F4L-
M35E'V=9<1BIHS .(ZTF32>X^M2*>))+%JDFI8FOCTA(*&G4FUQ)XP\,'&B39
M(@[%E\@/LZ(B0UC'A.S.*)2H2:F3VSX!D +4&O@:="EN.*397+/2($DBFGA_
M\'0!<*C-$"S1R,)&*G7TT!^[QIX]<?:EX_E2?=W$;H(P2'#@D&@TVM]OU/71
M"CJIRTZCAFFY=.I)8>%*:_4"G4K",*I0='&J;]W+7\53H3^SZ=*@8)QP2',*
MI4$:FNGB*$_X]<@HD6X=TJ02X!UJ*>/A2GCUQZ$*0KP,X9O"M3X]$=\I[$89
MBJ;-VS!55?'6M?.E*?X=(@8J2@(I7@FU,S MNI0_;IKTDXFI4]'3PQV)*D5B
MU5U!^A&E/K4^?0!'IT(-(F9MU-P#"J@^HBNH'EUV:$/,??&82!R*XMP'C@22
MW(V@"-MYKIN-#3Z=!4H#N#^A;-_H!/.WRI[G"2.0)_V12%7=:,3_ '%"#7[3
MUHGEK_U@]%'?W2J3ST=5LUW3I]RZ_5_B^\?^JO6ZMS=VK)RLW/F;:8BXYIQI
MKZ9HYEP<I7: Q"F[*A@-ZU(/EUC'F;_U"&G_  _>5HG*;RRR+AGJ/N5/#8\:
M8!5O7!\RT84LQIKI(:5ZR\U5L^IEIDB$V.XZOJ-]M%:?@_\ WN@S0_53\ BQ
MQ^ .J9!=OV@@UK]-W1Q#&\:G9KFW4VO$(.2PP>[2[7Z?[PG_ "Z-]-%TIZ^Y
MFT##BB<^-Q1W>U<(Q(%"6-/#PJ=?\.F4MM%JJ#Q28N9JT(33OK)0Y","BZEZ
M^D_9I]*]$N('#)/,?2BEOB[&XF_XI@NP DZT.FX:U'D!TG#MC7L$SB17W8(A
MN)&'0T5:$I?T_C\!8A(BU-69S6E?($GSZDH+:"I:3P23[J:F 2=>66#D%2\.
MT:^.E!J=PKX?4='=M43SXH. Q]6*2^JG/!-.\QV =WVLC?<3LU\*"O2?TL'2
MA^JF(K1-6YX[@Y79]JDDD^#4\OOZ.-LM'C4YV*'ZN<842!<<+Q,S,T40:OB-
MCGRTIKIY^'1)-KM-!H[%&-W,16B1I^U=G>-_+L*LQ/FZDU/BJ[CH:_9TZL-I
MM)8C&YYH0B&\G;W@,0G-@?BSE.124M<5$4:E&>22FNOJ.X4-/OZEX.7+#\_V
M]:93[I=9:<5,^ ^ L]VT<F3NL7:(2"8_<=VH5)VG;,/ _=U.V>V65N1WL HJ
M?=+P#Y5:_M]\/^V'"S#=9!\=<W,80N(XYF]2"HU,I%"QZD)YIF$1V+AX=,>W
M^A1+[V^G-0TT';\%<#%Y;A7$;!+2U%M''%M*JKK&10#\-6;2G32.&3QO&NY
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MO_!53RTC1U>.M2*U(UH=:D>76@LC,;!K([V5%&SN< :T)389VD))U)\:#KJ
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MNAEO=OGQD3"9Y;F2]R; ZB^<E?9W'\:PIY^%3]G2NS6Q\,3NKD .Q(;B!<W
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MP-&_N%-_\OVE,96@)_F#U!Q]O0:7'@F>H=*30Y16@&UJR+[<DD?I)8[3O*1
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M=5#PZ\\_<J>[[C(7+W4H>5YYF])5GEGD=MQ>BJ222= /V:]:?;^%$TVP%74
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M;JA!-2/MUKM)R(0EO\*N90@_^^'&0Q!KM@RU*DZ>, _RZ6^O9T'V+O""_/\
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M-NE4G::>'59N_)O=H;D7FWSQ"XXD$X]%1IIZTB__ %H\K/:6G;[TM_4CP_\
M[%"%_P#\L7\B#>7(L._O:!<<9'-LLV%YF+K;NJAD,6-DCKMTH--.K%:^7W,#
M(OVLT'B<:.=_NI-O^LOE5HH+"](_4B_WTEC_ )7WY/%MZ_(KL@JL2VV3%\\#
M:Z^H+B:!A76FGTZ>CR\O7 .DD9KICB<^*0/^L7DPN)=MFY%U<:&, GJ'C8#H
MP0O_ /S!_)R/0_(CLF3X@Q8GGC#3ZEL037KO^W5Y^C)'Z2?@E8O]9O*4)I%M
MNX-;QU"-WWRFB4;?_ED_DFD9][O]V;+CP:/$<V/GXD-C$8UZ*?+B].'BQ>WX
M*49_K<Y6:,=OO?[$7_V(_%_RT?R8@!$7R [.T(H=V&YL/V?_ (M8=)GRSNW_
M #31?^+X)U%_KDY6CQ&WW_\ 8B_^Q$KK_EFODW< @?(#LP'(]+MA^<&E?K3%
M>'0?]N]YR$T.D?UC_NI.7_7)RQ+GM]]_8B_^Q*F!_P"6D^2V+9I)OD%V=8E=
MK+!BN<Q[Q]H?%[:5^WII=^6N\S#3XL)P_,?]U2&T?ZYN0K27Q;_:MTDDK@6>
M&T ?_P PQK7&F5,5)6/_ .7:^1UK&D<W?;M)=(E0D4MES1%1#4L-XQLE:GR/
M5?G\H-VF=J\2('JJ?<%H-M_^B_EW:N%-FWN@%*L?&#[;@8>E+!_Y>CY"#;[?
M>GLY& ? V?-7&G@"/Z2 1]*]-?\ LONISF9CVIX/_P!)/+[_ /Y',-/_ )8O
M_P#2B5U_R]7R2NXS$.^'9Y?4761L9S8$-J-$&-51X_LZ4M_)3=87:O&ARZ3_
M +I2-S_^C?EM,.[L>\-_VH__ +U'F8_Y;[Y27WNK#\@.SB5T7W,1S=T *^(9
M<6QJ*]6.U\J;V-H,DD.OCB[X!4S=_P#] .5;L.BL]NW-EN<@X1N(PQQ\5U<>
MM1=D?^5]^5E^S'_O']D5W&K>Y@^?-_\ 6[<8"#]O4RWR]OXF_L98M7ZQ'_E*
MS6]_UE;#=/+_ *.]Q/%C/]])D7_*Q_)\.CR_(WL<RAAOV8'G^[:"*E0V. +T
M&E?/KCR)O-#2:*GZQ_W5%G_5MRXYX<^RO"*_DC_^Q6>L?^7<[^\;XM:\9XMW
MD[/6D,<2/=WDV#YD+O)WJBM;TBT+K:E_%0:%?+JDW?DQN]]N?\1N;F)S1DTN
M=@.H::5Z\**7;_K#Y7$/A16-XW_8C_\ LK[%!V<_Y97Y7<@OI;[)?(_LM-),
M[NX;"<_;:A<E;:(+BR$AC7TJ ?PCJX67EK+:0M9&Z(- R!(]R0=_K%Y>,;6&
MQO21QTQ]/ZZECL'_ ,M?W6X#W%PW,.Y_>'M7RW"\?9;VRP>*PW+D6ZR,+![5
MKU;VSC3V(I%#4"M4C4=3&W<C&WG,DSHR#2F?O%%!<U?ZMMOW'9G6NRVMW%=N
M!!)#&YC#$.)]BUJN/TR.?S+&(^>\(3;J$_I&:BBC)\%B40_A7RW"@ZN#ML#8
M_#CHO*7\Y237)O[K6^>0XUH</2H:YE^CIW+Y0+GVNY7;6"26)(X9)<5R,/&$
M#4WO';ON)+>(IT@-G</TA[5(Q\]0Q?*Q_J'Q4 M^A+W[5W>/O=VI52Q*@XOF
M#,%)\-OY3:33IG-L#WDD%N?7\%*VWF7!!0F.2O8WXJVGQ*_2M[M?'/O'PWN/
ME^Y';S-8K O<OE++#8[DD&5NQ(L?MBUEO(!:JRLFN^FG1]NV5]K-K?2@->/O
M";[_ .8L6\6+K,,> YA&.FF->@U6Z(4[%!_%1*ZGQ6G_ $=68FBR4T)*S,^>
M?PFY3\K.2\"RF O^.XR+BV$RV-FO,I)DXLC;RY#(65TDE@]A!(C(([5E97(U
M;3[,[YQY7GWV[CEB%6BE<^M3NT[I'MX[S:X]2S]L?TB_D;9EH)>XG;C(6BU]
MF6;^O0W7G3W +,*:=4T^6V]:CI?'IX8GX)R[>V.<74.)ZDJ'])#OZPUYUVX(
M\:%\WH:>1-A7HA\N-]&3X_6?@BG>F]!]B ;]([OZPI_>_;A?MWYP_P"'Y(]'
M9Y;[PYU)W,,?:4=F]LKB/N00_2([^ ;?[Z[<4J3XYSQ-/_O#I;_MI>4IJ;ZR
ME?XY$BQ_2"[_  &G.NVY\OQYXZ?_ (#UW_;.\_,WVH?X[#UH'_ZC[W_;4<[[
M:+]C-GB3]O\ \P^?7?\ ;.[XN'M13OT8P -/0@O_ *CU\@B*?WYVS'WOGS_@
M;(#H1Y<[C"=4#FE^6-<O4E(>8HXW:BTG#J1:7]'+Y!N^_P#O[MEX4'JSOTUT
M_)'HQY!WMPH7,H>L_!./YHAK\A]0^*3)/T9OD2[5'<+MA0BE'/(-/#_38 UZ
M:_\ ;&]X. ]:#^:&]!]B3Y?T8/D2Q/\ [^]L3]&5^0@5\B*V->N9Y97H=B1[
M4[CYNB8P-+34=B D_1:^14VDO/\ MDP ](#9_2OV_D0=*=.W>6MT0*.&'64+
M^;8'YM/L25+^B3\CY&T[A]KMA.OJY & K]/R'B.DG>6EWI(U#VHG\UV_!I]0
M2?-^A]\CI20O<+M;2AUD;D0UT\-EBOV^/2/_ &RO>D>U=_-=N?T3[$FG]#;Y
M+A2%[C=JU)'BIY%X_MQQ/0?]L[[B1[4H.;X *:7>Q$W_ $+/DO(Q8]Q^U8)\
M=>0BO_\ KAT#O+;=V?N'- .=25QYOA.37#U).N/T(ODY*KA>Y/:K4^FK\BI3
M=74#'U\.N'ESOWYV>L_!&;SC$#BUWL2>GZ"WR<HP?N1VH-?]+\B\:4_BQU>N
M/EUOWYV>L_!*CG*W_*?4%HG^FE^FCW@^&O>CEG<3N!RKA.<Q&?X/+QFVM>-#
M+?G8[[^JPWRS3_GK2*(6_LQD5#5+>75XY4Y2FV9WC7!&OCGFH'F#?XMT8&1-
M(RZ%N0?#P)^[QZO[Q5M JF%5_O9V2Y'W+SF-R>(RV)L(;.P:V:._BO#(S-+[
MC%3;JR &OF*]9OSER;=;]=QW5HYHD:RF)(^*M6S\P1;;;>"YI+JDUH.*A9?B
M)S85_P#>7C@-?*/(C_. 'JF_]L]]_P")'ZS\%,?SC#^5WJ"\O\1>;O3=R7C;
M:_\ R.4%!_\ @PZ7_P"VV]_\2+UGX)7^=V?D=[$2?X=<W))_N7C/[8,J3^\0
M'I%_EIOY/=FC _6=\$/\Z1'$M=[/BB,GPSYXZ@1\HXNIK4EX,K2E#IZ;8&M3
MT4>6?,/&:+^T[X)>+G>WC=J<QQ%.KXHD_P *>X3,6_NOB?W>UF!X#Z>R.N=Y
M9<P%I!FCI3\SO@ECS[:\(W^IOQ29+\'^Y$A/M\MXE&":DF',U/[[?[>H&3R9
MW:7.1GK=\$K%YA6S#C&_U#XI/?X*=S&8D<NX@:Z;C'F1Y 5(-OY=,9/(?='O
M+O&C%>MWP3L>95LWNADE.QOQ1>;X%]SY%"CF?#*5U!@S K^ZWKT4>0NYT/[>
M/UN^"'_N9;?\.3U-^*$M/@AW.MV);F7#7KX@09D!?N_X?6@ZE=M\E+VV:1)(
MRO:Y<?,RVH:1R9=#4??X,=S&IMYGQ!:5\(<R!Y?2#J2_[/7G"2/UE(#S)MSG
M')ZA\44D^"G=)MP',N&T/\7MYJOI\*C\OKT5OE3OD;Z1S1^$,L7?!)N\Q+9Q
MKX;_ %!)=W\">Z[HRP\SX46(.KQ9R@^F@M2#T^;Y:[]&/WL9)ZS\$F_S MWT
MHQX]#?BF-D/TY.]%YO*\]X&A8E@?;SX())-#2STTZX^7/,'"2.O:?@@'/=HX
MTE8\Q\<DS;W],/OK<EC'W'[?I6H.^+D;$@ZZ;;,4Z >6_,>?C,_M'X(?YVV<
M8>%+ZA\4R<C^D[W_ +XU7NAVZB-3M_X?D?\ JKJ?R-1H.D#Y:\R5/[6/^T?@
ME1SWL@H##+ZA\4WY_P!(+Y S @]U.W&OF8^3+_@,;)TB_P L^:"\%LS /UC\
M$8\][)_P9?4/BFQ=?HS?(B>3>O=OML/Q4!AY)H#]2,4/+IT/++F*5GASW#/#
M.?>=\%S>?-G::QPR!_6T?%:%?I]_"#N5\2,WW%R/.N8<7Y5#S'&8.TQZ\=AR
MXEM),;<7TUP;I\C;6\>R07";0H8U!UZOG)_*5SRX\NE>'5ZS[U3.8^8(]Z(#
9&D-'33[<5J/K]#^'[/'Z??UH50JG\%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tm2127058d1-tbl_vascu4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127058d1-tbl_vascu4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!V .2 P$1  (1 0,1 ?_$ 10  0 !! ,! 0$
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MOR6X-,[A7\D8N'JC!7VR9MF+5!FT13;MFJ2;=N@D0$TD44B%(DFF0H%*4I"
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M<!Y9C,?LLILK=R O94Q$W-8KJ;4MM>8MNZ+%NFYHMVM$SB8-WC9?N9=$5$S
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M$Y-.^4,_*2^R3;]K0SF9N.].7#*F*+ZLG,4"P;,D'#U4MH/1@KWX$DU#J'M
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MLRWA,9/OK)-"#<\B38('CXIT19O&,URB'"JY#K]!U!(HZ#5^&6-D/TI$]YS
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MYO!W=DZ/O.-A91[%HW@RQI!RESQUKW5'MW"*,FC;N3+:;#U#DBA" =4  !,
MAO&K6UMJ>I6&H0R#+'/*UX!P>(V2$L.-#DD8'4_DKR9V;[EU38&P-X[4UBT8
M;B[L+"6U=(QI=!)=W5K$^>,D9F]?I\LT=6D5:\<BU6^I/R,>_P"4YCC+%,#N
M%A\#Q,H90#!U<W#V9)Q,VV Q@#CZB5:+%$0U*(AKTUANS[4X-1NK\0DN##$"
M:X9@VA [Q!7:/VS]B7.R-#V>R[ 9+=6U[*&\?T<D^>,U[L9:>?G7?CZS>82=
M.FN@;>G01VCL[%=F4PKQIT+P76G%6E-6);,XY-('8F83 I=1W^@W"L+.=3Q
M?N<\K''0=.&W%H8453*)"( (E$=*J));2JI+&N/C+%+[&M^6TZ7E+!N%J81
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MP)+G5KD;S<%E-.O);ES@^AH!3"BT[<<X6=TG#A,MS- *FLJ0H=YF B!2J&*
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MTM=A7.>4!7-KJ4\L[(Y*4<ZG#\"[?*^G2SR\L_/?_P![7,I1$1TFH0-1'?\
MZ*6_M&O9W9H7#9ED12A8>1?*/[0X#^US4V.J6@MY>X%J,;882@&OI]FM]C+@
MP4- ND79&NRM;AWT#0?1[&W=]G=4F21N))R(0TC #..3V5.P-0T$--O:W[-M
M1GDXES:'AB<5%12A;3E[@'/5![6@=H1]/9M'HJL/>33,JPP$EGB]:!6A)X='
M>HI$">ANV^B.WI&F:;+4.:3S!.KC\9U6%K6@FA-:GD ( Y<<5( 0=P"/3Z >
MKV:ISSNP'MN94M8UX C ,E*TK3#EZ% E -V@CKN#78':'IWU'7GG=3E-!X4:
MT.&7*1*.>E*<AJ#R]Y2)2ZZ  #LVFU$-#=CTJJ,DC!^E-.' 5XBO<54D;&&G
MBDT' _C89@>]CT<B &OJ[-_3N[6T>W5!F<.4X 'U*5/0C6L=0!KA4G&E  #2
MIQ]7APQ4: .H%T[6T=M29G-H"3T?A1K8R: @\Q%:'U311IL#?TZ[_L=F@DD)
MXX<BDL+31['-[_+WL<4T_)MJ<\G.IR-YDV=C7TQ^_3.\\JI+!7! #=LU]6F=
MXY5.1IY,%(;#"&[4/4]<&[U:X9J/;G=0N!P/J%<MO%%YPWQ6DD#B.9P6_'U@
M8!\XF* T$?\ J&QSMU =!,R7TWB4--1KK?LP,IL-4>PM%-4N''D)\;DY_67H
M+[0\5=9V_@*?1RS&/ #+ZIZ 5JSCK'$;<L9<5YW=/*6M8%H*,$)F8;,%):6D
M).6452BX&W(GK6B,E+N>I.H<%%T44$$S***%#0!VW7=;GL9X-+L6-FU6Y:YP
M:XY8V,%*O>X!S@,?Q6.). "ZOVCM2QUBQO-Q:Q<FTVQI[VMDE:PO?)(^I$4+
M/%#GD#',]@ (QX@?A><#C,R,0ZQC==U3J[YPHS<VW=-N(QEPM52B4K9=J>#D
M)J'D&SXQ@!,"K$7XQX13'?5>GSZTRXE@UBW@A:P5$C'YHSS@E[6.!'=;3NJG
M7M(VC):VTFU[N\GNIGEIMYXA',V@%'-$,D\;FG\L._DE<$^L"^8Q\SC9*RKM
MCY"2*J>.9/K=F&CU^1 HJ+'9M7+1)PZ*DD G/U93<)0$1T *OH=8L;B(O@N8
M"T&A\8 -QIXQY!R=\BF!JL3<;1W%97$=G>65RRXF:#&,A)?AF<!P)+6@N( K
M1KN447Z(XWR$YDG4,WL*\EI=BW1>/8M&V9I609M'"8*-W3IHFS.X1;N"G 4S
MB7A.7: U0=>TIK!*^Y8(\U*U%"0:'*:T/L<YP-$>T=SRW4EE'IMV;N-@<69,
M:$ @FA( -<*FIPP%0ORB\?WS-JK(PUE7;+*MW#MHL2-MR7>G2<L#$*^;*%:M
M%3$<M.M)UB8@!D^(.("ZAK7+K%C;QMEN+F%C7L#A5V)!J!ACQIAR=U39[2W#
M?2"*UL+E[BXC!AP+:9FGD#@'--"1@>XOQB[(O&=2?K0=HW/-)19E"2BL5 RL
M@G&G2*)UDWYF;5<&:J9 $PE4X1T 1TT"HFUFQM@TW$[&%^+:D"K3P(QY<.YW
M5PV>V-=U&&6>QM)I8XO; ,>7, XYQEP<!B6@NP!YA6J,L2]9MH+^%LVZIAB7
MK>)Y%0$J_;%ZE8&RH&6;-#I@*3D03-MV&U#>&E3)K-E#)EFGC:*# N;FQ:'"
MHK@"W$&O"F&*Y+3:FX+VV\ZM;&XE@#B,[(W%GBN+" 2&DN#QE(I@01Q%%P!H
M^1!HZD"QS\T>R=),7;WN17N1L^7!8Z+-RY$O5(.5R-SB1,XE4$"&V!PFTN?/
MHA,VV<\"=[2X#ER>Z[W=Z*K$&RO_ #=]W'!-YM'((RXM  DKBPFM ZE" :.Y
MP *K-6'<%N,KQ=Y2??\ ;6^$&@@QMQ-VB)C7=>#YJ^D(^UV(BHGU:ZT=&+*&
M.''P"*8"'KPK7-?W5Z!EMH9(GROF<XOR_P"JB9E!>['B7/  X4!-<*+L78_9
MQ<;SM;^\\Z9:QVV2.#.T$W%Q(V1[(A0T'B1N)<":'*",05C&$LF\KA[H+!6E
M<LV+5PJT=]Z8*4DP:.D2]8LV<=Q-5C)+HI^N,0=H!6<N=5L[0_[Q/&S $5-*
MM=[4]VM1PKQYL5I%AM[<&I!S;*SGGD:\L?U;"X,>VN8..%*$8<XXT."NNZ<+
MY,M":B;>E;+N$\M.1,9,1;5A"R[Q1XA*1C:6*W0(1F51=^Q;NBE=)$*8R"H&
M(;:%8^RW3I5];ON(KB,,8\L-2!1P<6&O\FHJ#CXN-.19_5^SO=FBWT6FW-G+
M)>3P,EC$;7.:0^(2AI)#:/:'97@ @.! )%";50L:]74LZ@6]H70XG&)DRO89
M" EU95H*RA44>ZHY-H9VW!94W"3C('$;8&H[*R#M6LF0-N'W$0A>,'9A0TXT
M->04Z158>/:VX9[J73X+&X=J$303'D(<*D@5'$5((::%I((#JBB^5>U;G;2O
M>%S;5P(30-Q>&B%8=^63*U*U%X=T+ Z!70-2M"F4%3@X03#B$0#:%;-3MI;;
MSN&:,P5 +JX5-<*^ZKA1<4NW=9AOAILMI,+PMS9: D- J7$5X <O#ACBN -Z
MT1U ! !T[&WTO0J[:]V J0\BO!85]1XP;^CPQP'$5X5KP50:"&NFGIC]^A?)
M7B@ (P&*<(=C[8T$DG.JLK3S43A[5.L?SJ<L9P4:5!<\\JG(U93P>'_7%C#^
MG-L]'_S9K6O[IJ=NWH<</-W_ )I6[]FX W]HV _YC!^>%Z_ #37MCK7A1?8\
MXJ:(E$2B)1$HB41*(E$2B)1$HB41*(E$6.)ZX924DSVG:0I%?)$*>?GE2@JS
MMMNKQ%(DF7:1U<"_X:+<?6D*'&KH E U]!;Q0P>=WM>K=@Q@XO/.>9@X$\:D
M  XD6KIG23=1!0T]L?<]SF+NXN:MRTHNWBJ+-TSNI1R4!D9QZ(K2DBMKJ)W+
MDX<? &S0A>$A    H  51<7DUP QQ(A;P8/:M'<5<5M'"XO !D=Q=RGDQ]17
M7KMT[/8[79JS(7/54F4 H".@CIZGJ]BAJ!4J1B:!=77.+]:7A'EGDGN/;93+
MES-2"/$K9T#,P\=;MJ"!A$ZV0[VD7B,+:J92$']!,95UQB0#ID*8#UI6O[YT
M[1I?,;9IN=3I7(US U@YY'N<&M'>S.X>+BO6G8A]D+M![6K>/<^J_P#PNP#4
M^=SQ3/EGPP;9VT4;Y)W$THX]7$1F(D);E/0MD7GIYU^9Z5>#"Y1R0VA7W&V)
MCOD[QI=MXDBC& 0"/F[L=(V\A(*"(Z'5:/7Y!$0,74-W5U]N;<>MR%D=S<L:
M7$9+"-TE.XZ1YA%1P)!(.*^A>UOL]=@?9):L?JVBZ3/=01ATMWN>^@M^MY0Z
MWLK;TB]@(I1LC(G#@158ZN3ZMKZRO*5O(RC2Q<OS%NRS9*26B,M9-M".N!X<
M!(NW,[M=]=O=$>Y*&AA1=%*NDIL-H(5B;S9&^=1@+XQ=.M#2L<\K YQ&-2P/
M>W'F+L*<%N>V/M<_9&V%KC;9XTF'58SE9<:382.MXFD&HZ^2&"5PY"6Q4(.%
M5J%"RO,SR09GQ<^RC9N0K1<8LR.QR!&V==J#]A#R3\BK=.=5AGIC*Q,D>6BB
M&;*.6JJZ8@.@F$0&M5AGW)M+4X)=0;/#'#/UF1U:.)!#L?:',VHKFY5Z,U6P
M[$?M,[ UNTV-?Z5>7&L:9YF^Y@ Z^-D9:^%LC'!LS61RMC-',%.08T7:%(?6
M0\N6.^;O#_,OC&5RA*XNNZW<GW9F7 Y&)"&L++=Z6TXCEI6 9R<@T@'3NY)]
M1NH]6;O3(=0115/B4'JC;[)OS0K#7[?7-.=,[3I6/=-;M:*QS.80#0D,JY],
MU'<I/'!>,M-^QQVK;I[&=>[,-X6^D0;RT^[L;;2M8<\TO-.MKB-SHY'LC?<"
M.&!A$+'Q AS(V4:P&0=46&,_\TMNY1NMQRO7!DFVKGRK<[J9>VCBM*1E7LTJ
MK*OI)DQ5AHUJ]6DTXSOD<I0ZHP 01UV:Z=>Z-KNXXM3>-O27 EN)7/=&RI)J
M2:4P'##BO<W:1V8=B-_L.P^NVVTFXT_1-.9"VYO,K>J#(F,D?&]]'#-E!%!F
M)H/;$!=J]N<^GUE>*@6;Y'OZX+$.EP%;K\T_+W=MKP;E<0(F9LE=D#!2Z"(*
M*B()JNRMT3:E$3@ ZAVA;[DWE:#J[JY\WE)%?.[9X;4\@?$V6GJ@ <Z^?]_]
MG[[*.ZY#?;4TQFKZ<206Z#K,3[EIQ()M;\V#2W#_ %<CS7"E:!=L_)-]9Z?*
M,\WQ!S/1%L8TRG*IHN+"O* FH^2Q%EIF<J)>KM2[&TE(187$<ZO6 Q*NH)T]
M@"50HIUONW]Y.NKKT5KC(X;PC]'(QX=!-2@.1^%''B&D"HKRBB\?=NGV5(=J
MZ6=\]D=Q=ZMM%CB+NUGA?#J>G.J32>W()?"SVCIXW/:'XGQ7M<>XLJ@' NFP
M!*4W%KV=N@"&S=TZUOQY^ JO%%"#0A2=(BI3%4*0Y#E$IB'*!RF*(" @(#J!
M@$!Z=E1EY4Y*+!MP8/B077FL>R4ACBY%#*.%7-M+':Q<DX, ' DO#!UD:X3.
MH74QP1X]HCM'95_%>-+1%=MZR+GX.'>*M9+>IS0.+'<W(>^IM:XLC@5S'O$H
MB<EX0W!-Q$H<]NSF@ZB@\B7K5!Y#S,<^#4$%SI,BB8HE.8IBF J\MF0N;)&[
M-;/Q:1^:1R.!I4>J%%M</D!9(*3,-'#N<XYU>+?)<*D=)"YF,S8KI4@F EW,
MTF4;J Z=26YV+B1M%5R?>1$D@94X;0+L'2R(HKL&JOUNZ0=HIN&JJ3ANL4IT
MET%2*HJD, "4Z2J8F(H0Q1U 0'0:(OHHB41*(E$2B)1$HB41<)<W\W)_MPLH
M'JL5PK![G_[:U'_ S_[)ZD<0O..8.GL*>KH(#V:^$%]A?SM/ 2N[A/C'E6BE
MQP)]TFWL;>W5ID!PQ#CR'NI5W<4:U26D&A0DA &I !P. H?8J@*:COZ*9:@N
M!\4449CP36J4S%-:GO)F*:U"9BFM24S%-1J$S%-:)F*:T.*9BFM**<Q36BC,
M4UI13F*:T3,4UHF8IK2B9BHUV5(P4$X+L9^K[_A;)&[]HV]T=EQ*!7T ^PZ,
M\FX:TI2SY/\ %+.:*?&D'<'LKKP>CH\=_NE;]<-7@F_%+V7^L=[*PTA\=W?*
M^;6K149BFHT3,4UI1,Q37LZ?D]2JB&M S$UY0.3V/6JI!)/)1/3#[/Y-:G(2
M?%(IZO@XIFQH>*:_D^]VZC*,<14=_P!;#BF8U[B>AH- S,1EQ0NHFOJ[/M@
M^D&M,K2W"N8"M".Z!W<,:U3,4U&A! .!H!]P4!R#LJ'-RG*5.;F36HHF8IK4
MC!1F*:U"9BFM**<Q64,)C_UO8T_IO;G\IMZ[5[#RX=K.A $@&^;^:Y75CC=Q
MD^["] E?;1;>O+/SX?\ >VS-_'<'_P!%+?KV;V:_]EV7Y!7RF^T*/_UNZF>Z
MWV%J0.@&-KOU$0V=D=0VUOC?:#O!=(GCCQS??3388=P!H)C &T"@8!$==0
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M&<7G%QYSRGU5<QM *(;O6CZ :!TU; T&/(N>E>/!:Z9PRIEG&K5FZQO@F3S
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M17(BL7N)Z[07 IR@<NA@T 1$*WNP?YS%)94):]N=O\ES 75QYV@@]_@O.5_
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M@?Y:#[ZVR;OTC(Q_=0E8NI!(ATF+E=OW3UPI JLV+U:ATUE6XB('ZLQRZAJ
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M;,ZKB"]C2UPXM=5P\<' @T-<,."URSVMNC4(&/L=.O']: Z-T=O,_,' N!%
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M1JM(1SM=+]"5(0"J /K1"MET[6[+4]-9J]A.TVW5%Y#<IRM;4EKL31Y:,:]
M77VO;/UO;VXW;<O+>2#6A)U36N:]K),S\C71-(!D;(2!F::$N-"LUW#@JR+(
M+*3-]7E.H6Q"SB=EII6_#,'\]<U]1;%DZO)E"ED)"/C6EM6\N^*EW<L<YC*:
ME*F<P:5K%MN;6M3?'8Z3:PF]FAZTN<7Y&0N<6L+\03*2Q^ <S#*.<KLS4NS3
M:>@B:_U^]N(='@E%L!&V,RS7+6"25K"X%C8(A+'^D(<2XNK@ !:=_29,@26.
M[1L2[9R[HA1NG%0-NS%J1]L2%ORC]X1EW$\0@EG<7*NGPI)G%Z0YCJD_X0""
M42A>Z5&[38;K4=4ABMYVO!>Z-[GLE;C3*9'.<UH)%0'&G <ZP&Y[R/<MYIVB
M[5O;N[TZ5N6*":W9$8'$9BTF%C ]YRDAY&.7$XT7*7U@9&S\HV'8C*[$;C@K
MZE8"(8WHR8B5F5ZZG$K:N1!LU[I5([/ 2YCD']%+Q$*4QN'B *XM)W2[4-'N
MM1\W$<UM'*_JC6F1K'2QESCCBP-<:8$^UP7/NOLV@V_N_3-O17(O;._FAA\X
M:*^,Z1L-QE##_JWEX!J:  OYCR\]@BU7C&_OF\NRZ9J:QW<$5 RT1=%HL8%"
M94E+B):Z!K<D(JY+@(Z=&DUD^%NL1%0Z0B8 V#5I9;HU*TN;9^MPVT=O=1.>
MU\3W/+6M87FH=@" #S]U9O5NS+:]Y'?C:=W>RW>GW$44D-Q&UC)'NE;$T0N:
MZKG%SAE&)<2 *\G$R^.\)6A*NK+NZ_[Z7N^/,DUFI.T;2AY6SH"6%/C=1X&?
M7 SF9Q!BJ<J2ZZ2;;@.4_ 10  3<T&M[HU1C=2L[.V;8D8"5SVO>VOMG.!:Q
MF'M06FO/@:8RYVAV<;<>_1-?U+4Y->B=26:WBB=;PR$5R92USWMX![L[:4PK
M3''-P6&RC[#M2_(274E&$Q,7!:LV@X9]R*Q-PPPM'S<"%*JL!V$K#/B*I&.8
MI^L26+IH0=,Y9ZM<3ZI<:1J#,LL3&RLI^-&3E>*GCU;RP8#@?&Y*ZKK.U[2P
MVS9;BTJ?KK:XGF@FX#+,SQFY0VM!(QLCJ.-1EHT$ D8YTTV::#]G<&GI:;JS
MAJ#3BW"AYZBI]>JTF,DMJZ,QGF-:]_'GXCN+)>%VY'.7,:H'.L0JU[6VF8Z"
MRC=8H'E&Q1,DLB8BJ2@ .PQ1 0&L!NHTVW?'FMI/S2MX[-6CZP-'./\ S&'\
M\+UE!8,;I_#M\;Q_UYNG9M$ T_RIT5X47V/Q4^(,=\?7S\NKI_&E$3Q!COCZ
M^?EU=/XTHE$\08[X^OGY=73^-*(GB#'?'U\_+JZ?QI1$\08[X^OGY=73^-*)
M1/$&.^/KY^75T_C2B43Q C>F=O@?1OFZ?QI1%^2F/VV@BTNJ_6"O0LG=LD_,
M4.P",V,JT$/13&G%."_,]N7FR)_D:_3+J% H%)=UNQ\TW'A -1'O"O9[L3#T
MB*PAVNRP3%%'64&A2]5%V)/F#AZTXS,_:?'N PHHFA+O+KJ.PIE0 1V"8-]$
M4.;WEX\A1D,=7H)@$"K*0Y;=G&Q=->,Z/<D^2273+ILU:D4-N FNRF*=Q5-,
MGV<OL?/GEMJ /"*5XPTU9QN( U$J*ES1\6W=]HR)U"&_*F&B*YHRXX&:*)HB
M<AY4"B(&&-DF;X"& =! PMEU *(#O =!UH0G$X*U+Y$'[BSX#\(DY=+11P :
M!^PX%JZN%3;Z[0!7C4BCKL$#:=-9+3\K&SW)XQPD#\IY#1ZQ*LKNKG10\0Z2
MI_) Q^\LC5C5>KY7;E%FW<.G*R*#=LBJX<+N%2((H((IBHJLLJH8J::21"B)
MC"(  !J-4YF-)J:&E>CE5;(Y)7MCC:72.<  !4DDT  &)).  XKSMY)S5EWZ
MU3F$OCE6P#=)\<<J.*7::&:\G1"JBEP9#3"06CEXN =(E5:%C99PV<$8H["+
M)-SNEE#D,FA745]JFH;[UJ7;ND2=3H, '7S-]L\\K&NK0 TI7V*4/TPVUL/9
MGV.NR[3>V3M&L&:MVU:XQS])T^<$6]@UK6N;-<15;)(\%P<XU:T@B-@!:Y[K
MY^JGY1,:QEU\RW,7:L ZA+(NZZ[KPEA>$5=+.2)XYL]R>W+FN%TX6*<TBI=D
M]&%-UP*"4#ME1T#C H7.Q-KZ9:W-_J]K'DLY9'0Q UQB;0%]2<<[J\P\7!:U
M]L#MYWAKNW-H]E^NW7G.NV-G#J6JR'*'.OY_&BA(8&B(015.4"M)6U/BX]E7
M(C%N;6Y?VF.W1T#+8LR'EC&:945#*<$79N1KDBH$#B8 $JPP";43AH  <1 -
MFE;KMIIBTHVQK^@GEB'>9*YH]8"B\J=N]P=2[0';C=7K-8TZPU!]>62\LX9Y
M:=P2O>!Q.&)JMJ+EN6'M.*<3<\\;QL4T4;%?23M9-!@P27<)-^[)!RL<B+)@
M@94#++*"!$B )C#H UFYIXX(W2/P8T@'U?\ *NJ=/TZ[U2Z%E9,,EVYKBUHJ
M2XM!.5H%2YSJ4:T EQH!Q77ES.<^]A67CK/+'%-\VJYS3AN#N"?=VK)NFBCQ
MEXD*M)"12F84[I&02B+E3 C%BZ3 Q5UGR/5FX_6UJ>N;HM;:QO#ILL!U&VC<
MXL<X8!F)+A4$-/ .I0D\J])=D?V==T[FW7MH[OT^^M]A:]?V]LV[;$\1O\Y>
M8QU,KF]6Z2+%[V@NR9#G;1;BX0R0OD_'MI78Y4B'SVX;6AKA>R-K*.']D]U3
M+1%X=A;$^H)DI]DP%04Q72.<HG(;B$IO6%V/3[GSNW9< U#V!U1[0U]R>4#G
M%5T9O/;QVSN*\T8LFB9;74L(CN ([IO5NR_[Q":.B>>5C@TCA3E7GRNV^H6V
M?K_HY6058-X&8M![9<XHNLV*W(#W!=P&3*NJ<Y4D#+R;-ND<#B E XZAJ(!7
M35S=Q6_;)&'THZ$@G_\ =W&OJ>QCR+ZAZ!M^YU?_ .L2>2!LAU&TU2.>#*"2
M2=<@C( &)HQ[B*5Q'<6D/U0W,OB+E[YS<B,KQE8.V[$RLRG[/MR\YAZRC(B!
M,A<AI6W2/Y5VY08L8R5;(%1XSF @*BGJ8  *U7LXUZQT;<]S;W#XX[:[<X->
M\@!KL[LN)(P=@.A>@_MR]C^]>T[[/FWM5VY#=7FLZ!!%/-:Q1ODEF;);P-F>
MV)C'/<^/*Y[A3!K3SKT4<Y_/QBW"V!YVY<89<Q)=&2)>8M2U;/@(R[(*\'JZ
M]R7#&1LM)(0UOW0S>&[RV^Y=/"K*+)MB*I)\8F*;@-W?N+=5CH^GF>&YMWSO
M<UK6AP>XEQ J&M=B *GHJ<5\HNPO[/6[^T??T6CZ[H^LVVV[>&>>ZF=!);M9
M'#&YP!EF@<P&20-9ERN>0791@2,A8:YL8>ZXA.%RFP3QY.!(/V#,M]W'8T9(
M77:49'L>NR0Y@X*XKACK:M^5D9%-FW;K/UE15.4IS <P%'(66L,>W)>Y(9"\
MAH>YN9[1_K"T.\4'U14@85HM)W/V8W=DXZAMM\NH6>1I?YO!.YD$\CB6VHE<
MT&61K&/?G#6!S8W%H(!<-"_K0.0:"F&#_G=Y?DE;4S[AX(C(3IO ,&SN%OEC
M:"S62[Z/(TB/K)N)CF(* X(<4EVR D53,(@H&D[ZV=!<L=NW2B8M9M0)#[B0
M18X@"M<K>(.(XKU?]D/[36JZ/=,^SUVETU#LOU]S[&DKG-GLWW>:++%(YU!&
MZ62I:]I+7$EA'!9?Y)_K/;<S5(PN&<]M[?QIGP;?M679.&,HV4Q]D=C=EN15
MPP3ZU9E5XH1E.R<?(E,>+4.HH54#%2.H)3$)D=L;U9J<C-.UEC+;5LC7"A_1
M2-< 6EA)]L?<U.//6@T+[0/V4+W8%M/OOLTEN=8[,_.IXG9HG"\L7P2NCECN
M8VM_5QD BXRL:6N:YS0/&/;GU*2A=!XCZ"(?E!'7</%ZP0U]*NPP*\<1SE>,
M,Y PXC#BK.R4!"63,$T$3&4BDT0#37KU)F.*W'8&SA7, ^E62T@'S]M/<OZ.
MK=7UE8ZCC;&ONV?GM5^DUX0UW[=?1UV_9K&A7BJJ44"&O]RB*WYRU8"Y$TB3
M,:@\.W-QM7(\2+YFILT59OD!3=M50T_"(<H^E3DHBX$MAJD "IWS?I"%#0A!
MF6*O"4 T*7K%XA593A*&FIS&,/2(CMJ:]P***KQ&<>7=^^%8S\2TKWE*>(SC
MR[OWPK&?B6E>\B>(SCR[OWPM&?B6E>\HHGB,X\N[]\*QGXEI7O*4\1G'EW?O
MA6,_$M*]Y%P]Q62X);\X?QXOI3@B)(_ I*1HIGX6:QN X!#%$2&TT$-0U"L+
MN5U-N:@:#]AG_P!D]*5P7G_*3A3* F.<2#P\1Q 3&T /7&$  !,-?![5'F34
M[@D4_22?G.6BXAO\Y:R75!S:_-MABY$(:47MV*P9S 1$I.),'2L/'2DS>6 '
M<1&OY,B7<;5_*-H5XJU1.<JBY&BQB ()GTWO2[RT;V7:MIO6QMU)^L:?((G.
M;G=&R&^:][68/RL+V!SJ$ O:#3,*\S3EB?7@<O\ I+2.\<8*VE:>6[[4P6M>
M5T7OS;ST;<5PW'C6\<F2UL8?>.VCUO><)CV$=1]P7G:T=)13<R3-B?N4RBYG
M1B*E1.0>YMO[D;J6J:7HAU9MKIUGMV-[(X[FWMHY+P%K#!+<2->R*5S'/J2!
M( TM&7-5<C<E&C,UOB#FYONZ%CZV;(OAK'HNKCQYDR=Y:K5YIKCN&\,9)X>N
M6WI.Y<?7)@RRALVX+=P\U(M+/[+@,P2"\B^CFR*ZR:Q55%4 <)+HEV/6-=T6
MYO2S3+_2K??$^WXXX;DWD,D<5S'?3==%)=U#!,^T B9(XMJ"T-):YI/(W( 6
MN>TX=SGX\>99\L_"N*LH\P-MW$A@:Y(;#L?@R[F,/#7]CRX+0MP]S/LH(G6<
MJ6O<39MWN>R$:FHNQ0>(-W1&JAU2H)E. CHNL;OW)MOL_N;0:U:7.[GZVQSG
MVUS#/*(1;,'MXJU8'@M<\5!(#2XTHN)Y#&!A<TQD'F[GW?A6")['>48BV.6]
M6]K?E9/&5K8@NFRD[?N/EYR-S!O[4O1A=KEO$N[ALNUKNMJYFJ\Y8S5FSC9%
M9L]32!L<#G2%<IS]@V>N[,EUK<$6AW$,>OSZM'.98]2M;!D]NZ-SB(KB:*:-
MPCDSNDC9E+G/!K1M!R9F.ZS-2E?ONY_9Y1WL?LF;*NEC:6(L=WUCN\KPA#XG
MN=Y!7I<'+-<N0;Z;3=Q79-'B,1&MZ*O*ZX#$GBQ '8F2?3;]T91MPIJ.$#MU
M1KCTS5M!.M:AKVCZA8P2'4H62V[=3M[>VR11,$EV)'Q1.O#+)GJ(1$S,2X!P
M()@-#Y37#QA2M,?N[A]9=E_*Z%TEY;L"DOEO.M+S3P]CA*ZVMSMGK.Y&UQ)6
MC$)S"$\UDB)R#>72?E4*X(N4JQ50,!P VH5Y>[1CIAW]J_H=T3]*.HSF)T3F
MNB+'2.<#&YGBEAK5I!(I@"0%:RD%Y(XU/LE9XK2E0E2B5")1$HB41*(E$2B)
M1$HB[&OJ^OX5R1^X+?\ WQ*5] ?L-_K=P]ZS_P#<K/:-[:3U/977>^_;KO\
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M5L=HZCMVCM[.W[E;U4\#[<  ^H !ZU%TM^C>2]IS$N-3W:E93P?H.8L8[/\
M7FVM-?XV;5@-T?\ ;M[_ (9_YI6Y]FV&_P#1QR^D8/\ :!>ORO"B^R241*(E
M$2B)1$HB41*(E$2B)1%28I3E$ARE.4P:&*8 ,40'> @.H" T16P_LFTI(![L
MMJ"6.(B(+C&-".BF, @)DW22)'"1AUWE, TX<$6*W^.8%&_[49Q2]P0XMK>N
MR3!:/N:=,*#@%[>8(*(M'[Y[';$GJX:&1,70=.'L9&$ENF3'#];'[#ZJSD \
M\B'+D>?78K[\5KL9)&"/R)*KG !!/QAA+?ED^(=PJ][&5O.3E#3<"I!$!':
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M'@OR*&\1$1UX@$!)J \0@(_A%'0!THX$MR4\2@%"1A3FYN^I:^;JW,#:,=R
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MQ65[@ .<DT'231:1\D\8:[K6O[F3F$NLNKF-R'<ETIKNFW [C\<VA*/; Q3
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M.1C7 ]S&M.3DQ_R+PE?29]=OI'4SR3N?S5J34@5.%3S^J5M"4Y#@!B'*8I@
M0$I@$! =P@(#MJR5*JHB41*(E$2B)1$HB41*(N+G'*S.%EW;8P%<-8Q\X0,(
M 8"JHM55$S" [! #%"L5KMS+9:)>7D&$\5K*]O<<UCB#ZA 4MXBO!=+8<X6?
M-#:W<AIJ(!_D.'V[=@ (,J^55W]JSM@@NWV[+NVR,>X?J1P!( K7F6K^EKO'
M%O'# )YX6??*]OX"AO@=6_\ %GVR_*[2G]1_34>EKK^37O)YX6??*]OX"A?@
M51_%GVR_*[3XC^FGI:ZY:='X4\\+/OE@W\!0WP*I_BS[9?E=I\1_33TM=<E.
MA//"SYY8-_ 4+\"J/XL^V;Y7:?$?TT]+77<Z/PIYX6??*]OX"A?@53_%GVR_
M*[3X@>_3TM=<F7H_"GGA9\\KT/ 4-\"I_%GVS?*[3XC^FGI:Z[G1^%//"S[Y
M7M_ 4+\"I_%GVR_*[3XC^FGI:ZY,O1^%//"SYY8(> H7X%4?Q9]LWRNT^(_I
MIZ6NNYT?A3SPL^>6"'@*%^!4_BS[9OE=I\1_34^EKKN='X4\\+/GE@AX"A?@
M53_%GVR\EW:?$?TT]+77<Z/PIYX6?/*]#P%"_ JC^+/ME^5VGQ']-/2UUW.C
M\*>>%GSRP;^ H7X%4_Q9]LORNT^(_IJ/2UUW.C\*>>%GSRO0\!0OP*G\6?;-
M\KM/B/Z:GTM==SH_"GGA9\\KT/ 4+\"J/XL^V;Y7:?$?TT]+77<Z$\\+/OE@
MW\!0WP*G\6?;+\KM/B/Z:CTM=<E.C\*>>%GWRP;^ H;X%4_Q9]LORNT^(_II
MZ6N_Y/0GGA9\\L$/ 4+\"I_%GVR_*[3XC^FI]+77<Z/PIYX6?/+!#P%#?;!G
M4'[67;-\KM/B/Z:CTM=<XZ%N7R@9GR+E1]>R%ZS"4J2(:0ZL>5-@R:"@=TJ_
M(X,(M44A/QE1*'KM=!#9TUZV^R]VL[T[3IM9&[9H9F6;;7JNK8&4,GG&>N)K
M7(SO4[JRFF74UT'=:14+3MSS?Y[3<N$RW<@4B:ZI"!WCAAT*50P%#468B.@!
M7E*[^U=VQP74D,=U:!C7D#]"": \^85[ZQK]5N6O+<* \R_#SPL^>5Z'@*%^
M!5;?Q9]LWRNT^(_IJ/2UUW.A//"SYY8(> H7X%4_Q9]LORNT^(_IIZ6NNYT?
MA3SPL^>5Z'@*%^!5'\6?;-\KM/B/Z:>EKKN=">>%GSRP0\!0OP*G\6?;-\KM
M/B/Z:>EKKN='X4\\+/GE@W\!0WP*G\6?;+\KM/B/Z:>EKKN='X4\\+/GE>AX
M"A?@53_%GVS?*[3X@>_3TM==SH_"GGA9\\KT/ 4+\"J/XL^V;Y7:?$?TT]+7
M7<Z$\\+/GE>AX"A?@53_ !9]LWRNT^('OT]+77<Z/PIYX6?/+!#P%"_ JC^+
M/MF^5VGQ']-/2UUW.C\*>>%GSRP0\!0OP*G\6?;-\KM/B/Z:>EKKN='X4\\+
M/GE@W\!0WP*G\6?;-\KM/B/Z:>EKKN='X4\\+/GE>AX"A?@53_%GVS?*[3XC
M^FGI:Z[G1^%//"SYY8(> H7X%3^+/MF^5VGQ']-/2UUW.C\*>>%GSRP0\!0O
MP*H_BS[9OE=I\1_33TM==SH_"KZQCS49LN/(MD0,M=*+F,F+GAHU^@$-%)"L
MT>/D4%TP41:%4()DS[!*("&^M[[,_M*]JVY]^:5H.J7-JZPNKMK) V&CBT@D
M@'/APYBKFTU*>:X;%)3*XTX+M^KZ<+/+RT<^'_>VS/\ QW!_8M* ^]7LWLU_
M[,LOR"OE-]H3_P N:IWV>PM23;Q&M[;[4=Y=*$^,1W50(:U4#14N;F%$T#33
M4/5 /L4Y5& &15:=L/5"BJJJ1*(AIJ&WMU/#%4NJX44%+P](>K0FJI8"SBI
M=1Z/5J,%6'&N-%08 $1U, #Z55"M%QN#":DT*J*'".T=_P"3LU!-5+6Y3R50
M3>NT .D* 8502&N555"Y:XT2B)Z5%202<"E%5[";A >T/VPKBD]H[[N0KG@_
M:(_N_&:M^/K!?ZP\4?\ ]"XX_>3@?NUUMV7_ +%J7_Z5G_.7H#[1'_-= /\
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M&#S5ZLEM?47=61! ES6<=9-!=G<UE.X)=-<A%T')&:"$JBBHFIQHK$.W.MJ
M@(&*(@.H5W/"[K=*>P<&2,?ZCAE/KD+YN7WZ+6*GVSS(WU02[[R^T]A.H'5>
MP)E2WB:\1K;>D/)6BXX2@4J2,<JH"T 40#>P413XA$QDSB(ZV#> #N[[*YN
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MY>_$AR^8KS=C-S:J<C"J8MO9".EIU=N94)"3@%9!^NO<JC<J)SJ1K)DL^ZD
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M*H0P )3 8#% Q1#: E-M*(#T@8 V=FB*NB52BBJ44U2B)115<)<H_P"CD_\
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MT3ZY(=U1E\&WG7S)"_(0 UG5ATAPIXS@79 ?%KP Q5UL+HM"R&N0WC_*3/)
MY&EK?/&1C5M<AG#([&ZVDVK==R%EXYFDRD8B/1%-)),RYE#K&#4" )AQT]G<
M:G/:]1IYM8[1S\[CE&!;E#&TQ>'$5+C7@*'%9Z#7-!VY9ZK<7NM^E3JKHNJC
M E=D+9,YFD#Q2+JVT  I4N-1Q)_1+*%D>-9),9P.XO.VN/)0*]ROA ;,D#H
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MEKEQH1B:XX+);8W5HFSQ9Z=J>MQ:G/Z6CNNM:72-MHF%N9Q>X$ATGN:Y1E
MJ:'7N1O9A*X4DK;DI5P^NA7,B%U-$'9W:RX0RMK2S-^]*X4 Z"77R2B/&43
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M >M4! VI3GD$19I<)BZ_AF<!H(5E-*#?24!?[5LK2>\T@_>6!OZFRE:WBYA
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M+A5*6'DC"F:)M(I5 *R6-P&,2 (<"FTT'00'2L)N4Y=N:@>7S&X_V3_82E<
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MM]%_@O$F:XM2ZE,=,JNIM*VWJ<\_90-NZ)K-GINN>F#,^.2=ENY\/5$82N(
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MD7[N*@V2LE+=ZSJ_H"LJBP;**((*&3(X4*5(3I\?&7TS>7#K2U?<9"]L8+B
M?&+6XNIR$TK0&@)P) Q'P*VMH\>X=PV>@OF$#KZZB@:]WM&OE>(V.DI4AF9P
MSN <YK:N#'D93U@<I'UI;+F*NV$L^Y\</<<2+QB1PQ-(C)+OKK:G//.GEVL6
MZD6R@[5L&#@(=-=P_>R*IW+Q?N1LB<Y2G/I.W-]0:[((IHG6\A( S&I>#F\8
M"C0&-#15Q)J74 PJ?6';?]DB\[)])EU_2=5AU?3V2N9(8F!K+=X;"8[=TG6/
M?-=2NDD B;"QL<<0D?)^DRQ]LD#<-J7[#.'L!*0UTP+A5U'+NH]TTE8U=5 Y
MD'S)0Z)EVYSHG 2J$'70=@UOL4S)QGB(,?.#7OKQ[?Z=?:9,+;4(GPSEH=E>
M"#0\#0\AY%A+)[&5L"TWZ425Q,V.X>PR*\&)U%I6U2J33$HJP1C]8K*PF@Z&
M8:@LV*'['ZPNB 973&EUV,*^*X]#2L-?&D&'NFC_ #AZW.J6F<<68VMM:9NZ
M[&4-:\[E)Q;5OSBJ3Q:,7D[P40F8QN[<MFRR42FY=29R=8Z%)(AP IC%,(%J
MTUV\MK!MO<W;PQDL;!4U]M5T8KS#Q1B:+8-F[7UW>-S=Z=MFW==W5I%+.]C"
M*B&)@DD< 2,V4.Q J3R K3WZY:68Q?(9D&:!\K'RD+=V-9JU9%LJJBZ9W1'7
MI%.89RS61 3HKHN""8#;"AH.H@&M:%VAR&WVC=W+#21@8YAY6O#A0CNCN8KT
M_P#8BLG:C]I+0=+?&V:SN#/'/&X5:^!T+A(UPQ\4X8$$5HN<^J50DY7D*QA(
M7.N>2E+Y>9"N>:=N!$RLBO==XSKY=TOQE)JL[*XXSZ  <1AZ*J[-WS#:MK<S
M$=?(7RDCW3Y"^O2?\JX_MNQZ5;_:,US1]%C$6DV#+:SC8.#&VUM' &#$^*W)
M1O< 78#C%VH[L>!%80,X9MUHIR(#J'=$0\<1BP!N'8HU&NQM5CZJ_D'(ZCO*
M:'??7D2P=FM6UX@D=!(5_5CU>)1$HB41*(E$2B)1$HBX2Y=MN3_\2RG[R7K!
M;H_[:U'_  ,_^R>I'%><@?P?_:?>KX0ZC_S*X/\ ZCOSBM#Y!^45^8AKIMTT
MTZ/M5:Y@7%_M74PH.7I3U2F@!NJ/$I0BH!PY.GCT>NE2OQ7;I.$E45"%4373
M.DJF</6J)G*)3IF ==2'*(@/:&N1LG5RB9CCU@Q::4RD8#EQH*4X8XH*\>58
M,MSENQC;$]$SK-"ZI(+;?N)6TH&Y+ZN^YK2L^2<(KMN[[2M.<F'\#;SMNT>+
M(H*-D"&;HJG32$A#B%;YJG:;N?5M+?I5R^%L4L09*^.&..6=H& FD:,[Q7$@
MFCC0NQ *K+\* G@L\UUX%0IHB41*(E$2B)1$J:UXHE0B41*GBB5")1%%$*[&
MOJ^@_P JY)[;"W_U^5KZ!?8;_6;A'<L__=+.Z+[>0]Y=>#[]NN_W2M^N&KP3
MJ'[=-_6.]E863]8[OE?+5FJ$J0 30X#GYO4Y430!#0=H;AU !U+INT&N4/RC
M+G<?&X]SO8^RI!(X8*DI0*4I"Z%(4H$*4H !2E+H!0* :  % - "AD<0<SBX
MTICS<]>=0:N-7*1 /1[(CO$/0[54$M)XGFKRT/+ZAY$[RD-=OV/0[>RI#FM/
MBY@ <,>%.&%.0X\<5.9Q%"5&FW;NV]/]RJ/%K2A+:<],21W#440*1_)J'W-M
M<CG@X<2, :<E,,*GO 5P'*53C6O(J>$!V#Z@:;=NX=E4G(3C4"G '\'+Q[E5
M/>4C^0/[NRIZQV;/6A![_#ACASGD44(P"CAZ=?2_N](5!=E:&Q5#<21SD]W\
M"G'E550<M:,J&^RF/*E0B4J>"+*&$_ZWL9_TWMS^4V]=J]A__EG0?\>W\URN
M[']KC_+"] M?;-;@O+QST1$LXYLLR+-XN1<(J34,)%D6+E5(X%M2 *82*$3,
M4P 8! =!';LKV)V<7EG%LVR$LL;7!AXN:/9*^6G;_INJ7/:QJDMO;3OAJWQF
MQO<W@.4 A:E&@IWBT[RRVFS_ )N>=(?^IK>V7]AD!ZZ'A[MOA72SM%US.0+.
MZ+2?@I/>JOO!._$LMX.>>TU'I"P^'A\MOA7)Z#UKY'=?%2>]3O#.?$LMX.>>
MTU/G]C\/#Y;?"GH/6J8V=U\5)[U.\$[\2RW@UY[34>D+#X>'RV^%/0>M#_@[
MKXJ3WJ@8"<$-!AI;P<\]IJ1J%C\-#Y;?"H=H6M$4-G=4_JI/>H$#.  AWEE@
MV_%SSVFAU"PKC/#Y;?"H;H.M#A9W7Q4GO5/>&=#;WEEO!SSVFH](6'P\/EM\
M*EVAZU3]DNOBI/>IWAG/B:6[/\'//::>D+'X:'RV^%1Z$UL<;.ZI_52>]3O!
M.#L[RRW@YY[34^D+#X>'RV^%5'0]:I0V=U\5)[U/%Z<V?Y%EMF[_ "<\]IIZ
M1L/AX?+;X51Z#UG >9W>'_I2>]3O!._$LMX->>TU'I"P^'A\MOA5?H/6OD=U
M\5)[U2,#.C_S++>#GGM-//[#X>'RV^%0-"UD<+.Z^*D]ZH[P3OQ++>#GGM-/
M2%A\/#Y;?"I]!ZU\CNOBI/>JH8&=V?Y%EO!SSL=/Z#3S^P^'A\MOA5(T/6L:
MV=U\5)[U4A SO$'^19;<.O\ DYYTF#_T-<<E_8Y2!/#7\MO,>ZN>#1-9$\=;
M2ZI_52>Z'\E;X<_L5*.L@XJ.VC7[DA,#XY3,9!FX6*10K)SQD,9-,P%.0=-0
M':%=<]FEW:166HB26-I.JSG%P%1FXBIX+OG[0.F:E=:KH1@MYY&MV[9@Y8WF
MAR&H- <1R@K0_O#.[N\TMX.>:_K-=E>D+#X>'RV^%= #0=9'_!W7Q4GO4[P3
MOQ++>#GGM-/2%A\/#Y;?"I]":U\CNOBI/>IWAG/B66\'//::>D+#X>'RV^%/
M0>M?([KXJ3WJ@8";Z827\'/?::D:A8\D\/EM\*XWZ%K).-I=?$R>]4C 3@[X
M:5WA_P W/.C_ -C4#4+'X>+RV^%3Z"UA_B^9W?Q4GO5(P,Z(!_D66\'/.W_Z
M&GI"P^'A\MOA4C0]:!IYG=4_JI/>J.\,X&^%E@_S<\]IIZ0L/AX?+;X5)T/6
MCPL[K#_TI/>J.\$YN[S2W@YY[34^D+'X>'RV^%/0>M%O['=4_JI/>H%OS@;H
M66\'//::'4;$_P"OA\MOA1N@ZRWA9W7Q4GO4\7YL!U[RRVHC\7/-_3_YFGI&
MQX=?#Y;?"J/0.LYLPL[JE?@I/>J#0,\&Z%EMWQ:\]IJ1?Z>>,\/EM\*/T;7
M<+.Z^*D]ZI[PSGQ++>#7GM-1Y_8?#P^6WPJL:+K)_P"#NJ_U4GO5/>&=T_@6
M6\'/-G_Y-1Y_8?#P^6WPJ3H6M?([KXJ3WJH+!SHCMA97P<\]IJHW]@/]?%Y;
M?"N-NBZX_!UG=4_JI/>K].\,YI_ TMK_ !<\]IJGS^P^'A\MOA58T36ZD>9W
M5/ZJ3WJCO!._$LMX.>>TU/I"P^'A\MOA0Z+K0_X.Z^*D]ZG>&<^)I7P<\]IJ
M/2%A\/#Y;?"I]!ZT<?,[KXJ3WJ=X9WXEEO!SSVFI](6'P\/EM\*>@]:^1W7Q
M4GO5E#"4+-)9@QB=2(E"$)?%MF.<[!V4A0"6;")C&%$ *4H;]:P6YKVR?MZ]
M:V:(N-L^@#VD^U/=6X]G>CZO'OS1GRVERV,:C"23$\ >.,22V@"]=&H=D/5K
MPZOK^IHB41*(E$2B)1$HB@Q0,&@[O4HBQ?*04G:3]S<EF,S/&;MP9W<MGI&*
M4DD<PE.O+V^50R:+.?$!,*B0F!![H #U:GZ(:4"O: N"*N2.3E(EXF[:*&,0
MP@4Z*[9PF/"NR>M5B)N6+YJ?UBJ"I"*I' 2F* A4)R57-T1*(L=W2 R5T6/#
M /K$Y)]<CHF_5"&8+(-]0W"7OC)(CH/2&O161L_T=K<7%<<H8/Y_'U@597-'
MW$4!Q&;-Y.(]=83YMI(EL6+8MZN $S"R<V8HG98!TX48QU="%N/')C#H )M$
MYWKC#J&PE:IK-&6\5P\T$5Q&ZO)QI4]*[@[*&R7>K:EHT#<UWJ&BW<$0YY"U
MD@ [IZM=/_UUN;,@.[ZY;^7G"$&_OW(T#<Q\[25I0$$\NQZV=VT1Q&64Y?0\
M<DJLHF@N^?. $X%(F*9#&V"&O6W:=J]V;BST;1V.FU%DGG!8!F]J"UN8#FS%
MW"E0.5>Y?L!]G>U6:-NGM/[3KJ/3-FRV3=)CGDDZAKW7$L<\S8Y"*URVX8X-
MK5KG T )6S?+;B:/Q Z^K*M"8:N6MZCC;.-QW$5^R.UE235\VR7(5S$ET52)
MNFSOQBE-#E4 #@=L!#  ETK<-"LWZ;9:4US:/>QY>>7/+&Z5]>[F)JO/_:GN
MOZ::OVE:E;/9+I#+JTBMG-=5OFUC>6EA:]6>5HMXX@#RC%=R@:='8"MR'^:O
M(_LJP[F$I[MQ^@(ZB:1FW %_<T*MZ[_\(J_9J_M21;7!_DM'25:SXS1#ES$_
M=WE?M6*NE^1]O$7BV[]-!T[78V:[ZIQ((3N+I>^L;Y4I[,5IN&3><M67O*8[
M^'MR+@^6P;BN!8YVJBD<FM>\3,*R5MK-7**8I2+A9NCUHZG*< %.NN]X[?GU
M:S,#I8C)0Y0+;,14<0\.):0:8\.7%>W/LP=MFD=F^NQWDEE>Q:2QT0N)#K#X
M8J9O&<;4PY9FN;4.B <:8 M)JNDGEME<R87PK?EU\O?)U+SEWV39%]VMG;-%
M[7OXPQ5L.9&)<)S#BQ[?8/XJ/C'T=#KE.[)PNW"8D,D8X\)Q'JW09M7TG1YY
MM#TQSIV0.;<3OE!;[7'JVCF&)YJ4.!7T)[7++L][1^U/3M,[3]^V]MHMYJ-K
M<:/IEI8RQRS,8ZL+;R9[&DM<XY8C^-GJ&AU"NOODRMK+%]<U6&+8PS=4E9.2
M[CO$&41>,)U1G]L,7+%\:ZY]))<1*NG%VD#]=1(0$%$4SD'>&NA;1@O]1W/:
MPZ9(8KV24D/Y6C*XO/Q>>E>)(&%5Z^^TAJ6R-J=@NOZEONQ&H[0M-/C$EJ[V
MLS^NACM8J_B W3H/'H2P#, 2 #Z/><7&?UKF/XF\B6%S"M<Q6 WQ1-.+B:+V
M9"6C)N( RKB-N%$5%0<0CF?90ZYW*BG=2"IVNO5D,)1"N]-RV&_[:"<:??-N
M;86SLP=&UA(.8. H2"[+C6H[W*OD/V$[J^Q9N'4]/^F.V+S1-Q/UB,0N9=R7
M<#9 8W1.> ULS8C( P-$;P'5KAPZF>3/)N*[@QN;&'-+>M[7?:J<B6$QE8Z9
MI.V8?&TR,NXD5+A89(E+DC,<PK<[APJZ<$DFCSB,B5),/7%(?0=I:C8S:?Z/
MW ^>6T)R1QFK61'-7,)"0S&M<144Y5[+^TCM#=.D[VCWKV+V.DZ?JK8'S:A=
MN='+/>QNB:QL+[*..2Z>6M;E;DH/'S.(QI[+L(W39]V8[M]S8EW(WY;<2P96
MZTO%JD4C.XE(-F@Q6DVCA!!"/D$7)D^(7#0!:'4$P)CH70/2=A+!+;M\V>9(
M6M#0\U\;**$]VO.,#R+X7;NTK5=*UV>/6+7S*]F>Z8P9@XQ"1Q<&&AJTMX97
M4>VE' %?;E9DW/:YY R28NF$C!BDN8H"HFW4N.&7=(IG$-2%<&:I\0!O$@:[
MJS^DD-O,>6.0=+' >NM,U!I=;@ 5I(P]S!P-?NQYEA>Z,2Q5Y*YDMY:"BKDM
MFYI!EXT8\G"D\6[K;2-N1)G:R0B'^1Y]5PB82/"@)3*%#K"Z^O+::I:V=_80
M6M[&U]N^,M>2*UH]Q%>\#P%5F]L[AUS:FNLW!MRYEMM6M)FR121NRN8\ 'Q3
MR4./=J>9>=CZUTF5,48=PWRR1E]K79@B[<ANG-M#>AG2F6K D+639HHX]O5<
MRY2R\'%!=A%(ET"8F4:-R@)E !-53S[VF6^H:1IEKHC'E^D3W!ZO,3F:&T B
M=7!S!G!:1B*4/(OKW]@?4]@[][0->[6I+ 6/:)I6DD7%O QC;*X%PYSS=6[1
M0P2UMB)F$!IZP.8X^,!VN?5?1MZ\O*F4N1S)EPM[BF<1&AL@XZFT$E6S::Q9
M?B!1(HR0<+*+IHQMSMW21B>NZLY]-=!#3=MCPW.@B7:E_)UL]L&R1NI@Z)U*
M@5]RZK:+R-]K;5=#[5;G3/M";6M76=AKPDM[V!S@YT%_;$LHYS0 >NA:) <"
M:FH!!79_8I"L7M[0I!U2B[J671[!4YZ.C[A,0 W !%Y,]=K:A62.VNW'QY(,
M?YCW,'K-"\1VA:V2:W9[6.08_E,:\^NY9"K&J]2B)1$HB41*(E$2B)1%PER_
MS<G^SWDE=/1[A7T^S6#W,"[;>H 8DV,_^R<I'%><@=I1T ?^%&OA3J%E>>D;
MC]#+^M=^*[W1[BT2A %0?;*GA'L#Z@U9^87WP,OD.\"4*<(]@?4&GF%]\#+Y
M#O E"G"/8'U!IYA?4_4R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%]\#
M+Y#O E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%]\
M#+Y#O E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%]
M\#+Y#O E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%
M]\#+Y#O E"FANP/J#3S&^^!E\AW@2A3A'L#Z@T\POO@9?(=X$H4T'L#Z@U/F
M%]\!+Y#O E"HT'L#ZE1YA?? R^0[P**%=C7U?8Z2V2?W!;X[?W1*5[[^Q!#-
M!-N$3,<PD6E,P(K^U<ZSNC5#GU%, NNYYJ+QT.@_ME;H_P#2&KP??V5X;V:D
M,OZQWXCN?O+"R5ZPUXU7SZ#V!]0:M/,;[X&7R'>!4T*<(]@?4&GF%]\#+Y#O
M E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%]\#+Y#
MO E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%]\#+Y
M#O E"G"/8'U!J387QQZF7R'>!10IPCV!]0:CS"^^!E\AW@4T*<(]@?4&GF%]
M\#+Y#O E"G"/8'U!IYA?? R^0[P)0IPCV!]0:>87WP,OD.\"4*<(]@?4&GF%
M]\#+Y#O E"LH83 0R]C38/\ />W/4[YMQ^Y7:?8E9W;.U?0G/BD#1?-J2T@>
MU=W%=V(/G<9_EKT"5]JUMZX!6'@W2QUW$=%KN#Z"JLLQ9G6..A0#K#JI"8^P
M.G;LKD9/<-;E#GY>8$T7!):VKWESXXLQXDM:3ZI(*K+ VX(>MAH00V_\W,1#
M]9J/.;KDD?3ON5(L[,C"**GY+? G>"WOB6$\&,?:JJ\XN1_K'^44\RL_@H_)
M;X$[Q6[N[RPO@UCIK^HT\XN^/6/IWSX5/F5G3]5%Y+? G>&W?B:#\&L?:J"X
MNO=O\HJ/,[/X*+R6^!3WAMWXFA/!S'VFH\YNO=OZ3X4\TL_@HO);X$[Q6[\3
M0G@YC[34BYNS^._RBGF=G\%'Y+? J0@K=^)H3P:Q#_%#3K[OX1_E'PJ?,K,?
MZJ+R6^!3WBMWXEAA[81K'VFHZ^Z^$?7OGPIYG9_!1>2WP)WBMT=T-">G&L1_
MQ53YQ=CC(_RCX4-E9_!1>2WP)W@M[XFA/!C'VJGG-U\(_P H^%1YG9?!1>2W
MP*.\-O=,-"!Z,8Q#_%4\XNOA'^45/F5G\%%Y+? I[P6]\30>G\6L?:J><77#
MK'^45'F=G\%%Y+? H[PV[\3P?@UC[53K[KW;_**>9V?P47DM\"=X;>^)80?0
MC&/M51YQ=?"/\HIYE9_!1>2WP*@\!;HA_ T*!@$!_@UCLT[75#IJ%/.;FM.L
MDZ2GF=C6ACAJ/Y+? OU/%1#HX"[C(U8Z:94TQ<M&BYR(A^ 0@G(<2)%Z"AL"
MC9IV#Q'N )Y"1CW>ZJG6]K(?'C82!05 .')3CAW%'>&W=/X&A-?XN8_:ZFI\
MXNO=O\HJ/,[/AU4?DM\"=X;>^)80/1C&/M5/.+KX1_E%0;*S'^JB\EO@4=XK
M=UT[S0G@UC[54^<77NW^44\RL_@HO);X$[PV]T0L(/H1C$?\54><77PC_**G
MS*S^"B\EO@57>&W?B6%\&L?::CSFZ'^L?TE/,[/X*/R6^!0,#;VO\"PO@QB/
M^*"I\YNOA'^44\RL_@HO);X$"!MWXG@_!S$/\53SBZ^$?TE1YG9_!1^2WP*>
M\-N_$T)X.8^TU'G%U\(_I*GS.S^"C\EO@4# V\'_ #-">#6/W4@J?.+KW;_*
M*CS*S^"B\EO@5/>*W?B6$\&L/:J><7?PC_*/A4^96?P47DM\"D(*W1_YF@_3
MC6/M5/.+OX1_E%1YE9_!1>2WP($%;OQ-">#6(?XH:><7?PC_ "BI\RLQ_JHO
M);X%/>&W1W0T)X-8C_BJCSFZ]V_I*CS.S^"B\EO@4]X;=^)H3P<Q]IIYQ=G_
M %C^ER>9V?P4?DM\"=X;=^)H3P<Q]IIYQ=?"/Z3X5/F=G\%'Y+? @0%O?$L)
MZ4:Q#_%#3SFZ]V_RBH\SL^2*+R6^!!@K<#_F:$\',?::GSB[]V_RBI\SL_@H
M_);X%3WBMX=T+"^#6(_XH*><7?NW])0V=GRQ1>2WP*1A(%(2*)1,0DJ0Y#)G
M3CV95"G P"42&*CJ4X"&P>S4&XN*>.]Y;WW'I[B"TM&D%L<8<#@<K<.]AQYE
MRY #:&ST-@_W:XO85QPPY5^M2B41*(E$2B)1$HB410.T!#M418VN&V)2.?*W
M79 -23R@H]]H-TKW)"W:W1,4HIO5 (L$=-H(:]SOTR<0F*1-<%$=A2*YK:N>
M-N5D*[(%V[EL?N63BWR0-I.(?I@ +,)!KQJ=4NF.XQ3'25(('3.<ABF$G)57
M)4.K3#BBQZV KS)<@L B(0EJ-60;=A5I>2.\5V#^6ZIB0![59$^)I8;ROG)]
M0- ]E60.:_/,V(>N2L1<Y3BRFO+#FYWD*0"*M%MC^8<2<H!1,JQ.BF52.<-0
M*10_=B<H5 4.$HFZX"Z5K&NNM6Z/<.O"!:]6:UX=SUZ47;78S#N2X[4M#@VC
M$9]Q.OV"&/ YR:U::T%"W-6II2M5T7_40-;QS)D_F9YH\K3<C>U[KLK9L!&Y
MYQ8CI^9206//RR;<0("#)--&/9E J14TRD'A NFM=2=DIO-6N[[<&IO,UV<D
M8<>8U<X4 ',WOKZ0_P#V3#;O9YMC:/8UL2WBT_;,1GO'6\-0S.QHAB<XN)<]
MQ$DM72%SB<2:KMR<G4OGGWM86Y>MC,38AO5\Z5U*)6SVY7MMV]%\(E-H /EE
MIA+A-M$S PAJ ;.Z[US/.[2R!_2LB?._# 9BZ)@)_E,.:G,OG#I(?9=D&J:A
M( T7VM06C*GQI(XX674E!QRLEC:"[AF-%OV4-"@&HCVQW[QKFXA=7\,%8<P!
M5<A60F(;6\/>3PH]'%_H^S#T^!T:LE  -+N'?^I"/]H59RXWT0_D/_T%?U8Y
M7BX:;CW$I&/8Y!ZXC3/$%6X/VG5&=MB+E$BBK<5R*)$7*0P\!A*8"FT'0=-*
MI>SK&%E2*@C#CCS'G5S9W#;6[CN'1LD8QP=E=7*ZAK1U*&AIB.5=>V4.25L7
M#^7(&WL@YOO&4FF3RZ[;AI++UXMI1_=,='.'1+2-.DF696UH7A*-T47+8I$0
M;I*J @=(H@!=6NMLP.M98!+=$O(<!U[P<WN0[.*-=@"*@#DHO0.W.WC58MU:
M9JEWI^WHF6[1;O=Z+LC&(20!,Z(6[@^>)I<0\AY<:9P^BM&"Y=6_*]]65E#$
M#A&-6N2UL!Y?;W5/QY53%N:<>1]SRCN<!XY3*[<M'ZK[K4"*B)VZ9@2V<&E6
M,&CC0]D3:2X-,\=E('.;6CB&NJZIY36M.3F6QWW:7+VL_:MT_?+#*S3+W<MI
M);PO/ZB$SQAD0:TEC<C1E(:2#0&IK5>2WZM>\)>Q^>_E?FX,B"CYWE&(M4Z;
MHA3)C&7ZU?V+.:>N+HJ$+<;CJC;>!7A'0=-*\W]GDAAWG8/9[7K"P_SHG-/>
M7W.^VUIEIJOV7-X6MV\MA;902@BM<\-[:SQC ' OC:#R4JO9USRX,G.8_','
MAB"E;NMLM]W5%Q=RW?;4[*Q+6U[,9*]]KH7D6#%PDSG%9R+:&C6S=TDLW,NZ
M*8X 4@Z^H]S:4=:L/13731B9X!?&XMRM!!=4@BN9OBT(-:K\_/8+VAV799NR
M3?=W;V5X_3K=[X+>XACEZZY+7-M\I>TN8V*7+*]T;XW@-\1V:@75Y]7QR><T
MMB3ER8PS.TQY<>"P:-'<3 9!@'\\\&#)*RB<8M;"T6_C+?9W"QDH8IWPO6SQ
MP@)FQT@,BN(DT/9N@;@MC+8:JV&327!KF"1IK1KG !N2C6D8EV85]J<?Q?6W
MVH^VSL:W8VTW?V=R:I8]HA<YL\MI+U;'2=7&7F42YI>J<),L0B<QCP)6R .8
MPN]"D)#QT$P1BXF.8Q4<U*"32/CFC=BS;)%UX2(-FI$D$4PZ"E*&E=OL8UC0
MU@#0!P H/4"^;ES=75[.ZYO)))KAY)<][BYSCSDFI)[ZMW);47EB7,F&H"C&
MG>@(;P&..F_U#T.YJR&G_MD;?=.R^5A]]8Z[_9W.]SCT8_>7QV^L0]ZW3U8A
MU<A!VI+%V[-'!)-J4?1 K,M<URPML8N4MED;T93]]<4)K<R<SFL=TU\"\[OU
MY[:Y+VS?R>8BLBV6UR7/>9KS:QL212-B'TO/RTU8\7;P-+AD%FC5B^9N6A^H
M574!LD*INM R9A+70W:E/+/?Z5IL$?6ND?*T,)IB3$&D/J,CA0TJX \M:8?5
M/_Z^;'0=)V-V@]H.O7TFF0Z5#IY-TP3/$<9;J'7"6"-LG71N_1U'4R/%/$R^
M,3D&Q.8PL]S#\C&=7"KZ)NTI[CY*N9:$DVH1SQ"^&<<[2B5)!ND95B<"WMH8
M00.<$E5 *!NK$ACY6&^$VKZ5KC'$GQ[.Y!%"UX8]U'"E*B5M"6^*2?%.6A6@
M:EL@679GO_LUO&0]5&;;<VB.8_-'-:230@R6SW.,G5NL)W2!DP;*&@B5C9@X
M#OCM<03O7(B(" @JO:[_ %#;J*L"DRXM?P=T> ;.Q7<%R_K+.W'(QKV_YY=_
MI+YVP!HNIZ#QG.:2>?Q&@>Q3#D /$K(=6"O$HB41*(E$2B)1$HB41?FJ0JB9
MTS% Y3APF(8 $IBCL,40-L$!"J)&M>PL< 6D4(/ @X$'OHK8"R+, ! ;3MK7
M77;"1FWM_M7IK ':NURXUTVP/+^SQ8GOEB%K3C15^)%F>2=M> XSX+5?T5VO
M\VV'[O%[Q4Y&IXD6;Y)VWX#C/@M/HIM?YML/W>+WB9&IXDV=Y*6WX#B_@M1]
M%-L?-MA^[Q>\3(WF3Q(LWR3MOP'&?!:GZ*[8^;;#]WB]XF1J>)-G>2EM^ XO
MX+4?17;'S98?N\7O$R-YD\2+,\D[;\!QGP6I^BNU_FVP_=XO>)D:GB19GDG;
M?@.,^"T^BNU_FVP_=XO>ID:GB19ODG;7@.,^"T^BNU_FVP_=XO>)D:GB19OD
MG;7@.,^"T^BNU_FVP_=XO>)D:GB19GDG;7@.,^"U/T5VO\VV'[O%[Q,C4\2+
M,\D[:\!QGP6H^BNU_FVP_=XO>)D:GB19ODG;?@.,^"T^BNU_FVP_=XO>)D:G
MB19GDG;7@.,^"U/T5VO\VV'[O%[Q,C4\2+-\D[;\!QGP6H^BNU_FVP_=XO>)
MD:GB19GDG;7@.,^"U/T5VO\ -MA^[Q>\3(U/$BS/).VO <9\%I]%=K_-MA^[
MQ>\3(U/$BS/).VO <9\%I]%=K_-MA^[Q>\3(U0-D69H/^B5M^ XP/L@UV5!V
MKM<"OHVP_=XO>)D:N0CH"$B!4-$Q$9&&6 I5Q8,6S05@3XA(504$DQ.!>,=-
M==-:NK+2=*TUSWZ=:V\#G@!W5QQQUI6@.5K:TJ:<U54 !P7'^)-G".IK3MH3
M#M$PPD9Q"/2(_L4=HCVZM/HIM?B=-L*_X>+WJI(:3R54^)%F>2=M> XSX+4_
M17:_S;8?N\7O$R-3Q(LSR3MKP'&?!:?17:_S;8?N\7O$R-3Q(LSR3MKP'&?!
M:GZ*[7^;;#]WB]XF1J>)%G>2EN> XOX+4?13:_S;8?N\7O$R-Y@GB19ODG;?
MH]XXS7]ZT^BNU_FVP_=XO>)D;S)XD6;TVI;8^C!Q?P6GT4VO\VV'[O%[Q,C>
M9/$BS?).V_ <9\%I]%=K_-MA^[Q>\3(U/$BS?)2VQ]&#B_@M/HIM?YML/W>+
MWB9&\R>)%F>2=M> XSX+3Z*[7^;;#]WB]XF1J>)%F>2=M> XSX+3Z*;7^;;#
M]WB]XF1J>)%F]-J6V/HP<7\%I]%-K_-MA^[Q>\3(WF">)%F>2=M> XSX+3Z*
M[7^;;#]WB]XF5J>)%F>2=M^ XSX+3Z*[7^;;#]WB]ZF1J>)%F>2=M> XSX+3
MZ*[7^;;#]WB]XF1JJ2LZU&RZ+EK;, W<('!5%="'CT54E"#J0Z:B;<AR'*.X
M0$! >FJXMM;=MYFS6]A9,G;BUS8(VN!YPX-!"D- Q'%7-6<4KS/<[.3,CP7-
M+EV*A,@7K#1C28ADVL;%W3.1[%L12V()4Y&[1H^1;HE.H<3"!2AJ8PCO$:]<
M]GFB:3=;0M)KBWB?*YI)):"3ZJ^9';MN_<^F]JFI66GWUS%:-+:-:\AHP'(M
M639DRX41#YT\BAIT>.UR_C.MV&W-#> YUI 30?BA=0'M WFTT]*7@Q^$<%'S
MRY<'_M4R*/\ MM<OXSI]&M!'_"0>2$':!O0\-4O?C7>%4_/'E_B_K3R/P_TV
MN73^4ZGZ-Z!3]D@K^2%Q'?V]L_\ S2]I_6N\*J^>3+@;\IY&^6]R_C.GT;T'
MY)!Y(7(=_;S''5+WXUWA3YX\N?2GD;Y;W+^,ZCZ-Z#\D@\D*?I]O3YTO?C7>
M%/GCRY]*>1OEO<OXSI]&]!^20>2$^GN]#_U2]^-=X5/SQY=^E/(WRWN;\9T^
MC>@_)(/)"?3W>GSI>_&N\*!F3+P; RGD;Y;W+^,Z?1O0?DD'DA/I]O2G_-+W
MXUWA3YX\O?2GD;T[WN;\9T^C>@_)(/)"#?V]!PU2]^-=X5'SR9< ?ZU,BZ_T
MWN7\9T^C6@_)(/)"@]H&\P<=4O:_UKO"@YDRYTY4R-\M[E_&=!MK0>2T@\D(
M=_[S''5+WXUWA4_/)EW0/^M/(WRVN7\9U'T;T'Y)!Y(0;_WL>.J7M/ZUWA4?
M/'EWZ4\C:?TWN;\9U/T;T'Y)!Y(0[]WH/^J7M/ZUWA57SQY<WAE/(WRWN;9_
M^IU'T;T'Y)!Y(4#?V]N35+WXUWA3YX\NB<-<IY%V@(C_ *;7+V0#XR[%0[;V
MALC);:0# CV@YBN>'?N\W3,8[4[PM)!QD-:Y@./'AZBW?Y[<B9!MZ_L7MX&^
MKQA6[K!N/7KEO$W--1R3AZX:.3.'BZ;-ZB15RL;:=0P"<P[1&NNNSC1M)N;.
M_?<V\4@9JLS<6\&AW =Q=X]O>[-SZ;JNALTZ^N83+M^T>0QY:'/+:N<:<IY2
MM(0S%ET=!'*61@'?LO>Y=OH:R7]Z-=CNVSH; YT=I ]H(&+1R][F%%T2[?\
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MOZQ[JUH.(Y,30="U#>G8#J^VM%AN8-(W' ]LCQ=7FI6XL;.$#+D(#F.RA_C
M%\QJ0UK14U/8=-)#(V[*-5"'(:0AGZ!DC;3D%RQ5(*9M-Q@X]/1K=K65T5Q'
M+3%KVGN8$%>9+F(.CDA!J"' 'GXBO@6,[*>G/,VJ[6T*%P8MM\0U_",_B%C*
M.TA'LIIR8:].P:RMZ";:5@XQW;W'\E[6@?F^NK&V(\Y:]OZMT#0.^TNK[(71
M5];7+$MWZP/ZMJ8%8Z",;?\ ;CIPL4XDX6R>6+([L*8=Q2*-A$A^@2CH.S6N
M@^T"41;PV_*?U8F>3Y<6/L\>=?4W[%FG2:K]FWMATZ,9I)M+M0!QJ[J-1(IW
M<*^HN)YW(@<$\R658R&6/"VS?]V<OG->P42!OUK*Z&66X;'^4G\4#EJHV067
MBW:+U0_KC=:7B'=MKW$XZ1JURR(4BEDMKD4&%1/'#(>^<Q)HL=V+V\/:?V4:
M7/J1#[S2K'6=$<[,X/<ST;=:AIX=E(+@R2%D+&GQ2SQ2"N\NV;K=VUD20A[T
M<LP\8K>MA6"NEJDHA&3W5N)1JS;/DSBLG$3:P+<)4^L,BY%,13,!A!(.[G 2
M:7',.20CI *^9CPZ'4I+8@ AM>[4.+<> PI08+8DHZ@ Z[_2'_PU8!7)XJJB
MA*(E$2B)1$HB41*(N)GEUFL',.FYQ37;1;]PBH&FI%4&JJJ9MH" Z'*%8G7[
MF:ST.]O+8TN(K65[32M'-C<X&G<(4MXX\%TFCS89X+I_IPXUXM! &$< ;]NS
MN8PZ>G7R8NOM.=LD-S/$W51E:]P'Z*/A4CW*U4ZG= BCL*IYV&=O+=?WDP^"
M5:?Q/]LOSM_91^!1Z3O/=^LH\[#._ENN'_$H_P""4_B?[9?G7^RC]ZGI.[]W
MZRGSL,[>6Z_O*/\ @E/XG^V7YV_LH_ GI.\]WZR>=AG;RV7]Y,/@E1_$_P!L
MWSM_91^!/2=Y[OUD\[#._ELO[RC_ +C0*?Q/]LWSM_91^]3TG>>[]9/.PSMY
M;K^\H_X)4_Q/]LOSM_91^]3TG>>[]9/.PSMY;+^\F'P2H_B?[9?G;^RC]ZGI
M.\]WZRCSK\[>7#@?^(QX?\EJ?XG^V;YU'Q4?O4])WGN_64^=AG;RV7]YL/@E
M1_$_VS?.W]E'[U/2=Y[OUD\[#.WELO[S8?!*?Q/]LWSM_91^]3TG>>[]91YV
M&=_+=?WE'_!*G^)_MF^=?[*/WJ>E+SW?K*?.PSMY;+^\F'P2G\3_ &R_.W]E
M'[U/2=Y[OUD\[#._ENN'_$F'P2G\3_;+\ZCXJ/P)Z3O/=^LH\Z_._EPX]Y1_
MP0:?Q/\ ;+\ZCXJ/P)Z3O/=^LGG7YW\N%_>4?\$I_$_VR_.H^*C]ZI])W?N_
M64^=AG;RW7]Y,/@E1_$_VS?.W]E'[U1Z3O/=^LGG89V\ME_>;#X)4_Q/]LWS
MK_91^]3TG>>[]91YV&=]_CPX#_B,>/VVE2/M0=LHQ]*U/]5'[U/2=W[OUENM
MR<Y=R#DZ1OA"\Y]282BVD*HQ*HV;(]SG<K2)%Q*+=)$1XRI%WZ[J]?\ V5.U
M'>G:/+K(W7=-N6VWFW5^(UN7/U^:F6E:Y&\>;!973;J6Y+^M-0 *+3!US69U
M2=."%O=?A(NJ0H PCB@!2J&* ?M4=- "O)%W]IKMCM[F2"/5@6,>0/T4?(?R
M5BWZE=M>1FPJOP\[#._ENX]Y1_P.K;^)_MF^=1\5'X%'I2\]WZR>=AG?RX7]
MY1_P2G\3_;+\ZCXJ/P)Z3N_=^LGG89W\MUP_XE'_  2G\3_;+\ZCXJ/P(-3N
M^5_K*?.PSMY;+^\V'P2H_B?[9OG;^RC]ZGI.\]WZRCSL,[^6Z_O*/^"5/\3_
M &R_.O\ 91^]3TG>>[]9/.PSOY<./>,?\$J?XG^V3YU_LH_>IZ3N_=GH3SL,
M[^6[CWE'_!*C^)_ME^=?[*/WJ>E+SW?K*/.PSOY<+^\8_P""U/\ %!VR_.H^
M*C\">D[OW9Z JO.PSMY;+^\F'P2J?XG^V;YV_LH_>IZ3O/=^LGG89V\ME_>;
M#X)3^)_MF^=O[*/WJ>D[SW?K*/.PSOY;KC_Q*/#_ ))4_P 3_;+\ZCXJ/P(=
M3N^1_K*?.PSMY;+^\V'P2H_B?[9OG;^RC]ZGI.\]WZR>=CG;RV7]Y,/@E/XG
M^V;YV_LH_>IZ3O/=^LGG89V\ME_>3#X)3^)_MF^=O[*/WJ>D[SW?K*^\7\S&
M:+@R/8T'*7>LZC)>Z86.?MA9L2]>T=OD45TA4*T Y.-,X@ @(" UV#V6?:$[
M5=Q]H.DZ)JVHF73KF\:R1HCC&9I:XD>UKR<A"N+6_NI;AD;W5:YU#@NXVOJ0
MMB7EHY[]G-MF?^/(/_HE;]>S>S3_ +,LOR"OE-]H04[7-3[KF^PM1% _1!#M
MA]FM^C]H.\NC9,9"%4!.'4=== U'T WCL$:#QB*@Y>6F/K8>RJFM<QKG $D"
MM!S<O0IXB[@'41#=IIOUJ@$'QCA'7BCY&>*65)I7$4P]?V$,37: [@UW>ALW
M[]M1UK11OXY/J=/X%5*&DM <*N) [IJ*#N'B3R"G$J T'8&NP=-V_3?IZ=<F
M5P<:@Y,:'G(%3["J =3+0]8*CN&AH<?4-,,>Y53H.FP.QOV!IZ.@U2"XC-E=
MDY_N*@G*P.H<>/,.Y7EZ H$Q0+Q".W4 X>G;K]ZJ@UU/&ITUPY^109&Y.L86
MEG#B:U[U/OJ=FP=1]3M[!W]C;5)#QR COJ<PSM9A5S<Q_DX8#U52)]@;-XZ:
M;O1'TJD%@Q=44Q.' <G+Q.&'LJC-0#*!F)X$XX<3P5)=#&UUV:[]/OB%3XQ&
M5M,W+4TIZQ0-S/#N ...'A51BB.@CL['W]=:5 .5M2>7\'.CFEQQ(H%/:]+U
M*AU0>X5R#F&(4CM 0HI(J**DHZCINT"I(IBN(2<E%4&TP?[DWV#A7%)[0_=^
M*5=0&MPS[OQ@M^/K!/ZP\3Z!J/S"XXT[6K)P&O;$-]=;=EI_W/4@?:NU:>HY
M_&X+T!]HEKW:KH CH'_1VSQYADQH.7#NA8GP)CR-O*S,MS@8Y3R7<MJGL-*"
MA'$O<44U23G9.9;S#E7O!-0JCD2-VJ7#QJ"!.'73IK(;OU%]I<Z?:"[=9V\S
MYRZ0,$GM6QY002*"M:G$]S&BUSLLV_IFJZ7K>KG2G:O>V3+5K(B]T?C2239W
MU#A490P4)KXIHOOR5@=LZOOO18"49;C5E9L)<=^LINZVSZ QS-OTM'EON;K5
M,J=T/='"9)$PJN0%7J_7B41'BT;<Y@T</U)[Y)W3O9"6LHZ9K30.$9<*"E*F
MI'#GPN-W=F45WNHVFTXX;6R;:,GO6RS9VV<CP#U1G:S$@EP R5PIQ&-BM.7'
M(;R5N.-,M:S!I:\'#7/)W"_N:/;6V-MS[PC.'G&4SQ&1>,'C@P$*) ZSB];P
M\?K0R\F]-&9!#-&)G2RSN9U88#('-:\O8YN; MH3Q(-.2N&O_5%NJ2YN+:5U
MK#:VL+;A]P^4B%T4CF9)&/R@N:_.UHP:07<XHN<DL 7//3\ZE;\3;5HQ-J6Q
M9LQ<3B5OE%S#-&<_&M%$I_OU(H-1%O*JJ]=U"9#"B*@)EXQT$;2VW39PV,1G
M?--<7$TO5AL8#W97.&3+G.((+:UI0 E9#5.R_4]3UFZ&F0VECIUG;6TLSI+D
MNC:Q\<9ZX/ZEN#ZYL@9A6@)/&Z[ Y>I8S3)\;-HVK)JK8M&Z;*NU*X&:MK%[
MENVWV,A--)W4K9 (]DLJDN10H*I<6AB<6@#C-:W9;2SV4MMUS7"];')%D'6C
M# %F;\8FHH[D6R[3[*[X6&MV^JBUFZ[2S-:SB4BWJ"07-ER$TC! ?5E0'4I5
M8O6P!?J=S%MLIK=61&V4KS&ZT9YJ>S4[556,T+.*W#KW.FT,Y*9(I1 %3+:)
M@03& *V([MTIMH^]?US(S/U9B+1UHD-?$RYJ$BAQKP!*T63LLW0_6/1@\VD8
M+070NLY%MU(HW/GRDDDR"@RBIP7(M^6?(KA:86%U:"$%#0L7<*]UN+I8)6LY
MA)B3=PS.3CY8P FZ1&78J-3E*7K2.2BF) '?P'>FC^*&-N'3/EZL1A@,N<-S
M%KFYJ-\4%U0YWBT/+07;.QS=A,DDTEA'91P";KC,>I=&7A@>U_5@D9R&'Q:B
M0.;3"IX,V#KN+:TC=K.4LZ8;Q42%P/X>'N=C(7 UM\5R-C3"D8@!A!FDJH3C
M#CZXA5 ,8A2[:NV[IL//VZ?,V>*5Y$;'.8.K+W8@9LU0<0/:TPXK&3]FFOMT
M*XUN"2SN(X;9TCF12%TK8JEKI,I:T%K<A/M@X@X@47'YGB(N"OPS"(:IL6/B
MAC-[U"7X'=<MC:TY:07 #FVG=R+U98^W\-0=*M]DW-Q?:+UUT2ZX,TC<>8'&
MG.6T Y%>]K^GV&C[R-EIL99;FUMZAHS>,YA)-"1B2:D5XFM0LS+82M8N&133
M2<ES3'VFUS')%6>K @?'LH\,P;V\UBRJ"EWS:1YDI<ZG"*HHN3%'UI0TQ+=U
M7WTBRSD#;CIC:15_%E8#5Y/*'&-S *<2,>?:_JVTAVQ,D#'?3R*Q;J4Q+3XU
MO(6AL ;4Y7M9*V4XG#,. PXC&/*Q<EZ+V,\G+IM*U(._V"TI!'?W!'%GY".1
M4?ME7#&%4'KE 0=,#D.!S$ -O#J(;+G6-\6NGB>&.VN)KNV>&2!H\0$T(\?G
M+'!WM>)IW5C-F]CFI:]Z/N[R\LK2PU*%TL1>\F4M8Y[:B*@! <P@U>*8TK2I
MLV-P!>$JI**(35CMHUC-*6\QG)*[(]C#W%-)I(+'C[??+:)R*J9'*?&<.%%,
MQR@<Y1'9?3[KL+7(R6.?SAT(E,8:"]C"2,SQ6@!((&))H<,,</9]E.X-1?.Z
MVGL1:QW)A9*^5S8YGT!RQNR$DBHK4!HS-\;$@<HQY?;XAD+;N*ZXV!;Q\G=0
MVZVM.8NA""N"?E(ZZ$[;E81NS23</VZB+T3%4< 02(D$#@([AMY-VZ9=F:RT
M^20NR-<9FLS1M:02#4D5#APX5X45U!V5:YI;(-4W!%:B%\YB%K)<=5/+*TY'
M1M BD R.-2[' <!6J^-I@:[+C5GW4"M:31=J_NOO?91KP9N[I.VMIP^&1;1[
M-0 </SL&S8_ *H)*NBIB8A#"(A7*[=FGV[;9DXN"'11$R]6 S]*&]77QS3,Y
MS0:5#:UQI0\#.RS6;Y]W/IYM(S"^\#;;KG.F MS()6- B >(VL=1QR&0--&@
MDK@\IP45#Q>&G$8Q19JSN'XR;ESI%$AWTJI>U]QZCY4>,=5CM(]$ANCA3"KS
M0)Y)WZD)"*LU"@QX-ZBW-*4Q!)-#7EX+#[PT^#38M"\SA,;KG0FRS#E,GGE[
M'G..'B1QAPY0VE>58F$:V!:2!3%--GHT4<7=Q14JK'D64\'_ -<6,?Z<VSIX
M6:U@=T?]NWO^&?\ FE;KV;_]_:/_ /I&#\\+U^5X37V/2B)1$HB41*(E$2B)
M1$HB41*(E$6/<?!UK.??:<(R%VW N;4-H@W>F9%,([ ]<5MLK(ZD:21P\C(F
MCI%?OJRL@"V2?X20GO4\6GK56J>9Y!D]YL,1K.4TEFF#,'YRRZYZU-0W<T]<
M"MFV3;+@#@<J9-8D)PG"8#<7%KLX-:TV^#WZQ \8LAMYGD?RB8VL/<PS]_U%
MWGM,B#LIUFSC:?26LZSIEK"0:?HH&WLMRVG+5\EKWJ=U=5OU6UTW5$<KV<7E
MPK'D32.1I#.!4W!#-57C-S8D)=9X=P?C<=8:3N9RP;"8"?HA%# !!U#37>RB
M:YMMM:CJUP3USGN<RHI229M?5PS>K1>H?MXZ-HE]VR;6VOI#/T-O8LLI@TYA
MU=C+U>9M *>+5U"2 !QY5WYX=LY*Q,8V1:Y$NH7BX)L>3+Q=89:>D1/)W$\5
M/PI@99_.O7*YQ I0XU!T -U;U9QNAM8XG^V#!7\JGC'U35>%-RZ@S5MP7=_&
M28'SN$=>(B:<D0/Y,;6CU%DP1$ V!K5Q6G2L&L?QA.NR3<Z^TW<-K6JP W0!
MG+ZY'BA-FXP%*F(]H0K)2@,TJ <KI93T".GWU91&M_*/<QQ^N7U]@=*R#6.5
MZJ3%X@TW;0'=KN'4*8<"BZJ>?[ZOS%&>;-O&]&UMW;(Y0?2]FRP1UO7A<<8T
MOQQ%3<4P1MB4C"OG%O1R<E%'49!+&9*'B2+"[$#@D8IM)W9M/3-;M'.DB>ZZ
M&6@:\MSY3@UW$4QI6@(K6J]5_9[^TIOCLKW!8V,%W:1[>CBGA#IK=DGFK9V'
M-,PBCW.:X->8\U)<H9A6HZW(O!-IY/YBN;6=R/$V-=-P07)?D&"B'MCV>K#8
M6MB^+1B[>AI* L=>1E)23O25LR+E6B2\HLHG^R#JD(BEU)0)IATRSU'7=1GO
M6QR3MTR1OBM_0L<T-#FL)-7OCJ YYRXG "N'J,]HVX=I]DVR="VU-<V>DOWU
M93O$\^?4IX+@SNAFG:V...V@N6MD+(&F6C<H,CN7R_&2ZM11'0NQ4Q #3UHZ
M'$OK@UU'7I^Y7G%D?67#(JDG,&UYZG+AT]WOK[B7EZ;?2I-3XLC@=+QQ(#"X
MCARA>_[*7)K9N>.5W%F)59>1L^8Q[:MH/,>7C"J.DGEMSL9;B$<8ZB4<_BG+
MR&FF2RS5\V3<MSK-5CE343/PJ%]GWFWH-3T*'3"XQNCB:&/'%C@T &@(J/=-
M!%1@".*_+;MGMGUCL^[6M7W?';17FGW]_=>=6LF#98Y)GN\5Q:\,ECS9H9',
M>&/ +F/ +3K_ (%PGS1X[RVE"JX%PI9F*(^-[W77<\3FO+$VWR<W?%79BI"V
M/,/):,@'""'$HZ0DFCH#"8I".?7 J6UT>SUFTNG1&UMX+!I]LV9Y+^ KD+:,
M)Y02[OX+:.T?=?9?N;:S-5;N36]3WA.\EEM/I5K$VSH,Q!NF7.:9M2&L<R*/
MVKB6# &]S_5U\JMC7\O<AL:MHA";OI"_+3OZ&D'K*;QU?(N3.0CBJBLLU\6I
M-QJHD+A-1J)A%NNF8HHF"[?LS;CYC<B -NG3=;5IH0_B7#GJ2:@BBUIGVH>V
MINC1[<FU>2;08].%@8) '1R6K6AC(GMP(R!K<KFN:X90NSU-(Q$0**G6?H1"
M"82@'$(% HFV#IJ8/2K9@,IKR+SZXAQPP6!T&[AK::4DV2,K)8RNVX@303-J
M=S%(2;L5F9@ #:&<VZ]3.4-H@;AWUL4D@DO#')XL5U"S'D!R@!W=HX'V%AV
MQVV:/&2&1WJBM3WL"NN;ZRKET=9LNJRLA6]']^7UH\MO,)<=N'15*10;VLRX
M,+WYCY)J81V'E%8]\D!P_!#?Q .E=.;XT"?4KR)S11\%I<XTKE>UUNYO3D<%
M[L^RKVNV79]MO4])N7C)J6Y=":YE:!]L^'68+FO<:;B!U*$="U.^M[GVEW<O
M7+?S8PC(TM;5[8YG++GB-U?6I1F7\?EF[=77-P\(##W:@W5'B IBG3$NP1"M
M<[1;HOT2RW':MS6\D65P_DS,#F&O<DR\G$<Z[K^Q+MIS.T_='8=K,O4ZO9:B
MV:(\\NGW8@NF@5QZRTZ]HI6H=7@NXK 4XAD^Q<13DZW;/T;[Y=X%S*,UT05:
MNC).(TKU%1-0!XTCGD#;_7!Q;!#?7<>BW3KS:D$SL'YV$]]T0]FB^=W:AI,>
M@]JFMZ+$*0P7URQO<:V=]/6*S*5S*XV."3\[V>L,HE(VD1ZQW.6<D!@(BUE1
M$%'$Y;R9#% KP=7;,A/T<5RF%5.KE*U"M!W%E9LY0>(IN6JJ3ANL0JJ*Z*A%
M45DSAJ51)1,3$.0P;A =!HB_>B)1$HB41*(E$2B+A;E_FY/_ ,2RO[Q7K!;H
M_P"VM1I\AG_V3U(XKSCB'%H.O_G-W;'I[=?"#4'/&HW(S']:[\XK1<,#3\94
M[==!JW ?F#7FGK_Y50>XHVU1FD !)XBJG!-M1F?SHFNS76I+GTJ2F%$].I<Y
MS31SN7DQ04*;:IS/YTHFVF9_.B:C3,_G1-O9J<S^=,$V]FF9_.B;:C,_G1-1
MJ<S^=$VTS/YT3;49G\Z)MIF?SHFVF9_.B;>S4YG<_K(FHT#GUXHNQKZOL?\
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MN=MF5BV-F.9R49S23(SV*G4)Z-D6;907+,QD5D!#@!40,4V@#5K=[2O[J_\
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MN*V\TVV',=/Y?N.,E8NW)][=R[J/@%"!,-6\_"2,6W!!4ZK=+NX@N"F,IQ"
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M-*E5)YMV!?HFLCP(V]C2I1/-MP+]$UD>!&WWJ51/-MP+]$UD>!&WWJA$\VW
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MS0 '#E:[F<.?[U#RK\]7;)V+;[[#MVR;3WM:R138F"<-=U%S'4?I(9*97@5
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M_P!GK/\ Q)4HN&N*U[M) 3AS9)FCE+$21C$-;]H@!R@S6$Q!,2% X 8-FH"
MAT5A-RFFW-0/_P"2G_V3D K@#1= 8!PD ->(2B)1/IIQ"&P1$   U&O@_J9:
M=3N,OPDGYSEHQ]I_.75^RPO(6YEG.=RW5R4V[FMQ>N9WM]VEDEP_PNO()V^O
M;-H1D<U ;RED+B8JQ<G".% 3X2@3C Q-HC7?CMW07FV]'T[3MVRZ4+32V6\U
MJR*\<WK&R2N<ZL+2QP>U[034\,>"O7/C>T%TCL&TX.7YR&"<T3<YD.TK#@;I
MPY9&3(;-K>]S3]XV/?%D-Y+)=IOXR+NS&XD2?9$M:Z5KC>I.GC1%5K$)$16U
M34,=(U9>+?\ LZRTRRO=:N+;5M6L)+06XCAN8)GBWD8Y[+EM6VTL;(PX1N+'
M2$Y3FI50V2-S!G=5P:,?&^[_ "KG9''>6KU1Y?H^;Q*SQ+'\NC&X)FY;G0N:
MW)9M+BUQ9<5C-K6QXA!.G$BXMVY%),CEX:108BBW1(F"1E@ 26]CN?:NDWNK
M75MJAU:37KB+J;9\4K!!GO8YC)*7M#1)&&T8&.-7# Y:-,-F:UY %:_E>M7[
MRLW#UHY/R!RV<LV,D,*Q=EQ<&^Q-?2^2VUQVRM;T; 6T\870E<%JQR#@UT^/
M%S()=SJH+,D$D3/7)C.%"Z=;D=UZUH&W-^:_K]SJLE[/-#<6[;%T4P+I)(A'
MDE>6B'J8R:M<'$D@4%:D4/+2QP<2"YF'J_=ZZR]!<OEW0.(>7.U(VV89C<F/
M,XER)<R;=Q&$(T;/KGO68FY8':)^%^\D?& AERI&.LMUI@$!'4*U77.T+2=7
MWEKFI375P_2K[3'6\(<V3QB.KZMH815N4--#0 45<CP9I!^5^=X%B6U,,\R%
MT9"PY/91879'2UGN\RM,A7L6_;/1LF/0O6P[QMR D<4V);*K4C>/0=R+0Y5W
MC5.13,(=<94P*J!M.K;ZV):;;OM*V])'-:7'F#K6V\WN#<DPW=O)(VYN):DO
M(8\!L;\A% T %K4$C1@.04_SAP]18YD6%]Q./>0G$4AC2P.\V/,YX%AV&2K;
MO>W+AC+QC[/;.FH7;CV&AQ/.$)-Q#-20E%'I$"-$S*@)EAT4'*P2Z?/JN\]S
M,O\ 4C<7FB7KG6UQ!/$8'2QX0S22M;%XA+8H1$<Q:UA XE5$L(+B:?Y3]PZ%
MG:R\=Y[C&_+;C-_BY!E 81RQ*3EW7^M>%NGCINUV<%?<7;LE:\0U?K3Z[J25
MGVQW:+MNV,T*)@+UHA6FWVX-C@:_KL&IF2^UC2S'#;-@E:YDSNKSMDD+ R@R
M^(6NQX^+A2AQBSO(/C!OA5R\L6,<JXUOQG!H6G=./\'06/9:$0L6\KLLF_D(
M"ZSW#$.H1CC*Z(U%Q?8V0WB$GO6(RSHJ11,B5- IB;+'M0W1MO<>@-N'W4-]
MNR2Z8[K8(KFW+H<DN=US ]PMA,Y_5T,48=[;QBTD&)'A\9IQSX]!^[!;_ANK
MH%68X*:A2E$2B)1$HB5-$2H1*(NQKZOK^%<D_N"W_P!\2M?0'[#?ZS</>L__
M '2SVB^V?ZGLKKN>_MQW^Z5_UTU>"M0_;IOZQWLK"2?K#WU\U6BH0-FN[=T_
MDVT!H>3U2/OX'O*1]Y8&YD"76XQ=.1UL8HC,RI2S9]%W'9C^1BV*SJ >QCU%
M=Y$M9UNK#S,DT=&2$C-8Z'7%$W ?C I3;WL%VF0[A9/J6IRZ3)%3JKEC'EN<
M/:0)#'BQA%:O IA0X57-$:.775AZP>;K$W+FU@,2XJE[72O^4QM'1MBN[QM,
MMUX3M-EBN!CLC7K!QMYRQ;>C[@NR\H]<[6 Z[J(Q987*B15#K(AWMNC<'9?N
M7?\ YUN74HKD63;IQG9;R-AO9?.GFUA>8&A\L<,!:'SC&7J\H<10FZD-L]Y)
M-,>//5;FXIB;FM^PXK&,9RY3V/+4>R#^!N%>>R-9=P3!8VX(R3=SM^R;^)FI
MU_<LU)S*H@[%=8'RZ[@51$Q0'3K'7M6TRZW']*'Z]!>:G Z.6&..TGCC#X7L
MZJU8U\;6QQ-8T4(&4 8U)QX)6LSYV'Q!2BQ/9^-<[2MJ\NN!KSL4D+;&"KFQ
M_(W;EA*YX!]%WU#X4206L12UH)LZ//-GUX2\.P6?IO&S8C! %R =0>'78-5W
M%LF'4=<WKINH&34M7MIV068BD:^"2[;EF,KWCJRV,.>6EIJ[Q21S5-+ 2X8U
M%/4"R3>UNY)MCFA3S) 8?;9)M-QA1''RTC%SUK1M[1$R%W+SAVL4RN9_%-'4
M*]:@47?"Y2/Q%3,4JG"< PNCZIM_4.SENS;[5W:9K#-5\YHZ.8PNBZHLQ=$"
M<X<06\13-7D*,E9U#2>%?"K4P5@?(UE94L:_;D@XF"CGK3FTN.>M^*E&;UG8
MDGG'*.&[RMJSV9D2I)RBB,=:4@H]<M4Q:=V]9PCP'3$VP;M[0]M:IM:YT.SE
MDEN89](8R=\<C3=-L;>2&:=Q/ N)&5CSGRD$U<TTASP3W5CDW+3EL<.6U9_>
M)CW^C>3/F2PZZ:C-Q?5EO[(YX ;3B@<]T]2+=^#!0#N->J1T#C$-:R?UD[1?
MK-U>"=XMY=U:;?M(CDJ;>V$(F<<,'#JW%L?MG<@((54<@$S*\[1ZM6K(/S>Y
M6QEDS-EUQ., R_%9QL;&$3&E2N.UHL]E3%B62I9CZTIY*XGC#6QY-RX/*)N&
M0NSD=.7@&1U.F(X)NY=M;AV]I.FS:B[1KO1[NZ>XB&9WG3)Y8Y&R,ZMI'7 -
M+"V04RY,I;XRI8Y@R$FC0XYO6I[!7)8$Y;KEQC<^"7%U)1=PAC+EMN;&CZX^
MO2='8W'<-\6S<"L3$)NQ"1[TDC8PR":O  &1:IE-H.@5;[Q[2+#7;/5GZ1UM
MHZ]UZ"Y#&9V5ACAF8'N+*#K"]S7%E>)+J&A*CK(V.(8<725'>\;PA9QY8K"N
M#&6%K7LBYF*$;,0\K?BIF+9PV=-VT=,9#NN<@TT%FAU&Q4N\<DVT(4=$P'@T
M 2B :-VEZY8;DWA=:QI3G/MI8;2I>QS7.?':01R..< UZQCA7\;VV-:KBE)?
M)7N?>6?:T!<24190PG_6]C/^F]N?RFVKM;L0'_ZV-!/_ .?;^:Y7=C^UQ_EA
M>@6OMFMP7EHY[Q#SMLS]J;@_5\4[?#2O9O9K_P!F67Y!7RG^T+_Y;U3GJSV
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ML01TEFUJ1Y8X\F0#Z#U3UV510AM U(8!Z1K)[9L;C3],<^]!;J%Q(;@M/)4
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MO]P.T&S9Z(5V=2B^<?<55$2B)1$HB41*(E$2B+A+E_F[/_Q-*?89+U@]S_\
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MO<@>0]V_)N:^ U/I/3OAF=(\*CZ.[AY+.;H/@3YOK^ 0$;'N[8/"(^+DP
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M"]S_ & NV+5>S?MRL=LNE=]%=Q2-M;F,DY!* XV\U!@7QN+V#^3*X\:+$?U
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MBX$<"*$XKH;[2%OHO:M?7OV@^SZ:>XT&\N@R_M9W W.G3X-CSMS._P!UF%!
M]I+<P>PT( /:^0VH!N#9N#=M^R&E;Y4<B\A &B_2I4I1%HYSNW/&->7KF&L^
M^92*M"%NG$E\(6G=DB^2;13E^6V7'603XS@Q#-IONTO&@0@'!T@81)^B)F*.
M$W&ZW]"73)W,8TP/ S$4.&)/<J0/57;'86W56]KFW[K2+2>]N8=5MW9(V%QI
MU@!K2N %34BF'<7F<^HJRH]QMS>#9$KUZ$'G'',Q&1Y#F,1N[FK=E$Y.,=I
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MML?-MA^[P^\2G<'0GB59ODI;/I045\$I]%=L?-UA^[Q>\4 #F">)5F^2EM>
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M*LZWK8P%Y=?&2>^502#[W>YU['=*_ME1YA8_)HO)9X%4-:U<X>>W-?ZQ_OE
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MW0I'%=%7G#9L*)M,D7+H(B&QZ&GH /5B%?'J[[>^UZ&^E;'KET&B1XRAL-
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M0XTI0<RYZ1MNP\PP35W+1@G<M5#E0>)*.(FZ;7E6Q^!PBVE&1V\G&O6BY=!
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MC=0TYB.X345[BN>U#4)M-[/MK[/NF9=0T^SN[EXK5S?24T<D;'XX/#&-<6D
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M4=C]P7>/8T]]S=[@T0O#;>\VGJY(<:-<ZULY;V-M,07&2W 94>V(Q;Q&SN,
M-\W]H<0>N[Q1W%KMU**!>'A_O>#2MPU8AVI3.;P+UT=8?L;!C6G+QXD<Y5U3
M4-'3T:\B)1FD]CY!!1NZ;JE 2G3.78(#O(JF< ,0X:&3.4#%$! !K'X\BO.^
MK!@9*3LYZPM"Z7BT@P<'%I:=V.U#'7D2D*8Z<)<2HE(F2?02T*@L&I7R:8F'
MA6 Q3*<J$K*0" [O0].B*:(E$2B)1$HBX.YATMN?'_Y+*?O)>L'N?_MK4/\
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M9N*HH' @F  ,)#:".@Z6>L;:UO0!%+K-I<6T<S*QE["&O%.(K3$<HX\JI+7
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M%",D<4\620C\8">M<U<P;44JL<CH&@"&HB.H" :;@'79J/9K. DO=3!HIZU
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M&LW"Z:]/#:=OZU[-[-"#LRR[C"OE+]H<AG:UJCWD!M6\>\M2!$!$=*WN/QF
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MM V .G0(!537Y69&U!Y3]\<M?"IY:U4[ V::A^3HTZ:AKPT\"<>?DZ*U]5%
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MP.L(FY1.01T#UQ1"O579[N_;-EM6TL+^^AM[N-E2"[UB*"B^</;=V7=H&O\
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MUATSKJ2^2K-8KII=6 F.H1DHJIP[C 00'8-:9V@R]3M*Z=Q+C$VGY4\;?O\
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MN1V HK<T?J/9<0_=/#Z)NXO3TK)69!TZ[8./Z,^IFHK&?"]@/)XX]6BR H(
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M8"[![4[+-K:3NK<LEGJ$<EPR*!TC+:-S623N:Y@$;7NP/MBYP S%K2!BN:W
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M<\IW+-W)$*K6\UN&Q9VTD8JX9MG"D0DSPT-'/W!G*#0Y5%4N+A]?PC7:VK;
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MEMFL0W!AU1W)1EQ,,:X"N+%[R6,51&0<7!/WO 74X&+9JIK=RP)4HU5),!5
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M[4^T0X'5[^HYIW^%1YPN=_IGR?\ +>Y/QC0;0VT30:;:5_):A[4NT,"IUC4
M/ZY_A4^<+G?Z9LG_ "WN3\8T^B&V2<HTZTKS96H>U+M$;QUC4!_^,_PIYPF=
M_IGR?\M[D_&-/HCMGYNM/):I^M'M%^=]0^.?X4\X7._TSY/^6]R?C&H^B6V.
M73[/#^2U/K2[1*AOI?4,QX?IGX^N@<PN=^C,V3QTWAX[W+]R1I]$=L4S>CK2
MGY+5'UI=HA]KJ^H'_P#&?X4\X3._TSY/W^6]R?C&GT3VOP]'6GDM3ZT>T7(7
M^F-0H#B>N?0>NGG"YWZ,RY.'T;XN4-/_ -1J/HEMCYOM/)8A[4^T5O\ U>_I
MW9I!_I*/.&SM],^3_EO<NGJ]\:?1+:]:>C[2OY+4':EVB$5],:A\<_PH/,+G
M@/\ MFR=Z=[W*'_U&JAM#;)Q]'6M/R6J#VI]HC17TO?Y><SO'WT\X7.VS7,^
M3MN[_3>Y/L?Y1VT&T=LDT&G6E?R6H.U7M"X^F-0^/?X4\X7.V[YYLG=H/':Y
M.R ?&/9&I&T=M'AIUJ?YK5+NU3M#9B[6-0 [L[_#W0GG#9V^F?)WRWN3HW_\
MY=%1]$-M#CIUKY+4^M'M%/M=7U#XY_A4^<+G?Z9\G?+>Y/QB-/HAMGCZ.M,?
MY+54.U+M$(PU?4#3FF?X52/,)G?HS-D[3^FUR?C';3Z([9X'3[3,/Y+53]:?
M:,<6ZOJ!;S]<_P *!S"9VTU',V3P'^F]RAIZ/^4=M/HEMGYNM/):I^M+M% Q
MUC4/CG^%3YPN=QVAF?)VG]-[D_&51]$=L_-UIY+5'UI=HAX:QJ'QS_"GG"YV
M'_MGR</^V]R?C&I^B.V1_P!.M/):I^M/M#/#6-0K_7/\*><)G?HS/D_Y;7)^
M,!I]$=LG_IUIY+4^M/M$''5]0^.?X4\X7/'1F;)P^C>]RA_]1I]$=L?-UIY+
M4^M'M%Y-7U __C/\*><-G?IS/D[7L!>]RC_]1I]$-L_-UIY+5'UI]HE:'5[\
M'^O?X4\X7.WTS9/^6UR?C"GT0VS\W6GDM4CM2[1/G?4?CG^%/.%SO],^3_EM
M<OXQI]$=L?-UIY+4^M'M%^=]0^.?X4\X7._TSY/^6]R_C&GT0VS\W6GDM3ZT
M>T7YWU#XY_A62,.YXS9)96QS'R.6\COV#V\[>;/&;J\KA7;.6ZTFW(JBN@K(
M'3614*.ABF 0$!VU@]R[6V[!H%Y-!86S9F6[RT@ $$--"*<JV_L^[1]^WV^-
M)L[S5K]UK)?PM>TRN<'-+P"TAU10\#RKU0\.@::= CN$0UV=G7;7B\8&@J"O
MJ\:>HOTJM$HB41*(E$2B)1$HB41*(E$2B)1$HB416_=:_<]LW"MKIU<+)FU'
M30/V&MV:N;(9KV%O(9&^R%P7/[-)^0[V"N#@+<0[DLF24.N"\#;!(QL@/#U0
ME>M(DJBJNJ?6=<0D<!0T$ T..H:U7<7#VR3Q,]J^0U]0FGLJB&(=7$X\6M'L
M!7LJ/ @<QQ#0I!,<1V!H :F^Q5B!@ <2KL<<,%U9?5F)3[FX>?6Y9>$G(:/N
MKG9R;+0'?F-?QO?.-3C8%B$E'%?HHF=L%SM1 BR?$F?38(UIFT([MLVJ/NHW
ML#M2E+<S2W,VN#A48@\A%0>1>K/M/3Z0-.V!IFF75K=36FQM-CG,,C).KEZI
MKG129'.R2LKE?&ZCVD4< 5V&.2@KE.',("'<]ERXEUUVBXEX\O3T@"%=BM&7
M2W'D,P'^;5>1R0;YH/'JS[-%D>L>KM*(E$5@9*_FP3L^,=G@'IW7#AL[>@UD
M=+_:G?U,O^S<K.^_5-_K&?GA7_6.5XNKGZW@TTEREMW-O1DQ+2S#,.+9-!M!
MQ;J6?$)%S2S]9SW*T;N50003;CQ'$@E*(AKO"M,WY'<RZ!EM(WR3"XA.5K2X
MT#P2: $T %2>1>J/L<RZ5%VR@ZU<VMKI[M%U)CI)Y611UDMG,:W.]S6U<YP
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MV^4\Q\,I];':5\^:G^\R^^3SNY^$?TI\[F4_I%O;Y3S'PRI':QVEUIZ;U/\
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M W!J.HB Z;MM4UF<!@P1CA]U5)E:T_C"0\M!QY2<,.ZFP2ZE PAIKM(?74!
M-! "@8NT=G$ 535KGT=(W,.0$*HN8UGZ61Q:>=A!\/2%1UFP1]+40V@/H"4!
MV!Z&P*!XBE:7$",.!)/ #EY4=(X,+X\P8/QLM:'G IB>6E5^P:[- UV:AKN
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M !H!2AH&P-.SN"II04'(J.4CD5D([<E2.S\"RXD!'L":;EC  >B!1]2L@_\
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M%9O_ &UAY<A61*L%>)1$HBL7(0@$+'F'\$MUV<8WH>,T677TC&"LCIG[0_\
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MNJ]9NKN'LIWF=(U:SVZ[3]+O;6[U")DCKJUCFE:U[FM(8]U2&TZ.(KP5Q \
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MD'PIXCWMTV;=/R?E0_Y)3TGIY_UT7KJ/HIN3Y!-Y'])1XCWMY'75Z5O2P?\
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M>B;3N: E5>+9J&C)8-0UV;QJYLVUNX@/A&^R%PW!(MWG^2?87*0#$(R"A8T
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MNGG(YN;I64BE !X@$=H!J&H<.H5BJ*]& [BQYE<AQL*==)"8%8GO=.$,3_A
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MX=@"W, T^Z=F:#2O(*]U<<T]\X5MX\M,3FIB.84)^\OPE7#[(B;>W&L-<41
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M!*4*NH9-/MF%CFB8O.)I0M:.%/Y1XGDPIC6JX)&74T@<"&M:,.Z3QJ.;F7.
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'(E$2B+__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
